PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	KOUHARA, H; KOGA, M; KASAYAMA, S; TANAKA, A; KISHIMOTO, T; SATO, B				KOUHARA, H; KOGA, M; KASAYAMA, S; TANAKA, A; KISHIMOTO, T; SATO, B			TRANSFORMING ACTIVITY OF A NEWLY CLONED ANDROGEN-INDUCED GROWTH-FACTOR	ONCOGENE			English	Article							FACTOR FGF RECEPTOR; SHIONOGI CARCINOMA-115 CELLS; EXPRESSION CDNA CLONING; BREAST-CANCER-CELLS; SERUM-FREE CULTURE; POINT MUTATION; FACTOR-ALPHA; BASIC FGF; FIBROBLAST; PROLIFERATION	Our previous study demonstrated that androgen-dependent growth of mouse mammary carcinoma cells (SC-3) was mediated through an induction of heparin-binding growth factor, termed as androgen-induced growth factor (AIGF). Here, we report that NIH3T3 cells stably transfected with AIGF expression vector exhibit the abilities of tumor formation in nude mice, focus formation in monolayer culture and colony formation in soft agar. Thus, this newly cloned growth factor can be categorized as an oncogene. In addition, androgen-induced enhancement of DNA synthesis in SC-3 cells can be blocked by simultaneous incubation with AIGF antisense oligonucleotides. The possibility is also addressed that AIGF exerts its biological activity through an interaction with fibroblast growth factor (FGF) receptor. Transfection of expression vector encoding a variant form of FGF receptor-1 cloned from SC-3 cells into FGF receptor-negative L6 cells results in AIGF-dependent inhibition of differentiation. These results demonstrate that the ability of androgen to elicit transformed phenotype of SC-3 cells is mediated through AIGF induction and its interaction with FGF receptor-1,	OSAKA UNIV,SCH MED,DEPT MED 3,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT PATHOL,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University			Kishimoto, Tadamitsu/C-8470-2009					ABLAHAM JA, 1986, EMBO J, V5, P2523; ARTEAGA CL, 1988, MOL ENDOCRINOL, V2, P1064, DOI 10.1210/mend-2-11-1064; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE R, 1989, MOL ENDOCRINOL, V3, P372, DOI 10.1210/mend-3-2-372; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; HAGGINS C, 1952, CANCER RES, V12, P134; HARRIS SE, 1989, MOL ENDOCRINOL, V3, P1839, DOI 10.1210/mend-3-11-1839; HIGASHI T, 1990, P NATL ACAD SCI USA, V87, P2409, DOI 10.1073/pnas.87.7.2409; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; KASAYAMA S, 1991, J CELL PHYSIOL, V148, P260, DOI 10.1002/jcp.1041480211; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KOUHARA H, 1991, BIOCHEM BIOPH RES CO, V176, P31, DOI 10.1016/0006-291X(91)90885-B; LU J, 1989, CANCER RES, V49, P4963; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARICS I, 1989, ONCOGENE, V4, P335; MATSUO Y, 1987, CANCER RES, V47, P188; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NISHII K, 1991, CANCER RES, V51, P5573; NISHIZAWA Y, 1990, CANCER RES, V50, P3866; NOGUCHI S, 1987, CANCER RES, V47, P263; NONOMURA N, 1990, CANCER RES, V50, P2316; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SAITO H, 1991, BIOCHEM BIOPH RES CO, V174, P136, DOI 10.1016/0006-291X(91)90496-T; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; SATO B, 1988, PROGR ENDOCRINOLOGY, P99; STORY MT, 1987, BIOCHEM BIOPH RES CO, V142, P702, DOI 10.1016/0006-291X(87)91471-9; SUMITANI S, 1993, ENDOCRINOLOGY, V132, P1199, DOI 10.1210/en.132.3.1199; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	35	65	67	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					455	462						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290257				2022-12-25	WOS:A1994MW24800012
J	HENSEY, CE; HONG, F; DURFEE, T; QIAN, YW; LEE, EYHP; LEE, WH				HENSEY, CE; HONG, F; DURFEE, T; QIAN, YW; LEE, EYHP; LEE, WH			IDENTIFICATION OF DISCRETE STRUCTURAL DOMAINS IN THE RETINOBLASTOMA PROTEIN - AMINO-TERMINAL DOMAIN IS REQUIRED FOR ITS OLIGOMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR E2F; DNA-BINDING ACTIVITY; LARGE T-ANTIGEN; GENE-PRODUCT; SUSCEPTIBILITY GENE; CELL-CYCLE; INSECT CELLS; EXPRESSION; CLONING; REGIONS	To characterize the protein product of the retinoblastoma tumor suppressor gene biochemically, a recombinant human protein was produced in an Escherichia coli expression system. The full-length protein, p110RB, and an amino-terminal truncated form, p56RB, were expressed and purified to near homogeneity by conventional chromatographic procedures. To probe, the structural organization of the retinoblastoma protein the purified proteins were subjected to partial proteolysis by trypsin, chymotrypsin, and subtilisin. Four discrete structural domains were revealed in p110RB by this method. Two of these structural domains, found in both p56RB and p110RB, were mapped to the carboxyl-terminal half of the protein and corresponded to the SV40 large T binding domains defined previously by genetic methods. In addition two distinct domains in the amino-terminal half of the protein were also defined. A potential role for these newly defined amino-terminal domains was uncovered upon analysis of the purified proteins by nondenaturing polyacrylamide gel electrophoresis. p110RB revealed multiple bands by this method, suggesting the formation of oligomeric structures by the protein, while this property was not observed for p56RB. Electron microscopy of p110RB revealed linearly extended, macromolecular structures, further supporting the formation of homologous higher order structures by the full-length retinoblastoma protein. Analysis of the interactions between retinoblastoma protein molecules using the yeast two-hybrid system confirmed that the retinoblastoma protein could self-associate and that this association was mediated by interactions between the amino- and carboxyl-terminal ends of the protein. These observations suggest that the retinoblastoma protein contains multiple structural domains with the amino-terminal domains being required for oligomerization of the full-length protein.	UNIV TEXAS, HLTH SCI CTR, CTR MOLEC MED, INST BIOTECHNOL, SAN ANTONIO, TX 78245 USA	University of Texas System; University of Texas Health San Antonio			Hong, Frank/H-1019-2015; Hensey, Carmel/L-7456-2013	Hensey, Carmel/0000-0003-3319-4094; Hong, Frank/0000-0002-6814-4671	NATIONAL CANCER INSTITUTE [R01CA058318] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY005758] Funding Source: NIH RePORTER; NCI NIH HHS [CA58318] Funding Source: Medline; NEI NIH HHS [EY05758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BOOKSTEIN R, 1991, Critical Reviews in Oncogenesis, V2, P211; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDWARDS GM, 1992, J BIOL CHEM, V267, P7971; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GOODRICH D, 1991, CELL, V67, P1; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEE WH, 1991, ORIGINS OF HUMAN CANCER, P413; LEE WH, 1991, COLD SH Q B, V56, P211; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PRIVES C, 1991, COLD SPRING HARB SYM, V56, P227; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; ROSE GD, 1979, J MOL BIOL, V134, P447, DOI 10.1016/0022-2836(79)90363-2; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHEW JY, 1989, ONCOGENE RES, V4, P205; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; STIRDIVANT SM, 1992, J BIOL CHEM, V267, P14846; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; WANG NP, 1990, CELL GROWTH DIFFER, V1, P429; WETLAUFE.DB, 1973, P NATL ACAD SCI USA, V70, P697, DOI 10.1073/pnas.70.3.697; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILSON JE, 1991, METHOD BIOCHEM ANAL, V35, P207	50	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1380	1387						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288605				2022-12-25	WOS:A1994MR22000095
J	KUNAPULI, P; ONORATO, JJ; HOSEY, MM; BENOVIC, JL				KUNAPULI, P; ONORATO, JJ; HOSEY, MM; BENOVIC, JL			EXPRESSION, PURIFICATION, AND CHARACTERIZATION OF THE G-PROTEIN-COUPLED RECEPTOR KINASE GRK5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DEPENDENT PHOSPHORYLATION; RHODOPSIN KINASE; BETA-2-ADRENERGIC RECEPTOR; CATALYTIC SUBUNIT; AGONIST; FAMILY; TRANSLOCATION; INHIBITION; POLYANIONS	G protein-coupled receptor kinases (GRKs) such as rhodopsin kinase and the beta-adrenergic receptor kinase (betaARK) play an important role in agonist-specific phosphorylation and desensitization of G protein-coupled receptors. GRK5 is a recently identified member of the GRK family that has greater homology with rhodopsin kinase than with PARK. To further characterize the activity of GRK5, it has been overexpressed in Sf9 insect cells and purified by successive chromatography on S-Sepharose and Mono S columns. GRK5 phosphorylates the beta2-adrenergic receptor (beta2AR), m2 muscarinic cholinergic receptor, and rhodopsin in an agonist-dependent manner to maximal stoichiometries of approximately 2.5,1.5, and 1 mol of phosphate/mol of receptor, respectively, with K(m) values of approximately 0.5 muM for the beta2Ar, approximately muM for rhodopsin, and approximately 24 muM for ATP. Peptide phosphorylation studies suggest that in contrast to betaARK and rhodopsin kinase, GRK5 preferentially phosphorylates nonacidic peptides with a K(m) of approximately 1.5 mM. Heparin and dextran sulfate were found to be potent inhibitors of GRK5 with IC50 values of approximately 1 nM, thereby being at least 150-fold more potent on GRK5 than on betaARK. GRK5 can also be activated by polycations, with 10 mM polylysine promoting an approximately 2.6-fold activation. Overall, these studies demonstrate that GRK5 has unique properties that distinguish it from other members of the GRK family and that likely play an important role in modulating its mechanism of action.	NORTHWESTERN UNIV,SCH MED,DEPT PHARMACOL,CHICAGO,IL 60611; UNIV WISCONSIN,DEPT MED,NEPHROL SECT,MADISON,WI 53706	Northwestern University; University of Wisconsin System; University of Wisconsin Madison	KUNAPULI, P (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031601, R01HL045964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31601, HL45964] Funding Source: Medline; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASILL JA, 1991, P NATL ACAD SCI USA, V88, P11067; CHEN CY, 1993, J BIOL CHEM, V268, P7825; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GOMEZ J, 1992, MOL BIOL RECEPTORS T, P1; HARGRAVE PA, 1992, MOL BIOL RECEPTORS T, P49; HATHAWAY GM, 1984, J BIOL CHEM, V259, P7011; KIM CM, 1993, RECEPTOR, V3, P39; KUHN H, 1972, FEBS LETT, V20, P1, DOI 10.1016/0014-5793(72)80002-4; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN WJ, 1991, J BIOL CHEM, V266, P5664; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MAYOR F, 1987, J BIOL CHEM, V262, P6468; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P8764, DOI 10.1021/bi00448a013; PALCZEWSKI K, 1988, J BIOL CHEM, V263, P14067; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; SHICHI H, 1978, J BIOL CHEM, V253, P7040; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032	38	98	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1099	1105						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288567				2022-12-25	WOS:A1994MR22000052
J	SUN, M; LI, L; GAO, QS; PAUL, S				SUN, M; LI, L; GAO, QS; PAUL, S			ANTIGEN RECOGNITION BY AN ANTIBODY LIGHT-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; BINDING; HEAVY; HYDROLYSIS; COMPLEXES; PROTEINS	A monoclonal antibody to vasoactive intestinal polypeptide (VIP) was reduced and alkylated and its light and heavy chains were purified by denaturing gel filtration. Following renaturation, the light chain displayed sequence-specific binding of VIP. The specific VIP binding activity of several fractions spanning the light chain peak recovered from the gel filtration column was constant, the light chain was electrophoretically homogeneous, the VIP binding activity was precipitated by antilight chain antibody but not anti-heavy chain antibody and the activity remained associated with a light chain fraction recovered by resolutive chromatography on a hydroxylapatite column. N-terminal amino acid sequencing of the light and heavy chain, fractions confirmed the purity of these proteins and suggested that the V(L) and V(H) regions belonged to kappa-family II and gamma-family III, respectively. The VIP-binding affinity of the light chain was only 5-fold lower than that of the parent antibody and the light chain did not bind unrelated peptides. These observations suggest that light chains display structural characteristics necessary for high affinity antigen binding.	UNIV NEBRASKA,MED CTR,DEPT ANESTHESIOL,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT INTERNAL MED,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT PATHOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI031268, R01AI031268] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 44126] Funding Source: Medline; NIAID NIH HHS [AI 31268] Funding Source: Medline; PHS HHS [K 02217] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BJORK I, 1971, BIOCHEMISTRY-US, V10, P1289; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; EDELMAN GM, 1963, P NATL ACAD SCI USA, V50, P753, DOI 10.1073/pnas.50.4.753; EDMUNDSO.AB, 1974, BIOCHEMISTRY-US, V13, P3816, DOI 10.1021/bi00715a031; ERHAN S, 1974, NATURE, V251, P353, DOI 10.1038/251353a0; FLEISCHMAN JB, 1963, BIOCHEM J, V88, P220, DOI 10.1042/bj0880220; FRANEK F, 1963, BIOCHEMISTRY-MOSCOW+, V28, P193; GHERARDI E, 1992, NATURE, V357, P201, DOI 10.1038/357201a0; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HOPPER JE, 1986, CELL IMMUNOL, V101, P122, DOI 10.1016/0008-8749(86)90191-7; IOANNIDIS R A, 1989, Hematologic Pathology, V3, P169; KABAT EA, 1991, NIH913242 US DEP HLT; KING DJ, 1993, BIOCHEM J, V290, P723, DOI 10.1042/bj2900723; MEI S, 1991, J BIOL CHEM, V266, P15571; MERI S, 1992, J EXP MED, V175, P939, DOI 10.1084/jem.175.4.939; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; PAUL S, 1991, J BIOL CHEM, V266, P16128; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; PAUL S, 1992, J BIOL CHEM, V267, P13142; PAUL S, 1989, J NEUROIMMUNOL, V23, P133, DOI 10.1016/0165-5728(89)90032-5; ROHOLT O, 1963, P NATL ACAD SCI USA, V51, P173; SCHIFFER M, 1973, BIOCHEMISTRY-US, V12, P4620, DOI 10.1021/bi00747a013; STEVENS FJ, 1981, J MOL BIOL, V147, P185, DOI 10.1016/0022-2836(81)90086-3; STEVENS FJ, 1991, BIOCHEMISTRY-US, V30, P6803, DOI 10.1021/bi00242a001; UTSUMI S, 1964, BIOCHEMISTRY-US, V3, P1329, DOI 10.1021/bi00897a024; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WU TT, 1993, PROTEINS, V16, P1, DOI 10.1002/prot.340160102	27	54	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					734	738						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276876				2022-12-25	WOS:A1994MR21900115
J	TEBBEY, PW; MCGOWAN, KM; STEPHENS, JM; BUTTKE, TM; PEKALA, PH				TEBBEY, PW; MCGOWAN, KM; STEPHENS, JM; BUTTKE, TM; PEKALA, PH			ARACHIDONIC-ACID DOWN-REGULATES THE INSULIN-DEPENDENT GLUCOSE-TRANSPORTER GENE (GLUT4) IN 3T3-L1 ADIPOCYTES BY INHIBITING TRANSCRIPTION AND ENHANCING MESSENGER-RNA TURNOVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; STEAROYL-COA DESATURASE; FACTOR-ALPHA; DIABETES-MELLITUS; PLASMA-MEMBRANE; RAT ADIPOCYTES; PRETRANSLATIONAL SUPPRESSION; PLATELET PHOSPHOLIPIDS; GROWTH-FACTOR; EXPRESSION	Chronic exposure of fully differentiated 3T3-L1 adipocytes to 50 muM arachidonic acid (AA) resulted in an inhibition (approximately 91%) in cellular GLUT4 mRNA content after a 48-h exposure, without similarly affecting the mRNA content of the ubiquitous glucose transporter, GLUT1. Subsequent investigations revealed that transcription of the GLUT4 gene was reduced by approximately 50% in response to AA treatment and the half-life of GLUT4 mRNA decreased from 8.0 to 4.6 h. By contrast, AA increased the accumulation of GLUT1 mRNA by 65%, by a mechanism that also involved regulation at both transcriptional and mRNA stability levels. Western blot analysis revealed that AA was specifically reducing the insulin-responsive glucose transporter (GLUT4) in both plasma and intracellular membranes. Subsequently, AA was observed to alter the ability of the GLUT4 transporter to respond to insulin and mediate a significant enhancement of glucose uptake. The results presented in this study indicate that AA can partially mimic the effects of both tumor necrosis factor-alpha and insulin which, when chronically supplied to 3T3-L1 adipocytes, also down-regulate GLUT4 gene expression. Therefore, these data may have relevance to the insulin-resistance associated with non-insulin-dependent diabetes mellitus.	E CAROLINA UNIV,SCH MED,DEPT BIOCHEM,GREENVILLE,NC 27858; E CAROLINA UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,GREENVILLE,NC 27858	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University			Stephens, Jacqueline M/R-5217-2018		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032892] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32892] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVRUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334, DOI 10.1016/0005-2736(71)90331-2; BALY DL, 1988, BIOCHIM BIOPHYS ACTA, V947, P571, DOI 10.1016/0304-4157(88)90008-1; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BUTTKE TM, 1989, P NATL ACAD SCI USA, V86, P6133, DOI 10.1073/pnas.86.16.6133; BUTTKE TM, 1985, NUTR REP INT, V32, P749; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CHANG DJ, 1992, BIOCHEM BIOPH RES CO, V188, P538, DOI 10.1016/0006-291X(92)91089-9; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; CLARKE SD, 1992, FASEB J, V6, P3146, DOI 10.1096/fasebj.6.13.1397836; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; CORNELIUS P, 1988, BIOCHEM J, V249, P765, DOI 10.1042/bj2490765; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; EZAKI O, 1992, AM J PHYSIOL, V263, pE94, DOI 10.1152/ajpendo.1992.263.1.E94; FLORESRIVEROS JR, 1993, P NATL ACAD SCI USA, V90, P512, DOI 10.1073/pnas.90.2.512; GARVEY WT, 1991, J CLIN INVEST, V87, P1072, DOI 10.1172/JCI115068; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GLASGOW WC, 1992, J BIOL CHEM, V267, P1071; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HABENICHT AJR, 1990, NATURE, V345, P634, DOI 10.1038/345634a0; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; IP C, 1977, HORM METAB RES, V9, P218, DOI 10.1055/s-0028-1093540; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; KALOFOUTIS A, 1981, DIABETOLOGIA, V21, P540; LAVAU M, 1979, J LIPID RES, V20, P8; MURER E, 1992, DIABETES, V41, P1063, DOI 10.2337/diabetes.41.9.1063; NEUFELD EJ, 1983, J CLIN INVEST, V72, P214, DOI 10.1172/JCI110959; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; OKA Y, 1988, J BIOL CHEM, V263, P13432; PEKALA P, 1983, J EXP MED, V157, P1360, DOI 10.1084/jem.157.4.1360; PELIKANOVA T, 1991, CLIN CHIM ACTA, V203, P329, DOI 10.1016/0009-8981(91)90305-V; RANDLE PJ, 1988, DIABETES METAB REV, V4, P623, DOI 10.1002/dmr.5610040702; REID T, 1991, J BIOL CHEM, V266, P16580; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SINHA MK, 1991, DIABETES, V40, P472, DOI 10.2337/diabetes.40.4.472; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; STEPHENS JM, 1992, J BIOL CHEM, V267, P13580; STORLIEN LH, 1987, SCIENCE, V237, P885, DOI 10.1126/science.3303333; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAKAHASHI R, 1984, DIABETOLOGIA, V26, P134; TAKUWA N, 1988, J BIOL CHEM, V263, P9738; TAYLOR AS, 1985, BIOCHIM BIOPHYS ACTA, V883, P229; TEBBEY PW, 1992, BIOCHIM BIOPHYS ACTA, V1171, P27, DOI 10.1016/0167-4781(92)90136-N; THOIDIS G, 1993, J BIOL CHEM, V268, P11691; YANG J, 1992, BIOCHEM J, V281, P809, DOI 10.1042/bj2810809; YANG J, 1993, J BIOL CHEM, V268, P4600; YANG J, 1992, J BIOL CHEM, V267, P10393; YU NC, 1993, P NATL ACAD SCI USA, V90, P4042, DOI 10.1073/pnas.90.9.4042; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	59	81	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					639	644						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276864				2022-12-25	WOS:A1994MR21900101
J	ZAK, P; KLEIBL, K; LAVAL, F				ZAK, P; KLEIBL, K; LAVAL, F			REPAIR OF O6-METHYLGUANINE AND O4-METHYLTHYMINE BY THE HUMAN AND RAT O6-METHYLGUANINE-DNA METHYLTRANSFERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; ESCHERICHIA-COLI; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; MAMMALIAN-CELLS; ALKYLATED DNA; CDNA CLONING; O6-ALKYLGUANINE-DNA-ALKYLTRANSFERASE; EXPRESSION; RESIDUES; SEQUENCE	In order to compare the ability of the human and rat O6-methylguanine-DNA methyltransferases (transferases) to repair in vitro O6-methylguanine (O6-MeGua) and O4-methylthymine (O4-MeThy) residues, which are two mutagenic DNA adducts formed by alkylating agents, we have purified both proteins to homogeneity. Gel electrophoresis of the proteins shows that the O4-MeThy repair is due to the transfer of the methyl group from the alkylated base to the transferase molecules. However, both proteins repair with different efficiencies the O6-MeGua and O4-MeThy residues present in alkylated DNA, poly[d(G.C)], poly(dG.dC), or in alkylated poly[d(A.T)] and poly(dA.dT), respectively. Reaction of both proteins with either methylated residues follows a second-order kinetics. The rate constants are 1 x 10(9) M-1 min-1 for both proteins acting on O6-MeGua and 4.8 x 10(6) or 1.8 x 10(5) M-1 min-1 for the rat or human protein acting on 04-MeThy, respectively. The activity of the mammalian transferases on O4-MeThy present in a poly(dA.dT) substrate is inhibited by double-stranded DNA.	INST GUSTAVE ROUSSY,RADIOCHIM ADN GRP,UNITE 247,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,INSERM,F-94805 VILLEJUIF,FRANCE	UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy								BECKER RA, 1985, CARCINOGENESIS, V6, P313, DOI 10.1093/carcin/6.2.313; BELINSKY SA, 1986, CANCER RES, V46, P1280; BOITEUX S, 1985, CARCINOGENESIS, V6, P805, DOI 10.1093/carcin/6.5.805; BOITEUX S, 1984, EMBO J, V3, P2569, DOI 10.1002/j.1460-2075.1984.tb02175.x; BRENT TP, 1988, P NATL ACAD SCI USA, V85, P1759, DOI 10.1073/pnas.85.6.1759; CHAN CL, 1993, ARCH BIOCHEM BIOPHYS, V300, P193, DOI 10.1006/abbi.1993.1027; DOLAN ME, 1985, CARCINOGENESIS, V6, P1611, DOI 10.1093/carcin/6.11.1611; DOSANJH MK, 1991, BIOCHEMISTRY-US, V30, P7027, DOI 10.1021/bi00242a031; DRINKWATER NR, 1980, BIOCHEMISTRY-US, V19, P5087, DOI 10.1021/bi00563a023; GERSON SL, 1986, CARCINOGENESIS, V7, P745, DOI 10.1093/carcin/7.5.745; HAYAKAWA H, 1990, J MOL BIOL, V213, P739, DOI 10.1016/S0022-2836(05)80260-8; KOIKE G, 1990, J BIOL CHEM, V265, P14754; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAL F, 1977, RADIAT RES, V71, P571, DOI 10.2307/3574625; LAVAL F, 1992, INDUCED EFFECTS GENO, P39; LEFEBVRE P, 1985, CANCER RES, V46, P5701; LINDAHL T, 1982, EMBO J, V1, P1359, DOI 10.1002/j.1460-2075.1982.tb01323.x; LING-LING C, 1992, Carcinogenesis (Oxford), V13, P837, DOI 10.1093/carcin/13.5.837; LOMONOSSOFF GP, 1981, J MOL BIOL, V149, P745, DOI 10.1016/0022-2836(81)90356-9; MCCARTHY TV, 1985, NUCLEIC ACIDS RES, V13, P2683, DOI 10.1093/nar/13.8.2683; MCCARTHY TV, 1984, EMBO J, V3, P545, DOI 10.1002/j.1460-2075.1984.tb01844.x; PEGG AE, 1990, CANCER RES, V50, P6119; POTTER PM, 1987, NUCLEIC ACIDS RES, V15, P9177, DOI 10.1093/nar/15.22.9177; RAFFERTY JA, 1992, NUCLEIC ACIDS RES, V20, P1891, DOI 10.1093/nar/20.8.1891; RAHDENSTARON I, 1991, BIOCHEM BIOPH RES CO, V177, P597, DOI 10.1016/0006-291X(91)91830-6; REBECK GW, 1988, P NATL ACAD SCI USA, V85, P3039, DOI 10.1073/pnas.85.9.3039; RYDBERG B, 1990, J BIOL CHEM, V265, P9563; SAFFHILL R, 1985, BIOCHIM BIOPHYS ACTA, V823, P111, DOI 10.1016/0304-419X(85)90009-5; SASSANFAR M, 1991, J BIOL CHEM, V266, P2767; Singer B., 1983, MOL BIOL MUTAGENS CA; SWANN PF, 1990, MUTAT RES, V233, P81, DOI 10.1016/0027-5107(90)90153-U; TANO K, 1990, P NATL ACAD SCI USA, V87, P686, DOI 10.1073/pnas.87.2.686	32	62	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					730	733						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276875				2022-12-25	WOS:A1994MR21900114
J	ROTHSCHILD, KJ; MARTI, T; SONAR, S; HE, YW; RATH, P; FISCHER, W; KHORANA, HG				ROTHSCHILD, KJ; MARTI, T; SONAR, S; HE, YW; RATH, P; FISCHER, W; KHORANA, HG			ASP(96) DEPROTONATION AND TRANSMEMBRANE ALPHA-HELICAL STRUCTURAL-CHANGES IN BACTERIORHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFRARED DIFFERENCE SPECTROSCOPY; SCHIFF-BASE; N-INTERMEDIATE; PROTON TRANSLOCATION; PURPLE MEMBRANE; VIBRATIONAL SPECTROSCOPY; TRANSIENT SPECTROSCOPY; PROTEIN-STRUCTURE; ASPARTIC ACID-96; PHOTOCYCLE	The M-->N transition in the photocycle of bacteriorhodopsin involves the transfer of a proton from Asp96 to the retinylidene Schiff base, possibly through a network of hydrogen-bonded amino acid residues and water molecules (Rothschild, K. J., He, Y. W., Sonar, S., Marti, T., and Khorana, H. G. (1992) J. Biol. Chem. 267, 1615-1622). A conformational change of the protein backbone is also observed during this transition. In this work, we have investigated the effects of replacing the residue Thr46, which might be part of this chain, with an aspartic acid. Both Fourier transform infrared and resonance Raman spectroscopy show that the chromophore structure of this mutant (T46D) is normal. However, N formation is accelerated and N decay is significantly slowed compared to wild-type bacteriorhodopsin. This effect causes the N intermediate to accumulate under steady-state illumination thereby facilitating spectroscopic studies under normal pH conditions. Fourier transform infrared difference spectroscopy reveals that like native bacteriorhodopsin, N formation in T46D involves deprotonation of Asp96, reprotonation of the Schiff base, and a change in the backbone secondary structure. However, in contrast to bacteriorhodopsin, bands assigned to the C=O stretch mode of the carboxylic acid group of Asp96 are upshifted by 10 cm-1 reflecting a change in the Asp96 environment and a drop in its effective pK(a) throughout the photocycle. This change in the pK(a) can directly account for changes in the photocycle kinetics and indicates that Asp96 deprotonation/protonation are the rate limiting steps in the formation and decay of the N intermediate. By studying the effects of H/D exchange, evidence is found that the backbone structural changes involve transmembrane alpha-helices. It is proposed that these structural changes serve to modulate the local environment and protonation state of Asp96 during the photocycle and are also essential for formation of the proton conducting hydrogen bonded network which functions during Schiff base reprotonation.	BOSTON UNIV,MOLEC BIOPHYS LAB,BOSTON,MA 02215; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Boston University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	ROTHSCHILD, KJ (corresponding author), BOSTON UNIV,DEPT PHYS,BOSTON,MA 02215, USA.		; Rothschild, Kenneth/P-6177-2018	Fischer, Wolfgang/0000-0001-7753-1828; Rothschild, Kenneth/0000-0002-2847-6671	NIAID NIH HHS [AI11479] Funding Source: Medline; NIGMS NIH HHS [GM28289] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI011479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028289, R01GM028289] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGLEY K, 1982, P NATL ACAD SCI-BIOL, V79, P4972, DOI 10.1073/pnas.79.16.4972; Bellamy L. J., 1980, INFRARED SPECTRA COM, V2, P299; BOUSCHE O, 1992, PHOTOCHEM PHOTOBIOL, V56, P1085, DOI 10.1111/j.1751-1097.1992.tb09732.x; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BRAIMAN MS, 1992, BIOPHYS J, V62, P56, DOI 10.1016/S0006-3495(92)81777-0; BRAIMAN MS, 1988, ANNU REV BIOPHYS BIO, V17, P541; BRAIMAN MS, 1991, J BIOL CHEM, V266, P11063; CAO Y, 1991, BIOCHEMISTRY-US, V30, P10972, DOI 10.1021/bi00109a023; CAO Y, 1993, BIOCHEMISTRY-US, V32, P1981, DOI 10.1021/bi00059a015; DUNACH M, 1990, J BIOL CHEM, V265, P16978; EARNEST TN, 1986, BIOCHEMISTRY-US, V25, P7793, DOI 10.1021/bi00372a002; EARNEST TN, 1990, BIOPHYS J, V58, P1539, DOI 10.1016/S0006-3495(90)82498-X; FODOR SPA, 1988, BIOCHEMISTRY-US, V27, P7097, DOI 10.1021/bi00418a064; GERWERT K, 1989, P NATL ACAD SCI USA, V86, P4943, DOI 10.1073/pnas.86.13.4943; HACKETT NR, 1987, J BIOL CHEM, V262, P9277; HE YW, 1993, BIOCHEMISTRY-US, V32, P2282, DOI 10.1021/bi00060a021; HOLZ M, 1989, P NATL ACAD SCI USA, V86, P2167, DOI 10.1073/pnas.86.7.2167; KHORANA HG, 1988, J BIOL CHEM, V263, P7439; KOUYAMA T, 1988, BIOCHEMISTRY-US, V27, P5855, DOI 10.1021/bi00416a006; KREBS MP, 1993, J BACTERIOL, V175, P1555, DOI 10.1128/JB.175.6.1555-1560.1993; KRIMM S, 1982, SCIENCE, V216, P407, DOI 10.1126/science.6280277; MAEDA S, 1992, SPRINGER P PHYS, V68, P68; MARTI T, 1991, J BIOL CHEM, V266, P6919; MATHIES R, 1977, J MOL BIOL, V109, P367, DOI 10.1016/S0022-2836(77)80040-5; NAKAGAWA M, 1991, J MOL STRUCT, V242, P221, DOI 10.1016/0022-2860(91)87137-7; ORMOS P, 1991, P NATL ACAD SCI USA, V88, P473, DOI 10.1073/pnas.88.2.473; OTTO H, 1989, P NATL ACAD SCI USA, V86, P9228, DOI 10.1073/pnas.86.23.9228; OTTO H, 1990, P NATL ACAD SCI USA, V87, P1018, DOI 10.1073/pnas.87.3.1018; PELTIER S, 1959, COMPT RENDU, V248, P1148; PFEFFERLE JM, 1991, BIOCHEMISTRY-US, V30, P6548, DOI 10.1021/bi00240a027; RATH P, 1993, BIOCHEMISTRY-US, V32, P2272, DOI 10.1021/bi00060a020; ROEPE P, 1987, BIOCHEMISTRY-US, V26, P6696, DOI 10.1021/bi00395a020; ROTHSCHILD KJ, 1992, J BIOL CHEM, V267, P1615; ROTHSCHILD KJ, 1982, P NATL ACAD SCI-BIOL, V79, P4045, DOI 10.1073/pnas.79.13.4045; ROTHSCHILD KJ, 1984, BIOCHEMISTRY-US, V23, P6103, DOI 10.1021/bi00320a031; ROTHSCHILD KJ, 1981, BIOCHEM BIOPH RES CO, V103, P483, DOI 10.1016/0006-291X(81)90478-2; ROTHSCHILD KJ, 1992, J BIOENERG BIOMEMBR, V24, P147, DOI 10.1007/BF00762674; ROTHSCHILD KJ, 1979, SCIENCE, V204, P311, DOI 10.1126/science.432645; ROTHSCHILD KJ, 1979, BIOPHYS J, V25, P473, DOI 10.1016/S0006-3495(79)85317-5; ROTHSCHILD KJ, 1990, J BIOL CHEM, V265, P16985; SASAKI J, 1992, J BIOL CHEM, V267, P20782; SIEBERT F, 1982, FEBS LETT, V141, P82, DOI 10.1016/0014-5793(82)80021-5; SMITH SO, 1987, J AM CHEM SOC, V109, P3108, DOI 10.1021/ja00244a038; SONAR S, 1993, BIOCHEMISTRY-US, V32, P2263, DOI 10.1021/bi00060a019; STERN LJ, 1989, J BIOL CHEM, V264, P14202; SUBRAMANIAM S, 1991, P NATL ACAD SCI USA, V88, P6873, DOI 10.1073/pnas.88.15.6873; ZIMANYI L, 1989, BIOCHEMISTRY-US, V28, P5165, DOI 10.1021/bi00438a038	48	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27046	27052						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262942				2022-12-25	WOS:A1993MM26200034
J	STEGMANN, T				STEGMANN, T			MEMBRANE FUSION-INHIBITING PEPTIDES DO NOT INHIBIT INFLUENZA-VIRUS FUSION OR THE CA2+-INDUCED FUSION OF NEGATIVELY CHARGED VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENDAI VIRUS; PHOSPHOLIPID-VESICLES; BILAYER-MEMBRANES; PHASE-TRANSITION; L-ALPHA; LIPOSOMES; KINETICS; PH; DESTABILIZATION; GLYCOPROTEINS	Short hydrophobic N-carbobenzoxy oligopeptides are known to inhibit the infectivity of several enveloped viruses. Recently, it was shown that they inhibited the fusion of Sendai virus with N-methyl-dioleoylphosphatidylethanolamine (N-methyl-DOPE) liposomes as well as the low pH-induced fusion of these liposomes with each other (Kelsey, D. R., Flanagan, T. D., Young, J. E., and Yeagle, P. L. (1990) J. Biol. Chem. 265, 12178-12183). Therefore it was concluded that the peptides inhibit membrane fusion, an important step in viral infectivity. Here, it is shown that this peptide and a series of similar peptides did not inhibit influenza virus fusion with N-methyl-DOPE or other liposomes. In fact, some peptides enhanced the overall rate of fusion of influenza virus with N-methyl-DOPE liposomes. In our hands, the peptides did not inhibit influenza infectivity in Madin-Darby canine kidney cells or influenza-induced hemolysis either. They also did not inhibit the Ca2+-induced fusion between cardiolipin or phosphatidylserine liposomes. However, the inhibitory effect of one of the peptides on the fusion of Sendai virus with N-methyl-DOPE liposomes and on N-methyl-DOPE liposome-liposome fusion could be reproduced. These data indicate that the peptides do not, as had been suggested (Yeagle, P. L., Young, J. E., Hui, S. W., and Epand, R. M. (1992) Biochemistry 31, 3177-3183), act by preventing the formation of lipid structures with small radii of curvature, such as the inverted phase intermediates that are thought to be involved in N-methyl-DOPE fusion. The results also suggest that the mechanism of inhibition of Sendai virus infection and N-methyl-DOPE fusion by the peptides may be different after all.			STEGMANN, T (corresponding author), UNIV BASEL,BIOCTR,DEPT BIOPHYS CHEM,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.							ASANO K, 1988, BIOCHEMISTRY-US, V27, P1321, DOI 10.1021/bi00404a035; BENTZ J, 1993, VIRAL FUSION MECHANI, P163; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; CHOPPIN PW, 1980, REV INFECT DIS, V2, P40; DOMS RW, 1986, J VIROL, V57, P603, DOI 10.1128/JVI.57.2.603-613.1986; ELLENS H, 1986, BIOCHEMISTRY-US, V25, P285, DOI 10.1021/bi00350a001; ELLENS H, 1989, BIOCHEMISTRY-US, V28, P3692, DOI 10.1021/bi00435a011; ELLENS H, 1986, BIOCHEMISTRY-US, V25, P4141, DOI 10.1021/bi00362a023; EPAND RM, 1987, J BIOL CHEM, V262, P1526; FOLCH J, 1957, J BIOL CHEM, V226, P497; GAGNE J, 1985, BIOCHEMISTRY-US, V24, P4400, DOI 10.1021/bi00337a022; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; HULL JD, 1987, VIROLOGY, V159, P690; KELSEY DR, 1990, J BIOL CHEM, V265, P12178; KELSEY DR, 1991, VIROLOGY, V182, P690, DOI 10.1016/0042-6822(91)90610-N; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MILLER FA, 1968, APPL MICROBIOL, V16, P1489, DOI 10.1128/AEM.16.10.1489-1496.1968; NICOLAIDES E, 1968, J MED CHEM, V11, P74, DOI 10.1021/jm00307a016; NORRBY E, 1971, VIROLOGY, V44, P599, DOI 10.1016/0042-6822(71)90374-6; NOVICK SL, 1988, P NATL ACAD SCI USA, V85, P7433, DOI 10.1073/pnas.85.20.7433; PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V394, P579; RICHARDSON CD, 1980, VIROLOGY, V105, P205, DOI 10.1016/0042-6822(80)90168-3; RICHARDSON CD, 1983, VIROLOGY, V131, P518, DOI 10.1016/0042-6822(83)90517-2; ROTT R, 1984, EMBO J, V3, P3329, DOI 10.1002/j.1460-2075.1984.tb02299.x; SIEGEL DP, 1986, CHEM PHYS LIPIDS, V42, P279, DOI 10.1016/0009-3084(86)90087-3; SIEGEL DP, 1986, BIOPHYS J, V49, P1171, DOI 10.1016/S0006-3495(86)83745-6; SIEGEL DP, 1984, BIOPHYS J, V45, P399, DOI 10.1016/S0006-3495(84)84164-8; SIEGEL DP, 1993, VIRAL FUSION MECHANI, P475; STEGMANN T, 1985, BIOCHEMISTRY-US, V24, P3107, DOI 10.1021/bi00334a006; STEGMANN T, 1989, BIOCHEMISTRY-US, V28, P1698, DOI 10.1021/bi00430a041; STEGMANN T, 1993, J BIOL CHEM, V268, P1716; STEGMANN T, 1986, J BIOL CHEM, V261, P966; STEGMANN T, 1993, VIRAL FUSION MECHANI, P89; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; STUBBS CD, 1989, BIOCHIM BIOPHYS ACTA, V986, P89, DOI 10.1016/0005-2736(89)90276-9; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; VERKLEIJ AJ, 1980, BIOCHIM BIOPHYS ACTA, V600, P620, DOI 10.1016/0005-2736(80)90465-4; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WILSCHUT J, 1992, BIOCHEMISTRY-US, V31, P2629, DOI 10.1021/bi00125a001; WILSCHUT J, 1985, BIOCHEMISTRY-US, V24, P4630, DOI 10.1021/bi00338a023; WILSCHUT J, 1993, VIRAL FUSION MECHANI, P133; WILSCHUT J, 1990, MEMBRANE FUSION, P89; YEAGLE PL, 1992, BIOCHEMISTRY-US, V31, P3177, DOI 10.1021/bi00127a019	43	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26886	26892						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262922				2022-12-25	WOS:A1993MM26200012
J	DAHDAL, RY; COLLEY, KJ				DAHDAL, RY; COLLEY, KJ			SPECIFIC SEQUENCES IN THE SIGNAL ANCHOR OF THE BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE ARE NOT ESSENTIAL FOR GOLGI LOCALIZATION - MEMBRANE FLANKING SEQUENCES MAY SPECIFY GOLGI RETENTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; SPANNING DOMAIN; PROTEIN; APPARATUS; GLYCOSYLATION; CELLS; BETA-1,4-GALACTOSYLTRANSFERASE; GLYCOPROTEINS; SUFFICIENT	The beta-galactoside alpha-2,6-sialyltransferase is a trans Golgi/trans Golgi network glycosyltransferase which adds sialic acid residues to Asn-linked oligosaccharides of glycoproteins. Previous results suggested that the sialyltransferase stem and signal anchor including flanking sequences may be two independent Golgi retention regions. However, other experiments demonstrated that the sequence of the signal anchor itself was not important. To investigate whether the sialyltransferase signal anchor was necessary and sufficient for Golgi retention, several mutant and chimeric proteins were expressed and localized in Cos-1 and Chinese hamster ovary cells. We found that the signal anchor and flanking sequences were able to retain the sialyltransferase catalytic domain in the Golgi. However, efficient Golgi retention was still observed when the signal anchor was altered or entirely replaced in either the presence or absence of most of the luminal stem region. Chimeric proteins consisting of the sialyltransferase cytoplasmic tail and signal anchor fused to the extracellular domains of two different cell surface proteins demonstrated poor Golgi retention. A significant increase in the Golgi retention of one of these chimeras was observed when two lysines were placed next to the signal anchor on the luminal side. Taken together these results suggest that the sialyltransferase signal anchor is not necessary or sufficient for Golgi retention, rather, appropriately spaced cytoplasmic and luminal flanking sequences are the important elements of the sialyltransferase Golgi retention region.	UNIV ILLINOIS, COLL MED, DEPT BIOCHEM, 1819 W POLK ST, M-C 536, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048134, R01GM048134] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48134] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; COLMAN PM, 1985, CURR TOP MICROBIOL, V114, P177; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; FLEISCHER B, 1993, BIOCHEMISTRY-US, V32, P2076, DOI 10.1021/bi00059a027; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KEENAN TW, 1970, BIOCHEMISTRY-US, V9, P19, DOI 10.1021/bi00803a003; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUHN LC, 1984, CELL, V37, P95, DOI 10.1016/0092-8674(84)90304-0; KUNDU A, 1991, MOL CELL BIOL, V11, P2675, DOI 10.1128/MCB.11.5.2675; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Griffiths Gareth, 1993, Trends in Cell Biology, V3, P214, DOI 10.1016/0962-8924(93)90114-G; Machamer C E, 1991, Trends Cell Biol, V1, P141, DOI 10.1016/0962-8924(91)90001-P; MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; ORCI L, 1981, P NATL ACAD SCI-BIOL, V78, P293, DOI 10.1073/pnas.78.1.293; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PORUCHYNSKY MS, 1988, J CELL BIOL, V107, P1697, DOI 10.1083/jcb.107.5.1697; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; SEEGER M, 1992, J CELL BIOL, V118, P531, DOI 10.1083/jcb.118.3.531; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; STIRZAKER SC, 1989, CELL, V56, P741, DOI 10.1016/0092-8674(89)90677-6; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TANG BL, 1992, J BIOL CHEM, V267, P10122; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; WEISZ OA, MOL BIOL CELL, V3, pA189; WILCOX CA, 1992, MOL BIOL CELL, V3, P1353, DOI 10.1091/mbc.3.12.1353; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245; ZAMBRANO F, 1975, BIOCHIM BIOPHYS ACTA, V380, P357, DOI 10.1016/0005-2760(75)90104-6; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	51	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26310	26319						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253753				2022-12-25	WOS:A1993MK42500047
J	FANKHAUSER, C; HOMANS, SW; THOMASOATES, JE; MCCONVILLE, MJ; DESPONDS, C; CONZELMANN, A; FERGUSON, MAJ				FANKHAUSER, C; HOMANS, SW; THOMASOATES, JE; MCCONVILLE, MJ; DESPONDS, C; CONZELMANN, A; FERGUSON, MAJ			STRUCTURES OF GLYCOSYLPHOSPHATIDYLINOSITOL MEMBRANE ANCHORS FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; CLEAVAGE ATTACHMENT SITE; TRYPANOSOMA-BRUCEI; LEISHMANIA-MAJOR; PHOSPHOLIPASE-C; PROTEINS; BIOSYNTHESIS; ACID; OLIGOSACCHARIDES	Metabolic labeling studies suggest that Saccharomyces cerevisiae contains many glycoproteins that are anchored in the lipid bilayer by glycosylphosphatidylinositol membrane anchors. Membrane anchors were purified from a crude yeast membrane protein fraction and analyzed by two-dimensional H-1-H-1 NMR, fast atom bombardment-mass spectrometry, compositional and methylation linkage analyses, as well as chemical and enzymatic modifications. The yeast glycosylphosphatidylinositol anchors consist of the following structures: ethanolamine-PO4-6(R-2)Manalpha1-2Manalpha1-6Manalpha1-4Glc-NH2alpha1-6myo-inositol-1-PO4-lipid, where R is mainly Manalpha1- (80%) with some Manalpha1-2Manalpha1- (15%) and Manalpha1-3Manalpha1- (5%). The core region of the yeast anchors (ethanolamine-PO4-6Manalpha1-2Manalpha1-6Manalpha1-4GlcNH2alpha1-6myo-inositol-1-PO4) is identical to the conserved core region found in glycosylphosphatidylinositol anchors from protozoa and mammals. The lipid moieties of the total yeast glycosylphosphatidylinositol anchors are mainly ceramides, consisting mostly of C18:0 phytosphingosine and C26:0 fatty acid. However, the lipid moiety of the glycosylphosphatidylinositol anchor of the purified ggp125 protein is a lyso- or diacylglycerol, containing C26:0 fatty acids. This suggests that yeast adds different lipid components to the glycosylphosphatidylinositol anchors of different proteins.	UNIV FRIBOURG,INST BIOCHEM,CH-1700 FRIBOURG,SWITZERLAND; UNIV LAUSANNE,CH-1066 EPALINGES,SWITZERLAND; UNIV DUNDEE,DUNDEE DD1 4HN,SCOTLAND	University of Fribourg; University of Lausanne; University of Dundee			Ferguson, Michael A. J./F-7829-2010	Ferguson, Michael A. J./0000-0003-1321-8714	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENDIAK B, 1985, CARBOHYD RES, V144, P1, DOI 10.1016/0008-6215(85)85001-1; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUTIKOFER P, 1990, J BIOL CHEM, V265, P18983; CHAPLIN MF, 1986, CARBOHYDRATE ANAL PR, P2; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; CONZELMANN A, 1992, EMBO J, V11, P457, DOI 10.1002/j.1460-2075.1992.tb05075.x; CONZELMANN A, 1990, EMBO J, V9, P653, DOI 10.1002/j.1460-2075.1990.tb08157.x; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEEG MA, 1992, J BIOL CHEM, V267, P18573; DELL A, 1987, ADV CARBOHYD CHEM BI, V45, P19, DOI 10.1016/S0065-2318(08)60136-5; DOERING TL, 1990, J BIOL CHEM, V265, P611; FANKHAUSER C, 1991, EUR J BIOCHEM, V195, P439, DOI 10.1111/j.1432-1033.1991.tb15723.x; Ferguson M. A. J., 1992, LIPID MODIFICATION P, P191; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; FERGUSON MAJ, 1992, BIOCHEM J, V284, P297, DOI 10.1042/bj2840297; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4963; Ferguson MAJ, 1991, CURR OPIN STRUC BIOL, V1, P522, DOI 10.1016/S0959-440X(05)80072-7; FIELD MC, 1991, J BIOL CHEM, V266, P8392; GUTHER ML, 1992, J BIOL CHEM, V257, P6820; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDERKREMER RM, 1990, EUR J BIOCHEM, V192, P337; LEDERKREMER RM, 1991, J BIOL CHEM, V266, P23670; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LUHRS CA, 1989, J BIOL CHEM, V264, P21446; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MCCONVILLE MJ, 1989, J BIOL CHEM, V264, P757; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P157, DOI 10.1073/pnas.87.1.157; MORAN P, 1991, J BIOL CHEM, V266, P1250; NUOFFER C, 1991, MOL CELL BIOL, V11, P7; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; ROBERTS WL, 1987, P NATL ACAD SCI USA, V84, P7817, DOI 10.1073/pnas.84.22.7817; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SMITH SW, 1974, J BIOL CHEM, V249, P3395; STADLER J, 1989, EMBO J, V8, P371, DOI 10.1002/j.1460-2075.1989.tb03387.x; STAHL N, 1992, BIOCHEMISTRY-US, V31, P5043, DOI 10.1021/bi00136a600; TAKASAKI S, 1982, METHOD ENZYMOL, V83, P263; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; VAI M, 1991, J BIOL CHEM, V266, P12242; VAI M, 1990, BIOCHIM BIOPHYS ACTA, V1038, P277, DOI 10.1016/0167-4838(90)90237-A; WALTER EI, 1990, J IMMUNOL, V144, P1030; WICKERHAM LJ, 1946, J BACTERIOL, V52, P293, DOI 10.1128/JB.52.3.293-301.1946; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; YAMASHITA K, 1982, METHOD ENZYMOL, V83, P105	49	146	146	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26365	26374						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253761				2022-12-25	WOS:A1993MK42500055
J	HERRMANN, J; TURCK, CW; ATCHISON, RE; HUFLEJT, ME; POULTER, L; GITT, MA; BURLINGAME, AL; BARONDES, SH; LEFFLER, H				HERRMANN, J; TURCK, CW; ATCHISON, RE; HUFLEJT, ME; POULTER, L; GITT, MA; BURLINGAME, AL; BARONDES, SH; LEFFLER, H			PRIMARY STRUCTURE OF THE SOLUBLE LACTOSE BINDING LECTIN L-29 FROM RAT AND DOG AND INTERACTION OF ITS NONCOLLAGENOUS PROLINE-RICH, GLYCINE-RICH, TYROSINE-RICH SEQUENCE WITH BACTERIAL AND TISSUE COLLAGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSE-SPECIFIC LECTIN; AMINO-ACID-SEQUENCE; MASS-SPECTROMETRY; IV COLLAGENASE; DIFFERENTIAL RECOGNITION; MONONUCLEAR PHAGOCYTES; MONOCLONAL-ANTIBODIES; ENDOGENOUS LECTIN; IGE GLYCOFORMS; MAC-2 ANTIGEN	A lactose-binding lectin from rat lung (RL-29) and a related lectin from Madin-Darby canine kidney (MDCK) cells have been analyzed with the primary goal of identifying post-translational modifications. The sequences show that RL-29 and the dog lectin are homologues of a lectin designated here as L-29 and elsewhere as CBP-35, epsilonBP, Mac-2, or L-34. RL-29 has a 140-amino-acid COOH-terminal carbohydrate-binding domain, a 20-amino-acid NH2-terminal domain, and an intervening domain consisting of 11 repeating elements rich in Pro, Gly, and Tyr (R-domain). The dog homologue has 14 repeating elements in its R-domain explaining its larger size. The sensitivity of the R-domain to bacterial collagenase allowed us to isolate the NH2-terminal domain and show that the NH2 terminus was blocked by acetylation and, in the accompanying paper (Huflejt, M. E., Turck, C. W., Lindstedt, R., Barondes, S. H., and Leffler, H. (1993) J. Biol. Chem. 268, 26712-26718), that the NH2-terminal domain is phosphorylated. In addition, we unexpectedly found an endogenous component, resembling 92-kDa type IV collagenase, that co-purified with L-29 and slowly digested the R-domain. Hence, L-29 is a substrate for bacterial and tissue collagenases even though the R-domain is non-collagenous. Moreover, the co-purification suggests a non-enzymatic interaction between 92-kDa collagenase and L-29.	UNIV CALIF SAN FRANCISCO,LANGLEY PORTER NEUROPSYCHIAT INST,DEPT PSYCHIAT,BOX 0984,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Leffler, Hakon/A-2416-2019	Leffler, Hakon/0000-0003-4482-8945; Huflejt, Malgorzata/0000-0002-2016-8367	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038627] Funding Source: NIH RePORTER; NCRR NIH HHS [RRO1614] Funding Source: Medline; NHLBI NIH HHS [HL38627] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; BOND MD, 1984, BIOCHEMISTRY-US, V23, P3077, DOI 10.1021/bi00308a035; BRASSART D, 1992, EUR J BIOCHEM, V203, P393, DOI 10.1111/j.1432-1033.1992.tb16563.x; CERRA RF, 1985, J BIOL CHEM, V260, P10474; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; CLERCH LB, 1988, BIOCHEMISTRY-US, V27, P692, DOI 10.1021/bi00402a030; COLLIER IE, 1992, J BIOL CHEM, V267, P6776; CRITTENDEN SL, 1984, MOL CELL BIOL, V4, P1252, DOI 10.1128/MCB.4.7.1252; FALICK AM, 1989, ANAL BIOCHEM, V182, P165, DOI 10.1016/0003-2697(89)90736-7; FALICK AM, 1986, ANAL CHEM, V58, P1308, DOI 10.1021/ac00298a009; FISHER SJ, 1989, J CELL BIOL, V109, P891, DOI 10.1083/jcb.109.2.891; FLOTTE TJ, 1983, AM J PATHOL, V111, P112; FODDY L, 1990, J CELL SCI, V97, P139; FRENCH MF, 1992, J PROTEIN CHEM, V11, P83, DOI 10.1007/BF01025095; FRIGERI LG, 1992, J IMMUNOL, V148, P861; GRITZMACHER CA, 1992, BIOCHEMISTRY-US, V31, P9533, DOI 10.1021/bi00155a004; GROBELNY D, 1992, BIOCHEMISTRY-US, V31, P7152, DOI 10.1021/bi00146a017; HIRABAYASHI J, 1992, J BIOL CHEM, V267, P15485; HO MK, 1982, J IMMUNOL, V128, P1221; HSU DK, 1992, J BIOL CHEM, V267, P14167; HUFLEJT ME, 1993, J BIOL CHEM, V268, P26712; JIA SH, 1988, J BIOL CHEM, V263, P6009; LAING JG, 1989, J BIOL CHEM, V264, P1907; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; LINDSTEDT R, 1993, J BIOL CHEM, V268, P11750; LOTZ MM, 1993, P NATL ACAD SCI USA, V90, P3466, DOI 10.1073/pnas.90.8.3466; MASSA SM, 1993, BIOCHEMISTRY-US, V32, P260, DOI 10.1021/bi00052a033; MATSUSHIMA N, 1990, PROTEINS, V7, P125, DOI 10.1002/prot.340070204; MECHAM RP, 1989, J BIOL CHEM, V264, P16652; MEDZIHRADSZKY KF, 1992, EUR J BIOCHEM, V203, P327, DOI 10.1111/j.1432-1033.1992.tb16553.x; MOOKHTIAR KA, 1985, BIOCHEMISTRY-US, V27, P4299; MOUTSATSOS IK, 1986, J CELL BIOL, V102, P477, DOI 10.1083/jcb.102.2.477; NIBBERING PH, 1987, CELL IMMUNOL, V105, P374, DOI 10.1016/0008-8749(87)90085-2; ODA Y, 1993, J BIOL CHEM, V268, P5929; ODA Y, 1991, GENE, V99, P279; RAZ A, 1989, CANCER RES, V49, P3489; ROBERTSON MW, 1991, J IMMUNOL, V147, P3024; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; ROSE K, 1988, BIOCHEM J, V252, P191; ROSENBERG IM, 1993, J BIOL CHEM, V268, P12393; SAKAKURA Y, 1990, J BIOL CHEM, V265, P21573; Sambrook J, 1989, MOL CLONING LABORATO; SASTRY K, 1993, CURR OPIN IMMUNOL, V5, P59, DOI 10.1016/0952-7915(93)90082-4; SATO S, 1992, J BIOL CHEM, V267, P6983; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; THOLE JER, 1990, INFECT IMMUN, V58, P80, DOI 10.1128/IAI.58.1.80-87.1990; WALLS FC, 1990, BIOLOGICAL MASS SPECTROMETRY /, P197; WANG JL, 1992, BIOCHEM SOC T, V20, P269, DOI 10.1042/bst0200269; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOO HJ, 1990, J BIOL CHEM, V265, P7097; ZHANGKECK ZY, 1993, BIOCHEM J, V289, P735, DOI 10.1042/bj2890735	57	92	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26704	26711						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253805				2022-12-25	WOS:A1993MK42500101
J	LORENZ, RG; GORDON, JI				LORENZ, RG; GORDON, JI			USE OF TRANSGENIC MICE TO STUDY REGULATION OF GENE-EXPRESSION IN THE PARIETAL-CELL LINEAGE OF GASTRIC UNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING-PROTEIN; BETA-SUBUNIT GENE; SMALL INTESTINAL EPITHELIUM; HORMONE FUSION GENES; PEPSINOGEN-C GENE; INTRINSIC-FACTOR; DYNAMIC HISTOLOGY; ANTRAL EPITHELIUM; MOUSE STOMACH; ALPHA-SUBUNIT	The mechanisms that regulate cell lineage-specific and differentiation-dependent patterns of gene expression in the gastric units of the stomach are largely unknown. Transgenic mice were generated in order to identify cis-acting sequences that determine the zymogenic cell-specific pattern of expression of the mouse intrinsic factor (InF) gene and the parietal cell-specific pattern of expression of the mouse H+/K+-ATPase beta-subunit gene. Portions of the 5'-nontranscribed domains of each gene were linked to the human growth hormone (hGH) gene beginning at its nucleotide +3. RNA blot hybridization studies combined with multilabel immunocytochemical surveys using a panel of lineage-specific antibodies and lectins indicated that nucleotides -1035 to +24 of the mouse H+/K+-ATPase beta-subunit gene direct a pattern of reporter production which recapitulates the parietal cell-specific and developmental patterns of expression of the endogenous gene. Analysis of three mosaic founders containing H+/K+-ATPase beta-subunit -1035 to +24/hGH+3 revealed that they had monophenotypic gastric units: a given unit contained either a wholly hGH-positive or a wholly hGH-negative population of parietal cells. These latter findings provide very strong evidence that gastric units are monoclonal, i.e. they are supplied by stem cells having one genotype. Although some, but not all, parietal cells are apparently derived from the same committed progenitor as zymogenic cells, virtually all parietal cells in a given gastric unit, but none of its zymogenic cells, express InF-1029 to +55/hGH+3. This suggests that InF-1029 to +55 may contain cis-acting sequences which allow parietal cell expression in other species (e.g. humans) but lack additional elements which normally function in mice to suppress InF expression in this lineage. The absence of hGH in zymogenic cells also means that the transcriptional regulatory environments of parietal and zymogenic cells derived from the same precursor are distinguishable by InF-1029 to +55. H+/K-ATPase beta-subunit-1035 to +24 and InF-1029 to +55 are the only two sequences reported to date that are able to direct foreign gene expression exclusively to a gastric epithelial cell lineage in transgenic mice. This ability to deliver gene products to parietal cells can now be exploited to identify factors that control their normal proliferation and differentiation programs and/or to specifically alter their biological properties.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,BOX 8103,660 S EUCLID AVE,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Lorenz, Robin G/AAJ-1499-2021	Lorenz, Robin G/0000-0002-2514-9819	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK033487] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33487] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN RH, 1978, J CLIN INVEST, V61, P47, DOI 10.1172/JCI108924; CANFIELD VA, 1991, P NATL ACAD SCI USA, V88, P8247, DOI 10.1073/pnas.88.18.8247; CECI JD, 1991, ONCOGENE, V6, P323; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHWALINSKI S, 1988, CELL TISSUE KINET, V21, P317, DOI 10.1111/j.1365-2184.1988.tb00790.x; COHN SM, 1984, J BIOL CHEM, V259, P2456; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; COHN SM, 1991, P NATL ACAD SCI USA, V88, P1034, DOI 10.1073/pnas.88.3.1034; DAVIS BP, 1992, J BIOL CHEM, V267, P26070; DIECKGRAEFE BK, 1988, P NATL ACAD SCI USA, V85, P46, DOI 10.1073/pnas.85.1.46; FARLEY RA, 1985, J BIOL CHEM, V260, P3899; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HANLEY T, 1991, BIOTECHNIQUES, V10, P56; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; HAYANO T, 1988, J BIOL CHEM, V263, P1382; HERMISTON ML, 1992, J HISTOCHEM CYTOCHEM, V40, P1283, DOI 10.1177/40.9.1506665; HEWITT JE, 1991, GENOMICS, V10, P432, DOI 10.1016/0888-7543(91)90329-D; HOGAN BML, 1986, MANIPULATING MOUSE E, P171; ISHIHARA T, 1989, J BIOL CHEM, V264, P10193; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KAPADIA CR, 1983, J CLIN INVEST, V71, P440, DOI 10.1172/JCI110788; KARAM SM, 1993, ANAT RECORD, V236, P280, DOI 10.1002/ar.1092360203; KARAM SM, 1993, ANAT REC, V236, P314, DOI 10.1002/ar.1092360205; KARAM SM, 1993, ANAT REC, V236, P333, DOI 10.1002/ar.1092360206; KARAM SM, 1993, ANAT REC, V236, P297, DOI 10.1002/ar.1092360204; KARAM SM, 1993, ANAT REC, V236, P259, DOI 10.1002/ar.1092360202; LEE ER, 1985, AM J ANAT, V172, P205, DOI 10.1002/aja.1001720304; LEE ER, 1985, AM J ANAT, V172, P187, DOI 10.1002/aja.1001720303; LEE ER, 1982, AM J ANAT, V164, P187, DOI 10.1002/aja.1001640302; LEE ER, 1985, AM J ANAT, V172, P225, DOI 10.1002/aja.1001720305; LEE ER, 1985, AM J ANAT, V172, P241, DOI 10.1002/aja.1001720306; LEE EY, 1989, GASTROENTEROLOGY, V97, P1171, DOI 10.1016/0016-5085(89)91687-9; MAEDA M, 1991, J BIOL CHEM, V266, P21584; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MORLEY GP, 1992, J BIOL CHEM, V267, P1165; NEWMAN PR, 1991, GENOMICS, V11, P252, DOI 10.1016/0888-7543(91)90131-W; NEWMAN PR, 1990, DNA CELL BIOL, V9, P749, DOI 10.1089/dna.1990.9.749; OSHIMAN KI, 1991, FEBS LETT, V281, P250, DOI 10.1016/0014-5793(91)80404-Q; PILLER V, 1990, EUR J BIOCHEM, V191, P461, DOI 10.1111/j.1432-1033.1990.tb19144.x; ROTH KA, 1990, P NATL ACAD SCI USA, V87, P6408, DOI 10.1073/pnas.87.16.6408; ROTH KA, 1992, AM J PHYSIOL, V263, pG174, DOI 10.1152/ajpgi.1992.263.2.G174; ROTH KA, 1991, J BIOL CHEM, V266, P5949; ROTH KA, 1992, AM J PHYSIOL, V263, pG186, DOI 10.1152/ajpgi.1992.263.2.G186; ROTH KA, 1990, J CELL BIOL, V110, P1791, DOI 10.1083/jcb.110.5.1791; ROTH KA, 1991, P NATL ACAD SCI USA, V88, P9407, DOI 10.1073/pnas.88.21.9407; RUPP RAW, 1987, NUCLEIC ACIDS RES, V15, P9707, DOI 10.1093/nar/15.23.9707; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHENGRUND CL, 1989, J BIOL CHEM, V264, P13233; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SEETHARAM B, 1985, AM J PHYSIOL, V248, pG326, DOI 10.1152/ajpgi.1985.248.3.G326; SIMON TC, 1993, J BIOL CHEM, V268, P18345; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; TAMURA S, 1992, FEBS LETT, V298, P137, DOI 10.1016/0014-5793(92)80040-N; THOMPSON EM, 1990, DEVELOPMENT, V110, P477; TORRES BV, 1988, ARCH BIOCHEM BIOPHYS, V262, P1, DOI 10.1016/0003-9861(88)90161-0; WOOD C, 1978, ANN INST PASTEUR IMM, VC129, P143	59	62	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26559	26570						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253786				2022-12-25	WOS:A1993MK42500080
J	ONO, K; RADKE, GA; ROCHE, TE; RAHMATULLAH, M				ONO, K; RADKE, GA; ROCHE, TE; RAHMATULLAH, M			PARTIAL ACTIVATION OF THE PYRUVATE-DEHYDROGENASE KINASE BY THE LIPOYL DOMAIN REGION OF E2 AND INTERCHANGE OF THE KINASE BETWEEN LIPOYL DOMAIN REGIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROLIPOYL TRANSACETYLASE COMPONENT; PROTEIN-X COMPONENT; BOVINE KIDNEY; PHOSPHATASE-ACTIVITY; BINDING-SITES; COMPLEX; SUBUNIT; HEART; PURIFICATION; CORE	The binding of the pyruvate dehydrogenase (E1) component and the E1-specific kinase to the core-forming dihydrolipoyl acetyltransferase (E2) component facilitates a severalfold enhancement in the rate at which the kinase phosphorylates E1 (i.e. versus free kinase phosphorylating free E1). The kinase and E1 associate with small exterior linker region-connected domains in the E2 structure. The kinase binds to one of two lipoyl domains, and the E1 component binds to a domain in E2''s structure between the lipoyl domain region and the inner domain. Sixty of the latter domains assemble to form a dodecahedron-shaped inner core. Binding of the kinase to a detached lipoyl domain region enhanced kinase activity. This bi-lipoyl domain fragment induced a 2-fold enhancement in the slow rate of phosphorylation of peptide substrate and intact E260 gave only a 50% higher rate. In contrast, the lipoyl domain fragment gave only a 40% enhancement in the faster rate of phosphorylation of E1; whereas the rate of phosphorylation of E1 was markedly increased (4-10-fold depending on conditions) by kinase interaction with the intact E2 core. Binding of E1 to an E2 structure lacking only the bi-lipoyl domain region did not enhance kinase activity. Thus, binding of the kinase to the lipoyl domain region elicits a structural change which enhances kinase activity; however, other processes are required to explain the very large enhancement in phosphorylation of E1 effected by intact E2 core. Among the latter is a need for a mechanism allowing one kinase molecule to phosphorylate many E1 tetramers, whereas both E1 and the kinase stay bound to the oligomeric E2 core (i.e. phosphorylation appears to be much faster than the dissociation of either the kinase or E1 tetramers from E260 core). Exposure of kinase bound to the lipoyl domain fragment to intact E2 core for 10 s allowed a transition to a maximal (7-fold) activation of the kinase. In the opposite direction, an increasing level of the free bi-lipoyl domain fragment rapidly reduced, in a concentration-dependent manner, the activity of kinase bound initially to intact E2. The data strongly support kinase transfer between free lipoyl domains and the intact E2 core and fit about a 12-fold tighter binding of the kinase to intact E2 cores over binding to free lipoyl domains. Such an interchange of the kinase between these E2 structures was confirmed by sucrose gradient studies. Our results are consistent with movement of the tightly bound kinase between lipoyl domains and suggest the possibility of rapid movement by direct kinase transfer (i.e. without an intermediate step of kinase dissociation).	KANSAS STATE UNIV AGR & APPL SCI, DEPT BIOCHEM, 104 WILLARD HALL, MANHATTAN, KS 66506 USA	Kansas State University					NIDDK NIH HHS [DK18320] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK018320, R01DK018320] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLEILE DM, 1981, J BIOL CHEM, V256, P514; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P2958, DOI 10.1021/bi00281a027; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P2966, DOI 10.1021/bi00281a028; CATE RL, 1978, J BIOL CHEM, V253, P496; CATE RL, 1980, J BIOL CHEM, V255, P7556; DAVIS PF, 1977, BIOCHEM BIOPH RES CO, V75, P541, DOI 10.1016/0006-291X(77)91506-6; GOPALAKRISHNAN S, 1989, BIOCHEM BIOPH RES CO, V160, P715, DOI 10.1016/0006-291X(89)92492-3; GORMAN JJ, 1984, ANAL BIOCHEM, V136, P397, DOI 10.1016/0003-2697(84)90235-5; HO L, 1989, P NATL ACAD SCI USA, V86, P5330, DOI 10.1073/pnas.86.14.5330; HUCHO F, 1972, Archives of Biochemistry and Biophysics, V151, P328, DOI 10.1016/0003-9861(72)90504-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JE, 1991, BIOCHEMISTRY-US, V30, P2834, DOI 10.1021/bi00225a015; LI L, 1992, ARCH BIOCHEM BIOPHYS, V296, P497, DOI 10.1016/0003-9861(92)90603-T; LINN TC, 1972, ARCH BIOCHEM BIOPHYS, V148, P327, DOI 10.1016/0003-9861(72)90151-8; LIU S, 1992, FASEB J, V6, pA460; LIU S, 1993, FASEB J, V7, pA1239; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PETTIT FH, 1975, BIOCHEM BIOPH RES CO, V65, P575, DOI 10.1016/S0006-291X(75)80185-9; PETTIT FH, 1972, BIOCHEM BIOPH RES CO, V49, P563, DOI 10.1016/0006-291X(72)90448-2; POWERSGREENWOOD SL, 1989, J BIOL CHEM, V264, P3655; RADKE GA, 1993, BIOCHEM BIOPH RES CO, V190, P982, DOI 10.1006/bbrc.1993.1146; RAHMATULLAH M, 1986, J BIOL CHEM, V261, P6515; RAHMATULLAH M, 1990, J BIOL CHEM, V265, P14512; RAHMATULLAH M, 1988, J BIOL CHEM, V263, P8106; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P1245; RAHMATULLAH M, 1985, J BIOL CHEM, V260, P146; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P2221; RAHMATULLAH M, 1987, J BIOL CHEM, V262, P10265; ROCHE TE, 1993, BIOCHEMISTRY-US, V32, P5629, DOI 10.1021/bi00072a019; ROCHE TE, 1976, BIOCHEM BIOPH RES CO, V72, P1375, DOI 10.1016/S0006-291X(76)80166-0; ROCHE TE, 1989, ANN NY ACAD SCI, V573, P168, DOI 10.1111/j.1749-6632.1989.tb14994.x; ROCHE TE, 1977, ARCH BIOCHEM BIOPHYS, V183, P664, DOI 10.1016/0003-9861(77)90400-3; SCHMITZ KS, 1972, J PHYS CHEM-US, V76, P534, DOI 10.1021/j100648a015; STEPP LR, 1983, J BIOL CHEM, V258, P9454; WAGENKNECHT T, 1991, J BIOL CHEM, V266, P24650; WU TL, 1984, BIOCHEMISTRY-US, V23, P221, DOI 10.1021/bi00297a008; YEAMAN SJ, 1978, BIOCHEMISTRY-US, V17, P2364, DOI 10.1021/bi00605a017	38	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26135	26143						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253731				2022-12-25	WOS:A1993MK42500022
J	SARIBANSOHRABY, S; FISHER, RS; ABRAMOW, M				SARIBANSOHRABY, S; FISHER, RS; ABRAMOW, M			ALDOSTERONE-INDUCED AND GTP-STIMULATED METHYLATION OF A 90-KDA POLYPEPTIDE IN THE APICAL MEMBRANE OF A(6) EPITHELIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE SODIUM-CHANNEL; NA+ CHANNEL; CELL-LINE; AMILORIDE; TRANSPORT; PROTEIN; A6; SUBUNIT; CARBOXYL; MINERALOCORTICOIDS	Aldosterone treatment of A6 cultured renal epithelial cells methylates the apical membrane, and we examined the aldosterone-induced carboxymethylation of the apical membrane of these cells to determine the targeted polypeptides. Methionine-deprived A6 cells were incubated with aldosterone and [H-3]methionine. Homogenates and apical membranes were solubilized and analyzed by SDS-polyacrylamide gel electrophoresis. Label incorporation in a 90-kDa polypeptide was more intense (4-fold) in membranes after aldosterone compared to control. For in vitro methylation, membranes were isolated, incubated with S-adenosyl-L-[methyl-H-3]methionine, and analyzed for H-3-methyl uptake. Label incorporation was low in control membranes but markedly stimulated (4-fold) in membrane preparations from aldosterone-treated cells. Guanosine 5'-O-(3-thiotriphosphate) increased in vitro methylation of a 90-kDa polypeptide 5-fold in control membranes but after aldosterone, where methylation was already stimulated, little change was observed. We conclude that aldosterone induces methylation of an apical membrane 90-kDa polypeptide, possibly a subunit of the epithelial Na+ channel, in a GTP-dependent manner, and this may be one of the final steps in a cascade of reactions leading to the natriferic action of this hormone.	WALTER REED ARMY INST RES, DEPT NEPHROL, WASHINGTON, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	SARIBANSOHRABY, S (corresponding author), UNIV LIBRE BRUXELLES, PHYSIOPATHOL LAB, BAT E24107, 808 ROUTE LENNIK, B-1070 BRUSSELS, BELGIUM.							AUSIELLO DA, 1992, J BIOL CHEM, V267, P4759; BACKLUND PS, 1988, J BIOL CHEM, V263, P15864; BARBRY P, 1990, BIOCHEMISTRY-US, V29, P1039, DOI 10.1021/bi00456a028; BEAUWENS R, 1990, BASIC PRINCIPLES TRA, P1; BENOS DJ, 1987, J BIOL CHEM, V262, P10613; BENOS DJ, 1986, P NATL ACAD SCI USA, V83, P8525, DOI 10.1073/pnas.83.22.8525; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CANTIELLO HF, 1989, J BIOL CHEM, V264, P20867; CHELSKY D, 1985, BIOCHEMISTRY-US, V24, P6651, DOI 10.1021/bi00344a053; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; CRABBE J, 1961, J CLIN INVEST, V40, P2103, DOI 10.1172/JCI104436; ECKSTEIN F, 1979, J BIOL CHEM, V254, P9829; GARTY H, 1983, J GEN PHYSIOL, V81, P785, DOI 10.1085/jgp.81.6.785; GARTY H, 1989, AM J PHYSIOL, V256, pF965, DOI 10.1152/ajprenal.1989.256.5.F965; GOODMAN DBP, 1975, BIOCHEMISTRY-US, V14, P2803, DOI 10.1021/bi00684a003; HANDLER JS, 1981, AM J PHYSIOL, V240, pC103, DOI 10.1152/ajpcell.1981.240.3.C103; HIRATA F, 1980, SCIENCE, V209, P1082, DOI 10.1126/science.6157192; KEMENDY A, 1990, FASEB Journal, V4, pA445; KEMENDY AE, 1992, AM J PHYSIOL, V263, pC825, DOI 10.1152/ajpcell.1992.263.4.C825; KIPNOWSKI J, 1983, AM J PHYSIOL, V245, pF726, DOI 10.1152/ajprenal.1983.245.6.F726; KLEYMAN TR, 1991, J BIOL CHEM, V266, P3907; KLEYMAN TR, 1986, J BIOL CHEM, V261, P2839; KLEYMAN TR, 1989, J BIOL CHEM, V264, P11995; KOSHLAND DE, 1981, ANNU REV BIOCHEM, V50, P765, DOI 10.1146/annurev.bi.50.070181.004001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LUDENS JH, 1978, J MEMBRANE BIOL, V40, P199, DOI 10.1007/BF02026006; PALMER LG, 1982, J MEMBRANE BIOL, V64, P91, DOI 10.1007/BF01870771; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PORTER GA, 1968, MOL PHARMACOL, V4, P224; ROSSIER BC, 1989, CURR TOP MEMBR TRANS, V34, P167; SARIBANSOHRABY S, 1984, SCIENCE, V225, P745, DOI 10.1126/science.6463652; SARIBANSOHRABY S, 1992, AM J PHYSIOL, V263, pC1111, DOI 10.1152/ajpcell.1992.263.5.C1111; SARIBANSOHRABY S, 1988, J BIOL CHEM, V263, P13875; SARIBANSOHRABY S, 1984, J BIOL CHEM, V259, P1221; SCHAFER JA, 1992, KIDNEY INT, V41, P255, DOI 10.1038/ki.1992.37; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; TOUSSON A, 1989, J CELL SCI, V93, P349; WIESMANN WP, 1985, AM J PHYSIOL, V248, pF43, DOI 10.1152/ajprenal.1985.248.1.F43; YAMANE HK, 1993, ANNU REV PHARMACOL, V33, P201, DOI 10.1146/annurev.pharmtox.33.1.201; YORIO T, 1978, NATURE, V271, P79, DOI 10.1038/271079a0	42	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26613	26617						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253792				2022-12-25	WOS:A1993MK42500087
J	ALONIGRINSTEIN, R; ZANBAR, I; ALBOUM, I; GOLDFINGER, N; ROTTER, V				ALONIGRINSTEIN, R; ZANBAR, I; ALBOUM, I; GOLDFINGER, N; ROTTER, V			WILD-TYPE P53 FUNCTIONS AS A CONTROL PROTEIN IN THE DIFFERENTIATION PATHWAY OF THE B-CELL LINEAGE	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; MOUSE CELLS; TRANSCRIPTIONAL ACTIVATION; ATAXIA-TELANGIECTASIA; BURKITT-LYMPHOMA; CYCLE CONTROL; REGION GENES; MUTATIONS; EXPRESSION; MUTANT	An analysis of cell lines representing different stages of the B-cell differentiation pathway indicated that about 50% of the cell lines examined expressed exclusively wild type p53 protein. These lines therefore offer a convenient system to study the involvement of p53 in cell differentiation. When 70Z/3, a pre-B cell line which expresses wild type p53, was treated with the differentiation inducer lipopolysaccharide (LPS), it was seen that increased levels of p53 mRNA preceded specific changes in kappa (kappa) immunoglobulin expression. This increased expression of kappa specific mRNA, which was evaluated by specific PCR analysis, was blocked following transfection with mutant p53 coding plasmids. Treatment of 13A60, another cell line which endogenously expresses wild type p53, with LPS caused a secretion of IgA antibodies, also accompanied by increased p53 mRNA expression. The conclusion was that induction of B-cell differentiation involves the transcription of the p53 gene. This was further substantiated by experiments showing that differentiation of stable clones derived from the 70Z/3 cell line, harboring a p53-promoter-CAT plasmid, induced increased CAT activity. Furthermore, wild type p53 transactivated the promoter control sequences of the kappa light chain gene. Taken together, these results suggest that p53 is involved in B-cell differentiation, a pathway which involves DNA rearrangements that may be accompanied by generation of faulty DNA. The fact that wild type p53 was shown to function as a transcriptional factor, coupled with the notion that it is associated with DNA repair systems, may designate p53 as a control protein in the B-cell differentiation pathway.	TEL AVIV UNIV,SACKLER FAC MED,DEPT HUMAN MICROBIOL,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine	ROTTER, V (corresponding author), WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL.			Aloni-Grinstein, Ronit/0000-0003-1695-5576				AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; BOYD AW, 1981, J IMMUNOL, V126, P2461; CHENG J, 1992, CANCER RES, V52, P222; CORALIA IR, 1992, BLOOD, V79, P1982; DEPPERT W, 1990, ONCOGENE, V5, P1701; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; FENAUX P, 1992, LEUKEMIA, V6, P42; FENAUX P, 1992, BRIT J HAEMATOL, V80, P178, DOI 10.1111/j.1365-2141.1992.tb08897.x; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRITSCHE M, 1993, ONCOGENE, V8, P307; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1990, ONCOGENE, V5, P1285; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALL PA, 1993, ONCOGENE, V8, P203; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HECHT F, 1990, CANCER GENET CYTOGEN, V46, P9, DOI 10.1016/0165-4608(90)90003-S; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1991, CANCER RES, V51, P4279; KELMAN Z, 1989, BLOOD, V74, P2318; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7492; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEBOEUF RD, 1989, GENE, V82, P371, DOI 10.1016/0378-1119(89)90065-6; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MORA PT, 1980, NATURE, V288, P722, DOI 10.1038/288722a0; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5683; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAIGE CJ, 1978, J IMMUNOL, V121, P641; PERRY RP, 1979, CELL, V18, P1333, DOI 10.1016/0092-8674(79)90243-5; PORAT Y, 1993, BIOCH BIOPHYSICAL RE, V194, P391; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; Rotter Varda, 1993, Trends in Cell Biology, V3, P46, DOI 10.1016/0962-8924(93)90151-P; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; SANTO H, 1973, J EXP MED, V138, P593; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SORIANO P, 1991, CELL, V64, P639; STAVNEZER J, 1988, P NATL ACAD SCI USA, V85, P7704, DOI 10.1073/pnas.85.20.7704; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WIMAN KG, 1991, ONCOGENE, V6, P1633; WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	76	83	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3297	3305						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247532				2022-12-25	WOS:A1993MG78200013
J	HAYMAN, AR; COX, TM				HAYMAN, AR; COX, TM			PURPLE ACID-PHOSPHATASE OF THE HUMAN MACROPHAGE AND OSTEOCLAST - CHARACTERIZATION, MOLECULAR-PROPERTIES, AND CRYSTALLIZATION OF THE RECOMBINANT DI-IRON-OXO PROTEIN SECRETED BY BACULOVIRUS-INFECTED INSECT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOSINUS-TRICHOSPORIUM OB3B; BONE-RESORPTION; PORCINE UTEROFERRIN; METHANE MONOOXYGENASE; FREE-RADICALS; GENE-CLUSTER; SEQUENCE; EXPRESSION; CLONING; SPLEEN	The purple phosphatases catalyze hydrolysis of phosphate esters (optimum pH approximately 5) and are resistant to inhibition by dextro-rotatory tartrate; their distinctive, color is due to Fe(III)-phenolate charge-transfer transitions at their active site. Expression of human purple phosphatase, designated type 5 acid phosphatase, is restricted to osteoclasts and other activated cells of monohistiocytic lineage, but its biological role in relation to bone resorption and phagocytosis is unknown. To characterize this enzyme further, we have engineered the human type 5 acid phosphatase into a baculovirus vector expression system that enabled milligram quantities of purple protein to be purified from medium containing Sf9 host cells. The phosphatase cDNA was transcribed as a single RNA species of 1.5 kilobases as in human tissues. Tartrate-resistant acid phosphatase activity reacting with uteroferrin antisera appeared in the culture medium, from which up to 8 mg/liter was purified by two-step cation-exchange chromatography at pH 8.0. Two isoforms of approximately 36 kDa were identified by SDS-polyacrylamide electrophoresis and were converted to a single species of apparent molecular size 34 kDa upon treatment with N-glycosidase F, indicating secreted glycoforms of a single polypeptide. Mass spectroscopy showed that the mean molecular mass of the active, secreted glycoprotein was 35849 Da. The recombinant enzyme (specific activity, 190 mumol p-nitrophenol/min/mg at 37-degrees-C) contained 2 iron atoms/molecule and formed purple, monoclinic crystals. Exposure to the ferric chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, rapidly inactivated the enzyme, which was not inhibited by alpha,alpha'-bipyridyl, a ferrous chelator. That ferric iron is essential for enzymatic catalysis, was further indicated by the synergistic effects of the reductant, dithiothreitol, and bipyridyl on phosphatase activity. The recombinant purple phosphatase catalyzed the peroxidation of 5-aminophthalhydrazide (luminol), as evidenced by the induction of chemiluminescence; this reaction was inhibited by alpha,alpha'-bipyridyl at concentrations that did not inhibit phosphatase activity. The divalent iron moiety of human type 5 phosphatase may therefore participate in the generation of free radical species by fluid-phase reactions involving Fenton chemistry that are dissociated from its phosphatase function.	UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT MED, LEVEL 5, CAMBRIDGE CB2 2QQ, ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANTANAITIS B, 1983, STRUCTURE FUNCTION I, P503; ANTANAITIS BC, 1980, J BIOL CHEM, V255, P1204; ANTANAITIS BC, 1983, J BIOL CHEM, V258, P3166; ANTANAITIS BC, 1983, ADV INORG BIOCHEM, V5, P111; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BAUMBACH GA, 1984, P NATL ACAD SCI-BIOL, V81, P2985, DOI 10.1073/pnas.81.10.2985; BAX BE, 1992, BIOCHEM BIOPH RES CO, V183, P1153, DOI 10.1016/S0006-291X(05)80311-0; BECK JL, 1986, BIOCHIM BIOPHYS ACTA, V869, P61, DOI 10.1016/0167-4838(86)90310-9; BEVILACQUA MA, 1991, MOL BIOL MED, V8, P135; BOLDT DH, 1992, BLOOD, V80, pA182; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTONE MS, 1959, J HISTOCHEM CYTOCHEM, V7, P39, DOI 10.1177/7.1.39; CARDY DLN, 1991, MOL MICROBIOL, V5, P335, DOI 10.1111/j.1365-2958.1991.tb02114.x; CASSADY AI, 1993, IN PRESS GENE; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOY FYM, 1985, AM J MED GENET, V21, P519, DOI 10.1002/ajmg.1320210315; DAVIS JC, 1982, P NATL ACAD SCI-BIOL, V79, P4623, DOI 10.1073/pnas.79.15.4623; ECHETEBU ZO, 1987, CLIN CHEM, V33, P1832; FOX BG, 1990, BIOCHEMISTRY-US, V29, P6419, DOI 10.1021/bi00479a013; FOX BG, 1993, P NATL ACAD SCI USA, V90, P2486, DOI 10.1073/pnas.90.6.2486; GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485; GIGNAC SM, 1990, LEUKEMIA LYMPHOMA, V3, P19, DOI 10.3109/10428199009050971; GRIMES R, 1993, GENOMICS, V15, P421, DOI 10.1006/geno.1993.1079; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HAYMAN AR, 1989, BIOCHEM J, V261, P601, DOI 10.1042/bj2610601; HENLEY R, 1991, ARCH BIOCHEM BIOPHYS, V286, P238, DOI 10.1016/0003-9861(91)90035-H; JOHNSTON RB, 1978, J EXP MED, V148, P115; KETCHAM CM, 1989, J BIOL CHEM, V264, P557; KETCHAM CM, 1985, J BIOL CHEM, V260, P5768; KEY LL, 1990, BONE, V11, P115, DOI 10.1016/8756-3282(90)90058-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDERS JW, 1958, AM J CLIN PATHOL, V29, P590; LAU KHW, 1987, CLIN CHEM, V33, P458; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LI CY, 1970, J HISTOCHEM CYTOCHEM, V18, P901, DOI 10.1177/18.12.901; LORD DK, 1990, EUR J BIOCHEM, V189, P287, DOI 10.1111/j.1432-1033.1990.tb15488.x; Maniatis T, 1989, MOL CLONING; MCPHAIL LC, 1979, J CLIN INVEST, V63, P648, DOI 10.1172/JCI109347; McPherson A, 1982, PREPARATION ANAL PRO; MILLER SC, 1985, CALCIFIED TISSUE INT, V37, P526, DOI 10.1007/BF02557836; MOONGA BS, 1990, J PHYSIOL-LONDON, V429, P29, DOI 10.1113/jphysiol.1990.sp018242; MURRAY HW, 1980, J INVEST DERMATOL, V74, P285, DOI 10.1111/1523-1747.ep12543457; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; NORDLUND I, 1990, J BACTERIOL, V172, P6826, DOI 10.1128/jb.172.12.6826-6833.1990; OSDOBY P, 1987, BIOESSAYS, V7, P30, DOI 10.1002/bies.950070107; QUE L, 1990, PROG INORG CHEM, V38, P97; QUE L, 1988, ACS SYM SER, V372, P152; ROBERTS RM, 1986, FED PROC, V45, P2513; ROBERTS RM, 1984, BIOESSAYS, V1, P8, DOI 10.1002/bies.950010106; ROBINSON DB, 1980, CLIN CHEM, V26, P371; SCHINDELMEISER J, 1987, HISTOCHEMISTRY, V87, P13, DOI 10.1007/BF00518719; SCHLOSNAGLE DC, 1976, J BIOL CHEM, V251, P4680; SJOBERG BM, 1982, BIOCHEMISTRY-US, V21, P96; STENKAMP RE, 1981, NATURE, V291, P263, DOI 10.1038/291263a0; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; VINCENT JB, 1990, FEBS LETT, V263, P265, DOI 10.1016/0014-5793(90)81389-6; WHITAKER KB, 1989, CLIN CHEM, V35, P86; YAM LT, 1974, AM J MED, V56, P604, DOI 10.1016/0002-9343(74)90630-5; YAM LT, 1972, ARCH INTERN MED, V130, P248, DOI 10.1001/archinte.130.2.248; YEN KM, 1991, J BACTERIOL, V173, P5315, DOI 10.1128/jb.173.17.5315-5327.1991	61	119	127	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1294	1300						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288593				2022-12-25	WOS:A1994MR22000083
J	ISHII, K; CHEN, J; ISHII, M; KOCH, WJ; FREEDMAN, NJ; LEFKOWITZ, RJ; COUGHLIN, SR				ISHII, K; CHEN, J; ISHII, M; KOCH, WJ; FREEDMAN, NJ; LEFKOWITZ, RJ; COUGHLIN, SR			INHIBITION OF THROMBIN RECEPTOR SIGNALING BY A G-PROTEIN COUPLED RECEPTOR KINASE - FUNCTIONAL SPECIFICITY AMONG G-PROTEIN COUPLED RECEPTOR KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; RAT-BRAIN; 3T3 CELLS; FAMILY; ACTIVATION; PEPTIDES; CLONING; DESENSITIZATION; PURIFICATION; EXPRESSION	The thrombin receptor, a member of the seven membrane-spanning superfamily of G-protein coupled receptors, is activated by an irreversible proteolytic mechanism, but signaling by activated thrombin receptors shuts off soon after receptor activation. This shut-off mechanism is thought to be required for concentration-dependent responses to thrombin and an important determinant of the cell's sensitivity to thrombin. We report that the thrombin receptor is rapidly phosphorylated upon activation, consistent with the action of a G-protein-coupled receptor kinase. Moreover, the G-protein coupled receptor kinase BARK2 (beta-adrenergic receptor kinase 2) blocked signaling by thrombin receptors coexpressed in Xenopus oocytes. In this system, rhodopsin kinase was inactive and BARK1 was markedly less effective than BARK2. Thrombin receptor mutants which lacked potential serine and threonine phosphorylation sites in the receptor's cytoplasmic tail were insensitive to inhibition by exogenous BARK2 but did confer concentration-dependent responses to thrombin. Our studies demonstrate that a G-protein coupled receptor kinase can shut off thrombin receptor signaling but that additional mechanism(s) for terminating signaling exist. These studies also reveal functional specificity among G-protein coupled receptor kinases in a novel in vivo reconstitution system and show that heterologous expression of these kinases can be used to manipulate cellular responsiveness.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; DUKE UNIV,SCH MED,HOWARD HUGHES MED INST,DURHAM,NC 27706	University of California System; University of California San Francisco; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043821, R01HL016037, R01HL044907, R37HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43821, HL16037, HL44907] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; ARRIZA JL, 1992, J BIOL CHEM, V267, P1422; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HUGH DT, 1992, J CLIN INVEST, V89, P1350; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; ISHII K, 1993, J BIOL CHEM, V268, P9780; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LANZA F, 1991, J BIOL CHEM, V266, P10638; LIU LW, 1991, J BIOL CHEM, V266, P16977; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WALZ DA, 1986, ANN NY ACAD SCI, V485	34	224	228	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1125	1130						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288570				2022-12-25	WOS:A1994MR22000056
J	KHARBANDA, S; SALEEM, A; EMOTO, Y; STONE, R; RAPP, U; KUFE, D				KHARBANDA, S; SALEEM, A; EMOTO, Y; STONE, R; RAPP, U; KUFE, D			ACTIVATION OF RAF-1 AND MITOGEN-ACTIVATED PROTEIN-KINASES DURING MONOCYTIC DIFFERENTIATION OF HUMAN MYELOID-LEUKEMIA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TUMOR NECROSIS FACTOR; C-JUN EXPRESSION; GROWTH-FACTOR; OKADAIC ACID; MAP KINASE; GENE-EXPRESSION; FOS GENE; MOLECULAR-CLONING; INDUCTION	Treatment of human myeloid leukemia cells with 12-O-tetradecanoylphorbol-13-acetate (TPA), an activator of protein kinase C (PKC), is associated with induction of monocytic differentiation. Since PKC can act immediately upstream to the cytoplasmic Raf-1 serine/threonine protein kinase, we studied activation of Raf-1 during induction of the differentiated monocytic phenotype. The results demonstrate that Raf-1 is activated during TPA-induced monocytic differentiation of HL-60 cells. In contrast, there was little effect of TPA on this kinase in an HL-60 variant, designated HL-525, which is resistant to TPA-induced differentiation. Treatment of both HL-60 and HL-525 cells with okadaic acid, an inhibitor of serine/threonine protein phosphatases 1 and 2A, was associated with Raf-1 activation and induction of the monocytic phenotype. Since Raf-1 can activate the mitogen-activated protein (MAP) kinases, we also studied the relationship between MAP kinase activation and monocytic differentiation. Treatment of HL-60, but not HL-525, cells with TPA was associated with increased MAP kinase activity as determined by phosphorylation of myelin basic protein and the c-Jun Y peptide. Okadaic acid-induced differentiation of both HL-60 and HL-525 cells was similarly accompanied by increases in MAP kinase activity. These findings indicated that activation of Raf-1/MAP kinase signaling is associated with induction of a differentiated monocytic phenotype and that okadaic acid by-passes a defect in this cascade in TPA-treated HL-525 cells. While recent studies have shown that HL-525 cells are deficient in PKCbeta, the present results demonstrate that PKCbeta expression is up-regulated in the HL-525 variant by treatment with retinoic acid. The results also demonstrate that retinoic acid-treated HL-525 cells respond to TPA with activation of Raf-1 and MAP kinase, as well as induction of monocytic differentiation. Taken together, the results indicate that activation of Raf-1/MAP kinase signaling is associated with monocytic differentiation and that stimulation of serine/threonine protein phosphorylation by TPA or okadaic acid is sufficient for reversal of the leukemic HL-60 phenotype.	NCI,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	KHARBANDA, S (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,CLIN PHARMACOL LAB,BOSTON,MA 02115, USA.				NCI NIH HHS [CA42802] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042802] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COLLINS SJ, 1987, BLOOD, V70, P1233; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUNYAH SE, 1992, J CELL PHYSL, V151, P415; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GROSSO LE, 1985, CANCER RES, V45, P847; GUNJI H, 1992, J CLIN INVEST, V89, P954, DOI 10.1172/JCI115677; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIDAKA H, 1988, J BIOL CHEM, V263, P4523; HOMMA Y, 1986, P NATL ACAD SCI USA, V83, P7316, DOI 10.1073/pnas.83.19.7316; HORIGUCHI J, 1986, BIOCHEM BIOPH RES CO, V141, P924, DOI 10.1016/S0006-291X(86)80131-0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUBERMAN E, 1979, P NATL ACAD SCI USA, V76, P1293, DOI 10.1073/pnas.76.3.1293; KHARBANDA S, 1993, CELL GROWTH DIFFER, V4, P17; KHARBANDA S, 1992, CELL GROWTH DIFFER, V3, P391; KHARBANDA S, 1991, J CLIN INVEST, V88, P571, DOI 10.1172/JCI115341; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LOTEM J, 1979, P NATL ACAD SCI USA, V76, P5158, DOI 10.1073/pnas.76.10.5158; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; NAKAMURA T, 1991, CELL GROWTH DIFFER, V2, P267; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PANTAZIS P, 1986, P NATL ACAD SCI USA, V83, P6455, DOI 10.1073/pnas.83.17.6455; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAPP UR, 1991, ONCOGENE, V6, P495; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; ROVERA G, 1982, ANN NY ACAD SCI, V397, P211, DOI 10.1111/j.1749-6632.1982.tb43428.x; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; SOZERI O, 1992, ONCOGENE, V7, P2259; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; TONETTI DA, 1992, CELL GROWTH DIFFER, V3, P739; WANG AM, 1985, SCIENCE, V228, P149, DOI 10.1126/science.3856324; WILLIAM F, 1990, J BIOL CHEM, V265, P18166; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU BY, 1989, J BIOL CHEM, V264, P9000	56	114	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					872	878						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288641				2022-12-25	WOS:A1994MR22000019
J	RUSCH, SL; KENDALL, DA				RUSCH, SL; KENDALL, DA			TRANSPORT OF AN EXPORT-DEFECTIVE PROTEIN BY A HIGHLY HYDROPHOBIC SIGNAL PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID RESIDUES; COLI MEMBRANE-VESICLES; PROTON MOTIVE FORCE; ESCHERICHIA-COLI; INVITRO TRANSLOCATION; PRECURSOR PROTEINS; SECRETORY PROTEINS; POSITIVE CHARGE; INNER MEMBRANE; MATURE DOMAIN	We have examined the sequence constraints on the amino-terminal region of the mature portion of alkaline phosphatase that are important for its efficient transport in Escherichia coli. Using a homopolymeric sequence of serines to replace 6 residues in this region, a transport-incompetent mutant was produced. Reintroduction of residues from the native sequence which restore charge and beta-turn potential resulted in little improvement. However, by replacing the hydrophobic core of the signal peptide with a homopolymeric series of leucines, not only was transport restored but precursor processing was more efficient than for the wild type and was insensitive to disruption of the protonmotive force. Moreover, we have titrated the signal peptide with leucine to alanine substitutions (Doud, S. K., Chou, M. M., and Kendall, D. A. (1993) Bioehemistry 32,1251-1256) and determined the minimum level of hydrophobicity necessary to achieve transport of the mutant protein. The results indicate that signal peptide hydrophobicity can completely override possible requirements for negatively charged residues and strong beta-turn forming potential in the mature protein and that the polyleucine-containing signal peptide may act as a generic signal sequence for the transport of non-native proteins in E. coli.	UNIV CONNECTICUT,DEPT MOLEC & CELL BIOL,BOX U-44,STORRS,CT 06269	University of Connecticut					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037639] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37639] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON H, 1991, P NATL ACAD SCI USA, V88, P9751, DOI 10.1073/pnas.88.21.9751; ANDERSSON H, 1992, J BIOL CHEM, V267, P1491; BASSILANA M, 1992, J BIOL CHEM, V267, P25246; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; CHOU MM, 1990, J BIOL CHEM, V265, P2873; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DANIELS CJ, 1981, P NATL ACAD SCI-BIOL, V78, P5396, DOI 10.1073/pnas.78.9.5396; DOUD SK, 1993, BIOCHEMISTRY-US, V32, P1251, DOI 10.1021/bi00056a008; DRIESSEN AJM, 1991, P NATL ACAD SCI USA, V88, P2471, DOI 10.1073/pnas.88.6.2471; DUFFAUD G, 1988, J BIOL CHEM, V263, P10224; ENEQUIST HG, 1981, EUR J BIOCHEM, V116, P227, DOI 10.1111/j.1432-1033.1981.tb05323.x; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FERENCI T, 1987, J BACTERIOL, V169, P5339, DOI 10.1128/jb.169.12.5339-5342.1987; GELLER BL, 1986, P NATL ACAD SCI USA, V83, P4219, DOI 10.1073/pnas.83.12.4219; GENNITY J, 1990, J BIOENERG BIOMEMBR, V22, P223; GOLDSTEIN J, 1990, J BACTERIOL, V172, P1225, DOI 10.1128/jb.172.3.1225-1231.1990; HIKITA C, 1992, J BIOL CHEM, V267, P12375; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; INOUYE S, 1982, P NATL ACAD SCI-BIOL, V79, P3438, DOI 10.1073/pnas.79.11.3438; INOUYE S, 1986, J BIOL CHEM, V261, P970; KADONAGA JT, 1984, J BIOL CHEM, V259, P2149; KATO M, 1992, J BIOL CHEM, V267, P413; KENDALL DA, 1988, J BIOL CHEM, V263, P7261; KENDALL DA, 1986, NATURE, V321, P706, DOI 10.1038/321706a0; KUHN A, 1985, J BIOL CHEM, V260, P5914; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFORET GA, 1991, J BIOL CHEM, V266, P1326; LI P, 1988, P NATL ACAD SCI USA, V85, P7685, DOI 10.1073/pnas.85.20.7685; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LISS LR, 1985, J BACTERIOL, V164, P925, DOI 10.1128/JB.164.2.925-928.1985; MACINTYRE S, 1990, MOL GEN GENET, V221, P466; MCKNIGHT CJ, 1991, P NATL ACAD SCI USA, V88, P5799, DOI 10.1073/pnas.88.13.5799; Miller J.H., 1972, EXPT MOL GENETICS; MORENO F, 1980, NATURE, V286, P356, DOI 10.1038/286356a0; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PUZISS JW, 1989, J BACTERIOL, V171, P2303, DOI 10.1128/jb.171.5.2303-2311.1989; RANDALL LL, 1987, ANNU REV MICROBIOL, V41, P507; RASMUSSEN BA, 1987, GENE DEV, V1, P185, DOI 10.1101/gad.1.2.185; ROSENBLATT M, 1980, P NATL ACAD SCI-BIOL, V77, P3983, DOI 10.1073/pnas.77.7.3983; RUSSEL M, 1982, CELL, V28, P177, DOI 10.1016/0092-8674(82)90387-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHULDINER S, 1975, BIOCHEMISTRY-US, V14, P5451, DOI 10.1021/bi00696a011; SUMMERS RG, 1989, J BIOL CHEM, V264, P20074; SUMMERS RG, 1989, J BIOL CHEM, V264, P20082; SUNG CY, 1992, J BIOL CHEM, V267, P997; TOMMASSEN J, 1985, EMBO J, V4, P1041, DOI 10.1002/j.1460-2075.1985.tb03736.x; VLASUK GP, 1984, J BIOL CHEM, V259, P6195; VLASUK GP, 1983, J BIOL CHEM, V258, P7141; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; VONHEIJNE G, 1986, J MOL BIOL, V192, P287, DOI 10.1016/0022-2836(86)90365-7; YAMADA H, 1989, J BIOL CHEM, V264, P18577; YAMANE K, 1988, J BIOL CHEM, V263, P19690; YAMANE K, 1987, J BIOL CHEM, V262, P2358	56	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1243	1248						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288586				2022-12-25	WOS:A1994MR22000075
J	AVIEZER, D; LEVY, E; SAFRAN, M; SVAHN, C; BUDDECKE, E; SCHMIDT, A; DAVID, G; VLODAVSKY, I; YAYON, A				AVIEZER, D; LEVY, E; SAFRAN, M; SVAHN, C; BUDDECKE, E; SCHMIDT, A; DAVID, G; VLODAVSKY, I; YAYON, A			DIFFERENTIAL STRUCTURAL REQUIREMENTS OF HEPARIN AND HEPARAN-SULFATE PROTEOGLYCANS THAT PROMOTE BINDING OF BASIC FIBROBLAST GROWTH-FACTOR TO ITS RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBENDOTHELIAL EXTRACELLULAR-MATRIX; SMOOTH-MUSCLE CELLS; DIMETHYL-SULFOXIDE; MOLECULAR-SIZE; SURFACE; GLYCOSAMINOGLYCANS; DEGRADATION; SEQUENCE; RELEASE; PROLIFERATION	Heparan sulfate proteoglycans (HSPG) are obligatory for receptor binding and mitogenic activity of basic fibroblast growth factor (bFGF). The capacity of various species of heparin and heparan sulfate (HS) to promote bFGF receptor binding was investigated using both Chinese hamster ovary mutant cells deficient in cell surface HSPG and a soluble bFGF receptor-alkaline phosphatase fusion protein. Highly sulfated oligosaccharides were more effective than medium and low sulfate fractions of the same size oligosaccharide. O-Sulfation in heparin was found to be critical for its capacity to promote binding of bFGF to its receptors. The highest level of bFGF-receptor binding was achieved in the presence of over-sulfated heparin fragments (% sulfur >14) regardless of whether the N-position was sulfated or acetylated. Unlike receptor binding of bFGF which requires oligosaccharides containing at least 8-10 sugar units, displacement of heparin- or HS-bound bFGF was obtained by oligosaccharides containing as little as four sugar units and by an N-sulfated, O-desulfated heparin fragment (% sulfur = 5.3). A preparation of total cell surface-derived HS induced bFGF receptor binding. A preliminary survey of several defined and affinity purified species of cell surface HSPG, including syndecan, fibroglycan, and glypican failed to identify natural HSPG that promote high affinity receptor binding of bFGF. A similar lack of activity was observed with species of HS isolated from bovine arterial tissue and characterized for their effect on vascular smooth muscle cell proliferation. Moreover, most of these species of HS inhibited in a dose-dependent manner the restoration of bFGF-receptor binding induced by heparin or by total HSPG. These results suggest the involvement of defined heparin-like oligosaccharide sequences and unique species of cell surface and extracellular matrix HS in the regulation of bFGF receptor binding and biological activity.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; KABI PHARM,R&D CARDIOVASC,S-11287 STOCKHOLM,SWEDEN; HADASSAH HEBREW UNIV HOSP,DEPT ONCOL,IL-91120 JERUSALEM,ISRAEL; UNIV MUNSTER,INST ARTERIOSCLEROSIS RES,W-4400 MUNSTER,GERMANY; CTR HUMAN GENET,B-3000 LOUVAIN,BELGIUM	Weizmann Institute of Science; Hebrew University of Jerusalem; Hadassah University Medical Center; University of Munster								BARNER M, 1987, BLOOD, V70, P551; BASHKIN P, 1992, J CELL PHYSIOL, V151, P126, DOI 10.1002/jcp.1041510117; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BENEZRA M, 1993, IN PRESS BLOOD, V81; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BERNFIELD M, 1991, ANN NY ACAD SCI, V638, P182, DOI 10.1111/j.1749-6632.1991.tb49029.x; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CARDONCARDO C, 1990, LAB INVEST, V63, P832; CASTELLOT JJ, 1986, J CELL BIOL, V102, P1979, DOI 10.1083/jcb.102.5.1979; DAVID G, 1993, IN PRESS J CELL BIOL; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GOSPODAROWICZ D, 1976, P NATL ACAD SCI USA, V73, P4120, DOI 10.1073/pnas.73.11.4120; GOSPODAROWICZ D, 1977, EXP EYE RES, V25, P75, DOI 10.1016/0014-4835(77)90248-2; GOSPODAROWICZ D, 1978, J BIOL CHEM, V253, P3736; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLLMANN J, 1989, ARTERIOSCLEROSIS, V9, P154, DOI 10.1161/01.ATV.9.2.154; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; ISHAIMICHAELI R, 1992, CELL REGUL, V31, P2080; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Lindahl U., 1989, HEPARIN, P159; LLOYD AG, 1971, BIOCHEM PHARMACOL, V20, P637, DOI 10.1016/0006-2952(71)90150-X; LORIES V, 1989, J BIOL CHEM, V264, P7009; LORTAT-JACOB H, 1991, J CLIN INVEST, V87, P878, DOI 10.1172/JCI115093; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; NADER HB, 1987, P NATL ACAD SCI USA, V84, P3565, DOI 10.1073/pnas.84.11.3565; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; OGAMO A, 1985, BIOCHIM BIOPHYS ACTA, V841, P30; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHMIDT A, 1988, EXP CELL RES, V178, P242, DOI 10.1016/0014-4827(88)90395-3; SCHMIDT A, 1992, J BIOL CHEM, V267, P19242; SUDHALTER J, 1989, J BIOL CHEM, V264, P6892; THUNBERG L, 1980, FEBS LETT, V117, P203, DOI 10.1016/0014-5793(80)80945-8; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; VLODAVSKY I, 1993, BASEMENT MEMBRANES C, P463; VOLKIN DB, 1993, ARCH BIOCHEM BIOPHYS, V300, P30, DOI 10.1006/abbi.1993.1005; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	53	238	247	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					114	121						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276782				2022-12-25	WOS:A1994MR21900025
J	BARROW, RT; HEALEY, JF; LOLLAR, P				BARROW, RT; HEALEY, JF; LOLLAR, P			INHIBITION BY HEPARIN OF THROMBIN-CATALYZED ACTIVATION OF THE FACTOR-VIII VON-WILLEBRAND-FACTOR COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; HUMAN ALPHA-THROMBIN; ANTITHROMBIN-III; VONWILLEBRAND-FACTOR; FACTOR-XA; PROTEASE INACTIVATION; PROCOAGULANT ACTIVITY; TRANSIENT KINETICS; A1/A3-C1-C2 DIMER; SUBUNIT STRUCTURE	The activation of factor VIII (fVIII) by thrombin is associated with heavy chain cleavages at Arg372 and Arg740 and light chain cleavage at Arg1689. In a defined, plasma-free assay of fVIII activation and at physiological ionic strength and pH, heparin inhibited the rate of activation of either human or porcine fVIII by thrombin in either the presence or absence of von Willebrand factor (vWf). The inhibitory effect of heparin was associated with inhibition of all three thrombin-catalyzed bond cleavages. At plasma concentrations of fVIII (almost-equal-to 1 nM) and vWf (almost-equal-to 35 nM), the rate of fVIII activation was inhibited by 50% at approximately 0.1 unit/ml heparin, which is below the normal range of heparin concentrations in plasma during therapeutic anticoagulation (0.2-0.7 unit/ml). We propose that, in addition to catalyzing the inhibition of thrombin and other intrinsic pathway coagulation proteases by antithrombin, heparin functions as an anticoagulant by direct inhibition of the activation of the fVIII-vWf complex by thrombin.	EMORY UNIV, DEPT MED, DIV HEMATOL ONCOL, ATLANTA, GA 30322 USA	Emory University					NHLBI NIH HHS [R01 HL40921] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040921] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABILDGAARD U, 1968, SCAND J CLIN LAB INV, V21, P89, DOI 10.3109/00365516809076981; ALY AM, 1992, J CLIN INVEST, V89, P1382, DOI 10.1172/JCI115726; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BARUCH D, 1986, HAEMOSTASIS, V16, P71; BEGUIN S, 1988, THROMB HAEMOSTASIS, V60, P457; BJORK I, 1989, HEPARIN CHEM BIOL PR, P229; BODE W, 1992, THROMBIN STRUCTURE F, P3; Brinkhous KM, 1939, AM J PHYSIOL, V125, P683, DOI 10.1152/ajplegacy.1939.125.4.683; BROWN JE, 1980, THROMB RES, V17, P267, DOI 10.1016/0049-3848(80)90314-X; CHOPEK MW, 1986, BIOCHEMISTRY-US, V25, P3146, DOI 10.1021/bi00359a012; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FENTON JW, 1989, ANN NY ACAD SCI, V556, P158; FENTON JW, 1977, J BIOL CHEM, V252, P3587; GRIFFITH MJ, 1979, ARCH BIOCHEM BIOPHYS, V195, P378, DOI 10.1016/0003-9861(79)90363-1; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; HEMKER HC, 1990, HAEMOSTASIS, V20, P81; HILLEUBANKS DC, 1990, J BIOL CHEM, V265, P17854; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; HOYLAERTS M, 1984, J BIOL CHEM, V259, P5670; HULTIN MB, 1981, BLOOD, V57, P476; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1988, BLOOD, V71, P137; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; LOLLAR P, 1987, J BIOL CHEM, V262, P17572; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MIHALYI E, 1968, BIOCHEMISTRY-US, V7, P208, DOI 10.1021/bi00841a026; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NESHEIM M, 1986, J BIOL CHEM, V261, P3214; NESHEIM ME, 1983, J BIOL CHEM, V258, P4708; OBRIEN DP, 1990, BLOOD, V75, P1664; OFOSU F, 1980, THROMB RES, V20, P391, DOI 10.1016/0049-3848(80)90278-9; OFOSU FA, 1989, BIOCHEM J, V257, P143, DOI 10.1042/bj2570143; OFOSU FA, 1991, HAEMOSTASIS, V21, P240; OLSON ST, 1986, J BIOL CHEM, V261, P3151; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON TA, 1986, ANN NY ACAD SCI, V485, P96, DOI 10.1111/j.1749-6632.1986.tb34571.x; OWEN WG, 1977, BIOCHIM BIOPHYS ACTA, V494, P182, DOI 10.1016/0005-2795(77)90146-5; PIETERS J, 1989, BLOOD, V74, P1021; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; POMERANTZ MW, 1978, BIOCHIM BIOPHYS ACTA, V535, P66, DOI 10.1016/0005-2795(78)90033-8; Roden L., 1989, HEPARIN CHEM BIOL PR, P1; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; STONE SR, 1987, EUR J BIOCHEM, V169, P373, DOI 10.1111/j.1432-1033.1987.tb13622.x; STRAUGHN W, 1966, THROMB DIATH HAEMOST, V16, P198, DOI 10.1055/s-0038-1655637; TOLLEFSEN DM, 1989, HEPARIN CHEM BIOL PR, P257; VANPUTTEN J, 1982, CLIN CHIM ACTA, V122, P261, DOI 10.1016/0009-8981(82)90285-6; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V585, P405, DOI 10.1016/0304-4165(79)90085-0; YIN ET, 1970, BIOCHIM BIOPHYS ACTA, V201, P387, DOI 10.1016/0304-4165(70)90316-8	62	24	25	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					593	598						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276857				2022-12-25	WOS:A1994MR21900094
J	THELEN, MP; ONEL, K; HOLLOMAN, WK				THELEN, MP; ONEL, K; HOLLOMAN, WK			THE REC1 GENE OF USTILAGO-MAYDIS INVOLVED IN THE CELLULAR-RESPONSE TO DNA-DAMAGE ENCODES AN EXONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; ESCHERICHIA-COLI; EDITING EXONUCLEASE; 3'-5' EXONUCLEASE; KLENOW FRAGMENT; ACTIVE-SITE; AMINO-ACID; RECOMBINATION; SEQUENCE; ALIGNMENT	Mutation in the REC1 gene of Ustilago maydis is known to lead to a complex phenotype with alterations in DNA repair, recombination, mutagenesis, meiosis, and cell division. The predicted product of the REC1 gene is a polypeptide of 522 amino acid residues with a molecular mass of 56,866 daltons, with no overall sequence homology to any other known protein. The open reading frame of the REC1 gene placed by itself in a U. maydis expression vector was found to be sufficient to complement the rec1 mutant. Overexpression of REC1 in Escherichia coli gave rise to the anticipated 57-kDa product together with a 3'-->5' exonuclease activity. This activity was only present in cells overexpressing REC1 and its characteristics were distinguishable from the major bacterial nucleases, but it had certain enzymatic features in common with epsilon, the proofreading exonuclease subunit of E. coli DNA polymerase III holoenzyme. To facilitate isolation of the protein product from bacteria, the REC1 gene was overexpressed from a vector that fused a hexa-histidine-leader sequence onto the amino terminus, enabling the isolation of the HisREC1 product on an immobilized metal ion affinity column. The HisREC1 protein co-eluted with the novel exonuclease activity. Alignment of the amino acid sequence of the REC1 gene product with the conserved proofreading exonuclease motifs of DNA polymerases indicated significant homology.	CORNELL UNIV,MED CTR,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021	Cornell University			Thelen, Michael/C-6834-2008; Thelen, Michael P/G-2032-2014	Thelen, Michael/0000-0002-2479-5480; Thelen, Michael P/0000-0002-2479-5480	NIGMS NIH HHS [GM42482] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042482] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BLANCO L, 1992, GENE, V112, P139, DOI 10.1016/0378-1119(92)90316-H; BRENOWITZ S, 1991, J BIOL CHEM, V266, P7888; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CARTER DM, 1971, J BIOL CHEM, V246, P2502; CHASE JW, 1974, J BIOL CHEM, V249, P4545; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; ECHOLS H, 1983, P NATL ACAD SCI-BIOL, V80, P2189, DOI 10.1073/pnas.80.8.2189; FOTHERINGHAM S, 1990, GENETICS, V124, P833; FOTHERINGHAM S, 1989, MOL CELL BIOL, V9, P4052, DOI 10.1128/MCB.9.9.4052; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; FRIEDBERG EC, 1991, MOL CELLULAR BIOL YE, V1, P147; GRIEP MA, 1990, BIOCHEMISTRY-US, V29, P9006, DOI 10.1021/bi00490a018; GUPTA AP, 1984, NUCLEIC ACIDS RES, V12, P5897, DOI 10.1093/nar/12.14.5897; Haynes R.H., 1981, MOL BIOL YEAST SACCH, P371; HOLDEN DW, 1989, EMBO J, V8, P1927, DOI 10.1002/j.1460-2075.1989.tb03596.x; HOLDEN DW, 1991, CURR GENET, V20, P145, DOI 10.1007/BF00312777; HOLEN DW, 1989, NUCLEIC ACIDS RES, V17, P10489; HOLLIDAY R, 1965, MUTAT RES, V2, P557, DOI 10.1016/0027-5107(65)90022-9; HOLLIDAY R, 1976, GENET RES, V27, P413, DOI 10.1017/S0016672300016621; HOLLIDAY R, 1967, MUTAT RES, V4, P275, DOI 10.1016/0027-5107(67)90022-X; HOLLIDAY R, 1977, PHILOS T R SOC B, V277, P359, DOI 10.1098/rstb.1977.0024; HOLLOMAN WK, 1981, J BIOL CHEM, V56, P5087; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; LEHMAN IR, 1962, J BIOL CHEM, V237, P819; LEHMAN IR, 1964, J BIOL CHEM, V239, P2628; MARTINEZ HM, 1988, NUCLEIC ACIDS RES, V16, P1683, DOI 10.1093/nar/16.5.1683; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PORATH J, 1992, PROTEIN EXPRES PURIF, V3, P263, DOI 10.1016/1046-5928(92)90001-D; PUTNEY SD, 1981, P NATL ACAD SCI-BIOL, V78, P7350, DOI 10.1073/pnas.78.12.7350; RICHARDSON CC, 1964, J BIOL CHEM, V239, P251; SCHAAPER RM, 1989, GENETICS, V121, P205; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAKANO K, 1986, MOL GEN GENET, V205, P9, DOI 10.1007/BF02428026; THELEN M, 1992, J CEL LBIOCH SB, V16, P39; THOMPSON PR, 1992, THESIS AUSTR NATIONA, P99; TONEGUZZO F, 1988, BIOTECHNIQUES, V6, P460; TSUKUDA T, 1989, GENE, V85, P335, DOI 10.1016/0378-1119(89)90426-5; TSUKUDA T, 1988, MOL CELL BIOL, V8, P3703, DOI 10.1128/MCB.8.9.3703; UNRAU P, 1975, MUTAT RES, V29, P53, DOI 10.1016/0027-5107(75)90020-2; VANDESAN.JH, 1973, BIOCHEMISTRY-US, V12, P5050, DOI 10.1021/bi00749a004; WANG J, 1988, P NATL ACAD SCI USA, V85, P865, DOI 10.1073/pnas.85.3.865; WRIGHT M, 1971, J BIOL CHEM, V246, P6543	49	55	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					747	754						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276878				2022-12-25	WOS:A1994MR21900117
J	ZUTTER, MM; SANTORO, SA; PAINTER, AS; TSUNG, YL; GAFFORD, A				ZUTTER, MM; SANTORO, SA; PAINTER, AS; TSUNG, YL; GAFFORD, A			THE HUMAN ALPHA-2-INTEGRIN GENE PROMOTER - IDENTIFICATION OF POSITIVE AND NEGATIVE REGULATORY ELEMENTS IMPORTANT FOR CELL-TYPE AND DEVELOPMENTALLY RESTRICTED GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN RECEPTOR; MEGAKARYOCYTIC DIFFERENTIATION; FIBRONECTIN RECEPTOR; LAMININ RECEPTOR; MAMMALIAN-CELLS; GAMMA-GLOBIN; DNA; BINDING; SURFACE; VLA-2	The alpha2beta1 integrin serves as a collagen receptor or a collagen/laminin receptor, depending upon cell type. Expression of the integrin is regulated during normal cellular differentiation and is altered during carcinogenesis. We have previously demonstrated that increased expression of the alpha2beta1 integrin during megakaryocytic differentiation is a consequence of increased alpha2 mRNA due to transcriptional activation of the alpha2 integrin gene and that the decreased expression of the integrin in breast adenocarcinoma is due to decreased steady-state levels of alpha2 mRNA. We now report the identification and characterization of the 5'-flanking region of the alpha2 integrin gene. The 5'-untranslated region of the alpha2 mRNA extends 129 base pairs 5' to the site of translation initiation. The promoter region lacks TATA and CAAT boxes but contains an abbreviated initiator sequence and six Sp1 binding sites. Consensus binding sites for AP-1 and AP-2 complexes, a GATA box, a Pu.1 box, and two palindromic motifs with potential to bind the estrogen receptor are also present. A 961-base pair fragment of the 5'-flanking region directs both cell type- and differentiation-specific expression of a reporter gene in T47-D epithelial cells and in pluripotent hematopoietic K562 cells upon megakaryocytic differentiation.	WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	ZUTTER, MM (corresponding author), WASHINGTON UNIV, SCH MED, DEPT PATHOL, BOX 8118, 660 S EUCLID, ST LOUIS, MO 63110 USA.							ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AGURA ED, 1992, BLOOD, V79, P602; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; BRUTLAG DL, 1980, ANNU REV GENET, V14, P121, DOI 10.1146/annurev.ge.14.120180.001005; BURGER SR, 1992, EXP CELL RES, V202, P28, DOI 10.1016/0014-4827(92)90400-3; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHEN HM, 1993, J BIOL CHEM, V268, P8230; COLLER BS, 1989, BLOOD, V74, P182; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DUBAND JL, 1986, J CELL BIOL, V102, P160, DOI 10.1083/jcb.102.1.160; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMADA H, 1982, NATURE, V298, P396, DOI 10.1038/298396a0; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HICKSTEIN DD, 1992, P NATL ACAD SCI USA, V89, P2105, DOI 10.1073/pnas.89.6.2105; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LEARY JF, 1987, LEUKEMIA RES, V11, P807, DOI 10.1016/0145-2126(87)90065-8; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; NGUYEN VT, 1988, ANAL BIOCHEM, V171, P404, DOI 10.1016/0003-2697(88)90505-2; NISHIOKA Y, 1980, J BIOL CHEM, V255, P3691; Orkin SH, 1990, CURR OPIN CELL BIOL, V2, P1003, DOI 10.1016/0955-0674(90)90149-9; PRANDINI MH, 1988, BIOCHEM BIOPH RES CO, V156, P595, DOI 10.1016/S0006-291X(88)80884-2; PRANDINI MH, 1992, J BIOL CHEM, V267, P10370; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; ROY RJ, 1992, NUCLEIC ACIDS RES, V20, P401, DOI 10.1093/nar/20.3.401; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO SA, 1988, BIOCHEM BIOPH RES CO, V153, P217, DOI 10.1016/S0006-291X(88)81211-7; SLIGHTOM JL, 1980, CELL, V21, P627, DOI 10.1016/0092-8674(80)90426-2; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPANOPOULOU E, 1991, MOL CELL BIOL, V11, P2216, DOI 10.1128/MCB.11.4.2216; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TARANTINO MD, 1992, BLOOD, V80, pA127; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; ULRICH MJ, 1990, BLOOD, V75, P990; UZAN G, 1991, J BIOL CHEM, V266, P8932; YE RD, 1987, J BIOL CHEM, V262, P3718; ZUTTER MM, 1990, AM J PATHOL, V137, P113; ZUTTER MM, 1992, J BIOL CHEM, V267, P20233; ZUTTER MM, 1990, AM J PATHOL, V137, P863	55	105	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					463	469						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276836				2022-12-25	WOS:A1994MR21900077
J	EGNER, R; THUMM, M; STRAUB, M; SIMEON, A; SCHULLER, HJ; WOLF, DH				EGNER, R; THUMM, M; STRAUB, M; SIMEON, A; SCHULLER, HJ; WOLF, DH			TRACING INTRACELLULAR PROTEOLYTIC PATHWAYS - PROTEOLYSIS OF FATTY-ACID SYNTHASE AND OTHER CYTOPLASMIC PROTEINS IN THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-INDUCED PROTEOLYSIS; MULTIFUNCTIONAL PROTEINASE; CATABOLITE INACTIVATION; METABOLIC CONDITIONS; INVIVO FUNCTION; GENETIC-CONTROL; CELL-SURVIVAL; SYNTHETASE; DEGRADATION; ENZYME	Yeast fatty acid synthase consists of two independent polypeptide strains, alpha and beta. The functional multienzyme complex, composed of six alpha- and six beta-subunits, is rather stable against proteolysis in vivo. Mutations in one of the subunits or deletion of one subunit lead to degradation of the nonmutated remaining fatty acid synthase protein. We show that the unassembled alpha-subunit of this enzyme is short-lived, and degradation depends on the presence of active cytoplasmic proteinase yscE, the yeast proteasome. The unassembled beta-subunit is degraded by a nonvacuolar proteolytic system under vegetative growth conditions. However, starvation of a vacuolar proteinase mutant strain, which lacks the alpha-subunit of fatty acid synthase, leads to appearance of the unassembled beta-subunit in isolated vacuoles. This indicates that the major vacuolar peptidases proteinase yscA and yscB are at least partly involved in degradation of the beta-subunit of fatty acid synthase. In a proteinase yscA and yscB double mutant strain wild type for fatty acid synthase both subunits of fatty acid synthase, alpha and beta, are detectable in vacuoles. In addition, under the same starvation conditions other cytoplasmic proteins are found in the vacuole of a proteinase yscA and yscB double mutant strain. The experiments in conjunction with the previous finding of the appearance of vesicles in vacuoles of starved cells (Simeon, A., van der Klei, I. J., Veenhuis, M., and Wolf, D. H. (1992) FEBS Lett. 301, 231-235) indicate that transport of these tested cytoplasmic proteins into the vacuole is an unselective bulk process induced by nutritional stress.	UNIV STUTTGART,INST BIOCHEM,PFAFFENWALDRING 55,D-70569 STUTTGART,GERMANY; UNIV ERLANGEN NURNBERG,INST MIKROBIOL & BIOCHEM,LEHRSTUHL BIOCHEM,W-8520 ERLANGEN,GERMANY	University of Stuttgart; University of Erlangen Nuremberg			Thumm, Michael/A-8033-2015	Thumm, Michael/0000-0003-3238-4857				ACHSTETTER T, 1984, J BIOL CHEM, V259, P3344; Achstetter T, 1985, Yeast, V1, P139, DOI 10.1002/yea.320010203; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BECK J, 1987, FAT SCI TECHNOL, V89, P570; BETZ H, 1976, EUR J BIOCHEM, V62, P65, DOI 10.1111/j.1432-1033.1976.tb10098.x; BURKL G, 1972, MOL GEN GENET, V119, P315, DOI 10.1007/BF00272089; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; FUNAYAMA S, 1980, EUR J BIOCHEM, V109, P61, DOI 10.1111/j.1432-1033.1980.tb04767.x; HACKENJOS WA, 1987, BIOL CHEM H-S, V368, P19, DOI 10.1515/bchm3.1987.368.1.19; HANSEN RJ, 1977, BIOCHIM BIOPHYS ACTA, V496, P103, DOI 10.1016/0304-4165(77)90119-2; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HEMMINGS BA, 1981, P NATL ACAD SCI-BIOL, V78, P435, DOI 10.1073/pnas.78.1.435; HILT W, 1993, J BIOL CHEM, V268, P3479; HILT W, 1992, MOL MICROBIOL, V6, P2437; HIRSCH HH, 1992, EUR J BIOCHEM, V207, P867, DOI 10.1111/j.1432-1033.1992.tb17118.x; Hirsch HH., 1989, MOL CELL BIOL YEASTS, P134; HOLZER H, 1976, TRENDS BIOCHEM SCI, V1, P178, DOI 10.1016/S0968-0004(76)80018-7; JONES EW, 1991, J BIOL CHEM, V266, P7963; JONES EW, 1982, GENETICS, V102, P665; KATO N, 1979, BIOCHIM BIOPHYS ACTA, V566, P1, DOI 10.1016/0005-2744(79)90242-0; KLEINSCHMIDT JA, 1988, FEBS LETT, V239, P35, DOI 10.1016/0014-5793(88)80540-4; KOBAYASHI R, 1989, ANAL BIOCHEM, V183, P9, DOI 10.1016/0003-2697(89)90162-0; KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZ S, 1979, BIOCHEM J, V178, P769, DOI 10.1042/bj1780769; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNEN F, 1980, EUR J BIOCHEM, V112, P431; LYNEN F, 1969, METHOD ENZYMOL, V14, P17; MECHLER B, 1987, EMBO J, V6, P2157, DOI 10.1002/j.1460-2075.1987.tb02483.x; MEYER KH, 1976, EUR J BIOCHEM, V65, P317, DOI 10.1111/j.1432-1033.1976.tb10344.x; MOHAMED AH, 1988, J BIOL CHEM, V263, P12315; MULLER M, 1981, J BIOL CHEM, V256, P723; MULLER M, 1981, J BIOL CHEM, V256, P1962; PEREA J, 1982, ARCH MICROBIOL, V132, P141, DOI 10.1007/BF00508719; PRINGLE JR, 1990, METHOD ENZYMOL, V194, P565; RENDUELES PS, 1988, FEMS MICROBIOL LETT, V54, P17; RICHTERRUOFF B, 1992, FEBS LETT, V302, P192, DOI 10.1016/0014-5793(92)80438-M; SCHULLER HJ, 1992, EUR J BIOCHEM, V203, P607, DOI 10.1111/j.1432-1033.1992.tb16590.x; SCHULLER HJ, 1992, EMBO J, V11, P107, DOI 10.1002/j.1460-2075.1992.tb05033.x; SCHWEIZER E, 1978, MOL CELL BIOCHEM, V21, P95; SCHWEIZER E, 1987, FETT WISS TECHNOL, V89, P570; SCHWEIZER M, 1986, BIOCHEM SOC T, V14, P572, DOI 10.1042/bst0140572; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SIMEON A, 1992, FEBS LETT, V301, P231, DOI 10.1016/0014-5793(92)81254-J; SPORMANN DO, 1991, EUR J BIOCHEM, V197, P399, DOI 10.1111/j.1432-1033.1991.tb15924.x; TAGESHIGE K, 1992, J CELL BIOL, V119, P301; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERWILDEN M, 1973, Z NATURFORSCH, V280, P416; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WIEMKEN A, 1979, ARCH MICROBIOL, V123, P23, DOI 10.1007/BF00403499; WOOLFORD CA, 1993, J BIOL CHEM, V268, P8990; YOSHIHISA T, 1988, J BIOL CHEM, V263, P5158; YOSHIHISA T, 1993, J BIOL CHEM, V268, P8990	56	74	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27269	27276						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262967				2022-12-25	WOS:A1993MM26200063
J	SHIMIZU, K; SANTOCANALE, C; ROPP, PA; LONGHESE, MP; PLEVANI, P; LUCCHINI, G; SUGINO, A				SHIMIZU, K; SANTOCANALE, C; ROPP, PA; LONGHESE, MP; PLEVANI, P; LUCCHINI, G; SUGINO, A			PURIFICATION AND CHARACTERIZATION OF A NEW DNA-POLYMERASE FROM BUDDING YEAST SACCHAROMYCES-CEREVISIAE - A PROBABLE HOMOLOG OF MAMMALIAN DNA-POLYMERASE BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; CDC2 GENE; CLONING; SUBUNIT; TRANSFORMATION; REPLICATION; EXPRESSION; MUTATIONS; DELTA	A new DNA polymerase activity was identified and purified to near homogeneity from extracts of mitotic and meiotic cells of the yeast Saccharomyces cerevisiae. This activity increased at least 5-fold during meiosis, and it was shown to be associated with a 68-kDa polypeptide as determined by SDS-polyacrylamide gel electrophoresis. This new DNA polymerase did not have any detectable 3' --> 5' exonuclease activity and preferred small gapped DNA as a template-primer. The activity was inhibited by dideoxyribonucleoside 5'-triphosphates and N-ethylmaleimide but not by concentrations of aphidicolin which completely inhibit either DNA polymerases I (alpha), II (epsilon), or III (delta). Since no polypeptide(s) in the extensively purified DNA polymerase fractions cross-reacted with antibodies raised against yeast DNA polymerases I, II, and III, we called this enzyme DNA polymerase IV. The DNA polymerase IV activity increased at least 10-fold in a yeast strain overexpressing the gene product predicted from the YCR14C open-reading frame (identified on S. cerevisiae chromosome III and provisionally called POLX), while no activity was detected in a strain where POLX was deleted. These results strongly suggest that DNA polymerase IV is encoded by the POLX gene and is a probable homolog of mammalian DNA polymerase beta.	NIEHS,MOLEC GENET LAB,RES TRIANGLE PK,NC 27709; UNIV MILAN,DIPARTIMENTO GENET & BIOL MICROORGANISMI,I-20133 MILAN,ITALY; OSAKA UNIV,MICROBIAL DIS RES INST,DEPT MOLEC IMMUNOL,SUITA,OSAKA 565,JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Milan; Osaka University			Pia, Maria/AAK-2693-2020	Santocanale, Corrado/0000-0003-1337-5656; Longhese, Maria Pia/0000-0003-1726-2034; PLEVANI, PAOLO/0000-0003-1869-2626				ARAKI H, 1991, NUCLEIC ACIDS RES, V19, P4867, DOI 10.1093/nar/19.18.4867; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARAKI H, 1991, P NATL ACAD SCI USA, V88, P4601, DOI 10.1073/pnas.88.11.4601; BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BAUER GA, 1988, J BIOL CHEM, V263, P917; BORK P, 1992, PROTEIN SCI, V1, P1677, DOI 10.1002/pro.5560011216; BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; BUDD M, 1987, P NATL ACAD SCI USA, V84, P2838, DOI 10.1073/pnas.84.9.2838; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; BURGERS PMJ, 1988, NUCLEIC ACIDS RES, V16, P6297, DOI 10.1093/nar/16.14.6297; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; CHANG LMS, 1977, J BIOL CHEM, V252, P1873; CHANG LMS, 1982, P NATL ACAD SCI-BIOL, V79, P758, DOI 10.1073/pnas.79.3.758; FABRE F, 1991, MOL GEN GENET, V229, P353, DOI 10.1007/BF00267455; FOURY F, 1989, J BIOL CHEM, V264, P20552; FRANCESCONI S, 1991, P NATL ACAD SCI USA, V88, P3877, DOI 10.1073/pnas.88.9.3877; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; HIROSE F, 1989, EXP CELL RES, V181, P169, DOI 10.1016/0014-4827(89)90191-2; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON LM, 1985, CELL, V43, P369, DOI 10.1016/0092-8674(85)90042-X; LUCCHINI G, 1987, EMBO J, V6, P737, DOI 10.1002/j.1460-2075.1987.tb04815.x; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; MORRISON A, 1993, PROG NUCLEIC ACID RE, V46, P93, DOI 10.1016/S0079-6603(08)61019-3; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PLEVANI P, 1984, J BIOL CHEM, V259, P7534; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1983, METHOD ENZYMOL, V101, P201; Sambrook J, 1989, MOL CLONING LABORATO; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SITNEY KC, 1989, CELL, V56, P599, DOI 10.1016/0092-8674(89)90582-5; SUGINO A, 1988, P NATL ACAD SCI USA, V85, P3683, DOI 10.1073/pnas.85.11.3683; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; ZMUDZKA BZ, 1986, P NATL ACAD SCI USA, V83, P5106, DOI 10.1073/pnas.83.14.5106	36	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27148	27153						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262953				2022-12-25	WOS:A1993MM26200047
J	SOULA, M; ROTHHUT, B; CAMOIN, L; GUILLAUME, JL; STROSBERG, D; VORHERR, T; BURN, P; MEGGIO, F; FISCHER, S; FAGARD, R				SOULA, M; ROTHHUT, B; CAMOIN, L; GUILLAUME, JL; STROSBERG, D; VORHERR, T; BURN, P; MEGGIO, F; FISCHER, S; FAGARD, R			ANTI-CD3 AND PHORBOL ESTER INDUCE DISTINCT PHOSPHORYLATED SITES IN THE SH2 DOMAIN OF P56(LCK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN-KINASE-C; HUMAN LYMPHOCYTES-T; TYROSINE KINASE; SIGNAL TRANSDUCTION; ACTIVATION; P56LCK; COMPLEX; STIMULATION; CD4	p56lck is a protein tyrosine kinase of the Src family specifically expressed in T lymphocytes. Triggering of T cells with anti-CD3 or with phorbol 12-myristate 13-acetate (PMA) results in the appearance of slower migrating forms (shift) of p56lck. To investigate the phosphorylation sites on the shifted forms of p56lck and to assess the role of protein kinase C in this phosphorylation, Jurkat cells were treated with a selective inhibitor of this kinase (GF 109203X). This inhibitor completely reversed the shift induced by PMA but only partially reversed the one induced after triggering with anti-CD3. To analyze the shift further, p56lck was immunoprecipitated from in vivo labeled cells treated either with anti-CD3 or with PMA. Tryptic phosphopeptides were generated and analyzed by using a combination of thin layer chromatography, high reticulation polyacrylamide gel electrophoresis, reverse phase chromatography, and phosphopeptide sequencing. We identified serine 158 as a newly phosphorylated site after PMA treatment and tyrosine 192 and serine 194 in the major tryptic phosphopeptide obtained after anti-CD3 triggering. The three sites identified are located in the SH2 domain of p56lck; this suggests that their phosphorylation may regulate the interaction with other proteins or with other internal domains in p56lck.	INSERM,U332,F-75005 PARIS,FRANCE; INST COCHIN GENET MOLEC,CNRS,UNITE PROPRE RECH 0415,F-75014 PARIS,FRANCE; HOP PORT ROYAL,INSERM,U29,F-75674 PARIS 14,FRANCE; F HOFFMANN LA ROCHE & CO LTD,CH-4002 BASEL,SWITZERLAND; UNIV PADUA,DIPARTAMENTO CHIM BIOL,I-35121 PADUA,ITALY	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Roche Holding; University of Padua			Camoin, Luc/AAB-3856-2019	Camoin, Luc/0000-0002-1230-4787; Rothhut, Bernard/0000-0001-6467-8134				BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BLANKEMEYERMENGE B, 1990, TETRAHEDRON LETT, V31, P1701, DOI 10.1016/S0040-4039(00)88858-9; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CANTRELL D, 1987, NATURE, V325, P540, DOI 10.1038/325540a0; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CASNELLIE JE, 1990, FEBS LETT, V261, P331, DOI 10.1016/0014-5793(90)80584-6; CASNELLIE JE, 1987, J BIOL CHEM, V262, P9859; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHATILA TA, 1988, J IMMUNOL, V140, P4308; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P2183, DOI 10.1002/eji.1830191202; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; FISCHER S, 1987, BIOCHEM BIOPH RES CO, V143, P819, DOI 10.1016/0006-291X(87)90322-6; GASSMANN M, 1992, EUR J IMMUNOL, V22, P283, DOI 10.1002/eji.1830220142; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HSI ED, 1989, J BIOL CHEM, V264, P10836; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KITAS EA, 1991, HELV CHIM ACTA, V74, P1314, DOI 10.1002/hlca.19910740621; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOYASU S, 1992, J BIOL CHEM, V267, P3375; LONDON IM, 1981, COLD SPRING HARBOR C, V8, P941; LUO K, 1990, ONCOGENE, V5, P803; MARTH JD, 1989, J IMMUNOL, V142, P2430; MEUER SC, 1983, J EXP MED, V157, P705, DOI 10.1084/jem.157.2.705; MINAMI Y, 1987, J BIOL CHEM, V262, P13342; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; PATEL MD, 1987, J BIOL CHEM, V262, P5831; PURCHIO AF, 1985, SCIENCE, V229, P1393, DOI 10.1126/science.2994221; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SOULA M, 1992, INT IMMUNOL, V4, P295, DOI 10.1093/intimm/4.2.295; TARR GE, 1978, ANAL BIOCHEM, V84, P121; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TSOUKAS CD, 1985, J IMMUNOL, V135, P1719; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; VANWAUWE JP, 1980, J IMMUNOL, V124, P2708; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1992, ONCOGENE, V7, P971; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VONWUSSOW P, 1981, J IMMUNOL, V127, P1197; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302; WINKLER DG, 1993, P NATL ACAD SCI USA, V90, P5176, DOI 10.1073/pnas.90.11.5176	55	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27420	27427						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262984				2022-12-25	WOS:A1993MM26200083
J	YAMAGUCHI, T; SHIRATAKI, H; KISHIDA, S; MIYAZAKI, M; NISHIKAWA, J; WADA, K; NUMATA, S; KAIBUCHI, K; TAKAI, Y				YAMAGUCHI, T; SHIRATAKI, H; KISHIDA, S; MIYAZAKI, M; NISHIKAWA, J; WADA, K; NUMATA, S; KAIBUCHI, K; TAKAI, Y			2 FUNCTIONALLY DIFFERENT DOMAINS OF RABPHILIN-3A, RAB3A P25/SMG P25A-BINDING AND PHOSPHOLIPID-BINDING AND CA2+-BINDING DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP DISSOCIATION INHIBITOR; GDP/GTP EXCHANGE PROTEIN; SMG P25A; SYNAPTIC VESICLES; REGULATORY PROTEIN; KINASE-C; GTP; TISSUE; PURIFICATION; EXPRESSION	Rabphilin-3A is a putative target molecule for rab3A p25/smg p25A, which is a member of a ras p21-related small GTP-binding protein and implicated in neurotransmitter release from the synapse. Rabphilin-3A has two copies of an internal repeat that are homologous to the C2 domains of protein kinase C, synaptotagmin, and phospholipase A2, which are known to bind to phospholipid in a Ca2+-dependent manner. In the current study, we have investigated the functional domains of rabphilin-3A by use of three recombinant proteins as follows: full rabphilin-3A (1-704 amino acids), an N-terminal fragment (1-280 amino acids), and a C-terminal fragment containing the C2 domains (281-704 amino acids). Both rabphilin-3A and the C-terminal fragment bound to phospholipid in the presence of Ca2+, but the N-terminal fragment did not bind to phospholipid. Ca-45(2+) bound to rabphilin-3A and the C-terminal fragment only in the presence of phospholipid but did not bind to the N-terminal fragment. The GTPgammaS-bound form of rab3A p25 bound to both rabphilin-3A and the N-terminal fragment but did not bind to the C-terminal fragment. These results indicate that rabphilin-3A has at least two functionally different domains, the N-terminal rab3A p25-binding and C-terminal phospholipid- and Ca2+-binding domains.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Kobe University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)				kishida, shosei/0000-0003-0405-851X				ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BURSTEIN E, 1989, MOL CELL BIOL, V9, P4807, DOI 10.1128/MCB.9.11.4807; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; KABCENELL AK, 1990, J BIOL CHEM, V265, P9366; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KISHIDA S, 1993, J BIOL CHEM, V268, P22259; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE AW, 1988, J CELL BIOL, V106, P51, DOI 10.1083/jcb.106.1.51; LUO JH, 1993, J BIOL CHEM, V268, P3715; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MIZOGUCHI A, 1992, BIOCHEM BIOPH RES CO, V186, P1345, DOI 10.1016/S0006-291X(05)81554-2; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MIZOGUCHI A, 1989, BIOCHEM BIOPH RES CO, V162, P1438, DOI 10.1016/0006-291X(89)90835-8; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NONAKA H, 1991, BIOCHEM BIOPH RES CO, V174, P556, DOI 10.1016/0006-291X(91)91453-J; OGAWA Y, 1968, J BIOCHEM-TOKYO, V64, P255, DOI 10.1093/oxfordjournals.jbchem.a128887; OLOFSSON B, 1988, ONCOGENE, V3, P231; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; SALMINEN A, 1990, CELL, V265, P9366; Sambrook J, 1989, MOL CLONING LABORATO; SANO K, 1989, BIOCHEM BIOPH RES CO, V158, P377, DOI 10.1016/S0006-291X(89)80058-0; SASAKI T, 1991, MOL CELL BIOL, V11, P2909, DOI 10.1128/MCB.11.5.2909; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEDA T, 1991, BIOCHEMISTRY-US, V30, P909, DOI 10.1021/bi00218a005; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V	45	141	144	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27164	27170						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262955				2022-12-25	WOS:A1993MM26200050
J	DAVLETOV, BA; SUDHOF, TC				DAVLETOV, BA; SUDHOF, TC			A SINGLE C2 DOMAIN FROM SYNAPTOTAGMIN-I IS SUFFICIENT FOR HIGH-AFFINITY CA2+/PHOSPHOLIPID BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GLUTATHIONE-S-TRANSFERASE; TRANSMITTER RELEASE; ESCHERICHIA-COLI; ACTIVE ZONES; EXPRESSION; CALCIUM; RECEPTOR; FAMILY; P65	Synaptotagmin I is a Ca2+- and phospholipid-binding protein of synaptic vesicles with an essential function in neurotransmission. Ca2+/phospholipid binding by synaptotagmin I may be mediated by its C2 domains, sequence motifs that have been implicated in the Ca2+ regulation of a variety of proteins. However, it is currently unknown if C2 domains are sufficient for Ca2+/phospholipid binding or if they even directly participate in Ca2+/phospholipid binding. In order to address this question, we have studied the Ca2+/phospholipid-binding properties of the first C2 domain of synaptotagmin I. Our results show that this C2 domain by itself binds Ca2+ and phospholipids with high affinity (half-maximal binding at 4-6 muM free Ca2+) and exhibits strong positive cooperativity. The C2 domain is specific for negatively charged phospholipids and for those divalent cations that are known to stimulate synaptic vesicle exocytosis (Ca2+ > Sr2+, Ba2+ >>> Mg2+). These studies establish that C2 domains can serve as independently folding Ca2+/phospholipid-binding domains. Furthermore, the cation specificity and the cooperativity of Ca2+ binding by the C2 domain from synaptotagmin I support a role for this protein in mediating the Ca2+ signal in neurotransmitter release.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Davletov, Bazbek/ABA-8569-2021	Davletov, Bazbek/0000-0003-4658-3275				AKITA Y, 1990, J BIOL CHEM, V265, P354; ALMERS W, 1990, NEURON, V4, P813, DOI 10.1016/0896-6273(90)90134-2; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; LUO JH, 1993, J BIOL CHEM, V268, P3715; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; ONO Y, 1988, J BIOL CHEM, V263, P6927; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	35	421	432	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26386	26390						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253763				2022-12-25	WOS:A1993MK42500057
J	GUILLOT, D; LAVERGNE, JP; REBOUD, JP				GUILLOT, D; LAVERGNE, JP; REBOUD, JP			TRP(221) IS INVOLVED IN THE PROTECTIVE EFFECT OF ELONGATION-FACTOR EEF-2 ON THE RICIN ALPHA-SARCIN SITE OF THE RIBOSOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FACTOR-II; EUKARYOTIC RIBOSOMES; BINDING PROTEINS; CDNA SEQUENCE; RNA; ACID; MECHANISM; TRANSLOCATION; GTP	Elongation factor eEF-2 treated by N-bromosuccinimide under conditions which oxidize 2 Trp residues (Trp343 and Trp221) is inactivated in ribosome-dependent GTP hydrolysis and polyphenylalanine synthesis, and inactivation correlates with the specific oxidation of Trp221 (Guillot, D., Penin, F., Di Pietro, A., Sontag, B., Lavergne, J. P., and Reboud, J. P. (1993) J. Biol. Chem. 268, 20911-20916). It is shown here that this oxidation prevents neither GTP binding to eEF-2 nor the formation of the ribosome-eEF-2-GPP(NH)P complex, but that oxidized eEF-2 is no longer able to protect ribosomes against ricin inactivation. These observations suggest that Trp221 or an amino-acid sequence containing this residue interacts with the 28 S rRNA loop including the GAGA sequence, which is the target of ricin. Such a hypothesis is discussed in relation with data on RNA recognition motifs described in different proteins.	CNRS, INST BIOL & CHIM PROT, BIOCHIM MED LAB, 7 PASSAGE VERCORS, F-69367 LYON 07, FRANCE	Centre National de la Recherche Scientifique (CNRS)								BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRIGOTTI M, 1989, BIOCHEM J, V257, P723, DOI 10.1042/bj2570723; CONQUET F, 1987, EUR J BIOCHEM, V163, P15, DOI 10.1111/j.1432-1033.1987.tb10730.x; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ENDO Y, 1982, J BIOL CHEM, V257, P9054; FERNANDEZPUENTES C, 1976, EUR J BIOCHEM, V64, P437, DOI 10.1111/j.1432-1033.1976.tb10320.x; GUILLOT D, 1993, J BIOL CHEM, V268, P20911; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; KOHNO K, 1986, P NATL ACAD SCI USA, V83, P4978, DOI 10.1073/pnas.83.14.4978; LAVERGNE JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P231, DOI 10.1016/0167-4781(90)90061-6; MARZOUKI A, 1989, FEBS LETT, V255, P72, DOI 10.1016/0014-5793(89)81063-4; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; NILSSON L, 1988, EUR J BIOCHEM, V171, P293, DOI 10.1111/j.1432-1033.1988.tb13789.x; NYGARD O, 1984, EUR J BIOCHEM, V140, P93, DOI 10.1111/j.1432-1033.1984.tb08070.x; OLEINIKOV AV, 1989, FEBS LETT, V248, P131, DOI 10.1016/0014-5793(89)80447-8; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SONTAG B, 1993, BIOCHEMISTRY-US, V32, P1976, DOI 10.1021/bi00059a014; WOOL IG, 1992, TRENDS BIOCHEM SCI, V17, P266, DOI 10.1016/0968-0004(92)90407-Z; [No title captured]	20	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26082	26084						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253723				2022-12-25	WOS:A1993MK42500014
J	HAYASHI, T; SEKINE, T; OKAMOTO, T				HAYASHI, T; SEKINE, T; OKAMOTO, T			IDENTIFICATION OF A NEW SERINE KINASE THAT ACTIVATES NF-KAPPA-B BY DIRECT PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; DNA-BINDING SUBUNIT; DEPENDENT PROTEIN-KINASE; TRANSCRIPTION FACTOR; FACTOR-ALPHA; MAP KINASE; INVITRO ACTIVATION; ONCOGENE PRODUCT; PHORBOL ESTER	A novel serine kinase, named nuclear factor kappa B (NFkappaB) kinase, has been shown to be associated with the NFkappaB.IkappaB complex in the cytosol of human primary T lymphocytes. It activates the DNA binding activity of NFkappaB by directly phosphorylating its p65 and p50 subunits. There is no evidence that it phosphorylates IkappaB. Experiments with inhibitors and antisera showed that it is distinct from other known serine kinases such as mitogen-activated protein kinase or Mos. It has an apparent molecular size of 43 kDa determined by the substrate binding assay. This kinase might have a central role in mediating various signals to NFkappaB.	NATL CANC CTR, RES INST, DIV VIROL, 5-1-1 TSUKIJI, CHUO KU, TOKYO 104, JAPAN; NATL CANC CTR, RES INST, RI LAB, CHUO KU, TOKYO 104, JAPAN	National Cancer Center - Japan; National Cancer Center - Japan								BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; CAMPBELL S, 1990, P NATL ACAD SCI USA, V87, P1243, DOI 10.1073/pnas.87.3.1243; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINTER H, 1987, EMBO J, V6, P4067, DOI 10.1002/j.1460-2075.1987.tb02752.x; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; FEUILLARD J, 1991, CYTOKINE, V3, P257, DOI 10.1016/1043-4666(91)90025-9; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; HAGIWARA M, 1987, MOL PHARMACOL, V31, P523; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JAMIESON C, 1991, J IMMUNOL, V147, P416; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V125, P258, DOI 10.1016/S0006-291X(84)80362-9; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LAWRENCE DK, 1991, GENE DEV, V5, P1464; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MAEKAWA T, 1989, J BIOL CHEM, V264, P2826; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MOLITOR JA, 1991, NEW BIOL, V3, P987; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; OKAMOTO T, 1990, VIROLOGY, V177, P606, DOI 10.1016/0042-6822(90)90526-W; OKAMOTO T, 1989, AIDS RES HUM RETROV, V5, P131, DOI 10.1089/aid.1989.5.131; OKAMOTO T, 1992, INT IMMUNOL, V4, P811, DOI 10.1093/intimm/4.7.811; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SAHAL D, 1991, METHOD ENZYMOL, V200, P90; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P959, DOI 10.1128/MCB.9.3.959; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	50	92	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26790	26795						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253816				2022-12-25	WOS:A1993MK42500113
J	MCPHAUL, MJ; DESLYPERE, JP; ALLMAN, DR; GERARD, RD				MCPHAUL, MJ; DESLYPERE, JP; ALLMAN, DR; GERARD, RD			THE ADENOVIRUS-MEDIATED DELIVERY OF A REPORTER GENE PERMITS THE ASSESSMENT OF ANDROGEN RECEPTOR FUNCTION IN GENITAL SKIN FIBROBLAST-CULTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							D-DEPENDENT RICKETS; BINDING DOMAIN; RESISTANCE; MUTATIONS; PATIENT	Defects in the androgen receptor cause a spectrum of abnormalities in genetic males ranging from phenotypic women with testicular feminization to men with minor defects in fertility and/or virilization. The diagnosis of androgen resistance can be quite cumbersome, including analysis of the family history, karyotyping, endocrine studies, measurement of androgen binding in genital skin fibroblasts, and, in some instances, sequencing of mutant cDNAs. Furthermore, androgen-binding studies may be normal in patients with qualitative receptor abnormalities or mutations in the DNA-binding domain of the receptor. To circumvent these difficulties, we have used a recombinant adenovirus to deliver an androgen-responsive reporter gene (mouse mammary tumor virusluciferase) to fibroblasts cultured from genital skin from 12 normal controls and from eight individuals with complete testicular feminization. Following incubation with androgen (2 nM mibolerone) for 72 h, luciferase activity in normal fibroblasts increased >10-fold (range 11-200-fold) in a manner that corresponded with the level of androgen receptor detected in ligand-binding assays. By contrast, luciferase activity increased negligibly in fibroblasts from individuals with testicular feminization (average = 1.2-fold increase). This assay permits a direct assessment of endogenous androgen receptor function in cells and should be a powerful aid in the diagnosis of androgen resistance.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	MCPHAUL, MJ (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235, USA.		McPhaul, Michael/AAC-7124-2020					[Anonymous], METABOLIC BASIS INHE; CHEN TL, 1984, J CLIN ENDOCR METAB, V59, P383, DOI 10.1210/jcem-59-3-383; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; French F S, 1990, Recent Prog Horm Res, V46, P1; GAMBLIN GT, 1985, J CLIN INVEST, V75, P954, DOI 10.1172/JCI111796; GRIFFIN JE, 1983, J CLIN INVEST, V72, P1190, DOI 10.1172/JCI111074; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCELLI M, 1990, J CLIN INVEST, V85, P1522, DOI 10.1172/JCI114599; MCPHAUL MJ, 1992, J CLIN INVEST, V90, P2097, DOI 10.1172/JCI116093; MCPHAUL MJ, 1993, J CLIN ENDOCR METAB, V76, P17, DOI 10.1210/jc.76.1.17; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PINSKY L, 1992, CLIN INVEST MED, V15, P456; SHIH W, 1991, MOL ENDOCRINOL, V5, P300; Siegel S., 1956, NONPARAMETRIC STAT B; ZOPPI S, 1993, J CLIN INVEST, V91, P1105, DOI 10.1172/JCI116269; ZOPPI S, 1992, MOL ENDOCRINOL, V6, P409, DOI 10.1210/me.6.3.409	18	31	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26063	26066						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253718				2022-12-25	WOS:A1993MK42500009
J	OFFENZELLER, M; SU, Z; SANTER, G; MOSER, H; TRABER, R; MEMMERT, K; SCHNEIDERSCHERZER, E				OFFENZELLER, M; SU, Z; SANTER, G; MOSER, H; TRABER, R; MEMMERT, K; SCHNEIDERSCHERZER, E			BIOSYNTHESIS OF THE UNUSUAL AMINO-ACID (4R)-4-[(E)-2-BUTENYL]-4-METHYL-L-THREONINE OF CYCLOSPORINE-A - IDENTIFICATION OF 3(R)-HYDROXY-4(R)-METHYL-6(E)-OCTENOIC ACID AS A KEY INTERMEDIATE BY ENZYMATIC IN-VITRO SYNTHESIS AND BY IN-VIVO LABELING TECHNIQUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION CULTURES; POLYKETIDE BIOSYNTHESIS; 6-METHYLSALICYLIC ACID; PETROSELINUM-HORTENSE; SUBSTRATE-SPECIFICITY; FLAVANONE SYNTHASE; SYNTHETASE; DERIVATIVES; GENES	The biosynthesis of (4R)-4-[(E)-2-butenyl]-4-methyl-L-threonine (abbreviation: Bmt, systematic name: 2(S)-amino-3(R)-hydroxy-4(R)-methyl-6(E)-octenoic acid) is proposed to involve two principal phases: the formation of a polyketide backbone and a subsequent transformation process to the final product. Here we report on the identification of 3(R)-hydroxy-4(R)-methyl-6(E)-octenoic acid as the end product of the first phase. The primary indication of 3(R)-hydroxy-4(R)-methyl-6(E)-octenoic acid as the key intermediate in the proposed biosynthetic route came from in vivo labeling studies with [1-C-13, O-18(2)]acetate, demonstrating retention of O-18 in the 3-hydroxy group. Final identification of this intermediate in in vitro polyketide assays with enriched enzyme fractions of Tolypocladium niveum was achieved after development of highly sensitive and specific detection methods and by use of synthetic reference substances. Two additional methylated in vitro products could be detected and characterized as 4(R)-methyl-(E,E)-2,6-octadienoic acid and 4(R)-methyl-6(E)-octenoic acid by liquid chromatography-mass spectrometry analysis and comparison with synthetic reference samples. Their relevance for Bmt biosynthesis is discussed. Bmt polyketide synthase shows optimal activity at substrate concentrations of 200 muM acetyl-CoA, 150 muM malonyl-CoA, and 200 muM S-adenosylmethionine, around pH 7 and at 35-degrees-C. Interestingly the Bmt backbone is released from the enzyme as a coenzyme A thioester, suggesting that subsequent transformation to Bmt takes place upon this activated intermediate.	BIOCHEMIE GMBH,RES & DEV,A-6250 KUNDL,AUSTRIA; SANDOZ PHARMA LTD,ANALYT RES & DEV,CH-4002 BASEL,SWITZERLAND; SANDOZ PHARM LTD,PRECLIN RES,CH-4002 BASEL,SWITZERLAND	Novartis; Sandoz; Novartis; Sandoz								BOREL JF, 1989, PHARMACOL REV, V41, P259; DIMROTH P, 1970, EUR J BIOCHEM, V13, P98, DOI 10.1111/j.1432-1033.1970.tb00904.x; DIMROTH P, 1976, EUR J BIOCHEM, V68, P591, DOI 10.1111/j.1432-1033.1976.tb10847.x; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; EVANS DA, 1986, J AM CHEM SOC, V108, P6757, DOI 10.1021/ja00281a049; FEUTREN G, 1989, CURR OPIN IMMUNOL, V2, P239, DOI 10.1016/0952-7915(89)90194-5; FLIRI HG, 1990, BIOCH PEPTIDE ANTIBI, P246; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HRAZDINA G, 1976, ARCH BIOCHEM BIOPHYS, V175, P392, DOI 10.1016/0003-9861(76)90526-9; JORDAN PM, 1993, BIOCHEM SOC T, V21, P222, DOI 10.1042/bst0210222; KOBEL H, 1983, EXPERIENTIA, V39, P873, DOI 10.1007/BF01990413; KREUZALER F, 1975, EUR J BIOCHEM, V56, P205, DOI 10.1111/j.1432-1033.1975.tb02223.x; KURAOSAKI F, 1993, ARCH BIOCHEM BIOPHYS, V300, P157; LANZ T, 1991, J BIOL CHEM, V266, P9971; LAWEN A, 1989, J ANTIBIOT, V42, P1283, DOI 10.7164/antibiotics.42.1283; LAWEN A, 1990, J BIOL CHEM, V265, P11355; LYNEN F, 1980, EUR J BIOCHEM, V112, P431; MICHAL G, 1985, METHOD ENZYMAT AN, V7, P165; OHagan D., 1991, POLYKETIDE METABOLIT; OPPOLZER W, 1992, TETRAHEDRON LETT, V33, P2439, DOI 10.1016/S0040-4039(00)92209-3; OPPOLZER W, 1992, TETRAHEDRON LETT, V595, P155; PFLUGL G, 1993, NATURE, V361, P91, DOI 10.1038/361091a0; RICHARDSON DE, 1992, J CHROMATOGR, V595, P155, DOI 10.1016/0021-9673(92)85157-O; ROBINSON JA, 1991, PHILOS T ROY SOC B, V332, P107, DOI 10.1098/rstb.1991.0038; SCHUZ R, 1983, J BIOL CHEM, V258, P6730; SENN H, 1991, EUR J BIOCHEM, V199, P653, DOI 10.1111/j.1432-1033.1991.tb16167.x; SIMPSON TJ, 1987, CHEM SOC REV, V16, P123, DOI 10.1039/cs9871600123; SIMPSON TJ, 1987, NAT PROD REP, V4, P239; SPENCER JB, 1992, BIOCHEM J, V288, P839, DOI 10.1042/bj2880839; STROHL WR, 1991, J IND MICROBIOL, V7, P163, DOI 10.1007/BF01575879; THERIAULT Y, 1993, NATURE, V361, P88, DOI 10.1038/361088a0; VONWARTBURG A, 1986, PROG ALLERGY, V38, P28; [No title captured]	33	25	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26127	26134						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253730				2022-12-25	WOS:A1993MK42500021
J	PICCIOTTO, MR; CZERNIK, AJ; NAIRN, AC				PICCIOTTO, MR; CZERNIK, AJ; NAIRN, AC			CALCIUM CALMODULIN-DEPENDENT PROTEIN KINASE-I - CDNA CLONING AND IDENTIFICATION OF AUTOPHOSPHORYLATION SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; PHOSPHORYLATION SITES; CATALYTIC SUBUNIT; INTRASTERIC REGULATION; CONSERVED FEATURES; SEQUENCE-ANALYSIS; BINDING DOMAIN; SMOOTH-MUSCLE; SYNAPSIN-I; CYCLIC-AMP	Ca2+/calmodulin-dependent protein kinase I (CaM kinase I) was previously purified from bovine brain (Nairn, A. C., and Greengard, P. (1987) J. Biol. Chem. 262, 7273-7281) based on its ability to phosphorylate the synaptic vesicle protein, synapsin I at site 1. The cDNA for this protein kinase has now been cloned from both a rat and a bovine brain cDNA library and the complete amino acid sequence of rat CaM kinase I determined. The rat cDNA encoded a protein of 331 amino acids with a calculated M(r) of 37,545, and the encoded kinase was expressed in bacteria as a glutathione S-transferase fusion protein. The resulting fusion protein was purified by Sepharose-CaM affinity chromatography and shown to be totally dependent on Ca2+ and CaM for activity. Furthermore, the purified kinase phosphorylates synapsin I at the same site (site 1) as the endogenous brain enzyme. CaM kinase I is homologous to other known protein kinases and contains all nine invariant amino acids conserved in the catalytic domain of this class of enzymes. CaM kinase I was most identical to CaM kinase II both in the catalytic domain and in a short region at the COOH-terminal that is predicted to be the calmodulin-binding domain. CaM kinase I appeared to be encoded by a single gene. RNase protection assays detected the mRNA encoding CaM kinase I in all tissues examined. High concentrations of the kinase mRNA were found in all regions of the brain with frontal cortex showing the greatest level. CaM kinase I was autophosphorylated in a Ca2+/CaM-dependent manner at a threonyl residue (Thr-177) which is located at a position equivalent to that of the threonyl residue (Thr-197) autophosphorylated in cAMP-dependent protein kinase.	ROCKEFELLER UNIV, MOLEC & CELLULAR NEUROSCI LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA	Rockefeller University			Picciotto, Marina R./F-8747-2012	Picciotto, Marina R./0000-0002-4404-1280; Nairn, Angus/0000-0002-7075-0195				ALBAZZAZ F, 1981, EXP LUNG RES, V2, P121, DOI 10.3109/01902148109052308; BAGCHI IC, 1992, J BIOL CHEM, V267, P3024; BAGCHI IC, 1992, MOL ENDOCRINOL, V6, P621, DOI 10.1210/me.6.4.621; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BLACKSHEAR PJ, 1988, FASEB J, V2, P2957, DOI 10.1096/fasebj.2.14.2972578; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BOUCHER RC, 1989, J CLIN INVEST, V84, P1424, DOI 10.1172/JCI114316; BULLEIT RF, 1988, NEURON, V1, P63, DOI 10.1016/0896-6273(88)90210-3; Campbell A.K, 1983, INTRACELLULAR CALCIU; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18146; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DAVIS TN, 1992, CELL, V71, P557, DOI 10.1016/0092-8674(92)90590-9; DEREMER MF, 1992, J BIOL CHEM, V267, P13460; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GRAND RJA, 1979, BIOCHEM J, V177, P521, DOI 10.1042/bj1770521; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; GUERRIERO V, 1986, BIOCHEMISTRY-US, V25, P8372, DOI 10.1021/bi00374a007; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1991, METHOD ENZYMOL, V200, P525; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; HUTTNER WB, 1981, J BIOL CHEM, V256, P1482; HUTTNER WB, 1979, P NATL ACAD SCI USA, V76, P5402, DOI 10.1073/pnas.76.10.5402; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRETSINGER RH, 1992, SCIENCE, V258, P50, DOI 10.1126/science.1439768; KWIATKOWSKI AP, 1990, BIOCHEMISTRY-US, V29, P153, DOI 10.1021/bi00453a019; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; MEANS AR, 1991, ADV EXP MED BIOL, V304, P11; MIYANO O, 1992, J BIOL CHEM, V267, P1198; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; NAIRN AC, 1990, ADV SEC MESS PHOSPH, V24, P202; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; REDEREMER MF, 1992, J BIOL CHEM, V267, P13466; Sambrook J, 1989, MOL CLONING LABORATO; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENOLIKAR S, 1991, ADV 2ND MESSENGER PH, V23, P1; SILVA EFD, 1987, FEBS LETT, V220, P36, DOI 10.1016/0014-5793(87)80871-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; TAKIO K, 1986, BIOCHEMISTRY-US, V25, P8049, DOI 10.1021/bi00372a038; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; WILUMSEN NJ, 1989, AM J PHYSIOL, V256, pC226	59	96	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26512	26521						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253780				2022-12-25	WOS:A1993MK42500074
J	PLAAS, AHK; WONGPALMS, S				PLAAS, AHK; WONGPALMS, S			BIOSYNTHETIC MECHANISMS FOR THE ADDITION OF POLYLACTOSAMINE TO CHONDROCYTE FIBROMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL MEMBRANE-GLYCOPROTEINS; KERATAN SULFATE PROTEOGLYCAN; POLY-N-ACETYLLACTOSAMINE; ENDO-BETA-GALACTOSIDASE; CORNEAL STROMA; LINKED OLIGOSACCHARIDES; ESCHERICHIA-FREUNDII; LINKAGE REGION; CORE PROTEIN; CHICK	The cartilage matrix glycoprotein fibromodulin contains four N-linked glycosylation sites which act as acceptors for the addition of sulfated polylactosamine (keratan sulfate). In the present study we examined the biosynthetic processing of these N-linked oligosaccharides for subsequent addition of polylactosamine. Chondrocytes were treated with castanospermine, 1-(+)deoxymannojirimycin, and swainsonine, radiolabeled with [3,4,5-H-2]leucine, [2-H-1]mannose, or [6-H-3]glucosamine, and newly synthesized fibromodulin was immunoprecipitated for analysis. Castanospermine and 1-(+)deoxymannojirimycin inhibited polylactosamine addition, whereas swainsonine was not effective. This indicated that the linkage regions must be processed to GlcNAc(Man)5(GlcNAc)2Asn but do not require further modification to GlcNAc(Man)3(GlcNAc)2Asn. In both control and swainsonine-treated cells one or two N-linked oligosaccharides per molecule were modified with polylactosamine containing 4-6 repeating disaccharide units. Moreover, a single short chain was added either to the C-3 or the C-6 branch in control cultures, whereas only the C-3 branch was substituted in the presence of swainsonine. Analysis of endo-beta-galactosidase and keratanase II digestion products of the polylactosamine chains synthesized in both culture conditions showed that only about 25% of the hexosamine residues and less than 5% of the adjacent galactose residues were substituted with sulfate. These findings are discussed in relation to the regulation of fibromodulin glycosylation and the likely influence of polylactosamine structure on the extracellular interactions and turnover of fibromodulin.	UNIV S FLORIDA, SCH MED, DEPT BIOCHEM & MOLEC BIOL, TAMPA, FL 33620 USA	State University System of Florida; University of South Florida	PLAAS, AHK (corresponding author), SHRINERS HOSP CRIPPLED CHILDREN, CELL BIOL LAB, TAMPA UNIT, 12502 N PINE DR, TAMPA, FL 33612 USA.							ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; AXELSSON I, 1975, BIOCHEM J, V145, P4914; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; COSSU G, 1983, J BIOL CHEM, V258, P5603; DEAN JW, 1990, J BIOL CHEM, V265, P12553; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FODDY L, 1986, BIOCHEM J, V233, P697, DOI 10.1042/bj2330697; FUKUDA M, 1985, Biochimica et Biophysica Acta, V780, P119; FUKUDA M, 1988, J BIOL CHEM, V263, P5314; FUKUDA M, 1984, J BIOL CHEM, V259, P4782; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; FUKUDA MN, 1976, J BIOL CHEM, V251, P6218; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P24773; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GREGORY JD, 1982, J BIOL CHEM, V257, P6965; HART GW, 1978, J BIOL CHEM, V253, P5795; HASSELL JR, 1979, J BIOL CHEM, V254, P2346; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEINEGARD D, 1986, J BIOL CHEM, V261, P3866; HOPWOOD JJ, 1983, CARBOHYD RES, V117, P263, DOI 10.1016/0008-6215(83)88092-6; HUMPHRIES MJ, 1986, CANCER RES, V46, P5215; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEE N, 1990, J BIOL CHEM, V265, P20476; MCDOWELL W, 1988, BIOCHIMIE, V70, P1535, DOI 10.1016/0300-9084(88)90290-8; MIDURA RJ, 1989, J BIOL CHEM, V264, P1423; Nakazawa K., 1989, KERATAN SULPHATE CHE, P99; NILSSON B, 1983, J BIOL CHEM, V258, P6056; OEBEN M, 1987, BIOCHEM J, V248, P85, DOI 10.1042/bj2480085; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; PLAAS AHK, 1990, J BIOL CHEM, V265, P20634; PLAAS AHK, 1992, TRENDS GLYCOSCI GLYC, V4, P445; RADA JA, 1991, INVEST OPHTH VIS SCI, V32, P1010; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SATO S, 1992, J BIOL CHEM, V267, P6983; SCHRECENGOST PK, 1992, ARCH BIOCHEM BIOPHYS, V292, P54, DOI 10.1016/0003-9861(92)90050-7; SHIBATA S, 1992, J BIOL CHEM, V267, P6548; Stuhlsatz H.W., 1989, KERATAN SULPHATE PRO, P1; THORPE SJ, 1988, DEVELOPMENT, V102, P193; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; WANG WC, 1991, J BIOL CHEM, V266, P23185; YANAGISHITA M, 1989, METHOD ENZYMOL, V179, P435; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772; ZHU BCR, 1985, J BIOL CHEM, V260, P4041	45	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26634	26644						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253794				2022-12-25	WOS:A1993MK42500090
J	BARTLEY, GE; SCOLNIK, PA				BARTLEY, GE; SCOLNIK, PA			CDNA CLONING, EXPRESSION DURING DEVELOPMENT, AND GENOME MAPPING OF PSY2, A 2ND TOMATO GENE ENCODING PHYTOENE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAROTENOID BIOSYNTHESIS PATHWAY; LYCOPERSICON-ESCULENTUM; ANTISENSE RNA; ENZYME	The enzyme phytoene synthase (Psy) catalyzes the formation of phytoene, an intermediate in the carotenoid biosynthesis pathway. Expression of a previously described gene (PSY1) is induced by fruit ripening in tomato (Lycopersicon esculentum). We describe here the cloning of a partial cDNA for PSY2, a gene related to PSY1. A plasmid containing the PSY2 coding region under control of a bacterial promoter complements a Rhodobacter capsulatus phytoene synthase mutant, indicating that this gene has the capacity to encode an active enzyme. We used reverse transcriptase-polymerase chain reaction followed by digestion with a restriction enzyme to determine that both PSY1 and PSY2 are expressed during tomato development. PSY1 transcripts predominate in seedlings and in late stages of fruit ripening, whereas PSY2 transcripts are relatively more abundant in mature leaves. Both genes are expressed under photooxidative conditions induced by treatment with the carotenoid biosynthesis inhibitor Norflurazon. We used polymerase chain reaction-based restriction fragment length polymorphisms and alien addition lines to map PSY2 to chromosome 2. We conclude that PSY2 is a second tomato gene encoding phytoene synthase.	DUPONT CO INC, CENT RES & DEV, EXPTL STN, WILMINGTON, DE 19880 USA	DuPont								ANDERSON IC, 1960, PLANT PHYSIOL, V35, P531, DOI 10.1104/pp.35.4.531; BARTHOLOMEW DM, 1991, PLANT PHYSIOL, V96, P291, DOI 10.1104/pp.96.1.291; BARTLEY GE, 1992, J BIOL CHEM, V267, P5036; BARTLEY GE, 1991, P NATL ACAD SCI USA, V88, P6532, DOI 10.1073/pnas.88.15.6532; BARTLEY GE, 1991, CELL CULTURE SOMAT B, V7, P331; BIRD CR, 1991, BIO-TECHNOL, V9, P635, DOI 10.1038/nbt0791-635; BRAMLEY P, 1992, PLANT J, V2, P343, DOI 10.1111/j.1365-313X.1992.00343.x; DEVERNA JW, 1990, PLANT BIOL, V11, P247; GIULIANO G, 1993, PLANT CELL, V5, P379, DOI 10.1105/tpc.5.4.379; KINZER SM, 1990, THEOR APPL GENET, V79, P489, DOI 10.1007/BF00226158; MAUNDERS MJ, 1987, PLANT CELL ENVIRON, V10, P177; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; PICHERSKY E, 1986, P NATL ACAD SCI USA, V83, P3880, DOI 10.1073/pnas.83.11.3880; RAY J, 1992, PLANT MOL BIOL, V19, P401, DOI 10.1007/BF00023387; RICK CM, 1990, PLANT BIOL, V11, P19; SAGAR AD, 1990, PLANT PHYSIOL, V94, P1663, DOI 10.1104/pp.94.4.1663; TAYLOR WC, 1989, ANNU REV PLANT PHYS, V40, P211, DOI 10.1146/annurev.pp.40.060189.001235; TONKYN JC, 1992, PLANT PHYSIOL, V99, P1403; WILLIAMS MNV, 1991, THEOR APPL GENET, V82, P489, DOI 10.1007/BF00588604	19	119	132	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25718	25721						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245008				2022-12-25	WOS:A1993MK10000064
J	GRUPP, SA; CAMPBELL, K; MITCHELL, RN; CAMBIER, JC; ABBAS, AK				GRUPP, SA; CAMPBELL, K; MITCHELL, RN; CAMBIER, JC; ABBAS, AK			SIGNALING-DEFECTIVE MUTANTS OF THE B-LYMPHOCYTE ANTIGEN RECEPTOR FAIL TO ASSOCIATE WITH IG-ALPHA AND IG-BETA/GAMMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TYROSINE PHOSPHORYLATION; CELL-SURFACE; EARLY EVENT; T-CELLS; IMMUNOGLOBULIN; COMPLEX; MB-1; TRANSMEMBRANE; COMPONENTS; GENES	The B cell receptor for antigen, the membrane immunoglobulin (mIg) molecule, is normally expressed in association with at least two other proteins, mb-1 (Ig-alpha) and B29 (Ig-beta/gamma). We have previously described a set of murine B cell clones transfected with wild-type and mutated forms of membrane-bound IgM (mIgM) that vary in their ability to transduce signals to the cell interior. Analysis of the B cell receptor complex in signaling and nonsignaling mutants of mIgM reveals complete concordance between intact signaling ability and ability of the mIgM to associate with Ig-alpha and Ig-beta/gamma. These results point to the importance of the mIgM transmembrane region in mediating binding to accessory molecules, and provide support for a role of Ig-alpha and Ig-beta/gamma that extends beyond surface expression to signal transduction in B lymphocytes.	NATL JEWISH MED CTR,DEPT PEDIAT,DIV BASIC SCI,DENVER,CO 80206; HARVARD UNIV,SCH MED,BOSTON,MA 02115; BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND	National Jewish Health; Harvard University; Harvard Medical School	GRUPP, SA (corresponding author), BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV IMMUNOL RES,BOSTON,MA 02115, USA.			Cambier, John/0000-0002-7803-242X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022802, R01AI021768] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21768, AI22802] Funding Source: Medline; NIGMS NIH HHS [GM47726] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CAMPBELL KS, 1991, J IMMUNOL, V147, P1575; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; COSTA TE, 1992, J EXP MED, V175, P1669, DOI 10.1084/jem.175.6.1669; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GRUPP SA, 1987, CELL IMMUNOL, V109, P181, DOI 10.1016/0008-8749(87)90303-0; GRUPP SA, 1985, J IMMUNOL, V134, P4087; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KASHIWAMURA SI, 1990, J IMMUNOL, V145, P337; MATSUUCHI L, 1992, P NATL ACAD SCI USA, V89, P3404, DOI 10.1073/pnas.89.8.3404; MITCHELL RN, 1991, J BIOL CHEM, V266, P8856; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; SHAW AC, 1990, CELL, V63, P381, DOI 10.1016/0092-8674(90)90171-A; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973; VANNOESEL CJM, 1990, EUR J IMMUNOL, V20, P2789, DOI 10.1002/eji.1830201238; VANNOESEL CJM, 1992, J EXP MED, V175, P1511, DOI 10.1084/jem.175.6.1511; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WILLIAMS GT, 1990, J EXP MED, V171, P947, DOI 10.1084/jem.171.3.947	29	64	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25776	25779						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245014				2022-12-25	WOS:A1993MK10000073
J	HASHIMOTO, Y; SEKINE, M; IWASAKI, K; SUZUKI, A				HASHIMOTO, Y; SEKINE, M; IWASAKI, K; SUZUKI, A			PURIFICATION AND CHARACTERIZATION OF UDP-N-ACETYLGALACTOSAMINE G(M3)/G(D3) N-ACETYLGALACTOSAMINYLTRANSFERASE FROM MOUSE-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; EXPRESSION; GM2; GANGLIOSIDE; GD2; PROTEINS; SYNTHASE; ASSAY; BRAIN; GM1B	A UDP-N-acetylgalactosamine: Siaalpha2-3Galbeta1-4Glcbeta1-/Siaalpha2-8Siaalpha2-3Galbeta1-4Glcbeta1-1 ceramide N-acetylgalactosaminyltransferase has been purified to apparent homogeneity from mouse liver. The purification procedure involved differential centrifugation for preparation of Golgi membranes, extraction of the enzyme with Triton X-100, and sequential chromatography on phosphocellulose, UDP-aldehyde adipic acid hydrazone agarose, UDP-hexanolamine-Sepharose, CM-Sepharose, and DEAE-Sepharose. At the phosphocellulose column chromatography step, the recovery of the enzyme activity was less than 25%, but it was enhanced up to 70% when the enzyme assay was performed in the presence of the flow-through fraction from the phosphocellulose column. With this assay, the enzyme activity was found to be quantitatively recovered during all the column chromatographies, the enzyme finally being purified 171,000-fold with a specific activity of 3.6 mumol/min/mg protein. The apparent molecular mass of the purified enzyme is 65,000 daltons. The enzyme exhibits a pH optimum of 7.5-7.9 and requires 2.5-10 mM Mn2+ for the maximal activity. The K(m) value for UDP-N-acetylgalactosamine is 7 muM. Among the glycolipids tested as acceptor substrates, NeuGcalpha2-3Galbeta1-4Glcbeta1-1 ceramide, NeuAcalpha2-3Galbeta1-4Glcbeta1-1 ceramide, NeuGcalpha2-8NeuGcalpha2-3Galbeta1-4Glcbeta1-1 ceramide, and NeuAcalpha2-8NeuAcaalpha2-3Galbeta1-4Glcbeta1-1 ceramide are good ones, the K(m) values for them being 160, 2,100, 27, and 350 muM, respectively, but sialyllactose, NeuAcalpha2-3Galbeta1-4Glc, is not. This suggests that the enzyme recognizes not only the oligosaccharide portion but also the ceramide of gangliosides.	TOKYO METROPOLITAN INST MED SCI,DEPT MEMBRANE BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT PHYSIOL CHEM,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science								BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BLANKEN WM, 1985, J BIOL CHEM, V260, P2927; CAHAN LD, 1982, P NATL ACAD SCI-BIOL, V79, P7629, DOI 10.1073/pnas.79.24.7629; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FOLCH J, 1957, J BIOL CHEM, V226, P497; GASA S, 1991, SEIKAGAKU, V63, P788; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANDA S, 1964, JPN J EXP MED, V34, P293; HASHIMOTO Y, 1984, J BIOCHEM-TOKYO, V95, P1543, DOI 10.1093/oxfordjournals.jbchem.a134766; HASHIMOTO Y, 1983, J BIOCHEM-TOKYO, V93, P895, DOI 10.1093/jb/93.3.895; HASHIMOTO Y, 1985, GLYCOCONJUGATE J, V2, P255; HASHIMOTO Y, 1986, SEIKAGAKU, V58, P862; ITOH T, 1981, J BIOL CHEM, V256, P165; KAWANO M, 1989, ANAL BIOCHEM, V182, P9, DOI 10.1016/0003-2697(89)90709-4; KONO M, 1991, J BIOCHEM-TOKYO, V109, P132, DOI 10.1093/oxfordjournals.jbchem.a123333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDEEN R, 1988, BIOCHEMISTRY-US, V7, P2287; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; MAKITA A, 1963, JPN J EXP MED, V33, P361; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NAKAMURA K, 1984, J BIOCHEM-TOKYO, V96, P949, DOI 10.1093/oxfordjournals.jbchem.a134954; NISHIKAWA Y, 1988, J BIOL CHEM, V263, P8270; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; PRICE H, 1975, BIOCHEMISTRY-US, V14, P1512, DOI 10.1021/bi00678a026; SEKINE M, 1990, J BIOCHEM-TOKYO, V108, P103, DOI 10.1093/oxfordjournals.jbchem.a123147; SIDDIQUI B, 1971, J BIOL CHEM, V246, P5766; SUZUKI M, 1986, CARBOHYD RES, V151, P213, DOI 10.1016/S0008-6215(00)90342-2; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; SVENNERHOLM L, 1973, J BIOL CHEM, V248, P740; TANIGUCHI N, 1982, J BIOL CHEM, V257, P631; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; YAMAKAWA T, 1963, J BIOCHEM, V53, P28, DOI 10.1093/oxfordjournals.jbchem.a127654; YAMAKAWA T, 1951, J BIOCHEM-TOKYO, V38, P199, DOI 10.1093/oxfordjournals.jbchem.a126242; YANAGISAWA K, 1987, BIOCHIM BIOPHYS ACTA, V919, P213, DOI 10.1016/0005-2760(87)90260-8	38	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25857	25864						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245020				2022-12-25	WOS:A1993MK10000083
J	PILLOT, T; OUZZINE, M; FOURNELGIGLEUX, S; LAFAURIE, C; RADOMINSKA, A; BURCHELL, B; SIEST, G; MAGDALOU, J				PILLOT, T; OUZZINE, M; FOURNELGIGLEUX, S; LAFAURIE, C; RADOMINSKA, A; BURCHELL, B; SIEST, G; MAGDALOU, J			GLUCURONIDATION OF HYODEOXYCHOLIC ACID IN HUMAN LIVER - EVIDENCE FOR A SELECTIVE ROLE OF UDP-GLUCURONOSYLTRANSFERASE-2B4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GLUCURONOSYLTRANSFERASE; BILE-ACIDS; RAT-LIVER; STABLE EXPRESSION; CELL-CULTURE; MICROSOMES; GLUCURONYLTRANSFERASE; PURIFICATION; BILIRUBIN; CLONING	Monospecific polyclonal antibodies were raised against a variable amino-terminal domain (amino acids 14-150) of a human liver form of UDP-glucuronosyltransferase conjugating bile acids, UGT2B4 (Jackson, M. R., McCarthy, L. R., Harding, D., Wilson, S., Coughtrie, M. W., and Burchell, B. (1987) Biochem. J. 242, 581-588), expressed as a fusion protein in Escherichia coli. The antibodies were able to recognize the protein, stably expressed in a genetically engineered eukaryotic V79 cell line, against which they were directed. The specificity of these antibodies allowed their use for analyzing the substrate specificity of this isoform in human liver, as well as for determining its contribution to the total hepatic and extra-hepatic glucuronidation of hyodeoxycholic acid. Western blot analysis of microsomal proteins demonstrated the presence of UGT2B4 exclusively in human liver and not in human kidney. In human liver microsomes, the antibodies were able to inhibit and precipitate up to 90% of the total hyodeoxycholic acid 6-O-glucuronidation activity, but had no effect on activities toward several other substrates, such as phenols, bilirubin, or other bile acids, especially hyocholic acid and the steroids 4-hydroxyestrone and estriol. Moreover, Western blot analysis and immunoinhibition studies of human liver microsomes from healthy patients and from patients presenting liver diseases revealed a good correlation between the glucuronidation rate of hyodeoxycholic acid and the UGT2B4 expression level. The absence of immunoinhibition of hyodeoxycholic acid conjugation with UDP sugars other than UDP-glucuronic acid suggests the involvement of different enzymatic systems in the glucosidation and xylosylation of hyodeoxycholic acid. Altogether, the results provided strong evidence for the specific and predominant involvement of UGT2B4 in the 6-O-glucuronidation of this bile acid via a UDP-glucuronic acid-dependent mechanism.	FAC SCI PHARMACEUT & BIOL NANCY,CTR MEDICAMENT,CNRS,URA 597,30 RUE LIONNOIS,F-54000 NANCY,FRANCE; UNIV ARKANSAS MED SCI HOSP,DEPT INTERNAL MED,LITTLE ROCK,AR 72205; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT BIOCHEM MED,DUNDEE DD1 9SY,SCOTLAND	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; University of Arkansas System; University of Arkansas Medical Sciences; University of Dundee			Ouzzine, Mohamed/G-4368-2013	SIEST, Gerard/0000-0002-3001-760X; OUZZINE, Mohamed/0000-0003-0058-4950	NIDDK NIH HHS [DK-38678] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038678] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALME B, 1980, J STEROID BIOCHEM, V13, P907, DOI 10.1016/0022-4731(80)90164-8; ALME B, 1978, CLIN CHIM ACTA, V86, P251, DOI 10.1016/0009-8981(78)90379-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCHELL B, 1991, DNA CELL BIOL, V10, P487, DOI 10.1089/dna.1991.10.487; BURCHELL B, 1989, PHARMACOL THERAPEUT, V43, P261, DOI 10.1016/0163-7258(89)90122-8; COFFMAN BL, 1990, ARCH BIOCHEM BIOPHYS, V281, P170, DOI 10.1016/0003-9861(90)90428-2; DRAGACCI S, 1987, EUR J CLIN PHARMACOL, V32, P485, DOI 10.1007/BF00637675; DRAKE RR, 1992, J BIOL CHEM, V267, P11360; Dutton G.F., 1980, GLUCURONIDATION DRUG; FOURNELGIGLEUX S, 1991, MOL PHARMACOL, V39, P177; FOURNELGIGLEUX S, 1989, FEBS LETT, V243, P119, DOI 10.1016/0014-5793(89)80111-5; HEIRWEGH KP, 1972, BIOCHEM J, V129, P605, DOI 10.1042/bj1290605; HERBER R, 1992, BIOCHIM BIOPHYS ACTA, V1139, P20, DOI 10.1016/0925-4439(92)90077-Z; IRSHAID Y, 1991, PHARMACOL TOXICOL, V68, P212, DOI 10.1111/j.1600-0773.1991.tb01225.x; IRSHAID YM, 1987, MOL PHARMACOL, V31, P27; JACKSON MR, 1987, BIOCHEM J, V242, P581, DOI 10.1042/bj2420581; JIN CJ, 1993, J PHARMACOL EXP THER, V264, P475; KIRKPATRICK RB, 1985, J LIPID RES, V26, P1431; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKENZIE PI, 1990, J BIOL CHEM, V265, P3432; Maniatis T., 1982, MOL CLONING; MARSCHALL HU, 1987, BIOCHIM BIOPHYS ACTA, V921, P392, DOI 10.1016/0005-2760(87)90041-5; Marston F. A. O., 1987, DNA CLONING, P59; MATERN H, 1991, EUR J BIOCHEM, V200, P393, DOI 10.1111/j.1432-1033.1991.tb16197.x; NILSSON B, 1985, EMBO J, V4, P1075, DOI 10.1002/j.1460-2075.1985.tb03741.x; OTANI G, 1976, BIOCHEM PHARMACOL, V25, P1293, DOI 10.1016/0006-2952(76)90092-7; PARQUET M, 1985, FEBS LETT, V189, P183, DOI 10.1016/0014-5793(85)81020-6; PARQUET M, 1988, EUR J BIOCHEM, V171, P329, DOI 10.1111/j.1432-1033.1988.tb13794.x; PARQUET M, 1985, FALK S, V40, P411; RADOMINSKA A, 1993, J BIOL CHEM, V268, P15127; RADOMINSKA A, 1988, J LIPID RES, V29, P501; RADOMINSKA A, 1990, FASEB J, V4, pA1972; RADOMINSKA A, 1990, FALK S; RADOMINSKA A, 1991, BILE ACIDS THERAPEUT, P99; RADOMINSKAPYREK A, 1987, J CLIN INVEST, V80, P234, DOI 10.1172/JCI113053; RADOMINSKAPYREK A, 1986, J LIPID RES, V27, P89; RITTER JK, 1992, BIOCHEMISTRY-US, V31, P3409, DOI 10.1021/bi00128a015; RITTER JK, 1990, J BIOL CHEM, V265, P7900; TEPHLY TR, 1990, CHEM RES TOXICOL, V3, P509, DOI 10.1021/tx00018a004; UHLEN M, 1984, J BIOL CHEM, V259, P1695; VANES HHG, 1990, J CLIN INVEST, V85, P1199, DOI 10.1172/JCI114553; WOOSTER R, 1991, BIOCHEM J, V278, P465, DOI 10.1042/bj2780465; YOKOTA H, 1992, J BIOCHEM, V112, P192, DOI 10.1093/oxfordjournals.jbchem.a123876	43	80	80	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25636	25642						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244999				2022-12-25	WOS:A1993MK10000053
J	RINGEISEN, F; REYCAMPOS, J; YANIV, M				RINGEISEN, F; REYCAMPOS, J; YANIV, M			THE TRANSACTIVATION POTENTIAL OF VARIANT HEPATOCYTE NUCLEAR FACTOR-I IS MODIFIED BY ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; FACTOR-I; EXPRESSION; HNF1; DOMAIN; CELLS; TRANSCRIPTION; GENE; HOMEOPROTEIN; DIMERIZATION	Two forms of the transcription factor vHNF1 (HNF1beta or LFB3) have been previously described, derived by alternative splicing from a common premessenger RNA, and have been called vHNF1-A and vHNF1-B. vHNF1 proteins share a homologous homeo-related DNA-binding domain with the HNF1 protein, initially characterized as a liver-restricted transcription factor, and bind to a similar sequence motif. Here we demonstrate that vHNF1-A is a stronger transactivator than vHNF1-B when assayed in transient transfections using two different promoters. vHNF1-A also binds DNA with a higher affinity suggesting that a region of the protein located immediately upstream of the homeodomain can modulate the protein/DNA interaction and transactivation. Both vHNF1 transcripts were found at a constant ratio in every tissue where vHNF1 expression could be detected, using a quantitative reverse transcriptase-polymerase chain reaction.	INST PASTEUR,DEPT BIOTECHNOL,CNRS,UNITE VIRUS ONCOGENES 1644,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								Ausubel FM., 2006, ENZYMATIC MANIPULATI; BACH I, 1991, NUCLEIC ACIDS RES, V19, P3553, DOI 10.1093/nar/19.13.3553; BAUMHUETER S, 1988, EMBO J, V7, P2485, DOI 10.1002/j.1460-2075.1988.tb03095.x; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BLUMENFELD M, 1991, DEVELOPMENT, V113, P589; CEREGHINI S, 1992, DEVELOPMENT, V116, P783; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; GOGOS JA, 1992, SCIENCE, V257, P1951, DOI 10.1126/science.1290524; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HERBOMEL P, 1989, MOL CELL BIOL, V9, P4750, DOI 10.1128/MCB.9.11.4750; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; LAZZARO D, 1992, DEVELOPMENT, V114, P469; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTARRAS D, 1989, EMBO J, V8, P2203, DOI 10.1002/j.1460-2075.1989.tb08343.x; NICOSIA A, 1990, CELL, V61, P1225, DOI 10.1016/0092-8674(90)90687-A; OTT MO, 1991, MECH DEVELOP, V36, P47, DOI 10.1016/0925-4773(91)90071-D; RANEY AK, 1991, J VIROL, V65, P5774, DOI 10.1128/JVI.65.11.5774-5781.1991; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SOURDIVE DJD, 1993, CR ACAD SCI III-VIE, V316, P385; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; TOMEI L, 1992, EMBO J, V11, P4119, DOI 10.1002/j.1460-2075.1992.tb05505.x; TRONCHE F, 1991, J MOL BIOL, V221, P31; YEE C, 1985, AM J PATHOL, V119, P361	32	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25706	25711						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245006				2022-12-25	WOS:A1993MK10000062
J	CHRISTIE, KR; AWREY, DE; EDWARDS, AM; KANE, CM				CHRISTIE, KR; AWREY, DE; EDWARDS, AM; KANE, CM			PURIFIED YEAST RNA POLYMERASE-II READS THROUGH INTRINSIC BLOCKS TO ELONGATION IN RESPONSE TO THE YEAST TFIIS ANALOG, P37	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-S-II; ASCITES TUMOR-CELLS; TRANSCRIPTION ELONGATION; FACTOR-SII; ESCHERICHIA-COLI; TERNARY COMPLEXES; SACCHAROMYCES-CEREVISIAE; STIMULATORY FACTORS; STRUCTURAL-ANALYSIS; TERMINATION SITES	Saccharomyces cerevisiae has a TFIIS-related transcription elongation factor, originally called P37 (Sawadogo, M., Sentenac, A., and Fromageot, P. (1979) J. Biol. Chem. 255, 12-15; Nakanishi, T., Nakano, A., Nomura, K., Sekimizu, K., and Natori, S. (1992) J. Biol. Chem. 267, 13200-13204), which binds directly to RNA polymerase II and stimulates read-through of intrinsic blocks to elongation. To elucidate functional features of this protein:protein interaction, we tested the ability of several forms of RNA polymerase II to respond to either full-length or an amino-terminal truncation of TFIIS. The variants of the polymerase differed in the structure of the carboxyl-terminal domain of the largest subunit or lacked two of the smaller subunits. No differences in ability to recognize intrinsic blocks to elongation or to read through them in response to either form of TFIIS were detected among these variants. Furthermore, ternary complexes containing each variant form of RNA polymerase cleave the 3' end of the nascent transcripts in response to TFIIS, a reaction previously reported for mammalian and Drosophila TFIIS (Kassavetis, G. A., and Geiduschek, E. P. (1993) Science 259, 944-945) and likely to be important in TFIIS function. Thus the carboxyl-terminal domain of the largest subunit and subunits four and seven of the polymerase, required in vivo, are not required in vitro for recognition of intrinsic blocks to elongation, read-through in response to TFIIS, or TFIIS-stimulated cleavage of the nascent transcript.	UNIV CALIF BERKELEY,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720; MCMASTER UNIV,DEPT PATHOL,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,DEPT BIOCHEM,HAMILTON L8N 3Z5,ONTARIO,CANADA	University of California System; University of California Berkeley; McMaster University; McMaster University				Christie, Karen/0000-0001-5501-853X; Edwards, Aled/0000-0002-4782-6016				AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CHAMBERLIN MJ, 1993, IN PRESS HARVEY LECT; CHEN HC, 1992, GENE, V116, P253, DOI 10.1016/0378-1119(92)90522-Q; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; GU WG, 1993, J BIOL CHEM, V268, P25604; GUO HL, 1993, J BIOL CHEM, V268, P18762; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; HORIKOSHI M, 1985, J BIOL CHEM, V260, P5739; HORIKOSHI M, 1984, J BIOL CHEM, V259, P608; HORIKOSHI N, 1990, J BIOL CHEM, V265, P11854; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KANAI A, 1991, J BIOCHEM-TOKYO, V109, P674, DOI 10.1093/oxfordjournals.jbchem.a123439; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; KUHN A, 1990, NATURE, V344, P559, DOI 10.1038/344559a0; KUHN A, 1989, GENE DEV, V3, P224, DOI 10.1101/gad.3.2.224; LEE DN, 1992, J MOL BIOL, V228, P759, DOI 10.1016/0022-2836(92)90862-E; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; MARSHALL TK, 1990, NUCLEIC ACIDS RES, V18, P6293, DOI 10.1093/nar/18.21.6293; MCKUNE K, 1993, YEAST, V9, P295, DOI 10.1002/yea.320090309; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; NATORI S, 1982, MOL CELL BIOCHEM, V46, P173; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; RAPPAPORT J, 1988, MOL CELL BIOL, V8, P3136, DOI 10.1128/MCB.8.8.3136; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; RICE GA, 1993, NUCLEIC ACIDS RES, V21, P113, DOI 10.1093/nar/21.1.113; SAWADOGO M, 1980, J BIOL CHEM, V255, P12; SAWADOGO M, 1981, BIOCHEMISTRY-US, V20, P3542, DOI 10.1021/bi00515a037; SAWADOGO M, 1980, BIOCHEM BIOPH RES CO, V96, P258, DOI 10.1016/0006-291X(80)91208-5; SEKIMIZU K, 1979, BIOCHEMISTRY-US, V18, P1582, DOI 10.1021/bi00575a031; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; SPENCER CA, 1990, ONCOGENE, V5, P777; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; TURNBOUGH C, 1992, TRANSCRIPTIONAL REGU, P407; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WIELAND T, 1991, EXPERIENTIA, V47, P1186, DOI 10.1007/BF01918382; WIEST DK, 1992, J BIOL CHEM, V267, P7733; WOYCHIK NA, 1990, TRENDS BIOCHEM SCI, V15, P347, DOI 10.1016/0968-0004(90)90074-L; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073	66	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					936	943						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288647				2022-12-25	WOS:A1994MR22000028
J	DASCHER, C; BALCH, WE				DASCHER, C; BALCH, WE			DOMINANT INHIBITORY MUTANTS OF ARF1 BLOCK ENDOPLASMIC-RETICULUM TO GOLGI TRANSPORT AND TRIGGER DISASSEMBLY OF THE GOLGI-APPARATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING-PROTEIN; PERIPHERAL MEMBRANE-PROTEIN; SEMI-INTACT CELLS; BREFELDIN-A; PERMEABILIZED CELLS; VESICULAR TRANSPORT; GUANINE-NUCLEOTIDE; ENDOCYTIC PATHWAY; ER	Using three different trans dominant mutants of bovine ARF1 affecting GDP exchange or GTP hydrolysis we demonstrate the central role of ARF1 in controlling vesicular traffic from the endoplasmic reticulum (ER) to the Golgi apparatus and between successive Golgi compartments. Overexpression of ARF1(Q71L), a mutant likely to be restricted to the GTP-bound form, resulted in the accumulation of vesicular stomatitis virus glycoprotein in pre-Golgi intermediates, inhibited transport between successive Golgi compartments, and led to a striking association of beta-COP with pre-Golgi intermediates and the Golgi stack. In contrast, ARF1(T31N), a mutant which is likely to have a preferential affinity for GDP compared to the wild-type protein, inhibited export from the ER and triggered a brefeldin A-like phenotype, resulting in the redistribution of beta-COP from Golgi membranes to the cytosol and the collapse of the Golgi into the ER. This mutant, which may efficiently sequester an ARF-specific guanine nucleotide-exchange protein (ARF-GEF), suggests that ARF and ARF-GEF are essential for export from the ER. These results are discussed in the context of the GDP and GTP-bound forms of ARF in controlling both membrane structure and vesicular traffic through the early secretory pathway.	SCRIPPS RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 42336] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH WE, 1992, J BIOL CHEM, V267, P13053; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARLOWE C, 1993, J BIOL CHEM, V268, P873; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DENFERT C, 1991, J CELL BIOL, V114, P663, DOI 10.1083/jcb.114.4.663; DER CJ, 1988, ONCOGENE, V3, P105; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DER CJ, 1991, CANCER CELL-MON REV, V3, P331; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GRAHAM TR, 1993, EMBO J, V12, P869, DOI 10.1002/j.1460-2075.1993.tb05727.x; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HENDRICKS LC, 1993, MOL BIOL CELL, V4, P413, DOI 10.1091/mbc.4.4.413; HLEMS BJ, 1993, J CELL BIOL, V121, P751; JOHN J, 1993, J BIOL CHEM, V268, P923; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KOSHRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264; Lippincott-Schwartz Jennifer, 1993, Trends in Cell Biology, V3, P81, DOI 10.1016/0962-8924(93)90078-F; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; OKA T, 1991, J CELL BIOL, V114, P671, DOI 10.1083/jcb.114.4.671; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P15; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STUDIER RW, 1990, METHOD ENZYMOL, V185, P60; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4638; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; WAGNER P, 1992, METHOD ENZYMOL, V219, P369; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WATERS M G, 1991, Current Opinion in Cell Biology, V3, P615, DOI 10.1016/0955-0674(91)90031-S; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEISS O, 1989, J BIOL CHEM, V264, P21066; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P67; YAMAMOTO K, 1982, CURR OPIN CELL BIOL, V5, P613	69	349	353	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1437	1448						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288610				2022-12-25	WOS:A1994MR22000103
J	RAJPUROHIT, R; LEE, SO; PARK, JO; PAIK, WK; KIM, S				RAJPUROHIT, R; LEE, SO; PARK, JO; PAIK, WK; KIM, S			ENZYMATIC METHYLATION OF RECOMBINANT HETEROGENEOUS NUCLEAR RNP PROTEIN-A1 - DUAL SUBSTRATE-SPECIFICITY FOR S-ADENOSYLMETHIONINE - HISTONE-ARGININE N-METHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-BASIC-PROTEIN; HELIX-DESTABILIZING PROTEIN; AMINO-ACID SEQUENCE; CALF THYMUS; BINDING-PROTEINS; COMPLEX PROTEIN-A1; MOUSE-BRAIN; PURIFICATION; UP1; RIBONUCLEOPROTEIN	We have previously reported the existence of two different molecular species of protein methylase I (S-adenosylmethionine:protein-arginine N-methyltransferase, E.C. 2.1.1.23) in calf brain, one specific for myelin basic protein and the other for histone (Ghosh, S. K., Paik, W. K., and Kim, S. (1988) J. Biol. Chem. 263, 19024-19033). In the present study, however, we report that heterogeneous ribonucleoprotein particle protein Al is most likely an in vivo substrate for the ''histone-specific protein methylase I.'' The unmethylated recombinant protein A1 has been found to be a much superior methyl acceptor for the enzyme than histone with a K(m) value two orders of magnitude lower (0.19 muM) than that for histone (21 muM). Myelin basic protein, a specific inhibitor for histone protein methylase I, exhibited a lower IC50 for protein Al methylation (IC50 = 33 muM) compared with histone methylation (IC50 = 220 muM) and competitively inhibited the former with a K(i) value of 1.3 x 10(-6) M. The extent of inhibition of protein A1 and histone methylation by the polyclonal antibodies prepared against purified ''histone protein methylase I'' was identical. Maximally, 1.08-mol methyl groups were incorporated per mol of protein A1, which was 27-fold higher than that of histone (0.04 mol/mol of histone). HPLC analysis of the enzymatically methylated amino acid residues in protein Al revealed the formation of N-monomethylarginine and N(G),N(G)-dimethylarginine. The ratio of N(G),N(G)-dimethylarginine/N(G)-monomethylarginine increased as a function of incubation period; however, N(G),N'G-dimethylarginine was not detectable. Proteolytic cleavage of the methyl-H-3-labeled recombinant protein Al by trypsin and Staphylococcus aureus V8 endoprotease indicated that, protein A1 possesses multiple sites for methylation, one of which was identified as residue 194 arginine, which coincided with the in vivo methylation site.	TEMPLE UNIV, HLTH SCI CTR,SCH MED, FELS INST CANC RES & MOLEC BIOL,3420 N BROAD ST, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NCI NIH HHS [CA 122270] Funding Source: Medline; NIADDK NIH HHS [AM09602] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM009602] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R21CA122270] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDWIN GS, 1971, SCIENCE, V171, P579, DOI 10.1126/science.171.3971.579; BOFFA LC, 1979, BIOCHEM BIOPH RES CO, V89, P1322, DOI 10.1016/0006-291X(79)92153-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSTOFF S, 1971, P NATL ACAD SCI USA, V68, P765, DOI 10.1073/pnas.68.4.765; CHANDERKAR LP, 1986, BIOCHEM J, V240, P471, DOI 10.1042/bj2400471; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; COBIANCHI F, 1986, J BIOL CHEM, V261, P3536; DELANGE RJ, 1969, J BIOL CHEM, V244, P5669; DESROSIERS R, 1988, J BIOL CHEM, V263, P4686; Dixon G. H., 1975, CIBA F S, V28, P229; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; DUERRE JA, 1975, J BIOL CHEM, V250, P8457; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FAROOQUI J, 1981, J BIOL CHEM, V256, P5041; GHOSH SK, 1990, BIOCHIM BIOPHYS ACTA, V1039, P142, DOI 10.1016/0167-4838(90)90179-J; GHOSH SK, 1988, J BIOL CHEM, V263, P19024; GUPTA A, 1982, J BIOL CHEM, V257, P9677; HERRICK G, 1976, J BIOL CHEM, V251, P2124; HONDA BM, 1975, J BIOL CHEM, V250, P8681; KARN J, 1977, J BIOL CHEM, V252, P7307; KIM SD, 1984, METHOD ENZYMOL, V106, P295; KUMAR A, 1986, J BIOL CHEM, V261, P1266; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P10717, DOI 10.1021/bi00500a001; KUMAR A, 1990, J BIOL CHEM, V265, P17094; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; LISCHWE MA, 1990, PROTEIN METHYLATION, P97; MERRILL BM, 1986, J BIOL CHEM, V261, P878; MERRILL BM, 1987, INT J PEPT PROT RES, V29, P21; OLIVER CL, 1984, METHOD MOL BIOL, V2, P157; PAIK WK, 1968, J BIOL CHEM, V243, P2108; PAIK WK, 1990, PROTEIN METHYLATION, P23; PAIK WK, 1980, BIOCH SERIES MONOGRA, V1, P8; PARK GH, 1986, BIOCHIM BIOPHYS ACTA, V874, P30, DOI 10.1016/0167-4838(86)90098-1; PARK KS, 1987, J BIOL CHEM, V262, P14702; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1989, J CELL BIOL, V109, P2575, DOI 10.1083/jcb.109.6.2575; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RAJPUROHIT R, 1992, BIOCHIM BIOPHYS ACTA, V1122, P183, DOI 10.1016/0167-4838(92)90322-5; RAWAL N, 1992, BIOCHEM J, V287, P929, DOI 10.1042/bj2870929; RAWAL N, 1991, J NEUROSCI METH, V37, P133, DOI 10.1016/0165-0270(91)90123-H; REPORTER M, 1971, BIOCHEM BIOPH RES CO, V43, P644, DOI 10.1016/0006-291X(71)90663-2; RIVA S, 1986, EMBO J, V5, P2267, DOI 10.1002/j.1460-2075.1986.tb04494.x; STAHMANN MA, 1946, J BIOL CHEM, V164, P753; WILLIAMS KR, 1985, P NATL ACAD SCI USA, V82, P5666, DOI 10.1073/pnas.82.17.5666; ZAPPIA V, 1969, J BIOL CHEM, V244, P4499; 1984, 07124 WAT ASS OP MAN, P1	49	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1075	1082						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288564				2022-12-25	WOS:A1994MR22000049
J	SANDBRINK, R; MASTERS, CL; BEYREUTHER, K				SANDBRINK, R; MASTERS, CL; BEYREUTHER, K			BETA-A4-AMYLOID PROTEIN-PRECURSOR MESSENGER-RNA ISOFORMS WITHOUT EXON-15 ARE UBIQUITOUSLY EXPRESSED IN RAT-TISSUES INCLUDING BRAIN, BUT NOT IN NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PROTEIN; ALZHEIMERS-DISEASE; DIFFERENTIAL EXPRESSION; HIPPOCAMPAL-NEURONS; GENE; LOCALIZATION; PEPTIDE; CORTEX; APP; IDENTIFICATION	The betaA4-amyloid protein precursor (APP), the source of the betaA4-amyloid deposits found in Alzheimer brains, constitutes a family of transmembrane glycoproteins generated by alternative splicing. While exon 7 and exon 8 are well known to be alternatively spliced, APP mRNA isoforms without exon 15 were only recently identified in leukocytes and rat brain microglial cells and therefore denoted as L-APP mRNAs. In order to perform a detailed analysis of individual L-APP mRNA isoforms in perfused rat tissues, we developed a quantitative polymerase chain reaction assay from reverse transcribed RNA allowing us to analyze the alternatively spliced region in between exon 6 and 16. In all peripheral tissues examined, L-APP mRNA isoforms were detected comprising between 25% (skeletal muscle) and about 70% (aorta, pancreas) of total APP transcripts. All four possible A.PP mRNA isoforms without exon 15 were shown to exist, i.e. L-APP752, L-APP733, L-APP696, and L-APP677. L-APP expression in the central nervous system (approximately 4% of total APP mRNA) was then studied in more detail by analyzing different brain regions and tissues and primary cultured brain cells. The only cell type which was shown not to express L-APP mRNA to a detectable level is the neuronal cell. Ubiquitous expression of APP mRNAs lacking exon 15 except for neurons indicates an important function in non-neuronal cells and is especially remarkable since neurons are the primarily affected cells in Alzheimer's disease.	UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA	University of Melbourne	SANDBRINK, R (corresponding author), UNIV HEIDELBERG,CTR MOLEC BIOL HEIDELBERG ZMBH,NEUENHEIMER FELD 282,D-69120 HEIDELBERG,GERMANY.							AUSBUBEL FM, 1989, CURRENT PROTOCOLS MO; BANATI RB, 1993, IN PRESS GLIA, V9; BORRIELLO F, 1990, NUCLEIC ACIDS RES, V18, P5481, DOI 10.1093/nar/18.18.5481; BREWER GJ, 1989, BRAIN RES, V494, P65, DOI 10.1016/0006-8993(89)90144-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK MJ, 1985, EMBO J, V4, P113, DOI 10.1002/j.1460-2075.1985.tb02324.x; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; JACOBSEN JS, 1991, NEUROBIOL AGING, V12, P585, DOI 10.1016/0197-4580(91)90090-7; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; JOHNSON SA, 1988, EXP NEUROL, V102, P264, DOI 10.1016/0014-4886(88)90104-5; KANG J, 1990, BIOCHEM BIOPH RES CO, V166, P1192, DOI 10.1016/0006-291X(90)90992-V; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KANG J, 1989, NUCLEIC ACIDS RES, V17, P2130, DOI 10.1093/nar/17.5.2130; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KONIG G, 1991, MOL BRAIN RES, V9, P259, DOI 10.1016/0169-328X(91)90010-U; KONIG G, 1992, J BIOL CHEM, V267, P10804; KOO EH, 1990, NEURON, V2, P97; Krainer AR, 1988, TRANSCRIPTION SPLICI, P131; LEBLANC AC, 1991, FEBS LETT, V292, P171, DOI 10.1016/0014-5793(91)80861-V; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; MIYAZAKI K, 1993, NATURE, V362, P839, DOI 10.1038/362839a0; MONNING U, 1992, J BIOL CHEM, V267, P23950; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; NEVE RL, 1990, NEURON, V5, P329, DOI 10.1016/0896-6273(90)90169-G; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; OYAMA F, 1991, J NEUROPATH EXP NEUR, V50, P560, DOI 10.1097/00005072-199109000-00004; PALMERT MR, 1988, SCIENCE, V241, P1080, DOI 10.1126/science.2457949; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; Sambrook J, 1989, MOL CLONING LABORATO; SCHUBERT D, 1988, SCIENCE, V241, P223, DOI 10.1126/science.2968652; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SCHUBERT W, 1991, BRAIN RES, V563, P184, DOI 10.1016/0006-8993(91)91532-6; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TANAKA S, 1988, BIOCHEM BIOPH RES CO, V157, P472, DOI 10.1016/S0006-291X(88)80273-0; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WHITSON JS, 1989, SCIENCE, V243, P1488, DOI 10.1126/science.2928783; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	54	124	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1510	1517						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288617				2022-12-25	WOS:A1994MR22000112
J	SMIRNOV, MD; ESMON, CT				SMIRNOV, MD; ESMON, CT			PHOSPHATIDYLETHANOLAMINE INCORPORATION INTO VESICLES SELECTIVELY ENHANCES FACTOR VA INACTIVATION BY ACTIVATED PROTEIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BLOOD-COAGULATION; ENZYME COMPLEXES; MEMBRANE-BINDING; THROMBOMODULIN; PROTHROMBIN; THROMBIN	Membrane surfaces accelerate the proteolytic inactivation of factor Va by activated protein C. In most coagulation complexes, the most active membrane phospholipid is believed to be phosphatidylserine. In this study, we demonstrate that with phosphatidylserine-containing vesicles, incorporation of phosphatidylethanolamine increased the rate of factor Va inactivation approximately 10-fold at all concentrations of factor Va studied and at all vesicle concentrations at or below the optimum for prothrombin activation. In contrast, phosphatidylethanolamine had very little influence on prothrombin activation. Phosphatidylethanolamine was a critical component of vesicles for the vesicles to support activated protein C anticoagulant activity optimally in plasma. These results demonstrate that the membrane requirements for the different coagulation/anticoagulation complexes differ much more than previously appreciated.	UNIV OKLAHOMA,HLTH SCI CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73190; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104	Howard Hughes Medical Institute; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation	SMIRNOV, MD (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,HOWARD HUGHES MED INST,DEPT PATHOL,OKLAHOMA CITY,OK 73190, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030340] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL30340] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BEVERS EM, 1991, BLOOD REV, V5, P146, DOI 10.1016/0268-960X(91)90031-7; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON CT, 1973, THESIS WASHINGTON U; FERNLUND P, 1982, J BIOL CHEM, V257, P2170; JACKMAN RW, 1986, P NATL ACAD SCI USA, V83, P8834, DOI 10.1073/pnas.83.23.8834; LAURA R, 1980, BIOCHEMISTRY-US, V19, P4859, DOI 10.1021/bi00562a024; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; OWEN WG, 1974, J BIOL CHEM, V249, P594; PEI G, 1993, J BIOL CHEM, V268, P3226; RAUCH J, 1986, J BIOL CHEM, V261, P9672; SCHWALBE RA, 1989, J BIOL CHEM, V264, P20288; TANS G, 1991, BLOOD, V77, P2641; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; TRIPLETT DA, 1993, ARCH PATHOL LAB MED, V117, P78; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WALKER FJ, 1980, J BIOL CHEM, V255, P5521	27	163	171	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					816	819						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288632				2022-12-25	WOS:A1994MR22000009
J	BOERNER, RJ; BARRY, BA				BOERNER, RJ; BARRY, BA			EPR EVIDENCE THAT THE M+ RADICAL, WHICH IS OBSERVED IN 3 SITE-DIRECTED MUTANTS OF PHOTOSYSTEM-II, IS A TYROSINE RADICAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; OXYGEN-EVOLVING SYSTEM; GALACTOSE-OXIDASE; MODEL COMPOUNDS; D1 POLYPEPTIDE; SYNECHOCYSTIS-6803; SPECTROSCOPY; CONSTANTS; CATIONS; DONOR	Isotopic labeling of Synechocystis sp. PCC 6803 and EPR spectroscopy have been used to demonstrate that photosystem II contains two redox active tyrosines, D and Z (Barry, B. A. and Babcock, G. T. (1987) Proc. Natl. Acad. Sci. U.S.A. 84, 7099-7103; Boerner, R. J. and Barry, B. A. (1993) J. Biol. Chem. 268, 17151-17154). Another organic radical, M+, has recently been observed in site-directed mutants in which a non-redox active amino acid is substituted at either the putative D or putative Z sites (Boerner, R. J., Bixby, K. A., Nguyen, A. P., Noren, G. H., Debus, R. J., and Barry, B. A. (1993) J. Biol. Chem. 268, 1817-1823; Noren, G. H., and Barry, B. A. (1992) Biochemistry 31, 3335-3342). Here, we use isotopic labeling to determine the chemical identity of M+. Upon incorporation of perdeuterated tyrosine into photosystem II, the M+ EPR signal narrows to approximately 12-13 G. Labeling with 3,5-deuterated tyrosine results in an isotropic doublet with splittings of 11 G. Our results show that M+ is a tyrosine radical with unique spectroscopic properties.	UNIV MINNESOTA, DEPT BIOCHEM, ST PAUL, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043273] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43273] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABCOCK GT, 1992, J AM CHEM SOC, V114, P3727, DOI 10.1021/ja00036a023; BABCOCK GT, 1983, BIOCHIM BIOPHYS ACTA, V723, P276, DOI 10.1016/0005-2728(83)90127-5; BARRY BA, 1987, P NATL ACAD SCI USA, V84, P7099, DOI 10.1073/pnas.84.20.7099; BARRY BA, 1990, J BIOL CHEM, V265, P20139; BARRY BA, 1988, CHEM SCRIPTA, V28A, P117; BARRY BA, 1993, PHOTOCHEM PHOTOBIOL, V57, P179, DOI 10.1111/j.1751-1097.1993.tb02275.x; BOERNER RJ, 1993, J BIOL CHEM, V268, P1817; BOERNER RJ, 1993, J BIOL CHEM, V268, P17151; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; DEBUS RJ, 1988, P NATL ACAD SCI USA, V85, P427, DOI 10.1073/pnas.85.2.427; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DIXON WT, 1976, J CHEM SOC FARAD T 2, V72, P1221, DOI 10.1039/f29767201221; DIXON WT, 1974, J CHEM SOC FARAD T 2, V70, P1713, DOI 10.1039/f29747001713; GERFEN GJ, 1993, J AM CHEM SOC, V115, P6420, DOI 10.1021/ja00067a071; HOGANSON CW, 1992, BIOCHEMISTRY-US, V31, P11874, DOI 10.1021/bi00162a028; HOLTON DM, 1979, J CHEM SOC FARAD T 2, V75, P1637, DOI 10.1039/f29797501637; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; MATTOO AK, 1993, SOC EXP BIOL SEMIN S, V53, P65, DOI 10.1017/CBO9780511600401.006; METZ JG, 1989, BIOCHEMISTRY-US, V28, P6960, DOI 10.1021/bi00443a028; MU D, 1992, J BIOL CHEM, V267, P7979; NOREN GH, 1991, BIOCHEMISTRY-US, V30, P3943, DOI 10.1021/bi00230a020; NOREN GH, 1992, BIOCHEMISTRY-US, V31, P3335, DOI 10.1021/bi00128a005; VERMAAS WFJ, 1988, P NATL ACAD SCI USA, V85, P8477, DOI 10.1073/pnas.85.22.8477; WERTZ JE, 1986, ELECTRON SPIN RESONA; WHITTAKER MM, 1990, J BIOL CHEM, V265, P9610	26	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					134	137						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276786				2022-12-25	WOS:A1994MR21900028
J	GOPALAKRISHNAN, L; SCARPULLA, RC				GOPALAKRISHNAN, L; SCARPULLA, RC			DIFFERENTIAL REGULATION OF RESPIRATORY-CHAIN SUBUNITS BY A CREB-DEPENDENT SIGNAL-TRANSDUCTION PATHWAY - ROLE OF CYCLIC-AMP IN CYTOCHROME-C AND COXIV GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ELECTRON-TRANSPORT; MESSENGER-RNAS; SOMATOSTATIN GENE; THYROID-HORMONE; PROCESSED PSEUDOGENES; COORDINATE INDUCTION; CATALYTIC SUBUNIT; RIBONUCLEIC-ACID; SKELETAL-MUSCLE; PROTEIN-KINASE	In vertebrate organisms, the molecular mechanisms by which extracellular signals regulate mitochondrial function and biogenesis are largely unknown. We have previously identified multiple cis-acting elements in both cytochrome c and cytochrome oxidase subunit IV (COXIV) genes that are likely targets for the regulated expression of respiratory chain components. We now demonstrate that cytochrome c but not COXIV mRNA is induced by cAMP through a mechanism involving transcriptional activation. Maximal induction occurs within 3 h and does not require de novo protein synthesis. The differential response of these genes is mediated by two distinct cAMP response elements (CREs) in the cytochrome c promoter region. Both elements function independently to drive cAMP-dependent expression from a heterologous promoter and within the proper cytochrome c promoter context. In addition, the binding properties of both elements to nuclear factors were characterized by competition DNase I footprinting, methylation interference footprinting, site-directed mutagenesis, and UV-induced DNA-protein cross-linking. The results are all consistent with the specific recognition of both CREs by CRE binding protein (CREB). A highly purified preparation of recombinant CREB formed a specific complex with each of the cytochrome c CREs identical to that formed with a crude nuclear fraction. In addition, the trans-activation of cytochrome c gene expression by recombinant CREB and protein kinase A in transfected cells was completely dependent on functional CREs within the promoter. These results establish that respiratory chain gene expression can be regulated directly by cAMP through a CREB-dependent signal transduction pathway.	NORTHWESTERN UNIV, SCH MED, DEPT CELL MOLEC & STRUCT BIOL, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA	Northwestern University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032525, R56GM032525] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32525-11] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BOOTH FW, 1975, ARCH BIOCHEM BIOPHYS, V167, P674, DOI 10.1016/0003-9861(75)90511-1; CHAU CMA, 1992, J BIOL CHEM, V267, P6999; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; CLAYTON DA, 1992, INT REV CYTOL, V141, P217, DOI 10.1016/S0074-7696(08)62067-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS MJ, 1988, P NATL ACAD SCI USA, V85, P9625, DOI 10.1073/pnas.85.24.9625; EVANS MJ, 1988, MOL CELL BIOL, V8, P35, DOI 10.1128/MCB.8.1.35; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; EWART G, 1990, BIOCHIM BIOPHYS ACTA, V1018, P223, DOI 10.1016/0005-2728(90)90253-Z; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINK JS, 1988, P NATL ACAD SCI USA, V85, P6662, DOI 10.1073/pnas.85.18.6662; GLAICHENHAUS N, 1986, EMBO J, V5, P1261, DOI 10.1002/j.1460-2075.1986.tb04355.x; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUPTE SS, 1988, J BIOL CHEM, V263, P5248; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOOD DA, 1989, EUR J BIOCHEM, V179, P275, DOI 10.1111/j.1432-1033.1989.tb14551.x; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; KADOWAKI T, 1991, EXP CELL RES, V192, P243, DOI 10.1016/0014-4827(91)90182-T; KESSLER MA, 1986, ARCH BIOCHEM BIOPHYS, V251, P403, DOI 10.1016/0003-9861(86)90346-2; KU CY, 1991, MOL ENDOCRINOL, V5, P1669, DOI 10.1210/mend-5-11-1669; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; MEKALANOS JJ, 1988, METHOD ENZYMOL, V165, P169; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MUCHARDT C, 1992, EMBO J, V11, P2573, DOI 10.1002/j.1460-2075.1992.tb05322.x; MUCHARDT C, 1990, J VIROL, V64, P4296, DOI 10.1128/JVI.64.9.4296-4305.1990; MUTVEI A, 1989, ACTA ENDOCRINOL-COP, V121, P223, DOI 10.1530/acta.0.1210223; PARISI MA, 1993, MOL CELL BIOL, V13, P1951, DOI 10.1128/MCB.13.3.1951; POYTON RO, 1988, ANN NY ACAD SCI, V550, P289, DOI 10.1111/j.1749-6632.1988.tb35344.x; RIABOWOL KT, 1988, NATURE, V336, P83, DOI 10.1038/336083a0; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SCARPULLA RC, 1983, CELL, V32, P473, DOI 10.1016/0092-8674(83)90467-1; SCARPULLA RC, 1986, J BIOL CHEM, V261, P4660; SCARPULLA RC, 1984, MOL CELL BIOL, V4, P2279, DOI 10.1128/MCB.4.11.2279; SHAN B, 1990, EMBO J, V9, P4307, DOI 10.1002/j.1460-2075.1990.tb07879.x; SHORT JM, 1986, J BIOL CHEM, V261, P9721; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TORRONI A, 1990, J BIOL CHEM, V265, P20589; UHLER MD, 1987, J BIOL CHEM, V262, P15202; VANITALLIE CM, 1988, MOL ENDOCRINOL, V2, P332, DOI 10.1210/mend-2-4-332; VANITALLIE CM, 1990, ENDOCRINOLOGY, V127, P55, DOI 10.1210/endo-127-1-55; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; VIRBASIUS JV, 1990, NUCLEIC ACIDS RES, V18, P6581, DOI 10.1093/nar/18.22.6581; VIRBASIUS JV, 1988, J BIOL CHEM, V263, P6791; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	55	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					105	113						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276781				2022-12-25	WOS:A1994MR21900024
J	AOYAGI, T; IZUMO, S				AOYAGI, T; IZUMO, S			MAPPING OF THE PRESSURE RESPONSE ELEMENT OF THE C-FOS GENE BY DIRECT DNA INJECTION INTO BEATING HEARTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC MYOCYTES; PROTOONCOGENE INDUCTION; NERVOUS-SYSTEM; MUSCLE INVIVO; CYCLIC-AMP; EXPRESSION; HYPERTROPHY; THERAPY; SIGNALS; CELLS	In vivo gene transfer into various organs of postnatal animals has recently been demonstrated. We applied this technique in order to map the promoter element of the protooncogene c-fos in the myocardium that responds to left ventricular pressure overload in vivo. Beating rat hearts were directly injected with a recombinant plasmid containing a 356-base pair upstream regulatory element of the mouse c-fos gene fused to a reporter gene. Two days after the injection, the hearts were excised and buffer-perfused. Acute pressure overload was applied for 2 h by inflating an intraventricular balloon. Pressure overload increased the myocardial reporter gene activity by 3-8-fold (p < 0.01). Deletion and point mutations in the serum response element (SRE) of the c-fos promoter resulted in loss of pressure-induced reporter gene expression, indicating that the SRE is necessary for pressure response. The SRE alone was sufficient to confer pressure responsiveness to the minimal c-fos promoter, confirming that the pressure response element coincides with the SRE. A construct containing a point mutation at the p62TCF binding site of the SRE did not respond to pressure overload or to a protein kinase C activator but retained responsiveness to a calcium ionophore. This suggests that pressure overload may activate the c-fos promoter by a protein kinase C-dependent pathway. Thus, a directly injected gene can be regulated in the host cells by a physical stimulus to the intact organ. The in vivo DNA injection technique is a useful method to study complex organ physiology at the molecular level.	BETH ISRAEL HOSP, MOLEC MED UNIT, 330 BROOKLINE AVE, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DIV CARDIOVASC, BOSTON, MA 02215 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School								ACSADI G, 1991, NEW BIOL, V3, P71; AOYAGI T, 1991, J CARDIOVASC PHARM, V17, P647; AUSEBEL FM, 1988, CURRENT PROTOCOL MOL, P966; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CRYSTAL RG, 1992, AM J MED, V92, pS44; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; KITSIS RN, 1991, P NATL ACAD SCI USA, V88, P4138, DOI 10.1073/pnas.88.10.4138; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1991, J BIOL CHEM, V266, P1265; LEINWAND LA, 1991, TRENDS CARDIOVAS MED, V1, P271, DOI 10.1016/1050-1738(91)90042-D; LIN H, 1990, CIRCULATION, V82, P2217, DOI 10.1161/01.CIR.82.6.2217; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NABEL EG, 1991, J AM COLL CARDIOL, V17, pB189; NORDEEN SK, 1991, BIOTECHNIQUES, V6, P474; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; RIVERA V M, 1990, New Biologist, V2, P751; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SADOSHIMA J, 1992, P NATL ACAD SCI USA, V89, P9905, DOI 10.1073/pnas.89.20.9905; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SCHUNKERT H, 1991, P NATL ACAD SCI USA, V88, P11480, DOI 10.1073/pnas.88.24.11480; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; Treisman R, 1990, Semin Cancer Biol, V1, P47; VONHARSDORF R, 1993, CIRC RES, V72, P1688; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; WOLFF JA, 1991, BIOTECHNIQUES, V11, P474	32	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27176	27179						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262957				2022-12-25	WOS:A1993MM26200052
J	FURRIOLS, M; CHILLARON, J; MORA, C; CASTELLO, A; BERTRAN, J; CAMPS, M; TESTAR, X; VILARO, S; ZORZANO, A; PALACIN, M				FURRIOLS, M; CHILLARON, J; MORA, C; CASTELLO, A; BERTRAN, J; CAMPS, M; TESTAR, X; VILARO, S; ZORZANO, A; PALACIN, M			RBAT, RELATED TO L-CYSTINE TRANSPORT, IS LOCALIZED TO THE MICROVILLI OF PROXIMAL STRAIGHT TUBULES, AND ITS EXPRESSION IS REGULATED IN KIDNEY BY DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL BRUSH-BORDER; XENOPUS-LAEVIS OOCYTES; AMINO-ACID-TRANSPORT; RAT-KIDNEY; MEMBRANE-VESICLES; GLUTAMATE TRANSPORTER; MOLECULAR-CLONING; MESSENGER-RNA; BRAIN; CDNA	We have recently isolated a renal cDNA clone (rBAT) that induces amino acid transport in oocytes either as a component or as a specific activator of a system bo,+-like transporter. (Bertran, J., Werner, A., Moore, M. L., Stange, G., Markovich, D., Biber, J., Testar, X., Zorzano, A., Palacin, M., and Murer, H. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5601-5605. In order to obtain additional information on the rBAT protein, we have investigated the cellular localization of rBAT and its expression during development in rat kidney. A polyclonal antibody raised against rBAT recognizes a specific protein band of approximately 90 kDa, which is highly enriched in rat renal brush border membranes. Immunofluorescence and immunoelectron microscopy studies demonstrated that rBAT is expressed in the microvilli domain of S3 epithelial cells (i.e. straight tubules). The onset of rBAT mRNA expression in kidney was detected during late fetal life. In keeping with this, induction in oocytes of L-cystine uptake due to fetal rBAT-related mRNA was approximately 10% of the induction obtained with rBAT-related mRNA from adult kidneys. rBAT mRNA levels were low in early postnatal life, and only at the end of lactation did they increase steeply, attaining approximately 50% of adult values after weaning. rBAT protein was undetectable in total membrane preparations of kidneys from fetuses and early neonates, weakly detected during lactation, and represented <15% of adult values after weaning. The postnatal expression of rBAT and its specific location in the microvilli of epithelial cells from the S3 segment of the proximal tubule coincide with postnatal maturation of cystine resorption and with the site of high affinity resorption of cystine in kidney. This is consistent with the involvement of rBAT in a bo,+-like high-affinity resorption system for cystine in the proximal straight tubule of the nephron.	UNIV BARCELONA,FAC BIOL,DEPT BIOQUIM & FISIOL,AVDA DIAGONAL 645,E-08028 BARCELONA,SPAIN	University of Barcelona			Palacín, Manuel/G-9786-2015; Wilson, Matthew H/K-3193-2013; Camps, Marta/F-6557-2016; Farré, Anna Castelló/K-9637-2015; Chillaron, Josep/ABF-7663-2021; Zorzano, Antonio/R-5479-2018; Mora, Conchi/A-8280-2010	Camps, Marta/0000-0001-5392-1792; Farré, Anna Castelló/0000-0001-8497-6251; Chillaron, Josep/0000-0003-3068-7598; Mora, Conchi/0000-0002-5644-0537; Furriols, Marc/0000-0002-0656-1912; Palacin, Manuel/0000-0002-8670-293X				Bergeron M, 1985, KIDNEY PHYSL PATHOPH, P1725; BERTRAN J, 1993, J BIOL CHEM, V268, P14842; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; BERTRAN J, 1992, BIOCHEM J, V281, P717, DOI 10.1042/bj2810717; BIBER J, 1983, PFLUG ARCH EUR J PHY, V396, P335, DOI 10.1007/BF01063939; BIEMESDERFER D, 1992, AM J PHYSIOL, V262, pF55, DOI 10.1152/ajprenal.1992.262.1.F55; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETAUDIERE JP, 1984, METHOD ENZYMAT AN, V4, P75; BRODEHL J, 1968, PEDIATRICS, V42, P395; BULGER RE, 1988, CELL TISSUE BIOL TXB, P815; CAMPS L, 1991, J LIPID RES, V32, P1877; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; COICADAN L, 1980, PEDIATR RES, V14, P109, DOI 10.1203/00006450-198002000-00008; FOREMAN JW, 1980, METABOLISM, V29, P53, DOI 10.1016/0026-0495(80)90098-0; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; FURLONG TJ, 1990, AM J PHYSIOL, V258, pF321, DOI 10.1152/ajprenal.1990.258.2.F321; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P9608; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANAI Y, 1982, AM J PHYSIOL, V263, pF1087; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON L, 1975, J ULTRA MOL STRUCT R, V51, P119, DOI 10.1016/S0022-5320(75)80013-X; LARSSON L, 1975, J ULTRA MOL STRUCT R, V53, P254, DOI 10.1016/S0022-5320(75)80142-0; LIU AR, 1992, P NATL ACAD SCI USA, V89, P1214; MAGAGNIN S, 1992, J BIOL CHEM, V267, P15384; MARKOVICH D, 1993, J BIOL CHEM, V268, P1362; MCKUSICK VA, 1990, MENDELIAN INHERITANC, P1128; MCNAMARA PD, 1992, BIOCHIM BIOPHYS ACTA, V1103, P101, DOI 10.1016/0005-2736(92)90062-Q; MCNAMARA PD, 1981, BIOCHEM J, V194, P443, DOI 10.1042/bj1940443; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OZEGOVIC B, 1982, BIOSCIENCE REP, V2, P913, DOI 10.1007/BF01114898; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Rosen K., 1990, FOCUS, V12, P23; ROSENBERG LE, 1966, J CLIN INVEST, V45, P365, DOI 10.1172/JCI105351; SCHAFER JA, 1984, PFLUG ARCH EUR J PHY, V401, P143, DOI 10.1007/BF00583874; SCRIVER CR, 1985, J PEDIATR-US, V106, P411, DOI 10.1016/S0022-3476(85)80666-1; SEGAL S, 1969, P NATL ACAD SCI USA, V63, P926, DOI 10.1073/pnas.63.3.926; SEGAL S, 1977, SCIENCE, V197, P169, DOI 10.1126/science.877548; SEGAL S, 1989, METABOLIC BASIS INHE, P2479; SILBERNAGL S, 1988, PHYSIOL REV, V68, P911, DOI 10.1152/physrev.1988.68.3.911; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; THIER SO, 1965, J CLIN INVEST, V44, P442, DOI 10.1172/JCI105157; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; VOLKL H, 1982, PFLUG ARCH EUR J PHY, V395, P190, DOI 10.1007/BF00584808; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; YAN N, 1992, P NATL ACAD SCI USA, V89, P9982, DOI 10.1073/pnas.89.21.9982	52	101	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27060	27068						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262944				2022-12-25	WOS:A1993MM26200036
J	SUN, AQ; YUKSEL, KU; GRACY, RW				SUN, AQ; YUKSEL, KU; GRACY, RW			LIMITED PROTEOLYSIS OF TRIOSE-PHOSPHATE ISOMERASE AND CHARACTERIZATION OF THE CATALYTICALLY ACTIVE PEPTIDE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TRIOSEPHOSPHATE ISOMERASE; SITE MODIFICATION; PROTEINS; DISSOCIATION; DEGRADATION; QUANTITIES; REPRESSOR; SEQUENCES; ENZYME; REGION	Limited proteolysis of the triose-phosphate isomerase (EC 5.3.1.1) by subtilisin generates peptides that remain noncovalently attached and catalytically active. Edman degradation of the peptides showed that the primary proteolytic sites for yeast triose-phosphate isomerase are the Leu174-Ala175 bond followed by Ser52-Leu53. The Leu174-Ala175 site is of particular interest, since it forms part of the hinged lid that closes over the catalytic center, and this bond is only 12.2 angstrom (open) or 9.8 angstrom (closed) from the catalytic residue Glu165. The higher K(m), k(cat), and k(cat)/k(m) values exhibited by the catalytically active peptide complex suggest that the substrate is not bound as tightly to the catalytic center. In addition, increased methylglyoxal formation by the cleaved enzyme indicates that the enzyme-substrate complex is less protected from the solvent. Circular dichroic and fluorescence spectra show that the overall structure of the peptide complex is similar to the native enzyme but with local structural perturbations around the tryptophans. Also, the peptide complex is more susceptible to denaturation by guanidine and exhibits lower T(m) values, indicating a loose interaction between the fragments. Unfolding, dissociation, and refolding experiments suggest that the fragments have strong inherent secondary structural features and can reassociate into catalytically active structures.	UNIV N TEXAS, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, 3500 CAMP BOWIE BLVD, FT WORTH, TX 76107 USA	University of North Texas System; University of North Texas Health Science Center					NATIONAL INSTITUTE ON AGING [R01AG001274, R37AG001274] Funding Source: NIH RePORTER; NIA NIH HHS [AG01274] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHERN TJ, 1987, P NATL ACAD SCI USA, V84, P675, DOI 10.1073/pnas.84.3.675; ALBER T, 1981, PHILOS T ROY SOC B, V293, P159, DOI 10.1098/rstb.1981.0069; Anfinsen C B, 1967, Harvey Lect, V61, P95; BERGMEYER HU, 1984, METHOD ENZYMAT AN, V6, P593; BOWIE JU, 1989, BIOCHEMISTRY-US, V28, P7139, DOI 10.1021/bi00444a001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; EDER J, 1992, BIOCHEMISTRY-US, V31, P3617, DOI 10.1021/bi00129a010; GOLDBERG AL, 1974, ANNU REV BIOCHEM, V43, P835, DOI 10.1146/annurev.bi.43.070174.004155; GRACY RW, 1990, PROG CLIN BIOL RES, V344, P787; HARTMAN FC, 1971, BIOCHEMISTRY-US, V10, P146, DOI 10.1021/bi00777a021; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KIM HS, 1992, J BIOL CHEM, V267, P7177; KINOSHITA CM, 1992, PROTEIN SCI, V1, P700, DOI 10.1002/pro.5560010602; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS SD, 1992, PROTEIN SCI, V1, P998, DOI 10.1002/pro.5560010805; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6619, DOI 10.1021/bi00480a010; MAIZEL JV, 1971, METHOD VIROL, V5, P180; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; RICHARD JP, 1991, BIOCHEMISTRY-US, V30, P4581, DOI 10.1021/bi00232a031; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROJODOMINGUEZ A, 1990, BIOCHEMISTRY-US, V29, P8689, DOI 10.1021/bi00489a026; ROZACKY EE, 1971, ARCH BIOCHEM BIOPHYS, V146, P312, DOI 10.1016/S0003-9861(71)80069-3; SNAPKA RM, 1974, COMP BIOCHEM PHYSIOL, V49, P733, DOI 10.1016/0305-0491(74)90259-4; Speicher D.W., 1989, TECHNIQUES PROTEIN C, P24; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; SUN AQ, 1992, ARCH BIOCHEM BIOPHYS, V295, P421, DOI 10.1016/0003-9861(92)90536-6; SUN AQ, 1992, J BIOL CHEM, V267, P20168; SUN AW, 1992, ARCH BIOCHEM BIOPHYS, V293, P382, DOI 10.1016/0003-9861(92)90410-X; TASAYCO ML, 1992, SCIENCE, V255, P594, DOI 10.1126/science.1736361; WALEY SG, 1973, BIOCHEM J, V135, P165, DOI 10.1042/bj1350165; WIERENGA RK, 1991, J MOL BIOL, V220, P995, DOI 10.1016/0022-2836(91)90368-G; YUAN PM, 1981, BIOCHIM BIOPHYS ACTA, V671, P211, DOI 10.1016/0005-2795(81)90136-7; YUKSEL KU, 1986, ARCH BIOCHEM BIOPHYS, V248, P452, DOI 10.1016/0003-9861(86)90498-4	37	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26872	26878						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262920				2022-12-25	WOS:A1993MM26200010
J	BROWN, AM; WRIGHT, KL; TING, JPY				BROWN, AM; WRIGHT, KL; TING, JPY			HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II-ASSOCIATED INVARIANT CHAIN GENE PROMOTER - FUNCTIONAL-ANALYSIS AND IN-VIVO PROTEIN-DNA INTERACTIONS OF CONSTITUTIVE AND IFN-GAMMA-INDUCED EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; HLA-DRA GENE; INTERFERON CONSENSUS SEQUENCE; NECROSIS FACTOR-ALPHA; MACROPHAGE CELL-LINE; REGULATORY ELEMENTS; CHLORAMPHENICOL ACETYLTRANSFERASE; DIFFERENTIAL EXPRESSION; TRANSCRIPTIONAL CONTROL; INDUCIBLE REGULATION	Major histocompatibility complex (MHC) class II-associated invariant chain (Ii) gene and the MHC class II molecules are physically and functionally associated within class II-expressing cell types. These genes are generally co-expressed in various cell types and coordinately induced by cytokines such as interferon-gamma (IFN-gamma). Human Ii gene shares a regulatory mechanism with MHC class II genes via the X and Y cis-acting elements. Ii X and Y are required for constitutive expression in B lymphoid cell lines and for induction by IFN-gamma in a glioblastoma cell line. The Servenius element (S) contributes 5-fold transcriptional activity to class II gene HLA-DRA, and an S homologue has been implied in Ii gene regulation. Now we report that along with X and Y, the Ii S box functions in a positive manner to regulate Ii transcription in B cell lines but not in T cell lines. In addition, S, X, and Y are all necessary for induced expression of Ii in an IFN-gamma-regulated glioblastoma cell line and in primary untransformed glial cells. Transcriptional activity of Ii X and Y elements correlates with the presence of in vivo protein/DNA interactions in Ii-expressing cells. Most interestingly, in vivo interactions are induced upon IFN-gamma induction in a time-dependent fashion. Thus, the Ii promoter contains elements that coordinately regulate expression with the MHC class II genes, and these functional sites are contacted in vivo emphasizing their importance in Ii gene transcription.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	BROWN, AM (corresponding author), UNIV N CAROLINA,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI029564, R01AI029564] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29564] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARR CL, 1991, J BIOL CHEM, V266, P3475; BASTA PV, 1987, J IMMUNOL, V138, P1275; BASTA PV, 1988, P NATL ACAD SCI USA, V85, P8618, DOI 10.1073/pnas.85.22.8618; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BLANAR MA, 1989, EMBO J, V8, P1139, DOI 10.1002/j.1460-2075.1989.tb03484.x; BROWN AM, 1991, J IMMUNOL, V146, P3183; COGSWELL JP, 1991, J IMMUNOL, V146, P1361; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; CRESSWELL P, 1992, CURR OPIN IMMUNOL, V4, P87, DOI 10.1016/0952-7915(92)90131-W; DEDRICK RL, 1990, MOL CELL BIOL, V10, P593, DOI 10.1128/MCB.10.2.593; DEPREVAL C, 1985, NATURE, V318, P291, DOI 10.1038/318291a0; DEY A, 1992, MOL CELL BIOL, V12, P3590, DOI 10.1128/MCB.12.8.3590; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, P NATL ACAD SCI USA, V84, P6249, DOI 10.1073/pnas.84.17.6249; DOYLE C, 1990, P NATL ACAD SCI USA, V87, P4590, DOI 10.1073/pnas.87.12.4590; EADES AM, 1990, J IMMUNOL, V144, P4399; FINN PW, 1990, P NATL ACAD SCI USA, V87, P914, DOI 10.1073/pnas.87.3.914; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; ISRAEL A, 1986, NATURE, V322, P743, DOI 10.1038/322743a0; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KOCH N, 1984, J IMMUNOL, V132, P1361; KOCH N, 1984, J IMMUNOL, V132, P12; KUDO J, 1985, NUCLEIC ACIDS RES, V13, P8827, DOI 10.1093/nar/13.24.8827; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIOU HC, 1990, SCIENCE, V247, P1581, DOI 10.1126/science.2321018; LONG EO, 1985, SURV IMMUNOL RES, V4, P27; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MCGEER PL, 1988, ACTA NEUROPATHOL, V76, P550, DOI 10.1007/BF00689592; MIRKOVITCH J, 1992, MOL CELL BIOL, V12, P1; MOMBURG F, 1988, CLIN EXP IMMUNOL, V72, P367; MOMBURG F, 1986, J IMMUNOL, V136, P940; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NOELLE RJ, 1986, J IMMUNOL, V137, P1718; PAULNOCKKING D, 1985, J IMMUNOL, V135, P632; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PESSARA U, 1990, MOL CELL BIOL, V10, P4146, DOI 10.1128/MCB.10.8.4146; PESSARA U, 1988, EUR J IMMUNOL, V18, P1719, DOI 10.1002/eji.1830181110; POLLA BS, 1986, J IMMUNOL, V137, P3332; QUARANTA V, 1984, J IMMUNOL, V132, P1900; RAHMSDORF HJ, 1983, EMBO J, V2, P811, DOI 10.1002/j.1460-2075.1983.tb01507.x; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; SASAKI A, 1989, J NEUROIMMUNOL, V25, P63, DOI 10.1016/0165-5728(89)90087-8; SHERMAN PA, 1987, P NATL ACAD SCI USA, V84, P4254, DOI 10.1073/pnas.84.12.4254; SHIRAYOSHI Y, 1988, P NATL ACAD SCI USA, V85, P5884, DOI 10.1073/pnas.85.16.5884; SUGAWARA M, 1991, P NATL ACAD SCI USA, V88, P10347, DOI 10.1073/pnas.88.22.10347; SUGITA K, 1987, MOL CELL BIOL, V7, P2625, DOI 10.1128/MCB.7.7.2625; TAKIGUCHI M, 1985, EUR J IMMUNOL, V15, P809, DOI 10.1002/eji.1830150813; Teyton L, 1992, Trends Cell Biol, V2, P52, DOI 10.1016/0962-8924(92)90163-H; TSANG SY, 1988, P NATL ACAD SCI USA, V85, P8598, DOI 10.1073/pnas.85.22.8598; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VILEN BJ, 1992, J BIOL CHEM, V267, P23728; VILEN BJ, 1990, MOL CELL BIOL, V11, P2406; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; VOLCPLATZER B, 1984, J EXP MED, V159, P1784, DOI 10.1084/jem.159.6.1784; VOLIVA CF, 1992, MOL CELL BIOL, V12, P2383, DOI 10.1128/MCB.12.5.2383; WRIGHT KL, 1992, P NATL ACAD SCI USA, V89, P7601, DOI 10.1073/pnas.89.16.7601; ZELEZNIKLE NJ, 1991, P NATL ACAD SCI USA, V88, P1873, DOI 10.1073/pnas.88.5.1873; ZHU L, 1990, MOL CELL BIOL, V10, P3906, DOI 10.1128/MCB.10.8.3906	66	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26328	26333						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253755				2022-12-25	WOS:A1993MK42500049
J	GIRARD, LR; CASTLE, AM; HAND, AR; CASTLE, JD; MIRELS, L				GIRARD, LR; CASTLE, AM; HAND, AR; CASTLE, JD; MIRELS, L			CHARACTERIZATION OF COMMON SALIVARY PROTEIN-1, A PRODUCT OF RAT SUBMANDIBULAR, SUBLINGUAL, AND PAROTID-GLANDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERMINE BINDING-PROTEIN; SECRETORY PROTEINS; POLYACRYLAMIDE GELS; SEQUENCE-ANALYSIS; CELL-POPULATION; LOCALIZATION; EXPRESSION; CLEAVAGE; STORAGE; MEMBRANES	We have isolated and characterized cDNA clones derived from a developmentally regulated neonatal rat submandibular gland salivary protein gene called ''common salivary protein 1'' (CSP1). Identical clones were also identified in cDNA libraries from adult male parotid, submandibular, and sublingual glands. CSP1 transcripts are at least 10-fold more abundant in the sublingual gland than in the submandibular or parotid glands. In situ hybridization and immunocytochemical localization demonstrated the presence of CSP1 transcripts and proteins in sublingual gland serous demilune cells, parotid and submandibular gland intercalated duct cells, and in the type III (proacinar) cells of the neonatal submandibular gland. This cell-type distribution is similar to that described by Ball and colleagues (Ball, W. D., Hand, A. R., and Johnson, A. O. (1988) Dev. Biol. 125, 265-279) for the developmentally regulated submandibular gland B1-immunoreactive proteins. Immunoblotting of salivary secretion identified proteins of M(r) 20,000 in sublingual, 16,000 in submandibular and 22,000 and 16,000 in parotid gland. The M(r) 20,000 sublingual and 22,000 parotid proteins represent N-glycosylated forms of a M(r) 16,000 apoprotein, suggesting that these salivary proteins arise by post-translational modification of a common precursor.	UNIV CALIF SAN DIEGO, DEPT BIOL, 2425 BONNER HALL, 9500 GILMAN DR, LA JOLLA, CA 92093 USA; UNIV VIRGINIA, HLTH SCI CTR, INST MOLEC BIOL, DEPT ANAT & CELL BIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV CONNECTICUT, CTR HLTH, DEPT PEDIAT DENT & ORTHODONT, FARMINGTON, CT 06030 USA	University of California System; University of California San Diego; University of Virginia; University of Connecticut					NIDCR NIH HHS [DE09428, DE08941] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008941, R01DE009428] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANDEREGG RJ, 1988, BIOCHEMISTRY-US, V27, P4214, DOI 10.1021/bi00412a002; ANDERSON LC, 1984, J PHYSIOL-LONDON, V352, P163, DOI 10.1113/jphysiol.1984.sp015284; Arvan Peter, 1992, Trends in Cell Biology, V2, P327; AVIV H, 1977, P NATL ACAD SCI USA, V69, P1409; BALL WD, 1984, EUR J CELL BIOL, V33, P112; BALL WD, 1988, DEV BIOL, V129, P464, DOI 10.1016/0012-1606(88)90393-4; BALL WD, 1988, DEV BIOL, V125, P265, DOI 10.1016/0012-1606(88)90210-2; BALL WD, 1993, BIOL SALIVARY GLANDS, P355; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CASTLE AM, 1992, J BIOL CHEM, V267, P13093; CHANG WWL, 1974, ANAT RECORD, V178, P187, DOI 10.1002/ar.1091780204; COUWENHOVEN RI, 1990, J HISTOCHEM CYTOCHEM, V38, P1853, DOI 10.1177/38.12.2254649; CUTLER LS, 1974, DEV BIOL, V41, P31, DOI 10.1016/0012-1606(74)90280-2; Denny P C, 1990, Adv Dent Res, V4, P34; DENNY PC, 1993, BIOL SALIVARY GLANDS, P263; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HANKS CT, 1971, AM J ANAT, V130, P195, DOI 10.1002/aja.1001300206; HARLOW E, 1988, ANTIBODIES LABORATOR; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; JOHNSON DA, 1988, J DENT RES, V67, P1103, DOI 10.1177/00220345880670080801; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLS JS, 1987, NUCLEIC ACIDS RES, V15, P7709, DOI 10.1093/nar/15.19.7709; MINAGUCHI K, 1989, J DENT RES, V68, P2, DOI 10.1177/00220345890680010201; MIRELS L, 1987, J BIOL CHEM, V262, P7289; MIRELS L, 1992, J BIOL CHEM, V267, P2679; MOREIRA JE, 1991, AM J ANAT, V191, P167, DOI 10.1002/aja.1001910204; MOREIRA JE, 1990, DEV BIOL, V139, P370, DOI 10.1016/0012-1606(90)90306-4; PAPERMASTER DS, 1976, EXP EYE RES, V23, P105, DOI 10.1016/0014-4835(76)90194-9; REDMAN RS, 1970, J CELL BIOL, V46, P81, DOI 10.1083/jcb.46.1.81; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZARAD D, 1988, J ANAT, V161, P143; SIERRA F, 1986, MOL CELL BIOL, V6, P4067, DOI 10.1128/MCB.6.11.4067; Stone K.L., 1992, TECHNIQUES PROTEIN C, P23; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONZASTROW M, 1989, J BIOL CHEM, V264, P6566; VONZASTROW M, 1987, J CELL BIOL, V105, P2675, DOI 10.1083/jcb.105.6.2675; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WARD LD, 1990, CURRENT RES PROTEIN, P179; YAMASHINA S, 1972, J HISTOCHEM CYTOCHEM, V20, P855, DOI 10.1177/20.11.855; ZAJICEK G, 1985, ANAT REC, V213, P150, DOI 10.1002/ar.1092130206	49	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26592	26601						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253789				2022-12-25	WOS:A1993MK42500084
J	LOMBARDI, P; MULDER, M; VANDERBOOM, H; FRANTS, RR; HAVEKES, LM				LOMBARDI, P; MULDER, M; VANDERBOOM, H; FRANTS, RR; HAVEKES, LM			INEFFICIENT DEGRADATION OF TRIGLYCERIDE-RICH LIPOPROTEIN BY HEPG2 CELLS IS DUE TO A RETARDED TRANSPORT TO THE LYSOSOMAL COMPARTMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-E POLYMORPHISM; MOUSE PERITONEAL-MACROPHAGES; HUMAN-FIBROBLASTS; CELLULAR-BINDING; APOPROTEIN-E; HUMAN-PLASMA; RAT-LIVER; BETA-VLDL; RECEPTOR	Binding studies at 37-degrees-C showed that lipoprotein lipase-treated very low density lipoproteins (LPL-VLDL) and very low density lipoproteins (VLDL), once taken up via the low density lipoprotein (LDL) receptor, are poorly degraded by HepG2 cells as compared with LDL. Determination of the initial endocytotic rate for LPL-VLDL and VLDL as compared to LDL shows that LPL-VLDL and VLDL are internalized at a similar rate as LDL. Incubation of cells with labeled LDL, LPL-VLDL, and VLDL at 18-degrees-C for 4.5 h resulted in the accumulation of these particles in the early endosomes, without subsequent transport to the lysosomes and degradation. After washing the cells and a temperature shift to 37-degrees-C, the labeled LDL present in the early endosomes is transported to the lysosomal compartment almost completely within 15 min. Strikingly, for LPL-VLDL and for VLDL, only about 50% or less of the label was moved to the lysosomal compartment within 45 min. However, once present in the lysosomes, VLDL and LPL-VLDL are degraded about 1.6-fold more rapidly than LDL. Retroendocytosis accounts for less than 10% of the internalized LDL, whereas a higher rate of retroendocytosis, up to 20 and 40%, respectively, was observed for LPL-VLDL and VLDL. To evaluate the effect of the inefficient transport of VLDL and LPL-VLDL to the lysosomal compartment on cellular cholesterol homeostasis, acyl-CoA:cholesterol acyltransferase (ACAT) activity was measured. Incubation with 30 mug/ml of LDL induced a 2.5-fold increase in ACAT activity, whereas the incubation with similar amounts of both VLDL and LPL-VLDL failed to stimulate this enzyme. We conclude that both a slower transport to the lysosomal compartment and a higher rate of retroendocytosis, possibly as the consequence of the longer residence time in the early endosomes, are responsible for the poor degradation of VLDL and LPL-VLDL by HepG2 cells.	TNO,GAUBIUS LAB,IVVO,POB 430,2300 AK LEIDEN,NETHERLANDS; LEIDEN UNIV,DEPT HUMAN GENET,2300 RA LEIDEN,NETHERLANDS	Netherlands Organization Applied Science Research; Leiden University; Leiden University - Excl LUMC								ANDERSON RGW, 1982, J CELL BIOL, V93, P523, DOI 10.1083/jcb.93.3.523; AULINSKAS TH, 1985, ARTERIOSCLEROSIS, V5, P45, DOI 10.1161/01.ATV.5.1.45; BELTZ WF, 1985, J CLIN INVEST, V76, P575, DOI 10.1172/JCI112009; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOERWINKLE E, 1988, AM J HUM GENET, V42, P104; DEMANT T, 1991, J CLIN INVEST, V88, P1490, DOI 10.1172/JCI115459; DUNN WA, 1980, J BIOL CHEM, V255, P5971; EISENBERG S, 1988, ARTERIOSCLEROSIS, V8, P480, DOI 10.1161/01.ATV.8.5.480; EVANS AJ, 1992, J BIOL CHEM, V267, P10743; FRIEDMAN G, 1990, BIOCHIM BIOPHYS ACTA, V1044, P118, DOI 10.1016/0005-2760(90)90226-N; GOLDSTEIN JL, 1976, CELL, V7, P85, DOI 10.1016/0092-8674(76)90258-0; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; HARFORD J, 1983, J BIOL CHEM, V258, P3191; HAVEKES L, 1983, BIOCHEM J, V214, P951, DOI 10.1042/bj2140951; HAVEKES LM, 1987, BIOCHEM J, V247, P739, DOI 10.1042/bj2470739; HAVEL RJ, 1989, METABOLIC BASIS INHE, P1129; HAVEL RJ, 1988, HEPATOLOGY, V8, P1869; KESANIEMI YA, 1985, J CLIN INVEST, V76, P586, DOI 10.1172/JCI112010; KRUL ES, 1985, J CLIN INVEST, V75, P361, DOI 10.1172/JCI111708; LISCUM L, 1992, J LIPID RES, V33, P1039; LOMBARDI P, 1993, BIOCHEM J, V290, P509, DOI 10.1042/bj2900509; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MELLMAN I, 1984, J CELL BIOL, V98, P1170, DOI 10.1083/jcb.98.4.1170; MIRANIOOSTDIJK CP, 1985, SCAND J CLIN LAB INV, V45, P207, DOI 10.3109/00365518509160997; MULDER M, 1991, BIOCHIM BIOPHYS ACTA, V1081, P308, DOI 10.1016/0005-2760(91)90287-R; PITAS RE, 1979, P NATL ACAD SCI USA, V76, P2311, DOI 10.1073/pnas.76.5.2311; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; SMIT M, 1988, HUM GENET, V80, P287, DOI 10.1007/BF01790099; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; TABAS I, 1991, J CELL BIOL, V115, P1547, DOI 10.1083/jcb.115.6.1547; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; TORRIANI A, 1960, BIOCHIM BIOPHYS ACTA, V38, P460, DOI 10.1016/0006-3002(60)91281-6; UTERMANN G, 1987, AM HEART J, V113, P433, DOI 10.1016/0002-8703(87)90610-7; WILEY HS, 1981, CELL, V25, P433, DOI 10.1016/0092-8674(81)90061-1; WINDLER EET, 1980, J BIOL CHEM, V255, P464; WOLKOFF AW, 1984, J CELL BIOL, V98, P375, DOI 10.1083/jcb.98.2.375; XU XX, 1991, J BIOL CHEM, V266, P17040	39	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26113	26119						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253728				2022-12-25	WOS:A1993MK42500019
J	ZHU, PP; REIZER, J; REIZER, A; PETERKOFSKY, A				ZHU, PP; REIZER, J; REIZER, A; PETERKOFSKY, A			UNIQUE MONOCISTRONIC OPERON (PTSH) IN MYCOPLASMA-CAPRICOLUM ENCODING THE PHOSPHOCARRIER PROTEIN, HPR, OF THE PHOSPHOENOLPYRUVATE-SUGAR PHOSPHOTRANSFERASE SYSTEM - CLONING, SEQUENCING, AND CHARACTERIZATION OF PTSH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE-CONTAINING PROTEIN; ESCHERICHIA-COLI K-12; NUCLEOTIDE-SEQUENCE; POSITIVE REGULATION; TERTIARY STRUCTURE; BACILLUS-SUBTILIS; DNA-SEQUENCE; GENE; MUTANTS; GENOME	The region of the genome of Mycoplasma capricolum encompassing the gene (ptsH) encoding HPr, a general energy-coupling protein of the phosphoenolpyruvate: sugar phosphotransferase system, was cloned and sequenced. Examination of the sequence revealed a unique arrangement of the ptsH gene. In all other bacterial species characterized thus far, the ptsH gene is part of a polycistronic operon that includes the gene (ptsI) encoding Enzyme I of the phosphoenolpyruvate: sugar phosphotransferase system; the M. capricolum ptsH gene is part of a monocistronic operon that is situated between two open reading frames unrelated to phosphoenolpyruvate:sugar phosphotransferase system function. The gene immediately upstream of ptsH codes for a helicase, and the open reading frame immediately downstream of ptsH, although not homologous to any previously identified protein, contains a signature sequence characteristic of [C-5] cytosine-specific DNA methylases. The product of the ptsH gene has characteristics similar to the HPr protein produced by Gram-positive organisms: it has a greater sequence similarity to HPrs of Gram-positive bacteria than to those of Gram-negative organisms, it is phosphorylated by a protein kinase derived from Gram-positive organisms, and it complements sugar phosphorylation activity in Gram-positive extracts. The high calculated isoelectric point (pI = 9.18) and the absence of glutamate residues in the C-terminal region distinguish the M. capricolum HPr from all previously described HPrs.	NHLBI, BIOCHEM GENET LAB, BLDG 36, RM 4C-11, BETHESDA, MD 20892 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of California System; University of California San Diego					NIAID NIH HHS [2RO1AI14176, 5RO1AI21702] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014176, R01AI021702] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOUSSEKHRA A, 1989, NUCLEIC ACIDS RES, V17, P7211, DOI 10.1093/nar/17.18.7211; ANDERSON JW, 1991, BIOCHEMISTRY-US, V30, P9601, DOI 10.1021/bi00104a006; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; CIRILLO VP, 1979, MYCOPLASMAS, P323; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; DEREUSE H, 1992, J MOL BIOL, V226, P623, DOI 10.1016/0022-2836(92)90620-Y; DEREUSE H, 1991, J BACTERIOL, V173, P727, DOI 10.1128/jb.173.2.727-733.1991; DEREUSE H, 1985, GENE, V35, P199; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EBRIGHT RH, 1984, NATURE, V311, P232, DOI 10.1038/311232a0; ELKABBANI OAL, 1987, J BIOL CHEM, V262, P12926; FENG DF, 1990, METHOD ENZYMOL, V183, P375; FOX DK, 1992, P NATL ACAD SCI USA, V89, P7056, DOI 10.1073/pnas.89.15.7056; GEERSE RH, 1989, MOL GEN GENET, V216, P517, DOI 10.1007/BF00334399; IWAMI M, 1984, MOL GEN GENET, V196, P317, DOI 10.1007/BF00328065; KLEVIT RE, 1986, BIOCHEMISTRY-US, V25, P7774, DOI 10.1021/bi00371a073; MANILOFF J, 1983, ANNU REV MICROBIOL, V37, P477, DOI 10.1146/annurev.mi.37.100183.002401; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MILES RJ, 1992, J GEN MICROBIOL, V138, P1773, DOI 10.1099/00221287-138-9-1773; MISSET O, 1980, BIOCHEMISTRY-US, V19, P883, DOI 10.1021/bi00546a009; MIYATA M, 1991, FEMS MICROBIOL LETT, V79, P329, DOI 10.1111/j.1574-6968.1991.tb04550.x; MUGHARBIL U, 1978, J BACTERIOL, V133, P203, DOI 10.1128/JB.133.1.203-209.1978; MUTO A, 1987, ISRAEL J MED SCI, V23, P334; Muto Akira, 1992, P331; OH W, 1992, J BACTERIOL, V174, P7873, DOI 10.1128/JB.174.23.7873-7874.1992; ORCHARD LMD, 1990, P ROY SOC B-BIOL SCI, V242, P87, DOI 10.1098/rspb.1990.0108; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAZIN S, 1992, FEMS MICROBIOL LETT, V100, P423, DOI 10.1016/0378-1097(92)90241-F; RAZIN S, 1985, MICROBIOL REV, V49, P419, DOI 10.1128/MMBR.49.4.419-455.1985; Reddy P, 1991, Protein Expr Purif, V2, P179, DOI 10.1016/1046-5928(91)90069-U; REIZER A, 1993, IN PRESS METHODS MOL; REIZER J, 1992, J BIOL CHEM, V267, P9158; REIZER J, 1989, EMBO J, V8, P2111, DOI 10.1002/j.1460-2075.1989.tb03620.x; REIZER J, 1988, P NATL ACAD SCI USA, V85, P2041, DOI 10.1073/pnas.85.7.2041; REIZER J, 1984, J BACTERIOL, V160, P333, DOI 10.1128/JB.160.1.333-340.1984; REIZER J, 1993, PROTEIN SCI, V2, P506; REIZER J, 1987, SUGAR TRANSPORT META, P333; SALSER W, 1967, NATURE, V215, P588, DOI 10.1038/215588a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SMITH DW, 1988, COMPUT APPL BIOSCI, V4, P212; ULLAH AHJ, 1976, J BACTERIOL, V127, P1298, DOI 10.1128/JB.127.3.1298-1306.1976; ULLAH AHJ, 1977, J BACTERIOL, V131, P988, DOI 10.1128/JB.131.3.988-996.1977; WITTEKIND M, 1990, BIOCHEMISTRY-US, V29, P7191, DOI 10.1021/bi00483a006; WU LF, 1990, J MOL BIOL, V213, P687, DOI 10.1016/S0022-2836(05)80256-6	47	26	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26531	26540						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253782				2022-12-25	WOS:A1993MK42500076
J	DIETMEIER, K; ZARA, V; PALMISANO, A; PALMIERI, F; VOOS, W; SCHLOSSMANN, J; MOCZKO, M; KISPAL, G; PFANNER, N				DIETMEIER, K; ZARA, V; PALMISANO, A; PALMIERI, F; VOOS, W; SCHLOSSMANN, J; MOCZKO, M; KISPAL, G; PFANNER, N			TARGETING AND TRANSLOCATION OF THE PHOSPHATE CARRIER P-32 TO THE INNER MEMBRANE OF YEAST MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-ATP CARRIER; PROTEIN IMPORT MACHINERY; SACCHAROMYCES-CEREVISIAE; PRECURSOR PROTEINS; ADP/ATP CARRIER; OUTER-MEMBRANE; UNCOUPLING PROTEIN; CONTACT SITES; NUCLEOSIDE TRIPHOSPHATES; INTERMEMBRANE SPACE	We analyzed the submitochondrial location and biogenesis pathway of the phosphate carrier (P(i)C), also termed p32, of Saccharomyces cerevisiae mitochondria. P(i)C/p32 was found to behave as an integral membrane protein that cofractionated with the ADP/ATP carrier of the inner membrane. Import of the precursor of P(i)C/p32 required a membrane potential across the inner membrane, supporting its localization to the inner membrane. This makes it unlikely that the major function of P(i)C/p32 is that of an import receptor on the surface of the mitochondrial outer membrane. Furthermore, we found that both receptors MOM72 and MOM19 were involved in the import pathway of the precursor of P(i)C/p32 with MOM72 being responsible for the bulk of import. Yeast P(i)C/p32 is thus not only structurally homologous to the ADP/ATP carrier, but has a similar targeting mechanism and submitochondrial location, supporting its classification as a member of the inner membrane carrier family.	UNIV FREIBURG, INST BIOCHEM, HERMANN HERDER STR 7, D-79104 FREIBURG, GERMANY; UNIV MUNICH, INST PHYSIOL CHEM, D-80336 MUNICH, GERMANY; UNIV BARI, DIPARTIMENTO FARMACOBIOL, I-70125 BARI, ITALY; UNIV LECCE, DIPARTIMENTO BIOL, I-73100 LECCE, ITALY	University of Freiburg; University of Munich; Universita degli Studi di Bari Aldo Moro; University of Salento			Zara, Vincenzo/AAC-2900-2019; Pfanner, Nikolaus/AAV-7878-2021; Schlossmann, Jens/I-7743-2016	Schlossmann, Jens/0000-0002-2550-6839; Zara, Vincenzo/0000-0001-6592-4501				BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BECKER K, 1992, J BIOL CHEM, V267, P5637; BRANDOLIN G, 1992, MOL MECHANISMS TRANS, P135; Dolce V., 1991, J DNA SEQUENCING MAP, V2, P133, DOI 10.3109/10425179109039683; DOUGLAS MG, 1986, MICROBIOL REV, V50, P166, DOI 10.1128/MMBR.50.2.166-178.1986; EMMERMANN M, 1991, CURR GENET, V20, P405, DOI 10.1007/BF00317069; FERREIRA GC, 1990, J BIOL CHEM, V265, P21202; FERREIRA GC, 1989, J BIOL CHEM, V264, P15628; FLUGGE UI, 1989, EMBO J, V8, P39, DOI 10.1002/j.1460-2075.1989.tb03346.x; FLUGGE UI, 1991, NATURE, V353, P364, DOI 10.1038/353364a0; GLASER SM, 1990, J BIOL CHEM, V265, P8808; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GUERIN B, 1990, J BIOL CHEM, V265, P19736; HACKENBR.CR, 1968, P NATL ACAD SCI USA, V61, P598, DOI 10.1073/pnas.61.2.598; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; Horwich A, 1990, CURR OPIN CELL BIOL, V2, P625, DOI 10.1016/0955-0674(90)90103-L; HWANG ST, 1991, J BIOL CHEM, V266, P21083; KLINGENBERG M, 1992, BIOCHEM SOC T, V20, P547, DOI 10.1042/bst0200547; KRAMER R, 1989, BIOCHIM BIOPHYS ACTA, V974, P1, DOI 10.1016/S0005-2728(89)80160-4; Krumer R., 1992, MOL MECHANISMS BIOEN, P359, DOI DOI 10.1016/50167-7306(08)60184-2; LIU XQ, 1990, J BIOL CHEM, V265, P9; LIU XQ, 1988, J CELL BIOL, V107, P503, DOI 10.1083/jcb.107.2.503; MOCZKO M, 1992, FEBS LETT, V310, P265, DOI 10.1016/0014-5793(92)81345-M; MURAKAMI H, 1990, NATURE, V347, P488, DOI 10.1038/347488a0; MURAKAMI H, 1993, P NATL ACAD SCI USA, V90, P3358, DOI 10.1073/pnas.90.8.3358; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1986, FEBS LETT, V209, P152, DOI 10.1016/0014-5793(86)81101-2; PFANNER N, 1987, J BIOL CHEM, V262, P14851; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PFANNER N, 1991, TRENDS BIOCHEM SCI, V16, P63, DOI 10.1016/0968-0004(91)90026-R; PHELPS A, 1991, J BIOL CHEM, V266, P19882; PHELPS A, 1991, BIOCHEMISTRY-US, V30, P248, DOI 10.1021/bi00215a035; PON L, 1989, J CELL BIOL, V109, P2603, DOI 10.1083/jcb.109.6.2603; PRATT RD, 1991, J BIOL CHEM, V266, P1276; RASSOW J, 1991, FEBS LETT, V293, P85, DOI 10.1016/0014-5793(91)81157-4; RIEZMAN H, 1983, EMBO J, V2, P1113, DOI 10.1002/j.1460-2075.1983.tb01554.x; RUNSWICK MJ, 1987, EMBO J, V6, P1367, DOI 10.1002/j.1460-2075.1987.tb02377.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; SMAGULA C, 1988, J BIOL CHEM, V263, P6783; SMAGULA CS, 1988, J CELL BIOCHEM, V36, P323, DOI 10.1002/jcb.240360402; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; Walker J.E., 1992, CURR OPIN STRUC BIOL, V2, P519, DOI DOI 10.1016/0959-440X(92)90081-H; WOHLRAB H, 1986, BIOCHIM BIOPHYS ACTA, V853, P115, DOI 10.1016/0304-4173(86)90007-8; ZARA V, 1991, EUR J BIOCHEM, V198, P405, DOI 10.1111/j.1432-1033.1991.tb16029.x; ZARA V, 1992, J BIOL CHEM, V267, P12077; ZWIZINSKI C, 1984, J BIOL CHEM, V259, P7850	61	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25958	25964						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245029				2022-12-25	WOS:A1993MK10000096
J	LEONG, LEC; WALKER, PA; PORTER, AG				LEONG, LEC; WALKER, PA; PORTER, AG			HUMAN RHINOVIRUS-14 PROTEASE-3C (3C(PRO)) BINDS SPECIFICALLY TO THE 5'-NONCODING REGION OF THE VIRAL-RNA - EVIDENCE THAT 3C(PRO) HAS DIFFERENT DOMAINS FOR THE RNA-BINDING AND PROTEOLYTIC ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; 5' NONCODING REGION; COMMON COLD VIRUS; POLIOVIRUS RNA; SERINE PROTEASES; CYSTEINE PROTEASES; PROTEIN 3CD; CLEAVAGE; SEQUENCE; INVITRO	Protease 3C (3C(pro)) encoded by human rhinovirus type 14 was purified from recombinant Escherichia coli and shown to bind specifically to the 5'-terminal 126 nucleotides of the viral RNA (126 RNA) in addition to efficiently cleaving a synthetic peptide in trans. The binding of 3C(pro) to the viral RNA may be required for the initiation of plus strand viral RNA synthesis, suggesting a second non-proteolytic function for 3C(pro). Single amino acid substitutions were generated in 3C(pro) at residues that are highly conserved among picornaviruses or that lie within the putative catalytic triad. Conservative changes at Asp-85 (D85E and D85N) destroyed the ability of 3C(pro) to bind specifically to the 126 RNA, whereas the D85N mutation resulted in almost wild-type levels of proteolytic activity. Conversely, substitutions at His-40, Glu-71, or Cys-146 (H40D, E71A, or C146S) gave proteolytically inactive mutants that bound to the 126 RNA. These results suggest that the highly conserved Asp-85 is essential for specific binding to the 126 RNA, but is unlikely to function in proteolysis as the acidic member of the catalytic triad. Moreover, 3C(pro) appears to have different domains for the RNA binding and proteolytic activities.			LEONG, LEC (corresponding author), NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, 10 KENT RIDGE CRESCENT, SINGAPORE 0511, SINGAPORE.							ANDINO R, 1990, J VIROL, V64, P607, DOI 10.1128/JVI.64.2.607-612.1990; ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; CHEAH KC, 1990, J BIOL CHEM, V265, P7180; CORDINGLEY MG, 1989, J VIROL, V63, P5037, DOI 10.1128/JVI.63.12.5037-5045.1989; CORDINGLEY MG, 1990, J BIOL CHEM, V265, P9062; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7; HAMMERLE T, 1991, J BIOL CHEM, V266, P5412; JORE J, 1988, J GEN VIROL, V69, P1627, DOI 10.1099/0022-1317-69-7-1627; KEAN KM, 1991, VIROLOGY, V181, P609, DOI 10.1016/0042-6822(91)90894-H; LEONG LEC, 1992, J CRYST GROWTH, V122, P246, DOI 10.1016/0022-0248(92)90253-F; PALLAI PV, 1989, J BIOL CHEM, V264, P9738; PALMENBERG AC, 1990, ANNU REV MICROBIOL, V44, P603, DOI 10.1146/annurev.mi.44.100190.003131; RACANIELLO VR, 1986, VIROLOGY, V155, P498, DOI 10.1016/0042-6822(86)90211-4; RICHARDS OC, 1990, CURR TOP MICROBIOL, V161, P89; RIVERA VM, 1988, VIROLOGY, V165, P42, DOI 10.1016/0042-6822(88)90656-3; SIMOES EAF, 1991, J VIROL, V65, P913, DOI 10.1128/JVI.65.2.913-921.1991; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONENBERG N, 1990, CURR TOP MICROBIOL, V161, P23; STANWAY G, 1984, NUCLEIC ACIDS RES, V12, P7859, DOI 10.1093/nar/12.20.7859; TRONO D, 1988, J VIROL, V62, P2291, DOI 10.1128/JVI.62.7.2291-2299.1988; YPMAWONG MF, 1988, VIROLOGY, V166, P265, DOI 10.1016/0042-6822(88)90172-9	23	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25735	25739						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245010				2022-12-25	WOS:A1993MK10000067
J	BOUSSET, K; HENRIKSSON, M; LUSCHERFIRZLAFF, JM; LITCHFIELD, DW; LUSCHER, B				BOUSSET, K; HENRIKSSON, M; LUSCHERFIRZLAFF, JM; LITCHFIELD, DW; LUSCHER, B			IDENTIFICATION OF CASEIN KINASE-II PHOSPHORYLATION SITES IN MAX - EFFECTS ON DNA-BINDING KINETICS OF MAX HOMODIMER AND MYC/MAX HETERODIMERS	ONCOGENE			English	Article							SERUM RESPONSE FACTOR; C-MYC ONCOPROTEIN; PROTEIN-PHOSPHORYLATION; RAS COTRANSFORMATION; SEQUENCE; CELLS; TRANSCRIPTION; ACTIVATION; INCREASES; P34CDC2	Myc proteins have been implicated in the regulation of cell growth and differentiation. The identification of Max, a basic region/helix-loop-helix/leucine zipper protein, as a partner for Myc has provided insights into Myc's molecular function as a transcription factor. Recent evidence indicates that the relative abundance of Myc and Max is important to determine the level of specific gene transcription; In this report we have identified two major in vivo phosphorylation sites in Max (Ser-2 and -11) which can be modified in vitro by casein kinase II (CKII). Phosphorylation of these sites modulates DNA-binding by increasing both the on- and off-rates of Max homo- as well as Myc/Max heterodimers. In addition, our data indicate that the steady state binding of the shorter version of Max (p21) to DNA was similar yet its rate of dissociation faster than that of the longer version of Max (p22). These data argue that different Max complexes have different kinetic properties and that these can be modified by CKII phosphorylation. We propose this as an important biological mechanism by which different dimeric complexes can exchange with varying efficiencies on DNA, thereby responding to changes in cell growth conditions.	HANNOVER MED SCH,INST MOLEC BIOL,D-30623 HANNOVER,GERMANY; UNIV MANITOBA,MANITOBA INST CELL BIOL,WINNIPEG R3E 0V9,MB,CANADA	Hannover Medical School; University of Manitoba			Henriksson, Marie Arsenian/F-5010-2015; Litchfield, David/E-4636-2015; Luscher, Bernhard/A-7330-2011	Litchfield, David/0000-0002-2425-6620; Luscher, Bernhard/0000-0002-9622-8709				ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMATI B, 1993, CELL, V72, P235; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; HENRIKSSON M, 1993, IN PRESS ONCOGENE; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LITCHFIELD DW, 1993, IN PRESS MOL CHEM BI; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEEK DW, 1992, BIOCHEM J, V287, P1; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PINNA LA, 1981, BIOCHEM BIOPH RES CO, V100, P449, DOI 10.1016/S0006-291X(81)80117-9; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; SETH A, 1991, J BIOL CHEM, V266, P23521; SETH A, 1992, J BIOL CHEM, V267, P24796; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STREET AJ, 1990, CURR TOP MICROBIOL, V166, P251; VASTRIK I, 1993, ONCOGENE, V8, P503; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	46	86	87	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3211	3220						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247525				2022-12-25	WOS:A1993MG78200003
J	JACOBSON, DR; MILLS, NE				JACOBSON, DR; MILLS, NE			A HIGHLY SENSITIVE ASSAY FOR MUTANT RAS GENES AND ITS APPLICATION TO THE STUDY OF PRESENTATION AND RELAPSE GENOTYPES IN ACUTE-LEUKEMIA	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; POLYMERASE CHAIN-REACTION; ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; N-RAS; MYELODYSPLASTIC SYNDROMES; ONCOGENE MUTATIONS; POINT MUTATIONS; MYELOPROLIFERATIVE DISORDERS; CHROMOSOME-ABERRATIONS	Most studies of ras oncogene activation use assays for ras mutations based on the polymerase chain reaction (PCR) of DNA segments containing ras exons 1 and 2, followed by allele-specific oligonucleotide (ASO) hybridization or direct sequencing, which require that to be detectable, a mutation must be present in at least 3-25% of ras alleles. Thus, studies of tissues in which only a fraction of cells contains a ras mutation risk false negative results. To minimize this risk, we have developed a highly sensitive, non-radioactive assay for uas mutations. Ras genes were PCR-amplified using mismatched primers, to introduce restriction sites into products derived from normal alleles. Repeated restriction digestion and PCR enriched for mutant alleles, visualized by agarose gel electrophoresis. Serially diluted DNA samples containing I as mutations demonstrated detection of 1 mutant/10(6) normal alleles (four orders of magnitude more sensitive than PCR/ASO hybridization). This assay was applied to DNA from four patients with relapsed acute leukemia in whom ras mutations present at diagnosis were not detectable by PCR/ASO hybridization at relapse. In one case, the mutation present at diagnosis was demonstrated at relapse. In the others, loss of the mutation was confirmed, at a greatly increased sensitivity. This method is widely applicable to detection of mutant ras alleles admired with larger numbers of normal alleles.	NEW YORK VET AFFAIRS MED CTR,MED SERV,NEW YORK,NY; NYU,MED CTR,DEPT MED,NEW YORK,NY; NYU,MED CTR,KAPLAN COMPREHENS CANC CTR,NEW YORK,NY	New York University; New York University	JACOBSON, DR (corresponding author), NEW YORK VA MED CTR,RES SERV 151,423 E 23 ST,NEW YORK,NY 10010, USA.				NHLBI NIH HHS [T32HL07151] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007151] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHUJA HG, 1990, BLOOD, V75, P1684; BALL ED, 1990, PROG CLIN BIOL RES, V333, P499; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BARELI M, 1989, BLOOD, V73, P281; BARTRAM CR, 1992, HEMATOL ONCOL CLIN N, V6, P557, DOI 10.1016/S0889-8588(18)30328-9; BARTRAM CR, 1989, LEUKEMIA, V3, P247; BASHEY A, 1992, BLOOD, V79, P981; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BROWETT PJ, 1989, ONCOGENE, V4, P1029; CHEN J, 1991, ANAL BIOCHEM, V195, P51, DOI 10.1016/0003-2697(91)90293-3; CHIN IYM, 1992, ACTA HAEMATOL-BASEL, V87, P107; COGSWELL PC, 1989, BLOOD, V74, P2629; COLLINS SJ, 1991, ONCOGENE RES, V3, P117; FARR C, 1991, BRIT J HAEMATOL, V77, P323, DOI 10.1111/j.1365-2141.1991.tb08578.x; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FIALKOW PJ, 1987, NEW ENGL J MED, V317, P468, DOI 10.1056/NEJM198708203170802; GIRVITZ SC, 1980, ANAL BIOCHEM, V106, P492, DOI 10.1016/0003-2697(80)90553-9; HALIASSOS A, 1989, NUCLEIC ACIDS RES, V17, P8093, DOI 10.1093/nar/17.20.8093; HIRAI H, 1987, BIOCHEM BIOPH RES CO, V147, P108, DOI 10.1016/S0006-291X(87)80093-1; INOKUCHI K, 1991, ANN HEMATOL, V62, P211, DOI 10.1007/BF01729834; Jacobson D R, 1991, PCR Methods Appl, V1, P146; JACOBSON DR, 1992, HUM GENET, V89, P353; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; KAHN SM, 1991, ONCOGENE, V6, P1079; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LEVI S, 1991, CANCER RES, V51, P3497; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; LIU ET, 1990, CLIN LAB MED, V10, P797; LUBBERT M, 1992, ONCOGENE, V7, P263; LYONS J, 1988, BLOOD, V71, P1707; MANE SM, 1990, GENE CHROMOSOME CANC, V2, P71, DOI 10.1002/gcc.2870020113; MANO H, 1993, JPN J CANCER RES, V80, P102; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; MOSKOVITS T, 1992, AM J HEMATOL, V41, P302, DOI 10.1002/ajh.2830410422; NAKAGAWA T, 1992, ONCOLOGY, V49, P114; NAKAGAWA T, 1991, BRIT J HAEMATOL, V77, P250, DOI 10.1111/j.1365-2141.1991.tb07988.x; NEGRIN RS, 1991, BLOOD, V78, P255; PADUA RA, 1988, LEUKEMIA, V2, P503; PEDERSENBJERGAARD J, 1988, CANCER RES, V48, P1812; SAGLIO G, 1989, TUMORI, V75, P337, DOI 10.1177/030089168907500407; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SENN HP, 1988, INT J CANCER, V41, P59, DOI 10.1002/ijc.2910410112; SENN HP, 1988, BLOOD, V72, P931; SHEN WPV, 1987, ONCOGENE, V1, P157; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SMITH MT, 1992, J NATL CANCER I, V84, P1626; SYVANEN AC, 1992, INT J CANCER, V50, P713, DOI 10.1002/ijc.2910500508; TAYLOR JA, 1992, J NATL CANCER I, V84, P1626, DOI 10.1093/jnci/84.21.1626; TERADA N, 1990, BLOOD, V75, P453; TERADA N, 1991, LEUKEMIA RES, V15, P935, DOI 10.1016/0145-2126(91)90170-X; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; TODD AV, 1991, LEUKEMIA, V5, P160; TODD AV, 1991, AM J HEMATOL, V38, P207, DOI 10.1002/ajh.2830380310; TOKSOZ D, 1987, ONCOGENE, V1, P409; URBANOISPIZUA A, 1992, LEUKEMIA, V6, P342; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; YUNIS JJ, 1989, ONCOGENE, V4, P609	58	64	70	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					553	563						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290266				2022-12-25	WOS:A1994MW24800023
J	TOKSOZ, D; WILLIAMS, DA				TOKSOZ, D; WILLIAMS, DA			NOVEL HUMAN ONCOGENE IBC DETECTED BY TRANSFECTION WITH DISTINCT HOMOLOGY REGIONS TO SIGNAL-TRANSDUCTION PRODUCTS	ONCOGENE			English	Article							MOLECULAR-CLONING; TRANSFORMING GENE; MYELOID-LEUKEMIA; TYROSINE KINASE; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; CDC24 GENE; CELL-CYCLE; SEQUENCE; DBL	In order to isolate transforming genes involved in leukemias, DNA from a CML acute phase sample was transfected into NIH-3T3 Cells and found to be tumorigenic in nude mice. Partial genomic cloning using human repeat sequence as probe followed by cDNA cloning of this oncogene, termed Ibc, was undertaken. The lbc cDNA sequence shows no identity to known proteins and codes for a predicted hydrophilic protein product of 47 kD, which contains several consensus kinase phosphorylation sites. The N-terminus encodes a consensus E-F hand motif followed by a region of homology to the transforming human oncogene dbl associated with regulatory activity for the ras superfamily of small G proteins, while the C-terminus contains homology with pleckstrin and rac protein kinase in a region which overlaps with the recently defined PH (pleckstrin homology) domain. Lbc expression is restricted to human hematopoietic cells and skeletal muscle, lung and heart. Transfection of 3T3 cells with an expression vector encoding lbc cDNA results in focus formation, demonstrating its biological activity. These data indicate that the lbc oncogene encodes a novel product implicated in distinct cellular signal transduction functions.	INDIANA UNIV, RILEY HOSP CHILDREN, SCH MED, HOWARD HUGHES MED RES INST, INDIANAPOLIS, IN USA	Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children	TOKSOZ, D (corresponding author), HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT HEMATOL ONCOL, 320 LONGWOOD AVE, BOSTON, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER; NHLBI NIH HHS [2PO1-HL32262] Funding Source: Medline; PHS HHS [U03634] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS JM, 1992, ONCOGENE, V7, P611; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; Maniatis T., 1982, MOL CLONING; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIYAMOTO S, 1987, GENE, V54, P125, DOI 10.1016/0378-1119(87)90354-4; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1991, NEW BIOL, V3, P372; RON D, 1989, ONCOGENE, V4, P1067; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKEBE Y, 1988, MOL CELL BIOL, V466, P1431; TOKSOZ D, 1987, ONCOGENE, V1, P409; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	42	107	112	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					621	628						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290273				2022-12-25	WOS:A1994MW24800030
J	BUSH, J; RICHARDSON, J; CARDELLI, J				BUSH, J; RICHARDSON, J; CARDELLI, J			MOLECULAR-CLONING AND CHARACTERIZATION OF THE FULL-LENGTH CDNA-ENCODING THE DEVELOPMENTALLY-REGULATED LYSOSOMAL-ENZYME BETA-GLUCOSIDASE IN DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; ALPHA-MANNOSIDASE; NUCLEOTIDE-SEQUENCE; ACID-PHOSPHATASE; GENETIC-ANALYSIS; SECRETION; PROTEIN; TRANSPORT; HOMOLOGY; TRANSCRIPTION	The developmentally regulated Dictyostelium discoideum lysosomal enzyme beta-glucosidase is synthesized as a membrane-associated glycosylated precursor polypeptide which undergoes at least two proteolytic cleavage events to generate a soluble mature lysosomally Ioealized protein. To begin to analyze the mechanisms regulating the sorting of this protein and the regulation during development of the expression of the encoding gene, we have cloned and sequenced a 2.6-kilobase (kb) cDNA which contains a complete 2463-nucleotide open reading frame coding for beta-glucosidase. Conceptual translation of this open reading frame predicts a polypeptide similar in molecular mass to the primary translation product of 94 kDa that also contains the same amino acid sequences of two V8 protease derived-peptides generated from the purified beta-glucosidase enzyme. The D. discoideum enzyme contained regions highly homologous at the amino acid sequence level to both bacterial and fungal beta-glucosidases, although these regions did not overlap. A potential cleavable signal sequence was also found in the first 21 amino acids followed by a highly polar stretch of 49 amino acids which (based on amino acid sequencing of the mature beta-glucosidase) represents a pro region for this protein. This region is similar in location, size, and charge to the D. discoideum alpha-mannosidase pro-I region (Schatzle, J., Bush, J., and Cardelli, J. (1992) J. Biol. Chem. 267, 4000-4007). Several small hydrophobic stretches of amino acids were also distributed throughout the protein; however, no obvious transmembrane region(s) were identified which might explain the observed membrane association of the precursor protein. Finally, Northern blot analysis indicated that the gene encoding this enzyme was under developmental regulation. The steady state level of a 2.7-kb beta-glucosidase mRNA decreased significantly during the aggregation stage of development, from high levels during growth, and then increased in the form of a larger size 2.8-kb mRNA during the final stages of development.	LOUISIANA STATE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,1501 KINGS HIGHWAY,SHREVEPORT,LA 71130	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport					NIDDK NIH HHS [DK 39232] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039232, R29DK039232] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUSE E, 1980, BIOCHIM BIOPHYS ACTA, V626, P459, DOI 10.1016/0005-2795(80)90142-7; BUSH JM, 1990, ARCH BIOCHEM BIOPHYS, V283, P158, DOI 10.1016/0003-9861(90)90626-A; BUSH JM, 1989, J BIOL CHEM, V264, P7630; CARDELLI JA, 1981, DEV BIOL, V82, P180, DOI 10.1016/0012-1606(81)90440-1; CARDELLI JA, 1990, J BIOL CHEM, V265, P8847; CARDELLI JA, 1985, DEV BIOL, V110, P147, DOI 10.1016/0012-1606(85)90072-7; CARDELLI JA, 1990, DEV GENET, V11, P454, DOI 10.1002/dvg.1020110522; CARDELLI JA, 1986, J CELL BIOL, V102, P1264, DOI 10.1083/jcb.102.4.1264; CARDELLI JA, 1989, J BIOL CHEM, V264, P3454; CARDELLI JA, 1987, METHOD CELL BIOL, V28, P139; Cardelli JA, 1993, ENDOSOMES LYSOSOMES, P341; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLARKE M, 1988, DEV GENET, V9, P315, DOI 10.1002/dvg.1020090413; COSTON MB, 1969, J BACTERIOL, V100, P1208, DOI 10.1128/JB.100.3.1208-1217.1969; EBERT DL, 1990, J CELL SCI, V96, P491; FREE SJ, 1974, BIOCHIMIE, V56, P1525; FREEZE HH, 1989, J BIOL CHEM, V264, P19278; FREEZE HH, 1986, MOL CELL BIOCHEM, V72, P47; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOLUMBESKI GS, 1986, ANAL BIOCHEM, V154, P373, DOI 10.1016/0003-2697(86)90001-1; GOLUMBESKI GS, 1987, DEV BIOL, V123, P494, DOI 10.1016/0012-1606(87)90407-6; GRABNITZ F, 1989, MOL GEN GENET, V217, P70, DOI 10.1007/BF00330944; GRAHAM TR, 1988, J BIOL CHEM, V263, P16823; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KOHCHI C, 1985, NUCLEIC ACIDS RES, V13, P6273, DOI 10.1093/nar/13.17.6273; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LACOSTE CH, 1992, J BIOL CHEM, V267, P5942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOOMIS WF, 1980, DEV GENET, V1, P241; LOOMIS WF, 1982, DEV DICTYOSTELIUM DI, P1; Loomis WF., 1975, DICTYOSTELIUM DISCOI; MATSUOKA K, 1991, P NATL ACAD SCI USA, V88, P834, DOI 10.1073/pnas.88.3.834; MIERENDORF RC, 1985, J CELL BIOL, V100, P1777, DOI 10.1083/jcb.100.5.1777; MIERENDORF RC, 1983, J BIOL CHEM, V258, P5878; MORANELLI F, 1986, BIOCHEM INT, V12, P905; OHMIYA K, 1990, NUCLEIC ACIDS RES, V18, P671, DOI 10.1093/nar/18.3.671; PANNELL R, 1985, J CELL BIOL, V101, P2063; RAYNAL A, 1987, CURR GENET, V12, P175, DOI 10.1007/BF00436876; RICHARDSON JM, 1988, J CELL BIOL, V107, P2097, DOI 10.1083/jcb.107.6.2097; SCHATZLE J, 1991, MOL CELL BIOL, V11, P3339, DOI 10.1128/MCB.11.6.3339; SCHATZLE J, 1993, J BIOL CHEM, V268, P19632; SCHATZLE J, 1992, J BIOL CHEM, V267, P4000; SINGLETON CK, 1989, NUCLEIC ACIDS RES, V17, P9679, DOI 10.1093/nar/17.23.9679; STEEL LF, 1987, MOL CELL BIOL, V7, P965, DOI 10.1128/MCB.7.3.965; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X	48	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1468	1476						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288612				2022-12-25	WOS:A1994MR22000106
J	SKOUFIAS, DA; COLE, DG; WEDAMAN, KP; SCHOLEY, JM				SKOUFIAS, DA; COLE, DG; WEDAMAN, KP; SCHOLEY, JM			THE CARBOXYL-TERMINAL DOMAIN OF KINESIN HEAVY-CHAIN IS IMPORTANT FOR MEMBRANE-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN KINESIN; MICROTUBULES INVITRO; SUBCELLULAR-LOCALIZATION; LIGHT-CHAINS; IDENTIFICATION; ASSOCIATION; MOTILITY; ORGANELLES; GENERATION; TRANSITION	Sea urchin kinesin is a plus end-directed microtubule-based motor consisting of two heavy chains and two light chains and is proposed to be responsible (a) for the transport of membranous organelles along microtubules in sea urchin mitotic spindles (Wright, B. D., Henson, J. H., Wedaman, K. P., Willy, P. J., Morand, J. N., and Scholey, J. M. (1 99 1) J. Cell Biol. 113, 817-833) and (b) for the radial dispersion of endoplasmic reticulum and endosomal membranes in non-mitotic cultured coelomocytes (Henson, J. H., Nesbitt, D., Wright, B. D., and Scholey, J. M. (1992) J. Cell Sci. 103, 309-320). We report here that sea urchin kinesin is indeed able to bind in a concentration-dependent and saturable manner to microsomal membranes isolated from sea urchin eggs in the presence of MgATP. The kinesin light chains may not be essential for membrane binding since kinesin containing negligible amounts of light chains binds as well as kinesin containing stoichiometric amounts of light chains. Finally, we propose that kinesin binds to membranes with the carboxyl-terminal domain of the heavy chain (amino acid residues 858-1031) since the bacterially expressed and then isolated stalk-tail fragment of kinesin heavy chain, in contrast to the stalk fragment, is able (a) to bind membranes in a concentration-dependent and saturable manner and (b) to compete with native kinesin for membrane binding. Our results support the hypothesis that the carboxyl-terminal domains of the heavy chains attach kinesin molecules to their membranous cargo in mitotic and interphase sea urchin cells.			SKOUFIAS, DA (corresponding author), UNIV CALIF DAVIS,MOLEC & CELLULAR BIOL SECT,STORER HALL,DAVIS,CA 95616, USA.		Skoufias, Dimitrios A/A-5535-2016	Skoufias, Dimitrios/0000-0001-5595-3413	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046376] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 46376] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BRADY ST, 1991, NEURON, V7, P521, DOI 10.1016/0896-6273(91)90365-7; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; BUSTER D, 1991, J CELL SCI S, V14, P1096; CYR JL, 1991, P NATL ACAD SCI USA, V88, P10114, DOI 10.1073/pnas.88.22.10114; DECUEVAS M, 1992, J CELL BIOL, V116, P957, DOI 10.1083/jcb.116.4.957; ERICKSON HP, 1976, P NATL ACAD SCI USA, V73, P2813, DOI 10.1073/pnas.73.8.2813; GAUGER AK, 1993, J BIOL CHEM, V268, P13657; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HACKNEY DD, 1991, BIOCHEM BIOPH RES CO, V174, P810, DOI 10.1016/0006-291X(91)91490-4; HENSON JH, 1992, J CELL SCI, V103, P309; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; JOHNSON CS, 1990, CELL MOTIL CYTOSKEL, V16, P204, DOI 10.1002/cm.970160307; KLAUSNER RD, 1981, J BIOL CHEM, V256, P5879; KOSIK KS, 1990, J BIOL CHEM, V265, P3278; KUMAR N, 1981, J BIOL CHEM, V256, P5886; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; LACY ML, 1992, J BIOL CHEM, V267, P4793; LEOPOLD PL, 1992, CELL MOTIL CYTOSKEL, V23, P19, DOI 10.1002/cm.970230104; LYE RJ, 1987, CELL, V51, P309, DOI 10.1016/0092-8674(87)90157-7; MULTIGNER L, 1992, NATURE, V360, P33, DOI 10.1038/360033a0; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; OBERDORF JA, 1986, J CELL BIOL, V102, P2205, DOI 10.1083/jcb.102.6.2205; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; SCHNAPP BJ, 1992, J CELL BIOL, V119, P389, DOI 10.1083/jcb.119.2.389; SCHOLEY JM, 1985, NATURE, V318, P483, DOI 10.1038/318483a0; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SCHROER TA, 1991, ANNU REV PHYSIOL, V53, P629, DOI 10.1146/annurev.ph.53.030191.003213; Skoufias DA, 1993, CURR OPIN CELL BIOL, V5, P95, DOI 10.1016/S0955-0674(05)80014-6; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; URRUTIA R, 1991, P NATL ACAD SCI USA, V88, P6701, DOI 10.1073/pnas.88.15.6701; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; WEDAMAN KP, 1993, J MOL BIOL, V231, P155, DOI 10.1006/jmbi.1993.1267; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; YU H, 1992, J BIOL CHEM, V267, P20457	41	110	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1477	1485						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288613				2022-12-25	WOS:A1994MR22000107
J	URCELAY, E; BUTTA, N; CIPRES, G; MARTINREQUERO, A; AYUSO, MS; PARRILLA, R				URCELAY, E; BUTTA, N; CIPRES, G; MARTINREQUERO, A; AYUSO, MS; PARRILLA, R			FUNCTIONAL COUPLING OF NA+/H+ AND NA+/CA2+ EXCHANGERS IN THE ALPHA(1)-ADRENOCEPTOR-MEDIATED ACTIVATION OF HEPATIC-METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ADRENERGIC AGONISTS; ASCITES-TUMOR-CELLS; PERFUSED-RAT-LIVER; INTRACELLULAR PH; GROWTH-FACTOR; ALPHA-2-ADRENERGIC RECEPTORS; CA-2+ MOBILIZATION; HUMAN-PLATELETS; CALCIUM; STIMULATION	The purpose of this study was to characterize the role of ions other than Ca2+ in hepatic responses to alpha1-adrenergic stimulation. We report that the alpha1-adrenoreceptor activation of hepatic functions is accompanied by extracellular acidification and an increase in intracellular pH. These effects are dependent on extracellular Na+ concentration and are inhibited by the Na+/H+ antiporter blocker 5-(N-ethyl-N-isopropyl) amiloride under conditions that preclude antagonistic effects on agonist binding. Thus, the activation of plasma membrane Na+/H+ exchange is an essential feature of the hepatic alpha-adrenoreceptor-coupled signaling pathway. The following observations indicate that the sustained hepatic alpha1-adrenergic actions rely on a functional coupling between the plasma membrane Na+/H+ and Na+/Ca2+ exchangers, resulting in the stimulation of Ca2+ influx. 1) Inhibition of the Na+/K+-ATPase does not prevent the alpha1-adrenergic effects. However, alpha1-adrenoreceptor stimulation fails to induce intracellular alkalinization and to acidify the extracellular medium in the absence of extracellular Ca2+. 2) A non-receptor-induced increase in intracellular Na+ concentration, caused by the ionophore monensin, stimulates Ca2+ influx and increases vascular resistance. 3) Inhibition of Na+/Ca2+ exchange prevents, in a concentration-dependent manner, most of the alpha1-agonist-induced responses. 4) The actions of Ca2+-mobilizing vasoactive peptide receptors or alpha2-adrenoreceptors, which produce neither sustained extracellular acidification nor release of Ca2+, are insensitive to Na+/H+ exchange blockers.	CSIC,CTR INVEST BIOL,ENDOCRINE PHYSIOL UNIT,VELAZQUEZ 144,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consiglio Nazionale delle Ricerche (CNR)			Ayuso, Matilde Sánchez/B-2777-2008; Parrilla, Roberto/B-6307-2008; Martín-Requero, Angeles/K-3901-2014	Ayuso, Matilde Sánchez/0000-0003-2504-0925; Martín-Requero, Angeles/0000-0002-3416-9440; Urcelay, Elena/0000-0001-8470-8396				ALTHAUSSALZMANN M, 1980, EUR J BIOCHEM, V106, P241; BERGMEYER HU, 1975, METHODS ENZYMATIC AN; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BURNS CP, 1983, BIOCHEM BIOPH RES CO, V116, P931; BUTTA N, 1993, J BIOL CHEM, V268, P6081; BUXTON D, 1982, J BIOL CHEM, V257, P4318; CHOBANIAN MC, 1987, AM J PHYSIOL, V252, pF1073, DOI 10.1152/ajprenal.1987.252.6.F1073; CITTADINI A, 1978, J PHYSIOL-LONDON, V281, P29, DOI 10.1113/jphysiol.1978.sp012407; CONNOLLY TM, 1983, J BIOL CHEM, V258, P3907; DEHAYE JP, 1981, BIOCHEM J, V194, P949, DOI 10.1042/bj1940949; EXTON JH, 1988, FASEB J, V2, P2670, DOI 10.1096/fasebj.2.11.2456243; FABIATO A, 1978, J PHYSIOL-LONDON, V276, P233, DOI 10.1113/jphysiol.1978.sp012231; FEHLMANN M, 1981, J BIOL CHEM, V256, P7449; GARCIA ML, 1990, J BIOL CHEM, V265, P3763; GARCIASAINZ JA, 1985, P NATL ACAD SCI USA, V82, P6727, DOI 10.1073/pnas.82.20.6727; GESEK FA, 1989, AM J PHYSIOL, V257, pF623, DOI 10.1152/ajprenal.1989.257.4.F623; GIRBES T, 1983, ARCH BIOCHEM BIOPHYS, V226, P37, DOI 10.1016/0003-9861(83)90269-2; GONZALEZMANCHON C, 1988, ARCH BIOCHEM BIOPHYS, V265, P258, DOI 10.1016/0003-9861(88)90126-9; GOODHARDT M, 1986, HORMONAL CONTROL GLU, V2, P55; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAUSSINGER D, 1987, EUR J BIOCHEM, V163, P197, DOI 10.1111/j.1432-1033.1987.tb10755.x; HO AK, 1989, J BIOL CHEM, V264, P12983; HORSTMAN DA, 1990, J BIOL CHEM, V265, P21590; HOWARD MJ, 1987, MOL PHARMACOL, V32, P53; IKEDA U, 1988, J MOL CELL CARDIOL, V20, P493, DOI 10.1016/S0022-2828(88)80076-2; IWAKURA K, 1990, EUR J PHARMACOL, V186, P29; JAGADEESH G, 1990, J PHARMACOL EXP THER, V252, P1184; LESBURG C, 1990, J PHARMACOL EXP THER, V253, P530; LYNCH CJ, 1986, J BIOL CHEM, V261, P4551; MALY K, 1990, BIOCHEM BIOPH RES CO, V167, P1206, DOI 10.1016/0006-291X(90)90652-4; MARTINREQUERO A, 1986, ARCH BIOCHEM BIOPHYS, V246, P114, DOI 10.1016/0003-9861(86)90455-8; OWEN NE, 1986, J CELL BIOL, V103, P2053, DOI 10.1083/jcb.103.5.2053; POLLOCK AS, 1986, AM J PHYSIOL, V250, pF217, DOI 10.1152/ajprenal.1986.250.2.F217; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; PUCEAT M, 1993, AM J PHYSIOL, V264, pH310, DOI 10.1152/ajpheart.1993.264.2.H310; REEVES JP, 1992, ARCH BIOCHEM BIOPHYS, V292, P329, DOI 10.1016/0003-9861(92)90001-D; REINHART PH, 1984, BIOCHEM J, V220, P43, DOI 10.1042/bj2200043; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; SAZ JM, 1989, BIOCHEM BIOPH RES CO, V160, P480, DOI 10.1016/0006-291X(89)92458-3; SIFFERT W, 1987, FEBS LETT, V212, P123, DOI 10.1016/0014-5793(87)81569-7; SIFFERT W, 1987, NATURE, V325, P456, DOI 10.1038/325456a0; SIFFERT W, 1986, THROMB RES, V44, P235, DOI 10.1016/0049-3848(86)90139-8; SPENCER TL, 1976, BIOCHEM J, V154, P405, DOI 10.1042/bj1540405; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; URCELAY E, 1993, IN PRESS BIOCH BIOPH; URCELAY E, 1993, IN PRESS ENDOCRINOLO; WILLIAMSON JR, 1985, AM J PHYSIOL, V248, pC203, DOI 10.1152/ajpcell.1985.248.3.C203	48	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					860	867						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288639				2022-12-25	WOS:A1994MR22000017
J	WALKER, A; TURNBULL, JE; GALLAGHER, JT				WALKER, A; TURNBULL, JE; GALLAGHER, JT			SPECIFIC HEPARAN-SULFATE SACCHARIDES MEDIATE THE ACTIVITY OF BASIC FIBROBLAST GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR BINDING; CELL-SURFACE; RECEPTOR; DIFFERENTIATION; MOLECULES; BFGF	In a previous study, we showed that heparitinase releases a 14-saccharide sequence (Oligo-H) from heparan sulfate (HS) with the structure DELTAGlcUAbeta1,4GlcNSO3 alpha1,4[IdceA(2S)alpha1,4GlcNSO3]5alpha1,4IdceAalpha1,4GlcNAc (where IdceA(2S) represents iduronic acid 2-sulfate), which binds to basic fibroblast growth factor (bFGF) with high affinity (Turnbull, J. E., Fernig, D., Ke, Y., Wilkinson, M. C. & Gallagher, J. T. (1992) J. Biol. Chem. 267, 10337-10341). This paper describes further work on the binding properties of HS saccharides and their capacity to mediate bFGF activity in a mitogenesis assay in which responsiveness is dependent on the addition of HS or heparin. Saccharides prepared by heparinase or nitrous acid digestion and heparitinase-resistant fragments five disaccharide units (degree of polymerization (dp) = 10) or less in size were unable to activate bFGF. However, heparitinase-resistant saccharides of dp12-16 were active in the assay; the dp14 and dp16 fractions were equivalent in activity to heparin and more active than the parent HS. Saccharides of the same size and basic structure as the active fractions (greater-than-or-equal-to dp12) bound to bFGF with high relative affinity. Active saccharides were composed mainly of N-sulfated disaccharides, the predominant unit being IdceA(2S)-GlcNSO3. This was enriched at least 5-fold in the active saccharides by comparison with the original HS. In addition, the dp12 and dp14 active fractions had a notably low content of trisulfated disaccharides (IdceA(2S)-GlcNSO3(6S)) (where GlcNSO3(6S) represents N-sulfated glucosamine 6-sulfate), which are the major repeat units of heparin. The data show that sequences similar in size and basic structure to Oligo-H can mediate the mitogenic activity of bFGF. Overall, the results provide further evidence that specific HS sequences are generated biosynthetically in order to fulfill particular biological functions such as activation of bFGF.	UNIV MANCHESTER,CANC RES CAMPAIGN,DEPT MED ONCOL,MANCHESTER M13 9PL,LANCS,ENGLAND; CHRISTIE HOSP & HOLT RADIUM INST,CLIN RES DEPT,MANCHESTER M20 9BX,LANCS,ENGLAND	University of Manchester; Christie NHS Foundation Trust; Christie Hospital								GALLAGHER JT, 1992, GLYCOBIOLOGY, V2, P523, DOI 10.1093/glycob/2.6.523; GALLAGHER JT, 1992, ADV EXP MED BIOL, V313, P49; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Klagsbrun M, 1990, CURR OPIN CELL BIOL, V2, P857, DOI 10.1016/0955-0674(90)90084-R; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; Lindahl U., 1989, HEPARIN, P159; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; TURNBULL JE, 1993, BIOCHEM SOC T, V21, P477, DOI 10.1042/bst0210477; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	25	185	187	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					931	935						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288646				2022-12-25	WOS:A1994MR22000027
J	MARMIROLI, S; OGNIBENE, A; BAVELLONI, A; CINTI, C; COCCO, L; MARALDI, NM				MARMIROLI, S; OGNIBENE, A; BAVELLONI, A; CINTI, C; COCCO, L; MARALDI, NM			INTERLEUKIN-1-ALPHA STIMULATES NUCLEAR PHOSPHOLIPASE-C IN HUMAN OSTEOSARCOMA SAOS-2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SWISS 3T3 CELLS; PROTEIN-KINASE-C; SIGNAL TRANSDUCTION; INOSITOL LIPIDS; CYCLIC-AMP; RECEPTOR; DIACYLGLYCEROL; LOCALIZATION; MECHANISM; IL-1	Interleukin 1 (IL-1) is one of the most potent stimulators of bone resorption. However, the early biochemical events elicited by IL-1 receptor binding are not fully understood. Here we show that in human osteosarcoma SaOS-2 cells the treatment with IL-1alpha is able to evoke a rapid and transient increase of nuclear phospholipase C (PLC) activity. A parallel decrease of nuclear phosphatidylinositol monophosphate and phosphatidylinositol bisphosphate is observed. All these events are strictly confined to the nuclear compartment without affecting the cytoplasmatic inositol lipid pool. In addition we show that by Western blot analysis with specific monoclonal antibodies the PLC gamma is located both in the cytoplasm and in the nucleus, while PLC beta appears exclusively Iocalized in the nucleus. Moreover, the increase of PLC activity in response to IL-1alpha is completely neutralized by monoclonal antibody against the beta-form. While confirming the existence of an autonomous nuclear phosphoinositide signaling system, our data clearly indicate that in SaOS-2 cells one of the earliest events following IL-1alpha treatment is the breakdown of nuclear phosphatidylinositol monophosphate and phosphatidylinositol bisphosphate because of the activation of a specific nuclear PLC isoform.	CNR, IST CITOMORFOL NORMALE & PATOL, I-40136 BOLOGNA, ITALY; IST ORTOPED RIZZOLI, BIOL CELLULARE & MICROSCOPIA ELETTRON LAB, I-40136 BOLOGNA, ITALY; IST ANAT UMANA NORMALE, I-40126 BOLOGNA, ITALY	Consiglio Nazionale delle Ricerche (CNR); IRCCS Istituto Ortopedico Rizzoli	MARMIROLI, S (corresponding author), CNR, IST ORTOPED RIZZOLI, VIA BARBIANO 1-10, I-40136 BOLOGNA, ITALY.		Marmiroli, Sandra/J-5242-2016; Bavelloni, Alberto/E-5726-2019	Marmiroli, Sandra/0000-0001-5545-9319; Bavelloni, Alberto/0000-0002-6467-1431; Cinti, Caterina/0000-0001-8049-0369				ABRAHAM RT, 1987, J BIOL CHEM, V262, P2719; Auger K. R., 1990, METHODS INOSITIDE RE, P159; BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; CAPITANI S, 1990, CELL BIOL INT REP, V14, P783, DOI 10.1016/0309-1651(90)90005-J; CAPITANI S, 1989, FEBS LETT, V254, P194, DOI 10.1016/0014-5793(89)81037-3; CAPITANI S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P193, DOI 10.1016/0005-2760(90)90303-F; CARROLL GJ, 1985, ANN RHEUM DIS, V44, P631, DOI 10.1136/ard.44.9.631; CATALDI A, 1990, FEBS LETT, V269, P465, DOI 10.1016/0014-5793(90)81216-B; COCCO L, 1988, BIOCHEM BIOPH RES CO, V154, P1266, DOI 10.1016/0006-291X(88)90276-8; COCCO L, 1987, BIOCHEM J, V248, P765, DOI 10.1042/bj2480765; CURTIS BM, 1990, J IMMUNOL, V144, P1295; CURTIS BM, 1989, P NATL ACAD SCI USA, V86, P3045, DOI 10.1073/pnas.86.9.3045; DEDHAR S, 1989, EXP CELL RES, V183, P207, DOI 10.1016/0014-4827(89)90430-8; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; DIVECHA N, 1993, BIOCHEM J, V289, P617, DOI 10.1042/bj2890617; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GEORGILIS K, 1987, J IMMUNOL, V138, P3403; GRENFELL S, 1989, BIOCHEM J, V264, P813, DOI 10.1042/bj2640813; HEGUY A, 1991, CELL GROWTH DIFFER, V2, P311; Irvine R F, 1992, Semin Cell Biol, V3, P225, DOI 10.1016/1043-4682(92)90024-P; KILIAN PL, 1986, J IMMUNOL, V136, P4509; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTELLI AM, 1991, FEBS LETT, V283, P243, DOI 10.1016/0014-5793(91)80598-W; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MAZZONI M, 1992, BIOCHEM BIOPH RES CO, V187, P114, DOI 10.1016/S0006-291X(05)81466-4; MICHELL R H, 1992, Current Biology, V2, P200, DOI 10.1016/0960-9822(92)90533-G; MIZEL SB, 1989, FASEB J, V3, P2379, DOI 10.1096/fasebj.3.12.2676681; PARK DG, 1993, J BIOL CHEM, V268, P3710; RAY K, 1992, BIOCHEM J, V282, P59, DOI 10.1042/bj2820059; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RODAN SB, 1990, J IMMUNOL, V145, P1231; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SHIRAKAWA F, 1988, P NATL ACAD SCI USA, V85, P8201, DOI 10.1073/pnas.85.21.8201; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SMITH CD, 1983, J BIOL CHEM, V258, P9368; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; SUH PG, 1988, J BIOL CHEM, V263, P14497; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WIJELATH ES, 1988, BIOCHEM BIOPH RES CO, V152, P392, DOI 10.1016/S0006-291X(88)80726-5; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802; ZINI N, 1993, EXP CELL RES, V208, P257, DOI 10.1006/excr.1993.1245	43	80	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					13	16						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276785				2022-12-25	WOS:A1994MR21900004
J	PIKE, R; MCGRAW, W; POTEMPA, J; TRAVIS, J				PIKE, R; MCGRAW, W; POTEMPA, J; TRAVIS, J			LYSINE-SPECIFIC AND ARGININE-SPECIFIC PROTEINASES FROM PORPHYROMONAS-GINGIVALIS - ISOLATION, CHARACTERIZATION, AND EVIDENCE FOR THE EXISTENCE OF COMPLEXES WITH HEMAGGLUTININS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPSIN-LIKE PROTEASE; BACTEROIDES-GINGIVALIS; CULTURE SUPERNATANT; ENZYME-ACTIVITY; PURIFICATION; W50; PERIODONTITIS; VIRULENT; STRAINS; HEMIN	Porphyromonas gingivalis contains many virulence factors that have been implicated as participants in the progression of periodontal disease. lt has been shown to produce proteinases of ''trypsin-like'' specificity in a number of molecular forms, but previous work in our laboratory resulted in the purification of a major arginine-specific cysteine proteinase, gingipain, which contradicted this supposed specificity. In this study, separate proteinases with arginine and lysine specificity were isolated from a high molecular mass fraction of the P. gingivalis culture fluid. The arginine-specific enzyme was found, by amino acid sequencing studies, to be a high molecular mass form of gingipain, formed by the 50-kDa gingipain noncovalently complexed with 44-kDa binding proteins, subsequently identified as hemagglutinins. The 60-kDa lysine-specific proteinase, referred to as Lys-gingipain, was also found to have one of these hemagglutinins complexed with it in the same manner. Lys-gingipain was found to be a cysteine proteinase with optimal activity and stability at pH 8.0-8.5 and was extensively characterized in terms of its specificity and activation characteristics. The proteinase-hemagglutinin complexes may be important in the uptake of hemin, a vital metabolite for P. gingivalis, via hemagglutination and subsequent hemolysis of erythrocytes.	UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602; JAGIELLONIAN UNIV,INST MOLEC BIOL,DEPT MICROBIOL & IMMUNOL,PL-3120 KRAKOW,POLAND	University System of Georgia; University of Georgia; Jagiellonian University				Pike, Robert/0000-0002-2083-0269	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE009761] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 09761] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BICKEL M, 1985, J PERIODONTAL RES, V20, P35, DOI 10.1111/j.1600-0765.1985.tb00408.x; BIRKEDALHANSEN H, 1988, J PERIODONTAL RES, V23, P258, DOI 10.1111/j.1600-0765.1988.tb01369.x; CARMAN RJ, 1990, INFECT IMMUN, V58, P4016, DOI 10.1128/IAI.58.12.4016-4019.1990; CHEN ZX, 1991, INFECT IMMUN, V59, P2846, DOI 10.1128/IAI.59.8.2846-2850.1991; CHEN ZX, 1992, J BIOL CHEM, V267, P18896; FUJIMURA S, 1992, ORAL MICROBIOL IMMUN, V7, P212, DOI 10.1111/j.1399-302X.1992.tb00027.x; Garvey JS, 1977, METHODS IMMUNOLOGY, V3rd; GRENIER D, 1987, INFECT IMMUN, V55, P111, DOI 10.1128/IAI.55.1.111-117.1987; GRENIER D, 1987, J CLIN MICROBIOL, V25, P738, DOI 10.1128/JCM.25.4.738-740.1987; GRENIER D, 1987, INFECT IMMUN, V55, P3131, DOI 10.1128/IAI.55.12.3131-3136.1987; GRENIER D, 1989, INFECT IMMUN, V57, P95, DOI 10.1128/IAI.57.1.95-99.1989; HALKIER T, 1991, MECHANISMS BLOOD COA; HAYASHI H, 1992, ORAL MICROBIOL IMMUN, V7, P204, DOI 10.1111/j.1399-302X.1992.tb00026.x; HINODE D, 1991, INFECT IMMUN, V59, P3060, DOI 10.1128/IAI.59.9.3060-3068.1991; INOSHITA E, 1986, INFECT IMMUN, V52, P421, DOI 10.1128/IAI.52.2.421-427.1986; MARSH PD, 1989, FEMS MICROBIOL LETT, V59, P181; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCBRIDE BC, 1990, ARCH ORAL BIOL, V35, pS59, DOI 10.1016/0003-9969(90)90132-T; MCDERMID AS, 1988, INFECT IMMUN, V56, P1096, DOI 10.1128/IAI.56.5.1096-1100.1988; MCKEE AS, 1986, INFECT IMMUN, V52, P349, DOI 10.1128/IAI.52.2.349-355.1986; NISHIKATA M, 1991, BIOCHEM BIOPH RES CO, V178, P336, DOI 10.1016/0006-291X(91)91819-X; OKUDA K, 1986, INFECT IMMUN, V54, P659, DOI 10.1128/IAI.54.3.659-665.1986; Ono M, 1987, Oral Microbiol Immunol, V2, P77, DOI 10.1111/j.1399-302X.1987.tb00294.x; OTSUKA M, 1987, J PERIODONTAL RES, V22, P491, DOI 10.1111/j.1600-0765.1987.tb02060.x; SCOTT CF, 1993, J BIOL CHEM, V268, P7935; SHAGGER H, 1987, ANAL BIOCHEM, V166, P368; SHAH HN, 1992, J MED MICROBIOL, V36, P239, DOI 10.1099/00222615-36-4-239; SLOTS J, 1977, SCAND J DENT RES, V85, P114; SMALLEY JW, 1991, ORAL MICROBIOL IMMUN, V6, P202, DOI 10.1111/j.1399-302X.1991.tb00478.x; SMALLEY JW, 1989, ORAL MICROBIOL IMMUN, V4, P178, DOI 10.1111/j.1399-302X.1989.tb00249.x; SORSA T, 1987, J PERIODONTAL RES, V22, P375, DOI 10.1111/j.1600-0765.1987.tb01602.x; SUIDO H, 1987, J PERIODONTAL RES, V22, P412, DOI 10.1111/j.1600-0765.1987.tb01608.x; TSUTSUI H, 1987, INFECT IMMUN, V55, P420, DOI 10.1128/IAI.55.2.420-427.1987; UITTO VJ, 1987, J PERIODONTAL RES, V22, P58, DOI 10.1111/j.1600-0765.1987.tb01540.x; VANWINKELHOFF AJ, 1988, J CLIN PERIODONTOL, V15, P145; WHITE D, 1981, J PERIODONTAL RES, V16, P259, DOI 10.1111/j.1600-0765.1981.tb00974.x	37	309	320	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					406	411						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276827				2022-12-25	WOS:A1994MR21900069
J	KAWASHIMA, H; YAMAMOTO, K; OSAWA, T; IRIMURA, T				KAWASHIMA, H; YAMAMOTO, K; OSAWA, T; IRIMURA, T			PURIFICATION AND CHARACTERIZATION OF UDP-GLCNAC-GAL-BETA-1-4GLC(NAC) BETA-1,3-N-ACETYLGLUCOSAMINYLTRANSFERASE (POLY-N-ACETYLLACTOSAMINE EXTENSION ENZYME) FROM CALF SERUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; FULL-LENGTH CDNA; ACETYLGLUCOSAMINE (BETA-1-4)GALACTOSYLTRANSFERASE; LINKED OLIGOSACCHARIDES; CARBOHYDRATE STRUCTURE; PORCINE THYROGLOBULIN; BAND-3 GLYCOPROTEIN; RAT-KIDNEY; CLONING	UDP-GlcNAc:Galbeta1-4Glc(NAc) beta-1,3-N-acetylglucosaminyltransferase is involved in the initiation and the extension of poly-N-acetyllactosamine biosynthesis. This enzyme has been purified to about 125,000-fold with a 0.2% yield from calf serum. The purification was achieved by ammonium sulfate precipitation and chromatography on concanavalin A-Sepharose, DEAE-Toyopearl, SP-Toyopearl, Sephacryl S-200, AF-Blue-Toyopearl, and Mono Q columns. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed a single band corresponding to an apparent M(r) of 70,000. This component was specifically photoaffinity-labeled with 4-thiouridine diphosphate. Exoglycosidase digestion and methylation analysis of the reaction products demonstrated that the enzyme catalyzed the transfer of one N-acetylglucosamine to position C-3 of the terminal galactosyl residue of lactose or N-acetyllactosamine in the beta linkage. The enzyme required Mn2+ ions for its activity and showed a broad pH optimum around 7.0. Apparent K(m) values for lactose, N-acetyllactosamine, and UDP-GlcNAc were 18.2, 19.6, and 0.129 mM, respectively. Acceptor specificity was tested using several oligosaccharides. The results indicated that terminal Galbeta1-4Glc(NAc) sequences (type II chains) were preferred substrates for the enzyme. Terminal Galbeta1-3GlcNAc sequences (type I chains), Lewis X trisaccharides (Galbeta1-4(Fucalpha1-3)GlcNAc), and monosaccharides (galactose) did not serve as substrates.	UNIV TOKYO, FAC PHARMACEUT SCI, DIV CHEM TOXICOL & IMMUNOCHEM, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								BASU M, 1984, J BIOL CHEM, V259, P2557; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; CHEN C, 1989, BIOCHEMISTRY-US, V28, P2229, DOI 10.1021/bi00431a039; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CLAUSEN H, 1990, J BIOL CHEM, V265, P1139; Cuatrecasas P., 1971, METHOD ENZYMOL, V22, P345; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; ELICES MJ, 1990, CARBOHYD RES, V203, P109, DOI 10.1016/0008-6215(90)80050-D; FUKUDA M, 1981, P NATL ACAD SCI-BIOL, V78, P6299, DOI 10.1073/pnas.78.10.6299; FUKUDA M, 1979, J BIOL CHEM, V254, P3700; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA M, 1984, BIOCHIM BIOPHYS ACTA, V780, P119, DOI 10.1016/0304-419X(84)90002-7; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; HOLMES EH, 1987, J BIOL CHEM, V262, P15649; HOSOMI O, 1989, JPN J MED SCI BIOL, V42, P77, DOI 10.7883/yoken1952.42.77; IMAI Y, 1990, MOL IMMUNOL, V27, P335, DOI 10.1016/0161-5890(90)90046-3; KAWASHIMA H, 1990, GLYCOCONJUGATE J, V7, P323, DOI 10.1007/BF01073376; KETCHAM CM, 1992, J BIOL CHEM, V267, P11645; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE N, 1990, J BIOL CHEM, V265, P20476; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MURAMATSU H, 1983, J BIOCHEM-TOKYO, V94, P799, DOI 10.1093/oxfordjournals.jbchem.a134422; MURAMATSU T, 1978, P NATL ACAD SCI USA, V75, P2315, DOI 10.1073/pnas.75.5.2315; MURAMATSU T, 1979, CELL, V18, P183, DOI 10.1016/0092-8674(79)90367-2; NAKAZAWA K, 1988, J BIOCHEM-TOKYO, V104, P165, DOI 10.1093/oxfordjournals.jbchem.a122434; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; NISHIKAWA Y, 1988, J BIOL CHEM, V263, P8270; OGATA SI, 1976, NATURE, V259, P580, DOI 10.1038/259580a0; PILLER F, 1983, J BIOL CHEM, V258, P2293; POWELL JT, 1976, J BIOL CHEM, V251, P3645; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; TANIGUCHI N, 1984, J BIOL CHEM, V259, P5637; TSUJI T, 1981, BIOCHEM J, V195, P691, DOI 10.1042/bj1950691; TSUJI T, 1981, J BIOL CHEM, V256, P497; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; VANDENEIJNDEN DH, 1983, J BIOL CHEM, V258, P3435; WANG WC, 1991, J BIOL CHEM, V266, P23185; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; YAMAMOTO K, 1984, EUR J BIOCHEM, V143, P133, DOI 10.1111/j.1432-1033.1984.tb08352.x; YAMAMOTO K, 1981, BIOCHEM J, V195, P701, DOI 10.1042/bj1950701; YAMASHITA K, 1984, J BIOL CHEM, V259, P834; YATES AD, 1983, CARBOHYD RES, V120, P251, DOI 10.1016/0008-6215(83)88020-3; YAZAWA S, 1986, CARBOHYD RES, V149, P241, DOI 10.1016/S0008-6215(00)90381-1	49	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27118	27126						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262950				2022-12-25	WOS:A1993MM26200043
J	RICHAUD, C; MENGINLECREULX, D; POCHET, S; JOHNSON, EJ; COHEN, GN; MARLIERE, P				RICHAUD, C; MENGINLECREULX, D; POCHET, S; JOHNSON, EJ; COHEN, GN; MARLIERE, P			DIRECTED EVOLUTION OF BIOSYNTHETIC PATHWAYS - RECRUITMENT OF CYSTEINE THIOETHERS FOR CONSTRUCTING THE CELL-WALL OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; DIAMINOPIMELATE EPIMERASE; FUSOBACTERIUM-NUCLEATUM; CYTOPLASMIC STEPS; REGULATORY REGION; META GENE; PEPTIDOGLYCAN; CLONING; MUTAGENESIS; INSERTION	We report that expansion of thioether biosynthesis in Escherichia coli generates sulfur-containing amino acids that can replace meso-diaminopimelate, the essential amino acid used for cross-linking the cell wall. This was accomplished by jointly overexpressing the metB gene coding for L-cystathionine gamma-synthase and disrupting the metC gene, whose product, L-cystathionine beta-lyase, is responsible for the destruction of L-cystathionine and other L-cysteine thioethers. As a result, meso-lanthionine and L-allo-cystathionine were produced endogenously and incorporated in the peptidoglycan, thereby enabling E. coli strains auxotrophic for diaminopimelate to grow in its absence. Thus, current techniques of metabolic engineering can be applied to evolving the chemical constitution of living cells beyond its present state.	INST PASTEUR, UNITE PHYSIOL CELLULAIRE, CNRS, URA 1300, F-75724 PARIS 15, FRANCE; INST PASTEUR, UNITE CHIM ORGAN, CNRS, URA 487, F-75724 PARIS 15, FRANCE; INST PASTEUR, UNITE BIOCHIM CELLULAIRE, CNRS, URA 1129, F-75724 PARIS 15, FRANCE; UNIV PARIS 11, BIOCHIM MOLEC & CELLULAIRE LAB, CNRS, URA 1131, F-91405 ORSAY, FRANCE; TULANE UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, NEW ORLEANS, LA 70112 USA	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Tulane University				MENGIN-LECREULX, Dominique/0000-0003-3205-0275				BAILEY JE, 1991, SCIENCE, V252, P1668, DOI 10.1126/science.2047876; BELFAIZA J, 1986, P NATL ACAD SCI USA, V83, P867, DOI 10.1073/pnas.83.4.867; BOGOSIAN G, 1989, J BIOL CHEM, V264, P531; BOUVIER J, 1984, J BIOL CHEM, V259, P4829; Brown GB, 1941, J BIOL CHEM, V140, P767; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P2017, DOI 10.1021/bi00222a002; CAIRNSSMITH AG, 1982, GENETIC TAKEOVER MIN, P349; CAPARROS M, 1992, J BACTERIOL, V174, P5549; COHEN GN, 1987, ESCHERICHIA COLI SAL, P429; DAMANI LA, 1989, SULPHUR CONTAINING B, V1; DAMANI LA, 1989, SULPHUR CONTAINING A, V1; DEAN D, 1981, GENE, V15, P99, DOI 10.1016/0378-1119(81)90108-6; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; DUCLOS B, 1989, NUCLEIC ACIDS RES, V17, P2856, DOI 10.1093/nar/17.7.2856; DWIVEDI CM, 1982, BIOCHEMISTRY-US, V21, P3064, DOI 10.1021/bi00256a005; FLAVIN M, 1975, METABOLIC PATHWAYS, V7, P457; FREDRIKSEN A, 1991, J BACTERIOL, V173, P900, DOI 10.1128/jb.173.2.900-902.1991; GUGGENHEIM S, 1969, J BIOL CHEM, V244, P3722; HOPWOOD DA, 1985, NATURE, V314, P642, DOI 10.1038/314642a0; HUANG HT, 1963, BIOCHEMISTRY-US, V2, P296, DOI 10.1021/bi00902a018; JENSEN RA, 1976, ANNU REV MICROBIOL, V30, P409, DOI 10.1146/annurev.mi.30.100176.002205; KNUSEL F, 1967, PATHOL MICROBIOL, V30, P871, DOI 10.1159/000161753; KOCH AL, 1992, J BACTERIOL, V174, P4811, DOI 10.1128/JB.174.14.4811-4819.1992; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEMEIGNAN B, 1993, J MOL BIOL, V231, P161, DOI 10.1006/jmbi.1993.1269; LEVY S, 1988, MOL MICROBIOL, V2, P777, DOI 10.1111/j.1365-2958.1988.tb00089.x; Maniatis T., 1982, MOL CLONING; MAZEL D, 1989, NATURE, V341, P245, DOI 10.1038/341245a0; MENGINLECREULX D, 1988, J BACTERIOL, V170, P2031, DOI 10.1128/jb.170.5.2031-2039.1988; MENGINLECREULX D, 1982, J BACTERIOL, V151, P1109, DOI 10.1128/JB.151.3.1109-1117.1982; MENGINLECREULX D, 1985, J BACTERIOL, V163, P208, DOI 10.1128/JB.163.1.208-212.1985; MICHAELI S, 1984, J BACTERIOL, V160, P1158, DOI 10.1128/JB.160.3.1158-1162.1984; Mortlock R., 1992, EVOLUTION METABOLIC; NANNINGA N, 1991, MOL MICROBIOL, V5, P791, DOI 10.1111/j.1365-2958.1991.tb00751.x; PARKER B, 1988, GENE, V73, P531, DOI 10.1016/0378-1119(88)90517-3; POCHET S, 1990, NUCLEIC ACIDS RES, V18, P7127, DOI 10.1093/nar/18.23.7127; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; RHULAND LE, 1957, J BACTERIOL, V73, P778, DOI 10.1128/JB.73.6.778-783.1957; RICHAUD C, 1987, J BACTERIOL, V169, P1454, DOI 10.1128/jb.169.4.1454-1459.1987; RICHAUD C, 1984, J BIOL CHEM, V259, P4824; RICHAUD F, 1986, J BACTERIOL, V166, P297, DOI 10.1128/jb.166.1.297-300.1986; RICHMOND MH, 1962, BACTERIOL REV, V26, P398, DOI 10.1128/MMBR.26.4.398-420.1962; Rogers H.J., 1980, MICROBIAL CELL WALLS, P239; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SHAPIRA SK, 1983, GENE, V25, P71, DOI 10.1016/0378-1119(83)90169-5; SIMON M, 1983, J BACTERIOL, V153, P558, DOI 10.1128/JB.153.1.558-561.1983; VASSTRAND EN, 1979, INFECT IMMUN, V25, P775, DOI 10.1128/IAI.25.3.775-780.1979; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WANNER BL, 1986, J MOL BIOL, V191, P39, DOI 10.1016/0022-2836(86)90421-3; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; YCAS M, 1974, J THEOR BIOL, V44, P145, DOI 10.1016/S0022-5193(74)80035-4; ZAKIN MM, 1982, MOL GEN GENET, V187, P101, DOI 10.1007/BF00384390	53	67	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26827	26835						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262915				2022-12-25	WOS:A1993MM26200004
J	BIELAWSKA, A; CRANE, HM; LIOTTA, D; OBEID, LM; HANNUN, YA				BIELAWSKA, A; CRANE, HM; LIOTTA, D; OBEID, LM; HANNUN, YA			SELECTIVITY OF CERAMIDE-MEDIATED BIOLOGY - LACK OF ACTIVITY OF ERYTHRO-DIHYDROCERAMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NECROSIS-FACTOR-ALPHA; CELL-DIFFERENTIATION; SPHINGOMYELIN TURNOVER; SPHINGOSINE; SPHINGOLIPIDS; BIOSYNTHESIS	Ceramide is emerging as a putative second messenger mediating effects of extracellular agents on cell growth and differentiation (Okazaki, T., Bielawska, A., Bell, R. M., and Hannun, Y. (1990) J. Biol. Chem. 265, 15823-15831) and programed cell death (Obeid, L. M., Linardic, C. M., Karolak, L. A., and Hannun, Y. A. (1993) Science 259, 1769-1771). In this study, the eight stereoisomers of C2-ceramide and dihydroceramide were synthesized, and their Cellular activity was investigated. The four stereoisomers of C2-Ceramide were active in inhibition of cell growth and induction of apoptosis with modest differences in potency. On the other hand, with C2-dihydroceramide only the threo compounds were active in these assays whereas the erythro compounds were totally inactive. Thus, of the two naturally occurring molecules, the analog of D-erythro-ceramide (with the 4-5 trans double bond) was active, whereas the analog of D-erythro-dihydroceramide was inactive. These results demonstrate the specificity of ceramide action and suggest that the introduction of the double bond is critical for imparting the biochemical and biological activity of ceramide.	DUKE UNIV,MED CTR,DEPT MED,BOX 3355,DURHAM,NC 27710; EMORY UNIV,DEPT CHEM,ATLANTA,GA 30322	Duke University; Emory University				obeid, lina/0000-0002-0734-0847	NIGMS NIH HHS [GM-43825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BIELAWSKA A, 1992, J BIOL CHEM, V267, P18493; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HANNUN YA, 1992, ALFRED BENZON SYMP S, V33, P257; KIM MY, 1991, J BIOL CHEM, V266, P484; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MERRILL AH, 1992, NUTR REV, V50, P78; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; NIMKAR S, 1988, TETRAHEDRON LETT, V29, P3037, DOI 10.1016/0040-4039(88)85079-2; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P169, DOI 10.1515/bchm2.1973.354.1.169	23	296	303	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26226	26232						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253743				2022-12-25	WOS:A1993MK42500035
J	KOPPLER, P; MATTER, N; MALVIYA, AN				KOPPLER, P; MATTER, N; MALVIYA, AN			EVIDENCE FOR STEREOSPECIFIC INOSITOL 1,3,4,5-[H-3]TETRAKISPHOSPHATE BINDING-SITES ON RAT-LIVER NUCLEI - DELINEATING INOSITOL 1,3,4,5-TETRAKISPHOSPHATE INTERACTION IN NUCLEAR CALCIUM SIGNALING PROCESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; SWISS 3T3 CELLS; TYROSINE KINASE; CA-2+ RELEASE; HL-60 CELLS; RECEPTOR; PHOSPHATES; BRAIN; PHOSPHORYLATION; PURIFICATION	H-3-Labeled inositol 1,3,4,5-tetrakisphosphate (IP4) binding sites are observed on nuclei isolated from rat liver and devoid of any microsomal, mitochondrial, or plasma membrane constituents. A pH of about 6.5 is found optimum for maximum [H-3]IP4 specific binding that is sensitive to changes in pH. The [H-3]IP4 binding on the nuclei can be distinguished into a high affinity site and a low affinity site. The two binding sites are characterized by distinct K(D) and B(max) (1.6 nM versus 57.0 nm K(D); 0.25 pmol/mg protein and 3.7 pmol/mg protein B(max)). IP4 is capable of Ca-45(2+) uptake even in the absence of ATP. The calcium uptake by nuclei is highly sensitive to IP4 Since it is achieved even at 1 nm IP4 concentration. Furthermore, data are documented demonstrating that a rapid and transient Ca-45(2+) release by inositol 1,4,5-trisphosphate (IP3) from the intact nuclei can be reversed by IP4. The presence of IPs potentiates the action of IP4 in nuclear calcium reuptake as attested by the rate of calcium uptake by IP4 in the absence of IP3 (0.16 nmol/s/mg of protein) and in the presence of IPs (4.0 nmol/s/mg of protein). A novel mechanism of nuclear calcium signaling is proposed where IP4 brings calcium into the nuclei mediated by its specific putative binding sites.	CNRS,CTR NEUROCHIM,NEUROBIOL MOLEC INTERACT CELLULAIRES LAB,5 RUE BLAISE PASCAL,F-67084 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRCH BD, 1992, P NATL ACAD SCI USA, V89, P7978, DOI 10.1073/pnas.89.17.7978; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADFORD PG, 1987, BIOCHEM BIOPH RES CO, V149, P680, DOI 10.1016/0006-291X(87)90421-9; CHALLISS RAJ, 1991, BIOCHEM J, V274, P861, DOI 10.1042/bj2740861; DONIE F, 1989, FEBS LETT, V254, P155, DOI 10.1016/0014-5793(89)81029-4; DONIE F, 1991, BIOCHEM J, V275, P453, DOI 10.1042/bj2750453; GAWLER DJ, 1991, BIOCHEM J, V276, P163, DOI 10.1042/bj2760163; GAWLER DJ, 1991, BIOCHEM J, V273, P519; GILCHRIST JSC, 1993, J BIOL CHEM, V268, P4291; HADCOCK JR, 1992, J BIOL CHEM, V267, P26017; HANLEY MR, 1988, PHILOS T R SOC B, V320, P381, DOI 10.1098/rstb.1988.0083; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; HILL TD, 1990, J CELL PHYSIOL, V142, P163, DOI 10.1002/jcp.1041420120; Irvine R F, 1992, Semin Cell Biol, V3, P225, DOI 10.1016/1043-4682(92)90024-P; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Irvine Robin F., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P161; LANINI L, 1992, J BIOL CHEM, V267, P11548; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MASMOUDI A, 1989, J BIOL CHEM, V264, P1172; MATTER N, 1993, J BIOL CHEM, V268, P732; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PIETRI F, 1990, J BIOL CHEM, V265, P17478; PITTET D, 1989, J BIOL CHEM, V264, P7251; RODLAND KD, 1990, J BIOL CHEM, V265, P11000; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPAT A, 1987, BIOCHEM J, V244, P493; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; THEIBERT AB, 1990, BIOCHEM J, V267, P441, DOI 10.1042/bj2670441; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; YOO SH, 1991, BIOCHEM J, V278, P381, DOI 10.1042/bj2780381; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	37	46	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26248	26252						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253746				2022-12-25	WOS:A1993MK42500038
J	YONEMURA, K; RAINES, EW; AHN, NG; NARAYANAN, AS				YONEMURA, K; RAINES, EW; AHN, NG; NARAYANAN, AS			MITOGENIC SIGNALING MECHANISMS OF HUMAN CEMENTUM-DERIVED GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SMOOTH-MUSCLE CELLS; GINGIVAL FIBROBLASTS; INDUCED ACTIVATION; FACTOR RECEPTORS; PERTUSSIS TOXIN; BINDING-PROTEIN; PHOSPHOLIPASE-C; DNA-SYNTHESIS; FACTOR-BETA	Cementum-derived growth factor (CGF) is a M(r) 23,000 protein, which is sequestered in the mineralized matrix of tooth cementum. We have investigated the mitogenic signaling reactions induced by CGF using quiescent human gingival fibroblasts as target cells. Cells activated with CGF were compared with those treated with CGF plus epidermal growth factor (EGF) and other growth factors. CGF caused a transient increase in cytoplasmic Ca2+ concentration, and this was accompanied by enhancement of membrane protein kinase C activity, myelin basic protein and S6 kinase activities, inositol phosphate levels, and activation of c-fos and jun-B gene expression. Membranes obtained from cells activated with CGF contained several protein bands, which cross-reacted with antiphosphotyrosine antibody; however, proteins corresponding to a putative phosphorylated CGF receptor were not detected. DNA synthesis induced by CGF was inhibited by 65% in cells treated with pertussis toxin but only 25-29% in cultures exposed to H7 or 12-O-tetradecanoylphorbol-13-acetate; these values were different from those obtained when EGF, PDGF, or fetal bovine serum were used as mitogens. CGF and TGF-beta, but not EGF, caused an increase of PDGF-A chain mRNA expression 4 h after mitogen addition. However, while CGF was mitogenic for gingival fibroblasts, TGF-beta was not. Kinetics of DNA stimulation and experiments with anti-PDGF antibodies indicated that PDGF-A expression does not contribute significantly to CGF-induced DNA synthesis. When the stimulation of various signaling pathways induced by CGF and other growth factors was compared, the pattern of stimulation by CGF was different from other growth factors. The characteristic signaling reactions of CGF are likely to be important components of the mechanisms that regulate the formation and regeneration of cementum and adjacent connective tissues.	UNIV WASHINGTON,DEPT PATHOL,SM-30,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NCRR NIH HHS [RR-06236] Funding Source: Medline; NIDCR NIH HHS [DE-08229] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR006236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008229] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11495; BAIRD A, 1990, PEPTIDE GROWTH FACTO, P369; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BIRD TA, 1989, J IMMUNOL, V142, P126; BOWENPOPE DF, 1985, METHOD ENZYMOL, V109, P69; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO MV, 1992, CELL, V68, P95; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark R. A. F., 1988, MOL CELLULAR BIOL WO; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CUTRY AF, 1989, J BIOL CHEM, V264, P19700; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; ESCOBEDO JA, 1988, J BIOL CHEM, V263, P1482; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FISCHER JB, 1988, J BIOL CHEM, V263, P2808; FRANKLIN CC, 1992, BIOCHIM BIOPHYS ACTA, V1134, P137, DOI 10.1016/0167-4889(92)90036-B; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUANG CL, 1991, J BIOL CHEM, V266, P4045; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; KAMPS MP, 1988, ONCOGENE, V2, P305; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LETTERIO JJ, 1986, SCIENCE, V234, P1117, DOI 10.1126/science.3465038; MAGNALDO I, 1986, J BIOL CHEM, V261, P6916; MCCULLOCH CAG, 1987, ANAT RECORD, V219, P233, DOI 10.1002/ar.1092190304; MIKI Y, 1987, J DENT RES, V66, P1399, DOI 10.1177/00220345870660082301; NAKAE H, 1991, BIOCHEMISTRY-US, V30, P7047, DOI 10.1021/bi00243a002; NARAYANAN AS, 1989, BIOCHEM J, V260, P463, DOI 10.1042/bj2600463; NISHIMURA J, 1992, BIOCHEM BIOPH RES CO, V188, P1198, DOI 10.1016/0006-291X(92)91358-W; NISHIZAWA N, 1990, CELL REGUL, V1, P747, DOI 10.1091/mbc.1.10.747; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLSON RH, 1985, J PERIODONTOL, V56, P592, DOI 10.1902/jop.1985.56.10.592; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; POLSON AM, 1986, J CLIN PERIODONTOL, V13, P95; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SAMBROOK J, 1989, MOL CLONNG LABORATO; SEYEDIN SM, 1986, J BIOL CHEM, V261, P5693; SOMA Y, 1992, FASEB J, V6, P2996, DOI 10.1096/fasebj.6.11.1644262; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; THOMAS TP, 1987, METHOD ENZYMOL, V141, P399; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WOSIKOWSKI K, 1992, BIOCHEM BIOPH RES CO, V188, P1067, DOI 10.1016/0006-291X(92)91340-V; YONEMURA K, 1992, BONE MINER, V18, P187, DOI 10.1016/0169-6009(92)90806-O; ZHANG H, 1990, J BIOL CHEM, V265, P76	53	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26120	26126						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253729				2022-12-25	WOS:A1993MK42500020
J	BARKER, PE; SAVELYEVA, L; SCHWAB, M				BARKER, PE; SAVELYEVA, L; SCHWAB, M			TRANSLOCATION JUNCTIONS CLUSTER AT THE DISTAL SHORT ARM OF CHROMOSOME-1 (1P36.1-2) IN HUMAN NEUROBLASTOMA-CELLS	ONCOGENE			English	Article							HUMAN NEURO-BLASTOMA; INSITU HYBRIDIZATION; LINKAGE MAP; HETEROZYGOSITY; DELETIONS; FEATURES; CANCER; LINES; DNA	Human neuroblastoma cells show at high frequency structural changes of the distal short arm of chromosome 1 (1p). The commonly altered region has been identified in previous loss-of-heterozygosity (LOH) studies to involve deletion of 1p36.1-2. These bands are also the site of constitutional alterations in patients with neuroblastoma. In an approach to define the 1p36.1-2 alterations in more detail we here employ four neuroblastoma cell lines to map translocation breaks involving 1p36.1-2 by fluorescence in situ hybridization (FISH). A chromosomal interval flanked by loci DIS96 and DIS98 contained translocation junctions in each of four lines. This analysis identifies in 1p a restricted genomic region as involved in chromosomal rearrangement in different neuroblastomas. The specificity of neuroblastoma translocation junctions at the molecular level implicates this genomic region in tumor development.	GERMAN CANC RES CTR,DEPT CYTOGENET,D-69120 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)								BARKER PE, 1993, METHODS MOL GENETICS, V2, P129; BARKER PE, 1993, HUMAN NEUROBLASTOMA, P209; BERTHOLD F, 1990, NEUROBLASTOMA TUMOR, P1; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1989, CANCER GENET CYTOGEN, V41, P153, DOI 10.1016/0165-4608(89)90243-4; BUROKER N, 1987, HUM GENET, V77, P175, DOI 10.1007/BF00272388; COLLINS A, 1992, P NATL ACAD SCI USA, V2, P4589; DRACOPOLI NC, 1991, GENOMICS, V9, P686, DOI 10.1016/0888-7543(91)90362-I; ENGELSTEIN M, 1993, GENOMICS, V15, P251, DOI 10.1006/geno.1993.1054; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FONG CT, 1992, CANCER RES, V52, P1780; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; HAINSWORTH PJ, 1992, BRIT J CANCER, V66, P131, DOI 10.1038/bjc.1992.229; HARNETT PR, 1991, CANCER GENET CYTOGEN, V54, P109, DOI 10.1016/0165-4608(91)90037-U; HEIM S, 1992, RECENT ADV HISTOPATH, V15, P37; LAMB J, 1989, CYTOGENET CELL GENET, V51, P1029; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; LEISTER I, 1990, CANCER RES, V50, P7232; LICHTER P, 1991, GENET ANAL-BIOMOL E, V8, P24, DOI 10.1016/1050-3862(91)90005-C; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; MARTINSSON T, 1989, GENE CHROMOSOME CANC, V1, P67, DOI 10.1002/gcc.2870010111; MOLEY JF, 1992, CANCER RES, V52, P770; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1991, ADV NEUROBLASTOMA RE, P1; SRIVATSAN ES, 1993, GENE CHROMOSOME CANC, V7, P32, DOI 10.1002/gcc.2870070106; TAKAYAMA H, 1992, ONCOGENE, V7, P1185; TRASK BJ, 1991, TRENDS GENET, V7, P149, DOI 10.1016/0168-9525(91)90378-4; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x	33	12	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3353	3358						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247537				2022-12-25	WOS:A1993MG78200019
J	CHIEN, S; SILVERSTEIN, SC				CHIEN, S; SILVERSTEIN, SC			ECONOMIC-IMPACT OF APPLICATIONS OF MONOCLONAL-ANTIBODIES TO MEDICINE AND BIOLOGY	FASEB JOURNAL			English	Article							COSTS; CLONE; MICE		UNIV CALIF SAN DIEGO,DEPT AMES BIOENGN,LA JOLLA,CA 92093; COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL & CELLULAR BIOPHYS,NEW YORK,NY 10032; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego; Columbia University; University of California System; University of California San Diego	CHIEN, S (corresponding author), UNIV CALIF SAN DIEGO,INST BIOMED ENGN,LA JOLLA,CA 92093, USA.							ASKONAS BA, 1970, P NATL ACAD SCI USA, V67, P1398, DOI 10.1073/pnas.67.3.1398; Behring E, 1890, DEUT MED WOCHENSCHR, V16, P1113, DOI [10.1055/s-0029-1207589, DOI 10.1055/S-0029-1207589]; Berman SM., 1993, CAN IMPACT BASIC BIO; BURKE DS, 1989, CLIN LAB MED, V9, P369, DOI 10.1016/S0272-2712(18)30609-7; BURNET FM, 1959, CLONAL SELECTION THE; EDELMAN GM, 1962, J EXP MED, V116, P207; ERLICH P, 1900, P ROY SOC LOND B BIO, V66, P424; FUDENBURG HH, 1983, BIOMEDICAL I BIOMEDI, P11; Gutman AB, 1941, J CLIN INVEST, V20, P765, DOI 10.1172/JCI101269; HELLINGER FJ, 1990, PUBLIC HEALTH REP, V105, P1; HORIBATA K, 1970, EXP CELL RES, V60, P61, DOI 10.1016/0014-4827(70)90489-1; JERNE NK, 1955, P NATL ACAD SCI USA, V41, P849, DOI 10.1073/pnas.41.11.849; Kabat EA, 1939, J EXP MED, V69, P103, DOI 10.1084/jem.69.1.103; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOSTOFF RN, 1992, 3RD INT C MAN TECHN; LANDSTEINER K, 1947, SPECIFICITY SEROLOGI; LANDSTEINER KARL, 1940, PROC SOC EXP BIOL AND MED, V43, P223; LITTLEFIELD JW, 1964, SCIENCE, V145, P709, DOI 10.1126/science.145.3633.709; MANSFIELD E, 1991, RES POLICY, V20, P1, DOI 10.1016/0048-7333(91)90080-A; MILSTEIN C, 1980, SCI AM, V243, P66, DOI 10.1038/scientificamerican1080-66; MILSTEIN C, 1984, BIOSCIENCE REP, V4, P275; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; POTTER M, 1972, PHYSIOL REV, V52, P631, DOI 10.1152/physrev.1972.52.3.631; RAFF MC, 1973, J EXP MED, V137, P1024, DOI 10.1084/jem.137.4.1024; SCHWABER J, 1973, NATURE, V244, P444, DOI 10.1038/244444a0; SCITOVSKY AA, 1987, PUBLIC HEALTH REP, V102, P5; Selma J.Mushkin, 1979, BIOMEDICAL RES COSTS; SHULMAN M, 1978, NATURE, V276, P269, DOI 10.1038/276269a0; SILVERSTEIN AM, 1989, HIST IMMUNOLOGY, P327; TALMAGE DW, 1986, ANNU REV IMMUNOL, V4, P1; Tiselius A, 1939, J EXP MED, V69, P119, DOI 10.1084/jem.69.1.119; WEISBROD BA, 1971, J POLIT ECON, V79, P527, DOI 10.1086/259766; YELTON DE, 1981, ANNU REV BIOCHEM, V50, P657, DOI 10.1146/annurev.bi.50.070181.003301; 1989, UNPUB HLTH CARE COST; 1990, NIH903109 PUBL; 1968, TECHNOLOGY RETROSPEC; 1992, BIOTECHNOLOGY DIRECT; 1991, JOB RELATED IMPACTS; 1986, RES FUNDING INVESTME; UNPUB REGIONAL INPUT; 1973, INTERACTIONS SCI TEC; 1992, MONOCLONAL ANTIBODIE; 1969, AD495905	43	4	4	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1993	7	15					1426	1431		10.1096/fasebj.7.15.8262326	http://dx.doi.org/10.1096/fasebj.7.15.8262326			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ML740	8262326				2022-12-25	WOS:A1993ML74000002
J	BARBEAU, D; CHARBONNEAU, R; WHALEN, SG; BAYLEY, ST; BRANTON, PE				BARBEAU, D; CHARBONNEAU, R; WHALEN, SG; BAYLEY, ST; BRANTON, PE			FUNCTIONAL INTERACTIONS WITHIN ADENOVIRUS E1A PROTEIN COMPLEXES	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; HUMAN CYCLIN-A; EARLY REGION-1A POLYPEPTIDES; LARGE T-ANTIGENS; SV40 LARGE-T; CELL-CYCLE; PHOSPHORYLATION SITES; DNA-SYNTHESIS; 1A PROTEINS	The transforming potential of adenovirus E1A oncogene products derives largely from the formation of complexes with cellular proteins, including the p105(Rb) tumor suppressor and a related p107 species, p130 and p300 proteins, and cyclin A (p60(cycA)). Extensive quantitative analyses using E1A deletion mutants identified unique binding patterns for each of these polypeptides within the amino terminus and conserved regions 1 and 2 (CR1 and CR2) of E1A proteins. A novel protein, termed p400, was found by peptide mapping to be related to p300, and, like p300, to require the E1A amino terminus and a portion of CR1 for binding. p130 was shown to be related to p107, and like p107, to associate with p60(cycA). p107, p130 and p105(Rb) all interacted primarily with CR2, however, sequences within CR1 and the amino terminus were capable of weak interactions and appeared to function cooperatively with CR2 to bind these proteins. Protein kinase activity present in E1A complexes probably derives at least in part from p60(cycA)-linked p33(cdk2) associated with p107 and p130. In vitro phosphorylation of complexes purified by immunoprecipitation resulted in labeling of several proteins. p60(cycA) was phosphorylated to about the same extent in cyclin A complexes prepared from either AD5- or mock-infected KB cells, however, that of p130 and p107 was dramatically higher in p60(cycA) complexes from infected cells. p300 was also phosphorylated in complexes prepared using E1A-specific antibodies. Thus one role of E1A proteins in signal transduction and regulation of the cell cycle may be to control the biological activity of p107, p130 and p300 by enhancing their phosphorylation through complex formation.	DEPT BIOCHEM, MONTREAL H3G 1Y6, PQ, CANADA; MCMASTER UNIV, DEPT BIOL, HAMILTON L8S 4K1, ON, CANADA	McMaster University								BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARBEAU D, 1992, BIOCHEM CELL BIOL, V70, P1123, DOI 10.1139/o92-158; BELLETT AJD, 1989, J VIROL, V63, P303, DOI 10.1128/JVI.63.1.303-310.1989; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BRAITHWAITE AW, 1991, NEW BIOL, V3, P18; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUMONT DJ, 1993, J GEN VIROL, V74, P583, DOI 10.1099/0022-1317-74-4-583; DUMONT DJ, 1992, VIROLOGY, V189, P111, DOI 10.1016/0042-6822(92)90686-J; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EGAN C, 1989, ONCOGENE, V4, P383; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HALEY KP, 1984, P NATL ACAD SCI-BIOL, V81, P5734, DOI 10.1073/pnas.81.18.5734; HALL FL, 1993, ONCOGENE, V8, P1377; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1988, ANTIBODIES LABORATOR; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HOWE JA, 1992, VIROLOGY, V186, P15, DOI 10.1016/0042-6822(92)90057-V; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; JELSMA TN, 1988, VIROLOGY, V163, P494, DOI 10.1016/0042-6822(88)90290-5; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KITAGAWA M, 1992, ONCOGENE, V7, P1067; KLEINBERGER T, 1991, P NATL ACAD SCI USA, V88, P11143, DOI 10.1073/pnas.88.24.11143; KUPPUSWAMY MN, 1987, VIROLOGY, V159, P31, DOI 10.1016/0042-6822(87)90344-8; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MCKINNON RD, 1982, GENE, V19, P33, DOI 10.1016/0378-1119(82)90186-X; MONTELL C, 1982, NATURE, V295, P380, DOI 10.1038/295380a0; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NAKAJIMA T, 1987, MOL CELL BIOL, V7, P3846, DOI 10.1128/MCB.7.10.3846; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; ROWE DT, 1983, VIROLOGY, V127, P253, DOI 10.1016/0042-6822(83)90142-3; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; SVENSSON C, 1991, VIROLOGY, V182, P553, DOI 10.1016/0042-6822(91)90596-4; TREMBLAY ML, 1989, VIROLOGY, V169, P397, DOI 10.1016/0042-6822(89)90165-7; TREMBLAY ML, 1988, J BIOL CHEM, V263, P6375; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	94	116	117	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					359	373						15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290250				2022-12-25	WOS:A1994MW24800003
J	CAMPBELL, CE; HUANG, A; GURNEY, AL; KESSLER, PM; HEWITT, JA; WILLIAMS, BRG				CAMPBELL, CE; HUANG, A; GURNEY, AL; KESSLER, PM; HEWITT, JA; WILLIAMS, BRG			ANTISENSE TRANSCRIPTS AND PROTEIN-BINDING MOTIFS WITHIN THE WILMS-TUMOR (WT1) LOCUS	ONCOGENE			English	Article							DENYS-DRASH SYNDROME; ZINC-FINGER GENE; FAMILIAL PREDISPOSITION; HOMOZYGOUS DELETION; FUNCTIONAL-ANALYSIS; N-MYC; EXPRESSION; 11P13; PROMOTER; REGION	Transcription of the WT1 locus is restricted, both temporally and spatially, to a subset of epithelial cells in mammalian kidneys and gonads. WT1, one of the two divergent transcripts mapping to this locus encodes a zinc finger protein that is likely a transcriptional regulator. The other transcript, WIT1, encodes a product of unknown function that is subject to alternate splicing in the region immediately 5' of the WT1 gene. Analysis of the 5' end of this locus further revealed the presence of multiple transcriptional start sites for both genes, such that some of the WIT1 transcripts are encoded by the antisense strand of the first exon of WT1. The genomic region surrounding the transcriptional start sites appears to constitute part of a bi-directional promoter based on the ability of a DNA fragment derived from this region to direct expression of a chimeric CAT gene construct in transient transfection assays. Discrete sequences within the region are capable of interaction in vitro with nuclear extracts derived from a variety of rat and mouse tissues, Interestingly, recombinant WT1, representing the product of zinc finger region of the most abundant of the four alternatively spliced transcripts, is also capable of binding to sequences within this region.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON,CANADA	University of Toronto	CAMPBELL, CE (corresponding author), CLEVELAND CLIN FDN,DEPT CANC BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.		Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARMSTRONG BC, 1992, CELL GROWTH DIFFER, V3, P385; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BONETTA L, 1990, SCIENCE, V250, P994, DOI 10.1126/science.2173146; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COPPES MJ, 1993, P NATL ACAD SCI USA, V90, P1416, DOI 10.1073/pnas.90.4.1416; COPPES MJ, 1992, CANCER RES, V52, P6125; COPPES MJ, 1992, GENE CHROMOSOME CANC, V5, P326, DOI 10.1002/gcc.2870050408; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; COWELL JK, 1991, ONCOGENE, V6, P595; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FLENNIKEN AM, 1990, GENE DEV, V4, P1094, DOI 10.1101/gad.4.7.1094; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GERALD WL, 1992, AM J PATHOL, V140, P1031; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1992, CANCER RES, V52, P6117; HUFF V, 1991, AM J HUM GENET, V48, P997; KIKUCHI H, 1992, AM J PATHOL, V140, P781; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KNOX JJ, 1991, MOL CELL BIOL, V11, P2946, DOI 10.1128/MCB.11.6.2946; KOUFOS A, 1989, AM J HUM GENET, V44, P711; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAGA E, 1981, HUM GENET, V57, P231; MAW MA, 1992, CANCER RES, V52, P3094; MIWA H, 1992, J NATL CANCER I, V84, P181, DOI 10.1093/jnci/84.3.181; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RACKLEY RR, 1993, CELL GROWTH DIFFER, V4, P1; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; SCHWARTZ CE, 1991, GENOMICS, V10, P927, DOI 10.1016/0888-7543(91)90181-D; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; TADOKORO K, 1992, ONCOGENE, V7, P1215; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H; WANG ZY, 1992, J BIOL CHEM, V267, P21999; YEGER H, 1992, CELL GROWTH DIFFER, V3, P855	50	57	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					583	595						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290269				2022-12-25	WOS:A1994MW24800026
J	CROWE, AJ; MCGLADE, J; PAWSON, T; HAYMAN, MJ				CROWE, AJ; MCGLADE, J; PAWSON, T; HAYMAN, MJ			PHOSPHORYLATION OF THE SHC PROTEINS ON TYROSINE CORRELATES WITH THE TRANSFORMATION OF FIBROBLASTS AND ERYTHROBLASTS BY THE V-SEA TYROSINE KINASE	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR RECEPTORS; VIRUS; GAP; SRC; DOMAINS; S13; IDENTIFICATION; RETROVIRUS; EXPRESSION	The S13 avian erythroblastosis viral genome encodes an oncogenic tyrosine kinase, termed env-sea, that is capable of transforming fibroblasts and erythroblasts, Although the tyrosine kinase activity of the env-sea protein has been shown to be necessary for transformation, no substrates for this enzyme have been detected in vivo. Here we demonstrate that the recently described she proteins are phosphorylated on tyrosine residues in both S13 transformed fibroblasts and erythroblasts. Furthermore, using an S13 temperature sensitive mutant, we show that the phosphorylation of the she proteins occurs concomitantly with the activation of the tyrosine kinase activity of the env-sea protein. These observations make the phosphorylation of the she proteins a good candidate for being involved in oncogenic signaling by the env-sea oncoprotein.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,TORONTO M5G 1X5,ON,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ON,CANADA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Pawson, Tony J/E-4578-2013		NCI NIH HHS [CA42573, CA28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042573, P01CA028146] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; CROWE AJ, 1993, ONCOGENE, V8, P181; CROWE AJ, 1993, CELL GROWTH DIFFER, V4, P403; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; HAYMAN MJ, 1986, VIROLOGY, V150, P270, DOI 10.1016/0042-6822(86)90287-4; HAYMAN MJ, 1987, PATHOL IMMUNOPATH R, V6, P390, DOI 10.1159/000157065; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAMPS MP, 1988, ONCOGENE, V2, P305; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KNIGHT J, 1990, VIROLOGY, V178, P232, DOI 10.1016/0042-6822(90)90398-B; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Kowenz E, 1987, Haematol Blood Transfus, V31, P199; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1992, ELL, V70, P359; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	34	28	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					537	544						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290264				2022-12-25	WOS:A1994MW24800021
J	PURDIE, CA; HARRISON, DJ; PETER, A; DOBBIE, L; WHITE, S; HOWIE, SEM; SALTER, DM; BIRD, CC; WYLLIE, AH; HOOPER, ML; CLARKE, AR				PURDIE, CA; HARRISON, DJ; PETER, A; DOBBIE, L; WHITE, S; HOWIE, SEM; SALTER, DM; BIRD, CC; WYLLIE, AH; HOOPER, ML; CLARKE, AR			TUMOR-INCIDENCE, SPECTRUM AND PLOIDY IN MICE WITH A LARGE DELETION IN THE P53 GENE	ONCOGENE			English	Article							WILD-TYPE P53; CELL-CYCLE CHECKPOINT; CANCER; EXPRESSION; MUTATIONS; ANTIGEN; AMPLIFICATION; PROTEIN; LINE; IRRADIATION	In human tumourigenesis the tumour suppressor gene most commonly affected by mutation, inactivation or allele loss is p53. Loss of p53 function is associated both with failure to maintain a normal diploid status and inability to delete cells by apoptosis following DNA damage. To investigate further the role of p53 we have generated mice carrying a large deletion within the gene. All animals homozygous for this deletion develop spontaneous tumours, predominantly lymphomas, by the age of 6 months. 10% of heterozygotes develop a range of neoplasms, with a lower predisposition towards lymphoma, by 9 months. Both tumour incidence and spectrum in heterozygotes differ from those previously reported in another p53 mutant stock, suggesting either difference in exposure to carcinogens between the two stocks, or a role for modulating genes within different genetic backgrounds. Tumours showed frequent loss of diploid status, and the majority of those arising in heterozygotes showed loss of the wild type allele. These findings are consistent with the concept that p53 acts as a tumour suppressor by preventing the propagation of DNA damage to daughter cells.	UNIV EDINBURGH,SCH MED,DEPT PATHOL,CRC LABS,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Edinburgh			Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	rose, lorraine/0000-0001-5135-8262; Clarke, Alan/0000-0002-4281-426X; Purdie, Colin/0000-0002-1258-4010				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BODNER SM, 1992, ONCOGENE, V7, P743; CARDER P, 1993, ONCOGENE, V8, P1397; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FYFE L, 1993, IMMUNOL LETT, V35, P45, DOI 10.1016/0165-2478(93)90146-S; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HALL PA, 1993, ONCOGENE, V8, P203; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; KASTAN MB, 1991, CANCER RES, V51, P6304; Kerr J.F.R., 1987, P93; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PURDIE CA, 1991, AM J PATHOL, V138, P807; QUIRKE P, 1985, BRIT J CANCER, V51, P99, DOI 10.1038/bjc.1985.14; RAULET DH, 1985, NATURE, V314, P103, DOI 10.1038/314103a0; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; RUIZ JC, 1990, MOL CELL BIOL, V10, P3056, DOI 10.1128/MCB.10.6.3056; SAID JW, 1992, AM J PATHOL, V141, P1343; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHMID P, 1991, DEVELOPMENT, V113, P857; SMITH GS, 1973, J NATL CANCER I, V50, P1195, DOI 10.1093/jnci/50.5.1195; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SYMONDS H, 1991, J VIROL, V65, P5417, DOI 10.1128/JVI.65.10.5417-5424.1991; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	46	307	313	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					603	609						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290271				2022-12-25	WOS:A1994MW24800028
J	YAMAGUCHI, N; HATTORI, K; OHEDA, M; KOJIMA, T; IMAI, N; OCHI, N				YAMAGUCHI, N; HATTORI, K; OHEDA, M; KOJIMA, T; IMAI, N; OCHI, N			A NOVEL CYTOKINE EXHIBITING MEGAKARYOCYTE POTENTIATING ACTIVITY FROM A HUMAN PANCREATIC TUMOR-CELL LINE HPC-Y5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CHEMICALLY DEFINED MEDIUM; COLONY FORMATION; SERUM-FREE; INVITRO; INTERLEUKIN-11; GROWTH	Sixty-four kinds of cell lines were examined for their ability to produce megakaryocyte potentiating activity by means of conditioned media obtained from a protein-free culture system. Six human tumor cell lines were shown to produce this activity, and the cell line HPC-Y5, established from human pancreatic cancer, was shown to have the highest level of activity. The megakaryocyte potentiating factor (MPF) was purified from an HPC-Y5 conditioned medium by a combination of ion-exchange chromatography, gel filtration and reverse-phase HPLC. The purified MPF showed a megakaryocyte potentiating activity almost equal to human interleukin-6 in the presence of murine interleukin-3 in a colony formation assay with mouse bone marrow cells. The apparent molecular weight of MPF is 32,000 when determined by SDS-polyacrylamide gel electrophoresis. Glycopeptidase F digestion, and amino sugar analysis of the factor demonstrated that MPF is a glycoprotein carrying at least one N-linked sugar chain. The N-terminal amino acid sequence of MPF was determined to be Leu-Ala-Gly-Glu-Thr-Gly-Gln-Glu-Ala-Ala-Pro-Leu-Asp-Gly-Val-Leu-Ala-Asn. The same or homologous amino acid sequence has not been found in known proteins, demonstrating that MPF is a novel cytokine that has megakaryocyte potentiating activity in the murine assay system.	CHUGAI PHARMACEUT CO LTD,FUJI GOTEMBA RES LABS,KOMAKADO 1-135,GOTEMBA,SHIZUOKA 412,JAPAN; KYOTO PREFECTURAL UNIV MED,NEUROL DIS & GERIATR RES INST,DEPT CELL BIOL,KYOTO 602,JAPAN	Chugai Pharmaceutical Co., Ltd.; Roche Holding; Kyoto Prefectural University of Medicine								GORDON MS, 1992, BLOOD, V80, P302; HASEGAWA M, 1992, EUR J BIOCHEM, V210, P9, DOI 10.1111/j.1432-1033.1992.tb17384.x; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HIRANO T, 1989, PEPTIDE GROWTH FACTO, P633; IKEBUCHI K, 1987, P NATL ACAD SCI USA, V84, P9035, DOI 10.1073/pnas.84.24.9035; IMAI N, 1990, J BIOCHEM, V107, P352, DOI 10.1093/oxfordjournals.jbchem.a123050; ISHIBASHI T, 1989, P NATL ACAD SCI USA, V86, P5953, DOI 10.1073/pnas.86.15.5953; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; METCALF D, 1991, BLOOD, V77, P2150; METCALF D, 1975, P NATL ACAD SCI USA, V72, P1744, DOI 10.1073/pnas.72.5.1744; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; QUESENBERRY PJ, 1985, BLOOD, V65, P214; ROBINSON BE, 1987, J CLIN INVEST, V79, P1648, DOI 10.1172/JCI113002; TAYRIEN G, 1987, J BIOL CHEM, V262, P3262; TERAMURA M, 1992, BLOOD, V79, P327; TURNER KJ, 1991, BLOOD, V78, pA279; VANDAMME J, 1989, ANN NY ACAD SCI, V557, P104; WILLIAMS N, 1981, BLOOD, V57, P157; WILLIAMS N, 1982, J CELL PHYSIOL, V110, P101, DOI 10.1002/jcp.1041100116; YAMAGUCHI N, 1986, CANCER RES, V46, P5353; YAMAGUCHI N, 1990, CANCER RES, V50, P7008; YAMAGUCHI N, 1990, CANCER RES, V50, P658	22	80	167	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					805	808						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288629				2022-12-25	WOS:A1994MR22000006
J	AUSONI, S; CAMPIONE, M; PICARD, A; MORETTI, P; VITADELLO, M; DENARDI, C; SCHIAFFINO, S				AUSONI, S; CAMPIONE, M; PICARD, A; MORETTI, P; VITADELLO, M; DENARDI, C; SCHIAFFINO, S			STRUCTURE AND REGULATION OF THE MOUSE CARDIAC TROPONIN-I GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHITE SKELETAL-MUSCLE; RAT MYOCARDIAL-CELLS; AMINO-ACID SEQUENCE; HEAVY-CHAIN GENE; MESSENGER-RNA; CDNA CLONE; DEVELOPMENTAL EXPRESSION; BIOLOGICAL-ACTIVITY; MAMMALIAN-CELLS; ALPHA-ACTIN	The gene coding for mouse cardiac troponin I (TnI) has been cloned and sequenced. The cardiac TnI gene contains 8 exons and has an exon-intron organization similar to the quail fast skeletal TnI gene except for the region of exons 1-3, which is highly divergent. Comparative analysis suggests that cardiac TnI exon 1 corresponds to fast TnI exons 1 and 2 and that cardiac exon 3, which codes for most of the cardiac-specific amino-terminal extension and has no counterpart in the fast gene, evolved by exon insertion/deletion. The amino acid sequence of cardiac TnI exon 4 shows limited homology (36% identity) with fast TnI exon 4 but is remarkably similar (79% identity) to the corresponding sequence of slow TnI, possibly reflecting an isoform-specific TnC-binding site. The cardiac TnI gene is one of the very few contractile protein genes expressed exclusively in cardiac muscle. To identify the regulatory sequences responsible for the cardiac-specific expression of this gene we transfected cultured cardiac and skeletal muscle cells with fragments up to 4.0 kilobases of the 5'-flanking region linked to a reporter gene. Deletion analysis reveals four major regions in the 5'-flanking sequence, a minimal promoter region, which directs expression at low level in cardiac and skeletal muscle cells, and two upstream cardiac-specific positive regions separated by a negative region.	UNIV PADUA,DEPT BIOMED SCI,VIA TRIESTE 75,I-35121 PADUA,ITALY; UNIV PADUA,CNR,MUSCLE BIOL & PHYSIOPATHOL UNIT,I-35121 PADUA,ITALY	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua			Campione, Marina/G-9001-2013	CAMPIONE, MARINA/0000-0003-0582-5303; Schiaffino, Stefano/0000-0002-5607-6421	Telethon [A.012] Funding Source: Medline	Telethon(Fondazione Telethon)		AUSONI S, 1991, DEVELOPMENT, V112, P1041; BALDWIN AS, 1985, P NATL ACAD SCI USA, V82, P8080, DOI 10.1073/pnas.82.23.8080; BARBAS JA, 1991, GENE DEV, V5, P132, DOI 10.1101/gad.5.1.132; BEALL CJ, 1991, J CELL BIOL, V114, P941, DOI 10.1083/jcb.114.5.941; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE HA, 1975, BIOCHEM J, V149, P525, DOI 10.1042/bj1490525; DAUBAS P, 1985, NUCLEIC ACIDS RES, V13, P4623, DOI 10.1093/nar/13.13.4623; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLINK IL, 1992, J BIOL CHEM, V267, P9917; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORZA L, 1993, DEV BIOL, V156, P253, DOI 10.1006/dbio.1993.1074; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRAND RJA, 1982, BIOCHEM J, V203, P61, DOI 10.1042/bj2030061; HASTINGS KEM, 1991, J BIOL CHEM, V266, P19659; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; KOBAYASHI T, 1989, J BIOL CHEM, V264, P1551; KOPPE RI, 1989, J BIOL CHEM, V264, P14327; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; MABLY JD, 1993, J BIOL CHEM, V268, P476; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MOIR AJG, 1977, BIOCHEM J, V161, P371, DOI 10.1042/bj1610371; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P2602; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; NGAI SM, 1992, J BIOL CHEM, V267, P15715; NIKOVITS W, 1986, NUCLEIC ACIDS RES, V14, P3377, DOI 10.1093/nar/14.8.3377; ORDAHL CP, 1992, CURR TOP DEV BIOL, V26, P145, DOI 10.1016/S0070-2153(08)60444-5; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; PERRY SV, 1986, MYOLOGY, P613; QASBA P, 1992, MOL CELL BIOL, V12, P1107, DOI 10.1128/MCB.12.3.1107; RUOQIANSHEN SK, 1991, MOL CELL BIOL, V11, P1676; SAGGIN L, 1989, J BIOL CHEM, V264, P16299; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SCHIAFFINO S, 1993, TRENDS CARDIOVAS MED, V3, P12, DOI 10.1016/1050-1738(93)90022-X; SEN A, 1988, J CLIN INVEST, V82, P1333, DOI 10.1172/JCI113735; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; WINEGRAD S, 1990, P NATL ACAD SCI USA, V87, P2456, DOI 10.1073/pnas.87.7.2456; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	49	52	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					339	346						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276817				2022-12-25	WOS:A1994MR21900058
J	BALAKIN, AG; LEMPICKI, RA; HUANG, GM; FOURNIER, MJ				BALAKIN, AG; LEMPICKI, RA; HUANG, GM; FOURNIER, MJ			SACCHAROMYCES-CEREVISIAE U14 SMALL NUCLEAR-RNA HAS LITTLE SECONDARY STRUCTURE AND APPEARS TO BE PRODUCED BY POSTTRANSCRIPTIONAL PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-RIBOSOMAL-RNA; MOLECULAR-WEIGHT RNA; SMALL NUCLEOLAR RNA; REVERSE-TRANSCRIPTASE; PRIMER EXTENSION; MESSENGER-RNA; U3 SNRNA; BOX-C; YEAST; PROTEIN	Yeast U14 small nuclear (sn) RNA is required for normal processing of RNA. The sequence and folding properties of U14 were analyzed in the present study, with the aim of defining the structures of natural U14 subspecies and characterizing the folding properties of free U14 RNA. Natural U14 was determined to consist of four subspecies of 125-128 nucleotides, none containing a 5'-cap structure. Length heterogeneity occurs at both ends and is presumed to reflect post-transcriptional processing of U14 precursors. Results from nuclease and chemical probing revealed that U14 has surprisingly little secondary structure overall. Three essential sequence elements conserved among all U14 RNAs occur in regions that are largely single-stranded, i.e. box C, box D, and a 13-nucleotide segment complementary to 18 S rRNA, a non-essential 14-nucleotide sequence complementary to 18 S rRNA is also unpaired. Two non-conserved segments required for activity are part of a stably folded 32-base domain that is unique to yeast U14. Finally, a 5'-, 3'-stem shown earlier to be required for U14 accumulation appears to exist only in precursors to U14 and not in protein-free mature RNA. The implications of these results are discussed in terms of U14 synthesis and function.	UNIV MASSACHUSETTS, LEDERLE GRAD RES CTR, DEPT BIOCHEM & MOLEC BIOL, AMHERST, MA 01003 USA; UNIV MASSACHUSETTS, LEDERLE GRAD RES CTR, PROGRAM MOLEC & CELLULAR BIOL, AMHERST, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst			Lempicki, Richard A/E-1844-2012	Lempicki, Richard A/0000-0002-7059-409X	NIGMS NIH HHS [GM19351] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019351] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1990, NUCLEIC ACIDS RES, V18, P3035, DOI 10.1093/nar/18.10.3035; ALTMAN S, 1993, FASEB J, V7, P7, DOI 10.1096/fasebj.7.1.7916700; ARIS JP, 1991, METHOD ENZYMOL, V194, P735; BASERGA SJ, 1991, EMBO J, V10, P2645, DOI 10.1002/j.1460-2075.1991.tb07807.x; BRUCE AG, 1978, NUCLEIC ACIDS RES, V5, P3665, DOI 10.1093/nar/5.10.3665; DARR SC, 1992, TRENDS BIOCHEM SCI, V17, P178, DOI 10.1016/0968-0004(92)90262-8; FOURNIER MJ, 1993, TRENDS BIOCHEM SCI, V18, P131, DOI 10.1016/0968-0004(93)90020-N; GAUTHERET D, 1990, METHOD ENZYMOL, V183, P318; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; HUANG GM, 1992, MOL CELL BIOL, V12, P4456, DOI 10.1128/MCB.12.10.4456; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; JARMOLOWSKI A, 1990, EMBO J, V9, P4503, DOI 10.1002/j.1460-2075.1990.tb07901.x; JONES EW, 1977, GENETICS, V85, P23; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KONDO K, 1992, J BIOL CHEM, V267, P16259; LEE WC, 1992, MOL CELL BIOL, V12, P3865, DOI 10.1128/MCB.12.9.3865; LEMPEREUR L, 1985, NUCLEIC ACIDS RES, V13, P8339, DOI 10.1093/nar/13.23.8339; LEVERETTE R, CELL, V71, P1215; LI HV, 1990, MOL CELL BIOL, V10, P1145, DOI 10.1128/MCB.10.3.1145; LI HV, 1992, EMBO J, V11, P683, DOI 10.1002/j.1460-2075.1992.tb05100.x; LIU J, 1990, NUCLEIC ACIDS RES, V18, P6565, DOI 10.1093/nar/18.22.6565; LUND E, 1992, SCIENCE, V255, P327, DOI 10.1126/science.1549778; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MAXWELL ES, 1986, P NATL ACAD SCI USA, V83, P7261, DOI 10.1073/pnas.83.19.7261; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; MORRISSEY JP, 1993, MOL CELL BIOL, V13, P2469, DOI 10.1128/MCB.13.4.2469; MYSLINSKI E, 1990, SCIENCE, V247, P1213, DOI 10.1126/science.1690452; PARKER R, 1988, MOL CELL BIOL, V8, P3150, DOI 10.1128/MCB.8.8.3150; RIEDEL N, 1986, P NATL ACAD SCI USA, V83, P8097, DOI 10.1073/pnas.83.21.8097; RUSSELL ID, 1992, J CELL BIOL, V119, P737, DOI 10.1083/jcb.119.4.737; Sambrook J, 1989, MOL CLONING LABORATO; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; SEGAULT V, 1992, NUCLEIC ACIDS RES, V20, P3443, DOI 10.1093/nar/20.13.3443; SHANAB GM, 1991, NUCLEIC ACIDS RES, V19, P4891, DOI 10.1093/nar/19.18.4891; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SHELNESS GS, 1985, J BIOL CHEM, V260, P8637; SINGH L, 1984, NUCLEIC ACIDS RES, V12, P5627, DOI 10.1093/nar/12.14.5627; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; SOLLNERWEBB B, 1993, IN PRESS RIBOSOMAL R; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; TRINHROHLIK Q, 1988, NUCLEIC ACIDS RES, V16, P6041, DOI 10.1093/nar/16.13.6041; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; TYCOWSKI TK, 1993, GENE DEV, V7, P1176; WISE JA, 1991, METHOD ENZYMOL, V194, P405; WYATT JR, 1991, BIOTECHNIQUES, V11, P764; ZAFARULLAH M, 1992, EUR J BIOCHEM, V204, P893, DOI 10.1111/j.1432-1033.1992.tb16709.x; ZAGORSKI J, 1988, MOL CELL BIOL, V8, P3282, DOI 10.1128/MCB.8.8.3282; ZUBENKO GS, 1980, GENETICS, V96, P137; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	50	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					739	746						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276877				2022-12-25	WOS:A1994MR21900116
J	BRAXTON, BL; TLAPALSIMMONS, VL; REINHART, GD				BRAXTON, BL; TLAPALSIMMONS, VL; REINHART, GD			TEMPERATURE-INDUCED INVERSION OF ALLOSTERIC PHENOMENA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CARBAMYL-PHOSPHATE SYNTHETASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; PHOSPHOFRUCTOKINASE; PARAMETERS; BINDING	Two instances, involving the enzymes carbamoyl-phosphate synthetase from Escherichia coli and phosphofructokinase from Bacillus stearothermophilus, respectively, are described in which increasing temperature alone causes the actions of an allosteric ligand to change from inhibition to activation. In neither case are these effects due to a change in the activation energy of the enzyme catalyzed reaction induced by the allosteric ligand. Rather, they are due to temperature-dependent changes in the extent to which the binding of allosteric ligand modifies the affinity of the enzyme for substrate. The data can be readily explained by an analysis of the apparent DELTAH and DELTAS components of the coupling free energy, which quantitatively describe the actions of allosteric ligands that act in this manner. These observations underscore the shortcomings of expecting to explain the actions of an allosteric ligand solely by the structural perturbations that accompany the binding of an allosteric ligand such as those often revealed by x-ray crystallography.	UNIV OKLAHOMA,DEPT CHEM & BIOCHEM,NORMAN,OK 73019	University of Oklahoma System; University of Oklahoma - Norman					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033216] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 33216] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3157, DOI 10.1021/bi00874a012; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3164, DOI 10.1021/bi00874a013; ANDERSON PM, 1968, BIOCHEM BIOPH RES CO, V32, P928, DOI 10.1016/0006-291X(68)90116-2; BOETTCHER B, 1982, J BIOL CHEM, V257, P3971; Boyer, 1970, ENZYMES, P341, DOI DOI 10.1016/S1874-6047(08)60170-5; BRAXTON BL, 1992, BIOCHEMISTRY-US, V31, P2309, DOI 10.1021/bi00123a015; EVANS PR, 1979, NATURE, V279, P500, DOI 10.1038/279500a0; EVANS PR, 1981, PHILOS T ROY SOC B, V293, P53, DOI 10.1098/rstb.1981.0059; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; MEISTER A, 1978, ADV ENZYME REGUL, V16, P289; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MULLINS LS, 1991, J BIOL CHEM, V266, P8236; REINHART GD, 1989, P NATL ACAD SCI USA, V86, P4032, DOI 10.1073/pnas.86.11.4032; REINHART GD, 1983, ARCH BIOCHEM BIOPHYS, V224, P389, DOI 10.1016/0003-9861(83)90225-4; RYPNIEWSKI WR, 1989, J MOL BIOL, V207, P805, DOI 10.1016/0022-2836(89)90246-5; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; SYMCOX MM, 1992, ANAL BIOCHEM, V206, P394, DOI 10.1016/0003-2697(92)90384-J; Weber G, 1975, Adv Protein Chem, V29, P1, DOI 10.1016/S0065-3233(08)60410-6; WEBER G, 1972, BIOCHEMISTRY-US, V11, P864, DOI 10.1021/bi00755a028; 1992, REGULATION PROTEINS, V36	21	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					47	50						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276837				2022-12-25	WOS:A1994MR21900013
J	HSIEH, ML; TINTUT, Y; GRALLA, JD				HSIEH, ML; TINTUT, Y; GRALLA, JD			FUNCTIONAL ROLES FOR THE GLUTAMINES WITHIN THE GLUTAMINE-RICH REGION OF THE TRANSCRIPTION FACTOR-SIGMA-54	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; PROMOTER DNA; ACTIVATION; BINDING; DOMAINS; GLNA; INVIVO; EXPRESSION; PROTEIN	Single and multiple point mutations were introduced to change the 12 glutamine residues within a 37-amino acid region of sigma54. Multiple changes are shown to be required in order to interfere significantly with the function of this protein which is associated with enhancer-dependent bacterial transcription. Mutation of the central 4 glutamines leads to the production of less m-RNA, caused by an inability to fully open the promoter start site. DNA binding, however, is normal. Mutation of 4 other adjacent glutamines causes the promoter start site to open more readily than wild type, although this enhanced opening is not accompanied by more mRNA. The emhanced DNA melting is not caused by enhanced promoter binding, as indicated by normal protection of the polymerase-bound promoter against dimethyl sulfate attack. The results suggest that multiple glutamines play a role in transducing the melting signal from the enhancer protein to the polymerase.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Demer, Linda L/I-5770-2013	Demer, Linda L/0000-0002-9618-6895	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185, R01GM035754] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 07185, GM 35754] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKMAN K, 1981, P NATL ACAD SCI-BIOL, V78, P3743, DOI 10.1073/pnas.78.6.3743; BAGA M, 1988, CELL, V52, P197, DOI 10.1016/0092-8674(88)90508-9; BIRKMANN A, 1989, MOL MICROBIOL, V3, P187, DOI 10.1111/j.1365-2958.1989.tb01807.x; BUCK M, 1992, NATURE, V358, P422, DOI 10.1038/358422a0; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GRALLA JD, 1991, CELL, V66, P415, DOI 10.1016/0092-8674(81)90001-5; HIRSCHMAN J, 1985, P NATL ACAD SCI USA, V82, P7525, DOI 10.1073/pnas.82.22.7525; JIANG Y, 1993, J BIOL CHEM, V268, P6535; KNAUS R, 1988, EMBO J, V7, P2919, DOI 10.1002/j.1460-2075.1988.tb03150.x; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; KUSTU S, 1991, TRENDS BIOCHEM SCI, V16, P397, DOI 10.1016/0968-0004(91)90163-P; MAGASANIK B, 1988, TRENDS BIOCHEM SCI, V13, P475, DOI 10.1016/0968-0004(88)90234-4; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MORETT E, 1988, P NATL ACAD SCI USA, V85, P9401, DOI 10.1073/pnas.85.24.9401; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; REITZER LJ, 1985, P NATL ACAD SCI USA, V82, P1979, DOI 10.1073/pnas.82.7.1979; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; SASSEDWIGHT S, 1991, METHOD ENZYMOL, V208, P146; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SMITH GR, 1971, J BIOL CHEM, V246, P3320; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; VONGABAIN A, 1983, P NATL ACAD SCI-BIOL, V80, P653; WONG CN, 1992, J BIOL CHEM, V267, P24762	30	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					373	378						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276822				2022-12-25	WOS:A1994MR21900063
J	RONCO, LV; SILVERMAN, SL; WONG, SG; SLAMON, DJ; PARK, LS; GASSON, JC				RONCO, LV; SILVERMAN, SL; WONG, SG; SLAMON, DJ; PARK, LS; GASSON, JC			IDENTIFICATION OF CONSERVED AMINO-ACIDS IN THE HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR RECEPTOR-ALPHA SUBUNIT CRITICAL FOR FUNCTION - EVIDENCE FOR FORMATION OF A HETERODIMERIC RECEPTOR COMPLEX PRIOR TO LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; AFFINITY INTERLEUKIN-5 RECEPTOR; HUMAN MYELOID CELLS; GM-CSF RECEPTORS; SIGNAL TRANSDUCTION; BETA-CHAIN; TYROSINE PHOSPHORYLATION; EXTRACELLULAR DOMAIN; CYTOPLASMIC REGION; EXPRESSION CLONING	A superfamily of growth factor and cytokine receptors has recently been identified, which is characterized by four spatially conserved cysteine residues, a tryptophan-serine motif (WSXWS) in the extracellular domain, and a proline-rich cytoplasmic domain. The high affinity human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor (hGM-CSFR) consists of two subunits, alpha (hGM-CSFRalpha) and beta (hGM-CSFRbeta), both of which are members of the receptor superfamily. In this study, we prepared mutations in conserved amino acids of the receptor subunit necessary for GM-CSF binding (hGM-CSFRalpha) and analyzed mutant receptors for low affinity binding, internalization, and high affinity binding when complexed with the beta subunit. Mutations in the cytoplasmic domain did not affect GM-CSF binding or receptor internalization. Mutation of a single conserved serine residue within the WSXWS motif diminishes cell surface receptor expression but not ligand binding. Mutation of either the second or third conserved cysteine residue of hGM-CSFRalpha resulted in complete loss of low affinity binding; however, co-expression of the cysteine 2 mutant with hGM-CSFRbeta yielded a high affinity receptor complex. Since neither the cysteine 2 mutant nor the beta subunit can bind ligand alone, this result suggests that hGM-CSFRalpha and hGM-CSFRbeta exist in a preformed heterodimeric protein complex on the plasma membrane.	UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	RONCO, LV (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA.				NCI NIH HHS [CA09120, R01 CA40163] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040163] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDWIN GC, 1991, BLOOD, V78, P609, DOI 10.1182/blood.V78.3.609.bloodjournal783609; BALDWIN GC, 1989, BLOOD, V73, P1033; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; CHIBA S, 1990, LEUKEMIA, V4, P29; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; DIPERSIO J, 1988, J BIOL CHEM, V263, P1834; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GASSON JC, 1986, P NATL ACAD SCI USA, V83, P669, DOI 10.1073/pnas.83.3.669; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OKUDA K, 1991, BLOOD, V78, P1928; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; QUELLE DE, 1992, MOL CELL BIOL, V12, P4553, DOI 10.1128/MCB.12.10.4553; ROZAKISADCOCK M, 1991, J BIOL CHEM, V266, P16472; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHANAFELT AB, 1992, J BIOL CHEM, V267, P25466; TAKAKI S, 1991, EMBO J, V10, P2833, DOI 10.1002/j.1460-2075.1991.tb07832.x; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; YOSHIMURA A, 1992, J BIOL CHEM, V267, P11619; ZON LI, 1992, MOL CELL BIOL, V12, P2949, DOI 10.1128/MCB.12.7.2949	36	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					277	283						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276807				2022-12-25	WOS:A1994MR21900050
J	SCHREIBER, RE; PROSSNITZ, ER; YE, RD; COCHRANE, CG; BOKOCH, GM				SCHREIBER, RE; PROSSNITZ, ER; YE, RD; COCHRANE, CG; BOKOCH, GM			DOMAINS OF THE HUMAN NEUTROPHIL N-FORMYL PEPTIDE RECEPTOR INVOLVED IN G-PROTEIN COUPLING - MAPPING WITH RECEPTOR-DERIVED PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEINS; REAL-TIME ANALYSIS; PERTUSSIS TOXIN; REGULATORY PROTEIN; SYNTHETIC PEPTIDES; ALPHA-SUBUNIT; RHODOPSIN; LIGAND; TRANSDUCIN; FAMILY	Chemotactic signaling by the human neutrophil N-formyl peptide receptor requires its association with heterotrimeric G protein. Synthetic peptides and a fusion protein derived from the intracellular regions of the receptor were used to identify sites which interact with G protein. A peptide derived from the second intracellular loop (C12R), and peptides (F15R and S22L) and a fusion protein derived from the receptor's carboxyl terminus inhibited binding of anti-G(ialpha) antibody (R16,17) to G(ialpha) in a competitive enzyme-linked immunoassay, and antagonized pertussis-toxin catalyzed ADP-ribosylation of G(ialpha). C12R also inhibited G protein-dependent, high affinity ligand binding to the receptor and physical coupling of receptor to G protein. In contrast, a peptide consisting of the entire third loop of the N-formyl peptide receptor was totally inactive in these assays. Collectively, these data suggest that the second intracellular loop and the carboxyl-terminal tail are important for effective N-formyl peptide receptor/G protein coupling, but that the third intracellular loop is less important in coupling, unlike previous findings with other G protein-coupled receptor systems. The chemoattractant receptor family may rely on different structural determinants to interact with GTP-binding proteins.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			Ye, Richard/ABF-2413-2020; Prossnitz, Eric R./B-4543-2008; Ye, Richard/O-5223-2016	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; Prossnitz, Eric/0000-0001-9190-8302	NIGMS NIH HHS [GM39434, GM46572] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046572, R01GM039434] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOKOCH GM, 1988, J CELL BIOL, V106, P1927, DOI 10.1083/jcb.106.6.1927; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; BOKOCH GM, 1990, CURR TOP MEMBR TRANS, V35, P65; BOMMAKANTI RK, 1992, J BIOL CHEM, V267, P7576; BOMMAKANTI RK, 1992, CLIN RES, V40, pA352; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; CUPO JF, 1989, BIOCHIM BIOPHYS ACTA, V982, P31, DOI 10.1016/0005-2736(89)90170-3; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; FAY SP, 1991, BIOCHEMISTRY-US, V30, P5066, DOI 10.1021/bi00234a033; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; Hallet M. B., 1989, NEUTROPHIL CELLULAR, P1; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; KELLERMANN OK, 1982, METHOD ENZYMOL, V90, P459; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MASUMOTO T, 1987, BIOCHEM BIOPH RES CO, V143, P489; MUNCH G, 1991, EUR J BIOCHEM, V198, P357, DOI 10.1111/j.1432-1033.1991.tb16023.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1992, J BIOL CHEM, V267, P7637; OMANN GM, 1987, PHYSIOL REV, V67, P285, DOI 10.1152/physrev.1987.67.1.285; PROBST WC, 1992, DNA CELL BIOL, V2, P1; PROSSNITZ ER, 1991, BIOCHEM BIOPH RES CO, V179, P471, DOI 10.1016/0006-291X(91)91394-R; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHREIBER RE, 1993, J LEUKOCYTE BIOL, V53, P470, DOI 10.1002/jlb.53.4.470; SKLAR LA, 1984, J BIOL CHEM, V259, P5661; SKLAR LA, 1987, J BIOL CHEM, V262, P135; SKLAR LA, 1982, CYTOMETRY, V3, P161, DOI 10.1002/cyto.990030304; SNYDERMAN R, 1986, J LEUKOCYTE BIOL, V40, P785, DOI 10.1002/jlb.40.6.785; STRADER CD, 1989, FASEB J, V3; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; TAKEMOTO DJ, 1985, BIOCHEM J, V232, P669, DOI 10.1042/bj2320669; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; WEISS ER, 1988, FASEB J, V2, P2841, DOI 10.1096/fasebj.2.13.3139484	40	68	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					326	331						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276814				2022-12-25	WOS:A1994MR21900056
J	SPACCIAPOLI, P; NOSSAL, NG				SPACCIAPOLI, P; NOSSAL, NG			A SINGLE MUTATION IN BACTERIOPHAGE-T4 DNA-POLYMERASE (A737V, TSL141) DECREASES ITS PROCESSIVITY AS A POLYMERASE AND INCREASES ITS PROCESSIVITY AS A 3' -] 5' EXONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID POLYMERASE; ESCHERICHIA-COLI; ACCESSORY PROTEINS; CB120 ANTIMUTATOR; BIOCHEMICAL BASIS; KLENOW FRAGMENT; REPLICATION; SITE; GENE; PURIFICATION	The bacteriophage T4 DNA polymerase mutant A737V (tsL141 and tsCB120) was originally characterized as temperature-sensitive for DNA replication and an antimutator for transition mutations. Its antimutator phenotype is suppressed by the L771F mutation (Reha-Krantz, L. J., Stocki, S., Nonay, R., and Maughan, C. (1989) J. Cell. Biochem. 13D, 140). We find that the A737V polymerase arrests much more frequently than the wild type when polymerizing on primed single-stranded DNA templates. Although the 3' --> 5' exonuclease of the mutant is indistinguishable from the wild type on single-stranded DNA, it is more active than the wild type on duplex DNA. In a single encounter with the primer, the wild type polymerase can incorporate more than 50 nucleotides. The processivity of the A737V polymerase is less than the wild type as a polymerase, but is greater than the wild type as an exonuclease. The L771F polymerase resembles the wild type in each of these properties, while the double mutant (A737V, L771F) is intermediate between the two single mutants. Kinetic studies of wild type T4 DNA polymerase (Capson, T. L., Peliska, J. A., Kaboord, B. F., Frey, M. W., Lively, C., Dahlberg, M., and Benkovic, S. J. (1992) Biochemistry 31, 10984-10994) suggest that DNA binds first to the polymerase active site, before adopting a configuration in which it can be hydrolyzed by the exonuclease. Within this framework, our studies suggest that DNA moves more readily from the polymerase- to the exonuclease-competent configuration on the A737V mutant polymerase, and that this movement is decreased by the compensating L771F mutation.	NIDDKD,MOLEC & CELLULAR BIOL LAB,ROOM 2A-19,BETHESDA,MD 20892; NIDDKD,BIOCHEM PHARMACOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; BASU A, 1987, BIOCHEMISTRY-US, V26, P1704, DOI 10.1021/bi00380a032; BEAUCHAMP BB, 1988, P NATL ACAD SCI USA, V85, P2563, DOI 10.1073/pnas.85.8.2563; BLANCO L, 1992, GENE, V112, P139, DOI 10.1016/0378-1119(92)90316-H; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CHARETTE MF, 1986, NUCLEIC ACIDS RES, V14, P3343, DOI 10.1093/nar/14.8.3343; COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DEWAARD A, 1965, P NATL ACAD SCI USA, V54, P1241; DRAKE JW, 1969, NATURE, V221, P1128, DOI 10.1038/2211128a0; DRAKE JW, 1988, MOL GEN GENET, V214, P547, DOI 10.1007/BF00330493; DRAKE JW, 1968, COLD SPRING HARB SYM, V33, P339, DOI 10.1101/SQB.1968.033.01.039; DRAKE JW, 1970, P NATL ACAD SCI USA, V66, P823, DOI 10.1073/pnas.66.3.823; EPSTEIN RH, 1963, COLD SPRING HARB SYM, V28, P375, DOI 10.1101/SQB.1963.028.01.053; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GAUSS P, 1983, P NATL ACAD SCI-BIOL, V80, P1669, DOI 10.1073/pnas.80.6.1669; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GILLIN FD, 1975, BIOCHEM BIOPH RES CO, V64, P457, DOI 10.1016/0006-291X(75)90343-5; GILLIN FD, 1976, J BIOL CHEM, V251, P5219; GILLIN FD, 1976, J BIOL CHEM, V251, P5225; HERSHFIELD MS, 1973, J BIOL CHEM, V248, P1417; HINTON DM, 1985, J BIOL CHEM, V260, P2851; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; HUANG CC, 1981, J BIOL CHEM, V256, P4087; JARVIS TC, 1991, J BIOL CHEM, V266, P1830; Joyce CM, 1991, CURR OPIN STRUC BIOL, V1, P123, DOI 10.1016/0959-440X(91)90020-T; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIN TC, 1987, P NATL ACAD SCI USA, V84, P7000, DOI 10.1073/pnas.84.20.7000; LO KY, 1976, J BIOL CHEM, V251, P2480; LO KY, 1976, J BIOL CHEM, V251, P2475; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACE DC, 1984, J MOL BIOL, V177, P313, DOI 10.1016/0022-2836(84)90459-5; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; Nossal N.G., 1983, BACTERIOPHAGE T4, P71; NOSSAL NG, 1974, J BIOL CHEM, V249, P5668; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; NOSSAL NG, 1993, IN PRESS MOL BIOL BA; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; REDDY MK, 1992, J BIOL CHEM, V267, P14157; REHAKRANTZ LJ, 1993, J VIROL, V67, P60, DOI 10.1128/JVI.67.1.60-66.1993; REHAKRANTZ LJ, 1981, J MOL BIOL, V145, P677, DOI 10.1016/0022-2836(81)90309-0; REHAKRANTZ LJ, 1989, J VIROL, V63, P4762, DOI 10.1128/JVI.63.11.4762-4766.1989; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; REHAKRANTZ LJ, 1988, J MOL BIOL, V202, P711, DOI 10.1016/0022-2836(88)90552-9; REHAKRANTZ LJ, 1989, J CELL BIOL D, V13, P140; RIPLEY LS, 1983, MOL GEN GENET, V189, P113, DOI 10.1007/BF00326062; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; RIPLEY LS, 1975, MOL GEN GENET, V141, P23, DOI 10.1007/BF00332376; ROTH AC, 1982, J BIOL CHEM, V257, P1267; RUSH J, 1990, J BIOL CHEM, V265, P4821; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETO D, 1988, J BIOL CHEM, V263, P1494; SPACCIAPOLI P, J BIOL CHEM, V269, P447; SPICER EK, 1988, J BIOL CHEM, V263, P7478; TABOR S, 1990, J BIOL CHEM, V265, P8322; VENKATESAN M, 1982, J BIOL CHEM, V257, P2435; WURGLER SM, 1990, P NATL ACAD SCI USA, V87, P2740, DOI 10.1073/pnas.87.7.2740	60	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					438	446						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276833				2022-12-25	WOS:A1994MR21900074
J	TIAN, J; CHEN, JH; BANCROFT, C				TIAN, J; CHEN, JH; BANCROFT, C			EXPRESSION OF CONSTITUTIVELY ACTIVE G(S) ALPHA-SUBUNITS IN GH3 PITUITARY-CELLS STIMULATES PROLACTIN PROMOTER ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							THYROTROPIN-RELEASING-HORMONE; ADENYLYL CYCLASE; TRANSCRIPTION FACTOR; PHOSPHOLIPASE-C; GROWTH-HORMONE; G-PROTEIN; BINDING PROTEIN; PROXIMAL REGION; GENE; RECEPTOR	Although G protein alpha subunits are known to regulate such cellular functions as growth and enzymatic activity, the ability of these proteins to regulate target gene expression has not yet been directly investigated. Transient expression in GH3 pituitary cells of a target rat prolactin promoter-chloramphenicol acetyltransferase construct, (-1957)PRL-CAT, was increased by coexpressed constitutively active alpha(s) mutant Q227L-alpha(s) but not by wild-type alpha(s). Thus activated alpha(s) but not basal state alpha(s) can stimulate prolactin promoter activity. Q227L-alpha(s) also stimulated expression of construct (-187)PRL-CAT, showing that only the proximal prolactin promoter region is required for a response to activated alpha(s). The promoter specificity of the transcriptional influence of activated alpha(s) was demonstrated by the inability of either Q227L-alpha(s) or wild-type alpha(s) to stimulate expression of control target constructs containing either the rat growth hormone promoter or the thymidine kinase promoter. Previous studies have shown that the most proximal prolactin promoter binding site for the pituitary-specific transcription factor pit-1, site 1P, can act as an independent response element for either thyrotropin-releasing hormone or Ca2+. Two copies of site 1P conferred upon a heterologous metallothionein promoter a response to Q227L-alpha(s). This implies that site 1P can also serve as an independent response element for alpha(s) and suggests that pit-1 may be a mediator of the cellular regulation by alpha(s) of the prolactin promoter.	CUNY MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,BOX 1218,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NCI NIH HHS [CA44998] Funding Source: Medline; NIDA NIH HHS [DA-07859] Funding Source: Medline; NIGMS NIH HHS [GM-36847] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007859] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; BACHWICH D, 1992, MOL ENDOCRINOL, V6, P1175, DOI 10.1210/me.6.8.1175; CARILLO AJ, 1985, ENDOCRINOLOGY, V116, P202; CASTRILLO JL, 1989, SCIENCE, V243, P814, DOI 10.1126/science.2563596; COLEMAN DT, 1993, ENDOCRINOLOGY, V133, P2736, DOI 10.1210/en.133.6.2736; DAY RN, 1989, MOL ENDOCRINOL, V3, P3, DOI 10.1210/mend-3-1-3; DEMDEN MC, 1992, MOL ENDOCRINOL, V6, P581, DOI 10.1210/me.6.4.581; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; GRAEME M, 1993, TRENDS PHARMACOL SCI, V14, P239; HSIEH KP, 1992, MOL ENDOCRINOL, V6, P1673, DOI 10.1210/me.6.10.1673; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; JACKSON AE, 1988, MOL ENDOCRINOL, V2, P1139, DOI 10.1210/mend-2-11-1139; KEECH CA, 1992, MOL ENDOCRINOL, V6, P2059, DOI 10.1210/me.6.12.2059; KROLL SD, 1992, J BIOL CHEM, V267, P23183; LANDIS CA, 1990, J CLIN ENDOCR METAB, V71, P1416, DOI 10.1210/jcem-71-6-1416; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LIANG J, 1992, MOL ENDOCRINOL, V6, P885, DOI 10.1210/me.6.6.885; LUFKIN T, 1989, MOL ENDOCRINOL, V3, P559, DOI 10.1210/mend-3-3-559; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; MAURER RA, 1981, NATURE, V294, P94, DOI 10.1038/294094a0; MONTMAYEUR JP, 1993, MOL ENDOCRINOL, V7, P161, DOI 10.1210/me.7.2.161; MURDOCH GH, 1983, J BIOL CHEM, V258, P5329; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; PAN WT, 1990, J BIOL CHEM, V265, P7022; PAULSSEN RH, 1992, EUR J BIOCHEM, V204, P413, DOI 10.1111/j.1432-1033.1992.tb16651.x; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; WANG HL, 1992, EXP CELL RES, V203, P47, DOI 10.1016/0014-4827(92)90038-A; YAN GZ, 1991, MOL ENDOCRINOL, V5, P535, DOI 10.1210/mend-5-4-535; YAN GZ, 1991, MOL ENDOCRINOL, V5, P1488, DOI 10.1210/mend-5-10-1488; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K	32	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					33	36						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276815				2022-12-25	WOS:A1994MR21900009
J	VANDORT, HM; LOW, PS; CORDES, KA; SCHOPFER, LM; SALHANY, JM				VANDORT, HM; LOW, PS; CORDES, KA; SCHOPFER, LM; SALHANY, JM			CALORIMETRIC EVIDENCE FOR ALLOSTERIC SUBUNIT INTERACTIONS ASSOCIATED WITH INHIBITOR BINDING TO BAND-3 TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-ERYTHROCYTE-MEMBRANE; ANION TRANSPORT; KINETICS; EXCHANGE; TRANSITION; PROTEIN	A calorimetric endotherm occurring at 68-degrees-C (the C-transition) has been assigned previously to the integral domain of band 3 and was shown to be shifted to 78-degrees-C after covalent binding of 4,4'-diisothiocyanostilbene-2,2'-disulfonate (DIDS). In this study, we correlate the fractional appearance of the shifted C-transition with the fraction of DIDS bound to the band 3 monomer popuIation. Our results show a distinctly nonlinear correlation plot with the appearance of the shifted C-transition lagging behind DIDS labeling of the band 3 monomer population. The lag suggests that both monomers of a band 3 dimer must be labeled by DIDS in order for the shifted C-transition to appear at 78-degrees-C, implying that the thermal unfolding of the integral domain of band 3 is modulated by allosteric interactions between subunits. This is the first in situ structural evidence supporting ligand-mediated subunit interactions within a ''carrier''-type transporter protein oligomer.	UNIV NEBRASKA,MED CTR,VET ADM MED CTR,600 S 42ND ST,OMAHA,NE 68198; PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907; UNIV NEBRASKA,MED CTR,DEPT BIOCHEM & MOLEC BIOL,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT INTERNAL MED,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center				Low, Philip/0000-0001-9042-5528	NIGMS NIH HHS [GM 24417] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024417, R01GM024417] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; BRANDTS JF, 1977, BIOCHEMISTRY-US, V16, P3450, DOI 10.1021/bi00634a024; DAVIO SR, 1982, BIOCHEMISTRY-US, V21, P3585, DOI 10.1021/bi00258a009; EISINGER J, 1982, P NATL ACAD SCI-BIOL, V79, P408, DOI 10.1073/pnas.79.2.408; JANAS T, 1989, AM J PHYSIOL, V257, pC601, DOI 10.1152/ajpcell.1989.257.4.C601; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; JENNINGS ML, 1979, BIOCHIM BIOPHYS ACTA, V554, P498, DOI 10.1016/0005-2736(79)90387-0; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; SALHANY JM, 1981, J BIOL CHEM, V256, P1080; SALHANY JM, 1992, BIOCHEMISTRY-US, V31, P7301, DOI 10.1021/bi00147a014; SALHANY JM, 1978, BIOCHEMISTRY-US, V17, P3354, DOI 10.1021/bi00609a028; SALHANY JM, 1993, BIOCHEMISTRY-US, V32, P7413, DOI 10.1021/bi00080a011; SALHANY JM, 1992, PROGR CELL RES; SALHANY JM, 1990, ERYTHROCYTE, V3, P79; SCHOPFER LM, 1992, BIOCHEMISTRY-US, V31, P12610, DOI 10.1021/bi00165a010; SINGER SJ, 1977, J SUPRAMOL STR CELL, V6, P313, DOI 10.1002/jss.400060304; STEIN WD, 1990, CHANNELS CARRIERS PU, P127; WANG DN, 1993, EMBO J, V12, P2233, DOI 10.1002/j.1460-2075.1993.tb05876.x	19	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					59	61						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276856				2022-12-25	WOS:A1994MR21900016
J	ZHANG, K; MAX, EE; CHEAH, HK; SAXON, A				ZHANG, K; MAX, EE; CHEAH, HK; SAXON, A			COMPLEX ALTERNATIVE RNA SPLICING OF EPSILON-IMMUNOGLOBULIN TRANSCRIPTS PRODUCES MESSENGER-RNAS ENCODING 4 POTENTIAL SECRETED PROTEIN ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGE PRODUCTION; SINGLE GENE; B-CELLS; PATHWAYS; EXONS	In RNA from human IgE-producing lymphocytes, we previously discovered two alternatively spliced epsilon-immunoglobulin mRNA isoforms that encode a novel secreted form of IgE and a membrane-bound species. Further analysis using epsilon-specific reverse transcriptase polymerase chain reactions has elucidated several additional alternatively spliced species of epsilon mRNA. One RNA isoform is generated by splicing the CH4 exon to a novel distal splice acceptor site, forming an epsilon RNA species (designated CH4-M2'') that encodes a secreted epsilon protein 6 amino acids larger than the classic secreted epsilon protein. The other three novel epsilon RNAs are generated by splicing from within CH4 to a new exon structure (designated CH5) that is located between CH4 and the membrane exons. Since the three new mRNAs using CH5 share the same stop codon in CH5, they all encode the same novel protein, which is 10 amino acids shorter than the classic secreted epsilon heavy chain. The new alternatively spliced epsilon mRNAs reported here, in addition to the previously reported forms encoding membrane and larger secreted IgE, appear to reflect the normal splicing pattern in humans, as we have detected all these epsilon RNAs in all the human IgE-secreting cells and cell lines tested.	US FDA, CTR BIOL EVALUAT & RES, BETHESDA, MD 20892 USA	US Food & Drug Administration (FDA)	ZHANG, K (corresponding author), UNIV CALIF LOS ANGELES, SCH MED,DEPT MED,DIV CLIN IMMUNOL ALLERGY, HART & LOUISE LYON LAB, CTR HLTH SCI 52175, LOS ANGELES, CA 90024 USA.				NATIONAL CANCER INSTITUTE [R01CA030515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI015251, U01AI034567, U19AI034567, R01AI015251] Funding Source: NIH RePORTER; NCI NIH HHS [CA-30515] Funding Source: Medline; NIAID NIH HHS [AI-34567, AI-15251] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BREITBART RE, 1987, CELL, V49, P793, DOI 10.1016/0092-8674(87)90617-9; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; Hasemann CA, 1989, FUNDAMENTAL IMMUNOLO, P209; HELFMAN DM, 1986, MOL CELL BIOL, V6, P3582, DOI 10.1128/MCB.6.11.3582; HELLMAN L, 1993, EUR J IMMUNOL, V23, P159, DOI 10.1002/eji.1830230126; ISHIZAKA K, 1966, J IMMUNOL, V97, P75; MAX EE, 1982, CELL, V29, P691, DOI 10.1016/0092-8674(82)90185-4; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; PENG C, 1992, J IMMUNOL, V148, P129; PERIASAMY M, 1984, J BIOL CHEM, V259, P3595; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAXON A, 1976, J IMMUNOL METHODS, V12, P285, DOI 10.1016/0022-1759(76)90050-8; SAXON A, 1991, J IMMUNOL, V147, P4000; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; THYPHRONITIS G, 1991, J IMMUNOL, V146, P1496; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; ZHANG K, 1992, J EXP MED, V176, P233, DOI 10.1084/jem.176.1.233; ZHANG K, 1991, J IMMUNOL, V146, P1836; ZORN AM, 1991, BIOTECHNIQUES, V11, P180	21	44	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					456	462						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276835				2022-12-25	WOS:A1994MR21900076
J	ZHONG, ZY; HIGAKI, J; MURAKAMI, K; WANG, Y; CATALANO, R; QUON, D; CORDELL, B				ZHONG, ZY; HIGAKI, J; MURAKAMI, K; WANG, Y; CATALANO, R; QUON, D; CORDELL, B			SECRETION OF BETA-AMYLOID PRECURSOR PROTEIN INVOLVES MULTIPLE CLEAVAGE SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; SOLUBLE DERIVATIVES; TERMINAL FRAGMENTS; IDENTIFICATION; CELLS; BRAIN; BIOGENESIS; PEPTIDE	A major histopathological feature of Alzheimer's disease is deposits of a approximately 4-kDa beta-amyloid peptide derived by proteolytic processing from a precursor, the beta-amyloid precursor protein (beta-APP). Proteolytic cleavage of beta-APP within the approximately 4-kDa beta-amyloid domain permits the secretion of the amino-terminal portion of beta-APP while concomitantly producing a membrane bound approximately 9-kDa carboxyl-terminal fragment. We have characterized the proteolytic cleavage site for beta-APP secretion by amino acid sequence analysis of the approximately 9-kDa beta-APP carboxyl-terminal cleavage product produced by recombinant and native expression systems. Recombinant beta-APP was generated by a vaccinia virus expression system in CV-1 monkey fibroblasts; endogenous beta-APP was obtained using a fibroblast line derived from an individual with Down's syndrome. The sequences of both unlabeled and metabolically radiolabeled approximately 9-kDa fragment from CV-1 cells reveal that the major (60%) secretory cleavage site is after Lys16 of the beta-amyloid domain as reported previously; however, an additional cleavage site is seen after Phe19 (40%). Radiosequence analysis of the carboxyl-terminal fragment purified from Down's syndrome fibroblasts indicates cleavage sites after Phe19, Glu22, and Gly25 and not after Lys16. CV-1 cells expressing beta-APP mutants lacking 4 and 6 amino acids adjacent to Lys16 yielded approximately 9-kDa fragments with two identical cleavage sites, neither of which occurred after the retained Lys16 but were after Glu11 and His13. These data suggest that secretion of 6-APP involves multiple proteinases and that the composition of these proteinases may vary within different cell backgrounds.	SCIOS NOVA INC,2450 BAYSHORE PKWY,MT VIEW,CA 94043	Scios								ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GABUZDA D, 1991, J ACQ IMMUN DEF SYND, V4, P34; GANDY S, 1988, P NATL ACAD SCI USA, V85, P6218, DOI 10.1073/pnas.85.16.6218; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; LOWERY DE, 1991, J BIOL CHEM, V266, P19842; MANTLE D, 1990, J NEUROL SCI, V98, P13, DOI 10.1016/0022-510X(90)90178-P; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V179, P1670, DOI 10.1016/0006-291X(91)91767-7; MURPHY GM, 1990, PROG NEURO-PSYCHOPH, V14, P309, DOI 10.1016/0278-5846(90)90019-D; OVERLY CC, 1991, BIOCHEM BIOPH RES CO, V181, P513, DOI 10.1016/0006-291X(91)91218-2; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; PASTERNACK JM, 1992, BIOCHEMISTRY-US, V31, P10936, DOI 10.1021/bi00159a038; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; RAMABHADRAN TV, 1993, J BIOL CHEM, V268, P2009; SAHASRABUDHE SR, 1992, J BIOL CHEM, V267, P25602; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WANG R, 1991, J BIOL CHEM, V266, P16960; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WOLF D, 1990, EMBO J, V9, P2079, DOI 10.1002/j.1460-2075.1990.tb07375.x	29	60	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					627	632						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276862				2022-12-25	WOS:A1994MR21900099
J	CHU, A; DINKOVA, A; DAVIN, LB; BEDGAR, DL; LEWIS, NG				CHU, A; DINKOVA, A; DAVIN, LB; BEDGAR, DL; LEWIS, NG			STEREOSPECIFICITY OF (+)-PINORESINOL AND (+)-LARICIRESINOL REDUCTASES FROM FORSYTHIA-INTERMEDIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE-EXTRACTS; ALCOHOL-DEHYDROGENASE; LIGNANS; BIOSYNTHESIS; PURIFICATION; COMPONENTS; LACTONE; BINDING; LIVER	Pinoresinol/lariciresinol reductase catalyzes the first known example of a highly unusual benzylic ether reduction in plants; its mechanism of hydride transfer is described. The enzyme was found in Forsythia intermedia and catalyzes the presumed regulatory branch-points in the pathway leading to benzylaryltetrahydrofuran, dibenzylbutane, dibenzylbutyrolactone, and aryltetrahydronaphthalene lignans. Using [7,7'-H-2(2)]-pinoresinol and [7,7'-H-2(3)]lariciresinol as substrates, the hydride transfers of the highly unusual reductase were demonstrated to be completely stereospecific (>99%). The incoming hydrides were found to take up the pro-R position at C-7' (and/or C-7) in lariciresinol and secoisolariciresinol, thereby eliminating the possibility of random hydride delivery to a planar quinone methide intermediate. As might be expected, the mode of hydride abstraction from NADPH was also stereospecific: using [4R-H-3] and [4S-H-3]NADPH, it was found that only the 4 pro-R hydrogen was abstracted for enzymatic hydride transfer.	WASHINGTON STATE UNIV,INST BIOL CHEM,PULLMAN,WA 99163	Washington State University				Dinkova-Kostova, Albena/0000-0003-0316-9859; Lewis, Norman/0000-0001-5742-032X; Davin, Laurence/0000-0002-3248-6485				Adlercreutz H., 1991, Nutrition, toxicity, and cancer., P137; ADLERCREUTZ H, 1984, GASTROENTEROLOGY, V86, P761; Ayres D.C., 1990, LIGNANS CHEM BIOL CH; BELMARES H, 1979, IND ENG CHEM PROD RD, V18, P220, DOI 10.1021/i360071a014; BIELLMANN JF, 1979, EUR J BIOCHEM, V102, P107, DOI 10.1111/j.1432-1033.1979.tb06268.x; BINNS AN, 1987, P NATL ACAD SCI USA, V84, P980, DOI 10.1073/pnas.84.4.980; BORRIELLO SP, 1985, J APPL BACTERIOL, V58, P37, DOI 10.1111/j.1365-2672.1985.tb01427.x; Bovey F. A., 1969, NUCLEAR MAGNETIC RES; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIN LB, 1992, PHYTOCHEMISTRY, V31, P3869, DOI 10.1016/S0031-9422(00)97544-7; DAVIN LB, 1992, RECENT ADV PHYTOCHEM, V26, P325; ELAKOVICH SD, 1985, J CHEM ECOL, V11, P27, DOI 10.1007/BF00987601; FAURE M, 1990, PHYTOCHEMISTRY, V29, P3773, DOI 10.1016/0031-9422(90)85329-E; FUJIMOTO H, 1982, MOKUZAI GAKKAISHI, V28, P555; Grisebach H., 1981, The biochemistry of plants. A comprehensive treatise. Volume 7. Secondary plant products., P457; GRISEBACH H, 1977, PYRIDINE NUCLEOTIDE, P458; HARMATHA J, 1984, BIOCHEM SYST ECOL, V12, P95, DOI 10.1016/0305-1978(84)90015-2; HATTORI M, 1986, CHEM PHARM BULL, V34, P3885; KAMIL WM, 1986, PHYTOCHEMISTRY, V25, P2093, DOI 10.1016/0031-9422(86)80072-3; KATAYAMA T, 1992, PHYTOCHEMISTRY, V31, P3875, DOI 10.1016/S0031-9422(00)97545-9; KATAYAMA T, 1993, PHYTOCHEMISTRY, V33, P581, DOI 10.1016/0031-9422(93)85452-W; KLISCHIES M, 1978, PHYTOCHEMISTRY, V17, P1523, DOI 10.1016/S0031-9422(00)94634-X; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LEWIS NG, 1990, ANNU REV PLANT PHYS, V41, P455, DOI 10.1146/annurev.pp.41.060190.002323; LEWIS NG, 1992, B LIAISON GROUPE POL, V16, P98; MANSELL RL, 1974, PHYTOCHEMISTRY, V13, P2427, DOI 10.1016/S0031-9422(00)86917-4; MARKKANEN T, 1981, DRUG EXP CLIN RES, V7, P711; MORAN RG, 1984, ANAL BIOCHEM, V138, P196, DOI 10.1016/0003-2697(84)90788-7; OSAWA T, 1985, AGR BIOL CHEM TOKYO, V49, P3351, DOI 10.1080/00021369.1985.10867272; OZAWA S, 1993, PHYTOCHEMISTRY, V32, P643, DOI 10.1016/S0031-9422(00)95149-5; PROCHASKA HJ, 1986, J BIOL CHEM, V261, P1372; RAHMAN MMA, 1990, PHYTOCHEMISTRY, V29, P1841, DOI 10.1016/0031-9422(90)85025-B; SAKAKIBARA A, 1987, HOLZFORSCHUNG, V41, P1, DOI 10.1515/hfsg.1987.41.1.1; SCHRODER HC, 1990, Z NATURFORSCH C, V45, P1215; SLESSOR KN, 1971, CAN J CHEMISTRY, V49, P2874, DOI 10.1139/v71-477; UMEZAWA T, 1991, J BIOL CHEM, V266, P10210; UMEZAWA T, 1990, BIOCHEM BIOPH RES CO, V171, P1008, DOI 10.1016/0006-291X(90)90784-K; UMEZAWA T, 1990, J CHEM SOC CHEM COMM, P1405, DOI 10.1039/c39900001405	38	68	71	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27026	27033						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262939				2022-12-25	WOS:A1993MM26200031
J	DAS, T; BAEK, KJ; GRAY, C; IM, MJ				DAS, T; BAEK, KJ; GRAY, C; IM, MJ			EVIDENCE THAT THE G(H) PROTEIN IS A SIGNAL MEDIATOR FROM ALPHA(1)-ADRENOCEPTOR TO A PHOSPHOLIPASE-C .2. PURIFICATION AND CHARACTERIZATION OF A G(H)-COUPLED 69-KDA PHOSPHOLIPASE-C AND RECONSTITUTION OF ALPHA(1)-ADRENOCEPTOR, G(H) FAMILY, AND PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; LIVER PLASMA-MEMBRANES; BOVINE BRAIN; ALPHA-1-ADRENERGIC RECEPTOR; RAT-LIVER; GUANINE-NUCLEOTIDE; ALPHA-SUBUNITS; KINASE-C; ACTIVATION; BINDING	Our studies on the alpha1-adrenoceptor signaling have demonstrated that the G(h) family is a signal mediator. We report here that a 69-kDa phospholipase C (PLC) is the effector in this signal pathway. The enzyme was isolated by dissociating a G(h7)-PLC complex which was induced in the bovine liver membranes incubating with (-)-epinephrine and GTP. The enzyme displayed a marked preference hydrolysis for phosphatidylinositol 4,5-bisphosphate over other phosphatidylinositides at micromolar calcium. Reconstitution of PLC with the alpha1-adrenoceptor and G(h) (G(h7)) into phospholipid vesicles resulted in a lowered Ca2+ requirement for the substrate hydrolysis in the presence of guanosine 5'-3-O-(thio)triphosphate (GTPgammaS) when the receptor was activated with the alpha1-agonist. The formation of inositol phosphate was hormone concentration dependent and reached maximal within 3 min which was faster than the formation in the presence of the alpha1-antagonist. An G(h7alpha) antibody co-immunoprecipitated 80-85% of phospholipase C activity in the presence of GTPgammaS, but not in the presence of GDP or buffer, showing the association of PLC with the alpha-subunit of G(h) family. Thus, our novel approaches to identify the effector involved in the alpha1-adrenoceptor signaling, as well as the reconstitution studies, substantially demonstrate that the alpha1-adrenoceptor-mediated transmembrane signaling involves the G(h) family and a 69-kDa PLC.	CLEVELAND CLIN FDN,RES INST,DEPT CARDIOVASC BIOL,FFB1 37,9500 EUCLID AVE,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NIGMS NIH HHS [GM45985] Funding Source: Medline; NINDS NIH HHS [NS19583] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019583] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAEHR W, 1982, J BIOL CHEM, V257, P6452; BAEK KJ, 1993, J BIOL CHEM, V268, P27390; BENNETT CF, 1987, J BIOL CHEM, V262, P13789; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; FEDER D, 1986, EMBO J, V5, P1509, DOI 10.1002/j.1460-2075.1986.tb04390.x; GONZALES RA, 1985, BIOCHEM J, V232, P799, DOI 10.1042/bj2320799; HO AK, 1987, J BIOL CHEM, V262, P11764; HOMMA Y, 1988, J BIOL CHEM, V263, P6592; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1990, J BIOL CHEM, V265, P18944; IM MJ, 1992, J BIOL CHEM, V267, P8887; KATAN M, 1987, EUR J BIOCHEM, V168, P413, DOI 10.1111/j.1432-1033.1987.tb13435.x; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LLAHI S, 1992, J BIOL CHEM, V267, P3679; MARTIN KL, 1992, BIOCHEM BIOPH RES CO, V178, P679; MAY DC, 1988, BIOCHEMISTRY-US, V27, P4888, DOI 10.1021/bi00413a045; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; MINNEMAN KP, 1988, PHARMACOL REV, V40, P87; NAKANISHI O, 1988, BIOCHEM J, V256, P453, DOI 10.1042/bj2560453; PITTNER RA, 1991, BIOCHEM J, V277, P371, DOI 10.1042/bj2770371; PRPIC V, 1984, J BIOL CHEM, V259, P1382; RANSNAS LA, 1992, BIOCHEM J, V283, P519, DOI 10.1042/bj2830519; REBECCHI MJ, 1987, J BIOL CHEM, V262, P12526; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1987, J BIOL CHEM, V262, P12511; RYU SH, 1986, BIOCHEM BIOPH RES CO, V141, P137, DOI 10.1016/S0006-291X(86)80345-X; SAWUTZ DG, 1987, MOL PHARMACOL, V32, P565; SCHWINN DA, 1991, MOL PHARMACOL, V40, P619; SUH PG, 1988, J BIOL CHEM, V263, P14497; TAKENAWA T, 1981, J BIOL CHEM, V256, P6769; TAYLOR GD, 1992, BIOCHEM BIOPH RES CO, V188, P1176, DOI 10.1016/0006-291X(92)91355-T; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THOMAS GMH, 1991, EMBO J, V10, P2507, DOI 10.1002/j.1460-2075.1991.tb07790.x; UHING RJ, 1986, J BIOL CHEM, V261, P2140; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WILSON KM, 1990, J BIOL CHEM, V265, P17601; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811	41	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27398	27405						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262981				2022-12-25	WOS:A1993MM26200080
J	KARCHER, U; SCHRODER, H; HASLINGER, E; ALLMAIER, G; SCHREINER, R; WIELAND, F; HASELBECK, A; KONIG, H				KARCHER, U; SCHRODER, H; HASLINGER, E; ALLMAIER, G; SCHREINER, R; WIELAND, F; HASELBECK, A; KONIG, H			PRIMARY STRUCTURE OF THE HETEROSACCHARIDE OF THE SURFACE GLYCOPROTEIN OF METHANOTHERMUS-FERVIDUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAYER GLYCOPROTEINS; NMR-SPECTROSCOPY; SENSITIVITY; GLYCOSYLATION; METHANOGENS; OLIGOSACCHARIDES; BIOSYNTHESIS; PROTEINS; GLYCANS	The outer surface of the cells of the hyperthermophile Methanothermus fervidus is covered by crystalline glycoprotein subunits (S-layer). From the purified S-layer glycoprotein, a heterosaccharide was isolated. The heterosaccharide consists of D-3-O-methylmannose, D-mannose, and D-N-acetylgalactosamine in a molar ratio of 2:3:1 corresponding to a relative molecular mass of 1061.83 Da. 3-O-methylmannose could be partly replaced by 3-O-methylglucose. The primary structure of the glycan was revealed by methylation analysis, by plasma desorption mass spectrometry, and by high field NMR spectroscopy. The purified heterosaccharide is linked via N-acetylgalactosamine to an asparagine residue of the peptide moiety. The following structure is proposed for the heterosaccharide: alpha-D-3-O-MetManp-(1 --> 6)-alpha-D-3-O-MetManp-((1 --> 2)-alpha-D-Manp)3-(1 --> 4)-D-GalNAc.	UNIV ULM,ANGEW MIKROBIOL & MYKOL ABT,D-89069 ULM,GERMANY; BOEHRINGER MANNHEIM GMBH,D-82372 PENZBERG,GERMANY; UNIV ULM,ORGAN CHEM ABT 1,D-89069 ULM,GERMANY; UNIV VIENNA,INST ANALYT CHEM,A-1090 VIENNA,AUSTRIA; INST BIOCHEM 1,D-69120 HEIDELBERG,GERMANY	Ulm University; Ulm University; University of Vienna			Allmaier, Guenter/F-2604-2012					ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; BALCH WE, 1979, MICROBIOL REV, V43, P260, DOI 10.1128/MMBR.43.2.260-296.1979; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BERGMEYER HU, 1974, METHODEN ENZYMATISCH; BOCK K, 1975, ACTA CHEM SCAND B, VB 29, P258, DOI 10.3891/acta.chem.scand.29b-0181; BROCKL G, 1991, EUR J BIOCHEM, V199, P147, DOI 10.1111/j.1432-1033.1991.tb16102.x; FAGUY DM, 1992, FEMS MICROBIOL LETT, V90, P129, DOI 10.1016/0378-1097(92)90616-V; GERWIG GJ, 1991, EUR J BIOCHEM, V196, P115, DOI 10.1111/j.1432-1033.1991.tb15793.x; HARTMANN E, 1989, ARCH MICROBIOL, V151, P274, DOI 10.1007/BF00413142; HASSID WZ, 1957, METHOD ENZYMOL, V3, P34, DOI 10.1016/S0076-6879(57)03345-5; HOFFMAN J, 1972, ACTA CHEM SCAND, V26, P661, DOI 10.3891/acta.chem.scand.26-0661; Horton D., 1969, AMINO SUGARS       A, VI, P1; Hough L., 1963, METHODS CARBOHYDRATE, V2, P203; Jansson P-E., 1976, CHEM COMMUN U STOCKH, V8, P1; KANDLER O, 1993, BIOCH ARCHAEA; KAWAMURA T, 1983, J BIOL CHEM, V258, P9514; KESSLER H, 1989, J MAGN RESON, V85, P1, DOI 10.1016/0022-2364(89)90314-4; KONIG H, 1980, H-S Z PHYSIOL CHEM, V361, P981; LECHNER J, 1989, ANNU REV BIOCHEM, V58, P173, DOI 10.1146/annurev.bi.58.070189.001133; Lennarz W.J., 1980, BIOCH GLYCOPROTEINS; LERNER L, 1986, J MAGN RESON, V69, P375, DOI 10.1016/0022-2364(86)90091-0; LIKHOSHERSTOV LM, 1990, CARBOHYD RES, V199, P67, DOI 10.1016/0008-6215(90)84093-A; Lindberg B., 1975, ADV CARBOHYD CHEM BI, V31, P185; MENGELE R, 1992, J BIOL CHEM, V267, P8182; MESSNER P, 1992, ADV MICROB PHYSIOL, V33, P213, DOI 10.1016/S0065-2911(08)60218-0; Montreuil J, 1986, CARBOHYDRATE ANAL PR, P143; NIELSEN PF, 1988, BIOMED ENVIRON MASS, V17, P355, DOI 10.1002/bms.1200170503; NUSSER E, 1988, CRYSTALLINE BACTERIA, P21; OLDEN K, 1985, TRENDS BIOCHEM SCI, V10, P78, DOI 10.1016/0968-0004(85)90238-5; PARENTE JP, 1985, CARBOHYD RES, V141, P41, DOI 10.1016/S0008-6215(00)90753-5; PAUL G, 1986, J BIOL CHEM, V261, P1020; STETTER KO, 1981, ZBL BAKT MIK HYG I C, V2, P166, DOI 10.1016/S0721-9571(81)80038-5; SUMPER M, 1990, J BACTERIOL, V172, P7111, DOI 10.1128/jb.172.12.7111-7118.1990; Takasaki S, 1978, Methods Enzymol, V50, P50; TIPPER DJ, 1968, BIOCHEMISTRY-US, V7, P1441, DOI 10.1021/bi00844a029; WIELAND F, 1985, J BIOL CHEM, V260, P5180; WIELAND F, 1982, ZBL BAKT MIK HYG I C, V3, P161, DOI 10.1016/S0721-9571(82)80064-1	40	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26821	26826						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262914				2022-12-25	WOS:A1993MM26200003
J	MENDELMAN, LV; NOTARNICOLA, SM; RICHARDSON, CC				MENDELMAN, LV; NOTARNICOLA, SM; RICHARDSON, CC			EVIDENCE FOR DISTINCT PRIMASE AND HELICASE DOMAINS IN THE 63-KDA GENE-4 PROTEIN OF BACTERIOPHAGE-T7 - CHARACTERIZATION OF A NUCLEOTIDE-BINDING SITE MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE 5'-TRIPHOSPHATASE ACTIVITY; DNA-POLYMERASE; DEOXYRIBONUCLEIC-ACID; ADENYLATE KINASE; ESCHERICHIA-COLI; PRIMER SYNTHESIS; STRAND SYNTHESIS; REPLICATION; ATP; PURIFICATION	Gene 4 of bacteriophage T7 encodes two co-linear proteins, the 56- and 63-kDa gene 4 proteins. The 56-kDa protein translocates 5' to 3' on single-stranded DNA using nucleotide hydrolysis for energy and is a helicase. The 63-kDa gene 4 protein catalyzes all of the activities of the 56-kDa gene 4 protein and, in addition, catalyzes the synthesis of oligoribonucleotides on single-stranded DNA. Two conserved residues in a putative nucleotide binding site of the 63-kDa gene 4 protein were mutated by substituting Val and Met for wild-type residues Gly and Lys, at positions 317 and 318, respectively. The mutant 63-kDa gene 4 protein lacks the ability to catalyze the hydrolysis of a nucleoside 5'-triphosphate in a single-stranded DNA-dependent reaction and inhibits nucleotide hydrolysis by wild-type gene 4 proteins. The mutant primase contains 0.4% of the primase activity of the 63-kDa gene 4 protein on M13 single-stranded DNA and 12% of the wild-type primase activity on an oligonucleotide with a single primase recognition site. Addition of wild-type 56-kDa gene 4 protein stimulates the mutant primase activity over 50-fold on M13 single-stranded DNA and 8-fold on oligonucleotides. This increase in primase activity correlates with an increase in the affinity of the mutant primase-wild-type helicase complex for single-stranded DNA template.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School					NIAID NIH HHS [AI-06045] Funding Source: Medline; PHS HHS [1F32 A108630-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI006045, R01AI006045] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI KI, 1981, P NATL ACAD SCI-BIOL, V78, P707, DOI 10.1073/pnas.78.2.707; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; BROWN WC, 1989, J BIOL CHEM, V264, P6748; BURGERS PMJ, 1989, PROG NUCLEIC ACID RE, V37, P235; CALDER JM, 1990, NUCLEIC ACIDS RES, V18, P3573, DOI 10.1093/nar/18.12.3573; DODSON MS, 1991, P NATL ACAD SCI USA, V88, P1105, DOI 10.1073/pnas.88.4.1105; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; HINTON DM, 1987, J BIOL CHEM, V262, P10873; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; KORNBERG A, 1991, DNA REPLICATION, P275; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MENDELMAN LV, 1992, P NATL ACAD SCI USA, V89, P10638, DOI 10.1073/pnas.89.22.10638; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MILLER JH, 1987, METHOD ENZYMOL, V152, P163; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; ROMANO LJ, 1979, J BIOL CHEM, V254, P483; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; SCHERZINGER E, 1977, EUR J BIOCHEM, V72, P543, DOI 10.1111/j.1432-1033.1977.tb11278.x; SCHERZINGER E, 1977, NUCLEIC ACIDS RES, V4, P4151, DOI 10.1093/nar/4.12.4151; SEKI T, 1979, NUCLEIC ACIDS RES, V7, P1603, DOI 10.1093/nar/7.6.1603; SHRIMANKAR P, 1992, J BACTERIOL, V174, P7689, DOI 10.1128/JB.174.23.7689-7696.1992; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1987, THESIS HARVARD U; TAGAYA M, 1987, J BIOL CHEM, V262, P8257; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; ZIEGELIN G, 1993, EMBO J, V12, P3703, DOI 10.1002/j.1460-2075.1993.tb06045.x	39	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27208	27213						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262962				2022-12-25	WOS:A1993MM26200057
J	STOLZ, B; HUBER, M; MARKOVICHOUSLEY, Z; ERNI, B				STOLZ, B; HUBER, M; MARKOVICHOUSLEY, Z; ERNI, B			THE MANNOSE TRANSPORTER OF ESCHERICHIA-COLI - STRUCTURE AND FUNCTION OF THE IIAB(MAN)-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE PHOSPHOTRANSFERASE SYSTEM; SIGNAL-TRANSDUCING PROTEIN; PHOSPHORYLATING SUBUNIT; PHOSPHOCARRIER PROTEIN; ENZYME-III; PERMEASE; EXPRESSION; OPERON; PHOSPHOENOLPYRUVATE; PURIFICATION	The mannose transporter of the bacterial phosphotransferase system consists of two transmembrane subunits (IIC(Man) and IID(Man)) and a hydrophilic subunit (IIAB(Man)). IIAB(Man) has two flexibly linked domains containing one phosphorylation site each and occurs as a dimer. Substrate transport is coupled to phosphorylation. The phosphoryl group is transferred from a phosphoryl carrier protein to His10 on IIA, hence to His175 on IIB and finally to the substrate. IIAB(Man) mutants were analyzed in vitro for complementation, negative dominance, cysteine cross-linking and reactivity. Conclusions: (i) His10, Trp12, Lys48, and Ser72 form a functional unit (phosphorylation site 1); (ii) His86 on the IIA domain and His175 on the IIB domain of the same subunit form a functional unit (phosphorylation site 2); (iii) phosphoryl transfer can occur between His10 and His86 of the same as well as of different subunits and His86 is necessary for this transfer; (iv) the subunits in the dimer are interdependent; (v) The phosphorylation site mutant H175C is highly reactive toward thiol reagents and it forms extensive homo- and heterocross-links with other surface-exposed cysteines. The phosphorylation site mutant H10C is 1000-fold less reactive. The two residues might be in complementary locations, His10 buried in a concave, His175 exposed on a convex surface.	UNIV BERN,INST BIOCHEM,FREIESTR 3,CH-3012 BERN,SWITZERLAND	University of Bern								AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; AMSTERCHODER O, 1992, SCIENCE, V257, P540; ATKINS PW, 1982, PHYSICAL CHEM; DEMEYER R, 1992, THESIS U MARBURG; ERNI B, 1985, J BIOL CHEM, V260, P5495; ERNI B, 1992, INT REV CYTOL, V137A, P127; ERNI B, 1989, J BIOL CHEM, V264, P18733; ERNI B, 1987, J BIOL CHEM, V262, P5238; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GENOVESIOTAVERNE JC, 1990, J MOL BIOL, V216, P515, DOI 10.1016/0022-2836(90)90379-Z; HERZBERG O, 1992, J BIOL CHEM, V267, P24819; KALLIS GB, 1980, J BIOL CHEM, V255, P261; LOLKEMA JS, 1993, BIOCHEMISTRY-US, V32, P1396, DOI 10.1021/bi00057a002; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MARTINVERSTRAETE I, 1990, J MOL BIOL, V214, P657, DOI 10.1016/0022-2836(90)90284-S; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MEINS M, 1988, J BIOL CHEM, V263, P12986; MEINS M, 1993, J BIOL CHEM, V268, P11604; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5835, DOI 10.1021/bi00416a002; PELTON JG, 1991, P NATL ACAD SCI USA, V88, P3479, DOI 10.1073/pnas.88.8.3479; POSTMA PW, 1985, MICROBIOL REV, V49, P232, DOI 10.1128/MMBR.49.3.232-269.1985; PRESPER KA, 1989, P NATL ACAD SCI USA, V86, P4052, DOI 10.1073/pnas.86.11.4052; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; ROOSSIEN FF, 1983, BIOCHIM BIOPHYS ACTA, V760, P185, DOI 10.1016/0304-4165(83)90141-1; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNETZ K, 1990, P NATL ACAD SCI USA, V87, P5074, DOI 10.1073/pnas.87.13.5074; SCHOLTE BJ, 1981, EUR J BIOCHEM, P51; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; Traut R., 1989, PROTEIN FUNCTION PRA, P101; VOGLER AP, 1988, MOL GEN GENET, V213, P175, DOI 10.1007/BF00333417; VOGLER AP, 1988, MOL MICROBIOL, V2, P719, DOI 10.1111/j.1365-2958.1988.tb00082.x; WENG QP, 1992, J BIOL CHEM, V267, P19529	33	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27094	27099						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262947				2022-12-25	WOS:A1993MM26200040
J	HACK, N; SUEAQUAN, A; MILLS, GB; SKORECKI, KL				HACK, N; SUEAQUAN, A; MILLS, GB; SKORECKI, KL			EXPRESSION OF HUMAN TYROSINE KINASE-NEGATIVE EPIDERMAL GROWTH-FACTOR RECEPTOR AMPLIFIES SIGNALING THROUGH ENDOGENOUS MURINE EPIDERMAL GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; EGF RECEPTOR; REGULATED KINASES; PHOSPHORYLATION; CELLS; RAS; PHOSPHOLIPASE-A2; BINDING; AUTOPHOSPHORYLATION; ACTIVATION	Recent findings have suggested that certain ligand-dependent responses to EGF may be propagated in a manner that is not dependent on the intrinsic tyrosine kinase activity of the epidermal growth factor receptor (EGF-R, Campos-Gonzalez, R., and Glenney, J. R., Jr. (1992) J. Biol. Chem. 267, 14535-14538) or, alternatively, that these responses may occur through the interaction of the human tyrosine kinase-deficient EGF-R with an as yet unidentified kinase (Selva, E., Raden, D. L., and Davis, R. J. (1993) J. Biol. Chem. 268, 2250-2254). These conclusions represent a significant departure from our current understanding of signal transduction by receptor tyrosine kinases. Therefore we examined the effect of expression of tyrosine kinase-negative human EGF receptor in murine NIH-3T3-2.2 cells on the EGF-dependent phosphorylation of mitogen-activated protein (MAP-2) kinase. In parental cells (NIH-3T3-2.2) that express low levels of endogenous murine EGF-R, there was no demonstrable EGF-dependent coupling to MAP-2 kinase. In NIH-3T3-2.2 cells transfected with tyrosine kinase-negative human EGF-R, there was unexpected EGF-dependent phosphorylation of MAP-2 kinase. Analysis of the tyrosine kinase-negative human EGF-R in these cells revealed significant tyrosine phosphorylation of the EGF-R. A low level of endogenous murine EGF-R present in these cells were also phosphorylated on tyrosine residues and displayed autokinase activity. Similar results were obtained using an unrelated cell line (B82L cells), in which EGF-dependent phosphorylation of MAP-2 kinase was previously attributed to signal propagation through a tyrosine kinase-negative human EGF-R (Campos-Gonzalez, R., and Glenney, J. R., Jr. (1992) J. Biol. Chem. 267, 14535-14538). Taken together, these results suggest that the tyrosine kinase-negative human EGF-R are able to amplify the response to activation of low levels of endogenous murine EGF-R, thus leading to EGF-dependent phosphorylation of MAP-2 kinase in cells expressing tyrosine kinase-negative human EGF-R.	UNIV TORONTO,MRC,MEMBRANE BIOL GRP,TORONTO M5S 1A1,ONTARIO,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA; TORONTO GEN HOSP,TORONTO M5G 1L7,ONTARIO,CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital								Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BACCARINI M, 1991, J BIOL CHEM, V266, P10941; BELLOT F, 1990, J CELL BIOL, V110, P491, DOI 10.1083/jcb.110.2.491; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOLDBERG HJ, 1990, BIOCHEM J, V267, P461, DOI 10.1042/bj2670461; HACK N, 1990, BIOSCIENCE REP, V10, P353, DOI 10.1007/BF01117235; HACK N, 1991, BIOCHEM J, V275, P563, DOI 10.1042/bj2750563; HACK N, 1990, J AM SOC NEPHROL, V1, P471; HONNEGER AM, 1987, CELL, V51, P199; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LEE BA, 1991, J CELL BIOL, V113, P361, DOI 10.1083/jcb.113.2.361; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LICHTNER RB, 1992, J BIOL CHEM, V267, P11872; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SELVA E, 1993, J BIOL CHEM, V268, P2250; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZWILLER J, 1991, ONCOGENE, V6, P219	35	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26441	26446						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253771				2022-12-25	WOS:A1993MK42500065
J	HENNECKE, S; COSSON, P				HENNECKE, S; COSSON, P			ROLE OF TRANSMEMBRANE DOMAINS IN ASSEMBLY AND INTRACELLULAR-TRANSPORT OF THE CD8 MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; MONOCLONAL-ANTIBODIES; HELICAL INTERACTIONS; SURFACE EXPRESSION; ALPHA-CHAIN; COMPLEX; DEGRADATION; ASSOCIATION; PROTEINS; REGION	Previous studies have shown that CD8 can be present at the cell surface either as a disulfide-linked homodimer of CD8alpha or as a disulfide-linked heterodimer of CD8alpha and CD8beta. Here we analyzed the assembly and intracellular transport of CD8 with particular emphasis on the role of the transmembrane domains. A chimeric protein (alphaTalpha) made by replacing the transmembrane domain of CD8alpha with that of the interleukin-2 receptor alpha chain (Tac) exhibited reduced ability to form homodimers, while a mutant of Tac containing the CD8alpha transmembrane domain (Talphaalpha) dimerized efficiently. Contrary to CD8alpha, CD8beta expressed alone was retained in the endoplasmic reticulum (ER). Only a small amount of CD8beta formed homodimers, and these also remained in the ER. A mutant of CD8beta that dimerized efficiently was also retained in the ER, thus proving that ER retention of CD8beta is not due to its poor homodimerization. Rather, the extracellular domain of CD8beta requires interaction with that of CD8alpha to exit the ER. The transmembrane domain of CD8beta was also shown to participate in ER retention by preventing exit of monomeric CD8beta out of the ER. These findings demonstrate the role of transmembrane domains in assembly and intracellular transport of the CD8 molecule.			HENNECKE, S (corresponding author), BASEL INST IMMUNOL, GRENZACHERSTR 487 POSTFACH, CH-4005 BASEL, SWITZERLAND.							BLANC D, 1988, EUR J IMMUNOL, V18, P613, DOI 10.1002/eji.1830180419; BOLEN JB, 1989, TRENDS BIOCHEM SCI, V14, P404, DOI 10.1016/0968-0004(89)90288-0; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; COSSON P, 1992, SCIENCE, V258, P659, DOI 10.1126/science.1329208; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; GOLSTEIN P, 1982, IMMUNOL REV, V68, P5, DOI 10.1111/j.1600-065X.1982.tb01058.x; GORMAN SD, 1988, J IMMUNOL, V140, P3646; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUYGRAND D, 1991, J EXP MED, V173, P471, DOI 10.1084/jem.173.2.471; HAMMERLING GJ, 1979, J EXP MED, V150, P108, DOI 10.1084/jem.150.1.108; HEIMER GV, 1974, J CLIN PATHOL, V27, P254, DOI 10.1136/jcp.27.3.254; JONES DH, 1990, BIOTECHNIQUES, V8, P178; KIRSZBAUM L, 1989, J IMMUNOL, V142, P3931; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LEDBETTER JA, 1982, IMMUNOL REV, V68, P197, DOI 10.1111/j.1600-065X.1982.tb01065.x; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LETOURNEUR F, 1990, P NATL ACAD SCI USA, V87, P2339, DOI 10.1073/pnas.87.6.2339; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; PARNES JR, 1989, ADV IMMUNOL, V44, P265; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; RUTLEDGE T, 1992, EMBO J, V11, P3245, DOI 10.1002/j.1460-2075.1992.tb05402.x; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; TREUTLEIN HR, 1992, BIOCHEMISTRY-US, V31, P12; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; WHEELER CJ, 1992, NATURE, V357, P247, DOI 10.1038/357247a0; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	32	40	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26607	26612						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253791				2022-12-25	WOS:A1993MK42500086
J	HUFLEJT, ME; TURCK, CW; LINDSTEDT, R; BARONDES, SH; LEFFLER, H				HUFLEJT, ME; TURCK, CW; LINDSTEDT, R; BARONDES, SH; LEFFLER, H			L-29, A SOLUBLE LACTOSE-BINDING LECTIN, IS PHOSPHORYLATED ON SERINE-6 AND SERINE-12 IN-VIVO AND BY CASEIN KINASE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE-T-ANTIGEN; TRANSCRIPTIONAL ACTIVATION; RIBONUCLEOPROTEIN COMPLEX; MAC-2 ANTIGEN; P53 PROTEIN; CELLS; LOCALIZATION; RECOGNITION; FIBROBLASTS; EXPRESSION	L-29, a mammalian soluble lactose-binding lectin, was previously shown to be phosphorylated in confluent 3T3 fibroblasts (Cowles, E. A., Agrwal, N., Anderson, R. L., and Wang, J. L. (1990) J. Biol. Chem. 265, 17706-17712), which contain a small amount of this protein. We have determined the site of phosphorylation on L-29, taking advantage of the abundance of L-29 (about 1% of total soluble cell protein) in confluent polarized Madin-Darby canine kidney (MDCK) cells. Approximately 15-20% of the L-29 is phosphorylated in these cells. Phosphoamino acid analysis showed phosphate incorporation only at serine. Analysis of chymotryptic and endoproteinase Asp-N-generated NH2-terminal fragments by Edman degradation showed that 90% of the phosphate was at Ser6 and 10% at Ser12. The sequence surrounding Ser6, which is conserved in all known L-29 sequences, indicated that this serine might be phosphorylated by casein kinase I or casein kinase II. Reaction of human recombinant L-29 with [gamma-P-32]ATP and each of these casein kinases showed that only casein kinase I catalyzed significant incorporation of P-32 into L-29; and, as with the L-29 from the MDCK cell extracts, most of the phosphate was incorporated at Ser6 and a small amount was incorporated at Ser12.	UNIV CALIF SAN FRANCISCO, LANGLEY PORTER NEUROPSYCHIAT INST, DEPT PSYCHIAT, BOX F-0984, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Leffler, Hakon/A-2416-2019	Huflejt, Malgorzata/0000-0002-2016-8367; Leffler, Hakon/0000-0003-4482-8945				BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; COWLES EA, 1990, J BIOL CHEM, V265, P17706; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; HAMANN KK, 1991, EXP CELL RES, V196, P82, DOI 10.1016/0014-4827(91)90458-7; HATHAWAY GM, 1983, METHOD ENZYMOL, V99, P317, DOI 10.1016/0076-6879(83)99067-5; HATHAWAY GM, 1983, METHOD ENZYMOL, V99, P308, DOI 10.1016/0076-6879(83)99066-3; HERRMANN J, 1993, J BIOL CHEM, V268, P26704; HO MK, 1982, J IMMUNOL, V128, P1221; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; LAING JG, 1988, BIOCHEMISTRY-US, V27, P5329, DOI 10.1021/bi00414a057; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; LINDSTEDT R, 1993, J BIOL CHEM, V268, P11750; LOTZ MM, 1993, P NATL ACAD SCI USA, V90, P3466, DOI 10.1073/pnas.90.8.3466; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MILNE DM, 1992, ONCOGENE, V7, P1361; MOUTSATSOS IK, 1986, J CELL BIOL, V102, P477, DOI 10.1083/jcb.102.2.477; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; ODA Y, 1991, GENE, V99, P279; OROURKE RW, 1990, ONCOGENE, V5, P1829; PALEN E, 1991, BIOCHEMISTRY-US, V30, P5586, DOI 10.1021/bi00236a035; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROBERTSON MW, 1991, J IMMUNOL, V147, P3024; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; UMPHRESS JL, 1992, EUR J BIOCHEM, V203, P239, DOI 10.1111/j.1432-1033.1992.tb19852.x; WANG JL, 1992, BIOCHEM SOC T, V20, P269, DOI 10.1042/bst0200269; WOO HJ, 1990, J BIOL CHEM, V265, P7097	31	102	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26712	26718						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253806				2022-12-25	WOS:A1993MK42500102
J	SUNG, CH; DAVENPORT, CM; NATHANS, J				SUNG, CH; DAVENPORT, CM; NATHANS, J			RHODOPSIN MUTATIONS RESPONSIBLE FOR AUTOSOMAL-DOMINANT RETINITIS-PIGMENTOSA - CLUSTERING OF FUNCTIONAL CLASSES ALONG THE POLYPEPTIDE-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIFF-BASE COUNTERION; BOVINE RHODOPSIN; DARK-ADAPTATION; GENE; IDENTIFICATION; DETERMINANTS	Over 40 mutations in the rhodopsin gene have been identified in patients with autosomal dominant retinitis pigmentosa. Twenty-one of these mutations have been introduced into a human rhodopsin cDNA by site-directed mutagenesis, and the encoded proteins have been produced by transfection of a human embryonic kidney cell line (293S). Three of the mutant proteins (G51V, V345M, and P347S) resemble the wild type in yield, regenerability with 11-cis-retinal, and accumulation in the plasma membrane (class I). The remaining 18 mutant proteins are produced at lower levels, regenerate variably or not at all with 11-cis-retinal, and accumulate partially or predominantly in the endoplasmic reticulum (class II). Together with an earlier analysis of 13 mutant rhodopsins (Sung, C.-H., Schneider, B., Agarwal, N., Papermaster, D. S., and Nathans, J. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 8840-8844), these experiments define distinct classes of biochemical defects in human rhodopsin and further show that amino acid substitutions in class II reside within the transmembrane and extracellular domains, whereas class I mutants cluster in the first transmembrane domain and at the extreme carboxyl terminus.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT OPHTHALMOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	SUNG, CH (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,805 PCTB,725 N WOLFE ST,BALTIMORE,MD 21205, USA.			Nathans, Jeremy/0000-0001-8106-5460				ADAMUS G, 1988, Peptide Research, V1, P42; ARTLICH A, 1992, AM J HUM GENET, V50, P876; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; DRYJA TP, 1991, P NATL ACAD SCI USA, V88, P9370, DOI 10.1073/pnas.88.20.9370; FISHMAN GA, 1992, ARCH OPHTHALMOL-CHIC, V110, P646, DOI 10.1001/archopht.1992.01080170068026; FISHMAN GA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1582, DOI 10.1001/archopht.1992.01080230082026; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HARLOWE E, 1988, ANTIBODIES LABORATOR; Heckenlively J. R., 1988, RETINITIS PIGMENTOSA; INGLEHEARN CF, 1992, HUM MOL GENET, V1, P41, DOI 10.1093/hmg/1.1.41; JACOBSON SG, 1991, AM J OPHTHALMOL, V112, P256, DOI 10.1016/S0002-9394(14)76726-1; KEMP CM, 1992, AM J OPHTHALMOL, V113, P165, DOI 10.1016/S0002-9394(14)71529-6; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KNOWLES A, 1977, PHOTOBIOLOGY VISION, P347; MIN KC, 1993, J BIOL CHEM, V268, P9400; MOORE AT, 1992, BRIT J OPHTHALMOL, V76, P465, DOI 10.1136/bjo.76.8.465; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P937, DOI 10.1021/bi00456a013; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P9746, DOI 10.1021/bi00493a034; NATHANS J, 1992, ANNU REV GENET, V26, P401; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SHEFFIELD VC, 1991, AM J HUM GENET, V49, P699; STJULES RS, 1989, EXP EYE RES, V48, P653, DOI 10.1016/0014-4835(89)90007-9; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154	25	263	272	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26645	26649						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253795				2022-12-25	WOS:A1993MK42500091
J	SUNG, P; REYNOLDS, P; PRAKASH, L; PRAKASH, S				SUNG, P; REYNOLDS, P; PRAKASH, L; PRAKASH, S			PURIFICATION AND CHARACTERIZATION OF THE SACCHAROMYCES-CEREVISIAE RAD1 RAD10 ENDONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCISION REPAIR GENE; YEAST DNA-REPAIR; MITOTIC RECOMBINATION; NUCLEOTIDE-SEQUENCE; PROTEINS; MUTANTS; INCISION; VIABILITY; REMOVAL; ENCODES	The Saccharomyces cerevisiae RAD1 and RAD10 genes are required for the incision step of excision repair, and in addition, they function in mitotic recombination. The RAD1 and RAD10 proteins are associated in a tight complex, and genetic studies have indicated that complex formation is essential for the RAD1/RAD10 controlled biological activities. We had previously purified the RAD10 protein to near homogeneity from yeast and shown that it is a DNA-binding protein with a strong preference for single-stranded DNA. In this study, we purify the RAD1 protein to near homogeneity from yeast and show that it also binds single-stranded DNA preferentially and that the RAD1/RAD10 complex possesses an endonuclease activity. We characterize the RAD1/RAD10 endonuclease activity on both single-stranded and double-stranded DNAs, using agarose gel electrophoresis and trichloroacetic acid precipitation. The RAD1/RAD10 nuclease exhibits a much higher level of activity on single-stranded DNA than double-stranded DNA. The susceptibility of double-stranded DNA to nicking by the RAD1/RAD10 enzyme is markedly dependent on the degree of negative superhelicity, such that a 15-fold increase in nicking rate is observed from superhelical state sigma = zero to sigma = -0.08. The enzyme produces 3'-hydroxyl and 5'-phosphate termini on both single- and double-stranded DNAs. We discuss the role of RAD1/RAD10 endonuclease in nucleotide excision repair and in mitotic recombination.	UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT BIOPHYS,ROCHESTER,NY 14642	University of Rochester; University of Rochester			Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261	NATIONAL CANCER INSTITUTE [R01CA035035, R37CA035035] Funding Source: NIH RePORTER; NCI NIH HHS [CA35035] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILIS AM, 1992, MOL CELL BIOL, V12, P4988, DOI 10.1128/MCB.12.11.4988; BAILLY V, 1992, P NATL ACAD SCI USA, V89, P8273, DOI 10.1073/pnas.89.17.8273; BANG DD, 1992, NUCLEIC ACIDS RES, V20, P3925, DOI 10.1093/nar/20.15.3925; BANKMANN M, 1992, NATURE, V355, P555, DOI 10.1038/355555a0; BARDWELL L, 1992, MOL CELL BIOL, V12, P3041, DOI 10.1128/MCB.12.7.3041; FISHMANLOBELL J, 1992, SCIENCE, V258, P480, DOI 10.1126/science.1411547; FISHMANLOBELL J, 1992, MOL CELL BIOL, V12, P1292, DOI 10.1128/MCB.12.3.1292; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; HIGGINS DR, 1983, P NATL ACAD SCI-BIOL, V80, P5680, DOI 10.1073/pnas.80.18.5680; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KIM RA, 1992, J BIOL CHEM, V267, P17178; KLEIN HL, 1988, GENETICS, V120, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN FLM, 1990, MOL CELL BIOL, V10, P103, DOI 10.1128/MCB.10.1.103; LJUNGMAN M, 1992, P NATL ACAD SCI USA, V89, P6055, DOI 10.1073/pnas.89.13.6055; MARYON E, 1991, MOL CELL BIOL, V11, P3278, DOI 10.1128/MCB.11.6.3278; MILLER RD, 1982, MOL CELL BIOL, V2, P939, DOI 10.1128/MCB.2.8.939; MILLER RD, 1982, MOL GEN GENET, V188, P235, DOI 10.1007/BF00332681; NAUMOVSKI L, 1983, P NATL ACAD SCI-BIOL, V80, P4818, DOI 10.1073/pnas.80.15.4818; NORANELLI F, 1980, P NATL ACAD SCI USA, V77, P3201; PARK E, 1992, P NATL ACAD SCI USA, V89, P11416, DOI 10.1073/pnas.89.23.11416; REYNOLDS P, 1985, EMBO J, V4, P3549, DOI 10.1002/j.1460-2075.1985.tb04115.x; REYNOLDS P, 1987, MOL CELL BIOL, V7, P1012, DOI 10.1128/MCB.7.3.1012; REYNOLDS RJ, 1981, J BACTERIOL, V146, P692, DOI 10.1128/JB.146.2.692-704.1981; SCHIESTL RH, 1990, MOL CELL BIOL, V10, P2485, DOI 10.1128/MCB.10.6.2485; SCHIESTL RH, 1988, MOL CELL BIOL, V8, P3619, DOI 10.1128/MCB.8.9.3619; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; STEWART SE, 1989, MOL CELL BIOL, V9, P3464, DOI 10.1128/MCB.9.8.3464; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; SUNG P, 1992, NATURE, V355, P743, DOI 10.1038/355743a0; THOMAS BJ, 1989, GENETICS, V123, P725; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILCOX DR, 1981, J BACTERIOL, V148, P618, DOI 10.1128/JB.148.2.618-623.1981; ZEHFUS BR, 1990, GENETICS, V126, P41	37	106	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26391	26399						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253764				2022-12-25	WOS:A1993MK42500058
J	DEFORGE, LE; PRESTON, AM; TAKEUCHI, E; KENNEY, J; BOXER, LA; REMICK, DG				DEFORGE, LE; PRESTON, AM; TAKEUCHI, E; KENNEY, J; BOXER, LA; REMICK, DG			REGULATION OF INTERLEUKIN-8 GENE-EXPRESSION BY OXIDANT STRESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NEUTROPHIL CHEMOTACTIC FACTOR; HUMAN WHOLE-BLOOD; NF-KAPPA-B; MESSENGER-RNA; REPERFUSION INJURY; ENDOTHELIAL-CELLS; HUMAN-FIBROBLASTS; FREE-RADICALS; FACTOR-ALPHA	Interleukin 8 (IL-8) is a recently described cytokine that functions as a potent neutrophil chemoattractant and activator. We sought to examine the link between the generation of reactive oxygen intermediates (ROI) and the regulation of IL-8 gene expression to specifically test the hypothesis that ROI would induce production of IL-8 mRNA and protein. In lipopolysaccharide-stimulated human whole blood, the OH radical scavenger dimethyl sulfoxide (Me2SO) dramatically inhibited (approximately 90%) IL-8 production, but had minimal effects on the production of tumor necrosis factor, interleukin 1beta (IL-1), and IL-6. To determine whether NADPH-oxidase-generated free radicals were critical in the regulation of IL-8, studies were performed using blood from patients with chronic granulomatous disease. In both normal individuals and patients with chronic granulomatous disease, production of IL-8 could be initiated with lipopolysaccharide, phytohemagglutinin, or aggregated immune complexes, and this production could be inhibited by Me2SO (1% v/v). To examine if oxidant stress represents a ubiquitous mechanism for the induction of IL-8, experiments were performed in cultured cell lines. In the human hepatoma cell line Hep-G2, Me2SO dose-dependently inhibited tumor necrosis factor-stimulated IL-8 production, with a 74 +/- 1% reduction observed at a Me2SO concentration of 1%. Direct exposure to ROI demonstrated that H2O2 stimulated IL-8 production in a dose-dependent manner in Hep-G2 cells, A549 pulmonary type II epithelial cells, and human skin fibroblasts; this induction could be prevented by addition of catalase. The production of IL-8 appeared to be specific to an oxidant stress since exposure of the cells to heat shock or chemical stress did not induce expression of IL-8. These studies demonstrate that oxidant stress is an important regulator of IL-8 gene expression and support the hypothesis that low levels of ROI may serve to initiate IL-8 production which then serves to recruit neutrophils to sites of inflammation.	UNIV MICHIGAN, SCH MED, DEPT PATHOL, M2210 MED SCI BLDG 1, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT PEDIAT, ANN ARBOR, MI 48109 USA; SYNTEX INC, PALO ALTO, CA 94304 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Syntex Corporation				Remick, Daniel/0000-0002-2615-3713	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042455] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20065] Funding Source: Medline; NIDDK NIH HHS [DK-42455] Funding Source: Medline; NIGMS NIH HHS [GM-44918] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; BABIOR BM, 1991, AM J HEMATOL, V37, P263, DOI 10.1002/ajh.2830370410; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BAUTISTA AP, 1990, AM J PHYSIOL, V259, pG907, DOI 10.1152/ajpgi.1990.259.6.G907; COLLIER J, 1989, TRENDS PHARMACOL SCI, V10, P427, DOI 10.1016/S0165-6147(89)80001-X; DEFORGE LE, 1992, J IMMUNOL, V148, P2133; DEFORGE LE, 1992, AM J PATHOL, V140, P1045; DEFORGE LE, 1992, J CLIN INVEST, V90, P2123, DOI 10.1172/JCI116097; FREEMAN BA, 1982, LAB INVEST, V47, P412; GHEZZI P, 1991, CYTOKINE, V3, P189, DOI 10.1016/1043-4666(91)90015-6; GRANGER DN, 1988, AM J PHYSIOL, V255, pH1269, DOI 10.1152/ajpheart.1988.255.6.H1269; HALLIWELL B, 1991, AM J MED, V91, pS14, DOI 10.1016/0002-9343(91)90279-7; ISRAEL N, 1992, J IMMUNOL, V149, P3386; KENNEY JS, 1987, J IMMUNOL, V138, P4236; KOGA S, 1992, J CLIN INVEST, V90, P1007, DOI 10.1172/JCI115913; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MATSUBARA T, 1986, J IMMUNOL, V137, P3295; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MCCORD JM, 1987, FASEB J, V46, P2402; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; METINKO AP, 1992, J CLIN INVEST, V90, P791, DOI 10.1172/JCI115953; MIELKE V, 1990, J IMMUNOL, V144, P153; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; PEREZ HD, 1980, INFLAMMATION, V4, P313, DOI 10.1007/BF00915032; PETRONE WF, 1980, P NATL ACAD SCI-BIOL, V77, P1159, DOI 10.1073/pnas.77.2.1159; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; ROSEN GM, 1984, P NATL ACAD SCI-BIOL, V81, P7269, DOI 10.1073/pnas.81.23.7269; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SHINGU M, 1984, AM J PATHOL, V117, P201; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; STRIETER RM, 1989, J BIOL CHEM, V264, P10621; TAWARA T, 1991, INFLAMMATION, V15, P145, DOI 10.1007/BF00917509; THORNTON AJ, 1990, J IMMUNOL, V144, P2609; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WHARRAM BL, 1991, J IMMUNOL, V146, P1437; 1991, NEW ENGL J MED, V342, P509	41	352	356	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25568	25576						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244994				2022-12-25	WOS:A1993MK10000045
J	FURUKAWA, KI; SAKAI, K; WATANABE, S; MARUYAMA, K; MURAKAMI, M; YAMAGUCHI, K; OHIZUMI, Y				FURUKAWA, KI; SAKAI, K; WATANABE, S; MARUYAMA, K; MURAKAMI, M; YAMAGUCHI, K; OHIZUMI, Y			GONIODOMIN-A INDUCES MODULATION OF ACTOMYOSIN ATPASE ACTIVITY MEDIATED THROUGH CONFORMATIONAL CHANGE OF ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE CONTRACTION; MYOSIN SUBFRAGMENT-1; TROPOMYOSIN-TROPONIN; HEAVY-CHAIN; F-ACTIN; BINDING; POLYMERIZATION; XESTOQUINONE; MECHANISM; PUREALIN	Goniodomin A, one of the polyether macrolides, isolated from the dinoflagellate Goniodoma pseudogoniaulax stimulated skeletal actomyosin ATPase activity 2-3 times, with a peak at 3 x 10(-8) to 3 x 10(-7) M. The effect of goniodomin A was dependent on the concentration of actin, but not of myosin. The actomyosin ATPase activity was increased by pretreatment of actin (but not of myosin) with goniodomin A. Goniodomin A induced a sustained and concentration-dependent increase in the fluorescence intensity (excitation wavelength, 277 nm; emission wavelength, 329 nm) of actin. The maximum response was obtained with concentrations of goniodomin A in the 10(-5) to 10(-4) M range in the presence of 5 muM F-actin. However, the ATPase activity and fluorescence intensity of myosin were not changed by goniodomin A at concentrations from 10(-8) to 10(-5) M. Interestingly, goniodomin A induced a remarkable but transient increase in the fluorescence intensity of actomyosin in a concentration-dependent manner, with a peak at 3 X 10(-7) M. This profile was quite similar to that found in the stimulation of the actomyosin ATPase activity induced by goniodomin A. To investigate further the effect of goniodomin A, actin was labeled with N-(1-pyrenyl)iodoacetamide. Goniodomin A at 10(-6) M had no effect on the fluorescence intensity of pyrenyl-actin (excitation wavelength, 365 nm; emission wavelength, 407 nm), but increasing concentrations of goniodomin A to 3 x 10(-6) M remarkably decreased its intensity. This effect was potentiated by heavy meromyosin. Actin molecules treated with goniodomin A were completely sedimented by mild centrifugation (for 15 min at 12,000 x g). Electron microscopic observations suggest that actin filaments associate with each other to form a gel in the presence of 3 x 10(-6) M goniodomin A. The conformational change of actin molecules, resulting from stoichiometric binding of goniodomin A to actin monomers in filaments, may modify the interaction between actin and myosin.	TOHOKU UNIV,INST PHARMACEUT,DEPT PHARMACEUT MOLEC BIOL,AOBA KU,SENDAI,MIYAGI 980,JAPAN; CHIBA UNIV,FAC SCI,DEPT BIOL,INAGE KU,CHIBA 263,JAPAN; UNIV TOKYO,FAC AGR,MARINE BIOCHEM LAB,BUNKYO KU,TOKYO 113,JAPAN	Tohoku University; Chiba University; University of Tokyo			Furukawa, Ken-Ichi/N-9244-2014	Furukawa, Ken-Ichi/0000-0002-5680-007X				CHALOVICH JM, 1981, J BIOL CHEM, V256, P575; CHAN KM, 1986, ANAL BIOCHEM, V157, P375, DOI 10.1016/0003-2697(86)90640-8; COOKE R, 1982, METHOD ENZYMOL, V85, P574; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; ELSALEH SC, 1986, J MUSCLE RES CELL M, V7, P387, DOI 10.1007/BF01753582; HANNON JD, 1993, BIOPHYS J, V64, P1632, DOI 10.1016/S0006-3495(93)81517-0; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; Inoue A, 1979, Adv Biophys, V13, P1; KOBAYASHI M, 1991, J PHARMACOL EXP THER, V257, P82; KOBAYASHI M, 1991, J PHARMACOL EXP THER, V257, P90; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LABBE JP, 1982, BIOCHEMISTRY-US, V21, P6897, DOI 10.1021/bi00269a042; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MORNET D, 1981, NATURE, V292, P301, DOI 10.1038/292301a0; MURAKAMI M, 1988, TETRAHEDRON LETT, V29, P1149, DOI 10.1016/S0040-4039(00)86674-5; NAKAMURA Y, 1987, EUR J BIOCHEM, V167, P1, DOI 10.1111/j.1432-1033.1987.tb13296.x; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUTOH K, 1983, BIOCHEMISTRY-US, V22, P1579, DOI 10.1021/bi00276a009; TAKITO J, 1986, J BIOL CHEM, V261, P3861	22	51	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					26026	26031						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245035				2022-12-25	WOS:A1993MK10000104
J	WATANABE, A; HASEGAWA, M; SUZUKI, M; TAKIO, K; MORISHIMAKAWASHIMA, M; TITANI, K; ARAI, T; KOSIK, KS; IHARA, Y				WATANABE, A; HASEGAWA, M; SUZUKI, M; TAKIO, K; MORISHIMAKAWASHIMA, M; TITANI, K; ARAI, T; KOSIK, KS; IHARA, Y			IN-VIVO PHOSPHORYLATION SITES IN FETAL AND ADULT RAT-TAU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMER-LIKE STATE; PROTEIN-KINASE-C; NEUROFIBRILLARY TANGLES; DISEASE; EXPRESSION; SEQUENCE; EPITOPES; BRAIN; ELECTROPHORESIS	Fetal tau and tau in paired helical filaments show similar immunoreactivities with several phosphorylation-dependent paired helical filament-polyclonals and monoclonals, suggesting that the two molecules share several distinct phosphorylated epitopes. To make clear the similarities and differences between the two, we have undertaken work to identify the in vivo phosphorylation sites in fetal rat tau. We have approached this problem by identifying phosphopeptides by means of mass spectrometry and sequencing of those phosphopeptides after modification with ethanethiol. Although remarkable heterogeneity was present, fetal tau was found to bear at most 10 phosphates at Ser-189, Ser-190, Ser-193, Ser-226, Ser-387, Ser-395, Thr-172, Thr-222, and, presumably, Ser-391 and Thr-208 (numbering is according to the longest form of rat tau; Kosik, K. S., Orecchio, L. D., Bakalis, S., and Neve, R. L. (1989) Neuron 2, 1389-1397). In contrast, adult rat tau was much less phosphorylated; only Thr-172, Ser-190, Ser-193, Thr-222, and Ser-395 were phosphorylated to a slight-to-moderate extent. All these sites except for Ser-189 and Ser-391 were followed by Pro residues. Thus, tau is an in vivo substrate for proline-directed protein kinase(s), and its phosphorylation state is developmentally regulated.	UNIV TOKYO,FAC MED,INST BRAIN RES,DEPT NEUROPATHOL,TOKYO 113,JAPAN; SCI UNIV TOKYO,FAC SCI & TECHNOL,DEPT APPL BIOL SCI,NODA,CHIBA 278,JAPAN; INST PHYS & CHEM RES,DIV BIOMOLEC CHARACTERIZAT,WARO,SAITAMA 35101,JAPAN; INST PHYS & CHEM RES,BIODESIGN RES GRP,WAKO,SAITAMA 35101,JAPAN; FUJITA HLTH UNIV,SCH MED,INST COMPREHENS MED SCI,DIV BIOMED POLYMER SCI,TOYOAKE,AICHI 47011,JAPAN; HARVARD UNIV,BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115	University of Tokyo; Tokyo University of Science; RIKEN; RIKEN; Fujita Health University; Harvard University; Brigham & Women's Hospital								ARIOKA M, 1993, J NEUROCHEM, V60, P461, DOI 10.1111/j.1471-4159.1993.tb03173.x; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BUTLER M, 1986, J NEUROCHEM, V47, P1517, DOI 10.1111/j.1471-4159.1986.tb00788.x; CORREAS I, 1992, J BIOL CHEM, V267, P15721; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOEDERT M, 1992, FEBS LETT, V312, P95, DOI 10.1016/0014-5793(92)81418-L; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HASEGAWA M, 1993, J NEUROCHEM, V60, P2068, DOI 10.1111/j.1471-4159.1993.tb03491.x; HASEGAWA M, 1990, NEURON, V4, P909, DOI 10.1016/0896-6273(90)90144-5; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HOSHI M, 1987, FEBS LETT, V217, P237, DOI 10.1016/0014-5793(87)80670-1; IHARA Y, 1990, GERONTOLOGY, V36, P15; IHARA Y, 1986, J BIOCHEM-TOKYO, V99, P1807, DOI 10.1093/oxfordjournals.jbchem.a135662; ISHIGURO K, 1988, J BIOCHEM-TOKYO, V104, P319, DOI 10.1093/oxfordjournals.jbchem.a122465; ISHIGURO K, 1992, NEUROSCI LETT, V148, P202, DOI 10.1016/0304-3940(92)90839-Y; ISHIGURO K, 1993, FEBS LETT, V325, P167, DOI 10.1016/0014-5793(93)81066-9; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; IWATSUBO T, 1992, AM J PATHOL, V140, P277; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KANEMARU K, 1992, J NEUROCHEM, V58, P1667, DOI 10.1111/j.1471-4159.1992.tb10039.x; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KSIEZAKREDING H, 1990, J NEUROSCI RES, V25, P420, DOI 10.1002/jnr.490250320; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEW J, 1992, J BIOL CHEM, V267, P25922; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; MAWALDEWAN M, 1992, J BIOL CHEM, V267, P19705; MEYER HE, 1991, METHOD ENZYMOL, V201, P169; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; VULLIET R, 1992, J BIOL CHEM, V267, P22570; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; YOSHIDA H, 1993, J NEUROCHEM, V61, P1183, DOI 10.1111/j.1471-4159.1993.tb03642.x	43	221	225	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25712	25717						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245007				2022-12-25	WOS:A1993MK10000063
J	SCHULZ, RA; HOGUE, DA; THE, SM				SCHULZ, RA; HOGUE, DA; THE, SM			CHARACTERIZATION OF LETHAL ALLELES OF D-ELG, AN ETS PROTOONCOGENE RELATED GENE WITH MULTIPLE FUNCTIONS IN DROSOPHILA DEVELOPMENT	ONCOGENE			English	Article							POSTERIOR DETERMINANT; FAMILY; LOCALIZATION; POLARITY; DOMAIN; MELANOGASTER; SEQUENCE; PRODUCT; EMBRYO; OSKAR	We have used genetic complementation rescue to identify two lethal alleles of D-elg, an ets proto-oncogene related gene of Drosophila. Animals that are hemizygous or trans-heterozygous for the alleles die as pharate adults, demonstrating normal gene function is required to complete Drosophila development. Females trans-heterozygous for the 1(3)902 lethal allele and the previously characterized tne female sterile allele produce embryos with abdominal segmentation defects. This finding implicates a role for the D-elg gene in anterior-posterior patterning. The cloning and sequencing of the lethal alleles identified molecular mutations that may result in ELG protein truncation, altered ELG protein interactions, or defective D-elg mRNA splicing.			SCHULZ, RA (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; Ashburner M, 1989, DROSOPHILA LAB HDB, P139; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; GALEWSKY S, 1990, GENE, V96, P227, DOI 10.1016/0378-1119(90)90257-R; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLAMBT C, 1993, DEVELOPMENT, V117, P163; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LINDSLEY DL, 1992, GENOME DROSOPHILA MA; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MITCHISON TJ, 1983, DEV BIOL, V99, P261, DOI 10.1016/0012-1606(83)90275-0; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; PRIBYL LJ, 1991, ONCOGENE, V6, P1175; SCHULZ RA, 1993, IN PRESS P NATL ACAD; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; STJOHNSTON D, 1992, CELL, V68, P201; THE SM, 1992, ONCOGENE, V7, P2471; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; VANDAAL A, 1992, MOL BIOL CELL, V3, P593, DOI 10.1091/mbc.3.6.593; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; Wieschaus E., 1986, P199	28	7	7	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3369	3374						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247539				2022-12-25	WOS:A1993MG78200021
J	DESBOIS, C; HOGUE, DA; KARSENTY, G				DESBOIS, C; HOGUE, DA; KARSENTY, G			THE MOUSE OSTEOCALCIN GENE-CLUSTER CONTAINS 3 GENES WITH 2 SEPARATE SPATIAL AND TEMPORAL PATTERNS OF EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; MATRIX GLA-PROTEIN; CRYSTAL-GROWTH; BONE; INHIBITOR; STONES	Osteocalcin is the most abundant noncollagenous protein of bone. Here we report that the mouse genome contains an osteocalcin cluster composed of three genes arranged within a 23-kilobase span of genomic DNA. We named them osteocalcin gene 1 (OG1), osteocalcin gene 2 (OG2), and osteocalcin-related gene (ORG) in order from the 5' end to the 3' end of the cluster. Hybridization of polymerase chain reaction-amplified cDNAs with specific oligonucleotides and RNase protection assays showed that OG1 and OG2 are expressed only in bone, whereas ORG is transcribed in kidney but not in bone. Furthermore, during embryogenesis, OG1 and OG2 begin to be expressed at day 15.5, while ORG is transcribed as early as day 10.5. The protein encoded by ORG has a similar pattern of expression and identical structural features to nephrocalcin, a calcium-binding protein partially purified from kidney that plays a role in calcium reabsorption and in prevention of nephrolithiasis. The nephrocaicin gene has not been cloned in any species; we propose that ORG is the mouse nephrocalcin gene. The existence of several osteocalcin or osteocalcin-related sequences is not restricted to mouse but is present in every species we examined.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Morris, Christelle/M-8168-2014	Morris, Christelle/0000-0003-1575-4609	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR041059] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41059-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; COE FL, 1992, NEW ENGL J MED, V327, P1141, DOI 10.1056/NEJM199210153271607; DEYL Z, 1980, H-S Z PHYSIOL CHEM, V361, P1767, DOI 10.1515/bchm2.1980.361.2.1767; FRASER JD, 1988, J BIOL CHEM, V263, P11033; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; JOHANNES FJ, 1992, TRENDS GENET, V8, P48; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LIAN J, 1989, P NATL ACAD SCI USA, V86, P1143, DOI 10.1073/pnas.86.4.1143; NAKAGAWA Y, 1987, J CLIN INVEST, V79, P1782, DOI 10.1172/JCI113019; NAKAGAWA Y, 1983, J BIOL CHEM, V258, P2594; OH Y, 1992, J BIOL CHEM, V267, P18498; POSER JW, 1980, J BIOL CHEM, V255, P8685; POSER JW, 1979, J BIOL CHEM, V254, P431; PRICE PA, 1982, P NATL ACAD SCI-BIOL, V79, P7734, DOI 10.1073/pnas.79.24.7734; ROMBERG RW, 1986, BIOCHEMISTRY-US, V25, P1176, DOI 10.1021/bi00353a035; RUGH R, 1990, MOUSE ITS REPRODUCTI, P216; TERMINE JD, 1980, CALCIFIED TISSUE INT, V31, P247, DOI 10.1007/BF02407188; TROUTT AB, 1992, P NATL ACAD SCI USA, V89, P9823, DOI 10.1073/pnas.89.20.9823	18	193	198	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1183	1190						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288580				2022-12-25	WOS:A1994MR22000066
J	ARUNACHALAM, U; MASSEY, V; MILLER, SM				ARUNACHALAM, U; MASSEY, V; MILLER, SM			MECHANISM OF P-HYDROXYPHENYLACETATE-3-HYDROXYLASE - A 2-PROTEIN ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARA-HYDROXYBENZOATE HYDROXYLASE; PHENOL HYDROXYLASE; HALF-REACTION; INTERMEDIATE; PURIFICATION	p-Hydroxyphenylacetate-3-hydroxylase purified from Pseudomonas putida is a two-protein enzyme requiring a flavoprotein and a coupling protein for productive hydroxylation (Arunachalam, U., Massey, V., and Vaidyanathan, C. S. (1992) J. Biol. Chem. 267,25848-25855). This paper presents information on the mechanism of the enzyme from absorbance and fluorescence stopped-flow studies. The reduction of the substrate-free flavoprotein by NADH was slow and was not altered by the presence of the coupling protein. In contrast, the coupling protein has a dramatic effect in the oxidative half-reaction. The flavoprotein when present alone, both in the absence and presence of the aromatic substrate, reacts in a second-order fashion with oxygen to form oxidized flavoprotein, with no indication of flavin-oxygen intermediates. However, an intermediate identified as the C4a-flavin hydroperoxide is stabilized when the flavoprotein-coupling protein complex reacts with oxygen in the absence of the aromatic substrate, p-hydroxyphenylacetate, and at least three flavin-oxygen intermediates, attributed to the anionic (I) and protonated (I*) forms of the flavin hydroperoxide and the hydroxyflavin (III), are formed in the oxidative half-reaction in the presence of the aromatic substrate. A reaction mechanism for the two-protein complex is proposed in which the aromatic substrate has little effect on the rate of reduction of the enzyme flavin but has strict control in the oxidative half-reaction. In this phase the flavin hydroperoxide is remarkably stable in the absence of the substrate but disappears rapidly upon encountering the aromatic substrate.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM011106, R01GM011106] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-11106] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RF, 1990, J BIOL CHEM, V265, P1952; ARUNACHALAM U, 1992, J BIOL CHEM, V267, P2584; Ballou D. P., 1984, FLAVINS FLAVOPROTEIN, P605; BEATY NB, 1980, J BIOL CHEM, V255, P3817; BEATY NB, 1981, J BIOL CHEM, V256, P4611; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; BRISSETTE P, 1989, ANAL BIOCHEM, V181, P234, DOI 10.1016/0003-2697(89)90235-2; DETMER K, 1985, J BIOL CHEM, V260, P5998; ENTSCH B, 1991, J BIOL CHEM, V266, P17341; ENTSCH B, 1989, BIOCHIM BIOPHYS ACTA, V999, P313, DOI 10.1016/0167-4838(89)90014-9; ENTSCH B, 1974, BIOCHEM BIOPH RES CO, V57, P1018, DOI 10.1016/0006-291X(74)90798-0; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; HOWELL LG, 1972, J BIOL CHEM, V247, P4340; HUSAIN M, 1979, J BIOL CHEM, V254, P6657; MAEDAYORITA K, 1993, J BIOL CHEM, V268, P4134; Massey V, 1990, FLAVINS FLAVOPROTEIN, P59; SCHOPFER LM, 1979, J BIOL CHEM, V254, P634; STRICKLAND S, 1973, J BIOL CHEM, V248, P2944; TAYLOR MG, 1990, J BIOL CHEM, V265, P13687; VERVOORT J, 1986, BIOCHEMISTRY-US, V25, P8062, DOI 10.1021/bi00372a040; WHITESTE.RH, 1970, BIOCHEM BIOPH RES CO, V38, P882, DOI 10.1016/0006-291X(70)90803-X	21	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					150	155						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276789				2022-12-25	WOS:A1994MR21900031
J	CLAGUE, MJ; URBE, S; ANIENTO, F; GRUENBERG, J				CLAGUE, MJ; URBE, S; ANIENTO, F; GRUENBERG, J			VACUOLAR ATPASE ACTIVITY IS REQUIRED FOR ENDOSOMAL CARRIER VESICLE FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADP-RIBOSYLATION FACTOR; FUSION INVITRO; ENDOCYTIC PATHWAYS; CELLS; ACIDIFICATION; PROTEIN; BINDING; PH	A proton pump, the vacuolar ATPase, is known to generate the acidic lumenal environment of endosomes and lysosomes. We have investigated the role of the vacuolar ATPase in endocytic membrane traffic by combining electron microscopy in vivo with a cell-free assay that reconstitutes endosome fusion in vitro. Our observations show that inactivation of this proton pump with bafilomycin A1 has no significant effects on internalization or recycling back to the plasma membrane. However, early endosomes become highly tubular and endocytosed markers do not appear in late endosomes. Our data strongly suggest that, upon inactivation of the proton pump, the formation of a vesicular intermediate between early and late endosomes, which we term endosomal carrier vesicle, is impaired.	UNIV LIVERPOOL,DEPT PHYSIOL,POB 147,CROWN ST,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool	CLAGUE, MJ (corresponding author), EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY.		Aniento, Fernando/G-9781-2015; Clague, Michael/A-7199-2008	Aniento, Fernando/0000-0003-3553-585X; Clague, Michael/0000-0003-3355-9479; Urbe, Sylvie/0000-0003-4735-9814				ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ANIENTO F, 1993, IN PRESS J CELL BIOL; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; FUCHS R, 1989, J BIOL CHEM, V264, P2212; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Griffiths G, 1991, Trends Cell Biol, V1, P5, DOI 10.1016/0962-8924(91)90047-D; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; GRUENBERG J, 1992, PROTEIN TARGETING PR, P187; HARFORD J, 1983, J BIOL CHEM, V258, P3191; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LUDWIG T, 1991, J CELL BIOL, V115, P1561, DOI 10.1083/jcb.115.6.1561; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Murphy R F, 1991, Trends Cell Biol, V1, P77, DOI 10.1016/0962-8924(91)90022-2; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; PARTON RG, 1992, J CELL BIOL, V119, P123, DOI 10.1083/jcb.119.1.123; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; YILLA M, 1993, J BIOL CHEM, V268, P19092; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619	28	353	353	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					21	24						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276796				2022-12-25	WOS:A1994MR21900006
J	DOUGHERTY, BA; VANDERIJN, I				DOUGHERTY, BA; VANDERIJN, I			MOLECULAR CHARACTERIZATION OF HASA FROM AN OPERON REQUIRED FOR HYALURONIC-ACID SYNTHESIS IN GROUP A STREPTOCOCCI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; CAPSULE EXPRESSION; RHIZOBIUM-MELILOTI; SACCHAROMYCES-CEREVISIAE; SEQUENCE-ANALYSIS; CHITIN SYNTHESIS; S-CEREVISIAE; GENE; NODULATION; SYNTHASE	The mechanism by which group A streptococci produce the antiphagocytic hyaluronate (hyaluronic acid) capsule is incompletely understood. Enzymes known to be essential for synthesis of this polysaccharide include the membrane-associated hyaluronate synthase as well as those required for production of the substrate sugars UDP-N-acetylglucosamine and UDP-glucuronic acid. In this study, a Tn916 insertion that inactivates hyaluronate synthetic activity was localized to a gene designated hasA in the hyaluronic acid synthesis operon. This gene has recently been preliminarily identified as the group A streptococcal hyaluronate synthase. The DNA sequence and transcription start site of hasA were determined, and the predicted HasA protein was shown to have characteristics of a membrane protein. Amino acid sequence homology suggests that HasA is related to a family of proteins involved in polysaccharide production and cell differentiation. Finally, in addition to the loss of hyaluronate synthase activity, the hasA=Tn916 insertion was demonstrated to correlate with a loss of UDP-glucuronic acid dehydrogenase activity. These results suggest that the genes required for hyaluronate synthase activity and production of the UDP-glucuronic acid substrate are transcribed as a unit in group A streptococci.	WAKE FOREST UNIV, MED CTR, WINSTON SALEM, NC 27157 USA	Wake Forest University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007401] Funding Source: NIH RePORTER; NCI NIH HHS [CA12107] Funding Source: Medline; NHLBI NIH HHS [HL 30069] Funding Source: Medline; NIAID NIH HHS [T32-AI-07401] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUSTRIAN R, 1959, J EXP MED, V110, P585, DOI 10.1084/jem.110.4.585; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; AUYOUNG J, 1990, MOL MICROBIOL, V4, P197, DOI 10.1111/j.1365-2958.1990.tb00587.x; BOULNOIS GJ, 1990, CURR TOP MICROBIOL, V150, P1; BULAWA CE, 1986, CELL, V46, P213, DOI 10.1016/0092-8674(86)90738-5; BULAWA CE, 1992, MOL CELL BIOL, V12, P1764, DOI 10.1128/MCB.12.4.1764; BULAWA CE, 1991, NATURE, V353, P710, DOI 10.1038/353710b0; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLEWELL DB, 1988, J BACTERIOL, V170, P3046, DOI 10.1128/jb.170.7.3046-3052.1988; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOUGHERTY BA, 1993, J BIOL CHEM, V268, P7118; DOUGHERTY BA, 1992, J EXP MED, V175, P1291, DOI 10.1084/jem.175.5.1291; FARBER BF, 1990, J INFECT DIS, V161, P37, DOI 10.1093/infdis/161.1.37; FISCHETTI VA, 1971, J EXP MED, V133, P1105, DOI 10.1084/jem.133.5.1105; FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0; FOLEY MJ, 1959, J EXP MED, V110, P617, DOI 10.1084/jem.110.4.617; GLASER L, 1955, P NATL ACAD SCI USA, V41, P253, DOI 10.1073/pnas.41.5.253; HAMADA S, 1980, MICROBIOL REV, V44, P331, DOI 10.1128/MMBR.44.2.331-384.1980; Hirst GK, 1941, J EXP MED, V73, P493, DOI 10.1084/jem.73.4.493; HUANG TT, 1989, INFECT IMMUN, V57, P502, DOI 10.1128/IAI.57.2.502-506.1989; JACOBS TW, 1985, J BACTERIOL, V162, P469, DOI 10.1128/JB.162.2.469-476.1985; JAHNIG F, 1990, TRENDS BIOCHEM SCI, V15, P93, DOI 10.1016/0968-0004(90)90188-H; JOHN M, 1988, EMBO J, V7, P583, DOI 10.1002/j.1460-2075.1988.tb02850.x; JOHNSON BH, 1958, J INFECT DIS, V103, P135, DOI 10.1093/infdis/103.2.135; Kass EH, 1944, J EXP MED, V79, P319, DOI 10.1084/jem.79.3.319; KUYPERS JM, 1989, INFECT IMMUN, V57, P3058, DOI 10.1128/IAI.57.10.3058-3065.1989; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAPLACE F, 1989, FEMS MICROBIOL LETT, V65, P89, DOI 10.1016/0378-1097(89)90371-6; LEE CY, 1992, MOL MICROBIOL, V6, P1515, DOI 10.1111/j.1365-2958.1992.tb00872.x; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LONG SR, 1989, ANNU REV GENET, V23, P483, DOI 10.1146/annurev.ge.23.120189.002411; LUDWIG W, 1985, J GEN MICROBIOL, V131, P543; MARKOVITZ A, 1959, J BIOL CHEM, V234, P2343; MARKOVITZ A, 1977, SURFACE CARBOHYDRATE, P415; MCCARTY M, 1990, MICROBIOLOGY, P525; MORRISON DA, 1990, MOL MICROBIOL, V4, P1143, DOI 10.1111/j.1365-2958.1990.tb00689.x; ROBBINS PW, 1967, SCIENCE, V158, P1536, DOI 10.1126/science.158.3808.1536; ROBERTS IS, 1989, BIOCHEM SOC T, V17, P462, DOI 10.1042/bst0170462; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHILLER JG, 1973, BIOCHIM BIOPHYS ACTA, V293, P1, DOI 10.1016/0005-2744(73)90369-0; Seastone CV, 1939, J EXP MED, V70, P361, DOI 10.1084/jem.70.4.361; SILVERMAN SJ, 1989, YEAST, V5, P459, DOI 10.1002/yea.320050605; SLACK MPE, 1981, LANCET, V2, P502; SMITH EE, 1961, J BIOL CHEM, V236, P2179; STGEME JW, 1991, INFECT IMMUN, V59, P1325, DOI 10.1128/IAI.59.4.1325-1333.1991; TRISCOTT MX, 1986, J BIOL CHEM, V261, P6004; VANDERIJN I, 1983, J BACTERIOL, V156, P1059, DOI 10.1128/JB.156.3.1059-1065.1983; VANDERIJN I, 1992, J BIOL CHEM, V267, P24302; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317; WHITNACK E, 1981, INFECT IMMUN, V31, P985, DOI 10.1128/IAI.31.3.985-991.1981; ZWAHLEN A, 1989, MICROB PATHOGENESIS, V7, P225, DOI 10.1016/0882-4010(89)90058-2	54	97	121	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					169	175						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276791				2022-12-25	WOS:A1994MR21900034
J	PARANANDI, MV; GUZZETTA, AW; HANCOCK, WS; ASWAD, DW				PARANANDI, MV; GUZZETTA, AW; HANCOCK, WS; ASWAD, DW			DEAMIDATION AND ISOASPARTATE FORMATION DURING IN-VITRO AGING OF RECOMBINANT TISSUE-PLASMINOGEN ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CARBOXYL METHYLTRANSFERASE; HUMAN GROWTH-HORMONE; SUCCINIMIDE FORMATION; ASPARAGINYL RESIDUES; SPONTANEOUS DEGRADATION; BOVINE BRAIN; PEPTIDES; ASPARTYL; CALMODULIN; SEQUENCE	When incubated at pH 7.3, 37-degrees-C, human recombinant tissue plasminogen activator accumulated 0.77 mol of isoaspartate per mol of plasminogen activator over a 14-day period. Isoaspartate was detected by enzymatic transfer of H-3-labeled methyl groups from S-adenosyl-L-methionine in a reaction catalyzed by protein L-isoaspartyl methyltransferase. Analysis of tryptic peptides derived from aged plasminogen activator revealed that the two major sites of isoaspartate accumulation resulted from deamidation of Asn58 in the sequence -FNGG- and Asn77 in the sequence -GNSD-. Significant levels of isoaspartate also accumulated via deamidation of Asn37 in the sequence -CNSG-. All three sites occur in sequences predicted from studies with synthetic peptide to be unstable. All three sites appear to be on the surface of the protein, and all three occur in regions of the protein predicted to have higher than average chain mobility. These findings add support to the idea that sequence and flexibility play major roles in determining susceptibility to deamidation and peptide bond isomerization at Asn and Asp sites under mild conditions. These studies also illustrate the utility of enzymatic methylation for characterizing sites of deamidation in a large protein that contains numerous disulfide bonds and several sites of glycosylation.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717; GENENTECH INC,DEPT MED & ANALYT CHEM,S SAN FRANCISCO,CA 94080	University of California System; University of California Irvine; Roche Holding; Genentech					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029421] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-29421] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASWAD DW, 1984, J BIOL CHEM, V259, P714; ASWAD DW, 1990, ANN NY ACAD SCI, V613, P26, DOI 10.1111/j.1749-6632.1990.tb18145.x; Bornstein P, 1977, Methods Enzymol, V47, P132; CHIRPICH T, 1968, THESIS U CALIFORNIA; CHLOUPEK RC, 1989, J CHROMATOGR, V463, P375, DOI 10.1016/S0021-9673(01)84491-5; CLARKE S, 1987, INT J PEPT PROT RES, V30, P808, DOI 10.1111/j.1399-3011.1987.tb03390.x; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; GALLETTI P, 1988, BIOCHEMISTRY-US, V27, P1752, DOI 10.1021/bi00405a055; HENZEL WJ, 1989, J BIOL CHEM, V264, P15905; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1993, J BIOL CHEM, V268, P6174; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; JOHNSON BA, 1991, ANAL BIOCHEM, V192, P384, DOI 10.1016/0003-2697(91)90553-6; JOHNSON BA, 1989, ARCH BIOCHEM BIOPHYS, V268, P276, DOI 10.1016/0003-9861(89)90589-4; JOHNSON BA, 1989, J BIOL CHEM, V264, P14262; JOHNSON BA, 1990, PROTEIN METHYLATION, P195; JONES BN, 1981, J LIQ CHROMATOGR, V4, P565, DOI 10.1080/01483918108059956; KOSSIAKOFF AA, 1988, SCIENCE, V240, P191, DOI 10.1126/science.3353715; LI C, 1992, P NATL ACAD SCI USA, V89, P9885, DOI 10.1073/pnas.89.20.9885; LIU DTY, 1992, TRENDS BIOTECHNOL, V10, P364, DOI 10.1016/0167-7799(92)90269-2; LIU DTY, 1992, TRENDS BIOTECHNOL, V10, P114, DOI 10.1016/0167-7799(92)90192-X; LOWENSON JD, 1990, J BIOL CHEM, V265, P3106; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACFARLANE DE, 1984, J BIOL CHEM, V259, P1357; MANNING MC, 1989, PHARM RES-DORDR, V6, P903, DOI 10.1023/A:1015929109894; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; MURRAY ED, 1986, J BIOL CHEM, V261, P306; OTA IM, 1989, BIOCHEMISTRY-US, V28, P4020, DOI 10.1021/bi00435a058; OTA IM, 1990, PROTEIN METHYLATION, P179; PATEL K, 1990, PHARMACEUT RES, V7, P787, DOI 10.1023/A:1015999012852; POTTER SM, 1993, PROTEIN SCI, V2, P1648, DOI 10.1002/pro.5560021011; RAGONE R, 1989, PROTEIN ENG, V2, P497, DOI 10.1093/protein/2.7.497; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; TYLERCROSS R, 1991, J BIOL CHEM, V266, P22549; WRIGHT HT, 1991, PROTEIN ENG, V4, P283, DOI 10.1093/protein/4.3.283	36	71	72	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					243	253						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276801				2022-12-25	WOS:A1994MR21900045
J	RAMASWAMY, M; YEUNG, AT				RAMASWAMY, M; YEUNG, AT			SEQUENCE-SPECIFIC INTERACTIONS OF UVRABC ENDONUCLEASE WITH PSORALEN INTERSTRAND CROSS-LINKS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED DNA-STRUCTURE; ESCHERICHIA-COLI; (A)BC EXCINUCLEASE; EXCISION NUCLEASE; ENZYMATIC-PROPERTIES; PROTEIN COMPLEX; DAMAGED DNA; INCISION; BINDING; REPAIR	The nature of the Uvr protein-DNA complexes formed on psoralen-DNA interstrand cross-links was analyzed by DNase I footprinting and correlated with the incision efficiency of the UvrABC endonuclease on the cross-links of different DNA sequences. Our results indicate that the repair specificity is dependent on the DNA sequence and the psoralen orientation in the cross-link. On the strand that will be cut, a 30-nucleotide long UvrAB footprint with a DNase I hypersensitive site at the 11th nucleotide 5' to the lesion was observed and subsequently rearranged to a 22-nucleotide long UvrB-lesion footprint. On the strand that will not be cut, the UvrAB- lesion footprint had no 5' DNase I hypersensitive site and did not form the UvrB-lesion footprint. Although UvrABC incision requires the formation of UvrB-lesion complex on the strand which will be cut, the affinities of these complexes do not correlate with the incision efficiencies, suggesting that the overall reaction can be driven forward by a favorable next step such as UvrC incision. A study of the time-dependent interconversion of UvrAB-lesion complex to UvrB-lesion complex on a cross-link revealed a secondary recognition of the UvrB-lesion complex by UvrA2(B) proteins in vitro.	FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NCI NIH HHS [CA06927] Funding Source: Medline; NCRR NIH HHS [RR05539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELGUISEVALLADIER P, 1991, BIOCHEMISTRY-US, V30, P10091, DOI 10.1021/bi00106a005; BERTRANDBURGGRAF E, 1991, J MOL BIOL, V219, P27, DOI 10.1016/0022-2836(91)90854-Y; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.bi.54.070185.005443; GROSSMAN L, 1990, MUTAT RES, V236, P213, DOI 10.1016/0921-8777(90)90006-Q; JONES BK, 1988, P NATL ACAD SCI USA, V85, P8410, DOI 10.1073/pnas.85.22.8410; JONES BK, 1990, J BIOL CHEM, V265, P3489; KUMARESAN KR, 1992, BIOCHEMISTRY-US, V31, P6774, DOI 10.1021/bi00144a018; LIN JJ, 1992, J BIOL CHEM, V267, P17693; MAXAM A, 1980, METHOD ENZYMOL, V65, P498; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; MUNN MM, 1991, J BIOL CHEM, V266, P24748; OH EY, 1989, J BIOL CHEM, V264, P1336; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; ROCHE CJ, 1991, CHEM RES TOXICOL, V4, P311, DOI 10.1021/tx00021a009; RODRIGUEZ H, 1993, BIOCHEMISTRY-US, V32, P1759, DOI 10.1021/bi00058a009; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; SAGE E, 1987, BIOCHEMISTRY-US, V26, P3307, DOI 10.1021/bi00386a010; Sambrook J, 1989, MOL CLONING LABORATO; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SEEBERG E, 1990, P NATL ACAD SCI USA, V87, P191, DOI 10.1073/pnas.87.1.191; SHI Q, 1992, J MOL BIOL, V226, P425, DOI 10.1016/0022-2836(92)90957-L; SNOWDEN A, 1991, J MOL BIOL, V220, P19, DOI 10.1016/0022-2836(91)90378-J; SONG PS, 1979, PHOTOCHEM PHOTOBIOL, V29, P1177, DOI 10.1111/j.1751-1097.1979.tb07838.x; TOMIC MT, 1987, SCIENCE, V238, P1722, DOI 10.1126/science.3686011; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; VANHOUTEN B, 1987, J BIOL CHEM, V262, P13180; VANHOUTEN B, 1986, P NATL ACAD SCI USA, V83, P8077; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VEAUTE X, 1991, NUCLEIC ACIDS RES, V19, P5603, DOI 10.1093/nar/19.20.5603; VISSE R, 1992, J BIOL CHEM, V267, P6736; YEUNG AT, 1988, BIOCHEMISTRY-US, V27, P6332, DOI 10.1021/bi00417a020; YEUNG AT, 1988, NUCLEIC ACIDS RES, V16, P4539, DOI 10.1093/nar/16.10.4539; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157; YEUNG AT, 1988, BIOCHEMISTRY-US, V27, P3204, DOI 10.1021/bi00409a012; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P6157	40	19	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					485	492						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276840				2022-12-25	WOS:A1994MR21900080
J	YING, WL; SEPPLORENZINO, L; CAI, KW; ALOISE, P; COLEMAN, PS				YING, WL; SEPPLORENZINO, L; CAI, KW; ALOISE, P; COLEMAN, PS			PHOTOAFFINITY-LABELING PEPTIDE-SUBSTRATES FOR FARNESYL-PROTEIN TRANSFERASE AND THE INTERSUBUNIT LOCATION OF THE ACTIVE-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; P21RAS FARNESYLTRANSFERASE; CATALYTIC COOPERATIVITY; ISOPRENOID MODIFICATION; PRENYLATED PROTEINS; ALPHA-SUBUNIT; RAT-BRAIN; GERANYLGERANYLTRANSFERASE; F1-ATPASE; SEQUENCE	-CAAX motif peptides, which are substrates for isoprenylation, were synthetically derivatized with the light-sensitive benzophenone (Bz) group in order to determine their potential use as catalytic site-directed covalent photocross-linking ligands for one of the enzymes catalyzing protein isoprenylation, farnesyl-protein transferase (FPTase). Bz-peptides could be synthesized with [H-3]benzophenone and possessed either one or two benzophenone groups located at or near the peptide's NH2 terminus (e.g. the mono-Bz probes Bz-ACVIM and Bz-LPCVVM, and the di-Bz derivatized probe Bz-GY(Bz)PCVVM, referred to as BZ2-GYPCVVM). Each type of derivatized peptide behaved as a substrate for farnesylation in vitro without irradiation, while under 366-nm irradiation each demonstrated covalent cross-linking ability as a catalytic site-directed photoaffinity ligand with tissue-purified or enriched but impure fractions from rat and bovine brain FPTase, as well as with a recombinant human FPTase variant, FPTase(betaalpha(t)) expressed in Escherichia coli. Without photoactivation, Bz-ACVIM yielded a K(d) of 37 nm for the cloned variant of human FPTase. Pseudo first-order photolytic inhibition of FPTase preparations with Bz-peptides, as well as protection from photoinactivation by unmodified -CAAX motif peptides, supported the capacity of these Bz-peptides to serve as co-substrates and their specificity for seeking the catalytic site of the enzyme. SDS-polyacrylamide gel electrophoresis analysis subsequent to photolysis indicated that the mono-Bz-derivatized peptides (e.g. [H-3]Bz-LPCVVM or [H-3]Bz-ACVIM) became covalently cross-linked preferentially to the approximately 49-kDa beta subunit of the alphabeta dimeric FPTase. The farnesyl-PP co-substrate bound equally well to unmodified and Bz-ACVIM-labeled enzyme. The di-Bz derivative, [H-3]Bz2-GYPCVVM, in contrast, revealed exclusive photocovalent cross-linking with a species of molecular mass approximately 95-97 kDa, indicating that both FPTase subunits were tethered together covalently by the di-Bz probe. Similar differential SDS-polyacrylamide gel electrophoresis cross-linking patterns were obtained with homogeneous FPTases as well as with partially purified rat or bovine brain enzyme preparations. The absence of nonspecific photolabeling of any proteins in the partially purified rat or bovine brain enzyme preparations other than FPTase independently attested to the high efficiency of photocross-linking of the FPTase, and the selective catalytic site-seeking ability of these Bz-derivatized peptide substrates, verifying their potential as structural probes for the active site domain on the enzyme. Results with the BZ2-GYPCVVM imply that the catalytic domain on FPTase is comprised of an interfacial cleft at the contact region between alpha and beta subunits, a domain that is shared by both -CAAX and farnesyl substrate moieties.	BOSTON BIOMED RES INST,METAB REGULAT LABS,BOSTON,MA 02114	Boston Biomedical Research Institute								ACKERMAN SH, 1987, J BIOL CHEM, V262, P13765; ADMON A, 1987, BIOCHEMISTRY-US, V26, P3193, DOI 10.1021/bi00385a038; ANDRES DA, 1993, J BIOL CHEM, V268, P1383; BLACK SD, 1992, BIOCHEM BIOPH RES CO, V186, P1437, DOI 10.1016/S0006-291X(05)81567-0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRAUN PE, 1991, J NEUROSCI RES, V30, P540, DOI 10.1002/jnr.490300311; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; Dorman G., 1993, CHEMTRACTS ORG CHEM, V6, P131; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; GORKA J, 1989, Peptide Research, V2, P376; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOHL NE, 1991, J BIOL CHEM, V266, P18884; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; PAL PK, 1990, J BIOL CHEM, V265, P14996; PAL PK, 1992, J BIOL CHEM, V267, P25003; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; REISS Y, 1990, Methods (Orlando), V1, P241, DOI 10.1016/S1046-2023(05)80323-8; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1992, BIOCHEM SOC T, V20, P487, DOI 10.1042/bst0200487; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SEPPLORENZINO L, 1993, IN PRESS J NEUROCHEM; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; STIMMEL JB, 1990, BIOCHEMISTRY-US, V29, P9651, DOI 10.1021/bi00493a021; VOGEL HJ, 1982, J BIOL CHEM, V257, P4834; WILLIAMS KP, 1993, J BIOL CHEM, V268, P5361; WILLIAMS N, 1982, J BIOL CHEM, V257, P2834; YANG ZB, 1993, PLANT PHYSIOL, V101, P667, DOI 10.1104/pp.101.2.667; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055	50	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					470	477						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276838				2022-12-25	WOS:A1994MR21900078
J	GOPALAKRISHNA, R; CHEN, ZH; GUNDIMEDA, U				GOPALAKRISHNA, R; CHEN, ZH; GUNDIMEDA, U			NITRIC-OXIDE AND NITRIC OXIDE-GENERATING AGENTS INDUCE A REVERSIBLE INACTIVATION OF PROTEIN-KINASE-C ACTIVITY AND PHORBOL ESTER BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-NITROSYLATION; REGULATORY DOMAIN; RAT-BRAIN; ACTIVATION; RECEPTOR; SYNTHASE; CELLS; LIPOPOLYSACCHARIDE; PHOSPHORYLATION; TRANSLOCATION	Since S-nitrosylation of protein thiols is one of the cellular regulatory mechanisms induced by nitric oxide (NO), and since protein kinase C (PKC) has critical thiol residues which influence its kinase activity, we have determined whether NO could regulate this enzyme. Initial studies were carried out with purified PKC and the NO-generating agent S-nitrosocysteine. This agent decreased phosphotransferase activity of PKC in a Ca2+- and oxygen-dependent manner with an IC50 of 75 muM. Phorbol ester binding was affected partially only at higher concentrations (>100 muM) of S-nitrosocysteine. This inactivation of PKC was blocked by the NO scavenger oxyhemoglobin or reversed by dithiothreitol. It is likely that NO initially induced an S-nitrosylation of vicinal thiols, which were then oxidized to form an intramolecular disulfide. Other NO-generating agents such as S-nitroso-N-acetylpenicillamine and sodium nitroprusside, as well as authentic NO gas, induced similar types of PKC modifications. In intact B16 melanoma cells treated with S-nitrosocysteine a rapid decrease in PKC activity in both cytosol and membrane was observed. Unlike in experiments with purified PKC, in intact cells treated with S-nitrosocysteine the phorbol ester binding also decreased to a rate equal to that of PKC activity. These modifications were readily reversed by treating the homogenates with dithiothreitol in test tubes or by removing the NO-generating source from intact cells. To determine whether the limited amounts of NO generated within the intact cells could induce this type of PKC modification, the macrophage cell line IC-21 was treated with lipopolysacharide and Ca2+ ionophore A23187 to induce the NO production. With an increase in generation of NO (3-12-h period) in these cells, a parallel and irreversible decrease in PKC activity and phorbol ester binding was observed. A specific inhibitor for NO synthase, N(G)-monomethyl-L-arginine, inhibited both the production of NO and PKC inactivation. In experiments using purified enzyme or intact cells there was no decrease in cAMP-dependent protein kinase activity. Conceivably, NO production for limited time induces a reversible inactivation of PKC due to the formation of a disulfide bridge(s), whereas the chronic production of NO could induce irreversible inactivation of PKC. The reversible or irreversible inactivations of PKC may in part influence NO-mediated cytoprotective or cytotoxic actions, respectively.			GOPALAKRISHNA, R (corresponding author), USC,SCH MED,DEPT PHARMACOL & NUTR,2025 ZONAL AVE,MMR-330,LOS ANGELES,CA 90033, USA.				NATIONAL CANCER INSTITUTE [R29CA047142] Funding Source: NIH RePORTER; NCI NIH HHS [CA47142] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BELL RM, 1991, J BIOL CHEM, V266, P4661; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CLANCY RM, 1993, BIOCHEM BIOPH RES CO, V191, P847, DOI 10.1006/bbrc.1993.1294; CURRAN RD, 1991, FASEB J, V5, P2085, DOI 10.1096/fasebj.5.7.1707021; DIMMELER S, 1992, FEBS LETT, V315, P21; ETOH S, 1991, NEUROSCI LETT, V126, P119, DOI 10.1016/0304-3940(91)90533-Y; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GIRARD P, 1993, FEBS LETT, V320, P7, DOI 10.1016/0014-5793(93)81645-G; GOPALAKRISHNA R, 1992, FEBS LETT, V314, P149, DOI 10.1016/0014-5793(92)80962-G; GOPALAKRISHNA R, 1991, ARCH BIOCHEM BIOPHYS, V285, P382, DOI 10.1016/0003-9861(91)90377-U; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; GOPALAKRISHNA R, 1992, ANAL BIOCHEM, V206, P24, DOI 10.1016/S0003-2697(05)80006-5; GOPALAKRISHNA R, 1978, BIOCHEM MEDICA, V22, P70; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HORTELANO S, 1992, J BIOL CHEM, V267, P24937; HOUSEY GM, 1987, P NATL ACAD SCI USA, V84, P1065, DOI 10.1073/pnas.84.4.1065; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; JAKEN S, 1990, CANCER CELL-MON REV, V2, P401; KASS GEN, 1989, BIOCHEM J, V260, P499, DOI 10.1042/bj2600499; KHAN WA, 1993, J BIOL CHEM, V268, P5063; KIKKAWA U, 1987, FEBS LETT, V223, P212, DOI 10.1016/0014-5793(87)80291-0; KNOWLES RG, 1992, TRENDS BIOCHEM SCI, V17, P399, DOI 10.1016/0968-0004(92)90008-W; LANG D, 1991, BRIT J PHARMACOL, V104, P139, DOI 10.1111/j.1476-5381.1991.tb12398.x; LARSSON R, 1989, CANCER RES, V49, P5627; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; LI LM, 1991, CANCER RES, V51, P2531; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NORONHADUTRA AA, 1993, FEBS LETT, V321, P59, DOI 10.1016/0014-5793(93)80621-Z; PALUMBO EJ, 1992, BIOCHEM BIOPH RES CO, V187, P1439, DOI 10.1016/0006-291X(92)90463-U; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; RASMUSSEN H, 1987, FASEB J, V1, P177, DOI 10.1096/fasebj.1.3.3040504; ROGERS NE, 1992, BIOCHEM BIOPH RES CO, V189, P242, DOI 10.1016/0006-291X(92)91550-A; SEVERN A, 1992, BIOCHEM BIOPH RES CO, V188, P997, DOI 10.1016/0006-291X(92)91330-S; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P8087, DOI 10.1073/pnas.89.17.8087; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TAKAI Y, 1981, BIOCHEM BIOPH RES CO, V101, P61, DOI 10.1016/S0006-291X(81)80010-1; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; WINK DA, 1993, ARCH BIOCHEM BIOPHYS, V300, P115, DOI 10.1006/abbi.1993.1016	46	267	275	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27180	27185						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262958				2022-12-25	WOS:A1993MM26200053
J	MURPHY, BJ; ROSSIE, S; DEJONGH, KS; CATTERALL, WA				MURPHY, BJ; ROSSIE, S; DEJONGH, KS; CATTERALL, WA			IDENTIFICATION OF THE SITES OF SELECTIVE PHOSPHORYLATION AND DEPHOSPHORYLATION OF THE RAT-BRAIN NA+ CHANNEL ALPHA-SUBUNIT BY CAMP-DEPENDENT PROTEIN-KINASE AND PHOSPHOPROTEIN PHOSPHATASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE SODIUM-CHANNELS; RABBIT SKELETAL-MUSCLE; SOMATIC-CELL LINE; FUNCTIONAL MODULATION; XENOPUS-OOCYTES; EXPRESSION; NEURONS	Voltage-sensitive brain Na+ channels are regulated by cAMP-dependent protein kinase (cA-PK) and protein kinase C. Using synthetic peptides and protein microsequencing, we have determined that the a subunit of rat brain Na+ channel is selectively phosphorylated by cA-PK in vitro and in intact cells on 4 serine residues in the intracellular loop connecting homologous domains I and II. Ser-623 was most rapidly and extensively phosphorylated in vitro, whereas Ser-573, Ser-610, and Ser-687 were phosphorylated to lesser extents. In contrast, serine 687 was most extensively phosphorylated in mammalian cells transfected with the alpha subunit of type IIA Na+ channel in response to an increase in intracellular cAMP. Purified protein phosphatases dephosphorylated these sites selectively. Calcineurin rapidly and extensively dephosphorylated Ser-623 and also dephosphorylated Ser-573, Ser-610, and Ser-687 to lesser extents. Phosphatase 2A selectively dephosphorylated Ser-610. Together these results indicate that modulation of neuronal Na+ channel activity and therefore neuronal excitability by cAMP-dependent phosphorylation results from selective phosphorylation and dephosphorylation of four sites in the intracellular loop connecting homologous domains I and II of the alpha subunit.	PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	MURPHY, BJ (corresponding author), UNIV WASHINGTON, DEPT PHARMACOL, SJ-30, SEATTLE, WA 98195 USA.				NINDS NIH HHS [NS31221, NS15751] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031221, R29NS031221, R01NS015751] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; COHEN P, 1988, METHOD ENZYMOL, V159, P427; COHEN P, 1988, METHOD ENZYMOL, V159, P390; COSTA MRC, 1982, J BIOL CHEM, V257, P7918; COSTA MRC, 1984, CELL MOL NEUROBIOL, V4, P291, DOI 10.1007/BF00733592; COSTA MRC, 1984, J BIOL CHEM, V259, P8210; DOUCET JP, 1990, ANAL BIOCHEM, V190, P209, DOI 10.1016/0003-2697(90)90182-9; GERSHON E, 1992, J NEUROSCI, V12, P3743; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1992, NEURON, V8, P1151, DOI 10.1016/0896-6273(92)90135-Z; LOTAN I, 1990, FEBS LETT, V267, P25, DOI 10.1016/0014-5793(90)80279-R; Maizel JV, 1971, METHOD VIROL, V5, P179; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MURPHY BJ, 1992, J BIOL CHEM, V267, P16129; MUSZYNSKA G, 1986, BIOCHEMISTRY-US, V25, P6850, DOI 10.1021/bi00370a018; NAKAYAMA H, 1992, BIOCHIM BIOPHYS ACTA, V1175, P67, DOI 10.1016/0167-4889(92)90010-9; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; ROSSIE S, 1987, J BIOL CHEM, V262, P12735; ROSSIE S, 1989, J BIOL CHEM, V264, P14220; ROSSIE S, 1987, J BIOL CHEM, V262, P17530; ROTMAN EI, 1992, J BIOL CHEM, V267, P16100; SCHACTER E, 1984, ANAL BIOCHEM, V138, P416; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; TALVENHEIMO JA, 1982, J BIOL CHEM, V257, P1868; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P	35	112	112	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27355	27362						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262976				2022-12-25	WOS:A1993MM26200075
J	TANABE, J; FUJITA, H; IWAMATSU, A; MOHRI, H; OHKUBO, T				TANABE, J; FUJITA, H; IWAMATSU, A; MOHRI, H; OHKUBO, T			FIBRONECTIN INHIBITS PLATELET-AGGREGATION INDEPENDENTLY OF RGD SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; VONWILLEBRAND-FACTOR-BINDING; STIMULATED HUMAN-PLATELETS; FIBRINOGEN BINDING; PLASMA FIBRONECTIN; PROTEOLYTIC FRAGMENTS; MONOCLONAL-ANTIBODY; THROMBIN; RECEPTOR; ADHESION	Fibronectin binds to platelet membrane glycoprotein (GP) IIb-IIIa in Arg-Gly-Asp (RGD)-dependent and -independent manners. We have isolated and characterized the 29-kDa dispase fragment of fibronectin. Binding of I-125-fibronectin to thrombin-stimulated platelets was inhibited by the 29-kDa fragment and the GRGDSPA peptide with IC50 values of 1.5 +/- 0.4 and 8.1 +/- 0.9 muM, respectively. The NH2-terminal sequence of this fragment gave this result: Ala-Val-Thr-Thr-Ile-Pro-Ala-Pro-Thr-Asp. This established the position of this peptide within fibronectin as beginning with the residue tentatively designated 1597. Neither the RGDS sequence nor the RGD-independent binding domain of fibronectin (Bowditch, R. D., Halloran, C. E., Aota, S., Obara, M., Plow, E. F., Yamada, K. M., and Ginsberg, M. H. (1991) J. Biol. Chem. 266, 23323-23328) was contained in this fragment. The 29-kDa fragment inhibited ADP-induced aggregation of platelets and binding of fibrinogen to activated platelets. The fragment bound to immobilized GPIIb-IIIa. The I-125-labeled 29-kDa fragment directly bound to thrombin-stimulated platelets with 98,000 +/- 4,600 molecules/platelet (K(d) = 4.6 +/- 0.5 x 10(-6) M). Direct binding was inhibited by the unlabeled 29-kDa fragment but was not blocked by either the GRGDSPA peptide or the monoclonal anti-GPIIb-IIIa antibody. These results indicate that the additional RGD-independent binding domain(s) to GPIIb-IIIa are present on fibronectin. This additional binding domain(s) on fibronectin may prevent thrombus formation by interfering with the interaction of fibrinogen with GPIIb-IIIa.	YOKOHAMA CITY UNIV,SCH MED,DEPT INTERNAL MED 1,3-9 FUKUURA,KANAZAWA KU,YOKOHAMA,KANAGAWA 232,JAPAN; KIRIN BREWERY,CENT LABS KEY TECHNOL,YOKOHAMA 236,JAPAN	Yokohama City University; Kirin Brewery Company Limited								AOYAMA H, 1988, J PROTEIN CHEM, V7, P191; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BERLINER S, 1988, J BIOL CHEM, V263, P7500; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIXIT VM, 1985, P NATL ACAD SCI USA, V82, P3844, DOI 10.1073/pnas.82.11.3844; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FRACKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849; FUJITA H, 1992, JPN J THROMB HAEMOST, V3, P399; GARDNER JM, 1985, CELL, V42, P439, DOI 10.1016/0092-8674(85)90101-1; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1980, P NATL ACAD SCI-BIOL, V77, P1049, DOI 10.1073/pnas.77.2.1049; GINSBERG MH, 1986, FIBRONECTIN ITS ROLE, P86; HANDA M, 1986, J BIOL CHEM, V261, P2579; HOUDIJK WPM, 1985, BLOOD, V65, P598; HOUDIJK WPM, 1985, J CLIN INVEST, V75, P531, DOI 10.1172/JCI111729; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; KOUNS WC, 1992, BLOOD, V80, P2539; LOMBARDO VT, 1985, J CLIN INVEST, V76, P1950, DOI 10.1172/JCI112193; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MOHRI H, 1986, AM J HEMATOL, V22, P391, DOI 10.1002/ajh.2830220408; PARISE LV, 1985, J BIOL CHEM, V260, P698; PARISE LV, 1986, J BIOL CHEM, V261, P14011; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PIOTROWICZ RS, 1988, J CELL BIOL, V106, P1359, DOI 10.1083/jcb.106.4.1359; PLOW EF, 1985, BLOOD, V66, P26; PLOW EF, 1985, BLOOD, V66, P724; PLOW EF, 1981, J BIOL CHEM, V256, P9477; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; WALSH PN, 1977, BRIT J HAEMATOL, V36, P281, DOI 10.1111/j.1365-2141.1977.tb00649.x; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; ZUCKER MB, 1979, BLOOD, V54, P8	36	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27143	27147						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262952				2022-12-25	WOS:A1993MM26200046
J	GORDON, PB; HOLEN, I; FOSSE, M; ROTNES, JS; SEGLEN, PO				GORDON, PB; HOLEN, I; FOSSE, M; ROTNES, JS; SEGLEN, PO			DEPENDENCE OF HEPATOCYTIC AUTOPHAGY ON INTRACELLULARLY SEQUESTERED CALCIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; TRANS-GOLGI NETWORK; PROTEIN-DEGRADATION; ENDOPLASMIC-RETICULUM; AMINO-ACIDS; INOSITOL TRISPHOSPHATE; PROTEOLYTIC ACTIVITY; CA-2+ CONCENTRATION; CA2+ MOBILIZATION; CYTOSOLIC CA-2+	Autophagic sequestration of endogenous lactate dehydrogenase or electroinjected [H-3]raffinose in isolated rat hepatocytes was strongly suppressed by the Ca2+ chelator EGTA, unless the cells had previously been electroloaded in the presence of high concentrations of Ca2+ (1.2 mM. The extracellular Ca2+ chelator bis-(o-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid (BAPTA) and the intracellular Ca2+ chelator BAPTA/tetra(acetoxymethyl)-ester (BAPTA/AM) both inhibited autophagy to the same extent as did EGTA. Inhibitors of C2+2+-activated protein kinases (KN-62, H-7, W-7) had little or no effect on autophagy, indicating that the Ca2+ requirement of autophagy was not mediated by such kinases. Agents that elevate cytoslic Ca2+ by releasing Ca2+ from intracellular stores, like thapsigargin, 2,5-di-(tert-butyl)-1,4-benzohydroquinone (tBuBHQ) and the ionophores A23187 and ionomycin, inhibited autophagy strongly, implicating depletion of sequestered rather than of cytosolic intracellular Ca2+ as a common mechanism of inhibition. Lysosomal (propylamine-sensitive) protein degradation, known to be largely autophagy-dependent, was inhibited by thapsigargin and tBuBHQ. Thapsigargin had no effect on cellular ATP levels, but all agents tested (thapsigargin, tBuBHQ, ionophores) inhibited protein synthesis. Our results suggest that autophagy, like protein synthesis, is dependent on the presence of Ca2+ in some intracellular storage compartment.	NORWEGIAN RADIUM HOSP MONTEBELLO,INST CANC RES,DEPT TISSUE CULTURE,N-0310 OSLO,NORWAY; UNIV OSLO,INST PHYSIOL,N-0317 OSLO,NORWAY	University of Oslo				Holen, Ingunn/0000-0002-8759-6913				ARSTILA AU, 1968, AM J PATHOL, V53, P687; BEER DG, 1982, BIOCHEM BIOPH RES CO, V109, P1276, DOI 10.1016/0006-291X(82)91915-5; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BLACKMORE PF, 1982, J BIOL CHEM, V257, P190; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BROSTROM CO, 1989, J BIOL CHEM, V264, P1644; CARO LHP, 1989, STUDIES REGULATION A, P72; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; DECURTIS I, 1988, P NATL ACAD SCI USA, V85, P8052, DOI 10.1073/pnas.85.21.8052; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GJESSING R, 1980, EXP CELL RES, V129, P239, DOI 10.1016/0014-4827(80)90347-X; GLAUMANN H, 1981, INT REV CYTOL, V73, P149, DOI 10.1016/S0074-7696(08)61288-7; GRINDE B, 1983, BIOCHEM J, V216, P529, DOI 10.1042/bj2160529; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HINCKE MT, 1992, BIOCHEM J, V282, P877, DOI 10.1042/bj2820877; HOLEN I, 1992, BIOCHEM J, V284, P633, DOI 10.1042/bj2840633; KASS GEN, 1990, J BIOL CHEM, V265, P17486; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KASS GEN, 1991, REGULATION HEPATIC F, P344; KIMBALL SR, 1991, BIOCHEM BIOPH RES CO, V177, P1082, DOI 10.1016/0006-291X(91)90649-R; KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941; KOSHIYAMA H, 1991, BIOCHEM BIOPH RES CO, V177, P551, DOI 10.1016/0006-291X(91)92019-G; KOVACS AL, 1981, BIOCHIM BIOPHYS ACTA, V676, P213, DOI 10.1016/0304-4165(81)90189-6; KOVACS AL, 1981, EXP CELL RES, V133, P431, DOI 10.1016/0014-4827(81)90336-0; LANINI L, 1992, J BIOL CHEM, V267, P11548; LEHNINGER AL, 1963, BIOCHEM BIOPH RES CO, V10, P444, DOI 10.1016/0006-291X(63)90377-2; LEW VL, 1982, NATURE, V298, P478, DOI 10.1038/298478a0; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MIZUNO K, 1989, BIOCHEM BIOPH RES CO, V164, P780, DOI 10.1016/0006-291X(89)91527-1; MOORE L, 1975, J BIOL CHEM, V250, P4562; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; NICOTERA P, 1986, J BIOL CHEM, V261, P4628; ODA K, 1992, J BIOL CHEM, V267, P17465; PFEIFER U, 1976, VERH DTSCH GES PATH, V60, P28; PRESTON SF, 1992, CELL CALCIUM, V13, P303, DOI 10.1016/0143-4160(92)90065-Z; PROSTKO CR, 1992, J BIOL CHEM, V267, P16751; RICHTER C, 1991, CHEM-BIOL INTERACT, V77, P1, DOI 10.1016/0009-2797(91)90002-O; RODEMANN HP, 1982, J BIOL CHEM, V257, P8716; ROTNES JS, 1992, CELL CALCIUM, V13, P487, DOI 10.1016/0143-4160(92)90017-M; SCHWORER CM, 1979, P NATL ACAD SCI USA, V76, P3169, DOI 10.1073/pnas.76.7.3169; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; SEGLEN PO, 1979, EUR J BIOCHEM, V95, P215, DOI 10.1111/j.1432-1033.1979.tb12956.x; SEGLEN PO, 1978, BIOCHEM J, V174, P469, DOI 10.1042/bj1740469; SEGLEN PO, 1986, EXP CELL RES, V162, P273, DOI 10.1016/0014-4827(86)90446-5; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Seglen PO, 1987, LYSOSOMES THEIR ROLE, P369; Seglen PO, 1992, ENDOCYTOSIS, P247; SOMLYO AP, 1985, NATURE, V314, P622, DOI 10.1038/314622a0; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; TAKEMURA H, 1991, BIOCHEM BIOPH RES CO, V180, P1518, DOI 10.1016/S0006-291X(05)81368-3; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOKES ZA, 1989, J BIOL CHEM, V264, P15059; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; WICTOME M, 1992, FEBS LETT, V304, P109, DOI 10.1016/0014-5793(92)80599-C; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; WILLIAMSON JR, 1985, AM J PHYSIOL, V248, pC203, DOI 10.1152/ajpcell.1985.248.3.C203; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071; ZAMMIT VA, 1991, BIOCHEM J, V273, P485, DOI 10.1042/bj2730485; ZAMMIT VA, 1991, BIOCHEM J, V279, P377, DOI 10.1042/bj2790377; ZEMAN RJ, 1985, J BIOL CHEM, V260, P3619	66	150	155	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26107	26112						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253727				2022-12-25	WOS:A1993MK42500018
J	NEWMAN, J; GUTTERIDGE, S				NEWMAN, J; GUTTERIDGE, S			THE X-RAY STRUCTURE OF SYNECHOCOCCUS RIBULOSE-BISPHOSPHATE CARBOXYLASE OXYGENASE-ACTIVATED QUATERNARY COMPLEX AT 2.2-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; RIBULOSEBISPHOSPHATE CARBOXYLASE; RHODOSPIRILLUM-RUBRUM; CRYSTAL-STRUCTURE; LARGE SUBUNIT; 1,5-BISPHOSPHATE CARBOXYLASE; SUBSTRATE-SPECIFICITY; ESCHERICHIA-COLI; RUBISCO; SITE	The structure of the hexadecameric ribulose-bisphosphate carboxylase/oxygenase from Synechococcus PCC6301 has been solved to 2.2-angstrom resolution. Crystallization was in the presence of CO2, Mg+, and 2'-carboxyarabinitol bisphosphate to form a stable enzyme quaternary complex that mimics one of the intermediate states of the carboxylation reaction. The structure was solved by molecular replacement using the coordinates of spinach carboxylase. The deviations in Calpha positions of the L- and S-subunits are only 0.3 and 2.0 angstrom, respectively, and localized at specific regions of the two polypeptides. One region that shows significant divergence of the peptide backbone is loop 6 of the beta barrel in the L-subunit. Two other elements, the C terminus, and a highly conserved loop of the N-terminal domain of a second L-subunit, interact with loop 6 in the quaternary complex. These three regions, plus two other flexible segments, completely enfold the bisphosphate inhibitor. Significant alteration in their spatial relationship must occur to allow substrates or products access to and from the active site. The active site residues, activating cofactors, and inhibitor are well resolved in the electron density map. The disposition of these groups around the essential metal provides some indication of their role at different stages of the catalytic cycle.	DUPONT CO INC, EXPTL STN, DEPT CENT RES & DEV, WILMINGTON, DE 19880 USA; BIOMED CTR, DEPT MOLEC BIOL, S-75124 UPPSALA, SWEDEN	DuPont			Newman, Janet M/D-1857-2011	Newman, Janet M/0000-0003-2666-3219				ALLEAUME M, 1985, CAN J CHEM, V63, P3482, DOI 10.1139/v85-571; ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; Andrews T.J., 1987, BIOCH PLANTS, P131, DOI 10.1016/B978-0-12-675410-0.50009-9; ANDREWS TJ, 1985, J BIOL CHEM, V260, P4632; ANDREWS TJ, 1984, PLANT PHYSIOL, V75, P508, DOI 10.1104/pp.75.2.508; ANDREWS TJ, 1988, J BIOL CHEM, V263, P12213; BRANDEN CI, 1991, ACTA CRYSTALLOGR B, V47, P824, DOI 10.1107/S0108768191007127; BRANDEN CI, 1986, PHILOS T ROY SOC B, V313, P359, DOI 10.1098/rstb.1986.0043; CHAPMAN MS, 1988, SCIENCE, V241, P71, DOI 10.1126/science.3133767; CHEN Z, 1989, J BIOL CHEM, V264, P3053; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; CURMI PMG, 1992, J BIOL CHEM, V267, P16980; DECLERCQ JP, 1991, J MOL BIOL, V220, P1017, DOI 10.1016/0022-2836(91)90369-H; ESTELLE M, 1985, J BIOL CHEM, V260, P9523; GERLT JA, 1991, J AM CHEM SOC, V113, P9667, DOI 10.1021/ja00025a039; GUTTERIDGE S, 1990, BIOCHIM BIOPHYS ACTA, V1015, P1, DOI 10.1016/0005-2728(90)90210-U; GUTTERIDGE S, 1986, FEBS LETT, V196, P263, DOI 10.1016/0014-5793(86)80260-5; GUTTERIDGE S, 1993, J BIOL CHEM, V268, P7818; GUTTERIDGE S, 1988, PLANT PHYSIOL BIOCH, V26, P675; GUTTERIDGE S, 1984, EMBO J, V3, P2737, DOI 10.1002/j.1460-2075.1984.tb02204.x; GUTTERIDGE S, 1991, J BIOL CHEM, V266, P7359; GUTTERIDGE S, 1984, FEBS LETT, V170, P355, DOI 10.1016/0014-5793(84)81343-5; GUTTERIDGE S, 1989, BIOCHEM J, V260, P711, DOI 10.1042/bj2600711; GUTTERIDGE S, 1993, IN PRESS MOL PROCESS; HARTMAN FC, 1989, J BIOL CHEM, V264, P11784; HARTMAN FC, 1992, PLANT PROTEIN ENG, P61; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORDAN DB, 1981, NATURE, V291, P513, DOI 10.1038/291513a0; KETTLEBOROUGH CA, 1987, EUR J BIOCHEM, V170, P335, DOI 10.1111/j.1432-1033.1987.tb13704.x; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KOMIVES EA, 1991, BIOCHEMISTRY-US, V30, P3011, DOI 10.1021/bi00226a005; LORIMER GH, 1988, J BIOL CHEM, V263, P6468; LORIMER GH, 1989, J BIOL CHEM, V264, P9873; LORIMER GH, 1988, NATO P PLANT MOL BIO, P21; LUNDQVIST T, 1991, J BIOL CHEM, V266, P12604; LUNDQVIST T, 1988, J BIOL CHEM, V263, P3643; NEWMAN J, 1990, J BIOL CHEM, V265, P15154; NEWMAN J, 1993, IN PRESS ACTA CRYS D, V49; PARRY MAJ, 1989, J EXP BOT, V40, P317, DOI 10.1093/jxb/40.3.317; PARRY MAJ, 1992, PLANTA, V187, P109, DOI 10.1007/BF00201631; PIERCE J, 1986, BIOCHEMISTRY-US, V25, P1636, DOI 10.1021/bi00355a029; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RANTY B, 1991, EUR J BIOCHEM, V200, P353, DOI 10.1111/j.1432-1033.1991.tb16192.x; READ BA, 1992, BIOCHEMISTRY-US, V31, P5553, DOI 10.1021/bi00139a018; SAILLAND A, 1986, PLANT MOL BIOL, V7, P213, DOI 10.1007/BF00021333; SCHLOSS JV, 1990, NATO ADV SCI I C-MAT, V314, P321; SCHNEIDER G, 1990, EMBO J, V9, P2045, DOI 10.1002/j.1460-2075.1990.tb07371.x; SCHNEIDER G, 1986, EMBO J, V5, P3409, DOI 10.1002/j.1460-2075.1986.tb04662.x; SHINOZAKI K, 1983, P NATL ACAD SCI-BIOL, V80, P4050, DOI 10.1073/pnas.80.13.4050; SOLTIS DE, 1990, P NATL ACAD SCI USA, V87, P4640, DOI 10.1073/pnas.87.12.4640; TABITA FR, 1985, P NATL ACAD SCI USA, V82, P6100, DOI 10.1073/pnas.82.18.6100	51	121	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25876	25886						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245022				2022-12-25	WOS:A1993MK10000085
J	SCHODIN, BA; KRANZ, DM				SCHODIN, BA; KRANZ, DM			BINDING-AFFINITY AND INHIBITORY PROPERTIES OF A SINGLE-CHAIN ANTI-T-CELL RECEPTOR ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; LYMPHOCYTES-T; IMMUNE INTERVENTION; TRANSGENIC MICE; FV; RESPONSES; SUPERANTIGENS; RECOGNITION; EXPRESSION	The antigen-specific function of T cells is mediated through a surface receptor (alphabeta). Antibodies to the receptor can either inhibit or activate the T cell depending on the multimeric form of the antibody and the isotype of the antibody constant regions. To further examine and eventually control these antagonistic properties, an anti-receptor antibody (1B2) was engineered by linking the variable region genes of the heavy and light chains to form a single-chain binding domain (scFv). The native 1B2 antibody recognizes determinants on the variable regions of both the alpha and beta subunits of the T cell receptor. The scFv gene was expressed in Escherichia coli, and after folding by dilution of solubilized inclusion bodies, scFv protein was purified as both a 29,000-Da monomer and a noncovalently associated 54,000-Da dimer. The binding affinity of the monomer (K(D) = 17 nM) was 20-fold lower than that of 1B2 Fab fragments (K(D) = 0.9 nM). In contrast, the binding affinity of the dimer (K(D) = 1.6 nM) was approximately 2-fold lower than that of 1B2 Fab fragments. Both forms were able to inhibit recognition by the T cell, but the dimer was significantly more effective than the monomer. Inhibition was observed for T cell recognition of either the conventional ligand (a peptide bound to a class I product of the major histocompatibility complex) or the ''superantigen'' ligand (staphylococcal enterotoxin B bound to a class II product of the major histocompatibility complex). The results suggest that scFv dimers are the most active form of at least some scFv preparations and that the dimers may have the most potential for inhibiting detrimental in vivo T cell activity.	UNIV ILLINOIS,DEPT BIOCHEM,600 S MATHEWS AVE,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign					NIAID NIH HHS [AI24635] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI024635] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; ALLISON JP, 1987, ANNU REV IMMUNOL, V5, P503, DOI 10.1146/annurev.iy.05.040187.002443; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BLAZAR BR, 1993, J IMMUNOL, V150, P265; BRINKMANN U, 1993, J IMMUNOL, V150, P2774; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHOI YW, 1990, NATURE, V346, P471, DOI 10.1038/346471a0; DAVIS GT, 1991, BIO-TECHNOL, V9, P165, DOI 10.1038/nbt0291-165; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; FIELDS LE, 1992, P NATL ACAD SCI USA, V89, P5730, DOI 10.1073/pnas.89.13.5730; FRIEDMAN PN, 1993, J IMMUNOL, V150, P3054; GOSHORN SC, 1993, CANCER RES, V53, P2123; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HIRSCH R, 1990, TRANSPLANTATION, V49, P1117, DOI 10.1097/00007890-199006000-00018; HIRSCH R, 1989, J IMMUNOL, V142, P737; HOO WFS, 1992, P NATL ACAD SCI USA, V89, P4759, DOI 10.1073/pnas.89.10.4759; HOO WS, 1993, J IMMUNOL, V150, P4331; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P7922, DOI 10.1073/pnas.81.24.7922; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P573, DOI 10.1073/pnas.81.2.573; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LIPES MA, 1993, SCIENCE, V259, P1165, DOI 10.1126/science.8267690; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MILENIC DE, 1991, CANCER RES, V51, P6363; MORGANELLI P, 1992, CRIT REV IMMUNOL, V12, P101; PANTOLIANO MW, 1991, BIOCHEMISTRY-US, V30, P10117, DOI 10.1021/bi00106a007; PATTEN PA, 1993, J IMMUNOL, V150, P2281; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; VACCHIO MS, 1992, J EXP MED, V175, P1405, DOI 10.1084/jem.175.5.1405; WALDMANN H, 1989, ANNU REV IMMUNOL, V7, P407, DOI 10.1146/annurev.iy.07.040189.002203; WALDMANN TA, 1992, ANNU REV IMMUNOL, V10, P675, DOI 10.1146/annurev.immunol.10.1.675; WHITLOW M, 1991, Methods (Orlando), V2, P97, DOI 10.1016/S1046-2023(05)80209-9; WOODLAND DL, 1993, J EXP MED, V177, P433, DOI 10.1084/jem.177.2.433; WOODLE ES, 1991, TRANSPLANTATION, V52, P361, DOI 10.1097/00007890-199108000-00034; WRAITH DC, 1989, CELL, V57, P709, DOI 10.1016/0092-8674(89)90786-1; WRIGHT A, 1992, CRIT REV IMMUNOL, V12, P125; YOKOTA T, 1992, CANCER RES, V52, P3402	39	28	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25722	25727						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245009				2022-12-25	WOS:A1993MK10000065
J	BHATTACHARYA, G; LEE, L; REDDY, ESP; RAO, VN				BHATTACHARYA, G; LEE, L; REDDY, ESP; RAO, VN			TRANSCRIPTIONAL ACTIVATION DOMAINS OF ELK-1, DELTA-ELK-1 AND SAP-1 PROTEINS	ONCOGENE			English	Note							ETS-RELATED PROTEIN; LONG TERMINAL REPEAT; DNA-BINDING; C-FOS; C-ETS-1 PROTOONCOGENE; FACTOR P62TCF; SEQUENCES; ONCOGENE; GENE; COOPERATE	elk-1, an ets related gene codes for a sequence specific DNA binding transcriptional activator which in association with serum response factor (SRF) forms a ternary complex at the c-fos serum response element (SRE). Recently the C-terminal region of both elk-1 and Delta elk-1 proteins was shown to undergo phosphorylation by MAP kinases and function as an activator of MAP kinases. Here we show that Delta elk-1 and two other elk-1 related proteins SAP-1a and SAP-1b, like elk-1, can function as transcriptional activators. In this report we have localized the transcriptional activation domain of the SAP-I proteins (STA) to a large portion of the carboxy terminal region and have identified two autonomous transcriptional activation domains in the elk-1 protein, one at the amino (ETA-1) and the other at the carboxy terminal region (ETA-2). Delta elk-1 protein contains only the ETA-2 domain indicating differential usage of activation domains as a result of alternative splicing. We can speculate that the ETA-1 domain can function in vivo independent of ETA-2, but the ETA-2 domain can function either in the absence of ETA-1 (as seen in Delta elk-1) or in the presence of accessory proteins like SRF. The role of SRF in the activation of the ternary complex might be to bind to the ETA-1 domain, somehow conceal it's activation domain and in the process unmask the ETA-2 domain (for phosphorylation by MAP kinases) and activate transcription. The ETA-1 domain may be functioning as a negative regulatory transcriptional activation domain for ETA-2 These observations suggest that the elk-1 family of proteins may not only regulate fos and MAP kinases but also other elk-1 target genes that are essential for cellular growth control.	JEFFERSON CANC INST,PHILADELPHIA,PA 19107; PROGRAMME RESOURCES INC,FREDERICK,MD 21702	Jefferson University								BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MAKI RA, 1993, SCIENCE, V259, P1622; MARIAS R, 1993, CELL, V73, P381; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; RAO VN, 1993, CANCER RES, V53, P3449; RAO VN, 1992, ONCOGENE, V11, P2335; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1991, ONCOGENE, V6, P2285; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; [No title captured]	36	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3459	3464						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247551				2022-12-25	WOS:A1993MG78200033
J	DERIJKE, YB; VANBERKEL, TJC				DERIJKE, YB; VANBERKEL, TJC			RAT-LIVER KUPFFER AND ENDOTHELIAL-CELLS EXPRESS DIFFERENT BINDING-PROTEINS FOR MODIFIED LOW-DENSITY LIPOPROTEINS - KUPFFER CELLS EXPRESS A 95-KDA MEMBRANE-PROTEIN AS A SPECIFIC BINDING-SITE FOR OXIDIZED LOW-DENSITY LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOVINE SERUM-ALBUMIN; ATHEROSCLEROTIC LESIONS; CHOLESTEROL DEPOSITION; PLASMA-LIPOPROTEINS; SCAVENGER RECEPTORS; MACROPHAGE; INVIVO; METABOLISM; DEGRADATION; RECOGNITION	The liver is the major organ responsible for the uptake of oxidized low density lipoproteins (Ox-LDL) from the blood circulation with Kupffer cells as major cellular uptake site. Candidate binding proteins for Ox-LDL on membranes from Kupffer and endothelial liver cells were identified with ligand blots. Under nonreducing conditions, a major binding protein with an estimated molecular mass of 95 kDa and a minor stained protein of 220 kDa were detected on Kupffer cell membranes, while endothelial cell membranes expressed only a 220-kDa binding protein. Both the 95-kDa protein of Kupffer cell membranes and the 220-kDa protein of endothelial membranes displayed saturable binding of I-125-Ox-LDL with a K(d) of 15 and 5 mug/ml, respectively. LDL was a weak competitor for the binding of I-125-Ox-LDL to the 95-kDa protein, while the degree of competition appeared to be dependent on the oxidation grade of LDL with a complete competition with LDL oxidized for 20 h with 10 muM Cu2+. We conclude that the 95-kDa binding protein, highly concentrated on rat Kupffer cells, forms the most likely candidate for mediating the in vivo uptake of Ox-LDL from the blood circulation.	LEIDEN UNIV,LEIDEN AMSTERDAM CTR DRUG RES,DIV BIOPHARMACEUT,SYLVIUS LABS,2312 AV LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC			Van Berkel, Theo/ABD-7677-2021; de Rijke, Yolanda/AAQ-5497-2020					ARAI H, 1989, BIOCHEM BIOPH RES CO, V159, P1375, DOI 10.1016/0006-291X(89)92262-6; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; DERIJKE YB, 1992, J LIPID RES, V33, P1315; DRESEL HA, 1985, EMBO J, V4, P1157, DOI 10.1002/j.1460-2075.1985.tb03754.x; DRESEL HA, 1987, EMBO J, V6, P319, DOI 10.1002/j.1460-2075.1987.tb04757.x; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HAMPTON RY, 1988, J BIOL CHEM, V263, P14802; HORIUCHI S, 1985, J BIOL CHEM, V259, P53; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1979, J CLIN INVEST, V64, P743, DOI 10.1172/JCI109518; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; NAITO M, 1991, KUPFFER CELL F CELLS, V3, P497; OTTNAD E, 1990, BIOCHEM J, V265, P689, DOI 10.1042/bj2650689; OTTNAD E, 1992, BIOCHEM J, V281, P745, DOI 10.1042/bj2810745; OTTNAD E, 1993, 14 P ANN EUR C VASC, P90; PITAS RE, 1985, J CELL BIOL, V100, P103, DOI 10.1083/jcb.100.1.103; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STANTON LW, 1992, J BIOL CHEM, V267, P22446; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Steinberg D., 1988, ATHEROSCLER REV, V18, P1; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; VANBERKEL TJC, 1982, BIOCHEM J, V208, P493, DOI 10.1042/bj2080493; WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	37	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					824	827						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288634				2022-12-25	WOS:A1994MR22000011
J	PARK, IK; ROACH, P; BONDOR, J; FOX, SP; DEPAOLIROACH, AA				PARK, IK; ROACH, P; BONDOR, J; FOX, SP; DEPAOLIROACH, AA			MOLECULAR MECHANISM OF THE SYNERGISTIC PHOSPHORYLATION OF PHOSPHATASE INHIBITOR-2 - CLONING, EXPRESSION, AND SITE-DIRECTED MUTAGENESIS OF INHIBITOR-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT-SKELETAL-MUSCLE; GLYCOGEN-SYNTHASE KINASE-3; DEPENDENT PROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE; SUBUNIT STRUCTURE; REGULATORY SUBUNIT; CATALYTIC SUBUNIT; SEQUENCE-ANALYSIS; IDENTIFICATION; ACTIVATION	Inhibitor-2 (I-2) is the regulatory subunit of the ATP-Mg-dependent phosphatase, a cytosolic form of type 1 protein phosphatase. Phosphorylation of 1-2 at Thr-72 by the protein kinase glycogen synthase kinase-3 (GSK-3) leads to activation of the enzyme. Casein kinase II action was shown to synergistically enhance phosphorylation and activation by GSK-3 (DePaoli-Roach, A. A. (1984) J. Biol. Chem. 259, 12144-12152). Rabbit skeletal muscle and liver I-2 cDNA clones have been isolated. Rabbit skeletal muscle cDNAs could be placed in two subtypes, differing in the length of the 3'-untranslated region. The coding sequence of 612 nucleotides was identical in the two skeletal muscle and the liver cDNAs and predicted a protein of 204 amino acids, consistent with analysis of the purified protein. Northern hybridization analysis indicated that the two mRNAs of 1.7 and 2.7 kilobase pairs were present in all rabbit tissues examined, except in liver, where only the larger transcript was detected, and in testis, where additional transcripts were present. Expression in Escherichia coli of wild-type and phosphorylation site mutants resulted in the production of I-2 polypeptides with apparent M(r) values of approximately 31,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The inhibitory activity of the recombinant proteins was similar to that of native rabbit skeletal muscle I-2 and was unaffected by the substitution of alanine for the GSK-3 site (Thr-72) and for the casein kinase II sites (Ser-86 and Ser-120/121) or by substitution of glutamic acid and aspartic acid for Thr-72 and Ser-86. Recombinant wild-type I-2 and the Ala-120/121 mutant were phosphorylated synergistically by GSK-3 and casein kinase II. The Thr-72 and Ser-86 mutants, however, did not undergo this synergistic phosphorylation. Our studies indicate that Thr-72 is the only GSK-3 site and that Ser-86 is the casein kinase II site required for the potentiation of GSK-3 action. Furthermore, acidic residues cannot substitute for the phosphate group either in enhancing GSK-3 phosphorylation or in activating the phosphatase.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, 635 BARNHILL DR, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036569] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36569] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGOSTINIS P, 1987, FEBS LETT, V224, P385, DOI 10.1016/0014-5793(87)80489-1; ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; BALLOU LM, 1983, BIOCHEMISTRY-US, V22, P3393, DOI 10.1021/bi00283a014; BEULLENS M, 1992, J BIOL CHEM, V267, P16538; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN P, 1973, EUR J BIOCHEM, V34, P1, DOI 10.1111/j.1432-1033.1973.tb02721.x; DePaoli-Roach A A, 1985, FEBS Lett, V183, P423; DEPAOLIROACH AA, 1983, J BIOL CHEM, V258, P702; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; DEPAOLIROACH AA, 1993, FASEB J, V7, pA1157; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; FIOL CJ, 1992, J CELL BIOCH A S, V16, P97; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; GRUPPUSO PA, 1985, J BIOL CHEM, V260, P4288; GUBLER V, 1983, GENE, V25, P264; HEMMINGS BA, 1982, FEBS LETT, V150, P319, DOI 10.1016/0014-5793(82)80760-6; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HOLMES CFB, 1987, BIOCHIM BIOPHYS ACTA, V929, P208, DOI 10.1016/0167-4889(87)90178-9; HOLMES CFB, 1986, BIOCHIM BIOPHYS ACTA, V870, P408, DOI 10.1016/0167-4838(86)90248-7; HOLMES CFB, 1986, EUR J BIOCHEM, V155, P173, DOI 10.1111/j.1432-1033.1986.tb09473.x; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V180, P457, DOI 10.1111/j.1432-1033.1989.tb14668.x; INGEBRITSEN TS, 1980, FEBS LETT, V119, P9, DOI 10.1016/0014-5793(80)80987-2; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAWRENCE JC, 1988, BIOCHEM BIOPH RES CO, V150, P197, DOI 10.1016/0006-291X(88)90505-0; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; Maniatis T., 1982, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; NEWGARD CB, 1986, P NATL ACAD SCI USA, V83, P8132, DOI 10.1073/pnas.83.21.8132; ORGAD S, 1987, EUR J BIOCHEM, V164, P31, DOI 10.1111/j.1432-1033.1987.tb10988.x; OYEN O, 1989, FEBS LETT, V246, P57, DOI 10.1016/0014-5793(89)80253-4; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PONDAVEN P, 1987, EUR J BIOCHEM, V167, P135, DOI 10.1111/j.1432-1033.1987.tb13314.x; PUSKAS R, 1983, ARCH BIOCHEM BIOPHYS, V223, P503, DOI 10.1016/0003-9861(83)90615-X; RAMAKRISHNA S, 1990, BIOCHEMISTRY-US, V29, P7617, DOI 10.1021/bi00485a011; RECHSTEINER M, 1987, BIOCHEM BIOPH RES CO, V143, P194, DOI 10.1016/0006-291X(87)90649-8; ROACH P, 1985, J BIOL CHEM, V260, P6314; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SILVA OBD, 1987, FEBS LETT, V221, P415, DOI 10.1016/0014-5793(87)80966-3; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STALFORS P, 1985, EUR J BIOCHEM, V149, P295; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANG PM, 1991, J BIOL CHEM, V266, P15782; VANPATTEN SM, 1992, MOL ENDOCRINOL, V6, P2114, DOI 10.1210/me.6.12.2114; WALAAS SI, 1984, J NEUROSCI, V4, P84; WANG YH, 1991, P NATL ACAD SCI USA, V88, P2446, DOI 10.1073/pnas.88.6.2446; YANG SD, 1981, J BIOL CHEM, V256, P231; ZHANG WM, 1993, ARCH BIOCHEM BIOPHYS, V304, P219, DOI 10.1006/abbi.1993.1342; ZHANG ZJ, 1992, BIOCHEM BIOPH RES CO, V186, P1168, DOI 10.1016/0006-291X(92)90869-M	61	75	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					944	954						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288648				2022-12-25	WOS:A1994MR22000029
J	WU, KJ; WILSON, DR; SHIH, CH; DARLINGTON, GJ				WU, KJ; WILSON, DR; SHIH, CH; DARLINGTON, GJ			THE TRANSCRIPTION FACTOR HNF1 ACTS WITH C/EBP-ALPHA TO SYNERGISTICALLY ACTIVATE THE HUMAN ALBUMIN PROMOTER THROUGH A NOVEL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; FUNCTIONAL COOPERATIVITY; GENE-EXPRESSION; MAMMALIAN-CELLS; GLUTAMINE-RICH; REPORTER GENE; SEQUENCE; ELEMENTS; INVITRO; DISTINCT	HNF1 and C/EBPalpha are transcription factors that bind to and trans-activate the human albumin gene proximal promoter. Various 5' deletions of the human albumin promoter were coupled to a luciferase reporter gene (alb-luc constructs) and co-electroporated with HNF1 and/or C/EBPalpha expression vectors into HeLa cells. Luciferase activities from co-electroporation of the HNF1 and C/EBPalpha expression vectors with the alb-luc constructs were approximately 10-fold greater than the sum of the activities achieved with HNF1 and C/EBPalpha alone. Analysis of COOH-terminal or internal deletions of the HNF1 expression vector revealed that the domain important for collaborative interaction with C/EBPalpha could be localized to a 157 amino acid region not previously described. This domain is proline and glutamine-rich and is highly homologous (66%) to a portion of vHNF1, an evolutionarily related gene first identified in dedifferentiated hepatoma cells. A construct linking the negatively charged activation domain of herpes simplex virus protein VP16 to the DNA-binding domain of HNF1 showed that it could also synergize with C/EBPalpha to trans-activate the human albumin gene promoter. Our studies delineate a domain in HNF1 important for synergistic activation with C/EBPalpha.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MED BRANCH,DEPT PATHOL,GALVESTON,TX 77550	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Medical Branch Galveston			Wu, Kou-Juey/P-4654-2015; Shih, Chiaho/S-7017-2018		NIDDK NIH HHS [DK36089] Funding Source: Medline; NIGMS NIH HHS [GM32111] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032111] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHIU G, 1987, NUCLEIC ACIDS RES, V15, P1311; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DRIEVER W, 1989, NATURE, V342, P149, DOI 10.1038/342149a0; FOWLKES DM, 1984, P NATL ACAD SCI-BIOL, V81, P2313, DOI 10.1073/pnas.81.8.2313; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HARDWICK JM, 1992, J VIROL, V66, P5500, DOI 10.1128/JVI.66.9.5500-5508.1992; HERBOMEL P, 1989, MOL CELL BIOL, V9, P4750, DOI 10.1128/MCB.9.11.4750; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LAWN RM, 1981, NUCLEIC ACIDS RES, V9, P6103, DOI 10.1093/nar/9.22.6103; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; NICOSIA A, 1990, CELL, V61, P1225, DOI 10.1016/0092-8674(90)90687-A; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; PIRROTTA V, 1987, EMBO J, V6, P791, DOI 10.1002/j.1460-2075.1987.tb04821.x; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; RANEY AK, 1991, J VIROL, V65, P5774, DOI 10.1128/JVI.65.11.5774-5781.1991; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; SADOWSKI I, 1988, NATURE, V335, P559; SCHNEUWLY S, 1986, EMBO J, V5, P733, DOI 10.1002/j.1460-2075.1986.tb04275.x; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRONCHE F, 1991, J MOL BIOL, V221, P31; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; URANO Y, 1986, J BIOL CHEM, V261, P3244; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; WU KJ, 1991, MOL CELL BIOL, V11, P4423, DOI 10.1128/MCB.11.9.4423	52	70	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1177	1182						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288579				2022-12-25	WOS:A1994MR22000065
J	GARRETT, RM; RAJAGOPALAN, KV				GARRETT, RM; RAJAGOPALAN, KV			MOLECULAR-CLONING OF RAT-LIVER SULFITE OXIDASE - EXPRESSION OF A EUKARYOTIC MO-PTERIN-CONTAINING ENZYME IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRATE REDUCTASE; MOLYBDENUM COFACTOR; NUCLEOTIDE-SEQUENCE; CDNA; GENE; DOMAINS; SITE	The cDNA encoding sulfite oxidase has been cloned from a rat liver cDNA library. The gene contains a single open reading frame of 1464 nucleotides encoding a protein of 488 amino acids. The deduced amino acid sequence contains a 22-residue amino-terminal presequence that may serve as a mitochondrial targeting signal. The amino acid sequence deduced from the cDNA shows significant similarity to those of sulfite oxidase from chicken liver and nitrate reductases from algal, fungal, and plant sources. Two cysteine residues are conserved in all of these proteins, and it is proposed that one or both of these cysteines serve as ligands to molybdenum. The gene has been expressed in Escherichia coli to a level equivalent to that observed in rat liver. The recombinant enzyme has been found to contain the molybdopterin form of the molybdenum cofactor and is active as determined by the sulfite dependent reduction of cytochrome c.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044283] Funding Source: NIH RePORTER; NIEHS NIH HHS [T32 ES07031] Funding Source: Medline; NIGMS NIH HHS [GM00091, GM44283] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER MJ, 1990, J BIOL CHEM, V265, P20912; BELLISSIMO DB, 1988, THESIS DUKE U; BILOFSKY HS, 1988, NUCLEIC ACIDS RES, V16, P1861, DOI 10.1093/nar/16.5.1861; COHEN HJ, 1971, J BIOL CHEM, V246, P359; CRAMER SP, 1981, J AM CHEM SOC, V103, P7721, DOI 10.1021/ja00416a005; CRAMER SP, 1979, J AM CHEM SOC, V101, P2772, DOI 10.1021/ja00504a067; CRAWFORD NM, 1988, P NATL ACAD SCI USA, V85, P5006, DOI 10.1073/pnas.85.14.5006; CRAWFORD NM, 1986, P NATL ACAD SCI USA, V83, P8073, DOI 10.1073/pnas.83.21.8073; DANIELVEDELE F, 1989, GENE, V85, P371, DOI 10.1016/0378-1119(89)90430-7; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FRIEMANN A, 1991, MOL GEN GENET, V227, P97, DOI 10.1007/BF00260713; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; JOHNSON JL, 1991, J BIOL CHEM, V266, P12140; JOHNSON JL, 1974, J BIOL CHEM, V249, P5046; JOHNSON JL, 1976, J CLIN INVEST, V58, P543, DOI 10.1172/JCI108499; JOHNSTONE IL, 1990, GENE, V90, P181, DOI 10.1016/0378-1119(90)90178-T; KRAMER SP, 1987, J BIOL CHEM, V262, P16357; NEAME PJ, 1989, J BIOL CHEM, V264, P20894; OKOMATO PM, 1991, MOL GEN GENET, V227, P213; PATEMAN JA, 1964, NATURE, V201, P58, DOI 10.1038/201058a0; PROSSER IM, 1990, PLANT MOL BIOL, V15, P187, DOI 10.1007/BF00017743; Rajagopalan K.V., 1980, MOLYBDENUM MOLYBDENU, P241; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VAUCHERET H, 1989, PLANT MOL BIOL, V12, P597, DOI 10.1007/BF00036974; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x	27	67	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					272	276						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276806				2022-12-25	WOS:A1994MR21900049
J	KONG, H; ROEMER, SE; WAITEREES, PA; BENNER, JS; WILSON, GG; NWANKWO, DO				KONG, H; ROEMER, SE; WAITEREES, PA; BENNER, JS; WILSON, GG; NWANKWO, DO			CHARACTERIZATION OF BCGI, A NEW KIND OF RESTRICTION-MODIFICATION SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I DNA RESTRICTION; NUCLEOTIDE-SEQUENCE; RECOGNITION SEQUENCE; MODIFICATION ENZYMES; ANTICODON NUCLEASE; MODIFICATION GENES; CLONING; ENDONUCLEASE; EXPRESSION; PROTEINS	The BcgI restriction enzyme from Bacillus coagulans is unusual in that it cleaves on both sides of its recognition site, CGAN6TGC, releasing a fragment that includes the site and several bases on each side. We report the organization and nucleotide sequences of the genes for the BcgI restriction-modification system and the properties of the proteins that they encode. The system comprises two adjacent, similarly oriented genes. The proximal gene, bcgIA, codes for a 637-amino acid protein (molecular mass = 71.6 kDa) that resembles certain m6A-specific DNA-methyltransferases, particularly those that constitute the modification subunits of type I restriction-modification systems. The distal gene, bcgIB, codes for a 341-amino acid protein (molecular mass = 39.2 kDa) that resembles none of the sequences in the sequence data bases. The two genes overlap by several nucleotides. Alone, neither protein restricts or modifies DNA, but, together, they form a complex in the proportion A2B that does both. DNA binding assays showed that the DNA-protein complex can be formed only in the presence of both subunits, suggesting that the association of inactive subunits generates the active BcgI enzyme that can bind DNA and then either cleaves or methylates at target site.			KONG, H (corresponding author), NEW ENGLAND BIOLABS INC, BEVERLY, MA 01915 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMITSUR M, 1992, EMBO J, V11, P3129, DOI 10.1002/j.1460-2075.1992.tb05385.x; BOCKLAGE H, 1991, NUCLEIC ACIDS RES, V19, P1007, DOI 10.1093/nar/19.5.1007; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; Chandrasegaran S, 1988, STRUCTURE EXPRESSION, V1, P149; CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; CONRAD M, 1989, P NATL ACAD SCI USA, V86, P9707, DOI 10.1073/pnas.86.24.9707; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; ITO H, 1990, NUCLEIC ACIDS RES, V18, P3903, DOI 10.1093/nar/18.13.3903; JANULAITIS A, 1992, NUCLEIC ACIDS RES, V20, P6043, DOI 10.1093/nar/20.22.6043; JANULAITIS A, 1992, NUCLEIC ACIDS RES, V20, P6051, DOI 10.1093/nar/20.22.6051; KAWAKAMI B, 1991, AGR BIOL CHEM TOKYO, V55, P1553, DOI 10.1080/00021369.1991.10870835; KAWAKAMI B, 1990, AGR BIOL CHEM TOKYO, V54, P3227, DOI 10.1080/00021369.1990.10870493; KHORANA HG, 1961, J AM CHEM SOC, V83, P686, DOI 10.1021/ja01464a038; KONG H, 1993, Patent No. 5200336; KONG HM, 1993, NUCLEIC ACIDS RES, V21, P987, DOI 10.1093/nar/21.4.987; KRUGER DH, 1988, NUCLEIC ACIDS RES, V16, P3997; LANDRY D, 1989, GENE, V77, P1, DOI 10.1016/0378-1119(89)90353-3; LANDRY D, 1992, METHOD ENZYMOL, V216, P244; LINDER P, 1990, NUCLEIC ACIDS RES, V18, P7170, DOI 10.1093/nar/18.23.7170; LOENEN WAM, 1987, J MOL BIOL, V198, P159, DOI 10.1016/0022-2836(87)90303-2; LUNGU O, 1993, BIOTECHNIQUES, V14, P62; LUNNEN KD, 1988, GENE, V74, P25, DOI 10.1016/0378-1119(88)90242-9; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEISEL A, 1991, NUCLEIC ACIDS RES, V19, P3997, DOI 10.1093/nar/19.14.3997; PEIN CD, 1991, NUCLEIC ACIDS RES, V19, P5139, DOI 10.1093/nar/19.19.5139; PRICE C, 1989, J MOL BIOL, V205, P115, DOI 10.1016/0022-2836(89)90369-0; RIOZES G, 1991, DNA SEQUENCE, V2, P65; ROBERTS RJ, 1992, NUCLEIC ACIDS RES, V20, P2167, DOI 10.1093/nar/20.suppl.2167; SLATKO BE, 1987, NUCLEIC ACIDS RES, V15, P9781, DOI 10.1093/nar/15.23.9781; SMITH HO, 1990, P NATL ACAD SCI USA, V87, P826, DOI 10.1073/pnas.87.2.826; SMITH JD, 1972, J MOL BIOL, V63, P1, DOI 10.1016/0022-2836(72)90517-7; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SZYBALSKI W, 1991, GENE, V100, P13, DOI 10.1016/0378-1119(91)90345-C; TAO T, 1991, J BACTERIOL, V173, P1367, DOI 10.1128/jb.173.4.1367-1375.1991; TAYLOR JD, 1991, BIOCHEMISTRY-US, V30, P8743, DOI 10.1021/bi00100a005; THERIAULT G, 1985, NUCLEIC ACIDS RES, V13, P8441, DOI 10.1093/nar/13.23.8441; TOPAL MD, 1991, BIOCHEMISTRY-US, V30, P2006, DOI 10.1021/bi00221a038; VOVIS GF, 1975, J MOL BIOL, V95, P557, DOI 10.1016/0022-2836(75)90317-4; WAITEREES PA, 1991, J BACTERIOL, V173, P5207, DOI 10.1128/jb.173.16.5207-5219.1991; WILSON GG, 1992, METHOD ENZYMOL, V216, P259; WILSON GG, 1991, ANNU REV GENET, V25, P585, DOI 10.1146/annurev.ge.25.120191.003101; YUAN R, 1981, ANNU REV BIOCHEM, V50, P285, DOI 10.1146/annurev.bi.50.070181.001441; YUAN R, 1984, DNA METHYLATION BIOC, P11; ZEBALA JA, 1992, J BIOL CHEM, V267, P8097	45	47	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					683	690						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276869				2022-12-25	WOS:A1994MR21900107
J	PEREIRA, DS; DONALD, LJ; HOSFIELD, DJ; DUCKWORTH, HW				PEREIRA, DS; DONALD, LJ; HOSFIELD, DJ; DUCKWORTH, HW			ACTIVE-SITE MUTANTS OF ESCHERICHIA-COLI CITRATE SYNTHASE - EFFECTS OF MUTATIONS ON CATALYTIC AND ALLOSTERIC PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE ANALOG INHIBITOR; DIRECTED MUTAGENESIS; ACETYL-COA; CRYSTAL-STRUCTURE; TERNARY COMPLEX; COENZYME-A; OXALOACETATE; GENE; BINDING; SEQUENCE	We report properties of five active site mutants of Escherichia coli citrate synthase, in which histidine 264, aspartate 362, and phenylalanine 383 were replaced by alanines, and arginines 387 and 407 by leucines. All mutants have much lower turnover numbers than wild type enzyme; the strongest effect was with the arginine 387 mutant, perhaps because the substrate, oxaloacetate, binds in a different orientation. The arginine 407 mutant has lost most of its ability to distinguish alpha-ketoglutarate, a competitive inhibitor, from oxaloacetate. The mutations of histidine 264 and aspartate 362 affect steady-state kinetics as would be anticipated from current models for citrate synthase catalysis, and resemble mutations of these residues, in pig heart and E. coli enzyme, reported by others. Mutations of residues 264,362, and 383 also affect allosteric properties. With the phenylalanine 383 mutant, acetyl-CoA saturation is strongly sigmoid, even in the presence of the activator, KCl, implying a marked shift of the allosteric equilibrium toward the T state. The histidine 264 mutant appears to be shifted toward R state and shows weaker binding of the allosteric inhibitor, NADH; thus this mutation also affects the allosteric site, 25-30 angstrom away.	UNIV MANITOBA,DEPT CHEM,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba								ALTER GM, 1990, BIOCHEMISTRY-US, V29, P7557, DOI 10.1021/bi00485a003; ANDERSON DH, 1989, BIOCHEM CELL BIOL, V67, P98, DOI 10.1139/o89-015; ANDERSON DH, 1988, J BIOL CHEM, V263, P2163; ANDERSON DH, 1991, BIOCHEM CELL BIOL, V69, P232, DOI 10.1139/o91-035; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; DANSON MJ, 1973, BIOCHEM J, V135, P513, DOI 10.1042/bj1350513; DAVID M, 1991, BIOCHEM J, V278, P225, DOI 10.1042/bj2780225; DONALD LJ, 1991, J BIOL CHEM, V266, P20709; DONALD LJ, 1989, J BACTERIOL, V171, P5542, DOI 10.1128/jb.171.10.5542-5550.1989; DUCKWORTH HW, 1982, CAN J BIOCHEM CELL B, V60, P1143, DOI 10.1139/o82-146; DUCKWORTH HW, 1976, BIOCHEMISTRY-US, V15, P108, DOI 10.1021/bi00646a017; FALOONA GR, 1969, BIOCHEMISTRY-US, V8, P4497, DOI 10.1021/bi00839a041; FUKUYA M, 1990, J BACTERIOL, V172, P2096; HANDFORD PA, 1988, BIOCHIM BIOPHYS ACTA, V953, P232, DOI 10.1016/0167-4838(88)90030-1; HEINZEN RA, 1991, GENE, V109, P63, DOI 10.1016/0378-1119(91)90589-4; KARPUSAS M, 1990, BIOCHEMISTRY-US, V29, P2213, DOI 10.1021/bi00461a002; KARPUSAS M, 1991, BIOCHEMISTRY-US, V30, P6024, DOI 10.1021/bi00238a028; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURZ LC, 1992, BIOCHEMISTRY-US, V31, P7899, DOI 10.1021/bi00149a022; KURZ LC, 1987, BIOCHEMISTRY-US, V26, P2623, DOI 10.1021/bi00383a032; KURZ LC, 1985, BIOCHEMISTRY-US, V24, P452, DOI 10.1021/bi00323a031; KURZ LC, 1992, BIOCHEMISTRY-US, V31, P7908, DOI 10.1021/bi00149a023; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P6031, DOI 10.1021/bi00238a029; MAN WJ, 1991, BIOCHEM J, V280, P521, DOI 10.1042/bj2800521; MOLGAT GF, 1992, ARCH BIOCHEM BIOPHYS, V298, P238, DOI 10.1016/0003-9861(92)90118-G; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NER SS, 1983, BIOCHEMISTRY-US, V22, P5243, DOI 10.1021/bi00292a001; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; SCHENDEL FJ, 1992, APPL ENVIRON MICROB, V58, P335, DOI 10.1128/AEM.58.1.335-345.1992; SUTHERLAND KJ, 1990, EUR J BIOCHEM, V194, P839, DOI 10.1111/j.1432-1033.1990.tb19477.x; TALGOY MM, 1979, CAN J BIOCHEM CELL B, V57, P385, DOI 10.1139/o79-049; TALGOY MM, 1979, CAN J BIOCHEM CELL B, V57, P822, DOI 10.1139/o79-102; Weitzman P D, 1976, Curr Top Cell Regul, V10, P161; WIEGAND G, 1984, J MOL BIOL, V174, P205, DOI 10.1016/0022-2836(84)90373-5; WRIGHT JA, 1971, J BIOL CHEM, V246, P1689; WRIGHT JA, 1967, BIOCHEM BIOPH RES CO, V29, P34, DOI 10.1016/0006-291X(67)90536-0; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	37	33	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					412	417						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276829				2022-12-25	WOS:A1994MR21900070
J	DAMRON, DS; VANWAGONER, DR; MORAVEC, CS; BOND, M				DAMRON, DS; VANWAGONER, DR; MORAVEC, CS; BOND, M			ARACHIDONIC-ACID AND ENDOTHELIN POTENTIATE CA2+ TRANSIENTS IN RAT CARDIAC MYOCYTES VIA INHIBITION OF DISTINCT K+ CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; UNSATURATED FATTY-ACIDS; GUINEA-PIG ATRIA; SARCOPLASMIC-RETICULUM; VENTRICULAR MYOCYTES; SIGNAL TRANSDUCTION; TROPONIN-I; CALCIUM; CA-2+; ACTIVATION	The release of arachidonic acid by phospholipases in response to cell surface receptor activation may be an important step in the initiation of inotropic events in cardiac muscle. Endothelin has been shown to activate phospholipase A2 and release arachidonic acid in isolated rat hearts. Endothelin also has a positive inotropic effect in cardiac muscle, suggesting that endothelin increases Ca2+ influx or the amount of Ca2+ released from the sarcoplasmic reticulum. We used suspensions of adult rat ventricular myocytes loaded with fura-2/AM to compare the effects of arachidonic acid and endothelin on Ca2+ transients evoked by extracellular ATP. We showed recently (Damron, D. S., and Bond, M. (1993) Circ. Res. 72, 376-386) that pretreatment of cardiac myocytes with arachidonic acid significantly potentiated the amplitude of the ATP-triggered Ca2+ transient. We now report that endothelin also enhances the ATP-triggered Ca2+ transient and that the effect of the combination of maximal doses of endothelin and arachidonic acid is additive. Neither endothelin nor arachidonic acid was found to affect the size of the sarcoplasmic reticulum Ca2+ store. The potentiating effects of both arachidonic acid and endothelin were sensitive to inhibitors of protein kinase C. Endothelin was also found to stimulate phospholipase C but not phospholipase A2. Application of arachidonic acid to individual cardiac muscle cells resulted in inhibition of the transient outward K+ current, whereas application of endothelin inhibited the delayed rectifier current. These effects of arachidonic acid and endothelin were additive, and both effects could be blocked by the protein kinase C inhibitor, staurosporine. Similarly, staurosporine inhibited endothelin-induced increases in isometric contractions in ventricular papillary muscle. We conclude that arachidonic acid and endothelin may be involved in the modulation of inotropic activity in cardiac muscle by means of protein kinase C-dependent inhibition of two distinct K+ channels. This would result in a prolongation of action potential duration and thus an increase in Ca2+ influx across the sarcolemma.	CLEVELAND CLIN FDN,RES INST,DEPT CARDIOVASC BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Van Wagoner, David R/C-6783-2008	Van Wagoner, David R/0000-0001-8250-9828	NHLBI NIH HHS [HL33713, HL08726, HL41883] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008726, R01HL041883, P50HL033713] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN IS, 1988, CIRC RES, V62, P524, DOI 10.1161/01.RES.62.3.524; ALTSCHULD R, 1980, J MOL CELL CARDIOL, V12, P1383, DOI 10.1016/0022-2828(80)90123-6; APKON M, 1988, P NATL ACAD SCI USA, V85, P8756, DOI 10.1073/pnas.85.22.8756; BERS DM, 1987, CAN J PHYSIOL PHARM, V65, P610, DOI 10.1139/y87-103; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; CAPOGROSSI MC, 1990, CIRC RES, V66, P1143, DOI 10.1161/01.RES.66.4.1143; CHRISTIE A, 1992, J PHYSIOL-LONDON, V445, P369, DOI 10.1113/jphysiol.1992.sp018929; DAMRON DS, 1993, CIRC RES, V72, P376, DOI 10.1161/01.RES.72.2.376; DAMRON DS, 1993, NEUROCHEM RES, V18, P1231, DOI 10.1007/BF00975040; DEYOUNG MB, 1989, AM J PHYSIOL, V257, pC750, DOI 10.1152/ajpcell.1989.257.4.C750; DORMAN RV, 1988, BRAIN RES BULL, V21, P445, DOI 10.1016/0361-9230(88)90157-8; EDES I, 1990, CIRC RES, V67, P394, DOI 10.1161/01.RES.67.2.394; FILEP JG, 1991, BIOCHEM BIOPH RES CO, V177, P171, DOI 10.1016/0006-291X(91)91964-E; FREEMAN EJ, 1990, NEUROCHEM RES, V15, P743, DOI 10.1007/BF00973656; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANSFORD RG, 1987, J PHYSIOL-LONDON, V390, P453, DOI 10.1113/jphysiol.1987.sp016711; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; ISHII K, 1992, BIOCHEM BIOPH RES CO, V184, P1484, DOI 10.1016/S0006-291X(05)80050-6; ISHIKAWA T, 1988, AM J PHYSIOL, V255, pH970, DOI 10.1152/ajpheart.1988.255.4.H970; KAKU T, 1991, AM J PHYSIOL, V260, pC635, DOI 10.1152/ajpcell.1991.260.3.C635; KELLY RA, 1990, J CLIN INVEST, V86, P1164, DOI 10.1172/JCI114822; KIM DH, 1990, CIRC RES, V67, P1040, DOI 10.1161/01.RES.67.4.1040; KOHL C, 1990, BRIT J PHARMACOL, V101, P829, DOI 10.1111/j.1476-5381.1990.tb14165.x; KRAMER BK, 1991, CIRC RES, V68, P269, DOI 10.1161/01.RES.68.1.269; LACERDA AE, 1988, NATURE, V335, P249, DOI 10.1038/335249a0; LESTER DS, 1991, BIOCHEM BIOPH RES CO, V179, P1522, DOI 10.1016/0006-291X(91)91745-X; LIMAS CJ, 1980, BIOCHEM BIOPH RES CO, V96, P1378, DOI 10.1016/0006-291X(80)90103-5; LINDEN DJ, 1989, J PHYSIOL-LONDON, V419, P95, DOI 10.1113/jphysiol.1989.sp017863; LYNCH MA, 1989, BIOESSAYS, V10, P85, DOI 10.1002/bies.950100212; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MORAVEC CS, 1989, BIOCHEM BIOPH RES CO, V159, P14, DOI 10.1016/0006-291X(89)92397-8; MORAVEC CS, 1991, AM J PHYSIOL, V260, pH989, DOI 10.1152/ajpheart.1991.260.3.H989; MOVSESIAN MA, 1984, J BIOL CHEM, V259, P8029; MURAKAMI K, 1986, J BIOL CHEM, V261, P5424; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NOLAND TA, 1991, J BIOL CHEM, V266, P4974; OKUMURA K, 1988, J CARDIOVASC PHARM, V11, P651, DOI 10.1097/00005344-198806000-00004; PRASAD MR, 1991, BIOCHEM BIOPH RES CO, V174, P952, DOI 10.1016/0006-291X(91)91511-A; ROGERS TB, 1990, J BIOL CHEM, V265, P4302; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMONSON MS, 1990, J CLIN INVEST, V85, P790, DOI 10.1172/JCI114505; SIROIS MG, 1992, EUR J PHARMACOL, V214, P119, DOI 10.1016/0014-2999(92)90108-G; TAKASAGO T, 1991, J BIOCHEM-TOKYO, V109, P163, DOI 10.1093/oxfordjournals.jbchem.a123339; TEUTSCH I, 1987, EUR J PHARMACOL, V144, P363, DOI 10.1016/0014-2999(87)90389-X; VANWAGONER DR, 1993, CIRC RES, V72, P973, DOI 10.1161/01.RES.72.5.973; VENEMA RC, 1993, J BIOL CHEM, V268, P2705; VIGNE P, 1989, FEBS LETT, V249, P143, DOI 10.1016/0014-5793(89)80611-8; YOSHIDA K, 1992, P NATL ACAD SCI USA, V89, P6443, DOI 10.1073/pnas.89.14.6443; ZHENG JS, 1992, AM J PHYSIOL, V262, pC128, DOI 10.1152/ajpcell.1992.262.1.C128	53	81	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27335	27344						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262973				2022-12-25	WOS:A1993MM26200072
J	HEACOCK, DH; LIU, RQ; YU, CA; YU, L; DURHAM, B; MILLETT, F				HEACOCK, DH; LIU, RQ; YU, CA; YU, L; DURHAM, B; MILLETT, F			INTRACOMPLEX ELECTRON-TRANSFER BETWEEN RUTHENIUM-CYTOCHROME-C DERIVATIVES AND CYTOCHROME-C(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC CYTOCHROME-C1; BINDING; KINETICS; PROTEIN; COMPLEX; OXIDOREDUCTASE; SPHAEROIDES; PEROXIDASE; REDUCTION; OXIDASE	The reactions of a beef heart cytochrome c1 preparation containing the hinge protein with horse cytochrome c derivatives labeled at specific lysine amino groups with (dicarboxybipyridine)(bisbipyridine) ruthenium(II) (Ru(II)) were studied by flash photolysis. All of the ruthenium-cytochrome c derivatives formed complexes with cytochrome c1 in low ionic strength buffer (5 mm sodium phosphate, pH 7). Excitation of Ru(II) to Ru(II) with a 0.4-mus laser flash resulted in rapid electron transfer to the ferric heme group in cytochrome c, followed by electron transfer from the ferrous heme group of cytochrome c to the ferric heme group of cytochrome c1. The kinetic difference spectra displayed maxima at 546 nm and minima at 554 nm characteristic of electron transfer between the two cytochromes. The rate constants were independent of concentration at low ionic strength, indicating intracomplex electron transfer. The rate constants were 4,800, 6,800, 22,000, and 22,000 s-1 for cytochrome c derivatives modified at lysines 13, 27, 25, and 72, respectively. The observed rate constants were independent of ionic strength up to about 50 mm and then decreased progressively with further increases in ionic strength indicating dissociation of the complex. Second-order kinetics were observed at 310 mm ionic strength, with rate constants of 1.0 x 10(6), 1.6 x 10(7), 1.2 x 10(8), and 3.0 x 10(7) M-1 s-1 for the derivatives modified at lysines 13, 27, 25, and 72, respectively. The ionic strength dependence of the second-order rate constants is comparable to that involving native horse cytochrome c and is consistent with electron transfer reactions between oppositely charged proteins.	UNIV ARKANSAS,DEPT CHEM & BIOCHEM,115 CHEM BLDG,FAYETTEVILLE,AR 72701; OKLAHOMA STATE UNIV,DEPT BIOCHEM,STILLWATER,OK 74078	University of Arkansas System; University of Arkansas Fayetteville; Oklahoma State University System; Oklahoma State University - Stillwater					NCRR NIH HHS [RR07101] Funding Source: Medline; NIGMS NIH HHS [GM30721, GM20488] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R01GM030721] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED AJ, 1978, BIOCHEMISTRY-US, V17, P2479, DOI 10.1021/bi00606a003; BERRY EA, 1985, COENZYME Q, P365; BROGER C, 1983, EUR J BIOCHEM, V131, P349, DOI 10.1111/j.1432-1033.1983.tb07269.x; CAPALDI RA, 1982, BIOCHIM BIOPHYS ACTA, V694, P291, DOI 10.1016/0304-4157(82)90009-0; CHIANG YL, 1976, J BIOL CHEM, V251, P29; CROFTS AR, 1986, J BIOENERG BIOMEMBR, V18, P437, DOI 10.1007/BF00743014; DURHAM B, 1989, BIOCHEMISTRY-US, V28, P8659, DOI 10.1021/bi00447a057; DUTTON PL, 1970, BIOCHEMISTRY-US, V9, P5077, DOI 10.1021/bi00828a006; GABELLINNI N, 1988, J BIOENERG BIOMEMBR, V18, P59; GEREN L, 1991, BIOCHEMISTRY-US, V30, P9450, DOI 10.1021/bi00103a009; GREEN DE, 1959, BIOCHIM BIOPHYS ACTA, V31, P34, DOI 10.1016/0006-3002(59)90436-6; GUTWENIGER HE, 1983, BIOCHEM BIOPH RES CO, V116, P272, DOI 10.1016/0006-291X(83)90411-4; HAHM S, 1992, BIOCHEMISTRY-US, V31, P3472, DOI 10.1021/bi00128a022; KIM CH, 1983, J BIOL CHEM, V258, P3543; KIM CH, 1987, J BIOL CHEM, V262, P8103; KIM CH, 1984, P NATL ACAD SCI-BIOL, V81, P2026, DOI 10.1073/pnas.81.7.2026; KONIG BW, 1980, BIOCHIM BIOPHYS ACTA, V621, P283, DOI 10.1016/0005-2795(80)90180-4; KONIG BW, 1980, FEBS LETT, V111, P395, DOI 10.1016/0014-5793(80)80835-0; KONIG BW, 1981, BIOCHIM BIOPHYS ACTA, V636, P9, DOI 10.1016/0005-2728(81)90069-4; LIU RQ, 1992, BIOPHYS J, V61, P193; MARGALIT R, 1973, EUR J BIOCHEM, V32, P492, DOI 10.1111/j.1432-1033.1973.tb02633.x; OCKERBLOOM NE, 1956, J AM CHEM SOC, V78, P267, DOI 10.1021/ja01583a004; PAN LP, 1990, BIOCHEMISTRY-US, V29, P3231, DOI 10.1021/bi00465a013; PAN LP, 1993, BIOCHEMISTRY-US, V32, P8492, DOI 10.1021/bi00084a014; PAN LP, 1988, BIOCHEMISTRY-US, V27, P7180, DOI 10.1021/bi00419a003; RIEDER R, 1980, J BIOL CHEM, V255, P4732; SCHROEDL NA, 1977, BIOCHEMISTRY-US, V16, P4961, DOI 10.1021/bi00642a003; SMITH HT, 1981, J BIOL CHEM, V256, P4984; SPECK SH, 1979, P NATL ACAD SCI USA, V76, P155, DOI 10.1073/pnas.76.1.155; STONEHUERNER J, 1985, J BIOL CHEM, V260, P5392; WAKABAYASHI S, 1982, J BIOCHEM, V91, P2077, DOI 10.1093/oxfordjournals.jbchem.a133901; WAKABAYASHI S, 1982, J BIOL CHEM, V257, P9335; WILLIE A, 1992, BIOCHEMISTRY-US, V31, P7237, DOI 10.1021/bi00147a005; WILLIE A, 1993, BIOCHEMISTRY-US, V32, P7519, DOI 10.1021/bi00080a025; YU CA, 1972, J BIOL CHEM, V247, P1012; YU CA, 1983, BIOCHIM BIOPHYS ACTA, V736, P226, DOI 10.1016/0005-2736(83)90288-2; YU CA, 1973, J BIOL CHEM, V248, P528; YU L, 1984, J BIOL CHEM, V259, P5752	38	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27171	27175						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262956				2022-12-25	WOS:A1993MM26200051
J	KAIKAUS, RM; SUI, ZH; LYSENKO, N; WU, NY; DEMONTELLANO, PRO; OCKNER, RK; BASS, NM				KAIKAUS, RM; SUI, ZH; LYSENKO, N; WU, NY; DEMONTELLANO, PRO; OCKNER, RK; BASS, NM			REGULATION OF PATHWAYS OF EXTRAMITOCHONDRIAL FATTY-ACID OXIDATION AND LIVER FATTY-ACID-BINDING PROTEIN BY LONG-CHAIN MONOCARBOXYLIC FATTY-ACIDS IN HEPATOCYTES - EFFECT OF INHIBITION OF CARNITINE PALMITOYLTRANSFERASE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL BETA-OXIDATION; HYDROGENATED FISH OIL; ISOLATED RAT-LIVER; ACYL-COA OXIDASE; NUCLEOTIDE-SEQUENCE; ACTIVATED RECEPTOR; GENE-EXPRESSION; INDUCTION; IDENTIFICATION; PROLIFERATORS	The regulation of the extramitochondrial fatty acid oxidation pathways located in the peroxisomes and the endoplasmic reticulum is not fully understood. Although both long-chain dicarboxylic fatty acids, which are poorly metabolized in hepatocytes, and non-beta-oxidizable fatty acid analogs induce peroxisomal beta-oxidation and liver fatty acid-binding protein (L-FABP) by a pretranslational mechanism, monocarboxylic long-chain fatty acids, which are rapidly esterified and oxidized, do not. To establish whether impaired utilization and, hence, sustained intracellular levels of monocarboxylic long-chain fatty acids increase their efficacy as inducers, the effect of oleic acid on cytochrome P-450 4A1, peroxisomal beta-oxidation, and L-FABP during inhibition of mitochondrial beta-oxidation was determined. In primary hepatocyte cultures, oleic acid had no inducing effect, but in the presence of 2-tetradecylglycidic acid (TDGA), an inhibitor of carnitine palmitoyltransferase I, it induced P-450 4A1, peroxisomal beta-oxidation, and L-FABP pretranslationally. An increase in peroxisomal beta-oxidation was also noted in the presence of etomoxir, another inhibitor of carnitine palmitoyltransferase 1. Exposure of hepatocytes to TDGA for 1 h led to an expected decrease in incorporation of radiolabel from [1-C-14]oleate into CO2 and water-soluble products. In contrast, long-term exposure to TDGA increased incorporation of [1-C-14]oleate into oxidation products, most likely due to an adaptive induction of peroxisomal beta-oxidation. Both acute and long-term exposure of hepatocytes to TDGA decreased incorporation of oleic acid into triglycerides, an effect that may have contributed to the intracellular accumulation of fatty acids. These results provide support for a mechanism by which long-chain fatty acids or specific metabolites, including long-chain acyl-CoA esters and long-chain dicarboxylic acids, act as signals in the induction of P-450 4A1, peroxisomal beta-oxidation, and L-FABP under conditions in which long-chain fatty acids accumulate due to impaired entry into the mitochondrial beta-oxidation pathway.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	KAIKAUS, RM (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,BOX 0538,HSW 1120,3RD & PARNASSUS AVE,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002056, R01DK032926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025515, R37GM025515] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-02056, DK-32926] Funding Source: Medline; NIGMS NIH HHS [GM-25515] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARSLAND A, 1990, BIOCHIM BIOPHYS ACTA, V1033, P176, DOI 10.1016/0304-4165(90)90009-L; BARDOT Z, 1993, BIOCHEM BIOPH RES CO, V1932, P37; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; BASS NM, 1993, HEPATOLOGY, V18, pA125, DOI 10.1016/0270-9139(93)92029-Y; BISSELL DM, 1987, J CLIN INVEST, V79, P801, DOI 10.1172/JCI112887; BRANDES R, 1990, BIOCHIM BIOPHYS ACTA, V1034, P53, DOI 10.1016/0304-4165(90)90152-M; CABAUD PG, 1958, AM J CLIN PATHOL, V30, P234, DOI 10.1093/ajcp/30.3.234; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DISTEL RJ, 1992, J BIOL CHEM, V267, P5937; EACHO PI, 1988, BIOCHEM BIOPH RES CO, V157, P1148, DOI 10.1016/S0006-291X(88)80993-8; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLATMARK T, 1988, BIOCHIM BIOPHYS ACTA, V962, P122, DOI 10.1016/0005-2760(88)90103-8; FOLCH J, 1957, J BIOL CHEM, V226, P497; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GRIMALDI PA, 1992, P NATL ACAD SCI USA, V89, P10930, DOI 10.1073/pnas.89.22.10930; HARDWICK JP, 1987, J BIOL CHEM, V262, P801; HERTZ R, 1985, BIOCHIM BIOPHYS ACTA, V836, P192, DOI 10.1016/0005-2760(85)90066-9; HEUBI JE, 1987, HEPATOLOGY, V7, P155, DOI 10.1002/hep.1840070130; IDE T, 1981, J BIOL CHEM, V256, P247; INTRASUKSRI U, 1991, BIOCHEM PHARMACOL, V4, P184; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KAIKAUS RM, 1993, J BIOL CHEM, V268, P9593; KAIKAUS RM, 1990, EXPERIENTIA, V46, P617, DOI 10.1007/BF01939701; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KIORPES TC, 1984, J BIOL CHEM, V259, P9750; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; MA X, 1992, HEPATOLOGY, V16, pA450; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; MORTENSEN PB, 1992, BIOCHIM BIOPHYS ACTA, V1124, P71, DOI 10.1016/0005-2760(92)90128-I; MORTENSEN PB, 1982, BIOCHIM BIOPHYS ACTA, V710, P477, DOI 10.1016/0005-2760(82)90132-1; NILSSON A, 1987, BIOCHIM BIOPHYS ACTA, V920, P114, DOI 10.1016/0005-2760(87)90250-5; OSMUNDSEN H, 1991, BIOCHIM BIOPHYS ACTA, V1085, P141, DOI 10.1016/0005-2760(91)90089-Z; SALAH AEA, 1987, BIOCHEM PHARMACOL, V36, P4307; SCHULZ H, 1987, LIFE SCI, V40, P1443, DOI 10.1016/0024-3205(87)90375-4; SKORIN C, 1992, BIOCHEM J, V281, P561, DOI 10.1042/bj2810561; SKORVE J, 1990, BIOCHEM PHARMACOL, V40, P2005, DOI 10.1016/0006-2952(90)90230-I; SWEETSER DA, 1986, J BIOL CHEM, V261, P5553; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; TUTWILER GF, 1979, J BIOL CHEM, V254, P2935; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WOLF HPO, 1990, NEW ANTIDIABETIC DRU, P217	43	51	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26866	26871						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262919				2022-12-25	WOS:A1993MM26200009
J	SEKIMOTO, T; MATSUYAMA, T; FUKUI, T; TANIZAWA, K				SEKIMOTO, T; MATSUYAMA, T; FUKUI, T; TANIZAWA, K			EVIDENCE FOR LYSINE-80 AS GENERAL BASE CATALYST OF LEUCINE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; DEPENDENT GLUTAMATE-DEHYDROGENASE; COMPLETE NUCLEOTIDE-SEQUENCE; BACILLUS-STEAROTHERMOPHILUS; NAD(P)+-DEPENDENT DEHYDROGENASES; PHENYLALANINE DEHYDROGENASE; BOVINE ENZYME; CLONING; PHOSPHATE; LIVER	To elucidate the functional role of the lysyl residue highly conserved in NAD(P)+-dependent amino acid dehydrogenases, Lys-80 of leucine dehydrogenase from Bacillus stearothermophilus has been mutated into Ala, Arg, or Gln. All of the mutant enzymes had markedly reduced activities in the oxidative deamination, whereas the Michaelis constants for substrate and coenzyme did not change significantly upon the mutation, except for a 10-30-fold increase in K(m) values for alpha-keto-iso-caproate in the Ala and Gln mutants. The pH profiles of kinetic parameters of the mutants considerably differed from those of the wild type, in which two ionizable groups with pK(a) values of 8.9 and 10.7 must be unprotonated for catalysis and protonated for substrate binding, respectively. Combined with the analyses of solvent isotope effect and inhibition by substrate analogs, these results unequivocally show that the epsilon-amino group of Lys-80 participates in catalysis as a general base, assisting the nucleophilic attack of a water molecule to the substrate alpha-carbon atom. Furthermore, the Ala mutant was markedly stimulated by primary amines depending on the pK(a) and molecular volume, suggesting that in the Ala mutant the added amines can partially replace the general base function of Lys-80 in the wild type enzyme.	OSAKA UNIV,INST SCI & IND RES,IBARAKI,OSAKA 567,JAPAN	Osaka University								BAKER PJ, 1992, PROTEINS, V12, P75, DOI 10.1002/prot.340120109; BLUMENTHAL KM, 1975, J BIOL CHEM, V250, P3644; BROWN A, 1973, BIOCHEMISTRY-US, V12, P4367, DOI 10.1021/bi00746a011; Cleland W W, 1979, Methods Enzymol, V63, P103; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; HABERLAND ME, 1980, J BIOL CHEM, V255, P7984; JENCKS WP, 1968, HDB BIOCH MOL BIOL, P150; JULLIARD JH, 1979, J BIOL CHEM, V254, P3427; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURODA SI, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00456a025; LILLEY KS, 1991, BIOCHIM BIOPHYS ACTA, V1080, P191, DOI 10.1016/0167-4838(91)90001-G; LILLEY KS, 1992, EUR J BIOCHEM, V207, P533, DOI 10.1111/j.1432-1033.1992.tb17079.x; MATSUYAMA T, 1992, J BIOCHEM-TOKYO, V112, P258, DOI 10.1093/oxfordjournals.jbchem.a123887; MCPHERSON MJ, 1983, NUCLEIC ACIDS RES, V11, P5257, DOI 10.1093/nar/11.15.5257; MCPHERSON MJ, 1988, PROTEIN ENG, V2, P147, DOI 10.1093/protein/2.2.147; MOON K, 1973, J BIOL CHEM, V248, P3082; MOON K, 1972, P NATL ACAD SCI USA, V69, P1380, DOI 10.1073/pnas.69.6.1380; MOYE WS, 1985, J BIOL CHEM, V260, P8502; NAGATA S, 1988, BIOCHEMISTRY-US, V27, P9056, DOI 10.1021/bi00425a026; OHSHIMA T, 1978, J BIOL CHEM, V253, P5719; OHSHIMA T, 1985, ARCH MICROBIOL, V141, P407, DOI 10.1007/BF00428857; OKAZAKI N, 1988, GENE, V63, P337, DOI 10.1016/0378-1119(88)90537-9; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PISZKIEWICZ D, 1971, BIOCHEMISTRY-US, V10, P4544, DOI 10.1021/bi00800a031; RIFE JE, 1980, BIOCHEMISTRY-US, V19, P2328, DOI 10.1021/bi00552a008; SANDER F, 1977, P NATL ACAD SCI USA, V74, P5463; SINGH N, 1993, J BIOL CHEM, V268, P21; SMITH HB, 1991, BIOCHEMISTRY-US, V30, P5172, DOI 10.1021/bi00235a009; SODA K, 1971, BIOCHEM BIOPH RES CO, V44, P931, DOI 10.1016/0006-291X(71)90801-1; TAKADA H, 1991, J BIOCHEM-TOKYO, V109, P371, DOI 10.1093/oxfordjournals.jbchem.a123388; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; VALLE F, 1984, GENE, V27, P193, DOI 10.1016/0378-1119(84)90140-9; WOOTTON JC, 1974, P NATL ACAD SCI USA, V71, P4361, DOI 10.1073/pnas.71.11.4361; ZINK MW, 1962, ARCH BIOCHEM BIOPHYS, V99, P72, DOI 10.1016/0003-9861(62)90245-X	35	48	50	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27039	27045						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262941				2022-12-25	WOS:A1993MM26200033
J	BENKIRANE, N; FRIEDE, M; GUICHARD, G; BRIAND, JP; VANREGENMORTEL, MHV; MULLER, S				BENKIRANE, N; FRIEDE, M; GUICHARD, G; BRIAND, JP; VANREGENMORTEL, MHV; MULLER, S			ANTIGENICITY AND IMMUNOGENICITY OF MODIFIED SYNTHETIC PEPTIDES CONTAINING D-AMINO-ACID RESIDUES - ANTIBODIES TO A D-ENANTIOMER DO RECOGNIZE THE PARENT L-HEXAPEPTIDE AND RECIPROCALLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; SPECIFICITY; SURFACE	The effect of introducing D-amino acid residues in an hexapeptide was examined both at the antigenic and immunogenic levels. A series of D-analogues of the model peptide of sequence IRGERA corresponding to the COOH-terminal residues 130-135 of histone H3 were produced. Four analogues contained a single change of an L-residue by the corresponding enantiomer, one peptide contained two D-residues and another one contained only D-residues (D-enantiomer). A peptide analogue was also synthesized in which the 2 Arg residues were replaced by Lys residues. The parent peptide and peptide analogues were injected into mice after covalent coupling to small unilamellar liposomes containing monophosphoryl lipid A as adjuvant. The substitution of L-Arg131 to Lys or D-Arg was found to change neither the antigenic nor immunogenic properties of the resulting peptides. In contrast, the substitution of Glu133 , Arg134, and Ala135 by the respective enantiomers drastically altered the antigenicity of the modified peptides. Each of the SiX D-analogues induced an immune response with an unusually high level of IgG3 antibodies. The D-enantiomer produced IgG3 antibodies which reacted with the homologous peptide as well as with the all L-peptide and the parent protein H3 in solution but not with analogues containing one or two D-residues only. IgG3 antibodies produced against the all L-peptide reacted with the free all D-peptide but not with the other analogues containing D-residues in position 133, 134, and 135.	CNRS, UPR 9021, INST BIOL MOLEC & CELLULAIRE, F-67000 STRASBOURG, FRANCE; FAC PHARM ILLKIRCH, CHIM BIOORGAN LAB, CNRS, URA 1386, F-67400 ILLKIRCH GRAFFENSTADEN, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS)			Muller, Sylviane/J-5319-2014; Benkirane-Jessel, Nadia/H-6438-2016; GUICHARD, Gilles/I-3858-2016	GUICHARD, Gilles/0000-0002-2584-7502; Benkirane-Jessel, Nadia/0000-0003-3059-3559				ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; ARNON R, 1992, FASEB J, V6, P3265, DOI 10.1096/fasebj.6.14.1385242; BRIAND JP, 1992, J IMMUNOL METHODS, V156, P255, DOI 10.1016/0022-1759(92)90033-P; BRIAND JP, 1985, J IMMUNOL METHODS, V78, P59, DOI 10.1016/0022-1759(85)90329-1; BROWN F, 1990, SEMINARS VIROLOGY, V1, P67; BUTLER JE, 1992, J IMMUNOL METHODS, V150, P77, DOI 10.1016/0022-1759(92)90066-3; CUNG MT, 1991, BIOPOLYMERS, V31, P769, DOI 10.1002/bip.360310622; FAUCHERE JL, 1992, ADV DRUG RES, V23, P127; FRIEDE M, 1993, MOL IMMUNOL, V30, P539, DOI 10.1016/0161-5890(93)90028-A; FRIEDE M, 1992, PEPTIDE RES, V5, P145; FRISCH B, 1991, EUR J IMMUNOL, V21, P185, DOI 10.1002/eji.1830210128; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; GEYSEN HM, 1987, BETTER CARBOHYDRATE, P103; GRAY D, 1988, NATURE, V336, P70, DOI 10.1038/336070a0; GREENSPAN NS, 1992, IMMUNOL TODAY, V13, P164, DOI 10.1016/0167-5699(92)90120-V; GUPTASARMA P, 1992, FEBS LETT, V310, P205, DOI 10.1016/0014-5793(92)81333-H; HUDSON D, 1988, J ORG CHEM, V53, P617, DOI 10.1021/jo00238a026; JUNG G, 1992, ANGEW CHEM INT EDIT, V31, P1457, DOI 10.1002/anie.199214571; KING DS, 1990, INT J PEPT PROT RES, V36, P255; MCKEARN JP, 1982, IMMUNOL REV, V64, P5, DOI 10.1111/j.1600-065X.1982.tb00416.x; Milich D R, 1990, Semin Immunol, V2, P307; MILTON RCD, 1992, SCIENCE, V256, P1445, DOI 10.1126/science.1604320; MULLER S, 1982, EMBO J, V1, P421, DOI 10.1002/j.1460-2075.1982.tb01185.x; MULLER S, 1989, METHOD ENZYMOL, V170, P251; MULLER S, 1988, SYNTHETIC POLYPEPTID, P159; NEIMARK J, 1993, PEPTIDE RES, V6, P219; SNAPPER CM, 1993, IMMUNOL TODAY, V14, P15, DOI 10.1016/0167-5699(93)90318-F; SORENSEN K, 1986, J IMMUNOL METHODS, V95, P291, DOI 10.1016/0022-1759(86)90419-9; THERIEN HM, 1991, CELL IMMUNOL, V136, P402, DOI 10.1016/0008-8749(91)90362-F; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761	30	83	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26279	26285						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253750				2022-12-25	WOS:A1993MK42500043
J	MAREN, TH; CONROY, CW				MAREN, TH; CONROY, CW			A NEW CLASS OF CARBONIC-ANHYDRASE INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFONAMIDES; BINDING; SECRETION; KINETICS	Aliphatic sulfonamides, as CH3SO2NH2, are very weak inhibitors of the carbonic anhydrases (K(I) congruent-to 10(-4) M) and are extremely weak acids (K(a) congruent-to 10(-10.5) M). We now find CF3SO2NH2 a very potent inhibitor of carbonic anhydrase II (K(I) = 2 x 10(-5.8) M) and a much stronger acid (K(a) = 10-5.8) M). It freely dissolves in water, a 2% solution yielding pH 3.7, the strongest known sulfonamide acid. CHCl3/aqueous partition with this solution is very low, 0.006. The plot of CH3SO2NH2 and eight hydrophilic halo-alkyl congeners gives a linear relation over 5 orders of magnitude, pK(I) increasing as pK(a) declines. Transcorneal permeability of CFsSO2NH2 in rabbits is very high; from one drop on the cornea it rapidly gains access to the ciliary process, where it fully inhibits carbonic anhydrase and gives the maximum pressure drop (for any drug) of 6 mm Hg at 30-60 min. Action is short due to rapid disappearance of free drug from the eye at the rate of aqueous humor flow. Analyses are made of binding of CF3SO2NH2 to carbonic anhydrase and melanin in ciliary process. CF3SO2NH2 is not attacked by glutathione, is 75% bound to plasma protein, and is not taken into the renal secretory system. Excretion rate follows from glomerular filtration and tubular reabsorption. Intravenous injection thus leads to prolonged plasma levels (half-life, 24 h), a general diffusion into tissues and alkalinization of the urine, as with ''classic'' inhibitors. Drug is bound to carbonic anhydrase in red cells and decays with half-life of 4 days. The rapid and effective binding to carbonic anhydrase of this small hydrophilic molecule shows that complex lipophilic structures are not necessary for powerful inhibition of the enzyme. It does not appear essential for a sulfonamide to occupy a ''hydrophobic pocket'' in the active site cavity to react effectively at the zinc center.			MAREN, TH (corresponding author), UNIV FLORIDA,COLL MED,DEPT PHARMACOL & THERAPEUT,GAINESVILLE,FL 32610, USA.				NATIONAL EYE INSTITUTE [R01EY002227] Funding Source: NIH RePORTER; NEI NIH HHS [EYO2227] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BALDWIN JJ, 1989, J MED CHEM, V32, P2510, DOI 10.1021/jm00132a003; BLACKBURN GM, 1985, EUR J BIOCHEM, V153, P553, DOI 10.1111/j.1432-1033.1985.tb09336.x; BRECHUE WF, 1993, J PHARMACOL EXP THER, V264, P670; BRECHUE WF, 1991, BIOCHIM BIOPHYS ACTA, V1066, P201, DOI 10.1016/0005-2736(91)90187-D; Brice T.J., 1956, US Patent, Patent No. [2732398, 2,732,398]; BUCHHOLT HC, 1970, ACTA CHEM SCAND, V24, P2255, DOI 10.3891/acta.chem.scand.24-2255; COLEMAN JE, 1975, ANNU REV PHARMACOL, V15, P221, DOI 10.1146/annurev.pa.15.040175.001253; CONROY CW, 1992, EXP EYE RES, V55, P637, DOI 10.1016/S0014-4835(05)80176-9; CONROY CW, 1984, DRUG METAB DISPOS, V12, P614; HANSCH C, 1985, MOL PHARMACOL, V27, P493; HOWELLS RD, 1977, CHEM REV, V77, P69, DOI 10.1021/cr60305a005; JANKOWSKA LM, 1986, INVEST OPHTH VIS SCI, V27, P29; KAKEYA N, 1969, CHEM PHARM BULL, V17, P2558; KAKEYA N, 1969, CHEM PHARM BULL, V17, P1010; KHALIFAH RG, 1977, BIOCHEMISTRY-US, V16, P2241, DOI 10.1021/bi00629a031; KING RW, 1976, PROC R SOC SER B-BIO, V193, P107, DOI 10.1098/rspb.1976.0034; KREBS HA, 1948, BIOCHEM J, V43, P525, DOI 10.1042/bj0430525; Kvam D. C., 1989, U.S. Patent, Patent No. [4,824,866A, 4824866]; LINDAHL M, 1991, CARBONIC ANHYDRASE B, P110; LOGRASSO PV, 1991, BIOCHEMISTRY-US, V30, P8463, DOI 10.1021/bi00098a025; Mann T., 1940, NATURE, V146, P164, DOI [10.1038/146164a0, DOI 10.1038/146164A0]; MAREN TH, 1992, MOL PHARMACOL, V41, P419; MAREN TH, 1988, ANNU REV PHYSIOL, V50, P695; MAREN TH, 1983, ANNU REV PHARMACOL, V23, P439, DOI 10.1146/annurev.pa.23.040183.002255; MAREN TH, 1990, EXP EYE RES, V50, P27, DOI 10.1016/0014-4835(90)90007-H; MAREN TH, 1968, J MED CHEM, V11, P228, DOI 10.1021/jm00308a008; MAREN TH, 1993, MOL PHARMACOL, V44, P901; MAREN TH, 1977, INVEST OPHTH VIS SCI, V16, P730; MAREN TH, 1983, EXP EYE RES, V36, P457, DOI 10.1016/0014-4835(83)90041-6; MAREN TH, 1967, PHYSIOL REV, V47, P595, DOI 10.1152/physrev.1967.47.4.595; MARSHALL EK, 1913, J BIOL CHEM, V15, P283; MILLER WH, 1950, J AM CHEM SOC, V72, P4893, DOI 10.1021/ja01167a012; OLANDER J, 1973, J AM CHEM SOC, V95, P1616, DOI 10.1021/ja00786a042; OLANDER J, 1973, J AM CHEM SOC, V95, P4473; PRABHANANDA BS, 1987, BIOPHYS CHEM, V26, P217, DOI 10.1016/0301-4622(87)80024-8; Smith H. W., 1951, KIDNEY; TASHIAN RE, 1991, CARBONIC ANHYDRASE, P151; TREPKA RD, 1974, J ORG CHEM, V39, P1094, DOI 10.1021/jo00922a017; VIDGREN J, 1990, INT J BIOL MACROMOL, V12, P342, DOI 10.1016/0141-8130(90)90040-H; VOGH BP, 1989, J OCUL PHARMACOL, V5, P293, DOI 10.1089/jop.1989.5.293; [No title captured]	41	82	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26233	26239						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253744				2022-12-25	WOS:A1993MK42500036
J	OHNAKA, K; TAKAYANAGI, R; NISHIKAWA, M; HAJI, M; NAWATA, H				OHNAKA, K; TAKAYANAGI, R; NISHIKAWA, M; HAJI, M; NAWATA, H			PURIFICATION AND CHARACTERIZATION OF A PHOSPHORAMIDON-SENSITIVE ENDOTHELIN-CONVERTING ENZYME IN PORCINE AORTIC ENDOTHELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIG ENDOTHELIN-1; CATHEPSIN-D; METALLOPROTEINASE INHIBITOR; CELLS; CONVERSION; PROTEINS; INVIVO; ELECTROPHORESIS; IDENTIFICATION; SUPPRESSES	An enzyme that catalyzes the conversion of big endothelin-1 to endothelin-1, designated as endothelin-converting enzyme, was solubilized with Lubrol PX from the membrane fraction of porcine aortic endothelium and was purified by sequential chromatography on DEAE-agarose, Ricinus communis agglutinin 120-agarose, peanut agglutinin-agarose, Mono Q, and TSK G3000SW(XL) columns. Approximately 12,000-fold purification of the membrane fraction enzyme was achieved. The purified enzyme had a very narrow neutral pH optimum and was inhibited by EDTA, 1, 10-phenanthroline, phosphoramidon, and low concentrations of some divalent cations (Cu2+, Zn2+, Co2+, Fe2+) but not by thiorphan. Addition of Zn2+ was most effective for the restoration of the EDTA-inactivated enzyme. The purified enzyme showed the highest affinity for big endothelin-1 among big endothelin isopeptides, and the K(m) for big endothelin-1 and the corresponding V(max) for endothelin-1 formation were 3.3 +/- 0.3 muM and 0.41 +/- 0.02 mumol/min/mg of protein, respectively. The carboxyl-terminal sequence from His27 to Gly34 and Trp21 was essential for recognition by this enzyme, while the presence of the amino-terminal loop structure reduced the hydrolysis rate. The purified enzyme showed an isoelectric point of 4.1. The molecular mass was estimated to be 131 kDa by sucrose density gradient centrifugation, and a value of 120 kDa was obtained by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, indicating that endothelin-converting enzyme is a monomeric glycoprotein.	KYUSHU UNIV, FAC MED,DEPT INTERNAL MED 3,MAINASHI 3-1-1, HIGASHI KU, FUKUOKA 812, JAPAN; FUJISAWA PHARMACEUT CO LTD, EXPLORATORY RES LABS, TSUKUBA, IBARAKI 30026, JAPAN	Kyushu University; Astellas Pharmaceuticals								AHN K, 1992, P NATL ACAD SCI USA, V89, P8606, DOI 10.1073/pnas.89.18.8606; ANDREWS P, 1965, BIOCHEM J, V96, P595, DOI 10.1042/bj0960595; CUSHMAN DW, 1971, BIOCHEM PHARMACOL, V20, P1637, DOI 10.1016/0006-2952(71)90292-9; DAS M, 1975, J BIOL CHEM, V250, P6762; DENG YL, 1992, J BIOCHEM, V111, P346, DOI 10.1093/oxfordjournals.jbchem.a123760; FUKURODA T, 1990, BIOCHEM BIOPH RES CO, V172, P390, DOI 10.1016/0006-291X(90)90685-G; HAGA T, 1977, J BIOL CHEM, V252, P5776; IKEGAWA R, 1990, BIOCHEM BIOPH RES CO, V171, P669, DOI 10.1016/0006-291X(90)91198-2; IKEGAWA R, 1990, BIOCHEM BIOPH RES CO, V167, P860, DOI 10.1016/0006-291X(90)92104-8; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; KASHIWABARA T, 1989, FEBS LETT, V247, P73, DOI 10.1016/0014-5793(89)81243-8; KON V, 1989, J CLIN INVEST, V83, P1762, DOI 10.1172/JCI114079; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MASAOKA H, 1989, LANCET, V2, P1402; MATSUMURA Y, 1990, FEBS LETT, V272, P166, DOI 10.1016/0014-5793(90)80475-X; MATSUMURA Y, 1990, BIOCHEM BIOPH RES CO, V167, P203, DOI 10.1016/0006-291X(90)91751-D; MATSUMURA Y, 1990, EUR J PHARMACOL, V185, P103, DOI 10.1016/0014-2999(90)90216-S; MATSUMURA Y, 1991, BIOCHEM BIOPH RES CO, V178, P531, DOI 10.1016/0006-291X(91)90140-3; MCMAHON EG, 1991, P NATL ACAD SCI USA, V88, P703, DOI 10.1073/pnas.88.3.703; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHNAKA K, 1990, BIOCHEM BIOPH RES CO, V168, P1128, DOI 10.1016/0006-291X(90)91146-J; OHNAKA K, 1992, BIOCHEM BIOPH RES CO, V185, P611, DOI 10.1016/0006-291X(92)91668-G; OHNAKA K, 1991, J CARDIOVASC PHARM, V17, pS17, DOI 10.1097/00005344-199100177-00006; OKADA K, 1991, BIOCHEM BIOPH RES CO, V180, P1019, DOI 10.1016/S0006-291X(05)81167-2; OKADA K, 1990, BIOCHEM BIOPH RES CO, V171, P1192, DOI 10.1016/0006-291X(90)90811-Z; ORLEANSJUSTE PD, 1990, BIOCHEM PHARMACOL, V39, pR21, DOI 10.1016/0006-2952(90)90419-L; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SAWAMURA T, 1990, BIOCHEM BIOPH RES CO, V172, P883, DOI 10.1016/0006-291X(90)90758-F; SAWAMURA T, 1991, BIOCHEM BIOPH RES CO, V174, P779, DOI 10.1016/0006-291X(91)91485-U; SAWAMURA T, 1990, BIOCHEM BIOPH RES CO, V169, P1138, DOI 10.1016/0006-291X(90)92014-Q; SAWAMURA T, 1990, BIOCHEM BIOPH RES CO, V168, P1230, DOI 10.1016/0006-291X(90)91160-T; SHIELDS PP, 1991, BIOCHEM BIOPH RES CO, V177, P1006, DOI 10.1016/0006-291X(91)90638-N; TAKADA J, 1991, BIOCHEM BIOPH RES CO, V176, P860, DOI 10.1016/S0006-291X(05)80265-7; TAKAOKA M, 1990, BIOCHEM BIOPH RES CO, V173, P1218, DOI 10.1016/S0006-291X(05)80916-7; TASHEVA B, 1983, ANAL BIOCHEM, V129, P98, DOI 10.1016/0003-2697(83)90057-X; WATANABE T, 1990, NATURE, V344, P114, DOI 10.1038/344114a0; WATANABE T, 1991, CIRC RES, V69, P370, DOI 10.1161/01.RES.69.2.370; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; WUWONG JR, 1990, BIOCHEM BIOPH RES CO, V171, P1291, DOI 10.1016/0006-291X(90)90826-9; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	41	124	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26759	26766						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253812				2022-12-25	WOS:A1993MK42500109
J	ROESSLER, BJ; NOSAL, JM; SMITH, PR; HEIDLER, SA; PALELLA, TD; SWITZER, RL; BECKER, MA				ROESSLER, BJ; NOSAL, JM; SMITH, PR; HEIDLER, SA; PALELLA, TD; SWITZER, RL; BECKER, MA			HUMAN X-LINKED PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE SUPERACTIVITY IS ASSOCIATED WITH DISTINCT POINT MUTATIONS IN THE PRPS1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYROPHOSPHATE SYNTHETASE; SALMONELLA-TYPHIMURIUM; SUBUNIT-II; NUCLEOTIDE; IDENTIFICATION; LOCALIZATION; EXPRESSION; OVERPRODUCTION; PURIFICATION; FIBROBLASTS	Superactivity of phosphoribosylpyrophosphate synthetase (PRS) is an X chromosome-linked disorder of purine metabolism, characterized by gout with uric acid overproduction and, in some families, neurodevelopmental impairment. Two highly homologous isoforms of PRS (PRS1 and PRS2), each encoded by a distinct X chromosome-linked locus, have been identified, and PRS1 and 2 cDNAs have been cloned. The entire 954-base pair translated regions of PRS1 and 2 cDNAs derived from cultured lymphoblasts and fibroblasts from two patients in whom purine nucleotide feedback resistance of PRS is associated with enzyme superactivity and neurodevelopmental defects were examined by direct sequencing after polymerase chain reaction amplification of PRS transcripts. Nucleotide sequences of PRS2 cDNAs from the patients and normal individuals were identical. In contrast, PRS1 cDNAs from the patients differ from normal PRS1 cDNA, each by a single base substitution. PRS1 cDNA from patient N. B. showed an A to G transition at nucleotide 341, corresponding to an asparagine to serine change at amino acid residue 113 of mature PRS1. A G to C transversion at nucleotide 547, indicating an aspartic acid to histidine change at amino acid 182, was found for PRS1 cDNA from patient S. M. Point mutations at the sites identified in the PRS1 cDNAs of the two patients were confirmed by the results of RNase mapping analysis. Normal, N. B., and S. M. PRS1 cDNAs were introduced into Escherichia coli BL21(DE3)/pLysS, and recombinant N. B. and S. M. PRS1s showed the purine nucleotide feedback resistance phenotypes characteristic of PRS from patients' cells.	UNIV CHICAGO,MED CTR,DEPT MED,MC0930,5841 S MARYLAND AVE,CHICAGO,IL 60637; UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Chicago; University of Chicago Medical Center; University of Michigan System; University of Michigan; University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013488, R01DK028554, R29DK038932, R01DK038932] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 13488, DK 28554, DK 38932] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNVIG K, 1990, EUR J BIOCHEM, V192, P195, DOI 10.1111/j.1432-1033.1990.tb19214.x; Becker M A, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P281; BECKER MA, 1980, J CLIN INVEST, V65, P109, DOI 10.1172/JCI109640; BECKER MA, 1987, J BIOL CHEM, V262, P5596; BECKER MA, 1986, BIOCHIM BIOPHYS ACTA, V882, P168, DOI 10.1016/0304-4165(86)90151-0; BECKER MA, 1991, ADV EXP MED BIOL, V309, P129; BECKER MA, 1975, J BIOL CHEM, V250, P6822; BECKER MA, 1986, ARTHRITIS RHEUM, V29, P880, DOI 10.1002/art.1780290710; BECKER MA, 1988, AM J MED, V85, P383, DOI 10.1016/0002-9343(88)90591-8; BECKER MA, 1990, GENOMICS, V8, P555, DOI 10.1016/0888-7543(90)90043-T; BOWER SG, 1988, J BACTERIOL, V170, P3243, DOI 10.1128/jb.170.7.3243-3248.1988; BOWER SG, 1989, J BIOL CHEM, V264, P10287; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; DAVIDSON BL, 1991, AM J HUM GENET, V48, P951; FOX IH, 1971, J BIOL CHEM, V246, P5739; GIBBS RA, 1987, SCIENCE, V236, P303, DOI 10.1126/science.3563511; HARLOW KW, 1990, J BIOL CHEM, V265, P5487; HOVEJENSEN B, 1986, J BIOL CHEM, V261, P6765; HOVEJENSEN B, 1989, MOL MICROBIOL, V3, P1437; IIZASA T, 1989, FEBS LETT, V244, P47, DOI 10.1016/0014-5793(89)81159-7; KORNBERG A, 1955, J BIOL CHEM, V215, P389; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOSMAN MJ, 1985, J CLIN INVEST, V76, P1657, DOI 10.1172/JCI112151; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NOSAL JM, 1993, J BIOL CHEM, V268, P10168; ROESNBLOOM FM, 1909, J BIOL CHEM, V18, P193; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SIMMONDS HA, 1982, LANCET, V2, P68; SONODA T, 1991, J BIOCHEM-TOKYO, V109, P361; STUDIER RW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAIRA M, 1989, BIOCHIM BIOPHYS ACTA, V1007, P203, DOI 10.1016/0167-4781(89)90040-7; TAIRA M, 1987, J BIOL CHEM, V262, P14867; TAIRA M, 1989, SOMAT CELL MOLEC GEN, V15, P29, DOI 10.1007/BF01534667; YEN RCK, 1978, P NATL ACAD SCI USA, V75, P482, DOI 10.1073/pnas.75.1.482; ZOREF E, 1975, J CLIN INVEST, V56, P1093, DOI 10.1172/JCI108183	39	44	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26476	26481						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253776				2022-12-25	WOS:A1993MK42500070
J	VALCARCE, C; SELANDERSUNNERHAGEN, M; TAMLITZ, AM; DRAKENBERG, T; BJORK, I; STENFLO, J				VALCARCE, C; SELANDERSUNNERHAGEN, M; TAMLITZ, AM; DRAKENBERG, T; BJORK, I; STENFLO, J			CALCIUM AFFINITY OF THE NH2-TERMINAL EPIDERMAL GROWTH FACTOR-LIKE MODULE OF FACTOR-X - EFFECT OF THE GAMMA-CARBOXYGLUTAMIC ACID-CONTAINING MODULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-HYDROXYASPARTIC ACID; HUMAN FACTOR-IX; FACTOR-LIKE DOMAIN; COAGULATION FACTOR-X; DEPENDENT PROTEIN-S; EGF-LIKE DOMAINS; FACTOR PRECURSOR; LIGHT CHAIN; BINDING; RESIDUES	The NH2-terminal epidermal growth factor (EGF)-like module of vitamin K-dependent coagulation factors IX and X and protein C each has one calcium binding site. This module (residues 45-86) from factor X has been isolated previously and found to bind calcium with a K(d) of 2.2 mM at physiological pH and ionic strength. We have now demonstrated that it binds calcium with a K(d) of 120 muM in a fragment that consists of the Gla module and the NH2-terminal EGF-like module. The presence of the Gla module (residues 1-44) increases the calcium affinity of the site in the EGF-like module approximately 20-fold, thus making it essentially saturated in vivo. Decarboxylation of the Gla residues to Glu has no significant effect on the calcium affinity of the EGF-like module. A proteolytic fragment of factor X (residues 29-86) and a synthetic peptide (residues 34-86), folded to a native conformation, were used to demonstrate that the contribution of the Gla module to the calcium affinity of the site in the EGF-like module is mediated by its 17 COOH-terminal residues, 12 of which form an alpha-helix in the intact Gla module. In the NMR structure of the NH2-terminal EGF-like module in factor X, five calcium ligating groups have been identified (Selander-Sunnerhagen, M., Ullner, M., Persson, E., Teleman, O., Stenflo, J., and Drakenberg, T. (1992) J. Biol. Chem. 267, 19642-19649). As calcium usually requires seven to eight oxygen ligands, there is reason to believe that the Gla module contributes ligands, or negative charge, to increase the calcium affinity. Our findings suggest that the calcium affinity of EGF-like modules in other proteins may also be influenced by neighboring modules.	LUND UNIV,DEPT CLIN CHEM,S-21401 MALMO,SWEDEN; LUND UNIV,DEPT PHYS CHEM 2,S-22100 LUND,SWEDEN; SWEDISH UNIV AGR SCI,UPPSALA BIOMED CTR,DEPT VET MED,S-75123 UPPSALA,SWEDEN	Lund University; Lund University; Swedish University of Agricultural Sciences								APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; BARON M, 1992, PROTEIN SCI, V1, P81; DAHLBACK B, 1990, J BIOL CHEM, V265, P18481; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DRAKENBERG T, 1983, P NATL ACAD SCI-BIOL, V80, P1802, DOI 10.1073/pnas.80.7.1802; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; FERNLUND P, 1983, J BIOL CHEM, V258, P2509; GARCIA MWS, 1992, BIOCHEMISTRY-US, V31, P2554; GRONKE RS, 1989, P NATL ACAD SCI USA, V86, P3609, DOI 10.1073/pnas.86.10.3609; GRONKE RS, 1990, J BIOL CHEM, V265, P8558; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HANDFORD PA, 1991, NATUREJ, V351, P84; LINSE S, 1988, NATURE, V335, P651, DOI 10.1038/335651a0; MCMULLEN BA, 1983, BIOCHEMISTRY-US, V22, P2875, DOI 10.1021/bi00281a016; MCMULLEN BA, 1983, BIOCHEM BIOPH RES CO, V115, P8, DOI 10.1016/0006-291X(83)90961-0; Morissey J. H., 1981, ANAL BIOCHEM, V117, P307; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PERSSON E, 1991, J BIOL CHEM, V266, P2444; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; STENFLO J, 1991, BLOOD, V78, P1637; STENFLO J, 1989, P NATL ACAD SCI USA, V86, P444, DOI 10.1073/pnas.86.2.444; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; STENFLO J, 1987, P NATL ACAD SCI USA, V84, P368, DOI 10.1073/pnas.84.2.368; STENFLO J, 1977, ANNU REV BIOCHEM, V46, P157, DOI 10.1146/annurev.bi.46.070177.001105; [No title captured]	28	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26673	26678						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253800				2022-12-25	WOS:A1993MK42500096
J	FLINT, DH; SMYKRANDALL, E; TUMINELLO, JF; DRACZYNSKALUSIAK, B; BROWN, OR				FLINT, DH; SMYKRANDALL, E; TUMINELLO, JF; DRACZYNSKALUSIAK, B; BROWN, OR			THE INACTIVATION OF DIHYDROXY-ACID DEHYDRATASE IN ESCHERICHIA-COLI TREATED WITH HYPERBARIC-OXYGEN OCCURS BECAUSE OF THE DESTRUCTION OF ITS FE-S CLUSTER, BUT THE ENZYME REMAINS IN THE CELL IN A FORM THAT CAN BE REACTIVATED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTER; ELEMENT BINDING-PROTEIN; RNA-BINDING; ACONITASE; BIOSYNTHESIS; PURIFICATION; INHIBITION	The enzyme dihydroxy-acid dehydratase previously has been shown to be inactivated in vivo in Escherichia coli within minutes of exposure to hyperbaric O2. In this paper, we show its inactivation is due to the destruction of its catalytically active [4Fe-4S] cluster. The inactivation is not followed by an appreciable decrease in the amount of dihydroxy-acid dehydratase protein as determined by Western blots. Thus, the protein from the inactivated enzyme remains unproteolyzed in the cells. Dihydroxy-acid dehydratase activity recovers after the cells treated with hyperbaric O2 are returned to ambient oxygen. Since this recovery in activity is not accompanied by a significant increase in dihydroxy-acid dehydratase protein and is not prevented by chloramphenicol, it appears primarily to be due to reactivation of the previously inactivated enzyme. The reactivation occurs by reconstitution of the enzyme's Fe-S cluster. These results demonstrate that this enzyme can cycle between forms in which the Fe-S cluster is either present or absent. The facile ability to cycle between these two forms would be compatible with a regulatory role in addition to a catalytic role for this enzyme.	UNIV MISSOURI,DALTON RES CTR,COLUMBIA,MO 65201; UNIV MISSOURI,DEPT BIOMED SCI,COLUMBIA,MO 65211; UNIV MISSOURI,DEPT MOLEC MICROBIOL & IMMUNOL,COLUMBIA,MO 65211	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	FLINT, DH (corresponding author), DUPONT CO INC,DEPT CENT RES & DEV,POB 80328,WILMINGTON,DE 19880, USA.				NIEHS NIH HHS [5RO1-ES02566] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002566] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Beinert H, 1978, Methods Enzymol, V54, P435; BERNLOHR DA, 1981, BIOCHEMISTRY-US, V20, P5675, DOI 10.1021/bi00523a006; BOEHME DE, 1976, NATURE, V262, P418, DOI 10.1038/262418a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN OR, 1978, BIOCHEM BIOPH RES CO, V85, P1219, DOI 10.1016/0006-291X(78)90672-1; BROWN OR, 1972, MICROBIOS, V5, P7; EMPTAGE MH, 1983, P NATL ACAD SCI-BIOL, V80, P4674, DOI 10.1073/pnas.80.15.4674; EMPTAGE MH, 1988, METAL CLUSTERS PROTE, P343; FLINT DH, 1992, BIOCHEMISTRY-US, V31, P10331, DOI 10.1021/bi00157a022; FLINT DH, 1993, J BIOL CHEM, V268, P14732; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FLINT DH, 1988, J BIOL CHEM, V263, P3558; FLOYD RA, 1991, SCIENCE, V254, P1597, DOI 10.1126/science.1684251; FRIDOVICH I, 1972, ACCOUNTS CHEM RES, V5, P321, DOI 10.1021/ar50058a001; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GRANDONI JA, 1989, J BIOL CHEM, V264, P6058; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KENNEDY MC, 1984, J BIOL CHEM, V259, P4463; KUO CF, 1987, J BIOL CHEM, V262, P4724; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LAWTHER RP, 1987, NUCLEIC ACIDS RES, V15, P2137, DOI 10.1093/nar/15.5.2137; LIOCHEV SI, 1993, ARCH BIOCHEM BIOPHYS, V153, P379; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; SMYKRANDALL EM, 1987, ANAL BIOCHEM, V164, P434, DOI 10.1016/0003-2697(87)90516-1	27	92	106	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25547	25552						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244991				2022-12-25	WOS:A1993MK10000042
J	KWON, OS; CHURCHICH, JE				KWON, OS; CHURCHICH, JE			INTERACTION OF 70-KDA HEAT-SHOCK COGNATE PROTEIN WITH PEPTIDES AND MYOINOSITOL MONOPHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEINS; BINDING; CLATHRIN; PURIFICATION; ATPASE; HSP70	Fluorescence techniques have been used to investigate the interaction of bovine 70-kDA heat shock cognate protein (Hsc 70) with small molecular weight peptides and myo-inositol monophosphatase. The emission properties of Hsc 70 remain invariant upon addition of ATP. The results of steady-state fluorescence indicate that the tryptophan residues of Hsc 70 are exposed to the rapidly relaxing aqueous solvent. Binding of residues 1-20 of ribonuclease A (RNase S-peptide) to Hsc 70 causes protein fluorescence quenching which was used to determine a dissociation constant K(d) = 2.7 muM for the binary Hsc 70.RNase S-peptide complex. The octapeptide corresponding to the NH2-terminal portion of sickle cell hemoglobin recognizes Hsc 70 and binds with a K(d) = 9.3 muM. Binding of RNase S-peptide to Hsc 70 produces a small enhancement of ATPase activity. Unfolded myoinositol monophosphatase, tagged with the fluorescent probe 5-[2-(2-iodoacetamido)ethylamino]-1-naphthalenesulfonic acid, recognizes Hsc 70; the formation of a stable complex was detected by steady-state emission anisotropy measurements. The rate and extent of recovery of catalytic activity of unfolded myo-inositol monophosphatase is not influenced by Hsc 70. It is suggested that interaction of Hsc 70 with unfolded proteins in the cell may be able to delay the formation of misfolded structures.			KWON, OS (corresponding author), UNIV TENNESSEE,DEPT BIOCHEM,KNOXVILLE,TN 37996, USA.							BAIS R, 1975, ANAL BIOCHEM, V63, P271, DOI 10.1016/0003-2697(75)90215-8; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BIERZYNSKI A, 1982, P NATL ACAD SCI-BIOL, V79, P2470, DOI 10.1073/pnas.79.8.2470; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEMCHENKO AP, 1982, BIOPHYS CHEM, V15, P101, DOI 10.1016/0301-4622(82)80022-7; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GALLEY WC, 1970, P NATL ACAD SCI USA, V67, P1116, DOI 10.1073/pnas.67.3.1116; GEE NS, 1988, BIOCHEM J, V249, P880; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KWON OS, 1993, J BIOL CHEM, V268, P7912; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; MAZURENKO YT, 1970, OPT SPEKTROSK, V28, P905; MEEK JL, 1988, BIOCHEM BIOPH RES CO, V156, P143, DOI 10.1016/S0006-291X(88)80816-7; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; RICHARDS FM, 1959, J BIOL CHEM, V234, P1459; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; ROTHMAN JE, 1986, NATURE, V322, P209, DOI 10.1038/322209a0; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID SL, 1985, J BIOL CHEM, V260, P10050; STEVENSON MA, 1990, MOL CELL BIOL, V10, P1234, DOI 10.1128/MCB.10.3.1234; WASYLEWSKI Z, 1992, EUR J BIOCHEM, V206, P235, DOI 10.1111/j.1432-1033.1992.tb16921.x	29	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					266	271						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276805				2022-12-25	WOS:A1994MR21900048
J	OPOKU, J; SIMONS, SS				OPOKU, J; SIMONS, SS			ABSENCE OF INTRAMOLECULAR DISULFIDES IN THE STRUCTURE AND FUNCTION OF NATIVE RAT GLUCOCORTICOID RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; SITE-DIRECTED MUTAGENESIS; STEROID-BINDING; DEXAMETHASONE 21-MESYLATE; BOND FORMATION; SULFHYDRYL-GROUPS; REDOX REGULATION; PROTEIN; CYSTEINES; DOMAIN	The presence of intramolecular disulfides in different functional states of the native glucocorticoid receptor in the absence of added oxidants has been examined on nonreducing SDS-polyacrylamide gels. Possible disulfides were trapped by the reaction of thiols in crude receptor solutions with methyl methanethiolsulfonate or iodoacetamide. The presence of diffuse bands at lower molecular weights than either the fully reduced or the thiol-blocked species for both the intact 98-kDa receptor and the 42-kDa chymotryptic fragment was diagnostic of an intramolecular disulfide(s) that had undergone thiol-disulfide rearrangements. However, both the rearrangements and the formation of intramolecular disulfides were found to occur only with denatured receptors during gel analysis. It appears that the thiols normally complexed with zinc in the zinc fingers may be recruited for disulfide bond formation. Finally, even when a documented intramolecular disulfide was formed in solutions of the native protein, thiol-disulfide rearrangements did not occur. The tertiary structure of the receptor is thus constituted in a manner that not only limits the formation of disulfides but also prevents the usually facile rearrangements of disulfide bond-containing structures to receptor forms that may have greatly reduced activity. Therefore, although intramolecular disulfide bonds may be of transitory importance, the structural or functional changes of native glucocorticoid receptors that are associated with steroid binding, activation, and dissociation of heat shock protein 90 neither involve nor require the formation or reduction of stable intramolecular disulfides.	NIDDK,LMCB,STEROID HORMONES SECT,BLDG 8,RM B2A-07,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BLICQ S, 1988, BIOCHEMISTRY-US, V27, P8436, DOI 10.1021/bi00422a021; BODWELL JE, 1984, BIOCHEMISTRY-US, V23, P1392, DOI 10.1021/bi00302a009; BRESNICK EH, 1988, BIOCHEMISTRY-US, V27, P2866, DOI 10.1021/bi00408a030; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CAVANAUGH AH, 1990, BIOCHEMISTRY-US, V29, P996, DOI 10.1021/bi00456a023; CHAKRABORTI PK, 1990, ENDOCRINOLOGY, V127, P2530, DOI 10.1210/endo-127-5-2530; CHAKRABORTI PK, 1992, J BIOL CHEM, V267, P11366; CLARKE J, 1993, BIOCHEMISTRY-US, V32, P4322, DOI 10.1021/bi00067a022; EISEN LP, 1985, J BIOL CHEM, V260, P1805; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FISER A, 1992, FEBS LETT, V302, P117, DOI 10.1016/0014-5793(92)80419-H; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GRANBERG JP, 1977, ENDOCRINOLOGY, V100, P1160; GRIPPO JF, 1985, J BIOL CHEM, V260, P93; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HOECK W, 1989, J BIOL CHEM, V264, P14396; HUTCHISON KA, 1991, J BIOL CHEM, V266, P10505; JACOBSON BL, 1991, J BIOL CHEM, V266, P5220; KOSEN PA, 1992, BIOCHEMISTRY-US, V31, P5705, DOI 10.1021/bi00140a004; LANDGRAF W, 1991, J BIOL CHEM, V266, P16305; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MAYADAS TN, 1992, P NATL ACAD SCI USA, V89, P3531, DOI 10.1073/pnas.89.8.3531; MCBRIDE AA, 1992, P NATL ACAD SCI USA, V89, P7531, DOI 10.1073/pnas.89.16.7531; MESHINCHI S, 1990, J BIOL CHEM, V265, P11643; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MILLER NR, 1988, J BIOL CHEM, V263, P15217; OCONNOR TR, 1993, J BIOL CHEM, V268, P9063; OSHIMA H, 1992, MOL ENDOCRINOL, V6, P416, DOI 10.1210/me.6.3.416; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; REICHMAN ME, 1984, BIOCHEMISTRY-US, V23, P5376, DOI 10.1021/bi00317a042; ROTHWARF DM, 1992, P NATL ACAD SCI USA, V89, P7944, DOI 10.1073/pnas.89.17.7944; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; SILVA CM, 1989, J BIOL CHEM, V264, P6638; SIMONS SS, 1987, J BIOL CHEM, V262, P9676; SIMONS SS, 1990, J BIOL CHEM, V265, P1938; SIMONS SS, 1987, J BIOL CHEM, V262, P9669; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; SIMONS SS, 1981, P NATL ACAD SCI-BIOL, V78, P3541, DOI 10.1073/pnas.78.6.3541; SINGH R, 1991, J ORG CHEM, V56, P2332, DOI 10.1021/jo00007a018; SPANJAARD RA, 1993, MOL ENDOCRINOL, V7, P12, DOI 10.1210/me.7.1.12; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TANIYAMA Y, 1991, J BIOL CHEM, V266, P6456; TIENRUNGROJ W, 1987, J BIOL CHEM, V262, P6992; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	50	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					503	510						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276843				2022-12-25	WOS:A1994MR21900082
J	RANKIN, S; ROZENGURT, E				RANKIN, S; ROZENGURT, E			PLATELET-DERIVED GROWTH-FACTOR MODULATION OF FOCAL ADHESION KINASE (P125FAK) AND PAXILLIN TYROSINE PHOSPHORYLATION IN SWISS 3T3 CELLS - BELL-SHAPED DOSE-RESPONSE AND CROSS-TALK WITH BOMBESIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; PDGF RECEPTOR; SIGNAL TRANSDUCTION; ONCOGENIC TRANSFORMATION; SH3 DOMAINS; PROTEIN; ASSOCIATION; BINDING; VASOPRESSIN; STIMULATION	In the present study, we have identified several proteins in Swiss 3T3 cells that are phosphorylated on tyrosine in response to platelet-derived growth factor (PDGF) and exhibit an unusual bell-shaped dose-response curve with a maximum at 5 ng/ml platelet-derived growth factor (PDGF). These proteins include two that are associated with focal adhesions, namely the focal adhesion kinase (p125FAK), a novel cytosolic tyrosine kinase, and paxillin. At low concentrations of PDGF (1-5 ng/ml), these proteins are the predominant tyrosine-phosphorylated species. At 30 ng/ml PDGF, however, there was no stimulation of their phosphorylation over control levels. In contrast, tyrosine phosphorylation of previously described substrates of the PDGF receptor tyrosine kinase, namely the p21ras GTPase-activating protein, p120, phosphatidyl inositol 3' kinase, and phospholipase Cgamma exhibited sigmoidal dose-response curves with PDGF and were all efficiently phosphorylated on tyrosine at 30 ng/ml PDGF. Cytochalasin D, which disrupts the actin cytoskeleton, completely inhibited the tyrosine phosphorylation of p125FAK and paxillin by PDGF. Examination of the actin cytoskeleton after stimulation of cells with different concentrations of PDGF revealed that at 5 ng/ml PDGF, actin appears in stress fibers and in membrane ruffles, while at 30 ng/ml, PDGF disrupts the actin cytoskeleton. Bombesin stimulates actin stress fiber formation with no evidence of disruption of stress fibers at high concentrations. When cells were stimulated with bombesin (10 nm) in the presence of 30 ng/ml PDGF, however, the actin cytoskeleton was completely disrupted. Further, the tyrosine phosphorylation of both p125FAK and paxillin induced by bombesin (10 nm) was completely prevented when cells were stimulated with bombesin in the presence of 30 ng/ml PDGF. We propose that the inhibitory limb in the bell-shaped dose-response curve of PDGF and the novel cross-talk between PDGF and bombesin on tyrosine phosphorylation may be explained by the ability of PDGF at 30 ng/ml to disrupt the actin cytoskeleton.	IMPERIAL CANC RES FUND,POB 123,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND	Cancer Research UK								ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BOCKUS BJ, 1984, EXP CELL RES, V153, P186, DOI 10.1016/0014-4827(84)90460-9; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; DOWNING JR, 1991, ONCOGENE, V6, P607; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FORCE T, 1991, J BIOL CHEM, V266, P6650; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HERMAN B, 1985, J CELL BIOL, V100, P1031, DOI 10.1083/jcb.100.4.1031; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; MELLSTROM K, 1983, J MUSCLE RES CELL M, V4, P589, DOI 10.1007/BF00712117; MIURA Y, 1993, J BIOL CHEM, V268, P501; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SIEFERT RA, 1989, J BIOL CHEM, V264, P8771; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WESTERMARK B, 1991, CANCER RES, V51, P5087; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WOODS A, 1988, COLLAGEN REL RES, V8, P155; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	64	315	316	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					704	710						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276872				2022-12-25	WOS:A1994MR21900110
J	ROBERTS, RC; SPANGLER, C; HELINSKI, DR				ROBERTS, RC; SPANGLER, C; HELINSKI, DR			CHARACTERISTICS AND SIGNIFICANCE OF DNA-BINDING ACTIVITY OF PLASMID STABILIZATION PROTEIN PARD FROM THE BROAD-HOST-RANGE PLASMID RK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; SITE-SPECIFIC RECOMBINATION; F-PLASMID; AGROBACTERIUM-TUMEFACIENS; ESCHERICHIA-COLI; SYSTEM; REGION; PARTITION; SEQUENCE; LOCUS	A region of the plasmid RK2 has been shown to stabilize plasmid replicons in a broad host-range manner. This region encodes two divergently transcribed operons: parCBA and parDE. The parCBA operon specifies a multimer resolution system, while the parDE operon alone is capable of stabilizing an RK2-derived minireplicon under defined growth conditions in several different Gram-negative bacteria. The observed autoregulation of the parDE operon is most likely the result of ParD protein binding within the PparDE region. The characteristics of ParD binding to this region and the role of such binding in plasmid stabilization were examined with purified ParD protein. The results indicate that the binding of a single dimer of ParD protein to the promoter region most likely blocks interaction of RNA polymerase holoenzyme with the promoter. DNase I protection experiments indicate that ParD binds to a discrete sequence of 48 base pairs in length. While the binding of ParD to PparDE is essential for proper regulation of expression of the ParD and ParE proteins in vivo, the analyses of binding properties of mutant ParD proteins suggest that binding to this region does not play a direct role in plasmid stabilization.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI007194] Funding Source: NIH RePORTER; NIAID NIH HHS [AIO7194] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABELES AL, 1985, J MOL BIOL, V185, P261, DOI 10.1016/0022-2836(85)90402-4; Brand L., 1967, METHODS ENZYMOL, P776, DOI [10.1016/S0076-6879(67)11091-4, DOI 10.1016/S0076-6879(67)11091-4]; Cantor CR, 1980, BIOPHYSICAL CHEM 2, P461; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; DAVIS TL, 1992, MOL MICROBIOL, V6, P1981, DOI 10.1111/j.1365-2958.1992.tb01371.x; DODD HM, 1987, J GEN MICROBIOL, V133, P2031; EBERL L, 1992, MOL MICROBIOL, V9, P1969; FUNNELL BE, 1988, J BACTERIOL, V170, P954, DOI 10.1128/JB.170.2.954-960.1988; GALLIE DR, 1987, J MOL BIOL, V193, P465, DOI 10.1016/0022-2836(87)90260-9; GARNIER T, 1987, MOL MICROBIOL, V1, P371, DOI 10.1111/j.1365-2958.1987.tb01944.x; GERDES K, 1986, J MOL BIOL, V190, P269, DOI 10.1016/0022-2836(86)90001-X; GERDES K, 1990, New Biologist, V2, P946; GERLITZ M, 1990, J BACTERIOL, V172, P6194, DOI 10.1128/jb.172.11.6194-6203.1990; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRINTER NJ, 1989, PLASMID, V22, P203, DOI 10.1016/0147-619X(89)90003-6; GUEST CR, 1991, BIOCHEMISTRY-US, V30, P8759, DOI 10.1021/bi00100a007; HELSBERG M, 1986, J BACTERIOL, V165, P1043, DOI 10.1128/jb.165.3.1043-1045.1986; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; JAFFE A, 1985, J BACTERIOL, V163, P841; JAYARAM M, 1985, MOL CELL BIOL, V5, P2466, DOI 10.1128/MCB.5.9.2466; Kittell B. L., 1993, BACTERIAL CONJUGATIO, P223, DOI 10.1007/978-1-4757-9357-4_8; KUES U, 1989, MICROBIOL REV, V53, P491; KUSUKAWA N, 1987, MOL GEN GENET, V208, P365, DOI 10.1007/BF00328125; LANE D, 1987, MOL GEN GENET, V207, P406, DOI 10.1007/BF00331608; MARTIN KA, 1987, P NATL ACAD SCI USA, V84, P8544, DOI 10.1073/pnas.84.23.8544; MILLER CA, 1990, CELL, V62, P127, DOI 10.1016/0092-8674(90)90246-B; MORRISSEY TH, 1981, ANAL BIOCHEM, V43, P177; NORDSTROM K, 1989, ANNU REV GENET, V23, P37, DOI 10.1146/annurev.genet.23.1.37; ROBERTS RC, 1990, J BACTERIOL, V172, P6204, DOI 10.1128/jb.172.11.6204-6216.1990; ROBERTS RC, 1992, J BACTERIOL, V174, P8119, DOI 10.1128/JB.174.24.8119-8132.1992; Sambrook J, 1989, MOL CLONING LABORATO; SAURUGGER PN, 1986, J BIOTECHNOL, V4, P333, DOI 10.1016/0168-1656(86)90047-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TABUCHI A, 1988, J MOL BIOL, V202, P511, DOI 10.1016/0022-2836(88)90282-3; Thomas CM, 1989, PROMISCUOUS PLASMIDS, P1; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4	38	47	50	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27109	27117						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262949				2022-12-25	WOS:A1993MM26200042
J	SCHMALIX, W; BANDLOW, W				SCHMALIX, W; BANDLOW, W			THE ETHANOL-INDUCIBLE YAT1 GENE FROM YEAST ENCODES A PRESUMPTIVE MITOCHONDRIAL OUTER CARNITINE ACETYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; RAT-LIVER; CHOLINE-ACETYLTRANSFERASE; BINDING PROTEIN; PALMITOYLTRANSFERASE; CLONING; SYSTEM; SEQUENCES; CDNA; DNA	The gene YAT1 from Saccharomyces cerevisiae encodes a protein of 688 amino acids which displays significant sequence similarity to vertebrate L-carnitine acyltransferases and yeast inner mitochondrial L-carnitine acetyltransferase. Steady state levels of the respective mRNA are low during growth on glucose or galactose, derepressed on glycerol, and significantly induced when ethanol or acetate are the only carbon sources. The YAT1 promotor region confers the identical carbon source dependence also on the expression of beta-galactosidase when cloned 5' to the Escherichia coli lacZ-coding region. An antiserum directed against a beta-galactosidase/Yat1p fusion protein recognizes a protein of 78-kDa molecular mass in the mitochondrial fraction from yeast. In vitro translated Yat1p, which lacks a cleavable presequence, binds to mitochondria in a protease-sensitive location in a standard in vitro import assay. Deletion of the single copy gene in a haploid yeast strain yields no obvious phenotype with any carbon source. Carnitine acetyltransferase activities of intact mitochondria from a YAT1 deletion mutant are slightly lower than wild type, but are approximately alike in lysed mitochondria from mutant and control cells. Thus, the novel gene is nonessential and likely to code for a minor mitochondial outer carnitine acetyltransferase.	UNIV ULM, INST PATHOL & FORENS MED, W-7900 ULM, GERMANY; UNIV MUNICH, MOLEC BIOL LAB, D-80937 MUNICH, GERMANY; UNIV MUNICH, INST GENET & MICROBIOL, D-80938 MUNICH, GERMANY	Ulm University; University of Munich; University of Munich								ADOLPHUS, 1983, EMBO J, V2, P1765, DOI 10.1002/j.1460-2075.1983.tb01655.x; BARKER WC, 1983, ATLAS PROTEIN SEQUEN, V7; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BERRARD S, 1987, P NATL ACAD SCI USA, V84, P9280, DOI 10.1073/pnas.84.24.9280; BIEBER LL, 1972, ANAL BIOCHEM, V50, P509, DOI 10.1016/0003-2697(72)90061-9; BIEBER LL, 1983, ENZYMES, V16, P627; BURGLIN TR, 1987, EMBO J, V6, P2617, DOI 10.1002/j.1460-2075.1987.tb02552.x; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHASE JFA, 1970, BIOCHEM J, V116, P713, DOI 10.1042/bj1160713; CHATTERJEE B, 1988, BIOCHEMISTRY-US, V27, P9000, DOI 10.1021/bi00425a018; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DAUM G, 1982, J BIOL CHEM, V257, P3028; DOBSON MJ, 1982, NUCLEIC ACIDS RES, V10, P2625, DOI 10.1093/nar/10.8.2625; EINERHAND AWC, 1991, EUR J BIOCHEM, V200, P113, DOI 10.1111/j.1432-1033.1991.tb21056.x; ENTIAN KD, 1992, TRENDS BIOCHEM SCI, V17, P506, DOI 10.1016/0968-0004(92)90341-6; GANCEDO JM, 1992, EUR J BIOCHEM, V206, P297, DOI 10.1111/j.1432-1033.1992.tb16928.x; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOPPEL CH, 1985, ENZYMES BIOL MEMBR, V2, P139; HYMAN LE, 1991, MOL CELL BIOL, V11, P2004, DOI 10.1128/MCB.11.4.2004; ITOH N, 1986, P NATL ACAD SCI USA, V83, P4081, DOI 10.1073/pnas.83.11.4081; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; KISPAL G, 1993, J BIOL CHEM, V268, P1824; KUNAU WH, 1988, BIOCHEM SOC T, V16, P418, DOI 10.1042/bst0160418; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; MAGDOLEN V, 1992, FEBS LETT, V299, P267, DOI 10.1016/0014-5793(92)80129-5; MAGDOLEN V, 1988, MOL CELL BIOL, V8, P5108, DOI 10.1128/MCB.8.12.5108; Maniatis T., 1982, MOL CLONING; MIYAZAWA S, 1983, J BIOCHEM-TOKYO, V93, P453, DOI 10.1093/oxfordjournals.jbchem.a134199; MULLER G, 1989, BIOCHEMISTRY-US, V28, P9957; MURTHY MSR, 1987, P NATL ACAD SCI USA, V84, P378, DOI 10.1073/pnas.84.2.378; NICHOLSON DW, 1988, PROTEIN TRANSFER ORG, P677; OZASA H, 1983, J BIOCHEM-TOKYO, V94, P543, DOI 10.1093/oxfordjournals.jbchem.a134385; PANDE SV, 1980, J BIOL CHEM, V255, P2994; RAMSAY RR, 1976, EUR J BIOCHEM, V69, P299, DOI 10.1111/j.1432-1033.1976.tb10886.x; RODEL G, 1985, J BACTERIOL, V161, P7; RUSSO P, 1991, EMBO J, V10, P563, DOI 10.1002/j.1460-2075.1991.tb07983.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIKORSKI RS, 1989, GENETICS, V122, P19; SKONECZNY M, 1988, EUR J BIOCHEM, V174, P297, DOI 10.1111/j.1432-1033.1988.tb14097.x; TRUMBLY RJ, 1992, MOL MICROBIOL, V6, P15, DOI 10.1111/j.1365-2958.1992.tb00832.x; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WOELTJE KF, 1990, J BIOL CHEM, V265, P10720; WOELTJE KF, 1990, J BIOL CHEM, V265, P10714; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	53	66	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27428	27439						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262985				2022-12-25	WOS:A1993MM26200084
J	EADS, J; SACCHETTINI, JC; KROMMINGA, A; GORDON, JI				EADS, J; SACCHETTINI, JC; KROMMINGA, A; GORDON, JI			ESCHERICHIA-COLI-DERIVED RAT INTESTINAL FATTY-ACID-BINDING PROTEIN WITH BOUND MYRISTATE AT 1.5 ANGSTROM RESOLUTION AND I-FABP(ARG106-]GLN) WITH BOUND OLEATE AT 1.74 ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; 3-DIMENSIONAL STRUCTURE; N-MYRISTOYLTRANSFERASE; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURE; TRANSGENIC MICE; EXPRESSION; REFINEMENT; ANALOGS; GENE	Rat intestinal fatty acid binding protein (I-FABP) is a 131-residue protein composed of two short alpha-helices (alphaI and alphaII) and 10 anti-parallel beta-strands organized into two nearly orthogonal beta-sheets. The structure of crystalline I-FABP with bound tetradecanoate (myristate) has been refined to a resolution of 1.5 angstrom and compared to the 1.2 angstrom structure of apo-I-FABP, the 1.9 angstrom structure of I-FABP:hexadecanoate (palmitate) and the 1.75 angstrom structure of I-FABP:9Z-octadecanoate (oleate) to determine how this model fatty acid receptor accommodates changes in the length of its fatty acid ligand. Myristate is located in the interior of the protein. A highly ordered, electrostatic network containing 7 hydrogen (H)-bonds links the OE1 and OE2 atoms of myristate's carboxylate group, the indole nitrogen of Trp82, NH1, and NH2 of Arg106, NE2, and OE1 of Gln115, and 2 interior ordered waters. The hydrocarbon chain of the bound fatty acid is slightly bent. Its convex face lies in a crevice, forming van der Waals contacts with the side chains of several hydrophobic and aromatic residues. Its concave face is exposed to an array of 8 interior ordered waters whose positions are stabilized by H-bond interactions with other waters, H-bond interactions with the side chains of polar/ionizable residues, and van der Waals contacts with the surface of the fatty acid. Addition of 2 or 4 methylenes to myristate produces remarkably little change in the positions of I-FABP's main chain and side chain atoms and interior ordered waters. The principal alterations are in the conformation of a surface opening (portal) connecting external and internal solvent and in the position of the benzene side chain of Phe55. Changes in the conformation of the portal reflect movement of two of its components: the backbone of alphaII and a type I turn (Ala73, Asp74) connecting two beta-strands. The positions of the main chain atoms of Ala73 and Asp74 appear to be determined by their ability to form van der Waals contacts with the omega-terminus of the fatty acid. The side chain of Phe55 appears to function as an adjustable aromatic lid, located over the portal, whose position is dependent on an ability to form van der Waals contacts with a fatty acid's omega-terminus. The structure of I-FABPArg106-->Gln with bound oleate was refined to 1.74 angstrom and compared to the 1.75 angstrom structure of I-FABpArg106:oleate so that we could assess the contribution of the electrostatic network, which binds carboxylate, to the overall positioning of the fatty acid. This mutation results in destabilization of the electrostatic network as evidenced by the presence of several alternate positions for carboxylate in the electron density map. The discrete disorder of the carboxylate group is associated with movement of the hydrocarbon chain along the length of the binding pocket and extension of the methyl terminus beyond the boundary of the aromatic lid. Movement of the acyl chain does not perturb the positions of the protein's interior ordered waters or the side chain of its Phe55 residue. These findings provide insights about the potential manner in which I-FABP can accommodate fatty acids whose chain length exceeds 18 carbons. Together, our studies emphasize the contributions of ''feeble forces'' (ion pair, H-bond, and van der Waals interactions) to the binding enthalpy in this model fatty acid receptor system.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,1300 MORRIS PK AVE,BRONX,NY 10461; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Yeshiva University; Albert Einstein College of Medicine; Washington University (WUSTL)					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030292, R37DK030292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045859] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27179] Funding Source: Medline; NIDDK NIH HHS [DK30292] Funding Source: Medline; NIGMS NIH HHS [GM45859] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATWOOD JL, 1991, NATURE, V349, P683, DOI 10.1038/349683a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, XPLOR VERSION 2 1 MA; CHENG L, 1991, J BIOL CHEM, V266, P24404; CISTOLA DP, 1989, J BIOL CHEM, V264, P2700; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; DEVADAS B, 1992, J BIOL CHEM, V267, P7224; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1577, DOI 10.1021/bi00405a027; GREEN RP, 1992, DNA CELL BIOL, V11, P31, DOI 10.1089/dna.1992.11.31; JAKOBY MG, 1993, BIOCHEMISTRY-US, V32, P872, DOI 10.1021/bi00054a019; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KISHORE NS, 1993, J BIOL CHEM, V268, P4889; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE JB, 1987, J BIOL CHEM, V262, P5931; MULLERFAHRNOW A, 1991, EUR J BIOCHEM, V199, P271, DOI 10.1111/j.1432-1033.1991.tb16120.x; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; RUDNICK DA, 1992, P NATL ACAD SCI USA, V89, P10507, DOI 10.1073/pnas.89.21.10507; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1992, J BIOL CHEM, V267, P23534; SACCHETTINI JC, 1990, MOL CELL BIOCHEM, V98, P81; SCAPIN G, 1992, J BIOL CHEM, V267, P4253; SCAPIN G, 1993, IN PRESS MOL CELL BI; SCAPIN G, 1990, MOL CELL BIOCHEM, V98, P81; SHA RS, 1993, J BIOL CHEM, V268, P7885; STUMP DG, 1991, J BIOL CHEM, V266, P4622; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WINTER NS, 1993, J MOL BIOL, V230, P1247, DOI 10.1006/jmbi.1993.1239; XU ZH, 1993, J BIOL CHEM, V268, P7874; XU ZH, 1992, BIOCHEMISTRY-US, V31, P3484, DOI 10.1021/bi00128a024; ZANOTTI G, 1992, J BIOL CHEM, V267, P18541	35	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26375	26385						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253762				2022-12-25	WOS:A1993MK42500056
J	HIGH, S; MARTOGLIO, B; GORLICH, D; ANDERSEN, SSL; ASHFORD, AJ; GINER, A; HARTMANN, E; PREHN, S; RAPOPORT, TA; DOBBERSTEIN, B; BRUNNER, J				HIGH, S; MARTOGLIO, B; GORLICH, D; ANDERSEN, SSL; ASHFORD, AJ; GINER, A; HARTMANN, E; PREHN, S; RAPOPORT, TA; DOBBERSTEIN, B; BRUNNER, J			SITE-SPECIFIC PHOTOCROSS-LINKING REVEALS THAT SEC61P AND TRAM CONTACT DIFFERENT REGIONS OF A MEMBRANE-INSERTED SIGNAL SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; UNNATURAL AMINO-ACIDS; TRANSFER-RNA PHES; PROTEIN TRANSLOCATION; RECOGNITION PARTICLE; POLYPEPTIDE TRANSLOCATION; NASCENT PREPROLACTIN; NONNATURAL RESIDUES; ER MEMBRANE; YEAST	A chemically charged amber suppressor TRNA was used to introduce the photoactivatable amino acid (Tmd)Phe at a selected position within the signal sequence of the secretory protein preprolactin. This allowed the interactions of the NH2-terminal, the central, and the COOH-terminal regions of the signal Sequence to be investigated during insertion into the membrane of the endoplasmic reticulum (ER). We found that different regions of the nascent chains were photocross-linked to different ER proteins. The TRAM protein (translocating chain-associating membrane protein) contacts the NH2-terminal region of the signal sequence while the mammalian Sec61p contacts the hydrophobic core of the signal sequence and regions COOH-terminal of this. These results suggest that the ER translocation complex is composed of heterologous protein subunits which contact distinct regions of nascent polypeptides during their membrane insertion.	SWISS FED INST TECHNOL, CH-8092 ZURICH, SWITZERLAND; MAX DELBRUCK CTR MOLEC MED, W-1115 BERLIN, GERMANY; HUMBOLDT UNIV BERLIN, INST BIOCHEM, O-1040 BERLIN, GERMANY	Swiss Federal Institutes of Technology Domain; ETH Zurich; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin	HIGH, S (corresponding author), EUROPEAN MOLEC BIOL LAB, POSTFACH 102209, MEYERHOFSTR 1, W-6900 HEIDELBERG, GERMANY.		Hartmann, Enno/C-5687-2013; Andersen, Søren S. L./O-1915-2017; Görlich, Dirk/B-8296-2017	Andersen, Søren S. L./0000-0002-3625-1640; Görlich, Dirk/0000-0002-4343-5210; High, Stephen/0000-0002-4532-8152				BAIN JD, 1991, BIOCHEMISTRY-US, V30, P5411, DOI 10.1021/bi00236a013; BAIN JD, 1992, NATURE, V356, P537, DOI 10.1038/356537a0; BAIN JD, 1989, J AM CHEM SOC, V111, P8013, DOI 10.1021/ja00202a052; BAIN JD, 1991, J ORG CHEM, V56, P4615, DOI 10.1021/jo00015a011; BALDINI G, 1988, BIOCHEMISTRY-US, V27, P7951, DOI 10.1021/bi00420a054; BRUCE AG, 1982, BIOCHEMISTRY-US, V21, P855, DOI 10.1021/bi00534a007; BRUNNER J, 1980, J BIOL CHEM, V255, P3313; CHUNG HH, 1993, SCIENCE, V259, P806, DOI 10.1126/science.8430333; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; ELLMAN J, 1991, METHOD ENZYMOL, V202, P301; ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546; ELLMAN JA, 1992, J AM CHEM SOC, V114, P7959, DOI 10.1021/ja00046a080; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; HAEUPTLE MT, 1986, NUCLEIC ACIDS RES, V14, P1427, DOI 10.1093/nar/14.3.1427; HECKLER TG, 1984, BIOCHEMISTRY-US, V23, P1468, DOI 10.1021/bi00302a020; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; HIGH S, 1992, BIOESSAYS, V14, P535, DOI 10.1002/bies.950140807; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; HIGH S, 1992, MEMBRANE BIOGENESIS, V22, P105; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; MENDEL D, 1992, SCIENCE, V256, P1798, DOI 10.1126/science.1615324; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NASSAL M, 1984, J AM CHEM SOC, V106, P7540, DOI 10.1021/ja00336a038; NOREN CJ, 1990, NUCLEIC ACIDS RES, V18, P83, DOI 10.1093/nar/18.1.83; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; PAYNE RC, 1987, BIOCHEMISTRY-US, V26, P3197, DOI 10.1021/bi00385a039; PEZZUTO JM, 1980, J BIOL CHEM, V255, P865; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RAPOPORT TA, 1990, TRENDS BIOCHEM SCI, V15, P355, DOI 10.1016/0968-0004(90)90076-N; ROBERTSON SA, 1991, J AM CHEM SOC, V113, P2722, DOI 10.1021/ja00007a055; ROESSER JR, 1989, BIOCHEMISTRY-US, V28, P5185, DOI 10.1021/bi00438a041; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2	49	127	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26745	26751						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253810				2022-12-25	WOS:A1993MK42500107
J	NAKANISHISHINDO, Y; NAKAYAMA, K; TANAKA, A; TODA, Y; JIGAMI, Y				NAKANISHISHINDO, Y; NAKAYAMA, K; TANAKA, A; TODA, Y; JIGAMI, Y			STRUCTURE OF THE N-LINKED OLIGOSACCHARIDES THAT SHOW THE COMPLETE LOSS OF ALPHA-1,6-POLYMANNOSE OUTER CHAIN FROM OCH1, OCH1 MNN1, AND OCH1 MNN1 ALG3 MUTANTS OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR CHAINS; PROTEIN GLYCOSYLATION; EXTERNAL INVERTASE; GLYCOPROTEINS; ELONGATION; PYRIDYLAMINATION; HYDRAZINOLYSIS; SPECTROSCOPY; DEFICIENT	The periplasmic invertase was purified from Saccharomyces cerevisiae och1=LEU2 disruptant cells (DELTAoch1), which have a defect in elongation of the outer chain attached to the N-linked core oligosaccharides (Nakayama, K., Nagasu, T., Shimma, Y., Kuromatsu, J., and Jigami, Y. (1992) EMBO J. 11, 2511-2519). Structural analysis of the pyridylaminated (PA) neutral oligosaccharides released by hydrazinolysis and N-acetylation confirmed that the ochl mutation causes a complete loss of the alpha-1,6-polymannose outer chain, although the PA oligosaccharides (Man9GlcNAc2-PA and Man10GlcNAC2-PA), in which one or two alpha-1,3-linked mannose(s) attached to the endoplasmic reticulumn (ER)-form core oligosaccharide (Man8GlcNAc2) were also detected. Analysis of the DELTAoch1 mnn1 strain oligosaccharides released from total cell mannoprotein revealed that the DELTAoch1 mnn1 mutant eliminates the alpha-1,3-mannose attached to the core and accumulates predominantly a single ER-form oligosaccharide species (Man8GlcNAc2), suggesting a potential use of this strain as a host cell to produce glycoproteins containing mammalian high mannose type oligosaccharides. The DELTAoch1 mnn1 alg3 mutants accumulated Man5GlcNAC2 and Man8GlcNAC2 in total cell Tnannoprotein, confirming the lack of outer chain addition to the incomplete corelike oligosaccharide and the leaky phenotype of the alg3 mutation. All the results suggest that the OCH1 gene encodes an alpha-1,6-mannosyltransferase that is functional in the initiation of alpha-1,6-polymannose outer chain addition to the N-linked core oligosaccharide (Man5GlcNAC2 and Man8GlcNAC2) in yeast.	NATL INST BIOSCI & HUMAN TECHNOL, 1-1 HIGASHI, TSUKUBA, IBARAKI 305, JAPAN; ASAHI CHEM IND CO LTD, FUJI, SHIZUOKA 416, JAPAN	National Institute of Advanced Industrial Science & Technology (AIST)								ALVARADO E, 1990, BIOCHEMISTRY-US, V29, P2471, DOI 10.1021/bi00462a006; BALLOU L, 1986, P NATL ACAD SCI USA, V83, P3081, DOI 10.1073/pnas.83.10.3081; BALLOU L, 1990, P NATL ACAD SCI USA, V87, P3368, DOI 10.1073/pnas.87.9.3368; BALLOU L, 1980, J BIOL CHEM, V255, P5986; BALLOU L, 1989, J BIOL CHEM, V264, P11857; BLANKEN WM, 1985, ANAL BIOCHEM, V145, P322, DOI 10.1016/0003-2697(85)90369-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHEN RE, 1980, BIOCHEMISTRY-US, V19, P4345, DOI 10.1021/bi00559a031; ESMON B, 1984, J BIOL CHEM, V259, P322; FUKUDA M, 1976, J BIOCHEM, V80, P1223, DOI 10.1093/oxfordjournals.jbchem.a131393; GRAHAM TR, 1992, YEAST, V8, pS458; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; KOBATA A, 1987, METHOD ENZYMOL, V138, P779; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; KURAYA N, 1992, J BIOCHEM, V112, P122, DOI 10.1093/oxfordjournals.jbchem.a123850; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NAGASU T, 1992, YEAST, V8, P535, DOI 10.1002/yea.320080705; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; NATSUKA S, 1987, ANAL BIOCHEM, V167, P154, DOI 10.1016/0003-2697(87)90146-1; NEUMANN NP, 1967, BIOCHEMISTRY-US, V6, P468, DOI 10.1021/bi00854a015; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; PEAT S, 1961, J CHEM SOC, P29, DOI 10.1039/jr9610000029; ROMERO PA, 1989, J BIOL CHEM, V264, P1946; ROMERO PA, 1992, J CELL BIOCHEM     S, V16, P175; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SMITH WL, 1974, BIOCHEMISTRY-US, V13, P355, DOI 10.1021/bi00699a021; TAKAHASHI N, 1981, BIOCHIM BIOPHYS ACTA, V657, P451; TAKASAKI S, 1982, METHOD ENZYMOL, V83, P263; TRIMBLE RB, 1986, J BIOL CHEM, V261, P9815; TRIMBLE RB, 1977, J BIOL CHEM, V252, P4409; TSAI PK, 1984, J BIOL CHEM, V259, P3801; VEROSTEK MF, 1991, J BIOL CHEM, V266, P5547; ZIEGLER FD, 1988, J BIOL CHEM, V263, P6986	34	142	173	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26338	26345						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253757				2022-12-25	WOS:A1993MK42500051
J	GARDNER, AM; AVIEL, S; ARGON, Y				GARDNER, AM; AVIEL, S; ARGON, Y			RAPID DEGRADATION OF AN UNASSEMBLED IMMUNOGLOBULIN LIGHT-CHAIN IS MEDIATED BY A SERINE-PROTEASE AND OCCURS IN A PRE-GOLGI COMPARTMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL LYMPHOMA; ASIALOGLYCOPROTEIN RECEPTOR SUBUNITS; ISOLATED RAT HEPATOCYTES; ENDOPLASMIC-RETICULUM; LYMPHOCYTES-B; HEAVY-CHAINS; INTRACELLULAR DEGRADATION; SECRETED IMMUNOGLOBULIN; CYSTEINE PROTEASE; ANTIGEN RECEPTOR	The immunoglobulin kappa light chain produced by the CH12 lymphoma is unusual because it is not secreted when expressed in the absence of a heavy chain. Instead, it undergoes rapid intracellular degradation. This degradation is selective, as another light chain expressed in the same cell is not degraded. It is also a property of the CH12 kappa chain itself, since it is degraded rapidly when expressed either in another myeloma cell or in COS-1 fibroblasts. When provided a heavy chain, this kappa chain assembles into IgM and is then protected from proteolysis. The degradation of kappa requires ATP, is sensitive to reduced temperature and to the thiol reagent diamide. Of all the proteolytic inhibitors tested, 3,4-dichloroisocoumarin, L-1-tosylamido-2-phenylethyl chloromethyl ketone, and to a lesser extent 1-chloro-3-tosylamido-7-amino-2-heptanone, inhibit kappa degradation, suggesting the involvement of a serine protease. The degradation of kappa does not require transport to the Golgi complex, nor is it sensitive to a variety of lysosomotropic agents. Both immunofluorescence and the observed association with the endoplasmic reticulum (ER) stress proteins GRP78/BiP and GRP94 indicate that the kappa chain is localized mostly in the ER. When a point mutation which blocks transport to the Golgi complex is introduced into this kappa chain, the association with the stress proteins is enhanced but the rate of degradation is not significantly decreased. We conclude that the CH12 kappa chain is a particularly good substrate for an ER degradation machinery, and that its sensitivity to the protease(s) is governed by its state of assembly. This ER degradation provides a possible quality control mechanism during the differentiation of B lymphocytes.	DUKE UNIV, MED CTR, DEPT IMMUNOL, DURHAM, NC 27710 USA	Duke University				Gardner, Anne/0000-0001-7095-772X				ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; AMITAY R, 1991, J BIOL CHEM, V266, P12568; AMITAY R, 1992, J BIOL CHEM, V267, P20694; ARGON Y, 1984, J IMMUNOL, V133, P1627; ARNOLD LW, 1988, J IMMUNOL, V140, P4355; BACHHAWAT AK, 1991, J CELL BIOL, V115, P619, DOI 10.1083/jcb.115.3.619; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; CHAUDHURI B, 1992, EUR J BIOCHEM, V210, P811, DOI 10.1111/j.1432-1033.1992.tb17484.x; COWAN NJ, 1974, J MOL BIOL, V90, P691, DOI 10.1016/0022-2836(74)90533-6; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DUL JL, 1990, P NATL ACAD SCI USA, V87, P8135, DOI 10.1073/pnas.87.20.8135; DUL JL, 1992, J IMMUNOL, V149, P1927; DULIS BH, 1982, J BIOL CHEM, V257, P4369; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; ELOKDA M, 1992, AM J CLIN PATHOL, V97, P866, DOI 10.1093/ajcp/97.6.866; GIL G, 1985, CELL, V63, P503; GRAHAM KS, 1990, J BIOL CHEM, V265, P20463; GRINDE B, 1980, BIOCHIM BIOPHYS ACTA, V632, P73, DOI 10.1016/0304-4165(80)90250-0; GRONOSTAJSKI RM, 1985, J BIOL CHEM, V260, P3344; GROSSCHEDL R, 1984, CELL, V38, P647, DOI 10.1016/0092-8674(84)90259-9; HARPER JW, 1985, BIOCHEMISTRY-US, V24, P1831, DOI 10.1021/bi00329a005; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KING LB, 1989, P NATL ACAD SCI USA, V86, P2814, DOI 10.1073/pnas.86.8.2814; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KOSOWER EM, 1969, NATURE, V224, P117, DOI 10.1038/224117a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE A, 1990, J BIOL CHEM, V265, P14001; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MEDDA S, 1987, CELL, V50, P301, DOI 10.1016/0092-8674(87)90225-X; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOSMANN TR, 1980, CELL, V20, P283, DOI 10.1016/0092-8674(80)90614-5; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; PENNELL CA, 1988, J IMMUNOL, V141, P2788; SATO R, 1990, J BIOL CHEM, V265, P11880; SEGLEN PO, 1979, EUR J BIOCHEM, V95, P215, DOI 10.1111/j.1432-1033.1979.tb12956.x; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; SLATER EC, 1973, BIOCHIM BIOPHYS ACTA, V301, P129, DOI 10.1016/0304-4173(73)90002-5; SPRINGER TA, 1982, HYBRIDOMA, V1, P257, DOI 10.1089/hyb.1.1982.1.257; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; Stevens R H, 1974, Contemp Top Mol Immunol, V3, P85; STOCKDALE AM, 1987, J IMMUNOL, V139, P3527; STOLLER TJ, 1988, J CELL BIOL, V107, P2087, DOI 10.1083/jcb.107.6.2087; TARTAKOFF A, 1979, J CELL BIOL, V83, P284, DOI 10.1083/jcb.83.2.284; TARTAKOFF AM, 1977, J EXP MED, V146, P1332, DOI 10.1084/jem.146.5.1332; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973; URADE R, 1992, FEBS LETT, V312, P83, DOI 10.1016/0014-5793(92)81415-I; VALETTI C, 1991, J CELL BIOL, V115, P983, DOI 10.1083/jcb.115.4.983; VIRTANEN I, 1980, J CELL BIOL, V85, P429, DOI 10.1083/jcb.85.2.429; WIEST DL, 1990, J CELL BIOL, V110, P1501, DOI 10.1083/jcb.110.5.1501; WIKSTROM L, 1992, J BIOL CHEM, V267, P5; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; WILEMAN T, 1991, CELL REGUL, V2, P753, DOI 10.1091/mbc.2.9.753	64	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25940	25947						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245027				2022-12-25	WOS:A1993MK10000093
J	FOURNIER, L; WHITFIELD, JF; SCHWARTZ, JL; BEGINHEICK, N				FOURNIER, L; WHITFIELD, JF; SCHWARTZ, JL; BEGINHEICK, N			CYCLIC-AMP TRIGGERS LARGE [CA2+](I) OSCILLATIONS IN GLUCOSE-STIMULATED BETA-CELLS FROM OB OB MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC B-CELLS; BURSTING ELECTRICAL-ACTIVITY; SENSITIVE K+ CHANNELS; CYTOSOLIC FREE CA-2+; INSULIN RELEASE; ADENOSINE-MONOPHOSPHATE; ABNORMAL REGULATION; MOUSE ISLETS; ION CHANNELS; CAMP LEVELS	The modulation of intracellular free calcium concentration ([Ca2+]i) by cAMP was compared in pancreatic beta-cells of lean (+/+) and obese (ob/ob) mice. Neither forskolin nor 8-bromo-cAMP significantly affected basal [Ca2+]i in unstimulated lean and obese mouse beta-cells. In obese, but not in lean mouse beta-cells, adding forskolin or 8-bromo-cAMP during the glucose-induced [Ca2+]i response triggered external Ca2+-dependent [Ca2+]i oscillations with a duration of 5-11 s and a frequency of 2.3-4.8 min-1. The induction of oscillations by cAMP required both a stimulatory glucose concentration and membrane depolarization. (S(p))-cAMPS, did induce oscillations in lean mouse beta-cells. However, these oscillations were different from those seen in obese mouse beta-cells and required higher concentrations of (S(p))-cAMPS. The inducibility of fast oscillations in obese mouse beta-cells indicates hypersensitivity of these cells to cAMP, and suggests an abnormal behavior of K+ and/or Ca2+ channels.	UNIV OTTAWA,DEPT BIOCHEM,OTTAWA K1H 8M5,ONTARIO,CANADA; NATL RES COUNCIL CANADA,INST BIOL SCI,CELL SYST SECT,OTTAWA K1A 0R6,ONTARIO,CANADA; NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,MONTREAL,PQ,CANADA	University of Ottawa; National Research Council Canada; National Research Council Canada								BLACK M, 1986, BIOCHEM J, V238, P863, DOI 10.1042/bj2380863; BLACK MA, 1988, AM J PHYSIOL, V255, pE833, DOI 10.1152/ajpendo.1988.255.6.E833; EDDLESTONE GT, 1985, AM J PHYSIOL, V248, pC145, DOI 10.1152/ajpcell.1985.248.1.C145; FOURNIER L, 1992, J MEMBRANE BIOL, V129, P267; FOURNIER LA, 1993, AM J PHYSIOL, V246, pC1458; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; GRAPENGIESSER E, 1991, J BIOL CHEM, V266, P12207; GRAPENGIESSER E, 1989, ARCH BIOCHEM BIOPHYS, V268, P404, DOI 10.1016/0003-9861(89)90602-4; GYLFE E, 1988, J BIOL CHEM, V263, P5044; HELLMAN B, 1991, NUTRIENT REGULATION, P213; HENQUIN JC, 1984, ENDOCRINOLOGY, V115, P1125, DOI 10.1210/endo-115-3-1125; HENQUIN JC, 1983, BIOCHEM BIOPH RES CO, V112, P614, DOI 10.1016/0006-291X(83)91508-5; HENQUIN JC, 1990, PFLUG ARCH EUR J PHY, V416, P568, DOI 10.1007/BF00382691; HILL RS, 1987, DIABETES, V36, P440, DOI 10.2337/diabetes.36.4.440; HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0; HUGHES SJ, 1989, MOL CELL ENDOCRINOL, V65, P35, DOI 10.1016/0303-7207(89)90162-7; KUKULJAN M, 1991, J MEMBRANE BIOL, V119, P187, DOI 10.1007/BF01871418; LEVITAN IB, 1988, ANNU REV NEUROSCI, V11, P119, DOI 10.1146/annurev.neuro.11.1.119; LEVITAN IB, 1985, J MEMBRANE BIOL, V87, P177, DOI 10.1007/BF01871217; MALAISSE WJ, 1984, ENDOCRINOLOGY, V115, P2015, DOI 10.1210/endo-115-5-2015; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; PRENTKI M, 1987, FEBS LETT, V220, P103, DOI 10.1016/0014-5793(87)80884-0; RAJAN AS, 1989, DIABETES, V38, P874, DOI 10.2337/diabetes.38.7.874; ROE MW, 1993, J BIOL CHEM, V268, P9953; RORSMAN P, 1985, ACTA PHYSIOL SCAND, V125, P639, DOI 10.1111/j.1748-1716.1985.tb07766.x; RORSMAN P, 1991, NATURE, V349, P77, DOI 10.1038/349077a0; ROSARIO LM, 1985, Q J EXP PHYSIOL CMS, V70, P137, DOI 10.1113/expphysiol.1985.sp002885; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SEINO S, 1992, P NATL ACAD SCI USA, V89, P584, DOI 10.1073/pnas.89.2.584; SMITH PA, 1989, NATURE, V342, P550, DOI 10.1038/342550a0; SUSSMAN KE, 1987, DIABETES, V36, P571, DOI 10.2337/diabetes.36.5.571; VALDEOLMILLOS M, 1989, FEBS LETT, V259, P19, DOI 10.1016/0014-5793(89)81484-X; VELASCO JM, 1988, FEBS LETT, V231, P366, DOI 10.1016/0014-5793(88)80851-2; WIEDENKELLER DE, 1983, ENDOCRINOLOGY, V113, P2311, DOI 10.1210/endo-113-6-2311; YANEY GC, 1992, MOL ENDOCRINOL, V6, P2143, DOI 10.1210/me.6.12.2143	35	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1120	1124						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288569				2022-12-25	WOS:A1994MR22000055
J	GOETZL, EJ; SHAMES, RS; YANG, JH; BIRKE, FW; LIU, YF; ALBERT, PR; AN, SZ				GOETZL, EJ; SHAMES, RS; YANG, JH; BIRKE, FW; LIU, YF; ALBERT, PR; AN, SZ			INHIBITION OF HUMAN HL-60 CELL RESPONSES TO CHEMOTACTIC FACTORS BY ANTISENSE MESSENGER-RNA DEPLETION OF G-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; PITUITARY-CELLS; RECEPTORS; BINDING; LEUKOTRIENE-B4; PEPTIDE; IDENTIFICATION; ACTIVATION; SUBUNITS; AFFINITY	Chemotactic factors bound to receptors of the seven-transmembrane domain family signal leukocytes through associated guanine nucleotide-binding (G) proteins. Human leukocytes of the HL-60 line, which express G protein-coupled receptors for leukotriene B4 (LTB4) and N-formyl-methionyl-leucyl-phenylalanine (fMLP) after differentiation with vitamin D3 and transforming growth factor-beta, were transfected with expression plasmids containing antisense-oriented cDNAs encoding the alpha-chains of G(o), G(i1), G(i2), and G(i3). Antisense mRNA for G(o) and G(i2) alpha-chains suppressed by over 80% the level of the respective G protein. G(o)-deficient HL-60 cells had depressed functional and intracellular calcium responses to LTB4 and fMLP, but no alterations in the responses of cyclic adenosine 3',5'-monophosphate (cAMP). In contrast, HL-60 cells deficient in G(i2) lost only responses of the intracellular concentration of cAMP. Antisense mRNA suppression of distinct G proteins thus may delineate some transductional requirements for cellular responses.	UNIV CALIF SAN FRANCISCO,DEPT MOLEC IMMUNOL,SAN FRANCISCO,CA 94143; MCGILL UNIV,DEPT PHARMACOL & THERAPEUT,MONTREAL H3G 1Y6,QUEBEC,CANADA	University of California System; University of California San Francisco; McGill University	GOETZL, EJ (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,UB8B,BOX 0711,533 PARNASSUS AVE,SAN FRANCISCO,CA 94143, USA.		Albert, Paul/E-4804-2010	Albert, Paul/0000-0002-1809-3554	NHLBI NIH HHS [HL 31809] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; DIDSBURY JR, 1987, FEBS LETT, V21, P160; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EASON MG, 1992, J BIOL CHEM, V267, P15795; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDMAN DW, 1986, J IMMUNOL, V136, P4631; GOLDMAN DW, 1985, J EXP MED, V162, P145, DOI 10.1084/jem.162.1.145; GOLDMAN DW, 1984, J EXP MED, V159, P1027, DOI 10.1084/jem.159.4.1027; JONES DT, 1987, J BIOL CHEM, V262, P14241; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KOO C, 1983, J CLIN INVEST, V72, P748, DOI 10.1172/JCI111045; KRAUSE KH, 1985, J CLIN INVEST, V76, P1348, DOI 10.1172/JCI112109; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW SF, 1993, J BIOL CHEM, V268, P10721; LAW SF, 1991, J BIOL CHEM, V266, P17885; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; MUKAI H, 1992, J BIOL CHEM, V267, P16237; MURRAYWHELAN R, 1992, J BIOL CHEM, V267, P2960; OKUMA Y, 1992, J BIOL CHEM, V267, P14826; SCHEPERS TM, 1992, J BIOL CHEM, V267, P159; SHERMAN JW, 1992, J CELL BIOCHEM, V48, P367, DOI 10.1002/jcb.240480405; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986	25	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					809	812						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288630				2022-12-25	WOS:A1994MR22000007
J	SUEN, CS; YEN, PM; CHIN, WW				SUEN, CS; YEN, PM; CHIN, WW			IN-VITRO TRANSCRIPTIONAL STUDIES OF THE ROLES OF THE THYROID-HORMONE (T(3)) RESPONSE ELEMENTS AND MINIMAL PROMOTERS IN T(3)-STIMULATED GENE-TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; X-RECEPTOR; FUNCTIONAL-CHARACTERIZATION; AUXILIARY PROTEIN; ENHANCES BINDING; RXR-BETA; RAT; DNA; SITE; TRANSACTIVATION	Thyroid hormone receptors (TRs) are ligand-dependent nuclear transcription factors that are encoded by two different genes, TRalpha and TRbeta, and bind to thyroid hormone response elements (TREs) in the promoters of thyroid hormone (T3)-regulated genes. Retinoid X receptors (RXRs), major members of the thyroid hormone receptor auxiliary proteins, have recently been shown to enhance the binding of TRs to TREs. We previously showed that TPs extracted from rat pituitary GH3 cells retain ligand (T3) and DNA binding specificity and stimulate rat growth hormone (rGH) promoter activity in a cell-free in vitro transcription system. In this report, we have studied further how T3 activates endogenous TRs and stimulates transcription from different TRE-containing promoters. We found that T3 (10(-8) M) selectively stimulates transcription (rom rGH-TRE- and TREpal-, but not ME-TRE- and F2-TRE-, containing templates in which these TREs are linked in front of the rGH minimal promoter containing only the TATA box binding protein, but not any other proximal binding protein, sequence. In contrast, only the TREpal/AdML template, in which TREpal oligonucleotide was linked in front of the adenovirus major late gene (AdML) minimal promoter, was stimulated by T3. Electrophoretic mobility shift assay (EMSA) demonstrates that endogenous TR complexes specifically bind to either natural or idealized TRE (rGH-TRE, TREpal, ME-TRE, and F2-TRE) oligonucleotides. To further understand these receptor-DNA complexes formed on various TREs, isoform-specific anti-receptor antisera (TRalpha, TRbeta1, TRbeta2, and RXRbeta) were added in the EMSA. These antisera differentially supershifted TR.DNA complexes formed on the TREs. These data suggest either that endogenous TR isoforms and RXRbeta may form different complexes on the various TREs or that TR.RXR complexes have distinct conformations when bound to the various TREs. Taken together, these data suggest that particular TREs in which specific TR.RXR complexes are formed and different minimal promoters may provide specificity in T3-mediated transcriptional stimulation of gene expression.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	SUEN, CS (corresponding author), BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,DEPT MED,DIV GENET,GW THORN RES BLDG,BOSTON,MA 02115, USA.		Yen, Paul M/V-9857-2019	Yen, Paul/0000-0002-3790-8114				BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BRENT GA, 1989, J BIOL CHEM, V264, P178; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; BURNSIDE J, 1989, J BIOL CHEM, V264, P6886; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; DARLING DS, 1989, MOL ENDOCRINOL, V3, P1359, DOI 10.1210/mend-3-9-1359; DAVIS KD, 1993, ENDOCRINOLOGY, V132, P1469, DOI 10.1210/en.132.4.1469; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; HALLENBECK PL, 1993, J BIOL CHEM, V268, P3825; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MADER S, 1993, J BIOL CHEM, V268, P591; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; SAMBROOK KJ, 1989, MOL CLONING LABORATO; SAMUELS HH, 1988, J CLIN INVEST, V81, P957, DOI 10.1172/JCI113449; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SIMON MC, 1990, P NATL ACAD SCI USA, V87, P513, DOI 10.1073/pnas.87.2.513; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; SUEN CS, 1993, MOL CELL BIOL, V13, P1719, DOI 10.1128/MCB.13.3.1719; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YE ZS, 1988, J BIOL CHEM, V263, P7821; YEN PM, 1992, J BIOL CHEM, V267, P3565; YEN PM, 1992, ENDOCRINOLOGY, V130, P1539, DOI 10.1210/en.130.3.1539; YEN PM, 1992, J BIOL CHEM, V267, P23248; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	42	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1314	1322						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288596				2022-12-25	WOS:A1994MR22000086
J	BOEKHOFF, I; INGLESE, J; SCHLEICHER, S; KOCH, WJ; LEFKOWITZ, RJ; BREER, H				BOEKHOFF, I; INGLESE, J; SCHLEICHER, S; KOCH, WJ; LEFKOWITZ, RJ; BREER, H			OLFACTORY DESENSITIZATION REQUIRES MEMBRANE TARGETING OF RECEPTOR KINASE MEDIATED BY BETA-GAMMA-SUBUNITS OF HETEROTRIMERIC G-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MUSCARINIC ACETYLCHOLINE-RECEPTORS; LIGHT-DEPENDENT PHOSPHORYLATION; SIGNAL TRANSDUCTION; RHODOPSIN; ISOPRENYLATION; KINETICS; FAMILY; CILIA	Olfaction is mediated by G protein-coupled receptors. In isolated rat olfactory cilia, odorants such as citralva stimulate a burst of cAMP, which peaks in 50 ms and returns almost to base-line level within 150 ms in the continuing presence of odorant. This desensitization is mediated by the cAMP dependent protein kinase and a specialized G protein-coupled receptor kinase originally termed betaARK2BAR (GRK3). In vitro experiments suggest that the prenylated betagamma-subunits of heterotrimeric G proteins target the cytosolic betaARK1 (GRK2) enzyme to its membrane bound receptor substrate by binding to sites in its carboxyl terminus. Here we demonstrate that odorants stimulate translocation of GRK3 from cytosol to membranes in isolated rat olfactory cilia. We introduced a glutathione S-transferase-GRK3ct fusion protein, containing the carboxyl-terminal 222 amino acid residues of GRK3, which includes the betagamma binding site, or a 28-amino acid peptide derived therefrom, into permeabilized cilia preparations. These reagents block odorant-mediated enzyme translocation and desensitization while markedly attenuating odorant-stimulated phosphorylation of olfactory proteins. These findings suggest that betaggamma-subunits may physiologically regulate a G protein-coupled receptor kinase and that enzyme translocation may be a general and required feature of the activity of some members of this enzyme family.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,BOX 3821,DURHAM,NC 27710; UNIV HOHENHEIM,DEPT ZOOPHYSIOL,D-70593 STUTTGART,GERMANY; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; University Hohenheim; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adam G., 1968, STRUCTURAL CHEM MOL, P198; ANHOLT RRH, 1986, J NEUROSCI, V6, P1962; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BOEKHOFF I, 1992, P NATL ACAD SCI USA, V89, P11983, DOI 10.1073/pnas.89.24.11983; BOEKHOFF I, 1992, P NATL ACAD SCI USA, V89, P471, DOI 10.1073/pnas.89.2.471; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breer H, 1992, Curr Opin Neurobiol, V2, P439, DOI 10.1016/0959-4388(92)90177-M; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KIM CM, 1993, J BIOL CHEM, V268, P15412; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; LAMB TD, 1992, TRENDS NEUROSCI, V15, P291, DOI 10.1016/0166-2236(92)90079-N; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STEINER AL, 1972, J BIOL CHEM, V247, P1114; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032	32	95	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					37	40						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276821				2022-12-25	WOS:A1994MR21900010
J	HART, MJ; EVA, A; ZANGRILLI, D; AARONSON, SA; EVANS, T; CERIONE, RA; ZHENG, Y				HART, MJ; EVA, A; ZANGRILLI, D; AARONSON, SA; EVANS, T; CERIONE, RA; ZHENG, Y			CELLULAR-TRANSFORMATION AND GUANINE-NUCLEOTIDE EXCHANGE ACTIVITY ARE CATALYZED BY A COMMON DOMAIN ON THE DBL ONCOGENE PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEIN; MOLECULAR-CLONING; ACTIVATING PROTEIN; ESCHERICHIA-COLI; CDC42HS PROTEIN; RAS; YEAST; GENE; IDENTIFICATION; POLARITY	The dbl oncogene product contains a 238-amino acid domain, which is shared by an expanding family of growth regulatory proteins. These include the Saccharomyces cerevisiae cell division cycle protein, CDC24, the breakpoint cluster region protein, the ect2 and vav oncogene products, and the brain GDP-releasing factor for Ras. Previous studies have provided evidence that oncogenic Dbl or an associated protein stimulates GDP dissociation from the human species (Hs) homolog of CDC42. We show here that Dbl specifically complexes with the GDP-bound forms of CDC42Hs and RhoA, but not Rac1 or TC10, and that this specificity correlates with the ability of Dbl to act as a GDP-releasing factor. Small deletions throughout the Dbl domain, which inactivate transformation, eliminated the ability of Dbl to stimulate GDP dissociation, whereas deletions outside of this domain did not impair either function. Finally, the Dbl domain itself, when expressed and purified as a recombinant protein, was shown to stimulate GDP dissociation from purified, recombinant CDC42Hs. These findings establish that a minimal unit on Dbl that is critical to its transforming function directly regulates GDP-GTP exchange activity.	CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853; CORNELL UNIV,DEPT BIOCHEM & CELL & MOLEC BIOL,ITHACA,NY 14853; NCI,BETHESDA,MD 20892; ONYX PHARMACEUT,RICHMOND,CA 94806	Cornell University; Cornell University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Zheng, Yi/J-7235-2015; Eva, Alessandra/J-8268-2016	Zheng, Yi/0000-0001-7089-6074; Eva, Alessandra/0000-0003-2949-078X; Hart, Matthew/0000-0002-2683-480X	NIGMS NIH HHS [GM47458] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1987, ONCOGENE, V1, P355; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANI G, 1992, ONCOGENE, V7, P229; GRAZIANI G, 1989, ONCOGENE, V4, P823; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HART MJ, 1991, J BIOL CHEM, V266, P20840; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOLAND JG, 1990, BIOCHEM BIOPH RES CO, V166, P90, DOI 10.1016/0006-291X(90)91915-F; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1991, NEW BIOL, V3, P372; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SLOAT BR, 1990, J CELL BIOL, V111, P143; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STACEY DW, 1991, ONCOGENE, V6, P2297; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; ZHENG Y, 1993, J BIOL CHEM, V268, P24629	28	281	292	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					62	65						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276860				2022-12-25	WOS:A1994MR21900017
J	VANHORN, DJ; MYERS, MG; BACKER, JM				VANHORN, DJ; MYERS, MG; BACKER, JM			DIRECT ACTIVATION OF THE PHOSPHATIDYLINOSITOL 3'-KINASE BY THE INSULIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT HEPATOMA-CELLS; TYROSINE KINASE; 3-KINASE ACTIVITY; SIGNAL TRANSMISSION; GROWTH-FACTOR; INTACT RAT; PHOSPHORYLATION; EXPRESSION; IRS-1; STIMULATION	We have previously shown that phosphatidylinositol (PtdIns) 3'-kinase is activated by the binding of proteins or peptides containing the phosphorylated motif Y(P)XXM. In the present study, we examine interactions between PtdIns 3'-kinase and the human insulin receptor, which contains a C-terminal phosphorylation site in the sequence Y1322THM. Partially purified insulin receptors bound tightly to bacterial fusion proteins containing the N- or C-terminal SH2 domains from PtdIns 3'-kinase regulatory subunit (p85). In contrast, a mutant insulin receptor, truncated by 43 amino acids at the C terminus (IR(DELTACT)), bound poorly to the SH2 domains; these mutant receptors have normal kinase activity but lack the Y1322THM motif. Similarly, incubation with wild-type receptors increased the activity of immunopurified PtdIns 3'-kinase, whereas incubation with IR(DELTACT) receptors did not affect PtdIns 3'-kinase activity. Activation of PtdIns 3'-kinase by the wild-type receptor was mimicked by a tyrosyl phosphopeptide derived from the insulin receptor C terminus and containing the Y1322THM motif; non-phosphorylated peptide did not affect activity. Thus, the insulin receptor C terminus activates PtdIns 3'-kinase in vitro by binding to the SH2 domains of the 85-kDa regulatory subunit. These data support the hypothesis that binding of tyrosyl-phosphorylated receptors to p85 SH2 domains is a general mechanism for PtdIns 3'-kinase activation, and they suggest that direct interactions between the insulin receptor and PtdIns 3'-kinase may provide an alternative pathway for the activation of this enzyme by insulin.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOLEC PHARMACOL, 1300 MORRIS PK AVE, BRONX, NY 10461 USA; BRIGHAM & WOMENS HOSP, JOSLIN DIABET CTR, DEPT MED, DIV RES, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA	Yeshiva University; Albert Einstein College of Medicine; Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK-44541] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044541] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1989, J BIOL CHEM, V264, P1694; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FEENER EP, 1993, J BIOL CHEM, V268, P11256; FOLLI F, 1992, J BIOL CHEM, V267, P22171; HERRERA R, 1988, J BIOL CHEM, V263, P5560; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KELLY KL, 1993, J BIOL CHEM, V268, P4391; MYERS MG, 1991, J BIOL CHEM, V266, P10616; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1988, J BIOL CHEM, V263, P2969; YONEZAWA K, 1992, J BIOL CHEM, V267, P440; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	36	109	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					29	32						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276809				2022-12-25	WOS:A1994MR21900008
J	ZHANG, JZ; REDMAN, CM				ZHANG, JZ; REDMAN, CM			ROLE OF INTERCHAIN DISULFIDE BONDS ON THE ASSEMBLY AND SECRETION OF HUMAN FIBRINOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN FIBRINOGEN; ELECTRON-MICROSCOPY; MOLECULAR-STRUCTURE; CHAIN; IDENTIFICATION; DOMAINS; MODEL; CELLS	The cysteines involved in joining the 2 half-molecules of fibrinogen and also those located on either side of the alpha-helical coiled-coil region, were substituted, by site-directed mutagenesis, with serine. Fibrinogen assembly and secretion were determined in transiently transfected COS cells. Our studies indicate that in order to assemble the 2 half-molecules into a dimer, it is not sufficient to only have the disulfide linkages which keep the 2 half-molecules intact. The disulfide rings which flank the coil-coiled region also play important roles in dimer assembly. Intact interchain disulfide linkages at the NH2-terminal end of the coiled-coil region are essential for assembly of the 2 half-molecules. Disruption of these disulfide rings leads to the formation and secretion of half-molecules. Disruption of the interchain disulfide rings at the COOH-terminal end of the coiled-coil region allows dimer formation, but the 6-chain molecule which is assembled is not secreted. Disruption of both disulfide rings at either end of the coiled-coil region disallows assembly of half-molecules and of dimeric fibrinogen.	NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,NEW YORK,NY 10021	New York Blood Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037457] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37457] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNHART MI, 1962, P SOC EXP BIOL MED, V110, P734; BINNIE CG, 1993, BIOCHEMISTRY-US, V32, P107, DOI 10.1021/bi00052a015; BLOMBACK B, 1972, ANN NY ACAD SCI, V202, P77, DOI 10.1111/j.1749-6632.1972.tb16323.x; BLOMBACK B, 1968, NATURE, V218, P130, DOI 10.1038/218130a0; BLOMBACK B, 1974, THROMB RES, V4, P55, DOI 10.1016/0049-3848(74)90203-5; BLOMBACK B, 1976, THROMB RES, V8, P639, DOI 10.1016/0049-3848(76)90245-0; BOUMA H, 1978, THROMB RES, V713, P557; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DANISHEFSKY K, 1990, BIOCHIM BIOPHYS ACTA, V1048, P202, DOI 10.1016/0167-4781(90)90057-9; DOOLITTLE RF, 1978, J MOL BIOL, V120, P311, DOI 10.1016/0022-2836(78)90070-0; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; FARRELL DH, 1991, BIOCHEMISTRY-US, V30, P9414, DOI 10.1021/bi00103a004; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HARTWIG R, 1991, J BIOL CHEM, V266, P6578; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HENSCHEN A, 1964, ARK KEMI, V22, P355; HOEPRICH PD, 1983, BIOCHEMISTRY-US, V22, P2049, DOI 10.1021/bi00278a003; HUANG SM, 1993, J BIOL CHEM, V268, P8919; HUANG SM, 1993, BIOCHEM BIOPH RES CO, V190, P488, DOI 10.1006/bbrc.1993.1074; IWANAGA S, 1967, BIOCHIM BIOPHYS ACTA, V147, P606, DOI 10.1016/0005-2795(67)90025-6; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MOSESSON MW, 1981, J MOL BIOL, V153, P695, DOI 10.1016/0022-2836(81)90414-9; MURAKAWA M, 1993, THROMB HAEMOSTASIS, V69, P351; PROCYK R, 1992, BIOCHEMISTRY-US, V31, P2273, DOI 10.1021/bi00123a009; RAO SPS, 1991, J MOL BIOL, V222, P89, DOI 10.1016/0022-2836(91)90739-S; ROY SN, 1991, J BIOL CHEM, V266, P4758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; UU S, 1984, J BIOL CHEM, V259, P10574; WEISEL JW, 1981, NATURE, V289, P263, DOI 10.1038/289263a0; YU S, 1987, THROMB RES, V46, P281, DOI 10.1016/0049-3848(87)90290-8; YU S, 1983, J BIOL CHEM, V258, P3407; YU S, 1986, SCHEME INTRACELLULAR, P665; ZHANG JZ, 1992, J BIOL CHEM, V267, P21727; ZHANG JZ, 1993, J BIOL CHEM, V268, P11278; ZHANG JZ, 1992, MOL BIOL CELL, V3, pA113	36	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					652	658						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276866				2022-12-25	WOS:A1994MR21900103
J	BRESLIN, MB; LINDBERG, I; BENJANNET, S; MATHIS, JP; LAZURE, C; SEIDAH, NG				BRESLIN, MB; LINDBERG, I; BENJANNET, S; MATHIS, JP; LAZURE, C; SEIDAH, NG			DIFFERENTIAL PROCESSING OF PROENKEPHALIN BY PROHORMONE CONVERTASE-1(3) AND CONVERTASE-2 AND FURIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE REQUIREMENTS; VONWILLEBRAND-FACTOR; BETA-ENDORPHIN; GENE ENCODES; EXPRESSION; CELL; KEX2; RAT; IDENTIFICATION; CLEAVAGE	Recombinant vaccinia virus vectors were used to coexpress mouse prohormone convertase 1 (mPC1), mPC2, or human furin together with human proenkephalin in GH4C1 cells (rat pituitary somatomammotrophs) to examine the proteolytic processing of proenkephalin by these enzymes. Radioimmunoassays performed on high pressure gel permeation size-fractionated extracts obtained from GH4C1 cells and corresponding conditioned media revealed distinct profiles of immunoreactivity for products generated by each enzyme. PC1 produced intermediate sized processing products (3-10 kDa); the major immunoreactive enkephalin-containing species observed eluted at the positions of peptide B, the 5.3-kDa fragment, and free Leu5-enkephalin. PC2 exhibited a more complete processing profile. The major immunoreactive enkephalins produced were free Met5-enkephalin-Arg-Phe, free Met5-enkephalin-Arg-Gly-Leu, free Leu5-enkephalin, and free Met5-enkephalin. Thus PC2 appears to be more capable of generating active opioid units from proenkephalin than is PC1. Finally, furin cleaved proenkephalin to generate peptide B, an unidentified peak between the 18- and 5.3-kDa fragments, and a small amount of the 5.3-kDa fragment. Radiosequencing data verified that the production of the 5.3-kDa fragment by PC1 occurred as a result of a Lys-Lys cleavage. The ability of PC1 to cleave proenkephalin (but not proopiomelanocortin) at a Lys-Lys site implies that the structural context of the paired basic cleavage site may be more important in the determination of cleavage specificity than the particular pair of basic residues at the site.	LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, 1901 PERDIDO ST, NEW ORLEANS, LA 70112 USA; CLIN RES INST MONTREAL, JA DESEVE LAB, MONTREAL H2W 1R7, QUEBEC, CANADA	Louisiana State University System; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Seidah, Nabil/I-3596-2013; Lindberg, Iris/Q-3825-2019	Seidah, Nabil/0000-0001-6503-9342; 	NATIONAL INSTITUTE ON DRUG ABUSE [R56DA005084, R01DA005084] Funding Source: NIH RePORTER; NIDA NIH HHS [R56 DA005084, R01 DA005084] Funding Source: Medline; PHS HHS [05084] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BIRCH NP, 1986, FEBS LETT, V197, P173, DOI 10.1016/0014-5793(86)80321-0; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; DANDEKAR S, 1982, P NATL ACAD SCI-BIOL, V79, P1017, DOI 10.1073/pnas.79.4.1017; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; GIRAUD P, 1981, NEUROPEPTIDES, V1, P237, DOI 10.1016/0143-4179(81)90002-0; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; LINDBERG I, 1983, LIFE SCI, V33, P5, DOI 10.1016/0024-3205(83)90430-7; LINDBERG I, 1991, ENDOCRINOLOGY, V128, P1849, DOI 10.1210/endo-128-4-1849; LINDBERG I, 1986, J BIOL CHEM, V261, P6317; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MARRIOTT D, 1992, MOL ENDOCRINOL, V6, P1441, DOI 10.1210/me.6.9.1441; MATHIS JP, 1992, ENDOCRINOLOGY, V131, P2287, DOI 10.1210/en.131.5.2287; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; MOCCHETTI I, 1984, EUR J PHARMACOL, V106, P427, DOI 10.1016/0014-2999(84)90734-9; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; REHEMTULLA A, 1992, BLOOD, V79, P2349; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; SCHAFER MKH, 1993, NEUROSCIENCE, V13, P1258; SCHALKEN JA, 1987, J CLIN INVEST, V80, P1545, DOI 10.1172/JCI113240; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1978, P NATL ACAD SCI USA, V75, P3153, DOI 10.1073/pnas.75.7.3153; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; SONDERS M, 1984, BIOCHEM BIOPH RES CO, V122, P892, DOI 10.1016/0006-291X(84)91174-4; THOMAS G, 1988, BIOCHIMIE, V70, P89, DOI 10.1016/0300-9084(88)90163-0; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; UDENFRIEND S, 1983, ARCH BIOCHEM BIOPHYS, V221, P309, DOI 10.1016/0003-9861(83)90149-2; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; WATANABE T, 1992, J BIOL CHEM, V267, P8270; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; YANAGITA M, 1992, FEBS LETT, V311, P55, DOI 10.1016/0014-5793(92)81366-T; YI Z, 1993, J BIOL CHEM, V268, P5615; ZHOU A, 1993, J BIOL CHEM, V268, P1763	44	140	142	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27084	27093						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262946				2022-12-25	WOS:A1993MM26200039
J	FILHOL, O; CHAMBAZ, EM; GILL, GN; COCHET, C				FILHOL, O; CHAMBAZ, EM; GILL, GN; COCHET, C			EPIDERMAL GROWTH-FACTOR STIMULATES A PROTEIN-TYROSINE KINASE WHICH IS SEPARABLE FROM THE EPIDERMAL GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF RECEPTOR; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; SH3 DOMAINS; PHOSPHORYLATION; ASSOCIATION; CELLS; SRC; TERMINUS	The intrinsic protein tyrosine kinase activity of the epidermal growth factor (EGF) receptor is necessary for ligand-induced signaling. To determine whether cellular protein tyrosine kinases are substrates for EGF-activated receptors, phosphotyrosine-containing proteins were isolated from EGF-treated cells and assayed for tyrosine kinase activity using peptide substrates. A tyrosine kinase activity that is distinct from the EGF receptor was adsorbed to monoclonal anti-phosphotyrosine antibody columns and eluted with phenyl phosphate. Near-maximal tyrosine phosphorylation of this kinase occurred within 1 min of cell stimulation with an ED50 for EGF of 2.5 nM. The kinase was deactivated by incubation with purified CD45 tyrosine phosphatase in vitro, but activity could be restored by incubation with purified EGF receptor and Mn2+ ATP. These results suggest a cascade of tyrosine kinase signaling analogous to well characterized serine/threonine kinase cascades.	CEN,DBMS,BRCE,INSERM,U244,F-38041 GRENOBLE,FRANCE; UNIV CALIF SAN DIEGO,DEPT MED,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093	Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California San Diego			Filhol-Cochet, Odile/I-3962-2016	Filhol, Odile/0000-0003-1964-7958; Cochet, Claude/0000-0002-1772-4270	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013149, R01DK013149] Funding Source: NIH RePORTER; NIDDK NIH HHS [DDK 13149] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COCHET C, 1991, J BIOL CHEM, V266, P637; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DICKSON B, 1992, NATURE, V360, P603; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GILL GN, 1984, J BIOL CHEM, V259, P7755; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEE CY, 1977, ARCH BIOCHEM BIOPHYS, V178, P8, DOI 10.1016/0003-9861(77)90165-5; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; OLIVIER JP, 1993, SCIENCE, V260, P315; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SELVA E, 1993, J BIOL CHEM, V268, P2250; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WEDEGAERTNER PB, 1992, ARCH BIOCHEM BIOPHYS, V292, P273, DOI 10.1016/0003-9861(92)90079-C; ZACHARY I, 1991, J BIOL CHEM, V266, P24126	35	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26978	26982						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262933				2022-12-25	WOS:A1993MM26200024
J	FURUCHI, T; AIKAWA, K; ARAI, H; INOUE, K				FURUCHI, T; AIKAWA, K; ARAI, H; INOUE, K			BAFILOMYCIN-A(1), A SPECIFIC INHIBITOR OF VACUOLAR-TYPE H+-ATPASE, BLOCKS LYSOSOMAL CHOLESTEROL TRAFFICKING IN MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; NIEMANN-PICK DISEASE; HAMSTER OVARY CELLS; INTRACELLULAR-TRANSPORT; C FIBROBLASTS; FOAM CELLS; METABOLISM; ACCUMULATION; DEGRADATION	Certain steroids having an oxo group at the C-17 or C-20 position such as pregnenolone and dehydroisoandrosterone inhibit the cholesterol transport from lysosomes to other cellular sites. Taking advantage of the fact that the inhibition is reversed upon removal of the steroids, we studied the factors that control the cholesterol transport from lysosomes to other cellular sites in macrophages. Macrophages that accumulated unesterified cholesterol in their lysosomes were prepared by incubating cells with liposomes containing cholesterol and phosphatidylserine in the presence of a steroid inhibitor. These cells were chased by means of steroid washout, and then the effects of various pharmacological agents on the subsequent metabolism of cholesterol were examined. When the cells were chased in the absence of the agents, some of the cholesterol was converted to cholesteryl esters in the cells, and others were desorbed into the medium as unesterified forms, suggesting recovery of lysosomal cholesterol trafficking. Among the agents tested, bafilomycin A1, a specific inhibitor of vacuolar-type H+-ATPase, completely blocked both cholesterol esterification and cholesterol desorption at 10 nm. Moreover, agents that neutralize the lysosomal proton gradient, such as ammonium chloride and chloroquine, also reduced both of the processes. Fluorescent microscopic examination of bafilomycin A1-treated cells revealed extensive filipin-cholesterol staining of perinuclear lysosomes. From these data, we conclude that acidic pH is required for the efflux of cholesterol from lysosomes to other cellular sites.	UNIV TOKYO,FAC PHARMACEUT SCI,DEPT HLTH CHEM,HONGO 7-3-1,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BROWN MS, 1979, J CELL BIOL, V82, P597, DOI 10.1083/jcb.82.3.597; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; DAHL NK, 1992, J BIOL CHEM, V267, P4889; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GERRITY RG, 1981, AM J PATHOL, V103, P181; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; KOVAL M, 1990, J CELL BIOL, V111, P429, DOI 10.1083/jcb.111.2.429; KRUTH HS, 1986, J BIOL CHEM, V261, P6769; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1987, J BIOL CHEM, V262, P17002; LISCUM L, 1992, J LIPID RES, V33, P1239; LISCUM L, 1990, BIOCHIM BIOPHYS ACTA, V1045, P40, DOI 10.1016/0005-2760(90)90201-8; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LUKACS GL, 1991, J BIOL CHEM, V266, P24540; NISHIKAWA K, 1993, BIOCHIM BIOPHYS ACTA, V1169, P257; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; SCHAFFNER T, 1980, AM J PATHOL, V100, P57; SOKOL J, 1988, J BIOL CHEM, V263, P3411	23	79	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27345	27348						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262974				2022-12-25	WOS:A1993MM26200073
J	JIANG, XC; MASUCCIMAGOULAS, L; MAR, J; LIN, M; WALSH, A; BRESLOW, JL; TALL, A				JIANG, XC; MASUCCIMAGOULAS, L; MAR, J; LIN, M; WALSH, A; BRESLOW, JL; TALL, A			DOWN-REGULATION OF MESSENGER-RNA FOR THE LOW-DENSITY-LIPOPROTEIN RECEPTOR IN TRANSGENIC MICE CONTAINING THE GENE FOR HUMAN CHOLESTERYL ESTER TRANSFER PROTEIN - MECHANISM TO EXPLAIN ACCUMULATION OF LIPOPROTEIN-B PARTICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID TRANSFER PROTEIN; APOLIPOPROTEIN-E; PLASMA; METABOLISM; TRANSCRIPTION; HAMSTER; RABBIT; LIVER; RATES	To evaluate the effects of cholesteryl ester transfer protein (CETP) on apoB-containing lipoproteins, we analyzed plasma lipoproteins from three different lines of human CETP transgenic mice, with plasma CETP concentration ranging from low (1.5 mug/ml) to high levels (8.5 mug/ml). With increasing CETP concentration, very low density lipoprotein and low density lipoprotein (LDL) cholesteryl ester (CE) and apoB were progressively increased, and high density lipoprotein CE was decreased. To investigate the mechanism of accumulation of lipoproteins containing apoB (lipoprotein B), the abundance of hepatic LDL receptor mRNA was determined. LDL receptor mRNA was reduced as a result of CETP expression, with maximum repression to about 48% of the level of non-transgenic mice. Among the different lines of CETP transgenic mice there was an inverse relationship between plasma CETP concentration and hepatic LDL receptor mRNA abundance (r = -0.94, p < 0.01). CETP expression also led to increased cholesterol and cholesteryl ester content in liver and to decreased abundance of mRNAs encoding 3-hydroxy-3-methylglutaryl-coenzyme A reductase and 7-alpha-hydroxylase. Thus, CETP expression results in increased cholesteryl ester concentration in very low density lipoprotein and LDL, probably reflecting both CE transfer from high density lipoprotein and accumulation of lipoprotein B particles. The accumulation of lipoprotein B particles results from CETP-mediated down-regulation of liver LDL receptors, possibly due to enhanced return of cholesterol to the liver.	COLUMBIA UNIV,DEPT MED,DIV MOLEC MED,NEW YORK,NY 10032; ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,NEW YORK,NY 10021	Columbia University; Rockefeller University			Tall, Alan/AAT-8528-2021; Breslow, Jan L/B-7544-2008		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006, R01HL033714, R01HL043165] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43165, HL-21006, HL-33714] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGELLON LB, 1991, J BIOL CHEM, V266, P10796; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Bachorik P S, 1986, Methods Enzymol, V129, P78; CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; FORBES WR, 1985, ARTERIOSCLEROSIS, V5, P283; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GROENER JEM, 1989, BIOCHIM BIOPHYS ACTA, V1002, P93, DOI 10.1016/0005-2760(89)90070-2; HA YC, 1982, COMP BIOCHEM PHYS B, V71, P265, DOI 10.1016/0305-0491(82)90252-8; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; JIANG XC, 1992, J CLIN INVEST, V90, P1290, DOI 10.1172/JCI115993; JIANG XC, 1991, J BIOL CHEM, V266, P4631; KANE JP, 1980, P NATL ACAD SCI-BIOL, V77, P2465, DOI 10.1073/pnas.77.5.2465; KELZ HR, 1982, J BIOL CHEM, V257, P8061; KESNIEMI YA, 1983, J CLIN INVEST, V71, P950; KOIZUMI J, 1991, ATHEROSCLEROSIS, V90, P189, DOI 10.1016/0021-9150(91)90114-I; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; MARCEL YL, 1990, J CLIN INVEST, V85, P10, DOI 10.1172/JCI114397; MAROTTI KR, 1992, ARTERIOSCLER THROMB, V12, P736, DOI 10.1161/01.ATV.12.6.736; MCPHERSON R, 1991, ARTERIOSCLER THROMB, V11, P476, DOI 10.1161/01.ATV.11.3.476; MENZEL HJ, 1983, ARTERIOSCLEROSIS, V3, P310, DOI 10.1161/01.ATV.3.4.310; MOULIN P, 1992, J LIPID RES, V33, P1817; QUIG DW, 1986, BIOCHIM BIOPHYS ACTA, V879, P171, DOI 10.1016/0005-2760(86)90100-1; QUINET E, 1991, J CLIN INVEST, V87, P1559, DOI 10.1172/JCI115169; QUINET EM, 1990, J CLIN INVEST, V85, P357, DOI 10.1172/JCI114446; RUDLING M, 1992, J LIPID RES, V33, P493; RUDLING M, 1993, J CLIN INVEST, V91, P2796, DOI 10.1172/JCI116522; SEHAYEK E, 1991, J CLIN INVEST, V88, P553, DOI 10.1172/JCI115339; SPADY DK, 1985, P NATL ACAD SCI USA, V82, P4526, DOI 10.1073/pnas.82.13.4526; SPADY DK, 1985, J LIPID RES, V26, P465; SPADY DK, 1983, P NATL ACAD SCI-BIOL, V80, P3499, DOI 10.1073/pnas.80.11.3499; TALL A, 1987, J CLIN INVEST, V79, P1217, DOI 10.1172/JCI112940; TALL AR, 1986, J LIPID RES, V27, P361; WEINTRAUB MS, 1987, J CLIN INVEST, V80, P1571, DOI 10.1172/JCI113243; WHITLOCK ME, 1989, J CLIN INVEST, V84, P129, DOI 10.1172/JCI114132; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210	37	92	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27406	27412						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262982				2022-12-25	WOS:A1993MM26200081
J	LOBSANOV, YD; GITT, MA; LEFFLER, H; BARONDES, SH; RINI, JM				LOBSANOV, YD; GITT, MA; LEFFLER, H; BARONDES, SH; RINI, JM			X-RAY CRYSTAL-STRUCTURE OF THE HUMAN DIMERIC S-LAC LECTIN, L-14-II, IN COMPLEX WITH LACTOSE AT 2.9-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTIN; CARBOHYDRATE-RECOGNITION DOMAINS; AMINO-ACID-SEQUENCE; VERTEBRATE LECTINS; MAC-2 ANTIGEN; PROTEIN; SPECIFICITY; LAMININ; FAMILY; SITE	S-Lac lectins are a family of soluble lactose-binding animal lectins, some of which have been implicated in modulating cell-cell and cell-matrix interactions through specific carbohydrate-mediated recognition. We report here the x-ray crystal structure of a representative member of this family, the human dimeric S-Lac lectin, L-14-II, in complex with lactose, at 2.9-angstrom resolution. The two-fold symmetric dimer is made up of two extended anti-parallel beta-sheets, which associate in a beta-sandwich motif. Remarkably, the L-14-II monomer shares not only the same topology, but a very similar beta-sheet structure with that of the leguminous plant lectins, suggesting a conserved structure-function relationship. Carbohydrate binding by L-14-II was found to involve protein residues that are very highly conserved among all S-Lac lectins. These residues map to a single DNA exon, suggesting a carbohydrate binding cassette common to all S-Lac lectins.	UNIV TORONTO,INST MOLEC GENET,TORONTO M5S 1A8,ONTARIO,CANADA; RUSSIAN ACAD SCI,INST MOLEC GENET,MOSCOW 123182,RUSSIA; UNIV TORONTO,DEPT MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV CALIF SAN FRANCISCO,LANGLEY PORTER NEUROPSYCHIAT INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MOLEC GENET,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143	University of Toronto; Russian Academy of Sciences; University of Toronto; University of Toronto; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Leffler, Hakon/A-2416-2019	Leffler, Hakon/0000-0003-4482-8945				ABBOTT WM, 1991, J BIOL CHEM, V266, P5552; AHMED H, 1990, BIOCHEMISTRY-US, V29, P5315, DOI 10.1021/bi00474a015; BARONDES SH, 1984, SCIENCE, V223, P1259, DOI 10.1126/science.6367039; BRUNGER AT, 1992, X PLOR MANJUAL VERSI; CERRA RF, 1985, J BIOL CHEM, V260, P10474; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; CHILDS RA, 1990, J BIOL CHEM, V265, P20770; Colin Hughes R., 1992, CURR OPIN STRUC BIOL, V2, P687, DOI 10.1016/0959-440X(92)90202-I; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; DIAZ CL, 1989, NATURE, V338, P579, DOI 10.1038/338579a0; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GITT MA, 1986, P NATL ACAD SCI USA, V83, P7603, DOI 10.1073/pnas.83.20.7603; GITT MA, 1992, J BIOL CHEM, V267, P10601; GITT MA, 1991, BIOCHEMISTRY-US, V30, P82, DOI 10.1021/bi00215a013; GRITZMACHER CA, 1992, BIOCHEMISTRY-US, V31, P9533, DOI 10.1021/bi00155a004; HARRISON FL, 1991, J CELL SCI, V100, P9; HIRABAYASHI J, 1992, J BIOL CHEM, V267, P15485; HIRABAYASHI J, 1991, J BIOL CHEM, V266, P23648; HIRABAYASHI J, 1987, J BIOCHEM-TOKYO, V101, P775, DOI 10.1093/jb/101.3.775; HSU DK, 1992, J BIOL CHEM, V267, P14167; IMBERTY A, 1993, ADV BIOPH C, V0003; JIA SH, 1988, J BIOL CHEM, V263, P6009; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; LAING JG, 1989, J BIOL CHEM, V264, P1907; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEE RT, 1991, J BIOL CHEM, V266, P4810; LEE RT, 1990, J BIOL CHEM, V265, P7864; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; LEVI G, 1981, J BIOL CHEM, V256, P5735; LOBSANOV YD, 1993, J MOL BIOL, V233, P553, DOI 10.1006/jmbi.1993.1533; MARSCHAL P, 1992, J BIOL CHEM, V267, P12942; MASSA SM, 1993, BIOCHEMISTRY-US, V32, P260, DOI 10.1021/bi00052a033; ODA Y, 1993, J BIOL CHEM, V268, P5929; ODA Y, 1991, GENE, V99, P279; QUIOCHO FA, 1989, PURE APPL CHEM, V61, P1293, DOI 10.1351/pac198961071293; RINI JM, 1993, J BIOL CHEM, V268, P10126; ROSENBERG IM, 1993, J BIOL CHEM, V268, P12393; SATO S, 1992, J BIOL CHEM, V267, P6983; SOLOMON JC, 1991, CARBOHYD RES, V213, P293, DOI 10.1016/S0008-6215(00)90616-5; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WOO HJ, 1990, J BIOL CHEM, V265, P7097; ZHOU Q, 1990, ARCH BIOCHEM BIOPHYS, V281, P27, DOI 10.1016/0003-9861(90)90408-Q	49	275	288	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27034	27038						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262940				2022-12-25	WOS:A1993MM26200032
J	NOTARNICOLA, SM; RICHARDSON, CC				NOTARNICOLA, SM; RICHARDSON, CC			THE NUCLEOTIDE-BINDING SITE OF THE HELICASE-PRIMASE OF BACTERIOPHAGE-T7 - INTERACTION OF MUTANT AND WILD-TYPE PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID REPLICATION INVITRO; NUCLEOSIDE 5'-TRIPHOSPHATASE ACTIVITY; T7 DEOXYRIBONUCLEIC-ACID; DNAB GENE-PRODUCT; ESCHERICHIA-COLI; PHYSICAL-PROPERTIES; PRIMER SYNTHESIS; EXCISION REPAIR; RNA PRIMER; 4 PROTEIN	The helicase and primase activities of bacteriophage T7 are distributed between the 56- and 63-kDa gene 4 proteins. The 63-kDa protein catalyzes both helicase and primase activities. The 56-kDa gene 4 protein lacks the 63 amino acids at the N terminus of the colinear 63-kDa protein and catalyzes only helicase activity. Helicase activity is dependent on the hydrolysis of a nucleoside 5'-triphosphate. Sequence analysis reveals a single ''A-type'' nucleoside 5'-triphosphate binding site near the center of each gene 4 protein. We have examined the essential role of nucleoside triphosphate hydrolysis both in vivo and in vitro by using site-directed mutagenesis to alter the conserved, adjacent Gly and Lys residues within this nucleotide binding site. The mutant gene 4 proteins, expressed from plasmids carrying the cloned genes, do not complement a T7 phage lacking gene 4. Moreover, the mutations are dominant-lethal: they block productive infection by wild-type T7 phage. A nucleotide binding site mutant 56-kDa gene 4 protein, purified to homogeneity from cells over-expressing the gene, binds but lacks the ability to hydrolyze nucleotides and cannot bind to single-stranded DNA. Consequently, this mutant gene 4 protein also lacks helicase activity. The mutant gene 4 proteins inhibit the nucleotide hydrolysis activity of wild-type gene 4 proteins in a stoichiometric manner. The apparent inhibition constant (K(i) = 22 +/- 4.5 nM) of this interaction may reflect the gene 4 oligomer dissociation constant in the presence of nucleotide and single-stranded DNA. Analysis of the inhibition reaction indicates that this is a linear mixed-type inhibition, indicating that the mutant protein binds the wild-type protein to form an inactive complex on single-stranded DNA. Furthermore, the mutant 56-kDa gene 4 protein has the same affinity for both the wild-type 63- and 56-kDa gene 4 proteins, suggesting that there is no preference for the formation of homo-oligomeric complexes. The ability of the mutant proteins to inhibit the activity of the wild-type gene 4 proteins indicates that nucleotide hydrolysis is coordinated and cooperative among the members of the gene 4 protein complex as it binds and translocates on single-stranded DNA.			NOTARNICOLA, SM (corresponding author), HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA.				NIAID NIH HHS [AI-06045] Funding Source: Medline; PHS HHS [1 F32 A108630-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI006045, R01AI006045] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM KI, 1984, BIOCHEMISTRY-US, V23, P1176, DOI 10.1021/bi00301a023; ARAI K, 1981, J BIOL CHEM, V256, P5247; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; FUJIYAMA A, 1981, P NATL ACAD SCI-BIOL, V78, P903, DOI 10.1073/pnas.78.2.903; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HILL J, 1979, ANN BOT-LONDON, V43, P449, DOI 10.1093/oxfordjournals.aob.a085655; HUBER HE, 1988, J BIOL CHEM, V263, P13549; HUBER HE, 1988, CANCER CELL, V6, P11; KIM YT, 1992, J BIOL CHEM, V267, P15032; KOLODNER R, 1977, P NATL ACAD SCI USA, V74, P1525, DOI 10.1073/pnas.74.4.1525; KOLODNER R, 1978, J BIOL CHEM, V253, P566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MARSZALEK J, 1992, J BIOL CHEM, V267, P19334; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MENDELMAN LV, 1992, P NATL ACAD SCI USA, V89, P10638, DOI 10.1073/pnas.89.22.10638; MENDELMAN LV, 1993, J BIOL CHEM, V268, P27208; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MILLER H, 1987, METHOD ENZYMOL, V152, P145; NAKAI H, 1986, J BIOL CHEM, V261, P5217; NAKAI H, 1988, J BIOL CHEM, V263, P9831; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1993, J BIOL CHEM, V268, P10668; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; ROMANO LJ, 1979, J BIOL CHEM, V254, P476; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHERZINGER E, 1977, EUR J BIOCHEM, V72, P543, DOI 10.1111/j.1432-1033.1977.tb11278.x; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; SEGEL IH, 1976, BIOCH CALCULATIONS, P246; SHRIMANKAR P, 1992, J BACTERIOL, V174, P7689, DOI 10.1128/JB.174.23.7689-7696.1992; SOKOLOV BP, 1990, NUCLEIC ACIDS RES, V18, P3671, DOI 10.1093/nar/18.12.3671; STUDIER FW, 1969, VIROLOGY, V39, P562, DOI 10.1016/0042-6822(69)90104-4; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933	56	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27198	27207						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262961				2022-12-25	WOS:A1993MM26200056
J	LORSCHEIDER, FL; VIMY, MJ				LORSCHEIDER, FL; VIMY, MJ			EVALUATION OF THE SAFETY ISSUE OF MERCURY RELEASE FROM DENTAL FILLINGS	FASEB JOURNAL			English	Editorial Material							AMALGAMS				LORSCHEIDER, FL (corresponding author), UNIV CALGARY,FAC MED,DEPT MED PHYSIOL,CALGARY T2N 4N1,AB,CANADA.							APOSHIAN HV, 1992, FASEB J, V6, P2472, DOI 10.1096/fasebj.6.7.1563599; BEGLEY S, 1990, NEWSWEEK        1015, V116, P80; BOYD ND, 1991, AM J PHYSIOL, V261, pR1010, DOI 10.1152/ajpregu.1991.261.4.R1010; GOERING PL, 1992, FUND APPL TOXICOL, V19, P319, DOI 10.1016/0272-0590(92)90169-I; GROSS MJ, 1989, J APPL ELECTROCHEM, V19, P301, DOI 10.1007/BF01015227; HAHN LJ, 1990, FASEB J, V4, P3256, DOI 10.1096/fasebj.4.14.2227216; MITCHELL ED, 1984, NIDR ADA WORKSHOP BI, P416; SHEARER BG, 1993, ANTIMICROB AGENTS CH, V37, P1730, DOI 10.1128/AAC.37.8.1730; SUMMERS AO, 1993, ANTIMICROB AGENTS CH, V37, P825, DOI 10.1128/AAC.37.4.825; VIMY M J, 1990, Journal of Trace Elements in Experimental Medicine, V3, P111; 1990, J AM DENT ASSOC, V120, P395; 1991, ENV HLTH CRITERIA, V118, P36	12	14	14	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1993	7	15					1432	1433		10.1096/fasebj.7.15.8262327	http://dx.doi.org/10.1096/fasebj.7.15.8262327			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ML740	8262327				2022-12-25	WOS:A1993ML74000003
J	MAXWELL, SA; ROTH, JA				MAXWELL, SA; ROTH, JA			BINDING OF CELLULAR PROTEINS TO A CONFORMATIONAL DOMAIN OF TUMOR-SUPPRESSOR PROTEIN P53	ONCOGENE			English	Note							WILD-TYPE P53; T-ANTIGEN; ACTIVATING MUTATIONS; DNA-REPLICATION; GENE-PRODUCT; LUNG-CANCER; TRANSFORMATION; MUTANT; SEQUENCE; WILD-TYPE-P53	The genes regulated by p53, as well as the factors modulating its function, need to be identified before the mechanism of action of p53 in control of cell growth can be adequately understood, Binding of the SV40 large T-antigen protein to an evolutionally conserved (conformational) domain of p53 inhibits p53's DNA-binding and transcription activation activities. Cellular proteins might also bind to this same region of p53 to regulate its function. A hybrid protein composed of protein A fused to the conformational domain (amino acids 115-295) of p53 was expressed in Escherichia coli and used as an affinity probe for binding proteins in detergent lysates of non-small cell lung carcinoma (NSCLC) cells. The wildtype p53 hybrid protein associated with several major proteins of molecular weights 45 K, 56 K, and 70 K, as web as other minor species ranging in molecular weight from 30 K to 90 K. These proteins bound specifically to the p53 sequence of the hybrid protein. Protein A did not associate with these proteins and the two p53 hybrid proteins containing missense mutations at codons 273 and 175 exhibited a 40-80% weaker association. In addition, T antigen competed with the cellular proteins for binding to the conformational domain. The conditions of cell growth had a profound effect on the expression of the p53 binding proteins. Considerably more p53 binding proteins were expressed in actively growing cells than in culture's maintained under conditions for slow growth. Quantitative differences in expression of p53-binding proteins were observed among different NSCLC cell lines. The expression of p53-binding proteins was not restricted to NSCLC cell lines; detergent extracts of an osteosarcoma cell line yielded similar p53-binding proteins.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CARDIOVASC SURG,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	MAXWELL, SA (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT THORAC SURG,1515 HOLCOMBE BLVD,BOX 109,HOUSTON,TX 77030, USA.				NCI NIH HHS [2P30-CA16672-018, NCI CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARTEK J, 1993, EUR J CANCER, V29A, P101, DOI 10.1016/0959-8049(93)90584-3; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1992, CANCER SURV, V12, P59; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, VIROLOGY, V98, P308, DOI 10.1016/0042-6822(79)90554-3; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEDCALF EA, 1992, ONCOGENE, V7, P71; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER CW, 1990, CANCER RES, V50, P7950; MILNER J, 1990, ONCOGENE, V5, P1683; MITSUDOMI T, 1992, ONCOGENE, V7, P171; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1988, ONCOGENE, V3, P405; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	47	23	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3421	3426						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247546				2022-12-25	WOS:A1993MG78200028
J	WANG, YS; SZEKELY, L; OKAN, I; KLEIN, G; WIMAN, KG				WANG, YS; SZEKELY, L; OKAN, I; KLEIN, G; WIMAN, KG			WILD-TYPE P53-TRIGGERED APOPTOSIS IS INHIBITED BY BCL-2 IN A V-MYC-INDUCED T-CELL LYMPHOMA LINE	ONCOGENE			English	Note							TUMOR SUPPRESSOR GENE; C-MYC; B-CELLS; CHROMOSOME-TRANSLOCATION; FOLLICULAR LYMPHOMA; MEMBRANE PROTEIN; P53; DEATH; EXPRESSION; BREAKPOINT	Using a temperature sensitive p53 construct (ts p53), we have earlier shown that expression of wild-type (wt) p53 triggers apoptosis in a v-myc-induced T-cell lymphoma line that lacks endogenous p53, and in a Burkitt lymphoma line that carries mutant p53. We have suggested that apoptosis is elicited by the contradictory signals emanating from the constitutively activated myc gene and the growth arresting signal of wt p53 (Ramqvist et al., 1993; Wang et al., 1993). Work in other laboratories has shown that constitutive c-myc expression can induce apoptosis when cell proliferation is inhibited due to the lack of growth stimulating factors. Expression of bcl-2 could inhibit apoptosis. In order to test whether p53-induced apoptosis can be prevented by bcl-2, we have introduced a retrovirally driven bcl-2 construct into our v-myc-induced murine T-cell lymphoma line, previously transfected with ts p53. About 90% of the parental ts p53 transfected cells died of apoptosis within 3 days after induction of wt p53 expression at 32 degrees C. Two clones of ts p53/bcl-2 double transfectants that expressed high levels of bcl-2 from the introduced construct were completely protected from apoptosis, following transfer of the cells to 32 degrees C. One clone that expressed the exogenous bcl-2 only at a low level was partially protected from wt p53-induced apoptosis. Clones of the parental ts p53 carrying cells transfected with the puromycin resistance gene vector, without the bcl-2 gene underwent 90% apoptosis. These results suggest that bcl-2 may prevent apoptosis in cells simultaneously exposed to the proliferation-stimulating effect of activated myc and the growth arresting signal of wt p53.			WANG, YS (corresponding author), KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM,SWEDEN.		Wiman, Klas/AAB-8399-2021; Szekely, Laszlo/B-1268-2009	Wiman, Klas/0000-0002-7113-524X; 	NATIONAL CANCER INSTITUTE [R01CA014054] Funding Source: NIH RePORTER; NCI NIH HHS [CA14054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALNEMRI ES, 1992, CANCER RES, V52, P491; ASKEW DS, 1991, ONCOGENE, V6, P1915; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DEJONG D, 1988, NEW ENGL J MED, V318, P1373, DOI 10.1056/NEJM198805263182106; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FRITSCHE M, 1993, ONCOGENE, V8, P307; GAUWERKY CE, 1988, P NATL ACAD SCI USA, V85, P8548, DOI 10.1073/pnas.85.22.8548; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PEGORARO L, 1984, P NATL ACAD SCI-BIOL, V81, P7166, DOI 10.1073/pnas.81.22.7166; RAMQVIST T, 1993, ONCOGENE, V8, P1495; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; Sambrook J, 1989, MOL CLONING LABORATO; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG YS, 1992, ONCOGENE, V7, P1241; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WIMAN KG, 1991, ONCOGENE, V6, P1633; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	38	231	243	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3427	3431						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247547				2022-12-25	WOS:A1993MG78200029
J	KIMURA, K; SAIJO, M; UI, M; ENOMOTO, T				KIMURA, K; SAIJO, M; UI, M; ENOMOTO, T			GROWTH STATE-DEPENDENT AND CELL CYCLE-DEPENDENT FLUCTUATION IN THE EXPRESSION OF 2 FORMS OF DNA TOPOISOMERASE-II AND POSSIBLE SPECIFIC MODIFICATION OF THE HIGHER MOLECULAR-WEIGHT FORM IN THE M-PHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; MITOTIC CHROMOSOMES; LEUKEMIA-CELLS; PHORBOL ESTER; PHOSPHORYLATION; PROLIFERATION; CONDENSATION; LOCALIZATION; EXTRACTS; INVITRO	The fluctuations in the expression of two forms of DNA topoisomerase II, p170 and p180, were examined by immunoblotting during the transition of the growth state and the cell cycle in Swiss 3T3 cells. The level of p170 expression was higher during the exponentially growing phase than in the stationary phase, and the level of p180 did not appear to change when the cells changed the growth state. When quiescent cells were stimulated with serum, the p170 level began to increase at 12 h and reached a maximal level at 24-28 h, corresponding to the G2 phase. In contrast, the level of p180 was almost constant during the cell cycle, and the p180 band became obscure when the number of mitotic cells increased. Immunoblotting of the samples prepared from metaphase-synchronized HeLa cells did not have a p180 band, but did exhibit a band with a higher molecular weight. This band increased and p180 decreased in parallel with the increase in the number of mitotic cells. When the cells exited from the M phase, p180 reappeared and the higher molecular weight band disappeared.	UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; AUSTIN CA, 1990, FEBS LETT, V266, P115, DOI 10.1016/0014-5793(90)81520-X; AUSTIN CA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P283, DOI 10.1016/0167-4781(93)90215-Y; BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; CAPRANICO G, 1992, BIOCHIM BIOPHYS ACTA, V1132, P43, DOI 10.1016/0167-4781(92)90050-A; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CHARRON M, 1990, BIOCHEMISTRY-US, V29, P9531, DOI 10.1021/bi00493a006; CHOW KC, 1987, MOL CELL BIOL, V7, P3119, DOI 10.1128/MCB.7.9.3119; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; DEVORE RF, 1992, CANCER RES, V52, P2156; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRAKE FH, 1987, J BIOL CHEM, V262, P16739; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; DUGUET M, 1983, NUCLEIC ACIDS RES, V11, P1059, DOI 10.1093/nar/11.4.1059; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; FAIRMAN R, 1988, BIOCHEMISTRY-US, V27, P560, DOI 10.1021/bi00402a009; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HECK MMS, 1989, J BIOL CHEM, V264, P15161; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HSIANG YH, 1988, CANCER RES, V48, P3230; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; KROLL DJ, 1991, J BIOL CHEM, V266, P7957; MARKOVITS J, 1987, CANCER RES, V47, P2050; NEGRI C, 1992, EXP CELL RES, V200, P452, DOI 10.1016/0014-4827(92)90195-E; NELSON WG, 1987, CANCER RES, V47, P3246; NELSON WG, 1986, NATURE, V322, P187, DOI 10.1038/322187a0; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; SAIJO M, 1990, BIOCHEMISTRY-US, V29, P583, DOI 10.1021/bi00454a036; SAIJO M, 1992, BIOCHEMISTRY-US, V31, P359, DOI 10.1021/bi00117a007; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SULLIVAN DM, 1986, BIOCHEMISTRY-US, V25, P2248, DOI 10.1021/bi00356a060; TAKANO H, 1991, CANCER RES, V51, P3951; TAUDOU G, 1984, FEBS LETT, V176, P431, DOI 10.1016/0014-5793(84)81212-0; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; ZINI N, 1992, EXP CELL RES, V200, P460, DOI 10.1016/0014-4827(92)90196-F	50	94	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1173	1176						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288578				2022-12-25	WOS:A1994MR22000064
J	PELUFFO, RD; ROSSI, RC; GARRAHAN, PJ; REGA, AF				PELUFFO, RD; ROSSI, RC; GARRAHAN, PJ; REGA, AF			LOW-AFFINITY ACCELERATION OF THE PHOSPHORYLATION REACTION OF THE NA,K-ATPASE BY ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA++K+)-ATPASE; NA+,K+-ATPASE; BINDING; SODIUM; POTASSIUM; KINETICS; KIDNEY; K+	The maximum rate of phosphorylation (r(m)) of a highly purified Na,K-ATPase from red outer medulla of pig kidney was measured at 25-degrees-C as a function of ATP concentration in media with Mg2+, Na+, and no K+. When r(m) was plotted as a function of the concentration of ATP a biphasic response was observed with a hyperbolic component of high affinity (K(m) = 15.7 +/-2.6 muM) and low velocity ((r(m))max = 460 +/- 40 nmol of P(i)/(mg of protein . s)) plus a parabolic component which showed no saturation up to 1000 muM ATP, concentration at which r(m) was 1768.1 +/- 429.6 nmol P(i)/(mg protein.s) (mean +/- S.E.; n = 3). This low affinity effect of ATP on the rate of phosphorylation disappeared when the Na,K-ATPase underwent turnover in medium without K+ suggesting that, like superphosphorylation (Peluffo, R. D., Garrahan, P. J., and Rega, A. F. (1992) J. Biol. Chem. 267, 6596-660 1), it required the enzyme to be at rest. This property of the Na,K-ATPase was not predicted by the Albers-Post reaction scheme. The observed behavior of the enzyme could be simulated by a scheme that involves a resting enzyme (E(r)) functionally different from E1 or E2, which is able to bind three molecules of ATP, one with high and two with low affinity, and that after phosphorylation is converted into the phosphointermediates that are generally considered to participate in the reaction cycle described by Albers and Post.			PELUFFO, RD (corresponding author), FAC FARM & BIOQUIM BUENOS AIRES, INST QUIM & FISICOQUIM BIOL, JUNIN 956, RA-1113 BUENOS AIRES, ARGENTINA.							CAMPOS M, 1992, BIOCHIM BIOPHYS ACTA, V1105, P51, DOI 10.1016/0005-2736(92)90161-E; DAWSON RMC, 1969, DATA BIOCH RES, P426; ESMANN M, 1988, METHOD ENZYMOL, V156, P105; FERDINAND W, 1966, BIOCHEM J, V98, P278, DOI 10.1042/bj0980278; FROEHLICH JP, 1991, SOC GEN PHY, V46, P227; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; JENSEN J, 1984, J PHYSIOL-LONDON, V346, P219, DOI 10.1113/jphysiol.1984.sp015018; JENSEN J, 1983, BIOCHIM BIOPHYS ACTA, V731, P282, DOI 10.1016/0005-2736(83)90020-2; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; KARLISH SJD, 1978, BIOCHIM BIOPHYS ACTA, V527, P115, DOI 10.1016/0005-2744(78)90261-9; KLODOS I, 1985, SODIUM PUMP, P383; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARDH S, 1977, J BIOL CHEM, V252, P633; MARDH S, 1974, BIOCHIM BIOPHYS ACTA, V350, P473, DOI 10.1016/0005-2744(74)90523-3; NORBY JG, 1971, BIOCHIM BIOPHYS ACTA, V233, P104, DOI 10.1016/0005-2736(71)90362-2; PELUFFO RD, 1992, J BIOL CHEM, V267, P6596; ROSSI RC, 1989, BIOCHIM BIOPHYS ACTA, V981, P85, DOI 10.1016/0005-2736(89)90085-0; ROSSI RC, 1993, J BIOL CHEM, V268, P12579; ROSSI RC, 1985, SODIUM PUMP, P443; SKOU JC, 1983, BIOCHIM BIOPHYS ACTA, V746, P101, DOI 10.1016/0167-4838(83)90016-X; SUZUKI K, 1987, J BIOL CHEM, V262, P11752	21	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1051	1056						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288560				2022-12-25	WOS:A1994MR22000045
J	QIN, J; LAMAR, GN; DOU, Y; ADMIRAAL, SJ; IKEDASAITO, M				QIN, J; LAMAR, GN; DOU, Y; ADMIRAAL, SJ; IKEDASAITO, M			H-1-NMR STUDY OF THE SOLUTION MOLECULAR AND ELECTRONIC-STRUCTURE OF ENGINEERED DISTAL MYOGLOBIN HIS(64)(E7) VAL VAL(68)(E11) HIS DOUBLE MUTANT - COORDINATION OF HIS(64)(E11) AT THE 6TH POSITION IN BOTH LOW-SPIN AND HIGH-SPIN STATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SPERM WHALE MYOGLOBIN; FERRIC MYOGLOBIN; LIGAND-BINDING; HEME-PROTEINS; 1.6-A RESOLUTION; ESCHERICHIA-COLI; BOUND LIGAND; X-RAY; H-1-NMR	A genetically engineered human myoglobin (Mb) in which the distal His, His64(E7), and the distal Val, Val68(E11), are replaced by Val and His, respectively, has been expressed in Escherichia coli, for the purpose of assessing the potential role of a Ell residue in providing a hydrogen bond donor to the coordinated ligand. Molecular modeling indicates that such an interaction is possible. The H-1 NMR spectrum of the ferric form of the double mutant Mb exhibits large hyperfine shifts and strong paramagnetic relaxation for which the temperature dependence of the hyperfine shifts reveals a thermal equilibrium between a low-spin and high-spin state (70, 30% at 25-degrees-C, respectively). Standard sequence specific two-dimensional (2D) NMR assignments of the E and F helical backbones allow the identification of the peptide protons for the proximal His93(F8) and substituted distal His68(Ell). Steady-state nuclear Overhauser effect from these peptide protons locate strongly hyperfine shifted His93(F8) and His68(Ell) side chain protons which dictate that both the imidazole rings are coordinated to the iron. 2D bond correlation and one-dimensional and 2D dipolar correlation experiments locate and assign the resonances for the heme. The pattern of the heme contact shifts in both the low-spin and high-spin state, together with the nature of the temperature dependence of the His93(F8) and His68(E11) resonances, establish that the two His are ligated in the high-spin as well as low-spin forms. The pattern of heme methyl hyperfine shifts in the low-spin state, and the smaller hyperfine shifts for His68(E11) as compared to His93(F8) in the high-spin state, indicate that the axial bond to the distal His68(Ell) is weakened or strained as compared with that for the proximal His93(F8) in both spin states. This weak ligation originates from a tilted iron-His'' bond, the only conformation in which His'' can place its imidazole group sufficiently close to bind to the heme iron in the conventional Mb folding. Not only do these results support the belief that distal His is indispensable for the control of the ligand binding in Mb and hemoglobin, but also reveal the significance of the evolution that the stereochemical disposition of both His64 and Val68 are unique and non-exchangeable for interacting with the bound ligand.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Case Western Reserve University	QIN, J (corresponding author), UNIV CALIF DAVIS,DEPT CHEM,DAVIS,CA 95616, USA.		Ikeda-Saito, Masao/A-5992-2008; Ikeda-Saito, Masao/K-2703-2015	Qin, Jun/0000-0002-2647-9270	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016087, R01HL016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039492] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16087] Funding Source: Medline; NIGMS NIH HHS [GM39492] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLOCATELLI CT, 1993, BIOCHEMISTRY-US, V32, P6041; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN, P40; BAX A, 1984, 2 DIMENSIONAL NMR LI; BERTINI I, 1993, CHEM PHYS LETT, V203, P445, DOI 10.1016/0009-2614(93)85290-5; BERTINI I, 1980, NMR PARAMAGNETIC MOL; BOLOGNESI M, 1989, J MOL BIOL, V205, P529, DOI 10.1016/0022-2836(89)90224-6; BOLOGNESI M, 1990, J MOL BIOL, V213, P621, DOI 10.1016/S0022-2836(05)80249-9; BOLOGNESI M, 1982, J MOL BIOL, V158, P305, DOI 10.1016/0022-2836(82)90435-1; CARVER TE, 1991, BIOCHEMISTRY-US, V30, P4697, DOI 10.1021/bi00233a009; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; CUTNELL JD, 1981, J AM CHEM SOC, V103, P3567, DOI 10.1021/ja00402a053; CUTRUZZOLA F, 1991, FEBS LETT, V282, P281, DOI 10.1016/0014-5793(91)80495-O; EGEBERG KD, 1990, BIOCHEMISTRY-US, V29, P9783, DOI 10.1021/bi00494a004; EMERSON SD, 1990, BIOCHEMISTRY-US, V29, P1545, DOI 10.1021/bi00458a028; EMERSON SD, 1990, BIOCHEMISTRY-US, V29, P1556, DOI 10.1021/bi00458a029; HORI H, 1971, BIOCHIM BIOPHYS ACTA, V251, P227, DOI 10.1016/0005-2795(71)90106-1; IIZUKA T, 1974, BIOCHIM BIOPHYS ACTA, V371, P1, DOI 10.1016/0005-2795(74)90148-2; IKEDASAITO M, 1991, J BIOL CHEM, V266, P23641; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; JOHNSON KA, 1989, J MOL BIOL, V207, P459, DOI 10.1016/0022-2836(89)90269-6; KOTTALAM J, 1988, J AM CHEM SOC, V110, P7690, DOI 10.1021/ja00231a018; KURIYAN J, 1986, J MOL BIOL, V192, P123; La Mar G. N., 1979, PORPHYRINS, VIV, P61, DOI DOI 10.1016/B978-0-12-220104-2.50009-0; La Mar G.N, 1979, BIOL APPLICATIONS MA, P305; LAMAR GN, 1990, J BIOL CHEM, V265, P16173; LAMAR GN, 1984, J AM CHEM SOC, V106, P6395, DOI 10.1021/ja00333a050; LAMAR GN, 1983, BIOCHEMISTRY-US, V22, P6239, DOI 10.1021/bi00295a031; LECOMTE JTJ, 1985, BIOCHIM BIOPHYS ACTA, V829, P268, DOI 10.1016/0167-4838(85)90197-9; LEE KB, 1990, BIOCHEMISTRY-US, V29, P9623, DOI 10.1021/bi00493a017; MAYER A, 1974, J MOL BIOL, V86, P749, DOI 10.1016/0022-2836(74)90351-9; MORIKIS D, 1990, J BIOL CHEM, V265, P12143; PEYTON DH, 1991, BIOCHEM BIOPH RES CO, V175, P515, DOI 10.1016/0006-291X(91)91594-3; PHILLIPS SEV, 1981, NATURE, V292, P81, DOI 10.1038/292081a0; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; QIN J, 1992, J BIOMOL NMR, V2, P597, DOI 10.1007/BF02192849; QIN J, 1992, J MOL BIOL, V224, P891, DOI 10.1016/0022-2836(92)90456-T; RAJARATHNAM K, 1991, J AM CHEM SOC, V113, P7886, DOI 10.1021/ja00021a010; RAJARATHNAM K, 1992, J AM CHEM SOC, V114, P9048, DOI 10.1021/ja00049a042; RINGE D, 1984, BIOCHEMISTRY-US, V23, P2, DOI 10.1021/bi00296a001; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; Sambrook J, 1989, MOL CLONING LABORATO; SHULMAN RG, 1971, J MOL BIOL, V57, P93, DOI 10.1016/0022-2836(71)90121-5; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; UNGER SW, 1985, J MAGN RESON, V61, P448, DOI 10.1016/0022-2364(85)90185-4; VARADARAJAN R, 1989, BIOCHEMISTRY-US, V28, P3771, DOI 10.1021/bi00435a022; VARADARAJAN R, 1985, P NATL ACAD SCI USA, V82, P5681, DOI 10.1073/pnas.82.17.5681; WEBER PC, 1981, J BIOL CHEM, V256, P7702; WU JZ, 1991, BIOCHEMISTRY-US, V30, P2156, DOI 10.1021/bi00222a020; YAMAMOTO Y, 1989, BIOCHIM BIOPHYS ACTA, V996, P187, DOI 10.1016/0167-4838(89)90246-X; YU LPP, 1990, J AM CHEM SOC, V112, P9527, DOI 10.1021/ja00182a012; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	56	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1083	1090						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288565				2022-12-25	WOS:A1994MR22000050
J	SHAH, VK; ALLEN, JR; SPANGLER, NJ; LUDDEN, PW				SHAH, VK; ALLEN, JR; SPANGLER, NJ; LUDDEN, PW			IN-VITRO SYNTHESIS OF THE IRON-MOLYBDENUM COFACTOR OF NITROGENASE - PURIFICATION AND CHARACTERIZATION OF NIFB COFACTOR, THE PRODUCT OF NIFB PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE REDUCTION PROPERTIES; AZOTOBACTER-VINELANDII; KLEBSIELLA-PNEUMONIAE; MEMBRANE-PROTEINS; FIXATION; HOMOCITRATE; MUTANTS; GENES; IDENTIFICATION; DINITROGENASE	The requirement of NIFB activity for the biosynthesis of iron-molybedenum cofactor (FeMo-co) can be satisfied by the addition of the low molecular weight product of NIFB, termed NifB cofactor (NifB-co). NifB-co has been purified to homogeneity by a unique one-step method. Addition of NifB-co into the FeMo-co synthesis system generated nitrogenase activity of 27-32 nmol of ethylene formed/min/nmol of iron. Iron is the only metal detected in the NifB-co. NifB-co-dependent in vitro FeMo-co synthesis is absolutely dependent on the presence of molybdate, homocitrate and active NIFNE protein in the reaction mixture. The cofactor appears to be a small Fe-S cluster synthesized by NIFB, as a precursor of FeMo-co. NifB-co did not display any EPR signal at 4 K in 0-4000 gauss range. A solution of NifB-co is greenish-brown in color, similar to FeMo-co. NifB-co exhibits a broad absorbance between 400 and 700 nm with no distinctive peaks or shoulders. NifB-co is stable to repeated freeze-thaw cycles and is also stable in N-methylformamide, the solvent used for the isolation of FeMo-co. The NifB-co is stable to a 5-min heat treatment at 60-degrees-C. The cofactor is extremely O2-labile, with half-life of less then 15 s in air.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,COLL AGR & LIFE SCI,CTR STUDIES NITROGEN FIXAT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM35332] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035332, R37GM035332] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1993, J BIOL CHEM, V268, P23670; BISHOP PE, 1990, ANNU REV PLANT PHYS, V41, P109; BISHOP PE, 1986, SCIENCE, V232, P92, DOI 10.1126/science.232.4746.92; BRIGLE KE, 1987, J BACTERIOL, V169, P1547, DOI 10.1128/jb.169.4.1547-1553.1987; BULEN WA, 1966, P NATL ACAD SCI USA, V56, P979, DOI 10.1073/pnas.56.3.979; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; CHANG YC, 1992, ANAL BIOCHEM, V205, P22, DOI 10.1016/0003-2697(92)90573-P; HAGEMAN RV, 1978, BIOCHEMISTRY-US, V17, P4117, DOI 10.1021/bi00613a002; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; Hartzell C R, 1978, Methods Enzymol, V53, P54; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; HOOVER TR, 1987, NATURE, V329, P855, DOI 10.1038/329855a0; IMPERIAL J, 1989, BIOCHEMISTRY-US, V28, P7796, DOI 10.1021/bi00445a040; IMPERIAL J, 1988, NITROGEN FIXATION 10, P128; JOERGER RD, 1986, J BACTERIOL, V168, P673, DOI 10.1128/jb.168.2.673-682.1986; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; MACNEIL T, 1978, J BACTERIOL, V136, P253, DOI 10.1128/JB.136.1.253-266.1978; MADDEN MS, 1990, P NATL ACAD SCI USA, V87, P6517, DOI 10.1073/pnas.87.17.6517; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; NAGATANI HH, 1974, J BACTERIOL, V120, P697, DOI 10.1128/JB.120.2.697-701.1974; PAGANI S, 1991, FEBS LETT, V278, P151, DOI 10.1016/0014-5793(91)80105-C; PAGANI S, 1987, BIOCHEM J, V244, P485, DOI 10.1042/bj2440485; PAUSTIAN TD, 1989, P NATL ACAD SCI USA, V86, P6082, DOI 10.1073/pnas.86.16.6082; RAWLINGS J, 1978, J BIOL CHEM, V253, P1001; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; ROBINSON NC, 1984, BIOCHEMISTRY-US, V23, P6121, DOI 10.1021/bi00320a034; Shah V. K., 1980, Methods in Enzymology, V69, P792, DOI 10.1016/S0076-6879(80)69074-0; Shah V. K., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P115; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V305, P445, DOI 10.1016/0005-2728(73)90190-4; SHAH VK, 1978, BIOCHEM BIOPH RES CO, V81, P232, DOI 10.1016/0006-291X(78)91654-6; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V292, P246, DOI 10.1016/0005-2728(73)90269-7; TREMBLAY GY, 1969, J MOL BIOL, V40, P65, DOI 10.1016/0022-2836(69)90296-4; YANG SS, 1982, J BIOL CHEM, V257, P8042; YOCH DC, 1966, J BACTERIOL, V92, P618, DOI 10.1128/JB.92.3.618-622.1966; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754	42	92	91	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1154	1158						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288575				2022-12-25	WOS:A1994MR22000061
J	MIURA, O; NAKAMURA, N; IHLE, JN; AOKI, N				MIURA, O; NAKAMURA, N; IHLE, JN; AOKI, N			ERYTHROPOIETIN-DEPENDENT ASSOCIATION OF PHOSPHATIDYLINOSITOL 3-KINASE WITH TYROSINE-PHOSPHORYLATED ERYTHROPOIETIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; FACTOR-I RECEPTOR; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; EXPRESSION CLONING; CYTOPLASMIC REGION; BETA-RECEPTOR; SH2 DOMAINS; CELL-LINES; PROTEIN	Erythropoietin (Epo) regulates the proliferation and differentiation of erythroid precursors. The Epo receptor (EpoR) belongs to the cytokine receptor family and lacks a tyrosine kinase domain. However, Epo induces tyrosine phosphorylation of cellular substrates including the EpoR. To explore the functional significance of receptor tyrosine phosphorylation, we examined the possible interaction of the receptor with the 85-kDa regulatory subunit (p85) of phosphatidylinositol (PI) 3-kinase. After Epo stimulation, p85 was found to associate with the tyrosine-phosphorylated 72-kDa form of EpoR as well as a 92-kDa phosphotyrosyl protein, and PI 3-kinase activity was detectable in anti-EpoR immunoprecipitates. Anti-EpoR blotting of anti-p85 immunoprecipitates revealed that p85 binds specifically to the 72-kDa form of the EpoR and not to unphosphorylated 66- and 64-kDa forms. Association of p85 with the EpoR was Epo dose- and time-dependent and correlated with tyrosine phosphorylation of the receptor. Consistent with a role for tyrosine phosphorylation of the EpoR, PI 3-kinase did not associate with a mitogenically active receptor mutant that lacked tyrosine-phosphorylation sites in the carboxyl-terminal region. A recombinant fusion protein containing the carboxyl-terminal SH-2 domain of p85 was shown to bind to tyrosine-phosphorylated EpoR in vitro. Taken together, these results indicate that, following Epo stimulation, the EpoR recruits PI 3-kinase to the cell membrane by binding between the carboxyl-terminal SH-2 domain of p85 and the tyrosine-phosphorylated carboxyl-terminal region of the receptor. The association with PI 3-kinase is, however, not required for the growth signal transduction from the EpoR.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital	MIURA, O (corresponding author), TOKYO MED & DENT UNIV, DEPT INTERNAL MED 1, 1-5-45 YUSHIMA, BUNKYO KU, TOKYO 113, JAPAN.			Miura, Osamu/0000-0002-0981-3054				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DAMEN J, 1992, BLOOD, V80, P1923; DANDREA AD, 1990, J CLIN INVEST, V86, P681, DOI 10.1172/JCI114763; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DANEM JE, 1993, BLOOD, V81, P3204; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FUKUI Y, 1989, ONCOGENE RES, V4, P283; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; IHLE JN, 1990, INT J CELL CLONING, V8, P130, DOI 10.1002/stem.5530080712; IHLE JN, 1993, IN PRESS SEMIN IMMUN; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; KRANTZ SB, 1991, BLOOD, V77, P419; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LINNEKIN D, 1992, J BIOL CHEM, V267, P23993; LINNEKIN D, 1992, P NATL ACAD SCI USA, V89, P6237, DOI 10.1073/pnas.89.14.6237; MERIDA I, 1991, J IMMUNOL, V147, P2202; MERIDA I, 1993, J BIOL CHEM, V268, P6765; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA O, 1993, BLOOD, V81, P1739; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; QUELLE FW, 1991, J BIOL CHEM, V266, P609; QUELLE FW, 1992, J BIOL CHEM, V267, P17055; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; SHERR CJ, 1991, TRENDS GENET, V7, P398, DOI 10.1016/0168-9525(91)90263-P; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VENKITARAMAN AR, 1992, P NATL ACAD SCI USA, V89, P12083, DOI 10.1073/pnas.89.24.12083; VONSCHU P, 1993, SCIENCE, V260, P88; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223	67	127	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					614	620						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276859				2022-12-25	WOS:A1994MR21900097
J	WANG, MY; LIEHR, JG				WANG, MY; LIEHR, JG			IDENTIFICATION OF FATTY-ACID HYDROPEROXIDE COFACTORS IN THE CYTOCHROME P450-MEDIATED OXIDATION OF ESTROGENS TO QUINONE METABOLITES - ROLE AND BALANCE OF LIPID PEROXIDES DURING ESTROGEN-INDUCED CARCINOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-DEETHYLASE ACTIVITY; MALE SYRIAN-HAMSTERS; CUMENE HYDROPEROXIDE; RAT-LIVER; BENZO<A>PYRENE; ESTRADIOL; ENZYMES; DIETHYLSTILBESTROL; 7-ETHOXYRESORUFIN; CHROMATOGRAPHY	Lipid hydroperoxide-supported metabolic redox cycling between diethylstilbestrol (DES) or catecholestrogens and their corresponding quinones has been postulated previously to play a role in estrogen-induced toxicity and carcinogenesis. As part of an examination of this postulate, we investigated (a) the effectiveness of various lipid hydroperoxides as oxidants in microsome-mediated quinone formation, and (b) the dependence of DES oxidation to quinone on lipid hydroperoxide levels in liver and kidney of hamsters. Kinetic analyses of the lipid hydroperoxide-mediated conversion of DES to DES quinone revealed that of the peroxides tested (9Z,11E,13(S))- 13-hydroperoxyoctadecadien-1-oic acid was the most powerful oxidant (V(max) = 10.5 nmol min-1; K(m) = 21.3 muM) followed by (5(S),6E,8Z,11Z,14Z)-5-hydroperoxyeicosatetraen-1-oic acid (V(max) = 1.0 nmol min-1; K(m) 10.0 muM). The other pure fatty acid hydroperoxide isomers or mixtures had a lower affinity for the enzyme (K(m) values ranging from 23.1 to 130 muM) and/or lower maximal velocity (V(max) values ranging from 0.2 to 7.0 nmol min-1). Levels of Z,Z-dienestrol, which arises from spontaneous rearrangement of DES quinone, were not affected in liver of hamsters treated with estradiol implants for 9 days and an injection of 20 mg/kg DES but increased in kidney by 120% over levels observed in animals without implants (5.5 and 12.1 nmol/g of wet tissue, respectively). Z,Z-Dienestrol concentrations correlated directly with lipid hydroperoxide concentrations in liver and kidney of control and estradiol-treated hamsters. The increased conversion of DES to quinone in kidney compared with that in liver was catalyzed by comparable activities of cytochrome P450 IA, the enzyme family catalyzing this oxidation. These results demonstrated that theoxidation of DES to quinone was directly dependent on the lipid hydroperoxide levels in the organ of metabolic conversion in addition to the enzyme activity catalyzing this reaction. The elevated lipid hydroperoxide levels in kidney of estrogen-treated hamsters indicate enhanced estrogen quinone formation and therefore enhanced generation of free radicals by metabolic redox cycling of estrogens in this organ prior to the appearance of malignancy.	UNIV TEXAS,MED BRANCH,DEPT PHARMACOL & TOXICOL,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston					NCI NIH HHS [CA 43233] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043233, R37CA043233] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAKE RC, 1981, J BIOL CHEM, V256, P2127; BLANK JA, 1987, MOL PHARMACOL, V32, P168; CAPDEVILA J, 1980, ARCH BIOCHEM BIOPHYS, V200, P186, DOI 10.1016/0003-9861(80)90345-8; CAVALIERI E, 1987, BIOCHEM PHARMACOL, V36, P435, DOI 10.1016/0006-2952(87)90347-9; CAVALIERI EL, 1988, BIOCHEM PHARMACOL, V37, P2173, DOI 10.1016/0006-2952(88)90578-3; COON MJ, 1987, J BIOSCIENCE, V11, P35, DOI 10.1007/BF02704655; DIGNAM JD, 1977, BIOCHEMISTRY-US, V16, P1116, DOI 10.1021/bi00625a014; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; GUSTAFSSON JA, 1976, FEBS LETT, V70, P276, DOI 10.1016/0014-5793(76)80774-0; HRYCAY EG, 1976, EUR J BIOCHEM, V61, P43, DOI 10.1111/j.1432-1033.1976.tb09995.x; Kappus H., 1985, OXIDATIVE STRESS, V40, P273, DOI [DOI 10.1016/B978-0-12-642760-8.50016-8, 10.1016/B978-0-12-642760-8.50016-8]; KLOTZ AV, 1984, ANAL BIOCHEM, V140, P138, DOI 10.1016/0003-2697(84)90144-1; LIEHR JG, 1986, J BIOL CHEM, V261, P6865; LIEHR JG, 1983, BIOCHEM PHARMACOL, V32, P3711, DOI 10.1016/0006-2952(83)90139-9; OHISHI N, 1985, BIOCHEM INT, V10, P205; OMURA T, 1964, J BIOL CHEM, V239, P2370; POHL RJ, 1980, ANAL BIOCHEM, V107, P150, DOI 10.1016/0003-2697(80)90505-9; ROY D, 1992, MOL CELL BIOCHEM, V110, P31, DOI 10.1007/BF02385003; ROY D, 1991, CANCER RES, V51, P3882; ROY D, 1988, J BIOL CHEM, V263, P3646; ROY D, 1989, CANCER RES, V49, P1475; ROY D, 1992, ARCH BIOCHEM BIOPHYS, V296, P450, DOI 10.1016/0003-9861(92)90596-O; ROY D, 1991, ARCH BIOCHEM BIOPHYS, V285, P331, DOI 10.1016/0003-9861(91)90368-S; TATEISHI T, 1987, EXP GERONTOL, V22, P103, DOI 10.1016/0531-5565(87)90045-3; TENG JI, 1985, J CHROMATOGR, V350, P445, DOI 10.1016/S0021-9673(01)93550-2; VAZ ADN, 1987, P NATL ACAD SCI USA, V84, P1172, DOI 10.1073/pnas.84.5.1172; VAZ ADN, 1989, OXYGEN RADICALS BIOL, P501; WINTER ML, 1991, J BIOL CHEM, V266, P14446; WONG AKL, 1986, BIOCHEM PHARMACOL, V35, P1583, DOI 10.1016/0006-2952(86)90128-0	29	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					284	291						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276808				2022-12-25	WOS:A1994MR21900051
J	MURASAWA, S; MATSUBARA, H; URAKAMI, M; INADA, M				MURASAWA, S; MATSUBARA, H; URAKAMI, M; INADA, M			REGULATORY ELEMENTS THAT MEDIATE EXPRESSION OF THE GENE FOR THE ANGIOTENSIN-II TYPE-1A RECEPTOR FOR THE RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEOCHROMOCYTOMA CELLS; NEGATIVE REGULATION; SUBTYPES; MECHANISMS; PROMOTER; TRANSCRIPTION; SEQUENCES; SKELETAL; ENHANCER; BRAIN	To analyze the mechanism of the cell type-specific expression of rat angiotensin II type 1a receptor (AT1a-R) gene, we isolated the 5'-portion of the gene and identified multiple positive and negative regulatory sequences that regulate its transcription. Primer extension and S1 mapping identified a transcriptional initiation site at 33 (position +1) base pairs (bp) down-stream of TATA sequence. The transcriptional activities of various 5'-deletion mutants of the AT1a-R gene upstream region, fused to the chloramphenicol acetyltransferase (CAT) gene, were examined using rat vascular smooth muscle cells (A10) and glial cells expressing AT1a-R mRNA predominantly or PC12 cells expressing AT2-R and very small amounts of AT1a-R mRNA. A 980-bp 5'-flanking sequence contained at least three positive elements, P1 (-560 to -489), P2 (-331 to -201), and P3 (-201 to -61). P1 and P3 were active in the tested three cells, and P2 was functional only in glial and PC12 cells. In addition to these positive elements, there was negative element, N1 (-489 to -331), which was active only in PC12 cells. These elements, when cotransfected with the AT1a-CAT fusion gene, had competitive effects against its promoter activity. The present study suggests the presence of multiple trans-acting factors that act on these positive and negative cis-acting elements and regulate the cell type-specific expression of the rat AT1a-R gene.	KANSAI MED UNIV,DEPT INTERNAL MED 2,FUMIZONO CHO 1,MORIGUCHI,OSAKA 570,JAPAN	Kansai Medical University								AUSUBEL FM, 1983, CURRENT PROTOCOL MOL; BALLA T, 1991, MOL PHARMACOL, V40, P401; BERNSTEIN KE, 1992, ENDOCR REV, V13, P381, DOI 10.1210/er.13.2.381; BOUVAGNET PF, 1987, MOL CELL BIOL, V7, P4377, DOI 10.1128/MCB.7.12.4377; DEGASPARO M, 1990, J CARDIOVASC PHARM, V16, pS31, DOI 10.1097/00005344-199016004-00008; DUDLEY DT, 1991, MOL PHARMACOL, V40, P360; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; IMLER JL, 1987, MOL CELL BIOL, V7, P2558, DOI 10.1128/MCB.7.7.2558; IWAI N, 1991, BIOCHEM BIOPH RES CO, V177, P299, DOI 10.1016/0006-291X(91)91982-I; LANGFORD K, 1992, BIOCHEM BIOPH RES CO, V183, P1025, DOI 10.1016/S0006-291X(05)80293-1; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; MATSUBARA H, 1990, CIRC RES, V66, P176, DOI 10.1161/01.RES.66.1.176; MATSUBARA H, 1991, J BIOL CHEM, V266, P13324; Miller JH., 1972, EXPT MOL GENETICS; MIZUNO K, 1992, LIFE SCI, V51, P183; MUGLIA L, 1986, P NATL ACAD SCI USA, V83, P7653, DOI 10.1073/pnas.83.20.7653; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NIR U, 1986, P NATL ACAD SCI USA, V83, P3180, DOI 10.1073/pnas.83.10.3180; OBERMULLER N, 1991, NEUROSCI LETT, V132, P11, DOI 10.1016/0304-3940(91)90420-X; PEACH MJ, 1977, PHYSIOL REV, V57, P313, DOI 10.1152/physrev.1977.57.2.313; PUCELL AG, 1991, ENDOCRINOLOGY, V128, P1947, DOI 10.1210/endo-128-4-1947; Saneto RP., 1987, NEUROCHEMISTRY PRACT, P27; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SPETH RC, 1990, BIOCHEM BIOPH RES CO, V169, P997, DOI 10.1016/0006-291X(90)91993-3; SUMNERS C, 1991, P NATL ACAD SCI USA, V88, P7567, DOI 10.1073/pnas.88.17.7567; SUZUKI J, 1993, CIRC RES, V73, P439, DOI 10.1161/01.RES.73.3.439; TIMMERMANS PBMWM, 1991, TRENDS PHARMACOL SCI, V12, P55, DOI 10.1016/0165-6147(91)90498-H; WEBB ML, 1992, PEPTIDES, V13, P499, DOI 10.1016/0196-9781(92)90081-D; WHITEBREAD S, 1989, BIOCHEM BIOPH RES CO, V163, P284, DOI 10.1016/0006-291X(89)92133-5; WHITEBREAD SE, 1991, BIOCHEM BIOPH RES CO, V181, P1365, DOI 10.1016/0006-291X(91)92089-3	34	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26996	27003						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262935				2022-12-25	WOS:A1993MM26200027
J	TAKEUCHI, M; KURAMOCHI, S; FUSAKI, N; NADA, S; KAWAMURATSUZUKU, J; MATSUDA, S; SEMBA, K; TOYOSHIMA, K; OKADA, M; YAMAMOTO, T				TAKEUCHI, M; KURAMOCHI, S; FUSAKI, N; NADA, S; KAWAMURATSUZUKU, J; MATSUDA, S; SEMBA, K; TOYOSHIMA, K; OKADA, M; YAMAMOTO, T			FUNCTIONAL AND PHYSICAL INTERACTION OF PROTEIN-TYROSINE KINASES FYN AND CSK IN THE T-CELL SIGNALING SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-I; SRC FAMILY GENE; ANTIGEN RECEPTOR; ZETA-CHAIN; INTERLEUKIN-2 PRODUCTION; SH3 DOMAINS; C-SRC; TRANSDUCTION; ACTIVATION; EXPRESSION	The Src-like protein-tyrosine kinase Fyn is associated with T-cell antigen receptor. Transient expression of actively mutated Fyn, having Phe-528 instead of Tyr-528 or Thr-338 instead of Ile-338, in Jurkat T-cells stimulated the serum response element (SRE), 12-O-tetradecanoyl-phorbol-13-acetate response element, cyclic AMP response element, and c-fos promoter. The stimulation of SRE was particularly prominent not only with active Fyn but also with normal (wild-type) Fyn. SRE was also stimulated by both normal and active Lck. Furthermore, normal and active Fyn stimulated transcription from the IL-2 gene promoter when transfected cells were stimulated by concanavalin A plus 12-O-tetradecanoyl-phorbol-13-acetate Under the same conditions, Lck did not stimulate IL-2 promoter unless it was activated by mutation. Interestingly, a mutant Fyn, which has deletions within the SH2 region and so is able to transform chicken embryo fibroblasts, did not stimulate either the c-fos or IL-2 promoter, suggesting the importance of this region in T-cell signaling. Csk, which phosphorylates tyrosine residues in the negative regulatory sites of Src family kinases, down-regulated Fyn- and Lck-mediated stimulation of the serum response element and Fyn-mediated enhancement of IL-2 promoter activity. These data suggest that Fyn and Lck, whose activities are regulated by Csk, are involved in different phases of T-cell activation.	UNIV TOKYO,INST MED SCI,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN	University of Tokyo; Osaka University; Osaka University			Fusaki, Noemi/U-1628-2019					APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KATAGIRI T, 1989, P NATL ACAD SCI USA, V86, P10064, DOI 10.1073/pnas.86.24.10064; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOYASU S, 1992, J BIOL CHEM, V267, P3375; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUO KX, 1992, MOL CELL BIOL, V12, P4724, DOI 10.1128/MCB.12.10.4724; MANGER B, 1985, J IMMUNOL, V135, P3669; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OHTA M, 1990, JPN J CANCER RES, V81, P440, DOI 10.1111/j.1349-7006.1990.tb02588.x; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P1741, DOI 10.1073/pnas.88.5.1741; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SEMBA K, 1990, MOL CELL BIOL, V10, P3095, DOI 10.1128/MCB.10.6.3095; SEMBA K, 1990, GENES CANCER, P73; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; UCHIUMI F, 1992, MOL CELL BIOL, V12, P3784, DOI 10.1128/MCB.12.9.3784; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538	54	77	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27413	27419						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262983				2022-12-25	WOS:A1993MM26200082
J	KAMIJO, T; AOYAMA, T; MIYAZAKI, J; HASHIMOTO, T				KAMIJO, T; AOYAMA, T; MIYAZAKI, J; HASHIMOTO, T			MOLECULAR-CLONING OF THE CDNAS FOR THE SUBUNITS OF RAT MITOCHONDRIAL FATTY-ACID BETA-OXIDATION MULTIENZYME COMPLEX - STRUCTURAL AND FUNCTIONAL-RELATIONSHIPS TO OTHER MITOCHONDRIAL AND PEROXISOMAL BETA-OXIDATION ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; 3-HYDROXYACYL-COA DEHYDROGENASE; ENOYL-COA; DELTA-3,DELTA-2-ENOYL-COA ISOMERASE; 3-KETOACYL-COA THIOLASE; BIFUNCTIONAL ENZYME; LIVER MITOCHONDRIA; ZOOGLOEA-RAMIGERA; ESCHERICHIA-COLI; PURIFICATION	Rat liver mitochondrial fatty acid oxidation multienzyme complex consists of 4 mol of the alpha-subunit and 4 mol of the beta-subunit, and has three enzyme activities of long chain enoyl-CoA hydratase, long chain 3-hydroxyacyl-CoA dehydrogenase, and long chain 3-ketoacyl-CoA thiolase. The following cDNA clones for the rat enzyme complex were isolated, sequenced, and expressed: 1) the 2,789-base pair (bp) cDNA clone had a 2,289-bp open reading frame encoding a 82,511-Da precursor and a 78,637-Da mature subunit. The deduced amino acid sequence of this subunit revealed that this cDNA encodes the alpha-subunit and had regions similar to the structure of rat mitochondrial enoyl-CoA hydratase and rat mitochondrial enoyl-CoA isomerase on the amino-terminal side, and a part similar to that of pig mitochondrial 3-hydroxyacyl-CoA dehydrogenase on the carboxyl-terminal side. Expression of this cDNA in COS-1 cells yielded a protein with long chain enoyl-CoA hydratase and long chain 3-hydroxyacyl-CoA dehydrogenase activities. 2) The 1,943-bp cDNA clone had a 1,425-bp open reading frame encoding a 51,413-Da precursor and a 47,583-Da mature subunit. A high similarity of the structure to 3-ketoacyl-CoA thiolases and acetoacetyl-CoA thiolases from various sources suggests that this clone encodes the beta-subunits. Expression of this cDNA in COS-1 cells yielded a protein with long chain 3-ketoacyl-CoA thiolase activity. By phylogenetic analysis of the deduced amino acid sequences of the alpha- and beta-subunits with those of other beta-oxidation enzymes, it was suggested that the alpha-subunit is a descendant of short chain enoyl-CoA hydratase and short chain 3-hydroxyacyl-CoA dehydrogenase while the beta-subunit first diverged from a common ancestor gene of the thiolase family.	UNIV TOKYO,FAC MED,DEPT DIS RELATED GENE REGULAT RES SANDOZ,TOKYO 113,JAPAN; SHINSHU UNIV,SCH MED,DEPT BIOCHEM,MATSUMOTO,NAGANO 390,JAPAN	Novartis; Sandoz; University of Tokyo; Shinshu University	KAMIJO, T (corresponding author), SHINSHU UNIV,SCH MED,DEPT PEDIAT,MATSUMOTO,NAGANO 390,JAPAN.		Miyazaki, Jun-ichi/N-1976-2015	Miyazaki, Jun-ichi/0000-0003-2475-589X				ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; AMAYA Y, 1986, EUR J BIOCHEM, V156, P9, DOI 10.1111/j.1432-1033.1986.tb09541.x; ARAKAWA H, 1987, EMBO J, V6, P1361, DOI 10.1002/j.1460-2075.1987.tb02376.x; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIRKTOFT JJ, 1987, P NATL ACAD SCI USA, V84, P8262, DOI 10.1073/pnas.84.23.8262; BITAR KG, 1980, FEBS LETT, V116, P196, DOI 10.1016/0014-5793(80)80642-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FUKAO T, 1989, J BIOCHEM-TOKYO, V106, P197, DOI 10.1093/oxfordjournals.jbchem.a122832; FURUTA S, 1981, J BIOCHEM, V90, P1739, DOI 10.1093/oxfordjournals.jbchem.a133651; FURUTA S, 1980, J BIOCHEM, V88, P1059, DOI 10.1093/oxfordjournals.jbchem.a133057; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HIJIKATA M, 1987, J BIOL CHEM, V262, P8151; HULTUNEN JK, 1992, J BIOL CHEM, V267, P6646; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; IZAI K, 1992, J BIOL CHEM, V267, P1027; JAVED AA, 1988, P NATL ACAD SCI USA, V85, P1422; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MINAMIISHII N, 1989, EUR J BIOCHEM, V185, P73, DOI 10.1111/j.1432-1033.1989.tb15083.x; MIYAZAWA S, 1981, J BIOCHEM, V90, P511, DOI 10.1093/oxfordjournals.jbchem.a133499; Nei M., 1987, MOL EVOLUT GENET, P293; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NUTTLEY WM, 1988, GENE, V69, P171, DOI 10.1016/0378-1119(88)90428-3; OSUMI T, 1980, ARCH BIOCHEM BIOPHYS, V203, P372, DOI 10.1016/0003-9861(80)90189-7; OSUMI T, 1985, J BIOL CHEM, V260, P8905; PALOSAARI PM, 1991, J BIOL CHEM, V266, P10750; PEOPLES OP, 1987, J BIOL CHEM, V262, P97; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SAKAI I, 1987, BIOCHEM J, V242, P619, DOI 10.1042/bj2420619; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO S, 1992, J BIOCHEM-TOKYO, V111, P8, DOI 10.1093/oxfordjournals.jbchem.a123722; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; THOMPSON S, 1989, BIOCHEMISTRY-US, V28, P5735, DOI 10.1021/bi00440a006; TOMIOKA Y, 1992, BIOCHIM BIOPHYS ACTA, V1130, P109, DOI 10.1016/0167-4781(92)90473-D; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; YANG SY, 1990, J BIOL CHEM, V265, P10424; YANG XYH, 1991, BIOCHEMISTRY-US, V30, P6788, DOI 10.1021/bi00241a023	44	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26452	26460						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253773				2022-12-25	WOS:A1993MK42500067
J	KUMAR, KA; MAHALAKSHMI, S; MUNIYAPPA, K				KUMAR, KA; MAHALAKSHMI, S; MUNIYAPPA, K			DNA-INDUCED CONFORMATIONAL-CHANGES IN RECA PROTEIN - EVIDENCE FOR STRUCTURAL HETEROGENEITY AMONG NUCLEOPROTEIN FILAMENTS AND IMPLICATIONS FOR HOMOLOGOUS PAIRING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; PROMOTED ATP HYDROLYSIS; ESCHERICHIA-COLI; GENETIC-RECOMBINATION; INACTIVE FORMS; EXCHANGE; BINDING; COMPLEXES; ACTIVATION; MECHANISM	We have used circular dichroism as a probe to characterize the solution conformational changes in RecA protein upon binding to DNA. This approach revealed that RecA protein acquires significant amounts of alpha-helix upon interaction with DNA. These observations, consistent with the data from crystal structure (Story, R. M., Weber, I., and Steitz, T. (1992) Nature 355, 318-325), support the notion that some basic domains including the DNA binding motifs of RecA protein are unstructured and might contribute to the formation of alpha-helix. A comparison of nucleoprotein filaments comprised of RecA protein and a variety of DNA substrates revealed important structural heterogeneity. The most significant difference was observed with poly(dG) . poly(dC) and related polymers, rich in GC sequences, which induced minimal amounts of alpha-helix in ReaA protein. The magnitude of induction of alpha-helix in RecA protein, which occurred concomitant with the production of ternary complexes, was 2-fold higher with homologous than heterologous duplex DNA. Most importantly, the stimulation of ATP hydrolysis by high salt coincided with that of the induction of alpha-helix in RecA protein. These conformational differences provide a basis for thinking about the biochemical and structural transitions that RecA protein experiences during the formal steps of presynapsis, recognition, and alignment of homologous sequences.	INDIAN INST SCI, DEPT BIOCHEM, BANGALORE 560012, KARNATAKA, INDIA; INDIAN INST SCI, CTR GENET ENGN, BANGALORE 560012, KARNATAKA, INDIA	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore								ADZUMA K, 1992, GENE DEV, V6, P1679, DOI 10.1101/gad.6.9.1679; AMARATUNGA M, 1988, BIOCHEM BIOPH RES CO, V157, P127, DOI 10.1016/S0006-291X(88)80022-6; Blundell T.L., 1976, PROTEIN CRYSTALLOGRA; BRENNER SL, 1987, J BIOL CHEM, V262, P4011; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; CUNNINGHAM RP, 1980, CELL, V20, P223, DOI 10.1016/0092-8674(80)90250-0; DICAPUA E, 1992, J MOL BIOL, V226, P707, DOI 10.1016/0022-2836(92)90627-V; DICAPUA E, 1990, J STRUCT BIOL, V104, P91, DOI 10.1016/1047-8477(90)90062-H; FLORY J, 1984, P NATL ACAD SCI-BIOL, V81, P7026, DOI 10.1073/pnas.81.22.7026; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; GRIFFITH JD, 1988, CRC CR REV BIOCH MOL, V23, pS43, DOI 10.3109/10409238809083375; GRUSS A, 1991, J BIOL CHEM, V266, P6667; HEUSER J, 1989, J MOL BIOL, V210, P473, DOI 10.1016/0022-2836(89)90124-1; HONIGBERG SM, 1985, J BIOL CHEM, V260, P1845; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; JIAN S, 1992, J BIOL CHEM, V267, P4215; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KIM JI, 1992, J BIOL CHEM, V267, P16444; KIM JI, 1992, J BIOL CHEM, V267, P16438; KOBAYASHI N, 1987, BIOCHEMISTRY-US, V26, P6801, DOI 10.1021/bi00395a033; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KUBISTA M, 1990, J BIOL CHEM, V265, P18891; KUMAR KA, 1992, J BIOL CHEM, V267, P24824; LEAHY MC, 1986, J BIOL CHEM, V261, P6954; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7677, DOI 10.1021/bi00485a017; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MORRICAL SW, 1985, BIOCHEMISTRY-US, V24, P760, DOI 10.1021/bi00324a034; MUENCH KA, 1991, J BIOL CHEM, V266, P844; MUENCH KA, 1990, J BIOL CHEM, V265, P11560; MULLER B, 1990, J MOL BIOL, V212, P97, DOI 10.1016/0022-2836(90)90307-8; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; MUNIYAPPA K, 1990, NUCLEIC ACIDS RES, V18, P3967, DOI 10.1093/nar/18.13.3967; NORDEN B, 1992, J MOL BIOL, V226, P1175, DOI 10.1016/0022-2836(92)91060-3; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PUGH BF, 1988, J BIOL CHEM, V263, P76; RADDING CM, 1991, J BIOL CHEM, V266, P5355; RAMDAS J, 1989, J BIOL CHEM, V264, P17395; RIDDLES PW, 1985, J BIOL CHEM, V260, P170; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROSSELLI W, 1991, EMBO J, V10, P4391, DOI 10.1002/j.1460-2075.1991.tb05017.x; ROULD E, 1992, J MOL BIOL, V226, P127, DOI 10.1016/0022-2836(92)90129-8; SCHUTTE BC, 1988, BIOCHEMISTRY-US, V27, P7886, DOI 10.1021/bi00420a046; Stasiak A, 1988, GENETIC RECOMBINATIO, P265; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TSANG SS, 1985, J MOL BIOL, V185, P295, DOI 10.1016/0022-2836(85)90405-X; WANG WB, 1988, J BACTERIOL, V170, P4823, DOI 10.1128/jb.170.10.4823-4827.1988; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8829; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WUTHRICK K, 1986, NMR PROTEINS NUCLEIC; YU X, 1992, J MOL BIOL, V227, P334, DOI 10.1016/0022-2836(92)90702-L; YU X, 1990, BIOPHYS J, V57, P555, DOI 10.1016/S0006-3495(90)82571-6; ZHONG LX, 1992, P NATL ACAD SCI USA, V89, P4462, DOI 10.1073/pnas.89.10.4462	57	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26162	26170						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253735				2022-12-25	WOS:A1993MK42500026
J	SAGLIOCCO, FA; LASO, MRV; ZHU, DL; TUITE, MF; MCCARTHY, JEG; BROWN, AJP				SAGLIOCCO, FA; LASO, MRV; ZHU, DL; TUITE, MF; MCCARTHY, JEG; BROWN, AJP			THE INFLUENCE OF 5'-SECONDARY STRUCTURES UPON RIBOSOME BINDING TO MESSENGER-RNA DURING TRANSLATION IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; EUKARYOTIC RIBOSOMES; SECONDARY STRUCTURE; CODON USAGE; 5' LEADER; INITIATION; SEQUENCE; GENE; EFFICIENCY; REGION	The influence of 5'-secondary structure formation and 5'-leader length upon mRNA translation in yeast has been analyzed using a closely related set of cat mRNAs (Vega Laso, M. R., Zhu, D., Sagliocco, F. A., Brown, A. J. P., Tuite, M. F., and McCarthy, J. E. G. (1993) J. Biol. Chem. 268, 6453-6462). A cat mRNA with a relatively short unstructured 5'-leader (22 bases) had a ribosome loading about half that of a cat mRNA with an unstructured 5'-leader of 77 bases. The introduction of 5'-secondary structures at various positions throughout the 5'-leader of the cat mRNA inhibited translation initiation, the degree of inhibition being largely dependent upon the thermodynamic stability of the structure. Each mRNA carrying a 5'-secondary structure had a biphasic polysome distribution, indicating that the mRNA molecules were distributed between untranslated and well translated subpopulations. This suggests that once 5'-secondary structures are unwound, they reform slowly relative to the rate of translation initiation in yeast. Untranslated mRNA accumulated in 43 S preinitiation complexes, even when there were only 5 bases between the 5'-cap and the base of the hairpin. The data are consistent with the scanning hypothesis (Kozak, M. (1989) J. Cell. Biol. 108, 229-241) and suggest that 40 S ribosomal subunits bind to mRNA early in the scanning process, probably before mRNA unwinding has taken place.	UNIV ABERDEEN MARISCHAL COLL,DEPT MOLEC & CELL BIOL,ABERDEEN AB9 1AS,SCOTLAND; GESELL BIOTECHNOL FORSCH MBH,DEPT GENE EXPRESS,W-3300 BRAUNSCHWEIG,GERMANY; UNIV KENT,BIOL LAB,CANTERBURY CT2 7NZ,KENT,ENGLAND	University of Aberdeen; Gesellschaft fur Biotechnologische Forschung mbH; University of Kent			Tuite, Mick/ABC-7909-2020; Brown, Alistair J.P./B-6627-2014	Tuite, Mick/0000-0002-5214-540X; 				BAIM SB, 1988, MOL CELL BIOL, V8, P1591, DOI 10.1128/MCB.8.4.1591; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BETTANY AJE, 1989, YEAST, V5, P187, DOI 10.1002/yea.320050308; BLUM S, 1992, P NATL ACAD SCI USA, V89, P7664, DOI 10.1073/pnas.89.16.7664; CAPIEAUX E, 1989, J BIOL CHEM, V264, P7437; CIGAN AM, 1987, GENE, V59, P1; CIGAN AM, 1988, MOL CELL BIOL, V8, P2694; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GERSTEL B, 1992, MOL MICROBIOL, V6, P2339, DOI 10.1111/j.1365-2958.1992.tb01409.x; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1990, TRENDS BIOCHEM SCI, V15, P148, DOI 10.1016/0968-0004(90)90215-W; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; KOZAK M, 1991, GENE EXPRESSION, V1, P117; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1991, GENE EXPRESSION, V1, P111; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LASO MRV, 1993, J BIOL CHEM, V268, P6453; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LINDQUIST S, 1981, NATURE, V293, P311, DOI 10.1038/293311a0; LINDQUIST S, 1949, ENZYME, V44, P147; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MAICAS E, 1990, NUCLEIC ACIDS RES, V18, P5823, DOI 10.1093/nar/18.19.5823; MARUYAMA T, 1986, NUCLEIC ACIDS RES, V14, pR151, DOI 10.1093/nar/14.suppl.r151; MOORE PA, 1991, MOL CELL BIOL, V11, P5330, DOI 10.1128/MCB.11.10.5330; OLIVEIRA CC, 1993, MOL MICROBIOL, V9, P521, DOI 10.1111/j.1365-2958.1993.tb01713.x; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; SHARP PM, 1991, YEAST, V7, P657, DOI 10.1002/yea.320070702; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SONENBERG N, 1991, TRENDS GENET, V7, P105, DOI 10.1016/0168-9525(91)90440-2; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TZAMARIAS D, 1989, CELL, V57, P947, DOI 10.1016/0092-8674(89)90333-4; VANDENHEUVEL JJ, 1990, YEAST, V6, P473, DOI 10.1002/yea.320060604; VANDENHEUVEL JJ, 1989, GENE, V79, P83, DOI 10.1016/0378-1119(89)90094-2; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; YOON H, 1992, MOL MICROBIOL, V6, P1413, DOI 10.1111/j.1365-2958.1992.tb00861.x; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	44	57	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26522	26530						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253781				2022-12-25	WOS:A1993MK42500075
J	PILBEAM, CC; KAWAGUCHI, H; HAKEDA, Y; VOZNESENSKY, O; ALANDER, CB; RAISZ, LG				PILBEAM, CC; KAWAGUCHI, H; HAKEDA, Y; VOZNESENSKY, O; ALANDER, CB; RAISZ, LG			DIFFERENTIAL REGULATION OF INDUCIBLE AND CONSTITUTIVE PROSTAGLANDIN ENDOPEROXIDE SYNTHASE IN OSTEOBLASTIC MC3T3-E1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOOXYGENASE MESSENGER-RNA; RAT PREOVULATORY FOLLICLES; HUMAN ENDOTHELIAL-CELLS; GROWTH-FACTOR-BETA; H SYNTHASE; GENE-EXPRESSION; INDUCTION; GLUCOCORTICOIDS; PROTEIN; SERUM	Regulation of mRNA levels for the constitutive and inducible prostaglandin endoperoxide synthases, PGHS-1 and PGHS-2, was examined in murine osteoblastic MC3T3-E1 cells. Serum induction of PGHS-2 mRNA levels was rapid, transient, increased by cycloheximide, and inhibited 72% by cortisol. The cortisol inhibition was blocked by cycloheximide. Serum stimulation of PGHS-1 mRNA was slower, decreased by cycloheximide, and inhibited 28% by cortisol. Increased prostaglandin E2 (PGE2) production and induction of PGHS-2 immunoreactive protein paralleled changes in PGHS-2 mRNA. PGHS-2 mRNA was induced at 2 h in serum-free cells by transforming growth factor-beta (TGF-beta), phorbol 12-myristate 13-acetate, and, to a lesser extent, by forskolin. The combination of phorbol 12-myristate 13-acetate and forskolin was synergistic. TGF-beta induction was prolonged compared with serum, inhibited 67% by cortisol, and the inhibition was not blocked by cycloheximide. TGF-alpha had little effect on PGHS-2 mRNA at 2 h, but the combination of TGF-beta and TGF-alpha was synergistic for PGHS-1 and PGHS-2. PGE2 itself induced PGHS-2 mRNA, and inhibition of PGE2 production decreased the serum induction by 55%, suggesting an important role for autoamplification. The rapidity and amplitude of changes in PGHS-2 suggest that it may be involved in bone responses to acute stresses, such as mechanical strain, inflammation, and injury.			PILBEAM, CC (corresponding author), UNIV CONNECTICUT, CTR HLTH, FARMINGTON, CT 06030 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018063, P01AR038933] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 18063, AR 38933] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAILEY JM, 1991, ANAL BIOCHEM, V196, P11; BAILEY JM, 1988, BIOCHEM BIOPH RES CO, V157, P1159, DOI 10.1016/S0006-291X(88)80995-1; BOGGARAM V, 1991, MOL ENDOCRINOL, V5, P414, DOI 10.1210/mend-5-3-414; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DEWITT DL, 1990, ADV PROSTAGLANDIN TH, V21, P65; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FLOWER RJ, 1988, BRIT J PHARMACOL, V94, P987, DOI 10.1111/j.1476-5381.1988.tb11614.x; FU JY, 1990, J BIOL CHEM, V265, P16737; FULLER K, 1989, J BONE MINER RES, V4, P209; HIRATA F, 1987, J STEROID BIOCHEM, V27, P1053, DOI 10.1016/0022-4731(87)90189-0; HLA T, 1991, J BIOL CHEM, V266, P24059; IWAI Y, 1991, J BIOL CHEM, V266, P17959; KLEINNULEND J, 1991, ENDOCRINOLOGY, V128, P2503, DOI 10.1210/endo-128-5-2503; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LIN AH, 1989, J BIOL CHEM, V264, P17379; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MARUSIC A, 1991, J IMMUNOL, V146, P2633; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; MASFERRER JL, 1990, J CLIN INVEST, V86, P1375, DOI 10.1172/JCI114850; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OBANION MK, 1991, J BIOL CHEM, V266, P23261; OSHIMA T, 1991, J BIOL CHEM, V266, P13621; OTTO JC, 1993, J BIOL CHEM, V268, P18234; RAISZ LG, 1990, ENDOCRINOLOGY, V126, P1654, DOI 10.1210/endo-126-3-1654; RAISZ LG, 1984, BONE MINERAL RES ANN, V2, P286; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; ROSEN GD, 1989, BIOCHEM BIOPH RES CO, V164, P1358, DOI 10.1016/0006-291X(89)91819-6; SEIBERT K, 1991, ADV PROSTAG THROMB L, V21, P45; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Simmons D.L., 1991, PROSTAGLANDINS LEUKO, P67; SIMONSON MS, 1991, MOL ENDOCRINOL, V5, P441, DOI 10.1210/mend-5-3-441; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; SUMITANI K, 1989, ARCH BIOCHEM BIOPHYS, V270, P588, DOI 10.1016/0003-9861(89)90541-9; WONG WYL, 1992, ENDOCRINOLOGY, V130, P3512, DOI 10.1210/en.130.6.3512; WONG WYL, 1989, MOL ENDOCRINOL, V3, P1714, DOI 10.1210/mend-3-11-1714; WONG WYL, 1991, MOL ENDOCRINOL, V5, P1269, DOI 10.1210/mend-5-9-1269; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YAMAMOTO S, 1990, ADV PROSTAGLANDIN TH, V21, P53	39	161	161	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25643	25649						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245000				2022-12-25	WOS:A1993MK10000054
J	SHEN, BH; MARTIN, LL; BUTT, JN; ARMSTRONG, FA; STOUT, CD; JENSEN, GM; STEPHENS, PJ; LAMAR, GN; GORST, CM; BURGESS, BK				SHEN, BH; MARTIN, LL; BUTT, JN; ARMSTRONG, FA; STOUT, CD; JENSEN, GM; STEPHENS, PJ; LAMAR, GN; GORST, CM; BURGESS, BK			AZOTOBACTER-VINELANDII FERREDOXIN-I - ASPARTATE-15 FACILITATES PROTON-TRANSFER TO THE REDUCED [3FE-4S] CLUSTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC CIRCULAR-DICHROISM; ELECTRON-TRANSFER REACTIONS; SITE-DIRECTED MUTAGENESIS; PUTIDA 7-IRON FERREDOXINS; IRON-SULFUR CLUSTERS; FE-S CLUSTER; SPECTROSCOPIC CHARACTERIZATION; 4FE-4S CLUSTER; 7FE FERREDOXIN; PROTEINS	The [3Fe-4S]+/0 cluster of Azotobacter vinelandii ferredoxin I (AvFdI) has an unusually low and strongly pH-dependent reduction potential (E'0). The reduced cluster exists in two forms, depending upon pH, that exhibit substantially different magnetic circular dichroism (MCD) spectra. Recent studies have established that the MCD changes observed on decreasing the pH from 8.3 (alkaline form) to 6.0 (acid form) cannot be explained either by a change in spin state of the cluster (Stephens, P. J., Jensen, G. M., Devlin, F. J., Morgan, T. V., Stout, C. D., Martin, A. E., and Burgess, B. K. (1991) Biochemistry 30, 3200-3209) or by a major structural change (e.g. ligand exchange) (Stout, C. D. (1993) J. Biol. Chem. 268, 25920-25927). Here, we have examined the influence of aspartate 15 on the pH dependence of the spectroscopic and electrochemical properties of AvFdI by construction of a D15N mutant. Aspartate 15, which is salt-bridged to lysine 84 at the protein surface, is the closest ionizable residue to the [3Fe-4S] cluster. The results show that replacement of aspartate by asparagine results in an approximately 20-mV increase in E' 0 for the [3Fe-4S]+/0 cluster at high pH concomitant with an approximately 0.8-pH unit decrease in the pK of the reduced form. The major pH dependence of E' 0 is preserved as is the effect observed by MCD. These data eliminate the possibility that the MCD change is due to the presence of Asp-15 and support the conclusion that it originates in direct protonation of the [3Fe-4S]0 cluster, probably on a sulfide ion. Voltammetric studies show that interconversion between [3Fe-4S]+ and [3Fe-4S]0 at acidic pH involves rapid electron transfer followed by proton transfer (for reduction) and then proton transfer followed by electron transfer (for oxidation). Ionized aspartate 15 facilitates proton transfer. Thus, protonation and deprotonation are much slower for D15N relative to the native protein at pH >5.5. Proton transfer reactions necessary for further reduction of the [3Fe-4S]0 cluster to the [3Fe-4S]- and [3Fe-4S]2- states are also retarded in D15N. The results suggest that the carboxylate-ammonium salt bridge afforded by Asp-15-Lys-84 conducts protons between the cluster and solvent H2O molecules. Overproduction of D15N FdI, but not native FdI, in A. vinelandii has a negative effect on the growth rate of the organism, suggesting that the rate of protonation or deprotonation of the [3Fe-4S]0 cluster may be important in vivo.	UNIV CALIF IRVINE, DEPT MOLEC BIOL & BIOCHEM, IRVINE, CA 92717 USA; UNIV CALIF IRVINE, DEPT CHEM, IRVINE, CA 92717 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; UNIV SO CALIF, DEPT CHEM, LOS ANGELES, CA 90089 USA; UNIV CALIF DAVIS, DEPT CHEM, DAVIS, CA 95616 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; Scripps Research Institute; University of Southern California; University of California System; University of California Davis			Martin, Lisandra L/E-4482-2010; Butt, Julea/E-2133-2011	Martin, Lisandra L/0000-0003-0486-5813; Butt, Julea/0000-0002-9624-5226; Shen, Binghui/0000-0002-4408-407X	NIGMS NIH HHS [GM-45209, GM-36325] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036325, R01GM045209] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG FA, 1988, FEBS LETT, V234, P107, DOI 10.1016/0014-5793(88)81313-9; ARMSTRONG FA, 1989, FEBS LETT, V259, P15, DOI 10.1016/0014-5793(89)81483-8; ARMSTRONG FA, 1992, ADV INORG CHEM, V38, P117, DOI 10.1016/S0898-8838(08)60063-X; ARMSTRONG FA, 1993, METHOD ENZYMOL, V227, P479, DOI 10.1016/0076-6879(93)27020-H; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; BUTT JN, 1991, J AM CHEM SOC, V113, P8948, DOI 10.1021/ja00023a054; BUTT JN, 1991, J AM CHEM SOC, V113, P6663, DOI 10.1021/ja00017a045; BUTT JN, 1993, J AM CHEM SOC, V115, P1413, DOI 10.1021/ja00057a026; CHENG H, 1990, J BIOL CHEM, V265, P12388; CHENG H, 1992, J BIOL CHEM, V267, P8073; DEAMER DW, 1989, J MEMBRANE BIOL, V107, P91, DOI 10.1007/BF01871715; FEHER G, 1989, NATURE, V339, P111, DOI 10.1038/339111a0; FUNK WD, 1990, BIOCHEMISTRY-US, V29, P5500, DOI 10.1021/bi00475a013; GEORGE SJ, 1989, BIOCHEM J, V264, P275, DOI 10.1042/bj2640275; GEORGE SJ, 1984, BIOCHEM J, V224, P247, DOI 10.1042/bj2240247; HOLM L, 1987, EMBO J, V6, P2819, DOI 10.1002/j.1460-2075.1987.tb02578.x; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; JOHNSON MK, 1987, BIOCHIM BIOPHYS ACTA, V911, P81, DOI 10.1016/0167-4838(87)90273-1; JOHNSON MK, 1984, J BIOL CHEM, V259, P2274; KANO K, 1993, ANAL CHEM, V65, P1088, DOI 10.1021/ac00056a024; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; LAVIRON E, 1982, ELECTROANAL CHEM, V12, P53; LAVIRON E, 1979, J ELECTROANAL CHEM, V101, P19, DOI 10.1016/S0022-0728(79)80075-3; MARTIN AE, 1989, J BACTERIOL, V171, P3162, DOI 10.1128/jb.171.6.3162-3167.1989; MARTIN AE, 1990, P NATL ACAD SCI USA, V87, P598, DOI 10.1073/pnas.87.2.598; MERRITT EA, 1993, ACTA CRYSTALLOGR D, V49, P272, DOI 10.1107/S0907444992007248; MORGAN TV, 1984, FEBS LETT, V264, P275; MOURA JJG, 1982, J BIOL CHEM, V257, P6259; NAGLE JF, 1983, J MEMBRANE BIOL, V74, P1, DOI 10.1007/BF01870590; NAGLE JF, 1978, P NATL ACAD SCI USA, V75, P298, DOI 10.1073/pnas.75.1.298; NICHOLSON RS, 1964, ANAL CHEM, V36, P706, DOI 10.1021/ac60210a007; OKAMURA MY, 1992, ANNU REV BIOCHEM, V61, P861; ONATE YA, 1989, J BIOL CHEM, V264, P18386; REES DC, 1985, P NATL ACAD SCI USA, V82, P3082, DOI 10.1073/pnas.82.10.3082; RODGERS KK, 1991, J AM CHEM SOC, V113, P9419, DOI 10.1021/ja00024a087; RONGEY SH, 1993, P NATL ACAD SCI USA, V90, P1325, DOI 10.1073/pnas.90.4.1325; SILVERMAN DN, 1988, ACCOUNTS CHEM RES, V21, P30, DOI 10.1021/ar00145a005; SOMAN J, 1991, J BIOL CHEM, V266, P21558; STEPHENS PJ, 1991, BIOCHEMISTRY-US, V30, P3200, DOI 10.1021/bi00227a007; STOUT CD, 1988, J BIOL CHEM, V263, P9256; STOUT CD, 1989, J MOL BIOL, V205, P545, DOI 10.1016/0022-2836(89)90225-8; STOUT CD, 1979, J BIOL CHEM, V254, P3598; STOUT CD, 1993, J BIOL CHEM, V268, P25920; STOUT GH, 1988, P NATL ACAD SCI USA, V85, P1020, DOI 10.1073/pnas.85.4.1020; SUCHETA A, 1993, BIOCHEMISTRY-US, V32, P5455, DOI 10.1021/bi00071a023; TAKAHASHI E, 1991, FEBS LETT, V283, P140, DOI 10.1016/0014-5793(91)80572-K; Thomson A. J., 1985, METALLOPROTEINS 1, P79; THOMSON AJ, 1992, J INORG BIOCHEM, V47, P197, DOI 10.1016/0162-0134(92)84065-U; THOMSON AJ, 1991, FEBS LETT, V285, P230, DOI 10.1016/0014-5793(91)80807-F; WARSHEL A, 1989, BIOCHEMISTRY-US, V28, P3629, DOI 10.1021/bi00435a001; WILLIAMS RJP, 1991, BIOCHIM BIOPHYS ACTA, V1058, P71, DOI 10.1016/S0005-2728(05)80272-5; YOCH DC, 1978, J BACTERIOL, V136, P822, DOI 10.1128/JB.136.2.822-824.1978; ZHAO JD, 1992, BIOCHEMISTRY-US, V31, P5093, DOI 10.1021/bi00137a001	55	94	94	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25928	25939						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245026				2022-12-25	WOS:A1993MK10000092
J	VOGEL, SS; LEIKINA, EA; CHERNOMORDIK, LV				VOGEL, SS; LEIKINA, EA; CHERNOMORDIK, LV			LYSOPHOSPHATIDYLCHOLINE REVERSIBLY ARRESTS EXOCYTOSIS AND VIRAL FUSION AT A STAGE BETWEEN TRIGGERING AND MEMBRANE MERGER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; SQUID GIANT SYNAPSE; INFLUENZA HEMAGGLUTININ; CORTICAL REACTION; VESICLE FUSION; CALCIUM; VIRUS; GRANULES; PH; BACULOVIRUS	Little is known of the events occurring between membrane fusion triggering and subsequent fusion steps. To dissect this process we applied a reversible inhibitor of membrane fusion, lysophosphatidylcholine, to arrest exocytosis and virus-mediated syncytia formation. Next Ca2+ or H+ (the respective fusion triggers) was administered and later removed. Then, inhibitor was withdrawn and fusion ensued, demonstrating that triggering causes the formation of an ''activated state,'' which later develops into the fused state. Therefore, while different fusion processes utilize different triggers, the pivotal step involving membrane merger is trigger-independent and lipid-sensitive.	NICHHD, THEORET & PHYS BIOL LAB, BLDG 10, RM 6C-101, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Vogel, Steven/A-3585-2012	Vogel, Steven/0000-0002-3005-2667				ADLER EM, 1991, J NEUROSCI, V11, P1496; ALMERS W, 1990, NEURON, V4, P813, DOI 10.1016/0896-6273(90)90134-2; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BLISSARD GW, 1992, J VIROL, V66, P6829, DOI 10.1128/JVI.66.11.6829-6835.1992; BLUMENTHAL R, 1991, ANN NY ACAD SCI, V635, P285, DOI 10.1111/j.1749-6632.1991.tb36499.x; BRUNNER J, 1991, BIOCHEMISTRY-US, V30, P2432, DOI 10.1021/bi00223a019; CHANDLER DE, 1989, J CELL BIOL, V109, P1269, DOI 10.1083/jcb.109.3.1269; CHERNOMORDIK LV, 1987, BIOCHIM BIOPHYS ACTA, V906, P309, DOI 10.1016/0304-4157(87)90016-5; CHERNOMORDIK LV, 1985, BIOCHIM BIOPHYS ACTA, V812, P643, DOI 10.1016/0005-2736(85)90257-3; CHERNOMORDIK LV, 1993, FEBS LETT, V318, P71, DOI 10.1016/0014-5793(93)81330-3; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DECKER SJ, 1983, DEV BIOL, V96, P37, DOI 10.1016/0012-1606(83)90309-3; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GURAYA SS, 1982, INT REV CYTOL, V78, P257, DOI 10.1016/S0074-7696(08)60108-4; HOLZ RW, 1991, ANN NY ACAD SCI, V635, P382, DOI 10.1111/j.1749-6632.1991.tb36506.x; HYLANDER BL, 1981, DEV BIOL, V86, P1, DOI 10.1016/0012-1606(81)90309-2; KELSEY DR, 1990, J BIOL CHEM, V265, P12178; KRUMBIEGEL M, 1992, BIOCHIM BIOPHYS ACTA, V1110, P158, DOI 10.1016/0005-2736(92)90353-N; LEIKINA E, 1992, FEBS LETT, V304, P221, DOI 10.1016/0014-5793(92)80623-O; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MERKLE CJ, 1989, J MEMBRANE BIOL, V112, P223, DOI 10.1007/BF01870953; NOVICK SL, 1988, P NATL ACAD SCI USA, V85, P7433, DOI 10.1073/pnas.85.20.7433; SCHOCH C, 1992, FEBS LETT, V311, P221, DOI 10.1016/0014-5793(92)81107-W; SEKIGUCHI K, 1981, BIOCHIM BIOPHYS ACTA, V645, P211, DOI 10.1016/0005-2736(81)90191-7; SIEGEL DP, 1993, VIRAL FUSION MECHANI, P475; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; VOGEL SS, 1992, P NATL ACAD SCI USA, V89, P4749, DOI 10.1073/pnas.89.10.4749; VOGEL SS, 1991, ANN NY ACAD SCI, V635, P35, DOI 10.1111/j.1749-6632.1991.tb36479.x; VOGEL SS, 1992, J BIOL CHEM, V267, P25640; WHALLEY T, 1988, BIOSCIENCE REP, V8, P335, DOI 10.1007/BF01115224; White JM, 1989, CURR OPIN CELL BIOL, V1, P934, DOI 10.1016/0955-0674(89)90061-6; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WUNDERLIALLENSPACH H, 1993, BIOCHEMISTRY-US, V32, P900, DOI 10.1021/bi00054a022; ZIMMERBERG J, 1993, ANNU REV BIOPH BIOM, V22, P433, DOI 10.1146/annurev.bb.22.060193.002245; ZIMMERBERG J, 1985, NATURE, V315, P581, DOI 10.1038/315581a0; ZIMMERBERG J, 1985, J CELL BIOL, V101, P2398, DOI 10.1083/jcb.101.6.2398; ZUCKER RS, 1978, BIOCHIM BIOPHYS ACTA, V541, P459, DOI 10.1016/0304-4165(78)90155-1	39	93	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25764	25768						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245012				2022-12-25	WOS:A1993MK10000071
J	BUSCHER, D; DELLOSBARBA, P; HIPSKIND, RA; RAPP, UR; STANLEY, ER; BACCARINI, M				BUSCHER, D; DELLOSBARBA, P; HIPSKIND, RA; RAPP, UR; STANLEY, ER; BACCARINI, M			V-RAF CONFERS CSF-1 INDEPENDENT GROWTH TO A MACROPHAGE CELL-LINE AND LEADS TO IMMEDIATE-EARLY GENE-EXPRESSION WITHOUT MAP-KINASE ACTIVATION	ONCOGENE			English	Article							STIMULATING FACTOR-I; RECOMBINANT MURINE RETROVIRUS; PROTEIN-KINASE; C-FOS; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTIONAL ACTIVATION; BINDING-SITES; BONE-MARROW; RECEPTOR	The BAC-1.2F5 macrophage cell line depends on CSF-1 for proliferation and survival. Phosphorylation and activation of the RAF-1 kinase are among the early events in CSF-1 signal transduction. To characterize the role of RAF-1 in CSF-1-induced proliferation, we overexpressed oncogenically activated RAF-1, cellular RAF-1 and RAF-1 kinase-defective mutant proteins in BAC-1.2F5 cells. We were unable to establish stable cell lines expressing either kinase-negative or full length RAF-1 proteins, implying that expression of these molecules is not tolerated in BAC-1.2F5 cells. Oncogenically activated RAF-1 induces CSF-1-independent growth in the absence of autocrine growth factor production. Autonomous growth is not associated with dedifferentiation, since v-raf-expressing macrophages perform the same immunological functions as control cells. Intriguingly, autonomous growth correlates with the suppression of CSF-1-mediated MAP-Kinase activation and with the low constitutive expression of a number of CSF-1-inducible genes, including fos, jun, ets2, and myc, but also the genes for the inflammatory cytokines TNF alpha and IL-1 beta. Many of these genes have AP-1 binding sites in their promoters, and the v-raf-expressing cells contain constitutive AP-1 binding activity. These data indicate that RAF-1, but not MAP-Kinase, is a key component in CSF-1 mitogenic signal transduction, and are consistent with a working hypothesis in which RAF-1 mediates transcriptional activation of genes via AP-1.	FRAUNHOFER INST TOXICOL & MOLEC BIOL,DEPT IMMUNBIOL,HANNOVER,GERMANY; INST MOLEC BIOL,HANNOVER,GERMANY; UNIV FLORENCE,INST GEN PATHOL,FLORENCE,ITALY; NCI,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701; ALBERT EINSTEIN COLL MED,DEPT DEV & MOLEC BIOL,BRONX,NY 10461	Fraunhofer Gesellschaft; University of Florence; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Yeshiva University; Albert Einstein College of Medicine			Dello Sbarba, Persio/AAX-9887-2020; Stanley, Evan R/J-9154-2013; Baccarini, Manuela/B-6481-2014	Stanley, Evan R/0000-0002-2910-2065; Baccarini, Manuela/0000-0002-3033-391X	NATIONAL CANCER INSTITUTE [R01CA026504, R37CA026504] Funding Source: NIH RePORTER; NCI NIH HHS [CA 26504] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMBROSIO L, 1989, DEVELOPMENT, V106, P145; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; ANISOWICZ A, 1988, P NATL ACAD SCI USA, V85, P9645, DOI 10.1073/pnas.85.24.9645; Baccarini M, 1991, Receptor, V1, P243; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BACCARINI M, 1990, GROWTH FACTORS DIFFE, P188; BEUTLER B, 1988, BIOCHEMISTRY-US, V27, P7575, DOI 10.1021/bi00420a001; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BORTNER DM, 1991, GENE DEV, V5, P1777, DOI 10.1101/gad.5.10.1777; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DECKER T, 1986, INFECT IMMUN, V54, P477, DOI 10.1128/IAI.54.2.477-486.1986; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GIFFORD GE, 1987, J NATL CANCER I, V78, P121, DOI 10.1093/jnci/78.1.121; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HOWE LR, 1992, CELL, V71, P535; KALTREIDER HB, 1986, AM REV RESPIR DIS, V133, P1097; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, ONCOGENE, V8, P361; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; LI W, 1991, J BIOL CHEM, V266, P6808; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; ORLOFSKY A, 1987, EMBO J, V6, P2947, DOI 10.1002/j.1460-2075.1987.tb02599.x; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; REDDY MA, 1992, MOL ENDOCRINOL, V6, P1051, DOI 10.1210/me.6.7.1051; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; SCHWARZBAUM S, 1984, J IMMUNOL, V132, P1158; SENGUPTA A, 1988, P NATL ACAD SCI USA, V85, P8062, DOI 10.1073/pnas.85.21.8062; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SMITH MR, 1990, MOL CELL BIOL, V10, P3828, DOI 10.1128/MCB.10.7.3828; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STANLEY ER, 1985, METHOD ENZYMOL, V116, P565; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; WITSELL AL, 1992, P NATL ACAD SCI USA, V89, P4754, DOI 10.1073/pnas.89.10.4754; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011	73	52	52	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3323	3332						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247534				2022-12-25	WOS:A1993MG78200016
J	JIANG, W; KAHN, SM; ZHOU, P; ZHANG, YJ; CACACE, AM; INFANTE, AS; DOI, S; SANTELLA, RM; WEINSTEIN, IB				JIANG, W; KAHN, SM; ZHOU, P; ZHANG, YJ; CACACE, AM; INFANTE, AS; DOI, S; SANTELLA, RM; WEINSTEIN, IB			OVEREXPRESSION OF CYCLIN D1 IN RAT FIBROBLASTS CAUSES ABNORMALITIES IN GROWTH-CONTROL, CELL-CYCLE PROGRESSION AND GENE-EXPRESSION	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; CANDIDATE ONCOGENE; CHROMOSOME 11Q13; DNA-REPLICATION; PROTEIN-KINASE; MESSENGER-RNA; BCL-1 GENE; G1 PHASE; CLONING; CANCER	Cyclin D1, a putative G1 cyclin, has been implicated in cell cycle control. The human cyclin D1 gene is located on chromosome 11q13 where DNA rearrangement and amplification have been detected in several types of human cancer. Previous studies demonstrated that the cyclin D1 gene is not only rearranged or amplified but also overexpressed in some of these human tumors and tumor-derived cell lines. To further address the roles of cyclin DI in cell cycle control and tumorigenesis, we have stably overexpressed the human cyclin D1 cDNA in Rat6 embryo fibroblasts by using retrovirus mediated transduction. The cyclin D1 protein was overproduced about Ill-fold and was localized predominately in the nucleus. Cyclin D1 overexpressing cells displayed a decrease in the duration of the G1 phase, decreased cell size, and induced tumors when injected into athymic (nude) mice. In addition, overexpression of cyclin D1 in Rat6 cells perturbed the expression of several cellular growth-related genes including c-myc, c-jun, and cyclin A, but not cyclin D3. Taken together, these results indicate that deregulated expression of the cyclin D1 gene can cause disturbances in cell cycle control and gene expression and also enhance tumorigenesis.	COLUMBIA UNIV, COLL PHYS & SURG, COLUMBIA PRESBYTERIAN CANC CTR, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, INST CANC RES, NEW YORK, NY USA	Columbia University; Columbia University				Jiang, Wei/0000-0002-2309-9571	NCI NIH HHS [CA02111] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; CACACE AM, 1993, ONCOGENE, V8, P2095; CHELLAPAN SP, 1991, CELL, V68, P985; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FAUST JB, 1992, CANCER RES, V52, P2460; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HALL FL, 1993, ONCOGENE, V8, P1377; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HSIAO WLW, 1992, MOL CARCINOGEN, V5, P140, DOI 10.1002/mc.2940050210; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HUNTER T, 1993, CURR OPIN GENET DEV, V3, P1, DOI 10.1016/S0959-437X(05)80333-8; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JIANG W, 1992, CANCER RES, V52, P2980; JIANG W, 1993, IN PRESS NATL ACAD S; KATO J, 1993, GENE DEV, V7, P331; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KRISSHAN A, 1974, J CELL BIOL, V66, P1974; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEACH FS, 1993, CANCER RES, V53, P1986; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LU XP, 1992, J BIOL CHEM, V267, P2841; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NEVINS JR, 1992, SCIENCE, V258, P424; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHUURING E, 1992, ONCOGENE, V7, P355; SETO M, 1992, ONCOGENE, V7, P1401; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; WANG J, 1992, ONCOGENE, V7, P1653; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WILLIAMS ME, 1993, LEUKEMIA, V7, P241; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHANG YJ, 1993, UNPUB	72	450	459	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3447	3457						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247550				2022-12-25	WOS:A1993MG78200032
J	PICHEL, JG; LAKSO, M; WESTPHAL, H				PICHEL, JG; LAKSO, M; WESTPHAL, H			TIMING OF SV40 ONCOGENE ACTIVATION BY SITE-SPECIFIC RECOMBINATION DETERMINES SUBSEQUENT TUMOR PROGRESSION DINING MURINE LENS DEVELOPMENT	ONCOGENE			English	Article							TRANSGENIC MICE; ANTIGEN EXPRESSION; DNA RECOMBINATION; MAMMALIAN-CELLS; MOUSE LENS; GENE; CRYSTALLIN; PROMOTER; DIFFERENTIATION; TUMORIGENESIS	We generated mice that carry copies of a dormant transgene encoding the SV40 tumor antigens. The transgenes are specifically targeted to the lens and contain features that render their expression dependent on the action of Cre, a site-specific bacteriophage DNA recombinase. Timing of oncogene activation was controlled by making Cre available either prior to, or coincident with, the onset of primary fiber differentiation in the embryonic lens vesicle. Early expression of Cre resulted in oncogene activation in undifferentiated lens epithelial cells that rapidly proliferated inside the lens capsule. By contrast, when Cre accumulation was delayed to coincide with the onset of primary lens fiber differentiation, SV40 oncogenes were activated in cells that had begun to elongate and to accumulate lens-specific crystallins. During subsequent proliferation inside the lens capsule, transformed progeny cells maintained the profile of fiber differentiation that their parent cells had acquired at the time of oncogenic conversion. Developing lens tumors were confined within the capsule of the embryonic lens. However, if the capsule was perforated in an embryonic eye in organ culture, cells rapidly grew out while still maintaining features of differentiation. Our findings show that the differentiated state of the primary target cells is an important parameter of subsequent lens oncogenesis, and that an intact lens capsule can restrict invasive neoplastic growth.	NICHHD, MAMMALIAN GENES & DEV LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Pichel, Jose G/AAF-2255-2019	Pichel, Jose G/0000-0001-8580-0952				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; BUTEL JS, 1990, INTERVIROLOGY, V31, P85, DOI 10.1159/000150142; CHEN JD, 1992, ONCOGENE, V7, P1167; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FUKUSHIGE S, 1992, P NATL ACAD SCI USA, V89, P7905, DOI 10.1073/pnas.89.17.7905; FURTH PA, 1991, NUCLEIC ACIDS RES, V19, P6205, DOI 10.1093/nar/19.22.6205; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HOGAN B, 1986, MANIPULATING MOUSE E; KHILLAN JS, 1987, GENE DEV, V1, P1327, DOI 10.1101/gad.1.10.1327; KOTHARY R, 1991, MECH DEVELOP, V35, P25, DOI 10.1016/0925-4773(91)90038-8; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MCAVOY JW, 1980, DIFFERENTIATION, V17, P137, DOI 10.1111/j.1432-0436.1980.tb01091.x; NAKAMURA T, 1989, New Biologist, V1, P193; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; OVERBEEK PA, 1985, P NATL ACAD SCI USA, V82, P7815, DOI 10.1073/pnas.82.23.7815; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; SAUER B, 1987, MOL CELL BIOL, V7, P2087, DOI 10.1128/MCB.7.6.2087; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHMIDT EV, 1990, MOL CELL BIOL, V10, P4406, DOI 10.1128/MCB.10.8.4406; TRETON JA, 1991, DIFFERENTIATION, V47, P143, DOI 10.1111/j.1432-0436.1991.tb00232.x; VANDYKE TA, 1987, J VIROL, V61, P2029, DOI 10.1128/JVI.61.6.2029-2032.1987; WESTPHAL H, 1992, ADV DEV BIOL, V1, P183; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZWAAN J, 1983, DEV BIOL, V96, P173, DOI 10.1016/0012-1606(83)90320-2	28	23	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3333	3342						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247535				2022-12-25	WOS:A1993MG78200017
J	YAGI, T; SHIGETANI, Y; OKADO, N; TOKUNAGA, T; IKAWA, Y; AIZAWA, S				YAGI, T; SHIGETANI, Y; OKADO, N; TOKUNAGA, T; IKAWA, Y; AIZAWA, S			REGIONAL LOCALIZATION OF FYN IN ADULT BRAIN - STUDIES WITH MICE IN WHICH FYN GENE WAS REPLACED BY LACZ	ONCOGENE			English	Article							LONG-TERM POTENTIATION; RAT-BRAIN; TYROSINE PHOSPHORYLATION; NMDA RECEPTOR; STEM-CELLS; PROTEIN; RNA; PROTOONCOGENE; RECOMBINATION; EXPRESSION	Mutant mice in which beta-galactosidase gene (lacZ) was inserted into fyn locus were generated by homologous recombination in embryonic stem cells to examine the Fyn expression in the central nervous system. In adult brain, intensive beta-galactosidase activity was observed in olfactory bulb, cerebellum and hippocampus of the limbic system; the subcellular distribution of the activity was apparent not only in cell body but also in neural processes, and homozygous mutant mice live-born displayed an anatomical abnormality in the neural cell layer of the hippocampal formation. In spinal cord it was specifically expressed in dorsal horn, and in brain stem it was more characteristic in the sensory pathway, suggesting roles of Fyn in the sensory nervous network. In the white matter area, it was intense at postnatal day 10 but not detectable in adult, suggesting Fyn's role in myelinization.	UNIV TSUKUBA, INST BASIC MED SCI, DEPT ANAT, TSUKUBA, IBARAKI 305, JAPAN	University of Tsukuba	YAGI, T (corresponding author), INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, MOLEC ONCOL LAB, 3-1-1 KOYADAI, TSUKUBA, IBARAKI 305, JAPAN.							BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BOER PH, 1990, BIOCHEM GENET, V28, P299, DOI 10.1007/BF02401419; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; COOKE M P, 1989, New Biologist, V1, P66; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; ISHIGURO H, 1991, BRAIN RES, V563, P288, DOI 10.1016/0006-8993(91)91548-F; JACOBSON S, 1963, J COMP NEUROL, V121, P5, DOI 10.1002/cne.901210103; KATAGIRI T, 1989, MOL CELL BIOL, V9, P4914, DOI 10.1128/MCB.9.11.4914; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NOMURA S, 1989, DEVELOPMENT, V105, P575; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; RESNEKOV O, 1989, P NATL ACAD SCI USA, V86, P12, DOI 10.1073/pnas.86.1.12; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; YAGI T, 1993, IN PRESS ANAL BIOCH; ZHAO YH, 1991, ONCOGENE, V6, P1725	32	81	81	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3343	3351						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247536				2022-12-25	WOS:A1993MG78200018
J	ALAM, J; CAI, J; SMITH, A				ALAM, J; CAI, J; SMITH, A			ISOLATION AND CHARACTERIZATION OF THE MOUSE HEME OXYGENASE-1 GENE - DISTAL 5' SEQUENCES ARE REQUIRED FOR INDUCTION BY HEME OR HEAVY-METALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BALB/C 3T3 CELLS; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; REGULATORY ELEMENTS; MAMMALIAN-CELLS; TUMOR PROMOTERS; HEPATOMA-CELLS; OXIDANT STRESS; NUCLEAR FACTOR; EXPRESSION	Mouse genomic fragments encoding heme oxygenase-1 (HO-1) were isolated from a recombinant lambda library by in situ plaque hybridization. The mouse HO-1 gene, approximately 7 kilobase pairs (kbp) in length, is organized into 5 exons and 4 introns. The primary structure of the exons and 1287 base pairs (bp) of the 5'-flanking region was determined. The deduced amino acid sequence of the mouse HO-1 gene is identical to that of p32, initially identified as a stress-induced protein in mouse BALBc/3T3 cells. A single, major transcription initiation site is utilized for constitutive and heme- or metal-induced expression of the HO-1 gene in mouse hepatoma (Hepa) cells. The transcriptional activity of the 5'-flanking region was examined by transient expression assays using the chloramphenicol acetyltransferase gene as the reporter gene. Basal promoter activity in several cell lines was localized to within 149 bp of the upstream sequence by deletion analysis. This proximal promoter region of the mouse HO-1 gene contains several sequence elements that are not only conserved in both the rat and human HO-1 genes but also resemble consensus binding sites of various transcription factors including AP-1, AP-4, C/EBP and c-Myc:Max/USF. Heavy metals activate HO-1 gene transcription and the rat gene contains a putative metal regulatory element (Muller, R. M., Taguchi, H., and Shibahara, S. (1987) J. Biol. Chem. 262,6795-6802) that is completely conserved in the mouse gene. Transient expression analyses, however, indicate that this sequence, which contains a core heptanucleotide, TGCACTC, identical to that of the strongest metal regulatory element of the mouse metallothionein-1 gene, is not responsive to Cd2+ or Zn2+. Stable transfection of constructs containing the entire mouse HO-1 gene and various portions of the 5'-flanking region into rat C6 glioma cells and simultaneous, quantitative analysis of the mouse and rat HO-1 mRNAs indicate that distal 5' sequences, between positions -3.5 and -12.5 kbp, are required for induction of mouse HO-1 gene transcription by both heme and heavy metals. A 5-7-fold difference in the levels of induction between stably integrated and transiently expressed mouse HO-1 gene constructs is observed in this cell line. An HO-1/CAT fusion gene, pMH09cat, containing the HO-1 proximal promoter and the 9-kbp upstream fragment, is not inducible in C6 cells, but is activated 11- and 12-fold by Cd2+ and heme, respectively, in Hepa cells, indicating tissue-specific variation in the activation mechanism. The active, inducer-dependent element(s) is located within a 268-bp fragment previously shown to mediate 12-O-tetradecanoylphorbol-13-acetate induction of the mouse HO-1 gene (Alam, J., and Zhining, D. (1992) J. Biol. Chem. 267,21894-21900). Chromosomal integration of the HO-1/CAT constructs is required for heme- or Cd2+-mediated activation in Hepa cells, suggesting a role for chromatin organization in the induction process.	LOUISIANA STATE UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,NEW ORLEANS,LA 70121; UNIV MISSOURI,SCH BIOL SCI,KANSAS CITY,MO 64110	Louisiana State University System; University of Missouri System; University of Missouri Kansas City	ALAM, J (corresponding author), ALTON OCHSNER MED FDN & OCHSNER CLIN,DEPT MOLEC GENET,1516 JEFFERSON HIGHWAY,NEW ORLEANS,LA 70121, USA.		Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X	NIDDK NIH HHS [DK-43135, DK-37463] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037463, R01DK043135] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM J, 1989, J BIOL CHEM, V264, P17637; ALAM J, 1992, J BIOL CHEM, V267, P16379; ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; ALAM J, 1992, J BIOL CHEM, V267, P21894; ALAM J, 1989, J BIOL CHEM, V264, P6371; ALAM J, 1991, BIOTECHNIQUES, V10, P423; AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; APPLEGATE LA, 1991, CANCER RES, V51, P974; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CULLOTTA VC, 1989, MOL CELL BIOL, V9, P1376; EVANS CO, 1991, BIOCHEM J, V273, P659, DOI 10.1042/bj2730659; EWING JF, 1991, P NATL ACAD SCI USA, V88, P5364, DOI 10.1073/pnas.88.12.5364; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENE JJ, 1988, CURRENT PROTOCOLS MO; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIWASA T, 1982, P NATL ACAD SCI-BIOL, V79, P1800, DOI 10.1073/pnas.79.6.1800; HIWASA T, 1986, CANCER RES, V46, P2474; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; ISHIKAWA K, 1992, BIOCHEM BIOPH RES CO, V182, P981, DOI 10.1016/0006-291X(92)91828-E; JACOB M, 1989, NUCLEIC ACIDS RES, V17, P2159, DOI 10.1093/nar/17.6.2159; KAGEYAMA H, 1988, CANCER RES, V48, P4795; KEYSE SM, 1990, MOL CELL BIOL, V10, P4967, DOI 10.1128/MCB.10.9.4967; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; LIN JHC, 1990, EUR J BIOCHEM, V192, P577, DOI 10.1111/j.1432-1033.1990.tb19263.x; Locker J, 1990, DNA Seq, V1, P3, DOI 10.3109/10425179009041342; Maines M.D., 1992, HEME OXYGENASE CLIN; Maxam A M, 1980, Methods Enzymol, V65, P499; MITANI K, 1990, BIOCHEM BIOPH RES CO, V166, P1429, DOI 10.1016/0006-291X(90)91026-O; MULLER RM, 1987, J BIOL CHEM, V262, P6795; NASCIMENTO ALTO, 1993, NUCLEIC ACIDS RES, V21, P1103, DOI 10.1093/nar/21.5.1103; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO M, 1989, J BIOL CHEM, V264, P10251; SATO M, 1990, EUR J BIOCHEM, V188, P231, DOI 10.1111/j.1432-1033.1990.tb15394.x; SHIBAHARA S, 1989, EUR J BIOCHEM, V179, P557, DOI 10.1111/j.1432-1033.1989.tb14583.x; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; SMITH A, 1984, J BIOL CHEM, V259, P2049; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STUART GW, 1985, NATURE, V317, P828, DOI 10.1038/317828a0; TYRRELL RM, 1993, CARCINOGENESIS, V14, P761, DOI 10.1093/carcin/14.4.761; WEIL D, 1988, J BIOL CHEM, V263, P8561; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x	56	145	147	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1001	1009						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288554				2022-12-25	WOS:A1994MR22000037
J	LONG, GJ; ROSEN, JF; SCHANNE, FAX				LONG, GJ; ROSEN, JF; SCHANNE, FAX			LEAD ACTIVATION OF PROTEIN-KINASE-C FROM RAT-BRAIN - DETERMINATION OF FREE CALCIUM, LEAD, AND ZINC BY F-19-NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							OSTEOBLASTIC BONE-CELLS; INTRACELLULAR CALCIUM; MAMMALIAN-TISSUES; HEAVY-METALS; BINDING; CA-2+; PURIFICATION; EXPOSURE; NMR; PHOSPHOLIPIDS	Lead (Pb2+) has been reported to activate calcium/phospholipid-dependent protein kinase C (PKC) at subnanomolar concentrations (Markovac, J., and Goldstein, G. W. (1988) Nature 334, 732-734); however, others have failed to find any Pb2+-induced activation of PKC (Murakami, K., Feng, G., and Chen, S. G. (1993) J. Pharmacol. Exp. Ther. 264, 757-761). In neither of these studies was the actual free Pb2+ or Ca2+ concentration measured. In this study, 1,2-bis(2-amino-5-fluorophenoxy)ethane N,N,N',N'-tetraacetic acid (5F-BAPTA) was used to buffer Pb2+ and Ca2+ concentrations in the PKC reaction mixture. The specific free ion concentrations of Pb2+ and Ca2+, as well as Zn2+ and other divalent cations contained in the PKC reaction mixtures, were determined by F-19 NMR spectroscopy. Using this approach to set and confirm the free Pb2+ and Ca2+ concentrations, we measured the Pb2+-dependent and the Ca2+-dependent activation of phosphotydylserine/diolein-dependent incorporation of P-32 from ATP into histone and endogenous acid precipitable proteins in the 100,000 x g supernatant from homogenized rat brain cortex. We found that free Pb2+ activates PKC in the range from 10(-11) to 10(-8) M, K(act) = 5.5 x 10(-11) m, while Ca2+ activates PKC in the range from 10(-8) to 10(-5) M, K(cat) = 2.56 x 10(-7) M. These findings clearly resolve the activation of PKC by subnanomolar concentrations of free Pb2+ from activation induced by Ca2+ or other divalent cations. Furthermore, it documents the utility of 5F-BAPTA as buffer and indicator when resolving the contributions of multiple divalent cations in biochemical processes.	MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,DEPT PEDIAT,BRONX,NY 10467; MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,DEPT PATHOL,BRONX,NY 10467	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004006, R37ES001060, R23ES004006, R01ES001060, R29ES006087] Funding Source: NIH RePORTER; NIEHS NIH HHS [R29-ES06087, ES01060, ES04006] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALKON DL, 1988, SCIENCE, V239, P998, DOI 10.1126/science.2830669; [Anonymous], 1988, NATURE EXTENT LEAD P; AUDESIRK G, 1985, PROG NEUROBIOL, V24, P199, DOI 10.1016/0301-0082(85)90006-1; AUDESIRK G, 1991, NEUROTOXICOLOGY, V12, P519; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BELLINGER D, 1987, NEW ENGL J MED, V316, P1037, DOI 10.1056/NEJM198704233161701; BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; BRESSLER JP, 1991, BIOCHEM PHARMACOL, V41, P479, DOI 10.1016/0006-2952(91)90617-E; Byers RK, 1943, AM J DIS CHILD, V66, P471; COHAN CS, 1987, J NEUROSCI, V7, P3588; CONNOR JA, 1986, P NATL ACAD SCI USA, V83, P6179, DOI 10.1073/pnas.83.16.6179; COOPER GP, 1984, NEUROTOXICOLOGY, V5, P247; DOWD TL, 1993, P SOC MAGN RESON MED, V1, P407; FULLMER CS, 1985, J BIOL CHEM, V260, P6816; HABERMANN E, 1983, ARCH TOXICOL, V54, P61, DOI 10.1007/BF00277816; HARRISON SM, 1987, BIOCHIM BIOPHYS ACTA, V925, P133, DOI 10.1016/0304-4165(87)90102-4; HUANG KP, 1988, J BIOL CHEM, V263, P14839; INOUE M, 1977, J BIOL CHEM, V252, P7610; IRITA K, 1991, INT J BIOCHEM, V23, P301, DOI 10.1016/0020-711X(91)90110-9; JAKEN S, 1987, P NATL ACAD SCI USA, V84, P4418, DOI 10.1073/pnas.84.13.4418; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KLANN E, 1991, J BIOL CHEM, V266, P24253; KOSTIAL K, 1957, BRIT J PHARM CHEMOTH, V12, P219, DOI 10.1111/j.1476-5381.1957.tb00123.x; LONG GJ, 1990, TOXICOL APPL PHARM, V106, P270, DOI 10.1016/0041-008X(90)90246-Q; LONG GJ, 1991, CALCIFIED TISSUE INT, V50, P451; MANTON WI, 1984, BRIT J IND MED, V41, P313; MARKOVAC J, 1988, TOXICOL APPL PHARM, V96, P14, DOI 10.1016/0041-008X(88)90242-6; MARKOVAC J, 1988, NATURE, V334, P732; MAURER MC, 1992, BIOCHEMISTRY-US, V31, P7714, DOI 10.1021/bi00148a036; MCMICHAEL AJ, 1988, NEW ENGL J MED, V319, P468, DOI 10.1056/NEJM198808253190803; METCALFE JC, 1985, CELL CALCIUM, V6, P183, DOI 10.1016/0143-4160(85)90043-0; MINNEMA DJ, 1988, TOXICOL APPL PHARM, V92, P351, DOI 10.1016/0041-008X(88)90175-5; MURAKAMI K, 1993, J PHARMACOL EXP THER, V264, P757; MURAKAMI K, 1987, J BIOL CHEM, V262, P13902; POUNDS JG, 1984, NEUROTOXICOLOGY, V5, P295; POUNDS JG, 1982, TOXICOL APPL PHARM, V63, P389, DOI 10.1016/0041-008X(82)90268-X; RASMUSSEN H, 1986, NEW ENGL J MED, V314, P1094; RODRIGUEZPARIS JM, 1989, BIOCHEM BIOPH RES CO, V159, P495, DOI 10.1016/0006-291X(89)90020-X; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; SCHANNE FAX, 1990, ENVIRON HEALTH PERSP, V84, P99, DOI 10.2307/3430710; SCHANNE FAX, 1989, BRAIN RES, V503, P308, DOI 10.1016/0006-8993(89)91680-6; SCHANNE FAX, 1989, P NATL ACAD SCI USA, V86, P5133, DOI 10.1073/pnas.86.13.5133; SCHANNE FAX, 1990, BIOCHIM BIOPHYS ACTA, V1054, P250, DOI 10.1016/0167-4889(90)90249-D; SCHANNE FAX, 1992, BIOCHIM BIOPHYS ACTA, V1180, P187, DOI 10.1016/0925-4439(92)90067-W; Schoenmakers T. J., 1992, BIOTECHNIQUES, V12, P876; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; SIMONS TJB, 1987, J NEUROCHEM, V48, P383, DOI 10.1111/j.1471-4159.1987.tb04105.x; SIMONS TJB, 1986, BRIT MED BULL, V42, P431, DOI 10.1093/oxfordjournals.bmb.a072162; SMITH GA, 1983, P NATL ACAD SCI-BIOL, V80, P7178, DOI 10.1073/pnas.80.23.7178; SPEIZER LA, 1989, J BIOL CHEM, V264, P5581; TAKAI Y, 1977, J BIOL CHEM, V252, P7603; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; WATSON JB, 1992, P NATL ACAD SCI USA, V89, P8581, DOI 10.1073/pnas.89.18.8581; ZIDOVETZKI R, 1992, BIOCHIM BIOPHYS ACTA, V1134, P261, DOI 10.1016/0167-4889(92)90185-E; 1985, CDC992230 US DEP HLT	57	140	144	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					834	837						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288636				2022-12-25	WOS:A1994MR22000014
J	YATSUNAMI, K; OHTSU, H; TSUCHIKAWA, M; HIGUCHI, T; ISHIBASHI, K; SHIDA, A; SHIMA, Y; NAKAGAWA, S; YAMAUCHI, K; YAMAMOTO, M; HAYASHI, N; WATANABE, T; ICHIKAWA, A				YATSUNAMI, K; OHTSU, H; TSUCHIKAWA, M; HIGUCHI, T; ISHIBASHI, K; SHIDA, A; SHIMA, Y; NAKAGAWA, S; YAMAUCHI, K; YAMAMOTO, M; HAYASHI, N; WATANABE, T; ICHIKAWA, A			STRUCTURE OF THE L-HISTIDINE DECARBOXYLASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-CELL-LINE; CHRONIC MYELOGENOUS LEUKEMIA; MASTOCYTOMA P-815 CELLS; EXPRESSION; RNA; DIFFERENTIATION; HYBRIDIZATION; TRANSCRIPTS; CHROMOSOME; FRAGMENTS	Two species of L-histidine decarboxylase (HDC) mRNA were found in the KU-812-F basophilic cell line, but only the 2.4-kilobase (kb) one encodes the functional HDC (Mamune-Sato, R., Yamauchi, K., Tanno, Y., Ohkawara, Y., Ohtsu, H., Katayose, D., Maeyama, K., Watanabe, T., Shibahara, S., and Takishima, T. (1992) Eur. J. Biochem. 209, 533-539). The 3.4-kb one encodes a truncated HDC protein and is also found in human leukemia-derived cell lines HEL and KCL-22. To clarify the mechanisms that regulate transcription of the HDC gene and generate the two species of mRNA, we have isolated genomic DNA clones coding for the HDC from human genomic libraries. Structural analysis of the isolated clones revealed that the human HDC gene is composed of 12 exons spanning approximately 24 kb. Genomic DNA blot analysis suggested that HDC is encoded by a single copy gene. The structural analysis also demonstrated that the heterogeneity of the HDC mRNA is caused by an insertion of the seventh intron sequence and alternative use of the splicing acceptor site at the 12th exon. The transcription start site of the HDC gene and the nucleotide sequences of the promoter and first exon regions were determined. We found a TATA-like sequence, a GC box, four CACC boxes, four GATA consensus sequences, and six leader-binding protein-1 binding motifs in the promoter region of the HDC gene.	TOHOKU UNIV,SCH MED,DEPT PHARMACOL 1,SEIRYO MACHI 2-1,AOBA KU,SENDAI,MIYAGI 980,JAPAN; TOHOKU UNIV,SCH MED,DEPT INTERNAL MED 1,SENDAI,MIYAGI 980,JAPAN; KYOTO UNIV,FAC PHARMACEUT SCI,DEPT BUSINESS ADM,KYOTO 606,JAPAN; JAPAN TOBACCO INC,PHARMACEUT BASIC RES LABS,YOKOHAMA 236,JAPAN	Tohoku University; Tohoku University; Kyoto University; Japan Tobacco Inc.			Yamauchi, Kohei/N-2749-2016; Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Beaven M A, 1978, Monogr Allergy, V13, P1; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BURLAND WL, 1982, PHARM HISTAMINE RECE, P436; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIULLA TA, 1988, ANAL BIOCHEM, V174, P485, DOI 10.1016/0003-2697(88)90047-4; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; ENDO K, 1993, IN PRESS BR J HAEMAT; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUKUDA T, 1987, BLOOD, V70, P612; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; JOSEPH DR, 1990, P NATL ACAD SCI USA, V87, P733, DOI 10.1073/pnas.87.2.733; KAHLSON G, 1968, PHYSIOL REV, V48, P155, DOI 10.1152/physrev.1968.48.1.155; KAWAI H, 1992, BIOCHIM BIOPHYS ACTA, V1133, P172, DOI 10.1016/0167-4889(92)90066-K; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; KUBONISHI I, 1983, International Journal of Cell Cloning, V1, P105; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MAEYAMA K, 1988, BIOCHEM BIOPH RES CO, V151, P1402, DOI 10.1016/S0006-291X(88)80518-7; MAMUNESATO R, 1992, EUR J BIOCHEM, V209, P533, DOI 10.1111/j.1432-1033.1992.tb17317.x; Maniatis T., 1982, MOL CLONING; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X; MINOWADA J, 1977, J NATL CANCER I, V59, P83, DOI 10.1093/jnci/59.1.83; OHKUBO T, 1985, LEUKEMIA RES, V9, P921, DOI 10.1016/0145-2126(85)90314-5; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVANY A, 1988, BIOCHEM INT, V16, P559; SAVANY A, 1982, BIOCHEM J, V205, P405, DOI 10.1042/bj2050405; SHIGA K, 1990, P NATL ACAD SCI USA, V87, P3594, DOI 10.1073/pnas.87.9.3594; SULLIVAN PM, 1991, J BIOL CHEM, V266, P143; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WATANABE T, 1982, ADV HISTAMINE RES, P93; YAMAMOTO J, 1990, FEBS LETT, V276, P214, DOI 10.1016/0014-5793(90)80545-T; YAMAMOTO M, 1985, P NATL ACAD SCI USA, V82, P3702, DOI 10.1073/pnas.82.11.3702; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YAMAUCHI K, 1990, NUCLEIC ACIDS RES, V18, P5891, DOI 10.1093/nar/18.19.5891; YATSUNAMI K, 1993, AGENTS ACTIONS, V38, pC155, DOI 10.1007/BF01996445; YU CY, 1991, J BIOL CHEM, V266, P8907; Zahnow C A, 1991, DNA Seq, V1, P395, DOI 10.3109/10425179109020795; ZON LI, 1991, J BIOL CHEM, V266, P22948	42	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1554	1559						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288622				2022-12-25	WOS:A1994MR22000118
J	HAZARD, AL; SENIOR, AE				HAZARD, AL; SENIOR, AE			DEFECTIVE ENERGY COUPLING IN DELTA-SUBUNIT MUTANTS OF ESCHERICHIA-COLI F1F0-ATP SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ATP SYNTHASE; B UNCF-PROTEIN; ADENOSINE-TRIPHOSPHATASE; CRYOELECTRON MICROSCOPY; ELECTRON-MICROSCOPY; GAMMA-SUBUNIT; PROTON-ATPASE; ALPHA-SUBUNIT; H+-ATPASE; FACTOR-I	Membrane vesicles from 13 strains carrying mutations in the C-terminal region of the delta-subunit of Escherichia coli F1F0-ATP synthase were characterized in respect to ATPase activity, ATP-driven proton-pumping, dicyclohexylcarbodiimide sensitivity of ATPase, and oxidative phosphorylation. The salient finding was that energy-coupling between F1 and F0 sectors of the enzyme is impaired by several of the mutations. The deltaG150N mutant appeared completely uncoupled in vitro. The data emphasize the role of the C-terminal region of delta-subunit in integration of the proton conduction machinery in F0 with the three F1 catalytic sites. It is suggested that the C-terminal region of delta-subunit, speculatively located in the central region of the alpha3beta3 hexagon, acts functionally at the interface between the helical domain of the stalk and the F1 subunits to relay conformational signals which alter the affinities of the catalytic sites for substrates and products.			HAZARD, AL (corresponding author), UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,ROCHESTER,NY 14642, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025349, R37GM025349] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 25349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1993, EMBO J, V12, P1775, DOI 10.1002/j.1460-2075.1993.tb05825.x; AGGELER R, 1992, J BIOL CHEM, V267, P21355; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; BOEKEMA EJ, 1990, BIOCHIM BIOPHYS ACTA, V1020, P49, DOI 10.1016/0005-2728(90)90092-I; BOEKEMA EJ, 1988, BIOCHIM BIOPHYS ACTA, V933, P365, DOI 10.1016/0005-2728(88)90044-8; BOEKEMA EJ, 1992, BIOCHIM BIOPHYS ACTA, V1098, P131, DOI 10.1016/S0005-2728(05)80328-7; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG TM, 1974, J BIOL CHEM, V249, P1090; COX GB, 1984, BIOCHIM BIOPHYS ACTA, V768, P201, DOI 10.1016/0304-4173(84)90016-8; CROSS RL, 1981, ANNU REV BIOCHEM, V50, P681, DOI 10.1146/annurev.bi.50.070181.003341; DUNCAN TM, 1985, J BIOL CHEM, V260, P4901; ENGELBRECHT S, 1990, BIOCHIM BIOPHYS ACTA, V1015, P379, DOI 10.1016/0005-2728(90)90072-C; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FRAGA D, 1989, J BIOL CHEM, V264, P6796; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; HAZARD AL, J BIOL CHEM, V269; HERTZBERG EL, 1974, BIOCHEM BIOPH RES CO, V58, P178, DOI 10.1016/0006-291X(74)90908-5; ISSARTEL JP, 1991, BIOCHEMISTRY-US, V30, P4726, DOI 10.1021/bi00233a013; JOSHI S, 1992, J BIOL CHEM, V267, P12860; JOUNOUCHI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P376, DOI 10.1016/0003-9861(92)90005-H; LEE RSF, 1992, ARCH BIOCHEM BIOPHYS, V297, P334, DOI 10.1016/0003-9861(92)90681-L; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; LUNARDI J, 1988, P NATL ACAD SCI USA, V85, P8958, DOI 10.1073/pnas.85.23.8958; MAGGIO MB, 1988, J BIOL CHEM, V263, P4619; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P10987, DOI 10.1021/bi00109a025; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; MILLER MJ, 1989, J BIOL CHEM, V264, P305; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; NALIN CM, 1985, BIOCHEMISTRY-US, V24, P2318, DOI 10.1021/bi00330a029; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; PERLIN DS, 1985, ARCH BIOCHEM BIOPHYS, V236, P603, DOI 10.1016/0003-9861(85)90664-2; REENSTRA WW, 1980, BIOCHEMISTRY-US, V19, P1, DOI 10.1021/bi00542a001; SENIOR AE, 1979, BIOCHEM J, V180, P111, DOI 10.1042/bj1800111; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SHAPIRO AB, 1990, J BIOL CHEM, V265, P4340; SHAPIRO AB, 1988, J BIOL CHEM, V263, P14160; SHIN K, 1992, J BIOL CHEM, V267, P20835; TURINA P, 1993, J BIOL CHEM, V268, P6978; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WEBER J, 1993, J BIOL CHEM, V268, P20126; WILKENS S, 1992, ARCH BIOCHEM BIOPHYS, V299, P105, DOI 10.1016/0003-9861(92)90250-Z; WISE JG, 1985, BIOCHEMISTRY-US, V24, P6949, DOI 10.1021/bi00345a030	48	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					427	432						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276831				2022-12-25	WOS:A1994MR21900072
J	ROY, S; OVERTON, O; REDMAN, C				ROY, S; OVERTON, O; REDMAN, C			OVEREXPRESSION OF ANY FIBRINOGEN CHAIN BY HEP G2-CELLS SPECIFICALLY ELEVATES THE EXPRESSION OF THE OTHER 2 CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTARY DEOXYRIBONUCLEIC-ACID; PHASE PLASMA-PROTEINS; BETA-CHAIN; TRANSCRIPTIONAL REGULATION; ALPHA-CHAIN; GLUCOCORTICOIDS; DEXAMETHASONE; STIMULATION; DEGRADATION; SEQUENCES	Earlier studies showed that overexpression of Bbeta fibrinogen chains, by transfection of Hep G2 cells with Bbeta cDNA, specifically enhanced the synthesis of all three fibrinogen chains (Roy, S. N., Mukhopadhyay, G., and Redman, C. M. (1990) J. Biol. Chem. 265, 6389-6393). To determine whether overexpression of any of the three component chains of fibrinogen affects the synthesis of the other two chains, we developed stable Hep G2 cell lines transfected with individual fibrinogen chain cDNAs. As a control, cells were also transfected with expression vector, which did not contain fibrinogen cDNA. Transfection with any fibrinogen cDNA increased the synthesis of all three fibrinogen chains but not of other plasma proteins. Hep G2 cells transfected with Bbeta cDNA produced 3-4-fold more fibrinogen than control cells, and cells transfected with Aalpha or gamma cDNA made about 2-fold more fibrinogen. Northern blot analyses showed that levels of all 3 fibrinogen mRNAs were increased and were highest in Hep G2-Bbeta cells. Nuclear run-on transcription assays demonstrated that increased expression of the chains was due to increased transcriptional activity. These studies show that transcription of the three fibrinogen chains is tightly linked, and increased expression of any chain specifically leads to increased synthesis of the other two chains.	NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,310 E 67 ST,NEW YORK,NY 10021	New York Blood Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037457] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 37457] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUMANN H, 1987, J IMMUNOL, V139, P4122; BLOMBACK B, 1972, ANN NY ACAD SCI, V202, P77, DOI 10.1111/j.1749-6632.1972.tb16323.x; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3244, DOI 10.1021/bi00282a032; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3250, DOI 10.1021/bi00282a033; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; Crabtree G. R., 1987, MOL BASIS BLOOD DISE, P631; CRABTREE GR, 1982, J BIOL CHEM, V257, P7277; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; FU YP, 1992, BIOCHEMISTRY-US, V31, P11968, DOI 10.1021/bi00163a002; GEIGER T, 1988, EUR J IMMUNOL, V18, P712; GRAHAM FL, 1973, VIROLOGY, V52, P684; GRIENINGER G, 1978, P NATL ACAD SCI USA, V75, P5506, DOI 10.1073/pnas.75.11.5506; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HENRY I, 1984, AM J HUM GENET, V36, P760; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HUBER P, 1990, J BIOL CHEM, V265, P5695; KANT JA, 1985, P NATL ACAD SCI USA, V82, P2344, DOI 10.1073/pnas.82.8.2344; KANT JA, 1983, P NATL ACAD SCI-BIOL, V80, P3953, DOI 10.1073/pnas.80.13.3953; MANIATIS T, 1982, MOL CLONING LABORATO, P188; MARINKOVIC S, 1989, J IMMUNOL, V142, P808; MORGAN JG, 1988, MOL CELL BIOL, V8, P2628, DOI 10.1128/MCB.8.6.2628; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; NESBITT JE, 1991, BIOCHIM BIOPHYS ACTA, V1089, P88, DOI 10.1016/0167-4781(91)90089-5; NICKERSON JM, 1981, P NATL ACAD SCI USA, V78, P300; OTTO JM, 1987, J CELL BIOL, V105, P1067, DOI 10.1083/jcb.105.3.1067; RIXON MW, 1983, BIOCHEMISTRY-US, V22, P3237, DOI 10.1021/bi00282a031; ROY S, 1992, J BIOL CHEM, V267, P23151; ROY SN, 1991, J BIOL CHEM, V266, P4758; ROY SN, 1990, J BIOL CHEM, V265, P6389; YU S, 1984, J BIOL CHEM, V259, P574; YU S, 1983, J BIOL CHEM, V258, P3407; YU S, 1986, SCHEME INTRACELLULAR, V4, P665; ZHANG JZ, 1992, J BIOL CHEM, V267, P21727	36	35	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					691	695						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276870				2022-12-25	WOS:A1994MR21900108
J	CHEEK, TR; MORETON, RB; BERRIDGE, MJ; STAUDERMAN, KA; MURAWSKY, MM; BOOTMAN, MD				CHEEK, TR; MORETON, RB; BERRIDGE, MJ; STAUDERMAN, KA; MURAWSKY, MM; BOOTMAN, MD			QUANTAL CA2+ RELEASE FROM CAFFEINE-SENSITIVE STORES IN ADRENAL CHROMAFFIN CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; BULLFROG SYMPATHETIC NEURONS; CALCIUM RELEASE; INOSITOL 1,4,5-TRISPHOSPHATE; CA-2+ RELEASE; SKELETAL-MUSCLE; LUMINAL CA2+; INTRACELLULAR STORES; RYANODINE RECEPTOR; CHANNEL	In populations of fura-2-loaded chromaffin cells, caffeine caused a concentration-dependent increase in the intracellular Ca2+ concentration ([Ca2+]i), in the presence or absence of external Ca2+ ([Ca2+]o), that was saturable, reversible, and inhibited in a use-dependent fashion by ryanodine. These data confirm that caffeine mobilizes Ca2+ from the ryanodine-sensitive intracellular stores in chromaffin cells. In nominally Ca2+-free medium, sustained stimulation of cell populations or single cells with low caffeine concentrations failed to completely empty the caffeine-sensitive stores. In each case, there was a transient [Ca2+]i elevation, but a subsequent challenge with a higher caffeine concentration evoked a further [Ca2+]i rise, indicating that Ca2+ stores within individual cells were heterogeneous in their sensitivities to caffeine and that caffeine-induced Ca2+ release was quantal. The heterogeneous sensitivity was also demonstrated using ryanodine; pretreatment of cell populations with increasing caffeine concentrations with a constant ryanodine concentration, caused a dose-dependent irreversible inhibition of the response to the subsequent addition of a maximal caffeine concentration. We conclude that, within single chromaffin cells, intracellular Ca2+ stores are heterogeneous in their sensitivity to caffeine and the fraction of Ca2+ stores mobilized by caffeine increases in direct proportion to the caffeine concentration.	MERRELL DOW PHARMACEUT INC, RES INST, CINCINNATI, OH 45215 USA	Dow Chemical Company	CHEEK, TR (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, AFRC, MOLEC SIGNALLING LAB, DOWNING ST, CAMBRIDGE CB2 3EJ, ENGLAND.		Bootman, Martin/AAB-3330-2019	Bootman, Martin/0000-0002-6447-3451				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; BURGOYNE RD, 1989, NATURE, V342, P72, DOI 10.1038/342072a0; CHEEK TR, 1990, FEBS LETT, V266, P91, DOI 10.1016/0014-5793(90)81514-O; CHEEK TR, 1991, BIOCHEM J, V275, P697, DOI 10.1042/bj2750697; CHEEK TR, 1993, J CELL SCI, V105, P913; ELLISMAN MH, 1990, NEURON, V5, P135, DOI 10.1016/0896-6273(90)90304-X; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FILL M, 1988, TRENDS NEUROSCI, V11, P453, DOI 10.1016/0166-2236(88)90198-1; FRIEL DD, 1992, J PHYSIOL-LONDON, V450, P217, DOI 10.1113/jphysiol.1992.sp019125; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; HENZI V, 1992, NEUROSCIENCE, V46, P251, DOI 10.1016/0306-4522(92)90049-8; HIGASHIDA H, 1986, FEBS LETT, V208, P283, DOI 10.1016/0014-5793(86)81033-X; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INO M, 1989, J GEN PHYSIOL, V94, P363, DOI 10.1085/jgp.94.2.363; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KUBA K, 1980, J PHYSIOL-LONDON, V298, P251, DOI 10.1113/jphysiol.1980.sp013079; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LIPSCOMBE D, 1988, NEURON, V1, P355, DOI 10.1016/0896-6273(88)90185-7; LIU PS, 1991, J NEUROCHEM, V56, P172, DOI 10.1111/j.1471-4159.1991.tb02577.x; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MARRION NV, 1992, J PHYSIOL-LONDON, V445, P515, DOI 10.1113/jphysiol.1992.sp018937; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MISSIAEN L, 1992, J BIOL CHEM, V267, P22961; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MORETON RB, 1991, CELLULAR NEUROBIOLOG, P205; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NAGASAKI K, 1984, J BIOCHEM-TOKYO, V96, P1769, DOI 10.1093/oxfordjournals.jbchem.a135009; NELSON TE, 1990, FEBS LETT, V263, P292, DOI 10.1016/0014-5793(90)81396-6; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; ONDRIAS K, 1990, CIRC RES, V67, P1167, DOI 10.1161/01.RES.67.5.1167; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; ROBINSON IM, 1991, J NEUROCHEM, V56, P1587, DOI 10.1111/j.1471-4159.1991.tb02055.x; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; SALAMA G, 1992, CELL CALCIUM, V13, P635, DOI 10.1016/0143-4160(92)90074-3; SCHNEIDER MF, 1988, J PHYSIOL-LONDON, V405, P727, DOI 10.1113/jphysiol.1988.sp017358; STAUDERMAN KA, 1991, J BIOL CHEM, V266, P19150; STAUDERMAN KA, 1991, BIOCHEM J, V278, P643, DOI 10.1042/bj2780643; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; THAYER SA, 1988, J NEUROSCI, V8, P4089; THAYER SA, 1988, MOL PHARMACOL, V34, P664; TREGEAR RT, 1991, P ROY SOC B-BIOL SCI, V243, P263, DOI 10.1098/rspb.1991.0040; TSHIPAMBA M, 1993, J CELL PHYSIOL, V155, P96, DOI 10.1002/jcp.1041550113; WITCHER DR, 1991, J BIOL CHEM, V266, P11144	58	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27076	27083						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262945				2022-12-25	WOS:A1993MM26200038
J	HUANG, ZF; WUN, TC; BROZE, GJ				HUANG, ZF; WUN, TC; BROZE, GJ			KINETICS OF FACTOR-XA INHIBITION BY TISSUE FACTOR PATHWAY INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT-BINDING INHIBITORS; MOLECULAR-WEIGHT-DEPENDENCE; COAGULATION INHIBITOR; PROTHROMBINASE COMPLEX; FACTOR-VII; ADENOSINE-DEAMINASE; EXTRINSIC PATHWAY; BLOOD-COAGULATION; ANTI-THROMBIN; SLOW-BINDING	Tissue factor pathway inhibitor is a multivalent, Kunitz-type proteinase inhibitor. It directly inhibits factor Xa and, in a factor Xa-dependent fashion, produces feedback inhibition of the factor VIIa/tissue factor catalytic complex which is responsible for the initiation of coagulation. Human recombinant TFPI (rTFPI) produced in Escherichia coli was used to define the kinetic constants describing the human factor Xa:TFPI interaction. The inactivation of factor Xa by E. coli-rTFPI is indistinguishable from that of rTFPI produced in mammalian SK-hepatoma cells, suggesting that post-translational modifications such as glycosylation and phosphorylation do not play a major role in the inhibitory process. The slow, tight-binding inhibition of factor Xa follows the scheme: [GRAPHICS] Where the enzyme (E) and inhibitor (I) form an initial, immediate collision complex (EI) that then isomerizes slowly to a tightened final EI complex. In the absence of other additions, the initial K(i) (=k2/k1) and final K(i) for the inhibition of factor Xa by E. coli-rTFPI are 1.24 nM and 26.4 pM, respectively. In the presence of calcium ions (5 mM) the interaction between factor Xa and rTFPI is substantially weaker, with a K(i) of 42.7 nM and K(i) of 85.2 pM. The addition of other components of the prothrombinase complex produces enhanced factor Xa inhibition predominantly through an effect on the initial K(i). In the presence of calcium ions and saturating concentrations of phospholipids and factor Va, the K(i) and K(i) for factor Xa inactivation are 2.04 nM and 52.3 pm. The enhancing effect of heparin on the inhibitory process is concentration dependent and exhibits an optimum, reminiscent of the ''template'' model for heparin's acceleration of thrombin and factor IXa inhibition by antithrombin III. At optimal concentrations, the major mechanism of heparin action is also a reduction in the K(i) of the initial encounter complex between factor Xa and rTFPI.	WASHINGTON UNIV, JEWISH HOSP ST LOUIS,MED CTR,DIV HEMATOL ONCOL, 216 S KINGSHIGHWAY BLVD, ST LOUIS, MO 63110 USA; MONSANTO CO, CHESTERFIELD, MO 63198 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Monsanto					NHLBI NIH HHS [HL-34462] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034462] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONINI E, 1983, BIOPOLYMERS, V22, P363, DOI 10.1002/bip.360220147; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BROZE GJ, 1988, BLOOD, V71, P335; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; CASU B, 1981, BIOCHEM J, V197, P599, DOI 10.1042/bj1970599; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CHA S, 1976, BIOCHEM PHARMACOL, V25, P1561; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2187, DOI 10.1016/0006-2952(75)90051-9; CHA S, 1976, BIOCHEM PHARMACOL, V25, P2695, DOI 10.1016/0006-2952(76)90259-8; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; DAY KC, 1990, BLOOD, V76, P1538; DAY KC, 1992, THROMB RES, V68, P369, DOI 10.1016/0049-3848(92)90095-R; ELLIS V, 1986, BIOCHEM J, V238, P329, DOI 10.1042/bj2380329; GIRARD TJ, 1990, BIOCHEM J, V270, P621, DOI 10.1042/bj2700621; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; HASKEL EJ, 1991, CIRCULATION, V84, P821, DOI 10.1161/01.CIR.84.2.821; HIGGINS DL, 1985, J BIOL CHEM, V260, P3604; HIGUCHI DA, 1992, BLOOD, V79, P1712; HOLMER E, 1981, BIOCHEM J, V193, P395, DOI 10.1042/bj1930395; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISTENSEN HI, 1992, THROMB HAEMOSTASIS, V68, P310; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MANN KG, 1990, BLOOD, V76, P1; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NESHEIM ME, 1981, J BIOL CHEM, V256, P9874; NORDFANG O, 1991, BIOCHEMISTRY-US, V30, P10371, DOI 10.1021/bi00107a002; NOVOTNY WF, 1991, BLOOD, V78, P387; OLSON ST, 1993, IN PRESS SEMIN THROM; OOSTA GM, 1981, P NATL ACAD SCI-BIOL, V78, P829, DOI 10.1073/pnas.78.2.829; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; OWEN BA, 1990, BIOCHEMISTRY-US, V29, P9412, DOI 10.1021/bi00492a015; PALMIER MO, 1992, THROMB HAEMOSTASIS, V68, P33; RICH DH, 1980, BIOCHEM PHARMACOL, V29, P2205, DOI 10.1016/0006-2952(80)90199-9; SANDSET PM, 1988, THROMB RES, V50, P803, DOI 10.1016/0049-3848(88)90340-4; SILVERBERG SA, 1977, J BIOL CHEM, V252, P8481; SMITH PL, 1992, J BIOL CHEM, V267, P19140; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; THUNBERG L, 1979, BIOCHEM J, V181, P241, DOI 10.1042/bj1810241; WESSELSCHMIDT R, 1992, BLOOD, V79, P2004; WESSELSCHMIDT R, 1993, IN PRESS BLOOD COAGU; WUN TC, 1988, J BIOL CHEM, V263, P6001; ZUR M, 1980, J BIOL CHEM, V255, P5703	47	149	160	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26950	26955						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262929				2022-12-25	WOS:A1993MM26200020
J	KALAFATIS, M; MANN, KG				KALAFATIS, M; MANN, KG			ROLE OF THE MEMBRANE IN THE INACTIVATION OF FACTOR-VA BY ACTIVATED PROTEIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-V; BOVINE FACTOR-V; THROMBIN-CATALYZED ACTIVATION; HUMAN FACTOR-VIII; FACTOR-XA; PHOSPHOLIPID-VESICLES; BLOOD-COAGULATION; BINDING-SITE; PROTHROMBIN ACTIVATION; A1/A3-C1-C2 DIMER	Bovine factor Va inactivation by activated protein C (APC) was evaluated in the presence and absence of phospholipid vesicles and protein S. Following a 30-min incubation with APC (10 nM), membrane-bound factor Va (200 nM) is completely inactivated, whereas in the absence of phospholipid vesicles, after a 2-h incubation, the cofactor retains 60% of its initial co-factor activity. The complete loss of activity of membrane-bound factor Va is associated with the appearance of M(r) 40,000, 28,000, and 20,000 fragments derived from the heavy chain of the cofactor which correspond to cleavage at Arg306, Arg505, and Arg662. In the absence of a lipid bilayer, cleavage at Arg505 and Arg662 results in a cofactor with reduced activity. No difference is observed in the cleavage of the light chain of the cofactor by APC in the presence or absence of phospholipid vesicles. The rate of the cleavage of factor Va heavy chain at Arg306, Arg505, and Arg662 as well as the rate of the membrane-bound cofactor inactivation by APC were enhanced in the presence of protein S. Our data demonstrate that the anionic lipid-dependent cleavage of factor Va by APC at Arg306 is required for the complete inactivation of the cofactor.	UNIV VERMONT,COLL MED,DEPT BIOCHEM,GIVEN BLDG,HLTH SCI COMPLEX,BURLINGTON,VT 05405	University of Vermont					NHLBI NIH HHS [R37 HL34575, T32 HL07594, P01 HL46703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007594, P01HL046703, R37HL034575] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJAJ SP, 1973, J BIOL CHEM, V248, P7729; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BLOMBACK B, 1972, ANN NY ACAD SCI, V202, P77, DOI 10.1111/j.1749-6632.1972.tb16323.x; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; CHURCH WR, 1988, BLOOD, V72, P1911; COMP PC, 1984, J CLIN INVEST, V74, P2082, DOI 10.1172/JCI111632; CUTSFORTH GA, 1991, THROMB HAEMOSTASIS, V65, P858; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON NL, 1982, J BIOL CHEM, V257, P859; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FOSTER WB, 1983, J BIOL CHEM, V258, P3970; Gomori G, 1942, J LAB CLIN MED, V27, P955; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; HALEY PE, 1989, J BIOL CHEM, V264, P16303; HELDEBRANT CM, 1973, J BIOL CHEM, V248, P7149; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; JANE SM, 1989, J CLIN INVEST, V83, P222, DOI 10.1172/JCI113862; KALAFATIS M, 1993, METHOD ENZYMOL, V222, P224; KALAFATIS M, 1993, BLOOD, V81, P704; KALAFATIS M, 1990, J BIOL CHEM, V265, P21580; KALAFATIS M, 1992, CIRCULATION, V86, P1857; KALOUSEK F, 1975, FEBS LETT, V50, P382, DOI 10.1016/0014-5793(75)80533-3; KANE WH, 1988, BLOOD, V71, P539; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; KISIEL W, 1901, METHOD ENZYMOL, V80, P320; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; KRISHNASWAMY S, 1989, J BIOL CHEM, V264, P3160; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1991, J BIOL CHEM, V266, P11317; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; Lundblad R L, 1976, Methods Enzymol, V45, P156; MALHOTRA OP, 1985, J BIOL CHEM, V260, P279; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANNUCCI PM, 1986, THROMB HAEMOSTASIS, V55, P440; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1982, J BIOL CHEM, V257, P1443; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NESHEIM ME, 1980, METHOD ENZYMOL, V80, P243; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; OMAR MN, 1987, J BIOL CHEM, V262, P9750; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; TRACY PB, 1983, J BIOL CHEM, V258, P662; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1990, J BIOL CHEM, V265, P1484; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; XUE JC, 1993, BIOCHEMISTRY-US, V32, P5917, DOI 10.1021/bi00073a026	63	91	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27246	27257						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262965				2022-12-25	WOS:A1993MM26200061
J	CUI, T; SANKAR, S; PORTER, AG				CUI, T; SANKAR, S; PORTER, AG			BINDING OF ENCEPHALOMYOCARDITIS VIRUS-RNA POLYMERASE TO THE 3'-NONCODING REGION OF THE VIRAL-RNA IS SPECIFIC AND REQUIRES THE 3'-POLY(A) TAIL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-CELL PROTEIN; POLIOVIRUS RNA; ESCHERICHIA-COLI; MESSENGER-RNA; CODING REGION; LENGTH COPIES; INVITRO; REPLICASE; PURIFICATION; GENOME	An in vitro RNA bandshift assay has been developed to demonstrate the binding of purified recombinant encephalomyocarditis (EMC) virus RNA-dependent RNA polymerase (3D(pol)) to the 3'-noncoding region (NCR) and 30 nucleotides of the adjacent 3'-terminal poly(A) tail (3'-NCR(A)) of EMC virus RNA. The binding of 3D(pol) to the 3'-NCR(A) fragment was specific since four other unrelated proteins including an RNA polymerase did not bind, and unlabeled 3'-NCR(A), but not alpha-globin mRNA, tRNA, or pure poly(A), competed with radiolabeled 3'-NCR(A) for binding. Surprisingly, 3D(pol) failed to bind to the 3'-NCR of EMC virus RNA lacking the poly(A) tail. The results together show that EMC virus RNA template specificity depends only on 3D(pol), the 3'-NCR, and the poly(A) tail. This suggests that 3'-poly(A) is essential for viral RNA template selection by the EMC virus RNA polymerase.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,10 KENT RIDGE CRESCENT,SINGAPORE 0511,SINGAPORE	Agency for Science Technology & Research (ASTAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore								AHLQUIST P, 1979, NUCLEIC ACIDS RES, V7, P1195, DOI 10.1093/nar/7.5.1195; ANDREWS NC, 1985, J BIOL CHEM, V260, P7628; ANDREWS NC, 1986, P NATL ACAD SCI USA, V83, P221, DOI 10.1073/pnas.83.2.221; BARON MH, 1982, J BIOL CHEM, V257, P2351; BLUMENTHAL T, 1973, BIOCHEM BIOPH RES CO, V55, P680, DOI 10.1016/0006-291X(73)91198-4; BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; DASGUPTA A, 1980, CELL, V19, P423, DOI 10.1016/0092-8674(80)90516-4; DASGUPTA A, 1979, P NATL ACAD SCI USA, V76, P2679, DOI 10.1073/pnas.76.6.2679; DILDINE SL, 1992, J VIROL, V66, P4364, DOI 10.1128/JVI.66.7.4364-4376.1992; DMITRIEVA TM, 1979, VIROLOGY, V92, P271, DOI 10.1016/0042-6822(79)90131-4; DORSCHHASLER K, 1975, J VIROL, V16, P1512; FLANEGAN JB, 1990, NEW ASPECTS OF POSITIVE-STRAND RNA VIRUSES, P55; FLANEGAN JB, 1977, P NATL ACAD SCI USA, V74, P3677, DOI 10.1073/pnas.74.9.3677; FRISBY D, 1976, NUCLEIC ACIDS RES, V3, P2789, DOI 10.1093/nar/3.10.2789; GIVENS JF, 1976, NUCLEIC ACIDS RES, V3, P405, DOI 10.1093/nar/3.2.405; HEY TD, 1987, J VIROL, V61, P802, DOI 10.1128/JVI.61.3.802-811.1987; JACOBSON SJ, 1993, J VIROL, V67, P2961, DOI 10.1128/JVI.67.6.2961-2971.1993; JOBLING SA, 1987, NATURE, V325, P622, DOI 10.1038/325622a0; Kuhn R. J., 1987, The molecular biology of the positive strand RNA viruses, P17; MILLER WA, 1986, J MOL BIOL, V187, P537, DOI 10.1016/0022-2836(86)90332-3; MORROW CD, 1985, CELL, V40, P913, DOI 10.1016/0092-8674(85)90351-4; NEUFELD KL, 1991, J BIOL CHEM, V266, P24212; OBERSTE M S, 1988, Nucleic Acids Research, V16, P10339, DOI 10.1093/nar/16.21.10339; PALMENBERG AC, 1984, NUCLEIC ACIDS RES, V12, P2969, DOI 10.1093/nar/12.6.2969; RICHARDS OC, 1992, J BIOL CHEM, V267, P17141; ROTHSTEIN MA, 1988, VIROLOGY, V164, P301, DOI 10.1016/0042-6822(88)90542-9; Sambrook J, 1989, MOL CLONING LABORATO; SANKAR S, 1992, J BIOL CHEM, V267, P10168; SANKAR S, 1991, J VIROL, V65, P2993, DOI 10.1128/JVI.65.6.2993-3000.1991; SARNOW P, 1986, P NATL ACAD SCI USA, V83, P571, DOI 10.1073/pnas.83.3.571; SO AG, 1970, BIOCHEMISTRY-US, V9, P4788, DOI 10.1021/bi00826a024; SPECTOR DH, 1974, P NATL ACAD SCI USA, V71, P2983, DOI 10.1073/pnas.71.8.2983; SPECTOR DH, 1975, VIROLOGY, V67, P498, DOI 10.1016/0042-6822(75)90450-X; TAKEDA N, 1986, J VIROL, V60, P43, DOI 10.1128/JVI.60.1.43-53.1986; TAKEGAMI T, 1983, P NATL ACAD SCI-BIOL, V80, P7447, DOI 10.1073/pnas.80.24.7447; TENDAM E, 1992, BIOCHEMISTRY-US, V31, P11665, DOI 10.1021/bi00162a001; TOBIN GJ, 1989, CELL, V59, P511, DOI 10.1016/0092-8674(89)90034-2; TUSCHALL DM, 1982, J VIROL, V44, P209, DOI 10.1128/JVI.44.1.209-216.1982; VANDYKE TA, 1982, J BIOL CHEM, V257, P4610; VARTAPETIAN AB, 1984, EMBO J, V3, P2593, DOI 10.1002/j.1460-2075.1984.tb02179.x; YOGO Y, 1975, J MOL BIOL, V92, P467, DOI 10.1016/0022-2836(75)90292-2; YOUNG DC, 1985, J VIROL, V54, P256, DOI 10.1128/JVI.54.2.256-264.1985; ZABEL P, 1979, J VIROL, V29, P21, DOI 10.1128/JVI.29.1.21-33.1979	43	44	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26093	26098						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253725				2022-12-25	WOS:A1993MK42500016
J	DENNING, MF; DLUGOSZ, AA; HOWETT, MK; YUSPA, SH				DENNING, MF; DLUGOSZ, AA; HOWETT, MK; YUSPA, SH			EXPRESSION OF AN ONCOGENIC RAS(HA) GENE IN MURINE KERATINOCYTES INDUCES TYROSINE PHOSPHORYLATION AND REDUCED ACTIVITY OF PROTEIN-KINASE-C DELTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAS ONCOGENE; TERMINAL DIFFERENTIATION; SARCOMA-VIRUSES; PHORBOL ESTER; CELLS; STAUROSPORINE; REQUIREMENT; INHIBITOR; PROMOTER; INVITRO	Murine keratinocytes expressing an oncogenic ras(Ha) gene produce benign tumors in vivo and demonstrate altered responses to phorbol esters in vitro. Cultured keratinocytes transduced with the v-ras(Ha) gene (v-ras(Ha) keratinocytes) are resistant to Ca2+-induced terminal differentiation, a process that is dependent on protein kinase C (PKC) activation in normal keratinocytes. Five PKC isoforms expressed in keratinocytes (alpha, delta, epsilon, zeta, and eta) were examined for quantitative or qualitative changes in v-ras(Ha)-transformed cells. No quantitative changes were detected, but PKC delta was tyrosine-phosphorylated in v-ras(Ha) keratinocytes and in benign neoplastic keratinocyte cell lines expressing an activated allele of the c-ras(Ha) gene. Analysis of phosphorylated and non-phosphorylated forms of PKC delta from keratinocytes indicated that phosphorylated PKC delta was not stimulated by phorbol ester treatment. The protein kinase inhibitor staurosporine was able to induce differentiation in v-ras(Ha) keratinocytes and benign tumor cell lines, and concomitantly tyrosine phosphorylation of PKC delta decreased. This interaction between tyrosine kinases and PKC delta in cells expressing an oncogenic ras(Ha) gene may represent a molecular block to differentiation in neoplastic keratinocytes.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,DEPT MICROBIOL & IMMUNOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	DENNING, MF (corresponding author), NCI,DIV CANC ETIOL,CELLULAR CARCINOGENESIS & TUMOR PROMOT,BETHESDA,MD 20892, USA.							BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; DLUGOSZ AA, 1991, CANCER RES, V51, P4677; DLUGOSZ AA, 1992, MOL CARCINOGEN, V5, P286, DOI 10.1002/mc.2940050409; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P14778; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MORRIS JDH, 1989, ONCOGENE, V4, P27; NAKADATE T, 1988, BIOCHEM PHARMACOL, V37, P1541, DOI 10.1016/0006-2952(88)90016-0; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; REINERS JJ, 1983, CELL, V32, P247, DOI 10.1016/0092-8674(83)90515-9; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STACEY DW, 1991, ONCOGENE, V6, P2297; STRICKLAND JE, 1988, CANCER RES, V48, P165; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; YUSPA SH, 1985, NATURE, V314, P459, DOI 10.1038/314459a0; YUSPA SH, 1982, CANCER RES, V42, P2344	25	162	163	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26079	26081						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253722				2022-12-25	WOS:A1993MK42500013
J	MARSHALL, BA; MURATA, H; HRESKO, RC; MUECKLER, M				MARSHALL, BA; MURATA, H; HRESKO, RC; MUECKLER, M			DOMAINS THAT CONFER INTRACELLULAR SEQUESTRATION OF THE GLUT4 GLUCOSE-TRANSPORTER IN XENOPUS-OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; FUNCTIONAL EXPRESSION; ENDOPLASMIC-RETICULUM; RAT ADIPOCYTES; INSULIN; PROTEIN; ISOFORMS; MUSCLE; TRANSLOCATION; LOCALIZATION	The Glut4 glucose transporter is poorly functional compared with other glucose transporter isoforms when expressed in Xenopus oocytes. To investigate the molecular basis for this poor functionality, we compared the biosynthesis and targeting of Glut1 and Glut4 in oocytes after microinjection of the corresponding mRNAs. Both Glut1 and Glut4 were present as lower molecular weight endoglycosidase H-sensitive and higher molecular weight endoglycosidase H-resistant forms in oocyte intracellular membranes. Part of the Glut1 immunoreactivity was detected as an incompletely processed form that was endoglycosidase H-resistant. Subcellular fractionation indicated that Glut1 was targeted to the plasma membrane with a 6.6-fold greater efficiency than was Glut4. Confocal immunofluorescence microscopy confirmed the relative enrichment of Glut1 in the plasma membrane and the efficient intracellular sequestration of Glut4. As in mammalian cells, the endoglycosidase H-resistant form of Glut4 was concentrated in low-density intracellular vesicles, whereas Glut1 was distributed in intracellular vesicles of higher average density. The structural basis for the differential localization of Glut1 and Glut4 was investigated by determining the plasma membrane content of a series of chimeric Glut1/Glut4 molecules. These data indicated that two distinct regions of Glut4, encompassing residues 24-132 and the COOH-terminal cytoplasmic tail, confer intracellular sequestration on the chimeric transporter molecules. At least part of the sequestration effect of the more N-terminal domain was due to the incomplete maturation of chimeras containing this region, resulting in the accumulation of lower molecular weight endoglycosidase H-sensitive and endoglycosidase H-resistant forms, whereas the COOH-terminal cytoplasmic tail conferred sequestration of fully glycosylated chimeras in a low-density intracellular membrane compartment.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007120, R01DK038495, R01DK043695] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07120, DK38495, DK43695] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLARD WJ, 1985, J BIOL CHEM, V260, P8668; ASANO T, 1992, J BIOL CHEM, V267, P19636; BALDWIN SA, 1989, METHOD ENZYMOL, V174, P39; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BORNEMANN A, 1992, DIABETES, V41, P215, DOI 10.2337/diabetes.41.2.215; BURANT CF, 1992, BIOCHEMISTRY-US, V31, P10414, DOI 10.1021/bi00157a032; BURANT CF, 1991, RECENT PROG HORM RES, V47, P349; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DAVIES A, 1990, BIOCHEM J, V266, P799; DEVASKAR SU, 1992, PEDIATR RES, V31, P1, DOI 10.1203/00006450-199201000-00001; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HEBERT DN, 1992, J BIOL CHEM, V267, P23829; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; HUDSON AW, 1992, J CELL BIOL, V116, P785, DOI 10.1083/jcb.116.3.785; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JAUNIN P, 1992, J BIOL CHEM, V267, P577; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; KELLER K, 1989, J BIOL CHEM, V264, P18884; KOTLIAR N, 1992, MOL ENDOCRINOL, V6, P337, DOI 10.1210/me.6.3.337; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LODISH HF, 1988, J BIOL CHEM, V263, P2107; MARETTE A, 1992, AM J PHYSIOL, V263, pC443, DOI 10.1152/ajpcell.1992.263.2.C443; MUECKLER M, 1986, CELL, V44, P629, DOI 10.1016/0092-8674(86)90272-2; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NISHIMURA H, 1993, J BIOL CHEM, V268, P8514; PESSINO A, 1991, J BIOL CHEM, V266, P20213; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PIPER RC, 1992, J CELL BIOL, V117, P729, DOI 10.1083/jcb.117.4.729; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; SHIBASAKI Y, 1992, BIOCHEM J, V281, P829, DOI 10.1042/bj2810829; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; THOMAS HM, 1993, BIOCHEM J, V290, P707, DOI 10.1042/bj2900707; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	42	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26193	26199						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253739				2022-12-25	WOS:A1993MK42500030
J	SHIMODA, N; TOYODAYAMAMOTO, A; AOKI, S; MACHIDA, Y				SHIMODA, N; TOYODAYAMAMOTO, A; AOKI, S; MACHIDA, Y			GENETIC-EVIDENCE FOR AN INTERACTION BETWEEN THE VIRA SENSOR PROTEIN AND THE CHVE SUGAR-BINDING PROTEIN OF AGROBACTERIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-DNA TRANSFER; ESCHERICHIA-COLI; VIRULENCE GENES; NUCLEOTIDE-SEQUENCE; SIGNAL MOLECULES; PLANT-CELLS; TUMEFACIENS; MEMBRANE; PLASMID; MUTANT	Most vir genes of Agrobacterium, which are required for tumorigenicity of the bacterium, are expressed in response to plant phenolics. The induction of vir is markedly enhanced by specific monosaccharides. Signals generated by both types of compound are transduced into Agrobacterium cells via the functions of the VirA membrane-bound sensor protein. A putative sugar-binding protein, known as ChvE, also functions at a step of the enhancement of vir induction by monosaccharides. To investigate the signal pathway of the enhancement by the sugars, we first isolated a virA mutant of Agrobacterium with a base substitution mutation that caused a single amino acid change in the periplasmic domain. The mutant exhibited no enhancement of vir induction by sugar and had severely attenuated tumorigenicity on Kalanchoe leaves. We then isolated two chvE mutants that restored sugar enhancement on the background of this virA mutation. One chvE mutant, which exhibited a higher level of sugar enhancement, restored the tumorigenicity of the virA mutant. Wild-type and suppressor ChvE proteins were localized in the periplasmic space. These results provide genetic evidence for the physical interaction between VirA and ChvE proteins in the periplasmic space of Agrobacterium, which enhances the cytoplasmic signal generated by phenolics. We also discuss the molecular architecture of the operon to which the chvE gene belongs.			SHIMODA, N (corresponding author), NAGOYA UNIV,FAC SCI,DEPT BIOL,CHIKUSA KU,NAGOYA 46401,JAPAN.							AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; BURN J, 1987, GENE DEV, V1, P456, DOI 10.1101/gad.1.5.456; CANGELOSI GA, 1990, P NATL ACAD SCI USA, V87, P6708, DOI 10.1073/pnas.87.17.6708; CHANG CH, 1992, J BACTERIOL, V174, P7033, DOI 10.1128/JB.174.21.7033-7039.1992; CORNISH A, 1989, J GEN MICROBIOL, V135, P3001; ENDOH H, 1993, PLANT CELL PHYSIOL, V34, P227; Gelvin S.B., 1992, MOL SIGNALS PLANT MI, P137; HOGG RW, 1991, MOL GEN GENET, V229, P453, DOI 10.1007/BF00267469; HUANG MW, 1990, J BACTERIOL, V172, P1814, DOI 10.1128/jb.172.4.1814-1822.1990; HUANG Y, 1990, J BACTERIOL, V172, P1142, DOI 10.1128/jb.172.2.1142-1144.1990; JIN SG, 1990, J BACTERIOL, V172, P525, DOI 10.1128/jb.172.2.525-530.1990; KLEE HJ, 1982, J BACTERIOL, V150, P327, DOI 10.1128/JB.150.1.327-331.1982; KOSSMANN M, 1988, J BACTERIOL, V170, P4516, DOI 10.1128/jb.170.10.4516-4521.1988; LEE KH, 1992, P NATL ACAD SCI USA, V89, P8666, DOI 10.1073/pnas.89.18.8666; LEROUX B, 1987, EMBO J, V6, P849, DOI 10.1002/j.1460-2075.1987.tb04830.x; LIN JJC, 1978, P NATL ACAD SCI USA, V75, P4891, DOI 10.1073/pnas.75.10.4891; LIU JD, 1991, J BACTERIOL, V173, P4941, DOI 10.1128/jb.173.16.4941-4951.1991; MACHIDA Y, 1984, P NATL ACAD SCI-BIOL, V81, P7495, DOI 10.1073/pnas.81.23.7495; MACHIDA Y, 1989, BOT MAG TOKYO, V102, P331, DOI 10.1007/BF02488571; MANTIS N, 1992, J BACTERIOL, V176, P1189; MATTANOVICH D, 1989, NUCLEIC ACIDS RES, V17, P6747, DOI 10.1093/nar/17.16.6747; MELCHERS LS, 1989, EMBO J, V8, P1919, DOI 10.1002/j.1460-2075.1989.tb03595.x; MELCHERS LS, 1987, PLANT MOL BIOL, V11, P227; MOREL P, 1989, MOL MICROBIOL, V3, P1237, DOI 10.1111/j.1365-2958.1989.tb00274.x; OKAMOTO S, 1991, MOL GEN GENET, V228, P24, DOI 10.1007/BF00282443; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PETIT A, 1978, NATURE, V271, P570, DOI 10.1038/271570a0; SCHOLLE A, 1987, MOL GEN GENET, V208, P247, DOI 10.1007/BF00330450; SHIMODA N, 1990, P NATL ACAD SCI USA, V87, P6684, DOI 10.1073/pnas.87.17.6684; SPENCER PA, 1988, PHYTOCHEMISTRY, V27, P2781, DOI 10.1016/0031-9422(88)80663-0; STACHEL SE, 1986, P NATL ACAD SCI USA, V83, P379, DOI 10.1073/pnas.83.2.379; STACHEL SE, 1985, NATURE, V318, P624, DOI 10.1038/318624a0; TURK SCHJ, 1991, PLANT MOL BIOL, V16, P1051, DOI 10.1007/BF00016076; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WINANS SC, 1989, J BACTERIOL, V171, P1616, DOI 10.1128/jb.171.3.1616-1622.1989; WINANS SC, 1992, MICROBIOL REV, V56, P12, DOI 10.1128/MMBR.56.1.12-31.1992; ZAMBRYSKI PC, 1992, ANNU REV PLANT PHYS, V43, P465, DOI 10.1146/annurev.pp.43.060192.002341	37	73	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26552	26558						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253785				2022-12-25	WOS:A1993MK42500079
J	HAJNAL, A; KLEMENZ, R; SCHAFER, R				HAJNAL, A; KLEMENZ, R; SCHAFER, R			SUBTRACTION CLONING OF H-REV107, A GENE SPECIFICALLY EXPRESSED IN H-RAS RESISTANT FIBROBLASTS	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENES; GTPASE-ACTIVATING PROTEIN; WILD-TYPE P53; TRANSFORMED PHENOTYPE; FLAT REVERTANTS; CARCINOMA-CELLS; ADENOVIRUS E1A; T-ANTIGEN; V-MOS; ONCOGENE EXPRESSION	We have isolated by subtractive hybridization a novel gene, called H-rev107, which is specifically expressed in a phenotypic revertant of H-ras transformed 208F rat fibroblasts. Apart from oncogene revertants, strong expression of H-rev107 was found in REF52 and EK-3 cells, two fibroblast lines resistant to transformation by activated H-vas oncogenes. In contrast, transformation-sensitive fibroblasts like 208F or NIH3T3 cells expressed only very little H-rev107 RNA. In H-r as or v-src transformed fibroblasts, H-rev107 RNA was undetectable. Introduction of the adenovirus E1A nuclear oncogene into ras-resistant REF52 cells abolished their transformation resistance and repressed the H-rev107 gene. H-rev107 encodes a protein with a molecular weight of 18 kDa without any structural similarity to known proteins. p18(H-rev107) exists in two forms which can be distinguished by their electrophoretic mobility; one is localized predominantly in cell membranes, the other in the cytoplasm. In confluent contact-inhibited 208F cells, p18(H-rev107) accumulated in cell membranes, while growth arrest induced by serum starvation did not induce H-rev107. In REF52, cell density had no influence on the expression or localization of p18(H-rev107). Repression of the H-rev107 gene may be closely associated with the loss of density-dependent growth inhibition and with the expression of the neoplastic phenotype.	UNIV ZURICH,DEPT PATHOL,DIV CANC RES,CH-8091 ZURICH,SWITZERLAND	University of Zurich				Schafer, Reinhold/0000-0001-7952-2124				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BASSIN RH, 1987, ADV VIRAL ONCOL, V6, P103; BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHINNADURAI G, 1983, CELL, V33, P759, DOI 10.1016/0092-8674(83)90018-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIZDZIEL PE, 1991, MOL CARCINOGEN, V4, P14, DOI 10.1002/mc.2940040105; CRAIG RW, 1985, P NATL ACAD SCI USA, V82, P2062, DOI 10.1073/pnas.82.7.2062; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DEPPERT W, 1991, ONCOGENE, V6, P1931; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FUJITA H, 1990, EXP CELL RES, V186, P115, DOI 10.1016/0014-4827(90)90217-X; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAJNAL A, 1993, CANCER RES, V53, P1; HIGGINS PJ, 1991, BIOCHEM J, V279, P883, DOI 10.1042/bj2790883; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, ONCOGENE, V6, P1211; Iten E, 1989, Recent Results Cancer Res, V113, P78; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; JELINEK MA, 1992, ONCOGENE, V7, P1687; KANEKO M, 1989, BRIT J CANCER, V60, P880, DOI 10.1038/bjc.1989.384; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KATZ E, 1989, EUR J CELL BIOL, V49, P221; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KIKKAWA U, 1986, ANN REV CELL BIOL, V2, P146; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KOLCH W, 1993, ONCOGENE, V8, P361; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; KRZYZOSIAK WJ, 1992, P NATL ACAD SCI USA, V89, P4879, DOI 10.1073/pnas.89.11.4879; KUZUMAKI N, 1989, MOL CELL BIOL, V9, P2258, DOI 10.1128/MCB.9.5.2258; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LOMBARDI L, 1990, CELL MOTIL CYTOSKEL, V15, P220, DOI 10.1002/cm.970150405; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MERCER WE, 1990, ONCOGENE, V5, P973; MIRANTI C, 1990, SOMAT CELL MOLEC GEN, V16, P67, DOI 10.1007/BF01650481; MORRIS JF, 1991, ONCOGENE, V6, P2339; NEVINS JR, 1992, SCIENCE, V258, P424; NIELSCH U, 1991, ONCOGENE, V6, P1031; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; OKAYAMA H, 1982, MOL CELL BIOL, V2, P280; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; QUADE K, 1979, VIROLOGY, V98, P461, DOI 10.1016/0042-6822(79)90569-5; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SAKAI R, 1989, P NATL ACAD SCI USA, V86, P9946, DOI 10.1073/pnas.86.24.9946; SAMID D, 1984, BIOCHEM BIOPH RES CO, V119, P21, DOI 10.1016/0006-291X(84)91612-7; SANTOS E, 1984, FED PROC, V43, P2280; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SELIGER B, 1988, J VIROL, V62, P619, DOI 10.1128/JVI.62.2.619-621.1988; SELIGER B, 1987, J VIROL, V61, P2567, DOI 10.1128/JVI.61.8.2567-2572.1987; SERGIESCU D, 1986, P NATL ACAD SCI USA, V83, P5764, DOI 10.1073/pnas.83.16.5764; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; STODDART JH, 1989, EXP CELL RES, V184, P16; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; VANDAM H, 1989, ONCOGENE, V4, P1207; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; YAMADA H, 1991, J BIOL CHEM, V266, P4002; YANAGIHARA K, 1990, ONCOGENE, V5, P1179; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	85	99	112	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					479	490						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290259				2022-12-25	WOS:A1994MW24800015
J	FUKAMI, K; ENDO, T; IMAMURA, M; TAKENAWA, T				FUKAMI, K; ENDO, T; IMAMURA, M; TAKENAWA, T			ALPHA-ACTININ AND VINCULIN ARE PIP(2)-BINDING PROTEINS INVOLVED IN SIGNALING BY TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; RAT EMBRYO FIBROBLASTS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; GROWTH-FACTOR; PROFILIN; BINDING; PHOSPHORYLATION; DIACYLGLYCEROL; ASSOCIATION; PLATELET	Western blot analysis of Balb/c 3T3 cell lysates by an antibody specific to phosphatidylinositol 4,5-bisphosphate (PIP2) showed that several proteins exist in a PIP2-bound form. Among them, two proteins, 100 and 115 kDa in molecular mass, were detected as PIP2 abundant proteins. These were identified as alpha-actinin and vinculin by their antibodies. In Balb/c 3T3 cells, alpha-actinin in the cytoskeleton contains PIP2, while alpha-actinin in cytosol does not. The levels of PIP2 bound to alpha-aetinin decrease in response to platelet-derived growth factor (PDGF). Similarly, PIP2 bound to vinculin is decreased upon stimulation with PDGF. By immunofluorescent staining, PIP2 was found to be present densely in the central areas around nuclei, microfilament bundles, and focal contacts, where alpha-actinin and vinculin are distributed. PDGF stimulation decreases the intensity of PIP2 staining in these areas. In this paper we suggest that tyrosine kinase-activated phospholipase C hydrolyzes PIP2 bound to alpha-actinin and vinculin, leading to the simultaneous generation of second messengers and reorganization of the cytoskeleton.	UNIV TOKYO,INST MED SCI,DEPT MOLEC ONCOL,MINATO KU,TOKYO 108,JAPAN; CHIBA UNIV,FAC SCI,DEPT BIOL,INAGE KU,CHIBA 263,JAPAN; UNIV TSUKUBA,INST BASIC MED SCI,DEPT PHARMACOL,TSUKUBA,IBARAKI 305,JAPAN	University of Tokyo; Chiba University; University of Tsukuba								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; BURN P, 1985, NATURE, V314, P469, DOI 10.1038/314469a0; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; EBASHI S, 1964, NATURE, V203, P645, DOI 10.1038/203645a0; ENDO T, 1982, BIOCHEM BIOPH RES CO, V107, P1467, DOI 10.1016/S0006-291X(82)80164-2; ENDO T, 1984, J CELL BIOL, V99, P2322, DOI 10.1083/jcb.99.6.2322; FERAMISCO JR, 1980, J CELL BIOL, V86, P608; FUKAMI K, 1988, P NATL ACAD SCI USA, V85, P9057, DOI 10.1073/pnas.85.23.9057; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GENTRY LE, 1984, J VIROL, V51, P539, DOI 10.1128/JVI.51.2.539-546.1984; GOLDSCHMIDTCLERMONT PJ, 1991, CELL, V66, P419, DOI 10.1016/0092-8674(81)90002-7; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; ISENBERG G, 1991, J MUSCLE RES CELL M, V12, P136, DOI 10.1007/BF01774032; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LAZARIDES E, 1975, CELL, V6, P289, DOI 10.1016/0092-8674(75)90180-4; MACHESKY LM, 1990, CELL REGUL, V1, P937, DOI 10.1091/mbc.1.12.937; MALGOLIS B, 1988, CELL, V57, P1101; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MCBRIDE K, 1991, P NATL ACAD SCI USA, V88, P7111, DOI 10.1073/pnas.88.16.7111; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MELLSTROM K, 1983, J MUSCLE RES CELL M, V4, P589, DOI 10.1007/BF00712117; MIYATA H, 1989, J CELL BIOL, V109, P1519, DOI 10.1083/jcb.109.4.1519; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROHRSCHNEIDER LR, 1984, J VIROL, V51, P547, DOI 10.1128/JVI.51.2.547-552.1984; TOKUUE Y, 1991, EXP CELL RES, V197, P158, DOI 10.1016/0014-4827(91)90418-T; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912	41	184	184	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1518	1522						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288618				2022-12-25	WOS:A1994MR22000113
J	KUSTERS, R; BREUKINK, E; GALLUSSER, A; KUHN, A; DEKRUIJFF, B				KUSTERS, R; BREUKINK, E; GALLUSSER, A; KUHN, A; DEKRUIJFF, B			A DUAL ROLE FOR PHOSPHATIDYLGLYCEROL IN PROTEIN TRANSLOCATION ACROSS THE ESCHERICHIA-COLI INNER MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVELY CHARGED PHOSPHOLIPIDS; SIGNAL PEPTIDES; SECA-PROTEIN; ACIDIC PHOSPHOLIPIDS; PLASMA-MEMBRANE; MODEL MEMBRANES; PROCOAT PROTEIN; INITIAL STEPS; PHOE PROTEIN; M13 PROCOAT	The involvement of phosphatidylglycerol in the SecA-independent translocation of M13 procoat in Escherichia coli was demonstrated. Processing of procoat to mature coat protein was retarded when the level of phosphatidylglycerol was reduced. In vitro translocation experiments using inner membrane vesicles isolated from a strain with inducible synthesis of phosphatidylglycerol, showed that translocation of procoat and of a SecA-dependent procoat analog was proportional to the content of phosphatidylglycerol. Moreover, introduction of phosphatidylglycerol by means of a lipid transfer method into phosphatidylglycerol-depleted inner membrane vesicles, efficiently restored procoat translocation. The phosphatidylglycerol dependence in both the SecA-dependent and -independent translocation pathway indicates that phosphatidylglycerol plays a dual role in translocation. We suggest that besides membrane binding of SecA this lipid has a direct interaction with the M13 procoat in translocation across the inner membrane.	UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,DEPT BIOCHEM MEMBRANES,3584 CH UTRECHT,NETHERLANDS; UNIV UTRECHT,INST MOLEC BIOL & MED BIOTECHNOL,3584 CH UTRECHT,NETHERLANDS; UNIV KARLSRUHE,DEPT APPL MICROBIOL,W-7500 KARLSRUHE 1,GERMANY	Utrecht University; Utrecht University; Helmholtz Association; Karlsruhe Institute of Technology			Breukink, Eefjan/I-3039-2016	Breukink, Eefjan/0000-0002-7311-0660				BATENBURG AM, 1988, BIOCHEMISTRY-US, V27, P5678, DOI 10.1021/bi00415a043; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BRIGGS MS, 1985, SCIENCE, V228, P1096, DOI 10.1126/science.3158076; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CAMMACK KA, 1965, BIOCHEM J, V96, P671, DOI 10.1042/bj0960671; DEMEL RA, 1990, BIOCHIM BIOPHYS ACTA, V1027, P155, DOI 10.1016/0005-2736(90)90079-4; DEVRIJE GJ, 1990, MOL MICROBIOL, V4, P143; DEVRIJE T, 1987, BIOCHIM BIOPHYS ACTA, V900, P63, DOI 10.1016/0005-2736(87)90278-1; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FIDELIO GD, 1987, BIOCHEM J, V244, P295, DOI 10.1042/bj2440295; GALLUSSER A, 1990, EMBO J, V9, P2723, DOI 10.1002/j.1460-2075.1990.tb07459.x; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; HIKITA C, 1992, J BIOL CHEM, V267, P12375; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; ITO K, 1980, J BIOL CHEM, V255, P2123; KUHN A, 1986, EMBO J, V5, P3681, DOI 10.1002/j.1460-2075.1986.tb04699.x; KUHN A, 1990, EMBO J, V9, P2385, DOI 10.1002/j.1460-2075.1990.tb07413.x; KUSTERS R, 1992, FEBS LETT, V308, P97, DOI 10.1016/0014-5793(92)81060-Y; KUSTERS R, 1991, J BIOL CHEM, V266, P8659; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PHOENIX DA, 1993, J BIOL CHEM, V268, P17069; PHOENIX DA, 1993, FEBS LETT, V324, P113, DOI 10.1016/0014-5793(93)81543-9; POORTHUIS BJHM, 1983, METHOD ENZYMOL, V98, P592; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; VANDEENEN LLM, 1964, ADV LIPID RES, V2, P167; VANDERGOOT FG, 1993, EUR J BIOCHEM, V213, P217; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; WICKNER W, 1979, ANNU REV BIOCHEM, V48, P23, DOI 10.1146/annurev.bi.48.070179.000323; WOLFE PB, 1985, J BIOL CHEM, V260, P1836	36	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1560	1563						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288623				2022-12-25	WOS:A1994MR22000119
J	MURANTE, RS; HUANG, L; TURCHI, JJ; BAMBARA, RA				MURANTE, RS; HUANG, L; TURCHI, JJ; BAMBARA, RA			THE CALF 5'-EXONUCLEASE TO 3'-EXONUCLEASE IS ALSO AN ENDONUCLEASE WITH BOTH ACTIVITIES DEPENDENT ON PRIMERS ANNEALED UPSTREAM OF THE POINT OF CLEAVAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 DNA-POLYMERASES; SIMIAN VIRUS-40; REPLICATION; EPSILON; INVITRO; STRAND; DELTA	The catalytic activity of the calf thymus 5'- to 3'-exonuclease was measured on substrates consisting of two primers annealed adjacent to each other on a template. Exonucleolytic degradation of the downstream primer is very slow if the primers are separated by a gap of one nucleotide or if no upstream primer is present. When only a nick separates the primers, degradation is rapid. This suggests that the nuclease is designed to work with calf DNA polymerases such that synthesis from an upstream primer creates the favored nuclease substrate. Nuclease action then destroys the substrate, but it is regenerated by further polymerization. This process, termed nick translation, is necessary for both DNA replication and repair. lf the downstream primer has an unannealed 5'-region, that region is removed by an endonuclease activity residing in the same enzyme. Efficient endonuclease action also requires an upstream primer that is annealed such that its 3'-end is directly adjacent to the annealed region of the downstream primer. This reaction is likely to be important for removal of DNA segments that are damaged such that exonuclease cleavage of the damaged site is not possible.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester			Turchi, John J/B-5807-2015	Turchi, John J/0000-0001-5375-2992	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007102, R01GM024441] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32-GM07102, GM24441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HIBINO Y, 1991, BIOCHIM BIOPHYS ACTA, V1088, P305, DOI 10.1016/0167-4781(91)90068-W; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; KELLY RB, 1969, NATURE, V224, P495, DOI 10.1038/224495a0; KORNBERG A, 1991, DNA REPLICATION, P533; LEHMAN IR, 1976, SCIENCE, V193, P963, DOI 10.1126/science.781842; LUNDQUIST RC, 1982, CELL, V31, P53, DOI 10.1016/0092-8674(82)90404-4; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; SAMBROOK J, 1991, MOL CLONING LABORATO; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742	18	110	126	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1191	1196						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288581				2022-12-25	WOS:A1994MR22000067
J	LIN, GF; PEARSON, AE; SCAMURRA, RW; ZHOU, YL; BAARSCH, MJ; WEISS, DJ; MURTAUGH, MP				LIN, GF; PEARSON, AE; SCAMURRA, RW; ZHOU, YL; BAARSCH, MJ; WEISS, DJ; MURTAUGH, MP			REGULATION OF INTERLEUKIN-8 EXPRESSION IN PORCINE ALVEOLAR MACROPHAGES BY BACTERIAL LIPOPOLYSACCHARIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL CHEMOTACTIC FACTOR; TUMOR-NECROSIS-FACTOR; ATTRACTANT ACTIVATION PROTEIN-1; MESSENGER-RNA; GENE-EXPRESSION; BETA-THROMBOGLOBULIN; FACTOR-ALPHA; CYTOKINES; SEQUENCE; CELLS	Interleukin (IL)-8 is a macrophage-derived neutrophil chemotactic factor that plays an important role in the recruitment of neutrophils to inflammatory loci. Hence, expression of IL-8 by alveolar macrophages may be a significant factor in host defense in the lung and in the pathogenesis of pneumonia in swine. To initiate molecular studies of IL-8 regulation in pigs, we cloned IL-8 cDNA and examined the regulation of its mRNA in alveolar macrophages. The porcine IL-8 cDNA consists of 1491 base pairs including a coding region of 309 base pairs. The deduced amino acid sequence was 75 and 81% similar to human and rabbit IL-8, respectively. Resting macrophages contained low levels of IL-8 mRNA, which increased markedly after exposure to bacterial lipopolysaccharide (LPS). LPS induction of IL-8 was direct, not mediated through elevation of tumor necrosis factor or interleukin-1. The effect of LPS on IL-8 expression was dose dependent, and induction was observed at a concentration of 10 pg/ml. IL-8 mRNA expression was detectable within 0.5 h after stimulation with LPS, peaked at 3-6 h at about 30-fold higher levels than in resting cells, and was maintained for 24 h. Secreted IL-8, measured by neutrophil chemotaxis, was induced within 4 h by LPS, and accumulated in the media throughout the 24-h period. The mechanism of induction of IL-8 mRNA appeared to involve transcription and RNA processing. Nuclear run-on analysis showed that the IL-8 gene was actively transcribed in noninduced cells; upon stimulation with LPS, the rate of IL-8 transcription was increased about 4-fold. A single mature mRNA species was detected by primer extension analysis. The half-life of IL-8 mRNA transcripts in aveolar macrophages was approximately 2 h and did not change after LPS stimulation. The ability of LPS to induce IL-8 expression was suppressed by recombinant human IL-4 and dexamethasone in a concentration-dependent manner. These observations indicate that the expression of IL-8 is an early event in the sequelae to bacterial infection in the lung.	UNIV MINNESOTA,COLL VET MED,DEPT VET PATHOBIOL,1971 COMMONWEALTH AVE,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities								BAARSCH MJ, 1991, J IMMUNOL METHODS, V140, P15, DOI 10.1016/0022-1759(91)90121-U; BAGGIOLINI M, 1992, INFLAMMATION BASIC P, P248; BEGG GS, 1978, BIOCHEMISTRY-US, V17, P1739, DOI 10.1021/bi00602a024; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHOI C S, 1991, Animal Biotechnology, V2, P97, DOI 10.1080/10495399109525752; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEUEL TF, 1977, P NATL ACAD SCI USA, V74, P2256, DOI 10.1073/pnas.74.6.2256; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLDSTEIN RA, 1992, INFLAMMATION BASIC P, P1061; GOODMAN RB, 1991, J BIOL CHEM, V266, P8455; GREGORY H, 1988, BIOCHEM BIOPH RES CO, V151, P883, DOI 10.1016/S0006-291X(88)80364-4; HOLT JC, 1986, BIOCHEMISTRY-US, V25, P1988, DOI 10.1021/bi00356a023; HUETHER MJ, 1993, GENE, V129, P285, DOI 10.1016/0378-1119(93)90281-7; IGLESIAS G, 1989, ARCH VIROL, V104, P107, DOI 10.1007/BF01313812; KEITA K, 1991, J LEUKOCYTE BIOL, V50, P287; KOWALSKI J, 1989, MOL CELL BIOL, V9, P1946, DOI 10.1128/MCB.9.5.1946; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEONARD EJ, 1990, J IMMUNOL, V144, P1323; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; MULLER R, 1984, NATURE, V311, P433; NAKAMURA H, 1991, J BIOL CHEM, V266, P19611; NELSON RD, 1975, J IMMUNOL, V115, P1650; RANKIN JA, 1990, J CLIN INVEST, V86, P1556, DOI 10.1172/JCI114875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIMER RP, 1989, ALLERGY PRINCIPLES P, P739; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; STANDIFORD TJ, 1990, J IMMUNOL, V145, P1435; STOKES DC, 1989, J INFECT DIS, V160, P52, DOI 10.1093/infdis/160.1.52; STRIETER RM, 1990, BIOCHEM BIOPH RES CO, V166, P886, DOI 10.1016/0006-291X(90)90893-R; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; SYLVESTER I, 1990, AM REV RESPIR DIS, V141, P683, DOI 10.1164/ajrccm/141.3.683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WALZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755, DOI 10.1016/0006-291X(87)90432-3; WOLPE SD, 1989, P NATL ACAD SCI USA, V86, P612, DOI 10.1073/pnas.86.2.612; YOKOTA T, 1988, IMMUNOL REV, V102, P138; YOSHIMURA T, 1991, J IMMUNOL, V146, P3483; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; ZACHARIAE COC, 1991, J INVEST DERMATOL, V97, P593, DOI 10.1111/1523-1747.ep12481934; ZHOU YL, 1992, MOL IMMUNOL, V29, P965, DOI 10.1016/0161-5890(92)90135-K	47	72	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					77	85						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276881				2022-12-25	WOS:A1994MR21900020
J	LINDQVIST, L; KAISER, R; REEVES, PR; LINDBERG, AA				LINDQVIST, L; KAISER, R; REEVES, PR; LINDBERG, AA			PURIFICATION, CHARACTERIZATION, AND HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY ASSAY OF SALMONELLA GLUCOSE-1-PHOSPHATE CYTIDYLYLTRANSFERASE FROM THE CLONED RFBF GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPHIMURIUM; SEQUENCE	We report the purification and characterization of glucose-1-phosphate cytidylyltransferase, the first of five enzymes committed to biosynthesis of CDP-D-abequose from Salmonella enterica strain LT2. The purification was greatly facilitated by using a cloned rfbF gene encoding this enzyme. Pure enzyme was obtained by 64-fold enrichment in three chromatography steps. The NH2-terminal sequence of the purified enzyme was in agreement with the sequence predicted from the nucleotide sequence of the rfbF gene. The SDS-polyacrylamide gel electrophoresis estimated subunit M(r) of 31,000 agrees well with the M(r) of 29,035 calculated from the amino acid composition deduced from the nucleotide sequence of the rfbF gene. The glucose-1-phosphate cytidylyltransferase catalyzes a reversible bimolecular group transfer reaction and steady-state kinetic measurements, including product inhibition patterns, indicate that this reaction proceeds by a ''ping-pong'' type of mechanism. The K(m) values for CTP, alpha-D-glucose 1-phosphate, CDP-D-glucose, and pyrophosphate are 0.28, 0.64, 0.11, and 1.89 mM, respectively.	KAROLINSKA INST,DEPT CHEM 1,S-10401 STOCKHOLM 60,SWEDEN; UNIV SYDNEY,DEPT MICROBIOL,SYDNEY,NSW 2006,AUSTRALIA	Karolinska Institutet; University of Sydney	LINDQVIST, L (corresponding author), HUDDINGE HOSP,KAROLINSKA INST,DEPT CLIN BACTERIOL,S-14186 HUDDINGE,SWEDEN.		Reeves, Peter R/A-6064-2008	Reeves, Peter R/0000-0003-4479-7974				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMBHATT HN, 1988, J BACTERIOL, V170, P98; Cleland W. W, 1970, ENZYMES, V2, P1; GAREGG PJ, 1988, CARBOHYDRATE CHEM, P500; JIANG XM, 1991, MOL MICROBIOL, V5, P695, DOI 10.1111/j.1365-2958.1991.tb00741.x; MARUMO K, 1992, EUR J BIOCHEM, V204, P539, DOI 10.1111/j.1432-1033.1992.tb16665.x; MAYER RM, 1965, J BIOL CHEM, V240, P1900; NEUHARD J, 1976, J BACTERIOL, V126, P999, DOI 10.1128/JB.126.2.999-1001.1976; NIKAIDO H, 1967, P NATL ACAD SCI USA, V57, P1825, DOI 10.1073/pnas.57.6.1825; Plowman K. M., 1972, ENZYME KINETICS; REEVES PR, 1992, TRENDS GENET, V9, P17; ROMANA LK, 1991, BIOCHEM BIOPH RES CO, V174, P846, DOI 10.1016/0006-291X(91)91495-X; SANDERSON KE, 1983, MICROBIOL REV, V47, P410, DOI 10.1128/MMBR.47.3.410-453.1983; Segel I.H., 1975, ENZYME KINETICS; SHEU KFR, 1978, J BIOL CHEM, V253, P3378; TSUBOI KK, 1969, J BIOL CHEM, V244, P1008; WYK P, 1989, J BACTERIOL, V171, P5687, DOI 10.1128/jb.171.10.5687-5693.1989	17	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					122	126						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276783				2022-12-25	WOS:A1994MR21900026
J	MALLENDER, WD; VOSS, EW				MALLENDER, WD; VOSS, EW			CONSTRUCTION, EXPRESSION, AND ACTIVITY OF A BIVALENT BISPECIFIC SINGLE-CHAIN ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-SCATTERING; ESCHERICHIA-COLI; FLUORESCYL ANTIBODIES; TRICHODERMA-REESEI; IDIOTYPE FAMILY; IGG ANTIBODIES; STRANDED-DNA; FAB COMPLEX; MAB 4-4-20; PROTEINS	This report describes the design, construction, and expression of a bivalent bispecific single-chain antibody (SCA) protein in Escherichia coli. The bispecificity of the bivalent protein was based on two previously constructed monovalent single-chain antibody molecules possessing distinct specificities, SCA 4-4-20 (anti-fluorescein) and SCA 04-01 (anti-single-stranded DNA). A flexible linker, modeled after a secreted fungal cellulase protein, was incorporated as the interdomain linker covalently joining the two active sites. Bivalent bispecific SCA protein that accumulated in bacteria as insoluble inclusion bodies was harvested, denatured, refolded, and affinity-purified in vitro. Affinity-purified bivalent bispecific SCA showed nearly identical ligand binding properties at each site relative to the individual monovalent single-chain antibody prototype molecules. In both solid and solution phase binding assays, the bivalent bispecific single-chain antibody simultaneously bound both ligands (fluorescein and (dT)6). Construction of a model bivalent bispecific molecule provides a foundation for future assembly of similar molecules designed to identify parameters involved in enhanced binding of antibodies due to avidity and dual specificity.	UNIV ILLINOIS, DEPT MICROBIOL, 131 BURRILL HALL, 407 S GOODWIN AVE, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign								ABUJA PM, 1988, EUR BIOPHYS J BIOPHY, V15, P339, DOI 10.1007/BF00254721; BALLARD DW, 1984, J BIOL CHEM, V259, P3492; BATES RM, 1985, MOL IMMUNOL, V22, P871, DOI 10.1016/0161-5890(85)90072-0; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BEDZYK WD, 1990, J BIOL CHEM, V265, P1861; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; CHEONG HS, 1990, BIOCHEM BIOPH RES CO, V173, P795; CONDRA JH, 1990, J BIOL CHEM, V265, P2292; CROTHERS DM, 1972, IMMUNOCHEMISTRY, V9, P341, DOI 10.1016/0019-2791(72)90097-3; CUMBER AJ, 1992, J IMMUNOL, V149, P120; DENZIN LK, 1992, J BIOL CHEM, V267, P8925; DENZIN LK, 1991, J BIOL CHEM, V266, P14095; DENZIN LK, IN PRESS MOL IMMUNOL; DUNCANEL F, 1993, BIOTECHNOLOGY, V11, P601; FREUND C, 1993, FEBS LETT, V320, P97, DOI 10.1016/0014-5793(93)80070-B; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HERRON JN, 1984, FLUORESCEIN HAPTEN I, P49; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; HUSTON JS, 1991, METHOD ENZYMOL, V203, P46; KOSTELNY SA, 1992, J IMMUNOL, V148, P1547; KRANZ DM, 1982, J BIOL CHEM, V257, P6987; KRANZ DM, 1981, MOL IMMUNOL, V18, P889, DOI 10.1016/0161-5890(81)90012-2; LACY MJ, 1989, J IMMUNOL METHODS, V116, P87, DOI 10.1016/0022-1759(89)90316-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RL, 1982, BIOCHEMISTRY-US, V21, P2600, DOI 10.1021/bi00540a004; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MACLEAN JA, 1993, J IMMUNOL, V150, P1619; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; PACK P, 1992, BIOCHEMISTRY-US, V31, P1597; RUMBLEY CA, 1993, J BIOL CHEM, V268, P13667; SCANDELLA D, 1985, J CELL BIOCH B, V9, P203; SCHMUCK M, 1986, BIOTECHNOL LETT, V8, P397, DOI 10.1007/BF01026739; SMITH RA, 1983, APPL ENVIRON MICROB, V45, P586, DOI 10.1128/AEM.45.2.586-590.1983; SNIDER DP, 1992, J IMMUNOL, V148, P1163; STEVENS SY, 1993, J AM CHEM SOC, V115, P1585, DOI 10.1021/ja00057a059; SWINDLEHURST CA, 1991, BIOPHYS J, V59, P619, DOI 10.1016/S0006-3495(91)82277-9; TAKKINEN K, 1991, PROTEIN ENG, V4, P837, DOI 10.1093/protein/4.7.837; TETIN SY, 1993, BIOCHEMISTRY-US, V32, P9011, DOI 10.1021/bi00086a005; TETIN SY, 1992, BIOCHEMISTRY-US, V31, P12029, DOI 10.1021/bi00163a010; VOSS EW, 1989, FLUORESCENT BIOMOLOC, P249; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WATT RM, 1977, IMMUNOCHEMISTRY, V14, P533, DOI 10.1016/0019-2791(77)90308-1; WATT RM, 1978, IMMUNOCHEMISTRY, V15, P875, DOI 10.1016/0161-5890(78)90121-9; WEIDNER KM, 1992, J BIOL CHEM, V267, P10281; WEIDNER KM, 1993, MOL IMMUNOL, V30, P1003, DOI 10.1016/0161-5890(93)90125-U; WEIDNER KM, 1991, J BIOL CHEM, V266, P2513; WELS W, 1992, CANCER RES, V52, P6310; WU S, 1993, J IMMUNOL, V150, P2211; YOKOTA T, 1992, CANCER RES, V52, P3402	53	102	164	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					199	206						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276795				2022-12-25	WOS:A1994MR21900038
J	NUTTLEY, WM; BRADE, AM; EITZEN, GA; VEENHUIS, M; AITCHISON, JD; SZILARD, RK; GLOVER, JR; RACHUBINSKI, RA				NUTTLEY, WM; BRADE, AM; EITZEN, GA; VEENHUIS, M; AITCHISON, JD; SZILARD, RK; GLOVER, JR; RACHUBINSKI, RA			PAY4, A GENE REQUIRED FOR PEROXISOME ASSEMBLY IN THE YEAST YARROWIA-LIPOLYTICA, ENCODES A NOVEL MEMBER OF A FAMILY OF PUTATIVE ATPASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROBODY TARGETING SIGNAL; AMINO-ACID-SEQUENCE; SACCHAROMYCES-CEREVISIAE; CANDIDA-TROPICALIS; HANSENULA-POLYMORPHA; ZELLWEGER SYNDROME; DEFICIENT MUTANTS; PICHIA-PASTORIS; PROTEIN IMPORT; RAT-LIVER	PAY genes are required for peroxisome assembly in the yeast Yarrowia lipolytica. Here we characterize one mutant, pay4, and describe the cloning and sequencing of the PAY4 gene. The pay4 mutant shows no identifiable peroxisomes by biochemical and morphological criteria. The complementing PAY4 gene encodes a polypeptide, Pay4p, 1025 amino acids in length and having a predicted molecular mass of 112,258 Da. The predicted Pay4p sequence contains two putative ATP-binding domains and shows structural relationships to other potential ATP-binding proteins involved in biological processes as diverse as peroxisome biogenesis, vesicle-mediated protein transport, cell cycle control, and transcriptional regulation. These proteins all share a highly conserved stretch of approximately 175 amino acids that contains a consensus sequence for ATP binding. Pay4p shows sequence conservation with Pas1p and Pas5p, putative ATPases required for peroxisomal assembly in the yeasts Saccharomyces cerevisiae and Pichia pastoris, respectively. Pay4p, Pas1p, and Pas5p are presumably related members of a family of putative ATPases involved in peroxisome biogenesis. Pay4p is synthesized in low amounts in Y lipolytica cells grown in glucose, and there is a rapid and pronounced increase in the levels of Pay4p upon transfer of the cells to a medium containing oleic acid as the sole carbon source.	MCMASTER UNIV,DEPT BIOCHEM,1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA; UNIV GRONINGEN,ELECTRON MICROSCOPY LAB,9750 AA HAREN,NETHERLANDS	McMaster University; University of Groningen			Eitzen, Gary/D-3682-2009					AITCHISON JD, 1992, MOL MICROBIOL, V6, P3455, DOI 10.1111/j.1365-2958.1992.tb01780.x; AITCHISON JD, 1992, YEAST, V8, P721, DOI 10.1002/yea.320080905; AITCHISON JD, 1991, J BIOL CHEM, V266, P23197; ALEXSON SEH, 1985, J CELL BIOL, V101, P294, DOI 10.1083/jcb.101.1.294; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; BLATTNER J, 1992, J CELL BIOL, V119, P1129, DOI 10.1083/jcb.119.5.1129; BORST P, 1989, BIOCHIM BIOPHYS ACTA, V1008, P1, DOI 10.1016/0167-4781(89)90163-2; BORST P, 1986, BIOCHIM BIOPHYS ACTA, V866, P179, DOI 10.1016/0167-4781(86)90044-8; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CIGAN AM, 1987, GENE, V59, P1; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; COHEN G, 1988, EUR J BIOCHEM, V176, P159; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; CREGG JM, 1990, YEAST, V6, P87, DOI 10.1002/yea.320060202; DAVIDOW LS, 1987, J BACTERIOL, V169, P4621, DOI 10.1128/jb.169.10.4621-4629.1987; DAVIDOW LS, 1985, CURR GENET, V10, P39, DOI 10.1007/BF00418492; DEHOOP MJ, 1992, BIOCHEM J, V286, P657, DOI 10.1042/bj2860657; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; FUJIKI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7127, DOI 10.1073/pnas.81.22.7127; FUJIKI Y, 1986, J BIOL CHEM, V261, P5787; GAILLARDIN CM, 1973, ARCH MIKROBIOL, V92, P69, DOI 10.1007/BF00409513; GLEESON MA, 1988, YEAST, V4, P293, DOI 10.1002/yea.320040407; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; GOULD SJ, 1992, YEAST, V8, P613, DOI 10.1002/yea.320080805; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; HARTIG A, 1986, EUR J BIOCHEM, V160, P487, DOI 10.1111/j.1432-1033.1986.tb10065.x; HENIKOFF S, 1984, MOL CELL BIOL, V4, P1515, DOI 10.1128/MCB.4.8.1515; HESLOT H, 1992, MOL BIOL GENETIC ENG, P118; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; KAMIRYO T, 1984, MOL CELL BIOL, V4, P2136, DOI 10.1128/MCB.4.10.2136; KAMIRYO T, 1982, J BACTERIOL, V152, P269; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; KOTTIG H, 1991, MOL GEN GENET, V232, P423; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LIU H, 1992, J BACTERIOL, V174, P4943, DOI 10.1128/JB.174.15.4943-4951.1992; NEEDLEMAN RB, 1975, ANAL BIOCHEM, V64, P545, DOI 10.1016/0003-2697(75)90466-2; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; NUTTLEY WM, 1993, YEAST, V9, P507, DOI 10.1002/yea.320090506; NUTTLEY WM, 1990, J CELL SCI, V95, P463; OSUMI T, 1979, BIOCHEM BIOPH RES CO, V89, P580, DOI 10.1016/0006-291X(79)90669-7; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; SANGER F, 1977, P NATL ACAD SCI USA, V83, P6156; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHUTGENS RBH, 1986, EUR J PEDIATR, V144, P430, DOI 10.1007/BF00441734; SUBRAMANI S, 1992, J MEMBRANE BIOL, V125, P99; SUTTON A, 1985, MOL CELL BIOL, V5, P2770, DOI 10.1128/MCB.5.10.2770; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANDERLEIJ I, 1992, J CELL BIOL, V119, P153, DOI 10.1083/jcb.119.1.153; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATERHAM HR, 1992, YEAST, V8, P961, DOI 10.1002/yea.320081106; WIEBELL FF, 1992, NATURE, V359, P355; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; XUAN JW, 1990, MOL CELL BIOL, V10, P4795, DOI 10.1128/MCB.10.9.4795; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220; ZOELLER RA, 1989, J BIOL CHEM, V264, P21872	65	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					556	566						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276851				2022-12-25	WOS:A1994MR21900089
J	BENNETT, SE; SCHIMERLIK, MI; MOSBAUGH, DW				BENNETT, SE; SCHIMERLIK, MI; MOSBAUGH, DW			KINETICS OF THE URACIL-DNA GLYCOSYLASE INHIBITOR PROTEIN ASSOCIATION - UNG INTERACTION WITH UGI, NUCLEIC-ACIDS, AND URACIL COMPOUNDS .5.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACILLUS-SUBTILIS; EXCISION REPAIR; N-GLYCOSIDASE; RAT-LIVER; PURIFICATION; BACTERIOPHAGE-PBS2; SEQUENCE; IDENTIFICATION; OVERPRODUCTION	The bacteriophage PBS2 uracil-DNA glycosylase inhibitor (Ugi) inactivates Escherichia coli uracil-DNA glycosylase (Ung) by forming an Ung.Ugi protein complex with 1:1 stoichiometry. Stability of the Ung.Ugi complex was demonstrated by the inability of free Ugi to exchange with Ugi bound in preformed complex. Ung was reacted with fluorescein 5-isothiocyanate to produce fluorescent-Ung (F-Ung), which retained full uracil-DNA glycosylase activity and susceptibility to Ugi inactivation. Addition of Ugi to F-Ung under steady-state conditions resulted in saturable (15%) fluorescence quenching at a F-Ung.Ugi ratio of 1:1.4. Dissociation constants determined for the F-Ung interaction with M13 DNA, uracil-containing DNA, and poly(U) equaled 600, 220, and 190 muM, respectively. While F-Ung associated with nucleic acid polymers was able to bind Ugi efficiently, F-Ung bound in the F-Ung.Ugi complex could no longer effectively bind nucleic acid. Stopped-flow kinetic analysis suggested the F-Ung/Ugi association was described by a two-step mechanism. The first step entailed a rapid pre-equilibrium distinguished by the dissociation constant K(d) = 1.3 muM. The second step led irreversibly to the formation of the final complex and was characterized by the rate constant k = 195 s-1. We infer Ugi inactivates Ung through the formation of an exceptionally stable protein-protein complex.	OREGON STATE UNIV,DEPT AGR CHEM,CORVALLIS,OR 97331; OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331; OREGON STATE UNIV,CTR ENVIRONM HLTH SCI,CORVALLIS,OR 97331	Oregon State University; Oregon State University; Oregon State University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032823] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [GM32823] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT SE, 1992, J BIOL CHEM, V267, P22512; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONE R, 1977, BIOCHEMISTRY-US, V16, P3194, DOI 10.1021/bi00633a024; CROSBY B, 1981, NUCLEIC ACIDS RES, V9, P5797, DOI 10.1093/nar/9.21.5797; DOMENA JD, 1985, BIOCHEMISTRY-US, V24, P7320, DOI 10.1021/bi00346a045; DOMENA JD, 1988, BIOCHEMISTRY-US, V27, P6742, DOI 10.1021/bi00418a015; DUDLEY B, 1992, J BIOL CHEM, V267, P11964; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; DUNCAN BK, 1984, GENE, V28, P211, DOI 10.1016/0378-1119(84)90258-0; FRANKLIN WA, 1988, EMBO J, V7, P3617, DOI 10.1002/j.1460-2075.1988.tb03240.x; FRIEDBERG EC, 1975, J VIROL, V16, P315, DOI 10.1128/JVI.16.2.315-321.1975; Haugland R. P., 1983, EXCITED STATES BIOPO, P29; HAUGLAND RP, 1992, HDB FLUORESCENT PROB, P22; KARRAN P, 1981, BIOCHEMISTRY-US, V20, P6092, DOI 10.1021/bi00524a027; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL T, 1977, J BIOL CHEM, V252, P3286; LINN S, 1981, CHROMOSOME DAMAGE RE, P97; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; SAKUMI K, 1990, MUTAT RES, V236, P161, DOI 10.1016/0921-8777(90)90003-N; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; TIMMER RT, 1989, THESIS U TEXAS; TYE BK, 1978, P NATL ACAD SCI USA, V75, P233, DOI 10.1073/pnas.75.1.233; TYE BK, 1977, J MOL BIOL, V117, P293, DOI 10.1016/0022-2836(77)90128-0; VARSHNEY U, 1988, J BIOL CHEM, V263, P7776; VARSHNEY U, 1991, BIOCHEMISTRY-US, V30, P4055, DOI 10.1021/bi00230a033; WANG Z, 1989, J BIOL CHEM, V264, P1163; WANG ZG, 1988, J BACTERIOL, V170, P1082, DOI 10.1128/jb.170.3.1082-1091.1988; WANG ZG, 1991, GENE, V99, P31; WITTWER CU, 1989, BIOCHEMISTRY-US, V28, P780, DOI 10.1021/bi00428a055; WORRAD DM, 1988, J VIROL, V62, P4774, DOI 10.1128/JVI.62.12.4774-4777.1988	31	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26879	26885						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262921				2022-12-25	WOS:A1993MM26200011
J	MONTERO, M; GARCIASANCHO, J; ALVAREZ, J				MONTERO, M; GARCIASANCHO, J; ALVAREZ, J			INHIBITION OF THE CALCIUM STORE-OPERATED CALCIUM-ENTRY PATHWAY BY CHEMOTACTIC PEPTIDE AND BY PHORBOL ESTER DEVELOPS GRADUALLY AND INDEPENDENTLY ALONG DIFFERENTIATION OF HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMYELOCYTIC LEUKEMIA-CELLS; PROTEIN-KINASE-C; N-FORMYLMETHIONYL-LEUCYLPHENYLALANINE; HUMAN-NEUTROPHILS; POLYMORPHONUCLEAR LEUKOCYTES; TERMINAL DIFFERENTIATION; PLASMA-MEMBRANE; PHOSPHOLIPASE-D; CA-2+ INFLUX; ACTIVATION	N-Formyl-methionyl-leucyl-phenylalanine (fMLP) inhibited transiently the entry of Ca2+ and Mn2+ induced by emptying with thapsigargin the Ca2+ stores of HL60 cells differentiated toward granulocytes. Phorbol 12,13-dibutyrate (PDB) produced a permanent inhibition of this store-operated Ca2+ entry pathway (SOCP), suggesting that inhibition was due to protein phosphorylation mediated by protein kinase C (PKC). Inhibition by PDB was prevented by the PKC inhibitors staurosporin and chelerythrine. Inhibition by fMLP was prevented by chelerythrine but only partially by staurosporin. The characteristics of the inhibition were similar to those reported in human neutrophils (Montero, M., Alvarez, J., and Garcia-Sancho, J. (1993) J. Biol. Chem. 268, 13055-13061). Neither fMLP nor PDB inhibited significantly SOCP in undifferentiated HL60 cells. Single-cell [Ca2+]i measurements at different stages of differentiation showed that inhibition by fMLP and PDB developed independently, suggesting different inhibitory mechanisms. The simplest explanation would be that inhibition by fMLP takes place through activation of a protein kinase distinct from PKC and that the PDB-activated PKC isoform necessary to phosphorylate and inhibit SOCP is expressed only along differentiation. Additionally, inhibition by both fMLP and PDB developed gradually. At intermediate stages of differentiation, PDB was able to produce a partial and maintained inhibition and fMLP a partial and short-lived inhibition of SOCP.	UNIV VALLADOLID,FAC MED,DEPT BIOQUIM & BIOL MOLEC & FISIOL,E-47005 VALLADOLID,SPAIN	Universidad de Valladolid			Montero, Mayte/K-8212-2014; Alvarez, Javier/K-8210-2014; Garcia-Sancho, Javier/K-2975-2014	Montero, Mayte/0000-0001-7702-6653; Alvarez, Javier/0000-0003-0636-5521; Garcia-Sancho, Javier/0000-0003-4573-7930				ALONSOTORRE SR, 1993, BIOCHEM J, V289, P761, DOI 10.1042/bj2890761; ALVAREZ J, 1989, EUR J BIOCHEM, V183, P709, DOI 10.1111/j.1432-1033.1989.tb21102.x; ANDERSSON T, 1986, MOL PHARMACOL, V30, P437; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHABOT MC, 1992, BIOCHEM J, V286, P693, DOI 10.1042/bj2860693; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; DING JB, 1993, J BIOL CHEM, V268, P5234; FODER B, 1989, CELL CALCIUM, V10, P477, DOI 10.1016/0143-4160(89)90025-0; GELAS P, 1992, BIOCHEM J, V287, P67, DOI 10.1042/bj2870067; GLENNON MC, 1992, J BIOL CHEM, V267, P8230; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAINES KA, 1991, J CELL BIOL, V114, P433, DOI 10.1083/jcb.114.3.433; HELFMAN DM, 1983, CANCER RES, V43, P2955; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HEYWORTH PG, 1986, BIOCHEM J, V239, P723, DOI 10.1042/bj2390723; HUBERMAN E, 1979, P NATL ACAD SCI USA, V76, P1293, DOI 10.1073/pnas.76.3.1293; KESSELS GCR, 1991, J BIOL CHEM, V266, P23152; KORCHAK HM, 1984, J BIOL CHEM, V259, P4070; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MONTERO M, 1991, BIOCHEM J, V277, P73, DOI 10.1042/bj2770073; MONTERO M, 1992, BIOCHEM J, V288, P519, DOI 10.1042/bj2880519; MONTERO M, 1993, J BIOL CHEM, V268, P13055; NAKADATE T, 1988, BIOCHEM PHARMACOL, V37, P1541, DOI 10.1016/0006-2952(88)90016-0; NATH J, 1989, J BIOL CHEM, V264, P848; NIEDEL J, 1980, P NATL ACAD SCI-BIOL, V77, P1000, DOI 10.1073/pnas.77.2.1000; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; OHTSUKA T, 1990, J BIOL CHEM, V265, P15418; PERIANIN A, 1989, J BIOL CHEM, V264, P1005; POZZAN T, 1983, SCIENCE, V221, P1413, DOI 10.1126/science.6310757; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; REIBMAN J, 1988, J BIOL CHEM, V263, P6322; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THOMPSON HL, 1993, BIOCHEM J, V290, P483, DOI 10.1042/bj2900483	35	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26911	26919						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262925				2022-12-25	WOS:A1993MM26200015
J	TAKASAWA, S; TOHGO, A; NOGUCHI, N; KOGUMA, T; NATA, K; SUGIMOTO, T; YONEKURA, H; OKAMOTO, H				TAKASAWA, S; TOHGO, A; NOGUCHI, N; KOGUMA, T; NATA, K; SUGIMOTO, T; YONEKURA, H; OKAMOTO, H			SYNTHESIS AND HYDROLYSIS OF CYCLIC ADP-RIBOSE BY HUMAN-LEUKOCYTE ANTIGEN CD38 AND INHIBITION OF THE HYDROLYSIS BY ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PANCREATIC BETA-CELLS; INSULIN-SECRETION; GLUCOSE; EXPRESSION; CHANNELS; ENZYME; GENE; DIFFERENTIATION; PHOSPHATE; CYCLASE	Cyclic ADP-ribose (cADPR) has been recently shown to be generated in pancreatic beta-cells by glucose stimulation, serving as a second messenger for Ca2+ mobilization in the endoplasmic reticulum in the process of insulin secretion (Takasawa, S., Nata, K., Yonekura, H., and Okamoto, H. (1993) Science 259, 370-373). In the present study, we isolated a cDNA for CD38, which has been reported to be a human leukocyte antigen, from a human insulinoma and expressed the cDNA in COS-7 cells. CD38 expression was observed in the plasma membrane and the microsome fractions of the COS-7 cells. When we incubated the plasma membrane fraction with NAD+ and analyzed the reaction products by high pressure liquid chromatography, the formation of cADPR was observed in addition to the ADP-ribose (ADPR) formation. When the plasma membrane fraction was incubated with cADPR, cADPR was converted to ADPR stoichiometrically. These results suggest that CD38 has both cADPR-forming and -hydrolyzing activities. Moreover, we found that ATP (2-10 mM), generated in the glucose metabolism in beta-cells, inhibited the cADPR-hydrolyzing activity, resulting in the increased formation of cADPR. These findings indicate a role for CD38 in the synthesis and hydrolysis of cADPR in the process of insulin secretion in pancreatic beta-cells.	TOHOKU UNIV,SCH MED,DEPT BIOCHEM,2-1 SEIRYO MACHI,AOBA KU,SENDAI,MIYAGI 980,JAPAN	Tohoku University				Takasawa, Shin/0000-0002-4066-0199				ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; ASHCROFT SJ, 1973, BIOCHEM J, V132, P223, DOI 10.1042/bj1320223; ASHCROFT SJH, 1978, BIOCHIM BIOPHYS ACTA, V538, P334, DOI 10.1016/0304-4165(78)90361-6; BUKOWIECKI L, 1979, BIOCHIM BIOPHYS ACTA, V583, P370, DOI 10.1016/0304-4165(79)90461-6; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; CORKEY BE, 1988, J BIOL CHEM, V263, P4247; DALBECCO R, 1954, J EXP MED, V99, P167; GALIONE A, 1993, SCIENCE, V259, P325, DOI 10.1126/science.8380506; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; HUTTON JC, 1980, DIABETOLOGIA, V18, P395; INOUE C, 1987, P NATL ACAD SCI USA, V84, P6659, DOI 10.1073/pnas.84.19.6659; ITOH N, 1980, NATURE, V283, P100, DOI 10.1038/283100a0; ITOH N, 1983, NATURE, V304, P547, DOI 10.1038/304547a0; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KATO I, 1990, FEBS LETT, V269, P319, DOI 10.1016/0014-5793(90)81184-P; KAWAZU S, 1980, N-S ARCH PHARMACOL, V312, P277, DOI 10.1007/BF00499158; KITAGAWA M, 1991, FEBS LETT, V283, P210, DOI 10.1016/0014-5793(91)80590-Y; KNAPP W, 1989, TISSUE ANTIGENS, V33, P123; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1993, BIOCHEM BIOPH RES CO, V191, P639, DOI 10.1006/bbrc.1993.1265; MATSCHINSKY FM, 1986, J BIOL CHEM, V261, P14057; OKAMOTO H, 1993, DIABETES, V42, pA76; Okamoto H., 1992, 1 C INT UN BIOCH MOL, P218; Okamoto H., 1990, MOL BIOL ISLETS LANG; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; TAKASAWA S, 1986, DIABETES, V35, P1178, DOI 10.2337/diabetes.35.10.1178; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; UNNO M, 1993, J BIOL CHEM, V268, P15974; WATANABE T, 1990, J BIOL CHEM, V265, P7432	32	263	274	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26052	26054						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253715				2022-12-25	WOS:A1993MK42500006
J	WALSETH, TF; AARHUS, R; KERR, JA; LEE, HC				WALSETH, TF; AARHUS, R; KERR, JA; LEE, HC			IDENTIFICATION OF CYCLIC ADP-RIBOSE-BINDING PROTEINS BY PHOTOAFFINITY-LABELING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM RELEASE CHANNEL; MUSCLE SARCOPLASMIC-RETICULUM; SEA-URCHIN EGGS; RYANODINE RECEPTOR; CA-2+ RELEASE; INOSITOL TRISPHOSPHATE; MOLECULAR-CLONING; METABOLITE; NAD+; CDNA	We have synthesized 8-azido-cyclic ADP-ribose (8N3-cADPR) and [P-32]8-azido-cyclic ADP-ribose ([P-32]8N3-cADPR) in order to characterize cyclic ADP-ribose(cADPR) binding sites in sea urchin egg homogenates. 8N3-cADPR was an antagonist of cADPR since it did not induce Ca2+ release from egg microsomes but did inhibit the ability of cADPR to do so. The effect of 8N3-cADPR was reversible and could be overcome by high concentrations of cADPR, suggesting that both were acting on the same site. This was supported by the fact that 9N3-cADPR effectively competed for [P-32]CADPR binding to microsomes. Reciprocally, binding of [P-32]8N3-CADPR could also be selectively displaced by cADPR and 8N3-cADPR, but not by ADP-ribose. These results indicate that 8N3-cADPR binds specifically to the cADPR-binding sites and inhibits cADPR from releasing Ca2+. Photolysis of microsomes preincubated with [P-32]8N3-CADPR resulted in specific labeling of proteins of 140 and 100 kDa, which could be prevented by 8N3-cADPR or nanomolar concentrations of cADPR, but not by micromolar concentrations of ADP-ribose, AMP, ADP, ATP, cyclic AMP or inositol 1,4,5-trisphosphate. Caffeine, an agonist of Ca2+-induced Ca2+ release, preferentially inhibited the labeling of the 100 kDa as compared to the 140-kDa protein. These results suggest that cADPR may not interact directly with the ryanodine receptor, but may instead, exert its effect through intermediate proteins.	UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	WALSETH, TF (corresponding author), UNIV MINNESOTA,DEPT PHARMACOL,3-247 MILLARD HALL,MINNEAPOLIS,MN 55455, USA.		Lee, Hon Cheung/C-4329-2009; Walseth, Timothy F/F-9518-2010	Walseth, Timothy F/0000-0003-2558-7859	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA008131] Funding Source: NIH RePORTER; NICHD NIH HHS [HD17484] Funding Source: Medline; NIDA NIH HHS [DA08131] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AXELSON JT, 1981, ANAL BIOCHEM, V116, P357, DOI 10.1016/0003-2697(81)90371-7; CARTWRIGHT IL, 1976, NUCLEIC ACIDS RES, V3, P2331, DOI 10.1093/nar/3.9.2331; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GALIONE A, 1992, TRENDS PHARMACOL SCI, V13, P304, DOI 10.1016/0165-6147(92)90096-O; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HALEY B, 1976, METHOD ENZYMOL, V46, P339; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, BIOCHIM BIOPHYS ACTA, V1164, P68, DOI 10.1016/0167-4838(93)90113-6; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1993, J BIOL CHEM, V268, P293; LEE HC, 1991, J BIOL CHEM, V266, P2276; MARIASH CN, 1982, ANAL BIOCHEM, V121, P388, DOI 10.1016/0003-2697(82)90498-5; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OTSU K, 1990, J BIOL CHEM, V265, P13472; PRESCOTT M, 1990, ANAL BIOCHEM, V184, P330, DOI 10.1016/0003-2697(90)90690-B; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1993, FEBS LETT, V322, P105, DOI 10.1016/0014-5793(93)81547-D; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; WANG JX, 1992, NATURE, V359, P739, DOI 10.1038/359739a0; ZAIDI NF, 1989, J BIOL CHEM, V264, P21737; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	36	100	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26686	26691						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253802				2022-12-25	WOS:A1993MK42500098
J	WENG, SA; SPIRO, RG				WENG, SA; SPIRO, RG			DEMONSTRATION THAT A KIFUNENSINE-RESISTANT ALPHA-MANNOSIDASE WITH A UNIQUE PROCESSING ACTION ON N-LINKED OLIGOSACCHARIDES OCCURS IN RAT-LIVER ENDOPLASMIC-RETICULUM AND VARIOUS CULTURED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIMMING MAN9-MANNOSIDASE; GLYCOPROTEIN-BIOSYNTHESIS; PURIFICATION; PROTEIN; RECEPTOR; COMPLEX; ENZYME; SLICES	A novel alpha-mannosidase has been identified in rat liver endoplasmic reticulum (ER) which at neutral pH processes the Man9GlcNAc oligosaccharide of glycoproteins by specifically cleaving the terminal mannose residue of the alpha1,6-linked chain to yield Man8GlcNAc, isomer C. This enzyme accounted for about half of the total ER a-mannosidase activity and was fully active at the concentration (0.25 muM) of kifunensine (KIF) completely inhibitory to the action of the ER enzyme which by removing the terminal sugar of the middle chain converts Man9GlcNAc to Man8GlcNAc isomer B; both ER enzymes, however, were inhibited in a similar manner by 1-deoxymannojirimycin (IC50 = 0.2 mM) and their action could not be distinguished with this agent. The KIF-resistant mannosidase which functioned optimally in the presence of 0.1-0.5% Triton X-100 did not show the high susceptibility to EDTA demonstrated by the KIF-sensitive enzyme and unlike the latter had the capacity to hydrolyze p-nitrophenyl-alpha-D-mannoside (K(m) = 0.45 mM); it had no specific cation requirements, but its activity was greatly reduced in the presence of Zn2+. In isolated ER membranes as well as in intact carbonyl cyanide m-chlorophenylhydrazone-treated cells, the processing pattern was substantially different in the presence of KIF than in its absence; while in the latter instance Man9GlcNAc was readily converted to Man63GlcNAc, the KIF-resistant enzyme was limited in its capacity to go beyond Man8GlcNAc. The KIF-resistant alpha-mannosidase was found in substantial amounts in all cell lines examined (HL-60, BW5147.3, MOLT-4, K-562, HepG2, Chinese hamster ovary, F-9, Madin-Darby canine kidney, FRTL-5). The finding that mannose removal from N-linked oligosaccharides can be initiated in two distinctive manners substantially broadens our concept of the processing events which can occur before a glycoprotein reaches the Golgi complex or to which ER resident molecules can be exposed.	JOSLIN DIABET CTR,ELLIOTT P JOSLIN RES LAB,1 JOSLIN PL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT BIOL CHEM,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017477] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 17477] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANUMULA KR, 1983, J BIOL CHEM, V258, P5274; BISCHOFF J, 1983, J BIOL CHEM, V258, P7907; BISCHOFF J, 1984, BIOCHEM BIOPH RES CO, V125, P324, DOI 10.1016/S0006-291X(84)80371-X; BISCHOFF J, 1986, J BIOL CHEM, V261, P4768; DePierre J., 1976, BIOCH ANAL MEMBRANES, P79; ELBEIN AD, 1990, J BIOL CHEM, V265, P15599; GODELAIN ED, 1981, J BIOL CHEM, V256, P10161; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; HASE S, 1987, ANAL BIOCHEM, V72, P248; HICKMAN S, 1984, J CELL BIOL, V98, P407, DOI 10.1083/jcb.98.2.407; HIRAIZUMI S, 1993, J BIOL CHEM, V268, P9927; KABCENELL AK, 1985, J CELL BIOL, V101, P1270, DOI 10.1083/jcb.101.4.1270; KAYAKIRI H, 1989, J ORG CHEM, V54, P4015, DOI 10.1021/jo00278a003; KEDERSHA NL, 1985, BIOCHEMISTRY-US, V24, P5952, DOI 10.1021/bi00342a040; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LEWIS MJ, 1985, J BIOL CHEM, V260, P6926; LISCUM L, 1983, P NATL ACAD SCI-BIOL, V80, P7165, DOI 10.1073/pnas.80.23.7165; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RIZZOLO LJ, 1988, J BIOL CHEM, V263, P9520; ROSENFELD MG, 1984, J CELL BIOL, V99, P1076, DOI 10.1083/jcb.99.3.1076; ROTH J, 1990, EUR J CELL BIOL, V53, P131; SAJI M, 1992, ENDOCRINOLOGY, V130, P520, DOI 10.1210/en.130.1.520; SCHWEDEN J, 1989, BIOCHEM J, V264, P347, DOI 10.1042/bj2640347; SCHWEDEN J, 1986, EUR J BIOCHEM, V157, P563, DOI 10.1111/j.1432-1033.1986.tb09703.x; SPIRO MJ, 1985, J BIOL CHEM, V260, P5808; SPIRO MJ, 1976, J BIOL CHEM, V251, P6400; TARTAKOFF AM, 1977, J EXP MED, V146, P1332, DOI 10.1084/jem.146.5.1332; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227; VARKI A, 1983, J BIOL CHEM, V258, P2808	33	91	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25656	25663						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245001				2022-12-25	WOS:A1993MK10000056
J	MILNER, AE; GRAND, RJA; WATERS, CM; GREGORY, CD				MILNER, AE; GRAND, RJA; WATERS, CM; GREGORY, CD			APOPTOSIS IN BURKITT-LYMPHOMA CELLS IS DRIVEN BY C-MYC	ONCOGENE			English	Article							B-CELLS; GERMINAL-CENTERS; TRANSGENIC MICE; HEMATOPOIETIC-CELLS; PROTEIN EXPRESSION; GENE-EXPRESSION; MESSENGER-RNA; DAUDI CELLS; DEATH; ACTIVATION	Chromosomal translocation and subsequent de-regulation of the c-myc proto-oncogene are considered to be critical events in the multi-stage evolution of Burkitt lymphoma (BL). It is widely accepted that Myc protein functions as a competence factor for proliferation. However, recent studies indicate that it can also act in some cell types as a regulator of apoptosis. BL cell populations display a high frequency of apoptosis in vivo, a property which is also readily demonstrable in vitro in group I BL cell lines. Such lines are known to retain the cell surface marker characteristics of the parental tumour cells and, in the case of Epstein-Barr virus-positive tumours, their restricted viral protein expression. We have shown previously that apoptosis in a group I BL cell line is inhibited by interferon (IFN)-alpha. Here we show that IFN-alpha-mediated suppression of apoptosis in group I BL cells corresponds temporally with inhibition of Myc protein levels. Furthermore, inhibition of Myc expression following treatment with c-myc anti-sense oligonucleotides markedly enhanced survival of group I BL cells. These results indicate that, whilst c-myc may facilitate cycling of tumour cells in which it is de-regulated, it also stimulates their apoptosis.	UNIV BIRMINGHAM, SCH MED, DEPT IMMUNOL, BIRMINGHAM B15 2TT, ENGLAND; UNIV BIRMINGHAM, SCH MED, DEPT CANC STUDIES, BIRMINGHAM B15 2TT, ENGLAND; UNIV MANCHESTER, MOLEC PHARMACOL GRP, MANCHESTER M13 9PT, ENGLAND	University of Birmingham; University of Birmingham; University of Manchester			Gregory, Chris/C-6927-2019	Gregory, Chris/0000-0002-7553-0132	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1986, CURR TOP MICROBIOL, V132, P1; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1992, ONCOGENE, V7, P101; Berard C W, 1985, IARC Sci Publ, P31; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GRAND RJA, 1993, VIROLOGY, V193, P579, DOI 10.1006/viro.1993.1166; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1987, J IMMUNOL, V139, P313; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KLEIN G, 1985, IMMUNOL TODAY, V6, P208, DOI 10.1016/0167-5699(85)90036-2; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H; LOKE SL, 1988, CURR TOP MICROBIOL, V141, P282; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MANN RB, 1976, NEW ENGL J MED, V295, P685, DOI 10.1056/NEJM197609232951301; MILNER AE, 1992, INT J CANCER, V52, P636, DOI 10.1002/ijc.2910520424; MOGENSEN KE, 1983, EUR J BIOCHEM, V134, P355, DOI 10.1111/j.1432-1033.1983.tb07575.x; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; Penn L J, 1990, Semin Cancer Biol, V1, P69; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PEZZELLA F, 1990, AM J PATHOL, V137, P225; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; ROONEY CM, 1986, J NATL CANCER I, V77, P681, DOI 10.1093/jnci/77.3.681; ROWE M, 1986, INT J CANCER, V37, P367, DOI 10.1002/ijc.2910370307; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; STEIN CA, 1988, CANCER RES, V48, P2659; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WATSON PH, 1991, CANCER RES, V51, P3996; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028	47	89	89	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3385	3391						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247541				2022-12-25	WOS:A1993MG78200023
J	GIFFIN, W; TORRANCE, H; SAFFRAN, H; MACLEOD, HL; HACHE, RJG				GIFFIN, W; TORRANCE, H; SAFFRAN, H; MACLEOD, HL; HACHE, RJG			REPRESSION OF MOUSE MAMMARY-TUMOR VIRUS TRANSCRIPTION BY A TRANSCRIPTION FACTOR COMPLEX - BINDING OF INDIVIDUAL COMPONENTS TO SEPARATED DNA STRANDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; NEGATIVE REGULATORY ELEMENT; ZINC-FINGER PROTEIN; T-CELLS; C-MYC; INDUCIBLE PROMOTER; RESPONSIVE ELEMENT; HORMONE RECEPTORS; SINGLE-STRAND; FACTOR OTF-1	Expression of mouse mammary tumor virus in T lymphocytes appears to be required for accession of horizontally transmitted virus to the mammary gland. Further, deletions in the long terminal repeat which relax constraints on viral transcription promote T cell lymphoma. We have identified a polypurine transcriptional repressor element (NRE1) that is deleted from viruses that induce T cell lymphoma. NRE1 binding activity in nuclear extracts proved to be related to a growth inhibitory activity that represses c-myc expression in mature B cells. Mobility shift, DNA footprinting, and UV cross-linking identified three factors that interacted preferentially with double-stranded NRE1 or the separated single strands. NRE1 binding factor (NBF) (80 kDa) bound double and upper strand NRE1, apparently in concert with NRE1 associated factor (NAF) (95 kDa), which interacted directly with DNA only on the upper strand. NRE1 lower strand binding factor (NLF) (50 kDa) cross-linked specifically to lower strand NRE1. On sucrose gradients NBF, NAF, and NLF binding activities cosedimented at 8 S, implying an in vitro association of the 50-, 80-, and 95-kDa factors which precedes DNA binding. Therefore, NRE1 appears to be the site of action of a complex transcriptional repressor comprised of at least three factors that interact differentially with each DNA strand to repress steroid hormone-induced transcription of mouse mammary tumor virus in T cells.	UNIV OTTAWA,OTTAWA CIVIC HOSP,LOEB INST MED RES,DEPT MED,OTTAWA K1Y 4E9,ONTARIO,CANADA; UNIV OTTAWA,OTTAWA CIVIC HOSP,LOEB INST MED RES,DEPT BIOCHEM,OTTAWA K1Y 4E9,ONTARIO,CANADA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute								ACHAORBEA H, 1991, NATURE, V350, P203; ALLAN GF, 1991, J BIOL CHEM, V266, P5905; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BALL JK, 1988, J VIROL, V62, P2985, DOI 10.1128/JVI.62.8.2985-2993.1988; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRAKKE MK, 1970, ANAL BIOCHEM, V38, P56, DOI 10.1016/0003-2697(70)90155-7; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BUETTI E, 1989, NUCLEIC ACIDS RES, V17, P3065, DOI 10.1093/nar/17.8.3065; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDLEY JP, 1986, J VIROL, V57, P385, DOI 10.1128/JVI.57.1.385-388.1986; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOX KR, 1988, NUCLEIC ACIDS RES, V16, P2063, DOI 10.1093/nar/16.5.2063; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; GARCIABLANCO MA, 1989, GENE DEV, V3, P1866; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GOLOVKINA TV, 1992, CELL, V69, P637, DOI 10.1016/0092-8674(92)90227-4; GOUILLEUX F, 1991, NUCLEIC ACIDS RES, V19, P1563, DOI 10.1093/nar/19.7.1563; GRAYHACK EJ, 1992, MOL CELL BIOL, V12, P3573, DOI 10.1128/MCB.12.8.3573; GRODY WW, 1982, ENDOCR REV, V3, P141, DOI 10.1210/edrv-3-2-141; Hache R J, 1991, Receptor, V1, P217; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; HSU CLL, 1988, J VIROL, V62, P4644, DOI 10.1128/JVI.62.12.4644-4652.1988; JANSENDURR P, 1992, NUCLEIC ACIDS RES, V20, P1243, DOI 10.1093/nar/20.6.1243; KAKKIS E, 1988, NUCLEIC ACIDS RES, V16, P77, DOI 10.1093/nar/16.1.77; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KAKKIS E, 1987, P NATL ACAD SCI USA, V84, P7031, DOI 10.1073/pnas.84.20.7031; KALFF M, 1990, NATURE, V344, P360, DOI 10.1038/344360a0; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KUO WL, 1988, J VIROL, V62, P2394, DOI 10.1128/JVI.62.7.2394-2402.1988; LANNIGAN DA, 1989, P NATL ACAD SCI USA, V86, P863, DOI 10.1073/pnas.86.3.863; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LEE JW, 1991, J BIOL CHEM, V266, P24101; LEFEBVRE P, 1991, MOL CELL BIOL, V11, P2529, DOI 10.1128/MCB.11.5.2529; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCCORMICK L, 1992, J VIROL, V66, P3435, DOI 10.1128/JVI.66.6.3435-3447.1992; MINK S, 1990, NUCLEIC ACIDS RES, V18, P2017, DOI 10.1093/nar/18.8.2017; MORLEY KL, 1987, NUCLEIC ACIDS RES, V15, P6973, DOI 10.1093/nar/15.17.6973; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; PARTHUN MR, 1992, MOL CELL BIOL, V12, P4981, DOI 10.1128/MCB.12.11.4981; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PRATT WB, 1990, PROG CLIN BIOL RES, V322, P119; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; RINGOLD GM, 1975, CELL, V6, P299, DOI 10.1016/0092-8674(75)90181-6; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SCHUURING E, 1990, ONCOGENE, V5, P459; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SPITKOVSKY DD, 1992, NUCLEIC ACIDS RES, V20, P797, DOI 10.1093/nar/20.4.797; SQUARTINI F, 1970, CANCER RES, V30, P2069; STARK HC, 1992, P NATL ACAD SCI USA, V89, P2180, DOI 10.1073/pnas.89.6.2180; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STEWART TA, 1988, MOL CELL BIOL, V8, P473, DOI 10.1128/MCB.8.1.473; TANAKA H, 1991, P NATL ACAD SCI USA, V88, P5393, DOI 10.1073/pnas.88.12.5393; THEUNISSEN HJM, 1989, J VIROL, V63, P3466, DOI 10.1128/JVI.63.8.3466-3471.1989; TSUBURA A, 1988, CANCER RES, V48, P6555; UCKER DS, 1984, J BIOL CHEM, V259, P7416; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VANOOYEN A, 1990, J VIROL, V64, P4043; WILKISON WO, 1990, J BIOL CHEM, V265, P477; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0; YAGIL G, 1991, CRIT REV BIOCHEM MOL, V26, P475, DOI 10.3109/10409239109086791; YANAGAWA S, 1991, J VIROL, V65, P526, DOI 10.1128/JVI.65.1.526-531.1991; YANAGAWA SI, 1993, J VIROL, V67, P112, DOI 10.1128/JVI.67.1.112-118.1993; YANAGAWA SI, 1990, J VIROL, V64, P2474, DOI 10.1128/JVI.64.6.2474-2483.1990	78	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1449	1459						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288611				2022-12-25	WOS:A1994MR22000104
J	MAKINO, N; MOCHIZUKI, Y; BANNAI, S; SUGITA, Y				MAKINO, N; MOCHIZUKI, Y; BANNAI, S; SUGITA, Y			KINETIC-STUDIES ON THE REMOVAL OF EXTRACELLULAR HYDROGEN-PEROXIDE BY CULTURED FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIXED-FUNCTION OXIDATION; GLUTATHIONE-PEROXIDASE; DT-DIAPHORASE; RAT-LIVER; CATALASE; SYSTEMS; HEPATOCYTES; METABOLISM; PATHWAY; QUINONE	To investigate the function of antioxidant enzymes in intact cells, we examined the removal of extracellular H2O2 by cultured fibroblasts (IMR-90). H2O2 concentration dependence of the reaction rate was interpreted as that the process involves two kinetically different reactions (referred to as reactions 1 and 2). Reaction 1 was characterized by a relatively low K(m) value (about 40 muM), and reaction 2 by linear dependence of the rate up to 500 muM H2O2. The magnitude of reaction 1 was reduced by treatment of the cells with diethyl maleate or 6-aminonicotinamide, while reaction 2 was inhibited by 3-amino1, 2,4-triazole treatment. It was concluded that reactions 1 and 2 are principally due to GSH peroxidase and catalase, respectively. The values of kinetic parameters were estimated by curve-fitting, and it was inferred that 80 to 90% of H2O2 is decomposed by GSH peroxidase at H2O2 concentrations lower than 10 muM. The contribution of catalase increases with the increase in H2O2 concentration. The intact cells showed a low catalase activity (about 15%), as compared with the activity found in the solubilized cells. The low catalase activity was ascribed to the latency of the enzyme caused by localization in peroxisomes. Fibroblasts also removed intracellular H2O2 generated by menadione. Treatment with diethyl maleate greatly impaired the H2O2-removing capability and caused H2O2 efflux into the medium.			MAKINO, N (corresponding author), UNIV TSUKUBA, INST BASIC MED SCI, DIV BIOCHEM, TSUKUBA, IBARAKI 305, JAPAN.							AIKAWA J, 1991, P NATL ACAD SCI USA, V88, P10084, DOI 10.1073/pnas.88.22.10084; AWASTHI YC, 1975, J BIOL CHEM, V250, P5144; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; COHEN G, 1963, BIOCHEMISTRY-US, V2, P1420, DOI 10.1021/bi00906a038; DEDUVE C, 1966, PHYSIOL REV, V46, P323, DOI 10.1152/physrev.1966.46.2.323; DRAPER NR, 1966, APPLIED REGRESSION A, P273; EGGLESTON LV, 1974, BIOCHEM J, V138, P425, DOI 10.1042/bj1380425; ERICKSON RR, 1976, BIOCHEM PHARMACOL, V25, P1501, DOI 10.1016/0006-2952(76)90068-X; FISCHKOFF S, 1975, J GEN PHYSIOL, V65, P663, DOI 10.1085/jgp.65.5.663; FLOHE L, 1972, H-S Z PHYSIOL CHEM, V353, P987, DOI 10.1515/bchm2.1972.353.1.987; FLOHE L, 1971, H-S Z PHYSIOL CHEM, V352, P1401, DOI 10.1515/bchm2.1971.352.2.1401; GAETANI GF, 1989, BLOOD, V73, P334; IYANAGI T, 1990, FREE RADICAL RES COM, V8, P259, DOI 10.3109/10715769009053359; IYANAGI T, 1969, BIOCHIM BIOPHYS ACTA, V172, P370, DOI 10.1016/0005-2728(69)90133-9; IYANAGI T, 1970, BIOCHIM BIOPHYS ACTA, V216, P282, DOI 10.1016/0005-2728(70)90220-3; JONES DP, 1981, ARCH BIOCHEM BIOPHYS, V210, P505, DOI 10.1016/0003-9861(81)90215-0; KAUFFMAN FC, 1977, BIOCHEM J, V166, P583, DOI 10.1042/bj1660583; KAYE CI, 1975, J LAB CLIN MED, V86, P422; LIND C, 1982, ARCH BIOCHEM BIOPHYS, V216, P178, DOI 10.1016/0003-9861(82)90202-8; NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308; NICHOLLS P, 1972, BIOCHIM BIOPHYS ACTA, V279, P306, DOI 10.1016/0304-4165(72)90147-X; OLOUGHLIN MA, 1980, RADIAT RES, V84, P477, DOI 10.2307/3575486; POWIS G, 1979, PHARMACOL THERAPEUT, V7, P297, DOI 10.1016/0163-7258(79)90033-0; RAIVIO KO, 1981, BIOCHIM BIOPHYS ACTA, V678, P51, DOI 10.1016/0304-4165(81)90046-5; RUSH GF, 1986, TOXICOL APPL PHARM, V85, P324, DOI 10.1016/0041-008X(86)90339-X; Schonbaum G. R., 1976, ENZYMES, V13, P363, DOI [10.1016/S1874-6047(08)60245-0, DOI 10.1016/S1874-6047(08)60245-0]; SIES H, 1975, EUR J BIOCHEM, V57, P503, DOI 10.1111/j.1432-1033.1975.tb02325.x; THURMAN RG, 1973, EUR J BIOCHEM, V38, P73, DOI 10.1111/j.1432-1033.1973.tb03035.x; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TRIBBLE DL, 1990, BIOCHEM PHARMACOL, V39, P729, DOI 10.1016/0006-2952(90)90152-B; VANVELDHOVEN P, 1983, BIOCHEM J, V210, P685, DOI 10.1042/bj2100685; WILLIAMS DC, 1976, ANAL CHEM, V48, P1003, DOI 10.1021/ac60371a025; WINKLER BS, 1986, EXP EYE RES, V43, P829, DOI 10.1016/S0014-4835(86)80013-6; YAMASHOJI S, 1991, BIOCHIM BIOPHYS ACTA, V1059, P99, DOI 10.1016/S0005-2728(05)80191-4	34	109	113	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1020	1025						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288557				2022-12-25	WOS:A1994MR22000040
J	PILLINGER, MH; VOLKER, C; STOCK, JB; WEISSMANN, G; PHILIPS, MR				PILLINGER, MH; VOLKER, C; STOCK, JB; WEISSMANN, G; PHILIPS, MR			CHARACTERIZATION OF A PLASMA MEMBRANE-ASSOCIATED PRENYLCYSTEINE-DIRECTED ALPHA-CARBOXYL METHYLTRANSFERASE IN HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; LAMIN-B; SACCHAROMYCES-CEREVISIAE; TERMINAL METHYLATION; ALKALINE-PHOSPHATASE; CAAX MOTIF; SUBUNIT; CELLS; LOCALIZATION; MATURATION	Signal transduction in human neutrophils requires prenylcysteine-directed carboxyl methylation of ras-related low molecular weight GTP-binding proteins. We now report the subcellular localization and characterization of a neutrophil prenylcysteine alpha carboxyl methyltransferase. The highest carboxyl methyltransferase activity copurified with biotinylated neutrophil surface membranes, supporting a plasma membrane localization of the enzyme. Neutrophil nuclear fractions contained little or no methyltransferase activity. Methyltransferase activity was detergent-sensitive but could be reconstituted by removal of detergent in the presence of phosphatidyl choline and an anionic phospholipid. N-Acetyl-S-trans,trans-farnesyl-L-cysteine (AFC) and N-acetyl-S-all-trans-geranylgeranyl-L-cysteine (AGGC) were effective substrates for neutrophil prenylcysteine-directed methyltransferase; V(max) values for AFC and AGGC (16.4 and 22.1 pmol of methylated/mg protein/min, respectively) are among the highest yet reported. Although both GTPgammaS and the chemoattractant fMet-Leu-Phe stimulated methylation of ras-related proteins, neither affected methylation of AFC. These data suggest that neutrophil plasma membranes contain a phospholipid-dependent, prenylcysteine-directed carboxyl methyltransferase of relatively high specific activity that modifies ras-related protein substrates in the GTP-bound, activated state.	NYU MED CTR,SCH MED,DEPT MED,DIV RHEUMATOL,550 1ST AVE,NEW YORK,NY 10016; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544; PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544	New York University; Princeton University; Princeton University			Weissmann, Gerald/N-5273-2015	Weissmann, Gerald/0000-0002-4285-4552; Pillinger, Michael/0000-0003-3168-1542; Mark, Philips/0000-0002-1179-8156	NIAID NIH HHS [AI-20980] Funding Source: Medline; NIAMS NIH HHS [AR-07176-18] Funding Source: Medline; NIGMS NIH HHS [GM-8309] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008309] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO A, 1992, SCIENCE, V353, P668; AMUR SG, 1986, J NEUROSCI RES, V16, P367, DOI 10.1002/jnr.490160204; Aronson N N Jr, 1974, Methods Enzymol, V31, P90; BACKLUND PS, 1992, J BIOL CHEM, V267, P18432; BACKLUND PS, 1968, J BIOL CHEM, V263, P15864; BOKOCH GM, 1990, CURRENT TOPICS MEMBR, P65; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUONO BJ, 1989, J CELL PHYSL, V141, P636; CHELSKY D, 1985, BIOCHEMISTRY-US, V24, P6651, DOI 10.1021/bi00344a053; CHELSKY D, 1989, J BIOL CHEM, V264, P7637; CHELSKY D, 1987, J BIOL CHEM, V262, P4303; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DECHATELET LR, 1970, BIOCHEM MED METAB B, V4, P61, DOI 10.1016/0006-2944(70)90103-1; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P804, DOI 10.1016/0006-291X(90)91217-G; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HRYCYNA CA, 1992, J BIOL CHEM, V267, P10457; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; HUZOORAKBAR, 1991, J BIOL CHEM, V266, P4387; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LONG WK, 1987, J VIROL, V61, P221, DOI 10.1128/JVI.61.1.221-224.1987; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MANCOCK JF, 1989, CELL, V57, P1167; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; PHILIPS MR, 1991, J BIOL CHEM, V266, P1289; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PIKE MC, 1978, P NATL ACAD SCI USA, V75, P3928, DOI 10.1073/pnas.75.8.3928; ROSEN CL, 1992, J CELL BIOL, V117, P617, DOI 10.1083/jcb.117.3.617; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SENGELOV H, 1992, J BIOL CHEM, V267, P14912; SERHAN CN, 1983, BIOCHIM BIOPHYS ACTA, V762, P420, DOI 10.1016/0167-4889(83)90007-1; SERHAN CN, 1982, BIOCHEM BIOPH RES CO, V107, P951, DOI 10.1016/0006-291X(82)90615-5; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SMOLEN JE, 1982, TRENDS PHARMACOL SCI, V3, P483, DOI 10.1016/0165-6147(82)91247-0; SNYDERMAN R, 1988, INFLAMMATION BASIC P, P309; SOBOTKABRINER C, 1992, J BIOL CHEM, V267, P12116; STEPHENSON RC, 1992, J BIOL CHEM, V267, P13314; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; VOLKER C, 1990, Methods (Orlando), V1, P283, DOI 10.1016/S1046-2023(05)80329-9; VOLKER C, 1991, FEBS LETT, V295, P189, DOI 10.1016/0014-5793(91)81415-5; VOLKER C, 1991, J BIOL CHEM, V266, P21515; Zucker-Franklin D, 1988, ATLAS BLOOD CELLS FU	47	62	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1486	1492						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288614				2022-12-25	WOS:A1994MR22000108
J	FARRELL, DH; THIAGARAJAN, P				FARRELL, DH; THIAGARAJAN, P			BINDING OF RECOMBINANT FIBRINOGEN MUTANTS TO PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA FIBRINOGEN; GLYCOPROTEIN-IIB-IIIA; HUMAN-BLOOD PLATELETS; GAMMA-CHAIN; ALPHA-CHAIN; VONWILLEBRAND-FACTOR; AGGREGATION; FIBRONECTIN; RECOGNITION; INTEGRINS	Platelet aggregation is mediated by the interaction of fibrinogen with platelet membrane glycoprotein IIb-IIIa, a member of the integrin family (integrin alpha(IIb)beta3). Three different binding sites on fibrinogen for IIb-IIIa have been proposed, two RGD-containing sequences in the a chain and one dodecapeptide sequence at the carboxyl terminus of they chain. However, recent evidence shows that mutations in either of the a chain sequences have no effect on platelet aggregation, whereas the substitution of a variant gamma chain (gamma') for the gamma chain results in a major reduction in platelet aggregation activity. The present investigation demonstrates that the gamma' chain shows decreased binding to IIb-IIIa as measured by direct binding experiments. In addition, adhesion studies indicate that the binding of both stimulated and unstimulated platelets to immobilized fibrinogens is mediated primarily through the gamma chain carboxyl terminus. Furthermore, a peptide corresponding to the carboxyl terminus of the gamma chain inhibits fibrinogen binding and platelet adhesion, whereas a peptide corresponding to the carboxyl terminus of the gamma' chain is significantly less inhibitory. These data show that the defective platelet aggregation activity of the fibrinogen gamma' chain is due to decreased binding to platelet glycoprotein IIb-IIIa.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DIV HEMATOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040860, R01HL016919] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-16919, HL-40860] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMRANI DL, 1988, BLOOD, V72, P919; BEACHAM DA, 1992, J BIOL CHEM, V267, P3409; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; CHERESH DA, 1989, CELL, V16, P427; CHERNY RC, 1993, J BIOL CHEM, V268, P9725; CHUNG DW, 1984, BIOCHEMISTRY-US, V23, P4232, DOI 10.1021/bi00313a033; DEMPFLE CE, 1987, THROMB RES, V46, P19, DOI 10.1016/0049-3848(87)90203-9; DOOLITTLE RF, 1978, J MOL BIOL, V120, P311, DOI 10.1016/0022-2836(78)90070-0; DOOLITTLE RF, 1979, NATURE, V280, P464, DOI 10.1038/280464a0; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FARRELL DH, 1991, BIOCHEMISTRY-US, V30, P9414, DOI 10.1021/bi00103a004; FORNACE AJ, 1984, P NATL ACAD SCI USA, V259, P12826; FRANCIS CW, 1980, J BIOL CHEM, V255, P5599; GARTNER TK, 1993, IN PRESS THROMB RES; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; HAVERSTICK DM, 1985, BLOOD, V66, P946; HAWIGER J, 1989, BIOCHEMISTRY-US, V28, P2909, DOI 10.1021/bi00433a024; HENSCHEN A, 1980, PROTIDES BIOL FLUIDS, V28, P51; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KAZAL LA, 1963, P SOC EXP BIOL MED, V113, P989; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; KIRSCHBAUM NE, 1992, BLOOD, V79, P2643; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KUYAS C, 1990, THROMB HAEMOSTASIS, V63, P439; LASZ EC, 1993, BIOCHEM BIOPH RES CO, V190, P118, DOI 10.1006/bbrc.1993.1019; LINDON JN, 1986, BLOOD, V68, P355; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MARKWELL MAK, 1978, BIOCHEMISTRY-US, V17, P4807, DOI 10.1021/bi00615a031; MARTINEZ J, 1974, J CLIN INVEST, V53, P600, DOI 10.1172/JCI107595; MATTHIAS FR, 1975, THROMB RES, V7, P861, DOI 10.1016/0049-3848(75)90089-4; MCKEE PA, 1966, ARCH BIOCHEM BIOPHYS, V116, P271, DOI 10.1016/0003-9861(66)90033-6; NIEWIAROWSKI S, 1977, BLOOD, V49, P635; PEERSCHKE EIB, 1987, BLOOD, V69, P950; PEERSCHKE EIB, 1986, BLOOD, V67, P385; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WOLFENSTEINTODEL C, 1980, P NATL ACAD SCI-BIOL, V77, P5069, DOI 10.1073/pnas.77.9.5069	40	143	146	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					226	231						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276798				2022-12-25	WOS:A1994MR21900042
J	TAMAI, K; LI, K; UITTO, J				TAMAI, K; LI, K; UITTO, J			IDENTIFICATION OF A DNA-BINDING PROTEIN (KERATINOCYTE TRANSCRIPTIONAL PROTEIN-1) RECOGNIZING A KERATINOCYTE-SPECIFIC REGULATORY ELEMENT IN THE 230-KDA BULLOUS PEMPHIGOID ANTIGEN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT GENES; BASEMENT-MEMBRANE ZONE; FACTOR AP-2; ENHANCER ELEMENTS; CDNA CLONING; HUMAN-SKIN; I KERATIN; EXPRESSION; SEQUENCE; CONSERVATION	We have recently cloned and characterized the entire human 230-kDa bullous pemphigoid antigen gene, which is expressed at a relatively high level in the basal keratinocytes. A putative AP2 binding sequence (KRE2), identified in the position -1786 to -1778, was cloned in front of a heterologous thymidine kinase chloramphenicol acetyltransferase construct, and transient transfections of normal human keratinocytes indicated a marked enhancement of the promoter activity. Normal human keratinocyte nuclear extracts contained a protein, designated as keratinocyte transcriptional protein-1 (KTP-1), which complexed with the KRE2 oligomer when examined by gel mobility shift assays. This protein was not detected in human skin fibroblast or HeLa cell nuclear extracts that did, however, contain AP2. UV cross-linking studies and Southwestern analyses suggested that KTP-1 binds to DNA as a single polypeptide of approximately 110 kDa. These data suggest that KTP-1 is a DNA-binding protein clearly distinct from AP2, and this protein may be responsible for the basal keratinocyte-specific expression of the bullous pemphigoid antigen gene.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON INST MOLEC MED,DEPT DERMATOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University					NIAMS NIH HHS [T32-AR07561, P01-AR38923] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007561, P01AR038923] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; BOOTH BA, 1980, BIOCHIM BIOPHYS ACTA, V607, P145, DOI 10.1016/0005-2787(80)90228-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; DIAZ LA, 1990, J CLIN INVEST, V86, P1088, DOI 10.1172/JCI114812; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; GIUDICE GJ, 1991, J CLIN INVEST, V87, P734, DOI 10.1172/JCI115054; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; HOPKINSON SB, 1992, J INVEST DERMATOL, V99, P264, DOI 10.1111/1523-1747.ep12616615; HUFF CA, 1993, J BIOL CHEM, V268, P377; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; JORDON RE, 1967, J AMER MED ASSOC, V200, P751, DOI 10.1001/jama.200.9.751; JORDON RE, 1971, ARCH DERMATOL, V103, P486, DOI 10.1001/archderm.103.5.486; KRIEG TM, 1985, J BIOL CHEM, V260, P5867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LERSCH R, 1989, MOL CELL BIOL, V9, P3685, DOI 10.1128/MCB.9.9.3685; LEVER WF, 1965, PEMPHIGUS PEMPHIGOID, P75; LI K, 1991, J BIOL CHEM, V266, P24064; LI KH, 1993, J BIOL CHEM, V268, P8825; LI KH, 1992, J INVEST DERMATOL, V99, P258, DOI 10.1111/1523-1747.ep12616611; MARCHUK D, 1985, P NATL ACAD SCI USA, V82, P1609, DOI 10.1073/pnas.82.6.1609; MARCHUK D, 1984, CELL, V39, P491, DOI 10.1016/0092-8674(84)90456-2; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOLL R, 1982, DIFFERENTIATION, V23, P170, DOI 10.1111/j.1432-0436.1982.tb01280.x; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MUTASIM DF, 1985, J INVEST DERMATOL, V84, P47, DOI 10.1111/1523-1747.ep12274684; Sambrook J, 1989, MOL CLONING LABORATO; SAWAMURA D, 1990, GENOMICS, V8, P722, DOI 10.1016/0888-7543(90)90261-R; SAWAMURA D, 1991, J INVEST DERMATOL, V96, P908, DOI 10.1111/1523-1747.ep12475433; SAWAMURA D, 1991, J BIOL CHEM, V266, P17784; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SNAPE AM, 1991, DEVELOPMENT, V113, P283; SNAPE AM, 1990, DEVELOPMENT, V109, P157; STANLEY JR, 1983, J CELL BIOL, V96, P1809, DOI 10.1083/jcb.96.6.1809; STANLEY JR, 1989, J CLIN INVEST, V83, P1443, DOI 10.1172/JCI114036; STANLEY JR, 1981, CELL, V24, P897, DOI 10.1016/0092-8674(81)90115-X; Sun TT, 1984, CANCER CELLS, V1, P169; TAMAI K, 1993, J CLIN INVEST, V92, P814, DOI 10.1172/JCI116655; TANAKA T, 1991, J BIOL CHEM, V266, P12555; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TYNER AL, 1985, P NATL ACAD SCI USA, V82, P4683, DOI 10.1073/pnas.82.14.4683; UITTO J, 1992, J CLIN INVEST, V90, P687, DOI 10.1172/JCI115938; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WESTGATE GE, 1985, J INVEST DERMATOL, V84, P218, DOI 10.1111/1523-1747.ep12265229; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	51	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					493	502						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276841				2022-12-25	WOS:A1994MR21900081
J	WILLIMANN, TE; TRUEB, B				WILLIMANN, TE; TRUEB, B			IDENTIFICATION OF FUNCTIONAL ELEMENTS AND RECONSTITUTION OF THE ALPHA-1(VI) COLLAGEN PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; VI COLLAGEN; TRANSCRIPTION INITIATION; MAMMALIAN NUCLEI; GENE-EXPRESSION; CELLS; FIBROBLASTS; SUBUNIT; CLONING; DNA	To gain insight into the regulatory mechanisms of collagen VI synthesis we have characterized the cis-acting elements of the chicken alpha1(VI) collagen promoter. Footprinting experiments with nuclear extracts from chicken embryos revealed three distinct elements, designated A, B, and C, that were protected from DNase I digestion. The nuclear proteins that interact with the three sites were identified by gel retardation assays in combination with the use of various oligonucleotide competitors as well as specific antibodies raised against well characterized transcription factors. Site A was found to be a target for transcriptional activator AP1, whereas sites B and C were shown to be recognized each by two distinct nuclear proteins which belong to the Spl multigene family. To address the question whether the three sites alone are able to direct transcription, a minipromoter construct was created in which the sequences of sites A, B, and C were placed in front of a reporter gene. After transfection into chicken fibroblasts, this construct exhibited a high relative promoter activity when compared to a large genomic fragment containing the basic alpha1(VI) collagen promoter. Thus, the three sites are sufficient to induce transcription of this gene.			WILLIMANN, TE (corresponding author), SWISS FED INST TECHNOL, BIOCHEM 1 LAB, CH-8092 ZURICH, SWITZERLAND.		Trueb, Beat/AAL-9621-2020	Trueb, Beat/0000-0001-8684-6856				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BONALDO P, 1993, MATRIX, V13, P223, DOI 10.1016/S0934-8832(11)80006-5; CARTER WG, 1982, J BIOL CHEM, V257, P13805; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HATAMOCHI A, 1989, J BIOL CHEM, V264, P3494; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOLLER E, 1992, EUR J BIOCHEM, V208, P769, DOI 10.1111/j.1432-1033.1992.tb17246.x; KOLLER E, 1991, NUCLEIC ACIDS RES, V19, P485, DOI 10.1093/nar/19.3.485; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAR JH, 1988, J CELL BIOL, V107, P573, DOI 10.1083/jcb.107.2.573; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SCHREIER T, 1988, BIOCHEM J, V253, P381, DOI 10.1042/bj2530381; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; Timpl R., 1987, STRUCTURE FUNCTION C, P105, DOI [10.1016/B978--0--12--481280-2.50008---8, DOI 10.1016/B978--0--12--481280-2.50008---8]; TRUEB B, 1989, J BIOL CHEM, V264, P136; TRUEB B, 1985, J CELL BIOL, V100, P638, DOI 10.1083/jcb.100.2.638; TRUEB B, 1986, EMBO J, V5, P2815, DOI 10.1002/j.1460-2075.1986.tb04573.x; VALLE PL, 1993, J CELL BIOL, V121, P1173, DOI 10.1083/jcb.121.5.1173; WESTIN G, 1988, NUCLEIC ACIDS RES, V16, P5771, DOI 10.1093/nar/16.13.5771	36	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					332	338						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276816				2022-12-25	WOS:A1994MR21900057
J	MCLEAN, JR; KRISHNAKUMAR, S; ODONNELL, JM				MCLEAN, JR; KRISHNAKUMAR, S; ODONNELL, JM			MULTIPLE MESSENGER-RNAS FROM THE PUNCH LOCUS OF DROSOPHILA-MELANOGASTER ENCODE ISOFORMS OF GTP CYCLOHYDROLASE-I WITH DISTINCT N-TERMINAL DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; ADRENAL-MEDULLA; NITRIC-OXIDE; BIOSYNTHESIS; TETRAHYDROBIOPTERIN; GENE; PURIFICATION; SEQUENCE; ENZYME; CELLS	The GTP cyclohydrolase I gene of Drosophila melanogaster, the Punch locus, encodes alternative transcripts of 1.7 and 1.75 kilobases (kb). These transcripts are differentially expressed throughout Drosophila development. cDNA clones representing these transcripts, corresponding genomic regions and polymerase chain reaction-amplified primer extensions of the 5' ends of the RNAs were sequenced. Both RNAs contain five exons and derive from primary transcripts that extend over approximately 8 and 4 kb for the 1.7- and 1.75-kb RNAs, respectively. Their 5'-most exons are unique and spliced onto common 3' exons. The cDNAs each contain a single long open reading frame, which can be translated into a polypeptide of 273 amino acids for the 1.7-kb mRNA and 308 amino acids for the 1.75-kb mRNA. The unique exons confer distinct N-terminal domains to each predicted protein. Sequence comparisons reveal that the drosophila GTP cyclohydrolase isoforms encoded by the multiple transcripts are highly similar to GTP cyclohydrolases from humans, rodents, and bacteria, with one significant exception. The N-terminal domains encoded by the transcript-specific 5' exons cannot be aligned with the N termini of any other GTP cyclohydrolases. These domains are predicted to confer distinct physical characteristics to the alternate isoforms, and it is hypothesized that they aid in regulating the expression of the enzyme in diverse cellular environments.	UNIV ALABAMA,DEPT BIOL SCI,TUSCALOOSA,AL 35487; CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213	University of Alabama System; University of Alabama Tuscaloosa; Carnegie Mellon University					NIGMS NIH HHS [GM26757, GM08067] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026757] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUDONIA MM, 1981, P NATL ACAD SCI-BIOL, V78, P2703, DOI 10.1073/pnas.78.5.2703; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BABITZKE P, 1992, J BACTERIOL, V174, P2059, DOI 10.1128/JB.174.7.2059-2064.1992; CAVERNER DR, 1991, NUCLEIC ACIDS RES, V19, P1385; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLLNICK P, 1990, P NATL ACAD SCI USA, V87, P8726, DOI 10.1073/pnas.87.22.8726; GOLUMBESKI GS, 1991, GENE DEV, V5, P2060, DOI 10.1101/gad.5.11.2060; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; HATAKEYAMA K, 1989, J BIOL CHEM, V264, P21660; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HUBER C, 1990, CHEMISTRY AND BIOLOGY OF PTERIDINES 1989, P473; KATZENMEIER G, 1991, BIOL CHEM H-S, V372, P991, DOI 10.1515/bchm3.1991.372.2.991; LOVENBERG W, 1967, SCIENCE, V155, P217, DOI 10.1126/science.155.3759.217; MACKAY WJ, 1983, GENETICS, V105, P35; MACKAY WJ, 1985, GENETICS, V111, P885; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCLEAN JR, 1990, GENETICS, V126, P1007; MILSTIEN S, 1990, CHEMISTRY AND BIOLOGY OF PTERIDINES 1989, P505; MIWA S, 1985, ARCH BIOCHEM BIOPHYS, V239, P234, DOI 10.1016/0003-9861(85)90831-8; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; NOMURA T, 1993, BIOCHEM BIOPH RES CO, V191, P523, DOI 10.1006/bbrc.1993.1249; ODONNELL JM, 1989, DEV GENET, V10, P273, DOI 10.1002/dvg.1020100316; ODONNELL JM, 1993, CHEM BIOL PTERIDINES; REYNOLDS ER, 1987, DEV BIOL, V123, P430, DOI 10.1016/0012-1606(87)90401-5; REYNOLDS ER, 1988, GENETICS, V119, P609; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOEDON G, 1989, EUR J BIOCHEM, V178, P627, DOI 10.1111/j.1432-1033.1989.tb14491.x; SCHOEDON G, 1987, EUR J BIOCHEM, V166, P303, DOI 10.1111/j.1432-1033.1987.tb13515.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TANAKA K, 1989, P NATL ACAD SCI USA, V86, P5864, DOI 10.1073/pnas.86.15.5864; TOGARI A, 1992, BIOCHEM BIOPH RES CO, V187, P359, DOI 10.1016/S0006-291X(05)81501-3; VIVEROS OH, 1981, SCIENCE, V213, P349, DOI 10.1126/science.7017928; WEISBERG EP, 1986, J BIOL CHEM, V261, P1453; WERNER ER, 1990, J BIOL CHEM, V265, P3189; WERNERFELMAYER G, 1991, FASEB J, V5, pA1672; ZIEGLER I, 1987, UNCONJUGATED PTERINS, P169	42	39	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27191	27197						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262960				2022-12-25	WOS:A1993MM26200055
J	NYHOLM, S; MANN, GJ; JOHANSSON, AG; BERGERON, RJ; GRASLUND, A; THELANDER, L				NYHOLM, S; MANN, GJ; JOHANSSON, AG; BERGERON, RJ; GRASLUND, A; THELANDER, L			ROLE OF RIBONUCLEOTIDE REDUCTASE IN INHIBITION OF MAMMALIAN-CELL GROWTH BY POTENT IRON CHELATORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA-SYNTHESIS; DEPENDENT REGULATION; SUBUNIT; ENZYME; OXYGEN; PURIFICATION; PARABACTIN; MECHANISM; PROTEIN	Ribonucleotide reductase consists of two nonidentical subunits, proteins R1 and R2, the latter of which contains an iron-tyrosyl free radical center essential for activity. We have studied the in vivo effects on the R2 protein of the potent iron chelators parabactin and desferrioxamine using R2-overproducing mouse cells with a tyrosyl free radical signal easily quantifiable by EPR spectroscopy. Both chelators inhibited cell growth, and the inhibition was reversible by iron. Furthermore, both chelators, which penetrate cells and chelate the intracellular iron pool, caused a disappearance of the R2 tyrosyl free radical. In parallel, there was an accumulation of apo-R2 protein in the inhibited cells. In vitro studies using pure, Fe-59-labeled recombinant mouse R2 protein unexpectedly showed that its iron center is labile at physiological temperatures and that iron is spontaneously lost from the protein even in the absence of chelators in a temperature-dependent process. Our conclusion is that parabactin or desferrioxamine inhibits ribonucleotide reduction and cell growth not by directly attacking the iron-radical center of the R2 protein, but instead by chelating the intracellular iron pool. This prevents the regeneration of the iron-radical center both in newly synthesized apo-R2 protein and in apo-R2 protein continuously formed from active R2 protein by the loss of iron.	UMEA UNIV, DEPT MED BIOCHEM & BIOPHYS, S-90187 UMEA, SWEDEN; UNIV FLORIDA, DEPT MED CHEM, GAINESVILLE, FL 32610 USA	Umea University; State University System of Florida; University of Florida			Mann, Graham J/G-4758-2014	Mann, Graham J/0000-0003-1301-405X				ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BECTON DL, 1989, CANCER RES, V49, P4809; BERGERON RJ, 1982, J AM CHEM SOC, V104, P4489, DOI 10.1021/ja00380a032; BERGERON RJ, 1987, CANCER RES, V47, P6010; CAVANAUGH PF, 1985, CANCER RES, V45, P4754; CAZZOLA M, 1990, BLOOD, V75, P1903; ENGSTROM Y, 1979, BIOCHEMISTRY-US, V18, P2941, DOI 10.1021/bi00581a004; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; GANESHAGURU K, 1980, BIOCHEM PHARMACOL, V29, P1275, DOI 10.1016/0006-2952(80)90285-3; GOODWIN JF, 1965, NATURE, V205, P281, DOI 10.1038/205281b0; GRAF E, 1984, J BIOL CHEM, V259, P3620; HOFFBRAND AV, 1976, BRIT J HAEMATOL, V33, P517, DOI 10.1111/j.1365-2141.1976.tb03570.x; HOWELL ML, 1992, J BIOL CHEM, V267, P1705; KARLSSON M, 1992, J BIOL CHEM, V267, P12622; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; NOCENTINI G, 1993, CANCER RES, V53, P19; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NYHOLM S, 1993, IN PESS BIOCHEMISTRY; PETERSON T, 1980, J AM CHEM SOC, V102, P7715, DOI 10.1021/ja00546a013; PROBST H, 1989, BIOCHEM BIOPH RES CO, V163, P334, DOI 10.1016/0006-291X(89)92140-2; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SODERMAN K, 1986, ANAL BIOCHEM, V152, P89, DOI 10.1016/0003-2697(86)90124-7; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; SUTTLE DP, 1979, J BIOL CHEM, V254, P4602; TAIT GH, 1975, BIOCHEM J, V146, P191, DOI 10.1042/bj1460191; THELANDER L, 1983, J BIOL CHEM, V258, P4063; THELANDER L, 1983, BIOCHEM BIOPH RES CO, V110, P859, DOI 10.1016/0006-291X(83)91040-9; THELANDER L, 1993, GENE AMPLIFICATION M, P265	28	193	195	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26200	26205						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253740				2022-12-25	WOS:A1993MK42500031
J	POPOV, KM; KEDISHVILI, NY; ZHAO, Y; SHIMOMURA, Y; CRABB, DW; HARRIS, RA				POPOV, KM; KEDISHVILI, NY; ZHAO, Y; SHIMOMURA, Y; CRABB, DW; HARRIS, RA			PRIMARY STRUCTURE OF PYRUVATE-DEHYDROGENASE KINASE ESTABLISHES A NEW FAMILY OF EUKARYOTIC PROTEIN-KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-KETOACID DEHYDROGENASE; ACTIVATOR PROTEIN; BOVINE KIDNEY; COMPLEX; PHOSPHORYLATION; PURIFICATION; GENE	We recently reported molecular cloning of the branched chain alpha-ketoacid dehydrogenase kinase, the first mitochondrial protein kinase to be cloned (Popov, K. M., Zhao, Y., Shimomura, Y., Kuntz, M. J., and Harris, R. A. (1992) J. Biol. Chem. 267,13127-13130). From a search for proteins related to the branched chain alpha-ketoacid dehydrogenase kinase, a cDNA encoding the 434 amino acid residues corresponding to pyruvate dehydrogenase kinase has been cloned from a rat heart cDNA library. Evidence that the clone codes for pyruvate dehydrogenase kinase includes: (a) the deduced amino acid sequence is identical to the partial sequence of the kinase determined by direct sequencing, (b) expression of the cDNA in Escherichia coli resulted in synthesis of a protein that phosphorylated and inactivated the pyruvate dehydrogenase complex; (c) kinase activity of the recombinant protein is sensitive to inhibition by a specific inhibitor of pyruvate dehydrogenase kinase; and (d) antiserum raised against the recombinant protein recognized the protein subunit known to correspond to pyruvate dehydrogenase kinase in a highly purified preparation of the pyruvate dehydrogenase complex. Like the branched chain alpha-ketoacid dehydrogenase kinase, pyruvate dehydrogenase kinase lacks motifs usually associated with eukaryotic Ser/Thr-protein kinases. Considerable sequence similarity exists between these mitochondrial protein kinases and members of the prokaryotic histidine kinase family, a diverse set of sensing and response systems important in the regulation of bacterial processes. Thus, molecular cloning of these proteins establishes a new eukaryotic family of protein kinases that is related to a prokaryotic family of protein kinases.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, 635 BARNHILL DR, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis				Kedishvili, Natalia/0000-0001-6917-4891	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P60AM020542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019259] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM 20542] Funding Source: Medline; NIDDK NIH HHS [DK 19259] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P2958, DOI 10.1021/bi00281a027; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; JONES BS, 1991, BIOCHEM J, V275, P781, DOI 10.1042/bj2750781; KERBEY AL, 1984, FEBS LETT, V176, P115, DOI 10.1016/0014-5793(84)80923-0; LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234; PAXTON R, 1982, J BIOL CHEM, V257, P4433; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Popov K M, 1991, Protein Expr Purif, V2, P278, DOI 10.1016/1046-5928(91)90084-V; POPOV KM, 1992, J BIOL CHEM, V267, P13127; ROISE D, 1988, J BIOL CHEM, V263, P4509; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Sambrook J, 1989, MOL CLONING LABORATO; STEPP LR, 1983, J BIOL CHEM, V258, P9454; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; WHITEHOUSE S, 1974, BIOCHEM J, V141, P761, DOI 10.1042/bj1410761; WIRTZ E, 1991, MOL BIOCHEM PARASIT, V47, P119, DOI 10.1016/0166-6851(91)90154-X	21	128	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26602	26606						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253790				2022-12-25	WOS:A1993MK42500085
J	RODRIGUEZAGUILERA, JC; NAVARRO, F; ARROYO, A; VILLALBA, JM; NAVAS, P				RODRIGUEZAGUILERA, JC; NAVARRO, F; ARROYO, A; VILLALBA, JM; NAVAS, P			TRANSPLASMA MEMBRANE REDOX SYSTEM OF HL-60 CELLS IS CONTROLLED BY CAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; LIVER PLASMA-MEMBRANE; CYCLIC-AMP; SEMIDEHYDROASCORBATE REDUCTASE; ELECTRON-TRANSPORT; HUMAN-NEUTROPHILS; 47-KDA PROTEIN; ASCORBIC-ACID; GROWTH; FERRICYANIDE	Transplasma membrane redox activity of HL-60 cells was determined by measuring the prevention of ascorbate chemical oxidation. The ascorbate free radical produced as the first step of ascorbate oxidation was reduced back by the transplasma membrane electron transport system, causing then the regeneration of extracellular ascorbate. Agents that increase intracellular cAMP, such as forskolin and dibutyryl cAMP (db-cAMP), increased the rate of ascorbate regeneration by HL-60 cells. Also, the phosphodiesterase-resistant cAMP analogue S(p)-cAMP-S (agonist of the protein kinase A) increased the electron flow to the ascorbate free radical at the plasma membrane. R(p)-cAMP-S, antagonist of the protein kinase A, partially inhibited the redox activity of cells and abolished the effect of S(p)-cAMP-S. Inhibition obtained after preincubation of cells in R(p)-cAMP-S was reversed by S(p)-cAMP-S. Tunicamycin, a compound that inhibited the electron flow to the ascorbate free radical at the plasma membrane, also reduced the response of transplasma membrane redox system to S(p)-cAMP-S. Lactate slightly affected the ascorbate regeneration in nonstimulated cells, but showed a significant effect on S(P)-cAMP-S-stimulated plasma membrane electron flow. We show here a role for CAMP in the short-term modulation of transplasma membrane redox system measured as the regeneration of ascorbate at the cell surface of HL-60 cells, probably mediated by cAMP-dependent protein kinases.			RODRIGUEZAGUILERA, JC (corresponding author), UNIV CORDOBA, FAC CIENCIAS, DEPT BIOL CELULAR, CORDOBA, SPAIN.		NAVAS, PLACIDO/R-5943-2019; Arroyo, Antonio/K-4441-2012; Navarro Roldán, Francisco/H-8611-2015	NAVAS, PLACIDO/0000-0002-4115-7966; Navarro Roldán, Francisco/0000-0002-6384-5575; Villalba Montoro, Jose Manuel/0000-0001-8554-3802; Rodriguez Aguilera, Juan Carlos/0000-0002-3371-4128				ALCAIN FJ, 1990, CANCER RES, V50, P5887; ALCAIN FJ, 1991, BIOCHIM BIOPHYS ACTA, V1073, P380, DOI 10.1016/0304-4165(91)90146-8; BRIGHTMAN AO, 1992, BIOCHIM BIOPHYS ACTA, V1105, P109, DOI 10.1016/0005-2736(92)90168-L; BROWN WJ, 1984, J CELL BIOL, V99, P320, DOI 10.1083/jcb.99.1.320; BURDE R, 1989, N-S ARCH PHARMACOL, V340, P671, DOI 10.1007/BF00717743; COASSIN M, 1991, ARCH BIOCHEM BIOPHYS, V290, P458, DOI 10.1016/0003-9861(91)90566-2; CRANE FL, 1985, BIOCHIM BIOPHYS ACTA, V811, P233, DOI 10.1016/0304-4173(85)90013-8; CRANE FL, 1990, OXIDOREDUCTION PLASM, P101; CROWE RA, 1992, MOL BIOL CELL, V3, pA24; DOSTMANN WRG, 1991, BIOCHEMISTRY-US, V30, P8710, DOI 10.1021/bi00099a032; ELLEM KAO, 1983, BIOCHEM BIOPH RES CO, V112, P183, DOI 10.1016/0006-291X(83)91814-4; GIBSONBERRY KL, 1993, J NEUROIMMUNOL, V43, P59, DOI 10.1016/0165-5728(93)90075-A; GOLDENBERG H, 1980, BIOCHEM BIOPH RES CO, V94, P721, DOI 10.1016/0006-291X(80)91292-9; HOCHNER B, 1992, P NATL ACAD SCI USA, V89, P11476, DOI 10.1073/pnas.89.23.11476; IYANAGI T, 1985, BIOCHIM BIOPHYS ACTA, V806, P255, DOI 10.1016/0005-2728(85)90103-3; KHATAMI M, 1986, EXP EYE RES, V43, P167, DOI 10.1016/S0014-4835(86)80084-7; KRAMER IM, 1988, BIOCHIM BIOPHYS ACTA, V971, P189; KRAMER IM, 1988, J BIOL CHEM, V263, P2352; LANDSCHULZ W, 1984, J CELL BIOL, V98, P596, DOI 10.1083/jcb.98.2.596; LESUISSE E, 1991, BIOCHEM J, V280, P545, DOI 10.1042/bj2800545; MEDINA MA, 1992, FEBS LETT, V311, P99, DOI 10.1016/0014-5793(92)81376-W; NAKAMURA T, 1990, J BIOL CHEM, V265, P22011; NAVAS P, 1988, BIOCHEM BIOPH RES CO, V154, P1029, DOI 10.1016/0006-291X(88)90243-4; NAVAS P, 1992, FEBS LETT, V299, P223, DOI 10.1016/0014-5793(92)80119-2; NAVAS P, 1990, OXIDOREDUCTION PLASM, P225; NJUS D, 1991, FEBS LETT, V284, P147, DOI 10.1016/0014-5793(91)80672-P; PEREIRA ME, 1987, J BIOL CHEM, V262, P6093; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; SCHWEINZER E, 1992, EUR J BIOCHEM, V206, P807, DOI 10.1111/j.1432-1033.1992.tb16988.x; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; STAHL RL, 1985, BIOCHIM BIOPHYS ACTA, V839, P119, DOI 10.1016/0304-4165(85)90189-8; SUN IL, 1985, EXP CELL RES, V156, P528, DOI 10.1016/0014-4827(85)90559-2; VILLALBA JM, 1993, J BIOENERG BIOMEMBR, V25, P411, DOI 10.1007/BF00762467; VONFIGURA K, 1979, EUR J BIOCHEM, V101, P103; WENNER CE, 1990, OXIDOREDUCTION PLASM, P131; WINKLER BS, 1987, BIOCHIM BIOPHYS ACTA, V925, P258, DOI 10.1016/0304-4165(87)90190-5; WUNDERLING M, 1986, BIOL CHEM H-S, V367, P1047, DOI 10.1515/bchm3.1986.367.2.1047; YOSHIKAWA K, 1981, J INVEST DERMATOL, V77, P397, DOI 10.1111/1523-1747.ep12494579	38	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26346	26349						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253758				2022-12-25	WOS:A1993MK42500052
J	SAIKI, K; MOGI, T; OGURA, K; ANRAKU, Y				SAIKI, K; MOGI, T; OGURA, K; ANRAKU, Y			IN-VITRO HEME O SYNTHESIS BY THE CYOE GENE-PRODUCT FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYTOCHROME-C OXIDASES; TERMINAL OXIDASE; UBIQUINOL OXIDASE; COMPLEX; TRANSPORT; YEAST; BO	The cytochrome bo complex is a heme-copper terminal quinol oxidase in the aerobic respiratory chain of Escherichia coli and contains low spin heme B, high spin heme O and CU(B) as the redox metal centers in subunit I. Based on site-directed mutagenesis studies on the cyoE gene in the cytochrome bo operon, we have postulated that the cyoE gene encodes a protoheme IX farnesyltransferase (heme O synthase) (Saiki, K., Mogi, T., and Anraku, Y. (1992) Biochem. Biophys. Res. Commun. 189, 1491-1497). The present study demonstrates that the CyoE protein is localized in the cytoplasmic membrane and that the CyoE-overproduced membranes efficiently catalyze a conversion of exogenous ferrous protoheme IX and farnesyl diphosphate to heme O in the presence of divalent cations such as Mg2+ or Ca2+. Thus, the cyoABCDE operon in E. coli encodes not only subunits of the cytochrome bo complex but also heme O synthase that is specifically required for functional expression of the bo-type quinol oxidase. Heme O seems to be an intermediate in heme A biosynthesis.	UNIV TOKYO,GRAD SCH SCI,DEPT PLANT SCI,BUNKYO KU,TOKYO 113,JAPAN; TOHOKU UNIV,INST CHEM REACT SCI,SENDAI,MIYAGI 980,JAPAN	University of Tokyo; Tohoku University								ANRAKU Y, 1988, ANNU REV BIOCHEM, V57, P101, DOI 10.1146/annurev.bi.57.070188.000533; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; CHEPURI V, 1990, J BIOL CHEM, V265, P12978; DAVISSON VJ, 1985, METHOD ENZYMOL, V110, P130; FUTAI M, 1974, J MEMBRANE BIOL, V15, P15, DOI 10.1007/BF01870079; GENNIS RB, 1991, BIOCHIM BIOPHYS ACTA, V1058, P21, DOI 10.1016/S0005-2728(05)80260-9; HANSSON M, 1993, FEMS MICROBIOL LETT, V107, P121; HATA A, 1985, BIOCHIM BIOPHYS ACTA, V810, P62, DOI 10.1016/0005-2728(85)90206-3; HILL J, 1992, BIOCHEMISTRY-US, V31, P11435, DOI 10.1021/bi00161a023; KITA K, 1984, J BIOL CHEM, V259, P3368; MINGHETTI KC, 1992, BIOCHEMISTRY-US, V31, P17; NAKAMURA H, 1990, J BIOL CHEM, V265, P11193; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; PORRA RJ, 1963, BIOCHEM J, V87, P181, DOI 10.1042/bj0870181; PORRA RJ, 1993, FEBS LETT, V323, P31, DOI 10.1016/0014-5793(93)81442-3; Poulter C. D., 1981, BIOSYNTHESIS ISOPREN, V1, P161; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SAIKI K, 1993, J BIOL CHEM, V268, P26927; SAIKI K, 1992, BIOCHEM BIOPH RES CO, V189, P1491, DOI 10.1016/0006-291X(92)90243-E; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SINCLAIR P, 1967, BIOCHIM BIOPHYS ACTA, V143, P427, DOI 10.1016/0005-2728(67)90097-7; SVENNSON B, 1992, EBEC SHORT REPORTS, V7, P36; TAIT GH, 1968, PORPHYRINS RELATED C, P19; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P7456; UNO T, 1985, J BIOL CHEM, V260, P6755; WU W, 1992, J AM CHEM SOC, V114, P1182, DOI 10.1021/ja00030a009	29	77	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26041	26045						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253713				2022-12-25	WOS:A1993MK42500003
J	CHEN, JH; WRIGHT, CD				CHEN, JH; WRIGHT, CD			PEA3, OCT-1 AND OCT-2 POSITIVELY REGULATE THE HUMAN ETS1 PROMOTER	ONCOGENE			English	Article							LONG TERMINAL REPEAT; GLUTATHIONE-S-TRANSFERASE; C-ETS; TRANSCRIPTIONAL ACTIVATION; EXPRESSION SYSTEM; ESCHERICHIA-COLI; DNA-BINDING; GENE; ONCOGENE; C-ETS-1	The promoter of the human ETS1 gene contains binding site motifs for transcription factors Sp1, Ap1, Ap2, ETS, PEA3 and Oct. It has been shown previously that Ap1, Ap2, and ETS are positive regulators for the transcription of the ETS1 gene and that the ETS1 gene is autoregulated. In addition, two regions on the ETS1 promoter that contain negative regulatory sequences have also been identified. In this study, GST/PEA3 and GST/ets1 fusion proteins were used in gel mobility assays to analyse the interaction between these transcription factors with the binding motifs of PEA3 and ETS in the ETS1 promoter. Promoter constructs in which the binding site motifs are mutated were used to examine the effect of mutation on the activities of transcription factors PEA3, ets1 and Oct. Reporter plasmids containing different deletion mutants of the ETS1 promoter were used to examine the effect of different transcription factors (PEA3, Oct 1 and Oct 2) upon the expression of the ETS1 gene. The results of these studies indicate that PEA3 is a strong positive regulator of the ETS1 promoter and that other transcription factors increase the activity of the ETS1 promoter in an additive rather than synergistic fashion.			CHEN, JH (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPTL PEDIAT,HOUSTON,TX 77030, USA.							BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; CHEN JH, 1993, ONCOGENE, V8, P133; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN JH, 1990, ONCOGENE RES, V5, P277; FISHER RJ, 1991, ONCOGENE, V6, P2249; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JORCYK CL, 1991, ONCOGENE, V6, P523; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OKA T, 1991, ONCOGENE, V6, P2077; PROGNONEC B, 1988, EMBO J, V7, P979; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; Sambrook J, 1989, MOL CLONING LABORATO; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1992, GENE DEV, V6, P9665; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOOD WM, 1989, J BIOL CHEM, V264, P14840; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	30	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3375	3383						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247540				2022-12-25	WOS:A1993MG78200022
J	JUVEN, T; BARAK, Y; ZAUBERMAN, A; GEORGE, DL; OREN, M				JUVEN, T; BARAK, Y; ZAUBERMAN, A; GEORGE, DL; OREN, M			WILD-TYPE P53 CAN MEDIATE SEQUENCE-SPECIFIC TRANSACTIVATION OF AN INTERNAL PROMOTER WITHIN THE MDM2 GENE	ONCOGENE			English	Article							TUMOR SUPPRESSOR GENE; BINDING-SITE; PROTEIN; EXPRESSION; CELLS; MUTANT; TRANSFORMATION; SARCOMAS; PRODUCT; FORMS	The p53 tumor suppressor gene product can complex with polypeptides encoded by the mdm2 putative protooncogene. In addition, mdm2 mRNA levels have been shown to increase following the activation of wild type (wt) p53. To determine the basis for the effect of wt p53 on mdm2 mRNA, we studied the interaction of the mdma gene with p53. We report that wt p53 can bind sequence-specifically to a DNA region residing downstream to exon 1 of the mdm2 gene. This is correlated with a pronounced p53-dependent transcriptional activation. Efficient p53-dependent transactivation can be obtained with an mdm2 genomic DNA fragment lacking the putative mdm2 promoter. These findings suggest that p53 can induce transcription from an internal promoter located within the mdm2 gene. These findings raise the possibility that, in addition to increasing the overall levels of mdm2 mRNA, wt p53 may also modulate the repertoire of mdm2 transcripts present within the cell.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; UNIV PENN,DEPT GENET,PHILADELPHIA,PA 19104	Weizmann Institute of Science; University of Pennsylvania			Juven-Gershon, Tamar/AAC-7799-2022	Juven-Gershon, Tamar/0000-0003-2607-5476	NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; COLANTUONI V, 1987, EMBO J, V6, P631, DOI 10.1002/j.1460-2075.1987.tb04801.x; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1993, MOL CELL BIOL, V3, P301; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1990, ONCOGENE, V5, P1285; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MONTENARH M, 1992, Critical Reviews in Oncogenesis, V3, P233; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Rotter Varda, 1993, Trends in Cell Biology, V3, P46, DOI 10.1016/0962-8924(93)90151-P; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; TRUANT R, 1993, J BIOL CHEM, V268, P2284; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	39	374	381	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3411	3416						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247544				2022-12-25	WOS:A1993MG78200026
J	LEE, ST; STRUNK, KM; SPRITZ, RA				LEE, ST; STRUNK, KM; SPRITZ, RA			A SURVEY OF PROTEIN-TYROSINE KINASE MESSENGER-RNAS EXPRESSED IN NORMAL HUMAN MELANOCYTES	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; POLYMERASE CHAIN-REACTION; C-KIT; HUMAN PIEBALDISM; CATALYTIC DOMAIN; INSULIN-RECEPTOR; LEUKEMIA-CELLS; GENE; FAMILY; PROTOONCOGENE	We have used the reverse transcription-polymerase chain reaction to survey the repertoire of protein tyrosine kinases expressed in cultured normal human melanocytes, a differentiated cell type derived from the neural crest. We identified 25 different tyrosine kinase cDNAs among a total of 608 protein tyrosinase kinase-related cDNAs analyzed. Six encode receptor tyrosine kinases for known ligands, several of which have been implicated in controlling melanocyte proliferation in vitro. Two others encode apparent receptor tyrosine kinases for unknown ligands. Four encode known non-receptor tyrosine kinases and five encode previously identified anonymous protein tyrosine kinases. Of the eight other melanocyte-associated protein tyrosine kinases, most or all appear to be novel. These 25 protein tyrosine kinase genes exhibit distinct patterns of expression in cultured human melanocytes, human erythroleukemia cells, and a variety of normal human tissues. We mapped 16 of the corresponding protein tyrosine kinase genes to specific human chromosomes, identifying a total of 19 human genetic loci, some of which may constitute candidate genes for genetic disorders of mammalian development.	UNIV WISCONSIN, DEPT MED GENET, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT PEDIAT, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Lee, Seung-Taek/0000-0001-7300-9784	ACF HHS [AF-39892] Funding Source: Medline	ACF HHS		BOSCH TCG, 1989, MOL CELL BIOL, V9, P4141, DOI 10.1128/MCB.9.10.4141; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; DAURIOL L, 1988, HUM GENET, V78, P374, DOI 10.1007/BF00291740; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DEAN M, 1987, Genomics, V1, P167, DOI 10.1016/0888-7543(87)90009-7; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FLEISCHMAN RA, 1992, J CLIN INVEST, V89, P1713, DOI 10.1172/JCI115772; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FRANCKE U, 1986, COLD SPRING HARB SYM, V51, P855, DOI 10.1101/SQB.1986.051.01.099; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; GIEBEL LB, 1992, ONCOGENE, V7, P2207; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; HALABAN R, 1992, ONCOGENE, V7, P2195; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; ISACCHI A, 1990, NUCLEIC ACIDS RES, V18, P1906, DOI 10.1093/nar/18.7.1906; JHANWAR SC, 1984, CYTOGENET CELL GENET, V38, P73, DOI 10.1159/000132033; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LYON MF, 1990, GENETIC VARIANTS STR; MANO H, 1993, ONCOGENE, V8, P417; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MORRIS C, 1990, CYTOGENET CELL GENET, V53, P196, DOI 10.1159/000132929; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PITTELKOW MR, 1989, J CELL PHYSIOL, V140, P565, DOI 10.1002/jcp.1041400323; POLVI A, 1993, IN PRESS GENE; PRITCHARD MA, 1992, MAMM GENOME, V3, P36, DOI 10.1007/BF00355839; RUTA M, 1988, ONCOGENE, V3, P9; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHISHIDO E, 1991, FEBS LETT, V289, P235, DOI 10.1016/0014-5793(91)81078-M; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; SPRITZ RA, 1992, AM J HUM GENET, V51, P1058; SPRITZ RA, 1992, AM J HUM GENET, V50, P261; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; TRASK B, 1993, GENOMICS, V15, P133, DOI 10.1006/geno.1993.1021; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; ULLRICH A, 1990, CELL, V61, P2003; VANDENBARK GR, 1992, ONCOGENE, V7, P1259; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YUE CC, 1991, MOL IMMUNOL, V28, P399	53	98	117	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3403	3410						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247543				2022-12-25	WOS:A1993MG78200025
J	MAVROTHALASSITIS, G; FISHER, RJ; SMYTH, F; WATSON, DK; PAPAS, TS				MAVROTHALASSITIS, G; FISHER, RJ; SMYTH, F; WATSON, DK; PAPAS, TS			STRUCTURAL INFERENCES OF THE ETS1 DNA-BINDING DOMAIN DETERMINED BY MUTATIONAL ANALYSIS	ONCOGENE			English	Article							GENE FAMILY; C-FOS; TRANSCRIPTION FACTORS; ONCOGENIC ACTIVITY; PROTEIN; C-ETS-1; CELLS; MOTIF; PROTOONCOGENE; SEQUENCE	The ets family of transcription factors is characterized by a conserved region that harbors the DNA-binding activity. We performed extensive deletion and mutational analyses, as well as DNA-peptide interaction studies necessary to identify the determinants of the DNA-binding activity of the ETS1 oncoprotein. We found that amino acids beyond the 85 amino acid conserved region are required in order to afford maximum DNA-binding activity in a heterologous system. Mutation throughout the binding domain can have a detrimental effect on binding activity, indicating that proper folding of the entire domain is necessary for DNA binding. A peptide, as small as 37 residues (K37N), derived from the basic region of the ETS1 binding domain, is sufficient to exhibit sequence-specific DNA recognition. Total randomization of Lysine 379, Lysine 381 and Arginine 391 within this region fails to provide functional substitutions, indicating that these specific amino acids within the basic region are required for binding. Transactivation activity of the ETS1 proteins bearing mutations was consistent with their DNA-binding activity, indicating that the primary (if not only) function of this domain is to provide sequence-specific DNA recognition activity. Our mutational analysis, as well as modeling predictions, lead us to propose a helix-turn-helix structure for the basic region of the ETS1 binding domain that is able to interact directly with DNA. We also propose that the hydrophobic alpha-helical region, surrounding tryptophan 338, is fundamental for proper protein folding and;functioning of the ets binding domain.	PROGRAM RESOURCES INC,DYNCORP,FREDERICK,MD 21701		MAVROTHALASSITIS, G (corresponding author), NCI,MOLEC ONCOL LAB,POB B,FREDERICK,MD 21702, USA.		Fisher, Robert/B-1431-2009					BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1989, J IMMUNOL, V142, P672; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FISHER RJ, 1991, ONCOGENE, V6, P2249; FISHER RJ, 1992, J BIOL CHEM, V267, P17957; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Leung DW, 1989, TECHNIQUE, V1, P11; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WERNERT N, 1992, AM J PATHOL, V140, P119; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	35	21	21	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					425	435						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290254				2022-12-25	WOS:A1994MW24800009
J	SEN, M; MARSH, L				SEN, M; MARSH, L			NONCONTIGUOUS DOMAINS OF THE ALPHA-FACTOR RECEPTOR OF YEASTS CONFER LIGAND SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MATING-TYPE; SIGNAL TRANSDUCTION; PHEROMONE RECEPTOR; KLUYVERI; BINDING; PROTEIN; CELLS; STE2; GENE	The Saccharomyces cerevisiae alpha-factor receptor has a 3400-fold higher affinity for the S. cerevisiae alpha-factor peptide (c-alpha-f) than for the Saccharomyces kluyveri alpha-factor peptide (k-alpha-f) as determined by competition for [H-3]c-alpha-f binding. The S. kluyveri alpha-factor receptor has an approximately 2-fold higher affinity for k-alpha-f than for c-alpha-f. The S. kluyveri receptor gene (k-STE2) is incompletely regulated by S. cerevisiae mating type and poorly expressed on the surface of an S. cerevisiae mating type a strain. A chimeric receptor (c/kl) with amino acid residues 1-45 derived from S. cerevisiae and amino acid residues 46-427 from S. kluyveri exhibits the binding specificity of the S. kluyveri receptor. However, chimeric receptors containing residues 1-168 (c/k2) or 1-250 (c/k3) from S. cerevisiae and the remainder from the S. kluyveri receptor exhibit specificities similar to one another, but intermediate between the parent S. cerevisiae and S. kluyveri receptors. The relative ability of c-alpha-f and k-alpha-f to induce growth arrest in strains expressing chimeric receptors parallels relative affinity. Thus, two noncontiguous domains that include putative extracellular loops 1 and 3 and associated transmembrane segments, but exclude the extracellular NH2 terminus and loop 2, appear to contribute to alpha-factor receptor ligand specificity. COOH-terminal regions of the S. kluyveri receptor appear to confer a desensitization defect when expressed in S. cerevisiae. The S. cerevisiae receptor truncated at residue 296 retains ligand specificity for growth arrest.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,1300 MORRIS PARK AVE,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018738, R37AI018738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043365] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA13330] Funding Source: Medline; NIAID NIH HHS [AI18738] Funding Source: Medline; NIGMS NIH HHS [GM43365] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; DIETZEL C, 1987, CELL, V50, P1000; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EGELMITANI M, 1987, NUCLEIC ACIDS RES, V15, P6303, DOI 10.1093/nar/15.15.6303; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; FUJIMURA H, 1982, ARCH MICROBIOL, V132, P225, DOI 10.1007/BF00407955; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HARTIG A, 1986, MOL CELL BIOL, V6, P2106, DOI 10.1128/MCB.6.6.2106; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HIRAGA K, 1991, J GEN MICROBIOL, V137, P1; HISATOMI T, 1988, CURR GENET, V13, P25, DOI 10.1007/BF00365752; JENNESS DD, 1986, MOL CELL BIOL, V6, P318, DOI 10.1128/MCB.6.1.318; JI I, 1991, J BIOL CHEM, V266, P13076; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KONOPKA JB, 1991, CELL REGUL, V2, P439, DOI 10.1091/mbc.2.6.439; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; KURJAN J, 1992, ANNU REV BIOCHEM, V61, P1097; MALONEYHUSS K, 1992, J MOL BIOL, V225, P859, DOI 10.1016/0022-2836(92)90406-A; MARSH L, 1988, P NATL ACAD SCI USA, V85, P3855, DOI 10.1073/pnas.85.11.3855; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; MARSH L, 1992, MOL CELL BIOL, V12, P3959, DOI 10.1128/MCB.12.9.3959; MARSH L, 1988, COLD SPRING HARB SYM, V53, P557, DOI 10.1101/SQB.1988.053.01.064; MCCULLOUGH J, 1979, J BACTERIOL, V138, P146, DOI 10.1128/JB.138.1.146-154.1979; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; RATHS SK, 1988, J BIOL CHEM, V263, P17333; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; Rose MD., 1990, METHODS YEAST GENETI; SAKURAI A, 1984, FEBS LETT, V166, P339, DOI 10.1016/0014-5793(84)80108-8; Sambrook J, 1989, MOL CLONING LABORATO; SMAMA P, 1993, J BIOL CHEM, V268, P4625; Sprague G F Jr, 1990, Adv Genet, V27, P33; WEINER JL, 1993, J BIOL CHEM, V268, P8070; XIE YB, 1990, J BIOL CHEM, V265, P21411; ZOLLER MJ, 1987, METHOD ENZYMOL, V154, P329	40	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					968	973						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288649				2022-12-25	WOS:A1994MR22000032
J	CHOI, OH; ADELSTEIN, RS; BEAVEN, MA				CHOI, OH; ADELSTEIN, RS; BEAVEN, MA			SECRETION FROM RAT BASOPHILIC RBL-2H3 CELLS IS ASSOCIATED WITH DIPHOSPHORYLATION OF MYOSIN LIGHT-CHAINS BY MYOSIN LIGHT-CHAIN KINASE AS WELL AS PHOSPHORYLATION BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-CELLS; TYROSINE PHOSPHORYLATION; IGE RECEPTOR; HISTAMINE-RELEASE; MAST-CELLS; SIGNAL TRANSDUCTION; PLATELET MYOSIN; PHOSPHOLIPASE C-GAMMA-1; ANTIGEN STIMULATION; SYNERGISTIC SIGNALS	The phosphorylation of myosin light chains and heavy chains by protein kinase C is known to be temporally correlated with Ca2+-dependent secretion of granules from RBL-2H3 cells (Ludowyke, R. I., Peleg, I., Beaven, M. A., and Adelstein, IL S. (1989) J. Biol. Chem. 264, 12492-12501). We now report that whereas myosin light chains are predominantly monophosphorylated by the Ca2+/calmodulin-dependent myosin light chain kinase at serine 19 in unstimulated cells, stimulation of RBL-2H3 cells with antigen or other stimulants causes additional phosphorylation of myosin light chains by myosin light chain kinase at threonine 18, as well as by protein kinase C at serine 1 or serine 2. This diphosphorylation at serine 19 and threonine 18 by myosin light chain kinase and the monophosphorylation by protein kinase C is correlated with the rate and extent of degranulation. Secretion occurs whenever phosphorylation by both enzymes is stimulated by antigen or by the combination of low concentrations of A23187 (50 nM) and phorbol 12-myristate 13-acetate (20 nM). These phosphorylations appear to be closely associated with exocytosis in RBL-2H3 cells. Thus, phosphorylation, as well as secretion, can be blocked by the kinase inhibitors KT5926 and ML-7. More specifically, phorbol ester alone induces phosphorylation of myosin light chains by protein kinase C exclusively, but fails to induce secretion until accompanied by low concentrations of A23187, which activates myosin light chain kinase. Conversely, selective suppression of phosphorylation by protein kinase C (with Ro31-7549 in antigen-stimulated cells) suppresses degranulation, thereby indicating a requirement for protein kinase C.	NHLBI,MOLEC CARDIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	CHOI, OH (corresponding author), NHLBI,CHEM PHARMACOL LAB,BLDG 10,RM 8N108,BETHESDA,MD 20892, USA.			Adelstein, Robert/0000-0002-8683-2144				ALBER G, 1991, J BIOL CHEM, V266, P22613; ALI H, 1989, J IMMUNOL, V143, P2626; APGAR JR, 1991, CELL REGUL, V2, P181, DOI 10.1091/mbc.2.3.181; APGAR JR, 1991, J CELL BIOL, V112, P1157, DOI 10.1083/jcb.112.6.1157; BEAVEN MA, 1987, J CELL BIOL, V105, P1129, DOI 10.1083/jcb.105.3.1129; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BIRCH KA, 1992, J CELL BIOL, V118, P1501, DOI 10.1083/jcb.118.6.1501; CONRICODE KM, 1989, BIOCHIM BIOPHYS ACTA, V1003, P36, DOI 10.1016/0005-2760(89)90095-7; CONTI MA, 1991, BIOCHEMISTRY-US, V30, P966, DOI 10.1021/bi00218a012; CUNHAMELO JR, 1989, J IMMUNOL, V143, P2617; DANIEL JL, 1992, METHOD ENZYMOL, V215, P78; EGELHOFF TT, 1991, J CELL BIOL, V112, P677, DOI 10.1083/jcb.112.4.677; EISEMAN E, 1992, NATURE, V355, P78; ELLIOTT LH, 1990, BIOCHEM BIOPH RES CO, V171, P148, DOI 10.1016/0006-291X(90)91369-4; GRUCHALLA RS, 1990, J IMMUNOL, V144, P2334; HUANG FL, 1989, J BIOL CHEM, V264, P4238; IKEBE M, 1989, BIOCHEMISTRY-US, V28, P8750, DOI 10.1021/bi00448a011; ITOH K, 1992, BIOCHIM BIOPHYS ACTA, V1136, P52, DOI 10.1016/0167-4889(92)90084-O; ITOH K, 1992, BIOCHIM BIOPHYS ACTA, V1133, P286, DOI 10.1016/0167-4889(92)90049-H; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; KATAKAMI Y, 1984, BIOCHEM BIOPH RES CO, V121, P573, DOI 10.1016/0006-291X(84)90220-1; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; KITANI S, 1992, BIOCHEM BIOPH RES CO, V183, P48, DOI 10.1016/0006-291X(92)91607-R; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LO TN, 1987, J BIOL CHEM, V262, P4141; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; METZGER H, 1992, J IMMUNOL, V149, P1477; NAKABAYASHI H, 1991, FEBS LETT, V294, P144, DOI 10.1016/0014-5793(91)81362-C; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8808; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OLIVER JM, 1988, PROG ALLERGY, V42, P195; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PFEIFFER JR, 1985, J CELL BIOL, V101, P2145, DOI 10.1083/jcb.101.6.2145; SAGIEISENBERG R, 1987, IMMUNOLOGY, V61, P203; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SCHOLEY JM, 1980, NATURE, V287, P233, DOI 10.1038/287233a0; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SPUDICH A, 1990, J CELL BIOL, V111, P425; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; TESHIMA R, 1989, MOL IMMUNOL, V26, P641; WYSOLMERSKI RB, 1991, AM J PHYSIOL, V261, pC32, DOI 10.1152/ajpcell.1991.261.1.C32; YAMADA K, 1992, J IMMUNOL, V149, P1031; YU KT, 1991, J BIOL CHEM, V266, P22564	49	86	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					536	541						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276847				2022-12-25	WOS:A1994MR21900086
J	LOETSCHER, M; GEISER, T; OREILLY, T; ZWAHLEN, R; BAGGIOLINI, M; MOSER, B				LOETSCHER, M; GEISER, T; OREILLY, T; ZWAHLEN, R; BAGGIOLINI, M; MOSER, B			CLONING OF A HUMAN 7-TRANSMEMBRANE DOMAIN RECEPTOR, LESTR, THAT IS HIGHLY EXPRESSED IN LEUKOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; NEUTROPHIL-ACTIVATING PEPTIDE-2; NEUROPEPTIDE-Y RECEPTOR; HUMAN INTERLEUKIN-8 RECEPTOR; ANGIOTENSIN-II RECEPTOR; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; RESPIRATORY BURST; CYTOKINE FAMILY; HIGH-AFFINITY	Several chemotactic agonists including interleukin-8 (IL-8) and related cytokines have been shown to activate and attract leukocytes via seven-transmembrane domain, GTP-binding protein-coupled receptors. A cDNA clone, LESTR, encoding a protein of 352 amino acids, corresponding to a novel receptor of this type, was isolated from a human blood monocyte cDNA library. The sequence of the deduced protein, LESTR (leukocyte-derived seven-transmembrane domain receptor), has 92.6% identity with that of a recently reported bovine neuropeptide Y (NPY) receptor, boLCR1 (Rimland, J., Xin, W., Sweetnam, P., Saijoh, K., Nestler, E. J., and Duman, R. S. (1991) Mol. Pharmacol. 40, 869-875). LESTR, however, is more similar (>34%) to the IL-8 receptors, IL-SR, and IL-8R2, than to several NPY receptors of different origin (<20%). In the monocyte library, LESTR cDNA fragments were about 20 times as frequent as cDNA coding for IL-8R, and IL-8R2, and much higher levels of LESTR- than IL-8R-specific mRNA were found in human blood neutrophils and lymphocytes. LESTR transcripts, by contrast, were low or undetectable in several neuroblastoma cell lines that are widely used to study NPY functions. Transfected cells expressing high levels of LESTR mRNA did not bind radiolabeled NPY, IL-8, NAP-2, GROalpha, PF4, IP10, MCP-1, MCP-3, MIP-1alpha, HC14,I309, RANTES, C3a, or LTB4. NPY also failed to bind to neutrophils, monocytes, and lymphocytes, to elicit responses in vitro such as Ca2+ changes, shape change, chemotaxis, enzyme release, and the respiratory burst, and to induce leukocyte accumulation upon injection in rats and rabbits. Although the ligand for LESTR could not be identified among a large number of chemotactic cytokines, the high expression in white blood cells and the marked sequence relation to IL-8R1 and IL-8R2 suggest that LESTR may function in the activation of inflammatory cells.	PHARMA RES CIBA GEIGY, CH-4002 BASEL, SWITZERLAND; UNIV BERN, DEPT VET PATHOL, CH-3000 BERN, SWITZERLAND	University of Bern	LOETSCHER, M (corresponding author), UNIV BERN, THEODOR KOCHER INST, POB 99, CH-3000 BERN 9, SWITZERLAND.			Moser, Bernhard/0000-0002-4354-4572				ALLEN JM, 1990, ANN NY ACAD SCI, V611, P1; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BECKMANN MP, 1991, BIOCHEM BIOPH RES CO, V179, P784, DOI 10.1016/0006-291X(91)91885-G; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; DACEY RG, 1974, ANTIMICROB AGENTS CH, V6, P437, DOI 10.1128/AAC.6.4.437; EVA C, 1990, FEBS LETT, V271, P81, DOI 10.1016/0014-5793(90)80377-U; GEISER T, 1993, J BIOL CHEM, V268, P15419; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GORDON EA, 1990, J NEUROCHEM, V55, P506, DOI 10.1111/j.1471-4159.1990.tb04164.x; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; IWAI N, 1992, FEBS LETT, V298, P257, DOI 10.1016/0014-5793(92)80071-N; KASSIS S, 1987, J BIOL CHEM, V262, P3429; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KERNEN P, 1991, J CLIN INVEST, V87, P2012, DOI 10.1172/JCI115230; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUNA P, 1992, J IMMUNOL, V149, P636; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LI XJ, 1992, J BIOL CHEM, V267, P9; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; MEYERHOF W, 1991, DNA CELL BIOL, V10, P689, DOI 10.1089/dna.1991.10.689; MICHEL MC, 1991, TRENDS PHARMACOL SCI, V12, P389, DOI 10.1016/0165-6147(91)90610-5; MOSER B, 1991, J BIOL CHEM, V266, P10666; MOSER B, 1993, BIOCHEM J, V294, P285, DOI 10.1042/bj2940285; MURPHY PM, 1992, J BIOL CHEM, V267, P7637; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; RIMLAND J, 1991, MOL PHARMACOL, V40, P869; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; Sneath P.H.A., 1973, NUMERICAL TAXONOMY P; SREEDHARAN SP, 1991, P NATL ACAD SCI USA, V88, P4986, DOI 10.1073/pnas.88.11.4986; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; VANRIPER G, 1993, J EXP MED, V177, P851, DOI 10.1084/jem.177.3.851; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; WALZ A, 1991, J LEUKOCYTE BIOL, V50, P279, DOI 10.1002/jlb.50.3.279; WANG JM, 1993, J EXP MED, V177, P699, DOI 10.1084/jem.177.3.699; WESTON K, 1986, J MOL BIOL, V192, P177, DOI 10.1016/0022-2836(86)90359-1; WYMANN MP, 1987, ANAL BIOCHEM, V165, P371, DOI 10.1016/0003-2697(87)90284-3; YOSHIMURA T, 1990, J IMMUNOL, V145, P292	57	379	424	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					232	237						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276799				2022-12-25	WOS:A1994MR21900043
J	HEDBOM, E; HEINEGARD, D				HEDBOM, E; HEINEGARD, D			BINDING OF FIBROMODULIN AND DECORIN TO SEPARATE SITES ON FIBRILLAR COLLAGENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL INTERSTITIAL PROTEOGLYCANS; DERMATAN SULFATE PROTEOGLYCAN; ELECTRON-MICROSCOPY; FIBRONECTIN; PROTEIN; CARTILAGE; TENDON; GLYCOSAMINOGLYCANS; FIBROBLASTS; INHIBITION	The small proteoglycans, decorin, fibromodulin, bi-glycan, and lumican, represent a family of structurally related but genetically distinct molecules present in many types of connective tissues. Fibromodulin and decorin interact with collagens I and II (Hedbom, E., and Heinegard, D. (1989) J. Biol. Chem. 264, 6898-6905). These interactions have been characterized further by using native radiolabeled components from fibroblast cultures and nonlabeled proteoglycans purified from guanidine hydrochloride extracts of bovine tendon. Binding of metabolically labeled macromolecules to collagen I was measured in an assay based on precipitation of collagen fibrils formed in vitro. Among a large number of secreted fibroblast products, decorin and fibromodulin represented the vast majority of the collagen binding components. These molecules showed poor binding to denatured collagen, in contrast to fibronectin, which was also present in the medium. Decorin and fibromodulin bind to different sites on collagen I fibrils, since the binding of either radiolabeled component could be competed for only by the corresponding nonlabeled proteoglycan. Similarly, these proteoglycans showed binding to separate sites on collagen II. Binding of isolated fibromodulin and decorin to collagens in solution was measured in a solid-phase inhibition assay. Each of the proteoglycans interacted with triple helical molecules, but not with denatured collagen chain constituents or fragments. For fibromodulin, the data indicated an average of one binding site per collagen I molecule (K(d) = 9.9 nM). The data on decorin indicated additional interactions, some apparently mediated by the dermatan sulfate side chain. The results suggest that the small proteoglycans bind to distinct triple helical sites, apparently differing from several other similar structures within each collagen molecule.			HEDBOM, E (corresponding author), LUND UNIV, DEPT PHYSIOL CHEM, POB 94, S-22100 LUND, SWEDEN.							ANTONOPO.CA, 1967, BIOCHIM BIOPHYS ACTA, V148, P158, DOI 10.1016/0304-4165(67)90291-7; ANTONOPOULOS CA, 1991, J BIOL CHEM, V266, P16859; AXELSSON I, 1978, BIOCHEM J, V169, P517, DOI 10.1042/bj1690517; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; BORNSTEIN P, 1965, SCIENCE, V148, P1353, DOI 10.1126/science.148.3675.1353; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; BRUCKNER P, 1985, P NATL ACAD SCI USA, V82, P2608, DOI 10.1073/pnas.82.9.2608; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; ENGVALL E, 1978, J EXP MED, V147, P1584, DOI 10.1084/jem.147.6.1584; FRANSSON LA, 1982, J BIOL CHEM, V257, P6333; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEINEGARD D, 1986, J BIOL CHEM, V261, P3866; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; HEINEGARD D, 1985, BIOCHEM J, V230, P181, DOI 10.1042/bj2300181; Heinegard Dick, 1993, P189; Kielty Cay M., 1993, P103; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; MILLER EJ, 1987, METHOD ENZYMOL, V144, P3; MILLER EJ, 1972, BIOCHEMISTRY-US, V11, P4903, DOI 10.1021/bi00776a005; MORGELIN M, 1988, BIOCHEM J, V253, P175; MORGELIN M, 1989, J BIOL CHEM, V264, P12080; OBRINK B, 1973, EUR J BIOCHEM, V33, P387, DOI 10.1111/j.1432-1033.1973.tb02695.x; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; PAN TC, 1992, P NATL ACAD SCI USA, V89, P6565, DOI 10.1073/pnas.89.14.6565; PLAAS AHK, 1990, J BIOL CHEM, V265, P20634; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SCOTT JE, 1981, BIOCHEM J, V197, P213, DOI 10.1042/bj1970213; STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009-8981(67)90167-2; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VOGEL KG, 1985, J BIOL CHEM, V260, P9298; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WARD NP, 1987, BIOCHEM J, V242, P761, DOI 10.1042/bj2420761; WIGHT TN, 1991, CELL BIOL EXTRACELLU, P45, DOI DOI 10.1007/978-1-4615-3770-0_3	40	268	274	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27307	27312						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262971				2022-12-25	WOS:A1993MM26200068
J	KRAMER, RM; ROBERTS, EF; MANETTA, JV; HYSLOP, PA; JAKUBOWSKI, JA				KRAMER, RM; ROBERTS, EF; MANETTA, JV; HYSLOP, PA; JAKUBOWSKI, JA			THROMBIN-INDUCED PHOSPHORYLATION AND ACTIVATION OF CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A(2) IN HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; MACROPHAGE CELL-LINE; PROSTAGLANDIN-E2 PRODUCTION; THROMBOXANE BIOSYNTHESIS; STIMULATED PLATELETS; RABBIT PLATELETS; MESANGIAL CELLS; ACID RELEASE; CALCIUM	Receptor-mediated activation of human platelets by thrombin initiates a series of rapid biochemical events that include activation of phospholipase A2 to liberate arachidonic acid for further conversion to thromboxane A2. The identity of the phospholipase A2 involved has not been clear. Here we show by immunochemical analysis that human platelets contain significant amounts (60 ng/10(9) platelets) of the recently identified Ca2+-sensitive cytosolic phospholipase A2 (cPLA2). Metabolic labeling of human platelets with P-33i revealed that the extent of phosphorylation of cPLA2 was greatly increased after thrombin treatment. Upon stimulation of platelets with thrombin, cPLA2 exhibits enhanced catalytic activity, as well as a change in its electrophoretic and chromatographic properties compared with cPLA2 in resting platelets. These alterations of cPLA2 are reversed by treatment with phosphatase, demonstrating that they are the consequence of thrombin-stimulated phosphorylation. Thrombin-induced phosphorylation and activation of cPLA2 is rapid (half-maximal by 1 min at 1 unit/10(9) platelets) and dose-dependent. Agonist-induced phosphorylation of cPLA2 is more sensitive to thrombin than the generation of thromboxane A2, suggesting that it may be an early event in the sequence of steps leading to the mobilization and further metabolism of arachidonic acid. By comparing the functional properties of cPLA2 from control versus thrombin-stimulated platelets, we found that while activated cPLA2 exhibits the same Ca2+ requirement and apparent substrate affinity (K(m)), its catalytic activity (V(max)) is increased compared with control cPLA2. We conclude that 1) cPLA2 is likely to play an important role in agonist-induced mobilization of arachidonic acid and 2) thrombin elicits rapid and full activation of cPLA2 not only by promoting a rise in cytosolic free Ca2+ but also by inducing phosphorylation of cPLA2 thereby improving its catalytic activity.			KRAMER, RM (corresponding author), ELI LILLY & CO, LILLY RES LAB, INDIANAPOLIS, IN 46285 USA.							AXELROD J, 1990, BIOCHEM SOC T, V18, P503, DOI 10.1042/bst0180503; BONVENTRE JV, 1988, J CLIN INVEST, V82, P168, DOI 10.1172/JCI113566; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; BRASS LF, 1990, PROGR HEMOSTASIS THR, P127; BROEKMAN MJ, 1986, J LIPID RES, V27, P884; BROOKS RC, 1989, J BIOL CHEM, V264, P20147; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; DAWSON RMC, 1985, BIOCHEM J, V230, P61, DOI 10.1042/bj2300061; DEYKIN D, 1979, PROSTAGLANDINS, V18, P19, DOI 10.1016/S0090-6980(79)80019-2; DHAR A, 1993, BRIT J HAEMATOL, V84, P1, DOI 10.1111/j.1365-2141.1993.tb03018.x; DIEZ E, 1990, J BIOL CHEM, V265, P14654; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; GODING JW, 1986, MONOCLONAL ANTIBODIE, P83; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; HALENDA SP, 1989, BIOCHEMISTRY-US, V28, P7356, DOI 10.1021/bi00444a031; HARA S, 1991, J BIOCHEM, V110, P163, DOI 10.1093/oxfordjournals.jbchem.a123550; HARDINGER SA, 1991, BIOORG MED CHEM LETT, V1, P79, DOI 10.1016/S0960-894X(01)81097-0; HAWIGER J, 1989, METHOD ENZYMOL, V169, P191; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; INSEL PA, 1991, BIOCHEM SOC T, V19, P329, DOI 10.1042/bst0190329; JAKUBOWSKI JA, 1988, ARTERIOSCLEROSIS, V8, P436, DOI 10.1161/01.ATV.8.4.436; JAKUBOWSKI JA, 1985, BRIT J HAEMATOL, V60, P635, DOI 10.1111/j.1365-2141.1985.tb07467.x; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KIM DK, 1988, J BIOCHEM-TOKYO, V104, P492, DOI 10.1093/oxfordjournals.jbchem.a122496; KRAMER RM, 1986, BIOCHIM BIOPHYS ACTA, V878, P394, DOI 10.1016/0005-2760(86)90248-1; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1987, BIOCHEM J, V248, P779, DOI 10.1042/bj2480779; KRAMER RM, 1993, J LIPID MEDIATOR, V6, P209; KRAMER RM, 1988, BIOCHIM BIOPHYS ACTA, V959, P269, DOI 10.1016/0005-2760(88)90200-7; KRAMER RM, 1982, J BIOL CHEM, V257, P6844; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KROLL MH, 1989, BLOOD, V74, P1181; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOEB LA, 1986, J BIOL CHEM, V261, P467; MCINTYRE TM, 1987, J BIOL CHEM, V262, P15370; MUELLER HW, 1983, LIPIDS, V18, P814, DOI 10.1007/BF02534641; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; MURAYAMA T, 1990, J BIOL CHEM, V265, P4290; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NOZAWA Y, 1991, BIOCHIM BIOPHYS ACTA, V1082, P219, DOI 10.1016/0005-2760(91)90197-P; PARKER J, 1987, J BIOL CHEM, V262, P5385; PATRONO C, 1992, TRENDS CARDIOVAS MED, V2, P15, DOI 10.1016/1050-1738(92)90039-U; POLLOCK WK, 1986, BIOCHEM BIOPH RES CO, V139, P308, DOI 10.1016/S0006-291X(86)80114-0; PURDON AD, 1987, BIOCHIM BIOPHYS ACTA, V920, P205, DOI 10.1016/0005-2760(87)90096-8; RITTENHOUSE SE, 1984, BIOCHEM BIOPH RES CO, V123, P393, DOI 10.1016/0006-291X(84)90426-1; RITTENHOUSESIMM.S, 1981, PLATELETS BIOL PATHO, V2, P349; RITTENHOUSESIMMONS S, 1977, J CLIN INVEST, V60, P495, DOI 10.1172/JCI108801; SAMIEI M, 1993, BIOCHIM BIOPHYS ACTA, V1176, P287, DOI 10.1016/0167-4889(93)90057-V; SATO T, 1992, J BIOCHEM-TOKYO, V112, P756, DOI 10.1093/oxfordjournals.jbchem.a123971; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; WHATLEY RE, 1989, J BIOL CHEM, V264, P6325; WIGHTMAN PD, 1982, J BIOL CHEM, V257, P6650; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	64	190	191	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26796	26804						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253817				2022-12-25	WOS:A1993MK42500114
J	MATTINGLY, JR; IRIARTE, A; MARTINEZCARRION, M				MATTINGLY, JR; IRIARTE, A; MARTINEZCARRION, M			STRUCTURAL FEATURES WHICH CONTROL FOLDING OF HOMOLOGOUS PROTEINS IN CELL-FREE TRANSLATION SYSTEMS - THE EFFECT OF A MITOCHONDRIAL-TARGETING PRESEQUENCE ON ASPARTATE-AMINOTRANSFERASE ISOZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; MOLECULAR CHAPERONE; PRECURSOR PROTEIN; ESCHERICHIA-COLI; YEAST MITOCHONDRIA; STRESS PROTEINS; ATP HYDROLYSIS; COMPLEX; IMPORT; GROEL	When the precursor to mitochondrial aspartate aminotransferase (pmAspAT) is synthesized in a rabbit reticulocyte lysate translation system (RRL), its properties are quite unlike those of the purified protein (Mattingly, J. R., Jr., Youssef, J., Iriarte, A., and Martinez-Carrion, M. (1993) J. Biol. Chem. 268, 3925-3937). These results suggest that molecular chaperones present in RRL modulate the folding of pmAspAT. To investigate the structural basis for this, we have used protease resistance to monitor the extent of folding for several related AspATs after synthesis in RRL and in wheat germ extract (WGE). In addition to pmAspAT, the following proteins were examined: the mature form of pmAspAT (DELTA2-28 pmAspAT), its cytosolic counterpart (CAspAT), a chimeric protein consisting of the presequence of pmAspAT attached to the amino terminus of cAspAT (pCAspAT), and a pMAspAT variant in which the presequence and the amino-terminal domain of the mature enzyme are deleted (DELTA2-57 pmAspAT). In RRL, DELTA28 pmAspAT folds somewhat faster than intact pmAspAT, whereas the truncated DELTA2-57 pmAspAT is unable to fold. In contrast, CAspAT and pCAspAT both fold with extreme rapidity. After synthesis in WGE, pmAspAT and DELTA2-28 pmAspAT never acquire a protease-resistant conformation, whereas the folding of cAspAT and pcAspAT still occurs rapidly. We conclude that the presequence has only a minor role in determining the folding rate of the pmAspAT mitochondrial precursor protein in RRL or WGE and has no influence on the folding of the homologous cAspAT. Rather, the primary sequence of the mature part of the protein seems to dictate whether or how molecular chaperones regulate folding events.	UNIV MISSOURI,SCH BIOL SCI,DIV MOLEC BIOL & BIOCHEM,KANSAS CITY,MO 64110	University of Missouri System; University of Missouri Kansas City					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038184] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38412] Funding Source: Medline; NIGMS NIH HHS [GM-38184] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BRANDSCH R, 1992, J BIOL CHEM, V267, P20844; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; CHIRICO WJ, 1992, BIOCHEM BIOPH RES CO, V189, P1150, DOI 10.1016/0006-291X(92)92324-Q; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CYR DM, 1992, J BIOL CHEM, V267, P20927; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GUPTA RS, 1990, BIOCHEM INT, V20, P833; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; Hartl F U, 1991, Semin Immunol, V3, P5; IRIARTE A, 1984, J BIOL CHEM, V259, P723; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; JAUSSI R, 1982, J BIOL CHEM, V257, P13334; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MATTINGLY JR, 1993, J BIOL CHEM, V268, P3925; MEER L, 1984, CHEM BIOL ASPECTS  B, P227; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MIZZEN LA, 1991, CELL REGUL, V2, P165, DOI 10.1091/mbc.2.2.165; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; MURAKAMI K, 1990, EMBO J, V9, P3201, DOI 10.1002/j.1460-2075.1990.tb07518.x; ONO H, 1990, ARCH BIOCHEM BIOPHYS, V280, P299, DOI 10.1016/0003-9861(90)90333-T; ONO H, 1990, ARCH BIOCHEM BIOPHYS, V277, P368, DOI 10.1016/0003-9861(90)90592-M; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; SANDMEIER E, 1980, J BIOL CHEM, V257, P10284; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHMID D, 1992, EUR J BIOCHEM, V208, P699, DOI 10.1111/j.1432-1033.1992.tb17237.x; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; URSIC D, 1992, NATURE, V356, P392; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZAHN R, 1992, BIOCHEMISTRY-US, V31, P3249, DOI 10.1021/bi00127a029	50	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26320	26327						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253754				2022-12-25	WOS:A1993MK42500048
J	PUERTA, C; HERNANDEZ, F; GUTIERREZ, C; PINEIRO, M; LOPEZALARCON, L; PALACIAN, E				PUERTA, C; HERNANDEZ, F; GUTIERREZ, C; PINEIRO, M; LOPEZALARCON, L; PALACIAN, E			EFFICIENT TRANSCRIPTION OF A DNA-TEMPLATE ASSOCIATED WITH HISTONE (H3-CENTER-DOT-H4)(2) TETRAMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; ONE H2A.H2B DIMER; NUCLEOSOMAL TEMPLATES; CHROMATIN STRUCTURE; ELONGATION; INITIATION; INVITRO; CORE; INHIBIT; GENE	A histone-DNA transcription template has been assembled, by dialysis against decreasing salt concentrations, from pGEMEX-1 (4 kilobases), a plasmid containing a promoter for bacteriophage T7 RNA polymerase, and from isolated histone (H3.H4)2 tetramers. Electron microscopy after psoralen cross-linking shows that each histone tetramer protects approximately 80 base pairs of DNA from psoralen action and that, under the employed conditions, an average of 15 tetramer particles are assembled per DNA molecule. This (H3.H4)2-DNA template is efficiently transcribed in vitro by T7 RNA polymerase as compared to naked DNA. The presence of (H3-H4)2 tetramers does not affect initiation, in contrast with the complete histone octamer, (H2A.H2B.H3.H4)2, assembled with the complementary addition of H2A-H2B dimers, which causes transcriptional inhibition mainly by blocking initiation.	UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOLEC SEVERO OCHOA, E-28049 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Hernandez, Felix/L-2114-2015; Piñeiro, Manuel/I-5910-2015; Gutierrez, Crisanto/ABH-8782-2020	Hernandez, Felix/0000-0001-8753-8249; Piñeiro, Manuel/0000-0002-4640-6511; Gutierrez, Crisanto/0000-0001-8905-8222				ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ALMOUZNI G, 1991, MOL CELL BIOL, V11, P655, DOI 10.1128/MCB.11.2.655; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CECH TR, 1977, COLD SPRING HARB SYM, V42, P191; CLARK DJ, 1991, EMBO J, V10, P3419, DOI 10.1002/j.1460-2075.1991.tb04906.x; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; GONZALEZ PJ, 1989, J BIOL CHEM, V264, P18457; GONZALEZ PJ, 1987, J BIOL CHEM, V262, P11280; GRUSS C, 1990, EMBO J, V9, P2911, DOI 10.1002/j.1460-2075.1990.tb07482.x; GRUSS C, 1993, IN PRESS EMBO J; HANSEN JC, 1991, J BIOL CHEM, V266, P4276; HANSEN JC, 1992, BIOCHEMISTRY-US, V31, P7977, DOI 10.1021/bi00149a032; HANSON CV, 1976, SCIENCE, V193, P62, DOI 10.1126/science.935855; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HAYES JJ, 1992, P NATL ACAD SCI USA, V89, P1229, DOI 10.1073/pnas.89.4.1229; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; JACKSON V, 1987, BIOCHEMISTRY-US, V26, P2315, DOI 10.1021/bi00382a037; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LOIDL P, 1988, FEBS LETT, V227, P91, DOI 10.1016/0014-5793(88)80874-3; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LOSA R, 1987, CELL, V50, P801, DOI 10.1016/0092-8674(87)90338-2; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; PFAFFLE P, 1990, J BIOL CHEM, V265, P16830; PINEIRO M, 1991, BIOCHEM BIOPH RES CO, V177, P370, DOI 10.1016/0006-291X(91)91993-M; RUIZCARRILLO A, 1979, BIOCHEMISTRY-US, V18, P760, DOI 10.1021/bi00572a004; Sambrook J, 1989, MOL CLONING LABORATO; SOGO JM, 1989, METHOD ENZYMOL, V170, P142; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; TREMETHICK D, 1990, J BIOL CHEM, V265, P5014; van Holde KE., 1989, SPRINGER SERIES MOL; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; WOLFFE AP, 1989, P NATL ACAD SCI USA, V86, P9817, DOI 10.1073/pnas.86.24.9817	35	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26663	26667						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253798				2022-12-25	WOS:A1993MK42500094
J	QUINTO, I; RUOCCO, MR; BALDASSARRE, F; MALLARDO, M; DRAGONETTI, E; SCALA, G				QUINTO, I; RUOCCO, MR; BALDASSARRE, F; MALLARDO, M; DRAGONETTI, E; SCALA, G			THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 LONG TERMINAL REPEAT IS ACTIVATED BY MONOFUNCTIONAL AND BIFUNCTIONAL DNA ALKYLATING-AGENTS IN HUMAN-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; NF-KAPPA-B; CELL NUCLEAR-PROTEIN; TRANS-ACTIVATION; BINDING-PROTEIN; TRANSCRIPTIONAL REGULATION; TRANSACTIVATING REGION; INDUCED EXPRESSION; GENE-EXPRESSION; PHORBOL ESTER	The activation of the human immunodeficiency virus, type 1 (HIV-1) by the DNA alkylating agents ethyl methanesulfonate, methyl methanesulfonate, and mitomycin C was observed in human B lymphocytes transiently transfected with plasmids in which the HIV-1 long terminal repeat (LTR) directed the expression of the bacterial chloramphenicol acetyltransferase gene. Deletion of the two NF-kappaB-binding sites of LTR abolished the HIV-1 activation induced by the three mutagens, while deletion of the three Sp1-binding sites slightly reduced it. Electrophoretic mobility shift assays revealed an increased binding to the kappaB sites of HIV-1 LTR in the nuclear extracts of human B lymphocytes upon mutagen treatment, while binding to Sp1 sites was unaffected. The TAR region was also involved in the mutagen- mediated activation of HIV-1 LTR inasmuch as a small deletion in the TAR sequence (nucleotides +34 to +37) greatly decreased the induction of HIV-1 expression. Moreover, an enhanced binding activity to the TAR DNA sequence (nucleotides +24 to +47) was observed in nuclear extracts of mutagen-treated lymphocytes. Thus, both the enhancer and the 5'-untranslated region of HIV-1 functionally cooperate in the mutagen-mediated induction of HIV-1 expression.	UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	Universita Mediterranea di Reggio Calabria	QUINTO, I (corresponding author), UNIV FEDERICO 2,DIPARTIMENTO BIOCHIM & BIOTECNOL MED,VIA S PANSINI 5,I-80131 NAPLES,ITALY.		SCALA, GIUSEPPE/A-3280-2009	MALLARDO, Massimo/0000-0002-4001-3856; QUINTO, Ileana/0000-0001-8212-8515				ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; [Anonymous], 1985, DNA REPAIR; DAVIS MG, 1987, P NATL ACAD SCI USA, V84, P8642, DOI 10.1073/pnas.84.23.8642; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GATIGNOL A, 1989, P NATL ACAD SCI USA, V86, P7828, DOI 10.1073/pnas.86.20.7828; GAYNOR R, 1989, P NATL ACAD SCI USA, V86, P4858, DOI 10.1073/pnas.86.13.4858; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GIMBLE JM, 1988, J VIROL, V62, P4104, DOI 10.1128/JVI.62.11.4104-4112.1988; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HARRICH D, 1989, J VIROL, V63, P2585, DOI 10.1128/JVI.63.6.2585-2591.1989; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2555, DOI 10.1128/MCB.8.6.2555; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; JOSHI B, 1992, VACCINES 92 : MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P247; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KAUFMAN JD, 1987, MOL CELL BIOL, V7, P3759, DOI 10.1128/MCB.7.10.3759; KORNER M, 1990, BIOCHEM J, V265, P547, DOI 10.1042/bj2650547; LEONARD J, 1989, J VIROL, V63, P4919, DOI 10.1128/JVI.63.11.4919-4924.1989; LIN CS, 1990, P NATL ACAD SCI USA, V87, P36, DOI 10.1073/pnas.87.1.36; MAEKAWA T, 1989, J BIOL CHEM, V264, P14591; MALIM MH, 1989, J VIROL, V63, P3213, DOI 10.1128/JVI.63.8.3213-3219.1989; MALLON R, 1990, J VIROL, V64, P6282, DOI 10.1128/JVI.64.12.6282-6285.1990; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MORREY JD, 1991, J VIROL, V65, P5045, DOI 10.1128/JVI.65.9.5045-5051.1991; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PARROTT C, 1991, J VIROL, V65, P1414, DOI 10.1128/JVI.65.3.1414-1419.1991; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROSENBERG ZF, 1991, FASEB J, V5, P2382, DOI 10.1096/fasebj.5.10.1676689; ROUNSEVILLE MP, 1992, J VIROL, V66, P1688, DOI 10.1128/JVI.66.3.1688-1694.1992; ROY S, 1991, J VIROL, V65, P632, DOI 10.1128/JVI.65.2.632-640.1991; SCALA G, 1993, J VIROL, V67, P2853, DOI 10.1128/JVI.67.5.2853-2861.1993; SCALA G, 1990, J EXP MED, V172, P61, DOI 10.1084/jem.172.1.61; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHELINE CT, 1991, GENE DEV, V5, P2508, DOI 10.1101/gad.5.12b.2508; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; TONGSTARKSEN SE, 1989, J IMMUNOL, V142, P702; VALERIE K, 1990, New Biologist, V2, P712; VALERIE K, 1988, NATURE, V333, P78, DOI 10.1038/333078a0; WU F, 1991, GENE DEV, V5, P2128, DOI 10.1101/gad.5.11.2128; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x	56	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26719	26724						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253807				2022-12-25	WOS:A1993MK42500103
J	GERRIETS, JE; CURWIN, SL; LAST, JA				GERRIETS, JE; CURWIN, SL; LAST, JA			TENDON HYPERTROPHY IS ASSOCIATED WITH INCREASED HYDROXYLATION OF NONHELICAL LYSINE RESIDUES AT 2 SPECIFIC CROSS-LINKING SITES IN TYPE-I COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-HELICAL REGIONS; FIBROTIC COLLAGEN; LYSYL HYDROXYLASE; LUNGS; RATS; CROSSLINKING; AGE; QUANTITATION; METABOLISM; BLEOMYCIN	This study was designed to investigate whether the changes in lysine hydroxylation known to occur in hypertrophic tendon occur randomly or at specific lysine residues in the type I collagen molecule. Peptides corresponding to the two known major cross-linking sites of type I collagen (a lysine (or hydroxylysine) at position 9N cross-linked to a hydroxylysine at 930 and a lysine (or hydroxylysine) at position 16C cross-linked to a hydroxylysine at position 87) were prepared by collagenase digestion, size fractionation, and separation by high performance liquid chromatography from normal chicken tendon and from chicken tendon subjected to increased tensile load as a result of muscle hypertrophy. The ratio of the difunctional cross-links dihydroxylysinonorleucine to hydroxylysinonorleucine in normal tendon is 0.75:1; this ratio is increased to 6:1 in hypertrophic tendon. The dihydroxylysinonorleucine to hydroxylysinonorleucine ratio is increased to the same extent in samples of the purified cross-linked peptides derived from both the N-terminal and C-terminal lysine aldehyde residues. On the other hand, the relative hydroxylysine content of preparations of the pooled larger helical peptides obtained by cyanogen bromide digestion of normal and hypertrophic tendons was essentially identical. These results demonstrate that there is a specific increase in hydroxylation of only the N- and C-terminal non-hellical lysine residues that participate in the formation of the reducible difunctional cross-links of type I collagen in hypertrophic tendon, while the extent of hydroxylation of lysine residues in the helical regions is not affected. The specific mechanism by which the enzyme lysyl hydroxylase acting on its substrate can distinguish between lysine residues destined to be in non-helical versus helical regions in a nascent collagenous peptide that has not yet attained its final secondary structure remains to be defined.	UNIV CALIF DAVIS,SCH MED,CALIF REG PRIMATE RES CTR,DEPT INTERNAL MED,DAVIS,CA 95616	University of California System; University of California Davis					NCRR NIH HHS [RR-00169] Funding Source: Medline; NHLBI NIH HHS [HL32690] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000169] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032690] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANANTHANARAYANAN VS, 1992, ARCH BIOCHEM BIOPHYS, V298, P21, DOI 10.1016/0003-9861(92)90088-E; BAILEY AJ, 1975, BIOCHIM BIOPHYS ACTA, V405, P412, DOI 10.1016/0005-2795(75)90106-3; BARNES MJ, 1974, BIOCHEM J, V139, P461, DOI 10.1042/bj1390461; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BOEDTKER H, 1956, J AM CHEM SOC, V78, P4267, DOI 10.1021/ja01598a024; BRICKLEYPARSONS D, 1981, J BONE JOINT SURG AM, V63, P787, DOI 10.2106/00004623-198163050-00014; CURWIN SL, 1988, J APPL PHYSIOL, V65, P2297, DOI 10.1152/jappl.1988.65.5.2297; GALLOWAY D, 1982, COLLAGEN HLTH DISEAS, P528; GOMEZ MA, 1991, AM J SPORT MED, V19, P347, DOI 10.1177/036354659101900405; HALME T, 1986, BIOCHIM BIOPHYS ACTA, V881, P222, DOI 10.1016/0304-4165(86)90007-3; HARPER JI, 1985, BRIT J DERMATOL, V113, P145, DOI 10.1111/j.1365-2133.1985.tb02056.x; HARWOOD FL, 1992, J APPL PHYSIOL, V72, P1687, DOI 10.1152/jappl.1992.72.5.1687; HENKEL W, 1982, EUR J BIOCHEM, V122, P205, DOI 10.1111/j.1432-1033.1982.tb05868.x; JIANG P, 1991, J BIOL CHEM, V266, P22760; KIRSCH E, 1981, EUR J CLIN INVEST, V11, P39, DOI 10.1111/j.1365-2362.1981.tb01763.x; KIVIRIKKO KI, 1972, BIOCHEMISTRY-US, V11, P122, DOI 10.1021/bi00751a021; KIVIRIKKO KI, 1980, ENZYMOLOGY POST TRAN, P53; KUYPERS R, 1992, BIOCHEM J, V283, P129, DOI 10.1042/bj2830129; LAST JA, 1990, AM J RESP CELL MOL, V2, P543, DOI 10.1165/ajrcmb/2.6.543; LAST JA, 1990, AM REV RESPIR DIS, V141, P307, DOI 10.1164/ajrccm/141.2.307; LIGHT ND, 1979, FEBS LETT, V97, P183, DOI 10.1016/0014-5793(79)80080-0; MOREY ER, 1979, BIOSCIENCE, V29, P168, DOI 10.2307/1307797; MORIGUCHI T, 1979, J INVEST DERMATOL, V72, P143, DOI 10.1111/1523-1747.ep12530609; MORISHIMA I, 1990, COMP BIOCHEM PHYS B, V95, P551, DOI 10.1016/0305-0491(90)90019-P; REISER K M, 1986, Journal of Biochemical Toxicology, V1, P83, DOI 10.1002/jbt.2570010109; REISER KM, 1986, COLLAGEN REL RES, V6, P313; REISER KM, 1987, BIOCHEM MED METAB B, V37, P16, DOI 10.1016/0885-4505(87)90004-1; REISER KM, 1987, BIOCHIM BIOPHYS ACTA, V926, P339, DOI 10.1016/0304-4165(87)90220-0; REISER KM, 1980, ANAL BIOCHEM, V104, P87, DOI 10.1016/0003-2697(80)90280-8; REISER KM, 1983, J BIOL CHEM, V258, P269; REISER KM, 1983, LIQUID CHROMATOGR, V1, P498; RHYANEN L, 1975, BIOCHIM BIOPHYS ACTA, V397, P50; ROYCE PM, 1985, BIOCHEM J, V230, P475, DOI 10.1042/bj2300475; RUSSELL JE, 1990, J ORTHOPAED RES, V8, P13, DOI 10.1002/jor.1100080103; SCOTT PG, 1980, BIOCHEMISTRY-US, V19, P6118, DOI 10.1021/bi00567a026; TAKAHASHI K, 1987, BIOPOLYMERS, V26, P1781, DOI 10.1002/bip.360261010; VAILAS AC, 1988, J APPL PHYSIOL, V65, P373, DOI 10.1152/jappl.1988.65.1.373; VANDERREST M, 1982, EUR J BIOCHEM, V125, P491, DOI 10.1111/j.1432-1033.1982.tb06709.x; WAITE JH, 1989, J COMP PHYSIOL B, V159, P517, DOI 10.1007/BF00694376; WENSTRUP RJ, 1986, HUM GENET, V74, P47; YAMAUCHI M, 1986, BIOCHEMISTRY-US, V25, P4907, DOI 10.1021/bi00365a027	41	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25553	25560						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244992				2022-12-25	WOS:A1993MK10000043
J	ANDERSSON, M; OSTMAN, A; WESTERMARK, B; HELDIN, CH				ANDERSSON, M; OSTMAN, A; WESTERMARK, B; HELDIN, CH			CHARACTERIZATION OF THE RETENTION MOTIF IN THE C-TERMINAL PART OF THE LONG SPLICE FORM OF PLATELET-DERIVED GROWTH-FACTOR A-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR-PERMEABILITY FACTOR; SIMIAN SARCOMA-VIRUS; FACTOR PDGF; FACTOR RECEPTORS; B-CHAIN; KINASE ACTIVATION; GOLGI-COMPLEX; CDNA; EXPRESSION; GENE	Platelet-derived growth factor (PDGF) A-chain is found in two different splice variants; the long A-chain variant differs from the short one in that it contains a stretch of basic amino acid residues in the C-terminal part that mediates retention of the growth factor inside the producer cell and to the cell matrix. By analyzing mutants in which different amino acid residues in the retention motif had been changed to alanine residues, we found that the total positive charge of the sequence is of importance for the function of the retention motif. Moreover, we showed that retention also occurs if only one of the polypeptides in the PDGF dimer carries the retention motif. Surface iodination and competition with a peptide having the sequence of the retention motif revealed that the long A-chain variant, in contrast to the short A-chain variant, is localized on the outside of the cells and is also associated to the cell matrix. The association is likely to be mediated partially through heparan sulfate proteoglycans since treatment of matrix with heparitinase released the long A-chain variant.	UNIV HOSP UPPSALA,DEPT PATHOL,S-75185 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital	ANDERSSON, M (corresponding author), BIOMED CTR,LUDWIG INST CANC RES,BOX 595,S-75124 UPPSALA,SWEDEN.							ANDERSSON M, 1992, J BIOL CHEM, V267, P11260; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BETSHOLTZ C, 1990, NATURE, V344, P299, DOI 10.1038/344299a0; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; BYWATER M, 1988, MOL CELL BIOL, V8, P2753, DOI 10.1128/MCB.8.7.2753; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FORSBERG K, 1993, P NATL ACAD SCI USA, V90, P393, DOI 10.1073/pnas.90.2.393; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELDIN CH, 1993, TRANSPLANT P, V25, P2072; JOSEPHS SF, 1984, SCIENCE, V223, P487, DOI 10.1126/science.6318322; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KELLY JL, 1993, J CELL BIOL, V121, P1153, DOI 10.1083/jcb.121.5.1153; KHACHIGIAN LM, 1992, J BIOL CHEM, V267, P1660; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; OSTMAN A, 1988, J BIOL CHEM, V263, P16202; OSTMAN A, 1992, J CELL BIOL, V118, P509, DOI 10.1083/jcb.118.3.509; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; Pollock RA, 1992, GROWTH FACTORS, V7, P267, DOI 10.3109/08977199209046409; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; ROBBINS KC, 1985, EMBO J, V4, P1783, DOI 10.1002/j.1460-2075.1985.tb03851.x; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; STEIN J, 1991, ONCOGENE, V6, P601; THYBERG J, 1990, J CELL SCI, V97, P219; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	41	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					926	930						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288645				2022-12-25	WOS:A1994MR22000026
J	CHARLEMAGNE, D; ORLOWSKI, J; OLIVIERO, P; RANNOU, F; SAINTEBEUVE, C; SWYNGHEDAUW, B; LANE, LK				CHARLEMAGNE, D; ORLOWSKI, J; OLIVIERO, P; RANNOU, F; SAINTEBEUVE, C; SWYNGHEDAUW, B; LANE, LK			ALTERATION OF NA,K-ATPASE-SUBUNIT MESSENGER-RNA AND PROTEIN-LEVELS IN HYPERTROPHIED RAT-HEART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; SPONTANEOUSLY HYPERTENSIVE RATS; MYOSIN HEAVY-CHAIN; CARDIAC-HYPERTROPHY; BETA-SUBUNIT; CATALYTIC SUBUNIT; THYROID-HORMONE; GENE-EXPRESSION; BINDING-SITES; SARCOPLASMIC-RETICULUM	To determine if an altered expression of the Na,K-ATPase alpha isoform genes is responsible for an observed increase in cardiac glycoside sensitivity in compensatory hypertrophy, we performed Northern and slot blot analyses of RNA and specific immunological detection of Na,K-ATPase isoforms in rat hearts from normal and pressure overload-treated animals induced by abdominal aortic constriction. During the early phase of hypertrophy, the only alteration is a decrease in the alpha2 mRNA isoform. In the compensated hypertrophied heart, the levels of the predominant alpha1 isoform (mRNA and protein) and the beta1 subunit mRNA are unchanged. In contrast, the alpha2 isoform (mRNA and protein) is decreased by 35% and up to 61-64% in mild (<55%) and severe (>55%) hypertrophy, respectively. The alpha3 isoform (mRNA and protein), which is extremely Iow in adult heart, is increased up to 2-fold during hypertrophy but accounts for only congruent-to 5% of the total alpha isoform mRNA. These findings demonstrate that, in cardiac hypertrophy, the three a isoforms of the Na,K-ATPase are independently regulated and that regulation occurs at a pretranslational level. The pattern of expression in hypertrophied adult heart is similar to that of the neonatal heart where the inverse regulation between the alpha2 and alpha3 ouabain high affinity isoforms has been reported. This suggests that distinct regulatory mechanisms controlling Na,K-ATPase isoform expression may, at least in part, be involved in the sensitivity to cardiac glycosides.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT PHARMACOL & CELL BIOPHYS,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	CHARLEMAGNE, D (corresponding author), HOP LARIBOISIERE,INSERM,U127,41 BD CHAPELLE,F-75475 PARIS 10,FRANCE.			Orlowski, John/0000-0001-7371-175X				ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; ADAMS RJ, 1982, NATURE, V296, P167, DOI 10.1038/296167a0; AKERA T, 1990, CALCIUM HEART, P299; Aronson RS., 1991, J CARDIOVASC ELECTR, V2, P249, DOI 10.1111/j.1540-8167.1991.tb01323.x; BLACK FM, 1991, J CLIN INVEST, V88, P1581, DOI 10.1172/JCI115470; CHARLEMAGNE D, 1987, J BIOL CHEM, V262, P8941; CHARLEMAGNE D, 1986, J BIOL CHEM, V261, P185; CHEVALIER B, 1989, PFLUG ARCH EUR J PHY, V414, P311, DOI 10.1007/BF00584632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIRILLO M, 1984, CLIN SCI, V67, P535, DOI 10.1042/cs0670535; CUTILLETTA AF, 1975, J MOL CELL CARDIOL, V7, P767, DOI 10.1016/0022-2828(75)90042-5; DELABASTIE D, 1990, CIRC RES, V66, P554, DOI 10.1161/01.RES.66.2.554; ERDMANN E, 1980, BIOCHEM PHARMACOL, V29, P3219, DOI 10.1016/0006-2952(80)90295-6; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; GENY B, 1982, BIOCHIM BIOPHYS ACTA, V692, P345, DOI 10.1016/0005-2736(82)90383-2; GWATHMEY JK, 1985, CIRC RES, V57, P836, DOI 10.1161/01.RES.57.6.836; HERRERA VLM, 1987, J CELL BIOL, V105, P1855, DOI 10.1083/jcb.105.4.1855; HERRERA VLM, 1988, SCIENCE, V241, P221, DOI 10.1126/science.2838907; HICKERSON TW, 1988, MEMBRANE BIOPHYSICS, V3, P223; HOROWITZ B, 1990, J BIOL CHEM, V265, P14308; IZUMO S, 1987, J CLIN INVEST, V79, P1970; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; KAMITANI T, 1992, CIRC RES, V71, P1457, DOI 10.1161/01.RES.71.6.1457; LEE SW, 1983, HYPERTENSION, V5, P682, DOI 10.1161/01.HYP.5.5.682; LELIEVRE LG, 1986, AM J PHYSIOL, V250, pH923, DOI 10.1152/ajpheart.1986.250.6.H923; LOMPRE AM, 1991, CIRC RES, V69, P1380, DOI 10.1161/01.RES.69.5.1380; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCCHESI PA, 1991, J BIOL CHEM, V266, P9327; MANSIER P, 1982, NATURE, V300, P535, DOI 10.1038/300535a0; MELIKIAN J, 1991, J MEMBRANE BIOL, V119, P171, DOI 10.1007/BF01871416; MERCADIER JJ, 1989, AM J PHYSIOL, V257, pH979, DOI 10.1152/ajpheart.1989.257.3.H979; MOALIC JM, 1993, CARDIOVASC RES, V27, P231, DOI 10.1093/cvr/27.2.231; NAUDIN V, 1991, FEBS LETT, V285, P135, DOI 10.1016/0014-5793(91)80743-M; NOEL F, 1984, BIOCHEM PHARMACOL, V33, P47, DOI 10.1016/0006-2952(84)90369-1; NOGUCHI S, 1990, J BIOL CHEM, V265, P15991; ORLOWSKI J, 1990, J BIOL CHEM, V265, P3462; ORLOWSKI J, 1988, J BIOL CHEM, V263, P10436; REIBEL DK, 1986, AM J PHYSIOL, V250, pH1, DOI 10.1152/ajpheart.1986.250.1.H1; SCHWARTZ K, 1992, AM J PHYSIOL, V262, pR364, DOI 10.1152/ajpregu.1992.262.3.R364; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SHYJAN AW, 1990, J BIOL CHEM, V265, P5166; SWEADNER KJ, 1979, J BIOL CHEM, V254, P6060; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; SWEADNER KJ, 1992, J BIOL CHEM, V267, P769; URAYAMA O, 1989, J BIOL CHEM, V264, P8271; VORNANEN M, 1987, BASIC RES CARDIOL, V82, P82, DOI 10.1007/BF01907056; WALLICK ET, 1980, ARCH BIOCHEM BIOPHYS, V202, P442, DOI 10.1016/0003-9861(80)90448-8; WERDAN K, 1984, BIOCHEM PHARMACOL, V33, P1873, DOI 10.1016/0006-2952(84)90542-2; WIBO M, 1991, CIRC RES, V68, P662, DOI 10.1161/01.RES.68.3.662; YOUNG RM, 1987, BIOCHEM BIOPH RES CO, V145, P52, DOI 10.1016/0006-291X(87)91286-1; ZAHLER R, 1992, P NATL ACAD SCI USA, V89, P99, DOI 10.1073/pnas.89.1.99	52	96	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1541	1547						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288620				2022-12-25	WOS:A1994MR22000116
J	DAILEY, HA; SELLERS, VM; DAILEY, TA				DAILEY, HA; SELLERS, VM; DAILEY, TA			MAMMALIAN FERROCHELATASE - EXPRESSION AND CHARACTERIZATION OF NORMAL AND 2 HUMAN PROTOPORHYRIC FERROCHELATASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROPOIETIC PROTOPORPHYRIA; SACCHAROMYCES-CEREVISIAE; LIVER-TRANSPLANTATION; BOVINE PROTOPORPHYRIA; MOUSE FERROCHELATASE; MOLECULAR-CLONING; SKIN FIBROBLASTS; GENE; PURIFICATION; DISEASE	Ferrochelatase (EC 4.99.1.1) catalyzes the terminal step in the heme biosynthetic pathway, the insertion of ferrous iron into protoporphyrin IX. Herein we report the expression, purification, and characterization of the mature processed form of human and mouse ferrochelatase in Escherichia coli JM109. Metal analysis of the recombinant normal human ferrochelatase reveals that there are approximately 2 iron atoms/molecule of enzyme. This, along with the presence of spectral absorbance near 320 nm, is strongly suggestive that recombinant mammalian ferrochelatase as expressed in E. coli may contain an iron sulfur cluster. Two human protoporphyric ferrochelatases, F417S and M267I, were also expressed and characterized. The M267I mutant possesses the same K(m) and V(max) as the normal enzyme but exhibits increased thermolability when compared with normal human ferrochelatase. The F417S mutant has less than 2% of the normal activity. Since the Phe --> Ser substitution in this mutation is both chemically and structurally significant, three single amino acid substitutions (Lys, Tyr, and Trp) were engineered and characterized. None of these resulted in a protein with wild type activity. Additionally the carboxyl-terminal 10-amino acid segment, which contains Phe-417, from the yeast sequence was substituted, but this construct had no activity. Elimination of the carboxyl-terminal 30 amino acid residues (which include Phe-417) results in a protein the same length as the bacterial ferrochelatases, but it is an inactive enzyme.	UNIV GEORGIA,CTR METALLOENZYME STUDIES,ATHENS,GA 30602	University System of Georgia; University of Georgia	DAILEY, HA (corresponding author), UNIV GEORGIA,DEPT MICROBIOL,ATHENS,GA 30602, USA.				NIDDK NIH HHS [R56 DK032303, DK 32303, DK 35898] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035898, R01DK032303] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BLOOMER JR, 1976, LANCET, V2, P226; BLOOMER JR, 1975, AM J MED, V58, P869, DOI 10.1016/0002-9343(75)90644-0; BLOOMER JR, 1989, GASTROENTEROLOGY, V97, P188, DOI 10.1016/0016-5085(89)91434-0; BLOOMER JR, 1987, J BIOL CHEM, V262, P667; BONKOWSKY HL, 1975, J CLIN INVEST, V56, P1139, DOI 10.1172/JCI108189; BOTTOMLEY SS, 1975, J LAB CLIN MED, V86, P126; BOULECHFAR S, 1993, GENOMICS, V16, P645, DOI 10.1006/geno.1993.1242; BRENNER DA, 1991, P NATL ACAD SCI USA, V88, P849, DOI 10.1073/pnas.88.3.849; BRENNER DA, 1992, AM J HUM GENET, V50, P1203; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; CARTER P, 1971, ANAL BIOCHEM, V40, P450, DOI 10.1016/0003-2697(71)90405-2; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; DAILEY HA, 1977, J BACTERIOL, V129, P815, DOI 10.1128/JB.129.2.815-820.1977; DAILEY HA, 1989, BIOCHIM BIOPHYS ACTA, V999, P7, DOI 10.1016/0167-4838(89)90021-6; DAILEY HA, 1983, J BIOL CHEM, V258, P1453; DAILEY HA, 1986, METHOD ENZYMOL, V123, P401; de Goeij A F, 1975, Eur J Clin Invest, V5, P397; ELDRIDGE MG, 1992, PROTEIN SCI, V1, P271; FRUSTACI JM, 1992, J BACTERIOL, V174, P4223, DOI 10.1128/JB.174.13.4223-4229.1992; HANSSON M, 1992, J BACTERIOL, V174, P8081, DOI 10.1128/JB.174.24.8081-8093.1992; HARBIN BM, 1985, BIOCHEMISTRY-US, V24, P366, DOI 10.1021/bi00323a019; HERBERT A, 1991, GASTROENTEROLOGY, V100, P1753, DOI 10.1016/0016-5085(91)90680-J; JONES MS, 1969, BIOCHEM J, V113, P507, DOI 10.1042/bj1130507; KARR SR, 1988, BIOCHEM J, V254, P799, DOI 10.1042/bj2540799; LABBEBOIS R, 1990, J BIOL CHEM, V265, P7278; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMORIL J, 1991, BIOCHEM BIOPH RES CO, V181, P594, DOI 10.1016/0006-291X(91)91231-Z; Lavallee DK, 1988, MECH PRINCIPLES ENZY, P279; MATHEWSROTH MM, 1987, ARCH DERMATOL, V123, P429, DOI 10.1001/archderm.123.4.429; MIYAMOTO K, 1991, J MOL BIOL, V219, P393, DOI 10.1016/0022-2836(91)90180-E; NAKAHASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P748, DOI 10.1016/S0006-291X(05)80099-3; NAKAHIGASHI K, 1991, P NATL ACAD SCI USA, V88, P10520, DOI 10.1073/pnas.88.23.10520; PAJOT P, 1976, EUR J BIOCHEM, V63, P263, DOI 10.1111/j.1432-1033.1976.tb10228.x; PROULX KL, 1993, PROTEIN SCI, V2, P1092, DOI 10.1002/pro.5560020703; RUTH GR, 1977, SCIENCE, V198, P199, DOI 10.1126/science.905823; STRAKA JG, 1991, J BIOL CHEM, V266, P24637; TAKETANI S, 1990, J BIOL CHEM, V265, P19377; TUTOIS S, 1991, J CLIN INVEST, V88, P1730, DOI 10.1172/JCI115491	39	61	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					390	395						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276824				2022-12-25	WOS:A1994MR21900066
J	FIGUEIREDOPEREIRA, ME; YU, B; WILK, S				FIGUEIREDOPEREIRA, ME; YU, B; WILK, S			DISSOCIATION AND REASSOCIATION OF THE BOVINE PITUITARY MULTICATALYTIC PROTEINASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NEUTRAL ENDOPEPTIDASE; RAT SKELETAL-MUSCLE; REVERSIBLE ACTIVATION; PROTEASE; PURIFICATION; LIVER; SPECIFICITY; PROSOMES; CASEIN; LATENT	The eukaryotic multicatalytic proteinase complex (proteasome) is a high molecular mass enzyme which contains 13-15 nonidentical subunits of similar size (molecular masses of 21-31 kDa), but differing widely in net charge (isoelectric points ranging from 3 to 10). At least four catalytic components termed chyriotrypsin-like, trypsin-like, peptidylglutamyl peptide-hydrolyzing, and caseinolytic are associated with the proteinase. The catalytic nature of the components is unknown, since sequences of cloned subunits bear no homology to known proteinases and proteolytically active subunits have not been isolated. Analysis of the relationship between structure and catalytic function would be greatly facilitated if a means for reversibly dissociating and reassociating the proteinase were available. We provide the first evidence of reassembly of dissociated multicatalytic proteinase complex into a functional molecule. Incubation with the organic mercurial, p-chloromercuribenzoic acid disrupts in a concentration-dependent manner the quaternary structure of the enzyme, leading to formation of a heterogeneous population of subunits. Dissociation of the complex coincides with progressive loss of chymotrypsin-like, trypsin-like, and peptidylglutamyl peptide hydrolyzing activities. The caseinolytic activity of the residual undissociated enzyme is markedly activated. Exposure of the dissociated enzyme to dithiothreitol restores the catalytic profile and reassociates the enzyme. Evidence for catalytically active subcomplexes was not obtained indicating that structural integrity may be necessary for expression of all defined activities.	CUNY MT SINAI SCH MED,DEPT PHARMACOL,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NIMH NIH HHS [MH-00350] Funding Source: Medline; NINDS NIH HHS [NS-29936] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH000350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029936] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAUMEISTER W, 1988, FEBS LETT, V241, P239, DOI 10.1016/0014-5793(88)81069-X; CARDOZO C, 1992, BIOCHEMISTRY-US, V31, P7373, DOI 10.1021/bi00147a023; DAHLMANN B, 1985, BIOCHEM J, V228, P161, DOI 10.1042/bj2280161; DJABALLAH H, 1992, EUR J BIOCHEM, V209, P629, DOI 10.1111/j.1432-1033.1992.tb17329.x; HOAGLAND VD, 1967, J BIOL CHEM, V242, P4341; KOPP F, 1993, J MOL BIOL, V229, P14, DOI 10.1006/jmbi.1993.1003; KOPP F, 1986, BIOCHIM BIOPHYS ACTA, V872, P253, DOI 10.1016/0167-4838(86)90278-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADSEN NB, 1956, J BIOL CHEM, V223, P1055; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; NOTHWANG HG, 1992, EUR J BIOCHEM, V207, P621, DOI 10.1111/j.1432-1033.1992.tb17089.x; NOTHWANG HG, 1992, BIOCHEM J, V287, P733, DOI 10.1042/bj2870733; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; OZAKI M, 1992, J BIOL CHEM, V267, P21678; PEREIRA ME, 1992, J BIOL CHEM, V267, P7949; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; STRACK PR, 1992, INT J BIOCHEM, V24, P887, DOI 10.1016/0020-711X(92)90093-G; TAMAOKI T, 1967, J MOL BIOL, V23, P35, DOI 10.1016/S0022-2836(67)80065-2; TANAKA K, 1992, NEW BIOL, V4, P173; TANAKA K, 1989, BIOCHEM BIOPH RES CO, V158, P548, DOI 10.1016/S0006-291X(89)80084-1; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TANAKA K, 1989, J BIOCHEM-TOKYO, V106, P495, DOI 10.1093/oxfordjournals.jbchem.a122880; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEITMAN D, 1992, J BIOL CHEM, V267, P6977; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; YU B, 1991, J BIOL CHEM, V266, P17396; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	31	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					621	626						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276861				2022-12-25	WOS:A1994MR21900098
J	HUANG, N; WANG, D; HEPPEL, LA				HUANG, N; WANG, D; HEPPEL, LA			ROLE OF ADENOSINE 3'/5'-MONOPHOSPHATE-DEPENDENT PROTEIN-KINASE AND CAMP LEVELS IN ATP-DEPENDENT MITOGENESIS IN SWISS 3T3-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP ACCUMULATION; TRANSDUCTION PATHWAYS LEAD; ARACHIDONIC-ACID RELEASE; NERVE GROWTH-FACTOR; 3T3 CELLS; EXTRACELLULAR ATP; DNA-SYNTHESIS; PROSTAGLANDIN SYNTHESIS; STIMULATED MITOGENESIS; MAMMALIAN-CELLS	To investigate the role of cAMP-dependent protein kinase (PKA) and cAMP levels in ATP-dependent mitogenesis, Swiss 3T3 cells were transfected with an expression vector coding for (i) a mutated regulatory subunit of PKA (PKA mutant) or (ii) a yeast low K(m) cAMP phosphodiesterase gene (PDE mutant). The PKA mutant showed 70% reduced PKA activity. Phosphodiesterase activity increased 2.5-fold in the PDE mutant, leading to a great reduction of cAMP levels stimulated by ATP and other cAMP-increasing agents. The mitogenic responses of PKA and PDE mutants to insulin, epidermal growth factor, or 12-O-tetradecanoylphorbol-13-acetate were not significantly changed. However, the further stimulation by ATP, ADP, and adenosine 5'-(beta,gamma-imido)triphosphate in the presence of these growth factors was reduced by >80%. Mitogenic effect of prostaglandin E2, forskolin, cholera toxin, or adenosine was inhibited in both mutants. The mitogenic stimulation by dibutyryl cAMP, which is resistant to phosphodiesterase, was inhibited in the PKA mutant, but not in the PDE mutant. A partial reduction of platelet-derived growth factor- or bombesin-stimulated mitogenesis, which involves protein kinase C as well as the cAMP signal, was observed in the mutants. These genetic results confirm pharmacological data on the role of PKA and cAMP levels in mitogenesis due to ATP and other growth factors.	CORNELL UNIV, BIOCHEM MOLEC & CELL BIOL SECT, ITHACA, NY 14853 USA	Cornell University					NATIONAL CANCER INSTITUTE [R01CA058518] Funding Source: NIH RePORTER; NCI NIH HHS [5 RO1 CA58518] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM I, 1985, J BIOL CHEM, V260, P3934; BEAVO JA, 1974, P NATL ACAD SCI USA, V71, P3580, DOI 10.1073/pnas.71.9.3580; BULGAKOV R, 1983, BIOCHIM BIOPHYS ACTA, V756, P56, DOI 10.1016/0304-4165(83)90024-7; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; BURCH RM, 1989, J CELL PHYSIOL, V139, P29, DOI 10.1002/jcp.1041390106; CAMPAGNE MMV, 1990, J BIOL CHEM, V265, P5840; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; CORRELL LA, 1989, J BIOL CHEM, V264, P16672; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; FELDER CC, 1989, J BIOL CHEM, V264, P20356; GIL J, 1991, J CELL BIOL, V113, P943, DOI 10.1083/jcb.113.4.943; GINTY DD, 1991, J BIOL CHEM, V266, P15325; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HOOK VYH, 1982, BIOCHEM BIOPH RES CO, V106, P1364, DOI 10.1016/0006-291X(82)91264-5; HUANG NN, 1993, J BIOL CHEM, V268, P10789; HUANG NN, 1991, J CELL PHYSIOL, V146, P483, DOI 10.1002/jcp.1041460320; HUANG NN, 1989, P NATL ACAD SCI USA, V86, P7904, DOI 10.1073/pnas.86.20.7904; MILLAR JBA, 1988, J CELL PHYSIOL, V137, P214, DOI 10.1002/jcp.1041370203; MOOLENAAR WH, 1992, REV PHYSIOL BIOCH P, V119, P47; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; ROZENGURT E, 1981, P NATL ACAD SCI-BIOL, V78, P4392, DOI 10.1073/pnas.78.7.4392; ROZENGURT E, 1982, EXP CELL RES, V139, P71, DOI 10.1016/0014-4827(82)90319-6; ROZENGURT E, 1983, J CELL PHYSIOL, V116, P379, DOI 10.1002/jcp.1041160316; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1983, CELL, V34, P265, DOI 10.1016/0092-8674(83)90157-5; SCHECTERSON LC, 1991, MOL ENDOCRINOL, V5, P170, DOI 10.1210/mend-5-2-170; SCHUBERT D, 1978, NATURE, V273, P718, DOI 10.1038/273718a0; WANG D, 1990, BIOCHEM BIOPH RES CO, V166, P251, DOI 10.1016/0006-291X(90)91938-O; WANG DJ, 1991, J CELL PHYSIOL, V146, P473, DOI 10.1002/jcp.1041460319; WANG DJ, 1992, J CELL PHYSIOL, V153, P221, DOI 10.1002/jcp.1041530202; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K; ZURIER RB, 1988, EXP CELL RES, V176, P155, DOI 10.1016/0014-4827(88)90129-2	33	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					548	555						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276849				2022-12-25	WOS:A1994MR21900088
J	SU, Y; VARUGHESE, KI; XUONG, NH; BRAY, TL; ROCHE, DJ; WHITELEY, JM				SU, Y; VARUGHESE, KI; XUONG, NH; BRAY, TL; ROCHE, DJ; WHITELEY, JM			THE CRYSTALLOGRAPHIC STRUCTURE OF A HUMAN DIHYDROPTERIDINE REDUCTASE NADH BINARY COMPLEX EXPRESSED IN ESCHERICHIA-COLI BY A CDNA CONSTRUCTED FROM ITS RAT HOMOLOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; BINDING; PROTEIN; BACTERIOPHAGE-T4; PHENYLKETONURIA; DEFICIENCY	A human dihydropteridine reductase (EC 1.6.99.10) has been created from a rat cDNA clone by a single five-oligonucleotide mutagenesis reaction and expressed in good yield in Escherichia coli. The enzyme has been purified to homogeneity, and kinetic identity to the naturally occurring enzyme has been proven. Crystallization has also been achieved, and the crystal structure was solved using 2.5 angstrom data that was refined to an R value of 16.9%. The structure described in this report represents the first complete structural characterization of this important human enzyme.	UNIV CALIF SAN DIEGO, DEPT BIOL, 9500 GILMAN DR, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA; SCRIPPS RES INST, DEPT EXPTL & MOLEC MED, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Research Institute					NCI NIH HHS [CA 11778] Funding Source: Medline; NCRR NIH HHS [RR01644] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA011778] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001644] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALBER T, 1987, BIOCHEMISTRY-US, V26, P3754, DOI 10.1021/bi00387a002; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; CHAUVIN MM, 1979, CAN J BIOCHEM CELL B, V57, P178, DOI 10.1139/o79-022; Cleland W W, 1979, Methods Enzymol, V63, P103; DAHL HHM, 1987, NUCLEIC ACIDS RES, V15, P1921, DOI 10.1093/nar/15.5.1921; FIRGAIRA FA, 1987, METHOD ENZYMOL, V142, P116; FROMM M, 1982, Journal of Molecular and Applied Genetics, V1, P457; GRIMSHAW CE, 1992, J BIOL CHEM, V267, P15334; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KAUFMAN S, 1975, NEW ENGL J MED, V293, P785, DOI 10.1056/NEJM197510162931601; KAUFMAN S, 1985, FOLATES PTERINS, V2, P252; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIND KE, 1973, EUR J BIOCHEM, V33, P67, DOI 10.1111/j.1432-1033.1973.tb02655.x; LOCKYER J, 1987, P NATL ACAD SCI USA, V84, P3329, DOI 10.1073/pnas.84.10.3329; Maniatis T., 1982, MOL CLONING; MATTHEWS DA, 1986, J BIOL CHEM, V261, P3891; MATTHEWS DA, 1991, ARCH BIOCHEM BIOPHYS, V287, P234, DOI 10.1016/0003-9861(91)90412-C; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; SCRIVER CR, 1980, NEW ENGL J MED, V303, P1394, DOI 10.1056/NEJM198012113032404; SHAHBAZ M, 1987, J BIOL CHEM, V262, P16412; SHARP PM, 1988, NUCLEIC ACIDS RES, V16, P8207, DOI 10.1093/nar/16.17.8207; SHIMAN R, 1985, FOLATES PTERINS, V2, P179; SMOOKER PM, 1993, 10TH INT S CHEM BIOL; STRAUCH MA, 1989, EMBO J, V8, P1615, DOI 10.1002/j.1460-2075.1989.tb03546.x; VARUGHESE KI, 1992, P NATL ACAD SCI USA, V89, P6080, DOI 10.1073/pnas.89.13.6080; WEBBER S, 1978, J BIOL CHEM, V253, P6724; XUONG NH, 1985, ACTA CRYSTALLOGR B, V41, P267, DOI 10.1107/S0108768185002105	31	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26836	26841						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262916				2022-12-25	WOS:A1993MM26200005
J	CHURCHER, Y; MOSS, SE				CHURCHER, Y; MOSS, SE			MODULATION OF PROTEIN-TYROSINE PHOSPHORYLATION DURING G(1)/S TRANSITION IN ACTIVATED HUMAN T-LYMPHOBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; IL-2 RECEPTOR; MICE LACKING; KINASE; P56LCK; ASSOCIATION; GROWTH; CD4; CLONING; LINE	We report that in activated human T-lymphoblasts synchronized early in the G1-phase of the cell cycle, addition of interleukin 2 (IL-2) stimulates transition into S-phase in conjunction with specific and reproducible protein tyrosine phosphorylation events. Prominent among these was de novo phosphorylation of the p56lck tyrosine kinase, which appeared as a single polypeptide on SDS-polyacrylamide gel electrophoresis prior to the addition of IL-2, but as a doublet of approximately 56 and 59 kDa 3 h after IL-2 addition. Although the lck polypeptide doublet persisted into S-phase, the 59-kDa form was virtually undetectable in T-lymphoblasts in log phase growth. In T-lymphoblasts metabolically labeled with P-32i, antiphosphotyrosine antisera identified a major 56-kDa tyrosine-phosphorylated protein, whereas antisera to lck showed that phosphorylation of lck occurred on both the 56- and 59-kDa forms. Phosphoamino acid analyses identified phosphoserine as the major phosphoamino acid on both of the lck polypeptides, although small amounts of phosphotyrosine were also detected on the 56-kDa form. Immune complex kinase assays revealed that only the lower band of the lck doublet exhibited autocatalytic activity. Furthermore, the 59-kDa form neither displayed autocatalytic activity, nor was it a substrate for phosphorylation by the 56-kDa form. We conclude that entry into S-phase in activated human T-lymphoblasts is associated with tyrosine phosphorylation of a limited number of proteins and suggest that p56lck activity is regulated during G1/S.			CHURCHER, Y (corresponding author), UNIV LONDON UNIV COLL,DEPT PHYSIOL,LONDON WC1E 6BT,ENGLAND.							APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BURG DL, 1993, J BIOL CHEM, V268, P2304; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATEKEYAMA M, 1989, SCIENCE, V244, P551; HISATAKA S, 1991, INT IMMUNOL, V3, P1137; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; LANE D, 1988, ANTIBODIES LABORATOR; LEONARD WJ, 1984, NATURE, V311, P625; LEY SC, 1991, EUR J IMMUNOL, V21, P2203, DOI 10.1002/eji.1830210931; LUO K, 1990, ONCOGENE, V5, P803; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOSS SE, 1992, BIOCHIM BIOPHYS ACTA, V1160, P120, DOI 10.1016/0167-4838(92)90045-F; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; OANI H, 1992, P NATL ACAD SCI USA, V89, P2789; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; TAIEB J, 1993, J BIOL CHEM, V268, P9169; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; WINKLER DG, 1993, P NATL ACAD SCI USA, V90, P5176, DOI 10.1073/pnas.90.11.5176; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	31	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26144	26149						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253732				2022-12-25	WOS:A1993MK42500023
J	CREUWELS, LAJM; DEMEL, RA; VANGOLDE, LMG; BENSON, BJ; HAAGSMAN, HP				CREUWELS, LAJM; DEMEL, RA; VANGOLDE, LMG; BENSON, BJ; HAAGSMAN, HP			EFFECT OF ACYLATION ON STRUCTURE AND FUNCTION OF SURFACTANT PROTEIN-C AT THE AIR-LIQUID INTERFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG SURFACTANT; SP-B; MONOMOLECULAR LAYERS; PRECURSOR; LIPOPEPTIDE; ORIENTATION; MEMBRANES; BILAYER; BOVINE	Pulmonary surfactant protein C (SP-C) is a small hydrophobic peptide that is palmitoylated on 2 adjacent cysteine residues. SP-C enhances the adsorption of phospholipids into a monolayer. The function of the acylation is not clear yet. The experiments described in this article were carried out in order to investigate the function of SP-C acylation in (protein-catalyzed) lipid monolayer formation, and in bilayer interactions. Palmitoylated and nonpalmitoylated human recombinant SP-C were used. In addition, a nonacylated SP-C with a Cys --> Ser mutation was included in these studies. In Wilhelmy plate experiments using negatively charged, protein-containing phospholipid monolayers and negatively charged vesicles, CaCl2 was required to obtain a maximal insertion rate of lipids into the monolayer. If the negatively charged phospholipids in the monolayer were replaced by neutral phospholipids, CaCl2 was only required to show a maximal SP-C-catalyzed insertion rate (if the molecule is palmitoylated, but not if nonpalmitoylated proteins were added). In pressure area measurements, the palmitoylated protein showed a different change in pressure as a function of the surface area, as compared with the nonpalmitoylated proteins. Circular dichroism experiments showed that all three proteins had a high content of alpha-helix. All three proteins showed a preferential orientation at the air-water interface, but the palmitoylated protein has an orientation which is more parallel to the monolayer than that of the nonpalmitoylated proteins. It is concluded that acylation of SP-C alters structural and physical properties of this protein.	UNIV UTRECHT,VET BIOCHEM LAB,3508 TD UTRECHT,NETHERLANDS; UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,3508 TD UTRECHT,NETHERLANDS; SCIOS,MT VIEW,CA 94043	Utrecht University; Utrecht University; Scios			Haagsman, Henk P/F-8919-2010					CRONAN JE, 1981, P NATL ACAD SCI-BIOL, V78, P5440, DOI 10.1073/pnas.78.9.5440; CURSTEDT T, 1990, P NATL ACAD SCI USA, V87, P2985, DOI 10.1073/pnas.87.8.2985; HAAGSMAN HP, 1991, ANNU REV PHYSIOL, V53, P441, DOI 10.1146/annurev.ph.53.030191.002301; JOHANSSON J, 1991, FEBS LETT, V281, P119, DOI 10.1016/0014-5793(91)80373-B; KELLER A, 1992, AM J RESP CELL MOL, V6, P601, DOI 10.1165/ajrcmb/6.6.601; KELLER A, 1991, BIOCHEM J, V277, P493, DOI 10.1042/bj2770493; LIS LJ, 1982, BIOPHYS J, V37, P657; OOSTERLAKENDIJKSTERHUIS MA, 1992, BIOCHIM BIOPHYS ACTA, V1110, P45, DOI 10.1016/0005-2736(92)90292-T; OOSTERLAKENDIJKSTERHUIS MA, 1991, BIOCHEMISTRY-US, V30, P10965, DOI 10.1021/bi00109a022; OOSTERLAKENDIJKSTERHUIS MA, 1991, BIOCHEMISTRY-US, V30, P8276, DOI 10.1021/bi00247a024; PASTRANA B, 1991, BIOCHEMISTRY-US, V30, P10058, DOI 10.1021/bi00105a033; PEREZGIL J, 1992, BIOPHYS J, V63, P197, DOI 10.1016/S0006-3495(92)81582-5; PHIZACKERLEY PJR, 1979, BIOCHEM J, V183, P731, DOI 10.1042/bj1830731; ROBERTSON B, 1992, PULMONARY SURFACTANT; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHIFFER K, 1993, BIOCHEMISTRY-US, V32, P590, DOI 10.1021/bi00053a026; STULTS JT, 1991, AM J PHYSIOL, V261, pL118, DOI 10.1152/ajplung.1991.261.2.L118; TAKAHASHI A, 1986, BIOCHEM BIOPH RES CO, V135, P527, DOI 10.1016/0006-291X(86)90026-4; VANDENBUSSCHE G, 1992, EUR J BIOCHEM, V203, P201, DOI 10.1111/j.1432-1033.1992.tb19848.x; VOORHOUT WF, 1993, INPRESS MICROSC RES; VORBROKER DK, 1992, BIOCHIM BIOPHYS ACTA, V1105, P161, DOI 10.1016/0005-2736(92)90175-L; WARR RG, 1987, P NATL ACAD SCI USA, V84, P7915, DOI 10.1073/pnas.84.22.7915	22	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26752	26758						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253811				2022-12-25	WOS:A1993MK42500108
J	CRUZALEGUI, FH; MEANS, AR				CRUZALEGUI, FH; MEANS, AR			BIOCHEMICAL-CHARACTERIZATION OF THE MULTIFUNCTIONAL CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE TYPE-IV EXPRESSED IN INSECT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; CALMODULIN-BINDING; PHOSPHORYLATION; GENE; MECHANISM; GR; AUTOPHOSPHORYLATION; LOCALIZATION; CDNA	We have expressed the rat brain Ca2+/calmodulin (CaM)-dependent protein kinase type IV in insect cells. The recombinant enzyme is produced as a single polypeptide that migrates on SDS-polyacrylamide gel electrophoresis at 61 kDa. Recombinant CaM kinase IV undergoes slow CaM-dependent autophosphorylation. The autophosphorylation of CaM kinase IV occurs on serine residues but is not accompanied by the generation of a CaM-independent activity, as previously reported for the cerebellar enzyme. Comparison of peptide and protein phosphorylation by the recombinant CaM kinase IV and the cerebellar enzyme showed differences in their catalytic activities. The deduced primary sequence of CaM kinase IV contained a domain, 315Phe-Asn-Ala-Arg-Arg-Lys-Leu-Lys323 also found in the regulatory domain of CaM kinase IIalpha (residues 293-300). Truncation of CaM kinase IV at Leu313 (at a position analogous to Leu290 in CaM kinase IIalpha) generated a fully active, CaM-independent enzyme. This truncated enzyme no longer bound CaM. These data confirm that CaM kinase IV demonstrates intrasteric regulation by an autoinhibitory domain and provides insight into a potentially common mechanism for the regulation of the CaM-dependent multifunctional protein kinases. A number of synthetic peptides were examined for their phosphorylation by both CaM kinase II and IV. These studies showed that several peptides derived from phospholamban were preferential substrates for CaM kinase II whereas a peptide derived from S6 ribosomal protein was selectively phosphorylated by CaM kinase IV. Kinetic analysis of several peptide substrates suggests that while both CaM kinase II and IV recognize the sequence motif represented by R-X-X-T/S, other structural features are also involved in defining the unique substrate specificity of CaM kinase IV.	DUKE UNIV, MED CTR, DEPT PHARMACOL, BOX 3813, DURHAM, NC 27710 USA	Duke University					NICHD NIH HHS [HD 07503] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONTI MA, 1981, J BIOL CHEM, V256, P3178; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DENIS CL, 1991, J BIOL CHEM, V266, P17932; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P11309; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; KAMESHITA I, 1991, BIOCHEM BIOPH RES CO, V180, P191, DOI 10.1016/S0006-291X(05)81275-6; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MEANS AR, 1993, RECENT PROG HORM RES, V48, P79; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; MIYANO O, 1992, J BIOL CHEM, V267, P1198; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OLSEN DB, 1990, P NATL ACAD SCI USA, V87, P1451, DOI 10.1073/pnas.87.4.1451; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; PUTKEY JA, 1985, J BIOL CHEM, V260, P4704; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SIKELA JM, 1989, GENOMICS, V4, P21, DOI 10.1016/0888-7543(89)90309-1; SOBIESZEK A, 1991, EUR J BIOCHEM, V199, P735, DOI 10.1111/j.1432-1033.1991.tb16178.x; SUMMERS MD, 1988, TEX AGR EXP STN B, V1555; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370	33	117	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26171	26178						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253736				2022-12-25	WOS:A1993MK42500027
J	LOETSCHER, H; STUEBER, D; BANNER, D; MACKAY, F; LESSLAUER, W				LOETSCHER, H; STUEBER, D; BANNER, D; MACKAY, F; LESSLAUER, W			HUMAN TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA) MUTANTS WITH EXCLUSIVE SPECIFICITY FOR THE 55-KDA OR 75-KDA TNF RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; NF-KAPPA-B; MONOCLONAL-ANTIBODIES; MUTATIONAL ANALYSIS; ADHESION MOLECULE-1; HUMAN LYMPHOTOXIN; CYTO-TOXICITY; SEPTIC SHOCK; FACTOR-BETA; BINDING	To probe the ligand receptor interface, a number of point mutations were introduced in selected regions of human tumor necrosis factor (TNF) alpha by site-directed mutagenesis. The mutated proteins were expressed in Escherichia coli and analyzed for selective binding to recombinant 55- and 75-kDa TNF receptors in competition with radiolabeled wild-type TNFalpha. Generally, mutations in the loop from position 29 to 34 and at positions 86 and 146 preferentially impaired binding to the 75-kDa TNF receptor, whereas mutations in the region from 143 to 145 mainly affected binding to the 55-kDa TNF receptor. Mutation of the conserved Tyr87 resulted in a dramatic loss of binding activity to both receptors. The selectivity for one or the other receptor type was found to be enhanced by combining two or three point mutations, the effects of the single mutations with respect to receptor selectivity being at least additive. A combination of the mutations Arg32-->Trp and Ser86-->Thr yielded a double mutant (R32W-S86T) with wild-type binding to the 55 kDa, but no measurable binding to the 75-kDa TNF receptor. In contrast, combining the Asp143-->Asn and Ala145-->Arg mutations (D143N-A145R) resulted in a complete loss of binding to the 55-kDa TNF receptor, whereas binding to the 75-kDa TNF receptor was impaired by only 5-10-fold. In functional assays, selective activation of the 55-kDa TNF receptor by the R32W-S86T mutant elicited a full cytotoxic response in human KYM-1 cells and secretion of interleukin 6 and granulocyte-macrophate colony-stimulating factor in human umbilical vein endothelial cells. In contrast, stimulation of the 75-kDa TNF receptor with the D143N-A145R mutant as well as with agonistic antibodies failed to induce these responses.	F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES NEW TECHNOL,PRTB,BLDG 15-40,CH-4002 BASEL,SWITZERLAND	Roche Holding			Mackay, Fabienne/B-7440-2008	Mackay, Fabienne/0000-0002-6074-2693				BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BEUTLER BE, 1992, TUMOR NECROSIS FACTO; BILIAU A, 1992, CYTOKINE, V4, P259; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; BROUDY VC, 1986, P NATL ACAD SCI USA, V83, P7467, DOI 10.1073/pnas.83.19.7467; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CORDINGLEY FT, 1988, LANCET, V1, P969; DARCY A, 1993, J MOL BIOL, V229, P555, DOI 10.1006/jmbi.1993.1055; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ERIKSTEIN BK, 1991, EUR J IMMUNOL, V21, P1033, DOI 10.1002/eji.1830210426; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FISCHER E, 1992, J CLIN INVEST, V89, P1551, DOI 10.1172/JCI115748; GEHR G, 1992, J IMMUNOL, V149, P911; GOH CR, 1991, PROTEIN ENG, V4, P385, DOI 10.1093/protein/4.4.385; GOH CR, 1991, PROTEIN ENG, V4, P785; GRAU GE, 1987, SCIENCE, V237, P1210, DOI 10.1126/science.3306918; HELLER RA, 1992, CELL, V70, P47; HOHMANN HP, 1990, J BIOL CHEM, V265, P22408; JIRIK FR, 1989, J IMMUNOL, V142, P144; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KIRCHEIS R, 1992, IMMUNOLOGY, V76, P433; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LESSLAUER W, 1991, EUR J IMMUNOL, V21, P2883, DOI 10.1002/eji.1830211134; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1991, CANCER CELL-MON REV, V3, P221; LOETSCHER H, 1991, J BIOL CHEM, V266, P18324; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Loetscher H, 1991, Oxf Surv Eukaryot Genes, V7, P119; MACKAY F, 1992, J EXP MED, V177, P1277; MEAGER A, 1991, J IMMUNOL METHODS, V144, P141, DOI 10.1016/0022-1759(91)90239-C; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUSTAFA MM, 1989, J PEDIATR-US, V115, P208, DOI 10.1016/S0022-3476(89)80067-8; NAUME B, 1991, J IMMUNOL, V146, P3045; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PENNICA D, 1992, BIOCHEMISTRY-US, V31, P1134, DOI 10.1021/bi00119a023; POBER JS, 1987, J IMMUNOL, V138, P3319; RANGES GE, 1989, J IMMUNOL, V142, P1203; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHOENFELD HJ, 1991, J BIOL CHEM, V266, P3863; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STUEBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TAEUBER MG, 1992, J INFECT DIS, V166, P1045; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TAVERNIER J, 1990, J MOL BIOL, V211, P493, DOI 10.1016/0022-2836(90)90367-U; THORP KM, 1992, CYTOKINE, V4, P313, DOI 10.1016/1043-4666(92)90072-Y; TRACEY KJ, 1989, LANCET, V1, P1122; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; TREFZER U, 1991, J INVEST DERMATOL, V97, P911, DOI 10.1111/1523-1747.ep12491668; VANDENABEELE P, 1992, J EXP MED, V176, P1015, DOI 10.1084/jem.176.4.1015; VANOSTADE X, 1993, NATURE, V361, P266; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WAAGE A, 1987, LANCET, V1, P355; WAKABAYASHI T, 1990, J BIOL CHEM, V265, P7604; WERTHEIMER SJ, 1992, J BIOL CHEM, V267, P12030; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; YAMAGISHI J, 1990, PROTEIN ENG, V3, P713, DOI 10.1093/protein/3.8.713; ZHANG XM, 1992, J BIOL CHEM, V267, P24069	74	208	238	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26350	26357						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253759				2022-12-25	WOS:A1993MK42500053
J	PAGES, F; DETERRE, P; PFISTER, C				PAGES, F; DETERRE, P; PFISTER, C			ENHANCEMENT BY PHOSPHODIESTERASE SUBUNITS OF THE RATE OF GTP HYDROLYSIS BY TRANSDUCIN IN BOVINE RETINAL RODS - ESSENTIAL ROLE OF THE PHOSPHODIESTERASE CATALYTIC CORE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTORECEPTOR CGMP PHOSPHODIESTERASE; CYCLIC-GMP PHOSPHODIESTERASE; OUTER SEGMENTS; ALPHA-SUBUNIT; G-PROTEIN; MOLECULAR MECHANISM; VISUAL TRANSDUCTION; CROSS-LINKING; BETA-SUBUNIT; ACTIVATION	Phosphodiesterase (PDE) in bovine retinal rod outer segments is activated when it forms a membrane-bound complex with the alpha-subunit of transducin loaded with GTP (Talpha*). At maximal activation, this complex contains two Talpha* and all the subunits of native PDE (PDEalpha, PDEbeta, and two inhibitory PDEgamma). We observed previously (Pages, F., Deterre, P., and Pfister, C. (1992) J. Biol. Chem. 267,22018-22021) that the rate of GTP hydrolysis by transducin in a rod outer segment suspension is enhanced when Talpha* is bound to native PDE (PDEalphabetagamma2). In this article, we compare the effects of PDE species with different PDEgamma contents. We show that Talpha* hydrolyzes its GTP faster not only when bound to PDEalphabetagamma2, but also when bound to PDEalphabetagamma or PDEalphabeta. Moreover, trypsin-treated PDE (PDEgamma-deprived soluble PDE) also induces an acceleration of GTP hydrolysis. On the contrary, addition of isolated PDEgamma alone does not accelerate GTP hydrolysis. The interaction between Talpha* and PDEgamma, which is essential for the activation of PDE by Talpha*, is apparently not responsible of the feedback of PDE on Talpha*. The interaction of primary importance for the acceleration of GTP hydrolysis would be that existing between Talpha* and PDEalphabeta.	CENS, DEPT BIOL MOLEC & STRUCT, BIOPHYS MOLEC & CELLULAIRE, F-91191 GIF SUR YVETTE, FRANCE	CEA			Deterre, Philippe/O-8984-2017	Deterre, Philippe/0000-0001-9303-0791				ANTONNY B, 1993, BIOCHEMISTRY-US, V32, P8646, DOI 10.1021/bi00084a036; ARSHAVSKY VY, 1989, FEBS LETT, V250, P353, DOI 10.1016/0014-5793(89)80754-9; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BHOWN AS, 1980, ANAL BIOCHEM, V103, P184, DOI 10.1016/0003-2697(80)90254-7; BOURNE HR, 1992, NATURE, V358, P541, DOI 10.1038/358541a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; BRUCKERT F, 1992, BIOPHYS J, V63, P616, DOI 10.1016/S0006-3495(92)81650-8; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; CATTY P, 1992, J BIOL CHEM, V267, P19489; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CHABRE M, 1985, ANNU REV BIOPHYS BIO, V14, P331, DOI 10.1146/annurev.biophys.14.1.331; CLERC A, 1992, J BIOL CHEM, V267, P19948; CLERC A, 1992, J BIOL CHEM, V267, P6620; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; ERICKSON MA, 1992, SCIENCE, V257, P1255, DOI 10.1126/science.1519062; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; HINGORANI VN, 1988, J BIOL CHEM, V263, P6916; KROLL S, 1989, J BIOL CHEM, V264, P4490; KUHN H, 1981, CURR TOP MEMBR TRANS, V15, P171; LAMB TD, 1988, J PHYSIOL-LONDON, V407, P463, DOI 10.1113/jphysiol.1988.sp017426; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PAGES F, 1992, J BIOL CHEM, V267, P22018; PFISTER C, 1993, CELL SIGNAL, V5, P235, DOI 10.1016/0898-6568(93)90015-E; PITTLER SJ, 1990, GENOMICS, V6, P272, DOI 10.1016/0888-7543(90)90567-E; SATHER WA, 1987, P NATL ACAD SCI USA, V84, P9290, DOI 10.1073/pnas.84.24.9290; SITARAMAYYA A, 1988, BIOCHEMISTRY-US, V27, P4880, DOI 10.1021/bi00413a044; STRYER L, 1991, J BIOL CHEM, V266, P10711; SUGINO Y, 1964, J BIOL CHEM, V239, P2360; SWEENEY MI, 1992, FEBS LETT, V310, P66, DOI 10.1016/0014-5793(92)81148-F; TING TD, 1991, BIOCHEMISTRY-US, V30, P8996, DOI 10.1021/bi00101a013; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VUONG TM, 1984, NATURE, V311, P659, DOI 10.1038/311659a0; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YAMAZAKI A, 1993, J BIOL CHEM, V268, P8899	50	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26358	26364						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253760				2022-12-25	WOS:A1993MK42500054
J	SUPAKAR, PC; SONG, CS; JUNG, MH; SLOMCZYNSKA, MA; KIM, JM; VELLANOWETH, RL; CHATTERJEE, B; ROY, AK				SUPAKAR, PC; SONG, CS; JUNG, MH; SLOMCZYNSKA, MA; KIM, JM; VELLANOWETH, RL; CHATTERJEE, B; ROY, AK			A NOVEL REGULATORY ELEMENT ASSOCIATED WITH AGE-DEPENDENT EXPRESSION OF THE RAT ANDROGEN RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; POLYMERASE CHAIN-REACTION; TRANSCRIPTION FACTOR; ALPHA2U GLOBULIN; DOWN-REGULATION; LIFE-SPAN; RNA; PROTEIN; LIVER; DNA	A large body of evidence indicates that the genetic program of aging has co-evolved with the sexual mode of reproduction (Partridge, L., and Barton, N. H. (1993) Nature 362, 305-311). Age-dependent changes in target cell sensitivity to reproductive hormones can be considered part of this evolutionary linkage. Here we describe a novel regulatory element in the rat androgen receptor (AR) gene promoter associated with its age-dependent expression in the liver. This element consists of two (19 and 25 base pairs) contiguous sites, one specifically binding an Age-dependent Factor (ADF) and the other an Associated Factor (AF). Both deletion and point mutations of the ADF site result in about a 5-fold decline in the AR promoter function. Unlike AF, which is relatively tissue specific, ADF appears to be ubiquitous. The ubiquitous and evolutionarily conserved nature of ADF suggests a fundamental role of this novel transcription factor in programmed gene expression.	UNIV TEXAS, HLTH SCI CTR, DEPT CELLULAR & STRUCT BIOL, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK014744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG010486, P01AG006872] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG06872, R01 AG10486] Funding Source: Medline; NIDDK NIH HHS [R-37 DK14744] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMMENDOLA R, 1992, J BIOL CHEM, V267, P17944; BAARENDS WM, 1990, MOL CELL ENDOCRINOL, V74, P75, DOI 10.1016/0303-7207(90)90207-O; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BOUABOULA M, 1992, J BIOL CHEM, V267, P21830; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BURNSTEIN KL, 1990, J BIOL CHEM, V265, P7284; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; CHATTERJEE B, 1981, J BIOL CHEM, V256, P5939; CHATTERJEE B, 1989, FASEB J, V3, P169, DOI 10.1096/fasebj.3.2.2464518; CHATTERJEE B, 1987, J BIOL CHEM, V262, P822; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDSON JM, 1983, J CLIN ENDOCR METAB, V57, P71, DOI 10.1210/jcem-57-1-71; DEMYAN WF, 1992, MOL ENDOCRINOL, V6, P589, DOI 10.1210/me.6.4.589; DERMAN E, 1981, P NATL ACAD SCI-BIOL, V78, P5425, DOI 10.1073/pnas.78.9.5425; DEWET JR, 1987, MOL CELL BIOL, V2, P1044; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Finch CE, 1990, LONGEVITY SENESCENCE; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JOHNSON TE, 1990, SCIENCE, V249, P908, DOI 10.1126/science.2392681; Lee AK., 1985, EVOL ECOL; LEHMANN JM, 1991, NUCLEIC ACIDS RES, V19, P573, DOI 10.1093/nar/19.3.573; Martin G M, 1982, Natl Cancer Inst Monogr, V60, P241; McKusick V.A., 1992, MENDELIAN INHERITANC; Medawar P. B., 1957, UNIQUENESS INDIVIDUA; ONO K, 1988, GERONTOLOGY, V34, P128, DOI 10.1159/000212941; PARTRIDGE L, 1993, NATURE, V362, P305, DOI 10.1038/362305a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; QUARMBY VE, 1990, MOL ENDOCRINOL, V4, P22, DOI 10.1210/mend-4-1-22; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; ROBERTSON O, 1961, P NATL ACAD SCI USA, V47, P609, DOI 10.1073/pnas.47.4.609; ROEHRBORN CG, 1987, J CLIN INVEST, V79, P44, DOI 10.1172/JCI112805; Rose M.R., 1991, EVOLUTIONARY BIOL AG; ROY AK, 1976, FEBS LETT, V70, P137, DOI 10.1016/0014-5793(76)80743-0; ROY AK, 1973, ENDOCRINOLOGY, V92, P957, DOI 10.1210/endo-92-3-957; ROY AK, 1983, J BIOL CHEM, V258, P123; ROY AK, 1983, RECENT PROG HORM RES, V39, P425; SACEDA M, 1988, MOL ENDOCRINOL, V2, P1157, DOI 10.1210/mend-2-12-1157; SIKORA E, 1992, FEBS LETT, V312, P179, DOI 10.1016/0014-5793(92)80930-F; SONG CS, 1993, BIOCHEM J, V294, P779, DOI 10.1042/bj2940779; SONG CS, 1991, ENDOCRINOLOGY, V128, P349, DOI 10.1210/endo-128-1-349; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; TAKANE KK, 1991, ENDOCRINOLOGY, V129, P1093, DOI 10.1210/endo-129-2-1093; TILLEY WD, 1990, J BIOL CHEM, V265, P13776; TRUANT R, 1993, J BIOL CHEM, V268, P2284; VANVOORHIES WA, 1992, NATURE, V360, P456, DOI 10.1038/360456a0; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469	49	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26400	26408						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253765				2022-12-25	WOS:A1993MK42500059
J	BETTS, JC; CHESHIRE, JK; AKIRA, S; KISHIMOTO, T; WOO, P				BETTS, JC; CHESHIRE, JK; AKIRA, S; KISHIMOTO, T; WOO, P			THE ROLE OF NF-KAPPA-B AND NF-IL6 TRANSACTIVATING FACTORS IN THE SYNERGISTIC ACTIVATION OF HUMAN SERUM AMYLOID-A GENE-EXPRESSION BY INTERLEUKIN-1 AND INTERLEUKIN-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER BINDING-PROTEIN; PHASE RESPONSE ELEMENT; NECROSIS FACTOR-ALPHA; TRANSCRIPTION FACTOR; NUCLEAR FACTOR; INTERFERON-GAMMA; C/EBP-LIKE; ANGIOTENSINOGEN GENE; HEPATOMA-CELLS; P50 SUBUNIT	To understand the mechanisms by which large increases in serum amyloid A (SAA) occur during the acute phase response, human hepatoma cells were transfected with SAA2 gene reporter plasmids and stimulated with combinations of cytokines. Although interleukin-1 (IL-1) and interleukin-6 (IL-6) stimulated transcription from this promoter individually, addition of both mediators produced a response between two and nine times greater than the expected additive response. This synergistic activation was dependent on the integrity of at least two cis-acting sequences in the SAA2 enhancer. The SAA2 NF-kappaB site was required functionally for the response to both IL-1 and IL-6 alone as well as for synergistic activation; however, IL-6 did not directly induce binding of nuclear proteins to the NF-kappaB sequence. A NF-IL-6 site was required for full induction by IL-1 and IL-6, and also mediated strong transactivation by recombinant NF-IL6. Furthermore, transfected NF-IL6 synergized strongly with co-transfected NF-kappaB, particularly with RelA (p65). However synergy between IL-1 and IL-6 was only partly reduced by mutation of the NF-IL6 site, indicating further levels of interaction in addition to the NF-kappaB/NF-IL6 cooperativity.	MRC,CLIN RES CTR,MOLEC RHEUMATOL SECT,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,DIV IMMUNOL,SUITA,OSAKA 565,JAPAN	Medical Research Council Clinical Trials Unit; Osaka University			Kishimoto, Tadamitsu/C-8470-2009; Akira, Shizuo/C-3134-2009	Brusko, Todd/0000-0003-2878-9296				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANDUS T, 1988, EUR J IMMUNOL, V18, P739, DOI 10.1002/eji.1830180513; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BETTS JC, 1991, SCAND J IMMUNOL, V34, P471, DOI 10.1111/j.1365-3083.1991.tb01570.x; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; BRINCKERHOFF CE, 1989, SCIENCE, V243, P655, DOI 10.1126/science.2536953; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; COETZEE GA, 1986, J BIOL CHEM, V261, P9644; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDBROOKE MR, 1989, MOL CELL BIOL, V9, P1908, DOI 10.1128/MCB.9.5.1908; EDBROOKE MR, 1991, CYTOKINE, V3, P380, DOI 10.1016/1043-4666(91)90041-B; ELIAS JA, 1989, J IMMUNOL, V142, P509; EMILIE D, 1988, EUR J IMMUNOL, V18, P2043, DOI 10.1002/eji.1830181226; ESPARZA I, 1987, J EXP MED, V166, P589, DOI 10.1084/jem.166.2.589; Fey G H, 1990, Prog Liver Dis, V9, P89; GANTER U, 1989, EMBO J, V8, P3773, DOI 10.1002/j.1460-2075.1989.tb08554.x; GOLLAHER CJ, 1989, P SOC EXP BIOL MED, V194, P245; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; HOUSSIAU FA, 1988, EUR J IMMUNOL, V18, P653, DOI 10.1002/eji.1830180427; HUANG JH, 1990, MOL CELL BIOL, V10, P3619, DOI 10.1128/MCB.10.7.3619; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LI X, 1992, NUCLEIC ACIDS RES, V20, P4765, DOI 10.1093/nar/20.18.4765; LI XX, 1991, J BIOL CHEM, V266, P15192; LOWELL CA, 1986, J BIOL CHEM, V261, P8442; LOWELL CA, 1986, J BIOL CHEM, V261, P8453; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MITCHELL TI, 1991, J CLIN INVEST, V87, P1177, DOI 10.1172/JCI115116; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NONAKA M, 1990, MOL CELL BIOL, V10, P6283, DOI 10.1128/MCB.10.12.6283; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289; RIENHOFF HY, 1988, MOL CELL BIOL, V8, P3710, DOI 10.1128/MCB.8.9.3710; RIENHOFF HY, 1990, MOL BIOL MED, V7, P287; RON D, 1990, MOL CELL BIOL, V10, P1023, DOI 10.1128/MCB.10.3.1023; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SACK GH, 1989, GENE, V84, P509, DOI 10.1016/0378-1119(89)90528-3; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; STOECKLE MY, 1991, NUCLEIC ACIDS RES, V19, P917, DOI 10.1093/nar/19.4.917; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; WATSON G, 1992, SCAND J IMMUNOL, V36, P703, DOI 10.1111/j.1365-3083.1992.tb03131.x; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WHITEHEAD AS, 1992, J BIOL CHEM, V267, P3862; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; ZURAW BL, 1990, J BIOL CHEM, V265, P12664	59	175	180	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25624	25631						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244997				2022-12-25	WOS:A1993MK10000051
J	WILSON, BA; KHALIL, M; TAMANOI, F; CANNON, JF				WILSON, BA; KHALIL, M; TAMANOI, F; CANNON, JF			NEW ACTIVATED RAS2 MUTATIONS IDENTIFIED IN SACCHAROMYCES-CEREVISIAE	ONCOGENE			English	Note							GUANINE-NUCLEOTIDE; ADENYLATE-CYCLASE; GTPASE ACTIVITY; PROTEINS; YEAST; GENE; PATHWAY; IRA2; P21; GAP	Activating mutations in RAS proto-oncogenes encode proteins with greater GTP binding. Such mutant proteins are responsible for many human cancers. Six new amino acids were discovered that can yield an activated Saccharomyces cerevisiae RAS2 protein when they are altered. These new RAS2 alleles were found among a collection of 35 random mutations that exhibit a dominant reduction of glycogen accumulation. The RAS2-P41S and RAS2-E99K alleles encode proteins that have lost responsiveness to GTPase activating proteins. They affect amino acids in loop 2 and helix 3 respectively and illustrate that GTPase activating proteins recognize a larger portion of the RAS structure than previously realized. RAS2 mutations E130K, S153F, A154T, and A157S alter amino acids proximal to the guanine binding site and probably influence nucleotide binding either directly or indirectly.	UNIV MISSOURI, SCH MED, DEPT MOLEC MICROBIOL & IMMUNOL, COLUMBIA, MO 65212 USA; UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA	University of Missouri System; University of Missouri Columbia; University of California System; University of California Los Angeles				Cannon, John/0000-0001-6698-176X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030054] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30054] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CANNON JF, 1986, GENETICS, V113, P247; CHESTER VE, 1968, J GEN MICROBIOL, V51, P47, DOI 10.1099/00221287-51-1-49; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KASSIR Y, 1991, METHOD ENZYMOL, V194, P94; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LACAL JC, 1986, MOL CELL BIOL, V6, P4214, DOI 10.1128/MCB.6.12.4214; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARUTA H, 1991, J BIOL CHEM, V266, P11661; Matsumoto K, 1985, Yeast, V1, P15, DOI 10.1002/yea.320010103; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; TAMANOI F, 1988, BIOCHIM BIOPHYS ACTA, V948, P1, DOI 10.1016/0304-419X(88)90002-9; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1992, MOL CELL BIOL, V12, P631, DOI 10.1128/MCB.12.2.631; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; THON VJ, 1993, J BIOL CHEM, V268, P7509; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; ZHANG K, 1991, SCIENCE, V254, P1630, DOI 10.1126/science.1749934	34	8	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3441	3445						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247549				2022-12-25	WOS:A1993MG78200031
J	YEUNG, RS; BELL, DW; TESTA, JR; MAYOL, X; BALDI, A; GRANA, X; KLINGALEVAN, K; KNUDSON, AG; GIORDANO, A				YEUNG, RS; BELL, DW; TESTA, JR; MAYOL, X; BALDI, A; GRANA, X; KLINGALEVAN, K; KNUDSON, AG; GIORDANO, A			THE RETINOBLASTOMA-RELATED GENE, RB2, MAPS TO HUMAN-CHROMOSOME-16Q12 AND RAT CHROMOSOME-19	ONCOGENE			English	Article							BREAST-CANCER; ALLELOTYPE; PROTEIN; PRODUCT	A retinoblastoma-related human gene, referred to as R B 2, has been cloned based on sequence homology of the E1A-binding domain of the retinoblastoma gene. Structural homology with the retinoblastoma gene suggests a possible function of R B 2 as a tumor suppressor gene. In this study, we have mapped this gene to human chromosome 16q12.2 and rat chromosome 19, using fluorescence in situ hybridization and somatic hybrid cell analysis, respectively. Based on known syntenic relationships among human, rat and mouse, the data suggest that the mouse homolog resides on chromosome 8. Deletions of chromosome 16q have been found in several human neoplasias (including breast, ovarian, hepatic, and prostatic cancers) which is in support of an involvement of R B 2 in human cancer as a tumor suppressor gene.	FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; UNIV GOTHENBURG,DEPT GENET,S-41390 GOTHENBURG,SWEDEN	Fox Chase Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Gothenburg	YEUNG, RS (corresponding author), FOX CHASE CANC CTR,DIV MED SCI,7701 BURHOLME AVE,PHILADELPHIA,PA 19111, USA.		Giordano, Antonio/F-1927-2010; Mayol, Xavier/C-1391-2012; Baldi, Alfonso/ABG-2397-2021	Giordano, Antonio/0000-0002-5959-016X; Grana, Xavier/0000-0001-7134-0473; Baldi, Alfonso/0000-0002-8693-3842; Mayol, Xavier/0000-0001-7288-195X	NCI NIH HHS [CA-06927, CA-45745] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045745, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FUJIMORI M, 1991, CANCER RES, V51, P89; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; LEVAN G, 1991, GENOMICS, V10, P699, DOI 10.1016/0888-7543(91)90455-N; LINDBLOM A, 1993, CANCER RES, V53, P3707; MAYOL X, 1993, ONCOGENE, V8, P261; NEVINS JR, 1992, SCIENCE, V258, P424; REEDERS ST, 1991, CYTOGENET CELL GENET, V58, P643, DOI 10.1159/000133176; SATO T, 1991, CANCER RES, V51, P5118; SATO T, 1990, CANCER RES, V50, P7184; SERIKAWA T, 1992, GENETICS, V131, P701; TAGUCHI T, 1993, CANCER RES, V53, P4349; YEUNG RS, 1993, CYTOGENET CELL GENET, V62, P149, DOI 10.1159/000133459; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	18	76	78	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3465	3468						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247552				2022-12-25	WOS:A1993MG78200034
J	GU, ZM; PIM, D; LABRECQUE, S; BANKS, L; MATLASHEWSKI, G				GU, ZM; PIM, D; LABRECQUE, S; BANKS, L; MATLASHEWSKI, G			DNA-DAMAGE INDUCED P53 MEDIATED TRANSCRIPTION IS INHIBITED BY HUMAN PAPILLOMAVIRUS TYPE-18 E6	ONCOGENE			English	Article							PRIMARY HUMAN KERATINOCYTES; WILD-TYPE P53; TRANSFORMING ACTIVITY; CERVICAL-CANCER; E5 GENE; CELLS; PROTEIN; TRANSACTIVATION; SEQUENCES; IDENTIFICATION	Cervical cancer is similar to other human cancers in that it develops through a multistep process. However, infection with oncogenic human papillomaviruses (HPVs) is believed to be essential for the initiation of this disease. Although HPV may play a central role in the early stages of neoplasia, the accumulation of mutations in an assortment of genes precedes the development of malignant cervical carcinoma. The mechanisms by which abnormalities accumulate are various, but it is possible that viral proteins are involved. In particular, the viral E6 oncoprotein has been shown to interact with the cellular tumour suppressor protein p53, which is involved in DNA damage repair pathways. Hence, E6 may contribute to the genomic instability through this interaction with p53. We have tested this hypothesis by monitoring the effects of E6 upon DNA damage induced p53 transcriptional activity. This study shows that HPV-18 E6 inhibits p53 transcriptional activity following genotoxic stress with UV radiation. No effect was observed when a mutant E6 unable to direct the degradation of p53 was included in this assay. These results suggest that continued E6 expression may contribute to the accumulation of DNA damage associated with the progression of cervical cancer.	MCGILL UNIV, INST PARASITOL, ST ANNE DE BELLEVUE H9X 3V9, PQ, CANADA; MCGILL UNIV, CTR CANC, MONTREAL, PQ, CANADA; INT CTR GENET ENGN & BIOTECHNOL, I-34012 TRIESTE, ITALY	McGill University; McGill University; International Center for Genetic Engineering & Biotechnology (ICGEB)								AUERSPERG N, 1964, J NATL CANCER I, V32, P135; BANKS L, 1990, ONCOGENE, V5, P1383; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; CHEN SL, 1990, J VIROL, V64, P3226, DOI 10.1128/JVI.64.7.3226-3233.1990; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRANCO EL, 1993, INFECT MED, V10, P57; HALL PA, 1993, ONCOGENE, V8, P203; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LORINCZ AT, 1992, OBSTET GYNECOL, V79, P328, DOI 10.1097/00006250-199203000-00002; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MUNGER K, 1989, J VIROL, V63, P4417; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIM D, 1992, ONCOGENE, V7, P27; PONTEN J, 1967, INT J CANCER, V2, P434, DOI 10.1002/ijc.2910020505; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; TOMMASINO M, 1993, ONCOGENE, V8, P195; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	42	49	52	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					629	633						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290274				2022-12-25	WOS:A1994MW24800031
J	AIRD, WC; PARVIN, JD; SHARP, PA; ROSENBERG, RD				AIRD, WC; PARVIN, JD; SHARP, PA; ROSENBERG, RD			THE INTERACTION OF GATA-BINDING PROTEINS AND BASAL TRANSCRIPTION FACTORS WITH GATA BOX-CONTAINING CORE PROMOTERS A MODEL OF TISSUE-SPECIFIC GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; DNA-BINDING; TATA BOX; ACCURATE TRANSCRIPTION; INITIATION; INVITRO; REPRESSOR; ELEMENTS; YEAST; ACTIVATION	The core promoters of the rat platelet factor 4 (PF4), mouse erythropoietin and chicken beta globin genes contain a GATA motif in place of the consensus TATAAA site. In the case of the PF4 gene, this site has been shown to play a critical role in restricting transcription to the megakaryocyte lineage. In order to understand the mechanism of tissue specificity, we investigated the function of the GATA box-containing promoters in vitro. Our studies show that the TATA-binding protein of TFIID is required for initiation of transcription from the GATA box-containing promoters. GATA-1 interacts with the core promoter GATA motif and inhibits generation of preinitiation complexes. The functional significance of the inhibition of preinitiation complexes is supported by in vitro transcription assays in which transcription from the PF4 and erythropoietin core promoters is suppressed by GATA-1. We also demonstrate that GATA-2 inhibits initiation of transcription from the PF4 core promoter. Based on these results, we propose a model in which repression of PF4 expression in nonmegakaryocytes is mediated, in part, by competition between GATA-binding proteins and basal factors for the core promoter.	MIT, DEPT BIOL, E25-229, 77 MASSACHUSETTS AVE, CAMBRIDGE, MA 02139 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center			Parvin, Jeffrey D/C-8955-2009		NATIONAL CANCER INSTITUTE [P30CA014051, P01CA042063] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL039753] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-14051, P01-CA42063] Funding Source: Medline; NHLBI NIH HHS [HL39753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARTHEW RW, 1988, J BIOL CHEM, V263, P17128; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; DOSTATNI N, 1991, GENE DEV, V5, P1657, DOI 10.1101/gad.5.9.1657; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; KAUFMAN PD, 1991, P NATL ACAD SCI USA, V88, P2613, DOI 10.1073/pnas.88.7.2613; KIM CG, 1990, MOL CELL BIOL, V10, P5958, DOI 10.1128/MCB.10.11.5958; LEE ME, 1990, J BIOL CHEM, V265, P10446; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P2289, DOI 10.1073/pnas.87.6.2289; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PETERSON MG, 1991, NATURE, V354, P369; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAHUEL C, 1992, EMBO J, V11, P4095, DOI 10.1002/j.1460-2075.1992.tb05502.x; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; RAVID K, 1991, P NATL ACAD SCI USA, V88, P1521, DOI 10.1073/pnas.88.4.1521; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	36	77	77	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					883	889						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288642				2022-12-25	WOS:A1994MR22000021
J	CARROLL, MP; MAY, WS				CARROLL, MP; MAY, WS			PROTEIN KINASE-C-MEDIATED SERINE PHOSPHORYLATION DIRECTLY ACTIVATES RAF-1 IN MURINE HEMATOPOIETIC-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TYROSINE PHOSPHORYLATION; MAP KINASE; INTERLEUKIN-2 RECEPTOR; GROWTH-FACTORS; ERYTHROPOIETIN; EXPRESSION; FAMILY; IDENTIFICATION; PROTOONCOGENE	We have previously found that Raf-1, which is activated by hematopoietic growth factors in association with phosphorylation, is required for hematopoietic cell proliferation. Recently, 12-O-tetradecanoylphorbol 13-acetate has been found to mediate Raf-l phosphorylation, suggesting that protein kinase C (PKC) may be involved in the Raf-l activation mechanism(s). Since PKC can be activated by hematopoietic growth factors, it was investigated as a potential ''Raf-l kinase-kinase.'' Results demonstrate that bryostatin 1, a pharmacologic activator of PKC, induces activation of Raf-l in FDC-P1 cells. PKC inhibitors H7 and staurosporine block both bryostatin 1- and interleukin-3-mediated Raf-l phosphorylation and FDC-P1 cell proliferation. Additionally, an antisense c-raf oligodeoxyribonucleotide specifically inhibits bryostatin 1-mediated proliferation, indicating a necessary role for Raf-l in PKC signaling. Purified PKC can phosphorylate Raf-l serine residues to high stoichiometry in vitro. Comparative phosphopeptide maps localize two PKC phosphorylation sites to Raf-l phosphopeptides isolated from hematopoietic growth factor- or bryostatin 1-stimulated cells. The sites of PKC-mediated Raf-l phosphorylation are deduced to be Ser497 and Ser619. Furthermore, PKC-mediated serine phosphorylation is sufficient to activate the enzymatic function of Raf-l in vitro. These findings demonstrate that activated PKC can promote hematopoietic cell growth by regulating the enzymatic activity of Raf-1 through direct serine phosphorylation.	JOHNS HOPKINS ONCOL CTR, 424 N BOND ST, BALTIMORE, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine					NCI NIH HHS [CA 01679, CA 44649, CA 47993] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001679, R01CA044649, R01CA047993] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, 1992, J BIOL CHEM, V267, P13135; ADUNYAH SE, 1991, J BIOL CHEM, V266, P5670; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DURONIO V, 1989, BIOCHEM BIOPH RES CO, V164, P804, DOI 10.1016/0006-291X(89)91530-1; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; GOMEZCAMBRONERO J, 1989, P NATL ACAD SCI USA, V86, P3569, DOI 10.1073/pnas.86.10.3569; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOGANS BB, 1988, J CELL PHYSIOL, V137, P346, DOI 10.1002/jcp.1041370219; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; MAY WS, 1993, IN PRESS C INSERM, V229; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; OKUDA K, 1992, BLOOD, V79, P2880; ORR JW, 1992, J BIOL CHEM, V267, P15263; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; QUELLE FW, 1991, J BIOL CHEM, V266, P609; SETH A, 1991, J BIOL CHEM, V266, P23521; SHERR CJ, 1990, BLOOD, V75, P1; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; SOZERI O, 1992, ONCOGENE, V7, P2259; SPANGLER R, 1991, J BIOL CHEM, V266, P681; SUMMERS MD, 1988, MANUAL METHODS BACUL, P10; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; ZOLLER MJ, 1979, J BIOL CHEM, V254, P8363	47	205	209	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1249	1256						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288587				2022-12-25	WOS:A1994MR22000076
J	RYABOVA, L; VOLIANIK, E; KURNASOV, O; SPIRIN, A; WU, Y; KRAMER, FR				RYABOVA, L; VOLIANIK, E; KURNASOV, O; SPIRIN, A; WU, Y; KRAMER, FR			COUPLED REPLICATION-TRANSLATION OF AMPLIFIABLE MESSENGER-RNA - A CELL-FREE PROTEIN-SYNTHESIS SYSTEM THAT MIMICS VIRAL-INFECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							Q-BETA-REPLICASE; NUCLEOTIDE-SEQUENCE; RECOMBINANT-RNA; MOLECULE; EVOLUTION	Amplifiable messenger RNAs (Wu, Y., Zhang, D. Y., and Kramer, F. R. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 11769-11773) were used as templates in coupled replication-translation reactions. These amplifiable mRNAs contained a preselected messenger sequence embedded within the sequence of MDV-1 RNA, which is a small, naturally occurring template for Qbeta replicase. When these recombinant mRNAs were incubated in vitro in reactions that contained both an Escherichia coli cell-free translation system and Qbeta replicase, the encoded protein was synthesized more efficiently than in corresponding reactions that did not contain Qbeta replicase. Moreover, when coupled replication-translation reactions were carried out in a continuous-flow format (Spirin, A. S., Baranov, V. I., Ryabova, L. A., Ovodov, S. Yu., and Alakhov, Yu. B. (1988) Science 242, 1162-1164), the synthesis of biologically active protein continued for a prolonged period. The results suggest that the mechanism of replication and translation in coupled reactions is similar to the mechanism by which Qbeta phage genomic RNA is simultaneously replicated and translated in Qbeta-infected E. coli: protein synthesis occurs on nascent RNA strands; many more sense strands are synthesized than antisense strands; and the integrity of the messenger sequence is preserved because a relatively small number of antisense strands serve as master templates for the synthesis of new messenger strands.	RUSSIAN ACAD SCI,INST PROT RES,142292 PUSHCHINO,RUSSIA; PUBL HLTH RES INST CITY NEW YORK INC,DEPT MOLEC GENET,NEW YORK,NY 10016	Russian Academy of Sciences				Ryabova, Lyubov/0000-0003-1989-203X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043521] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43521] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANERJEE AK, 1969, J MOL BIOL, V45, P181, DOI 10.1016/0022-2836(69)90098-9; BIEBRICHER CK, 1987, COLD SPRING HARB SYM, V52, P299, DOI 10.1101/SQB.1987.052.01.035; BILLETER MA, 1966, J BIOL CHEM, V241, P4750; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CHEN HZ, 1983, METHOD ENZYMOL, V101, P674; CHETVERIN AB, 1991, J MOL BIOL, V222, P3, DOI 10.1016/0022-2836(91)90729-P; DOBKIN C, 1979, BIOCHEMISTRY-US, V18, P2038, DOI 10.1021/bi00577a030; DOMINGO E, 1978, CELL, V13, P735, DOI 10.1016/0092-8674(78)90223-4; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HARUNA I, 1965, P NATL ACAD SCI USA, V54, P1189, DOI 10.1073/pnas.54.4.1189; HARUNA I, 1965, SCIENCE, V150, P884, DOI 10.1126/science.150.3698.884; HODGES WM, 1987, ANAL BIOCHEM, V160, P65, DOI 10.1016/0003-2697(87)90614-2; HOTHAMIGLEWSKI B, 1968, NATURE, V219, P700, DOI 10.1038/219700a0; KACIAN DL, 1972, P NATL ACAD SCI USA, V69, P3038, DOI 10.1073/pnas.69.10.3038; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIZARDI PM, 1988, BIO-TECHNOL, V6, P1197, DOI 10.1038/nbt1088-1197; MIELE EA, 1983, J MOL BIOL, V171, P281, DOI 10.1016/0022-2836(83)90094-3; MILLS DR, 1975, P NATL ACAD SCI USA, V72, P4252, DOI 10.1073/pnas.72.11.4252; MILLS DR, 1973, SCIENCE, V180, P916, DOI 10.1126/science.180.4089.916; MOROZOV IY, 1993, P NATL ACAD SCI USA, V90, P9325, DOI 10.1073/pnas.90.20.9325; MUNISHKIN AV, 1991, J MOL BIOL, V221, P463, DOI 10.1016/0022-2836(91)80067-5; MUNISHKIN AV, 1988, NATURE, V333, P473, DOI 10.1038/333473a0; NISHIHARA T, 1983, J BIOCHEM, V93, P669, DOI 10.1093/jb/93.3.669; PRIANO C, 1987, COLD SPRING HARB SYM, V52, P321, DOI 10.1101/SQB.1987.052.01.037; SCHAFFNER W, 1977, J MOL BIOL, V117, P877, DOI 10.1016/S0022-2836(77)80004-1; SPIRIN AS, 1988, SCIENCE, V242, P1162, DOI 10.1126/science.3055301; SPIRIN AS, 1991, FRONTIERS BIOPROCESS, V2, P31; WU Y, 1992, P NATL ACAD SCI USA, V89, P11769, DOI 10.1073/pnas.89.24.11769	28	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1501	1505						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288616				2022-12-25	WOS:A1994MR22000110
J	BLUML, K; MUTSCHLER, E; WESS, J				BLUML, K; MUTSCHLER, E; WESS, J			IDENTIFICATION OF AN INTRACELLULAR TYROSINE RESIDUE CRITICAL FOR MUSCARINIC RECEPTOR-MEDIATED STIMULATION OF PHOSPHATIDYLINOSITOL HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; 3RD CYTOPLASMIC LOOP; ACETYLCHOLINE-RECEPTOR; LIGAND-BINDING; DOMAINS; GS; SELECTIVITY; ACTIVATION; SUBTYPES; DELINEATION	Several lines of evidence suggest that the N-terminal portion of the third cytoplasmic loop (i3) of muscarinic and other G protein-coupled receptors is of pivotal importance for G protein recognition and activation. The present study was designed to identify specific amino acids within this domain required for muscarinic receptor-induced activation of G proteins mediating stimulation of phosphatidylinositol (PI) hydrolysis. Among the five mammalian muscarinic receptors (m1-m5), only the m1, m3, and m5 receptors are efficiently coupled to this second messenger pathway. Initially, we created a series of rat m3 receptor mutants in which short segments in the N terminus of the i3 loop were replaced with the corresponding m2 receptor sequences. The effect of these substitutions on m3 receptor-mediated stimulation of PI hydrolysis was studied in transiently transfected COS-7 cells. We found that a stretch of 4 amino acids (Arg252-Ile253-Tyr254-Lys255) located at the beginning of the i3 domain of the m3 muscarinic receptor is critically involved in receptor-mediated stimulation of PI hydrolysis. Further mutational analysis of this 4-amino acid segment by single amino acid substitutions demonstrated that only Tyr254 is essential for efficient activation of the PI pathway. This tyrosine residue is conserved among all PI-coupled muscarinic receptors as well as in many other biogenic amine and glycoprotein hormone receptors, suggesting that it may also play an important functional role in other G protein-coupled receptors.	NIDDKD,BIOORGAN CHEM LAB,BLDG 8A,RM B1A-09,BETHESDA,MD 20892; UNIV FRANKFURT,W-6000 FRANKFURT,GERMANY	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Goethe University Frankfurt								ARDEN JR, 1992, BIOCHEM BIOPH RES CO, V188, P1111, DOI 10.1016/0006-291X(92)91346-R; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; Higuchi R., 1989, PCR TECHNOLOGY, P61; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRADER CD, 1987, J BIOL CHEM, V262, P16439; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3; WESS J, 1990, MOL PHARMACOL, V38, P517; WESS J, 1990, MOL PHARMACOL, V38, P872; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; WONG SKF, 1990, J BIOL CHEM, V265, P6219	27	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					402	405						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276826				2022-12-25	WOS:A1994MR21900068
J	COURTY, Y; ROSINSKICHUPIN, I; ROUGEON, F				COURTY, Y; ROSINSKICHUPIN, I; ROUGEON, F			A NEW PROLINE-RICH PROTEIN-PRECURSOR EXPRESSED IN THE SALIVARY-GLANDS OF THE RAT IS ENCODED BY A GENE HOMOLOGOUS TO THE GENE CODING FOR THE PROHORMONE-LIKE PROTEIN SMR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBMANDIBULAR-GLAND; MULTIGENE FAMILIES; SUBMAXILLARY-GLAND; STREPTOCOCCUS-GORDONII; SEQUENCES; GLYCOPROTEINS; ORGANIZATION; PEPTIDES; ADHESION	A gene encoding a prohormone-like protein, (SMR1) has previously been characterized and shown to be expressed in the rat submandibular glands under androgenic control (Rosinski-Chupin, I., Tronik, D., and Rougeon, F. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 8553-8557). This gene, now named VCS-alpha1, belongs to a multigene family (Rosinski-Chupin, I., and Rougeon, F. (1990) DNA Cell Biol. 9, 553-559). We now describe the structure and the expression of a second member (VCS-beta1) of this family. The two genes differ principally in the protein-coding region, therefore we have named these related genes VCS (variable coding sequence). Genomic clones containing the VCS-beta1 gene were obtained by screening a lambdaEMBL3 library with a probe corresponding to the VCS-alpha1 cDNA. The nucleotide sequence of VCS-beta1 predicted a structure containing three exons. This structure, confirmed by sequencing a BCS-beta1 cDNA obtained by reverse polymerase chain reaction, is identical to the organization of the VCS-alpha1 gene. Comparison of the VCS-beta1 and VCS-alpha1 genomic sequences indicates regions of hemology which are unevenly distributed, suggesting a differential evolution of some areas (particularly the third exon) of the VCS genes. The VCS-beta1 cDNA codes for a proline-rich protein precursor named PR-Vbeta1 (148 amino acids, 39.2% proline, 10.8% glycine) and characterized by a secretory signal-peptide and three repeats of a unit rich in proline residues surrounded by two clusters of potential endoprotease cleavage sites. mRNA coding for PR-Vbeta1 was detected in the submandibular-sublingual gland complex of male and female rats. PR-Vbeta1 is homologous to the proline-rich peptide B isolated from human saliva (Isemura, S., Saitoh, E., and Sanada, K. (1979) J. Biochem. (Tokyo) 86, 79-86) and to the submandibular proline-rich protein precursor MSG1 of the mouse (D. Tronik-Le Roux, M. Senorale-Pose, and F. Rougeon, manuscript in preparation). Our observations provide evidence that in addition to the known proline-rich protein genes, there is, in rodent and probably human genomes, another class of genes coding for salivary proline-rich proteins. The high conservation of various sites for bacterial collagenases localized in the repeat region of PR-Vbeta1, MSG1, and PRP-B suggest a protective function of these proteins in the oral cavity.	INST PASTEUR, DEPT IMMUNOL,CNRS,UNITE GENET & BIOCHIM DEV, URA 361,25 RUE DR ROUX, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				Courty, Yves/0000-0003-3694-8517				ANN DK, 1987, J BIOL CHEM, V262, P3958; BARKA T, 1980, J HISTOCHEM CYTOCHEM, V28, P836, DOI 10.1177/28.8.7003006; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENNICK A, 1982, MOL CELL BIOCHEM, V45, P83; BENNICK A, 1983, BIOCHEM J, V213, P11, DOI 10.1042/bj2130011; BOULIKAS T, 1992, J MOL EVOL, V35, P156, DOI 10.1007/BF00183227; CARLSON DM, 1988, BIOCHIMIE, V70, P1689, DOI 10.1016/0300-9084(88)90304-5; CARLSON DM, 1991, PROG NUCLEIC ACID RE, V41, P1; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEMENTS S, 1985, J BIOL CHEM, V260, P3471; COOPER LF, 1991, J BIOL CHEM, V266, P3532; DICKINSON DP, 1988, MOL BIOL EVOL, V6, P80; DURET L, 1993, NUCLEIC ACIDS RES, V21, P2315, DOI 10.1093/nar/21.10.2315; FICKETT JW, 1982, NUCLEIC ACIDS RES, V10, P5303, DOI 10.1093/nar/10.17.5303; GIBBONS RJ, 1991, INFECT IMMUN, V59, P2948, DOI 10.1128/IAI.59.9.2948-2954.1991; GILLECECASTRO BL, 1991, J BIOL CHEM, V266, P17358; HEINRICH G, 1987, J BIOL CHEM, V262, P5262; HOLT S C, 1991, Critical Reviews in Oral Biology and Medicine, V2, P177; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; ISEMURA S, 1979, J BIOCHEM-TOKYO, V86, P79; KAUFFMAN DL, 1991, BIOCHEMISTRY-US, V30, P3351, DOI 10.1021/bi00228a001; KEIL B, 1992, SPECIFICITY PROTEOLY, P193; KIM HS, 1993, MAMM GENOME, V4, P3, DOI 10.1007/BF00364656; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; LYONS KM, 1988, GENETICS, V120, P267; LYONS KM, 1988, GENETICS, V120, P255; MAEDA N, 1985, J BIOL CHEM, V260, P1123; MAYRAND D, 1985, CAN J MICROBIOL, V31, P134, DOI 10.1139/m85-026; MEHANSHO H, 1983, P NATL ACAD SCI-BIOL, V80, P3948, DOI 10.1073/pnas.80.13.3948; MIRELS L, 1987, J BIOL CHEM, V262, P7289; MORI M, 1992, ACTA HISTOCHEM CYTOC, V25, P325, DOI 10.1267/ahc.25.325; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OPPENHEIM FG, 1988, J BIOL CHEM, V263, P7472; PANTHIER JJ, 1983, EMBO J, V2, P675, DOI 10.1002/j.1460-2075.1983.tb01483.x; PUGSLEY AP, 1989, PROTEIN TARGETING, P45; ROSINSKICHUPIN I, 1988, P NATL ACAD SCI USA, V85, P8553, DOI 10.1073/pnas.85.22.8553; ROSINSKICHUPIN I, 1990, J BIOL CHEM, V265, P10709; ROSINSKICHUPIN I, 1990, DNA CELL BIOL, V9, P553, DOI 10.1089/dna.1990.9.553; STINSON MW, 1992, INFECT IMMUN, V60, P2598, DOI 10.1128/IAI.60.7.2598-2604.1992; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; ZIEMER MA, 1984, J BIOL CHEM, V259, P475	42	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					520	527						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276845				2022-12-25	WOS:A1994MR21900084
J	GALLAGHER, MJ; BLUMENTHAL, KM				GALLAGHER, MJ; BLUMENTHAL, KM			IMPORTANCE OF THE UNIQUE CATIONIC RESIDUES ARGININE-12 AND LYSINE-49 IN THE ACTIVITY OF THE CARDIOTONIC POLYPEPTIDE ANTHOPLEURIN-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; XANTHOGRAMMICA HEART STIMULANT; POTENTIAL NA+ IONOPHORE; SEA-ANEMONE TOXIN; H-1-NMR ASSIGNMENTS; SECONDARY STRUCTURE; SODIUM-CHANNEL; PHARMACOLOGICAL PROPERTIES; STICHODACTYLA-HELIANTHUS; SCORPION TOXIN	Sea anemone toxins are potentially important tools for understanding the pharmacology of voltage-sensitive sodium channels. We have previously described a bacterial expression system capable of producing large amounts of one such toxin, anthopleurin B (ApB), which delays channel repolarization (Gallagher, M. J., and Blumenthal K. M. (1992) J. Biol. Chem. 267,13958-13963). It has been suggested that cationic residues are a major determinant of anemone toxin binding. In this paper, we describe characterization of three mutants at each of two unique cationic sites of ApB, Arg-12 and Lys-49. The activities of all mutants on cardiac and neuronal sodium channels have been compared with that of wild-type ApB. Mutation of Lys-49 has relatively minor effects on toxicity, whereas the mutant R12A, but not R12S or R12K, is severely impaired. These results indicate that cationic residues per se are not absolutely required at either position, but that polar side chains at position 12 contribute significantly to binding affinity. Furthermore, Arg-12 appears to be involved in the toxin's ability to discriminate between neuronal and cardiac sodium channels.	UNIV CINCINNATI,DEPT MICROBIOL,CINCINNATI,OH 45267; UNIV CINCINNATI,DEPT BIOCHEM,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	GALLAGHER, MJ (corresponding author), UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET,CINCINNATI,OH 45267, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041543] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41543] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALSEN C, 1983, FED PROC, V42, P101; BERGMAN C, 1976, BIOCHIM BIOPHYS ACTA, V455, P173, DOI 10.1016/0005-2736(76)90162-0; BLAIR RW, 1978, J PHARMACOL EXP THER, V207, P271; CATTERALL WA, 1976, J BIOL CHEM, V251, P5528; CATTERALL WA, 1981, MOL PHARMACOL, V20, P533; CATTERALL WA, 1978, J BIOL CHEM, V253, P7393; CATTERALL WA, 1977, J BIOL CHEM, V252, P8660; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Cleland W W, 1979, Methods Enzymol, V63, P103; DONAHUE LM, 1991, DEV BIOL, V147, P415, DOI 10.1016/0012-1606(91)90299-I; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FOGH RH, 1989, BIOCHEMISTRY-US, V28, P1826, DOI 10.1021/bi00430a060; FRELIN C, 1984, MOL PHARMACOL, V26, P70; GALLAGHER MJ, 1992, J BIOL CHEM, V267, P13958; GOULD AR, 1991, EUR J BIOCHEM, V206, P641; GROSS GJ, 1985, EUR J PHARMACOL, V110, P271, DOI 10.1016/0014-2999(85)90223-7; HOWELL ML, 1989, J BIOL CHEM, V264, P15268; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KEM WR, 1989, BIOCHEMISTRY-US, V28, P3483, DOI 10.1021/bi00434a050; KODAMA I, 1981, BRIT J PHARMACOL, V72, P239; MABBUTT BC, 1990, EUR J BIOCHEM, V187, P555, DOI 10.1111/j.1432-1033.1990.tb15337.x; Maniatis T., 1982, MOL CLONING; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; NELSON PG, 1973, NATURE-NEW BIOL, V246, P124; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; NORTON RS, 1991, TOXICON, V29, P1051, DOI 10.1016/0041-0101(91)90205-6; NORTON TR, 1976, J PHARM SCI, V65, P1368, DOI 10.1002/jps.2600650927; NORTON TR, 1981, FED PROC, V40, P21; REIMER NS, 1985, J BIOL CHEM, V260, P8690; RENAUD JF, 1986, EUR J PHARMACOL, V120, P161, DOI 10.1016/0014-2999(86)90536-4; ROGART RB, 1989, P NATL ACAD SCI USA, V73, P4055; ROMEY G, 1976, P NATL ACAD SCI USA, V73, P4055, DOI 10.1073/pnas.73.11.4055; SCHWEITZ H, 1981, BIOCHEMISTRY-US, V20, P5245, DOI 10.1021/bi00521a023; SHIBATA S, 1978, J PHARMACOL EXP THER, V205, P683; TANAKA M, 1977, BIOCHEMISTRY-US, V16, P204, DOI 10.1021/bi00621a007; WIDMER H, 1988, EUR J BIOCHEM, V171, P177, DOI 10.1111/j.1432-1033.1988.tb13774.x; ZENG D, 1993, IN PRESS 1993 SOC NE	37	42	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					254	259						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276803				2022-12-25	WOS:A1994MR21900046
J	MAUVIEL, A; LAPIERE, JC; HALCIN, C; EVANS, CH; UITTO, J				MAUVIEL, A; LAPIERE, JC; HALCIN, C; EVANS, CH; UITTO, J			DIFFERENTIAL CYTOKINE REGULATION OF TYPE-I AND TYPE-VII COLLAGEN GENE-EXPRESSION IN CULTURED HUMAN DERMAL FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; NECROSIS-FACTOR-ALPHA; MESSENGER-RNA LEVELS; HUMAN SYNOVIAL-CELLS; EPIDERMOLYSIS-BULLOSA; TRANSCRIPTIONAL ACTIVATION; EPIDERMAL-KERATINOCYTES; STIMULATES COLLAGENASE; LEUKOREGULIN; SKIN	Type VII collagen is the major component of anchoring fibrils in the cutaneous basement membrane zone. In this study, we have examined the effects of various cytokines on the expression of types I and VII collagen genes in dermal fibroblasts in culture. The pro-inflammatory cytokines, interleukin-1alpha (IL-1alpha), interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), and leukoregulin (LR) strongly elevated (approximately 5-9-fold) type VII collagen mRNA levels, as measured by Northern blot hybridizations. These effects were also observed at the protein level by indirect immunofluorescence using a monoclonal antibody specific for type VII collagen. By contrast, IL-1beta had only a slight stimulatory effect (approximately 2-fold) on type I collagen gene expression, while TNF-alpha and LR markedly reduced type I collagen mRNA steady-state levels. Interestingly, IL-1, TNF-alpha and LR had additive effects with transforming growth factor-beta (TGF-beta) on type VII collagen gene expression, whereas they counteracted the up-regulatory effect of TGF-beta on type I collagen gene expression. Thus, our data indicate that the modulation of type I and type VII collagen gene expression by cytokines involves different regulatory pathways.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL,DEPT DERMATOL,233 S 10TH ST, RM 450, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT BIOCHEM & MOLEC BIOL, PHILADELPHIA, PA 19107 USA; NCI, TUMOR BIOL SECT, BIOL LAB, BETHESDA, MD 20892 USA	Jefferson University; Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			MAUVIEL, Alain/F-6251-2013	Mauviel, Alain/0000-0002-0438-2793	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007561, P01AR038923] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01-AR38923, T32-AR07561] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRENNER D, 1989, NATURE, V348, P661; BURGESON RE, 1990, ANN NY ACAD SCI, V580, P32, DOI 10.1111/j.1749-6632.1990.tb17915.x; CHIRGWIN J, 1979, BIOCHEMISTRY-US, V18, P5293; CHU ML, 1985, J BIOL CHEM, V260, P2315; CONCA W, 1989, J CLIN INVEST, V83, P1753, DOI 10.1172/JCI114077; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; DAYER JM, 1976, P NATL ACAD SCI USA, V73, P945, DOI 10.1073/pnas.73.3.945; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; EVANS CH, 1989, ANAL BIOCHEM, V177, P358, DOI 10.1016/0003-2697(89)90066-3; FINE JD, 1991, J AM ACAD DERMATOL, V24, P119, DOI 10.1016/0190-9622(91)70021-S; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HEINO J, 1990, BIOCHEM J, V271, P827, DOI 10.1042/bj2710827; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KONIG A, 1991, J INVEST DERMATOL, V96, P803, DOI 10.1111/1523-1747.ep12474424; KONIG A, 1992, J CELL BIOL, V117, P679, DOI 10.1083/jcb.117.3.679; LI KH, 1993, J BIOL CHEM, V268, P8825; MAUVIEL A, 1993, WOUNDS, V5, P137; MAUVIEL A, 1991, J INVEST DERMATOL, V96, P243, DOI 10.1111/1523-1747.ep12462185; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; MAUVIEL A, 1992, J CELL BIOCHEM, V50, P53, DOI 10.1002/jcb.240500110; MAUVIEL A, 1992, BIOCHEM J, V284, P629, DOI 10.1042/bj2840629; MAUVIEL A, 1992, J BIOL CHEM, V267, P5644; OH SP, IN PRESS P NATL ACAD; PALLER AS, 1985, J INVEST DERMATOL, V82, P215; PARENTE MG, 1991, P NATL ACAD SCI USA, V88, P6931, DOI 10.1073/pnas.88.16.6931; RYYNANEN J, 1991, BIOCHEM BIOPH RES CO, V180, P673, DOI 10.1016/S0006-291X(05)81118-0; RYYNANEN J, 1992, J CLIN INVEST, V89, P163, DOI 10.1172/JCI115557; SAKAI LY, 1986, J CELL BIOL, V103, P1577, DOI 10.1083/jcb.103.4.1577; Uitto J, 1992, Exp Dermatol, V1, P2, DOI 10.1111/j.1600-0625.1992.tb00065.x; UITTO J, 1992, J CLIN INVEST, V90, P687, DOI 10.1172/JCI115938; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VARGA J, 1987, BIOCHEM BIOPH RES CO, V147, P1282, DOI 10.1016/S0006-291X(87)80209-7; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WOODLEY DT, 1985, BIOCHEM BIOPH RES CO, V130, P1267, DOI 10.1016/0006-291X(85)91751-6	36	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					25	28						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276802				2022-12-25	WOS:A1994MR21900007
J	MIURA, Y; KAWABATA, S; IWANAGA, S				MIURA, Y; KAWABATA, S; IWANAGA, S			A LIMULUS INTRACELLULAR COAGULATION INHIBITOR WITH CHARACTERISTICS OF THE SERPIN SUPERFAMILY - PURIFICATION, CHARACTERIZATION, AND CDNA CLONING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRAB TACHYPLEUS-TRIDENTATUS; AMINO-ACID-SEQUENCE; SERINE-PROTEASE ZYMOGEN; PLASMINOGEN-ACTIVATOR INHIBITOR; FACTOR-C; TRYPSIN-INHIBITOR; HEMOCYTES; HEMOLYMPH; POLYPHEMUS; AMEBOCYTES	A limulus intracellular coagulation inhibitor, designated LICI, was isolated from hemocytes of the Japanese horseshoe crab (Tachypleus tridentatus), using three steps of chromatography, including dextran sulfate-Sepharose CL-6B, Sephacryl S-200, and Mono S. LICI is a single-chain glycoprotein with an apparent M(r) = 48,000 estimated by SDS-polyacrylamide gel electrophoresis. It blocks the amidolytic activities of Limulus lipopolysaccharide-sensitive serine protease, factor CBAR, by forming a covalent 1:1 complex with the protease. The second-order rate constant for inhibition of factor CBAR was 2.5 x 10(6) m-1 s-1 at 37-degrees-C. LICI also inhibited human alpha-thrombin, rat salivary kallikrein, bovine plasmin, and trypsin but not Limulus clotting enzyme, Limulus factor BBAR, bovine factor Xa, human factor XIa, human tissue plasminogen activator, human urokinase, chymotrypsin, elastase, and papain. Glycosaminoglycans such as heparin and heparan sulfate had no effect on the inhibitory activity. A cDNA coding for LICI was isolated from a hemocyte cDNA library. The open reading frame of the 1,257-base pair cDNA codes for the mature protein of 394 amino acids, of which 223 residues were confirmed by amino acid sequence analysis. LICI shows significant sequence identities to members of the serpin superfamily, such as human plasminogen activator inhibitor type 2 (40%) and human monocyte/neutrophil elastase inhibitor (39%). LICI contains a putative reactive site, -Arg-Ser-, at the corresponding position present in several inhibitors of the serpin superfamily. The subcellular localization, determined using an anti-LICI polyclonal antibody, indicated that LICI colocates with the Limulus serine protease zymogens in large granules in the hemocyte.	KYUSHU UNIV 33,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN; KYUSHU UNIV 33,GRAD SCH MED SCI,DEPT MOLEC BIOL,FUKUOKA 812,JAPAN	Kyushu University; Kyushu University			Miura, Yoshiki/U-8875-2019	Miura, Yoshiki/0000-0002-7596-0482				AKETAGAWA J, 1986, J BIOL CHEM, V261, P7357; BJORK I, 1986, PROTEINASE INHIBITOR, P489; Brehelin M., 1986, P36; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CHASE T, 1970, METHOD ENZYMOL, V19, P20; DONOVAN MA, 1991, J BIOL CHEM, V266, P2121; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; EVANS DL, 1992, BIOCHEMISTRY-US, V31, P12629, DOI 10.1021/bi00165a013; HARLOW E, 1989, ANTIBODIES LABORATOR, P471; HASHIMOTO N, 1985, J BIOCHEM, V97, P1347, DOI 10.1093/oxfordjournals.jbchem.a135187; HEUSSEN C, 1984, J BIOL CHEM, V259, P1635; JESTY J, 1979, J BIOL CHEM, V254, P44; JOSLIN G, 1991, J BIOL CHEM, V266, P11282; KANOST MR, 1989, J BIOL CHEM, V264, P965; KATO H, 1987, J BIOCHEM, V102, P1389, DOI 10.1093/oxfordjournals.jbchem.a122185; KATO H, 1980, J BIOCHEM-TOKYO, V88, P183; KAWABATA S, 1985, J BIOCHEM-TOKYO, V67, P1073; KAWABATA SI, 1988, EUR J BIOCHEM, V172, P17, DOI 10.1111/j.1432-1033.1988.tb13849.x; KURACHI K, 1981, METHOD ENZYMOL, V80, P211; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LEVIN J, 1964, B JOHNS HOPKINS HOSP, V115, P265; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MINETTI CASA, 1991, J BIOL CHEM, V266, P20773; MIURA Y, 1992, J BIOCHEM-TOKYO, V112, P476, DOI 10.1093/oxfordjournals.jbchem.a123924; MIYATA T, 1984, J BIOL CHEM, V259, P8924; MORITA T, 1981, FEBS LETT, V129, P318, DOI 10.1016/0014-5793(81)80192-5; MUTA T, 1991, J BIOL CHEM, V266, P6554; NAKAMURA T, 1986, EUR J BIOCHEM, V154, P511, DOI 10.1111/j.1432-1033.1986.tb09427.x; NAKAMURA T, 1987, J BIOCHEM, V101, P1297, DOI 10.1093/oxfordjournals.jbchem.a121994; NAKAMURA T, 1986, J BIOCHEM, V99, P847, DOI 10.1093/oxfordjournals.jbchem.a135545; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; NGUYEN NY, 1986, J BIOL CHEM, V261, P456; Ornberg R.L., 1979, Progress in Clinical and Biological Research, V29, P125; OUIGLEY JP, 1983, J BIOL CHEM, V258, P7903; Petersen TE, 1979, PHYSL INHIBITORS BLO, P43; REMOLDODONNELL E, 1992, P NATL ACAD SCI USA, V89, P5635, DOI 10.1073/pnas.89.12.5635; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI T, 1991, EUR J BIOCHEM, V202, P255, DOI 10.1111/j.1432-1033.1991.tb16370.x; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHIGENAGA T, 1993, J BIOCHEM-TOKYO, V114, P307, DOI 10.1093/oxfordjournals.jbchem.a124173; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; Stormer L., 1952, Journal of Paleontology, V26, P630; TAKAGI H, 1990, J BIOCHEM, V108, P372, DOI 10.1093/oxfordjournals.jbchem.a123208; TOH Y, 1991, CELL TISSUE RES, V266, P137, DOI 10.1007/BF00678720; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; YE RD, 1987, J BIOL CHEM, V262, P3718	49	75	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					542	547						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276848				2022-12-25	WOS:A1994MR21900087
J	COWAN, DB; WEISEL, RD; WILLIAMS, WG; MICKLE, DAG				COWAN, DB; WEISEL, RD; WILLIAMS, WG; MICKLE, DAG			IDENTIFICATION OF OXYGEN RESPONSIVE ELEMENTS IN THE 5'-FLANKING REGION OF THE HUMAN GLUTATHIONE-PEROXIDASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN GENE; DNA-BINDING PROTEINS; YEAST HAP1 ACTIVATOR; ENZYME-ACTIVITIES; OXIDATIVE STRESS; MAMMALIAN-CELLS; DIRECT CLONING; PCR PRODUCTS; SEQUENCE; EXPRESSION	The -1389 to +588 region of the human genomic glutathione peroxidase gene (hgpx1) was amplified using the polymerase chain reaction. This DNA fragment was cloned and sequenced, and various deletion constructs derived from the hgpx1 5'-flanking region were fused to the chloramphenicol acetyltransferase gene. These reporter genes were analyzed in transient transfection assays using primary cultured human ventricular cardiomyocytes obtained from patients with tetralogy of Fallot. Two distinct regions upstream from the transcription start site, which was determined using S1 nuclease analysis, were identified to be responsive to the oxygen tension in culture (pO2 values of 150 or 40 mm Hg). Methylation interference footprinting assays revealed proteins closely apposed to two sequences located at -1232 to -1213 and -282 to -275. We have designated these oxygen responsive elements ORE1 and ORE2, respectively. Gel mobility shift assays using double-stranded oligonucleotides corresponding to each site have demonstrated the formation of specific complexes using both cultured human cardiomyocyte and HeLa nuclear extracts. ORE1 and ORE2 bind disparate proteins with equal precision as bound complexes could be competed away with identical sequences but not with either the other ORE or an unrelated sequence. Insertion of these oxygen responsive elements into a reporter gene governed by a SV40 promoter similarly regulated chloramphenicol acetyltransferase activity according to the oxygen tension in culture.	UNIV TORONTO,TORONTO HOSP,DEPT CLIN BIOCHEM,EATON WING S 3-404A,200 ELIZABETH ST,TORONTO M5G 2C4,ON,CANADA; UNIV TORONTO,TORONTO HOSP,CTR CARDIOVASC RES,TORONTO M5G 2C4,ON,CANADA; UNIV TORONTO,TORONTO HOSP,DIV CARDIOVASC SURG,TORONTO M5G 2C4,ON,CANADA; UNIV TORONTO,HOSP SICK CHILDREN DIV CARDIOVASC,TORONTO M5G 2C4,ON,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Williams, William Galbraith/AAF-2104-2019	Cowan, Douglas/0000-0002-6309-2737				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AGRON PG, 1993, P NATL ACAD SCI USA, V90, P3506, DOI 10.1073/pnas.90.8.3506; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BALDWIN AS, 1988, CURRENT PROTOCOLS MO; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHADA S, 1990, GENOMICS, V6, P268, DOI 10.1016/0888-7543(90)90566-D; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; CHU FF, 1993, J BIOL CHEM, V268, P2571; CLERCH LB, 1993, J CLIN INVEST, V91, P499, DOI 10.1172/JCI116228; COWAN DB, 1992, J MOL CELL CARDIOL, V24, P423, DOI 10.1016/0022-2828(92)93196-Q; COWAN DB, 1991, BIOCHEM J, V274, P687, DOI 10.1042/bj2740687; DELNIDO PJ, 1988, J THORAC CARDIOV SUR, V95, P223; DIAMOND AM, 1992, GENE, V122, P377, DOI 10.1016/0378-1119(92)90230-M; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FUCHS O, 1990, BIOMED BIOCHIM ACTA, V49, pS47; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENE JJ, 1988, CURRENT PROTOCOLS MO; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARABIN AL, 1990, J APPL PHYSIOL, V69, P328, DOI 10.1152/jappl.1990.69.1.328; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; HO YS, 1992, FEBS LETT, V301, P5, DOI 10.1016/0014-5793(92)80198-P; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; JONOT L, 1992, AM J RESPIR CELL MOL, V6, P107; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KINGSTON RE, 1988, CURRENT PROTOCOLS MO; KURATA H, 1992, FEBS LETT, V312, P10, DOI 10.1016/0014-5793(92)81400-G; LI RK, 1989, J MOL CELL CARDIOL, V21, P567, DOI 10.1016/0022-2828(89)90822-5; LI RK, 1992, J TISS CULT METHODS, V14, P93; MABLY JD, 1993, J BIOL CHEM, V268, P476; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCBRIDE O W, 1988, Biofactors, V1, P285; MOSCOW JA, 1992, J BIOL CHEM, V267, P5949; MULLENBACH GT, 1987, NUCLEIC ACIDS RES, V15, P5484, DOI 10.1093/nar/15.13.5484; MULLENBACH GT, 1988, PROTEIN ENG, V2, P239, DOI 10.1093/protein/2.3.239; PALMER M, 1989, RED BOOK B S, V7; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; PFEIFER K, 1987, CELL, V49, P19, DOI 10.1016/0092-8674(87)90751-3; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; RISTER M, 1976, J CLIN INVEST, V58, P1174, DOI 10.1172/JCI108570; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P707; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Sambrook J, 1989, MOL CLONING LABORATO; SELA S, 1993, NEPHRON, V63, P199; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SPALLHOLZ JE, 1991, PEROXIDASES CHEM BIO, V1, P259; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; SUKENAGA Y, 1987, NUCLEIC ACIDS RES, V15, P7198; TEOH KH, 1992, J THORAC CARDIOV SUR, V104, P159; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; WEBSTER KA, 1987, MOL CELL BIOCHEM, V77, P19; WEBSTER KA, 1992, J MOL CELL CARDIOL, V24, P741, DOI 10.1016/0022-2828(92)93388-Z; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	54	107	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26904	26910						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262924				2022-12-25	WOS:A1993MM26200014
J	JOLY, A; EDWARDS, PA				JOLY, A; EDWARDS, PA			EFFECT OF SITE-DIRECTED MUTAGENESIS OF CONSERVED ASPARTATE AND ARGININE RESIDUES UPON FARNESYL DIPHOSPHATE SYNTHASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYROPHOSPHATE SYNTHETASE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; CAROTENOID BIOSYNTHESIS; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; CATALYTIC SITE; GENE; PRENYLTRANSFERASE; IDENTIFICATION	All polyprenyl synthases catalyze the condensation of the allylic substrate, isopentenyl diphosphate, with a specific homoallylic diphosphate substrate. Polyprenyl synthases from Homo sapiens, Ratus rattus, Escherichia coli, Saccharomyces cerevisiae, Neurospora crassa, and Erwinia herbicola contain two conserved ''aspartate-rich domains'' (Ashby, M. N., and Edwards, P.A. (1992) J. Biol. Chem. 267, 4128-4136). In order to determine the importance of these domains in catalysis, the conserved aspartates or arginines in domains I and II of rat farnesyl diphosphate synthase were individually mutated to glutamate or lysine, respectively. The putative ''active site'' arginine (Brems, D. N., Breunger, E., and Rilling, H. C. (1981) Biochemistry 20, 3711-3718) was mutated to lysine. Each mutant enzyme was overexpressed in E. coli and purified to apparent homogeneity. Detailed kinetic analyses of the wild type and mutant enzymes indicated that mutagenesis of Asp104, Asp107, Arg112, Arg113, and Asp243 resulted in a decreased V(max) of approximately 1000-fold compared to wild type. However, no significant change in the K(m) values for either the isopentenyl diphosphate or geranyl diphosphate substrate were observed. The results strongly suggest that these amino acids, and to a lesser extent Asp244, are involved in either the condensation of isopentenyl diphosphate and geranyl diphosphate to form farnesyl diphosphate and/or the release of the farnesyl diphosphate product from farnesyl diphosphate synthase. The conservation of these amino acid residues in different enzymes from several species suggests that these domains play a similar role in other polyprenyl synthases.	UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	JOLY, A (corresponding author), UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30568] Funding Source: Medline; NIGMS NIH HHS [GM 21326] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MS, 1989, J BIOL CHEM, V264, P19176; ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; ARMSTRONG GA, 1990, P NATL ACAD SCI USA, V87, P9975, DOI 10.1073/pnas.87.24.9975; ASHBY MN, 1992, J BIOL CHEM, V267, P4128; ASHBY MN, 1989, J BIOL CHEM, V264, P635; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BARNARD GF, 1981, BIOCHIM BIOPHYS ACTA, V661, P87, DOI 10.1016/0005-2744(81)90086-3; BARNARD GF, 1980, BIOCHIM BIOPHYS ACTA, V617, P169, DOI 10.1016/0005-2760(80)90160-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMS DN, 1981, BIOCHEMISTRY-US, V20, P3711, DOI 10.1021/bi00516a007; BREMS DN, 1979, BIOCHEMISTRY-US, V18, P860, DOI 10.1021/bi00572a019; CARATTOLI A, 1991, J BIOL CHEM, V266, P5854; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; EBERHARDT NL, 1975, J BIOL CHEM, V250, P863; FUJISAKI S, 1986, J BIOCHEM-TOKYO, V99, P1327, DOI 10.1093/oxfordjournals.jbchem.a135600; FUJISAKI S, 1990, J BIOCHEM-TOKYO, V108, P995, DOI 10.1093/oxfordjournals.jbchem.a123327; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOODMAN DS, 1960, J LIPID RES, V1, P286; HOLLOWAY PW, 1967, BIOCHEM J, V104, P57, DOI 10.1042/bj1040057; ITAKURA K, 1984, ANNU REV BIOCHEM, V53, P323; JENNINGS SM, 1991, P NATL ACAD SCI USA, V88, P6038, DOI 10.1073/pnas.88.14.6038; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOVICS FM, 1981, BIOCHEMISTRY-US, V20, P1893, DOI 10.1021/bi00510a027; LASKOVICS FM, 1979, J BIOL CHEM, V254, P9458; Maniatis T., 1982, MOL CLONING; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; MATH SK, 1992, P NATL ACAD SCI USA, V89, P6761, DOI 10.1073/pnas.89.15.6761; PISZKIEWICZ D, 1977, KINETICS CHEM ENZYME, P79; Poulter C. D., 1981, BIOSYNTHESIS ISOPREN, V1, P161; POULTER CD, 1990, ACCOUNTS CHEM RES, V23, P70, DOI 10.1021/ar00171a003; REED BC, 1975, BIOCHEMISTRY-US, V14, P50, DOI 10.1021/bi00672a009; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGEL IH, 1975, ENZYME KINETICS, P18; STREET IP, 1990, BIOCHEMISTRY-US, V29, P7531, DOI 10.1021/bi00484a023; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; WILKIN DJ, 1990, J BIOL CHEM, V265, P4607; YEH LS, 1977, ARCH BIOCHEM BIOPHYS, V183, P718, DOI 10.1016/0003-9861(77)90405-2	38	135	149	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26983	26989						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262934				2022-12-25	WOS:A1993MM26200025
J	KREBS, JF; IPPOLITO, JA; CHRISTIANSON, DW; FIERKE, CA				KREBS, JF; IPPOLITO, JA; CHRISTIANSON, DW; FIERKE, CA			STRUCTURAL AND FUNCTIONAL IMPORTANCE OF A CONSERVED HYDROGEN-BOND NETWORK IN HUMAN CARBONIC ANHYDRASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC MECHANISM; HYDROPHOBIC POCKET; MACROMOLECULAR STRUCTURES; PROTEIN-STRUCTURE; ESCHERICHIA-COLI; PROTON-TRANSFER; BINDING; HYDRATION; ZINC; BUFFER	Amino acid substitutions at Thr199 of human carbonic anhydrase II (CAII) (Thr199 --> Ser, Ala, Val, and Pro) were characterized to investigate the importance of a conserved hydrogen bonding network. The three-dimensional structures of azide-bound and sulfate-bound T199V CAIIs were determined by x-ray crystallographic methods at 2.25 and 2.4 angstrom, respectively (final crystallographic R factors are 0.173 and 0.174, respectively). The CO2 hydrase activities of T199S and T199P variants suggest that the side chain methyl and backbone amino functionalities stabilize the transition state by almost-equal-to 0.4 and 0.8 kcal/mol, respectively. The side chain hydroxyl group causes: stabilization of zinc-hydroxide relative to zinc-water (pK(a) increases almost-equal-to 2 units); stabilization of the transition state for bicarbonate dehydration relative to the CAII.HCO3- complex (almost-equal-to 5 kcal/mol); and destabilization of the CAII.HCO3- complex (almost-equal-to 0.8 kcal/mol). An inverse correlation between log(k(cat)CO2/K(M)) and the pk(a) of zinc-water (r = 0.95, slope = -1) indicates that the hydrogen bonding network stabilizes the chemical transition state and zinc-hydroxide similarly. These data are consistent with the hydroxyl group of Thr199 forming a hydrogen bond with the transition state and a non-hydrogen-bonded van der Waals contact with CAII.HCO3-.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104	Duke University; University of Pennsylvania					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045614, T32GM008275, R01GM040602, R29GM040602, R29GM045614] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40602, GM08275, GM45614] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER RS, 1991, BIOCHEMISTRY-US, V30, P11064, DOI 10.1021/bi00110a008; ALEXANDER RS, 1993, BIOCHEMISTRY-US, V32, P1510, DOI 10.1021/bi00057a015; ARMSTRONG JM, 1966, J BIOL CHEM, V241, P5137; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; CHRISTIANSON DW, 1989, J AM CHEM SOC, V111, P6412, DOI 10.1021/ja00198a065; DURBIN RM, 1986, SCIENCE, V232, P1127, DOI 10.1126/science.3704639; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; EPSTEIN DM, 1992, BIOCHEMISTRY-US, V31, P11216, DOI 10.1021/bi00160a036; ERIKSSON AE, 1988, PROTEINS, V4, P274, DOI 10.1002/prot.340040406; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0; FIERKE CA, 1989, BIOCHEMISTRY-US, V28, P478, DOI 10.1021/bi00428a011; FIERKE CA, 1991, BIOCHEMISTRY-US, V30, P11054, DOI 10.1021/bi00110a007; GANDOUR RD, 1981, BIOORG CHEM, V10, P169, DOI 10.1016/0045-2068(81)90020-1; GLASOE PK, 1960, J PHYS CHEM-US, V64, P188, DOI 10.1021/j100830a521; GROVES JT, 1985, INORG CHEM, V24, P2715, DOI 10.1021/ic00212a001; HAKANSSON K, 1992, J MOL BIOL, V227, P1192, DOI 10.1016/0022-2836(92)90531-N; HAKANSSON K, 1992, J MOL BIOL, V228, P1212, DOI 10.1016/0022-2836(92)90327-G; HAKANSSON K, 1992, THESIS U LUND SWEDEN; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HEWETTEMMETT D, 1991, CARBONIC ANHYDRASES; HUDSON RF, 1974, CHEM REACTIVITY REAC; IPPOLITO JA, 1993, BIOCHEMISTRY-US, V32, P9901, DOI 10.1021/bi00089a005; IPPOLITO JA, 1990, J MOL BIOL, V215, P457, DOI 10.1016/S0022-2836(05)80364-X; JACOB O, 1990, J AM CHEM SOC, V112, P8692, DOI 10.1021/ja00180a009; JENCKS WP, 1986, J AM CHEM SOC, V108, P479, DOI 10.1021/ja00263a019; JENCKS WP, 1987, ADV CHEM, V215, P155; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONSSON BH, 1976, FEBS LETT, V64, P310, DOI 10.1016/0014-5793(76)80317-1; KANNAN KK, 1977, FEBS LETT, V73, P115, DOI 10.1016/0014-5793(77)80028-8; KHALIFAH RG, 1971, J BIOL CHEM, V246, P2561; KIMURA E, 1990, J AM CHEM SOC, V112, P5805, DOI 10.1021/ja00171a020; KREBS JF, 1991, BIOCHEMISTRY-US, V30, P9153, DOI 10.1021/bi00102a005; KREBS JF, 1993, J BIOL CHEM, V268, P948; KREBS JF, 1993, BIOCHEMISTRY-US, V32, P4496, DOI 10.1021/bi00068a004; LIANG JY, 1990, P NATL ACAD SCI USA, V87, P3675, DOI 10.1073/pnas.87.10.3675; LIANG JY, 1987, BIOCHEMISTRY-US, V26, P5293, DOI 10.1021/bi00391a012; LIANG ZW, 1993, EUR J BIOCHEM, V211, P821, DOI 10.1111/j.1432-1033.1993.tb17614.x; LINDAHL M, 1992, ACTA CRYSTALLOGR B, V48, P281, DOI 10.1107/S0108768191013757; LINDAHL M, 1993, PROTEINS, V15, P177, DOI 10.1002/prot.340150207; LINDSKOG S, 1984, J MOL CATAL, V23, P357, DOI 10.1016/0304-5102(84)80021-8; LOGRASSO PV, 1993, BIOCHEMISTRY-US, V32, P5786, DOI 10.1021/bi00073a010; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MARTIN RB, 1976, J INORG NUCL CHEM, V38, P511, DOI 10.1016/0022-1902(76)80294-1; MERZ KM, 1990, J MOL BIOL, V214, P799, DOI 10.1016/0022-2836(90)90333-H; MERZ KM, 1991, J AM CHEM SOC, V113, P406, DOI 10.1021/ja00002a004; NAIR SK, 1993, EUR J BIOCHEM, V213, P507, DOI 10.1111/j.1432-1033.1993.tb17788.x; NAIR SK, 1993, BIOCHEMISTRY-US, V32, P4506, DOI 10.1021/bi00068a005; NAIR SK, 1991, J BIOL CHEM, V266, P17320; OSBORNE WRA, 1975, ANAL BIOCHEM, V64, P297, DOI 10.1016/0003-2697(75)90434-0; Pocker Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P149; ROWLETT RS, 1982, J AM CHEM SOC, V104, P6737, DOI 10.1021/ja00388a043; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schowen R. L., 1977, ISOTOPE EFFECTS ENZY, P64; SEGEL IH, 1975, ENZYME KINETICS, P34; SILLEN LG, 1964, STABILITY CONSTANTS, P61; SILVERMAN DN, 1988, ACCOUNTS CHEM RES, V21, P30, DOI 10.1021/ar00145a005; SOLA M, 1992, J AM CHEM SOC, V114, P869, DOI 10.1021/ja00029a010; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; STEIGEMANN W, 1974, THESIS M PLANCK I BI; STEINER H, 1975, EUR J BIOCHEM, V59, P253, DOI 10.1111/j.1432-1033.1975.tb02449.x; TU CK, 1982, BIOCHEMISTRY-US, V21, P6353, DOI 10.1021/bi00268a006; TU CK, 1990, BIOCHEMISTRY-US, V29, P6400, DOI 10.1021/bi00479a009; TU CK, 1989, BIOCHEMISTRY-US, V28, P7913, DOI 10.1021/bi00445a054; XUE YF, 1993, PROTEINS, V17, P93, DOI 10.1002/prot.340170112; XUE YF, 1993, PROTEINS, V15, P80, DOI 10.1002/prot.340150110	68	88	89	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27458	27466						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262987				2022-12-25	WOS:A1993MM26200087
J	MORAD, I; CHAPMANSHIMSHONI, D; AMITSUR, M; KAUFMANN, G				MORAD, I; CHAPMANSHIMSHONI, D; AMITSUR, M; KAUFMANN, G			FUNCTIONAL EXPRESSION AND PROPERTIES OF THE TRANSFER RNA(LYS)-SPECIFIC CORE ANTICODON NUCLEASE ENCODED BY ESCHERICHIA-COLI-PRRC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLONING VECTORS; DNA; RESTRICTION; PLASMID; PHAGE; GENE; BACTERIOPHAGE-T4; CONSTRUCTION; DERIVATIVES; FUSIONS	Escherichia coli carrying the optional locus prr harbor a latent, tRNA(Lys)-specific anticodon nuclease, activated by the product of phage T4 stp. Anticodon nuclease latency is ascribed to the masking of prrC, implicated with the enzymatic activity, by flanking, type Ic DNA restriction modification genes (prrA, B&D-hsdM, S&R). Overexpression of plasmid-borne prrC elicited anticodon nuclease activity in uninfected E. coli. In vitro, the prrC-coded core activity was indifferent to a synthetic Stp polypeptide, GTP, ATP, and endogenous DNA, effectors that synergistically activate the latent enzyme. Several facts suggested that PrrC is highly labile in the absence of the masking proteins. The core activity decayed with t1/2 below 1 min at 30-degrees-C, and the PrrC portion of a fusion protein was unstable. Moreover, expression of prrC from its own promoter at low plasmid copy number did not allow detection of core activity. Yet, it sufficed for establishment of a latent, T4-inducible enzyme when complemented by the masking Hsd proteins, which were provided by another replicon. Interaction between the antagonistic components of latent anticodon nuclease was also demonstrated immunochemically. The coupling of anticodon nuclease with a DNA restriction modification system may serve to ward off its inadvertent toxicity and maintain it as an antiviral contingency.	TEL AVIV UNIV,DEPT BIOCHEM,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University								ABDULJABBAR M, 1984, J VIROL, V51, P522; AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; AMITSUR M, 1989, EMBO J, V8, P2411, DOI 10.1002/j.1460-2075.1989.tb08371.x; AMITSUR M, 1992, EMBO J, V11, P3129, DOI 10.1002/j.1460-2075.1992.tb05385.x; BALBAS P, 1986, GENE, V50, P3, DOI 10.1016/0378-1119(86)90307-0; BICKLE TA, 1987, ESCHERICHIA COLI SAL, P692; CAMI B, 1978, NUCLEIC ACIDS RES, V5, P2381, DOI 10.1093/nar/5.7.2381; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHAPMAN D, 1988, J MOL BIOL, V99, P373; CHURCHWARD G, 1984, GENE, V31, P165, DOI 10.1016/0378-1119(84)90207-5; DAVID M, 1982, VIROLOGY, V123, P480, DOI 10.1016/0042-6822(82)90284-7; DAVID M, 1982, P NATL ACAD SCI-BIOL, V79, P7097, DOI 10.1073/pnas.79.23.7097; DEPEW RE, 1974, J VIROL, V13, P888, DOI 10.1128/JVI.13.4.888-897.1974; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; HARLOW E, 1988, ANTIBODIES; INNIS MA, 1990, PROTOCOLS GUIDE METH; KAUFMANN G, 1986, J MOL BIOL, V188, P15, DOI 10.1016/0022-2836(86)90476-6; LEVITZ R, 1990, EMBO J, V9, P1383, DOI 10.1002/j.1460-2075.1990.tb08253.x; LINDER P, 1990, NUCLEIC ACIDS RES, V18, P7170, DOI 10.1093/nar/18.23.7170; LIU JD, 1989, J BACTERIOL, V171, P1254, DOI 10.1128/jb.171.3.1254-1261.1989; PRICE C, 1987, EUR J BIOCHEM, V167, P111, DOI 10.1111/j.1432-1033.1987.tb13310.x; RUNNELS JM, 1982, J MOL BIOL, V154, P273, DOI 10.1016/0022-2836(82)90064-X; Sambrook J, 1989, MOL CLONING LABORATO; SIROTKIN K, 1978, J MOL BIOL, V123, P221, DOI 10.1016/0022-2836(78)90322-4; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNYDER L, 1976, P NATL ACAD SCI USA, V73, P3098, DOI 10.1073/pnas.73.9.3098; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; Wiberg J. S., 1983, BACTERIOPHAGE T4, P193; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	30	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26842	26849						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262917				2022-12-25	WOS:A1993MM26200006
J	WEIGEL, PH; OKA, JA				WEIGEL, PH; OKA, JA			REGULATION OF ASIALOGLYCOPROTEIN RECEPTOR ACTIVITY BY A NOVEL INACTIVATION REACTIVATION CYCLE - RECEPTOR REACTIVATION IN PERMEABLE RAT HEPATOCYTES IS MEDIATED BY FATTY ACYL COENZYME-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; MEMBRANE-BOUND ENZYMES; EUKARYOTIC PROTEINS; TRANSPORT VESICLES; GOLGI CISTERNAE; COA; ENDOCYTOSIS; QUANTITATION; DEGRADATION; MACROPHAGES	We previously reported that a subpopulation of asialoglycoprotein receptors (ASGP-Rs), designated State 2 ASGP-Rs, can be inactivated in digitonin-permeabilized hepatocytes in the absence of cytosol by a process that is temperature- and ATP-dependent (Medh, J. D., and Weigel, P. H. (1991) J. Biol. Chem. 266, 8771-8778). Here we show that these inactivated ASGP-Rs are reactivated by the sole addition of fatty acyl-CoA. Of the derivatives tested (acyl chain length 4-18), palmitoyl-CoA was the most effective, although stearoyl-CoA (C18) and myristoyl-CoA (C14) were also active. Lauroyl-CoA (C12) was about half as effective as palmitoyl-CoA, and decanoyl-CoA (C10) and butyl-CoA (C4) were inactive. ASGP-R reactivation did not take place in the presence of free palmitate and coenzyme A, but did occur if low levels of ATP were also added to drive palmitoyl-CoA synthesis by the permeable cells. Addition of ATP after ASGP-R reactivation with palmitoyl-CoA again resulted in a rapid inactivation of these receptors. The extent and rate of this second ASGP-R inactivation process were proportional to ATP concentration; half-maximal effects occurred at approximately 0.5 mM ATP. ATP also rapidly reversed the ASGP-R reactivation seen with the other fatty acyl-CoAs. The results demonstrate the existence of a previously unrecognized pathway that regulates the activity of the ASGP-R population responsible for the majority of ligand endocytosis and processing in hepatocytes. This novel receptor inactivation/reaction cycle could ensure the high efficiency of segregating ligand and receptor during endocytosis and receptor recycling.			WEIGEL, PH (corresponding author), UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555, USA.				NIGMS NIH HHS [GM 49695, GM 30218] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049695, R01GM030218] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKKEN AM, 1992, BIOCHEM J, V288, P763, DOI 10.1042/bj2880763; BOLDT DH, 1987, J CELL PHYSIOL, V132, P331, DOI 10.1002/jcp.1041320219; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRECHER P, 1983, MOL CELL BIOCHEM, V57, P3; CLARKE BL, 1985, J BIOL CHEM, V260, P128; CLARKE BL, 1987, J BIOL CHEM, V262, P17384; COLEMAN RA, 1992, BIOCHIM BIOPHYS ACTA, V1125, P203, DOI 10.1016/0005-2760(92)90046-X; CONSTANTINIDES PP, 1985, J BIOL CHEM, V260, P7573; DALET C, 1982, ANAL BIOCHEM, V122, P119, DOI 10.1016/0003-2697(82)90259-7; DAS AK, 1992, J BIOL CHEM, V267, P9724; DAS AK, 1992, J BIOL CHEM, V267, P9731; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; GREENSPAN P, 1984, J BIOL CHEM, V259, P1703; ITO M, 1987, BIOCHIM BIOPHYS ACTA, V922, P287; MCABEE DD, 1987, J BIOL CHEM, V262, P1942; MEDH JD, 1991, J BIOL CHEM, V266, P8771; OLSON EN, 1988, PROG LIPID RES, V27, P177, DOI 10.1016/0163-7827(88)90012-4; PATHAK RK, 1988, J CELL BIOL, V106, P1831, DOI 10.1083/jcb.106.6.1831; PEREZGIL J, 1990, MOL CELL BIOCHEM, V94, P167, DOI 10.1007/BF00214123; PFANNER N, 1990, J CELL BIOL, V110, P955, DOI 10.1083/jcb.110.4.955; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; POWELL GL, 1985, FED PROC, V44, P81; POWELL GL, 1981, J BIOL CHEM, V256, P2740; SAMUELSON AC, 1988, AM J PHYSIOL, V254, P829; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; SHEPHERD VL, 1990, J IMMUNOL, V145, P1530; SMITH RH, 1986, ARCH BIOCHEM BIOPHYS, V244, P357, DOI 10.1016/0003-9861(86)90124-4; STAHL P, 1986, J CLIN INVEST, V77, P657, DOI 10.1172/JCI112359; TOLLESHAUG H, 1981, J BIOL CHEM, V256, P6526; VENTURA MA, 1987, EXP CELL RES, V170, P290, DOI 10.1016/0014-4827(87)90307-7; WEIGEL PH, 1982, J BIOL CHEM, V257, P1201; WEIGEL PH, 1983, ANAL BIOCHEM, V133, P437, DOI 10.1016/0003-2697(83)90106-9; WEIGEL PH, 1983, J BIOL CHEM, V258, P5089; WEIGEL PH, 1984, J BIOL CHEM, V259, P1150; WEIGEL PH, 1992, MECH CONTROL GLYCOCO, P421; [No title captured]	38	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27186	27190						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262959				2022-12-25	WOS:A1993MM26200054
J	ALLEGRETTO, EA; MCCLURG, MR; LAZARCHIK, SB; CLEMM, DL; KERNER, SA; ELGORT, MG; BOEHM, MF; WHITE, SK; PIKE, JW; HEYMAN, RA				ALLEGRETTO, EA; MCCLURG, MR; LAZARCHIK, SB; CLEMM, DL; KERNER, SA; ELGORT, MG; BOEHM, MF; WHITE, SK; PIKE, JW; HEYMAN, RA			TRANSACTIVATION PROPERTIES OF RETINOIC ACID AND RETINOID-X RECEPTORS IN MAMMALIAN-CELLS AND YEAST - CORRELATION WITH HORMONE-BINDING AND EFFECTS OF METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D RECEPTOR; THYROID-HORMONE; SACCHAROMYCES-CEREVISIAE; ESTROGEN-RECEPTOR; SIGNALING PATHWAYS; RESPONSE ELEMENTS; NUCLEAR RECEPTORS; ENHANCES BINDING; DNA-BINDING; BETA-GENE	The binding affinities of 9-cis-retinoic acid (9-cis-RA) and all-trans-retinoic acid (t-RA) for retinoic acid receptors (RAR) alpha, beta, and gamma and for retinoid X receptors (RXR) alpha, beta, and gamma were determined using the recombinant receptor proteins and were compared with each hormone's ability to activate transcription through the receptors in mammalian and yeast cell systems. 9-cis-RA bound to both the RXRs (K(d) = 1.4-2.4 nM) and the RARs (K(d) = 0.2-0.8 nM). The ability of 9-cis-RA to bind to the RARs and RXRs correlated with its ability to produce similar transactivation profiles with these receptors in mammalian and yeast cell assays. t-RA bound to the RARs (K(d) = 0.2-0.4 nM) and activated transcription through the RARs in mammalian and yeast cells. In contrast, while t-RA did not bind to the RXRs, it did activate the RXRs, albeit less potently than 9-cis-RA, in mammalian cells. In yeast, however, the RXRs activated transcription only in the presence of 9-cis-RA, not with t-RA. While RARgamma is activated in yeast by either t-RA or 9-cis-RA, the overall level of transcription was increased upon the addition of hormone-occupied RXR. Metabolism studies suggest that while there was no cell-dependent interconversion between t-RA and 9-cis-RA in yeast, there was cell-dependent conversion of 9-cis-RA to t-RA in mammalian cells.	LIGAND PHARMACEUT INC,DEPT CHEM,SAN DIEGO,CA 92121; LIGAND PHARMACEUT INC,DEPT MOLEC BIOL,SAN DIEGO,CA 92121; LIGAND PHARMACEUT INC,DEPT CELL BIOL,SAN DIEGO,CA 92121	Ligand Pharmaceuticals; Ligand Pharmaceuticals; Ligand Pharmaceuticals	ALLEGRETTO, EA (corresponding author), LIGAND PHARMACEUT INC,DEPT BIOCHEM,11149 TORREY PINES RD,SUITE 110,SAN DIEGO,CA 92121, USA.							ALI M, 1992, BIOCHEM BIOPH RES CO, V182, P1032, DOI 10.1016/0006-291X(92)91835-E; ALLEGRETTO EA, 1983, BIOCHEM BIOPH RES CO, V116, P75, DOI 10.1016/0006-291X(83)90382-0; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; APFEL C, 1991, RETINOIDS : 10 YEARS ON, P110; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRASER DR, 1973, NATURE-NEW BIOL, V241, P163, DOI 10.1038/newbio241163a0; FULLER PJ, 1991, FASEB J, V5, P3092, DOI 10.1096/fasebj.5.15.1743440; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GILBERT DM, 1993, MOL CELL BIOL, V13, P462, DOI 10.1128/MCB.13.1.462; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; KEIDEL S, 1992, EUR J BIOCHEM, V204, P1141, DOI 10.1111/j.1432-1033.1992.tb16739.x; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MANGELSDORF DJ, 1994, IN PRESS RETINOIDS B; MCDONNELL DP, 1991, J STEROID BIOCHEM, V39, P291, DOI 10.1016/0960-0760(91)90038-7; MCDONNELL DP, 1989, MOL CELL BIOL, V9, P3517, DOI 10.1128/MCB.9.8.3517; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; O'Reilly DR, 1992, BACULOVIRUS EXPRESSI, P139; Oro AE, 1992, CURR OPIN GENET DEV, V2, P269, DOI 10.1016/S0959-437X(05)80284-9; OZONO K, 1991, J BONE MINER RES, V6, P1021; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PHAM TA, 1991, J BIOL CHEM, V266, P18179; ROBERTS AB, 1984, RETINOIDS, V2, P209; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SONE T, 1991, MOL ENDOCRINOL, V5, P1578, DOI 10.1210/mend-5-11-1578; SONE T, 1990, J BIOL CHEM, V265, P21997; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; WILLIAMS D, 1974, BIOCHEMISTRY-US, V13, P5537, DOI 10.1021/bi00724a013; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	56	184	190	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26625	26633						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253793				2022-12-25	WOS:A1993MK42500089
J	WANG, TF; CHANG, JH; WANG, C				WANG, TF; CHANG, JH; WANG, C			IDENTIFICATION OF THE PEPTIDE BINDING DOMAIN OF HSC70 - 18-KILODALTON FRAGMENT LOCATED IMMEDIATELY AFTER ATPASE DOMAIN IS SUFFICIENT FOR HIGH-AFFINITY BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SHOCK COGNATE PROTEIN; UNCOATING PROTEIN; HOMOLOG; ACTIN	Recombinant hsc70, a purified glutathione S-transferase (GST) fusion protein containing the C-terminal domain of hsc70 (GST-Ct), and an internal 18-kDa polypeptide located immediately after the 44-kDa ATPase domain of hsc70 were investigated for their peptide binding properties. The dissociation constants of the S-peptide for native hsc70 (K(d) = 5-8 muM), GST-Ct (K(d) = 6.5 muM), and the 18-kDa fragment (K(d) = 8.1 muM) are virtually identical. In addition, polylysine and (Pro-Pro-Gly)5 do not show high affinity toward hsc70, GST-Ct, and the 18-kDa fragment, whereas peptide GT4 and P3a show comparably high affinity toward these polypeptides. These observations indicate that the peptide binding domain of hsc70 is confined in the internal 18-kDa fragment.	ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN	Academia Sinica - Taiwan			Wang, Ting-Fang/ABI-3818-2020	Wang, Ting-Fang/0000-0001-6306-9505				ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CHANG LH, 1990, BIOCHEMISTRY-US, V29, P744, DOI 10.1021/bi00455a022; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CYR DM, 1992, J BIOL CHEM, V267, P20927; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Holmes Ken C., 1993, Trends in Cell Biology, V3, P53, DOI 10.1016/0962-8924(93)90161-S; HUANG SP, 1993, J BIOL CHEM, V268, P2063; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; OMALLEY K, 1985, MOL CELL BIOL, V5, P3476, DOI 10.1128/MCB.5.12.3476; STEITZ TA, 1976, J MOL BIOL, V104, P197, DOI 10.1016/0022-2836(76)90009-7; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; TSAI MY, 1993, IN PRESS J BIOL CHEM; WANG C, 1993, BIOCHEM J, V294, P69, DOI 10.1042/bj2940069	19	159	161	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26049	26051						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253714				2022-12-25	WOS:A1993MK42500005
J	LEE, SB; SHIN, SH; HEPLER, JR; GILMAN, AG; RHEE, SG				LEE, SB; SHIN, SH; HEPLER, JR; GILMAN, AG; RHEE, SG			ACTIVATION OF PHOSPHOLIPASE C-BETA-2 MUTANTS BY G-PROTEIN ALPHA(Q)-SUBUNIT AND BETA-GAMMA-SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION SYSTEM; ALPHA-SUBUNITS; VACCINIA VIRUS; ISOZYME; PURIFICATION; POLYMERASE; DIVERSITY; SEQUENCE; CLONING; MEMBERS	The beta- but not the gamma- and delta-type isozymes of inositol phospholipid-specific phospholipase C (PLC) are activated by G protein alpha(q) and betagamma subunits. The beta-type PLC isozymes differ from other isozymes in that they contain a long carboxyl-terminal region downstream of the Y catalytic domain and a region rich in acidic amino acids between the two separated X and Y catalytic domains. To determine the sites on PLC-beta2 that participate in the interaction of the enzyme with alpha(q) and betagamma subunits, we introduced specific truncations and substitutions in the PLC-beta2 cDNA at positions corresponding to the carboxyl-terminal and acidic amino acid-rich regions, respectively. After transient expression of these cDNA clones in CV-1 cells, the mutant enzymes were partially purified and their capacity to be activated by alpha(q) and betagamma subunits determined. Substitution of glutamine residues for three or all seven of a stretch of consecutive glutamic acids in the acidic domain of PLC-beta2 affected neither alpha(q)- nor betagamma-dependent activation significantly. Carboxyl-terminal truncation to residue Gly-934 or to residue Ala-867 resulted in enzymes that were activated by betagamma but not by alpha(q). This result suggests that the carboxyl-terminal region of PLC-beta2 is required for activation by alpha(q) and that betagamma subunits interact with a different region of the enzyme. Thus, alpha(q) and betagamma subunits may independently modulate a single PLC-beta2 molecule concurrently.	NHLBI, BIOCHEM LAB, BLDG 3, RM 122, BETHESDA, MD 20892 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BOYER JL, 1992, J BIOL CHEM, V267, P25451; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAROZZI AJ, 1993, EUR J BIOCHEM, V210, P521; COCKCROFT S, 1992, BIOCHEM J, V288, P1; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HOFMANN SL, 1982, J BIOL CHEM, V257, P4359; JHON DY, 1993, J BIOL CHEM, V268, P6654; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEE CW, 1993, J BIOL CHEM, V268, P21318; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; PARK D, 1992, J BIOL CHEM, V267, P16048; PARK DG, 1993, J BIOL CHEM, V268, P4573; PARK DG, 1993, J BIOL CHEM, V268, P3710; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WU DQ, 1993, J BIOL CHEM, V268, P3704; WU DQ, 1992, J BIOL CHEM, V267, P1811	33	126	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25952	25957						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245028				2022-12-25	WOS:A1993MK10000095
J	SEHGAL, PB; MARGULIES, L				SEHGAL, PB; MARGULIES, L			CELL-TYPE-DEPENDENT AND PROMOTER-DEPENDENT TS PHENOTYPE OF P53 VAL(135)	ONCOGENE			English	Note							WILD-TYPE P53; INTERLEUKIN-6 PROMOTER; RESPONSIVE ELEMENT; GENE-PRODUCT; ENHANCER; INHIBITION; REPRESSION; EXPRESSION; PROTEIN; MUTANT	The p53 mutant Val(135) is widely considered to have a wild-type (wt) phenotype at 32.5 degrees C, but not at 37 degrees C. The ability of wt murine p53 and its Val(135) mutant to modulate transcription from the muscle-specific creatine kinase promoter (- 3.3 kb pMCK), from a reporter construct containing two copies of the p53-binding DNA element from within MCK (p50-2), and from the interleukin-6 (IL-6) promoter (pTC225) was evaluated in transient transfection experiments in CV1 and HeLa cells. In CV1 cells, wt p53 was confirmed to activate the pMCK and p50-2 reporters, but to repress the IL-6 promoter. However, although in these cells p53 Val(135) had the expected wt-like phenotype with respect to activation of the p50-2 reporter at 32.5 degrees C (32.5 degrees C) 37 degrees C), this mutant had little effect on expression from pMCK at either temperature, and activated rather than repressed the IL-6 promoter at 32.5 degrees C. In HeLa cells, although wt p53 activated p50-2 but repressed the MCK and IL-6 promoters, p53 Val(135) activated all three reporters. Unexpectedly, in these cells the upregulation of p50-2 and pIC225 was basically temperature-independent, and that of pMCK was inversely ts (37 degrees C>32.5 degrees C). The novel ts properties of p53 Val(135) show that this mutant is not always wt-like at 32.5 degrees C but exhibits strong cell-type and promoter-dependent differences in its ts phenotype for transcriptional modulation.	NEW YORK MED COLL, DEPT MED, VALHALLA, NY 10595 USA	New York Medical College	SEHGAL, PB (corresponding author), NEW YORK MED COLL, DEPT MICROBIOL & IMMUNOL, VALHALLA, NY 10595 USA.							BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	20	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3417	3419						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247545				2022-12-25	WOS:A1993MG78200027
J	BAZENET, CE; KAZLAUSKAS, A				BAZENET, CE; KAZLAUSKAS, A			THE PDGF RECEPTOR-ALPHA SUBUNIT ACTIVATES P21(RAS) AND TRIGGERS DNA-SYNTHESIS WITHOUT INTERACTING WITH RASGAP	ONCOGENE			English	Article							PHOSPHOLIPASE-C-GAMMA; GROWTH-FACTOR RECEPTORS; GAP-ASSOCIATED PROTEINS; FACTOR-I RECEPTOR; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL KINASE; BINDING; CELLS; SRC	There are two closely related, but distinct platelet-derived growth factor receptor (PDGFR) subunits: alpha and beta. Recent studies have indicated that relay of a biological signal from the activated PDGFR P subunit is determined to a large degree by the intracellular signal transduction enzymes with which the beta subunit associates. Like the beta subunit, the PDGFR alpha subunit encodes a tyrosine kinase that is activated and tyrosine phosphorylated upon binding of PDGF. To investigate the mechanism by which the PDGFR alpha subunit mediates signal transduction, we examined the proteins that associate with the activated PDGFR alpha subunit. The human alpha subunit was expressed in PhB cells, fibroblasts derived from Ph/Ph mouse embryos, which express the beta subunit but do not express the PDGFR alpha subunit. In response to binding of PDGF, the alpha subunit stably associated with phospholipase C gamma 1 (PLC-gamma 1), phosphatidylinositol 3 kinase (PI3K), the phosphotyrosine phosphatase Syp, and a 120 kd protein. These same proteins were detected binding to the activated PDGFR beta subunit. Unlike the PDGFR beta subunit, the PDGF-activated alpha subunit did not stably associate with the GTPase activating protein of ras (rasGAP), nor did it mediate tyrosine phosphorylation of rasGAP. Despite its apparent inability to interact with rasGAP, the alpha subunit was fully able to trigger PDGF-dependent p21(ras) activation and DNA synthesis. We conclude that the PDGFR alpha subunit does not mediate tyrosine phosphorylation or associate with rasGAP, and that these events are not required for PDGF-AA-mediated activation of p21(ras) or DNA synthesis.	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DIV BASIC SCI, DENVER, CO 80206 USA	National Jewish Health					NATIONAL CANCER INSTITUTE [R29CA055063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048339] Funding Source: NIH RePORTER; NCI NIH HHS [CA55063] Funding Source: Medline; NIGMS NIH HHS [GM48339] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BALK SD, 1971, P NATL ACAD SCI USA, V68, P271, DOI 10.1073/pnas.68.2.271; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FRETTO LJ, 1993, J BIOL CHEM, V268, P3625; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; HEIDARAN MA, 1992, ONCOGENE, V7, P147; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISONGRAHAM K, 1992, DEVELOPMENT, V115, P133; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PALMIERI SL, 1992, MECH DEVELOP, V39, P181, DOI 10.1016/0925-4773(92)90045-L; PORRAS A, 1992, J BIOL CHEM, V267, P21124; PRONK GJ, 1992, J BIOL CHEM, V267, P24058; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCATTERMAN GC, 1992, DEVELOPMENT, V115, P123; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SEIFERT RA, 1993, J BIOL CHEM, V268, P4473; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SERTH J, 1992, BIOCHEMISTRY-US, V31, P6361, DOI 10.1021/bi00143a001; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; STOCKSCHLAEDER MAR, 1991, HUM GENE THER, V2, P33, DOI 10.1089/hum.1991.2.1-33; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YEH HJ, 1993, P NATL ACAD SCI USA, V90, P1952, DOI 10.1073/pnas.90.5.1952; YEH HJ, 1991, CELL, V64, P209, DOI 10.1016/0092-8674(91)90222-K; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	77	43	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					517	525						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290262				2022-12-25	WOS:A1994MW24800019
J	ROUSSEL, MF; DAVIS, JN; CLEVELAND, JL; GHYSDAEL, J; HIEBERT, SW				ROUSSEL, MF; DAVIS, JN; CLEVELAND, JL; GHYSDAEL, J; HIEBERT, SW			DUAL CONTROL OF MYC EXPRESSION THROUGH A SINGLE DNA-BINDING SITE TARGETED BY ETS FAMILY PROTEINS AND E2F-1	ONCOGENE			English	Article							TRANSCRIPTION FACTOR E2F; STIMULATING FACTOR-I; HUMAN C-MYC; RETINOBLASTOMA PROTEIN; TRANS-ACTIVATION; CELL-CYCLE; PUTATIVE ONCOGENE; LEUKEMIA-VIRUS; NUCLEAR FACTOR; GENE-PRODUCT	NIH3T3 cells expressing a mutant colony-stimulating factor-1 receptor (CSF-1R) containing a phenylalanine for tyrosine substitution in the tyrosine kinase domain at codon 809 exhibit defective myc regulation and do not enter S phase when stimulated by CSF-1. Enforced expression of either ets-1 or ets-2 in these cells restores their mitogenic response, albeit less efficiently than myc itself, suggesting that ets proteins may regulate c-myc expression. Ets-1 transactivates reporter genes driven by the human and mouse c-myc promoters through the binding site for the transcription factor E2F, the latter being required for E1A- and serum-induced c-mye expression. Analysis of E2F-1 sequences identified a minimal DNA binding domain that is related to those of ets proteins. Although E2F and ets proteins interact with similar consensus DNA binding sites, in vitro binding assays revealed that E2F can bind DNA as a homodimer, whereas ets proteins bind these sites as monomers. E2F and ets proteins do not form heterodimers in vitro and do not transactivate c-mye synergistically. Thus, E2F-1 and ets family members may independently regulate c-mye transcription through the same binding site at different times following growth factor stimulation.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, COLL MED, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; INST CURIE, CNRS, URA 1443, F-91405 ORSAY, FRANCE	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	ROUSSEL, MF (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA.		GHYSDAEL, Jacques/F-3377-2013; Roussel, Martine F/F-1469-2016	Roussel, Martine F/0000-0002-1740-8139	NCI NIH HHS [CA-47064, CA-56819] Funding Source: Medline; NIDDK NIH HHS [DK 44158] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047064, R01CA056819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; Ghysdael J, 1991, CURR OPIN CELL BIOL, V3, P484, DOI 10.1016/0955-0674(91)90077-C; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIPP M, 1989, ONCOGENE, V4, P535; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCKEON C, 1988, CANCER RES, V48, P4307; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OWEN RD, 1990, MOL CELL BIOL, V10, P1; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; POGNONEC P, 1990, ONCOGENE, V5, P603; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROUSSEL MF, 1993, CURR OPIN HEMATOL, V1, P11; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0	59	126	126	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					405	415						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290253				2022-12-25	WOS:A1994MW24800007
J	BANGE, FC; VOGEL, U; FLOHR, T; KIEKENBECK, M; DENECKE, B; BOTTGER, EC				BANGE, FC; VOGEL, U; FLOHR, T; KIEKENBECK, M; DENECKE, B; BOTTGER, EC			IFP-35 IS AN INTERFERON-INDUCED LEUCINE-ZIPPER PROTEIN THAT UNDERGOES INTERFERON-REGULATED CELLULAR REDISTRIBUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASE; MAJOR HISTOCOMPATIBILITY COMPLEX; DNA-BINDING PROTEINS; CHAIN RELEASE FACTOR; CLASS-II REGION; GAMMA-INTERFERON; IFN-GAMMA; MOLECULAR-CLONING; MESSENGER-RNA; GENE-EXPRESSION	We have isolated a new human cDNA, named IFP 35, whose expression is regulated by interferons (IFN). Induction of IFP 35 mRNA in HeLa cells by IFN is due, at least in part, to increased transcription. In response to IFN treatment, the expression of IFP 35 mRNA is seen in a wide range of different cell types, including fibroblasts, macrophages, and epithelial cells. The cDNA sequence encodes a 282-amino acid protein with a deduced molecular mass of 31,130 Da. In vitro translation of mRNA obtained by both in vitro transcription and hybrid selection resulted in the synthesis of a 35-kDa protein. Antisera raised against IFP 35 recognized a protein with an apparent molecular mass of 35 kDa in HeLa cells. Amino acid sequence analysis revealed a leucine zipper motif in an alpha-helical configuration at the extreme amino terminus of IFP 35. Notably IFP 35 is a unique novel leucine zipper protein in that it lacks a basic domain critical for DNA binding. IFP 35 can specifically form homodimers in vitro. Western blot analysis of fractionated cell extracts indicates increased nuclear localization following IFN treatment.	HANNOVER MED SCH,INST MED MIKROBIOL,D-30623 HANNOVER,GERMANY	Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf			Böttger, Erik C./F-6175-2011					ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P591, DOI 10.1093/nar/19.3.591; Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; ARNHEITER H, 1988, EMBO J, V7, P1315, DOI 10.1002/j.1460-2075.1988.tb02946.x; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BANGE FC, 1992, FEBS LETT, V300, P162, DOI 10.1016/0014-5793(92)80187-L; BAUERLE PA, 1988, CELL, V53, P211; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLANAR MA, 1988, P NATL ACAD SCI USA, V85, P4672, DOI 10.1073/pnas.85.13.4672; BOTTGER EC, 1988, IMMUNOGENETICS, V28, P215, DOI 10.1007/BF00345497; BOTTGER EC, 1988, BIOTECHNIQUES, V6, P650; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; BUWITT U, 1992, EMBO J, V11, P489, DOI 10.1002/j.1460-2075.1992.tb05079.x; CAPTEN HS, 1988, J BIOL CHEM, V263, P332; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COX PM, 1992, NUCLEIC ACIDS RES, V20, P4881, DOI 10.1093/nar/20.18.4881; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DEMAEYER E, 1988, INTERFERONS OTHER RE, P91; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAN XD, 1989, MOL CELL BIOL, V9, P1922, DOI 10.1128/MCB.9.5.1922; FARBER JM, 1992, MOL CELL BIOL, V12, P1535, DOI 10.1128/MCB.12.4.1535; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; FLECKNER J, 1991, P NATL ACAD SCI USA, V88, P11520, DOI 10.1073/pnas.88.24.11520; FLOHR T, 1992, INFECT IMMUN, V60, P4418, DOI 10.1128/IAI.60.10.4418-4421.1992; FLOHR T, 1992, EUR J IMMUNOL, V22, P975, DOI 10.1002/eji.1830220415; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; GAUTAM S, 1992, J IMMUNOL, V148, P1725; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; JACOB CO, 1987, J EXP MED, V166, P798, DOI 10.1084/jem.166.3.798; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KOWARY K, 1991, MOL CELL BIOL, V11, P2451; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MAGGI E, 1992, J IMMUNOL, V148, P2142; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERLIN G, 1983, P NATL ACAD SCI-BIOL, V80, P4904, DOI 10.1073/pnas.80.16.4904; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAKAMURA M, 1984, NATURE, V307, P381, DOI 10.1038/307381a0; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFERKORN ER, 1986, J INTERFERON RES, V6, P267, DOI 10.1089/jir.1986.6.267; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RUBIN BY, 1991, J BIOL CHEM, V266, P24245; Sambrook J, 1989, MOL CLONING LABORATO; SAMUEL EC, 1984, P NATL ACAD SCI USA, V76, P515; SAUNDERS ME, 1985, EMBO J, V4, P1761, DOI 10.1002/j.1460-2075.1985.tb03848.x; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; STREHLOW I, 1992, NUCLEIC ACIDS RES, V20, P3865, DOI 10.1093/nar/20.15.3865; Tamm I, 1987, Interferon, V9, P13; VILCEK J, 1989, HDB EXPT PATHOLOGY, P3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	65	63	67	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1091	1098						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288566				2022-12-25	WOS:A1994MR22000051
J	GARCIAHIGUERA, I; PENELA, P; MURGA, C; EGEA, G; BONAY, P; BENOVIC, JL; MAYOR, F				GARCIAHIGUERA, I; PENELA, P; MURGA, C; EGEA, G; BONAY, P; BENOVIC, JL; MAYOR, F			ASSOCIATION OF THE REGULATORY BETA-ADRENERGIC-RECEPTOR KINASE WITH RAT-LIVER MICROSOMAL-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DEPENDENT PHOSPHORYLATION; ROUGH ENDOPLASMIC-RETICULUM; G-PROTEIN; SUBCELLULAR-LOCALIZATION; SIGNAL TRANSDUCTION; COUPLED RECEPTORS; GOLGI MEMBRANES; GAMMA-SUBUNITS; TRANSLOCATION; AGONIST	Beta-adrenergic receptor kinase (betaARK) is a regulatory enzyme involved in the modulation of beta-adrenergic and other G protein-coupled receptors. lt has been described that betaARK is a cytosolic protein that transiently translocates to the plasma membrane in order to specifically phosphorylate agonist-occupied receptors. In this report, we used betaARK-specific antibodies to demonstrate that a significant amount of this kinase is present in rat liver microsomal membranes. BeatARK seems to be peripherally associated with the cytosolic side of microsomal membranes since it can be stripped from the membranes by mild salt treatment. Cell-free association experiments indicate that the interaction of betaARK is reversible, saturable, and strongly inhibited by protease or heat treatment of the microsomes, thus suggesting that betaARK interacts with a protein component of the microsomal membrane. Gradient fractionation studies indicate that the highest betaARK-specific activity co-migrates with endoplasmic reticulum enzymatic markers. Furthermore, indirect immunofluorescence and immunogold electron microscopy experiments performed in cultured cells using affinity-purified anti-betaARK antibodies are consistent with this subcellular localization pattern. Taken together, our data suggest that several betaARK pools (i.e. microsome-bound, plasma membrane-bound, and cytosolic) may exist inside the cell. Such results are in line with recent reports showing that proteins involved in plasma membrane signal transduction, such as heterotrimeric G proteins, are also associated with membranes of different intracellular organelles.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC SEVERO OCHOA,E-28049 MADRID,SPAIN; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Jefferson University			Garcia-Higuera, Irene/L-5004-2014; Egea, Gustavo/I-2394-2014; Mayor, Federico/N-7644-2016; Murga, Cristina/E-1965-2014	Garcia-Higuera, Irene/0000-0001-6331-075X; Egea, Gustavo/0000-0001-5242-150X; Murga, Cristina/0000-0002-8964-4077; Mayor Menendez, Federico/0000-0003-1434-8449	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON NG, 1989, BIOCHEM J, V262, P867, DOI 10.1042/bj2620867; ARONIN N, 1992, J NEUROSCI, V12, P3435; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; AUDIGIER Y, 1988, J BIOL CHEM, V263, P16352; BALCH W E, 1992, Current Biology, V2, P157, DOI 10.1016/0960-9822(92)90276-G; BANSKIN AR, 1991, CELL, V66, P685; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1986, NATURE, V321, P869, DOI 10.1038/321869a0; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BONAY P, 1991, EUR J BIOCHEM, V197, P229, DOI 10.1111/j.1432-1033.1991.tb15903.x; BONAY P, 1991, EUR J CELL BIOL, V202, P321; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GARCIAHIGUERA I, 1992, FEBS LETT, V302, P61, DOI 10.1016/0014-5793(92)80285-O; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; HAGA K, 1992, J BIOL CHEM, V267, P2222; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KIM CM, 1993, J BIOL CHEM, V268, P15412; KIM CM, 1993, RECEPTOR, V3, P39; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LEWIS JM, 1991, CELL REGUL, V2, P1097, DOI 10.1091/mbc.2.12.1097; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Magee Tony, 1992, Trends in Cell Biology, V2, P318, DOI 10.1016/0962-8924(92)90172-J; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MAYOR F, 1987, J BIOL CHEM, V262, P6468; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; NIGAM SK, 1989, J BIOL CHEM, V264, P16927; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; ROTH J, 1981, J HISTOCHEM CYTOCHEM, V29, P663, DOI 10.1177/29.5.6166664; ROTH J, 1982, TECHNIQUES IMMUNOCYT, V1, P107; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; TRAUB LM, 1991, J BIOL CHEM, V266, P24642; TRAUB LM, 1991, BIOCHEM J, V280, P171, DOI 10.1042/bj2800171; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239	48	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1348	1355						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288600				2022-12-25	WOS:A1994MR22000090
J	SANTALA, P; LARJAVA, H; NISSINEN, L; RIIKONEN, T; MAATTA, A; HEINO, J				SANTALA, P; LARJAVA, H; NISSINEN, L; RIIKONEN, T; MAATTA, A; HEINO, J			SUPPRESSED COLLAGEN GENE-EXPRESSION AND INDUCTION OF ALPHA-2-BETA-1-INTEGRIN-TYPE COLLAGEN RECEPTOR IN TUMORIGENIC DERIVATIVES OF HUMAN OSTEOGENIC-SARCOMA (HOS) CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-BETA; LAMININ-BINDING INTEGRIN; FIBRONECTIN RECEPTOR; ADHESION RECEPTORS; ALTERED GLYCOSYLATION; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; MELANOMA-CELLS; ALPHA-SUBUNIT; VLA-2	Cell-matrix interactions and integrin-type cell adhesion receptors are involved in the regulation of tumor cell invasion and metastasis. We have analyzed the expression of matrix proteins and their cellular receptors in human osteosarcoma cells (HOS) and in their virally (KHOS-NP) and chemically (HOS-MNNG) transformed tumorigenic subclones. Transformation decreased dramatically the cellular mRNA levels of alpha1(I) collagen. Concomitantly with down-regulation of collagen mRNA levels the synthesis of the collagen receptor, alpha2beta1 integrin, was induced. No alpha2 integrin mRNA was found in HOS cells, suggesting that its expression was regulated most probably at the transcriptional level. 5-Azacytidine alone or combined with alpha2 integrin-stimulating cytokines, transforming growth factor-beta1, and interleukin-1beta, did not turn on the alpha2 integrin gene. In chemically transformed cells, however, alpha2 integrin expression could be regulated by cytokines. Thus, we suggest that HOS cells have a strong element, probably other than cell culture-generated de novo promoter methylation, suppressing alpha2 integrin expression and that this factor is lost in both chemical and viral transformation. Furthermore, the mechanism used by cytokines and malignant transformation to increase alpha2 integrin expression seems not to be identical. Other transformation-related changes in beta1 integrins were (i) reduction of the intracellular pool of precursor beta1 (in HOS-MNNG cells), leading to faster maturation rate of beta1 subunit and slower maturation rate of alpha subunits, and (ii) decreased electrophoretic mobility of both alpha and beta1 subunits. At the cellular level both chemical and viral transformation increased cell adhesion to type I collagen.	UNIV TURKU,DEPT MED BIOCHEM,MEDICITY RES LAB,KIINAMYLLYNKATU 10,SF-20520 TURKU 52,FINLAND; UNIV TURKU,DEPT PERIODONT,SF-20520 TURKU 52,FINLAND	University of Turku; University of Turku			Larjava, Hannu/GRO-4325-2022	Nissinen, Liisa/0000-0002-6743-6736; Vihinen, Pia/0000-0003-1763-5363; Maatta, Arto/0000-0003-3759-1310				ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AKIYAMA SK, 1990, CANCER RES, V50, P1601; AKIYAMA SK, 1987, J BIOL CHEM, V262, P17536; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CERVELLA P, 1993, J BIOL CHEM, V268, P5148; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHEN FA, 1991, J EXP MED, V173, P1111, DOI 10.1084/jem.173.5.1111; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V10, P5291; DEDHAR S, 1990, J CELL BIOL, V110, P481, DOI 10.1083/jcb.110.2.481; DEFILIPPI P, 1991, J CELL BIOL, V114, P855, DOI 10.1083/jcb.114.4.855; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GRZESIAK JJ, 1992, J CELL BIOL, V117, P1109, DOI 10.1083/jcb.117.5.1109; HEINO J, 1989, J BIOL CHEM, V264, P21806; HEINO J, 1989, J BIOL CHEM, V264, P380; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; IGNOTZ RA, 1989, J BIOL CHEM, V264, P389; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; KANTOR RRS, 1987, J BIOL CHEM, V262, P15158; KLEIN CE, 1991, J INVEST DERMATOL, V96, P281, DOI 10.1111/1523-1747.ep12464485; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; MAKELA JK, 1988, NUCLEIC ACIDS RES, V16, P349, DOI 10.1093/nar/16.1.349; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NIKKARI L, 1993, AM J PATHOL, V142, P1019; OZ OK, 1989, INT J CANCER, V44, P343, DOI 10.1002/ijc.2910440226; PISCHEL KD, 1987, J IMMUNOL, V138, P226; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; RHIM JS, 1977, INT J CANCER, V19, P505, DOI 10.1002/ijc.2910190411; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; ROSSINO P, 1990, EXP CELL RES, V189, P100, DOI 10.1016/0014-4827(90)90262-9; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1992, BRIT J CANCER, V66, P239, DOI 10.1038/bjc.1992.250; SANTALA P, 1991, J BIOL CHEM, V266, P23505; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; SEKIGUCHI K, 1986, BIOCHEMISTRY-US, V25, P4936, DOI 10.1021/bi00365a032; SHELLEY CS, 1991, P NATL ACAD SCI USA, V88, P10525, DOI 10.1073/pnas.88.23.10525; SLACK JL, 1992, MOL CELL BIOL, V12, P4714, DOI 10.1128/MCB.12.10.4714; SONNENBERG A, 1988, J BIOL CHEM, V263, P14030; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; SYMINGTON BE, 1989, J BIOL CHEM, V264, P13258; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; UZAN G, 1991, J BIOL CHEM, V266, P8932; VANDEWATER L, 1988, CANCER RES, V48, P5730; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; YLANNE J, 1989, INT J CANCER, V43, P1126, DOI 10.1002/ijc.2910430628; YNES RO, 1992, CELL, V69, P11	56	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1276	1283						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288590				2022-12-25	WOS:A1994MR22000080
J	YANG, MJ; TRUMPOWER, BL				YANG, MJ; TRUMPOWER, BL			DELETION OF QCR6, THE GENE ENCODING SUBUNIT 6 OF THE MITOCHONDRIAL CYTOCHROME BC1 COMPLEX, BLOCKS MATURATION OF CYTOCHROME-C1, AND CAUSES TEMPERATURE-SENSITIVE PETITE GROWTH IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTONMOTIVE Q-CYCLE; IRON-SULFUR PROTEIN; ELECTRON-TRANSFER; HINGE PROTEIN; RHODOSPIRILLUM-RUBRUM; ENERGY TRANSDUCTION; MUTATIONAL ANALYSIS; C OXIDOREDUCTASE; YEAST; UBIQUINOL	It was previously reported that disruption or deletion of QCR6, the nuclear gene encoding subunit 6 of the cytochrome bc1 complex, does not impair growth of yeast on non-fermentable carbon sources (Schoppink, P. J., Hemrika, W., Reyne, J. M., Grivell, L. A., and Berden, J. A. (1988) Eur. J. Biochem. 113, 115-122; Crivellone, M. D., Wu, M. M., and Tzagoloff, A. (1988) J. Biol. Chem. 262, 14323-14333; Schmitt, M. E., and Trumpower, B. L. (1990) J. Biol. Chem. 265,17005-17011). We have discovered that deletion of QCR6 results in a temperature-sensitive petite phenotype, manifested at 37-degrees-C, and that this phenotype can be masked by spontaneously arising suppressor mutations. Mitochondrial membranes from the deletion strain grown at 37-degrees-C lack ubiquinol-cytochrome c reductase activity, and optical spectra reveal an extensive decrease in cytochrome b absorption, but little or no decrease in cytochrome c1 absorption. lmmunoblots of mitochondrial membrane proteins from the deletion strain indicate that processing of cytochrome cl from intermediate to mature size is blocked coincident with the loss of subunit 6. This is the first example where mutation of a subunit within the bc1 complex blocks maturation of cytochrome c1.	DARTMOUTH COLL SCH MED, DEPT BIOCHEM, 7200 VAIL BLDG, HANOVER, NH 03755 USA	Dartmouth College					NIGMS NIH HHS [GM20379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BRANDT U, 1993, J BIOL CHEM, V268, P8387; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; GRAHAM LA, 1993, J BIOENERG BIOMEMBR, V25, P245, DOI 10.1007/BF00762586; GRAHAM LA, 1991, J BIOL CHEM, V266, P22485; Hanahan D., 1985, DNA CLONING; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; KIM CH, 1981, BIOCHEM BIOPH RES CO, V101, P607, DOI 10.1016/0006-291X(81)91302-4; KIM CH, 1990, FEBS LETT, V266, P78, DOI 10.1016/0014-5793(90)81511-L; KIM CH, 1987, J BIOL CHEM, V262, P8103; LEONARD K, 1981, J MOL BIOL, V149, P259, DOI 10.1016/0022-2836(81)90301-6; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; LJUNGDAHL PO, 1989, J BIOL CHEM, V264, P3723; MAJEWSKI C, 1990, MOL GEN GENET, V224, P373, DOI 10.1007/BF00262431; MUKAI K, 1986, J BIOCHEM-TOKYO, V100, P1165, DOI 10.1093/oxfordjournals.jbchem.a121820; NALECZ MJ, 1985, ARCH BIOCHEM BIOPHYS, V236, P619; NEEDLEMAN RB, 1975, ANAL BIOCHEM, V64, P545, DOI 10.1016/0003-2697(75)90466-2; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; OHASHI A, 1982, J BIOL CHEM, V257, P3042; OHTA S, 1987, FEBS LETT, V226, P171, DOI 10.1016/0014-5793(87)80573-2; PHILLIPS JD, 1993, J BIOL CHEM, V268, P11727; ROBERTSON DE, 1993, BIOCHEMISTRY-US, V32, P1310, DOI 10.1021/bi00056a016; SCHMITT ME, 1990, J BIOL CHEM, V265, P17005; SCHMITT ME, 1991, J BIOL CHEM, V266, P14958; SCHOPPINK PJ, 1989, BIOCHIM BIOPHYS ACTA, V974, P192, DOI 10.1016/S0005-2728(89)80372-X; SCHOPPINK PJ, 1988, EUR J BIOCHEM, V173, P115, DOI 10.1111/j.1432-1033.1988.tb13974.x; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P102; VANLOON APGM, 1984, EMBO J, V3, P1039, DOI 10.1002/j.1460-2075.1984.tb01924.x; WAKABAYASHI S, 1982, J BIOCHEM, V91, P2077, DOI 10.1093/oxfordjournals.jbchem.a133901; WYNN RM, 1986, PHOTOSYNTH RES, V9, P181, DOI 10.1007/BF00029743; YANG XH, 1986, J BIOL CHEM, V261, P2282; YANG XH, 1988, J BIOL CHEM, V263, P11962	33	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1270	1275						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288589				2022-12-25	WOS:A1994MR22000079
J	BRAKENHOFF, JPJ; DEHON, FD; FONTAINE, V; TENBOEKEL, E; SCHOOLTINK, H; ROSEJOHN, S; HEINRICH, PC; CONTENT, J; AARDEN, LA				BRAKENHOFF, JPJ; DEHON, FD; FONTAINE, V; TENBOEKEL, E; SCHOOLTINK, H; ROSEJOHN, S; HEINRICH, PC; CONTENT, J; AARDEN, LA			DEVELOPMENT OF A HUMAN INTERLEUKIN-6 RECEPTOR ANTAGONIST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; IL-6 SIGNAL TRANSDUCER; STIMULATORY FACTOR-II; HIGH-AFFINITY BINDING; ESCHERICHIA-COLI; AMINO-ACIDS; SCANNING MUTAGENESIS; EXTRACELLULAR DOMAIN; BIOLOGICAL-ACTIVITY; INTERNAL DELETIONS	Neutralizing monoclonal antibodies specific for human interleukin-6 (IL-6) bind two distinct sites on the IL-6 protein (sites I and II). Their interference with IL-6 receptor binding suggested that site I is a receptor-binding site of IL-6, whereas site II is important for signal transduction. Mutagenesis of site II could therefore result in the isolation of IL-6 receptor antagonists. To test this hypothesis, a panel of IL-6 mutant proteins was constructed that did not bind to a site II-specific monoclonal antibody. One such site II mutant protein (with double substitution of Gln-160 with Glu and Thr-163 with Pro) was found to be an antagonist of human IL-6. It was inactive on human CESS cells, weakly active on human HepG2 cells, but active on mouse B9 cells. It could specifically antagonize the activity of wild-type IL-6 on CESS and HepG2 cells. The binding affinity of this variant for the 80-kDa IL-6 receptor was similar to that of wild-type IL-6. High affinity binding to CESS cells, however, was abolished, suggesting that the mutant protein is inactive because the complex of the 80-kDa IL-6 receptor and the mutant protein cannot associate with the signal transducer gp130. The human IL-6 antagonist protein may be potentially useful as a therapeutic agent.	RHEIN WESTFAL TH AACHEN,INST BIOCHEM,W-5100 AACHEN,GERMANY; INST PASTEUR,B-1180 BRUSSELS,BELGIUM	RWTH Aachen University	BRAKENHOFF, JPJ (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,DEPT AUTOIMMUNE DIS,CENT LAB,1066 CX AMSTERDAM,NETHERLANDS.		Rose-John, Stefan/A-7998-2010	Rose-John, Stefan/0000-0002-7519-3279; Fontaine, Veronique/0000-0001-7588-5462				AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; ARCONE R, 1991, FEBS LETT, V288, P197, DOI 10.1016/0014-5793(91)81033-5; AREND WP, 1990, J CLIN INVEST, V85, P1694, DOI 10.1172/JCI114622; BAUER J, 1991, ANN HEMATOL, V62, P203, DOI 10.1007/BF01729833; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; BRAKENHOFF JPJ, 1987, J IMMUNOL, V139, P4116; BRAKENHOFF JPJ, 1989, J IMMUNOL, V143, P1175; BRAKENHOFF JPJ, 1992, SERONO S PUBLICATION, V88, P33; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; COULIE PG, 1987, EUR J IMMUNOL, V17, P1435, DOI 10.1002/eji.1830171008; COULIE PG, 1989, EUR J IMMUNOL, V19, P2107, DOI 10.1002/eji.1830191121; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DALESSANDRO F, 1993, J BIOL CHEM, V268, P2149; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Dinarello C A, 1992, Eur Cytokine Netw, V3, P7; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; ELDERING E, 1988, J BIOL CHEM, V263, P11776; FONTAINE V, 1993, EUR J BIOCHEM, V211, P749, DOI 10.1111/j.1432-1033.1993.tb17605.x; FONTAINE V, 1991, GENE, V104, P227, DOI 10.1016/0378-1119(91)90254-9; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Grau G E, 1990, Eur Cytokine Netw, V1, P203; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KLEIN B, 1991, BLOOD, V78, P1198; KRUTTGEN A, 1990, FEBS LETT, V273, P95, DOI 10.1016/0014-5793(90)81059-W; KRUTTGEN A, 1990, FEBS LETT, V262, P323, DOI 10.1016/0014-5793(90)80219-9; LEEBEEK FWG, 1992, J BIOL CHEM, V267, P14832; LIU JW, 1992, J BIOL CHEM, V267, P16763; LUTTICKEN C, 1991, FEBS LETT, V282, P265, DOI 10.1016/0014-5793(91)80491-K; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; PIETZKO D, 1993, J BIOL CHEM, V268, P4250; POUPART P, 1987, EMBO J, V6, P1219, DOI 10.1002/j.1460-2075.1987.tb02357.x; ROODMAN GD, 1992, J CLIN INVEST, V89, P46, DOI 10.1172/JCI115584; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; ROSEJOHN S, 1991, J BIOL CHEM, V266, P3841; SEHGAL PB, 1990, P SOC EXP BIOL MED, V195, P183; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SNYERS L, 1990, P NATL ACAD SCI USA, V87, P2838, DOI 10.1073/pnas.87.7.2838; STRASSMANN G, 1992, J CLIN INVEST, V89, P1681, DOI 10.1172/JCI115767; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TAGA T, 1987, J EXP MED, V166, P967, DOI 10.1084/jem.166.4.967; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZURAW BL, 1990, J BIOL CHEM, V265, P12664; ZURAWSKI SM, 1992, EMBO J, V11, P3905, DOI 10.1002/j.1460-2075.1992.tb05483.x	62	108	170	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					86	93						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276883				2022-12-25	WOS:A1994MR21900021
J	HARE, JF; TAYLOR, K; HOLOCHER, A				HARE, JF; TAYLOR, K; HOLOCHER, A			ENERGY-DEPENDENT PROTEIN-TRIACYLGLYCEROL INTERACTION IN A CELL-FREE SYSTEM FROM 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL ACYLTRANSFERASE; INTERACTION INVITRO; VESICLES; VIMENTIN; FUSION; LIPIDS; RECONSTITUTION	Triacylglycerol is synthesized from the precursors sn-1,2-diacylglycerol and palmitoyl-CoA in a reaction catalyzed by the microsomal enzyme diacylglycerol acyltransferase (EC 2.3.1.20). lsolated 3T3-L1 adipocyte microsomal vesicles from cells pulse-labeled with L-[S-35]methionine were found to release microsomal proteins into a low density form during the synthesis of triacylglycerol. The proteins released, which represent a subset of those present in the labeled microsomes, include a 62-kDa protein found in high concentration in mature fat droplets. The formation of the triacylglycerol-protein complexes was dependent on time and temperature, was not stimulated by cytosol, and required ATP as well as diacylglycerol and palmitoyl-CoA. Only nucleoside triphosphates and not non-hydrolyzable analogues could replace ATP in the reaction. Unlike the enzyme reaction that measures the synthesis of triacylglycerol, the formation of low density membrane is thus dependent on ATP hydrolysis as well as enzyme substrates. The newly formed, low density particles are selectively enriched in triacylglycerol synthesized during the reaction as well as that synthesized prior to the reaction. The cell-free system described thus appears to represent an early adipogenic event leading to the lipid vacuoles found in mature adipocytes.			HARE, JF (corresponding author), OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201, USA.							BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BRAELL WA, 1987, P NATL ACAD SCI USA, V84, P1137, DOI 10.1073/pnas.84.5.1137; Cabral F, 1979, Methods Enzymol, V56, P602; COLEMAN R, 1976, J BIOL CHEM, V251, P4537; DAVEY J, 1985, CELL, V43, P643, DOI 10.1016/0092-8674(85)90236-3; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; FABER JL, 1981, ARCH BIOCHEM BIOPHYS, V211, P312; FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X; FROST SC, 1985, J BIOL CHEM, V260, P2646; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; HAAGSMAN HP, 1982, J BIOL CHEM, V257, P593; Jarett L, 1974, Methods Enzymol, V31, P60; MAIZEL JV, 1969, FUNDAMENTAL TECHNIQU, P334; MULLOCK BM, 1989, J CELL BIOL, V108, P2093, DOI 10.1083/jcb.108.6.2093; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; OZASA S, 1989, J LIPID RES, V30, P1759; PERIDES G, 1986, EUR J CELL BIOL, V41, P313; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; POLOKOFF MA, 1978, J BIOL CHEM, V253, P7173; SLAVIN BG, 1979, ANAT RECORD, V195, P63, DOI 10.1002/ar.1091950106; TRAUB P, 1986, J BIOL CHEM, V261, P558; TRAUB P, 1985, FEBS LETT, V193, P217, DOI 10.1016/0014-5793(85)80155-1; WOODMAN PG, 1986, J CELL BIOL, V103, P1829, DOI 10.1083/jcb.103.5.1829; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	25	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					771	776						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276882				2022-12-25	WOS:A1994MR21900121
J	HORDIJK, PL; VERLAAN, I; VANCORVEN, EJ; MOOLENAAR, WH				HORDIJK, PL; VERLAAN, I; VANCORVEN, EJ; MOOLENAAR, WH			PROTEIN-TYROSINE PHOSPHORYLATION-INDUCED BY LYSOPHOSPHATIDIC ACID IN RAT-1 FIBROBLASTS - EVIDENCE THAT PHOSPHORYLATION OF MAP KINASE IS MEDIATED BY THE GI-P21RAS PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; GTPASE-ACTIVATING PROTEIN; PHOSPHOLIPASE-C; P21(RAS) ACTIVATION; SIGNALING PATHWAYS; PHOSPHATIDIC-ACID; MESANGIAL CELLS; FOCAL ADHESIONS; GROWTH-FACTORS; ENDOTHELIN	Lysophosphatidic acid (LPA) is a platelet-derived phospholipid that serves as a mitogen for fibroblasts. LPA activates its own G protein-coupled receptor(s) leading to stimulation of phospholipase C and inhibition of adenylate cyclase. Furthermore, LPA rapidly activates p21ras through a pertussis toxin-sensitive pathway. In this study, we have examined LPA-induced protein tyrosine phosphorylation in Rat-1 fibroblasts. LPA action was compared with that of endothelin, which is a stronger activator of phospholipase C than LPA but fails to activate p21ras and to stimulate DNA synthesis in these cells. LPA and, more effectively, endothelin rapidly stimulate tyrosine phosphorylation of proteins of 110-130, 95, and 65-75 kDa. The effect of LPA is dose- and time-dependent, being half-maximal at 3-30 nm and peaking after 2-5 min. Among the 110-130-kDa group of phosphotyrosyl proteins is the 125-kDa ''focal adhesion kinase'' (p125FAK) but not the 120-kDa p21ras GTPase-activating protein. Furthermore, LPA, like epidermal growth factor, causes tyrosine phosphorylation and activation of the p42/p44 mitogen-activated protein (MAP) kinases, paralleling p21ras activation. In contrast, endothelin fails to phosphorylate MAP kinase. Treatment of the cells with pertussis toxin blocks LPA-induced MAP kinase phosphorylation without affecting the other tyrosine phosphorylations. The kinase inhibitor staurosporine (1 muM) blocks LPA-induced, but not epidermal growth factor-induced, activation of p21ras and MAP kinase, consistent with an intermediate protein kinase linking the LPA receptor to p21ras activation. The results support a model in which LPA-induced phosphorylation of MAP kinase is mediated by p21ras and tyrosine phosphorylation of the other substrates, including p125FAK, is associated with phospholipase C activation.	NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				Hordijk, Peter/0000-0002-3348-078X				AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FALLON RJ, 1990, BIOCHEM BIOPH RES CO, V170, P1191, DOI 10.1016/0006-291X(90)90519-S; FORCE T, 1991, J BIOL CHEM, V266, P6650; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; JALINK K, 1993, P NATL ACAD SCI USA, V90, P1857, DOI 10.1073/pnas.90.5.1857; JALINK K, 1990, J BIOL CHEM, V265, P12232; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MOLLOY CJ, 1992, MOL CELL BIOL, V12, P3903, DOI 10.1128/MCB.12.9.3903; MOOLENAAR WH, 1991, CELL GROWTH DIFFER, V2, P359; MOOLENAAR WH, 1992, REV PHYSL BIOCH PHAR, V119, P48; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OFFERMANNS S, 1993, BIOCHEM J, V290, P27, DOI 10.1042/bj2900027; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PLEVIN R, 1991, BIOCHEM J, V280, P609, DOI 10.1042/bj2800609; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SECRIST JP, 1990, J BIOL CHEM, V265, P20394; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THOMAS G, 1992, CELL, V68, P1; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TIGYI G, 1992, J BIOL CHEM, V267, P21360; TORTI M, 1992, J BIOL CHEM, V267, P8293; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1259; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	56	239	240	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					645	651						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276865				2022-12-25	WOS:A1994MR21900102
J	JIANG, HB; WANG, Y; KANOST, MR				JIANG, HB; WANG, Y; KANOST, MR			MUTUALLY EXCLUSIVE EXON USE AND REACTIVE CENTER DIVERSITY IN INSECT SERPINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACTIVATOR INHIBITOR-1 GENE; PROTEINASE-INHIBITORS; MANDUCA-SEXTA; HEMOLYMPH; SEQUENCES	We have isolated 38 cDNA clones for serpins from a lepidopteran insect, Manduca sexta, and have found that they are identical in sequence, except for a region encoding the carboxyl-terminal 40-45 residues, which includes the reactive center. Among these clones, there are 11 variants of the reactive center region, each encoded by a different version of the ninth exon in the serpin gene. Thus, evolution of this insect serpin gene has resulted from duplication and sequence divergence of only the exon encoding the reactive site. Alternative pre-mRNA splicing then generates inhibitor diversity and the potential to regulate a variety of proteinases, using the same protein framework joined to different reactive site region cassettes.	KANSAS STATE UNIV AGR & APPL SCI, DEPT BIOCHEM, MANHATTAN, KS 66506 USA	Kansas State University			Jiang, Haobo/A-6519-2008	Jiang, Haobo/0000-0003-1357-1315; Kanost, Michael/0000-0002-6827-0061	NIGMS NIH HHS [GM41247, R37 GM041247] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041247, R29GM041247, R01GM041247] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBAS JA, 1993, MOL CELL BIOL, V13, P1433, DOI 10.1128/MCB.13.3.1433; BORRIELLO F, 1991, P NATL ACAD SCI USA, V88, P9417, DOI 10.1073/pnas.88.21.9417; BOSMA PJ, 1988, J BIOL CHEM, V263, P9129; BOSWELL DR, 1988, BIOESSAYS, V8, P83, DOI 10.1002/bies.950080209; BRUZDZINSKI CJ, 1990, J BIOL CHEM, V265, P2078; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; COLE KD, 1990, INSECT BIOCHEM, V20, P381, DOI 10.1016/0020-1790(90)90058-3; FENG DF, 1990, METHOD ENZYMOL, V183, P375; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; Kanost M.R., 1990, P139; KANOST MR, 1989, J BIOL CHEM, V264, P965; KANOST MR, 1990, INSECT BIOCHEM, V20, P141, DOI 10.1016/0020-1790(90)90006-G; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; NARUMI H, 1993, EUR J BIOCHEM, V214, P181, DOI 10.1111/j.1432-1033.1993.tb17911.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI T, 1991, EUR J BIOCHEM, V202, P255, DOI 10.1111/j.1432-1033.1991.tb16370.x; SAVAKIS C, 1986, DEV BIOL, V114, P194, DOI 10.1016/0012-1606(86)90395-7; SMITH CWJ, 1989, CELL, V56, P749, DOI 10.1016/0092-8674(89)90678-8; SUGUMARAN M, 1993, PARASITES PATHOGENS, V1, P317; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WRIGHT HT, 1993, J MOL EVOL, V36, P136, DOI 10.1007/BF00166249	22	54	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					55	58						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276850				2022-12-25	WOS:A1994MR21900015
J	MCENERY, MW; SNOWMAN, AM; SNYDER, SH				MCENERY, MW; SNOWMAN, AM; SNYDER, SH			THE ASSOCIATION OF ENDOGENOUS-G(OMICRON-ALPHA) WITH THE PURIFIED OMEGA-CONOTOXIN GVIA RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT SYMPATHETIC NEURONS; NUCLEOTIDE-BINDING PROTEIN; BETA-GAMMA-SUBUNITS; CALCIUM CHANNELS; N-TYPE; P-TYPE; REGULATORY PROTEINS; VOLTAGE DEPENDENCE; PERIPHERAL NEURONS; SYNAPTIC VESICLES	Modulation of the neuronal omega-conotoxin GVIA-sensitive N-type voltage-dependent calcium channel (VDCC) by neurotransmitters and guanine nucleotides suggests a dynamic interaction between activated G-protein a subunits and the N-type VDCC. Our previous report on the purification of the N-type VDCC (McEnery, M. W., Snowman, A. M., Sharp, A. H., Adams, M. E., and Snyder, S. H. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 11095-11099), has led us to investigate a possible association of CTXR with an endogenous G(alpha) subunit. The addition of the G-protein activator AlF4- modulated the I-125-CTX binding characteristics of the solubilized CTXR. Further immunological analyses employing G(alpha) subunit-specific antibodies to monitor the cofractionation of G(alpha) with I-125-CTX binding activity throughout the purification procedure indicate the selective recovery of G(oalpha) in the purified CTXR preparation, as neither G(salpha), G(ialpha), nor G(betagamma) could be detected. Furthermore, G(oalpha) associated with CTXR acted as a substrate for pertussis toxin-dependent ADP-ribosylation only upon the addition of exogenous G(betagamma) subunits. These results strongly indicate a high affinity complex between an activated G(oalpha) and CTXR maintained throughout biochemical purification of the I-125-CTX receptor.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; CASE WESTERN RESERVE SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT, BALTIMORE, MD 21205 USA	Johns Hopkins University; Case Western Reserve University; Johns Hopkins University; Johns Hopkins University								ANWYL R, 1991, BRAIN RES REV, V16, P265, DOI 10.1016/0165-0173(91)90010-6; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BEECH DJ, 1992, NEURON, V8, P97, DOI 10.1016/0896-6273(92)90111-P; BEGAMASCHI S, 1992, J NEUROCHEM, V59, P536; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BERNHEIM L, 1991, NEURON, V6, P859, DOI 10.1016/0896-6273(91)90226-P; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; BOLAND LM, 1993, J NEUROSCI, V13, P516; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; DELCOUR AH, 1993, SCIENCE, V259, P980, DOI 10.1126/science.8094902; DOLPHIN AC, 1990, ANNU REV PHYSIOL, V52, P243; ELMSLIE KS, 1992, J PHYSIOL-LONDON, V451, P229, DOI 10.1113/jphysiol.1992.sp019162; ELMSLIE KS, 1990, NEURON, V5, P75, DOI 10.1016/0896-6273(90)90035-E; EWALD DA, 1988, P NATL ACAD SCI USA, V85, P3633, DOI 10.1073/pnas.85.10.3633; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HAMILTON SL, 1991, J BIOL CHEM, V266, P19528; HARRISWARRICK RM, 1988, NEURON, V1, P27, DOI 10.1016/0896-6273(88)90206-1; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; HOLZ GG, 1986, NATURE, V319, P670, DOI 10.1038/319670a0; HUFF RM, 1985, J BIOL CHEM, V260, P864; IKEDA SR, 1991, J PHYSIOL-LONDON, V439, P181, DOI 10.1113/jphysiol.1991.sp018663; JONES SW, 1991, BIOPHYS J, V60, P502, DOI 10.1016/S0006-3495(91)82077-X; KASAI H, 1989, PFLUG ARCH EUR J PHY, V414, P145, DOI 10.1007/BF00580956; KASAI H, 1991, P NATL ACAD SCI USA, V88, P8855, DOI 10.1073/pnas.88.19.8855; KATADA T, 1986, J BIOL CHEM, V261, P8182; KOBAYASHI I, 1989, FEBS LETT, V257, P177, DOI 10.1016/0014-5793(89)81815-0; KOMURO H, 1992, NATURE, V257, P806; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LLINAS R, 1992, TRENDS NEUROSCI, V15, P351, DOI 10.1016/0166-2236(92)90053-B; MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825; MAEDA N, 1989, BRAIN RES, V489, P21, DOI 10.1016/0006-8993(89)90004-8; MATHIE A, 1992, NEURON, V8, P907, DOI 10.1016/0896-6273(92)90205-R; MCCORMICK DA, 1989, P NATL ACAD SCI USA, V86, P8098, DOI 10.1073/pnas.86.20.8098; MCENERY MW, 1990, BIOPHYS J, V57, pA516; MCENERY MW, 1984, J BIOL CHEM, V259, P4642; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; MCENERY MW, IN PRESS ANN NY ACAD; MCENERY MW, 1993, MOL CELLULAR BIOL PH, V7, P3; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PLUMMER MR, 1991, J NEUROSCI, V11, P2339; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; SCHULTZ G, 1990, ANNU REV PHYSIOL, V52, P275, DOI 10.1146/annurev.ph.52.030190.001423; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STERNWEIS PC, 1982, J BIOL CHEM, V79, P4888; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; TAKAHASHI M, 1991, BRAIN RES, V551, P279, DOI 10.1016/0006-8993(91)90942-O; TAKEMURA M, 1989, NEUROSCIENCE, V32, P405, DOI 10.1016/0306-4522(89)90089-4; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; TURNER TJ, 1991, ANN NY ACAD SCI, V635, P497, DOI 10.1111/j.1749-6632.1991.tb36538.x; WAGNER JA, 1988, J NEUROSCI, V8, P3354; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WORLEY PF, 1986, P NATL ACAD SCI USA, V83, P4561, DOI 10.1073/pnas.83.12.4561; YATANI A, 1988, J BIOL CHEM, V263, P9887	65	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					5	8						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276842				2022-12-25	WOS:A1994MR21900002
J	TAYLOR, LK; SWANSON, KD; KERIGAN, J; MOBLEY, W; LANDRETH, GE				TAYLOR, LK; SWANSON, KD; KERIGAN, J; MOBLEY, W; LANDRETH, GE			ISOLATION AND CHARACTERIZATION OF A NERVE GROWTH FACTOR-REGULATED FOS KINASE FROM PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MICROTUBULE-ASSOCIATED PROTEIN-2; TRK PROTOONCOGENE PRODUCT; C-FOS; SERUM STIMULATION; TYROSINE KINASES; PHOSPHORYLATION; ACTIVATION; TRANSCRIPTION; PC12-CELLS	Nerve growth factor (NGF) treatment of PC12 cells activates a protein kinase that phosphorylates c-Fos protein at a site near its C terminus, as well as a peptide corresponding to a C-terminal region of c-Fos (Taylor, L. K., Marshak, D. R., and Landreth, G. E. (1993) Proc. Natl. Acad. Sci. U. S. A. 90,368-372). This serine/threonine kinase, termed Fos kinase, has been purified >24,000-fold through five column steps to near homogeneity and is shown to be a 37-kDa protein as determined by SDS-polyacrylamide gel electrophoresis (PAGE) with a pI = 6.0. Fos kinase is distinguishable from previously characterized NGF-regulated kinases by its chromatographic behavior, its response to specific kinase inhibitors, and its substrate specificity. The concentration of NGF required to activate Fos kinase is consistent with signaling from the high affinity NGF receptor. Fos kinase phosphorylates c-Fos at its C terminus as indicated by competitive inhibition with a peptide corresponding to C-terminal phosphorylation sites and lack of phosphorylation of a C-terminal deletion mutant of c-Fos. Hyperphosphorylation of c-Fos in vivo, as detected by reduced electrophoretic mobility of c-Fos, is induced by the same ligands which activate Fos kinase. Moreover, Fos kinase phosphorylation of c-Fos in vitro results in a similar electrophoretic mobility shift, demonstrating that Fos kinase may be responsible for growth factor-stimulated alterations in mobility on SDS-PAGE and phosphorylation of this transcription factor. The ability of this unique growth factor-responsive kinase to phosphorylate c-Fos at its C terminus, a region essential for the transrepressive properties of c-Fos, suggests that Fos kinase may play a role in the regulation of the transcriptional repressive activity of c-Fos.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT NEUROL,ALZHEIMER RES LAB,E504,10900 EUCLID AVE,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT NEUROSCI,CLEVELAND,OH 44106; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143	Case Western Reserve University; Case Western Reserve University; University of California System; University of California San Francisco					NIGMS NIH HHS [GM34908] Funding Source: Medline; NINDS NIH HHS [NS/AG10672, NS24054] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024054, F31NS010672] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABATE C, 1991, ONCOGENE, V6, P2179; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHENG HC, 1986, J BIOL CHEM, V261, P989; CURRAN T, 1986, P NATL ACAD SCI USA, V83, P8521, DOI 10.1073/pnas.83.22.8521; CURRAN T, 1984, CELL, V36, P259; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; GUIS D, 1990, MOL CELL BIOL, V10, P4243; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HEASLEY LE, 1989, MOL PHARMACOL, V35, P331; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; LANDRETH GE, 1990, J NEUROCHEM, V55, P514, DOI 10.1111/j.1471-4159.1990.tb04165.x; LONGO FM, 1990, CELL REGUL, V1, P189, DOI 10.1091/mbc.1.2.189; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MUTOH T, 1988, J BIOL CHEM, V263, P15853; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; Qui MS, 1991, NEURON, V7, P937, DOI [DOI 10.1016/0896-6273(91)90339-2, 10.1016/0896-6273(91)90339-2]; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROWLAND EA, 1987, J BIOL CHEM, V262, P7504; ROWLANDGAGNE E, 1990, J NEUROCHEM, V54, P424, DOI 10.1111/j.1471-4159.1990.tb01890.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMITH AP, 1968, BIOCHEMISTRY-US, V7, P3259, DOI 10.1021/bi00849a032; SMITH DS, 1989, J NEUROCHEM, V53, P800, DOI 10.1111/j.1471-4159.1989.tb11776.x; TAYLOR LK, 1993, P NATL ACAD SCI USA, V90, P368, DOI 10.1073/pnas.90.2.368; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; WOODGETT J, 1992, METHOD ENZYMOL, V200, P564	46	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					308	318						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276812				2022-12-25	WOS:A1994MR21900054
J	BLUM, JH; STEVENS, TL; DEFRANCO, AL				BLUM, JH; STEVENS, TL; DEFRANCO, AL			ROLE OF THE MU IMMUNOGLOBULIN HEAVY-CHAIN TRANSMEMBRANE AND CYTOPLASMIC DOMAINS IN B-CELL ANTIGEN RECEPTOR EXPRESSION AND SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TYROSINE PHOSPHORYLATION; LYMPHOCYTE-B; MEMBRANE IMMUNOGLOBULIN; GAMMA-CHAINS; NUCLEOTIDE-SEQUENCE; CA-2+ MOBILIZATION; PHOSPHOLIPASE-C; MESSENGER-RNA; KINASE-C; T-CELLS	Membrane immunoglobulins (mIg) serve as the recognition components of B lymphocyte antigen receptors. Binding of antigen to these receptors leads to dramatic effects on B cell growth and viability. We have examined the structural elements of mIgM that are involved in antigen receptor assembly and function. Expression of transfected wild-type mIgM in a B cell line led to assembly with the other two known components of the antigen receptor, Ig-alpha and Ig-beta, expression on the cell surface, and when cross-linked by anti-IgM antibodies, stimulation of signal transductin reactions, including tyrosine protein phosphorylation, inositol phosphate production, and increases in cytoplasmic calcium concentration. Replacement of the highly conserved COOH-terminal 41 amino acids of mIgM heavy chain (mu(m)) with the transmembrane and cytoplasmic domains of human CD8alpha resulted in a molecule which was expressed on the B cell surface at levels comparable to wild-type mIgM, but which did not form a complex with Ig-alpha or Ig-beta and did not stimulate any of the signaling reactions mentioned above. Replacement of the basic three-amino-acid cytoplasmic domain of mu(m) with a different but similarly charged sequence had no effect on cell-surface expression or signaling function. On the other hand, removal of the entire cytoplasmic domain resulted in a molecule which did not bind Ig-alpha and Ig-beta and which did not transduce signals. This effect is probably due to altered post-translational processing of this mutant molecule. Finally, a series of eight single-amino-acid substitutions in the transmembrane domain was constructed. Most of these resulted in the removal of hydroxyl groups from conserved residues postulated to be important for interactions with other components. Each of these mutant molecules was capable of transducing signals when cross-linked by anti-IgM, but one was partially defective. Since alteration of any single residue was not sufficient to disrupt signaling completely, the interactions required for signaling are likely to involve multiple residues, so that elimination of one hydroxyl group does not prevent the interaction. We propose that the cytoplasmic domain of mu(m) does not play a critical role in receptor function but that the transmembrane domain specifies interactions with other components, probably Ig-alpha and Ig-beta, required for proper antigen receptor signal transduction.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,GEORGE WILLIAMS HOOPER FDN,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCI NIH HHS [CA09043] Funding Source: Medline; NIAID NIH HHS [AI20038] Funding Source: Medline; NIGMS NIH HHS [GM07618] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009043] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020038, R01AI020038, R56AI020038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007618] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESMARTINEZ JE, 1988, P NATL ACAD SCI USA, V85, P6919, DOI 10.1073/pnas.85.18.6919; BERNSTEIN KE, 1984, J IMMUNOL, V132, P490; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BOYD AW, 1981, J IMMUNOL, V126, P2466; BROWN AMC, 1987, DNA CLONING, V3, P189; BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER J, 1988, P NATL ACAD SCI USA, V85, P6493, DOI 10.1073/pnas.85.17.6493; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHENG HL, 1982, NATURE, V296, P410, DOI 10.1038/296410a0; COSTA TE, 1992, J EXP MED, V175, P1669, DOI 10.1084/jem.175.6.1669; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEFRANCO A L, 1992, Current Biology, V2, P477; DORAI H, 1989, NUCLEIC ACIDS RES, V17, P6412, DOI 10.1093/nar/17.15.6412; DUBOIS PM, 1992, EUR J IMMUNOL, V22, P851, DOI 10.1002/eji.1830220333; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GROSSCHEDL R, 1984, CELL, V38, P647, DOI 10.1016/0092-8674(84)90259-9; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; ISHIDA N, 1982, EMBO J, V1, P1117, DOI 10.1002/j.1460-2075.1982.tb01306.x; KOKUBU F, 1988, EMBO J, V7, P1979, DOI 10.1002/j.1460-2075.1988.tb03036.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANE PJL, 1990, J IMMUNOL, V144, P3684; LANE PJL, 1991, J IMMUNOL, V146, P715; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LYNCH CJ, 1985, MOL PHARMACOL, V28, P93; MATSUUCHI L, 1992, P NATL ACAD SCI USA, V89, P3404, DOI 10.1073/pnas.89.8.3404; MITCHELL RN, 1991, J BIOL CHEM, V266, P8856; MIZUGUCHI J, 1986, J IMMUNOL, V137, P2162; MONROE JG, 1989, MOL IMMUNOL, V26, P593, DOI 10.1016/0161-5890(89)90041-2; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NORMENT AM, 1989, J IMMUNOL, V142, P3312; OI VT, 1980, J EXP MED, V151, P1260, DOI 10.1084/jem.151.5.1260; PADEH S, 1991, J CLIN INVEST, V87, P1114, DOI 10.1172/JCI115074; PAGE DM, 1991, J BIOL CHEM, V266, P5563; PAGE DM, 1988, J IMMUNOL, V140, P3717; PARIKH VS, 1991, J EXP MED, V174, P1103, DOI 10.1084/jem.174.5.1103; PARIKH VS, 1992, J EXP MED, V176, P1025, DOI 10.1084/jem.176.4.1025; PIKE BL, 1982, P NATL ACAD SCI-BIOL, V79, P2013, DOI 10.1073/pnas.79.6.2013; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; ROGERS J, 1981, CELL, V26, P19, DOI 10.1016/0092-8674(81)90029-5; ROGERS J, 1984, ADV IMMUNOL, V35, P39, DOI 10.1016/S0065-2776(08)60573-8; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SCHENA M, 1988, US BIOCH EDITORIAL C, V15, P23; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SHAW AC, 1990, CELL, V63, P381, DOI 10.1016/0092-8674(90)90171-A; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; TISCH R, 1988, P NATL ACAD SCI USA, V85, P6914, DOI 10.1073/pnas.85.18.6914; TYLER BM, 1982, P NATL ACAD SCI-BIOL, V79, P2008, DOI 10.1073/pnas.79.6.2008; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WARNER NL, 1979, IMMUNOL REV, V48, P197, DOI 10.1111/j.1600-065X.1979.tb00304.x; WEBB CF, 1989, P NATL ACAD SCI USA, V86, P1977, DOI 10.1073/pnas.86.6.1977; WILLIAMS GT, 1990, J EXP MED, V171, P947, DOI 10.1084/jem.171.3.947; Word C J, 1989, Int Immunol, V1, P296, DOI 10.1093/intimm/1.3.296; WORD CJ, 1983, EMBO J, V2, P887, DOI 10.1002/j.1460-2075.1983.tb01518.x; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMAWAKIKATAOKA Y, 1982, P NATL ACAD SCI-BIOL, V79, P2623, DOI 10.1073/pnas.79.8.2623	60	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27236	27245						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262964				2022-12-25	WOS:A1993MM26200060
J	LUKA, S; SANJUAN, J; CARLSON, RW; STACEY, G				LUKA, S; SANJUAN, J; CARLSON, RW; STACEY, G			NOLMNO GENES OF BRADYRHIZOBIUM-JAPONICUM ARE CO-TRANSCRIBED WITH NODYABCSUIJ, AND NOLO IS INVOLVED IN THE SYNTHESIS OF THE LIPO-OLIGOSACCHARIDE NODULATION SIGNALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; RHIZOBIUM-MELILOTI; HOST-SPECIFICITY; NOD GENES; STRAIN NGR234; EXPRESSION; FAMILY; RANGE; BRADYRHIZOBIUM-JAPONICUM-NODD1; MUTAGENESIS	A host-inducible lacZ fusion was mapped downstream of the nodYABCSUIJ operon in Bradyrhizobium japonicum strain USDA110. Sequencing of this region identified three novel genes, nolMNO. RNA dot blot analysis showed that nolO transcription is nodD1-dependent and that a polar mutation in nodS, located 5 kilobases upstream of nolO, blocks the transcription of nolO. Coupled with the host- inducible nature of nolO expression, these results indicate that nolMNO are part of a 9-kilobase operon, nodYABCSUIJnolMNO. The lipo-oligosaccharide nodulation signals produced by strains SL67(nolO-) and SL65(nolNO-) were purified, and their chemical structures were determined. In addition to the wild-type signal molecules, both mutants produced modified compounds that are not produced by the parent strain USDA110. The most prevalent difference observed was the absence of the 2-O-methylfucosyl residue from the mutant structures. In addition, metabolites were found in which the N-acetylglucosamine residue at the reducing end was glycosidically linked to glycerol. These alterations in the profiles of nodulation signals produced by strains SL67 and SL65 were accompanied by reduced nodulation efficiency on all hosts tested.	UNIV TENNESSEE,DEPT MICROBIOL,CTR LEGUME RES,KNOXVILLE,TN 37996; UNIV GEORGIA,COMPLEX CARBOHYDRATE RES CTR,ATHENS,GA 30602	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; University System of Georgia; University of Georgia				Sanjuan, Juan/0000-0002-6404-8754	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039583] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM39583] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANFALVI Z, 1988, MOL GEN GENET, V214, P420, DOI 10.1007/BF00330475; CARLSON RW, 1993, J BIOL CHEM, V268, P18372; DEVINE TE, 1990, THEOR APPL GENET, V80, P33, DOI 10.1007/BF00224012; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; FESTL H, 1986, APPL ENVIRON MICROB, V52, P1190, DOI 10.1128/AEM.52.5.1190-1194.1986; FISHER RF, 1988, GENE DEV, V2, P282, DOI 10.1101/gad.2.3.282; GEELEN D, 1993, MOL MICROBIOL, V9, P145, DOI 10.1111/j.1365-2958.1993.tb01676.x; GERHOLD D, 1989, THESIS U TENNESSEE K; GOTTFERT M, 1990, MOL PLANT MICROBE IN, V3, P308, DOI 10.1094/MPMI-3-308; GOTTFERT M, 1992, MOL PLANT MICROBE IN, V5, P257, DOI 10.1094/MPMI-5-257; HALVERSON LJ, 1985, PLANT PHYSIOL, V77, P621, DOI 10.1104/pp.77.3.621; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; HONG GF, 1987, NUCLEIC ACIDS RES, V15, P9677, DOI 10.1093/nar/15.23.9677; KRISHNAN HB, 1992, MOL MICROBIOL, V6, P3321, DOI 10.1111/j.1365-2958.1992.tb02200.x; KUYKENDALL LD, 1976, APPL ENVIRON MICROB, V32, P511, DOI 10.1128/AEM.32.4.511-519.1976; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LEWIN A, 1990, MOL PLANT MICROBE IN, V3, P317, DOI 10.1094/MPMI-3-317; LONG SR, 1989, CELL, V56, P203, DOI 10.1016/0092-8674(89)90893-3; Maniatis T., 1982, MOL CLONING; MESSING J, 1991, GENE, V100, P3, DOI 10.1016/0378-1119(91)90344-B; NIEUWKOOP AJ, 1987, J BACTERIOL, V169, P2631, DOI 10.1128/jb.169.6.2631-2638.1987; ROCHE P, 1991, J BIOL CHEM, V266, P10933; ROSTAS K, 1986, P NATL ACAD SCI USA, V83, P1757, DOI 10.1073/pnas.83.6.1757; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANJUAN J, 1992, P NATL ACAD SCI USA, V89, P8789, DOI 10.1073/pnas.89.18.8789; SCHLAMAN HRM, 1992, J BACTERIOL, V174, P5177, DOI 10.1128/JB.174.16.5177-5182.1992; SCHULTZE M, 1992, P NATL ACAD SCI USA, V89, P192, DOI 10.1073/pnas.89.1.192; SCHWEDOCK J, 1990, NATURE, V348, P644, DOI 10.1038/348644a0; SCHWEDOCK J, 1989, Molecular Plant-Microbe Interactions, V2, P181, DOI 10.1094/MPMI-2-181; SCOTT KF, 1986, NUCLEIC ACIDS RES, V14, P2905, DOI 10.1093/nar/14.7.2905; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SMIT G, 1992, J BIOL CHEM, V267, P310; SO JS, 1987, MOL GEN GENET, V207, P15, DOI 10.1007/BF00331485; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; TRUCHET G, 1991, NATURE, V351, P670, DOI 10.1038/351670a0; VEST G, 1972, CROP SCI, V12, P692, DOI 10.2135/cropsci1972.0011183X001200050042x; WANG SP, 1990, MOL GEN GENET, V223, P329, DOI 10.1007/BF00265071; WANG SP, 1991, J BACTERIOL, V173, P3356, DOI 10.1128/jb.173.11.3356-3365.1991; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1	39	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27053	27059						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262943				2022-12-25	WOS:A1993MM26200035
J	CODIGNOLA, A; TARRONI, P; CLEMENTI, F; POLLO, A; LOVALLO, M; CARBONE, E; SHER, E				CODIGNOLA, A; TARRONI, P; CLEMENTI, F; POLLO, A; LOVALLO, M; CARBONE, E; SHER, E			CALCIUM-CHANNEL SUBTYPES CONTROLLING SEROTONIN RELEASE FROM HUMAN SMALL-CELL LUNG-CARCINOMA CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EATON MYASTHENIC SYNDROME; OMEGA-CONOTOXIN; PERIPHERAL NEURONS; GROWTH-FACTORS; CA2+ CHANNELS; FREE CA-2+; P-TYPE; DIHYDROPYRIDINE; CANCER; AUTOANTIBODIES	Small cell lung carcinoma is an aggressive neuroendocrine tumor that secretes several hormones, some of which act as autocrine growth factors. In order to obtain more information on the process of hormone secretion from this tumor, we have studied the role of intracellular free Ca2+ concentrations and voltage-operated calcium channels in the control of [H-3]serotonin release from in vitro growing cell lines. We found that the Ca2+ ionophore ionomycin and the Ca2+-ATPase antagonist thapsigargin induced a dose-dependent increase of intracellular Ca2+ and a parallel enhancement of [H-3]serotonin release. KCl-induced depolarization also stimulated a dose- and Ca2+-dependent [H-3]serotonin release that in the GLC8 cell line was effectively inhibited by Ca2+ channel antagonists (Cd2+, nitrendipine, verapamil, omega-conotoxin GVIA, and omega-agatoxin IVA) and potentiated by the Ca2+ channel agonist BayK8644. Autoantibodies against Ca2+ channels present in the sera of Lambert-Eaton myasthenic patients antagonized KCl- but not ionomycin-induced [H-3]serotonin release. Polymerase chain reaction analysis indicated that GLC8 cells express L-, N-, and P-type neuronal Ca2+ channel alpha1 subunits, together with two types of Ca2+ channel beta subunits. The presence of three functionally distinct high threshold Ca2+ channels was also revealed by patch clamp experiments; high threshold Ca2+ channels were identified as dihydropyridine-sensitive (L-type), omega-conotoxin GVIA-sensitive (N-type), and omega-agatoxin IVA-sensitive (P-type). Our data demonstrate that [H-3]serotonin is released by small cell lung carcinoma cells in a Ca2+-dependent manner and that depolarization-induced [H-3]serotonin release is mediated by Ca2+ influx through distinct, neuron-like, Ca2+ channel subtypes.	UNIV MILAN, DEPT MED PHARMACOL,CNR,CTR CYTOPHARMACOL, VIA VANVITELLI 32, I-20129 MILAN, ITALY; UNIV TURIN, DEPT HUMAN ANAT & PHYSIOL, I-10125 TURIN, ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Milan; University of Turin				Tarroni, Paola/0000-0001-7398-0722; Carbone, Emilio/0000-0003-2239-6280	Telethon [386] Funding Source: Medline	Telethon(Fondazione Telethon)		AUGUSTINE GJ, 1986, J PHYSIOL-LONDON, V381, P619, DOI 10.1113/jphysiol.1986.sp016347; BARRY ELR, 1991, J CELL BIOL S, V115, P466; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BURGOYNE RD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P174, DOI 10.1016/0304-4157(91)90024-Q; CARBONE E, 1990, PFLUG ARCH EUR J PHY, V416, P170, DOI 10.1007/BF00370239; CARBONE E, 1989, PROG BIOPHYS MOL BIO, V54, P31, DOI 10.1016/0079-6107(89)90008-4; CARBONE E, 1984, NATURE, V310, P501, DOI 10.1038/310501a0; CHINI B, 1992, P NATL ACAD SCI USA, V89, P1572, DOI 10.1073/pnas.89.5.1572; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DAYANITHI G, 1988, BIOCHEM BIOPH RES CO, V156, P255, DOI 10.1016/S0006-291X(88)80833-7; DEAIZPURUA HJ, 1988, CANCER RES, V48, P4719; DUBY A, 1990, CURRENT PROTOCOL S20, V1; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gandia L, 1990, Neuroreport, V1, P119, DOI 10.1097/00001756-199010000-00009; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HERDON H, 1989, N-S ARCH PHARMACOL, V340, P36; HOLZ GG, 1988, J NEUROSCI, V8, P463; HSER E, 1992, EUR J PHARMACOL, V216, P407; KASAI H, 1992, J PHYSIOL-LONDON, V448, P161, DOI 10.1113/jphysiol.1992.sp019035; KIM YI, 1988, SCIENCE, V239, P405, DOI 10.1126/science.2447652; LLINAS R, 1992, TRENDS NEUROSCI, V15, P351, DOI 10.1016/0166-2236(92)90053-B; LOGIN IS, 1987, ANN NEUROL, V22, P610, DOI 10.1002/ana.410220509; LUNDY PM, 1991, EUR J PHARM-MOLEC PH, V206, P61, DOI 10.1016/0922-4106(91)90147-A; MCCANN FV, 1981, SCIENCE, V212, P1155, DOI 10.1126/science.6262914; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; NAKANISHI Y, 1988, J CLIN INVEST, V82, P354, DOI 10.1172/JCI113594; OGUROOKANO M, 1992, MAYO CLIN PROC, V67, P1150, DOI 10.1016/S0025-6196(12)61144-6; OSHAUGHNESSY TJ, 1992, SOC NEUR ABSTR, V118, P435; PANCRAZIO JJ, 1992, ACTA PHYSIOL SCAND, V144, P463, DOI 10.1111/j.1748-1716.1992.tb09321.x; PEERS C, 1990, J PHYSIOL-LONDON, V421, P293, DOI 10.1113/jphysiol.1990.sp017945; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; POLLO A, 1992, PFLUG ARCH EUR J PHY, V422, P75; POLLO A, 1993, PFLUG ARCH EUR J PHY, V423, P462, DOI 10.1007/BF00374942; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; RINK TJ, 1982, FEBS LETT, V148, P21, DOI 10.1016/0014-5793(82)81234-9; ROBERTS A, 1985, NATURE, V317, P737, DOI 10.1038/317737a0; ROSENFELD MR, 1993, ANN NEUROL, V33, P113, DOI 10.1002/ana.410330126; SHER E, 1989, LANCET, V2, P640; SHER E, 1990, CANCER RES, V50, P3892; SHER E, 1991, NEUROSCIENCE, V42, P301, DOI 10.1016/0306-4522(91)90376-Y; SHER E, 1991, FASEB J, V5, P2677, DOI 10.1096/fasebj.5.12.1655547; SORENSON GD, 1981, CANCER, V47, P1289, DOI 10.1002/1097-0142(19810315)47:6<1289::AID-CNCR2820470610>3.0.CO;2-B; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; TARELLI FT, 1991, BRAIN RES, V547, P331, DOI 10.1016/0006-8993(91)90981-Z; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Viglione Michael P., 1992, Society for Neuroscience Abstracts, V18, P435; VINCENT A, 1989, TRENDS NEUROSCI, V12, P496, DOI 10.1016/0166-2236(89)90109-4; WEYNANTS P, 1990, EUR RESPIR J, V3, P699; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; WOLL PJ, 1991, BRIT J CANCER, V63, P469, DOI 10.1038/bjc.1991.110; WOLLHEIM CB, 1984, J BIOL CHEM, V259, P2262; YU A, 1991, J CELL BIOL S, V115, P466	53	83	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26240	26247						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253745				2022-12-25	WOS:A1993MK42500037
J	DUFF, JL; MARRERO, MB; PAXTON, WG; CHARLES, CH; LAU, LF; BERNSTEIN, KE; BERK, BC				DUFF, JL; MARRERO, MB; PAXTON, WG; CHARLES, CH; LAU, LF; BERNSTEIN, KE; BERK, BC			ANGIOTENSIN-II INDUCES 3CH134, A PROTEIN-TYROSINE-PHOSPHATASE, IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GENE-EXPRESSION; ENCODED PROTEIN; KINASE-ACTIVITY; VACCINIA VIRUS; MAP KINASE; PHOSPHORYLATION; IDENTIFICATION; ACTIVATION; PROLIFERATION; MOBILIZATION	Angiotensin II is a potent growth factor for vascular smooth muscle cells and shares many signal transduction mechanisms with mitogens, including stimulation of mitogen-activated protein (MAP) kinases and protein tyrosine phosphorylation. Regulation of tyrosine phosphorylation involves both protein-tyrosine kinases and protein-tyrosine phosphatases (PTPases). To investigate the role of PTPases in angiotensin II-mediated events, we studied the expression of a transcriptionally regulated PTPase, 3CH134, which has selective activity toward MAP kinase. Angiotensin II rapidly induced 3CH134 mRNA (30 min maximum) in a concentration-dependent manner (100 nM maximum). Platelet-derived growth factor, alpha-thrombin, hydrogen peroxide, phorbol 12-myristate 13-acetate, and ionomycin also induced 3CH134 but to levels lower than angiotensin H. Induction of 3CH134 by angiotensin II was partially inhibited after down-regulating protein kinase C but was fully inhibited after chelating intracellular Ca2+. Treatment with both phorbol 12-myristate 13-acetate and ionomycin induced 3CH134 mRNA to levels seen with angiotensin II, indicating that Ca2+ mobilization and protein kinase C activation can act synergistically to induce 3CH134. Angiotensin II stimulated 3CH134 protein synthesis after 1 h as measured by immunoprecipitation of 3CH134 from [S-35]methionine-labeled cells using affinity-purified antibodies. These results establish 3CH134 as a dynamically regulated, immediate early gene in vascular smooth muscle cells and suggest a role for PTPases in regulating angiotensin II-stimulated events mediated by MAP kinases and tyrosine kinases.	EMORY UNIV,SCH MED,DEPT MED,DIV CARDIOL,PO DRAWER LL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PATHOL,ATLANTA,GA 30322; UNIV ILLINOIS,SCH MED,DEPT GENET,CHICAGO,IL 60612	Emory University; Emory University; Emory University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Bernstein, Kenneth/0000-0001-8097-3272; Lau, Lester/0000-0002-4364-2914; Berk, Bradford/0000-0002-2767-4115				ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BERK BC, 1987, J BIOL CHEM, V262, P5065; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BLANK RS, 1992, J BIOL CHEM, V267, P984; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; FORT P, 1985, NUCLEIC ACIDS RES, V13, P141; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUNTHER S, 1980, CIRC RES, V47, P278, DOI 10.1161/01.RES.47.2.278; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOHNO M, 1986, BIOCHEM J, V238, P451, DOI 10.1042/bj2380451; KRUG LM, 1992, HYPERTENSION, V20, P144, DOI 10.1161/01.HYP.20.2.144; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RAO GN, 1990, J BIOL CHEM, V265, P19393; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; STOUFFER GA, 1992, CIRC RES, V70, P820, DOI 10.1161/01.RES.70.4.820; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TRAVO P, 1980, BLOOD VESSELS, V17, P110; TSUDA T, 1991, FEBS LETT, V285, P44, DOI 10.1016/0014-5793(91)80721-E	35	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26037	26040						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253712				2022-12-25	WOS:A1993MK42500002
J	ROBITAILLE, PML; RATH, DP; ABDULJALIL, AM; ODONNELL, JM; JIANG, ZC; ZHANG, HZ; HAMLIN, RL				ROBITAILLE, PML; RATH, DP; ABDULJALIL, AM; ODONNELL, JM; JIANG, ZC; ZHANG, HZ; HAMLIN, RL			DYNAMIC C-13 NMR ANALYSIS OF OXIDATIVE-METABOLISM IN THE IN-VIVO CANINE MYOCARDIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CITRIC-ACID CYCLE; PERFUSED RAT-HEART; TRICARBOXYLATE CYCLE; CARBON FLUX; WORK LOAD; SPECTROSCOPY; SUBSTRATE; EXCITATION; GLYCOLYSIS; PATHWAYS	Oxidative metabolism in the in vivo canine myocardium was studied noninvasively using C-13-enriched acetate and non-steady state C-13 NMR techniques. Under low workload conditions, the myocardium oxidized the infused [2-C-13]acetate and incorporated the labeled carbon into the glutamate pool as expected. This conclusion stems from the rapid enrichment of the C-2, C-3, and C-4 carbons of glutamic acid both under in vivo conditions and in extracts. Surprisingly, [2-C-13]acetate uptake was not observed at high workloads as reflected by an absence of glutamate pool enrichment at these rate pressure products. Rather, the myocardium selected its substrate from an endogenous pool. Since free acetate can directly cross the inner mitochondrial membrane and be converted to acetyl-CoA through acetyl-CoA synthetase, these results support workload-dependent regulation of substrate access to the mitochondrial CoASH pool. As such, we advance the hypothesis that the selection of substrate for condensation with CoASH and subsequent oxidation in the tricarboxylic acid cycle is regulated kinetically through the K(m) values of the appropriate condensation enzymes and through the absolute levels of free CoASH in the mitochondria.	OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT RADIOL,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT VET PHYSIOL & PHARMACOL,COLUMBUS,OH 43210	Ohio State University; Ohio State University; Ohio State University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045120] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-1 HL45120] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILEY IA, 1981, FEBS LETT, V123, P315, DOI 10.1016/0014-5793(81)80317-1; BALABAN RS, 1986, SCIENCE, V232, P1121, DOI 10.1126/science.3704638; BENDALL MR, 1986, J MAGN RESON, V67, P376, DOI 10.1016/0022-2364(86)90447-6; CHANCE EM, 1983, J BIOL CHEM, V258, P3785; Chase J.F.A., 1969, METHOD ENZYMOL, V13, P387, DOI 10.1016/0076-6879(69)13066-9; COONEY GJ, 1981, BIOCHEM J, V200, P701, DOI 10.1042/bj2000701; DAVIS EJ, 1977, BIOCHEM BIOPH RES CO, V79, P1155; FROM AHL, 1990, BIOCHEMISTRY-US, V29, P3731, DOI 10.1021/bi00467a020; GEHRING U, 1968, EUR J BIOCHEM, V6, P264, DOI 10.1111/j.1432-1033.1968.tb00446.x; LEWANDOWSKI ED, 1992, CIRC RES, V70, P576, DOI 10.1161/01.RES.70.3.576; LEWANDOWSKI ED, 1991, MAGNET RESON MED, V19, P186, DOI 10.1002/mrm.1910190118; LUMENG L, 1973, FEBS LETT, V29, P124, DOI 10.1016/0014-5793(73)80541-1; MALLOY CR, 1990, AM J PHYSIOL, V259, pH987, DOI 10.1152/ajpheart.1990.259.3.H987; MALLOY CR, 1987, FEBS LETT, V212, P58, DOI 10.1016/0014-5793(87)81556-9; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; MASSEY V, 1960, BIOCHIM BIOPHYS ACTA, V38, P447, DOI 10.1016/0006-3002(60)91280-4; MASSIE B, 1992, SOC MAGNETIC RES MED; NEELY JR, 1972, BIOCHEM J, V128, P147, DOI 10.1042/bj1280147; Opie L.H., 1991, HEART PHYSL METABOLI; PETTIT FH, 1982, METHOD ENZYMOL, V89, P376; PRUSKI J, 1991, MAGNET RESON MED, V27, P329; RAMSAY RR, 1975, FEBS LETT, V54, P21, DOI 10.1016/0014-5793(75)81059-3; RANDLE PJ, 1970, BIOCHEM J, V117, P677, DOI 10.1042/bj1170677; ROBITAILLE PM, 1990, MAGN RESON MED, V16, P91, DOI 10.1002/mrm.1910160110; ROBITAILLE PML, 1993, MAGNET RESON MED, V30, P262, DOI 10.1002/mrm.1910300218; RUSSELL RR, 1990, J CLIN INVEST, V87, P384; SHERRY AD, 1988, BIOCHEM J, V254, P593, DOI 10.1042/bj2540593; SHERRY AD, 1985, J BIOL CHEM, V260, P9272; SKINNER TE, 1992, J MAGN RESON, V98, P14, DOI 10.1016/0022-2364(92)90105-G; TAEGTMEYER H, 1983, BASIC RES CARDIOL, V78, P435, DOI 10.1007/BF02070167; TAEGTMEYER H, 1980, BIOCHEM J, V186, P701, DOI 10.1042/bj1860701; UGURBIL K, 1988, J MAGN RESON, V80, P448, DOI 10.1016/0022-2364(88)90241-7; WEBSTER LT, 1969, METHOD ENZYMOL, V13, P375; WILLIAMS.DH, 1971, BIOCHEM J, V121, P41, DOI 10.1042/bj1210041; Williamson J R, 1979, Methods Enzymol, V55, P200; Williamson J R, 1973, Symp Soc Exp Biol, V27, P241; WILLIAMSON JR, 1965, J BIOL CHEM, V240, P2308; WILLIAMSON JR, 1980, FEBS LETT, V117, pK73, DOI 10.1016/0014-5793(80)80572-2; ZHANG J, 1992, SOC MAGNETIC RES MED; ZIMMERMAN ANE, 1962, LANCET, V2, P757	40	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26296	26301						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253751				2022-12-25	WOS:A1993MK42500045
J	DAVIS, JM; BACHINGER, HP				DAVIS, JM; BACHINGER, HP			HYSTERESIS IN THE TRIPLE HELIX-COIL TRANSITION OF TYPE-III COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME TYPE-IV; THERMAL-STABILITY; RAT SKIN; PROCOLLAGEN; ISOMERIZATION; ISOMERASE; INVITRO; CONFORMATION; MECHANISM; CATALYSIS	A hysteresis is observed in the triple helix-coil transition of type III collagen. This hysteresis appears in the thermal transition, where it is not solvent-dependent, and also in the transition induced by guanidinium hydrochloride. The transitions are observed both by optical rotatory dispersion and by trypsin digestion. Experiments with various fragments of type III collagen, which, like the intact protein, contain a set of disulfide bonds at the carboxyl-terminal end, which functions as an effective nucleus for refolding, indicate that the hysteresis depends on the amino acid sequence, rather than being a general property of the triple helix. The carboxyl-terminal one-quarter fragment of type III collagen does not show a hysteresis, whereas a mutant type III collagen missing residues 595-1008 shows a hysteresis of the same magnitude as normal type III collagen. Several fragments were produced that are missing parts of the amino-terminal end, and these fragments show no hysteresis. The amino-terminal part of the triple helix of type III collagen consists of a stable region containing six Gly-Pro-Hyp tripeptide units within the first 16 tripeptide units. This region forms an amino-terminal clamp for the triple helix and, together with the set of disulfide bonds at the carboxyl-terminal end, allows for highly cooperative unfolding of the triple helix. The presence of this amino-terminal region is a prerequisite for the observed hysteresis.	SHRINERS HOSP CRIPPLED CHILDREN,RES DEPT,3101 SW SAM JACKSON PK RD,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201	Oregon Health & Science University								BACHINGER HP, 1993, AM J MED GENET, V45, P152, DOI 10.1002/ajmg.1320450204; BACHINGER HP, 1991, INT J BIOL MACROMOL, V13, P152, DOI 10.1016/0141-8130(91)90040-2; BACHINGER HP, 1987, J BIOL CHEM, V262, P17144; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BACHINGER HP, 1989, CYTOSKELETAL EXTRACE, P171; BOEDTKER H, 1956, J AM CHEM SOC, V78, P4267, DOI 10.1021/ja01598a024; BRUCKNER P, 1984, EUR J BIOCHEM, V140, P397, DOI 10.1111/j.1432-1033.1984.tb08115.x; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BRUCKNER P, 1984, EUR J BIOCHEM, V140, P391, DOI 10.1111/j.1432-1033.1984.tb08114.x; BRUCKNER P, 1978, EUR J BIOCHEM, V90, P595, DOI 10.1111/j.1432-1033.1978.tb12640.x; BYERS PH, 1974, BIOCHEMISTRY-US, V13, P5243, DOI 10.1021/bi00722a030; COMPTON LA, 1992, EUR J BIOCHEM, V206, P927, DOI 10.1111/j.1432-1033.1992.tb17002.x; DANIELSEN CC, 1982, BIOCHEM J, V203, P323, DOI 10.1042/bj2030323; DANIELSEN CC, 1987, BIOCHEM J, V247, P725, DOI 10.1042/bj2470725; FESSLER LI, 1981, J BIOL CHEM, V256, P9646; GERMANN HP, 1988, BIOPOLYMERS, V27, P157, DOI 10.1002/bip.360270112; GLANVILLE RW, 1982, IMMUNOCHEMISTRY EXTR, V1, P43; HILL TL, 1960, STATISTICAL THERMODY, P235; Ising E, 1925, Z PHYS, V31, P253, DOI 10.1007/BF02980577; KUHN K, 1987, STRUCTURE FUNCTION C, P1; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LIN LN, 1988, BIOCHIM BIOPHYS ACTA, V956, P256, DOI 10.1016/0167-4838(88)90142-2; MATTICE WL, 1988, MACROMOLECULES, V21, P2811, DOI 10.1021/ma00187a029; MORRIS NP, 1990, J BIOL CHEM, V265, P10081; NA GC, 1986, BIOCHEMISTRY-US, V25, P958, DOI 10.1021/bi00353a003; NA GC, 1986, BIOCHEMISTRY-US, V25, P967, DOI 10.1021/bi00353a004; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; Rees D A, 1969, Adv Carbohydr Chem Biochem, V24, P267; RYHANEN L, 1983, ARCH BIOCHEM BIOPHYS, V223, P562, DOI 10.1016/0003-9861(83)90621-5; STANKOWSKI S, 1980, BIOPHYS CHEM, V12, P167, DOI 10.1016/0301-4622(80)80049-4; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; SUPERTIFURGA A, 1989, HUM GENET, V82, P104, DOI 10.1007/BF00284038; VISSING H, 1991, J BIOL CHEM, V266, P5244	33	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25965	25972						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245030				2022-12-25	WOS:A1993MK10000097
J	HAKALA, BE; WHITE, C; RECKLIES, AD				HAKALA, BE; WHITE, C; RECKLIES, AD			HUMAN CARTILAGE GP-39, A MAJOR SECRETORY PRODUCT OF ARTICULAR CHONDROCYTES AND SYNOVIAL-CELLS, IS A MAMMALIAN MEMBER OF A CHITINASE PROTEIN FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE CLEAVAGE SITES; BABOON PAPIO-ANUBIS; NONLACTATING PERIOD; EXPRESSION; SIGNAL; ACID; INHIBITORS; INVITRO; CLONING; DNA	One of the major secreted proteins of human articular chondrocytes in monolayer or explant culture and of synovial fibroblasts is a glycoprotein with an apparent molecular weight of approximately 39,000, referred to as human cartilage glycoprotein-39 (HC gp-39). The protein was purified, and its complete cDNA sequence was determined. It contained an open reading frame coding for a 383-amino acid long peptide. Comparison of the deduced amino acid sequence with known sequences revealed that HC gp-39 contained regions displaying significant homology with a group of bacterial and fungal chitinases and a similar enzyme found in the nematode, Brugia malayi. In addition significant homologies were observed with three mammalian secretory proteins of as yet unknown function, suggesting that a related protein family exists in mammals. The human protein does not possess any glycosidic activity against chitinase substrates, arguing against any function as an endoglycosidase with specificity for N-acetylglucosamine. Analysis by Northern blotting and by reverse transcription/polymerase chain reaction showed mRNA for HC gp-39 to be present in human articular chondrocytes as well is in liver, while mRNA was undetectable in muscle tissues, lung, pancreas, mononuclear cells, or fibroblasts. Neither the protein nor mRNA for HC gp-39 was detectable in normal newborn or adult human articular cartilage obtained at surgery, while mRNA for HC gp-39 was detectable both in synovial specimens and in cartilage obtained from patients with rheumatoid arthritis. These observations suggest that the expression of HC gp-39 may be related to a response of these cells to an altered tissue environment.	SHRINERS HOSP CRIPPLED CHILDREN,JOINT DIS LAB,1529 CEDAR AVE,MONTREAL H3G 1A6,PQ,CANADA; MCGILL UNIV,DEPT SURG,MONTREAL H3G 1Y6,QUEBEC,CANADA; WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110	McGill University; McGill University; Washington University (WUSTL)								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BENYA PD, 1988, PATHOL IMMUNOPATH R, V7, P51, DOI 10.1159/000157093; BULAWA CE, 1992, MOL CELL BIOL, V12, P1764, DOI 10.1128/MCB.12.4.1764; BUTLER AR, 1991, EUR J BIOCHEM, V199, P483, DOI 10.1111/j.1432-1033.1991.tb16147.x; CHARBONNEAU H, 1989, PRACTICAL GUIDE PROT, P17; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DONNELLY KM, 1991, MOL ENDOCRINOL, V5, P356, DOI 10.1210/mend-5-3-356; FISHER KJ, 1989, J BIOL CHEM, V3, P523; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; FUHRMAN JA, 1992, P NATL ACAD SCI USA, V89, P1548, DOI 10.1073/pnas.89.5.1548; GOLDRING MB, 1988, J CLIN INVEST, V82, P2026, DOI 10.1172/JCI113823; HAKALA BE, 1991, T ORTHOP RES SOC, V16, P310; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; JOHANSEN JS, 1992, J BONE MINER RES, V7, P501; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LONG SR, 1989, CELL, V56, P203, DOI 10.1016/0092-8674(89)90893-3; MANKIN HJ, 1971, J BONE JOINT SURG AM, VA 53, P523, DOI 10.2106/00004623-197153030-00009; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCONNELL M, 1987, J CELL BIOL, V105, P1087, DOI 10.1083/jcb.105.3.1087; MEYER K, 1971, ENZYMES, V2, P307; MIDDLETON JFS, 1992, ANN RHEUM DIS, V51, P440, DOI 10.1136/ard.51.4.440; NYIRKOS P, 1990, BIOCHEM J, V269, P265, DOI 10.1042/bj2690265; RECKLIES AD, 1992, ARTHRITIS RHEUM, V35, P1510, DOI 10.1002/art.1780351215; REJMAN JJ, 1988, BIOCHEM BIOPH RES CO, V150, P329, DOI 10.1016/0006-291X(88)90524-4; ROBBINS PW, 1988, J BIOL CHEM, V263, P443; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; THOMPSON RC, 1979, J BONE JOINT SURG AM, V61, P407, DOI 10.2106/00004623-197961030-00017; TYLER JA, 1985, BIOCHEM J, V227, P869, DOI 10.1042/bj2270869; VERHAGE HG, 1989, ENDOCRINOLOGY, V124, P2464, DOI 10.1210/endo-124-5-2464; VILLIGER PM, 1992, J CLIN INVEST, V90, P488, DOI 10.1172/JCI115885; VILLIGER PM, 1992, J CELL PHYSIOL, V151, P318, DOI 10.1002/jcp.1041510213; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	38	530	576	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25803	25810						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245017				2022-12-25	WOS:A1993MK10000077
J	TARLE, I; BORHANI, DW; WILSON, DK; QUIOCHO, FA; PETRASH, JM				TARLE, I; BORHANI, DW; WILSON, DK; QUIOCHO, FA; PETRASH, JM			PROBING THE ACTIVE-SITE OF HUMAN ALDOSE REDUCTASE - SITE-DIRECTED MUTAGENESIS OF ASP-43, TYR-48, LYS-77, AND HIS-110	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDEHYDE REDUCTASE; DIABETIC COMPLICATIONS; KINETIC MECHANISM; CRYSTAL-STRUCTURE; HYDRIDE TRANSFER; DEHYDROGENASE; CLONING; BINDING; MUSCLE; PURIFICATION	Structural models of human aldose reductase complexed with NADPH have revealed the apposition of C4 of the nicotinamide ring with tyrosine 48 and histidine 110, suggesting that either of these residues could function as the proton donor in the reaction mechanism. Tyrosine 48 is also part of a hydrogen-bonding network that includes lysine 77 and aspartate 43. In order to study the potential catalytic roles of these 4 residues, we evaluated the kinetic properties of mutants containing structurally conservative replacements at these sites. Enzymatic activity was undetectable when Tyr-48 was mutated to phenylalanine (Y48F) although affinity for NADPH was unchanged. In contrast, a mutant containing asparagine substituted for His-110 (H110N) was characterized by an almost 80,000-fold increase in K(m), but only about a 14-fold reduction in k(cat) measured with D-glyceraldehyde. Modest changes in catalytic properties were observed in the mutant containing aspartate 43 substituted with asparagine (D43N): K(m) for aldehyde substrates was elevated up to 17-fold, and k(cat) decreased less than 16-fold. However, the K(d(NADP)) values for D43N were about 5 times higher than those for wild type. Mutant enzyme containing methionine substituted for lysine 77 (K77M) was up to 1,460-fold less active than the wild type. These results are consistent with Tyr-48 acting as the acid-base catalyst in human aldose reductase and confirm the importance of Asp-43, Lys-77, and His-110 to the structure and function of the active site.	WASHINGTON UNIV,SCH MED,DEPT OPHTHALMOL & VISUAL SCI,660 S EUCLID AVE,CAMPUS BOX 8096,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; BIOCRYST PHARMACEUT INC,BIRMINGHAM,AL 35244; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030	Washington University (WUSTL); Washington University (WUSTL); Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine				Borhani, David/0000-0002-8486-8792	NEI NIH HHS [5T32 EY07108, EY05856] Funding Source: Medline; NIDDK NIH HHS [P60 DK20579] Funding Source: Medline; NATIONAL EYE INSTITUTE [R55EY005856, R23EY005856, R01EY005856, T32EY007108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMARSSON O, 1993, J AM CHEM SOC, V115, P2125, DOI 10.1021/ja00059a005; ALMARSSON O, 1992, J AM CHEM SOC, V114, P8702, DOI 10.1021/ja00048a055; ASKONAS LJ, 1991, BIOCHEM J, V278, P835, DOI 10.1042/bj2780835; BHATNAGAR A, 1988, ARCH BIOCHEM BIOPHYS, V261, P264, DOI 10.1016/0003-9861(88)90341-4; BOHREN KM, 1987, BIOCHIM BIOPHYS ACTA, V916, P185, DOI 10.1016/0167-4838(87)90107-5; BORHANI DW, 1992, J BIOL CHEM, V267, P24841; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNE CM, 1985, J AM CHEM SOC, V107, P2703, DOI 10.1021/ja00295a024; BURGI HB, 1973, J AM CHEM SOC, V95, P5065, DOI 10.1021/ja00796a058; Cleland W W, 1979, Methods Enzymol, V63, P103; CROMLISH JA, 1983, J BIOL CHEM, V258, P3416; DAS B, 1985, DIABETES, V34, P1145, DOI 10.2337/diabetes.34.11.1145; DAVIDSON WS, 1979, BIOCHEM J, V177, P595, DOI 10.1042/bj1770595; DEJONGH KS, 1987, BIOCHEM J, V242, P143, DOI 10.1042/bj2420143; FELDMAN HB, 1977, BIOCHIM BIOPHYS ACTA, V480, P14, DOI 10.1016/0005-2744(77)90316-3; FERSHT A, 1985, ENZYME STRUCTURE MEC, P190; FLYNN TG, 1986, METABOLISM, V35, P105, DOI 10.1016/0026-0495(86)90197-6; FUJII Y, 1990, J BIOL CHEM, V265, P9914; GRIMSHAW CE, 1990, BIOCHEMISTRY-US, V29, P9947, DOI 10.1021/bi00494a027; HAYMAN S, 1965, J BIOL CHEM, V240, P877; KADOR PF, 1988, MED RES REV, V8, P325, DOI 10.1002/med.2610080302; KINOSHITA JH, 1988, DIABETES METAB REV, V4, P323, DOI 10.1002/dmr.5610040403; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBISESKI TJ, 1992, J BIOL CHEM, V267, P6510; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU S, 1989, ARCH BIOCHEM BIOPHYS, V275, P112, DOI 10.1016/0003-9861(89)90355-X; LIU SQ, 1992, BIOCHEM PHARMACOL, V44, P2427, DOI 10.1016/0006-2952(92)90693-D; MIZOGUCHI T, 1990, ENZYMOLOGY MOL BIOL, P205; MORJANA NA, 1989, J BIOL CHEM, V264, P2912; NISHIMURA C, 1990, J BIOL CHEM, V265, P9788; OEFNER C, 1990, NATURE, V343, P284, DOI 10.1038/343284a0; OLINS PO, 1990, METHOD ENZYMOL, V185, P115; PAULING L, 1948, NATURE, V161, P707, DOI 10.1038/161707a0; PAWLOWSKI JE, 1991, J BIOL CHEM, V266, P8820; PETRASH JM, 1992, J BIOL CHEM, V267, P24833; PETRASH JM, 1991, ELECTROPHORESIS, V12, P84, DOI 10.1002/elps.1150120116; Riordan J F, 1972, Methods Enzymol, V25, P515, DOI 10.1016/S0076-6879(72)25048-0; RONDEAU JM, 1992, NATURE, V355, P469, DOI 10.1038/355469a0; Sarges R, 1993, Prog Drug Res, V40, P99; TAPIA O, 1988, J AM CHEM SOC, V110, P4046, DOI 10.1021/ja00220a058; TILTON RG, 1989, DIABETES, V38, P1258, DOI 10.2337/diabetes.38.10.1258; VANDERJAGT DL, 1990, J BIOL CHEM, V265, P10912; VANDERJAGT DL, 1992, J BIOL CHEM, V267, P4364; WALTON DJ, 1972, BIOCHEMISTRY-US, V12, P3472; WARREN JC, 1993, BIOCHEMISTRY-US, V32, P1401, DOI 10.1021/bi00057a003; WATANABE K, 1988, P NATL ACAD SCI USA, V85, P11, DOI 10.1073/pnas.85.1.11; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; WINTERS CJ, 1990, BIOCHEMISTRY-US, V29, P1080, DOI 10.1021/bi00456a034; WU YD, 1991, J AM CHEM SOC, V113, P2353, DOI 10.1021/ja00007a002; WU YD, 1987, J AM CHEM SOC, V109, P2226, DOI 10.1021/ja00241a074; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	52	116	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25687	25693						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245005				2022-12-25	WOS:A1993MK10000060
J	DEGROOT, RP; DELMAS, V; SASSONECORSI, P				DEGROOT, RP; DELMAS, V; SASSONECORSI, P			DNA BENDING BY TRANSCRIPTION FACTORS CREM AND CREB	ONCOGENE			English	Article							CYCLIC-AMP; BINDING-PROTEINS; GENE-TRANSCRIPTION; SOMATOSTATIN GENE; C-FOS; ELEMENT; ACTIVATION; SITE; PROMOTER; IDENTIFICATION	DNA bending is postulated to be a major determinant of gene expression and has been shown to be specifically induced by some regulatory proteins with DNA-binding properties. Here we show that nuclear factors which naturally bind to CREs (cAMP-responsive elements) are able to induce bending in the sequences flanking this recognition site. In our assays we used a permutated binding site/gel retardation assay and bacterially generated nuclear factors. We have been studying the cAMP-responsive-element modulator (CREM) gene, which encodes both repressors (CREM alpha, beta and gamma) and an activator (CREM tau) of cAMP-responsive transcription by alternative splicing. Tn addition, two alternative DNA-binding domains can be encoded in different CREM isoforms. No differences in induction of DNA bending by the CREM proteins with the two DNA binding domains were detected. The activator CREB induced DNA bending in a fashion similar to CREM. Importantly, we show that phosphorylation of CREM or CREB alters their mobilities in a regular gel shift assay as well as enhances the angle of DNA bending induced by these proteins.	INST CHIM BIOL,FAC MED,GENET MOLEC EUCARYOTES LAB,CNRS,INSERM,U184,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Delmas, veronique/0000-0001-7368-3664				ANDRISANI OM, 1987, NUCLEIC ACIDS RES, V15, P5715, DOI 10.1093/nar/15.14.5715; BORRELLI E, 1992, Critical Reviews in Oncogenesis, V3, P321; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1991, P NATL ACAD SCI USA, V88, P5448, DOI 10.1073/pnas.88.12.5448; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAGERMAN PJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P125, DOI 10.1016/0167-4781(92)90066-9; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MELLSTROM B, 1993, NEURON, V10, P655, DOI 10.1016/0896-6273(93)90167-P; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NARDULLI AM, 1992, MOL CELL BIOL, V12, P2037, DOI 10.1128/MCB.12.5.2037; PRENTKI P, 1987, EMBO J, V6, P2479, DOI 10.1002/j.1460-2075.1987.tb02529.x; ROJO F, 1990, J MOL BIOL, V211, P713, DOI 10.1016/0022-2836(90)90072-T; SALVO JJ, 1988, EMBO J, V7, P3609, DOI 10.1002/j.1460-2075.1988.tb03239.x; SASSONECORSI P, 1986, TRENDS GENET, V2, P215, DOI 10.1016/0168-9525(86)90233-7; SASSONECORSI P, 1988, P NATL ACAD SCI USA, V85, P7192, DOI 10.1073/pnas.85.19.7192; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SCHROTH GP, 1989, NATURE, V340, P487, DOI 10.1038/340487a0; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZAHN K, 1985, EMBO J, V4, P3605, DOI 10.1002/j.1460-2075.1985.tb04124.x; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	47	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					463	468						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290258				2022-12-25	WOS:A1994MW24800013
J	SANTORO, M; DATHAN, NA; BERLINGIERI, MT; BONGARZONE, I; PAULIN, C; GRIECO, M; PIEROTTI, MA; VECCHIO, G; FUSCO, A				SANTORO, M; DATHAN, NA; BERLINGIERI, MT; BONGARZONE, I; PAULIN, C; GRIECO, M; PIEROTTI, MA; VECCHIO, G; FUSCO, A			MOLECULAR CHARACTERIZATION OF RET/PTC3 - A NOVEL REARRANGED VERSION OF THE RET PROTOONCOGENE IN A HUMAN THYROID PAPILLARY CARCINOMA	ONCOGENE			English	Article							RET PROTO-ONCOGENE; TRANSFORMING GENE; TYROSINE KINASE; MESSENGER-RNAS; II ONCOGENE; ACTIVATION; PROTOONCOGENE; PRODUCT; PTC; IDENTIFICATION	The RET proto-oncogene encodes a transmembrane receptor of the tyrosine kinase family and has frequently been found activated in human thyroid carcinomas of the papillary subtype. In most cases the activation consisted of the fusion of its tyrosine-kinase domain with the 5'-terminal region of a gene designated H4 or D10S170. We have named the resulting H4/RET chimeric oncogene RET/PTC. Another activated form of the RET oncogene has subsequently been found in a thyroid carcinoma and is now referred to as RET/PTC2. Here we report the identification and cloning of a novel rearranged version of the RET oncogene in a human thyroid papillary carcinoma. In this case the tyrosine-kinase domain of RET was fused to a sequence 790 bp long belonging to a new gene that we have named RFG (RET I;used Gene). This novel chimeric oncogene has been designated RET/PTC3. In order to have more insights into the function of RI;G we have completely cloned and sequenced its cDNA. RFG predicted amino-acid sequence does not have any significant homology to any already known genes and is ubiquitously expressed in human and mouse tissues. Finally we provide evidence indicating that the rearrangement leading to the generation of RET/PTC3 occurred in vivo in the original tumor DNA.	UNIV NAPOLI,FAC MED & CHIRURG,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,I-80131 NAPLES,ITALY; IST NAZL TUMORI,DIV ONCOL SPERIMENTALE A,I-20133 MILAN,ITALY; CTR HOSP LYON SUD,HISTOL & CYTOL LAB,F-69310 PIERRE BENITE,FRANCE; FAC MED LYON SUD,CNRS,URA 1454,F-69600 OULLINS,FRANCE; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CANTANZARO,ITALY	University of Naples Federico II; Fondazione IRCCS Istituto Nazionale Tumori Milan; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Universita Mediterranea di Reggio Calabria	SANTORO, M (corresponding author), CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,VIA S PANSINI 5,I-80131 NAPLES,ITALY.		Bongarzone, Italia/B-9544-2017	Bongarzone, Italia/0000-0003-2530-9170; Grieco, Michele/0000-0002-4212-7814; Pierotti, Marco Alessandro/0000-0002-7431-8332; Fusco, Alfredo/0000-0003-3332-5197				ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; BONGARZONE I, 1989, ONCOGENE, V4, P1457; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FABIEN N, 1992, BRIT J CANCER, V66, P1094, DOI 10.1038/bjc.1992.416; FUSCO A, 1987, NATURE, V328, P7072; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; IKEDA I, 1990, ONCOGENE, V5, P1291; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; JHIANG SM, 1992, ONCOGENE, V7, P1331; KODA T, 1988, Hokkaido Journal of Medical Science, V63, P913; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANZI C, 1992, ONCOGENE, V7, P2189; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; OU JH, 1984, P NATL ACAD SCI USA, V82, P83; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1993, BRIT J CANCER, V68, pH60; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; WAJJWALKU W, 1992, JPN J CANCER RES, V83, P671, DOI 10.1111/j.1349-7006.1992.tb01963.x; [No title captured]	32	289	299	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					509	516						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290261				2022-12-25	WOS:A1994MW24800018
J	XU, NZ; MCCORMICK, F; GUTKIND, JS				XU, NZ; MCCORMICK, F; GUTKIND, JS			THE NONCATALYTIC DOMAIN OF RAS-GAP INHIBITS TRANSFORMATION-INDUCED BY G-PROTEIN COUPLED RECEPTORS	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; TYROSINE PHOSPHORYLATION; OVEREXPRESSION; CELLS; DNA	We have studied the relationship between vas-GAP and G protein coupled receptors in a proliferative setting comprised of NIH3T3 expressing transfected muscarinic receptors (mAChRs). GAP expression plasmids were engineered to encode wild-type GAP, its carboxyl-terminal catalytic domain, a mutant lacking a portion of the catalytic domain, and an amino-terminal domain which contained the hydrophobic region as well as SH2-SH3 domains. Cotransfection of each GAP expression plasmid into NIH3T3 cells did not affect the transforming ability of the v-mos oncogene, but plasmids encoding wild-type GAP or the mutant consisting of an intact catalytic domain inhibited transformation induced by normal c-ras. Wild-type GAP also prevented transformation by mi mAChRs, whereas the mutant consisting of only its catalytic domain lacked any demonstrable effect. In contrast, the N-terminal non-catalytic domain of GAP effectively prevented m1-induced focus-formation. Cell lines coexpressing m1 receptors and each of the GAP constructs revealed that GAP proteins do not affect mi receptor density, receptor ligand binding characteristics or coupling to the PI-PLC signal transduction pathway. Thus, our findings suggest a role for the N-terminal non-catalytic domain of GAP in regulating biological functions mediated by G protein-coupled receptors.	NIDR,CELLULAR DEV & ONCOL LAB,MOLEC SIGNALING UNIT,BETHESDA,MD 20892; ONYX PHARMACEUT,RICHMOND,CA 94806	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BLAIR DG, 1980, P NATL ACAD SCI-BIOL, V77, P3504, DOI 10.1073/pnas.77.6.3504; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUIDEON P, 1992, MOL CELL BIOL, V12, P2050; GUTKIND JS, 1992, BIOCHEM BIOPH RES CO, V188, P155; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	23	16	16	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					597	601						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290270				2022-12-25	WOS:A1994MW24800027
J	DOU, QP; ZHAO, SC; LEVIN, AH; WANG, J; HELIN, K; PARDEE, AB				DOU, QP; ZHAO, SC; LEVIN, AH; WANG, J; HELIN, K; PARDEE, AB			G1/S-REGULATED E2F-CONTAINING PROTEIN COMPLEXES BIND TO THE MOUSE THYMIDINE KINASE GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR E2F; CELL-CYCLE REGULATION; RETINOBLASTOMA PROTEIN; LABILE PROTEIN; DNA-BINDING; PRODUCT; EXPRESSION; GROWTH; PHASE; SITE	By performing DNase I footprint analysis, we had identified three distinct protein binding sequences (MT1, MT2, and MT3) located on the mouse thymidine kinase (TK) upstream promoter (Dou, Q.-P., Fridovich-Keil, J. L., and Pardee, A. B. (1991) Proc. Natl. Acad. Sci. U. S. A. 88,1157-1161). Here we report that MT2 includes an E2F-like binding site (GTTCGCGGGCAAA), as shown by the following evidence. (i) Mt2 bound specifically to an affinity-purified fusion human E2F protein. (ii) Both MT2 and an authentic E2F site (TTTCGCGCGCTTT) bound specifically to similar or identical nuclear protein complexes. (iii) Formation of both these DNA-protein complexes were cell cycle-dependent: a G0/G1 phase-specific complex (E2F.G0/G1) was replaced by an S phase-specific complex(es) (E2F.S), whereas ''free'' E2F increased after the G1/S transition. (iv) Pulse inhibition of protein synthesis with cycloheximide interchanged these complexes with similar kinetics. (v) When MT2-shifted E2F.G0/Gl, E2F.S, and free E2F were eluted and analyzed by Western blot assay using a specific antiserum to human E2F-1, two forms of murine E2F (62 and 66 kDa) were observed from all three complexes. The compositions of these MT2-bound complexes were also investigated. Studies using specific antibodies revealed that p107, a retinoblastoma-like protein, was present in both E2F.G0/G1 and E2F.S, whereas cyclin E.cyclin A.cdk2 were only present in E2F.S complex(es). These data suggest that removal of the p107-containing E2F.G0/Gl complex, a candidate repressor, from the MT2 site in late G1 may be essential for S phase-dependent transcription of the mouse TK gene.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELL GROWTH & REGULAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, CTR CANC, BOSTON, MA 02129 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital			Helin, Kristian/HDM-8306-2022; Helin, Kristian/K-2526-2019	Helin, Kristian/0000-0003-1975-6097; Dou, Qingping/0000-0002-6465-1473	NATIONAL CANCER INSTITUTE [P01CA022427] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024571] Funding Source: NIH RePORTER; NCI NIH HHS [CA22427] Funding Source: Medline; NCRR NIH HHS [2 S07RR05526-28] Funding Source: Medline; NIGMS NIH HHS [GM24571] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BASERGA R, 1985, BIOL CELL REPRODUCTI, P134; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BRADLEY DW, 1990, P NATL ACAD SCI USA, V87, P9310, DOI 10.1073/pnas.87.23.9310; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAMPISI J, 1982, P NATL ACAD SCI-BIOL, V79, P436, DOI 10.1073/pnas.79.2.436; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COPPOCK DL, 1985, J CELL PHYSIOL, V124, P269, DOI 10.1002/jcp.1041240215; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOI QP, 1992, P NATL ACAD SCI USA, V89, P3256; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; DOU QP, 1993, CANCER RES, V53, P1493; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; FRIDOVICHKEIL JL, 1993, CELL GROWTH DIFFER, V4, P679; FRIDOVICHKEIL JL, 1991, CELL GROWTH DIFFER, V2, P67; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIM YK, 1992, J BIOL CHEM, V267, P2723; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MOSCOVITIS G, 1980, ANAL BIOCHEM, V101, P221, DOI 10.1016/0003-2697(80)90064-0; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEVINS JR, 1992, SCIENCE, V258, P424; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; WADE M, 1992, MOL CELL BIOL, V12, P4364, DOI 10.1128/MCB.12.10.4364; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	49	94	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1306	1313						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288595				2022-12-25	WOS:A1994MR22000085
J	HAMA, H; WILSON, TH				HAMA, H; WILSON, TH			REPLACEMENT OF ALANINE-58 BY ASPARAGINE ENABLES THE MELIBIOSE CARRIER OF KLEBSIELLA-PNEUMONIAE TO COUPLE SUGAR-TRANSPORT TO NA+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CATION SPECIFICITY; COTRANSPORT; SYSTEM; SITE; GENE	The melibiose carrier of Klebsiella pneumoniae couples sugar transport to H+ and Li+, while that of Escherichia coli uses Na+ besides the other two cation species (Hama and Wilson, 1992). We have shown that the K. pneumoniae melibiose carrier is capable of recognizing Na+ when the amino-terminal 81 residues are replaced by the corresponding region of the E. coli melibiose carrier (Hama and Wilson, 1993). In this amino-terminal region there are 5 residues that are not conserved between the two carriers. In this study, we changed each of the 5 residues of the K. pneumoniae carrier to the one in the E. coli carrier. The substitutions are Ile-36 --> Val, Val-43 --> Leu, Leu-54 --> Trp, Ala-58 --> Asn, and Cys-68 --> Ala. With four of the five mutants, Ile-36 --> Val, Val-43 --> Leu, Leu-54 --> Trp, and Cys-68 --> Ala, sugar accumulation was not affected by Na+. In striking contrast, melibiose and methyl-1-thio-beta-D-galactopyranoside accumulation was greatly stimulated by Na+ with the Ala-58 --> Asn, mutant. Furthermore, Na+ uptake coupled to downhill melibiose transport was observed with the Ala-58 --> Asn mutant. These results indicate that the Ala-58 --> Asn substitution enables the K. pneumoniae melibiose carrier to couple sugar transport to Na+. It is clear that the Asn-58 residue (Asn-54 in the E. coli carrier) is involved in Na+ recognition.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NIDDK NIH HHS [DK05736] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK005736, R01DK005736] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOTFIELD MC, 1988, J BIOL CHEM, V263, P12909; BOTFIELD MC, 1992, J BIOL CHEM, V267, P1818; DEVRIJ W, 1989, J BACTERIOL, V171, P1118, DOI 10.1128/jb.171.2.1118-1125.1989; DIMROTH P, 1987, MICROBIOL REV, V51, P320, DOI 10.1128/MMBR.51.3.320-340.1987; HAMA H, 1993, J BIOL CHEM, V268, P10060; HAMA H, 1992, J BIOL CHEM, V267, P18371; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAMATA H, 1992, J BIOL CHEM, V267, P21650; KAWAKAMI T, 1988, J BIOL CHEM, V263, P14276; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; POURCHER T, 1991, BIOCHEM BIOPH RES CO, V178, P1176, DOI 10.1016/0006-291X(91)91016-6; POURCHER T, 1993, J BIOL CHEM, V268, P3209; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TSUCHIYA T, 1985, ANN NY ACAD SCI, V456, P342, DOI 10.1111/j.1749-6632.1985.tb14884.x; TSUCHIYA T, 1978, MEMBRANE BIOCHEM, V2, P63, DOI 10.3109/09687687809063858; WILSON DM, 1992, J BACTERIOL, V174, P3083, DOI 10.1128/JB.174.9.3083-3086.1992; WILSON DM, 1987, BIOCHIM BIOPHYS ACTA, V904, P191, DOI 10.1016/0005-2736(87)90368-3; YAZYU H, 1984, J BIOL CHEM, V259, P4320; YAZYU H, 1985, J BACTERIOL, V162, P933, DOI 10.1128/JB.162.3.933-937.1985	21	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1063	1067						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288562				2022-12-25	WOS:A1994MR22000047
J	MATTHEWS, G; SHENNAN, KIJ; SEAL, AJ; TAYLOR, NA; COLMAN, A; DOCHERTY, K				MATTHEWS, G; SHENNAN, KIJ; SEAL, AJ; TAYLOR, NA; COLMAN, A; DOCHERTY, K			AUTOCATALYTIC MATURATION OF THE PROHORMONE CONVERTASE PC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; CONSTITUTIVE SECRETORY PATHWAY; MICROINJECTED XENOPUS OOCYTES; ESCHERICHIA-COLI; KEX2 PROTEASE; PRO-REGION; PROCESSING ENDOPROTEASES; PRECURSOR CLEAVAGE; SUBTILISIN-E; SEQUENCE	PC2 is a member of the eukaryotic family of subtilisin-like proteases, which is thought to participate in the processing of prohormones and proneuropeptides in neuroendocrine cells. PC2 is synthesized as a 69-kDa prepropolypeptide. The NH2-terminal signal sequence is removed during segregation within the endoplasmic reticulum, where glycosylation occurs to generate a 75-kDa propolypeptide. A combination of site-directed mutagenesis and a cell-free translation/translocation system from Xenopus eggs was used to investigate the processing of the pro-PC2 precursor. The 75-kDa polypeptide underwent slow cleavage after the sequence Arg-Lys-Lys-Arg84 to generate a 68-kDa mature enzyme. Cleavage was blocked when the tetrahasic sequence was deleted (PC2M3) or when the active site Asp142 Was changed to Asn (PC2M4). This latter observation suggested that cleavage of the 75-kDa propolypeptide to the mature 68-kDa enzyme was autocatalytic. Incubation of the PC2M4 mutant with the wild type PC2 precursor resulted in cleavage of both the wild type polypeptide and the catalytically inactive PC2M4 mutant. This indicates that cleavage could occur through an intermolecular reaction. The results also demonstrate that the novel Xenopus egg extract translation/translocation system represents a powerful cell-free method for studying proteolytic processing of propolypeptides.	UNIV BIRMINGHAM,SCH BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham			Seal, Andrew/C-8550-2014	Seal, Andrew/0000-0003-3656-4054; Docherty, Kevin/0000-0001-6765-2060	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAIYLES EM, 1992, BIOCHEM J, V285, P391; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BIRCH NP, 1991, BIOCHEM BIOPH RES CO, V179, P1311, DOI 10.1016/0006-291X(91)91716-P; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CARTER P, 1987, SCIENCE, V237, P394, DOI 10.1126/science.3299704; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; FABRE E, 1991, J BIOL CHEM, V266, P3782; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GERMAIN D, 1992, FEBS LETT, V299, P283, DOI 10.1016/0014-5793(92)80132-Z; GUEST PC, 1992, J BIOL CHEM, V267, P22401; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; MATTHEWS G, 1991, NUCLEIC ACIDS RES, V19, P6405, DOI 10.1093/nar/19.23.6405; MIZUNO K, 1989, BIOCHEM BIOPH RES CO, V159, P305, DOI 10.1016/0006-291X(89)92438-8; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; NEBES VL, 1991, J BIOL CHEM, V266, P22851; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V89, P8235, DOI 10.1073/pnas.89.17.8235; RHODES CJ, 1992, J BIOL CHEM, V267, P22719; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1991, J BIOL CHEM, V266, P24011; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STEINER D F, 1991, Current Biology, V1, P375, DOI 10.1016/0960-9822(91)90198-6; STEINER DF, 1992, J BIOL CHEM, V267, P23435; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; WATANABE T, 1992, J BIOL CHEM, V267, P8270; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; WONG SL, 1984, P NATL ACAD SCI-BIOL, V81, P1184, DOI 10.1073/pnas.81.4.1184; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	47	75	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					588	592						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276855				2022-12-25	WOS:A1994MR21900093
J	DAWSON, GW; HICK, AJ; BENNETT, RN; DONALD, A; PICKETT, JA; WALLSGROVE, RM				DAWSON, GW; HICK, AJ; BENNETT, RN; DONALD, A; PICKETT, JA; WALLSGROVE, RM			SYNTHESIS OF GLUCOSINOLATE PRECURSORS AND INVESTIGATIONS INTO THE BIOSYNTHESIS OF PHENYLALKYLGLUCOSINOCATES AND METHYLTHIOALKYLGLUCOSINOLATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BICOLOR L MOENCH; BRASSICA-CARINATA; METABOLITES; DHURRIN; PLANTS; NAPUS	The alkenyl and aromatic glucosinolates in oilseed rape (Brassica napus) are biosynthesized from chain-extended homologues of protein amino acids, including methionine and phenylalanine. Homologues of these two amino acids, homophenylalanine (2-amino-4-phenylbutyric acid) and dihomomethionine (2-amino-6-methylthiohexanoic acid) were synthesized both with and without a 1-C-14 label. Microsomal preparations from oilseed rape leaves were shown to contain enzyme systems which metabolize these compounds, with loss of (CO2)-C-14, and produce the aldoxime intermediates possible in the biosynthetic pathway utilizing homophenylalanine. These were characterized by comparison with authenticated synthetic compounds. Potential intermediates on the pathway between homophenylalanine and its corresponding aldoxime, the N-hydroxyamino- and the oximino acids, were synthesized and their possible role in the pathway investigated.	AFRC, INST ARABLE CROPS RES, ROTHAMSTED EXPTL STN, HARPENDEN AL5 2JQ, HERTS, ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research								AHMAD A, 1974, B CHEM SOC JPN, V47, P1819, DOI 10.1246/bcsj.47.1819; BALLINI R, 1992, TETRAHEDRON LETT, V33, P4835, DOI 10.1016/S0040-4039(00)61298-4; Blight M.M., 1989, Aspects of Applied Biology, V23, P329; BLIGHT MM, 1992, 8TH P INT S INS PLAN, P105; CHAPPLE CCS, 1988, PHYTOCHEMISTRY, V27, P3461, DOI 10.1016/0031-9422(88)80748-9; CHAPPLE CCS, 1990, PLANT PHYSIOL, V94, P1887, DOI 10.1104/pp.94.4.1887; DAWSON GW, 1989, PESTIC SCI, V27, P191, DOI 10.1002/ps.2780270209; ELLIOTT M, 1988, PESTIC SCI, V22, P231, DOI 10.1002/ps.2780220305; ETTLINGER MG, 1961, P NATL ACAD SCI USA, V47, P1875, DOI 10.1073/pnas.47.12.1875; ETTLINGER MG, 1956, J AM CHEM SOC, V78, P4172, DOI 10.1021/ja01597a090; FENWICK GR, 1983, CRC CR REV FOOD SCI, V18, P123, DOI 10.1080/10408398209527361; GLOVER JR, 1988, PHYTOCHEMISTRY, V27, P1345, DOI 10.1016/0031-9422(88)80190-0; HALKIER BA, 1991, P NATL ACAD SCI USA, V88, P487, DOI 10.1073/pnas.88.2.487; HALKIER BA, 1991, PLANT PHYSIOL, V96, P10, DOI 10.1104/pp.96.1.10; Hallahan D. L., 1992, Plant genetic manipulation for crop protection., P215; HARBORNE JB, 1991, PLANT DEFENSES MAMMA, P45; HAUGHN GW, 1991, PLANT PHYSIOL, V97, P217, DOI 10.1104/pp.97.1.217; JAIN JC, 1989, ANAL BIOCHEM, V178, P137, DOI 10.1016/0003-2697(89)90369-2; KINDL H, 1968, PHYTOCHEMISTRY, V7, P745, DOI 10.1016/S0031-9422(00)84827-X; KOCH B, 1992, ARCH BIOCHEM BIOPHYS, V292, P141, DOI 10.1016/0003-9861(92)90062-2; Larsen PO, 1981, BIOCH PLANT PRODUCTS, V7, P501; LUDWIGMULLER J, 1988, PHYSIOL PLANTARUM, V74, P240, DOI 10.1111/j.1399-3054.1988.tb00627.x; MEISTER A, 1957, METHOD ENZYMOL, V3, P404, DOI 10.1016/S0076-6879(57)03405-9; PORTER AJR, 1991, ANN APPL BIOL, V118, P461, DOI 10.1111/j.1744-7348.1991.tb05647.x; Renwick J.A.A., 1992, Chemoecology, V3, P33, DOI 10.1007/BF01261454; TRAYNIER RMM, 1991, J CHEM ECOL, V17, P1371, DOI 10.1007/BF00983770; VAUGHAN JG, 1976, BIOL CHEM CRUCIFERAE, P191	27	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27154	27159						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262954				2022-12-25	WOS:A1993MM26200048
J	DELLANO, JJM; JONES, W; SCHNEIDER, K; CHAIT, BT; MANNING, JM; RODGERS, G; BENJAMIN, LJ; WEKSLER, B				DELLANO, JJM; JONES, W; SCHNEIDER, K; CHAIT, BT; MANNING, JM; RODGERS, G; BENJAMIN, LJ; WEKSLER, B			BIOCHEMICAL AND FUNCTIONAL-PROPERTIES OF RECOMBINANT HUMAN SICKLE HEMOGLOBIN EXPRESSED IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S POLYMERIZATION; COVALENT BINDING; GLUTATHIONE; DEOXYHEMOGLOBIN	Previous studies had indicated that recombinant and natural human sickle hemoglobin had similar chemical properties (Martin de Llano, J. J., Schneewind, O., Stetler, G., and Manning, J. M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 918-922). In the present study, additional biochemical and physiological characterization of some primary through quaternary structural features of recombinant sickle hemoglobin are described. The molecular weight of the purified recombinant sickle hemoglobin was identical to natural sickle hemoglobin as determined by mass spectrometry, thus excluding extensive post-translational modification in the yeast system. Carboxypeptidases A and B together catalyzed the release of COOH-terminal amino acids at the same rate for recombinant and natural hemoglobin S, consistent with identity in their primary and secondary structures in this region of the molecule. The tryptic peptide maps of natural and recombinant hemoglobins were practically indistinguishable, indicating the same internal protein sequences for recombinant and natural hemoglobins. As a probe of the secondary structure of recombinant sickle Hb, the reactivity of the SH group of Cys-93(beta) was investigated for the glutathione sickle hemoglobin adduct, which has significant anti-gelling and anti-sickling properties. The position of glutathione at Cys-93(beta) was established by direct mass spectrometric analysis of enzyme digests; reduction of this derivative to the unmodified chains was also observed by mass spectrometry and by isoelectric focusing. The oxygen equilibrium curves of recombinant and natural sickle hemoglobin at high protein concentration were superimposable with identical Hill coefficients of 3.3. The response of recombinant sickle hemoglobin to chloride with respect to a lowered oxygen affinity was identical to that of natural sickle hemoglobin. The gelation properties of recombinant and natural sickle hemoglobins were identical at the high hemoglobin concentrations that occur in the red cell. Therefore, the yeast expression system synthesizes a completely functional recombinant sickle hemoglobin with the same biochemical and physiological properties as natural sickle hemoglobin with respect to features characteristic of its primary through quaternary structures.	ROCKEFELLER UNIV,NEW YORK,NY 10021; NIDDKD,CHEM BIOL LAB,MOLEC HEMATOL UNIT,BETHESDA,MD 20892; MONTEFIORE MED CTR,BRONX,NY 10467; CORNELL UNIV,MED CTR,COLL MED,DIV HEMATOL,NEW YORK,NY 10021	Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Cornell University			Schneider, Klaus/N-6604-2014; de Llano, José Javier Martín/K-6610-2012	Schneider, Klaus/0000-0002-3068-8681; de Llano, José Javier Martín/0000-0001-5933-9592	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL018819, R01HL018819] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00862] Funding Source: Medline; NHLBI NIH HHS [HL-18819] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1993, J BIOL CHEM, V268, P21650; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P432, DOI 10.1002/rcm.1290031207; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P233, DOI 10.1002/rcm.1290030708; BEAVIS RC, 1990, ANAL CHEM, V62, P1836, DOI 10.1021/ac00216a020; BENESCH RE, 1978, ANAL BIOCHEM, V89, P162, DOI 10.1016/0003-2697(78)90737-6; BIRCHMEIER W, 1973, BIOCHEMISTRY-US, V12, P3667, DOI 10.1021/bi00743a015; BOOKCHIN RM, 1967, J BIOL CHEM, V242, P248; CRAESCU CT, 1986, J BIOL CHEM, V261, P4710; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DELLANO JJM, 1993, P NATL ACAD SCI USA, V90, P918, DOI 10.1073/pnas.90.3.918; EDELSTEIN SJ, 1979, J MOL BIOL, V134, P851, DOI 10.1016/0022-2836(79)90491-1; GAREL MC, 1982, EUR J BIOCHEM, V123, P513; GAREL MC, 1986, J BIOL CHEM, V261, P4704; Herrick J.B., 1910, ARCH INTERN MED, V6, P517; HUISMAN THJ, 1987, J CHROMATOGR-BIOMED, V418, P277, DOI 10.1016/0378-4347(87)80012-9; INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0; Manning J M, 1981, Methods Enzymol, V76, P159; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; PERUTZ MF, 1980, J MOL BIOL, V138, P649, DOI 10.1016/S0022-2836(80)80022-2; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57; WELLEMS TE, 1979, J MOL BIOL, V135, P651, DOI 10.1016/0022-2836(79)90170-0; WILSON JB, 1990, HPLC BIOL MACROMOLEC, P457; WINTERBOURN C C, 1976, Hemoglobin, V1, P1, DOI 10.3109/03630267609031018; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2; WODAK SJ, 1986, J BIOL CHEM, V261, P4717; XSRIVASTAVA SK, 1970, BIOCHEM J, V119, P353	27	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27004	27011						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262936				2022-12-25	WOS:A1993MM26200028
J	FARINA, AR; DAVISSMYTH, T; GARDNER, K; LEVENS, D				FARINA, AR; DAVISSMYTH, T; GARDNER, K; LEVENS, D			AN EARLY RESPONSE OF AN AP1-JUND COMPLEX DURING T-CELL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; APE LEUKEMIA-VIRUS; DNA-BINDING ACTIVITY; PHORBOL ESTER; TRANSCRIPTIONAL ACTIVITY; HYBRIDIZATION PROBES; 5'-FLANKING REGION; INTERLEUKIN-2 GENE; ENHANCER ELEMENTS; MOUSE FIBROBLASTS	Activated T-cell extracts contain an activity (T-AP1) composed of at least two dissociable protein components which bind to the AP1 consensus sequence in the enhancer of the gibbon ape leukemia virus (GALV)LTR (GALV-TRE). This activity is inducible by 12-O-tetradecanoyl-phorbol-14-acetate (TPA) even in the presence of protein synthesis inhibitors. Although one component of this complex (CORE) is related immunologically and biochemically to junD, it nevertheless displays significant biochemical properties which distinguish CORE from recombinant junD. The second component of the complex, flowthrough, interacts more efficiently with CORE than with recombinant junD. GALV-TRE enhancer activity is increased within 2 h in vivo with T cells treated with TPA in the presence of protein synthesis inhibitors; this increase in enhancer activity is paralleled by the increased GALV-TRE-mediated transcriptional activity present in extracts of these cells. Purified T-cell junD activates GALV-TRE-driven RNA synthesis in vitro. The rapidity and the protein synthesis-independent nature of TPA-induced T-AP1 activation suggests that this complex is involved in the earliest stages of T-cell activation.	NCI,PATHOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Levens, David/C-9216-2009	Levens, David/0000-0002-7616-922X; FARINA, Antonietta Rosella/0000-0003-0962-6088				ALBERT F, 1985, J IMMUNOL, V134, P3649; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENBROOK DM, 1990, ONCOGENE, V5, P295; BLACKSHEAR PJ, 1987, J BIOL CHEM, V262, P7774; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GIARDINA SL, 1987, ANAL BIOCHEM, V161, P109, DOI 10.1016/0003-2697(87)90659-2; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GQUINN JP, 1989, J VIROL, V63, P4713; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOLBROOK NJ, 1987, VIROLOGY, V159, P178, DOI 10.1016/0042-6822(87)90364-3; HOLBROOK NJ, 1987, MOL CELL BIOL, V7, P2610, DOI 10.1128/MCB.7.7.2610; HSINFANG YY, 1990, NEW BIOL, V2, P351; IMBODEN JB, 1985, J IMMUNOL, V134, P663; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MACKAY AR, 1992, INVAS METAST, V12, P168; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MINORI T, 1986, J BIOL CHEM, V261, P10375; MINORI T, 1986, J BIOL CHEM, V261, P2274; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OSHEA JJ, 1986, J IMMUNOL, V137, P971; QUINN JP, 1989, MOL CELL BIOL, V9, P4713, DOI 10.1128/MCB.9.11.4713; QUINN JP, 1987, MOL CELL BIOL, V7, P2735, DOI 10.1128/MCB.7.8.2735; QUINN JP, 1991, FEBS LETT, V286, P225, DOI 10.1016/0014-5793(91)80979-D; ROSENSTREICH DL, 1979, J IMMUNOL, V123, P1749; ROSENTHA.AS, 1973, J EXP MED, V138, P1194, DOI 10.1084/jem.138.5.1194; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SASAKI T, 1987, FEBS LETT, V218, P87, DOI 10.1016/0014-5793(87)81024-4; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; TAYLOR MV, 1984, NATURE, V312, P462, DOI 10.1038/312462a0; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; VACCA A, 1992, J EXP MED, V175, P637, DOI 10.1084/jem.175.3.637; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WISKOCIL R, 1985, J IMMUNOL, V134, P1599; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	62	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26466	26475						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253775				2022-12-25	WOS:A1993MK42500069
J	KARIYA, K; FARRANCE, IKG; SIMPSON, PC				KARIYA, K; FARRANCE, IKG; SIMPSON, PC			TRANSCRIPTIONAL ENHANCER FACTOR-I IN CARDIAC MYOCYTES INTERACTS WITH AN ALPHA(1)-ADRENERGIC-PROTEIN AND BETA-PROTEIN KINASE-C-INDUCIBLE ELEMENT IN THE RAT BETA-MYOSIN HEAVY-CHAIN PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; CAT BINDING-FACTOR; DNA-BINDING; CYCLIC-AMP; SIGNAL TRANSDUCTION; NUCLEAR-PROTEIN; HEART MYOCYTES; LEUCINE ZIPPER; PHOSPHORYLATION; ACTIVATION	In cultured rat cardiac myocytes, a 20-base pair sequence (-215/-196) of the rat beta-myosin heavy chain (MHC) promoter mediates induction by both alpha1-adrenergic stimulation and a constitutively activated beta-protein kinase C (PKC), and binds cardiac myocyte nuclear factor(s) through an ''enhancer core'' element (5'-TGTGGTATG-3') (Kariya, K, Karns, L. R., and Simpson, P. C. (1994) J. Biol. Chem. 269, in press). Here, we report identification of this enhancer core binding factor as the rat homologue of transcriptional enhancer factor-1 (TEF-1), a human transcription factor for viral enhancers. In gel mobility shift and immunoblot analyses, the myocyte factor and human TEF-1 were indistinguishable in terms of sequence recognition, mobility, and immunoreactivity. Furthermore, DNA binding activity for the beta-MHC enhancer core and TEF-1 immunoreactivity correlated closely. These results are the first to suggest a role for TEF-1 in transcriptional regulation by PKC. The data also provide direct evidence for interaction of TEF-1 with the beta-MHC promoter, supporting a function for TEF-1 in regulation of cellular gene expression, as well as viral, and outline a pathway for alpha1-adrenergic regulation of beta-MHC gene transcription in cardiac myocytes.	VET AFFAIRS MED CTR, DIV CARDIOL, 4150 CLEMENT ST, SAN FRANCISCO, CA 94121 USA; VET AFFAIRS MED CTR, RES SERV, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031113] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL031113] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BLATT C, 1993, NUCLEIC ACIDS RES, V21, P747, DOI 10.1093/nar/21.3.747; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FLINK IL, 1992, J BIOL CHEM, V267, P9917; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GOODE N, 1992, J BIOL CHEM, V267, P16878; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HATA A, 1989, FEBS LETT, V252, P144, DOI 10.1016/0014-5793(89)80907-X; HATA A, 1993, J BIOL CHEM, V268, P9122; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; HORI Y, 1990, ONCOGENE, V5, P1201; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KARIYA K, 1994, IN PRESS J BIOL CHEM, V269; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MEEK DW, 1992, BIOCHEM J, V287, P1; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; ORDAHL CP, 1992, CURR TOP DEV BIOL, V26, P145, DOI 10.1016/S0070-2153(08)60444-5; PARK EA, 1993, J BIOL CHEM, V268, P613; PARKER TG, 1991, J VASC MED BIOL, V3, P38; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SASSONECORSI P, 1986, TRENDS GENET, V2, P215, DOI 10.1016/0168-9525(86)90233-7; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SIMPSON PC, 1991, MOL CELL BIOCHEM, V104, P35; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; WU JP, 1991, MOL ENDOCRINOL, V5, P1311, DOI 10.1210/mend-5-9-1311; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G	64	90	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26658	26662						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253797				2022-12-25	WOS:A1993MK42500093
J	TSUNEOKA, M; NAKAYAMA, K; HATSUZAWA, K; KOMADA, M; KITAMURA, N; MEKADA, E				TSUNEOKA, M; NAKAYAMA, K; HATSUZAWA, K; KOMADA, M; KITAMURA, N; MEKADA, E			EVIDENCE FOR INVOLVEMENT OF FURIN IN CLEAVAGE AND ACTIVATION OF DIPHTHERIA-TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE SECRETORY PATHWAY; PROCESSING ENDOPROTEASE; FUNCTIONAL EXPRESSION; PRECURSOR CLEAVAGE; KEX2-LIKE ENDOPROTEASE; PROTECTIVE ANTIGEN; FRAGMENT-A; VERO CELLS; YEAST KEX2; SEQUENCE	Proteolytic cleavage (nicking) of diphtheria toxin (DT) in the 14-amino acid loop subtended by the disulfide bond between Cys186 and Cys201 is required for the cytotoxic action of DT. The loop includes the consensus motif for cleavage by a membrane-anchored protease, furin. We found that a soluble form of furin cleaves intact DT between Arg198 and Ser194 in vitro. LoVo cells, a human colon carcinoma cell line, do not produce functional furin. We show here that intact DT is not cleaved by LoVo cells. The cells are resistant to intact DT, although they are sensitive to DT nicked by furin before it is added to the medium. When intact DT is added to LoVo/Fur1 cells, a stable transfectant of LoVo cells expressing mouse furin, nicked DT associated with the cells is observed. LoVo/Fur1 cells are sensitive to both intact and nicked DT. These results indicate that furin is involved in the toxicity of intact DT. Bafilomycin A1, an inhibitor of intracellular vesicle acidification, did not inhibit cleavage of intact DT by LoVo/Fur1 or Vero cells, indicating that cleavage can proceed in a neutral environment. Inhibitors of endocytosis decreased DT cleavage but did not eliminate it. We also found a small amount of nicked DT in the culture medium. These results may indicate that intact DT is cleaved by cell-associated furin on the cell surface as well as in endocytotic vesicles.	KURUME UNIV,FAC LIFE SCI,2432-3 AIKAWA,KURUME,FUKUOKA 830,JAPAN; UNIV TSUKUBA,INST BIOL SCI,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,CTR GENE EXPT,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN; KANSAI MED UNIV,INST LIVER RES,MORIGUCHI,OSAKA 570,JAPAN	Kurume University; University of Tsukuba; University of Tsukuba; University of Tsukuba; Kansai Medical University			Nakayama, Kazuhisa/ABF-2924-2020	Nakayama, Kazuhisa/0000-0001-7701-7183; Mekada, Eisuke/0000-0001-8858-4781				ARIANSEN S, 1993, BIOCHEMISTRY-US, V32, P83, DOI 10.1021/bi00052a012; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CIEPLAK W, 1988, BIOCHEM BIOPH RES CO, V157, P747, DOI 10.1016/S0006-291X(88)80313-9; CIEPLAK W, 1987, J BIOL CHEM, V262, P13246; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; DRAZIN R, 1971, J BIOL CHEM, V246, P1504; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; GILL DM, 1971, J BIOL CHEM, V246, P1485; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; IWAMOTO R, 1991, J BIOL CHEM, V266, P20463; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KOMADA M, 1993, FEBS LETT, V3288, P25; KORNER J, 1991, P NATL ACAD SCI USA, V88, P6834, DOI 10.1073/pnas.88.15.6834; MEKADA E, 1985, J BIOL CHEM, V260, P2148; MEKADA E, 1988, J CELL BIOL, V107, P511, DOI 10.1083/jcb.107.2.511; MEKADA E, 1979, EXP CELL RES, V123, P137, DOI 10.1016/0014-4827(79)90430-0; MIDDLEBROOK JL, 1982, EXP CELL RES, V138, P175, DOI 10.1016/0014-4827(82)90103-3; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MISUMI Y, 1990, NUCLEIC ACIDS RES, V18, P6719, DOI 10.1093/nar/18.22.6719; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MOEHRING JM, 1993, J BIOL CHEM, V268, P2590; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SCHALKEN JA, 1987, J CLIN INVEST, V80, P1545, DOI 10.1172/JCI113240; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; TAKAHASHI S, INPRESS BIOCH BIOPHY; UCHIDA T, 1973, J BIOL CHEM, V248, P3838; UMATA T, 1990, J BIOL CHEM, V265, P21940; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; WATANABE T, 1992, J BIOL CHEM, V267, P8270; WILLIAMS DP, 1990, J BIOL CHEM, V265, P20673; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378	43	121	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26461	26465						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253774				2022-12-25	WOS:A1993MK42500068
J	DELWEL, GO; HOGERVORST, F; KUIKMAN, I; PAULSSON, M; TIMPL, R; SONNENBERG, A				DELWEL, GO; HOGERVORST, F; KUIKMAN, I; PAULSSON, M; TIMPL, R; SONNENBERG, A			EXPRESSION AND FUNCTION OF THE CYTOPLASMIC VARIANTS OF THE INTEGRIN-ALPHA-6 SUBUNIT IN TRANSFECTED K562 CELLS - ACTIVATION-DEPENDENT ADHESION AND INTERACTION WITH ISOFORMS OF LAMININ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE ADHESION; TYROSINE PHOSPHORYLATION; NEUROMUSCULAR-JUNCTION; EXTRACELLULAR-MATRIX; SIGNAL TRANSDUCTION; SYNAPTIC CLEFT; BETA-SUBUNIT; ALPHA-CHAIN; LONG ARM; T-CELLS	Two variants of the cytoplasmic domain of the integrin alpha6 subunit have been identified (alpha6A and alpha6B). To determine the role of each variant in mediating cell adhesion to laminin, we have independently expressed the alpha6A and alpha6B subunits in K562 cells. Both variants associated with endogenous beta1 and were present at comparable levels on the surface of transfected K562 cells. After activation with phorbol ester (phorbol 12-myristate 13-acetate; PMA) or the stimulatory anti-beta1 antibody TS2/16, alpha6Abeta1 as well as alpha6Bbeta1 mediated cell adhesion to laminin and more specifically to its fragment E8. Furthermore, both integrin variants interacted with the laminin isoforms kalinin and merosin. Cell adhesion to laminin isoforms was inhibited by the alpha6-specific monoclonal antibody GoH3. PMA was less efficient in stimulating adhesion than TS2/16 and stimulated adhesion of alpha6B transfectants better than of alpha6A transfectants. In contrast, TS2/16 stimulated the adhesion of the alpha6A and alpha6B transfectants to laminin to a similar extent. These findings indicate that the cells may regulate the activation of the two alpha6 variants independently. Activation by PMA was associated with the phosphorylation of both alpha6A and alpha6B subunits, but there was no relationship between the degree of phosphorylation and the ability of the transfectants to adhere to laminin since alpha6A became phosphorylated much more strongly by PMA than alpha6B. Thus, both alpha6Abeta1 and alpha6Bbeta1 on K562 cells are activation-dependent receptors for different isoforms of laminin.	NETHERLANDS CANC INST,DEPT CELL BIOL,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS; UNIV BERN,ME MULLER INST BIOMECH,CH-3010 BERN,SWITZERLAND; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	Netherlands Cancer Institute; University of Bern; Max Planck Society								ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BROWN JC, 1991, FEBS LETT, V282, P5, DOI 10.1016/0014-5793(91)80432-3; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; COOPER HM, 1991, J CELL BIOL, V115, P843, DOI 10.1083/jcb.115.3.843; DAMSKY CH, 1992, J CLIN INVEST, V89, P210, DOI 10.1172/JCI115565; DEUTZMANN R, 1988, EUR J BIOCHEM, V177, P35, DOI 10.1111/j.1432-1033.1988.tb14342.x; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ENGVALL E, 1992, EXP CELL RES, V198, P115, DOI 10.1016/0014-4827(92)90156-3; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; GISMONDI A, 1992, J EXP MED, V176, P1251, DOI 10.1084/jem.176.5.1251; GREEN TL, 1992, J BIOL CHEM, V267, P2014; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HIERCK BP, 1993, CELL ADHES COMMUN, V1, P33, DOI 10.3109/15419069309095680; HOGERVORST F, 1993, J CELL BIOL, V121, P179, DOI 10.1083/jcb.121.1.179; HOGERVORST F, 1991, EUR J BIOCHEM, V199, P425, DOI 10.1111/j.1432-1033.1991.tb16140.x; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KALLUNKI P, 1992, J CELL BIOL, V119, P679, DOI 10.1083/jcb.119.3.679; KEIZER GD, 1987, EUR J IMMUNOL, V17, P1317, DOI 10.1002/eji.1830170915; KENNEL SJ, 1990, HYBRIDOMA, V9, P243, DOI 10.1089/hyb.1990.9.243; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; LEIVO I, 1988, P NATL ACAD SCI USA, V85, P1544, DOI 10.1073/pnas.85.5.1544; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PAULSSON M, 1985, EMBO J, V4, P309, DOI 10.1002/j.1460-2075.1985.tb03630.x; PAULSSON M, 1991, J BIOL CHEM, V266, P17546; PAULSSON M, 1989, J BIOL CHEM, V264, P18725; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; Sambrook J, 1989, MOL CLONING LABORATO; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; SONNENBERG A, 1986, CANCER RES, V46, P5913; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; SONNENBERG A, 1987, J BIOL CHEM, V262, P10376; SONNENBERG A, 1991, EXP CELL RES, V197, P234, DOI 10.1016/0014-4827(91)90428-W; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; SOROKIN L, 1990, J CELL BIOL, V111, P1265, DOI 10.1083/jcb.111.3.1265; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TAMURA RN, 1991, P NATL ACAD SCI USA, V88, P10183, DOI 10.1073/pnas.88.22.10183; TIMPL R, 1987, METHOD ENZYMOL, V145, P363; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877	60	108	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25865	25875						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245021				2022-12-25	WOS:A1993MK10000084
J	WILSON, RE; TAYLOR, SL; ATHERTON, GT; JOHNSTON, D; WATERS, CM; NORTON, JD				WILSON, RE; TAYLOR, SL; ATHERTON, GT; JOHNSTON, D; WATERS, CM; NORTON, JD			EARLY RESPONSE GENE SIGNALING CASCADES ACTIVATED BY IONIZING-RADIATION IN PRIMARY HUMAN B-CELLS	ONCOGENE			English	Article							PROTEIN-KINASE-C; LYMPHOCYTIC-LEUKEMIA CELLS; INDUCED PLASMACYTOID DIFFERENTIATION; IONIZING-RADIATION; MYC PROTEIN; TRANSCRIPTION FACTORS; BINDING-ACTIVITY; CULTURED-CELLS; GROWTH-FACTORS; EXPRESSION	We have used a panel of 13 protein kinase C-responsive immediate early gene probes to dissect the cellular signalling pathways activated by ionising gamma radiation in primary human B cells. Of these 13 genes, a delayed transient induction was observed for only 8: c-fos, c-jun, jun-B, jun-D, c-myc, ergI/krox 24 and two 'anonymous' genes, 3L3 and 19A. Expression of c-myc and c-fos mRNAs was paralleled by the appearance of their encoded proteins suggesting that these oncoproteins may couple radiation signalling to cellular responses. Of three protein kinase C-coupled transcription factors examined by gel retardation assay, (AP1, NF kappa B, EgrI/Krox24) only NF kappa B and, to a lesser extent, AP1 was stimulated in response to irradiation. These observations are not obviously compatible with a simple model invoking protein kinase C in radiation signalling in primary B cells and suggest that the pleiotropic effects of ionising radiation on this cell type are mediated through a distinct cellular signalling cascade.	CHRISTIE HOSP NHS TRUST,PATERSON INST CANC RES,CRC,DEPT CARCINOGENESIS,MANCHESTER M20 9BX,ENGLAND; CHRISTIE HOSP NHS TRUST,PATERSON INST CANC RES,DEPT GENE REGULAT,MANCHESTER M20 9BX,ENGLAND; UNIV MANCHESTER,DEPT PHYSIOL SCI,MOLEC PHARMACOL & TOXICOL GRP,MANCHESTER M13 9PT,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Manchester			Atherton, Graham/GZK-4237-2022	Atherton, Graham/0000-0002-7425-3153	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; Anderson R E, 1976, Adv Immunol, V24, P215, DOI 10.1016/S0065-2776(08)60331-4; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BRACH MA, 1993, BIOL CHEM, V268, P8466; CELANO P, 1989, BIOFEEDBACK, V7; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHILES TC, 1991, J IMMUNOL, V146, P1730; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; DEED RW, 1993, ONCOGENE, V8, P599; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FACHINI A, 1976, RADIAT RES, V68, P339; FOLCH H, 1982, IMMUNOL LETT, V5, P337, DOI 10.1016/0165-2478(82)90124-9; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HALL EJ, 1988, RADIOBIOLOGY RADIOLO, P17; HALLAHAN DE, 1992, RADIAT RES, V129, P345, DOI 10.2307/3578035; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; HALLAHAN DE, 1991, CANCER RES, V51, P4565; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; LARSSON LG, 1987, P NATL ACAD SCI USA, V84, P223, DOI 10.1073/pnas.84.1.223; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEEK DW, 1992, BIOCHEM J, V287, P1; MOORE JP, 1988, BIOCHIM BIOPHYS ACTA, V965, P60, DOI 10.1016/0304-4165(88)90151-1; MURPHY JJ, 1990, FEBS LETT, V267, P242, DOI 10.1016/0014-5793(90)80935-C; MURPHY JJ, 1990, BIOCHIM BIOPHYS ACTA, V1049, P261; MURPHY JJ, 1991, BIOCHIM BIOPHYS ACTA, V1092, P110, DOI 10.1016/0167-4889(91)90184-Y; MURPHY JJ, 1993, IN PRESS LEUKAEMIA R; OBRIAN CA, 1988, BIOCHEM BIOPH RES CO, V155, P1374, DOI 10.1016/S0006-291X(88)81293-2; OJEDA F, 1990, INT J RADIAT BIOL, V59, P53; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PARKCHAE H, 1993, CANCER RES, V53, P447; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SAXON A, 1976, J IMMUNOL METHODS, V12, P285, DOI 10.1016/0022-1759(76)90050-8; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SHERMAN ML, 1991, J CLIN INVEST, V87, P1794, DOI 10.1172/JCI115199; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SONOBE MH, 1991, ONCOGENE, V6, P1531; SULLIVAN NF, 1989, ONCOGENE, V4, P1497; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; WATERS CM, 1990, ONCOGENE, V5, P669; WATERS CM, 1991, ONCOGENE, V6, P797; WITTE L, 1989, CANCER RES, V49, P5066; WOLOSCHAK GE, 1990, CANCER RES, V50, P3963; WOLOSCHAK GE, 1990, CANCER RES, V50, P339; WOLTERS H, 1987, INT J RADIAT BIOL, V51, P619, DOI 10.1080/09553008414552151; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	62	56	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3229	3237						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247526				2022-12-25	WOS:A1993MG78200005
J	YADA, T; SAKURADA, M; IHIDA, K; NAKATA, M; MURATA, F; ARIMURA, A; KIKUCHI, M				YADA, T; SAKURADA, M; IHIDA, K; NAKATA, M; MURATA, F; ARIMURA, A; KIKUCHI, M			PITUITARY ADENYLATE-CYCLASE ACTIVATING POLYPEPTIDE IS AN EXTRAORDINARILY POTENT INTRAPANCREATIC REGULATOR OF INSULIN-SECRETION FROM ISLET BETA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED RAT PANCREAS; HYPOTHALAMIC PEPTIDE; OVINE HYPOTHALAMUS; RELEASE; CA-2+; CALCIUM; GLUCOSE; INCREASE; SINGLE; PACAP	Insulin secretion from pancreatic islets is controlled by peptides as well as by nutrients. We report here a novel, extraordinarily potent peptidergic regulation of insulin secretion. A 27-residue form of pituitary adenylate cyclase activating polypeptide (PACAP27) as low as 10(-14) to 10(-13) M stimulated insulin release from rat islets in a glucose-dependent manner. PACAP27 also increased cytosolic free Ca2+ concentration ([Ca2+]i) in islet beta-cells. Nitrendipine, a blocker of the L-type Ca2+ channel, abolished both [Ca2+]i and insulin responses. Vasoactive intestinal peptide, a peptide exhibiting 68% amino acid homology with PACAP, also increased [Ca2+]i in beta-cells but only at concentrations in the nanomolar range, indicating that PACAP27 is 4 logs more potent. A 38-residue form of the peptide (PACAP38) stimulated insulin release and increased beta-cell [Ca2+]i in a manner similar to that of PACAP27. PACAP-like immunoreactivity was demonstrated in pancreatic nerve fibers, islets, and capillaries. The results indicate that PACAP is a physiologically occurring peptide in pancreas and that PACAP, in a glucose-dependent manner, activates beta-cells presumably via a high affinity PACAP-selective receptor, raises [Ca2+]i by increasing the activity of L-type Ca2+ channels, and consequently stimulates insulin release. PACAP appears to be by far the most potent insulinotropic peptide known.	KAGOSHIMA UNIV,SCH MED,DEPT ANAT,KAGOSHIMA 890,JAPAN; ASAHI LIFE FDN,INST ADULT DIS,TOKYO 160,JAPAN; TULANE UNIV,HEBERT CTR,UNITED STATES JAPAN BIOMED RES LABS,BELLE CHASSE,LA 70037	Kagoshima University; Asahi Life Foundation; Tulane University	YADA, T (corresponding author), KAGOSHIMA UNIV,SCH MED,DEPT PHYSIOL,8-35-1 SAKURAGAOKA,KAGOSHIMA 890,JAPAN.							AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; ARIMURA A, 1991, ENDOCRINOLOGY, V129, P2787, DOI 10.1210/endo-129-5-2787; ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; CANNY BJ, 1992, ENDOCRINOLOGY, V130, P211, DOI 10.1210/en.130.1.211; FRIDOLF T, 1992, CELL TISSUE RES, V269, P275, DOI 10.1007/BF00319618; GOTH MI, 1992, ENDOCRINOLOGY, V130, P939, DOI 10.1210/en.130.2.939; GOTTSCHALL PE, 1990, ENDOCRINOLOGY, V127, P272, DOI 10.1210/endo-127-1-272; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; GRAPENGIESSER E, 1988, BIOCHEM BIOPH RES CO, V150, P419, DOI 10.1016/0006-291X(88)90537-2; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HACKER GW, 1988, J HISTOTECHNOL, V11, P213, DOI 10.1179/his.1988.11.4.213; ISOBE K, 1993, ENDOCRINOLOGY, V132, P1757, DOI 10.1210/en.132.4.1757; KAWAI K, 1992, LIFE SCI, V50, P257, DOI 10.1016/0024-3205(92)90332-J; KOVES K, 1989, J HISTOCHEM CYTOCHEM, V37, P903, DOI 10.1177/37.6.2723405; KOVES K, 1990, ENDOCRINOLOGY, V127, P264; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1990, BIOCHEM BIOPH RES CO, V170, P643, DOI 10.1016/0006-291X(90)92140-U; MOJSOV S, 1987, J CLIN INVEST, V79, P616, DOI 10.1172/JCI112855; MUNGAN Z, 1991, PEPTIDES, V12, P559, DOI 10.1016/0196-9781(91)90101-T; ORSKOV C, 1992, DIABETOLOGIA, V35, P701; PENNER R, 1988, J EXP BIOL, V139, P329; PIPELEERS D, 1982, P NATL ACAD SCI-BIOL, V79, P7322, DOI 10.1073/pnas.79.23.7322; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; RAUFMAN JP, 1991, REGUL PEPTIDES, V36, P121, DOI 10.1016/0167-0115(91)90200-Z; ROTH J, 1982, J HISTOCHEM CYTOCHEM, V30, P691, DOI 10.1177/30.7.7050239; SAKURADA M, 1993, ENDOCRINOLOGY, V132, P2659, DOI 10.1210/en.132.6.2659; SMITH PA, 1989, NATURE, V342, P550, DOI 10.1038/342550a0; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TATSUNO I, 1992, ENDOCRINOLOGY, V131, P73, DOI 10.1210/en.131.1.73; WARREN JB, 1991, EUR J PHARMACOL, V197, P131, DOI 10.1016/0014-2999(91)90511-N; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; YADA T, 1992, CELL CALCIUM, V13, P69, DOI 10.1016/0143-4160(92)90031-M; YADA T, 1993, PEPTIDES, V14, P235, DOI 10.1016/0196-9781(93)90035-F; YADA T, 1989, J BIOL CHEM, V264, P2455; YADA T, 1993, IN PRESS ENDOCRINOLO	36	243	244	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1290	1293						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288592				2022-12-25	WOS:A1994MR22000082
J	FRITZ, TA; LUGEMWA, FN; SARKAR, AK; ESKO, JD				FRITZ, TA; LUGEMWA, FN; SARKAR, AK; ESKO, JD			BIOSYNTHESIS OF HEPARAN-SULFATE ON BETA-D-XYLOSIDES DEPENDS ON AGLYCONE STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE; DERMATAN SULFATE; GLYCOSAMINOGLYCAN BIOSYNTHESIS; N-SULFOTRANSFERASE; D-GALACTOSIDES; BREFELDIN-A; CARTILAGE; OLIGOSACCHARIDES; PROTEOGLYCAN; LOCALIZATION	We have reported that 3-estradiol-beta-D-xyloside-primes heparan sulfate synthesis in Chinese hamster ovary cells and that the proportion of heparan sulfate made rises with increasing concentration of xyloside (Lugemwa, F. N. and Esko, J. D. (1991) J. Biol. Chem. 266, 6674-6677). Using estradiol as a guide, we varied the structure of the aglycone and showed that beta-D-xylosides containing two fused aromatic rings efficiently prime heparan sulfate. Thus, 2-naphthol-beta-D-xyloside primed heparan sulfate at low dose (less-than-or-equal-to 10 muM) and the proportion of heparan sulfate increased with concentration (up to 50% of total glycosaminoglycan). Various ring additions and heterocyclic ring substitutions altered the efficiency of heparan sulfate priming, but had no effect on the overall level of glycosaminoglycan synthesis. Replacement of the bridging oxygen with sulfur (2-naphthalenethiol-beta-D-xyloside) increased the efficiency of heparan sulfate priming. Priming of heparan sulfate correlated with hydrophobicity of the xyloside, but several exceptions suggested that the chemical structure of the aglycone played an equally important role. Interestingly, the heparan sulfate chains generated on 2-naphthol-beta-D-xyloside showed a 2-fold decrease in the proportion of disaccharides containing 6-O-sulfate groups and a striking diminution in non-sulfated iduronic acid containing disaccharides compared to the chains attached to cellular proteoglycans. Thus, both the type of glycosaminoglycan made on a xyloside and its fine structure depends on the aglycone.	UNIV ALABAMA,SCH MED,DEPT BIOCHEM & MOLEC GENET,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NCI NIH HHS [CA46462] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046462] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAME KJ, 1991, J BIOL CHEM, V266, P10287; BAME KJ, 1989, J BIOL CHEM, V264, P8059; CHIOU CT, 1977, ENVIRON SCI TECHNOL, V11, P475, DOI 10.1021/es60128a001; Conchie J, 1963, METHODS CARBOHYDRATE, V2, P335; COSTER L, 1991, BIOCHEM J, V276, P533, DOI 10.1042/bj2760533; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; FRANSSON LA, 1991, GLYCOCONJUGATE J, V8, P108, DOI 10.1007/BF00731020; FRANSSON LA, 1992, GLYCOCONJUGATE J, V9, P45, DOI 10.1007/BF00731177; FREEZE HH, 1993, J BIOL CHEM, V268, P1618; GIBSON KD, 1977, BIOCHEM J, V162, P217, DOI 10.1042/bj1620217; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; GUO YC, 1988, ANAL BIOCHEM, V168, P54, DOI 10.1016/0003-2697(88)90009-7; HELFERICH B, 1962, CHEM BER-RECL, V95, P2616, DOI 10.1002/cber.19620951105; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Koenigs W, 1901, BER DTSCH CHEM GES, V34, P957, DOI 10.1002/cber.190103401162; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LINDAHL U, 1973, J BIOL CHEM, V248, P7234; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUGEMWA FN, 1991, J BIOL CHEM, V266, P6674; OKAYAMA M, 1973, J BIOCHEM-TOKYO, V74, P1069; Pagano RE, 1990, CURR OPIN CELL BIOL, V2, P652, DOI 10.1016/0955-0674(90)90107-P; PAULSEN H, 1981, CHEM BER-RECL, V114, P3102, DOI 10.1002/cber.19811140916; PLANT AL, 1985, J CELL BIOL, V100, P1295, DOI 10.1083/jcb.100.4.1295; ROBINSON HC, 1975, BIOCHEM J, V148, P25, DOI 10.1042/bj1480025; ROBINSON HC, 1981, BIOCHEM J, V194, P575, DOI 10.1042/bj1940575; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; SCHWARTZ NB, 1974, P NATL ACAD SCI USA, V71, P4047, DOI 10.1073/pnas.71.10.4047; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SOBUE M, 1987, BIOCHEM J, V241, P591, DOI 10.1042/bj2410591; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; STEVENS RL, 1982, J BIOL CHEM, V257, P253; SUDHAKARAN PR, 1981, H-S Z PHYSIOL CHEM, V362, P39, DOI 10.1515/bchm2.1981.362.1.39; SUGUMARAN G, 1992, J BIOL CHEM, V267, P8802; UHLINHANSEN L, 1993, J BIOL CHEM, V268, P17370; VANAKEN T, 1986, METHOD ENZYMOL, V125, P27; WOLFROM ML, 1963, METHODS CARBOHYDRATE, V2, P341	37	126	126	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					300	307						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276811				2022-12-25	WOS:A1994MR21900053
J	MONACO, L; VICINI, E; CONTI, M				MONACO, L; VICINI, E; CONTI, M			STRUCTURE OF 2 RAT GENES-CODING FOR CLOSELY-RELATED ROLIPRAM-SENSITIVE CAMP PHOSPHODIESTERASES - MULTIPLE MESSENGER-RNA VARIANTS ORIGINATE FROM ALTERNATIVE SPLICING AND MULTIPLE START SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; DROSOPHILA DUNCE+ GENE; AMP PHOSPHODIESTERASE; HORMONAL-REGULATION; SEQUENCES; DNA; EXPRESSION; CLONING; CELLS; CHROMATOGRAPHY	The products of two phosphodiesterase (PDE) genes (ratPDE3/IVd and ratPDE4/IVb) are present in the rat Sertoli cell in culture, and their expression is under the control of the gonadotropin follicle-stimulating hormone (Swinnen, J. V., Tsikalas, K. E., and Conti, M. (1991) J. Biol. Chem. 266,18370-18377). To understand the basis of the sequence heterogeneity found in the 5'-region of the different cDNAs thus far characterized, the structure of the coding region of these two cAMP PDE genes was investigated. Analysis of five ratPDE3/IVd and ratPDE4/IVb genomic clones showed that the coding region of these genes expressed in the Sertoli cell is divided into 11 exons distributed over 35-45 kilobases of genomic DNA. The intron/exon boundaries agreed, with some exceptions, with the established consensus sequences and were located in the same position in the coding region of the two genes. Also present were similarities to the exon composition of the Drosophila melanogaster ''dunce'' gene, the ancestor of these mammalian cAMP PDEs. Multiple AUG codons and short open reading frames were present at the 5'-untranslated end of the ratPDE4/IVb mRNA, but not in the ratPDE3 mRNA. By using polymerase chain reaction amplification or Northern analysis, it was determined that at least two forms of ratPDE3/IVd mRNA are present in rat Sertoli and FRTL-5 thyroid cells, but not in the brain. These mRNA variants are generated by inclusion or removal of an intron sequence that produces a frameshift affecting the position of the initiation AUG codon. Both mRNA species were efficiently translated into cAMP PDE proteins with different molecular masses in a transient transfection assay in COS cells. Polymerase chain reaction amplification demonstrated that heterogeneity of ratPDE4/IVb mRNAs was present in the same location as in the ratPDE3/IVd mRNA. Two ratPDE4/IVb mRNAs with different 5'-ends were expressed in Sertoli and FRTL-5 cells and in the brain. This heterogeneity is caused by the presence of an intron promoter that controls the transcription of this mRNA in Sertoli and FRTL-5 cells, but not in the brain. Upstream exons and additional promoters are probably present and necessary to generate the brain-specific mRNAs. These findings demonstrate that the cAMP-specific PDE genes have complex structure and that cAMP PDE proteins with different amino termini are derived from these genes.	UNIV ROME, INST HISTOL & GEN EMBRYOL, I-00161 ROME, ITALY	Sapienza University Rome			Monaco, Lucia/A-4031-2010	Vicini, Elena/0000-0003-0399-0145	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20788] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; CONTI M, 1991, ENDOCR REV, V12, P218, DOI 10.1210/edrv-12-3-218; CONTI M, 1990, CYCLIC NUCLEOTIDE PH, P3; DAVIS RL, 1991, TRENDS GENET, V7, P224, DOI 10.1016/0168-9525(91)90369-2; DAVIS RL, 1989, P NATL ACAD SCI USA, V86, P3604, DOI 10.1073/pnas.86.10.3604; DEMAZANCOURT P, 1988, METHOD ENZYMOL, V159, P766; EPSTEIN PM, 1982, ARCH BIOCHEM BIOPHYS, V218, P119, DOI 10.1016/0003-9861(82)90327-7; EPSTEIN PM, 1984, ADV CYCLIC NUCL PROT, V16, P303; FAURE M, 1990, MOL CELL BIOL, V10, P1921, DOI 10.1128/MCB.10.5.1921; FISHER R, 1985, J BIOL CHEM, V260, P1223; FOUGIER S, 1986, BIOCHEM BIOPH RES CO, V138, P205, DOI 10.1016/0006-291X(86)90267-6; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; JIN SLC, 1992, J BIOL CHEM, V267, P18929; KINCAID RL, 1985, J BIOL CHEM, V260, P9009; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LIVI GP, 1990, MOL CELL BIOL, V10, P2678, DOI 10.1128/MCB.10.6.2678; MCLAUGHLIN MM, 1993, J BIOL CHEM, V268, P6470; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; QIU YH, 1991, J MOL BIOL, V222, P553, DOI 10.1016/0022-2836(91)90496-S; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STROOP SD, 1989, J BIOL CHEM, V264, P13718; SWINNEN JV, 1991, J BIOL CHEM, V266, P18370; SWINNEN JV, 1991, J BIOL CHEM, V266, P14383; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; TUCKER MM, 1981, J BIOL CHEM, V256, P9051; WEBER B, 1991, NUCLEIC ACIDS RES, V19, P6263, DOI 10.1093/nar/19.22.6263; WEIL D, 1990, MOL CELL BIOL, V10, P5865, DOI 10.1128/MCB.10.11.5865; WELCH JE, 1992, BIOL REPROD, V46, P1027, DOI 10.1095/biolreprod46.6.1027; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	39	93	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					347	357						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276818				2022-12-25	WOS:A1994MR21900059
J	SPACCIAPOLI, P; NOSSAL, NG				SPACCIAPOLI, P; NOSSAL, NG			INTERACTION OF DNA-POLYMERASE AND DNA HELICASE WITHIN THE BACTERIOPHAGE-T4 DNA-REPLICATION COMPLEX - LEADING-STRAND SYNTHESIS BY THE T4 DNA-POLYMERASE MUTANT A737V (TSL141) REQUIRES THE T4 GENE-59 HELICASE ASSEMBLY PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY PROTEINS; RNA PRIMERS; TEMPLATE; INVITRO; ANTIMUTATOR; MECHANISMS; HOLOENZYME; MUTATOR; FORK	The bacteriophage T4 tsL141 (A737V) mutant in T4 DNA polymerase is temperature-sensitive for DNA replication and an antimutator for some types of mutations. In the accompanying paper (Spacciapoli, P., and Nossal, N. G. (1993) J. Biol. Chem. 269,438-446), we show that the purified A737V T4 DNA polymerase is less processive than the wild type enzyme as a polymerase, but is more processive as an exonuclease. The bacteriophage T4 multienzyme replication complex reconstituted with the A737V mutant polymerase is defective in both lagging and leading strand synthesis. On lagging strand templates, the A737V polymerase is stimulated by the gene 44/62 and 45 polymerase accessory proteins and the gene 32 DNA binding protein, but is still arrested at pause sites much more frequently than the wild type. In contrast to wild type T4 DNA polymerase, the A737V polymerase does not catalyze leading strand synthesis on a forked duplex template with the polymerase accessory proteins, 32 protein, and the gene 41 protein helicase. The A737V polymerase requires the T4 gene 59 helicase assembly protein, as well as the other proteins, to carry out this reaction. Each of these defects is suppressed by the intragenic L771F mutation that suppresses the antimutator phenotype of the A737V polymerase in vivo (Reha-Krantz, L. J., Stocki, S., Nonay, R., and Maughan, C. (1989) J. Cell. Biochem. 13D, 140).	NIDDKD,MOLEC & CELLULAR BIOL,BLDG 8,ROOM 2A-19,BETHESDA,MD 20892; NIDDKD,BIOCHEM PHARMACOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; BEDINGER P, 1989, J BIOL CHEM, V264, P16880; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; CHA TA, 1989, J BIOL CHEM, V264, P12220; DRAKE JW, 1988, MOL GEN GENET, V214, P547, DOI 10.1007/BF00330493; DRAKE JW, 1968, COLD SPRING HARB SYM, V33, P339, DOI 10.1101/SQB.1968.033.01.039; EPSTEIN RH, 1963, COLD SPRING HARB SYM, V28, P375, DOI 10.1101/SQB.1963.028.01.053; GILLIN FD, 1976, J BIOL CHEM, V251, P5225; HACKER K, 1989, J CELL BIOCHEM, V13, P87; HAHN S, 1989, NUCLEIC ACIDS RES, V17, P6729, DOI 10.1093/nar/17.16.6729; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; HUANG CC, 1981, J BIOL CHEM, V256, P4087; HUANG CC, 1981, NUCLEIC ACIDS RES, V9, P5587, DOI 10.1093/nar/9.21.5587; KREUZER KN, 1993, IN PRESS MOL BIOL BA; Nossal N.G., 1983, BACTERIOPHAGE T4, P71; NOSSAL NG, 1974, J BIOL CHEM, V249, P5668; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; NOSSAL NG, 1993, IN PRESS MOL BIOL BA; REHAKRANTZ LJ, 1989, J CELL BIOL D, V13, P140; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RICHARDSON RW, 1990, UCLA SYM BI, V127, P247; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; RIPLEY LS, 1983, MOL GEN GENET, V189, P113, DOI 10.1007/BF00326062; ROTH AC, 1982, J BIOL CHEM, V257, P1267; SPACCIAPOLI P, J BIOL CHEM, V269, P438; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	29	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					447	455						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276834				2022-12-25	WOS:A1994MR21900075
J	SUGAWARA, A; YEN, PM; APRILETTI, JW; RIBEIRO, RCJ; SACKS, DB; BAXTER, JD; CHIN, WW				SUGAWARA, A; YEN, PM; APRILETTI, JW; RIBEIRO, RCJ; SACKS, DB; BAXTER, JD; CHIN, WW			PHOSPHORYLATION SELECTIVELY INCREASES TRIIODOTHYRONINE RECEPTOR HOMODIMER BINDING TO DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; RETINOID-X-RECEPTOR; INSULIN-STIMULATED PHOSPHORYLATION; PROTEIN-KINASE-C; RESPONSE ELEMENTS; AUXILIARY PROTEIN; TRANSCRIPTIONAL ACTIVITY; ENHANCES BINDING; ACID RECEPTORS; RAT-LIVER	Thyroid hormone receptors (TRs) are ligand-regulated transcription factors that bind to thyroid hormone response elements (TREs) as monomers and homodimers, and as heterodimers with nuclear proteins such as TR auxiliary proteins and retinoid X receptors. Recently, bacterially expressed human TRbeta-1 (hTRbeta-1) was shown to be phosphorylated in vitro by HeLa cytosolic extract. However, little is known about the consequences of phosphorylation on the nature of TR complexes. Therefore, we studied the effect of phosphorylation on TR binding to TREs. Bacterially expressed hTRbeta-1 was phosphorylated in vitro with ATP by HeLa cytosolic extract. The ratio of phosphoserine to phosphothreonine was approximately 5:1. We then analyzed phosphorylated hTRbeta-1 binding to several TREs by electrophoretic mobility shift assay. Phosphorylated hTRbeta-1 bound better as a homodimer to the TREs than hTRbeta-1 incubated with preheated cytosolic extract. Alkaline phosphatase treatment of the phosphorylated hTRbeta3-1 eliminated the enhanced homodimer binding to DNA. In contrast, phosphorylation did not affect TR/TR auxiliary protein or TR/retinoid X receptor heterodimer binding to DNA. Triiodothyronine decreased both phosphorylated and unphosphorylated hTRbeta-1 homodimer binding to several TREs, and the addition of okadaic acid did not alter this triiodothyronine effect. These results indicate that phosphorylation, in addition to ligand binding, modulates TR dimer binding to TREs. As such, it is possible that phosphorylation may also participate in TR-mediated regulation of transcription.	BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,DEPT PATHOL,BOSTON,MA 02115; UNIV CALIF SAN FRANCISCO,METAB RES UNIT,SAN FRANCISCO,CA 94143; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Harvard University; Harvard Medical School	SUGAWARA, A (corresponding author), BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,DEPT MED,DIV GENET,G W THORN RES BLDG,RM 905,BOSTON,MA 02115, USA.		Yen, Paul M/V-9857-2019	Sacks, David/0000-0003-3100-0735; Yen, Paul/0000-0002-3790-8114; Sugawara, Akira/0000-0003-4511-8101	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043682] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43682] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; APRILETTI JW, 1988, J BIOL CHEM, V263, P9409; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRENT G A, 1989, New Biologist, V1, P329; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GLINEUR C, 1989, ONCOGENE, V4, P1247; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; HAWKINS PT, 1983, BIOCHEM J, V210, P717, DOI 10.1042/bj2100717; HOLLOWAY JM, 1990, P NATL ACAD SCI USA, V87, P8160, DOI 10.1073/pnas.87.20.8160; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIN KH, 1992, P NATL ACAD SCI USA, V89, P7737, DOI 10.1073/pnas.89.16.7737; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MINAKAMI S, 1965, BIOCHEM BIOPH RES CO, V18, P345, DOI 10.1016/0006-291X(65)90711-4; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; SACKS DB, 1988, J BIOL CHEM, V263, P2377; SACKS DB, 1992, BIOCHEM J, V286, P211, DOI 10.1042/bj2860211; SUGAWARA A, 1993, ENDOCRINOLOGY, V133, P965, DOI 10.1210/en.133.3.965; YEN PM, 1992, J BIOL CHEM, V267, P3565; YEN PM, 1992, ENDOCRINOLOGY, V130, P1539, DOI 10.1210/en.130.3.1539; YEN PM, 1992, J BIOL CHEM, V267, P23248; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1991, NEW BIOL, V3, P169; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	43	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					433	437						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276832				2022-12-25	WOS:A1994MR21900073
J	TSCHANTZ, WR; SUNG, M; DELGADOPARTIN, VM; DALBEY, RE				TSCHANTZ, WR; SUNG, M; DELGADOPARTIN, VM; DALBEY, RE			A SERINE AND A LYSINE RESIDUE IMPLICATED IN THE CATALYTIC MECHANISM OF THE ESCHERICHIA-COLI LEADER PEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROSOMAL SIGNAL PEPTIDASE; ACYL-ENZYME INTERMEDIATE; BETA-LACTAMASE; DIRECTED MUTAGENESIS; CLEAVAGE SITE; COAT PROTEIN; AMINO-ACIDS; PURIFICATION; MEMBRANE; PENICILLIN	We report that a thiol leader peptidase, produced by replacing the critical serine at position 90 with a cysteine residue, is enzymatically active. In contrast to the wild-type leader peptidase, the thiol enzyme can be inactivated with N-ethylmaleimide, a cysteine-specific reagent. This strongly suggests that the serine 90 is involved in catalysis and is located at the active site. Of the three conserved basic residues in the signal peptidase family, only lysine 145 appears to be critical for catalysis; when lysine 145 was mutated to an alanine residue, leader peptidase K145A protein was inactive both in vitro and in vivo. A control experiment showed that the K145A mutant competes with the wild-type leader peptidase for substrate binding, confirming that the K145A mutation did not cause a global conformational change. The data provides evidence that catalysis of leader peptidase is carried out by a serine-lysine dyad.	OHIO STATE UNIV, DEPT CHEM, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University								ADACHI H, 1991, J BIOL CHEM, V266, P3186; BAKER RK, 1987, BIOCHEMISTRY-US, V26, P8561, DOI 10.1021/bi00400a010; BLACK MT, 1992, BIOCHEM J, V282, P539, DOI 10.1042/bj2820539; BOEKE JD, 1980, J MOL BIOL, V144, P103, DOI 10.1016/0022-2836(80)90027-3; CITRI N, 1960, J BIOL CHEM, V235, P3454; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; DALBEY RE, 1987, SCIENCE, V235, P783, DOI 10.1126/science.3544218; Dunn BM., 1989, PROTEOLYTIC ENZYMES, P57; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FIKES JD, 1990, J BIOL CHEM, V265, P3417; FOLZ RJ, 1988, J BIOL CHEM, V263, P2070; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; INADA T, 1989, J BACTERIOL, V171, P585, DOI 10.1128/jb.171.1.585-587.1989; ITO K, 1980, J BIOL CHEM, V255, P2123; Jackson R C, 1980, Ann N Y Acad Sci, V343, P391, DOI 10.1111/j.1749-6632.1980.tb47268.x; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; KELLY JA, 1986, SCIENCE, V231, P1429, DOI 10.1126/science.3082007; KELLY JA, 1985, J BIOL CHEM, V260, P6449; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LIN LL, 1988, J BACTERIOL, V170, P2163, DOI 10.1128/jb.170.5.2163-2173.1988; LIN LL, 1989, J MOL BIOL, V210, P439, DOI 10.1016/0022-2836(89)90121-6; Maniatis T., 1982, MOL CLONING; NEURATH H, 1989, PROTEOLYTIC ENZYMES, P1; OGAWARA H, 1981, J BIOL CHEM, V256, P2649; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; SHEN LM, 1991, BIOCHEMISTRY-US, V30, P11775, DOI 10.1021/bi00115a006; SLILATY SN, 1986, BIOCHEMISTRY-US, V25, P6866, DOI 10.1021/bi00370a020; SLILATY SN, 1987, P NATL ACAD SCI USA, V84, P3987, DOI 10.1073/pnas.84.12.3987; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; SUNG M, 1992, J BIOL CHEM, V267, P13154; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VANDIJL JM, 1990, MOL GEN GENET, V223, P233, DOI 10.1007/BF00265059; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WOLFE PB, 1982, J BIOL CHEM, V257, P7898; YADEAU JT, 1989, J BIOL CHEM, V264, P2928; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468; ZWIZINSKI C, 1980, J BIOL CHEM, V255, P7973; ZWIZINSKI C, 1981, J BIOL CHEM, V256, P3593	41	108	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27349	27354						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262975				2022-12-25	WOS:A1993MM26200074
J	ZHU, YJ; ALVARES, K; HUANG, Q; RAO, MS; REDDY, JK				ZHU, YJ; ALVARES, K; HUANG, Q; RAO, MS; REDDY, JK			CLONING OF A NEW MEMBER OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GENE FAMILY FROM MOUSE-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACYL-COA OXIDASE; BETA-OXIDATION; FATTY-ACIDS; RAT-LIVER; MECHANISMS; IDENTIFICATION; SUPERFAMILY; CLOFIBRATE; INDUCTION	Peroxisome proliferators are postulated to elicit predictable pleiotropic responses in the liver by activating a peroxisome proliferator-activated receptor (PPAR). PPARs from mouse liver (mPPAR), rat liver (rPPAR), and Xenopus liver (xPPARgamma) have been cloned recently. We now report the cloning of a new member from mouse liver which we designate mPPARgamma. mPPARgamma cDNA contained an open reading frame encoding a 475-amino acid protein exhibiting 75% amino acid similarity to xPPARgamma, while it showed only 55% identity with mPPAR. The ligand-binding and DNA-binding domains are best conserved between mPPARgamma, mPPAR, and xPPARgamma. Like rPPAR, mPPARgamma is able to impart peroxisome proliferator responsiveness to the promoter of peroxisomal bifunctional gene, which encodes the second enzyme of the peroxisomal fatty acid beta-oxidation system. Northern blot analysis revealed high expression of mPPARgamma gene in mouse liver, kidney, and heart and low expression in the lung, testis, brain, skeletal muscle, and spleen. In mice treated with ciprofibrate, a peroxisome proliferator, a 2-fold increase in mPPARgamma mRNA was observed in the liver and kidney. The presence of two PPARs in the mouse liver suggests the possibility of multiple signaling pathways for the peroxisome proliferator-induced pleiotropic responses.	NORTHWESTERN UNIV,SCH MED,DEPT PATHOL,303 E CHICAGO AVE,CHICAGO,IL 60611	Northwestern University				Alvares, Keith/0000-0003-3710-4367	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023750, R01GM023750] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23750] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVARES K, 1990, P NATL ACAD SCI USA, V87, P5293, DOI 10.1073/pnas.87.14.5293; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; HASHIMOTO T, 1982, ANN NY ACAD SCI, V386, P5, DOI 10.1111/j.1749-6632.1982.tb21403.x; HESS R, 1965, NATURE, V208, P856, DOI 10.1038/208856a0; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; Maniatis T., 1982, MOL CLONING; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; NEMALI MR, 1988, CANCER RES, V48, P5316; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; REDDY JK, 1986, TRENDS PHARMACOL SCI, V7, P438, DOI 10.1016/0165-6147(86)90416-5; REDDY JK, 1975, SCIENCE, V190, P787, DOI 10.1126/science.1198095; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; REDDY JK, 1990, BIOCHEM SOC T, V18, P92, DOI 10.1042/bst0180092; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; ZHANG BW, 1993, J BIOL CHEM, V268, P12939; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	26	339	354	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26817	26820						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262913				2022-12-25	WOS:A1993MM26200002
J	GALLAGHER, PJ; HERRING, BP; TRAFNY, A; SOWADSKI, J; STULL, JT				GALLAGHER, PJ; HERRING, BP; TRAFNY, A; SOWADSKI, J; STULL, JT			A MOLECULAR MECHANISM FOR AUTOINHIBITION OF MYOSIN LIGHT-CHAIN KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; CALMODULIN-BINDING; INTRASTERIC REGULATION; PROTEIN-KINASE; BASIC RESIDUES; ACTIVATION; SKELETAL; PSEUDOSUBSTRATE; SITE; PHOSPHORYLATION	It is postulated that basic residues within the inhibitory region of myosin light chain kinase (MLCK) bind acidic residues within the catalytic core to maintain the kinase in an inactive form. In this study, we identified residues within the catalytic cores of the skeletal and smooth muscle MLCKs that may bind basic residues in inhibitory region. Acidic residues within the catalytic core of the rabbit skeletal and smooth muscle MLCKs were mutated and the kinetic properties of the mutant kinases determined. Mutation of 6 and 8 acidic residues in the skeletal and smooth muscle MLCKs, respectively, result in mutant MLCKs with decreases in K(CaM) (the concentration of calmodulin required for half-maximal activation of myosin light chain kinase) value ranging from 2- to 100-fold. Two inhibitory domain binding residues identified in each kinase also bind a basic residue in light chain substrate. The remaining mutants all have wild-type K(m) values for light chain. The predicted inhibitory domain binding residues are distributed in a linear fashion across the surface of the lower lobe of the proposed molecular model of the smooth muscle MLCK catalytic core. As 6 of the inhibitory domain binding residues in the smooth muscle MLCK are conserved in other Ca2+/calmodulin-dependent protein kinases, the structural basis for autoinhibition and activation may be similar.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235; UNIV CALIF SAN DIEGO,DEPT MED & BIOL,LA JOLLA,CA 92093	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Diego					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026043, R37HL026043] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL026043, R01 HL026043, R01 HL026043-20, HL26043] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGCHI IC, 1992, MOL ENDOCRINOL, V6, P621, DOI 10.1210/me.6.4.621; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; BLUMENTHAL DK, 1982, BIOCHEMISTRY-US, V21, P2386, DOI 10.1021/bi00539a017; FITZSIMONS DP, 1992, J BIOL CHEM, V267, P23903; FOSTER CJ, 1990, ARCH BIOCHEM BIOPHYS, V280, P397, DOI 10.1016/0003-9861(90)90348-3; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATHAWAY DR, 1983, ANAL BIOCHEM, V135, P37, DOI 10.1016/0003-2697(83)90726-1; HERRING BP, 1991, J BIOL CHEM, V266, P11838; HERRING BP, 1992, J BIOL CHEM, V267, P25945; HERRING BP, 1990, J BIOL CHEM, V265, P16588; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KEMP BE, 1990, PEPTIDES PROTEIN PHO; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KORN ED, 1988, ANNU REV BIOPHYS BIO, V17, P23; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEACHMAN SA, 1992, J BIOL CHEM, V267, P4930; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MILLER JR, 1983, MOL PHARMACOL, V24, P235; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; STULL JT, 1990, J BIOL CHEM, V265, P16683; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	27	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26578	26582						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253787				2022-12-25	WOS:A1993MK42500082
J	ABOUAKIL, N; MAS, E; BRUNEAU, N; BENAJIBA, A; LOMBARDO, D				ABOUAKIL, N; MAS, E; BRUNEAU, N; BENAJIBA, A; LOMBARDO, D			BILE SALT-DEPENDENT LIPASE BIOSYNTHESIS IN RAT PANCREATIC AR-4-2 J-CELLS - ESSENTIAL REQUIREMENT OF N-LINKED OLIGOSACCHARIDE FOR SECRETION AND EXPRESSION OF A FULLY ACTIVE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; CARBOXYL ESTER HYDROLASE; CHOLESTEROL ESTERASE; ENDOPLASMIC-RETICULUM; CDNA CLONING; PURIFICATION; GLYCOSYLATION; GLYCOPROTEINS; PROTEINS; INHIBITION	This study used the rat pancreatic AR 4-2 J cell line as a model system to investigate the role of glycosylation in bile salt-dependent lipase (BSDL) secretion and esterolytic activity. Results indicated that AR 4-2 J cells synthesized BSDL, the esterolytic activity of which was the greater part of the cell activity toward 4-nitrophenylcaproate. The protein thus expressed was glycosylated and had a molecular mass almost-equal-to 74 kDa. Exposure of these cells to tunicamycin significantly decreased [H-3]mannose incorporation, while [S-35]methionine incorporation in trichloroacetic acid-precipitable material was not modified. Tunicamycin treatment of AR 4-2 J cells lead to a lower molecular mass form (approximately 70 kDa) of BSDL which did not incorporate [H-3]mannose. The nonglycosylated low M(r) form of the enzyme was not secreted as shown by the decreasing activity in cell-free medium which paralleled the time-dependent secretion of the enzyme. Tunicamycin had no effect on BSDL synthesis. Nevertheless, the nonglycosylated BSDL was apparently not degraded in any cell compartment as shown in part by the enzyme activity accumulation within cells upon brefeldin A treatment. The BSDL expressed by AR 4-2 J cells was characterized by a K(m) of 68 +/- 30 muM and a k(cat) of 106 +/- 19 min-1. The sequestrated BSDL due to tunicamycin treatment of cells presents a significant increase of K(m) of over 10 times to 757 +/- 303 muM. k(cat) was affected by a factor of approximately 4-445 +/- 22 min-1. These data correlated with an approximately 2.5-fold decrease of the esterolytic activity following inhibition of the N-glycosylation of the protein. The nonglycosylated BSDL was less stable to temperature than the native form. Processing inhibitors (castano-spermine, 1-deoxymannojirimycin, and swainsonine) had no effect either on the enzyme activity or on its secretion. Results suggested first that the transfer of the oligosaccharide precursor to the nascent BSDL is essential for the folding of the fully active BSDL. Second that the glycan structure is required for the enzyme secretion	FAC MED MARSEILLE,INSERM,U260,UNITE RECH PHYSIOPATHOL REGULAT HORMONONUTR,F-13385 MARSEILLE 5,FRANCE; ECOLE NATL SUPER TETOUAN MARTIL,TETOUAN,MEXICO	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			Mas, Eric/O-9569-2017; Mas, Eric/AAC-9837-2022; Bruneau, Nadine/O-2100-2016	Mas, Eric/0000-0002-8925-9195; Bruneau, Nadine/0000-0002-1523-3128; ABOUAKIL, Nezha/0000-0002-7293-3702				ABOUAKIL N, 1988, BIOCHIM BIOPHYS ACTA, V961, P299, DOI 10.1016/0005-2760(88)90077-X; ALBERS GHR, 1987, DIFFERENTIATION, V34, P210, DOI 10.1111/j.1432-0436.1987.tb00068.x; AOYAGI T, 1969, J ANTIBIOT, V22, P283, DOI 10.7164/antibiotics.22.283; BABA T, 1991, BIOCHEMISTRY-US, V30, P500, DOI 10.1021/bi00216a028; CHOW V, 1984, J BIOL CHEM, V259, P6622; DANIELSEN EM, 1992, BIOCHEMISTRY-US, V31, P2266, DOI 10.1021/bi00123a008; DIPERSIO LP, 1990, J BIOL CHEM, V265, P16801; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; ERLANSONALBERTS.C, 1986, MOL CELLULAR BASIS D, P297; ESCRIBANO MJ, 1989, J BIOL CHEM, V264, P21865; FUHRMANN U, 1985, BIOCHIM BIOPHYS ACTA, V825, P95, DOI 10.1016/0167-4781(85)90095-8; GJELLESVIK DR, 1992, BIOCHIM BIOPHYS ACTA, V1124, P123, DOI 10.1016/0005-2760(92)90088-D; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HORI H, 1984, ARCH BIOCHEM BIOPHYS, V228, P525, DOI 10.1016/0003-9861(84)90019-5; HUANG Y, 1991, J BIOL CHEM, V266, P6720; HYUN J, 1969, J BIOL CHEM, V244, P1937; JACOBSON PW, 1990, J BIOL CHEM, V265, P515; KISSEL JA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P227, DOI 10.1016/0005-2760(89)90201-4; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KYGER EM, 1989, BIOCHEM BIOPH RES CO, V164, P1302, DOI 10.1016/0006-291X(89)91811-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Legler G, 1977, Methods Enzymol, V46, P368; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LOMBARDO D, 1978, BIOCHIM BIOPHYS ACTA, V527, P142, DOI 10.1016/0005-2744(78)90263-2; LOMBARDO D, 1980, BIOCHIM BIOPHYS ACTA, V611, P147, DOI 10.1016/0005-2744(80)90050-9; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MAS E, 1993, BIOCHEM J, V289, P609, DOI 10.1042/bj2890609; MCDOWELL W, 1988, BIOCHIMIE, V70, P1535, DOI 10.1016/0300-9084(88)90290-8; MERLIE JP, 1982, J BIOL CHEM, V257, P2694; MIRALLES F, 1993, EUR J CELL BIOL, V60, P115; MOMSEN WE, 1977, BIOCHIM BIOPHYS ACTA, V486, P103, DOI 10.1016/0005-2760(77)90074-1; OLDEN K, 1982, BIOCHIM BIOPHYS ACTA, V650, P209, DOI 10.1016/0304-4157(82)90017-X; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; REUE K, 1991, J LIPID RES, V32, P267; Rudd E.A., 1984, P185; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; STRUCK DK, 1977, J BIOL CHEM, V252, P1007; TULSIANI DRP, 1983, J BIOL CHEM, V258, P7578; TULSIANI DRP, 1982, J BIOL CHEM, V257, P7936	42	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25755	25763						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245011				2022-12-25	WOS:A1993MK10000070
J	HUANG, CH; REID, M; DANIELS, G; BLUMENFELD, OO				HUANG, CH; REID, M; DANIELS, G; BLUMENFELD, OO			ALTERATION OF SPLICE-SITE SELECTION BY AN EXON MUTATION IN THE HUMAN GLYCOPHORIN-A GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; HUMAN-ERYTHROCYTE MEMBRANE; MOLECULAR ANALYSIS; CDNA CLONES; NUCLEOTIDE-SEQUENCE; IDENTIFICATION; DNA; DELTA; EXPRESSION; MECHANISM	We report the identification in human glycophorin A gene of a novel exon mutation that affects splice site selection. DNA mapping showed that the mutation has abolished a unique MspI site marking the exon III-intron 3 splice junction (ACCG/GT). Genomic sequencing confirmed the occurrence of a single G --> A transition at the terminal nucleotide position of exon III. Analysis of the mRNA composition demonstrated a partial inactivation of the altered 5' splice site as well as skipping of exons involving the alternative use of other constitutive splice sites. The full-length transcript with the cognate A change encodes a variant glycophorin with an arginine replacing a glycine at position 59 and defining the ERIK epitope, whereas the exon III-deleted transcript specifies a shorter glycophorin carrying the St(a) antigen. Also identified were the misspliced mRNA species with exon I-IV and exon I-V connections generated by selection of 5' splice sites far distant from the mutated site. Although having a correct translation frame, the predicted polypeptides of such exon-skipping products were not assembled on the erythrocyte membrane probably due to the severe truncation of the signal sequence required for targeting and translocation. These observations reveal a new mechanism for antigenic diversity of human glycophorins.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; MRC,BLOOD GRP UNIT,LONDON NW1 2HE,ENGLAND; NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,NEW YORK,NY 10021	Yeshiva University; Albert Einstein College of Medicine; New York Blood Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM016389] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 16389] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKLI S, 1990, J BIOL CHEM, V265, P7324; ANDREWS LG, 1992, J BIOL CHEM, V267, P7834; BLANCHARD D, 1987, EUR J BIOCHEM, V167, P361, DOI 10.1111/j.1432-1033.1987.tb13345.x; CARTRON JP, 1990, BLOOD CELL BIOCH, V1, P299; DANIELS GL, 1993, TRANSFUSION MED, V3, P129, DOI 10.1111/j.1365-3148.1993.tb00050.x; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Goossens M, 1981, Methods Enzymol, V76, P805; GOTODA T, 1991, J BIOL CHEM, V266, P24757; Huang C H, 1991, Baillieres Clin Haematol, V4, P821, DOI 10.1016/S0950-3536(06)80032-6; HUANG CH, 1988, P NATL ACAD SCI USA, V85, P9640, DOI 10.1073/pnas.85.24.9640; HUANG CH, 1987, BLOOD, V70, P1830; HUANG CH, 1991, BLOOD, V77, P381; HUANG CH, 1989, BLOOD, V74, P836; HUANG CH, 1992, BLOOD, V80, P2379; HUANG CH, 1992, J BIOL CHEM, V267, P3336; HUANG CH, 1992, BLOOD, V80, P257; HUANG CH, 1991, BLOOD, V77, P1813; HUANG CH, 1991, J BIOL CHEM, V266, P7248; HUANG CH, 1991, J BIOL CHEM, V266, P23306; HUANG CH, 1993, J BIOL CHEM, V268, P4945; HUANG CH, 1992, BLOOD S, V80, pA274; HUANG CH, 1986, CHIN BIOCH J, V2, P9; KAZAZIAN HH, 1990, SEMIN HEMATOL, V27, P209; KUDO S, 1990, J BIOL CHEM, V265, P13825; KUDO S, 1990, J BIOL CHEM, V265, P1102; KUDO S, 1989, P NATL ACAD SCI USA, V86, P4619, DOI 10.1073/pnas.86.12.4619; KUIVANIEMI H, 1990, J BIOL CHEM, V265, P12067; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; LU YQ, 1987, BLOOD, V69, P618; Maniatis T., 1982, MOL CLONING; MARVIT J, 1987, NUCLEIC ACIDS RES, V15, P5613, DOI 10.1093/nar/15.14.5613; MITCHELL PJ, 1986, MOL CELL BIOL, V6, P1926, DOI 10.1128/MCB.6.6.1926; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RAHUEL C, 1988, EUR J BIOCHEM, V172, P147, DOI 10.1111/j.1432-1033.1988.tb13866.x; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; REARDEN A, 1990, J BIOL CHEM, V265, P9259; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; ROGERS J, 1980, P NATL ACAD SCI-BIOL, V77, P1877, DOI 10.1073/pnas.77.4.1877; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SIEBERT PD, 1987, P NATL ACAD SCI USA, V84, P6735, DOI 10.1073/pnas.84.19.6735; SIEBERT PD, 1986, P NATL ACAD SCI USA, V83, P1665, DOI 10.1073/pnas.83.6.1665; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TATE CG, 1988, BIOCHEM J, V254, P743, DOI 10.1042/bj2540743; VIDAUD M, 1989, P NATL ACAD SCI USA, V86, P1041, DOI 10.1073/pnas.86.3.1041; VIGNAL A, 1989, EUR J BIOCHEM, V184, P337, DOI 10.1111/j.1432-1033.1989.tb15024.x; VIGNAL A, 1990, EUR J BIOCHEM, V191, P619, DOI 10.1111/j.1432-1033.1990.tb19166.x; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WEIL D, 1989, EMBO J, V8, P1705, DOI 10.1002/j.1460-2075.1989.tb03562.x; WEIL D, 1988, J BIOL CHEM, V263, P8561; YOON SH, 1991, J BIOL CHEM, V266, P8490	53	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25902	25908						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245024				2022-12-25	WOS:A1993MK10000088
J	KARN, T; HOLTRICH, U; BRAUNINGER, A; BOHME, B; WOLF, G; RUBSAMENWAIGMANN, H; STREBHARDT, K				KARN, T; HOLTRICH, U; BRAUNINGER, A; BOHME, B; WOLF, G; RUBSAMENWAIGMANN, H; STREBHARDT, K			STRUCTURE, EXPRESSION AND CHROMOSOMAL MAPPING OF TKT FROM MAN AND MOUSE - A NEW SUBCLASS OF RECEPTOR TYROSINE KINASES WITH A FACTOR VIII-LIKE DOMAIN	ONCOGENE			English	Note							FIBROBLAST GROWTH-FACTOR; HUMAN INSULIN-RECEPTOR; CDNA CLONING; PUTATIVE RECEPTOR; FAMILY; GENE; SEQUENCE; PROTEINS; ENCODES; DEFINE	Using a polymerase chain reaction-mediated approach we have characterized cDNAs from human and mouse origin representing a novel type of receptor protein tyrosine kinase (RTK). The deduced amino acid sequence (855 amino acids) of the Longest open reading frame has a unique extracellular region encompassing a factor VIII-like domain, not previously described for RTKs. The most closely related RTKs are members of the neurotrophin receptors (TRK), which showed 47-49% homology with the kinase domain of the new RTK. Therefore, the new gene has been called TKT (Tyrosine-Kinase related to TRK). TKT orthologs from man and mouse were 98% similar. In both species a major transcript of 10 kb was found to be expressed at high levels in heart and lung. Low levels of this mRNA-species were detected in human brain, placenta, liver, skeletal muscle, kidney and in mouse brain and testis. Analysing human/mouse somatic cell hybrids we demonstrated that TKT segregates with human chromosome 1.	CHEMOTHERAPEUT FORSCHUNGSINST,D-60596 FRANKFURT,GERMANY				Strebhardt, Klaus/E-8765-2011; karn, t/C-7452-2013; Karn, Thomas/AAE-7723-2019	karn, t/0000-0002-3264-6573; Karn, Thomas/0000-0002-3264-6573; Strebhardt, Klaus/0000-0003-2173-9763				BOHME B, 1993, IN PRESS ONCOGENE; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; DUMONT DJ, 1993, ONCOGENE, V8, P1293; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLTRICH U, 1991, P NATL ACAD SCI USA, V88, P10411, DOI 10.1073/pnas.88.23.10411; IWAMOTO T, 1993, ONCOGENE, V8, P1087; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MORRIS CM, 1991, ONCOGENE, V6, P1093; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; RESCIGNO J, 1991, ONCOGENE, V6, P1909; SHIER P, 1989, J BIOL CHEM, V264, P14605; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLECKE K, 1990, EUR J CELL BIOL, V53, P275; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZIEGLER SF, 1993, ONCOGENE, V8, P663	36	67	76	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3433	3440						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247548				2022-12-25	WOS:A1993MG78200030
J	ROSSI, AD; LARSSON, O; MANZO, L; ORRENIUS, S; VAHTER, M; BERGGREN, PO; NICOTERA, P				ROSSI, AD; LARSSON, O; MANZO, L; ORRENIUS, S; VAHTER, M; BERGGREN, PO; NICOTERA, P			MODIFICATIONS OF CA2+ SIGNALING BY INORGANIC MERCURY IN PC12 CELLS	FASEB JOURNAL			English	Note						SIGNAL TRANSDUCTION; CA2+ CHANNELS; INOSITOL POLYPHOSPHATES	NERVE GROWTH-FACTOR; PROTEIN KINASE-C; RAT PHEOCHROMOCYTOMA CELLS; CALCIUM CHANNELS; SARCOPLASMIC-RETICULUM; INTRACELLULAR CA2+; HEAVY-METALS; RELEASE; BRAIN; OSCILLATIONS	The effects of different levels of inorganic mercury (Hg2+) on depolarization- or agonist-stimulated Ca2+ signals were studied in PC12 cells. Exposure to 50-300 nM Hg2+ did not alter the resting cytosolic free Ca2+ concentration ([Ca2+]i), but enhanced the Ca2+ response to KCl-induced depolarization. Patch-clamp experiments revealed that these Hg2+ concentrations increased the voltage-dependent Ca2+ current through L-type channels. Also, Hg2+ treatment amplified the intracellular [Ca2+]i transients elicited by extracellular ATP. In contrast, the Ca2+ increase stimulated by bradykinin was unaffected. At slightly higher concentrations (1 to 2 muM), Hg2+ caused a sustained rise of the resting [Ca2+]i. This increase did not occur in Ca2+-free medium and was prevented by pretreatment with NiCl2 or with the L-type Ca2+ channel blockers, verapamil and nifedipine. Hg2+ did not mobilize Ca2+ from intracellular stores sensitive to thapsigargin, 2,5-di-(tert-butyl)-benzohydroquinone, or caffeine. At 2 muM, Hg2+ inhibited the [Ca2+]i transients elicited by bradykinin, ATP, or KCl-induced depolarization. The loss of the intracellular Ca2+ response to bradykinin was independent from the Ca2+ overload elicited by Hg2+; instead, it was associated with inhibition of polyphosphoinositide generation. Exposure to the lower Hg2+ concentrations (0.3-0.5 muM) greatly potentiated NGF-induced PC12 cell differentiation. Conversely, treatment with 2 muM Hg2+ caused cell death. Our results show that inorganic mercury has selective and different effects on Ca2+ signaling in PC12 cells depending on the concentration, within a narrow range.	KAROLINSKA INST, INST ENVIRONM MED, DEPT TOXICOL, BOX 60 400, S-10401 STOCKHOLM 60, SWEDEN; KAROLINSKA INST, INST ENVIRONM MED, DEPT ENDOCRINOL, S-10401 STOCKHOLM, SWEDEN; UNIV PAVIA, TOXICOL UNIT, I-27100 PAVIA, ITALY; LAVORO MED CTR CLIN, PAVIA, ITALY	Karolinska Institutet; Karolinska Institutet; University of Pavia			Vahter, Marie/HGB-1674-2022	Berggren, Per-Olof/0000-0001-8991-413X				ABRAMSON JJ, 1983, P NATL ACAD SCI-BIOL, V80, P1526, DOI 10.1073/pnas.80.6.1526; ATCHISON WD, 1982, NEUROTOXICOLOGY, V3, P37; ATZORI L, 1990, J CELL PHYSIOL, V143, P165, DOI 10.1002/jcp.1041430123; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BELLOMO G, 1987, J BIOL CHEM, V262, P1530; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BOTTENSTEIN JE, 1985, CELL CULTURE NEUROSC, P3; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHOW SC, 1992, ARCH BIOCHEM BIOPHYS, V298, P143, DOI 10.1016/0003-9861(92)90105-6; COTGREAVE IA, 1986, J BIOCHEM BIOPH METH, V13, P231, DOI 10.1016/0165-022X(86)90102-8; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; DIVIRGILIO F, 1987, J BIOL CHEM, V262, P9189; FASOLATO C, 1990, J BIOL CHEM, V265, P20351; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRIS CC, 1991, CANCER RES, V51, pS5023; HEWETT SJ, 1992, TOXICOL APPL PHARM, V113, P267, DOI 10.1016/0041-008X(92)90124-B; HINKLE PM, 1987, J BIOL CHEM, V262, P16333; HOSEY MM, 1988, J MEMBRANE BIOL, V104, P81, DOI 10.1007/BF01870922; INOUE Y, 1988, PHARMACOL TOXICOL, V62, P278, DOI 10.1111/j.1600-0773.1988.tb01887.x; ISLAM MS, 1993, FEBS LETT, V319, P128, DOI 10.1016/0014-5793(93)80051-U; JANIGRO D, 1989, FEBS LETT, V255, P398, DOI 10.1016/0014-5793(89)81131-7; JUNG KY, 1990, BIOCHEM BIOPH RES CO, V173, P606, DOI 10.1016/S0006-291X(05)80078-6; JUNTTIBERGGREN L, 1993, SCIENCE, V261, P86, DOI 10.1126/science.7686306; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KATER SB, 1988, TRENDS NEUROSCI, V11, P315, DOI 10.1016/0166-2236(88)90094-X; KIM YI, 1988, SCIENCE, V239, P405, DOI 10.1126/science.2447652; MAGOS L, 1972, J ASSOC OFF ANA CHEM, V55, P966; MANDEL G, 1988, P NATL ACAD SCI USA, V85, P924, DOI 10.1073/pnas.85.3.924; MARKOVAC J, 1988, NATURE, V334, P71, DOI 10.1038/334071a0; MERRITT JE, 1988, J BIOL CHEM, V263, P6161; MILLER RJ, 1988, TRENDS NEUROSCI, V11, P415, DOI 10.1016/0166-2236(88)90191-9; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MURPHY BJ, 1990, BIOCHIM BIOPHYS ACTA, V1052, P33; NAKAE H, 1991, BRAIN RES, V558, P348, DOI 10.1016/0006-8993(91)90791-S; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; Rosen J F, 1993, TOXICOLOGIST, V13, P1630; ROSSI A, 1991, PHARMACOL TOXICOL, V68, P424, DOI 10.1111/j.1600-0773.1991.tb01265.x; SALAMA G, 1992, J PHYSIOL-LONDON, V454, P389, DOI 10.1113/jphysiol.1992.sp019270; Sarkar B, 1983, BIOL ASPECTS METALS, P183; SHAFER TJ, 1991, J PHARMACOL EXP THER, V258, P149; SHAPIRO IM, 1982, LANCET, V1, P1147; SINGER R, 1987, ARCH ENVIRON HEALTH, V42, P181; SMITH JB, 1989, J BIOL CHEM, V264, P7115; SMITH RG, 1992, NEW ENGL J MED, V327, P1721, DOI 10.1056/NEJM199212103272405; SPEIZER LA, 1989, J BIOL CHEM, V264, P5581; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; ZACCHETTI D, 1991, J BIOL CHEM, V266, P20152	53	61	63	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1993	7	15					1507	1514		10.1096/fasebj.7.15.8262335	http://dx.doi.org/10.1096/fasebj.7.15.8262335			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ML740	8262335				2022-12-25	WOS:A1993ML74000014
J	KAWAGISHI, H; YAMAWAKI, M; ISOBE, S; USUI, T; KIMURA, A; CHIBA, S				KAWAGISHI, H; YAMAWAKI, M; ISOBE, S; USUI, T; KIMURA, A; CHIBA, S			2 LECTINS FROM THE MARINE SPONGE HALICHONDRIA-OKADAI - AN N-ACETYL-SUGAR-SPECIFIC LECTIN (HOL-I) AND AN N-ACETYLLACTOSAMINE-SPECIFIC LECTIN (HOL-II)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; GALACTOSIDASES; HEMAGGLUTININ; AGGLUTININ; POLYETHER; BINDING	Two lectins (HOL-I and HOL-II) were isolated from the marine sponge Halichondria okadai by affinity chromatography on a bovine submaxillary mucin (BSM)-Toyopearl and an acid-treated Sepharose 4B columns, respectively. In hemagglutination inhibition assays, GlcNAc, GalNAc, and their methyl glycosides were the most potent inhibitors among the monosaccharides tested against the HOL-I-mediated hemagglutination, suggesting that HOL-I can especially recognize the N-acetyl groups of the sugars. This N-acetyl specificity was supported by H-1 NMR analyses; the highest field-shifts of the signal of the N-acetyl group among all the signals in Me betaGlcNAc were observed in H-1 NMR spectra of mixtures of HOL-I and the sugar. Among the oligosaccharides tested, GlcNAcbeta1-->4(GlcNAcbeta1-->2)Manalpha1-O(CH2)2 CH3 was the most potent inhibitor, and the inhibitory potency of the oligosaccharide was 2(4) times greater than those of GlcNAc and GalNAc. On the other hand, N-acetyllactosamine (Galbeta1-->4GlcNAc) and its analogs were the strongest inhibitors toward HOL-II-induced hemagglutination. The agglutination was completely inert to Galbeta1-->3GlcNAc, Galbeta1-->6GlcNAc, Galbeta1-->3GalNAc, Galbeta1-4GalNAc, and Galbeta1-->6GalNAc. Furthermore, HOL-II exhibited no binding ability to BSM, asialo-BSM, fetuin, asialofetuin, alpha1-acid glycoprotein, and human transferrin. These results indicate that HOL-II strictly recognizes simple Galbeta1-->4GlcNAc unit.	HOKKAIDO UNIV,FAC AGR,DEPT APPL BIOSCI,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University	KAWAGISHI, H (corresponding author), SHIZUOKA UNIV,FAC AGR,DEPT APPL BIOL CHEM,OYA,SHIZUOKA 422,JAPAN.							BRETTING H, 1976, BIOCHEMISTRY-US, V15, P3228, DOI 10.1021/bi00660a011; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; ERRSON B, 1973, BIOCHIM BIOPHYS ACTA, V310, P446; HEDBYS L, 1989, GLYCOCONJUGATE J, V6, P161, DOI 10.1007/BF01050645; HIRATA Y, 1986, PURE APPL CHEM, V58, P701, DOI 10.1351/pac198658050701; KAMIYA H, 1990, NIPPON SUISAN GAKK, V56, P1159, DOI 10.2331/suisan.56.1159; KAMIYA H, 1986, B JPN SOC SCI FISH, V52, P2205; KAWAGISHI H, 1991, BIOCHIM BIOPHYS ACTA, V1076, P179, DOI 10.1016/0167-4838(91)90263-Y; KAWAGISHI H, 1990, BIOCHIM BIOPHYS ACTA, V1034, P247, DOI 10.1016/0304-4165(90)90045-X; KRONIS KA, 1982, BIOCHEMISTRY-US, V21, P3050, DOI 10.1021/bi00256a003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTAN R, 1975, J BIOL CHEM, V250, P8518; PANDOLFINO ER, 1980, J BIOL CHEM, V225, P870; SAKAI K, 1992, J CARBOHYD CHEM, V11, P553, DOI 10.1080/07328309208016148; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; UEMURA D, 1985, J AM CHEM SOC, V107, P4796, DOI 10.1021/ja00302a042; UMETSU K, 1993, ARCH BIOCHEM BIOPHYS, V301, P200, DOI 10.1006/abbi.1993.1133; USUI T, 1993, CARBOHYD RES, V244, P315, DOI 10.1016/0008-6215(83)85010-1; VAITH P, 1979, DEV COMP IMMUNOL, V3, P399, DOI 10.1016/S0145-305X(79)80037-3	20	55	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1375	1379						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288604				2022-12-25	WOS:A1994MR22000094
J	NISHIYORI, A; TASHIRO, H; KIMURA, A; AKAGI, K; YAMAMURA, K; MORI, M; TAKIGUCHI, M				NISHIYORI, A; TASHIRO, H; KIMURA, A; AKAGI, K; YAMAMURA, K; MORI, M; TAKIGUCHI, M			DETERMINATION OF TISSUE-SPECIFICITY OF THE ENHANCER BY COMBINATORIAL OPERATION OF TISSUE-ENRICHED TRANSCRIPTION FACTORS - BOTH HNF-4 AND C/EBP-BETA ARE REQUIRED FOR LIVER-SPECIFIC ACTIVITY OF THE ORNITHINE TRANSCARBAMYLASE ENHANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE SYNTHETASE-I; DNA-BINDING PROTEIN; NUCLEAR FACTOR-IV; GENE-EXPRESSION; TRANSGENIC MICE; LEUCINE ZIPPER; RAT-LIVER; CARBAMOYLTRANSFERASE GENE; RECEPTOR SUPERFAMILY; ACTIVATOR PROTEIN	The enhancer of the rat ornithine transcarbamylase gene is located 11 kilobases upstream from the transcription start site and has been shown to be hepatoma cell-specific. Using transgenic mice, we showed that this enhancer is capable of activating transcription in a liver-specific manner, inverting the tissue specificity of the homologous promoter that is by itself more active in the small intestine than in the liver. Transient transfection analysis with cultured hepatoma cells indicated that the enhancer activity resides in the approximately 110-base pair region containing four protein-binding sites, two for hepatocyte nuclear factor-4 (HNF-4) and two for CCAAT/enhancer binding protein (C/EBP), both of which are liver-selective transcription factors. Concatemerization of a region containing one HNF-4 and one C/EBP site led to reconstitution of the hepatoma cell-specific enhancer, and intactness of these two sites was strictly required for the enhancer activity. Furthermore, cotransfection experiments showed that both HNF-4 and C/EBPbeta are necessary, and neither alone sufficient, for activation of the reconstituted enhancer in nonhepatic cells. Requirement of combinatorial operation of at least two liver-enriched transcription factors for transcriptional activation successfully explains why these liver-selective but not strictly liver-specific factors can confer more restricted liver specificity on transcription of their target genes.	KUMAMOTO UNIV,SCH MED,DEPT MOLEC GENET,KUHONJI 4-24-1,KUMAMOTO 862,JAPAN; KUMAMOTO UNIV,SCH MED,INST MOLEC EMBRYOL & GENET,KUMAMOTO 862,JAPAN	Kumamoto University; Kumamoto University								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BEEKMAN JM, 1991, NUCLEIC ACIDS RES, V19, P5371, DOI 10.1093/nar/19.19.5371; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GERLINGER P, 1986, NUCLEIC ACIDS RES, V14, P6565, DOI 10.1093/nar/14.16.6565; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HAMMER RE, 1987, MOL CELL BIOL, V7, P2956, DOI 10.1128/MCB.7.8.2956; HOWELL BW, 1989, MOL CELL BIOL, V9, P2928, DOI 10.1128/MCB.9.7.2928; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JONES SN, 1990, J BIOL CHEM, V265, P14684; KIMURA A, 1993, J BIOL CHEM, V268, P11125; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIYAZAKI J, 1989, GENE, V79, P269; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MULLER MM, 1988, EUR J BIOCHEM, V176, P485, DOI 10.1111/j.1432-1033.1988.tb14306.x; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MURAKAMI T, 1989, DEV GENET, V10, P393, DOI 10.1002/dvg.1020100507; MURAKAMI T, 1990, MOL CELL BIOL, V10, P1180, DOI 10.1128/MCB.10.3.1180; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; QI S-L, 1991, Methods in Molecular and Cellular Biology, V2, P119; RYALL JC, 1986, EUR J BIOCHEM, V156, P453, DOI 10.1111/j.1432-1033.1986.tb09603.x; SCHAFER BW, 1990, NATURE, V344, P454, DOI 10.1038/344454a0; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHERER SE, 1988, NUCLEIC ACIDS RES, V16, P1593, DOI 10.1093/nar/16.4.1593; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TAKIGUCHI M, 1989, BIOESSAYS, V10, P163, DOI 10.1002/bies.950100506; TAKIGUCHI M, 1987, P NATL ACAD SCI USA, V84, P6136, DOI 10.1073/pnas.84.17.6136; TAKIGUCHI M, 1991, J BIOL CHEM, V266, P9186; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VANOOIJ C, 1992, MOL CELL BIOL, V12, P3023, DOI 10.1128/MCB.12.7.3023; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WRAIGHT C, 1985, EUR J BIOCHEM, V153, P239, DOI 10.1111/j.1432-1033.1985.tb09292.x; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807	61	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1323	1331						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288597				2022-12-25	WOS:A1994MR22000087
J	DIXON, KH; LANPHER, BC; CHIU, J; KELLEY, K; COWAN, KH				DIXON, KH; LANPHER, BC; CHIU, J; KELLEY, K; COWAN, KH			A NOVEL CDNA RESTORES REDUCED FOLATE CARRIER ACTIVITY AND METHOTREXATE SENSITIVITY TO TRANSPORT DEFICIENT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BINDING PROTEINS; TUMOR-CELLS; RECEPTOR; RESISTANCE; TOXICITY	Mammalian cells accumulate reduced folates and methotrexate, a folate antagonist, through the reduced-folate carrier (RFC) (Goldman, I. D., Lichtenstein, N. S., and Oliverio, V. T. (1968) J. Biol. Chem. 243, 5007-5017). This study describes the isolation and expression of a cDNA clone that restores RFC activity to human breast cancer cells defective in this transporter. The cDNA codes for a peptide (mRFC1) of 58 kDa, whose hydropathy plot, resembling those of mammalian sugar transporters, predicts that it may be a member of a superfamily of transporter genes. Transfection of methotrexate-resistant (MTX(R)) ZR-75-1 cells with an expression vector, pRFC1, that codes for this peptide restores their ability to accumulate methotrexate. Furthermore, transport of methotrexate into pRFC1-transfected cells is blocked by a 10-fold molar excess of the reduced folate, 5-formyltetrahydrofolic acid, but is unaffected by folic acid. The increase in methotrexate uptake that is observed in pRFC1-transfected MTX(R) ZR-75-1 cells reverses their resistance to this antitumor agent.			DIXON, KH (corresponding author), NCI, MED BRANCH, MED BREAST CANC SECT, BETHESDA, MD 20892 USA.							ANTONY AC, 1981, J BIOL CHEM, V256, P9684; CHELLO PL, 1977, CANCER RES, V37, P4297; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COWAN KH, 1984, J BIOL CHEM, V259, P793; DIXON KH, 1991, CANCER COMMUN-US, V3, P357, DOI 10.3727/095535491820873687; DIXON KH, 1992, J BIOL CHEM, V267, P24140; ELWOOD PC, 1986, J BIOL CHEM, V261, P5416; FAN JG, 1991, J BIOL CHEM, V266, P14862; FREISHEIM JH, 1989, ADV ENZYME REGUL, V29, P13, DOI 10.1016/0065-2571(89)90091-5; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; GOLDMAN ID, 1968, J BIOL CHEM, V243, P5007; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; GROGER R, 1989, GENE, V83, P3951; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; HENDERSON GB, 1991, J BIOL CHEM, V266, P1641; HERBERT DN, 1991, CURR OPIN CELL BIOL, V3, P702; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOLM J, 1991, BIOCHEM J, V280, P267, DOI 10.1042/bj2800267; KAMEN BA, 1989, J CLIN INVEST, V84, P1379, DOI 10.1172/JCI114310; KAPLAN JH, 1993, J BIOL CHEM, V72, P13; KISLIUK RL, 1984, FOLATE ANTAGONISTS T, V1, P1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MATHERLY LH, 1992, J BIOL CHEM, V267, P23253; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Sambrook J, 1989, MOL CLONING LABORATO; SIROTNAK FM, 1987, NCI MONOGRAPHS, V5, P27; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; TRIPPETT T, 1992, BLOOD, V80, P1158; VANDERVEER LJ, 1989, LEUKEMIA RES, V13, P981, DOI 10.1016/0145-2126(89)90005-2; WEITMAN SD, 1992, CANCER RES, V52, P6708	35	211	217	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					17	20						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276792				2022-12-25	WOS:A1994MR21900005
J	JAULT, JM; ALLISON, WS				JAULT, JM; ALLISON, WS			HYSTERETIC INHIBITION OF THE BOVINE HEART MITOCHONDRIAL F1-ATPASE IS DUE TO SATURATION OF NONCATALYTIC SITES WITH ADP WHICH BLOCKS ACTIVATION OF THE ENZYME BY ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-SITES; BETA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; CATALYTIC SITE; KINETIC MECHANISM; F1 ATPASE; IDENTIFICATION; 5'-TRIPHOSPHATASE; INACTIVATION; DIPHOSPHATE	Prior incubation of the bovine heart mitochondrial F1-ATPase depleted of endogenous nucleotides (nd-MF1) with saturating ADP in the presence or absence of Mg2+ induces inhibition of hydrolysis of 2 mM ATP or ITP. After incubation of nd-MF1 with free ADP, inhibition develops hysteretically which is characterized by an uninhibited initial rate which decelerates to an inhibited, steady-state rate. When prior incubation of nd-MF1 is performed with ADP in the presence of Mg2+, the enzyme is partially inhibited when diluted into assay medium and more extensive inhibition develops hysteretically during turnover. Correlation of binding of [C-14]ADP, in the presence or absence of Mg2+, with the extent of hysteretic inhibition induced suggests that maximal inhibition occurs when at least two noncatalytic sites are filled with ADP. Hysteretic inhibition is also induced by prior incubation of the enzyme with 2-N3-ADP. Prior incubation of nd-MF1 with increasing concentrations of 2-N3-[beta-P-32]ADP, in the presence or absence of Mg2+, increases the extent of induced inhibition which correlates with increasing derivatization of tyrosine beta368 following irradiation of loaded enzyme. This demonstrates that binding of ADP to noncatalytic sites is, in part, responsible for induction of hysteretic inhibition. After inducing inhibition by prior incubation with ADP, the steady-state kinetic behavior of nd-MF1 differs from that of uninhibited enzyme. Lineweaver-Burk plots of steady-state rates of inhibited enzyme as a function of ATP concentration are linear rather than biphasic which is observed for uninhibited enzyme. The composite results suggest that prior saturation of noncatalytic sites of nd-MF1 with ADP prevents activation of the enzyme by blocking the binding of ATP to these sites which is necessary to promote dissociation of inhibitory MgADP from a catalytic site.	UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093	University of California System; University of California San Diego			jault, jean-michel/G-2086-2012	jault, jean-michel/0000-0003-1743-2777	NIGMS NIH HHS [GM-16974] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON WS, 1986, METHOD ENZYMOL, V126, P741; ALLISON WS, 1992, J BIOENERG BIOMEMBR, V24, P469, DOI 10.1007/BF00762364; BAUBICHON H, 1981, BIOCHEM BIOPH RES CO, V100, P1032, DOI 10.1016/0006-291X(81)91927-6; BERDEN JA, 1991, BIOCHIM BIOPHYS ACTA, V1057, P151, DOI 10.1016/S0005-2728(05)80099-4; BULLOUGH DA, 1986, J BIOL CHEM, V261, P5722; BULLOUGH DA, 1988, J BIOL CHEM, V263, P14053; BULLOUGH DA, 1986, J BIOL CHEM, V261, P14171; CHERNYAK BV, 1992, ARCH BIOCHEM BIOPHYS, V295, P247, DOI 10.1016/0003-9861(92)90514-W; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; CROSS RL, 1982, J BIOL CHEM, V257, P2874; CROSS RL, 1988, J BIOENERG BIOMEMBR, V20, P395, DOI 10.1007/BF00762200; Czarnecki J, 1979, Methods Enzymol, V56, P642; CZARNECKI JJ, 1984, BIOCHIM BIOPHYS ACTA, V800, P41, DOI 10.1016/0304-4165(84)90092-8; DIPIETRO A, 1980, BIOCHEMISTRY-US, V19, P5671, DOI 10.1021/bi00566a002; DIPIETRO A, 1981, BIOCHEMISTRY-US, V20, P6312, DOI 10.1021/bi00525a005; DIPIETRO A, 1986, BIOCHIM BIOPHYS ACTA, V851, P283, DOI 10.1016/0005-2728(86)90136-2; DROBINSKAYA IY, 1985, FEBS LETT, V182, P419, DOI 10.1016/0014-5793(85)80346-X; ESCH FS, 1978, J BIOL CHEM, V253, P6100; FELLOUS G, 1984, BIOCHEMISTRY-US, V23, P5294, DOI 10.1021/bi00317a030; FITIN AF, 1979, BIOCHEM BIOPH RES CO, V86, P434, DOI 10.1016/0006-291X(79)90884-2; GARIN J, 1986, BIOCHEMISTRY-US, V25, P4431, DOI 10.1021/bi00363a039; GARRETT NE, 1975, J BIOL CHEM, V250, P6640; HARRIS DA, 1993, FEBS LETT, V316, P209, DOI 10.1016/0014-5793(93)81295-B; JAULT JM, 1993, J BIOL CHEM, V268, P1558; KALASHNIKOVA TY, 1988, EUR J BIOCHEM, V177, P213, DOI 10.1111/j.1432-1033.1988.tb14364.x; KNOWLES AF, 1972, J BIOL CHEM, V247, P6617; LARDY HA, 1975, J SUPRAMOL STR CELL, V3, P214, DOI 10.1002/jss.400030303; MELESE T, 1985, J BIOL CHEM, V260, P5398; MILGROM YM, 1990, J BIOL CHEM, V265, P18725; MILGROM YM, 1990, BIOCHIM BIOPHYS ACTA, V1020, P43, DOI 10.1016/0005-2728(90)90091-H; MILGROM YM, 1989, BIOCHIM BIOPHYS ACTA, V975, P50, DOI 10.1016/S0005-2728(89)80200-2; MILGROM YM, 1991, J BIOL CHEM, V266, P11551; MINKOV IB, 1979, BIOCHEM BIOPH RES CO, V89, P1300, DOI 10.1016/0006-291X(79)92150-8; MURATALIEV MB, 1991, BIOCHEMISTRY-US, V30, P8305, DOI 10.1021/bi00098a004; MURATALIEV MB, 1992, BIOCHEMISTRY-US, V31, P12885, DOI 10.1021/bi00166a025; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; SCHUSTER SM, 1975, J BIOL CHEM, V250, P7848; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; VASILYEVA EA, 1982, BIOCHEM J, V202, P9, DOI 10.1042/bj2020009; VOGEL PD, 1991, J BIOL CHEM, V266, P6101; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; YSERN X, 1988, J BIOENERG BIOMEMBR, V20, P423, DOI 10.1007/BF00762202; ZHUO SQ, 1992, J BIOL CHEM, V267, P12916	45	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					319	325						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276813				2022-12-25	WOS:A1994MR21900055
J	RAJENDRAN, VM; BINDER, HJ				RAJENDRAN, VM; BINDER, HJ			DIFFERENTIAL MODULATION OF NA-HCO3 COTRANSPORT AND NA-H EXCHANGE BY PH IN BASOLATERAL MEMBRANE-VESICLES OF RAT DISTAL COLON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOLIC-ACIDOSIS; ADAPTATION; ANTIPORTER; CELLS	This study was designed to investigate the function of intravesicular proton on two pH gradient-dependent transport processes, a novel Na-HCO3 cotransport and a Na-H exchange, that are present in basolateral membrane vesicles of rat distal colon. Increasing intravesicular proton concentration saturated Na-22 uptake via both Na-H exchange and Na-HCO3 cotransport; reduced the apparent K(m) for sodium for Na-H exchange from 94.9 to 35.6 mM, without alteration in the V(max); but enhanced the V(max) for Na-HCO3 cotransport from 4.3 to 11.7 nmol/mg protein.6 s, while not changing the K(m) for sodium. The effect of a 10-fold proton concentration gradient at two different absolute proton concentrations on both systems was also determined. Na-22 uptake via Na-HCO3 cotransport, but not via Na-H exchange, was enhanced at the higher proton concentration, indicating that the magnitude of the proton concentration gradient is primarily responsible for proton stimulation of Na-H exchange, whereas the absolute proton concentration is critical for proton enhancement of Na-HCO3 cotransport. These studies also demonstrate saturation of both transport systems as a function of intravesicular proton concentration without an exponential component. These results indicate that proton stimulated Na-H exchange and Na-HCO3 cotransport are regulated by distinct and separate mechanisms that may reflect their different cellular functions.	YALE UNIV,SCH MED,DEPT INTERNAL MED,333 CEDAR ST,NEW HAVEN,CT 06510	Yale University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK014669] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-14669] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIBA T, 1987, J CLIN INVEST, V80, P308, DOI 10.1172/JCI113074; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BIBER J, 1983, BIOCHIM BIOPHYS ACTA, V735, P1, DOI 10.1016/0005-2736(83)90255-9; BINDER HJ, 1986, AM J PHYSIOL, V251, pG382, DOI 10.1152/ajpgi.1986.251.3.G382; Binder HJ, 1991, LARGE INTESTINE PHYS, P141; DELCASTILLO JR, 1991, AM J PHYSIOL, V261, pG1005, DOI 10.1152/ajpgi.1991.261.6.G1005; FELIPE A, 1990, BIOCHIM BIOPHYS ACTA, V1029, P61, DOI 10.1016/0005-2736(90)90436-R; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MONTROSE MH, 1988, NA H EXCHANGE, P57; PREISIG PA, 1988, J CLIN INVEST, V82, P1445, DOI 10.1172/JCI113750; RAJENDRAN VM, 1993, AM J PHYSIOL, V264, pG874, DOI 10.1152/ajpgi.1993.264.5.G874; RAJENDRAN VM, 1991, J CLIN INVEST, V88, P1379, DOI 10.1172/JCI115444; RENNER EL, 1989, J CLIN INVEST, V83, P1225, DOI 10.1172/JCI114005; SOLEIMANI M, 1991, J CLIN INVEST, V88, P1135, DOI 10.1172/JCI115413; VILELLA S, 1992, PFLUG ARCH EUR J PHY, V420, P275, DOI 10.1007/BF00374459; WARNOCK DG, 1988, NA PLUS H PLUS EXCHA, P77; ZAMIR A, 1991, GASTROENTEROLOGY, V100, pA710	18	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					156	160						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276790				2022-12-25	WOS:A1994MR21900032
J	TAKAHASHI, M; TANZAWA, K; TAKAHASHI, S				TAKAHASHI, M; TANZAWA, K; TAKAHASHI, S			ADENOPHOSTINS, NEWLY DISCOVERED METABOLITES OF PENICILLIUM-BREVICOMPACTUM, ACT AS POTENT AGONISTS OF THE INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; TRISPHOSPHATE RECEPTOR; CALCIUM RELEASE; PLASMA-MEMBRANE; ANIMAL-TISSUES; RAT-BRAIN; CELL; BINDING; 1,3,4,5-TETRAKISPHOSPHATE; SOLUBILIZATION	Potent inositol 1,4,5-trisphosphate (IP3) receptor agonists, adenophostin A and B, were found from fungal products. In spite of the striking structural difference from IP3, adenophostins were found to inhibit [H]IP3 binding more potently than IP3: the K(i) values for adenophostin A and B were both calculated to be 0.18 nM, while that of IP3 was 15 nM. Adenophostins induced Ca2+ release both from cerebellar microsomes and from intracellular Ca2+ stores in permeabilized NG108-15 cells. Adenophostins at concentration as low as 1 nM produced a significant Ca2+ release from cerebellar microsomes, and their activities were 100-fold more potent than IP3. In addition, heparin, an IP3 receptor antagonist, completely blocked the Ca2+ releasing activity of adenophostins. Adenophostins were resistant to phosphorylation and dephosphorylation by IP3-metabolizing enzymes, thereby providing a possible explanation for their prolonged activities. Adenophostin also bound to plasma membrane IP3 receptor with a high affinity and inhibited [H-3]IP, binding to jurkat human T-cell plasma membranes: the IC50 value for adenophostin A was 0.95 nM. Adenophostin may prove to be a powerful tool for investigating the physiological properties of IP3 and its receptor.			TAKAHASHI, M (corresponding author), SANKYO CO LTD,FERMENTAT RES LABS,1-2-58 HIROMACHI,SHINAGAWA KU,TOKYO 140,JAPAN.							BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; CHADWICK CC, 1992, J BIOL CHEM, V267, P3473; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; HIGASHIDA H, 1986, NATURE, V323, P333, DOI 10.1038/323333a0; HIRATA M, 1989, J BIOL CHEM, V264, P20303; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; IRVINE RF, 1984, BIOCHEM J, V222, P269, DOI 10.1042/bj2220269; JEAN T, 1986, J BIOL CHEM, V261, P6414; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1991, J BIOL CHEM, V266, P2276; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; NAHORSKI SR, 1989, TRENDS PHARMACOL SCI, V10, P139, DOI 10.1016/0165-6147(89)90165-X; OGURA A, 1990, J BIOL CHEM, V265, P3577; PRESTWICH GD, 1991, J AM CHEM SOC, V113, P1822, DOI 10.1021/ja00005a055; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; STAUDERMAN KA, 1988, BIOCHEM J, V255, P667; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAKAHASHI M, 1993, IN PRESS J ANTIBIOT; TAKAHASHI S, IN PRESS J ANTIBIOT; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; THEIBERT AB, 1990, BIOCHEM J, V267, P441, DOI 10.1042/bj2670441; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	37	205	206	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					369	372						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276820				2022-12-25	WOS:A1994MR21900062
J	ZHANG, CH; EVANS, T				ZHANG, CH; EVANS, T			DIFFERENTIAL REGULATION OF THE 2 XGATA-1 GENES DURING XENOPUS DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID TRANSCRIPTION FACTOR; BONE MORPHOGENETIC PROTEIN-4; HEMATOPOIETIC-CELLS; VENTRALIZING FACTOR; FACTOR GATA-1; EXPRESSION; LAEVIS; MESODERM; INDUCTION; PROMOTER	Xenopus laevis provides an established developmental system to study the regulation of cell lineage establishment and the generation of tissue-specific patterns of gene expression. We have isolated from Xenopus erythroid cell RNA two distinct cDNA clones encoding the xGATA-1 transcription factor. We have identified, in erythroid nuclear extracts, the sequence-specific DNA-binding protein they encode. By characterizing the expression patterns for RNA derived from two distinct homologues, we find that the two xGATA-1 genes are differentially regulated. The xGATA-1a mRNA predominates in embryos prior to terminal differentiation of erythroid cells, while the differentiated cells contain RNA derived predominantly from the xGATA-1b gene. Both proteins activate a target globin promoter in transient transfection assays. During early development, GATA-1 transcripts are localized to ventral regions of the embryo. GATA-1 should therefore provide a useful early marker for studying signalling pathways which result in the generation of ventral mesoderm. The differentially regulated genes may be distinct markers for targets of ventral mesoderm induction.	UNIV PITTSBURGH,DEPT BIOL SCI,LANGLEY HALL,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044167] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44167] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DALE L, 1987, DEVELOPMENT, V99, P527; DALE L, 1992, DEVELOPMENT, V115, P573; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; JONES CM, 1992, DEVELOPMENT, V115, P639; KAU CL, 1983, J IMMUNOL, V131, P2262; KELLER RE, 1976, DEV BIOL, V51, P118, DOI 10.1016/0012-1606(76)90127-5; MAENO M, 1985, DEV BIOL, V110, P503, DOI 10.1016/0012-1606(85)90108-3; MAENO M, 1985, DEV GROWTH DIFFER, V27, P137; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; ORKIN SH, 1992, BLOOD, V80, P575; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SCHWARTZBAUER G, 1992, NUCLEIC ACIDS RES, V20, P4429, DOI 10.1093/nar/20.17.4429; SIMON MC, 1993, P SOC EXP BIOL MED, V202, P115; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; TRAINOR CD, 1990, NATURE, V343, P92, DOI 10.1038/343092a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10642, DOI 10.1073/pnas.88.23.10642	30	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					478	484						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276839				2022-12-25	WOS:A1994MR21900079
J	BRADFORD, HN; JAMESON, BA; ADAM, AA; WASSELL, RP; COLMAN, RW				BRADFORD, HN; JAMESON, BA; ADAM, AA; WASSELL, RP; COLMAN, RW			CONTIGUOUS BINDING AND INHIBITORY SITES ON KININOGENS REQUIRED FOR THE INHIBITION OF PLATELET CALPAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-MOLECULAR-WEIGHT; THIOL PROTEINASE-INHIBITORS; EGG-WHITE CYSTATIN; BROWN NORWAY RATS; CYSTEINE PROTEINASES; T-KININOGEN; MONOCLONAL-ANTIBODIES; HUMAN-NEUTROPHILS; KATHOLIEK STRAIN; PURIFICATION	Both high molecular weight kininogen (HK) and low molecular weight kininogens (LK) are potent tight binding inhibitors of platelet calpain (K(i) = 2 nM), but the molecular basis for the inhibitory function is not well delineated. The amino acid sequences of the calpain inhibitory domain 2 from human and rat HK were compared for homology with the noninhibitory domains from human and rat domain 3 and from domain 2 of rat T-kininogen, and two areas of nonconserved differences were detected. Computer three-dimensional models were constructed on a template built using the x-ray crystallographic data for cystatin, an evolutionary precursor of HK. Two nonconserved regions in the calpain inhibitory domains flank the highly conserved motif QVVAG to form a continuous surface for interaction with cysteine proteases. Three peptide sequences, components of the modeled surface, were chosen for synthesis from HK D-2: VHPISTQSPDLE (peptide 146-156, NH2-terminal), CTDNAYIDIQLRIASFSQNC (peptide 229-248, COOH-terminal), and CQRQVVAGLNFRIC (185-189, central) containing QVVAG. This last peptide differs from the natural sequence by substitutions of A185C and T195C. Peptides 185-198 and 229-248 were folded by air oxidation of their cysteine residues and then tested for their ability to inhibit calpain and papain. The folded peptide 229-248 inhibited calpain with an IC50 35 muM and unfolding reduced this effect. The folded peptide 185-198 did not inhibit calpain, but when preincubated with calpain, could block the inhibition by HK indicating a probable enzyme binding site. Peptide 146-157 did not inhibit calpain but could inhibit papain with an IC50 of 20 muM. We have thus defined separate binding and inhibitory sequences on HK which form a contiguous surface for thiol protease interactions.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,SOL SHERRY THROMBOSIS RES CTR,3400 N BROAD ST,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT MED,PHILADELPHIA,PA 19140; THOMAS JEFFERSON UNIV,INST CANC,PHILADELPHIA,PA 19107; UNIV MONTREAL,FAC PHARM,MONTREAL H3C 3J7,QUEBEC,CANADA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University; Universite de Montreal				Bradford, Harlan/0000-0001-5582-278X	NHLBI NIH HHS [HL45486] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL045486] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM A, 1989, BIOCHEM CELL BIOL, V67, P86, DOI 10.1139/o89-013; ANASTASI A, 1983, BIOCHEM J, V211, P129, DOI 10.1042/bj2110129; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BRADFORD HN, 1990, BIOCHEM J, V270, P83, DOI 10.1042/bj2700083; BRADFORD HN, 1988, BLOOD, V71, P388; COLLER BS, 1982, BLOOD, V60, P731; COLMAN RW, 1975, J CLIN INVEST, V56, P1650, DOI 10.1172/JCI108247; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ENJYOJI K, 1988, J BIOL CHEM, V263, P973; GOUNARIS AD, 1984, BIOCHEM J, V221, P445, DOI 10.1042/bj2210445; GUSTAFSON EJ, 1986, J CLIN INVEST, V78, P310, DOI 10.1172/JCI112567; GUSTAFSON EJ, 1989, J CLIN INVEST, V84, P28, DOI 10.1172/JCI114151; HAYASHI I, 1985, THROMB RES, V39, P313, DOI 10.1016/0049-3848(85)90227-0; HIGASHIYAMA S, 1986, LIFE SCI, V39, P1639, DOI 10.1016/0024-3205(86)90160-8; ISHIGURO H, 1987, BIOCHEMISTRY-US, V26, P7021, DOI 10.1021/bi00396a025; JOHNSON DA, 1987, THROMB RES, V48, P187, DOI 10.1016/0049-3848(87)90415-4; KANAOKA Y, 1977, CHEM PHARM BULL, V25, P3126; KOSOWER NS, 1983, P NATL ACAD SCI-BIOL, V80, P7542, DOI 10.1073/pnas.80.24.7542; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACHLEIDT W, 1989, FEBS LETT, V243, P234, DOI 10.1016/0014-5793(89)80135-8; MATSUEDA R, 1990, CHEM LETT, V389, P191; MOREAU T, 1988, EUR J BIOCHEM, V173, P185, DOI 10.1111/j.1432-1033.1988.tb13983.x; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; OHISHI S, 1982, THROMB RES, V28, P143, DOI 10.1016/0049-3848(82)90043-3; OKADA Y, 1985, CHEM PHARM BULL, V33, P5149; PONTREMOLI S, 1986, P NATL ACAD SCI USA, V83, P1685, DOI 10.1073/pnas.83.6.1685; PONTREMOLI S, 1988, J BIOL CHEM, V263, P1915; PURI RN, 1988, T AM ASS PHYSICIANS, V100, P232; REIS ML, 1985, BIOCHIM BIOPHYS ACTA, V831, P106, DOI 10.1016/0167-4838(85)90156-6; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; SCHMAIER AH, 1986, BLOOD, V67, P119; SCHMAIER AH, 1986, J CLIN INVEST, V77, P1565, DOI 10.1172/JCI112472; SCHMAIER AH, 1983, J CLIN INVEST, V71, P1477, DOI 10.1172/JCI110901; SCHMAIER AH, 1987, J BIOL CHEM, V262, P1405; SCHMAIER AH, 1990, BLOOD, V75, P1273; SCHMAIER AH, 1988, J BIOL CHEM, V263, P1; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SCICLI AG, 1984, CLIN EXP HYPERTENS A, V6, P1731, DOI 10.3109/10641968409046068; SCOTT CF, 1985, J BIOL CHEM, V260, P856; SCOTT CF, 1984, J CLIN INVEST, V73, P954, DOI 10.1172/JCI111319; SHEPPARD A, 1991, BIOCHIM BIOPHYS ACTA, V1076, P156, DOI 10.1016/0167-4838(91)90234-Q; TAKAGAKI Y, 1985, J BIOL CHEM, V260, P8601; TENO N, 1987, INT J PEPT PROT RES, V30, P93	43	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26546	26551						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253784				2022-12-25	WOS:A1993MK42500078
J	FEINSTEIN, R; KANETY, H; PAPA, MZ; LUNENFELD, B; KARASIK, A				FEINSTEIN, R; KANETY, H; PAPA, MZ; LUNENFELD, B; KARASIK, A			TUMOR-NECROSIS-FACTOR-ALPHA SUPPRESSES INSULIN-INDUCED TYROSINE PHOSPHORYLATION OF INSULIN-RECEPTOR AND ITS SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FACTOR SIGNAL TRANSDUCTION; SERINE PHOSPHORYLATION; HEPATOMA-CELLS; PROTEIN; KINASE; INVIVO; RESISTANCE; MODULATE; SEPSIS; RATS	Tumor necrosis factor-alpha (TNF) has recently been shown to induce insulin resistance. We have examined the possible effect of TNF on the early events in insulin transmembrane signaling. Incubation of the insulin-sensitive rat hepatoma Fao cells with 5 nM TNF for 1 h led to a 65% decrease in insulin-induced tyrosine phosphorylation of both the insulin receptor beta-subunit and IPS-1, its major cytosolic substrate. TNF-induced impairment of tyrosine phosphorylation was maximal at 0.5 nM and was not accompanied by any reduction in insulin binding. Sixteen hours of TNF incubation led to further impairment in insulin-induced tyrosine phosphorylation of these proteins. Our findings suggest that TNF may exert its anti-insulin effect by interrupting the early insulin-stimulated tyrosine phosphorylation events, which are crucial to insulin transmembrane signature.	BAR ILAN UNIV,DEPT LIFE SCI,IL-52900 RAMAT GAN,ISRAEL; CHAIM SHEBA MED CTR,DEPT SURG,IL-52621 TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,INST ENDOCRINOL,IL-52621 TEL HASHOMER,ISRAEL	Bar Ilan University; Chaim Sheba Medical Center; Chaim Sheba Medical Center								BENNEGARD K, 1986, CLIN PHYSIOL, V6, P539; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DONATO NJ, 1992, CELL GROWTH DIFFER, V3, P259; FEINGOLD KR, 1987, J CLIN INVEST, V80, P184, DOI 10.1172/JCI113046; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FONG Y, 1990, CLIN IMMUNOL IMMUNOP, V55, P157, DOI 10.1016/0090-1229(90)90094-7; Holm-Hansen O., 1978, METHOD ENZYMOL, V57, P73, DOI [10.1016/0076-6879(78)57010-9, DOI 10.1016/0076-6879(78)57010-9]; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HURRELL DG, 1989, ENDOCRINOLOGY, V125, P2454, DOI 10.1210/endo-125-5-2454; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; LANG CH, 1989, AM J PHYSIOL, V257, pE301, DOI 10.1152/ajpendo.1989.257.3.E301; MIRALPEIX M, 1992, BIOCHEMISTRY-US, V31, P9031, DOI 10.1021/bi00152a046; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; OFFNER F, 1990, J LAB CLIN MED, V116, P100; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SCHUTZE S, 1989, J BIOL CHEM, V264, P3562; SHAFRIR E, 1990, DIABETES MELLITUS TH, P299; SPIEGELMAN BM, 1993, J BIOL CHEM, V268, P6823; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TOTPAL K, 1992, CANCER RES, V52, P2557; VANLINT J, 1992, J BIOL CHEM, V267, P25916; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	30	445	451	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26055	26058						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253716				2022-12-25	WOS:A1993MK42500007
J	LONGO, FM; MARTIGNETTI, JA; LEBEAU, JM; ZHANG, JS; BARNES, JP; BROSIUS, J				LONGO, FM; MARTIGNETTI, JA; LEBEAU, JM; ZHANG, JS; BARNES, JP; BROSIUS, J			LEUKOCYTE COMMON ANTIGEN-RELATED RECEPTOR-LINKED TYROSINE PHOSPHATASE - REGULATION OF MESSENGER-RNA EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; NEURAL DEVELOPMENT; NEURONAL DIFFERENTIATION; EXTRACELLULAR-MATRIX; ENDOCRINE NEOPLASIA; GROWTH; CLONING; CD45; LAR; DOMAINS	Receptor-linked tyrosine phosphatases regulate cell growth by dephosphorylating proteins involved in tyrosine kinase signal transduction. Within this gene family, the leukocyte common antigen-related (LAR) gene is of particular interest with respect to the nervous system because it has sequence similarity to the neural cell adhesion molecule N-CAM and is located in a chromosomal region (1p32-33) frequently deleted in neuroectodermal tumors. However, immunostaining has detected LAR in non-neural tissues, but not in the central nervous system, peripheral neurons, or adrenal medulla. In this study, rat brain cDNA library LAR clones corresponding to cytoplasmic and 3'-untranslated regions of human LAR were identified. Using probes derived from these clones, high stringency Northern blots revealed approximately 8 kilobase and variable length tissue- and cell-specific LAR transcripts in cortex, brainstem, cerebellum, spinal cord, peripheral tissues, and cultured neural, glial, and pheochromocytoma cells. In situ hybridization showed expression by brain and dorsal root ganglion neurons. LAR expression was developmentally regulated in a region-dependent manner. Changes in LAR expression were also found during nerve growth factor-induced PC12 pheochromocytoma cell differentiation and with contact-mediated inhibition of fibroblast growth. These observations and studies demonstrating neurotrophins functioning via tyrosine kinase receptors suggest that LAR represents an additional mechanism regulating neural development.	UNIV CALIF SAN FRANCISCO,VET AFFAIRS MED CTR,DEPT NEUROL,SAN FRANCISCO,CA 94121; MT SINAI MED CTR,FISHBERG RES CTR NEUROBIOL,NEW YORK,NY 10029; MT SINAI MED CTR,DEPT PEDIAT,NEW YORK,NY 10029; EASTERN VIRGINIA MED SCH,INST DIABET,NORFOLK,VA 23501	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Eastern Virginia Medical School			Brosius, Jürgen/F-5029-2016	Brosius, Jürgen/0000-0003-1650-2059	NIA NIH HHS [R01 AG09873] Funding Source: Medline; NIMH NIH HHS [R01 MH38819] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009873] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APARICIO LF, 1992, CELL GROWTH DIFFER, V3, P363; ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BRAUTIGAN DL, 1992, BIOCHIM BIOPHYS ACTA, V1114, P63, DOI 10.1016/0304-419X(92)90007-L; Burridge K., 1992, Current Biology, V2, P537, DOI 10.1016/0960-9822(92)90020-B; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHO HJ, 1992, BIOCHEMISTRY-US, V31, P133, DOI 10.1021/bi00116a019; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; Doherty P, 1992, Curr Opin Neurobiol, V2, P595, DOI 10.1016/0959-4388(92)90024-F; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; HUTNER T, 1989, CELL, V58, P1013; Jacobson M, 1978, DEV NEUROBIOL, P57; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; JIRIK FR, 1992, CYTOGENET CELL GENET, V61, P266, DOI 10.1159/000133418; JOHNSON NA, 1989, J BIOL CHEM, V264, P6220; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KIMMEL DW, 1992, ANN NEUROL, V31, P534, DOI 10.1002/ana.410310512; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LEBEAU JM, 1991, J NEUROSCI RES, V28, P299, DOI 10.1002/jnr.490280217; LEVITT RC, 1991, GENOMICS, V11, P484, DOI 10.1016/0888-7543(91)90168-E; LEVY JB, 1993, J BIOL CHEM, V268, P10573; MAGAL E, 1991, J NEUROSCI RES, V30, P560, DOI 10.1002/jnr.490300314; MATHEW CGP, 1987, NATURE, V328, P524, DOI 10.1038/328524a0; MOBLEY WC, 1986, MOL BRAIN RES, V1, P53, DOI 10.1016/0169-328X(86)90020-3; MOLEY JF, 1992, CANCER RES, V52, P770; Nairn A C, 1992, Curr Opin Neurobiol, V2, P296, DOI 10.1016/0959-4388(92)90118-5; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; POT DA, 1991, J BIOL CHEM, V266, P19688; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; RITKE MK, 1989, CYTOGENET CELL GENET, V50, P84, DOI 10.1159/000132729; ROTHSTEIN DM, 1992, J BIOL CHEM, V267, P7139; RUTISHAUSER U, 1988, PHYSIOL REV, V68, P819, DOI 10.1152/physrev.1988.68.3.819; SAGA Y, 1990, P NATL ACAD SCI USA, V87, P3728, DOI 10.1073/pnas.87.10.3728; Sambrook J, 1989, MOL CLONING LABORATO; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P2579, DOI 10.1073/pnas.74.6.2579; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; YU Q, 1992, ONCOGENE, V7, P1051; ZHANG WR, 1991, BIOCHEM BIOPH RES CO, V178, P1291, DOI 10.1016/0006-291X(91)91034-A	52	71	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26503	26511						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253779				2022-12-25	WOS:A1993MK42500073
J	MENON, SD; QIN, SX; GUY, GR; TAN, YH				MENON, SD; QIN, SX; GUY, GR; TAN, YH			DIFFERENTIAL INDUCTION OF NUCLEAR NF-KAPPA-B BY PROTEIN PHOSPHATASE INHIBITORS IN PRIMARY AND TRANSFORMED HUMAN-CELLS - REQUIREMENT FOR BOTH OXIDATION AND PHOSPHORYLATION IN NUCLEAR TRANSLOCATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; KINASE-C; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION; OKADAIC ACID; HUMAN-FIBROBLASTS; FACTOR-ALPHA; ACTIVATION; BINDING	Phosphoseryl/threonyl protein phosphatase inhibitors, viz. okadaic acid and calyculin-A, failed to induce nuclear factor-kappaB (NF-kappaB) nuclear translocation in several primary human cells although a marked and rapid induction was observed in their simian virus 40 transformed counterparts. Inability to induce NF-kappaB cannot be due to a non-activatable system since NF-kappaB was strongly activated by tumor necrosis factor in all the five primary cell types tested. It is also unlikely that the differential induction was due to differential sensitivity of primary and transformed cells to phosphatase inhibitors as the intracellular phosphatase activities of both cell types were equally inhibited by these inhibitors. However, pretreatment with hydrogen peroxide or buthionine sulfoximine, chemicals known to directly or indirectly elevate the intracellular free-radical levels, enabled okadaic acid to induce nuclear translocation of NF-kappaB in primary cells. Conversely cysteine, an antioxidant and precursor of the free radical scavenger, glutathione, inhibited the induction of NF-kappaB by tumor necrosis factor in primary cells, and by okadaic acid or tumor necrosis factor in transformed cells. These data, taken together, suggest that free radical-dependent oxidation and protein phosphorylation are not independent modes of NF-kappaB induction, but are both required for the release of NF-kappaB from IkappaB. Furthermore, the differential induction of NF-kappaB nuclear translocation by okadaic acid in primary and transformed human cells, reported herein, reflects intrinsic differences in the intracellular oxidative state between the two groups of cells. The induction of NF-kappaB by tumor necrosis factor in primary cells suggests that this cytokine fulfills the requirement for oxidation, possibly by inducing the production of free radicals.	NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, 10 KENT RIDGE CRESCENT, SINGAPORE 0511, SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore								BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, COLD SPRING HARB SYM, V53, P789, DOI 10.1101/SQB.1988.053.01.089; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; CAO XM, 1992, J BIOL CHEM, V267, P12991; CHAN WK, 1990, NUCLEIC ACIDS RES, V18, P763, DOI 10.1093/nar/18.4.763; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHRISTIANSEN NO, 1988, FEBS LETT, V239, P195, DOI 10.1016/0014-5793(88)80915-3; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FRIEDL HP, 1989, FASEB J, V3, P2512, DOI 10.1096/fasebj.3.13.2806779; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GRILLI M, 1993, INT REV CYTOL, P143; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUY GR, 1991, J BIOL CHEM, V266, P14343; GUY GR, 1992, J BIOL CHEM, V267, P1846; GUY GR, 1993, J BIOL CHEM, V268, P2141; HALLIWELL B, 1989, FREE RADICAL BIO MED, P79; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; ISRAEL N, 1992, J IMMUNOL, V149, P3386; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; LANDGRAF W, 1991, J BIOL CHEM, V266, P16305; LINK E, 1992, J BIOL CHEM, V267, P239; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MEISTER A, 1992, CHEMTRACTS BIOCH MOL, V3, P75; MINERS JO, 1984, BIOCHEM PHARMACOL, V33, P2995, DOI 10.1016/0006-2952(84)90599-9; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Schmitz M L, 1991, Trends Cell Biol, V1, P130, DOI 10.1016/0962-8924(91)90118-S; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; Schulze-Osthoff K, 1991, Trends Cell Biol, V1, P150, DOI 10.1016/0962-8924(91)90003-R; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; SUGANUMA M, 1990, CANCER RES, V50, P3521; SWAIN JE, 1991, J NEUROBIOL, V22, P855, DOI 10.1002/neu.480220806; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; THEVENIN C, 1990, New Biologist, V2, P793; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328	50	91	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26805	26812						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253818				2022-12-25	WOS:A1993MK42500115
J	MURPHYULLRICH, JE; GURUSIDDAPPA, S; FRAZIER, WA; HOOK, M				MURPHYULLRICH, JE; GURUSIDDAPPA, S; FRAZIER, WA; HOOK, M			HEPARIN-BINDING PEPTIDES FROM THROMBOSPONDIN-1 AND THROMBOSPONDIN-2 CONTAIN FOCAL ADHESION-LABILIZING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLATELET THROMBOSPONDIN; HUMAN-MELANOMA CELLS; ENDOTHELIAL-CELLS; SULFATED GLYCOLIPIDS; GENE FAMILY; I REPEATS; RECEPTOR; GROWTH; ATTACHMENT; EXPRESSION	The cell adhesion regulating extracellular matrix glycoprotein, thrombospondin (TSP), causes a loss of focal adhesion plaques from spread endothelial cells and fibroblasts. To localize the site on TSP that has focal adhesion-labilizing activity, we initially tested proteolytic fragments of TSP for activity. The heparin-binding fragment has significant focal adhesion-labilizing activity, whereas the nonheparin-binding 140-kDa fragment had no significant activity. These results were consistent with previous data that showed that both a monoclonal antibody to the heparin-binding domain of TSP (A2.5) and heparin neutralized TSP activity. Peptides from putative heparin binding sequences of the amino-terminal heparin-binding domain of TSP were synthesized and tested for their ability to cause loss of focal adhesions. The hep I peptide (amino acids 17-35) caused maximal loss of focal adhesions and was active at 0.1 muM, whereas peptide hep II (74-95) and peptide hep III (170-189) were inactive. The activity of the hep I peptide was neutralized by the addition of heparin and heparan sulfate but not by chondroitin sulfate. The basic amino acids in the hep I sequence appear to be required for focal adhesion-labilizing activity, because modification of the lysine residues at amino acids 24 and 32 rendered the peptide completely inactive. In addition, a peptide from the analogous sequence of mouse TSP 2, in which basic residues are conserved, was nearly as active as hep I from TSP1. These data show that the anti-adhesive activity of TSP is conserved in both TSP1 and TSP2 and that the active site is located in a 19-amino acid sequence in the heparin-binding domain of TSPs.	TEXAS A&M UNIV SYST, INST BIOSCI & TECHNOL, HOUSTON, TX 77030 USA; WASHINGTON UNIV, SCH MED, DEPT BIOL CHEM, ST LOUIS, MO 63110 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Washington University (WUSTL)	MURPHYULLRICH, JE (corresponding author), UNIV ALABAMA, DEPT PATHOL, DIV MOLEC & CELLULAR BIOL, G038 VOLKER HALL, BIRMINGHAM, AL 35294 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044575] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44575] Funding Source: Medline; NIADDK NIH HHS [AM-27087] Funding Source: Medline; NICHD NIH HHS [HD27712] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACHARYA AS, 1984, J CHROMATOGR, V297, P37, DOI 10.1016/S0021-9673(01)89027-0; ASCH AS, 1991, J BIOL CHEM, V266, P1740; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BAGAVANDOSS P, 1990, BIOCHEM BIOPH RES CO, V163, P56; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BORNSTEIN P, 1991, P NATL ACAD SCI USA, V88, P8636, DOI 10.1073/pnas.88.19.8636; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Chiquet-Ehrismann R, 1991, CURR OPIN CELL BIOL, V3, P800, DOI 10.1016/0955-0674(91)90053-2; COUCHMAN JR, 1979, J CELL SCI, V39, P149; DIXIT VM, 1984, J BIOL CHEM, V259, P100; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GALVIN NJ, 1985, J CELL BIOL, V101, P1434, DOI 10.1083/jcb.101.4.1434; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; KAESBERG PR, 1989, J CLIN INVEST, V83, P994, DOI 10.1172/JCI113986; LABELL TL, 1992, GENOMICS, V12, P421, DOI 10.1016/0888-7543(92)90430-Z; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LAWLER J, 1993, J CELL BIOL, V120, P1059, DOI 10.1083/jcb.120.4.1059; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1992, BIOCHEMISTRY-US, V31, P1173, DOI 10.1021/bi00119a029; LAWLER J, 1991, J BIOL CHEM, V266, P8039; MAJACK RA, 1986, P NATL ACAD SCI USA, V83, P9050, DOI 10.1073/pnas.83.23.9050; MOSHER DF, 1990, ANNU REV MED, V41, P85; MURPHYULLRICH JE, 1987, SEMIN THROMB HEMOST, V13, P343, DOI 10.1055/s-2007-1003510; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; MURPHYULLRICH JE, 1987, J CELL BIOL, V105, P1603, DOI 10.1083/jcb.105.4.1603; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; ROBERTS DD, 1988, CANCER RES, V48, P6785; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; ROBERTS DD, 1987, J CELL BIOL, V104, P131, DOI 10.1083/jcb.104.1.131; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SILVERSTEIN RL, 1992, J BIOL CHEM, V267, P16607; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TARABOLETTI G, 1987, J CELL BIOL, V105, P2409, DOI 10.1083/jcb.105.5.2409; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; VOS HL, 1992, J BIOL CHEM, V267, P12192; YABKOWITZ R, 1989, J BIOL CHEM, V264, P10888; YABKOWITZ R, 1991, CANCER RES, V51, P3648	45	142	146	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26784	26789						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253815				2022-12-25	WOS:A1993MK42500112
J	TCHOU, J; MICHAELS, ML; MILLER, JH; GROLLMAN, AP				TCHOU, J; MICHAELS, ML; MILLER, JH; GROLLMAN, AP			FUNCTION OF THE ZINC-FINGER IN ESCHERICHIA-COLI FPG PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE; APURINIC APYRIMIDINIC SITES; POLY(ADP-RIBOSE) POLYMERASE; SUBSTRATE-SPECIFICITY; IONIZING-RADIATION; IMIDAZOLE RINGS; DAMAGED DNA; MUTAGENESIS; EXCISION; 8-HYDROXYGUANINE	Fpg protein of Escherichia coli cleaves duplex DNA containing the oxidatively damaged base 8-oxo-7,8-dihydroguanine (Tchou, J., Kasai, H., Shibutani, S., Chung, M.-H., Laval, J., Grollman, A. P., and Nishimura, S. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 4690-4694). This DNA repair enzyme contains one zinc atom/protein molecule (Boiteux, S., O'Connor, T. R., Lederer, F., Gougette, A., and Laval, J. (1990) J. Biol. Chem. 265, 3916-3922); its N-glycosylase and apurinic/apyrimidinic lyase activities are physically associated. Amino acid sequence analysis reveals a putative single zinc finger motif of the CC/CC type located near the carboxyl terminus. A gel mobility shift assay was used to assay binding of Fpg protein to a non-cleavable substrate analog, namely an oligodeoxynucleotide duplex containing a single tetrahydrofuran residue. High resolution hydroxyl radical DNA footprinting showed protection centered around the tetrahydrofuran residue. No footprint was observed on the complementary strand. To establish the role of COOH-terminal zinc finger in DNA binding and/or DNA cleavage, amino acid substitutions and an amber mutation were introduced at Cys-244 (C244S, C244H, C244A, and C244amber). In addition, a double amino acid substitution was generated at Cys-244 and Cys-247 (C244S/C247S). These mutant Fpg proteins lack DNA binding or cleavage activity, as tested in crude lysates of Escherichia coli. Wild type Fpg protein contains one zinc/protein molecule, whereas the mutant Fpg protein (C244S/C247S) lacks zinc, as measured by atomic absorption spectroscopy. This mutation did not significantly alter secondary structure, as assessed by circular dichroism spectroscopy. Our results suggest that Fpg protein utilizes its single COOH-terminal zinc finger motif in DNA binding.	UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	TCHOU, J (corresponding author), SUNY STONY BROOK,DEPT PHARMACOL SCI,STONY BROOK,NY 11794, USA.				NATIONAL CANCER INSTITUTE [R37CA017395, R01CA017395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032184] Funding Source: NIH RePORTER; NCI NIH HHS [CA-17395] Funding Source: Medline; NIGMS NIH HHS [GM-32184, GM07518] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BODEPUDI V, 1991, NUCLEOS NUCLEOT NUCL, V10, P755, DOI 10.1080/07328319108046660; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BOITEUX S, 1989, CARCINOGENESIS, V10, P1905, DOI 10.1093/carcin/10.10.1905; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREIMER LH, 1984, NUCLEIC ACIDS RES, V12, P6359, DOI 10.1093/nar/12.16.6359; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHETSANGA CJ, 1983, CARCINOGENESIS, V4, P997, DOI 10.1093/carcin/4.8.997; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; DOWD DR, 1990, J BIOL CHEM, V265, P3424; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; GROLLMAN AP, 1992, 7TH P CONV BIOM STER, V1, P165; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; JONES JS, 1988, NUCLEIC ACIDS RES, V16, P7119, DOI 10.1093/nar/16.14.7119; Kaptein R, 1991, CURR OPIN STRUC BIOL, V1, P63, DOI 10.1016/0959-440X(91)90013-J; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAL J, 1990, MUTAT RES, V233, P73, DOI 10.1016/0027-5107(90)90152-T; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4689, DOI 10.1093/nar/17.12.4689; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3269; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3834, DOI 10.1021/bi00230a005; NAVARATNAM S, 1989, J BIOL CHEM, V264, P16067; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; RYDBERG B, 1991, P NATL ACAD SCI USA, V88, P6839, DOI 10.1073/pnas.88.15.6839; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	42	89	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26738	26744						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253809				2022-12-25	WOS:A1993MK42500106
J	BOMSEL, M; MOSTOV, KE				BOMSEL, M; MOSTOV, KE			POSSIBLE ROLE OF BOTH THE ALPHA-SUBUNIT AND BETA-GAMMA-SUBUNIT OF THE HETEROTRIMERIC G-PROTEIN, G(S), IN TRANSCYTOSIS OF THE POLYMERIC IMMUNOGLOBULIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEINS; CANINE KIDNEY-CELLS; MDCK CELLS; ADP-RIBOSYLATION; REGULATORY PROTEINS; TRANSPORT VESICLES; MEMBRANE-PROTEIN; EPITHELIAL-CELLS; CHOLERA-TOXIN; BREFELDIN-A	In endosomes the polymeric immunoglobulin receptor (pIgR) is sorted into transcytotic vesicles. Transcytosis of the pIgR in polarized Madin-Darby canine kidney (MDCK) cells is regulated both by phosphorylation of Ser664 and by binding of ligand, dimeric IgA (dIgA). Mutation of Ser664 to Ala (pIgR-Ala664) greatly reduces transcytosis of the pIgR without dIgA bound. Here we report that cholera toxin, which specifically activates the heterotrimeric G protein, G(s), stimulates transcytosis of pIgR-Ala664 when dIgA is not bound. However, transcytosis of the wild-type pIgR without dIgA bound was not stimulated by cholera toxin. To further analyze the involvement of G(s) in transcytosis, we reconstituted part of the transcytotic pathway. Vesicles containing endocytosed ligand bound to the pIgR could be released from MDCK cells whose apical surface had been mechanically perforated. Release of these vesicles was controlled by phosphorylation of the pIgR and by binding of dIgA. The use of perforated cells allowed us to directly address the involvement of G(s). Our data suggest that both subunits of G(s), G(salpha) and betagamma, function together to control vesicular release and may therefore be involved in transcytosis in vivo.	UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Bomsel, Morgane/GSN-1948-2022	Bomsel, Morgane/0000-0002-9577-7474; mostov, keith/0000-0002-8123-6247	NIAID NIH HHS [R01 AI25144] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025144] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APODACA G, 1991, J CLIN INVEST, V87, P1877, DOI 10.1172/JCI115211; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; BENNETT MK, 1988, EMBO J, V7, P4075, DOI 10.1002/j.1460-2075.1988.tb03301.x; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BOBAK DA, 1990, BIOCHEMISTRY-US, V29, P855, DOI 10.1021/bi00456a600; BOMSEL M, 1989, J CELL BIOL, V109, P3243, DOI 10.1083/jcb.109.6.3243; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BOMSEL M, 1991, Current Opinion in Cell Biology, V3, P647, DOI 10.1016/0955-0674(91)90036-X; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; BREITFELD PP, 1989, J CELL BIOL, V109, P475, DOI 10.1083/jcb.109.2.475; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CODINA J, 1988, BIOCHEM BIOPH RES CO, V150, P848, DOI 10.1016/0006-291X(88)90469-X; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1991, METHOD ENZYMOL, V195, P192; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; LINDER ME, 1991, METHOD ENZYMOL, V195, P202; MERESSE S, 1990, J BIOL CHEM, V265, P18833; MOSS J, 1991, METHOD ENZYMOL, V195, P243; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; NEGISHI M, 1992, J BIOL CHEM, V267, P2364; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; RANSNAS LA, 1989, P NATL ACAD SCI USA, V86, P7900, DOI 10.1073/pnas.86.20.7900; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WANG N, 1990, J BIOL CHEM, V265, P1239	43	76	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25824	25835						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245019				2022-12-25	WOS:A1993MK10000080
J	LAVENU, A; POURNIN, S; BABINET, C; MORELLO, D				LAVENU, A; POURNIN, S; BABINET, C; MORELLO, D			THE CIS-ACTING ELEMENTS KNOWN TO REGULATE C-MYC EXPRESSION EX-VIVO ARE NOT SUFFICIENT FOR CORRECT TRANSCRIPTION IN-VIVO	ONCOGENE			English	Article							LOCUS ACTIVATION REGION; RNA POLYMERASE-II; TRANSGENIC MICE; BURKITT-LYMPHOMA; CHROMATIN STRUCTURE; MESSENGER-RNA; CHROMOSOME-TRANSLOCATION; EFFICIENT TRANSCRIPTION; MODULATE EXPRESSION; NEOPLASTIC-CELLS	Much of our knowledge about the regulation of the c-myc proto-oncogene expression has come from studies of c-myc gene expression in several well defined ex vivo systems, including differentiation systems and tumor cells. However, very few investigations have been performed to determine the factors and cis-acting sequences that regulate c-myc expression in vivo. In order to obtain information on the sequences required to regulate c-myc gene transcription from the two major P1 and P2 initiation sites in the mouse, we have generated several constructs containing human or murine c-myc genomic sequences with various 5' flanking sequences and derived corresponding transgenic mice. A sensitive S1 nuclease protection assay was performed to analyse and to compare transgene expression with that of the endogeneous c-myc mRNA, either in adult organs, or during development. None of the transgenic mice expressed the construct appropriately, although several strains exhibited unexpected expression most probably due to position effects. Our results indicate that the cis-acting elements described to regulate c-myc expression ex vivo are not sufficient to drive the correct expression of c-myc gene in vivo and strongly suggest that additional regulatory elements located upstream from -3500 (with respect to mouse P1 promoter) and downstream 1500 bp from polyadenylation sites are required.	INST PASTEUR, DEPT IMMUNOL, UNITE GENET MAMMIFERES, F-75724 PARIS 15, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								ASSELIN C, 1989, ONCOGENE, V4, P549; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DUBIK D, 1992, ONCOGENE, V7, P1587; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; FINVER SN, 1988, P NATL ACAD SCI USA, V85, P3052, DOI 10.1073/pnas.85.9.3052; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HAMMER RE, 1987, MOL CELL BIOL, V7, P2956, DOI 10.1128/MCB.7.8.2956; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KAKKIS E, 1987, P NATL ACAD SCI USA, V84, P7031, DOI 10.1073/pnas.84.20.7031; KESSLER DJ, 1992, ONCOGENE, V7, P2447; KUMAR S, 1991, J MOL BIOL, V222, P45, DOI 10.1016/0022-2836(91)90736-P; LAIRDOFFRINGA IA, 1992, BIOESSAYS, V14, P119, DOI 10.1002/bies.950140209; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LIPP M, 1989, ONCOGENE, V4, P535; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; MANGO SE, 1989, MOL CELL BIOL, V9, P3482, DOI 10.1128/MCB.9.8.3482; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MEULIA T, 1992, MOL CELL BIOL, V12, P4590, DOI 10.1128/MCB.12.10.4590; MORELLO D, 1989, ONCOGENE, V4, P955; MORELLO D, 1989, ONCOGENE RES, V4, P111; MORELLO D, 1993, ONCOGENE, V8, P1921; NISHIKURA K, 1985, MOL CELL BIOL, V5, P1434, DOI 10.1128/MCB.5.6.1434; NISHIKURA K, 1986, MOL CELL BIOL, V6, P4093, DOI 10.1128/MCB.6.11.4093; Orkin SH, 1990, CURR OPIN CELL BIOL, V2, P1003, DOI 10.1016/0955-0674(90)90149-9; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; RAY R, 1991, MOL CELL BIOL, V11, P2154, DOI 10.1128/MCB.11.4.2154; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; RICHMAN A, 1989, MOL CELL BIOL, V9, P4962, DOI 10.1128/MCB.9.11.4962; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; ROBERTS S, 1992, GENE DEV, V6, P1562, DOI 10.1101/gad.6.8.1562; ROLAND J, 1993, CELL GROWTH DIFFER, V4, P891; SACCA R, 1990, ONCOGENE, V5, P1499; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WEI Y, 1990, GENE, V93, P301, DOI 10.1016/0378-1119(90)90240-R; WEISINGER G, 1988, ONCOGENE, V3, P635; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x; ZAJAC-KAYE M, 1990, J BIOL CHEM, V265, P4547; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZIMMERMAN K, 1990, MOL CELL BIOL, V10, P2096, DOI 10.1128/MCB.10.5.2096; ZOBEL A, 1991, ONCOGENE, V6, P1397	65	30	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					527	536						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290263				2022-12-25	WOS:A1994MW24800020
J	BERGSTEN, P; MOURA, AS; ATWATER, I; LEVINE, M				BERGSTEN, P; MOURA, AS; ATWATER, I; LEVINE, M			ASCORBIC-ACID AND INSULIN-SECRETION IN PANCREATIC-ISLETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMIDATING MONOOXYGENASE; BETA-CELL; VITAMIN-C; DEHYDROASCORBIC ACID; DIABETES-MELLITUS; HUMAN NEUTROPHILS; CHROMAFFIN CELLS; RAT PANCREAS; HUMAN-PLASMA; GLUCOSE	The effect of ascorbic acid on glucose-induced insulin release from single pancreatic islets was measured using a new, ultra-sensitive enzyme-linked immunosorbent insulin assay. Within 20 s ascorbic acid inhibited insulin secretion; inhibition was dose dependent and completely reversible. There was a 50% inhibition of the secretory response with 200 muM ascorbic acid and 90% inhibition with 400 muM ascorbic acid. The decrease in insulin secretion was recorded as a reduction of the amplitudes of the fast insulin transients, which give rise to the oscillatory nature of insulin secretion. The inhibition of glucose-induced insulin release by ascorbic acid was associated with hyperpolarization of the pancreatic beta-cell. Suppression of glucose-induced membrane depolarization was evident after 20 s, was dose dependent, and was completely reversible. The data here may provide the first explanation of why plasma ascorbate concentrations are tightly controlled.	NIDDKD,CELL BIOL & GENET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ATWATER I, 1978, J PHYSIOL-LONDON, V278, P117, DOI 10.1113/jphysiol.1978.sp012296; ATWATER I, 1976, J PHYSIOL-PARIS, V72, P769; BALCKE P, 1984, ANN INTERN MED, V101, P344, DOI 10.7326/0003-4819-101-3-344; BERGSTEN P, 1993, DIABETES, V42, P670, DOI 10.2337/diabetes.42.5.670; BERGSTEN P, 1993, BIOCHEM BIOPH RES CO, V192, P1182, DOI 10.1006/bbrc.1993.1541; BERGSTEN P, 1984, ENDOCRINOLOGY, V114, P1854, DOI 10.1210/endo-114-5-1854; CHEN MS, 1983, DIABETES, V32, P1078, DOI 10.2337/diabetes.32.11.1078; DHARIWAL KR, 1991, AM J CLIN NUTR, V54, P712, DOI 10.1093/ajcn/54.4.712; DILIBERTO EJ, 1991, AM J CLIN NUTR, V54, pS1163, DOI 10.1093/ajcn/54.6.1163s; EIPPER BA, 1991, AM J CLIN NUTR, V54, pS1153, DOI 10.1093/ajcn/54.6.1153s; Friedman GJ, 1940, J CLIN INVEST, V19, P685, DOI 10.1172/JCI101171; GARDINER TW, 1985, BRAIN RES, V344, P181, DOI 10.1016/0006-8993(85)91207-7; GOODNER CJ, 1988, DIABETES, V37, P1316, DOI 10.2337/diabetes.37.10.1316; GRAPENGIESSER E, 1988, BIOCHEM BIOPH RES CO, V151, P1299, DOI 10.1016/S0006-291X(88)80503-5; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; HELLMAN B, 1965, ANN NY ACAD SCI, V131, P541, DOI 10.1111/j.1749-6632.1965.tb34819.x; IRWIN MI, 1976, J NUTR, V106, P823; KITABCHI AE, 1967, NATURE, V215, P1385, DOI 10.1038/2151385a0; KNOTH J, 1987, J BIOL CHEM, V262, P14036; KOHNERT KD, 1979, MOL CELL ENDOCRINOL, V16, P205, DOI 10.1016/0303-7207(79)90027-3; LANG DA, 1979, NEW ENGL J MED, V301, P1023, DOI 10.1056/NEJM197911083011903; LEVINE M, 1985, VITAM HORM, V42, P1; LEVINE M, 1983, J BIOL CHEM, V258, P3111; LEVINE M, 1986, NEW ENGL J MED, V314, P892, DOI 10.1056/NEJM198604033141407; LIU TZ, 1982, CLIN CHEM, V28, P2225; MACKIN RB, 1987, GEN COMP ENDOCR, V67, P263, DOI 10.1016/0016-6480(87)90156-0; MALTESE JY, 1989, BIOCHEM BIOPH RES CO, V158, P244, DOI 10.1016/S0006-291X(89)80204-9; MCLENNAN S, 1988, DIABETES, V37, P359, DOI 10.2337/diabetes.37.3.359; MELETHIL S, 1986, INT J PHARM, V31, P83, DOI 10.1016/0378-5173(86)90216-4; ORAHILLY S, 1988, NEW ENGL J MED, V318, P1225, DOI 10.1056/NEJM198805123181902; OUAFIK LH, 1986, BIOCHEM BIOPH RES CO, V138, P179, DOI 10.1016/0006-291X(86)90263-9; PATTERSON JW, 1950, J BIOL CHEM, V183, P81; Piesse J. W., 1985, International Clinical Nutrition Review, V5, P110; Ralli EP, 1938, J CLIN INVEST, V17, P765, DOI 10.1172/JCI101006; RIVERS JM, 1987, ANN NY ACAD SCI, V498, P445, DOI 10.1111/j.1749-6632.1987.tb23780.x; SAUBERLICH HE, 1975, ANN NY ACAD SCI, V258, P438, DOI 10.1111/j.1749-6632.1975.tb29302.x; SCHARFMANN R, 1988, ENDOCRINOLOGY, V123, P1329, DOI 10.1210/endo-123-3-1329; SCOTT AM, 1981, DIABETOLOGIA, V21, P470; SOM S, 1981, METABOLISM, V30, P572, DOI 10.1016/0026-0495(81)90133-5; STANKOVA L, 1984, METABOLISM, V33, P347, DOI 10.1016/0026-0495(84)90197-5; STEIN HB, 1976, ANN INTERN MED, V84, P385, DOI 10.7326/0003-4819-84-4-385; TOGGENBURGER G, 1981, BIOCHIM BIOPHYS ACTA, V646, P433, DOI 10.1016/0005-2736(81)90312-6; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; WAND GS, 1985, METABOLISM, V34, P1044, DOI 10.1016/0026-0495(85)90077-0; WASHKO P, 1992, J BIOL CHEM, V267, P23568; WASHKO P, 1991, AM J CLIN NUTR, V54, pS1221, DOI 10.1093/ajcn/54.6.1221s; WASHKO PW, 1989, ANAL BIOCHEM, V181, P276, DOI 10.1016/0003-2697(89)90243-1; ZHOU A, 1991, DIABETOLOGIA, V34, P839, DOI 10.1007/BF00408361; ZHOU A, 1991, BIOCHEM J, V274, P739, DOI 10.1042/bj2740739	49	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1041	1045						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288558				2022-12-25	WOS:A1994MR22000043
J	HENSON, JW				HENSON, JW			REGULATION OF THE GLIAL-SPECIFIC JC VIRUS EARLY PROMOTER BY THE TRANSCRIPTION FACTOR-SP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; GENE-EXPRESSION; BRAIN-CELLS; PROTEIN; SP1; DNA; ENHANCER; SEQUENCES; SITES; MOUSE	The regulation of glial-specific JC virus early gene expression was addressed by functional dissection of a previously uncharacterized form of the JC virus promoter (MH-1). The MH-1 promoter directed 31-fold higher reporter gene expression in U87MG glioma cells than in HeLa cells in a transient transfection assay. Transfection of promoter constructs containing proximal or proximal plus upstream regions revealed that reporter gene expression was activated by both proximal and tandem repeat regions in glioma cells. The proximal region contains a guanine-rich sequence, the GA box, which was found to regulate the promoter, and was recognized specifically by the transcription factor Spl. The GA box is also present in the promoters of three glial-specific cellular genes. Together with paired AP-1 and NF-1 sites in the tandem repeats, the GA box is part of a motif that is conserved between several glial-specific promoters, and is thus a potential determinant of glial-specific gene expression. These results delineate the promoter regions required for activation of the MH-I JC virus promoter, suggest a new determinant of glial specificity, and establish a model for the investigation of combinatorial activation of a glial-specific viral promoter.			HENSON, JW (corresponding author), MASSACHUSETTS GEN HOSP,MOLEC NEUROONCOL LAB,BLDG 149,13TH ST,BOSTON,MA 02129, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001650] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 01650] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHMED S, 1990, J BIOL CHEM, V265, P13899; AMEMIYA K, 1992, J BIOL CHEM, V267, P14204; DEVINEBEACH K, 1990, J BIOL CHEM, V265, P13830; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FEIGENBAUM L, 1992, J VIROL, V66, P1176, DOI 10.1128/JVI.66.2.1176-1182.1992; GENCIC S, 1990, J NEUROSCI, V10, P117; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; HENSON J, 1992, ANN NEUROL, V32, P72, DOI 10.1002/ana.410320112; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KENNEY S, 1984, SCIENCE, V226, P1337, DOI 10.1126/science.6095453; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KINGSTON RE, 1991, CURRENT PROTOCOLS MO; KUMAR KU, 1993, J VIROL, V67, P572, DOI 10.1128/JVI.67.1.572-576.1993; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MARTIN JD, 1985, J VIROL, V53, P306, DOI 10.1128/JVI.53.1.306-311.1985; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; TADA H, 1992, J VIROL, V66, P6885, DOI 10.1128/JVI.66.12.6885-6892.1992; TAMURA T, 1988, BIOCHEM BIOPH RES CO, V157, P419, DOI 10.1016/S0006-291X(88)80265-1; WEGNER M, 1993, P NATL ACAD SCI USA, V90, P4743, DOI 10.1073/pnas.90.10.4743	23	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1046	1050						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288559				2022-12-25	WOS:A1994MR22000044
J	YONESAKI, T				YONESAKI, T			THE PURIFICATION AND CHARACTERIZATION OF GENE-59 PROTEIN FROM BACTERIOPHAGE-T4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-RECOMBINATION; UVSX-PROTEIN; AFFINITY-CHROMATOGRAPHY; DNA-REPLICATION; STRANDED-DNA; T4; SPECIFICITY; MUTATIONS; FILAMENTS; BINDING	Gene 59 of bacteriophage T4 is involved in genetic recombination and recombination-dependent DNA replication. We purified the protein encoded by gene 59 after cloning the gene in an expression vector. The molecular weight and the sequence of seven N-terminal amino acids of the protein were consistent with the nucleotide sequence of the gene (Hahn, S., Kruse, U., and Ruger, W. (1986) Nucleic Acids Res. 14, 9311-9327). The purified 59 protein appeared to be a monomer under nondenaturing conditions, and it bound to single-stranded DNA in preference to double-stranded DNA. The protein could bind to a 24-nucleotide-long single-stranded DNA molecule that had previously bound either 32 protein (single-stranded DNA-binding protein) or uvsY protein (enhancer of uvsX protein), but it would not bind to this DNA if it had previously bound uvsX protein (synaptase). The binding occurred rapidly with 32 protein-bound DNA and slowly with uvsY protein-bound DNA. Accordingly, 32 protein bound specifically to an agarose matrix containing immobilized 59 protein. The 41 protein (DNA helicase) also bound specifically to this agarose matrix.			YONESAKI, T (corresponding author), OSAKA UNIV,COLL GEN EDUC,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024020, R01GM024020] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24020] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROKER TR, 1971, J MOL BIOL, V60, P131, DOI 10.1016/0022-2836(71)90453-0; CHA TA, 1988, CANCER CELL, V6, P1; CUNNINGHAM RP, 1977, VIROLOGY, V80, P67, DOI 10.1016/0042-6822(77)90381-6; CUPIDO M, 1980, MUTAT RES, V70, P131, DOI 10.1016/0027-5107(80)90152-9; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FORMOSA T, 1984, COLD SPRING HARB SYM, V49, P363, DOI 10.1101/SQB.1984.049.01.043; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; FREITAG N, 1988, J BIOL CHEM, V263, P19525; GRIFFITH J, 1985, J BIOL CHEM, V260, P4484; HAHN S, 1986, NUCLEIC ACIDS RES, V14, P9311, DOI 10.1093/nar/14.23.9311; HARRIS LD, 1989, J MOL BIOL, V206, P19, DOI 10.1016/0022-2836(89)90520-2; HASHIMOTO K, 1991, J BIOL CHEM, V266, P4883; KODADEK T, 1989, J BIOL CHEM, V264, P16451; LIU CC, 1981, J BIOL CHEM, V256, P2813; MINAGAWA T, 1978, VIROLOGY, V91, P222, DOI 10.1016/0042-6822(78)90371-9; MIZUUCHI K, 1982, CELL, V29, P357, DOI 10.1016/0092-8674(82)90152-0; MOSIG G, 1987, ANNU REV GENET, V21, P347, DOI 10.1146/annurev.ge.21.120187.002023; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; PRASHAD N, 1972, J MOL BIOL, V70, P617, DOI 10.1016/0022-2836(72)90562-1; SHAH DB, 1976, J VIROL, V17, P175, DOI 10.1128/JVI.17.1.175-182.1976; TOMIZAWA JI, 1966, J MOL BIOL, V21, P247, DOI 10.1016/0022-2836(66)90095-7; WAKEM LP, 1981, VIROLOGY, V112, P472; WU JR, 1984, J VIROL, V52, P1028, DOI 10.1128/JVI.52.3.1028-1031.1984; WU R, 1975, J VIROL, V16, P5, DOI 10.1128/JVI.16.1.5-16.1975; YONESAKI T, 1989, J BIOL CHEM, V264, P7814; YONESAKI T, 1987, GENETICS, V115, P219; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x; YONESAKI T, 1984, Memoirs of the Faculty of Science Kyoto University Series of Biology, V9, P87	30	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1284	1289						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288591				2022-12-25	WOS:A1994MR22000081
J	CADENA, DL; CHAN, CL; GILL, GN				CADENA, DL; CHAN, CL; GILL, GN			THE INTRACELLULAR TYROSINE KINASE DOMAIN OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR UNDERGOES A CONFORMATIONAL CHANGE UPON AUTOPHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED INTERNALIZATION; FACTOR EGF RECEPTOR; SELF-PHOSPHORYLATION; CARBOXYL TERMINUS; BINDING; DIMERIZATION; ACTIVATION; SITES; IDENTIFICATION; AGGREGATION	The intracellular portion of the epidermal growth factor receptor consists of a tyrosine kinase domain of approximately 290 amino acids and a COOH-terminal regulatory domain of approximately 230 amino acids that contains five sites of autophosphorylation. The effect of autophosphorylation on the conformation of the intracellular domain has been analyzed using gel filtration. Both phosphorylated and dephosphorylated forms of the intracellular domain exist as monomers and as dimers and appear to have an extended conformation. The Stokes' radii of phosphorylated monomers and dimers were larger than those of the dephosphorylated forms, indicating that the dephosphorylated form is more compact. These results indicate that a significant conformational change occurs in the intracellular portion of the epidermal growth factor receptor upon tyrosine autophosphorylation.	UNIV CALIF SAN DIEGO,SCH MED,DEPT MED 0650,9500 GILMAN DR,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013149, R37DK013149, T32DK007044] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK13149, DK07044] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4493, DOI 10.1021/bi00133a016; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHANG CP, 1991, J BIOL CHEM, V266, P23467; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COCHET C, 1988, J BIOL CHEM, V263, P3290; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERBERG FW, 1993, IN PRESS PROTEIN ENG; HSU CYJ, 1991, J BIOL CHEM, V266, P603; HSU CYJ, 1990, CELL GROWTH DIFFER, V1, P191; HSUAN JJ, 1989, BIOCHEM J, V262, P659, DOI 10.1042/bj2620659; HUBLER L, 1989, J BIOL CHEM, V264, P1558; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAX I, 1991, J BIOL CHEM, V266, P13828; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MCGLYNN E, 1992, EUR J BIOCHEM, V207, P265, DOI 10.1111/j.1432-1033.1992.tb17047.x; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WEDEGAERTNER PB, 1992, ARCH BIOCHEM BIOPHYS, V292, P273, DOI 10.1016/0003-9861(92)90079-C; WEDEGAERTNER PB, 1989, J BIOL CHEM, V264, P11346; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	30	70	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					260	265						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276804				2022-12-25	WOS:A1994MR21900047
J	CORRELL, CC; EDWARDS, PA				CORRELL, CC; EDWARDS, PA			MEVALONIC ACID-DEPENDENT DEGRADATION OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE IN-VIVO AND IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; STEROL-ENHANCED DEGRADATION; MEMBRANE-BOUND DOMAIN; ENDOPLASMIC-RETICULUM; REGULATED DEGRADATION; RAT-LIVER; BETA-GALACTOSIDASE; MOLECULAR-CLONING; MAMMALIAN-CELLS; COA REDUCTASE	The microsomal enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is subject to rapid degradation when cells are incubated with sterols or mevalonic acid (MVA). It has been shown that this rapid degradation is dependent upon both a sterol and another MVA-derived metabolite (Nakanishi, M., Goldstein, J. L., and Brown, M. S. (1988) J. Biol. Chem. 258, 8929-8937). In the current study, inhibitors of the isoprene biosynthetic pathway were used to define further this mevalonic acid derivative involved in the accelerated degradation of HMG-CoA reductase. The accelerated degradation of HMG-CoA reductase in met-18b-2 cells, which is induced by the addition of MVA, was inhibited by the presence of the squalene synthase inhibitor, zaragozic acid/squalestatin, or the squalene epoxidase inhibitor, NB-598. Accelerated degradation of HMG-CoA reductase was observed when NB-598-treated cells were incubated with both MVA and sterols. In contrast, the addition of MVA and sterols to zaragozic acid/squalestatin-treated cells did not result in rapid enzyme degradation. This MVA- and sterol-dependent degradation of HMG-CoA reductase persisted in cells permeabilized with reduced streptolysin O. Finally, the selective degradation of HMG-CoA reductase was also observed in rat hepatic microsomes incubated in vitro in the absence of ATP and cytosol. We conclude that the MVA-derived component that is required for the accelerated degradation of HMG-CoA reductase is derived from farnesyl diphosphate and/or squalene in the isoprenoid biosynthetic pathway. We propose that this component has a permissive effect and does not, by itself, induce the degradation of HMG-CoA reductase. We also conclude that the degradation of HMG-CoA occurs in the endoplasmic reticulum, and, once the degradation of HMGCoA reductase has been initiated by MVA and sterols, all necessary components for the continued degradation of HMG-CoA reductase reside in the endoplasmic reticulum.	UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, 10833 LE CONTE AVE, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DIV CARDIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NHLBI NIH HHS [HL 30568] Funding Source: Medline; NIGMS NIH HHS [GM 07185] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANHERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BAXTER A, 1992, J BIOL CHEM, V267, P11705; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DAWSON MJ, 1992, J ANTIBIOT, V45, P614; EDWARDS PA, 1983, J BIOL CHEM, V258, P219; EDWARDS PA, 1983, J BIOL CHEM, V258, P7272; EDWARDS PA, 1977, J BIOL CHEM, V252, P1057; EDWARDS PA, 1991, BIOCH LIPIDS LIPOPRO, P383; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FAUST J, 1987, J BIOL CHEM, V262, P1996; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HORIE M, 1990, J BIOL CHEM, V265, P18075; JINGAMI H, 1987, J CELL BIOL, V104, P1693, DOI 10.1083/jcb.104.6.1693; JOLY A, 1991, CURR OPIN LIPIDOL, V2, P283; KIM CM, 1992, J BIOL CHEM, V267, P23113; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI AC, 1988, J LIPID RES, V29, P781; LISCUM L, 1985, J BIOL CHEM, V260, P522; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MEIGS TE, 1992, J BIOL CHEM, V267, P13547; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; NESS GC, 1986, BIOCHEM J, V233, P167, DOI 10.1042/bj2330167; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; PANINI SR, 1989, J BIOL CHEM, V264, P11044; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; ROSSER DSE, 1989, J BIOL CHEM, V264, P12653; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SINENSKY M, 1983, J BIOL CHEM, V258, P8547; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; WIKSTROM L, 1992, J BIOL CHEM, V267, P5	41	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					633	638						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276863				2022-12-25	WOS:A1994MR21900100
J	FIORE, MM; NEUENSCHWANDER, PF; MORRISSEY, JH				FIORE, MM; NEUENSCHWANDER, PF; MORRISSEY, JH			THE BIOCHEMICAL BASIS FOR THE APPARENT DEFECT OF SOLUBLE MUTANT TISSUE FACTOR IN ENHANCING THE PROTEOLYTIC ACTIVITIES OF FACTOR-VIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-VII; ACTIVATED FACTOR-IX; BLOOD-COAGULATION; FACTOR-X; FACTOR-XII; DEPENDENT AUTOACTIVATION; ENZYMATIC-PROPERTIES; COFACTOR FUNCTION; HAGEMAN-FACTOR; FACTOR PATHWAY	Tissue factor (TF), an integral membrane protein, is the cofactor for the serine protease, coagulation factor VIIa (FVIIa). Previous studies of the isolated extracellular domain of TF (sTF) reported a k(cat) for factor X (FX) activation by the sTF-VIIa complex only 4% that of wild-type TF.VIIa and furthermore, a complete inability of sTF to support FVII autoactivation. We now report that in the presence of poly(L-lysine), sTF promoted both FX activation and FVII autoactivation, the latter with an apparent second-order rate constant higher than reported previously for wild-type TF in phospholipid vesicles. This led us to reexamine the cofactor ability of sTF, using high concentrations of phospholipid to promote nearly quantitative binding of sTF.VII(a) complexes to the phospholipid surface. Rate constants for the activation of FX or FVII by sTF.VIIa were similar to those of wild-type TF.VIIa, indicating that the apparent deficiency of sTF is largely attributable to kinetic consequences of relatively weak affinity of FVIIa (and sTF.VIIa) for phospholipid surfaces in these surface-dependent reactions, compared with TF being embedded in the membrane. This supports the notion that sTF recapitulates the protein-protein interactions of wild-type TF with high, and possibly full, catalytic activity. lt also provides a biochemical explanation for the specificity of our recently described, sTF-based clotting assay for plasma FVIIa.	OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,825 NE 13TH ST,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation			Morrissey, James H./GLR-5645-2022; Morrissey, James H/H-4933-2011	Morrissey, James H/0000-0002-1570-1569	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008710, R01HL047014] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-47014, F32 HL-08710] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; Bevington P. R., 1969, DATA REDUCTION ERROR; CARSON SD, 1993, BLOOD COAGUL FIBRIN, V4, P281, DOI 10.1097/00001721-199304000-00010; FIORE MM, 1992, BLOOD, V80, P3127; GRIFFITH MJ, 1985, J CLIN INVEST, V75, P4, DOI 10.1172/JCI111694; HAPAK RC, 1991, FASEB J, V6, P330; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P4189, DOI 10.1021/bi00638a009; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; LAAKE K, 1974, THROMB RES, V5, P759, DOI 10.1016/0049-3848(74)90119-4; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LUNDBLAD RL, 1982, THROMB RES, V25, P319, DOI 10.1016/0049-3848(82)90232-8; MANN KG, 1992, SEMIN HEMATOL, V29, P213; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MASYS DR, 1982, BLOOD, V60, P1143; MIMMS LT, 1981, BIOCHEMISTRY-US, V17, P2134; MORRISSEY JH, 1993, BLOOD, V81, P734; MORRISSEY JH, 1988, THROMB RES, V50, P481, DOI 10.1016/0049-3848(88)90197-1; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10820; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; NEMERSON Y, 1966, BIOCHEMISTRY-US, V5, P601, DOI 10.1021/bi00866a029; NEMERSON Y, 1973, P NATL ACAD SCI USA, V70, P310, DOI 10.1073/pnas.70.2.310; NEMERSON Y, 1985, THROMB RES, V40, P351, DOI 10.1016/0049-3848(85)90270-1; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; NEUENSCHWANDER PF, 1993, J BIOL CHEM, V268, P21489; NEUENSCHWANDER PF, 1991, BLOOD S1, V78, P61; NEUENSCHWANDER PF, 1993, IN PRESS THROMB HAEM; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; PABORSKY LR, 1991, J BIOL CHEM, V266, P21911; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; PEDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P9331, DOI 10.1021/bi00450a013; RADCLIFFE R, 1975, J BIOL CHEM, V250, P388; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RAWALASHEIKH R, 1992, BLOOD, V79, P398; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; RUF W, 1991, J BIOL CHEM, V266, P16256; SELIGSOHN U, 1979, J CLIN INVEST, V64, P1056, DOI 10.1172/JCI109543; SHIGEMATSU Y, 1992, J BIOL CHEM, V267, P21329; SMALL DM, 1967, J LIPID RES, V8, P551; TANKERSLEY DL, 1984, BIOCHEMISTRY-US, V23, P273, DOI 10.1021/bi00297a016; TANS G, 1987, J BIOL CHEM, V262, P11308; TANS G, 1983, J BIOL CHEM, V258, P8215; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011; YAMAMOTO M, 1992, J BIOL CHEM, V267, P19089	48	57	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					143	149						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276788				2022-12-25	WOS:A1994MR21900030
J	HYUN, SW; PARK, K; LEE, YS; LEE, YI; KIM, SJ				HYUN, SW; PARK, K; LEE, YS; LEE, YI; KIM, SJ			INHIBITION OF PROTEIN PHOSPHATASES ACTIVATES P4 PROMOTER OF THE HUMAN INSULIN-LIKE GROWTH FACTOR-II GENE THROUGH THE SPECIFIC PROMOTER ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR SUPPRESSOR WT1; HEPATITIS-B VIRUS; OKADAIC ACID; TRANSCRIPTION FACTOR; 3T3 CELLS; C-FOS; EXPRESSION; PHOSPHORYLATION; REPRESSION; SEQUENCES	To understand the transcriptional regulation of the human insulin-like growth factor II (IGF-II) gene, we examined the effects of okadaic acid, a potent in vitro inhibitor of protein phosphatases, on the activation of human IGF-II gene expression. Treatment of A-549 human lung adenocarcinoma cells with okadaic acid increased expression of the IGF-II mRNAs. Since the 4.8-kb mRNA is transcribed under the control of human IGF-II P4 promoter, we examined the P4 promoter element responsible for the okadaic acid-mediated transcriptional activation. Transfection of IGF-II P4 promoter-chloramphenicol acetyltransferase constructs demonstrated that the effects of okadaic acid on the induction of IGF-II gene expression are mediated through multiple promoter elements, including an Egr-1 consensus element. We have also shown that okadaic acid induced the expression of the transcription factor Egr-1. Moreover, by using a GAL4-Egr-1 fusion protein, we have directly demonstrated that okadaic acid positively regulates Egr-1 transcriptional activity in vivo. These results indicate that protein phosphatases play an-important role in the transcriptional regulation of the IGF-II.	KOREA INST SCI & TECHNOL, GENET ENGN RES INST, MOLEC GENET LAB, TAEJON 305606, SOUTH KOREA; NCI, CHEMOPREVENT, BETHESDA, MD 20892 USA; CATHOLIC MED UNIV, SEOUL 137040, SOUTH KOREA	Korea Institute of Science & Technology (KIST); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Catholic University of Korea								ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BOHMANN D, 1990, CANCER CELL-MON REV, V2, P337; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CARIANI E, 1991, HEPATOLOGY, V13, P644, DOI 10.1002/hep.1840130406; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DARVILLE CN, 1991, HEPATOLOGY, V13, P310, DOI 10.1002/hep.1840130217; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ERODI F, 1988, BIOCHEM BIOPH RES CO, V153, P156; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GILARDI P, 1984, NUCLEIC ACIDS RES, V12, P7877, DOI 10.1093/nar/12.20.7877; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HESCHELER J, 1988, PFLUG ARCH EUR J PHY, V412, P248, DOI 10.1007/BF00582504; HOLTHUIZEN P, 1990, BIOCHIM BIOPHYS ACTA, V1087, P341, DOI 10.1016/0167-4781(90)90010-Y; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIM RW, 1987, ONCOGENE, V1, P263; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SARA VR, 1990, PHYSIOL REV, V70, P591, DOI 10.1152/physrev.1990.70.3.591; SASSA T, 1989, BIOCHEM BIOPH RES CO, V159, P939, DOI 10.1016/0006-291X(89)92199-2; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; XI XF, 1988, J VIROL, V62, P3422	35	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					364	368						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276819				2022-12-25	WOS:A1994MR21900061
J	LIU, XJ; LAM, E				LIU, XJ; LAM, E			2 BINDING-SITES FOR THE PLANT TRANSCRIPTION FACTOR ASF-1 CAN RESPOND TO AUXIN TREATMENTS IN TRANSGENIC TOBACCO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCTOPINE SYNTHASE ENHANCER; TISSUE-SPECIFIC EXPRESSION; WHEAT HISTONE GENES; REGULATED GENE; T-DNA; MESOPHYLL PROTOPLASTS; MESSENGER-RNAS; OCS-ELEMENT; PROTEIN; PROMOTER	The hormone, auxin, plays an important role, in the differentiation and growth of plant cells. A number of auxin-responsive genes have been characterized but until now minimal auxin-responsive cis-elements within these promoter regions have not been identified. Here we show that two related DNA sequences of 21 base pairs can respond to auxin treatment in transgenic tobacco. In contrast, treatments with cytokinin or abscisic acid do not cause any apparent increase in promoter activity of these cis-acting elements. These sequences are present in the promoter regions of the nopaline synthase gene from the T-DNA of Agrobacterium tumefaciens and the 35 S promoter from cauliflower mosaic virus. Both sequences have been shown to be binding sites for the tobacco transcription factor ASF-1. Pretreatment of leaves with cycloheximide does not inhibit the response to auxin treatment, suggesting that hormone sensitivity of these promoter elements does not involve de novo synthesis of ASF-1. In addition, promoter elements from some auxin-responsive plant genes can bind ASF-1 in vitro. Based on these results, we propose that transcriptional activation by ASF-1 may be modulated by auxin through modification of pre-existing factors. Our results also suggest a role for ASF-1 in mediating some of the effects of auxin in vivo.	RUTGERS UNIV,WAKSMAN INST MICROBIOL,CTR AGBIOTECH,PISCATAWAY,NJ 08854; RUTGERS UNIV,DEPT PLANT SCI,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University New Brunswick								AINLEY WM, 1988, J BIOL CHEM, V263, P10658; ALLIOTTE T, 1989, PLANT PHYSIOL, V89, P743, DOI 10.1104/pp.89.3.743; ALONI R, 1987, ANNU REV PLANT PHYS, V38, P179, DOI 10.1146/annurev.pp.38.060187.001143; AN GH, 1990, PLANT CELL, V2, P225, DOI 10.1105/tpc.2.3.225; BENFEY PN, 1989, EMBO J, V8, P2195, DOI 10.1002/j.1460-2075.1989.tb08342.x; BENFEY PN, 1990, EMBO J, V9, P1685, DOI 10.1002/j.1460-2075.1990.tb08292.x; BOUCHEZ D, 1989, EMBO J, V8, P4197, DOI 10.1002/j.1460-2075.1989.tb08605.x; CZARNECKA E, 1984, PLANT MOL BIOL, V3, P45, DOI 10.1007/BF00023415; ELLIS JG, 1987, EMBO J, V6, P3203, DOI 10.1002/j.1460-2075.1987.tb02636.x; FLUHR R, 1986, EMBO J, V5, P2063, DOI 10.1002/j.1460-2075.1986.tb04467.x; FRALEY RT, 1985, BIO-TECHNOL, V3, P629, DOI 10.1038/nbt0785-629; FRANCO AR, 1990, J BIOL CHEM, V265, P15845; FROMM H, 1991, MOL GEN GENET, V229, P181, DOI 10.1007/BF00272154; FROMM H, 1989, PLANT CELL, V1, P977, DOI 10.1105/tpc.1.10.977; GEE MA, 1991, PLANT CELL, V3, P419, DOI 10.1105/tpc.3.4.419; GREEN PJ, 1989, PLANT MOL BIOL MANUA, V3, P303; HAGEN G, 1991, PLANT MOL BIOL, V17, P567, DOI 10.1007/BF00040658; HAGEN G, 1989, New Biologist, V1, P19; JACOBS M, 1976, PLANT PHYSIOL, V58, P203, DOI 10.1104/pp.58.2.203; JEFFERSON RA, 1987, EMBO J, V6, P3901; KATAGIRI F, 1990, GENE DEV, V4, P1899, DOI 10.1101/gad.4.11.1899; KATAGIRI F, 1992, TRENDS GENET, V8, P22, DOI 10.1016/0168-9525(92)90020-5; KATAGIRI F, 1989, NATURE, V340, P727, DOI 10.1038/340727a0; KORBER H, 1991, EMBO J, V10, P3983, DOI 10.1002/j.1460-2075.1991.tb04973.x; Krikorian A. D., 1987, Plant hormones and their role in plant growth and development., P593; KUHLEMEIER C, 1989, PLANT CELL, V1, P471, DOI 10.1105/tpc.1.4.471; LAM E, 1989, P NATL ACAD SCI USA, V86, P7890, DOI 10.1073/pnas.86.20.7890; LAM E, 1990, J BIOL CHEM, V265, P9909; LAM E, 1990, SCIENCE, V248, P471, DOI 10.1126/science.2330508; LANGRIDGE WHR, 1989, P NATL ACAD SCI USA, V86, P3219, DOI 10.1073/pnas.86.9.3219; MCCLURE BA, 1989, PLANT CELL, V1, P229, DOI 10.1105/tpc.1.2.229; MIKAMI K, 1987, FEBS LETT, V223, P273, DOI 10.1016/0014-5793(87)80303-4; PALME K, 1991, MECH DEVELOP, V33, P97, DOI 10.1016/0925-4773(91)90076-I; Rubery P. H., 1987, Plant hormones and their role in plant growth and development., P341; TABATA T, 1989, SCIENCE, V245, P965, DOI 10.1126/science.2772648; TAKAHASHI Y, 1989, P NATL ACAD SCI USA, V86, P9279, DOI 10.1073/pnas.86.23.9279; TAKAHASHI Y, 1991, PLANT J, V1, P327, DOI 10.1046/j.1365-313X.1991.t01-2-00999.x; THEOLOGIS A, 1985, J MOL BIOL, V183, P53, DOI 10.1016/0022-2836(85)90280-3; TOKUHISA JG, 1990, PLANT CELL, V2, P215, DOI 10.1105/tpc.2.3.215; VANDERZAAL EJ, 1987, PLANT MOL BIOL, V10, P145, DOI 10.1007/BF00016152; VANDERZAAL EJ, 1991, PLANT MOL BIOL, V16, P983, DOI 10.1007/BF00016071; VANONCKELEN H, 1986, FEBS LETT, V198, P357, DOI 10.1016/0014-5793(86)80436-7	42	77	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					668	675						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276868				2022-12-25	WOS:A1994MR21900105
J	VANDYCK, L; PEARCE, DA; SHERMAN, F				VANDYCK, L; PEARCE, DA; SHERMAN, F			PIM1 ENCODES A MITOCHONDRIAL ATP-DEPENDENT PROTEASE THAT IS REQUIRED FOR MITOCHONDRIAL-FUNCTION IN THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LIVER-MITOCHONDRIA; DNA REPLICATION; GENE; PROTEINS; SEQUENCE; TRANSFORMATION; DEGRADATION; MAINTENANCE; NUCLEAR	The PIM1 nuclear gene in the yeast Saccharomyces cerevisiae encodes a mitochondrial ATP-dependent protease that exhibits over 30% identity with ATP-dependent protease La from Escherichia coli, Lon from Bacillus brevis, and one from Myxococcus xanthus. In addition, Pim1 is 1133 amino acids long and has a putative mitochondrial import signal in the N-terminal region. Enzymatic comparisons of normal PIM1+ and deficient pim1-A strains revealed that the ATP-dependent protease is located within the mitochondrial matrix. The pim1-A strains are unable to utilize nonfermentable substrates as the sole carbon source and are unable to maintain functional mitochondrial DNA, indicating that the Pim1 protease is required for mitochondrial function. PIM1 mRNA is constitutively expressed but is increased after thermal stress, suggesting that Pim1 may play a role in the heat shock response.	UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA; UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM; UNIV ROCHESTER, SCH MED & DENT, DEPT BIOPHYS, ROCHESTER, NY 14642 USA	University of Rochester; Universite Catholique Louvain; University of Rochester					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM012702] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 12702] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMERIK A, 1988, SOV J BIOORG CHEM, V14, P408; AMERIK AY, 1991, FEBS LETT, V287, P211, DOI 10.1016/0014-5793(91)80053-6; BAIROCH A, 1990, PROSITE DICT PROTEIN; CHIN DT, 1988, J BIOL CHEM, V263, P11718; DESAUTELS M, 1982, P NATL ACAD SCI-BIOL, V79, P1869, DOI 10.1073/pnas.79.6.1869; DESAUTELS M, 1982, J BIOL CHEM, V257, P1673; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; GENGA A, 1986, J BIOL CHEM, V261, P9328; GILL RE, 1993, J BACTERIOL, V175, P4538, DOI 10.1128/JB.175.14.4538-4544.1993; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GREENLEAF AL, 1986, P NATL ACAD SCI USA, V83, P3391, DOI 10.1073/pnas.83.10.3391; HAHN S, 1988, MOL CELL BIOL, V8, P655, DOI 10.1128/MCB.8.2.655; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEINEMEYER W, 1991, BIOCHEM SOC T, V19, P724, DOI 10.1042/bst0190724; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; ITO K, 1992, J BACTERIOL, V174, P2281, DOI 10.1128/JB.174.7.2281-2287.1992; KAO LR, 1993, P NATL ACAD SCI USA, V90, P5598, DOI 10.1073/pnas.90.12.5598; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KUTEJOVA E, 1993, FEBS LETT, V329, P47, DOI 10.1016/0014-5793(93)80190-6; LEONHARDT SA, 1993, MOL CELL BIOL, V13, P6304, DOI 10.1128/MCB.13.10.6304; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LUZIKOV VN, 1991, CELL BIOL REV, V25, P245; MEGRAW TL, 1993, J BIOL CHEM, V268, P12758; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Rivett AJ, 1990, CURR OPIN CELL BIOL, V2, P1143, DOI 10.1016/0955-0674(90)90168-E; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J, 1989, MOL CLONING LABORATO; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SHERMAN F, 1964, BIOCHIM BIOPHYS ACTA, V90, P1, DOI 10.1016/0304-4165(64)90113-8; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; THIERRY A, 1990, YEAST, V6, P521, DOI 10.1002/yea.320060609; TOJO T, 1993, J BACTERIOL, V175, P2271; VALENS M, 1991, BIOCHIMIE, V12, P1525; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; WATABE S, 1985, J BIOL CHEM, V260, P5511; WATABE S, 1993, J BIOCHEM-TOKYO, V113, P672, DOI 10.1093/oxfordjournals.jbchem.a124101; WATABE S, 1985, J BIOL CHEM, V260, P11498; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944	40	186	189	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					238	242						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276800				2022-12-25	WOS:A1994MR21900044
J	WITKOWSKI, A; WITKOWSKA, HE; SMITH, S				WITKOWSKI, A; WITKOWSKA, HE; SMITH, S			REENGINEERING THE SPECIFICITY OF A SERINE ACTIVE-SITE ENZYME - 2 ACTIVE-SITE MUTATIONS CONVERT A HYDROLASE TO A TRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHETASE; RAT MAMMARY-GLAND; THIOESTERASE-II; PEPTIDE ANTIBIOTICS; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; SYNTHASE; DOMAIN; PURIFICATION; BIOSYNTHESIS	Two residues are known to play important catalytic roles in fatty acyl-thioester hydrolase, thioesterase II: Ser-101, the site of a covalent acyl-enzyme intermediate, and His-237 which is within hydrogen bonding distance of Ser-101 and facilitates catalysis by increasing the nucleophilicity of this residue. In this study we have examined the effect of mutations at these two residues on the ability of the enzyme to function as a hydrolase and, in the presence of a thiol acceptor, as an acyltransferase. In the hydrolase reaction k(cat) values for the wild-type, H237R, S101C, and S101C, H237R thioesterase enzymes were 0.11, <0.002, 0.10, and <0.002 s-1, respectively, and at steady state, the proportion of each enzyme present as the covalent acyl-enzyme intermediate was 11, 91, 71, and 100%, respectively. In the acyltransferase reaction no activity could be detected for the wild-type or H237R enzymes but the specific activities of the S101C and S101C/H237R thioesterases were 170 and 1300 nmol/min/mg of protein, respectively. From this data we conclude the following: the wild-type enzyme functions exclusively as a hydrolase. The H237R mutant acts ineffectively as a hydrolase primarily because the deacylation reaction is drastically retarded. The S101C enzyme functions well as a hydrolase, even though the rate of deacylation is adversely affected, and this enzyme can also perform as an acyltransferase. Mutation of both catalytic residues leads to a complete loss of hydrolase activity and the S101C,H237R mutant functions as an effective acyltransferase exhibiting k(cat) values higher then those of the wild-type enzyme acting as a hydrolase. This study reveals that, with only two amino acid replacements, an enzyme capable of functioning exclusively as a hydrolase can be converted into an equally active enzyme performing solely as an acyltransferase.	CHILDRENS HOSP,OAKLAND RES INST,747 52ND ST,OAKLAND,CA 94609	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute				Witkowski, Andrzej/0000-0002-0442-4586	NCRR NIH HHS [RR-06505] Funding Source: Medline; NIDDK NIH HHS [DK-16073, DK-34400] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR006505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016073, R01DK034400] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEVITT DJ, 1992, EUR J BIOCHEM, V204, P39, DOI 10.1111/j.1432-1033.1992.tb16603.x; DERENOBALES M, 1980, ARCH BIOCHEM BIOPHYS, V205, P464, DOI 10.1016/0003-9861(80)90129-0; Dixon M., 1979, ENZYMES, P47; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; HARDIE DG, 1985, BIOCHIM BIOPHYS ACTA, V828, P380, DOI 10.1016/0167-4838(85)90320-6; KATZ E, 1977, BACTERIOL REV, V41, P449, DOI 10.1128/MMBR.41.2.449-474.1977; KLEINKAUF H, 1990, EUR J BIOCHEM, V192, P1, DOI 10.1111/j.1432-1033.1990.tb19188.x; KNUDSEN J, 1976, BIOCHEM J, V160, P683, DOI 10.1042/bj1600683; KRATZSCHMAR J, 1989, J BACTERIOL, V171, P5422; LIBERTINI L, 1976, FED PROC, V35, P1069; LIBERTINI LJ, 1978, J BIOL CHEM, V253, P1393; LIN CY, 1978, J BIOL CHEM, V253, P1954; LIPPMAN F, 1980, ADV MICROBIOL PHYSL, V21, P227; NAGGERT J, 1991, BIOCHEM J, V273, P787, DOI 10.1042/bj2730787; NAGGERT J, 1988, J BIOL CHEM, V263, P1146; PAZIRANDEH M, 1991, J BIOL CHEM, V266, P20946; RAIBAUD A, 1991, J BACTERIOL, V173, P4454, DOI 10.1128/JB.173.14.4454-4463.1991; RANDHAWA ZI, 1987, EUR J BIOCHEM, V162, P577, DOI 10.1111/j.1432-1033.1987.tb10678.x; ROGERS L, 1982, J BIOL CHEM, V157, P880; TAI MH, 1993, P NATL ACAD SCI USA, V90, P1852, DOI 10.1073/pnas.90.5.1852; WITKOWSKA HE, 1990, J BIOL CHEM, V265, P5662; WITKOWSKI A, 1991, EUR J BIOCHEM, V198, P571, DOI 10.1111/j.1432-1033.1991.tb16052.x; WITKOWSKI A, 1985, ARCH BIOCHEM BIOPHYS, V243, P420, DOI 10.1016/0003-9861(85)90518-1; WITKOWSKI A, 1991, J BIOL CHEM, V266, P18514; WITKOWSKI A, 1992, J BIOL CHEM, V267, P18488	26	56	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					379	383						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276823				2022-12-25	WOS:A1994MR21900064
J	GERWIG, GJ; KAMERLING, JP; VLIEGENTHART, JFG; MORAG, E; LAMED, R; BAYER, EA				GERWIG, GJ; KAMERLING, JP; VLIEGENTHART, JFG; MORAG, E; LAMED, R; BAYER, EA			THE NATURE OF THE CARBOHYDRATE-PEPTIDE LINKAGE REGION IN GLYCOPROTEINS FROM THE CELLULOSOMES OF CLOSTRIDIUM-THERMOCELLUM AND BACTEROIDES-CELLULOSOLVENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULASE COMPLEX; CELLULOMONAS-FIMI; BINDING DOMAINS; GENE; ENDOGLUCANASE; SEQUENCE; CLONING; CHAINS	The cellulase complexes of two cellulolytic bacteria, Clostridium thermocellum and Bacteroides cellulosolvens, were subjected to extensive Pronase digestion. Glycopeptide fractions were isolated by gel permeation and fast protein liquid chromatography and analyzed by monosaccharide analysis, amino acid analysis, methylation analysis, and H-1 NMR spectroscopy. Alkaline boro-hydride-induced deglycosylation/amino acid conversion and periodate oxidation studies on the glycopeptide fraction of the C. thermocellum cellulosome demonstrated that the earlier established collection of carbohydrate moieties with 3-O-Me-D-GlcpNAc-alpha(1-->2)-[D-Galp-alpha(1-->3)]-D-Galf-alpha(1-->2)-D-Gal (where 3-O-Me-D-GlcpNAc is 3-O-methyl-N-acetylglucopyranosamine, Galp is galactopyranose, and Galf is galactofuranose) as the major component, is O-linked to threonine via galactopyranose. Using the same approach for the glycopeptide fraction of the cellulase complex of B. cellulosolvens, it was found that the reported collection of carbohydrate moieties with D-Galf-alpha(1-->3)-D-GlcpNAc-alpha(1-->2)-D-Galf-alpha(1-->2)-[D-Galf-beta(1-->3)]-D-Gal as the major component, is O-linked mainly to threonine and partly to serine via galactopyranose. In both species, the hydroxyamino-acid-bound galactopyranose residue has probably an alpha-configuration. The carbohydrate chains appear as clusters located in highly Thr/Pro-rich peptide regions of the glycoproteins. The results are consistent with the notion that the glycosylation sites are localized in linker sequences which connect the various binding domains of the noncatalytic S1 subunit of the cellulosome.	UNIV UTRECHT, BIJVOET CTR, DEPT BIOORGAN CHEM, POB 80075, 3508 TB UTRECHT, NETHERLANDS; TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, IL-69978 TEL AVIV, ISRAEL; WEIZMANN INST SCI, DEPT BIOPHYS, IL-76100 REHOVOT, ISRAEL	Utrecht University; Tel Aviv University; Weizmann Institute of Science								ALLEN AK, 1978, BIOCHEM J, V171, P665, DOI 10.1042/bj1710665; BAYER EA, 1985, J BACTERIOL, V163, P552, DOI 10.1128/JB.163.2.552-559.1985; BEGUIN P, 1985, J BACTERIOL, V162, P102; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DEBAAIJ JA, 1986, SCI TOOLS, V33, P17; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FUJINO T, 1992, FEMS MICROBIOL LETT, V94, P165; GERWIG GJ, 1989, J BIOL CHEM, V264, P1027; GERWIG GJ, 1991, EUR J BIOCHEM, V196, P115, DOI 10.1111/j.1432-1033.1991.tb15793.x; GERWIG GJ, 1992, EUR J BIOCHEM, V205, P799, DOI 10.1111/j.1432-1033.1992.tb16844.x; GHANGAS GS, 1988, APPL ENVIRON MICROB, V54, P2521, DOI 10.1128/AEM.54.10.2521-2526.1988; GILBERT HJ, 1990, MOL MICROBIOL, V4, P759, DOI 10.1111/j.1365-2958.1990.tb00646.x; GILKES NR, 1991, MICROBIOL REV, V55, P303, DOI 10.1128/MMBR.55.2.303-315.1991; GILKES NR, 1988, J BIOL CHEM, V263, P10401; GREPINET O, 1986, NUCLEIC ACIDS RES, V14, P1791, DOI 10.1093/nar/14.4.1791; HESTRIN S, 1949, J BIOL CHEM, V180, P249; HONNAMI K, 1986, ARCH MICROBIOL, V145, P13, DOI 10.1007/BF00413021; Kamerling J. P., 1989, MASS SPECTROMETRY, P176; LAMED R, 1983, BIOTECHNOL BIOENG, P163; Lamed R., 1988, Biochemistry and genetics of cellulose degradation, P101; LAMED R, 1991, CURR MICROBIOL, V22, P27, DOI 10.1007/BF02106209; LAMED R, 1987, J BACTERIOL, V169, P3792, DOI 10.1128/jb.169.8.3792-3800.1987; LAMED R, 1988, ADV APPL MICROBIOL, V33, P1, DOI 10.1016/S0065-2164(08)70203-X; LAMPORT DTA, 1973, BIOCHEM J, V133, P125, DOI 10.1042/bj1330125; LECHNER J, 1989, ANNU REV BIOCHEM, V58, P173, DOI 10.1146/annurev.bi.58.070189.001133; MCGAVIN M, 1989, J BACTERIOL, V171, P3310, DOI 10.1128/jb.171.6.3310-3315.1989; MUIR L, 1970, J BIOL CHEM, V245, P502; MURRAY WD, 1986, LETT APPL MICROBIOL, V3, P69, DOI 10.1111/j.1472-765X.1986.tb01550.x; ONEILL G, 1986, GENE, V44, P325, DOI 10.1016/0378-1119(86)90197-6; POOLE DM, 1993, IN PRESS FEMS MICROB; Schauer R, 1978, Methods Enzymol, V50, P64; SUMPER M, 1990, J BACTERIOL, V172, P7111, DOI 10.1128/jb.172.12.7111-7118.1990; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WARREN R A J, 1986, Proteins Structure Function and Genetics, V1, P335, DOI 10.1002/prot.340010407	34	75	79	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26956	26960						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262930				2022-12-25	WOS:A1993MM26200021
J	OLIVEIRA, MGD; ROGANA, E; ROSA, JC; REINHOLD, BB; ANDRADE, MH; GREENE, LJ; MARESGUIA, M				OLIVEIRA, MGD; ROGANA, E; ROSA, JC; REINHOLD, BB; ANDRADE, MH; GREENE, LJ; MARESGUIA, M			TYROSINE-151 IS PART OF THE SUBSTRATE ACTIVATION BINDING-SITE OF BOVINE TRYPSIN - IDENTIFICATION BY COVALENT LABELING WITH P-DIAZONIUMBENZAMIDINE AND KINETIC CHARACTERIZATION OF TYR-151-(P-BENZAMIDINO)-AZO-BETA-TRYPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARA-NITROANILIDE; SERINE PROTEASE; HYDROLYSIS; INHIBITION; ACID	Identification of the substrate activation site of beta-trypsin by a 1:1 reacton with p-diazoniumbenzamidine chloride was confirmed by spectral anaylsis. Proteolysis of Cm-p-benzamidino-azo-beta-trypsin provided peptides containing modified tyrosine residues. The major product, Ser-146 to Lys-156, which corresponded to labeling at Tyr-151, was recovered in 35% yield, and its structure was demonstrated by amino acid analysis, Edman degradation, and mass spectrometry. Yields of labeled Tyr-151, Tyr-39, and Tyr-172, identified by peptide analysis, were in the proportion of 100:7:3. Tyr-151-(p-benzamidino)-azo-beta-trypsin is permanently activated, but can be further activated by substrates. Values of k(cat), Ks', and k(cat) vary from two to three times the equivalent values for trypsin. Berenil (4,4'-diazoamino-bis-benzamidine), a parabolic competitive inhibitor of beta-trypsin, was a hyperbolic competitive inhibitor of azo-beta-trypsin. Thus, Tyr-151, part of subsite S'2, affects the catalytic process and, when modified covalently, permanently activates trypsin. Equilibrium binding with berenil supported the kinetic data obtained with substrates. This permits the integration of protein modification, kinetics, equilibrium binding, and crystallographic data to demonstrate a fine interaction between subsites S1-S3 and S'2 in trypsin and azo-beta-trypsin, resulting in subtle structural changes when the native enzyme is covalently modified at Tyr-151.	FED UNIV MINAS GERAIS,INST BIOL SCI,DEPT BIOCHEM & IMMUNOL,POB 2486,BR-31270540 BELO HORIZONT,MG,BRAZIL; USP,CTR INTERDEPT PROT CHEM,BR-14049900 RIBEIRAO PRET,SP,BRAZIL; USP,FAC MED RIBEIRAO PRETO,DEPT GYNECOL & OBSTET,BR-14049900 RIBEIRAO PRET,SP,BRAZIL; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Universidade de Sao Paulo; Universidade de Sao Paulo; Harvard University; Harvard T.H. Chan School of Public Health			OLIVEIRA, Maria Goreti A./AGP-5215-2022; Greene, Lewis J/L-6098-2017; Rosa, Jose C/A-1966-2013; de Alemida Oliveira, Maria Goreti/P-9332-2017	Greene, Lewis J/0000-0003-0144-9726; Rosa, Jose C/0000-0002-6917-0230; de Alemida Oliveira, Maria Goreti/0000-0001-5603-9471				ALONZO N, 1968, ANAL BIOCHEM, V23, P272, DOI 10.1016/0003-2697(68)90359-X; ANDRADE MHG, 1990, BRAZ J MED BIOL RES, V23, P1223; BAINES NJ, 1964, BIOCHEM J, V90, P470, DOI 10.1042/bj0900470; Bidlingmeyer BA, 1986, METHODS PROTEIN SEQU, P229; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; Bratton AC, 1939, J BIOL CHEM, V128, P537; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; CHRISTOVA E, 1982, ARCH BIOCHEM BIOPHYS, V218, P626, DOI 10.1016/0003-9861(82)90390-3; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DIAS CLF, 1986, BRAZ J MED BIOL RES, V19, P11; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; ERLANGER BF, 1961, ARCH BIOCHEM BIOPHYS, V95, P271, DOI 10.1016/0003-9861(61)90145-X; FAIRCLOUGH GF, 1966, BIOCHEMISTRY-US, V5, P673, DOI 10.1021/bi00866a038; FUSHITANI K, 1988, J BIOL CHEM, V263, P6502; Hartley BS, 1971, ENZYMES, V3, P323; HESTRIN S, 1949, J BIOL CHEM, V180, P249; HUBER R, 1974, BAYER S, V5, P497; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; Inagami T, 1972, PROTEIN-STRUCT FUNCT, P1; JUNQUEIRA RG, 1990, BRAZ J MED BIOL RES, V23, P773; JUNQUEIRA RG, 1992, BRAZ J MED BIOL RES, V25, P873; KUNITZ M, 1947, J GEN PHYSIOL, V30, P291, DOI 10.1085/jgp.30.4.291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MAGALHAESROCHA NM, 1980, ARCH BIOCHEM BIOPHYS, V200, P61, DOI 10.1016/0003-9861(80)90330-6; MARESGUIA M, 1981, J BIOL CHEM, V256, P1661; MARESGUIA M, 1965, J BIOL CHEM, V240, P1579; NAKATA H, 1970, BIOCHEM BIOPH RES CO, V41, P393, DOI 10.1016/0006-291X(70)90517-6; NAKATA H, 1972, J BIOCHEM-TOKYO, V72, P281, DOI 10.1093/oxfordjournals.jbchem.a129907; NIELSEN BL, 1984, ANAL BIOCHEM, V141, P311, DOI 10.1016/0003-2697(84)90047-2; RIORDAN JF, 1972, ENZYME STRUCTURE, V20, P521; ROSA JC, 1992, 21 M BRAZ SOC BIOCH, P12; RUHLMANN A, 1973, J MOL BIOL, V77, P417, DOI 10.1016/0022-2836(73)90448-8; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P100; SCHOELLMANN G, 1963, BIOCHEMISTRY-US, V2, P252, DOI 10.1021/bi00902a008; SCHROEDER DD, 1968, J BIOL CHEM, V243, P2943; SCHWERT GW, 1955, BIOCHIM BIOPHYS ACTA, V16, P571; SHAW ELLIOTT, 1965, BIOCHEMISTRY, V4, P2219, DOI 10.1021/bi00886a039; SOKOLOVS.M, 1966, BIOCHEMISTRY-US, V5, P3574, DOI 10.1021/bi00875a028; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; SPRANG S, 1987, SCIENCE, V237, P905, DOI 10.1126/science.3112942; STROUD RM, 1974, SCI AM, V231, P74, DOI 10.1038/scientificamerican0774-74; TABACHNICK M, 1959, J BIOL CHEM, V234, P1726; TRENHOLM HL, 1969, BIOCHEMISTRY-US, V8, P1741, DOI 10.1021/bi00832a057; TROWBRIDGE CG, 1963, BIOCHEMISTRY-US, V2, P843, DOI 10.1021/bi00904a037; TSUNEMATSU H, 1983, J BIOCHEM-TOKYO, V94, P123, DOI 10.1093/oxfordjournals.jbchem.a134320; VILLELA L, 1984, ARQ BIOL TECHNOL, V27, P281	49	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26893	26903						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262923				2022-12-25	WOS:A1993MM26200013
J	BARFOD, ET; ZHENG, Y; KUANG, WJ; HART, MJ; EVANS, T; CERIONE, RA; ASHKENAZI, A				BARFOD, ET; ZHENG, Y; KUANG, WJ; HART, MJ; EVANS, T; CERIONE, RA; ASHKENAZI, A			CLONING AND EXPRESSION OF A HUMAN CDC42 GTPASE-ACTIVATING PROTEIN REVEALS A FUNCTIONAL SH3-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SACCHAROMYCES-CEREVISIAE GENE; BINDING PROTEIN; CELL POLARITY; MOLECULAR-CLONING; FOCAL ADHESIONS; HUMAN HOMOLOG; IDENTIFICATION; RHO; PURIFICATION; THROMBIN	CDC42, a member of the Rho family of small GTP-binding proteins, regulates cytoskeletal rearrangements required for cell division. Activating mutations in CDC42 that are refractory to GTPase activation confer a phenotype of large, multinucleated cells. Like other small GTP-binding proteins, CDC42 is activated by a guanosine exchange factor and inactivated by a GTPase-activating protein (GAP). An unidentified 25-kDa platelet protein has been shown to function as a specific CDC42GAP. Here we report the cloning of a cDNA encoding this GAP from a human platelet-precursor cell line. Sequence analysis reveals the presence of three consensus box regions characteristic of rhoGAPs. A glutathione S-transferase fusion protein containing the three boxes derived from the new clone strongly stimulated the GTPase activity of CDC42 but was much less effective on other Rho proteins. This indicates that the cDNA clone encodes a specific GAP for CDC42. Sequence analysis also reveals a potential proline-rich Src homology 3 (SH3)-binding domain preceding the first consensus box. Binding experiments show that this motif can interact with the SH3 domains of p85alpha and of c-Src. Thus, CDC42GAP may function as a link between CDC42 and other signaling pathways.	GENENTECH INC, DEPT MOLEC BIOL, S SAN FRANCISCO, CA 94080 USA; CORNELL UNIV, DEPT PHARMACOL, ITHACA, NY 14853 USA	Roche Holding; Genentech; Cornell University			Zheng, Yi/J-7235-2015; Ashkenazi, Avi/ABG-2712-2020	Zheng, Yi/0000-0001-7089-6074; Ashkenazi, Avi/0000-0002-6890-4589; Hart, Matthew/0000-0002-2683-480X	NIGMS NIH HHS [GM47458] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BOGUSKI MS, 1993, IN PRESS NATURE; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN WN, 1993, J BIOL CHEM, V268, P13280; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; EVANS T, 1986, J BIOL CHEM, V261, P7052; GARRETT MD, 1991, BIOCHEM J, V276, P833, DOI 10.1042/bj2760833; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hall A, 1993, CURR OPIN CELL BIOL, V5, P265, DOI 10.1016/0955-0674(93)90114-6; HART MJ, 1990, J BIOL CHEM, V265, P5990; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HART MJ, 1991, J BIOL CHEM, V266, P20840; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; POLAKIS PG, 1989, BIOCHEM BIOPH RES CO, V160, P25, DOI 10.1016/0006-291X(89)91615-X; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO T, 1989, BRIT J HAEMATOL, V72, P184, DOI 10.1111/j.1365-2141.1989.tb07681.x; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHENG Y, 1993, J BIOL CHEM, V268, P24629; ZIMAN M, 1991, MOL CELL BIOL, V11, P3537, DOI 10.1128/MCB.11.7.3537	40	113	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26059	26062						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253717				2022-12-25	WOS:A1993MK42500008
J	SHIAO, YJ; VANCE, JE				SHIAO, YJ; VANCE, JE			SPHINGOMYELIN TRANSPORT TO THE CELL-SURFACE OCCURS INDEPENDENTLY OF PROTEIN SECRETION IN RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; BREFELDIN-A; ENDOPLASMIC-RETICULUM; GOLGI-COMPLEX; INTRACELLULAR-TRANSPORT; CULTURED FIBROBLASTS; LIPID TRANSPORT; KIDNEY CELLS; CHOLESTEROL; LIVER	The transport of sphingomyelin from its site of synthesis, in the cis/medial-Golgi, to the plasma membrane has been investigated in monolayer cultures of rat hepatocytes. Sphingomyelin was synthesized intracellularly from [methyl-H-3]choline, and the arrival of sphingomyelin at the plasma membrane was monitored by treatment of the cells with sphingomyelinase, which hydrolyzed only sphingomyelin at the cell surface. When hepatocytes were maintained at temperatures from 5 to 37-degrees-C, both protein secretion and sphingomyelin trafficking to the cell surface were inhibited at low temperatures, especially at temperatures below 25-degrees-C. Treatment of cells with the energy poison potassium cyanide prevented protein secretion and reduced the incorporation of [H-3]choline into sphingomyelin, but did not affect the percentage of newly synthesized sphingomyelin that was transported to the cell surface. Brefeldin A and monensin, both of which disrupt protein movement through the Golgi apparatus, were used to evaluate the mechanism of transport of sphingomyelin to the plasma membrane. Although brefeldin A and monensin each effectively blocked protein secretion, sphingomyelin movement to the cell surface was not inhibited, even though sphingomyelin synthesis normally occurs in the Golgi. We conclude that the most likely mechanism of sphingomyelin transport to the cell surface is a vesicle-mediated process (because of the known topology of sphingomyelin synthesis and distribution). However, the putative vesicles that are involved in the movement of sphingomyelin to the plasma membrane are distinct from those that transport proteins for secretion. In addition, the route of trafficking of sphingomyelin to the plasma membrane is not one that requires an obligatory passage through the Golgi apparatus.	UNIV ALBERTA,DEPT MED,EDMONTON T6G 2S2,AB,CANADA	University of Alberta	SHIAO, YJ (corresponding author), UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON T6G 2S2,AB,CANADA.		Shiao, Young-Ji/AAA-9647-2022					ALLAN D, 1988, BIOCHEM J, V254, P765, DOI 10.1042/bj2540765; BERNERT JT, 1981, BIOCHIM BIOPHYS ACTA, V666, P99, DOI 10.1016/0005-2760(81)90095-3; BRUNING A, 1992, J BIOL CHEM, V267, P5052; COLBEAU A, 1971, BIOCHIM BIOPHYS ACTA, V249, P462, DOI 10.1016/0005-2736(71)90123-4; DAVIDOWICZ EA, 1987, ANNU REV BIOCHEM, V56, P43; DAVIS RA, 1979, J BIOL CHEM, V254, P2010; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; HATCH GM, 1992, J BIOL CHEM, V267, P12443; HELMS JB, 1990, J BIOL CHEM, V265, P20027; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KALLEN KJ, 1993, BIOCHEM J, V289, P307, DOI 10.1042/bj2890307; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KOBAYASHI T, 1989, J BIOL CHEM, V264, P5966; KOBAYASHI T, 1992, FEBS LETT, V300, P227, DOI 10.1016/0014-5793(92)80851-7; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LINARDIC CM, 1992, J BIOL CHEM, V267, P14909; LIPSKY NG, 1983, P NATL ACAD SCI-BIOL, V80, P2608, DOI 10.1073/pnas.80.9.2608; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGGRAF WD, 1987, BIOCHIM BIOPHYS ACTA, V897, P57, DOI 10.1016/0005-2736(87)90315-4; MARTIN OC, 1987, J BIOL CHEM, V262, P5890; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; PERRET B, 1979, BIOCHIM BIOPHYS ACTA, V556, P434, DOI 10.1016/0005-2736(79)90131-7; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; QUINN P, 1983, J CELL BIOL, V96, P851, DOI 10.1083/jcb.96.3.851; SRIBNEY M, 1971, CAN J BIOCHEM CELL B, V49, P306, DOI 10.1139/o71-044; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; URBANI L, 1990, J BIOL CHEM, V265, P1919; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; Van Meer Gerrit, 1992, Trends in Cell Biology, V2, P332; VANCE DE, 1984, BIOCHIM BIOPHYS ACTA, V792, P39, DOI 10.1016/0005-2760(84)90280-7; VANCE JE, 1991, J LIPID RES, V32, P1971; VANCE JE, 1991, J BIOL CHEM, V266, P8241; VANGOLDE LM, 1974, BIOCHIM BIOPHYS ACTA, V360, P179, DOI 10.1016/0005-2760(74)90168-4; VANTHOF W, 1992, BIOCHEM J, V283, P913, DOI 10.1042/bj2830913; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; VOELKER DR, 1991, MICROBIOL REV, V55, P543, DOI 10.1128/MMBR.55.4.543-560.1991; VOELKER DR, 1991, BIOCH LIPIDS LIPOPRO, P489; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; WATTENBERG BW, 1990, J CELL BIOL, V111, P421, DOI 10.1083/jcb.111.2.421; WEIGEL PH, 1975, J BIOL CHEM, V250, P8536; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YEAGLE PL, 1986, J BIOL CHEM, V261, P8175; YOUNG WW, 1992, J BIOL CHEM, V267, P12011	51	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26085	26092						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253724				2022-12-25	WOS:A1993MK42500015
J	FRUEN, BR; MICKELSON, JR; SHOMER, NH; ROGHAIR, TJ; LOUIS, CF				FRUEN, BR; MICKELSON, JR; SHOMER, NH; ROGHAIR, TJ; LOUIS, CF			REGULATION OF THE SARCOPLASMIC-RETICULUM RYANODINE RECEPTOR BY INORGANIC-PHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE FIBERS; MALIGNANT HYPERTHERMIA; CALCIUM-RELEASE; CARDIAC-MUSCLE; MAMMALIAN SKELETAL; RABBIT SKELETAL; XENOPUS-LAEVIS; FATIGUE; CONTRACTION; CHANNEL	To better understand the mechanisms regulating myoplasmic Ca2+ during muscle activity, we have examined the effect of inorganic phosphate (P(i)) on the ryanodine receptor (RyR) Ca2+ release channel of the sarcoplasmic reticulum (SR). We report that P(i) at concentrations reached in exercising skeletal muscle (3-30 mM) produced a dose-dependent stimulation of ryanodine binding to skeletal muscle SR. Ryanodine binding was increased by 84% in the presence of 30 mM P(i) with half-maximal stimulation at 4 mM P(i). In contrast to its effect on skeletal muscle SR, ryanodine binding to cardiac muscle SR was not stimulated by P(i) (3-30 mM). Stimulation of ryanodine binding to skeletal muscle SR was maximal in the presence of micromolar Ca2+ and was associated with an increased affinity of the RyR for ryanodine (K(d) = 204 nM in the absence, versus 107 nM in the presence of 10 mM P(i)). P(i) (10 mM) also increased the rate of Ca2+ release from Ca-45(2+)-filled skeletal muscle SR vesicles by 50% in the presence of micromolar Ca2+. Conversely, arsenate and sulfate (10 mM) had no effect on either ryanodine binding or Ca2+-induced Ca2+ release, demonstrating the specificity of the P(i) effect. Single-channel recordings of purified skeletal muscle SR RyR incorporated into planar lipid bilayers showed that addition of 10 mM P(i) to the cis chamber increased the open probability of the channel by 91%. These results demonstrate that concentrations of P(i) which occur in vivo during exercise significantly stimuIate the in vitro activity of the skeletal muscle RyR Ca2+ release channel.	UNIV MINNESOTA, DEPT BIOCHEM, ST PAUL, MN 55108 USA; UNIV MINNESOTA, DEPT VET PATHOBIOL, ST PAUL, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities				Mickelson, James/0000-0001-6951-0234; Shomer, Nirah/0000-0003-2520-0108	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031382] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31382] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN DG, 1989, J PHYSIOL-LONDON, V415, P433, DOI 10.1113/jphysiol.1989.sp017730; ALLEN DG, 1987, CIRC RES, V60, P153, DOI 10.1161/01.RES.60.2.153; ALVES EW, 1987, EUR J BIOCHEM, V166, P647, DOI 10.1111/j.1432-1033.1987.tb13562.x; CADY EB, 1989, J PHYSIOL-LONDON, V418, P311, DOI 10.1113/jphysiol.1989.sp017842; CHASE PB, 1988, BIOPHYS J, V53, P935, DOI 10.1016/S0006-3495(88)83174-6; COOKE R, 1985, BIOPHYS J, V48, P789, DOI 10.1016/S0006-3495(85)83837-6; DAWSON MJ, 1978, NATURE, V274, P861, DOI 10.1038/274861a0; ERVASTI JM, 1991, AM J PHYSIOL, V260, pC58, DOI 10.1152/ajpcell.1991.260.1.C58; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GODT RE, 1989, J PHYSIOL-LONDON, V412, P155, DOI 10.1113/jphysiol.1989.sp017609; HAMILTON SL, 1989, ANAL BIOCHEM, V183, P31, DOI 10.1016/0003-2697(89)90167-X; KUSHMERICK MJ, 1992, P NATL ACAD SCI USA, V89, P7521, DOI 10.1073/pnas.89.16.7521; LAI FA, 1992, AM J PHYSIOL, V263, pC365, DOI 10.1152/ajpcell.1992.263.2.C365; LAI FA, 1988, NATURE, V331, P135; LAI FA, 1989, J BIOL CHEM, V264, P1677; LANNERGREN J, 1991, J PHYSIOL-LONDON, V434, P307; LEE JA, 1991, J PHYSIOL-LONDON, V433, P307, DOI 10.1113/jphysiol.1991.sp018427; MEISSNER G, 1992, MOL CELL BIOCHEM, V114, P119; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MEISSNER G, 1988, MOL CELL BIOCHEM, V82, P59; MICHALAK M, 1988, BIOCHIM BIOPHYS ACTA, V939, P587, DOI 10.1016/0005-2736(88)90106-X; MICKELSON JR, 1988, J BIOL CHEM, V263, P9310; MICKELSON JR, 1986, BIOCHIM BIOPHYS ACTA, V862, P318, DOI 10.1016/0005-2736(86)90234-8; MICKELSON JR, 1990, ARCH BIOCHEM BIOPHYS, V278, P251, DOI 10.1016/0003-9861(90)90255-W; MOORE SA, 1983, J BIOL CHEM, V258, P6266; NOSEK TM, 1990, AM J PHYSIOL, V259, pC933, DOI 10.1152/ajpcell.1990.259.6.C933; OTSU K, 1990, J BIOL CHEM, V265, P13472; ROUSSEAU E, 1986, BIOPHYS J, V50, P1009, DOI 10.1016/S0006-3495(86)83543-3; ROUSSEAU E, 1990, PFLUG ARCH EUR J PHY, V415, P645, DOI 10.1007/BF02583520; SHOMER NH, 1993, AM J PHYSIOL, V264, pC125, DOI 10.1152/ajpcell.1993.264.1.C125; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SMITH JS, 1986, J GEN PHYSIOL, V88, P773; STRAND MA, 1993, BIOCHIM BIOPHYS ACTA, V1175, P319, DOI 10.1016/0167-4889(93)90224-D; WESTERBLAD H, 1991, J GEN PHYSIOL, V98, P615, DOI 10.1085/jgp.98.3.615; WESTERBLAD H, 1991, AM J PHYSIOL, V261, pC195, DOI 10.1152/ajpcell.1991.261.2.C195	36	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					192	198						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276794				2022-12-25	WOS:A1994MR21900037
J	GALEANO, NF; MILNE, R; MARCEL, YL; WALSH, MT; LEVY, E; NGUYEN, TD; GLEESON, A; ARAD, Y; WITTE, L; ALHAIDERI, M; RUMSEY, SC; DECKELBAUM, RJ				GALEANO, NF; MILNE, R; MARCEL, YL; WALSH, MT; LEVY, E; NGUYEN, TD; GLEESON, A; ARAD, Y; WITTE, L; ALHAIDERI, M; RUMSEY, SC; DECKELBAUM, RJ			APOPROTEIN-B STRUCTURE AND RECEPTOR RECOGNITION OF TRIGLYCERIDE-RICH LOW-DENSITY-LIPOPROTEIN (LDL) IS MODIFIED IN SMALL LDL BUT NOT IN TRIGLYCERIDE-RICH LDL OF NORMAL SIZE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SKIN FIBROBLASTS; APOLIPOPROTEIN-B; MONOCLONAL-ANTIBODIES; FATTY-ACIDS; HUMAN-PLASMA; BINDING; CELLS; HYPERTRIGLYCERIDEMIA; EXPRESSION; METABOLISM	We compared the effect of lipid composition and particle size of triglyceride-rich low density lipoprotein (LDL) upon apoprotein B conformation and binding to the LDL receptor. Three groups of triglyceride-rich LDL were studied: (a) LDL isolated from chronic hypertriglyceridemic individuals (HTG-LDL); (b) normal LDL made triglyceride-rich by in vitro incubation with triglyceride emulsion and the neutral lipid transfer protein (R-LDL); and (c) LDL from normolipidemic individuals made acutely hypertriglyceridemic by intravenous infusion of 10% Intralipid (IV-LDL). HTG-LDL was small and dense, whereas R-LDL and IV-LDL had normal size. HTG-LDL, but not R-LDL or IV-LDL, exhibited decreased binding to the LDL receptor on human skin fibroblasts in studies at 4-degrees-C and reduced degradation at 37-degrees-C. Apoprotein B conformation was assessed by circular dichroism and by analyzing the immunoreactivity of different monoclonal antibodies. HTG-LDL but not R-LDL or IV-LDL showed a change in the CD spectra and a consistent decrease in the immunoreactivity of monoclonal antibody 3F5 (2.5-fold) which recognizes an epitope adjacent to the receptor binding domain of apoprotein B. These findings suggest that in triglyceride-rich LDL, the relative content of neutral lipid in the core of LDL in the absence of changes in the size of the particle does not significantly affect apoprotein B conformation or its affinity for the LDL receptor.	COLUMBIA UNIV,DEPT PEDIAT,630 W 168TH ST,NEW YORK,NY 10032; COLUMBIA UNIV,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV,INST HUMAN NUTR,NEW YORK,NY 10032; UNIV OTTAWA,INST HEART,LIPOPROT & ATHEROSCLEROSIS GRP,OTTAWA K1Y 4E9,ONTARIO,CANADA; BOSTON UNIV,MED CTR,INST BIOPHYS,BOSTON,MA 02118; UNIV MONTREAL,DEPT NUTR,MONTREAL H3T 1CS,PQ,CANADA	Columbia University; Columbia University; Columbia University; University of Ottawa; University of Ottawa Heart Institute; Boston University; Universite de Montreal					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000065] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040404, P50HL021006] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1RR0065] Funding Source: Medline; NHLBI NIH HHS [HL-21006, HL-40404] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGNANI G, 1991, ARTERIOSCLER THROMB, V11, P1021, DOI 10.1161/01.ATV.11.4.1021; ARAD Y, 1992, CIRCULATION, V86, P551; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; AVIRAM M, 1988, J BIOL CHEM, V263, P15416; AVIRAM M, 1988, J BIOL CHEM, V263, P16842; AVIRAM M, 1991, J BIOL CHEM, V266, P11567; AVIRAM M, 1993, J CLIN INVEST, V91, P1942, DOI 10.1172/JCI116413; AVIRAM M, 1989, ARTERIOSCLEROSIS, V9, P67, DOI 10.1161/01.ATV.9.1.67; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BAUDET MF, 1986, CLIN PHYSIOL BIOCH, V4, P173; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; Buege J A, 1978, Methods Enzymol, V52, P302; CASTELLI WP, 1990, ATHER REV, V21, P7; CHAIT A, 1984, BIOCHIM BIOPHYS ACTA, V795, P314, DOI 10.1016/0005-2760(84)90081-X; CHAPPELL DA, 1991, J BIOL CHEM, V266, P19296; CHAPPELL DA, 1992, J BIOL CHEM, V267, P270; DECKELBAUM RJ, 1984, ARTERIOSCLEROSIS, V4, P225, DOI 10.1161/01.ATV.4.3.225; DECKELBAUM RJ, 1982, J BIOL CHEM, V257, P6509; DECKELBAUM RJ, 1988, BIOCHIM BIOPHYS ACTA, V961, P233; DEGRAAF J, 1991, ARTERIOSCLER THROMB, V11, P298, DOI 10.1161/01.ATV.11.2.298; DEJAGER S, 1993, J LIPID RES, V34, P295; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; EISENBERG S, 1984, J CLIN INVEST, V74, P470, DOI 10.1172/JCI111444; GIBSON JC, 1983, J LIPID RES, V24, P886; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GRANOT E, 1985, BIOCHIM BIOPHYS ACTA, V833, P308, DOI 10.1016/0005-2760(85)90203-6; HIRAMATSU K, 1985, DIABETES, V34, P8, DOI 10.2337/diabetes.34.1.8; HURTCAMEJO E, 1990, J LIPID RES, V31, P1387; Innerarity T L, 1986, Methods Enzymol, V129, P542; INNERARITY TL, 1987, P NATL ACAD SCI USA, V84, P6919, DOI 10.1073/pnas.84.19.6919; KINOSHITA M, 1990, J LIPID RES, V31, P701; KLEINMAN Y, 1985, J CLIN INVEST, V75, P1796, DOI 10.1172/JCI111892; KLEINMAN Y, 1988, J LIPID RES, V29, P729; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KRIEGER M, 1978, J BIOL CHEM, V253, P4093; KRIEGER M, 1979, J BIOL CHEM, V254, P3845; KUNITAKE ST, 1990, J BIOL CHEM, V265, P20739; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P51; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCEL YL, 1988, ARTERIOSCLEROSIS, V8, P832, DOI 10.1161/01.ATV.8.6.832; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MCKEONE BJ, 1993, J CLIN INVEST, V91, P1926, DOI 10.1172/JCI116411; MCNAMARA JR, 1987, ARTERIOSCLEROSIS, V7, P483, DOI 10.1161/01.ATV.7.5.483; MILNE R, 1989, J BIOL CHEM, V264, P19754; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; NENSETER MS, 1992, ARTERIOSCLER THROMB, V12, P369, DOI 10.1161/01.ATV.12.3.369; NIGON F, 1991, J LIPID RES, V32, P1741; PATSCH JR, 1974, J LIPID RES, V15, P356; PEASE RJ, 1990, J BIOL CHEM, V265, P553; SCHONFELD G, 1979, J CLIN INVEST, V64, P1288, DOI 10.1172/JCI109584; SCHONFELD G, 1986, J LIPID RES, V27, P583; SHEN MMS, 1981, J LIPID RES, V22, P236; SHEPHERD J, 1985, ARTERIOSCLEROSIS, V5, P162, DOI 10.1161/01.ATV.5.2.162; SMITH JB, 1976, J LAB CLIN MED, V88, P167; TENG B, 1983, P NATL ACAD SCI-BIOL, V80, P6662, DOI 10.1073/pnas.80.21.6662; TENG B, 1985, J BIOL CHEM, V260, P5067; TIKKANEN MJ, 1983, J LIPID RES, V24, P1494; TILLEY L, 1988, J BIOL CHEM, V263, P17541; VAKAKIS N, 1983, BIOCHIM BIOPHYS ACTA, V751, P280, DOI 10.1016/0005-2760(83)90285-0; VEGA GL, 1986, ARTERIOSCLEROSIS, V6, P395, DOI 10.1161/01.ATV.6.4.395; WALSH MT, 1990, BIOCHEMISTRY-US, V29, P6250, DOI 10.1021/bi00478a020; WINDLER E, 1980, J BIOL CHEM, V255, P8303; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YOUNG SG, 1987, J CLIN INVEST, V79, P1831, DOI 10.1172/JCI113025	64	147	150	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					511	519						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276844				2022-12-25	WOS:A1994MR21900083
J	OTTONELLO, S; SCITA, G; MANTOVANI, G; CAVAZZINI, D; ROSSI, GL				OTTONELLO, S; SCITA, G; MANTOVANI, G; CAVAZZINI, D; ROSSI, GL			RETINOL BOUND TO CELLULAR RETINOL-BINDING PROTEIN IS A SUBSTRATE FOR CYTOSOLIC RETINOIC ACID SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; VITAMIN-A; PIGMENT-EPITHELIUM; SMALL-INTESTINE; BOVINE RETINA; ACYL-COA; METABOLISM; ESTERIFICATION; CELLS; DIFFERENTIATION	Retinol bound to cellular retinol-binding protein (CRBP) was found to be oxidized to retinoic acid by a soluble activity from calf liver. Cytosolic retinoic acid synthesis from retinol-CRBP was strictly dependent on the exogenous supply of either NAD or NADP. NAD-supported reactions carried out in the presence or in the absence of dimethyl sulfoxide yielded apparent K(m) and V(max) values for the retinol-CRBP complex of 3.5 +/- 0.6 muM, 611 +/- 49 pmol h-1 (mg of protein)-1, and 0.84 +/- 0.12 muM, 601 +/- 38 pmol h-1 (mg of protein)-1, respectively. The corresponding values for the oxidation of free retinol, dissolved in dimethyl sulfoxide, were 7.1 +/- 0.3 muM and 948 +/- 47 pmol h-1 (mg of protein)-1. Since the dissociation constant of the bovine retinol-CRBP complex is less than 10(-8) M, whereas the K(m) for retinol-CRBP is of the same order as the K(m) for free retinol, synthesis of retinoic acid from retinol-CRBP does not rely on prior dissociation of retinol. ApoCRBP proved to be a specific inhibitor of retinoic acid synthesis from CRBP-bound retinol. Its inhibitory effect was indistinguishable from the dilution of the radioactive retinol-CRBP substrate that was obtained by the addition of unlabeled holoCRBP. In contrast, the oxidation of CRBP-bound retinol was not inhibited by the addition of other retinoid binding proteins nor by the addition of either free retinol or retinol complexed with proteins distinct from CRBP. These results indicate that the protein moiety of holoCRBP is specifically recognized by the cytosolic enzyme system that catalyzes retinoic acid synthesis from CRBP-bound retinol.			OTTONELLO, S (corresponding author), UNIV PARMA,INST BIOCHEM SCI,I-43100 PARMA,ITALY.		Cavazzini, Davide/C-8154-2014; Scita, Giorgio/J-9670-2012	Cavazzini, Davide/0000-0002-1743-2390; Scita, Giorgio/0000-0001-7984-1889				Baginski ES, 1974, METH ENZYMOL; Bergmeyer HU., 1974, METHODS ENZYMATIC AN, P574, DOI [10.1016/B978-0-12-091302-2.50010-4, DOI 10.1016/B978-0-12-091302-2.50010-4]; BERMAN ER, 1980, BIOCHIM BIOPHYS ACTA, V630, P36, DOI 10.1016/0304-4165(80)90135-X; BERNI R, 1989, COMP BIOCHEM PHYS B, V94, P79, DOI 10.1016/0305-0491(89)90014-X; BLOMHOFF R, 1991, PHYSIOL REV, V71, P951, DOI 10.1152/physrev.1991.71.4.951; BOERMAN MHEM, 1991, J BIOL CHEM, V266, P22273; BRADFORD MM, 1976, ANAL BIOCHEM, V150, P273; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; CHYTIL F, 1984, RETINOIDS, V2, P89; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; COLANTUONI V, 1985, BIOCHEM BIOPH RES CO, V130, P431, DOI 10.1016/0006-291X(85)90435-8; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; CROW JA, 1987, ARCH BIOCHEM BIOPHYS, V254, P372, DOI 10.1016/0003-9861(87)90113-5; DE LUCA LM, 1991, FASEB J, V5, P2924; DIETZ AA, 1967, ANAL BIOCHEM, V20, P246, DOI 10.1016/0003-2697(67)90030-9; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; ERIKSSON U, 1987, J CELL PHYSIOL, V133, P482, DOI 10.1002/jcp.1041330308; FIORELLA PD, 1991, J BIOL CHEM, V266, P16572; FUGATE RD, 1980, BIOCHIM BIOPHYS ACTA, V625, P28, DOI 10.1016/0005-2795(80)90105-1; Haq R, 1988, Biochem Biophys Res Commun, V156, P712, DOI 10.1016/S0006-291X(88)80901-X; HARRISON EH, 1987, J LIPID RES, V28, P973; HERR FM, 1992, BIOCHEMISTRY-US, V31, P6748, DOI 10.1021/bi00144a014; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; KAKKAD BP, 1988, J BIOL CHEM, V263, P12916; KIM CI, 1992, ARCH BIOCHEM BIOPHYS, V294, P388, DOI 10.1016/0003-9861(92)90700-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEO MA, 1984, ARCH BIOCHEM BIOPHYS, V234, P305, DOI 10.1016/0003-9861(84)90353-9; LEO MA, 1985, J BIOL CHEM, V260, P5228; LEO MA, 1987, ARCH BIOCHEM BIOPHYS, V259, P241, DOI 10.1016/0003-9861(87)90492-9; LEROY P, 1992, RETINOIDS NORMAL DEV, P7; NAPOLI JL, 1987, ARCH BIOCHEM BIOPHYS, V255, P95, DOI 10.1016/0003-9861(87)90298-0; NAPOLI JL, 1991, BIOMED PHARMACOTHER, V45, P131, DOI 10.1016/0753-3322(91)90101-X; NAPOLI JL, 1986, J BIOL CHEM, V261, P3592; NAPOLI JL, 1990, BIOCHIM BIOPHYS ACTA, V1034, P228, DOI 10.1016/0304-4165(90)90081-7; NAPOLI JL, 1990, METHOD ENZYMOL, V189, P470; NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012; Ong D, 1980, Methods Enzymol, V67, P288; ONG DE, 1987, J BIOL CHEM, V262, P2729; ONG DE, 1988, J BIOL CHEM, V263, P5789; OTTONELLO S, 1984, CURR EYE RES, V3, P1085, DOI 10.3109/02713688409000806; OTTONELLO S, 1987, J BIOL CHEM, V262, P3975; POSCH KC, 1992, J BIOL CHEM, V267, P19676; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; POSCH KC, 1989, ARCH BIOCHEM BIOPHYS, V274, P171, DOI 10.1016/0003-9861(89)90428-1; ROBERTS AB, 1980, ARCH BIOCHEM BIOPHYS, V199, P374, DOI 10.1016/0003-9861(80)90293-3; ROSS AC, 1993, FASEB J, V7, P317, DOI 10.1096/fasebj.7.2.8440409; ROSS AC, 1982, J BIOL CHEM, V257, P2453; SAARI JC, 1982, BIOCHIM BIOPHYS ACTA, V716, P266, DOI 10.1016/0304-4165(82)90277-X; SHIH TW, 1991, DRUG METAB DISPOS, V19, P332; SHINGLETON JL, 1989, BIOCHEMISTRY-US, V28, P9641, DOI 10.1021/bi00451a015; SIEGENTHALER G, 1990, METHOD ENZYMOL, V189, P530; SIEGENTHALER G, 1990, BIOCHEM J, V268, P371, DOI 10.1042/bj2680371; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STUMP DG, 1991, J BIOL CHEM, V266, P4622; TAKASE S, 1979, P NATL ACAD SCI USA, V76, P2204, DOI 10.1073/pnas.76.5.2204; THALLER C, 1988, DEVELOPMENT, V103, P473; TIMMERS AMM, 1986, J LIPID RES, V27, P979; WEI LN, 1989, MOL ENDOCRINOL, V3, P454, DOI 10.1210/mend-3-3-454; WILLIAMS JB, 1985, P NATL ACAD SCI USA, V82, P4658, DOI 10.1073/pnas.82.14.4658; WOLF G, 1984, PHYSIOL REV, V64, P873, DOI 10.1152/physrev.1984.64.3.873; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; YOST RW, 1988, J BIOL CHEM, V263, P18693	62	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27133	27142						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262951				2022-12-25	WOS:A1993MM26200045
J	OZAWA, K; HAGIWARA, H; TANG, XR; SAKA, F; KITABAYASHI, I; SHIROKI, K; FUJINAGA, K; ISRAEL, A; GACHELIN, G; YOKOYAMA, K				OZAWA, K; HAGIWARA, H; TANG, XR; SAKA, F; KITABAYASHI, I; SHIROKI, K; FUJINAGA, K; ISRAEL, A; GACHELIN, G; YOKOYAMA, K			NEGATIVE REGULATION OF THE GENE FOR H-2K(B) CLASS-I ANTIGEN BY ADENOVIRUS 12-E1A IS MEDIATED BY A CAA REPEATED ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTIONAL CONTROL; TRANSFORMED-CELLS; MESSENGER-RNA; RETINOIC ACID; RAT-CELLS; E1A; EXPRESSION; PROMOTER; SEQUENCES	Both positive and negative regulatory elements responsive to the product of the adenovirus type 12 E1A gene are located in the promoter region of the gene for mouse H-2K(bm1) major histocompatibility complex (MHC) class I antigen (1). We have analyzed the negative regulatory element that is affected by E1A and identified a target CAA repeated motif, CAA(A)CAAA, within -1725 to -1705 and -1591 to -1568 in a 316-bp sequence located in the far upstream region of H-2K(b) promoter (-1837 to -1522; +1 refers to the cap site). The extent of cell surface expression of the MHC class 1 antigen was significantly decreased in the case of transfectants obtained by introducing an expression plasmid that included MHC class 1 cDNA with the CAA repeated element, as compared with that of a plasmid with mutated CAA repeats. We have also characterized the nuclear proteins that bind to this motif. The analysis of the effects of mutations during competition assays of in vivo and gel retardation competition assays demonstrated that the CAA repeated element is essential not only for E1A-dependent repression of transcription but also for the cell surface expression of the product of the mouse H-2K(b) class I gene, presumably through nuclear proteins that specifically bind to it.	INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, 3-1-1 KOYADAI, TSUKUBA, IBARAKI 305, JAPAN; UNIV TOKYO, INST MED, TOKYO 108, JAPAN; SAPPORO UNIV, SCH MED, SAPPORO 060, JAPAN; INST PASTEUR, UNITE BIOL MOLEC GENE, F-75724 PARIS 15, FRANCE	RIKEN; University of Tokyo; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Kitabayashi, Issay/G-2204-2017	Kitabayashi, Issay/0000-0002-8409-0407				ACKIL AM, 1988, ONCOGENE, V3, P483; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERK AJ, 1986, CANCER SURV, V5, P367; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COCHET M, 1986, IMMUNOGENETICS, V24, P267, DOI 10.1007/BF00364531; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EAGER KB, 1985, P NATL ACAD SCI USA, V82, P5525, DOI 10.1073/pnas.82.16.5525; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FLINT SJ, 1980, MOL BIOL TUMOR VIRUS, V2, P547; FRIED M, 1981, NUCLEIC ACIDS RES, V5, P3157; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; GALLIMORE PH, 1979, COLD SPRING HARB SYM, V44, P703, DOI 10.1101/SQB.1980.044.01.075; GE RW, 1992, J VIROL, V66, P6969, DOI 10.1128/JVI.66.12.6969-6978.1992; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1984, ADENOVIRUSES, P339; GRAND RJA, 1987, BIOCHEM J, V241, P25, DOI 10.1042/bj2410025; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HEN R, 1986, NATURE, V321, P249, DOI 10.1038/321249a0; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; KATOH S, 1990, EMBO J, V9, P127, DOI 10.1002/j.1460-2075.1990.tb08088.x; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KITABAYASHI I, 1992, EMBO J, V11, P167, DOI 10.1002/j.1460-2075.1992.tb05039.x; KRALLI A, 1992, J VIROL, V66, P6979, DOI 10.1128/JVI.66.12.6979-6988.1992; LERNARDO M, 1989, EMBO J, V8, P3351; LITTLE JW, 1986, CELL, V46, P1043; MAK S, 1979, VIROLOGY, V98, P456, DOI 10.1016/0042-6822(79)90568-3; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MEIJER I, 1989, J VIROL, V63, P4039, DOI 10.1128/JVI.63.9.4039-4042.1989; MIYAZAKI J, 1986, P NATL ACAD SCI USA, V83, P9537, DOI 10.1073/pnas.83.24.9537; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; OZAWA K, 1990, NUCLEIC ACIDS RES, V18, P4185, DOI 10.1093/nar/18.14.4185; REYES AA, 1981, IMMUNOGENETICS, V14, P383, DOI 10.1007/BF00373318; REYES AA, 1982, P NATL ACAD SCI-BIOL, V79, P3270, DOI 10.1073/pnas.79.10.3270; ROEHM N, 1982, P NATL ACAD SCI USA, V79, P3270; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADA Y, 1985, VIROLOGY, V147, P413, DOI 10.1016/0042-6822(85)90143-6; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SCHULZE DH, 1983, P NATL ACAD SCI-BIOL, V80, P2007, DOI 10.1073/pnas.80.7.2007; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIROKI K, 1992, J VIROL, V66, P1449, DOI 10.1128/JVI.66.3.1449-1457.1992; SHIROKI K, 1984, J VIROL, V50, P854, DOI 10.1128/JVI.50.3.854-863.1984; SOGAWA K, 1989, EUR J BIOCHEM, V181, P539, DOI 10.1111/j.1432-1033.1989.tb14757.x; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; STEINMETZ M, 1981, CELL, V24, P125, DOI 10.1016/0092-8674(81)90508-0; TIMMERS HTM, 1989, J VIROL, V63, P1470, DOI 10.1128/JVI.63.3.1470-1473.1989; VAESSEN RTMJ, 1986, EMBO J, V5, P335, DOI 10.1002/j.1460-2075.1986.tb04217.x; VAESSEN RTMJ, 1987, SCIENCE, V235, P1486, DOI 10.1126/science.3823900; VANDENELSEN P, 1982, GENE, V18, P175, DOI 10.1016/0378-1119(82)90115-9; VELCICH A, 1986, MOL CELL BIOL, V6, P4019, DOI 10.1128/MCB.6.11.4019; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YAMASHITA T, 1982, Tumor Research, V17, P9; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363; YOUNG KS, 1989, MOL CELL BIOL, V9, P3109, DOI 10.1128/MCB.9.7.3109; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	63	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27258	27268						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262966				2022-12-25	WOS:A1993MM26200062
J	SPERLING, P; LINSCHEID, M; STOCKER, S; MUHLBACH, HP; HEINZ, E				SPERLING, P; LINSCHEID, M; STOCKER, S; MUHLBACH, HP; HEINZ, E			IN-VIVO DESATURATION OF CIS-DELTA-9-MONOUNSATURATED TO CIS-DELTA-9,12-DIUNSATURATED ALKENYLETHER GLYCEROLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION CULTURES; OLEOYL-PHOSPHATIDYLCHOLINE; ETHER GLYCEROLIPIDS; LINOLEIC-ACID; PLANT LIPIDS; FATTY-ACIDS; CHROMATOGRAPHY; RAPE; ALKYLGLYCEROLS; PHOSPHOLIPIDS	Plants convert lipid-bound cis-n-9 monoenoic to polyenoic fatty acid residues without involvement of corresponding CoA-thioesters. To provide additional evidence for this type of lipid-linked desaturation we incubated sn-1-O- and 2-O-(cis-9)octadecenylglycerol isomers with photoautotrophic cell cultures from tomato. After 14 days the fractions of phosphatidylcholine and monogalactosyldiacylglycerol were isolated and the incorporated glycerol ether backbones released by treatment with LiAlH4 (reduction of ester bonds) and short acid hydrolysis (cleavage of enol ether bonds). High performance liquid chromatography and mass spectroscopy of the products in appropriately derivatized form showed that the (cis-9)octadecenyl group in the sn-1 position of the phospholipid was nearly completely desaturated to a (cis-9,12)octadecadienyl residue having the same double bond arrangement as linoleic acid. In the galactolipid fraction the desaturation had progressed to octadecatrienyl residues. Similarly, the octadecenyl residue in the sn-2 position of the phospholipid was nearly completely desaturated to an octadecadienyl group. These results are unambiguous proof for lipid-linked desaturation by both microsomal and plastidial desaturase systems of plants.	UNIV HAMBURG,INST ALLGEMEINE BOT,OHNHORSTSTR 18,D-22609 HAMBURG,GERMANY; INST SPEKTROCHEM & ANGEW SPEKTROSKOPIE,D-44139 DORTMUND,GERMANY	University of Hamburg			Linscheid, Michael W/D-2125-2009; Linscheid, Michael/ABB-7808-2020	Linscheid, Michael W/0000-0002-8902-1734; 				BROWSE J, 1991, ANNU REV PLANT PHYS, V42, P467, DOI 10.1146/annurev.pp.42.060191.002343; Egge H., 1983, ETHER LIPIDS, P17, DOI [10.1016/B978-0-12-468780-6.50007-X, DOI 10.1016/B978-0-12-468780-6.50007-X]; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; FRANCIS GW, 1981, CHEM PHYS LIPIDS, V29, P369, DOI 10.1016/0009-3084(81)90070-0; HEINZ E, 1977, H-S Z PHYSIOL CHEM, V358, P897, DOI 10.1515/bchm2.1977.358.2.897; HEINZ E, 1979, CHEM PHYS LIPIDS, V24, P265, DOI 10.1016/0009-3084(79)90032-X; HOLLOWAY PW, 1983, ENZYMES, V16, P63; HUSEMANN W, 1977, PHYSIOL PLANTARUM, V40, P77, DOI 10.1111/j.1399-3054.1977.tb01498.x; JONES AVM, 1980, BIOCHEM J, V190, P851, DOI 10.1042/bj1900851; KAUFMANN HP, 1971, CHEM PHYS LIPIDS, V6, P325, DOI 10.1016/0009-3084(71)90044-2; KESSELMEIER J, 1985, ANAL BIOCHEM, V144, P319, DOI 10.1016/0003-2697(85)90124-1; KONDO Y, 1981, BIOCHIM BIOPHYS ACTA, V665, P471, DOI 10.1016/0005-2760(81)90260-5; LALAGUNA F, 1908, J AM OIL CHEM SOC, V65, P1808; MARTIN BA, 1986, PLANT PHYSIOL, V81, P41, DOI 10.1104/pp.81.1.41; MYHER JJ, 1974, J LIPID RES, V15, P586; NORMAN HA, 1991, PHYTOCHEMISTRY, V30, P2217, DOI 10.1016/0031-9422(91)83617-T; POHL P, 1970, J CHROMATOGR, V49, P488, DOI 10.1016/S0021-9673(00)93664-1; PUGH EL, 1977, J BIOL CHEM, V252, P68; PUGH EL, 1979, LIPIDS, V14, P159, DOI 10.1007/BF02533867; ROUGHAN PG, 1982, ANNU REV PLANT PHYS, V33, P97, DOI 10.1146/annurev.pp.33.060182.000525; SCHMID HHO, 1967, BIOCHIM BIOPHYS ACTA, V144, P344, DOI 10.1016/0005-2760(67)90163-4; SCHMIDT H, 1993, BIOCHEM J, V289, P777, DOI 10.1042/bj2890777; SIEBERTZ HP, 1977, Z NATURFORSCH C, V32, P193; SLACK CR, 1979, BIOCHEM J, V179, P649, DOI 10.1042/bj1790649; SPERLING P, 1993, EUR J BIOCHEM, V213, P965, DOI 10.1111/j.1432-1033.1993.tb17841.x; STYMNE S, 1978, EUR J BIOCHEM, V90, P223, DOI 10.1111/j.1432-1033.1978.tb12594.x; SZOLDERITS G, 1991, BIOCHIM BIOPHYS ACTA, V1063, P197, DOI 10.1016/0005-2736(91)90371-E; VECHTEL B, 1992, PLANT CELL PHYSIOL, V33, P41; WEBER N, 1985, EUR J BIOCHEM, V146, P323, DOI 10.1111/j.1432-1033.1985.tb08656.x; WEBER N, 1984, APPL MICROBIOL BIOT, V20, P238, DOI 10.1007/BF00250632; WEBER N, 1983, PLANTA, V158, P111, DOI 10.1007/BF00397703; WEBER N, 1982, PLANTA, V155, P225, DOI 10.1007/BF00392720; WEBER N, 1987, FEBS LETT, V211, P225, DOI 10.1016/0014-5793(87)81441-2; YAMAMOTO K, 1991, LIPIDS, V26, P948, DOI 10.1007/BF02535982; YAMAMOTO K, 1991, CHEM PHYS LIPIDS, V60, P39, DOI 10.1016/0009-3084(91)90013-2	35	41	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26935	26940						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262928				2022-12-25	WOS:A1993MM26200018
J	ZHANG, ZJ; SNIDERMAN, AD; KALANT, D; VU, H; MONGE, JC; TAO, YZ; CIANFLONE, K				ZHANG, ZJ; SNIDERMAN, AD; KALANT, D; VU, H; MONGE, JC; TAO, YZ; CIANFLONE, K			THE ROLE OF AMINO-ACIDS IN APOB100 SYNTHESIS AND CATABOLISM IN HUMAN HEPG2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; PERFUSED-RAT-LIVER; AMBULATORY PERITONEAL-DIALYSIS; APOLIPOPROTEIN-B SECRETION; PROTEIN-SYNTHESIS; HEPATOMA-CELLS; ALBUMIN SYNTHESIS; MESSENGER-RNA; HEPATOCYTES; GENE	The object of this study was to examine the effects of extracellular amino acids on hepatic apoB100 metabolism using a transformed human liver cell line (HepG2) as a hepatocyte model. The data demonstrate that reduced extracellular amino acids resulted in marked increases in apoB100 concentrations in the medium (87 +/- 10% increase; p < 0.002). These data contrast with the effects of amino acids on secretion of total hepatic protein into the medium, which increased by 541 +/- 83% at 5.5 mg/ml amino acids compared to the low (0.5 mg/ml) amino acid medium (p < 0.01), pointing to a positive relationship between the concentration of amino acids in the medium and overall secretion of protein by the HepG2 cells. No significant effect of medium amino acid concentration on intracellular synthesis of cholesterol ester, cholesterol, triglyceride, or apoA1 secretion was evident. Amino acids also affected the activity of the low density lipoprotein pathway: at lower medium amino acid concentration, specific cell-associated radioactivity and cellular degradation were increased (117 +/- 24 and 233 +/- 13% at 0.5 versus 5.5 mg/ml amino acids, respectively). Pulse-chase analysis demonstrated that there was no difference in secretion efficiency of apoB (36 +/- 6 versus 46 +/- 8% in low versus high amino acid medium, respectively), but that the initial amount of [H-3]apoB synthesized was greater in the low amino acid medium (10.5 +/- 3.8 versus 5.7 +/- 1.7 x 10(3) dpm [H-3] apoB/mg of cell protein; p < 0.05). In contrast, the initial amount of [H-3]albumin synthesized was much greater in the high amino acid medium (26.6 +/- 5.0 versus 54.6 +/- 19.0 x 10(3) dpm [H-3]albumin/mg of cell protein in low versus high amino acid medium, respectively; p < 0.05). Slot blot analysis of apoB mRNA was 87 +/- 22% higher in lower amino acid medium as compared to the high amino acid medium (p < 0.01). These results demonstrate that amino acids have a profound negative regulatory effect on apoB synthesis and secretion and may shed light on the pathogenesis of some clinical dyslipidemias such as the increased plasma apoB levels in patients treated with continuous ambulatory peritoneal dialysis.	ROYAL VICTORIA HOSP, MCGILL UNIT PREVENT CARDIOVASC DIS, 687 PINE AVE W, MONTREAL H3A 1A1, QUEBEC, CANADA	McGill University; Royal Victoria Hospital								BERGSTROM J, 1990, CLIN SCI, V79, P331, DOI 10.1042/cs0790331; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESLOW JL, 1985, P NATL ACAD SCI USA, V82, P6825; BRUNO M, 1989, KIDNEY INT, V35, P1189, DOI 10.1038/ki.1989.109; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIANFLONE K, 1992, ARTERIOSCLER THROMB, V12, P271, DOI 10.1161/01.ATV.12.3.271; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; CIANFLONE KM, 1990, J CLIN INVEST, V85, P722, DOI 10.1172/JCI114497; DAVIS RA, 1980, J BIOL CHEM, V255, P2039; DIXON JL, 1991, J BIOL CHEM, V266, P5080; EAGLE H, 1959, SCIENCE, V130, P432, DOI 10.1126/science.130.3373.432; EVERSON WV, 1989, AM J PHYSIOL, V256, pC18, DOI 10.1152/ajpcell.1989.256.1.C18; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERNSTROM JD, 1979, AM J CLIN NUTR, V32, P1912, DOI 10.1093/ajcn/32.9.1912; FLAIM KE, 1982, J BIOL CHEM, V257, P2939; FLAIM KE, 1982, J BIOL CHEM, V257, P2932; FUKI IV, 1989, BIOCHIM BIOPHYS ACTA, V1001, P235, DOI 10.1016/0005-2760(89)90153-7; GOLDBERG ACK, 1977, KIDNEY INT, V12, P23, DOI 10.1038/ki.1977.75; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GROVE RI, 1991, J BIOL CHEM, V266, P18194; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEVIA P, 1980, J NUTR, V110, P1231, DOI 10.1093/jn/110.6.1231; HUTSON SM, 1987, AM J PHYSIOL, V252, pE291, DOI 10.1152/ajpendo.1987.252.3.E291; JACKSON TK, 1990, J CLIN INVEST, V86, P1746, DOI 10.1172/JCI114900; KATAN MB, 1982, ATHEROSCLEROSIS, V43, P381, DOI 10.1016/0021-9150(82)90037-5; KOPPLE JD, 1982, AM J CLIN NUTR, V36, P395, DOI 10.1093/ajcn/36.3.395; KUROWSKA EM, 1991, J NUTR BIOCHEM, V2, P656, DOI 10.1016/0955-2863(91)90064-C; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARDEUX BR, 1987, J BIOL CHEM, V262, P14514; LEDFORD BE, 1985, EUR J BIOCHEM, V152, P611, DOI 10.1111/j.1432-1033.1985.tb09239.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCKENZIE IF, 1968, J CLIN INVEST, V47, P1685, DOI 10.1172/JCI105859; MONTOYA A, 1989, IN VITRO CELL DEV B, V25, P358; MORTIMORE GE, 1988, METHOD ENZYMOL, V166, P461; NASSET ES, 1969, P SOC EXP BIOL MED, V132, P1077, DOI 10.3181/00379727-132-34370; PULLINGER CR, 1989, J LIPID RES, V30, P1065; REMESY C, 1978, BIOCHEM J, V170, P321, DOI 10.1042/bj1700321; SHEN MMS, 1981, J LIPID RES, V22, P236; SNIDERMAN A, 1987, ATHEROSCLEROSIS, V65, P257, DOI 10.1016/0021-9150(87)90041-4; SORCITHOMAS M, 1991, J BIOL CHEM, V266, P18045; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; THERIAULT A, 1992, BIOCHEM BIOPH RES CO, V186, P617, DOI 10.1016/0006-291X(92)90791-I; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WADE DP, 1988, EUR J BIOCHEM, V174, P213, DOI 10.1111/j.1432-1033.1988.tb14084.x; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WURTMAN RJ, 1968, NEW ENGL J MED, V279, P171, DOI 10.1056/NEJM196807252790401; YAMAUCHI A, 1992, AM J PHYSIOL, V263, pC397, DOI 10.1152/ajpcell.1992.263.2.C397; YOUNG G A, 1991, Amino Acids (Vienna), V1, P183, DOI 10.1007/BF00806915; YOUNG GA, 1989, NEPHROL DIAL TRANSPL, V4, P285, DOI 10.1093/oxfordjournals.ndt.a091874; YOUNG SG, 1986, CLIN CHEM, V32, P1484	53	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26920	26926						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262926				2022-12-25	WOS:A1993MM26200016
J	BELDENT, V; MICHAUD, A; WEI, L; CHAUVET, MT; CORVOL, P				BELDENT, V; MICHAUD, A; WEI, L; CHAUVET, MT; CORVOL, P			PROTEOLYTIC RELEASE OF HUMAN ANGIOTENSIN-CONVERTING ENZYME - LOCALIZATION OF THE CLEAVAGE SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 HOMOLOGOUS DOMAINS; IMMOBILIZED ANHYDROTRYPSIN; CONSENSUS SEQUENCE; MOLECULAR-CLONING; ENDOTHELIAL-CELLS; MONOBASIC SITES; MESSENGER-RNAS; PRECURSOR; PROTEINS; MEMBRANE	Angiotensin-converting enzyme (EC 3.4.15.1, ACE) is a transmembrane protein with a short carboxyl-terminal cytoplasmic domain, a 17-amino acid hydrophobic anchor domain, and a large N-terminal extracellular region containing two catalytically homologous domains. An active soluble form of ACE circulates in human plasma and is produced in culture medium of Chinese hamster ovary (CHO) cells transfected with the full-length human ACE cDNA. The mechanism of ACE release in CHO cells involves a post-translational proteolytic cleavage occurring in the carboxyl-terminal region. The carboxyl terminus of the secreted recombinant ACE, AGQR, was established by carboxyl-terminal microsequencing and corresponds to a cleavage site between Arg-1137 and Leu-1138. Two independent studies confirmed this proposed cleavage site: amino acid analysis of a carboxyl-terminal peptide derived from soluble ACE and immunocharacterization of membrane-bound and soluble ACE with antibodies raised against three peptides located along the carboxyl-terminal ACE sequence. In order to assess the importance of. Arg-1137, this amino acid was mutated to a glutamine residue. This mutation did not prevent the secretion of ACE, suggesting that the solubilizing enzyme can accommodate this change or can use an alternative cleavage site. Finally, the production of soluble ACE in CHO cells appears to be proportional to the level of cellular ACE, implying that the solubilizing enzyme is not a limiting factor. In addition, the carboxyl-terminal sequence of the human plasma ACE was identified as AGQR, thus supporting the fact that a similar mechanism could operate in human vascular cells.	COLL FRANCE,INSERM,U36,3 RUE ULM,F-75231 PARIS 05,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France								BENOIT R, 1987, SCIENCE, V238, P1126, DOI 10.1126/science.2891188; BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BREDDAM K, 1987, CARLSBERG RES COMMUN, V52, P55, DOI 10.1007/BF02910427; BRUNEVAL P, 1986, HISTOCHEMISTRY, V85, P73, DOI 10.1007/BF00508656; CUSHMAN DW, 1971, BIOCHEM PHARMACOL, V20, P1637, DOI 10.1016/0006-2952(71)90292-9; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; DICKINSON ES, 1986, ARTERIOSCLEROSIS, V6, P627, DOI 10.1161/01.ATV.6.6.627; EHLERS MRW, 1991, P NATL ACAD SCI USA, V88, P1009, DOI 10.1073/pnas.88.3.1009; EHLERS MRW, 1989, P NATL ACAD SCI USA, V86, P7741, DOI 10.1073/pnas.86.20.7741; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; HOOPER NM, 1987, BIOCHEM J, V247, P85, DOI 10.1042/bj2470085; HOOPER NM, 1991, INT J BIOCHEM, V23, P641, DOI 10.1016/0020-711X(91)90032-I; HOOPER NM, 1987, BIOCHEM J, V241, P25; HORIUCHI M, 1982, J CHROMATOGR, V233, P123, DOI 10.1016/S0378-4347(00)81738-7; HUBERT C, 1991, J BIOL CHEM, V266, P15377; ISHII SI, 1983, METHOD ENZYMOL, V91, P378; JONES BN, 1986, METHODS PROTEIN MICR, P337; KUMAR RS, 1991, J BIOL CHEM, V266, P3854; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; KUMAZAKI T, 1987, J BIOCHEM-TOKYO, V102, P1539, DOI 10.1093/oxfordjournals.jbchem.a122202; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATTION AL, 1989, FEBS LETT, V252, P99, DOI 10.1016/0014-5793(89)80897-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAROUX S, 1987, STRUCTURAL TOPOLOGIC, P15; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V179, P1670, DOI 10.1016/0006-291X(91)91767-7; MENDELSOHN FAO, 1982, J CLIN INVEST, V70, P684, DOI 10.1172/JCI110663; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; PANTOLIANO MW, 1984, BIOCHEMISTRY-US, V23, P1037, DOI 10.1021/bi00300a036; SAHASRABUDHE SR, 1992, J BIOL CHEM, V267, P25602; SEN I, 1991, J BIOL CHEM, V266, P21985; SHAI SY, 1992, CIRC RES, V70, P1274, DOI 10.1161/01.RES.70.6.1274; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; SKIGDEL RA, 1985, P NATL ACAD SCI USA, V82, P1025; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; THEKKUMKARA TJ, 1992, NUCLEIC ACIDS RES, V20, P683, DOI 10.1093/nar/20.4.683; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WANG R, 1991, J BIOL CHEM, V266, P16960; WEI L, 1991, J BIOL CHEM, V266, P9002; YANG HYT, 1970, BIOCHIM BIOPHYS ACTA, V214, P374, DOI 10.1016/0005-2795(70)90017-6	44	114	120	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26428	26434						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253769				2022-12-25	WOS:A1993MK42500063
J	COPELAND, WC; WANG, TSF				COPELAND, WC; WANG, TSF			ENZYMATIC CHARACTERIZATION OF THE INDIVIDUAL MAMMALIAN PRIMASE SUBUNITS REVEALS A BIPHASIC MECHANISM FOR INITIATION OF DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER EMBRYOS; SINGLE ESSENTIAL GENE; POLYMERASE-ALPHA; SACCHAROMYCES-CEREVISIAE; P49 SUBUNIT; KB CELLS; COMPLEX; PURIFICATION; CLONING	The enzymatic mechanism of primase was investigated using Escherichia coli and baculoviral overexpressed mouse primase subunits, p49 and p58. Neither of the singly purified primase subunits displayed primase activity alone, but the p49 subunit was able to extend a riboprimer, indicating that this subunit contains an RNA polymerase activity. The p58 subunit cooperated with the p49 subunit in binding the initiating purine to form the initial dinucleotide. After initiation, the p49 subunit alone was sufficient to extend the growing primer, but both the rate of p49 primer extension and its stability were influenced by the p58 subunit. The K(m(ATP)) in primer synthesis on poly(dT) of the p49-p58 heterodimeric primase complex was 10-fold higher than the K(m(ATP)) of the single p49 subunit in a ribo(A) primer extension assay. In addition, labeled ATP cross-linked to both of the individually purified subunits but with a striking difference in affinities; cross-linking was 11-fold more efficient to the p49 subunit. The interaction of the two primase subunits with polymerase a was also investigated. Immunoprecipitation experiments indicate that only the p58 subunit directly contacts the p180 subunit of DNA polymerase alpha. Competition experiments in the coupled primase-polymerase assay with a catalytically inactive mutant of DNA polymerase alpha and the Klenow fragment suggest that the DNA polymerase alpha-primase complex does not dissociate from the primer during the transition from RNA to DNA synthesis.	STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,300 PASTEUR DR,STANFORD,CA 94305	Stanford University			Copeland, William/C-4242-2019	Copeland, William/0000-0002-0359-0953	NCI NIH HHS [CA14835] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014835] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER DA, 1991, GENOMICS, V9, P642, DOI 10.1016/0888-7543(91)90357-K; BISWAS SB, 1984, J BIOL CHEM, V259, P7990; CONAWAY RC, 1982, P NATL ACAD SCI-BIOL, V79, P2523, DOI 10.1073/pnas.79.8.2523; COPELAND WC, 1993, J BIOL CHEM, V268, P11028; COPELAND WC, 1991, J BIOL CHEM, V266, P22739; COTTERILL S, 1987, J BIOL CHEM, V262, P16105; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; FIOANI M, 1988, J BIO LCHEM, V264, P2189; FOIANI M, 1989, MOL CELL BIOL, V9, P3081, DOI 10.1128/MCB.9.7.3081; FRANCESCONI S, 1993, IN PRESS MOL GEN GEN; GRONOSTAJSKI RM, 1984, J BIOL CHEM, V259, P9479; HU SZ, 1984, J BIOL CHEM, V259, P2602; KAGUNI LS, 1983, J BIOL CHEM, V258, P9037; KORNBERG A, 1992, DNA REPLICATION, P243; KUCHTA RD, 1990, J BIOL CHEM, V265, P16158; LONGHESE MP, 1993, GENETICS, V133, P183; LUCCHINI G, 1987, EMBO J, V6, P737, DOI 10.1002/j.1460-2075.1987.tb04815.x; MIYAZAWA H, 1993, J BIOL CHEM, V268, P8111; NASHEUER HP, 1988, J BIOL CHEM, V263, P8981; PLEVANI P, 1987, NUCLEIC ACIDS RES, V15, P7975; PRUSSAK CE, 1989, J BIOL CHEM, V264, P4957; ROTH YF, 1987, EUR J BIOCHEM, V165, P473, DOI 10.1111/j.1432-1033.1987.tb11463.x; SANTOCANALE C, 1993, J BIOL CHEM, V268, P1343; SHEAFF RJ, 1993, BIOCHEMISTRY-US, V32, P3027, DOI 10.1021/bi00063a014; SHIODA M, 1982, P NATL ACAD SCI-BIOL, V79, P7209, DOI 10.1073/pnas.79.23.7209; TSENG BY, 1983, J BIOL CHEM, V258, P9845; TSENG BY, 1979, J MOL BIOL, V129, P531, DOI 10.1016/0022-2836(79)90467-4; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WANG TSF, 1984, J BIOL CHEM, V259, P1854	29	98	99	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26179	26189						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253737				2022-12-25	WOS:A1993MK42500028
J	EPPLER, CM; HULMES, JD; WANG, JB; JOHNSON, B; CORBETT, M; LUTHIN, DR; UHL, GR; LINDEN, J				EPPLER, CM; HULMES, JD; WANG, JB; JOHNSON, B; CORBETT, M; LUTHIN, DR; UHL, GR; LINDEN, J			PURIFICATION AND PARTIAL AMINO-ACID-SEQUENCE OF A MU-OPIOID RECEPTOR FROM RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPIATE RECEPTORS; ADENYLATE-CYCLASE; BINDING-PROTEIN; KAPPA-RECEPTOR; GUINEA-PIG; MEMBRANES; EXPRESSION; PITUITARY; CLONING; LIGAND	A rat brain opioid receptor protein was isolated by binding [epsilon-biotinyl-Lys32]beta-endorphin to membranes, solubilizing the receptor-ligand (R.L) complex with deoxycholate-lysophosphatidylcholine and purifying on immobilized streptavidin and wheat germ agglutinin. The purified glycoprotein had a molecular mass of 60-70 kDa. Recovery of this protein was blocked by the nonselective opioid antagonist naloxone and the highly mu-selective agonist [D-Ala2,N-methyl-Phe4,Glyol5]enkephalin but not by the highly delta-selective agonist [D-Pen2,4'-Cl-Phe4 D-Pen5]enkephalin when these compounds were added as competitors at the binding step. The 60-70-kDa receptor protein co-purified through the streptavidin column with 40-kDa protein recognized by anti-G(ialpha) antibodies. GTP and Na+ influenced dissociation of the solubilized R.I-125-L complex and elution of the receptor and G protein from streptavidin in fashions consistent with the pharmacology of mu-opioid receptors. A 23-amino acid residue sequence from the purified receptor differs at 4 positions from a similar sequence in the murine delta-opioid receptor and is encoded within a novel rat brain cDNA isolated by polymerase chain reaction with oligonucleotide primers related to the murine delta-opioid receptor gene.	AMER CYANAMID CO,MED RES DIV,PEARL RIVER,NY 10965; UNIV VIRGINIA,DEPT INTERNAL MED CARDIOL,CHARLOTTESVILLE,VA 22908; NIDA,CTR ADDICT RES,MOLEC NEUROBIOL BRANCH,BALTIMORE,MD; JOHNS HOPKINS UNIV,DEPT NEUROL,BALTIMORE,MD 21224; UNIV VIRGINIA,DEPT PHYSIOL,CHARLOTTESVILLE,VA 22908; JOHNS HOPKINS UNIV,DEPT GEOSCI,BALTIMORE,MD 21224	University of Virginia; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Johns Hopkins University; University of Virginia; Johns Hopkins University	EPPLER, CM (corresponding author), AMER CYANAMID CO,AGR RES DIV,PRINCETON,NJ 08543, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049078] Funding Source: NIH RePORTER; NHLBI NIH HHS [R0I HL49078] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMED MS, 1989, LIFE SCI, V44, P861, DOI 10.1016/0024-3205(89)90586-9; AKIYAMA K, 1985, P NATL ACAD SCI USA, V82, P2543, DOI 10.1073/pnas.82.8.2543; BIDLACK JM, 1981, P NATL ACAD SCI-BIOL, V78, P636, DOI 10.1073/pnas.78.1.636; BLUME AJ, 1978, P NATL ACAD SCI USA, V75, P1713, DOI 10.1073/pnas.75.4.1713; BROWN PJ, 1993, J BIOL CHEM, V268, P6668; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CHILDERS SR, 1978, LIFE SCI, V23, P759, DOI 10.1016/0024-3205(78)90077-2; CHO TM, 1986, P NATL ACAD SCI USA, V83, P4138, DOI 10.1073/pnas.83.12.4138; CLARK MJ, 1988, EUR J PHARMACOL, V148, P343, DOI 10.1016/0014-2999(88)90112-4; COTTON R, 1984, EUR J PHARMACOL, V97, P331, DOI 10.1016/0014-2999(84)90470-9; DEMOLIOUMASON CD, 1986, J NEUROCHEM, V46, P1118, DOI 10.1111/j.1471-4159.1986.tb00626.x; EPPLER CM, 1992, J BIOL CHEM, V267, P15603; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FRANCES B, 1985, EUR J PHARMACOL, V117, P223, DOI 10.1016/0014-2999(85)90607-7; GILLAN MGC, 1982, BRIT J PHARMACOL, V77, P461, DOI 10.1111/j.1476-5381.1982.tb09319.x; GIOANNINI TL, 1985, J BIOL CHEM, V260, P5117; HOCHHAUS G, 1988, J BIOL CHEM, V263, P92; HULMES JD, 1992, BIOCHEM BIOPH RES CO, V184, P131, DOI 10.1016/0006-291X(92)91168-P; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KNAPP RJ, 1992, BIOCHEM PHARMACOL, V44, P1687, DOI 10.1016/0006-2952(92)90060-V; KOSKI G, 1982, J BIOL CHEM, V257, P4035; KOSKI G, 1981, P NATL ACAD SCI-BIOL, V78, P4185, DOI 10.1073/pnas.78.7.4185; KOSTERLITZ HW, 1980, PHLOS T R SOC LONDON, V20, P113; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHTI RA, 1985, EUR J PHARMACOL, V109, P281, DOI 10.1016/0014-2999(85)90431-5; LUTHIN DR, 1993, J BIOL CHEM, V268, P5990; MAKMAN MH, 1988, BRAIN RES, V400, P185; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MUNSHI R, 1991, J BIOL CHEM, V266, P22285; NICOLAS P, 1991, METHODS NEUROSCIENCE, V5, P385; PASTERNAK GW, 1986, BIOCHEM PHARMACOL, V35, P361, DOI 10.1016/0006-2952(86)90205-4; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; SCHOFIELD PR, 1989, EMBO J, V8, P489, DOI 10.1002/j.1460-2075.1989.tb03402.x; SENOGLES SE, 1987, J BIOL CHEM, V262, P4860; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SIMON EJ, 1973, P NATL ACAD SCI USA, V70, P1947, DOI 10.1073/pnas.70.7.1947; SIMON J, 1987, NEUROPEPTIDES, V10, P19, DOI 10.1016/0143-4179(87)90085-0; SIMONDS WF, 1985, P NATL ACAD SCI USA, V82, P4974, DOI 10.1073/pnas.82.15.4974; SLATER P, 1991, METHODS NEUROSCI, V5, P459; TERENIUS L, 1973, ACTA PHARMACOL TOX, V32, P317; UEDA H, 1987, NEUROSCI LETT, V75, P339, DOI 10.1016/0304-3940(87)90546-5; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	42	58	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26447	26451						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253772				2022-12-25	WOS:A1993MK42500066
J	HILDT, E; URBAN, S; LAUER, U; HOFSCHNEIDER, PH; KEKULE, AS				HILDT, E; URBAN, S; LAUER, U; HOFSCHNEIDER, PH; KEKULE, AS			ER-LOCALIZATION AND FUNCTIONAL EXPRESSION OF THE HBV TRANSACTIVATOR MHBS(T)	ONCOGENE			English	Article							HEPATITIS-B-VIRUS; HUMAN HEPATOCELLULAR-CARCINOMA; TRANSCRIPTIONAL TRANSACTIVATOR; NUCLEOTIDE-SEQUENCE; SURFACE-ANTIGEN; DNA; REGION; INTEGRATION	In two recently reported cases, integrated hepatitis B virus (HBV) DNAs cloned from hepatocellular carcinoma were found to express a transcriptional transactivator from 3'-terminally truncated HBV surface (preS/S) genes. In this study, we characterized the transactivator at the protein level. Expression of a 3'-truncated preS2/S gene in Spodoptera frugiperda (Sf9) insect cells resulted in a C-terminally truncated middle surface protein of 76 amino acids (MHBs(t76)), which was found to be associated with membranes of the endoplasmic reticulum and retained from Golgi processing and secretion, Accordingly, the microsome fraction of MHBs(t76)-expressing Sf9 cells displayed transactivator activity after electric field-mediated transfer into Chang liver cells. In contrast to full-length MHBs, MHBs(t76) is unglycosylated, and glycosylation is not required for transactivation as shown by mutation of the glycosylation site at asparagine-4. Since highly purified MHBs(t76) derived from an E. coli expression system also showed transactivator activity, it is concluded that unglycosylated MHBs(t76) protein is the authentic transactivating factor. As the transactivator protein derives from inactive MHbs by rearrangements of integrated HBV DNA, it may be important for HBV-associated liver carcinogenesis.			HILDT, E (corresponding author), MAX PLANCK INST BIOCHEM, DEPT VIRUS RES, D-82152 MARTINSRIED, GERMANY.		Hildt, Eberhard/A-1040-2015					BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; CASELMANN WH, 1990, P NATL ACAD SCI USA, V87, P2970, DOI 10.1073/pnas.87.8.2970; EBLE BE, 1987, MOL CELL BIOL, V7, P3591, DOI 10.1128/MCB.7.10.3591; EBLE BE, 1990, J VIROL, V64, P1414, DOI 10.1128/JVI.64.3.1414-1419.1990; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GANEM D, 1991, CURR TOP MICROBIOL, V168, P61; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARTELSCHENK S, 1991, BIOCHIM BIOPHYS ACTA, V1115, P108, DOI 10.1016/0304-4165(91)90019-D; Heermann KH, 1991, MOL BIOL HEPATITIS B, P109; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; LAUER U, 1992, J VIROL, V66, P5284, DOI 10.1128/JVI.66.9.5284-5289.1992; MATSUBARA K, 1991, MOL BIOL HEPATITIS B, P245; MEYER M, 1992, EMBO J, V11, P2991, DOI 10.1002/j.1460-2075.1992.tb05369.x; MIMMS LT, 1990, VIROLOGY, V176, P604, DOI 10.1016/0042-6822(90)90031-L; NAGAYA T, 1987, GENE DEV, V1, P773, DOI 10.1101/gad.1.8.773; NATOLI G, 1992, VIROLOGY, V187, P663, DOI 10.1016/0042-6822(92)90469-6; NEURATH AR, 1987, MOL IMMUNOL, V24, P975, DOI 10.1016/0161-5890(87)90009-5; OZOLS J, 1990, METHOD ENZYMOL, V182, P225; SAMBROOK J, 1989, MOL CLONING LABORATO, P1402; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLUTER V, 1992, UNPUB J CLIN INVEST; SCULLY LJ, 1988, VIRAL HEPATITIS LIVE, P365; SHERKER AH, 1991, ANNU REV MICROBIOL, V45, P475; Summers MD, 1987, MANUAL METHODS BACUL; WEBB N R, 1990, Technique (Philadelphia), V2, P173; WILL H, 1985, P NATL ACAD SCI USA, V82, P891, DOI 10.1073/pnas.82.3.891	31	28	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3359	3367						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247538				2022-12-25	WOS:A1993MG78200020
J	SKINNER, A; HURST, HC				SKINNER, A; HURST, HC			TRANSCRIPTIONAL REGULATION OF THE C-ERBB-3 GENE IN HUMAN BREAST-CARCINOMA CELL-LINES	ONCOGENE			English	Article							OVEREXPRESSION; AMPLIFICATION; MECHANISMS; EXPRESSION; PROMOTER; ONCOGENE; MEMBER; FAMILY; CANCER; ERBB3	The c-erbB-3 gene is a member of the EGF receptor family of membrane tyrosine kinases. Previous work has shown that the expression of this gene is frequently unregulated in human breast carcinoma-derived cell lines and in tumour biopsy material. As there is no evidence of gene amplification, we decided to examine the control of c-erbB-3 transcription in overexpressing cells. In this paper we describe the cloning of the c-erbB-3 promoter and its functional analysis within mammary-derived cell lines. We show that the promoter is more active in overexpressing cells and this is largely due to the action of the OB2-1 transcription factor which we have recently identified as mediating overexpression of the c-erbB-2 promoter in similar cell lines.	HAMMERSMITH HOSP,RPMS,ICRF,ONCOL GRP,GENE TRANSCRIPT LAB,LONDON W12 0HS,ENGLAND	Imperial College London								Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HURST HC, 1991, METHOD MOL BIOL, V8, P141; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; Maniatis T, 1989, DECONTAMINATION DILU; Merlino G T, 1990, Semin Cancer Biol, V1, P277; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597	19	37	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3393	3401						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247542				2022-12-25	WOS:A1993MG78200024
J	BOYER, MJ; GUTMANN, DH; COLLINS, FS; BARSAGI, D				BOYER, MJ; GUTMANN, DH; COLLINS, FS; BARSAGI, D			CROSS-LINKING OF THE SURFACE-IMMUNOGLOBULIN RECEPTOR IN B-LYMPHOCYTES INDUCES A REDISTRIBUTION OF NEUROFIBROMIN BUT NOT P120-GAP	ONCOGENE			English	Article							TYPE-1 GENE-PRODUCT; RAS PROTEINS; CELLS; GAP; P21; IDENTIFICATION; MUTATIONS; SEQUENCE; ENCODES; MUTANTS	The activation of Ras proteins is a key step in the signal transduction pathways triggered by ligand-bound cell surface receptors. The GTPase activating proteins (GAPs) p120-GAP and neurofibromin, the neurofibromatosis-type 1 (NF1) gene product, are thought to play an essential role in the regulation of Ras activity by increasing the GTPase activity of wild type, but not activated Ras in vitro. Both GAPs are widely expressed in mammalian tissues thus raising the question of whether or not they have different regulatory functions. In this study, we have analysed the distribution of p120-GAP and neurofibromin in splenic B lymphocytes by immunofluorescent staining. Crosslinking of surface immunoglobulin (sig), the B-lymphocyte antigen receptor, induced the redistribution of neurofibromin. In contrast, no apparent change in the cellular localization of p120-GAP occurred followed the cross-linking of sig. The redistribution of neurofibromin coincided both spatially and temporally with the relocalization of crosslinked slg and was inhibited by the cytoskeletal disrupting agents colchicine and cytochalasin D. These findings indicated that neurofibromin and p120-GAP can be differentially regulated in vivo and suggest that neurofibromin is a component of the signaling pathway initiated by crosslinking of B lymphocyte sig. Furthermore, our observations that cocapping neurofibromin with sig is independent of the p21(ras) redistribution suggests that the role of neurofibromin in B cells is not solely related to its ability to act as a Ras regulator.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; UNIV MICHIGAN,DEPT NEUROL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109	Cold Spring Harbor Laboratory; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan				Bar-Sagi, Dafna/0000-0003-2597-8948; Gutmann, David/0000-0002-3127-5045	NATIONAL CANCER INSTITUTE [R37CA055360, R01CA055360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001590] Funding Source: NIH RePORTER; NCI NIH HHS [CA55360] Funding Source: Medline; NINDS NIH HHS [NS-01590, NS02340] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADCOCK MR, 1993, NATURE, V363, P83; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOLLAG G, 1993, EMBO J, V12, P1923, DOI 10.1002/j.1460-2075.1993.tb05841.x; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BORISY GG, 1967, J CELL BIOL, V34, P525, DOI 10.1083/jcb.34.2.525; BOURGUIGNON LYW, 1978, J CELL PHYSIOL, V95, P239, DOI 10.1002/jcp.1040950302; BRAUN J, 1980, IMMUNOL REV, V52, P3, DOI 10.1111/j.1600-065X.1980.tb00328.x; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DATSON MM, 1992, NEURON, V8, P415; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; EDELMAN GM, 1973, P NATL ACAD SCI USA, V70, P1442, DOI 10.1073/pnas.70.5.1442; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GABBIANI G, 1977, NATURE, V269, P697, DOI 10.1038/269697a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOLD MR, 1993, J IMMUNOL, V150, P377; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; GREGORY PE, 1993, SOMAT CELL MOLEC GEN, V19, P265, DOI 10.1007/BF01233074; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; GUTMANN DH, 1993, J NEUROSCI RES, V36, P206; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; QIU MS, 1991, J CELL BIOL, V115, P795, DOI 10.1083/jcb.115.3.795; SEVERSON CD, 1987, IMMUNOL LETT, V15, P291, DOI 10.1016/0165-2478(87)90130-1; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; TAYLOR RB, 1971, NATURE-NEW BIOL, V233, P225, DOI 10.1038/newbio233225a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; Weihing R R, 1979, Methods Achiev Exp Pathol, V8, P42; WESSELLS NK, 1971, SCIENCE, V171, P135, DOI 10.1126/science.171.3967.135; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YAHARA I, 1978, CELL, V15, P251, DOI 10.1016/0092-8674(78)90100-9	41	21	21	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					349	357						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290249				2022-12-25	WOS:A1994MW24800002
J	CHATTON, B; BOCCO, JL; GOETZ, J; GAIRE, M; LUTZ, Y; KEDINGER, C				CHATTON, B; BOCCO, JL; GOETZ, J; GAIRE, M; LUTZ, Y; KEDINGER, C			JUN AND FOS HETERODIMERIZE WITH ATFA, A MEMBER OF THE ATF/CREB FAMILY AND MODULATE ITS TRANSCRIPTIONAL ACTIVITY	ONCOGENE			English	Article							ELEMENT-BINDING-PROTEIN; AMP RESPONSE ELEMENT; LEUCINE ZIPPER STRUCTURE; NUCLEAR FACTOR CREB; DNA-BINDING; CYCLIC-AMP; CDNA CLONES; HELA-CELLS; CROSS-TALK; ENHANCER	Three related clones encoding proteins (ATFa1, 2 and 3) with specific ATF/CRE DNA-binding activities have been isolated from HeLa cell cDNA libraries. All three isoforms have weak effects on the basal activity of the adenovirus E2a promoter. We present evidence suggesting that a C-terminal element of the ATFa molecules negatively interferes with the intrinsic activation function of these proteins. We also show that coexpression of ATFa with c-Jun, Jun-B or Jun-D stimulates ATFa-dependent reporter activity, while coexpression of c-Fos has no effect. Deletion analyses indicate that the metal-binding region of ATFa is dispensible for this effect, but that the domain comprising the leucine-zipper region of ATFa is required. Reciprocal co-immunoprecipitation experiments and electrophoretic band-shift assays with in vitro synthesized proteins reveal direct interactions between ATFa and Jun or Fos. The ATFa/c-Jun heterodimers, but not the ATFa/c-Fos complexes, bind efficiently to ATF, CRE or AP1 sites. The detection of ATFa-Jun complexes in crude extracts from HeLa cells transfected with ATFa and c-Jun expression vectors suggests that such ATFa/c-Jun heterodimers also form in vivo. Altogether these results indicate that the ATFa proteins may contribute to the modulation of the activity of the Jun/Fos complexes by altering their DNA-binding and transcriptional properties.	INST CHIM BIOL,GENET MOLEC EUCARYOTES LAB,CNRS,INSERM,U184,F-67000 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			CHATTON, Bruno/R-3813-2019	CHATTON, Bruno/0000-0003-4515-7119; Bocco, Jose Luis/0000-0002-9682-1270				ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; ABDELHAFIZ HAM, 1992, MOL ENDO, V6, P2080; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BENBROOK DM, 1990, ONCOGENE, V5, P295; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; FLINT KJ, 1991, ONCOGENE, V6, P2019; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GILLESPIE DAF, 1991, SEMINARS VIROLOGY, V2, P329; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KAPRINSKI BA, 1992, P NATL ACAD SCI USA, V85, P7192; KARA CJ, 1990, MOL CELL BIOL, V10, P1347, DOI 10.1128/MCB.10.4.1347; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE KAW, 1992, J CELL SCI, V103, P9; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MATSUDA S, 1991, J BIOL CHEM, V266, P18188; MERMOD N, 1989, CELL, V57, P859; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; NOMURA N, 1993, J BIOL CHEM, V268, P4259; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; ZU YL, 1991, J BIOL CHEM, V35, P24134	62	78	80	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					375	385						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290251				2022-12-25	WOS:A1994MW24800004
J	DONOVANPELUSO, M; GEORGE, LD; HASSETT, AC				DONOVANPELUSO, M; GEORGE, LD; HASSETT, AC			LIPOPOLYSACCHARIDE INDUCTION OF TISSUE FACTOR EXPRESSION IN THP-1 MONOCYTIC CELLS - PROTEIN-DNA INTERACTIONS WITH THE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR GENE; TRANSCRIPTIONAL ACTIVATION; THROMBOPLASTIN ACTIVITY; PROCOAGULANT RESPONSE; RNA; BINDING; MACROPHAGES; INITIATION; RECEPTOR; ENHANCER	Tissue factor, the cellular receptor for factor VII/VIIa, activates both the intrinsic and extrinsic pathways of blood coagulation. In this analysis we have used DNase I footprinting to map the sites of protein-DNA interaction along the promoter (-383 to +8) using nuclear extracts prepared from uninduced and lipopolysaccharide-induced THP-1 cells. We have identified six regions that interact with nuclear factors in both uninduced and induced extracts. Four footprints are contained within a region reported to confer base-line high level expression and lipopolysaccharide and serum induction. Two additional footprints map to a region reported to reduce basal transcription by 50%. The only qualitative change in the footprint pattern with uninduced and induced extracts is the appearance of two hypersensitive sites with uninduced extracts. In addition, changes in the level of protein- DNA binding are detected with only one probe by DNA mobility shift analysis. A combination of well characterized transcription factors (AP1), primarily lymphoid cell specific regulatory proteins (NF-kappaB- and/or Ets-1-related proteins), as well as additional, uncharacterized proteins appear to interact with these sequences. Our data suggest that post-translational modification of existing transcription factors, and not induction of new DNA-binding activity, mediates the lipopolysaccharide induction of tissue factor synthesis in THP-1 cells.			DONOVANPELUSO, M (corresponding author), UNIV PITTSBURGH,SCH MED,SCH MED,DEPT PATHOL,S709 SCAIFE HALL,PITTSBURGH,PA 15261, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR006009] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045621] Funding Source: NIH RePORTER; NCRR NIH HHS [1 P41 RR06009] Funding Source: Medline; NHLBI NIH HHS [1R29HL45621-01A1] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1988, P NATL ACAD SCI USA, V85, P7462, DOI 10.1073/pnas.85.20.7462; BAUER KA, 1989, THROMB RES, V563, P425; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND K, 1991, MOL CELL BIOL, V11, P4732, DOI 10.1128/MCB.11.9.4732; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAUSS M, 1990, J BIOL CHEM, V265, P7078; CONKLING PR, 1988, BLOOD, V72, P128; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; FURIE B, 1988, CELL, V53, pA505; GREGORY SA, 1989, MOL CELL BIOL, V9, P2752, DOI 10.1128/MCB.9.6.2752; KEY NS, 1990, P NATL ACAD SCI USA, V87, P7095, DOI 10.1073/pnas.87.18.7095; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LYBERG T, 1981, BIOCHEM J, V194, P699, DOI 10.1042/bj1940699; LYBERG T, 1987, J CELL PHYSIOL, V132, P367, DOI 10.1002/jcp.1041320226; MACKMAN N, 1990, P NATL ACAD SCI USA, V87, P2254, DOI 10.1073/pnas.87.6.2254; MACKMAN N, 1989, BIOCHEMISTRY-US, V28, P1755, DOI 10.1021/bi00430a050; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; NAKAMURA S, 1989, THROMB HAEMOSTASIS, V62; ONEILL D, 1990, NUCLEIC ACIDS RES, V18, P1977, DOI 10.1093/nar/18.8.1977; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TIPPING PG, 1989, ATHEROSCLEROSIS, V79, P237, DOI 10.1016/0021-9150(89)90129-9; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	30	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1361	1369						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288602				2022-12-25	WOS:A1994MR22000092
J	FURUKAWA, K; TAGAYA, M; TANIZAWA, K; FUKUI, T				FURUKAWA, K; TAGAYA, M; TANIZAWA, K; FUKUI, T			IDENTIFICATION OF LYS(277) AT THE ACTIVE-SITE OF ESCHERICHIA-COLI GLYCOGEN-SYNTHASE - APPLICATION OF AFFINITY LABELING COMBINED WITH SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING SITE; ADENOSINE DIPHOSPHOPYRIDOXAL; BACTERIAL GLYCOGEN; ADENYLATE KINASE; BETA-SUBUNIT; ADP-GLUCOSE; SEQUENCE; TETRAPHOSPHOPYRIDOXAL; TRIPHOSPHOPYRIDOXAL; BIOSYNTHESIS	Lys15 in Escherichia coli glycogen synthase, which is specifically labeled by adenosine diphosphopyridoxal, is mainly involved in binding of the substrate ADP-glucose (Furukawa, K., Tagaya, M., Tanizawa, K., and Fukui, T. (1993) J. Biol. Chem. 268, 23837-23842). We have found that the mutant glycogen synthase in which Lys15 is replaced by Gln via site-directed mutagenesis is inactivated by adenosine diphosphopyridoxal at concentrations higher than those required for the inactivation of the wild-type enzyme. ADP and ADP-glucose offered protective effects on inactivation, suggesting that the label binds to the ADP-glucose-binding site in the mutant enzyme. Sequence analysis of the labeled peptide revealed that the labeled residue is Lys277. This lysyl residue is conserved in maize starch synthase, which shows about 30% amino acid identity to E. coli glycogen synthase. Substitution of Gln for Lys277 by site-directed mutagenesis resulted in a 140-fold decrease in the k(cat) value with little changes in the K(m) values for ADP-glucose and glycogen. These results suggest that Lys277 at the active site participates in the catalytic reaction rather than binding of substrate. The present study shows the usefulness of the combined application of affinity labeling and site-directed mutagenesis.	OSAKA UNIV,INST SCI & IND RES,IBARAKI,OSAKA 567,JAPAN	Osaka University			Furukawa, Koji/L-6909-2018	Furukawa, Koji/0000-0002-5701-2497				AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNER MF, 1989, P NATL ACAD SCI USA, V86, P1443, DOI 10.1073/pnas.86.5.1443; FARKAS I, 1990, J BIOL CHEM, V265, P20879; FOX J, 1976, BIOCHEMISTRY-US, V15, P849, DOI 10.1021/bi00649a019; FURUKAWA K, 1993, J BIOL CHEM, V268, P23837; FURUKAWA K, 1990, J BIOL CHEM, V265, P2086; HERMODSON MA, 1973, BIOCHEMISTRY-US, V12, P3146, DOI 10.1021/bi00741a002; Higuchi R., 1989, PCR TECHNOLOGY, P61; IDA K, 1991, J BIOL CHEM, V266, P5424; KLOESGEN R B, 1986, Molecular and General Genetics, V203, P237; KUMAR A, 1986, J BIOL CHEM, V261, P6256; NOUMI T, 1987, J BIOL CHEM, V262, P7686; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAGAYA M, 1987, J BIOL CHEM, V262, P8257; TAGAYA M, 1985, J BIOL CHEM, V260, P6670; TAGAYA M, 1986, BIOCHEMISTRY-US, V25, P2958, DOI 10.1021/bi00358a034; TAGAYA M, 1988, FEBS LETT, V233, P347, DOI 10.1016/0014-5793(88)80457-5; TAGAYA M, 1993, MOL ASPECTS ENZYME C, P73; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; YAGAMI T, 1988, FEBS LETT, V229, P261, DOI 10.1016/0014-5793(88)81137-2	21	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					868	871						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288640				2022-12-25	WOS:A1994MR22000018
J	LEINGARTNER, A; HEISENBERG, CP; KOLBECK, R; THOENEN, H; LINDHOLM, D				LEINGARTNER, A; HEISENBERG, CP; KOLBECK, R; THOENEN, H; LINDHOLM, D			BRAIN-DERIVED NEUROTROPHIC FACTOR INCREASES NEUROTROPHIN-3 EXPRESSION IN CEREBELLAR GRANULE NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NERVE GROWTH-FACTOR; FACTOR MESSENGER-RNA; FACTOR NGF SYNTHESIS; TYROSINE PROTEIN-KINASE; DIFFERENTIAL REGULATION; ASTROCYTES; RECEPTOR; CULTURES; INTERLEUKIN-1; INHIBITOR	Neurotrophin-3 (NT-3) is a member of the neurotrophin gene family and is highly expressed in the developing rat cerebellum. Here we show that brain-derived neurotrophic factor (BDNF) increased by approximately 10-fold the NT-3 mRNA levels in cultured cerebellar granule neurons isolated from postnatal rats, whereas nerve growth factor (NGF) and NT-3 itself had no effect. The effect of BDNF was additive to that of triiodothyronine (T3), which also increased NT-3 mRNA in these neurons. The drug K252a inhibited the BDNF-mediated stimulation of NT-3 expression, suggesting an involvement of trkB receptors. Nuclear run-on experiments showed that BDNF enhanced NT-3 transcription, whereas the stability of NT-3 mRNA remained unchanged. The data presented are the first demonstration that one neurotrophin regulates the expression of another and provide evidence that NT-3 production in granule neurons is regulated by both BDNF and T3.	MAX PLANCK INST PSYCHIAT, DEPT NEUROCHEM, AM KLOPFERSPITZ 18A, D-82152 MARTINSRIED, GERMANY; MAX PLANCK INST PSYCHIAT, DEPT NEUROBIOCHEM, D-82152 MARTINSRIED, GERMANY	Max Planck Society; Max Planck Society			Lindholm, Dan/B-3777-2014	Heisenberg, Carl-Philipp/0000-0002-0912-4566				BARBANY G, 1992, EUR J NEUROSCI, V4, P396, DOI 10.1111/j.1460-9568.1992.tb00888.x; BERG MM, 1992, J BIOL CHEM, V267, P13; BERZAGHI MD, 1993, J NEUROSCI, V13, P3818; CARMANKRZAN M, 1991, J NEUROCHEM, V56, P636, DOI 10.1111/j.1471-4159.1991.tb08197.x; CASTREN E, 1992, P NATL ACAD SCI USA, V89, P9444, DOI 10.1073/pnas.89.20.9444; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUSSAULT JH, 1987, ANNU REV PHYSIOL, V49, P321, DOI 10.1146/annurev.ph.49.030187.001541; ERNFORS P, 1991, NEURON, V7, P165, DOI 10.1016/0896-6273(91)90084-D; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; GOTZ R, 1992, EUR J BIOCHEM, V204, P745, DOI 10.1111/j.1432-1033.1992.tb16689.x; HEISENBERG CP, 1992, NEUROREPORT, V3, P685, DOI 10.1097/00001756-199208000-00008; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KOIZUMI S, 1988, J NEUROSCI, V8, P715; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LINDHOLM D, 1993, EUR J NEUROSCI, V5, P1455, DOI 10.1111/j.1460-9568.1993.tb00213.x; LINDHOLM D, 1988, J BIOL CHEM, V263, P16348; Lindholm D, 1990, Neuroreport, V1, P9; LINDHOLM D, 1993, J CELL BIOL, V122, P443, DOI 10.1083/jcb.122.2.443; LINDHOLM D, 1992, EUR J NEUROSCI, V4, P404, DOI 10.1111/j.1460-9568.1992.tb00889.x; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MATSUDA Y, 1988, NEUROSCI LETT, V87, P11, DOI 10.1016/0304-3940(88)90137-1; MATSUOKA I, 1991, J NEUROSCI, V11, P3165; ROCAMORA N, 1992, MOL BRAIN RES, V13, P27, DOI 10.1016/0169-328X(92)90041-9; ROCAMORA N, 1993, MOL BRAIN RES, V17, P1, DOI 10.1016/0169-328X(93)90065-W; SEGAL RA, 1992, NEURON, V9, P1041, DOI 10.1016/0896-6273(92)90064-K; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; TAPLEY P, 1992, ONCOGENE, V7, P371; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; YOSHIDA K, 1992, BRAIN RES, V569, P14, DOI 10.1016/0006-8993(92)90364-F; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x; ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037; ZAFRA F, 1992, J NEUROSCI, V12, P4793	36	62	62	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					828	830						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288635				2022-12-25	WOS:A1994MR22000012
J	MOEHREN, G; GUSTAVSSON, L; HOEK, JB				MOEHREN, G; GUSTAVSSON, L; HOEK, JB			ACTIVATION AND DESENSITIZATION OF PHOSPHOLIPASE-D IN INTACT RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PLASMA-MEMBRANES; PHOSPHATIDYLCHOLINE BREAKDOWN; PHOSPHATIDYLETHANOL FORMATION; PHORBOL ESTER; DIACYLGLYCEROL FORMATION; RAPID DESENSITIZATION; SIGNAL-TRANSDUCTION; ETHANOL TREATMENT; CELLS; ACCUMULATION	Activation of phospholipase D (PLD) by receptor-coupled stimuli (vasopressin, ATP), phorbol esters, and Ca2+ ionophores was studied in isolated rat hepatocytes, double labeled with [H-3]arachidonate and [C-14]stearate. Phosphatidylethanol (Peth) was formed when cells were stimulated in the presence of ethanol. The effect of combinations of agonists was not additive, indicating that the same PLD isozyme(s) were activated. With all agonists, the H-3- and C-14-specific radioactivity in Peth was higher than in any of the main phospholipid classes. The H-3/C-14 ratios of Peth and phosphatidylcholine (PC) were identical and differed from other phospholipid classes, indicating that the predominant PLD substrate was a PC pool labeled preferentially with radioactive fatty acids. Ethanol (50-300 mm) decreased the initial rate cif phosphatidic acid (PA) formation, but did not affect total PLD activity. Agonist-induced changes in steady state accumulation of PA or 1,2-diacylglycerol were also unaffected. A slow degradation of Peth (apparent t1/2 > 60 min) occurred after ethanol removal from cells prestimulated with vasopressin. The rate of degradation was unaffected by agonists that stimulate PLD. Thus, Peth formation is a suitable cumulative indicator for PLD activation in intact hepatocytes. Peth accumulation declined over a period of 5-20 min, depending on the agonist. The decline was not due to increased Peth degradation, or limitations in substrate supply to PLD, or enzyme inhibition by accumulated Peth. Instead, a homologous desensitization of PLD occurs with all agonists. This desensitization may involve the action of selective protein kinase C isozymes.	THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, 1020 LOCUST ST, PHILADELPHIA, PA 19107 USA; LUND UNIV, DEPT PSYCHIAT & NEUROCHEM, S-22009 LUND, SWEDEN	Jefferson University; Lund University				Hoek, Jan/0000-0001-7127-4218	NIAAA NIH HHS [AA08714, AA07215, AA07186] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008714, P50AA007186] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALLING C, 1983, FEBS LETT, V152, P24, DOI 10.1016/0014-5793(83)80474-8; ALLING C, 1984, BIOCHIM BIOPHYS ACTA, V793, P119, DOI 10.1016/0005-2760(84)90060-2; AUGERT G, 1989, J BIOL CHEM, V264, P2574; AUGERT G, 1989, J BIOL CHEM, V264, P21689; BALSINDE J, 1989, EUR J BIOCHEM, V186, P717, DOI 10.1111/j.1432-1033.1989.tb15265.x; BENTHIN G, 1985, BIOCHIM BIOPHYS ACTA, V835, P385, DOI 10.1016/0005-2760(85)90295-4; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; COOK SJ, 1992, REV PHYSIOL BIOCH P, V119, P13; Eibl H, 1981, Methods Enzymol, V72, P632; EXTON JH, 1988, REV PHYSIOL BIOCH P, V111, P117; EXTON JH, 1991, MOL CELL BIOCHEM, V104, P81; GATALICA Z, 1993, BIOCHIM BIOPHYS ACTA, V1177, P87, DOI 10.1016/0167-4889(93)90162-I; GUSTAVSSON L, 1991, ANN NY ACAD SCI, V625, P438, DOI 10.1111/j.1749-6632.1991.tb33873.x; GUSTAVSSON L, 1987, BIOCHEM BIOPH RES CO, V142, P958, DOI 10.1016/0006-291X(87)91507-5; GUSTAVSSON L, 1994, J BIOL CHEM, V269, P849; GUSTAVSSON L, 1990, J NEUROCHEM, V54, P737, DOI 10.1111/j.1471-4159.1990.tb02313.x; Heller M, 1978, Adv Lipid Res, V16, P267; HIGASHI K, 1991, J BIOL CHEM, V266, P2178; HOEK HB, 1993, LAB INVEST, V69, P1; HOEK JB, 1992, FASEB J, V6, P2386, DOI 10.1096/fasebj.6.7.1563591; HOEK JB, 1987, J BIOL CHEM, V262, P682; Holub B J, 1978, Adv Lipid Res, V16, P1; HUANG CF, 1992, J BIOL CHEM, V267, P16859; HUANG CF, 1990, J BIOL CHEM, V265, P14858; HURST KM, 1990, BIOCHEM J, V272, P749, DOI 10.1042/bj2720749; IRVING HR, 1987, J BIOL CHEM, V262, P3440; KANFER JN, 1980, CAN J BIOCHEM CELL B, V58, P1370, DOI 10.1139/o80-186; KISS Z, 1990, J BIOL CHEM, V265, P7345; KISS Z, 1990, PROG LIPID RES, V29, P141, DOI 10.1016/0163-7827(90)90001-2; KOBAYASHI M, 1987, J NEUROCHEM, V48, P1597, DOI 10.1111/j.1471-4159.1987.tb05707.x; LYNCH CJ, 1985, J BIOL CHEM, V260, P2844; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; MCKENZIE FR, 1992, J BIOL CHEM, V267, P22759; METZ SA, 1991, BIOCHEM PHARMACOL, V41, pR1, DOI 10.1016/0006-2952(91)90470-P; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; OMODEOSALE F, 1991, BIOCHEMISTRY-US, V30, P2477, DOI 10.1021/bi00223a026; PAI JK, 1987, CARCINOGENESIS, V8, P173, DOI 10.1093/carcin/8.1.173; PITTNER RA, 1992, BIOCHIM BIOPHYS ACTA, V1133, P316, DOI 10.1016/0167-4889(92)90053-E; PLEIN P, 1992, BIOL CHEM H-S, V373, P151, DOI 10.1515/bchm3.1992.373.1.151; PLEVIN R, 1992, BIOCHEM J, V285, P759, DOI 10.1042/bj2850759; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; ROBLESFLORES M, 1991, BIOCHIM BIOPHYS ACTA, V1094, P77, DOI 10.1016/0167-4889(91)90028-V; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; SIDDIQUI RA, 1992, J BIOL CHEM, V267, P5755; STADDON JM, 1989, EUR J BIOCHEM, V179, P47, DOI 10.1111/j.1432-1033.1989.tb14519.x; TROYER DA, 1992, AM J PHYSIOL, V262, pF185, DOI 10.1152/ajprenal.1992.262.2.F185; WAKELAM MJO, 1986, NATURE, V323, P68, DOI 10.1038/323068a0; WANG P, 1991, J BIOL CHEM, V266, P14877	51	58	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					838	848						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288637				2022-12-25	WOS:A1994MR22000015
J	GUPTA, M; ZHU, CX; TSEDINH, YC				GUPTA, M; ZHU, CX; TSEDINH, YC			MUTATIONS OF VACCINIA VIRUS-DNA TOPOISOMERASE-I THAT STABILIZE THE CLEAVAGE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE TYROSINE; ESCHERICHIA-COLI; ANTITUMOR DRUGS; CAMPTOTHECIN; SPECIFICITY; EXPRESSION; MUTANTS; GENE; MUTAGENESIS; SUBSTRATE	Two mutations in vaccinia virus topoisomerase I, K167D and G226N, have been characterized. SOS induction was observed in Escherichia coli expressing vaccinia topoisomerase I with either one of these mutations. The mutant enzymes were purified to homogeneity and compared with the wild type enzyme for relaxation activity and the partial activities of substrate binding, site-specific DNA cleavage and DNA religation to determine the mechanism of SOS induction. The K167D mutant enzyme had reduced binding affinity for the DNA substrate with a K(app) that was 10-fold higher than wild type. Nevertheless, in reactions with high enzyme concentration, its substrate cleavage activity was 90% that of wild type. The G226N mutant enzyme had virtually wild type binding and cleavage activities. However, intermolecular religation by these two mutants were observed to be significantly reduced. The cleavage complexes formed with the K167D and G226N mutants were more stable to high salt than the wild type cleavable complex. We propose that these mutants in vivo induce the SOS response in E. coli due to the shift of topoisomerase cleavage-religation equilibrium towards cleavage and increased stability of the cleavage complex. The mutation thus has a similar effect as the topoisomerase-targeting inhibitors that turn topoisomerases into DNA damaging agents.	NYU,COLL MED,DEPT BIOCHEM & MOLEC BIOL,VALHALLA,NY 10595	New York University								ANDERSEN AH, 1991, J BIOL CHEM, V266, P9203; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CARON PR, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P1; CHAMPOUX JJ, 1989, J BIOL CHEM, V264, P1010; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; FERNANDEZBEROS ME, 1992, J BACTERIOL, V174, P7059, DOI 10.1128/JB.174.21.7059-7062.1992; GILMOUR DS, 1987, MOL CELL BIOL, V7, P141, DOI 10.1128/MCB.7.1.141; GUPTA M, 1992, J BIOL CHEM, V267, P24177; HANIFORD DB, 1989, CELL, V59, P385, DOI 10.1016/0092-8674(89)90299-7; HAUNG WM, 1990, DNA TOPOLOGY ITS BIO, P265; HEITMAN J, 1991, GENE, V103, P1, DOI 10.1016/0378-1119(91)90383-M; HEITMAN J, 1990, EMBO J, V9, P3369, DOI 10.1002/j.1460-2075.1990.tb07538.x; HEITMAN J, 1987, J BACTERIOL, V169, P3243, DOI 10.1128/jb.169.7.3243-3250.1987; HOOPER DC, 1991, NEW ENGL J MED, V324, P384, DOI 10.1056/NEJM199102073240606; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; KENYON CJ, 1980, P NATL ACAD SCI-BIOL, V77, P2819, DOI 10.1073/pnas.77.5.2819; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P6402, DOI 10.1021/bi00394a015; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; Schneider E, 1990, Adv Pharmacol, V21, P149, DOI 10.1016/S1054-3589(08)60342-7; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P3489, DOI 10.1073/pnas.86.10.3489; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; SMITH CL, 1983, P NATL ACAD SCI-BIOL, V80, P2510, DOI 10.1073/pnas.80.9.2510; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; SVESTRUP JQ, 1991, J MOL BIOL, V222, P669; THOMSEN B, 1987, EMBO J, V6, P1817, DOI 10.1002/j.1460-2075.1987.tb02436.x; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WEISEMANN JM, 1984, J BACTERIOL, V160, P112, DOI 10.1128/JB.160.1.112-121.1984	39	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					573	578						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276853				2022-12-25	WOS:A1994MR21900091
J	KANDROR, K; PILCH, PF				KANDROR, K; PILCH, PF			IDENTIFICATION AND ISOLATION OF GLYCOPROTEINS THAT TRANSLOCATE TO THE CELL-SURFACE FROM GLUT4-ENRICHED VESICLES IN AN INSULIN-DEPENDENT FASHION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORTER-CONTAINING VESICLES; RAT ADIPOSE-CELLS; GLUCOSE-TRANSPORTER; SUBCELLULAR-DISTRIBUTION; PLASMA-MEMBRANE; ADIPOCYTES; PROTEINS; TISSUES; GLUT4	It has previously been shown that in fat cells, the intracellular reservoir of the glucose transporter isoform GLUT4 consists of a membrane vesicle population highly enriched in this transporter (approximately 15% of the protein content) that has a relatively simple protein pattern as revealed by SDS-polyacrylamide gel electrophoresis and silver staining (Zorzano, A., Wilkinson, W., Kotliar, N., Thoidis, G., Wadzinski, B. E., Ruoho, A. E., and Pilch, P. F. (1989) J. Biol. Chem. 264,12358-12363). Upon exposure of adipocytes to insulin, the cell-surface (plasma membrane) content of GLUT4 is dramatically enhanced, and this transporter appears to continually cycle from intracellular vesicles to the plasma membrane. To identify other proteins that may recycle in a similar fashion to GLUT4 and that may participate in the insulin-dependent alteration in the cellular location of GLUT4 and other membrane proteins, we performed immunoadsorption of GLUT4-enriched vesicles together with biotinylation of membranes using a cell-impermeant analog of biotin. We find that immunoadsorbed GLUT4-containing vesicles can be fractionated into Triton X-100-soluble and -insoluble fractions. The first includes three major glycoprotein components with molecular masses of 110, 160, and 230 kDa and a few minor polypeptides with lower molecular masses. A Triton X-100-resistant fraction consists of GLUT4 and an approximately 25-kDa protein. All three major Triton-soluble proteins (110, 160, and 230 kDa) isolated from the immunoimmobilized vesicles on wheat germ agglutinin-agarose are strongly biotinylated in an insulin-dependent fashion, i.e. they cycle to and from the cell surface in an apparently identical manner to GLUT4. Sequence analysis of two tryptic fragments from p160 reveals that it is a novel protein containing sequence with no homology to known proteins.			KANDROR, K (corresponding author), BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02118 USA.			Pilch, Paul/0000-0003-1997-0499; Kandror, Konstantin/0000-0002-8601-9313	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030425] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK30425-11] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BURANT CF, 1991, RECENT PROG HORM RES, V47, P349; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CORMONT M, 1991, ENDOCRINOLOGY, V129, P3343, DOI 10.1210/endo-129-6-3343; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J BIOL CHEM, V268, P9187; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; HARE JF, 1989, BIOCHEMISTRY-US, V28, P574, DOI 10.1021/bi00428a024; HARE JF, 1992, ARCH BIOCHEM BIOPHYS, V293, P416, DOI 10.1016/0003-9861(92)90414-R; HARE JF, 1990, BIOCHEMISTRY-US, V265, P21758; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1988, BIOCHEM J, V256, P725, DOI 10.1042/bj2560725; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1987, J BIOL CHEM, V262, P11817; JHUN BH, 1992, J BIOL CHEM, V267, P17710; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OKA Y, 1988, J BIOL CHEM, V263, P13432; RODBELL M, 1964, J BIOL CHEM, V239, P375; SHOELSON SE, 1993, J BIOL CHEM, V268, P4085; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; THOIDIS G, 1993, J BIOL CHEM, V268, P11691; YANG J, 1992, BIOCHEM J, V281, P809, DOI 10.1042/bj2810809; YANG J, 1993, J BIOL CHEM, V268, P4600; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	28	87	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					138	142						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276787				2022-12-25	WOS:A1994MR21900029
J	LAMA, J; PAUL, AV; HARRIS, KS; WIMMER, E				LAMA, J; PAUL, AV; HARRIS, KS; WIMMER, E			PROPERTIES OF PURIFIED RECOMBINANT POLIOVIRUS PROTEIN 3AB AS SUBSTRATE FOR VIRAL PROTEINASES AND AS COFACTOR FOR RNA-POLYMERASE 3D(POL)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; REPLICATION; EXPRESSION; PRECURSOR; POLYPEPTIDE; VPG; INITIATION; CLEAVAGE; INVITRO; CELLS	The poliovirus-specific polypeptide 3AB (B = VPg) was expressed in Escherichia coli and purified to near homogeneity. Corresponding to its known association with membranes in poliovirus-infected HeLa cells, 3AB expressed in E. coli was also membrane-associated, and it could be solubilized only in detergent-containing buffers. In soluble form, 3AB was resistant to digestion with the virus-specific proteinases 3C(pro) and 3CD(pro). However, it was cleaved by these enzymes to 3A and VPg when bound to the bacterial membranes, an observation suggesting that 3AB may deliver the genome-linked protein VPg to the membrane-associated poliovirus replication complex. The specific activity of 3CD(pro) in processing 3AB was significantly higher than that of 3C(pro). Soluble 3AB was found to stimulate nearly 100-fold poly(A)-dependent, primer-dependent poly(U) synthesis, catalyzed by purified poliovirus RNA polymerase 3D(pol). We propose that 3AB has a dual function in poliovirus genome replication: as a precursor for VPg, and as a co-factor for 3D(pol).	SUNY STONY BROOK, HLTH SCI CTR, SCH MED, DEPT MICROBIOL, STONY BROOK, NY 11794 USA; UNIV AUTONOMA MADRID, FAC CIENCIAS, CTR BIOL MOLEC SEVERO OCHOA, E-28049 MADRID, SPAIN	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Autonomous University of Madrid					NCI NIH HHS [CA-28146] Funding Source: Medline; NIAID NIH HHS [AI-15122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015122, R01AI015122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; BERNSTEIN HD, 1988, J VIROL, V62, P2922, DOI 10.1128/JVI.62.8.2922-2928.1988; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; FLANEGAN JB, 1977, P NATL ACAD SCI USA, V74, P3677, DOI 10.1073/pnas.74.9.3677; GIACHETTI C, 1991, J VIROL, V65, P2647, DOI 10.1128/JVI.65.5.2647-2654.1991; GUINEA R, 1991, VIROLOGY, V185, P473, DOI 10.1016/0042-6822(91)90802-I; HARRIS KS, 1992, J VIROL, V66, P7481, DOI 10.1128/JVI.66.12.7481-7489.1992; Harris KS, 1990, SEMINARS VIROLOGY, V1, P323; HELLEN CUT, 1989, BIOCHEMISTRY-US, V28, P9881, DOI 10.1021/bi00452a001; HUANG KS, 1980, P NATL ACAD SCI-BIOL, V77, P323, DOI 10.1073/pnas.77.1.323; JABLONSKI SA, 1993, J VIROL, V67, P373, DOI 10.1128/JVI.67.1.373-381.1993; JORE J, 1988, J GEN VIROL, V69, P1627, DOI 10.1099/0022-1317-69-7-1627; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; Kuhn R. J., 1987, The molecular biology of the positive strand RNA viruses, P17; LAMA J, 1992, J BIOL CHEM, V267, P15932; LAMA J, 1992, BIOCHEM BIOPH RES CO, V188, P972, DOI 10.1016/0006-291X(92)91327-M; LAWSON MA, 1992, VIROLOGY, V191, P309, DOI 10.1016/0042-6822(92)90193-S; Maniatis T., 1982, MOL CLONING; MOLLA A, 1993, J VIROL, V67, P5932, DOI 10.1128/JVI.67.10.5932-5938.1993; NICKLIN MJH, 1988, J VIROL, V62, P4586, DOI 10.1128/JVI.62.12.4586-4593.1988; RICHARDS OC, 1990, CURR TOP MICROBIOL, V161, P89; RUECKERT RR, 1984, J VIROL, V50, P957, DOI 10.1128/JVI.50.3.957-959.1984; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEMLER BL, 1981, P NATL ACAD SCI-BIOL, V78, P3464, DOI 10.1073/pnas.78.6.3464; SEMLER BL, 1982, CELL, V28, P405, DOI 10.1016/0092-8674(82)90358-0; TAKEDA N, 1986, J VIROL, V60, P43, DOI 10.1128/JVI.60.1.43-53.1986; TAKEGAMI T, 1983, VIROLOGY, V128, P33, DOI 10.1016/0042-6822(83)90316-1; TAKEGAMI T, 1983, P NATL ACAD SCI-BIOL, V80, P7447, DOI 10.1073/pnas.80.24.7447; TOBIN GJ, 1989, CELL, V59, P511, DOI 10.1016/0092-8674(89)90034-2; VANDYKE TA, 1980, J VIROL, V35, P732, DOI 10.1128/JVI.35.3.732-740.1980; WIMMER E, 1982, CELL, V28, P199, DOI 10.1016/0092-8674(82)90335-X; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033; WU SX, 1992, P NATL ACAD SCI USA, V89, P11136, DOI 10.1073/pnas.89.23.11136; YPMAWONG MF, 1988, VIROLOGY, V166, P265, DOI 10.1016/0042-6822(88)90172-9	34	104	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					66	70						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276867				2022-12-25	WOS:A1994MR21900018
J	MANABE, R; SAITO, T; KUMAZAKI, T; SAKAITANI, T; NAKATA, N; OCHIAI, H				MANABE, R; SAITO, T; KUMAZAKI, T; SAKAITANI, T; NAKATA, N; OCHIAI, H			MOLECULAR-CLONING AND THE COOH-TERMINAL PROCESSING OF GP64, A PUTATIVE CELL-CELL ADHESION PROTEIN OF THE CELLULAR SLIME-MOLD POLYSPHONDYLIUM-PALLIDUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-A GLYCOPROTEIN; AGGREGATING DICTYOSTELIUM CELLS; EUKARYOTIC MESSENGER-RNAS; MONOCLONAL-ANTIBODIES; MEMBRANE; DISCOIDEUM; SEQUENCE; SIGNAL; CHROMATOGRAPHY; RESOLUTION	The cellular slime mold Polysphondylium pallidum expresses a cell surface glycoprotein (referred to as gp64), which seems to be implicated in cell-cell adhesion. We identified a near full-length gp64 cDNA (1,104 base) upon screening a P. pallidum lambdagt11 library with a monoclonal antibody. The open reading frame encodes a protein of 320 amino acids with a molecular mass of 32,752 Da; the protein includes hydrophobic segments at both a NH2- and a COOH-terminal ends. By an Edman degradation analysis of S-pyridylethylated gp64 and its COOH-terminal peptide, it was found that the NH2- and COOH-terminal segments are both removed from the precursor protein of gp64. The COOH-terminal segment was isolated from a lysyl endopeptidase digest of gp64 by an affinity method. The COOH-terminal segment was identified at positions 266-279 in the primary sequence deduced from the cDNA sequence. The mature gp64 consisted of 279 amino acid residues and extremely rich in Cys residues (36 Cys/279 amino acids = 12.9%). Although there was already maximal accumulation of gp64 mRNA in vegetative cells, the protein reached a maximal level during aggregation stage, decreased, and then leveled off through the developmental cycle.	HOKKAIDO UNIV,FAC SCI,DEPT BIOL,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,FAC PHARMACEUT SCI,DEPT BIOCHEM,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University; Hokkaido University								AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIRD P, 1990, J BIOL CHEM, V265, P8420; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOZZARO S, 1981, EXP CELL RES, V134, P181, DOI 10.1016/0014-4827(81)90475-4; CARAS IW, 1989, J CELL BIOL, V108, P1387, DOI 10.1083/jcb.108.4.1387; DUSTIN ML, 1987, NATURE, V329, P846, DOI 10.1038/329846a0; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUCHS M, 1993, IN PRESS J COMPUTER; FUKUI Y, 1987, METHOD CELL BIOL, V28, P347; GERISCH G, 1980, CELL ADHESION MOTILI, P293; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HERMODSON MA, 1973, BIOCHEMISTRY-US, V12, P3146, DOI 10.1021/bi00741a002; HINTERMANN R, 1979, FEBS LETT, V108, P219, DOI 10.1016/0014-5793(79)81214-4; ISHIHARA A, 1987, P NATL ACAD SCI USA, V84, P1290, DOI 10.1073/pnas.84.5.1290; KAMBOJ RK, 1989, CELL, V59, P615, DOI 10.1016/0092-8674(89)90007-X; KIMMEL AR, 1983, NUCLEIC ACIDS RES, V11, P541, DOI 10.1093/nar/11.2.541; KIMMEL AR, 1982, DEV DICTYOSTELIUM DI, P234; KODUKULA K, 1993, J CELL BIOL, V120, P657, DOI 10.1083/jcb.120.3.657; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUMAZAKI T, 1987, J BIOCHEM-TOKYO, V102, P1539, DOI 10.1093/oxfordjournals.jbchem.a122202; KUMAZAKI T, 1986, Proteins Structure Function and Genetics, V1, P100, DOI 10.1002/prot.340010115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LODISH HF, 1977, DEV DIFFERENTIATION, P253; MANABE R, 1990, J BIOCHEM-TOKYO, V108, P852, DOI 10.1093/oxfordjournals.jbchem.a123292; MATSUNAGA T, 1987, SCAND J IMMUNOL, V25, P485, DOI 10.1111/j.1365-3083.1987.tb02220.x; MCCARTY KS, 1974, ANAL BIOCHEM, V61, P165, DOI 10.1016/0003-2697(74)90343-1; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MULLER K, 1979, EUR J BIOCHEM, V99, P419, DOI 10.1111/j.1432-1033.1979.tb13271.x; NODA M, 1987, J CELL BIOL, V105, P1671, DOI 10.1083/jcb.105.4.1671; NOEGEL A, 1986, EMBO J, V5, P1473, DOI 10.1002/j.1460-2075.1986.tb04384.x; OCHIAI H, 1990, ELECTROPHORESIS, V11, P856, DOI 10.1002/elps.1150111015; OHNO S, 1987, EXP CLIN IMMUNOGENET, V4, P181; POWLL SK, 1991, ANAL CHEM, V43, P880; SAITO T, 1993, EUR J BIOCHEM, V211, P147, DOI 10.1111/j.1432-1033.1993.tb19881.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAXENA A, 1987, MOL CELL BIOL, V7, P3409, DOI 10.1128/MCB.7.10.3409; SIU CH, 1987, J CELL BIOL, V105, P2523, DOI 10.1083/jcb.105.6.2523; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; STADLER J, 1989, EMBO J, V8, P371, DOI 10.1002/j.1460-2075.1989.tb03387.x; STEINEMANN C, 1979, FEBS LETT, V108, P379, DOI 10.1016/0014-5793(79)80568-2; THOMAS J, 1987, BIOPHYS J, V51, P522; TODA K, 1984, EUR J BIOCHEM, V140, P73, DOI 10.1111/j.1432-1033.1984.tb08068.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	45	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					528	535						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276846				2022-12-25	WOS:A1994MR21900085
J	REAGAN, JD				REAGAN, JD			EXPRESSION CLONING OF AN INSECT DIURETIC HORMONE-RECEPTOR - A MEMBER OF THE CALCITONIN SECRETIN RECEPTOR FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MANDUCA-SEXTA; ACHETA-DOMESTICUS; MOLECULAR-CLONING; TOBACCO HORNWORM; IDENTIFICATION; PEPTIDE; PROTEIN	Insect diuretic hormones and their receptors regulate fluid and ion secretion and thus are attractive targets for the design of novel insect control agents. A complementary DNA clone encoding a corticotropin-releasing factor-related diuretic hormone receptor from the tobacco hornworm Manduca sexta was isolated by expression cloning in COS-7 cells. The receptor consists of 395 amino acids and contains seven putative transmembrane domains. The expressed receptor binds M. sexta diuretic hormone, as well as several related insect diuretic peptides with high affinity. Furthermore, each of these peptides stimulate adenylate cyclase in COS-7 cells transfected with the receptor. The M. sexta diuretic hormone receptor is homologous to the receptors for calcitonin, secretin, vasoactive intestinal peptide, parathyroid hormone, glucagon-like peptide 1, growth hormone-releasing hormone, pituitary adenylate cyclase-activating polypeptide, and glucagon. The M. sexta diuretic hormone receptor is the first nonmammalian member of this family to be identified.			REAGAN, JD (corresponding author), SANDOZ AGRO INC,DIV RES,PALO ALTO,CA 94304, USA.							AUDSLEY N, 1993, J EXP BIOL, V178, P231; BLACKBURN MB, 1991, BIOCHEM BIOPH RES CO, V181, P927, DOI 10.1016/0006-291X(91)92025-F; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; COAST GM, 1992, J EXP BIOL, V162, P331; DEKKER LV, 1992, FEBS LETT, V312, P195, DOI 10.1016/0014-5793(92)80934-9; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KATAOKA H, 1989, P NATL ACAD SCI USA, V86, P2976, DOI 10.1073/pnas.86.8.2976; KAY I, 1992, REGUL PEPTIDES, V42, P111, DOI 10.1016/0167-0115(92)90091-8; KAY I, 1991, BIOL CHEM H-S, V372, P505, DOI 10.1515/bchm3.1991.372.2.505; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEHMBERG E, 1991, BIOCHEM BIOPH RES CO, V179, P1036, DOI 10.1016/0006-291X(91)91923-Z; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MAYO KE, 1992, MOL ENDOCRINOL, V6, P1734, DOI 10.1210/me.6.10.1734; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; PISEGNA PR, 1993, P NATL ACAD SCI USA, V90, P6345; REAGAN JD, 1993, ARCH INSECT BIOCHEM, V23, P135, DOI 10.1002/arch.940230305; Sambrook J, 1989, MOL CLONING LABORATO; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WRAY V, 1993, BIOCHEMISTRY-US, V32, P5832, DOI 10.1021/bi00073a016	25	105	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					9	12						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276884				2022-12-25	WOS:A1994MR21900003
J	CHEN, YP; FARACO, J; YIN, WS; GERMILLER, J; FRANCKE, U; BONADIO, J				CHEN, YP; FARACO, J; YIN, WS; GERMILLER, J; FRANCKE, U; BONADIO, J			STRUCTURE, CHROMOSOMAL LOCALIZATION, AND EXPRESSION PATTERN OF THE MURINE MAGP GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELASTIN-ASSOCIATED MICROFIBRILS; MESSENGER-RNAS; INSITU HYBRIDIZATION; FIBRILLIN; GLYCOPROTEIN; COMPONENT; TISSUES; MUTATION; PROTEIN; PROBES	The microfibril- associated glycoprotein (MAGP) was recently established as a discrete constituent of 10-nm microfibrils. We have characterized the primary structure of the mouse transcript, the structure and chromosomal localization of the murine gene, and the developmental pattern of gene expression. The transcript consists of 1,037 base pairs as determined by cDNA cloning, Northern blot analysis, S1 nuclease mapping, and primer extension mapping. Using a cDNA fragment as a probe, we isolated a single genomic clone that contained the entire mouse gene. Analysis of this clone indicated that Magp is fragmented into 9 exons, with the initiator Met codon located in exon 2. As determined by analysis of somatic cell hybrid lines and by fluorescence in situ hybridization, the mouse gene was mapped to chromosome 4 at a location corresponding to region D3-E1. Genomic sequence immediately upstream of the transcription start site was found to be GC-rich but lacked TATA or CCAAT boxes as well as other cis-acting motifs known to regulate transcription. Promoters of this type are usually found in genes that exhibit broad temporal and spatial patterns of expression. Consistent with this idea, the Magp transcript appeared to be the widespread product of mesenchymal/connective tissue cells throughout mouse development. This study presents the first comprehensive evaluation of microfibril gene expression during mammalian development.	UNIV MICHIGAN, DEPT PATHOL, MSRB I, RM 3510, 1150 W MED CTR DR, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, ORTHOPAED RES LABS, ORTHOPAED SURG SECT, ANN ARBOR, MI 48109 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Stanford University; Howard Hughes Medical Institute; Stanford University								ARBEILLE BB, 1991, J HISTOCHEM CYTOCHEM, V39, P1367, DOI 10.1177/39.10.1940308; BRESSAN GM, 1993, J CELL BIOL, V121, P201, DOI 10.1083/jcb.121.1.201; CLEARY EG, 1983, INT REV CONNECT TISS, V10, P97; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; DIETZ HC, 1992, J CLIN INVEST, V89, P1674, DOI 10.1172/JCI115766; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FARACO J, 1993, AM J MED GENET, V47, P148; FISHER C, 1984, DEV BIOL, V102, P290, DOI 10.1016/0012-1606(84)90194-5; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GEORGE DL, 1980, CYTOGENET CELL GENET, V28, P217, DOI 10.1159/000131535; GIBSON MA, 1986, J BIOL CHEM, V261, P1429; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; GIBSON MA, 1991, J BIOL CHEM, V266, P7596; GIBSON MA, 1987, IMMUNOL CELL BIOL, V65, P345, DOI 10.1038/icb.1987.39; GIBSON MA, 1993, AM J MED GENET, V47, P148; HOLBROOK KA, 1982, J CELL BIOL, V92, P387, DOI 10.1083/jcb.92.2.387; HORRIGAN SK, 1992, J BIOL CHEM, V267, P10087; KAINULAINEN K, 1992, P NATL ACAD SCI USA, V89, P5917, DOI 10.1073/pnas.89.13.5917; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P145; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P441, DOI 10.1177/39.4.2005373; KOBAYASHI R, 1989, J BIOL CHEM, V264, P17437; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; LOW FN, 1962, ANAT REC, V142, P131, DOI 10.1002/ar.1091420205; LUTZNER MA, 1985, JNCI-J NATL CANCER I, V75, P161; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MILATOVICH A, 1991, GENOMICS, V11, P1040, DOI 10.1016/0888-7543(91)90030-I; PATTERSON E, 1989, J BIOL CHEM, V264, P10083; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; Ross R, 1977, Adv Exp Med Biol, V79, P7; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sambrook J, 1989, MOL CLONING LABORATO; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; TSIPOURAS P, 1992, NEW ENGL J MED, V326, P905, DOI 10.1056/NEJM199204023261401; VRACKO R, 1990, J MOL CELL CARDIOL, V22, P749, DOI 10.1016/0022-2828(90)90087-I; YANGFENG TL, 1986, P NATL ACAD SCI USA, V83, P8679, DOI 10.1073/pnas.83.22.8679	38	25	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27381	27389						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262979				2022-12-25	WOS:A1993MM26200078
J	HO, KC; MARSCHKE, KB; TAN, JA; POWER, SGA; WILSON, EM; FRENCH, FS				HO, KC; MARSCHKE, KB; TAN, JA; POWER, SGA; WILSON, EM; FRENCH, FS			A COMPLEX RESPONSE ELEMENT IN INTRON-1 OF THE ANDROGEN-REGULATED 20-KDA PROTEIN GENE DISPLAYS CELL TYPE-DEPENDENT ANDROGEN RECEPTOR SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRAL PROSTATE; MAMMARY-TUMOR VIRUS; GLUCOCORTICOID RECEPTOR; DNA-BINDING; TRANSCRIPTION FACTORS; MAMMALIAN-CELLS; 1ST INTRON; C-JUN; EXPRESSION; HORMONE	The androgen-regulated 20-kDa protein gene consists of four exons that code for a major secretory protein of rat ventral prostate. Analysis of its potential cis-acting transcriptional regulatory elements revealed that a large intron 1 region (In-1) had stronger androgen response element (ARE) activity than did the 5'-flanking DNA. In cotransfected CV1 cells, In-1 and its most active subfragment In-1c functioned as AREs but not glucocorticoid response elements (GRE). Nevertheless several ARE/GRE-like partial palindromic sequences are present in In-1c, and it bound both androgen receptors and glucocorticoid receptors in mobility shift assays. A cluster of three ARE/GRE-like sequences contained within a 39-base pair sequence of In-1c had both ARE and GRE activities when analyzed as an isolated oligonucleotide, suggesting that other elements within In-1c determined its ARE specificity. In addition to ARE/GRE-like sequences, In-1c contains putative response elements for the transcription factors AP1, CREB, AP2, OCT-1, C/EBP, and a number of inverted and direct repeats. The ARE specificity of In-1c observed in CV1 cells was diminished in PC3 and HeLa cells transiently cotransfected with an androgen receptor or glucocorticoid receptor expression vector together with an In-1c reporter vector; however, the ARE activity of In-1c was greater than its GRE activity in these cell lines. Interestingly, a 131-base pair subfragment of In-1c retained ARE specificity in all three cell lines.	UNIV N CAROLINA,REPROD BIOL LABS,CB 7500,MACNIDER BLDG,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007315, R37HD004466, R01HD004466, P30HD018968] Funding Source: NIH RePORTER; NICHD NIH HHS [P30-HD18968, T32-HDQ7315, HD04466] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADLER AJ, 1991, MOL ENDOCRINOL, V5, P1587, DOI 10.1210/mend-5-11-1587; ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BURLEIGH BD, 1980, MOL CELL ENDOCRINOL, V19, P183, DOI 10.1016/0303-7207(80)90021-0; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAESSENS F, 1989, BIOCHEM BIOPH RES CO, V164, P833, DOI 10.1016/0006-291X(89)91534-9; COLLINS S, 1988, FEBS LETT, V223, P173; DENISON SH, 1989, ENDOCRINOLOGY, V124, P1091, DOI 10.1210/endo-124-2-1091; DEVOS P, 1991, J BIOL CHEM, V266, P3439; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; HARRIS SE, 1988, CELLULAR FACTORS DEV, P53; HO KC, 1992, J BIOL CHEM, V267, P12660; HO KC, 1989, BIOCHEMISTRY-US, V28, P6367, DOI 10.1021/bi00441a032; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; LANGE AJ, 1992, J BIOL CHEM, V267, P15673; LOCKER J, 1990, J DNA SEQUENCING MAP, V1, P3; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; LUND SD, 1991, MOL CELL BIOL, V11, P5426, DOI 10.1128/MCB.11.11.5426; MANIATIS T, 1982, MOL CLONING LABORATO, P353; MARSCHKE KB, 1993, NEW PERSPECTIVES END, V99, P41; MARTIKAINEN P, 1987, ENDOCRINOLOGY, V121, P604, DOI 10.1210/endo-121-2-604; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; RATAJCZAK T, 1992, J BIOL CHEM, V267, P11111; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; RENNIE PS, 1989, MOL ENDOCRINOL, V3, P703, DOI 10.1210/mend-3-4-703; RHEE M, 1991, MOL ENDOCRINOL, V5, P564, DOI 10.1210/mend-5-4-564; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; SANGER F, 1977, P NATL ACAD SCI USA, V74, P560; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; TAN JA, 1992, J BIOL CHEM, V267, P4456; Thompson T C, 1987, Prog Clin Biol Res, V239, P239; VERCAEREN I, 1992, ENDOCRINOLOGY, V131, P2496, DOI 10.1210/endo-131-6-2496; WILSON EM, 1976, J BIOL CHEM, V251, P5620; WINDERICKX J, 1990, MOL ENDOCRINOL, V4, P657, DOI 10.1210/mend-4-4-657; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YARBROUGH WG, 1990, J BIOL CHEM, V265, P8893; ZHANG HY, 1991, J BIOL CHEM, V266, P24332	54	56	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27226	27235						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262963				2022-12-25	WOS:A1993MM26200059
J	TAN, EC; LEUNG, T; MANSER, E; LIM, L				TAN, EC; LEUNG, T; MANSER, E; LIM, L			THE HUMAN ACTIVE BREAKPOINT CLUSTER REGION-RELATED GENE ENCODES A BRAIN PROTEIN WITH HOMOLOGY TO GUANINE-NUCLEOTIDE EXCHANGE PROTEINS AND GTPASE-ACTIVATING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MILLER-DIEKER SYNDROME; BCR-GENE; TYROSINE KINASE; NEUROFIBROMATOSIS GENE; MOLECULAR-CLONING; BINDING PROTEINS; C-ABL; IDENTIFICATION; PRODUCT; SEQUENCES	GTPase-activating proteins (GAPs) modulate the activity of the ras superfamily of proteins by converting active GTP-bound to inactive GDP-bound p21s. Employing a novel GAP overlay assay (Manser, E., Leung, T., Monfries, C., Teo, M., Hall, C., and Lim, L. (1992) J. Biol. Chem. 267, 16025-16028), we demonstrated a diversity of proteins with GAP activities in different tissues. Using a polymerase chain reaction strategy exploiting conserved residues in the GAP domains of n-chimaerin and the product of the breakpoint cluster region gene (BCR), we isolated a human brain 5.3-kilobase cDNA containing a 486-base pair region with complete identity to a previously reported active BCR-related (ABR) gene sequence on human chromosome 17. The brain cDNA encoded a 98-kDa protein (ABR) resembling BCR (68% identity), containing both the oncogene dbl-related domain at the N terminus and the GAP domain at the C terminus; however, it lacks the N-terminal BCR protein kinase domain. The ABR GAP domain expressed as an Escherichia coli fusion protein was active against Rac1 and Cdc42 of the rho subfamily. The ABR mRNA is highly enriched in the brain. ABR probably corresponds to the brain-enriched 100-kDa GAP for Rac and Cdc42Hs previously detected. The relationship of ABR to Miller-Dieker syndrome, a neurological disorder co-mapping to 17p13.3, is discussed.	INST NEUROL,LONDON WC1N 1PJ,ENGLAND	University of London; University College London	TAN, EC (corresponding author), NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,SINGAPORE 0511,SINGAPORE.		Tan, EC/W-6304-2019; Manser, Edward/ABD-2301-2020					BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DHUT S, 1988, ONCOGENE, V3, P561; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DISILVESTRE D, 1990, NUCLEIC ACIDS RES, V18, P5924, DOI 10.1093/nar/18.19.5924; DOBYNS WB, 1991, AM J HUM GENET, V48, P584; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HARTWELL LH, 1973, GENETICS, V74, P267; HEISTERKAMP N, 1989, NUCLEIC ACIDS RES, V17, P8821, DOI 10.1093/nar/17.21.8821; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KWIATKOWSKI DJ, 1990, AM J HUM GENET, V46, P559; LEDBETTER SA, 1990, GENOMICS, V7, P264, DOI 10.1016/0888-7543(90)90549-A; LEUNG T, 1993, J BIOL CHEM, V268, P3813; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MANSER E, 1992, J BIOL CHEM, V267, P16025; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MELO JV, 1993, BLOOD, V81, P158; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NOWELL PC, 1960, SCIENCE, V132, P1197; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; TIMMONS MS, 1989, ONCOGENE, V4, P559; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; ZIMAN M, 1991, MOL CELL BIOL, V11, P3537, DOI 10.1128/MCB.11.7.3537	39	55	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27291	27298						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262969				2022-12-25	WOS:A1993MM26200066
J	ADHAM, IM; BURKHARDT, E; BENAHMED, M; ENGEL, W				ADHAM, IM; BURKHARDT, E; BENAHMED, M; ENGEL, W			CLONING OF A CDNA FOR A NOVEL INSULIN-LIKE PEPTIDE OF THE TESTICULAR LEYDIG-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; PORCINE RELAXIN; GEL-ELECTROPHORESIS; MOLECULAR-CLONING; RIBONUCLEIC-ACID; SEQUENCE; GENE; SPERMATOGENESIS; EXPRESSION; PRECURSOR	We have isolated complementary DNA clones coding for a novel member of the insulin-like hormone superfamily from a boar testis cDNA library. Northern blot analysis and in situ hybridization revealed that the gene is expressed exclusively in prenatal and postnatal Leydig cells. We have tentatively proposed the name Leydig insulin-like (Ley I-L) for the gene and its encoded protein. The Leydig insulin-like protein is synthesized as a 131-amino acid preproprotein, which contains a 24-amino acid signal peptide. Comparison of the deduced amino acid sequence of pro-Leydig insulin-like protein with members of the insulin-like hormone superfamily predicts that the biologically active protein, after proteolytic processing of the C-peptide, consists of a 32-residue-long B-chain and a 26-residue-long A-chain and has a molecular size of 6.25 kDa.	UNIV GOTTINGEN,INST HUMANGENET,GOSSLERSTR 12D,D-37073 GOTTINGEN,GERMANY; CTR HOSP LYON SUD,HOP ST EUGENIE,BIOCHEM LAB,F-69310 PIERRE BENITE,FRANCE	University of Gottingen; CHU Lyon								ADHAM IM, 1989, EUR J BIOCHEM, V182, P563, DOI 10.1111/j.1432-1033.1989.tb14864.x; ADHAM IM, 1990, HUM GENET, V84, P125; BEDARKAR S, 1977, NATURE, V270, P449, DOI 10.1038/270449a0; BELL GI, 1980, NATURE, V284, P26, DOI 10.1038/284026a0; BELL GI, 1984, NATURE, V310, P775, DOI 10.1038/310775a0; BENAHMED M, 1987, MOL CELL ENDOCRINOL, V50, P69, DOI 10.1016/0303-7207(87)90078-5; BENTLEY G, 1976, NATURE, V261, P166, DOI 10.1038/261166a0; Blundell T., 1972, ADV PROTEIN CHEM, V26, P279; BLUNDELL TL, 1980, NATURE, V287, P781, DOI 10.1038/287781a0; CHANCE RE, 1968, SCIENCE, V161, P165, DOI 10.1126/science.161.3837.165; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DULL TJ, 1984, NATURE, V310, P777, DOI 10.1038/310777a0; FRANCIS GL, 1989, J ENDOCRINOL, V122, P681, DOI 10.1677/joe.0.1220681; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GUBLER U, 1983, P NATL ACAD SCI-BIOL, V80, P4311, DOI 10.1073/pnas.80.14.4311; HALEY J, 1987, J BIOL CHEM, V262, P11940; HANAUER A, 1983, NUCLEIC ACIDS RES, V11, P3503, DOI 10.1093/nar/11.11.3503; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; HUDSON P, 1983, NATURE, V301, P628, DOI 10.1038/301628a0; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; JAMES R, 1977, NATURE, V267, P544, DOI 10.1038/267544a0; JANSEN M, 1983, NATURE, V306, P609, DOI 10.1038/306609a0; KOTAKI A, 1963, J BIOCHEM-TOKYO, V53, P61, DOI 10.1093/oxfordjournals.jbchem.a127658; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MANSOURI A, 1983, DIFFERENTIATION, V24, P149, DOI 10.1111/j.1432-0436.1983.tb01315.x; ROBINSON R, 1981, BIOL REPROD, V24, P1032, DOI 10.1095/biolreprod24.5.1032; Sambrook J, 1989, MOL CLONING LABORATO; SARGENT TD, 1987, METHOD ENZYMOL, V152, P423; SCHWABE C, 1977, BIOCHEM BIOPH RES CO, V75, P503, DOI 10.1016/0006-291X(77)91070-1; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; SHARPE RM, 1990, AM J ANAT, V188, P3, DOI 10.1002/aja.1001880103; SKINNER MK, 1991, ENDOCR REV, V12, P45, DOI 10.1210/edrv-12-1-45; SODER O, 1992, ENDOCRINOLOGY, V131, P2344, DOI 10.1210/en.131.5.2344; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAVAKKOL A, 1988, MOL ENDOCRINOL, V2, P674, DOI 10.1210/mend-2-8-674	38	232	241	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26668	26672						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253799				2022-12-25	WOS:A1993MK42500095
J	CHUANG, TH; BOHL, BP; BOKOCH, GM				CHUANG, TH; BOHL, BP; BOKOCH, GM			BIOLOGICALLY-ACTIVE LIPIDS ARE REGULATORS OF RAC-CENTER-DOT-GDI COMPLEXATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; CELL-FREE SYSTEM; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; DEPENDENT SUPEROXIDE PRODUCTION; GDP/GTP EXCHANGE PROTEINS; SODIUM DODECYL-SULFATE; NADPH OXIDASE; HUMAN-NEUTROPHILS; PHOSPHATIDIC-ACID; PHOSPHOLIPASE-D	Members of the Rho family of GTP-binding proteins are localized in the cytosol of cells by complexation with a protein known as (Rho)GDI. We show by sucrose gradient equilibrium sedimentation analysis that all of the Rac protein present in human neutrophil cytosol exists as a complex with (Rho)GDI under non-activating conditions. This interaction can be disrupted in the presence of various lipids which have been shown to have biological activity in a variety of systems, including NADPH oxidase activation. Particularly effective were arachidonic acid, phosphatidic acid, and phosphatidylinositols. These lipids were active at concentrations from 0.5-50 muM and were capable of disrupting complexation of (Rho)GD1 with both GDP- and GTP-bound forms of Rac, although the latter were more sensitive to lipid. These data suggest that certain lipids generated in chemoattractant-stimulated neutrophils may play a role in modulating the activity of Rac and thus NADPH oxidase activity.	Scripps Res Inst, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			Chuang, Tsung-Hsien/F-9679-2010		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00833] Funding Source: Medline; NHLBI NIH HHS [HL48008] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; BADWEY JA, 1981, J BIOL CHEM, V256, P2640; BADWEY JA, 1984, J BIOL CHEM, V259, P7870; BARSAGI D, 1988, J CELL BIOL, V106, P1649, DOI 10.1083/jcb.106.5.1649; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BOKOCH GM, 1980, J BIOL CHEM, V255, P223; BOKOCH GM, 1988, J CELL BIOL, V106, P1927, DOI 10.1083/jcb.106.6.1927; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BORMANN BJ, 1984, P NATL ACAD SCI-BIOL, V81, P767, DOI 10.1073/pnas.81.3.767; BOSNER RW, 1989, BIOCHEM J, V264, P617; BOURMEYSTER N, 1992, BIOCHEMISTRY-US, V31, P12863, DOI 10.1021/bi00166a022; BROMBERG Y, 1983, CELL IMMUNOL, V79, P240, DOI 10.1016/0008-8749(83)90067-9; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CHUANG TH, 1993, J BIOL CHEM, V268, P775; CLARK RA, 1987, J BIOL CHEM, V262, P4065; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; EXTON JH, 1990, J BIOL CHEM, V265, P1; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HENDERSON LM, 1989, BIOCHEM J, V264, P249, DOI 10.1042/bj2640249; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; KAKINUMA K, 1974, BIOCHIM BIOPHYS ACTA, V348, P76; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; LEONARD D, 1992, J BIOL CHEM, V267, P22860; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; OHTSUKA T, 1989, J BIOCHEM-TOKYO, V106, P259, DOI 10.1093/oxfordjournals.jbchem.a122841; PAI JK, 1988, J BIOL CHEM, V263, P12472; QUINN MT, 1993, J BIOL CHEM, V268, P20983; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; SMOLEN JE, 1980, BIOCHEM PHARMACOL, V29, P533, DOI 10.1016/0006-2952(80)90373-1; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; UEDA T, 1990, J BIOL CHEM, V265, P9373	48	195	197	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26206	26211						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253741				2022-12-25	WOS:A1993MK42500032
J	GUIDOT, DM; MCCORD, JM; WRIGHT, RM; REPINE, JE				GUIDOT, DM; MCCORD, JM; WRIGHT, RM; REPINE, JE			ABSENCE OF ELECTRON-TRANSPORT (RHO(0) STATE) RESTORES GROWTH OF A MANGANESE-SUPEROXIDE DISMUTASE-DEFICIENT SACCHAROMYCES-CEREVISIAE IN HYPEROXIA - EVIDENCE FOR ELECTRON-TRANSPORT AS A MAJOR SOURCE OF SUPEROXIDE GENERATION IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C OXIDASE; HEART-MITOCHONDRIA; HYDROGEN-PEROXIDE; POLYMORPHONUCLEAR LEUKOCYTES; LIPID-PEROXIDATION; ESCHERICHIA-COLI; RAT-LIVER; FERRITIN; UBIQUINONE; RADICALS	To address the possibility that electron transport is a biologically significant source of superoxide anion (O2 radical anion) during exposure to hyperoxia in vivo, we constricted Saccharomyces cerevisiae strains with selective disruptions in the gene encoding the mitochondrial manganese-containing superoxide dismutase (Mn-SOD) and/or genes encoding proteins critical for complexes in electron transport. We hypothesized that complete absence of electron transport would restore growth in hyperoxia to a Mn-SOD-deficient yeast. We found that yeast deficient in Mn-SOD activity failed to grow normally in hyperoxia (95% O2, 5% CO2). In contrast, Mn-SOD-deficient yeast with complete absence of electron transport (the Rho0 state) grew normally in hyperoxia. By comparison, Mn-SOD-deficient yeast which were deficient only in cytochrome-c-oxidase, the terminal step in electron transport, had only partially restored growth in hyperoxia. Our results indicate that electron transport is a major source of O2 radical anion in vivo, and that the principal site of this O2 radical anion production is proximal to the cytochrome-c-oxidase complex.			GUIDOT, DM (corresponding author), WEBB WARING INST BIOMED RES, BOX C322, 4200 E 9TH AVE, DENVER, CO 80262 USA.		McCord, Joe/GWU-8607-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL027353, K11HL002690] Funding Source: NIH RePORTER; NHLBI NIH HHS [K11-HL02690, P50-HL27353] Funding Source: Medline; PHS HHS [R01-45582] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BIEMOND P, 1984, J CLIN INVEST, V73, P1576, DOI 10.1172/JCI111364; BOLANN BJ, 1987, BIOCHEM J, V243, P55, DOI 10.1042/bj2430055; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; CUMSKY MG, 1985, P NATL ACAD SCI USA, V82, P2235, DOI 10.1073/pnas.82.8.2235; FREDERIKS WM, 1986, VIRCHOWS ARCH B, V51, P321, DOI 10.1007/BF02899041; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENNINGS RB, 1976, CIRC RES, V38, P80; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCCORD JM, 1988, FREE RADICAL BIO MED, V5, P363, DOI 10.1016/0891-5849(88)90109-8; MCEWEN JE, 1985, J BACTERIOL, V161, P831, DOI 10.1128/JB.161.3.831-835.1985; NISHIDA T, 1987, BIOCHIM BIOPHYS ACTA, V890, P82, DOI 10.1016/0005-2728(87)90071-5; NOHL H, 1981, FEBS LETT, V123, P241, DOI 10.1016/0014-5793(81)80297-9; SALIN ML, 1974, J CLIN INVEST, V54, P1005, DOI 10.1172/JCI107816; THOMAS CE, 1985, J BIOL CHEM, V260, P3275; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P401, DOI 10.1016/0003-9861(82)90518-5; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; WEFERS H, 1988, EUR J BIOCHEM, V174, P353, DOI 10.1111/j.1432-1033.1988.tb14105.x; WRIGHT RM, 1989, NUCLEIC ACIDS RES, V17, P1103, DOI 10.1093/nar/17.3.1103; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	28	141	145	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26699	26703						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253804				2022-12-25	WOS:A1993MK42500100
J	HOESCHE, C; SAUERWALD, A; VEH, RW; KRIPPL, B; KILIMANN, MW				HOESCHE, C; SAUERWALD, A; VEH, RW; KRIPPL, B; KILIMANN, MW			THE 5'-FLANKING REGION OF THE RAT SYNAPSIN-I GENE DIRECTS NEURON-SPECIFIC AND DEVELOPMENTALLY-REGULATED REPORTER GENE-EXPRESSION IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPING NERVOUS-SYSTEM; LOOP-HELIX GENES; CHLORAMPHENICOL ACETYLTRANSFERASE; PROTEIN-I; TRANSCRIPTION; BRAIN; CELLS; POU; PROMOTER; CNS	The expression of the synapsin I gene is neuron-specific and developmentally regulated. As a step toward characterizing the molecular mechanisms that are responsible for its transcriptional regulation in vivo, we have generated transgenic mice that carry the chloramphenicol acetyltransferase (CAT) reporter gene under the control of approximately 4,300 nucleotides of 5'-flanking sequence of the rat synapsin I gene. In four independent transgenic mouse lines, high level CAT expression is observed specifically in the brain and other neural tissues. Two of these lines also exhibit notable CAT expression in testis. The transgene is expressed at similar levels in many different regions of the central nervous system. Immunohistochemical staining detects the CAT marker protein in various cell populations of neuronal morphology within the brain and the spinal cord. Transgene expression is developmentally regulated in a way that correlates well with the expression of the endogenous synapsin I gene. Both follow a characteristic, biphasic postnatal time course with a maximum around day 20. We conclude that the DNA region investigated contains cis-regulatory elements sufficient to drive the expression of a reporter gene in a spatial and temporal pattern that resembles the expression of the endogenous synapsin I gene.	RUHR UNIV BOCHUM,INST PHYSIOL CHEM,BIOCHEM SUPRAMOLEK SYST ABT,D-44780 BOCHUM,GERMANY; RUHR UNIV BOCHUM,INST ANAT,D-44780 BOCHUM,GERMANY; RUHR UNIV BOCHUM,INST PHYSIOL CHEM,BIOCHEM INTERMEDIARSTOFFWECHSELS ABT,D-44780 BOCHUM,GERMANY	Ruhr University Bochum; Ruhr University Bochum; Ruhr University Bochum								ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN L, 1992, P NATL ACAD SCI USA, V89, P8492, DOI 10.1073/pnas.89.18.8492; CROSBY SD, 1992, P NATL ACAD SCI USA, V89, P4739, DOI 10.1073/pnas.89.10.4739; DECAMILLI P, 1979, P NATL ACAD SCI USA, V76, P5977; DECAMILLI P, 1983, J CELL BIOL, V96, P1337, DOI 10.1083/jcb.96.5.1337; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DESMARAIS D, 1992, EMBO J, V11, P2971, DOI 10.1002/j.1460-2075.1992.tb05367.x; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; FORSSPETTER S, 1990, NEURON, V5, P17; GOELZ SE, 1981, P NATL ACAD SCI-BIOL, V78, P2130, DOI 10.1073/pnas.78.4.2130; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; GRUMMT I, 1980, MOL GEN GENET, V177, P223, DOI 10.1007/BF00267433; HAAS CA, 1988, J CELL BIOL, V106, P195, DOI 10.1083/jcb.106.1.195; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; HARLAN RE, 1991, BIOTECHNIQUES, V10, P304; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; HOGAN B, 1986, MANIPULATING MOUSE E; HOWLAND DS, 1991, MOL BRAIN RES, V11, P345, DOI 10.1016/0169-328X(91)90044-X; IBANEZ CF, 1991, P NATL ACAD SCI USA, V88, P3676, DOI 10.1073/pnas.88.9.3676; KILIMANN MW, 1985, EMBO J, V4, P1997, DOI 10.1002/j.1460-2075.1985.tb03883.x; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; LIPKOWITZ S, 1992, J BIOL CHEM, V267, P21065; MATHIS JM, 1992, EMBO J, V11, P2551, DOI 10.1002/j.1460-2075.1992.tb05320.x; MELLONI RH, 1993, J COMP NEUROL, V327, P507, DOI 10.1002/cne.903270404; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; PATIL N, 1990, NEURON, V2, P437; PERSSON H, 1990, MOL CELL BIOL, V10, P4701, DOI 10.1128/MCB.10.9.4701; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; STOYKOVA AS, 1992, NEURON, V8, P541, DOI 10.1016/0896-6273(92)90282-I; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; THIEL G, 1991, P NATL ACAD SCI USA, V88, P3431, DOI 10.1073/pnas.88.8.3431; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; VALTORTA F, 1992, J BIOL CHEM, V267, P7195; WANG YB, 1992, J BIOL CHEM, V267, P15105; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WIRAK DO, 1991, EMBO J, V10, P289, DOI 10.1002/j.1460-2075.1991.tb07949.x; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X	45	79	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26494	26502						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253778				2022-12-25	WOS:A1993MK42500072
J	LAHAYE, A; LETERME, S; FOURY, F				LAHAYE, A; LETERME, S; FOURY, F			PIF1 DNA HELICASE FROM SACCHAROMYCES-CEREVISIAE - BIOCHEMICAL-CHARACTERIZATION OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; YEAST MITOCHONDRIA; PUTATIVE HELICASES; REPLICATION FORK; GENE-4 PROTEIN; REP PROTEIN; BACTERIOPHAGE-T4; RECOMBINATION; PURIFICATION; REQUIREMENTS	Overexpressed PIF1 DNA helicase was purified from mitochondria to near homogeneity. Its ATPase and unwinding properties were characterized. The enzyme specifically utilizes ATP (or dATP) and MgCl2 (and to a lesser extent MnCl2). ATPase activity requires single-stranded DNA as an effector, duplex DNA being 100-fold less effective. The K(eff), defined as the concentration of DNA required to achieve half-maximal ATPase activity, does not depend on single-stranded DNA length. Long duplex DNAs are poorly unwound and, moreover, dilution of the enzyme and its DNA substrate in the assay decreases DNA helicase activity. These data indicate that PIF1 helicase is a distributive enzyme, frequently turning from one DNA molecule to another. When forked substrates are used, unwinding by PIF1 is markedly stimulated. The enzyme has a sedimentation coefficient of 6.5 S, suggesting that it exists as a monomer in solution.	UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, PL CROIX SUD 2-20, B-1348 LOUVAIN, BELGIUM	Universite Catholique Louvain								Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ARAI N, 1981, J BIOL CHEM, V256, P5294; DAUM G, 1982, J BIOL CHEM, V257, P3028; EICHLER DC, 1977, J BIOL CHEM, V252, P499; FOURY F, 1987, EMBO J, V6, P1441, DOI 10.1002/j.1460-2075.1987.tb02385.x; FOURY F, 1983, P NATL ACAD SCI-BIOL, V80, P5345, DOI 10.1073/pnas.80.17.5345; FOURY F, 1985, EMBO J, V4, P3525, DOI 10.1002/j.1460-2075.1985.tb04112.x; FOURY F, 1990, THESIS U CATHOLIQUE; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1988, NATURE, V333, P22, DOI 10.1038/333022a0; HODGMAN TC, 1988, NATURE, V333, P578, DOI 10.1038/333578a0; JONGENEEL CV, 1984, J BIOL CHEM, V259, P2925; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHAYE A, 1991, EMBO J, V10, P997, DOI 10.1002/j.1460-2075.1991.tb08034.x; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LIU CC, 1981, J BIOL CHEM, V256, P2813; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1987, J BIOL CHEM, V262, P2066; MATSON SW, 1983, J BIOL CHEM, V258, P4017; NAKAI H, 1988, J BIOL CHEM, V263, P9818; OH EY, 1989, J BIOL CHEM, V264, P1336; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; ROBERTS B, 1989, BIOCHIM BIOPHYS ACTA, V1008, P263, DOI 10.1016/0167-4781(89)90016-X; SMITH KR, 1989, J BIOL CHEM, V264, P6119; SUISSA M, 1983, ANAL BIOCHEM, V133, P511, DOI 10.1016/0003-2697(83)90117-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V87, P5363; VEKNATESAN M, 1982, J BIOL CHEM, V257, P12426; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	34	83	86	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26155	26161						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253734				2022-12-25	WOS:A1993MK42500025
J	LAPPALAINEN, P; AASA, R; MALMSTROM, BG; SARASTE, M				LAPPALAINEN, P; AASA, R; MALMSTROM, BG; SARASTE, M			SOLUBLE CU(A)-BINDING DOMAIN FROM THE PARACOCCUS CYTOCHROME-C-OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-STUTZERI; MULTICOPPER ENZYME; REDUCTASE; EPR; DENITRIFICANS; SPECTROSCOPY; PROTEINS; OXYGEN	In cytochrome c oxidase the C-terminal part of subunit II is outside the membrane and contains a copper center called Cu(A). We have expressed this domain of the Paracoccus denitrificans oxidase in a soluble form. Data obtained by quantitative copper-to-protein measurements, electrospray mass spectrometry, and electron paramagnetic resonance spectroscopy show that the center contains two copper atoms probably in a mixed valence configuration. Its absorbance spectrum is similar to that of the copper center A in nitrous oxide reductase. The EPR spectrum suggests that the center in the soluble protein is closely related to the native Cu(A) site in the cytochrome oxidase complex. However, it seems likely that the copper center in the soluble domain is more exposed to the aqueous milieu than in the intact complex because its absorbance and EPR spectra are sensitive to pH. At alkaline pH one of the coppers in the site acquires type-2 character, indicating that it may be coordinated to a new ligand. The pK of this reversible change is about 8.2. The Cu(A)-binding fragment is able to oxidize cytochrome c.	EUROPEAN MOLEC BIOL LAB, MEYERHOFSTR 1, POSTFACH 102209, D-69012 HEIDELBERG, GERMANY; CHALMERS UNIV TECHNOL, DEPT BIOCHEM & BIOPHYS, S-41296 GOTHENBURG, SWEDEN; GOTHENBURG UNIV, S-41296 GOTHENBURG, SWEDEN	European Molecular Biology Laboratory (EMBL); Chalmers University of Technology; University of Gothenburg				Lappalainen, Pekka/0000-0001-6227-0354				AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; ANTHOLINE WE, 1992, EUR J BIOCHEM, V209, P875, DOI 10.1111/j.1432-1033.1992.tb17360.x; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BROMAN L, 1962, J MOL BIOL, V5, P301, DOI 10.1016/S0022-2836(62)80074-6; BROWN S, 1993, FEBS LETT, V316, P216, DOI 10.1016/0014-5793(93)81296-C; CHAN SI, 1990, BIOCHEMISTRY-US, V29, P1, DOI 10.1021/bi00453a001; COYLE CL, 1985, EUR J BIOCHEM, V153, P459, DOI 10.1111/j.1432-1033.1985.tb09324.x; FARRAR JA, 1991, FEBS LETT, V294, P11, DOI 10.1016/0014-5793(91)81331-2; GREENWOOD C, 1988, ANN NY ACAD SCI, V550, P47, DOI 10.1111/j.1749-6632.1988.tb35321.x; HALTIA T, 1992, MOL MECHANISMS BIOEN, P217; HARTZELL CR, 1974, BIOCHIM BIOPHYS ACTA, V368, P318, DOI 10.1016/0005-2728(74)90178-9; HILL BC, 1991, J BIOL CHEM, V266, P2219; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; KELLY M, 1993, J BIOL CHEM, V268, P16781; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALMSTROM BG, 1993, FEBS LETT, V325, P49, DOI 10.1016/0014-5793(93)81411-R; MANN M, 1989, ANAL CHEM, V61, P1702, DOI 10.1021/ac00190a023; RAITIO M, 1987, EMBO J, V6, P2825, DOI 10.1002/j.1460-2075.1987.tb02579.x; RIESTER J, 1989, EUR J BIOCHEM, V178, P751, DOI 10.1111/j.1432-1033.1989.tb14506.x; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; STEFFENS GCM, 1993, EUR J BIOCHEM, V213, P1149, DOI 10.1111/j.1432-1033.1993.tb17865.x; STEINRUCKE P, 1987, EUR J BIOCHEM, V167, P431, DOI 10.1111/j.1432-1033.1987.tb13356.x; TAHA TSM, 1992, BIOCHEMISTRY-US, V31, P9090, DOI 10.1021/bi00152a053; ZUMFT WG, 1992, EUR J BIOCHEM, V11, P3209	26	166	166	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26416	26421						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253767				2022-12-25	WOS:A1993MK42500061
J	LEE, EH; HARPEL, MR; CHEN, YR; HARTMAN, FC				LEE, EH; HARPEL, MR; CHEN, YR; HARTMAN, FC			PERTURBATION OF REACTION-INTERMEDIATE PARTITIONING BY A SITE-DIRECTED MUTANT OF RIBULOSE-BISPHOSPHATE CARBOXYLASE OXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; RIBULOSEBISPHOSPHATE CARBOXYLASE; RHODOSPIRILLUM-RUBRUM; 1,5-BISPHOSPHATE CARBOXYLASE; INTERSUBUNIT INTERACTION; CRYSTAL-STRUCTURE; MUTAGENESIS; CATALYSIS; RESOLUTION	To explore the roles of active-site Glu48 of ribulose-bisphosphate carboxylase/oxygenase from Rhodospirillum rubrum, the E48Q mutant has been characterized with respect to kinetics and product distribution. Although the k(cat) for carboxylase activity is only 0.6% of the wild-type value, the mutant retains full activity in catalyzing the conversion of the carboxylated reaction intermediate to 3-phosphoglycerate and retains 10% of the normal activity in catalyzing the enolization of ribulore bisphosphate. Thus, the mutant is preferentially impaired in the carboxylation step. Partitioning of the enediol(ate) intermediate during turnover of ribulose bisphosphate is perturbed dramatically in the case of the mutant protein. Whereas the wild-type enzyme displays a CO2/O2 specificity factor of 11, the corresponding parameter of the mutant is only 0.3, thereby signifying a shift of the relative reactivity of the enediol(ate) in favor of O2. The mutant protein is also unable to protect the enediol(ate) against misprotonation with consequential conversion of ribulose bisphosphate to xylulose bisphosphate. This side reaction, undetected with wild-type R. rubrum enzyme, proceeds as rapidly as carboxylation Of D-ribulose 1,5-bisphosphate by the E48Q mutant. Formation of xylulose bisphosphate by the mutant does not appear to account for the decline in carboxylase activity that occurs during the course of an assay. These studies demonstrate the multiple functionalities of Glu48 in the facilitation of catalysis and in directing intermediate partitioning in the preferred direction.	OAK RIDGE NATL LAB,DIV BIOL,PROT ENGN PROGRAM,POB 2009,OAK RIDGE,TN 37831	United States Department of Energy (DOE); Oak Ridge National Laboratory								ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; Andrews T.J., 1987, BIOCH PLANTS, P131, DOI 10.1016/B978-0-12-675410-0.50009-9; ANDREWS TJ, 1991, J BIOL CHEM, V266, P9447; CHAPMAN MS, 1988, SCIENCE, V241, P71, DOI 10.1126/science.3133767; DAY AG, 1993, BIOCHEMISTRY-US, V32, P1940, DOI 10.1021/bi00059a009; EDMONDSON DL, 1990, FEBS LETT, V260, P62, DOI 10.1016/0014-5793(90)80066-R; EDMONDSON DL, 1990, PLANT PHYSIOL, V93, P1376, DOI 10.1104/pp.93.4.1376; GUTTERIDGE S, 1993, J BIOL CHEM, V268, P7818; HARPEL MR, 1993, ANAL BIOCHEM, V209, P367, DOI 10.1006/abio.1993.1136; HARPEL MR, 1991, J BIOL CHEM, V266, P24734; HARTMAN FC, 1987, BIOCHEM BIOPH RES CO, V145, P1158, DOI 10.1016/0006-291X(87)91558-0; HARTMAN FC, 1993, ADV ENZYMOL RAMB, V67, P1; HARTMAN FC, 1989, J BIOL CHEM, V264, P11784; HARTMAN FC, 1992, PLANT PROTEIN ENG, V1, P61; Horecker B. L., 1958, BIOCHEM PREP, V6, P83; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KUEHN GD, 1978, BIOCHEM J, V175, P909, DOI 10.1042/bj1750909; LAING WA, 1974, PLANT PHYSIOL, V54, P678, DOI 10.1104/pp.54.5.678; LARIMER FW, 1987, J BIOL CHEM, V262, P15327; LEE EH, 1987, BIOCHEMISTRY-US, V26, P4599, DOI 10.1021/bi00389a001; LORIMER GH, 1981, BIOCHEMISTRY-US, V20, P1236, DOI 10.1021/bi00508a028; LORIMER GH, 1993, BIOCHEMISTRY-US, V32, P9018, DOI 10.1021/bi00086a006; LUNDQVIST T, 1991, BIOCHEMISTRY-US, V30, P904, DOI 10.1021/bi00218a004; MURAL RJ, 1990, J BIOL CHEM, V265, P6501; NIYOGI SK, 1986, J BIOL CHEM, V261, P87; PIERCE J, 1986, J BIOL CHEM, V261, P248; PIERCE J, 1986, BIOCHEMISTRY-US, V25, P1635; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; SCHLOSS JV, 1982, METHOD ENZYMOL, V23, P570; SCHNEIDER G, 1990, J MOL BIOL, V211, P989, DOI 10.1016/0022-2836(90)90088-4; SMITH HB, 1990, J BIOL CHEM, V265, P1243; SOPER TS, 1988, PROTEIN ENG, V2, P39, DOI 10.1093/protein/2.1.39; SUE JM, 1982, BIOCHEMISTRY-US, V21, P5404, DOI 10.1021/bi00265a004; YOKOTA A, 1991, PLANT CELL PHYSIOL, V32, P755; ZHU GH, 1991, PLANT PHYSIOL, V97, P1354, DOI 10.1104/pp.97.4.1354; ZHU GH, 1991, PLANT PHYSIOL, V97, P1348, DOI 10.1104/pp.97.4.1348	36	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26583	26591						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253788				2022-12-25	WOS:A1993MK42500083
J	MULLER, A; SAENGER, W				MULLER, A; SAENGER, W			STUDIES ON THE INHIBITORY-ACTION OF MERCURY UPON PROTEINASE-K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY; 3-DIMENSIONAL STRUCTURE; RESOLUTION; DETECTOR	In proteinase K, Cys73 is located ''below'' the imidazole of the active site His69. In a 2.4-angstrom resolution x-ray crystal structure of the complex formed between the enzyme and HgAc2, two Hg(II) positions are found: a fully occupied site, covalently bound to Cys73(Sgamma), which disrupts the catalytic triad (Asp39-His69-Ser224), and a 2-fold disordered (25 and 35% occupancy), noncovalent complexation to His72, Cys73, and Thr76 of lower affinity. The enzyme is inhibited noncompetitively at low concentrations and competitively above stoichiometric concentrations of Hg(II), but it retains 7% residual activity. This can be rationalized if the molecule is flexible enough to permit transient formation of the catalytic triad. Except for the active site, only minor structural changes are observed upon binding of Hg(II), but the thermal stability is reduced by 4-degrees-C.	FREE UNIV BERLIN,INST KRISTALLOG,TAKUSTR 6,D-14195 BERLIN,GERMANY	Free University of Berlin								BAGGER S, 1991, J INORG BIOCHEM, V42, P97, DOI 10.1016/0162-0134(91)80036-H; BAJORATH J, 1988, EUR J BIOCHEM, V176, P441, DOI 10.1111/j.1432-1033.1988.tb14301.x; BELCHER S, 1977, FLUORESCENCE PHOSPHO; BETZEL C, 1988, EUR J BIOCHEM, V178, P155, DOI 10.1111/j.1432-1033.1988.tb14440.x; Blundell T. L., 1976, PROTEIN CRYSTALLOGRA, P183; CARTY AJ, 1976, J CHEM SOC CHEM COMM, P214; CLARKSON TW, 1972, ANNU REV PHARMACOLOG, V12, P375, DOI 10.1146/annurev.pa.12.040172.002111; COTTON FA, 1980, ADV INORG CHEM, P589; HUBBARD R, 1990, FRODO VERSION E4 4; JANY KD, 1986, BIOL CHEM HOPPESEYLE, V366, P485; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KELLER E, 1988, SCHAKAL88; LAVERY R, 1981, INT J QUANTUM CHEM, V20, P49, DOI 10.1002/qua.560200106; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; PAHLER A, 1984, EMBO J, V3, P1311, DOI 10.1002/j.1460-2075.1984.tb01968.x; TAYLOR NJ, 1975, J CHEM SOC DALTON, P438, DOI 10.1039/dt9750000438; TAYLOR NJ, 1977, J AM CHEM SOC, V99, P6143, DOI 10.1021/ja00460a072; TOMARELLI RM, 1949, J LAB CLIN MED, V34, P428; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WOLF WM, 1991, J BIOL CHEM, V266, P17695; WONG YS, 1977, J CHEM SOC DALTON, P1157, DOI 10.1039/dt9770001157	22	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26150	26154						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253733				2022-12-25	WOS:A1993MK42500024
J	STRAUSAK, D; WASER, M; SOLIOZ, M				STRAUSAK, D; WASER, M; SOLIOZ, M			FUNCTIONAL EXPRESSION OF THE ENTEROCOCCUS-HIRAE NAH-ANTIPORTER IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/H+ ANTIPORTER; STREPTOCOCCUS-FAECALIS; MOLECULAR-CLONING; PROTON ANTIPORTER; ALKALINE PH; GENE; EXCHANGER; SODIUM; SEQUENCE; ATPASE	We recently described the cloning of napA, the putative structural gene for the NaH-antiporter of Enterococcus hirae (Waser, M., Bienz-Hess, D., Davies, K., and Solioz, M. (1992) J. Biol. Chem 267, 5396-5400). To analyze the gene product of napA, we expressed it in Escherichia coli. When placed under the control of a T7 promotor, napA could be transcribed and labeled specifically with [S-35]methionine. The resultant gene product exhibited an apparent M(r) of 3,4 x 10(4) when subjected to sodium dodecyl sulfate-gel electrophoresis. The function of NapA was tested by expressing it from its own promotor in the E. coli mutant EP432. This mutant lacks both of the endemic NaH-antiporters, NhaA and NhaB; its growth is thus very sensitive to Na+ and Li+ and membranes derived from this strain do not exhibit NaH-antiport activity. When complemented with napA, EP432 gained tolerance to Na+ or Li+. Membranes prepared from the complemented mutant exhibited NaH-antiport activity. The properties of this activity were determined by acridine fluorescence measurements on vesicles energized with lactate. The NaH-antiporter expressed by napA exhibited a K(m) of 1 mM for Na+ and 0.1 mM for Li+ at pH 7.5. At pH 8.5, the relative rate of NaH-antiport activity was 50%, with little change in the K(m), and approached zero at pH 9. These results demonstrate that napA is the structural gene for the NaH-antiporter of E. hirae. NapA exhibits properties different from those of the two E. coli NaH-antiporters encoded by nhaA and nhaB, yet functionally complements a defect in these genes.	UNIV BERN,DEPT CLIN PHARMACOL,MURTENSTR 35,CH-3010 BERN,SWITZERLAND	University of Bern			Solioz, Marc/I-3162-2013	Solioz, Marc/0000-0002-7989-6721				Ausubel FM., 1988, CURRENT PROTOCOLS MO; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREY RN, 1980, J BIOL CHEM, V255, P39; DEGUCHI Y, 1990, J BIOL CHEM, V265, P21704; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; HILDEBRANDT F, 1991, BIOCHIM BIOPHYS ACTA, V1129, P105, DOI 10.1016/0167-4781(91)90221-7; IVEY DM, 1991, J BIOL CHEM, V266, P23483; JIA ZP, 1992, EMBO J, V11, P1631, DOI 10.1002/j.1460-2075.1992.tb05209.x; KAKINUMA Y, 1990, FEBS LETT, V261, P135, DOI 10.1016/0014-5793(90)80654-2; KAKINUMA Y, 1990, J BACTERIOL, V172, P1732, DOI 10.1128/jb.172.4.1732-1735.1990; KAKINUMA Y, 1989, J BIOENERG BIOMEMBR, V21, P679, DOI 10.1007/BF00762686; KAKINUMA Y, 1987, J BACTERIOL, V169, P3886, DOI 10.1128/jb.169.9.3886-3890.1987; KARPEL R, 1988, J BIOL CHEM, V263, P10408; KINOSHITA N, 1984, J BACTERIOL, V158, P844, DOI 10.1128/JB.158.3.844-848.1984; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; PADAN E, 1989, J BIOL CHEM, V264, P20297; PINNER E, 1992, J BIOL CHEM, V267, P11064; PINNER E, 1993, J BIOL CHEM, V268, P1729; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAKASE K, 1993, J BIOL CHEM, V268, P11610; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; TSE CM, 1992, J BIOL CHEM, V267, P9340; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; WASER M, 1992, J BIOL CHEM, V267, P5396; [No title captured]	28	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26334	26337						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253756				2022-12-25	WOS:A1993MK42500050
J	BURNS, EL; PRICE, EM				BURNS, EL; PRICE, EM			RANDOM MUTAGENESIS OF THE SHEEP NA,K-ATPASE-ALPHA-1 SUBUNIT GENERATES A NOVEL T797N MUTATION THAT RESULTS IN A OUABAIN-RESISTANT ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ALPHA-SUBUNIT; PRIMARY SEQUENCE; BETA-SUBUNIT; BINDING; DNA	Site-directed mutagenesis of the Na,K-ATPase has provided a rational approach to identify several amino acids that appear to be involved in ouabain sensitivity. In order to identify additional amino acids that play a role in ouabain binding, we used formic acid to randomly mutagenize a cDNA cassette encoding amino acids 691-946 of the sheep Na,K-ATPase alpha subunit. This was then used to replace the wild type cDNA cassette in the full-length cDNA, and pools of mutants were electroporated into HeLa cells. Ouabain-resistant cells were selected in 0.5 muM ouabain, and the polymerase chain reaction was used to amplify the region corresponding to the mutagenized cassette from the genomic DNA of the resistant cells. Sequence analysis of the polymerase chain reaction product revealed a single amino acid substitution, T797N. Site-directed mutagenesis was used to reproduce this change in the wild type sheep alpha subunit, and this construct was able to confer resistance to HeLa cells, verifying the role of the mutation in ouabain resistance. The mutant sheep enzyme was found to be as resistant to ouabain as is the rat Na,K-ATPase. These data suggest that T797N, predicted to be in the fifth putative transmembrane domain, is involved in the interaction between ouabain and the Na,K-ATPase.	UNIV N CAROLINA, DEPT PHARMACOL, CB7365, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046469] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL46469] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNAIZ GRD, 1992, MOL NEUROBIOL, V6, P359, DOI 10.1007/BF02757941; ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; Higuchi R, 1989, PCR TECHNOLOGY PRINC, P31; JAISSER F, 1992, J BIOL CHEM, V267, P16895; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; MEFORD RM, 1991, J BIOL CHEM, V266, P18308; OBRIEN WJ, 1993, J BIOL CHEM, V268, P7707; PRICE EM, 1989, J BIOL CHEM, V264, P21902; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PRICE EM, 1990, J BIOL CHEM, V265, P6638; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTHEIS PJ, 1993, BIOCHEMISTRY-US, V32, P544, DOI 10.1021/bi00053a020; SCHWARTZ A, 1969, J PHARMACOL EXP THER, V168, P31; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; VERREY F, 1989, AM J PHYSIOL, V256, pF1034, DOI 10.1152/ajprenal.1989.256.6.F1034; ZHAO X, 1993, FASEB J, V7, pA1	20	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25632	25635						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244998				2022-12-25	WOS:A1993MK10000052
J	HUANG, LY; THOLANIKUNNEL, BG; VAKALOPOULOU, E; MALBON, CC				HUANG, LY; THOLANIKUNNEL, BG; VAKALOPOULOU, E; MALBON, CC			THE M(R) 35,000 BETA-ADRENERGIC-RECEPTOR MESSENGER RNA-BINDING PROTEIN-INDUCED BY AGONISTS REQUIRES BOTH AN AUUUA PENTAMER AND U-RICH DOMAINS FOR RNA RECOGNITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; 3' UNTRANSLATED REGION; CELL-FREE SYSTEM; STABILITY INVITRO; BETA-2-ADRENERGIC RECEPTORS; GM-CSF; TURNOVER; GENE; SPECIFICITIES; DEGRADATION	Delineating the molecular basis for agonist-induced destabilization of mRNA of G-protein-linked receptors that contributes to receptor down-regulation is fundamental to our understanding of long-term regulation of receptors by agonist. Previously we identified a prominent, M(r) 35,000 cytosolic RNA-binding protein that (i) binds selectively to beta1- and beta2-adrenergic receptor mRNAs, both of which undergo agonist-induced down-regulation; (ii) does not bind either to alpha1b-adrenergic receptor mRNA, which does not undergo agonist-induced down-regulation, or to beta-globin mRNA; (iii) displays binding to beta2-adrenergic receptor mRNA that is selectively competed by poly(U) RNA, but not poly(A), -(C), or -(G) RNA; and (iv) its abundance varies inversely with the level of receptor mRNA, being induced by agonists that down-regulate receptor mRNA (Port, J. D., Huang, L.-y., and Malbon (1992) J. Biol. Chem. 267,24103-24108). We demonstrate here that the binding of beta-adrenergic receptor mRNA by this protein, termed beta-ARB protein, is sensitive to competition by AU-rich domains of the 3'-untranslated regions of c-fos, c-myc, and human granulocyte-macrophage colony-stimulating factor. Using the AU-rich 3'-untranslated regions of wild-type adenovirus IVa2 mRNA and variants with defined mutations in the AUUUA pentamer, AU-rich, and U-rich domains, we were able to define sequences critical to the binding of the beta2-receptor mRNA by the beta-ARB protein. Recognition of beta-ARB protein requires not only an AUUUA destabilization pentamer, but also a flanking U-rich domain(s). Using radiolabeled 3'-untranslated regions of short-lived mRNA, we were able to identify this same M(r) 35,000 cytosolic RNA-binding protein(s), beta-ARB protein, as selective for beta2-adrenergic receptor mRNA.	SUNY STONY BROOK, HLTH SCI CTR, SCH MED, DEPT PHARMACOL, DMDRP, STONY BROOK, NY 11794 USA; SCHERING AG, INST BIOCHEM, W-1000 BERLIN, GERMANY	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Schering AG			malbon, craig/ABF-3604-2020		NIDDK NIH HHS [DK30111, DK25410] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025410, R01DK030111] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CLEVELAND DW, 1988, TRENDS BIOCHEM SCI, V13, P339, DOI 10.1016/0968-0004(88)90103-X; COLLINS S, 1988, J BIOL CHEM, V263, P9067; COLLINS S, 1991, ANNU REV PHYSIOL, V53, P497, DOI 10.1146/annurev.physiol.53.1.497; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HADCOCK JR, 1989, J BIOL CHEM, V264, P13956; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HADCOCK JR, 1991, TRENDS NEUROSCI, V14, P242, DOI 10.1016/0166-2236(91)90124-D; HADCOCK JR, 1993, J NEUROCHEM, V60, P1, DOI 10.1111/j.1471-4159.1993.tb05816.x; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORRIS GM, 1991, J BIOL CHEM, V266, P2233; PEI R, 1988, MOL CELL BIOL, V8, P2860, DOI 10.1128/MCB.8.7.2860; PELTZ SW, 1991, CRIT REV EUKAR GENE, V1, P99; PORT JD, 1992, J BIOL CHEM, V267, P24103; RAGHOW R, 1987, TRENDS BIOCHEM SCI, V12, P358, DOI 10.1016/0968-0004(87)90165-4; ROSS J, 1988, MOL BIOL MED, V5, P1; SCARPACE PJ, 1985, MOL PHARMACOL, V28, P495; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIMOMURA H, 1990, NUCLEIC ACIDS RES, V18, P4591, DOI 10.1093/nar/18.15.4591; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; STEITZ JA, 1982, COLD SPRING HARB SYM, V47, P893, DOI 10.1101/SQB.1983.047.01.103; STOLLE CA, 1988, GENE, V62, P65, DOI 10.1016/0378-1119(88)90580-X; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WILUSZ J, 1990, MOL CELL BIOL, V10, P6397, DOI 10.1128/MCB.10.12.6397; WILUSZ J, 1988, CELL, V52, P221, DOI 10.1016/0092-8674(88)90510-7; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WRESCHNER DH, 1988, EUR J BIOCHEM, V172, P333, DOI 10.1111/j.1432-1033.1988.tb13891.x	43	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25769	25775						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245013				2022-12-25	WOS:A1993MK10000072
J	SHORT, AD; KLEIN, MG; SCHNEIDER, MF; GILL, DL				SHORT, AD; KLEIN, MG; SCHNEIDER, MF; GILL, DL			INOSITOL 1,4,5-TRISPHOSPHATE-MEDIATED QUANTAL CA2+ RELEASE MEASURED BY HIGH-RESOLUTION IMAGING OF CA2+ WITHIN ORGANELLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CELL-LINE; ENDOPLASMIC-RETICULUM; CALCIUM RELEASE; INTRACELLULAR CALCIUM; REGULATORY MECHANISM; GUANINE-NUCLEOTIDES; CA-2+ RELEASE; GTP; THAPSIGARGIN; RECEPTOR	The distribution and operation of Ca2+ pools within cells has been directly studied in situ by monitoring the Ca2+ inside Ca2+ dye-loaded organelles using high resolution imaging procedures. Using DDT1MF-2 smooth muscle cells, loaded with fura-2 under conditions favoring dye entry into organelles and subjected to carefully controlled permeabilization still attached to coverslips, the Ca2+ within organelles was analyzed by high resolution, z axis-controlled imaging, and deblurring methods. Saturation analysis of entrapped fura-2 indicated that the dye reported Ca2+ identically to fura-2 in solution. Areas containing high Ca2+-sequestering organelles (>5 muM free Ca2+) were observed to predominate around the nucleus and close to the periphery of the cell. Analysis of the actions of inositol 1,4,5-trisphosphate (InsP3) within small (3 mum2) selected intracellular areas, revealed a ''quantal' release phenomenon, with rapid attainment of limited stable release at submaximal InsPs levels. The apparent EC50 for InsP3 Was approximately 3 muM, higher than within suspensions of permeabilized cells. The action of InsP3 was competitively blocked by 10 mug/ml of the InsP3 antagonist, heparin. Applied after maximal InsP3-mediated Ca2+ release, heparin reversed InsP3-induced Ca2+ release resulting in reuptake of Ca2+ into Ca2+-pumping organelles with identical spatial distribution as before Ca2+ release. InsP3 released Ca2+ from all areas of high Ca2+-pumping organelles; extensive areas of high fura-2-loading, but low intraorganelle Ca2+, were unchanged by InsP3. GTP induced no alteration in Ca2+ release (in contrast to suspensions of permeabilized cells), suggesting that the InsP3-sensitive Ca2+ pool was functioning as a single homogeneous pool. Opening of InsP3-sensitive channels was also monitored by assessing InsP3-activated channel-mediated Mn2+ quenching of organelle-loaded fura-2; the results revealed a similar pattern of quantal release, with slightly increased apparent InsP3 sensitivity. The results provide the first high resolution in situ localization of Ca2+ signaling organelles and demonstrate the quantal operation of InsP3-sensitive Ca2+ pools within highly discrete subcellular loci.	UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,108 N GREENE ST,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore					NINDS NIH HHS [NS19304] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019304] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAKSH S, 1991, J BIOL CHEM, V266, P21458; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIAN JH, 1991, J BIOL CHEM, V266, P8801; CHUEH SH, 1987, J BIOL CHEM, V262, P13857; CHUEH SH, 1986, J BIOL CHEM, V261, P13883; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GILL DL, 1985, J BIOL CHEM, V260, P9289; GILL DL, 1986, NATURE, V320, P461, DOI 10.1038/320461a0; Gill Donald L., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P265; GLENNON MC, 1992, J BIOL CHEM, V267, P8230; GLENNON MC, 1992, J BIOL CHEM, V267, P25568; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTER TE, 1988, AM J PHYSIOL, V255, pC304, DOI 10.1152/ajpcell.1988.255.3.C304; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KLEIN MG, 1988, BIOPHYS J, V53, P971, DOI 10.1016/S0006-3495(88)83178-3; KOCH GLE, 1990, BIOESSAYS, V12, P527, DOI 10.1002/bies.950121105; LODISH HF, 1992, J BIOL CHEM, V267, P12753; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MUALLEM S, 1989, J BIOL CHEM, V264, P205; MULLANEY JM, 1987, J BIOL CHEM, V262, P13865; MULLANEY JM, 1988, P NATL ACAD SCI USA, V85, P2499, DOI 10.1073/pnas.85.8.2499; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; OZAWA M, 1993, J BIOL CHEM, V268, P699; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P311; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; TSIEN R, 1989, CELL CALCIUM, V11, P93; UEDA T, 1986, J BIOL CHEM, V261, P3184; VOLPE P, 1988, P NATL ACAD SCI USA, V85, P1091, DOI 10.1073/pnas.85.4.1091; VOLPE P, 1991, FEBS LETT, V278, P274, DOI 10.1016/0014-5793(91)80134-O	40	85	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25887	25893						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245023				2022-12-25	WOS:A1993MK10000086
J	BASELGA, J; MAERZ, WJ; MOY, D; MILLER, WH; CASTRO, L; REUTER, VE; YAO, TJ; MASUI, H; DMITROVSKY, E				BASELGA, J; MAERZ, WJ; MOY, D; MILLER, WH; CASTRO, L; REUTER, VE; YAO, TJ; MASUI, H; DMITROVSKY, E			OVER-EXPRESSION OF TRANSFORMING GROWTH-FACTOR-ALPHA ANTAGONIZES THE ANTI-TUMORIGENIC BUT NOT THE DIFFERENTIATION ACTIONS OF RETINOIC ACID IN A HUMAN TERATOCARCINOMA CELL	ONCOGENE			English	Article							EMBRYONAL CARCINOMA-CELLS; RIBONUCLEIC-ACID; LINE TERA-2; RECEPTOR; INVITRO; CANCER; ANTIBODIES; INDUCTION; CLONING	All-trans retinoic acid (RA) treatment of the multipotent human teratocarcinoma (TC) cell line NTERA-2 clone D1 (abbreviated NT2/D1) induces a neuronal phenotype and other cell lineages. NT2/D1 cells basally express transforming growth factor alpha (TGF-alpha) mRNA and secreted protein. After RA-treatment TGF-alpha expression is markedly reduced. This decline in TGF-alpha expression accompanies the induction of the neuronal phenotype and a marked reduction of tumorigenicity in athymic mice. This suggested a causal link between reduced TGF-alpha expression and the induced differentiation or loss of tumorigenicity of these RA-treated TC cells. To evaluate this possibility, an RA-refractory NT2/D1 subclone was analysed. This subclone, designated NT2/D1-R1, failed to induce differentiation or to decrease TGF-alpha expression despite RA treatment. To further explore the relationship between TGF-alpha expression and RA actions in this human TC cell, a TGF-alpha cDNA was stably transfected and expressed in NT2/D1 cells. RA-treatment of independently obtained TGF-alpha over-expressing clones and a representative control transfectant only expressing the neomycin resistance gene produced a neuronal phenotype similar to parental NT2/D1 cells as assessed by morphologic, immunophenotypic, and gene expression markers of differentiation. RA-treatment of these clones also induced a G1 arrest similar to parental cells. However, only the TGF-alpha over-expressing clones that secreted high levels of TGF-alpha protein into the conditioned media before and after RA treatment still developed tumors in athymic mice despite prior exposure of these cells to RA. This finding demonstrates that TGF-alpha can inhibit the anti-tumorigenic effects of RA in human TCs. Thus, over-expression of a single growth factor that normally declines with RA treatment antagonizes the antitumorigenic but not the differentiation actions of RA in this human tumor cell.	CORNELL UNIV,MED CTR,MEM SLOAN KETTERING CANC CTR,DEPT MED,DIV SOLID TUMOR ONCOL,MOLEC MED LAB,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,MEM SLOAN KETTERING CANC CTR,DEPT MED,DIV SOLID TUMOR ONCOL,RECEPT BIOL LAB,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,MEM SLOAN KETTERING CANC CTR,DEPT BIOSTAT,NEW YORK,NY 10021	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [1R01-CA54494-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1986, DIFFERENTIATION, V31, P119, DOI 10.1111/j.1432-0436.1986.tb00392.x; ANDREWS PW, 1984, LAB INVEST, V50, P147; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BRAND N, 1988, NATURE, V332, P851; BROOKES S, 1989, ONCOGENE, V4, P429; CARLIN CR, 1985, EXP CELL RES, V159, P17, DOI 10.1016/S0014-4827(85)80033-1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DAVIS LG, 1986, BASIC METHODS MOL BI, P286; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DIPPOLD WG, 1980, P NATL ACAD SCI-BIOL, V77, P6114, DOI 10.1073/pnas.77.10.6114; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; ENGSTROM W, 1985, J CELL SCI, V73, P361; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; FOGH J, 1978, NUDE MOUSE EXPT CLIN, P215; GILL GN, 1984, J BIOL CHEM, V259, P7755; GROUCH GD, 1991, CANCER RES, V51, P4882; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; KURIE JM, IN PRESS DIFFERENTIA; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MIETTINEN OS, 1985, THEORETICAL EPIDEMIO, P135; MILLER WH, 1990, ONCOGENE, V5, P511; MILLER WH, 1993, IN PRESS DIFFERENTIA; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SCHOFIELD PN, 1987, J CELL SCI, V88, P57; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WEIMA SM, 1989, DIFFERENTIATION, V41, P245, DOI 10.1111/j.1432-0436.1989.tb00753.x; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V155, P1324, DOI 10.1016/S0006-291X(88)81286-5; ZELEN M, 1971, BIOMETRIKA, V58, P129, DOI 10.1093/biomet/58.1.129	34	18	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3257	3263						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247529				2022-12-25	WOS:A1993MG78200008
J	QUINLAN, MP				QUINLAN, MP			E1A 12S IN THE ABSENCE OF E1B OR OTHER COOPERATING ONCOGENES ENABLES CELLS TO OVERCOME APOPTOSIS	ONCOGENE			English	Article							RAT VENTRAL PROSTATE; PRIMARY EPITHELIAL-CELLS; TUMOR-NECROSIS-FACTOR; GROWTH FACTOR-BETA; ADENOVIRUS TYPE-5; C-MYC; E1A-12S PROTEIN; TERMINAL REGION; GENE-PRODUCTS; DNA FRAGMENTS	Neonatal rat kidneys are still undergoing growth and differentiation. Within 24 h after placing these cells in culture, programmed cell death has been activated. This is evidence by intranucleosomal DNA digestion. Cellular DNA synthesis and proliferation cease between 48 and 72 h after plating and the epithelial cells begin to die. The adenovirus E1A 12S gene, in the presence or absence of the E1B gene products, restarts the proliferation program of these cells, retaining their differentiated states. 12S can accomplish this in the presence and absence of serum. Expression of the E1A 13S gene results in cellular DNA degradation due to necrosis, but not apoptosis, brought on by the expression of the 13S-dependent viral genes. Those cells that retain the 12S sequences escape apoptosis and proceed to become immortal. In addition, 12S enables Madin Darby canine kidney (MDCK) epithelial cells to overcome TGF-beta 1 induced inhibition of proliferation and apoptosis. Thus, E1A 12S may be an anti-apoptotic gene.			QUINLAN, MP (corresponding author), UNIV TENNESSEE, DEPT MICROBIOL & IMMUNOL, 858 MADISON AVE, MEMPHIS, TN 38163 USA.				NCI NIH HHS [CA50540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI GR, 1990, J VIROL, V64, P3427, DOI 10.1128/JVI.64.7.3427-3436.1990; BELLETT AJD, 1985, MOL CELL BIOL, V5, P1933, DOI 10.1128/MCB.5.8.1933; BERK AJ, 1986, CANCER SURV, V5, P367; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BRENNER BM, 1990, J AM SOC NEPHROL, V1, P127; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; COLOMBEL M, 1992, CANCER RES, V52, P4313; Cope FO., 1991, APOPTOSIS MOL BASIS, P47; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GAYNOR RB, 1983, CELL, V33, P683, DOI 10.1016/0092-8674(83)90011-9; GERSCHENSON LE, 1992, FASEB J, V6, P2450, DOI 10.1096/fasebj.6.7.1563596; GRAHAM FL, 1974, COLD SPRING HARB SYM, V39, P637, DOI 10.1101/SQB.1974.039.01.077; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; Kerr J. F., 1991, APOPTOSIS MOL BASIS, V3, P5; KERR JFR, 1965, J PATHOL BACTERIOL, V90, P419, DOI 10.1002/path.1700900210; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; KYPRIANOU N, 1988, ENDOCRINOLOGY, V122, P552, DOI 10.1210/endo-122-2-552; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; LASTER SM, 1988, J IMMUNOL, V141, P2629; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; NEVINS JR, 1981, CELL, V26, P213, DOI 10.1016/0092-8674(81)90304-4; QUARMBY VE, 1987, MOL ENDOCRINOL, V1, P865, DOI 10.1210/mend-1-12-865; QUINLAN MP, 1989, ONCOGENE, V4, P1051; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; QUINLAN MP, 1992, J VIROL, V66, P2020, DOI 10.1128/JVI.66.4.2020-2030.1992; QUINLAN MP, 1987, P NATL ACAD SCI USA, V84, P3283, DOI 10.1073/pnas.84.10.3283; QUINLAN MP, 1993, ONCOGENE, V8, P257; QUINLAN MP, 1986, CANCER CELL, V4, P327; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROTELLO R J, 1990, Journal of Cell Biology, V111, p477A; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SEARLE J, 1982, PATHOL ANNU, V17, P229; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; SHENK T, 1991, ADV CANCER RES, V57, P47; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPINDLER KR, 1985, J VIROL, V53, P742, DOI 10.1128/JVI.53.3.742-750.1985; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; SUBRAMANIAN T, 1991, ONCOGENE, V6, P1171; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; TAUB M, 1984, METHODS SERUM FREE C, P3; TELLING GC, 1993, J VIROL, V67, P1600, DOI 10.1128/JVI.67.3.1600-1611.1993; TOMEI LD, 1988, BIOCHEM BIOPH RES CO, V155, P324, DOI 10.1016/S0006-291X(88)81088-X; Tomei LD, 1991, APOPTOSIS MOL BASIS, P279; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VANDENELSEN P, 1983, VIROLOGY, V131, P242, DOI 10.1016/0042-6822(83)90549-4; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WILLIAMS G T, 1992, Trends in Cell Biology, V2, P263, DOI 10.1016/0962-8924(92)90198-V; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Wyllie A.H., 1981, CELL DEATH BIOL PATH, P9; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	59	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3289	3296						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247531				2022-12-25	WOS:A1993MG78200012
J	MERLO, GR; VENESIO, T; TAVERNA, D; MARTE, BM; CALLAHAN, R; HYNES, NE				MERLO, GR; VENESIO, T; TAVERNA, D; MARTE, BM; CALLAHAN, R; HYNES, NE			GROWTH SUPPRESSION OF NORMAL MAMMARY EPITHELIAL-CELLS BY WILD-TYPE P53	ONCOGENE			English	Article							HUMAN BREAST-CANCER; CELLULAR TUMOR-ANTIGEN; BETA-CASEIN GENE; MUTANT P53; EMBRYO FIBROBLASTS; SV40 DNA; MUTATIONS; PROTEIN; TRANSFORMATION; EXPRESSION	p53 mutations are frequent in human breast cancer. In order to understand the role of p53 in the context of the accumulation of mutations in breast cancer, a model of non transformed mammary cells was sought. The HC11 cells are immortalized, non transformed rodent mammary epithelial cells which synthesize milk proteins following stimulation with lactogenic hormones. p53 protein was readily detected in HC11 protein extracts with the PAb421 antibody. Two mutations were identified in the p53 cDNA from HC11 cells: a missense mutation at codon 138, substituting Trp for Cys, and a microdeletion, codon 123 to 130, of exon 5. The latter results from an intronic mutation of the splice acceptor site at the intron 4/exon 5 junction. The mutations affect separate p53 alleles, and no wt allele was found. Wt p53 was introduced into HC11 cells by means of a retroviral vector, under the control of a Cd++-inducible promoter. In the presence of CdSO4 a dramatic growth inhibition was observed. A temperature-sensitive mutant p53 gene was also transfected into HC11 cells. This resulted in a marked inhibition of cells growth at 32 degrees C, when the p53 is in the wt conformation, while no effect was observed at 37 degrees C, when the mutant conformation is predominant. wt p53-mediated inhibition of monolayer growth does not involve induction of programmed cell death and does not activate de novo synthesis of differentiation-specific milk proteins. We conclude that mutations in the p53 gene likely played a role in their immortalization. The HC11 cells provide a model for assessing the cooperative action of other mutations in mammary tumorigenesis.	USL 1,S GIOVANNI HOSP,I-10123 TURIN,ITALY; NCI,ONCOGENET SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	MERLO, GR (corresponding author), FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND.		; taverna, daniela/J-8358-2016	Venesio, Tiziana/0000-0002-9035-056X; taverna, daniela/0000-0002-6365-527X				ANDERSEN RD, 1987, MOL CELL BIOL, V7, P3574, DOI 10.1128/MCB.7.10.3574; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BARTEK J, 1990, INT J CANCER, V45, P1105, DOI 10.1002/ijc.2910450620; BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; CALLAHAN R, 1992, CANCER, V69, P1582, DOI 10.1002/1097-0142(19920315)69:6+<1582::AID-CNCR2820691313>3.0.CO;2-Y; CASEY G, 1991, ONCOGENE, V6, P1791; CEPKO CL, 1992, CURRENT PROTOCOLS MO; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG J, 1992, CANCER RES, V52, P222; CZOSNEK HH, 1984, MOL CELL BIOL, V4, P1638, DOI 10.1128/MCB.4.8.1638; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; DAVIDOFF AM, 1991, CANCER RES, V51, P2605; DEVILEE P, 1990, CYTOGENET CELL GENET, V53, P52, DOI 10.1159/000132893; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GARCIA I, 1991, CANCER RES, V51, P294; GONOS ES, 1992, INT J ONCOL, V1, P209; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HAPP B, 1993, CELL GROWTH DIFFER, V4, P9; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; ISOLA J, 1992, J NATL CANCER I, V84, P1109, DOI 10.1093/jnci/84.14.1109; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATOZAKI T, 1992, CANCER RES, V52, P4335; MAZARS R, 1992, CANCER RES, V52, P3918; MCGEADY ML, 1989, ONCOGENE, V4, P1375; MEDINA D, 1993, CARCINOGENESIS, V14, P25, DOI 10.1093/carcin/14.1.25; MERLO GR, 1993, INT J CANCER, V54, P531, DOI 10.1002/ijc.2910540402; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; MONTENARH M, 1992, ONCOGENE, V7, P1673; OSBORNE RJ, 1991, CANCER RES, V51, P6194; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; REDMOND SMS, 1988, ONCOGENE, V2, P259; ROVINSKI B, 1988, ONCOGENE, V2, P445; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SATO T, 1990, CANCER RES, V50, P7184; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; TAYLOR WR, 1992, ONCOGENE, V7, P1383; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VARLEY JM, 1991, ONCOGENE, V6, P413; VENESIO T, 1992, CELL GROWTH DIFFER, V3, P63; VOJTESEK B, 1993, J CELL SCI, V105, P607; WANG NP, 1993, ONCOGENE, V8, P279; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WOODWORTH CD, 1993, CELL GROWTH DIFFER, V4, P367	65	47	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					443	453						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290256				2022-12-25	WOS:A1994MW24800011
J	ROUSSELOT, P; HARDAS, B; PATEL, A; GUIDEZ, F; GAKEN, J; CASTAIGNE, S; DEJEAN, A; DETHE, H; DEGOS, L; FARZANEH, F; CHOMIENNE, C				ROUSSELOT, P; HARDAS, B; PATEL, A; GUIDEZ, F; GAKEN, J; CASTAIGNE, S; DEJEAN, A; DETHE, H; DEGOS, L; FARZANEH, F; CHOMIENNE, C			THE PML-RAR-ALPHA GENE-PRODUCT OF THE T(1517) TRANSLOCATION INHIBITS RETINOIC ACID-INDUCED GRANULOCYTIC DIFFERENTIATION AND MEDIATED TRANSACTIVATION IN HUMAN MYELOID CELLS	ONCOGENE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; RECEPTOR-ALPHA; MAMMALIAN-CELLS; T(15-17) TRANSLOCATION; RESPONSIVE ELEMENT; EXPRESSION; PROTEINS; THERAPY; INVITRO; BINDING	Acute promyelocytic leukemia (APL) is characterized by an arrest of granulocytic differentiation and a reciprocal t(15;17) translocation fusing the PML gene to the retinoic acid receptor alpha (RAR alpha) gene. PML was recently identified as a potential transcription factor. In non hematopoietic cells, the transfected PML-RAR alpha product binds all trans retinoic acid and exhibits altered transactivating properties when compared with RAR alpha. A major question raised by these observations is whether PML-RAR alpha contributes to the inhibition of myeloid differentiation. We find that in myeloid cell lines responsive to retinoic acid, PML-RAR alpha blocks retinoic acid mediated transactivation and totally abrogates the retinoic acid mediated granulocytic differentiation. These findings strongly suggest that PML-RAR alpha may, by blocking normal retinoic acid dependent myeloid differentiation, participate in the leukemogenesis of APL. The fact that high doses of all-trans retinoic acid relieve the inhibitory effect of PML-RAR alpha corroborates the therapeutic effect of all-trans retinoic acid in APL patients.	KINGS COLL,SCH MED & DENT,MOLEC MED UNIT,LONDON,ENGLAND; INST PASTEUR,INSERM,U163,PARIS,FRANCE; HOP ST LOUIS,SERV CLIN MALAD SANG,PARIS,FRANCE; INST HEMATOL,UPR 43,PARIS,FRANCE; LAB BIOL CELLULAIRE HEMATOPOIET,PARIS,FRANCE	University of London; King's College London; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite			Guidez, Fabien/P-4220-2019; Dejean, Anne/L-5145-2018; Guidez, Fabien/B-3750-2009; Farzaneh, Farzin/B-4902-2009	Guidez, Fabien/0000-0003-1380-4473; Farzaneh, Farzin/0000-0002-9275-2415				ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BREITMAN TR, 1981, BLOOD, V57, P1000; BREITMAN TR, 1983, CANCER SURV, V2, P265; CASTAIGNE S, 1990, BLOOD, V76, P1704; CASTAIGNE S, 1992, BLOOD, V79, P3110; CHEN Z, 1993, EMBO J, V12, P111; CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHOMIENNE C, 1990, LEUKEMIA, V4, P802; CHOMIENNE C, 1989, LANCET, V1, P746; CHYTIL F, 1987, ANNU REV NUTR, V7, P321, DOI 10.1146/annurev.nu.07.070187.001541; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DEGOS L, 1990, LANCET, V11, P1140; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DOUER D, 1982, EXP CELL RES, V138, P193, DOI 10.1016/0014-4827(82)90105-7; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRATAS C, 1993, LEUKEMIA, V7, P1156; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; ITANI T, 1987, GENE, V56, P267; JONES ME, 1978, AM J MED, V75, P673; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LEFEBVRE P, 1991, LEUKEMIA, V5, P1054; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; NERVI C, 1992, CANCER RES, V52, P3687; NGUYEN VT, 1988, ANAL BIOCHEM, V171, P404, DOI 10.1016/0003-2697(88)90505-2; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; SAKASHITA A, 1993, BLOOD, V81, P1009; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	44	125	127	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					545	551						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290265				2022-12-25	WOS:A1994MW24800022
J	TAKADA, S; KIDO, H; FUKUTOMI, A; MORI, T; KOIKE, K				TAKADA, S; KIDO, H; FUKUTOMI, A; MORI, T; KOIKE, K			INTERACTION OF HEPATITIS-B VIRUS-X PROTEIN WITH A SERINE-PROTEASE, TRYPTASE TL(2) AS AN INHIBITOR	ONCOGENE			English	Article							EUKARYOTIC TRANSCRIPTIONAL ACTIVATORS; ERYTHROID-POTENTIATING ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS; PROMOTER TRANS-ACTIVATION; LONG TERMINAL REPEAT; RAT MAST-CELLS; NUCLEOTIDE-SEQUENCE; GENE-PRODUCT; TRANSACTIVATION FUNCTION; HUMAN LYMPHOCYTES-T4+	X protein of hepatitis B virus (HBV) transactivates transcription of various viral and cellular genes. It has been suggested that X protein plays a major role in hepatocarcinogenesis by HBV. The protein possesses amino acid sequence homology to the functionally essential domain of Kunitz-type serine protease inhibitors. This Kunitz domain-like sequence in X protein is indispensable for the transactivation function. To clarify whether X protein has a serine protease inhibitor activity, a search was made for serine proteases which interact with, but not degrade X protein. Tryptase TL,, one of serine proteases in hepatic cells, was found to directly interact with X protein without degradation. Moreover, the activities of tryptase TL, and an analogous protease were substantially inhibited by X protein. These results suggest that transactivation function of X protein is exerted by modulation of the hepatic serine protease activity, giving rise to quantitative or qualitative change of cellular transcription factor(s) through protection from proteolytic degradation and/or suppression of processing.	JFCR,INST CANC,DEPT GENE RES,TOSHIMA KU,TOKYO,TOKYO 170,JAPAN; UNIV TOKUSHIMA,INST ENZYME RES,DIV ENZYME CHEM,TOKUSHIMA 770,JAPAN	Japanese Foundation for Cancer Research; Tokushima University								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANDERSON S, 1983, P NATL ACAD SCI-BIOL, V80, P6838, DOI 10.1073/pnas.80.22.6838; ARII M, 1992, ONCOGENE, V7, P397; AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; BERAUD C, 1991, EMBO J, V10, P3795, DOI 10.1002/j.1460-2075.1991.tb04949.x; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; EDWARDS DR, 1986, NUCLEIC ACIDS RES, V14, P8863, DOI 10.1093/nar/14.22.8863; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GILMAN M, 1993, NATURE, V361, P687, DOI 10.1038/361687a0; HU KQ, 1990, P NATL ACAD SCI USA, V87, P7140, DOI 10.1073/pnas.87.18.7140; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KATO I, 1979, FED PROC, V38, P832; KATUNUMA N, 1975, EUR J BIOCHEM, V52, P37, DOI 10.1111/j.1432-1033.1975.tb03970.x; KIDO H, 1990, J BIOL CHEM, V265, P21979; KIDO H, 1991, FEBS LETT, V286, P233, DOI 10.1016/0014-5793(91)80981-8; KIDO H, 1988, J BIOL CHEM, V263, P18104; KIDO H, 1985, ARCH BIOCHEM BIOPHYS, V239, P436, DOI 10.1016/0003-9861(85)90709-X; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KOBAYASHI M, 1984, GENE, V30, P227; KODAMA K, 1985, J VIROL, V56, P978, DOI 10.1128/JVI.56.3.978-986.1985; KOIKE K, 1989, MOL BIOL MED, V6, P151; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LIVINGSTON DM, 1987, MOL BIOL MED, V4, P63; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MAHE Y, 1991, J BIOL CHEM, V266, P13759; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MCKEEHAN WL, 1986, J BIOL CHEM, V261, P5378; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; OKAMOTO H, 1986, J GEN VIROL, V67, P2305, DOI 10.1099/0022-1317-67-11-2305; ONO Y, 1983, NUCLEIC ACIDS RES, V11, P1747, DOI 10.1093/nar/11.6.1747; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PATARCA R, 1985, NATURE, V318, P390, DOI 10.1038/318390a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; SASSONECORSI P, 1987, P NATL ACAD SCI USA, V84, P6430, DOI 10.1073/pnas.84.18.6430; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; TAKADA S, 1990, JPN J CANCER RES, V81, P1191, DOI 10.1111/j.1349-7006.1990.tb02675.x; TANAKA K, 1992, NEW BIOL, V4, P173; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TWU JS, 1989, J VIROL, V63, P2857, DOI 10.1128/JVI.63.6.2857-2860.1989; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZAHM P, 1988, ONCOGENE, V3, P169	54	57	59	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					341	348						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290248				2022-12-25	WOS:A1994MW24800001
J	FRAPPIER, L; GOLDSMITH, K; BENDELL, L				FRAPPIER, L; GOLDSMITH, K; BENDELL, L			STABILIZATION OF THE EBNA1-PROTEIN ON THE EPSTEIN-BARR-VIRUS LATENT ORIGIN OF DNA-REPLICATION BY A DNA LOOPING MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR ANTIGEN EBNA-1; PLASMID REPLICATION; INITIATOR PROTEIN; ENHANCER; BINDING; CELLS; SITES; ORIP; FORM	DNA replication from the Epstein-Barr virus latent origin of replication, oriP, is activated by Epstein-Barr nuclear antigen 1 (EBNA1). This activation involves the binding of EBNA1 dimers to multiple sites present in the two noncontiguous functional elements of oriP, the dyad symmetry element (DS) from which replication initiates, and the family of repeats (FR) enhancer element. EBNA1 complexes formed on the FR and DS elements of oriP interact by a DNA looping mechanism. This interaction requires EBNA1 sequences in addition to those required for DNA binding and dimerization. To map the EBNA1 sequences required for the efficient interaction of FR- and DS-bound EBNA1 complexes, we have overproduced in Escherichia coli and purified a series of EBNA1 N-terminal truncation mutants, all of which retain the DNA binding and dimerization domains. The results of electron microscopy and ligation-enhancement assays using these mutants indicated that EBNA1 sequences between amino acids 350 and 361 are required for the efficient interaction of FR- and DS-bound EBNA1 complexes. EBNA1-mediated FR-DS interactions were shown to stabilize EBNA1 binding to the DS element, while EBNA1-mediated DS-DS interactions did not. These results suggest that the stabilization of EBNA1 on the DS element, which occurs as a result of EBNA1-mediated oriP looping, may be important for the activation of DNA replication from the DS element.			FRAPPIER, L (corresponding author), MCMASTER UNIV,MOLEC VIROL & IMMUNOL PROGRAM,1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA.		Goldsmith, Kimberley/B-9107-2011	Goldsmith, Kimberley/0000-0002-0620-7868				ADAMS A, 1987, J VIROL, V61, P1743, DOI 10.1128/JVI.61.5.1743-1746.1987; AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; CHATTORAJ DK, 1988, CELL, V52, P551, DOI 10.1016/0092-8674(88)90468-0; FRAPPIER L, 1991, P NATL ACAD SCI USA, V88, P10875, DOI 10.1073/pnas.88.23.10875; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; GOLDSMITH K, 1993, J VIROL, V67, P3418, DOI 10.1128/JVI.67.6.3418-3426.1993; HEARING J, 1992, J VIROL, V66, P694, DOI 10.1128/JVI.66.2.694-705.1992; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; MIDDLETON T, 1992, J VIROL, V66, P489, DOI 10.1128/JVI.66.1.489-495.1992; MIRON A, 1992, EMBO J, V11, P1205, DOI 10.1002/j.1460-2075.1992.tb05161.x; MUKHERJEE S, 1988, CELL, V52, P375, DOI 10.1016/S0092-8674(88)80030-8; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SHAH WA, 1992, J VIROL, V66, P3355, DOI 10.1128/JVI.66.6.3355-3362.1992; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SU W, 1991, P NATL ACAD SCI USA, V88, P10870, DOI 10.1073/pnas.88.23.10870; TARTOF KD, 1987, FOCUS, V9, P12; WYSOKENSKI DA, 1989, J VIROL, V63, P2657, DOI 10.1128/JVI.63.6.2657-2666.1989; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YATES JL, 1991, J VIROL, V65, P483, DOI 10.1128/JVI.65.1.483-488.1991	22	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1057	1062						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288561				2022-12-25	WOS:A1994MR22000046
J	SANDSTROM, PA; TEBBEY, PW; VANCLEAVE, S; BUTTKE, TM				SANDSTROM, PA; TEBBEY, PW; VANCLEAVE, S; BUTTKE, TM			LIPID HYDROPEROXIDES INDUCE APOPTOSIS IN T-CELLS DISPLAYING A HIV-ASSOCIATED GLUTATHIONE-PEROXIDASE DEFICIENCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; ARACHIDONIC-ACID; FACTOR-ALPHA; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; ACTIVATION; INFECTION; INDIVIDUALS; METABOLITES	8E5 is a chronically human immunodeficiency virus (HIV)-infected human T cell line, which we have previously shown to be extremely susceptible to hydrogen peroxide (H2O2)-induced apoptosis due to a HIV-associated catalase deficiency. Here we report that HIV gene expression additionally renders 8E5 cells 10-fold more sensitive than either uninfected A3.01 cells or HIV-infected but nonexpressing 8E5L cells to killing by 15-hydroperoxyeicosatetraenoic acid (15-HPETE), as well as several other hydroperoxy fatty acids. Whereas the viability of A3.01 and 8E5L cells was relatively unaffected by exposure to 10 muM 15-HPETE, similarly treated 8E5 cells underwent apoptosis, as demonstrated by morphological changes and the presence of fragmented DNA. The unique susceptibility of 8E5 cells was attributable to their inability to convert 15-HPETE to 15-hydroxyeicosatetraenoic acid (15-HETE) owing to a marked reduction in glutathione peroxidase activity. Since oxidized lipids have been reported to accumulate in oxidatively stressed, HIV-infected individuals, a HIV-associated glutathione peroxidase deficiency may contribute to the depletion of CD4 T cells that occurs in the acquired immune deficiency syndrome (AIDS).	E CAROLINA UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,GREENVILLE,NC 27858	University of North Carolina; East Carolina University								BARUCHEL S, 1992, J LEUKOCYTE BIOL, V52, P111, DOI 10.1002/jlb.52.1.111; BUHL R, 1993, J IMMUNOL, V150, P1019; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; CHANG DJ, 1992, BIOCHEM BIOPH RES CO, V188, P538, DOI 10.1016/0006-291X(92)91089-9; CHAUDHRI G, 1986, J IMMUNOL, V137, P2646; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DROGE W, 1992, IMMUNOL TODAY, V13, P211, DOI 10.1016/0167-5699(92)90156-2; DWORKIN BM, 1988, BIOL TRACE ELEM RES, V15, P167, DOI 10.1007/BF02990135; FAUCI AS, 1991, ANN INTERN MED, V114, P678, DOI 10.7326/0003-4819-114-8-678; FLORES SC, 1993, P NATL ACAD SCI USA, V90, P7632, DOI 10.1073/pnas.90.16.7632; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; FOLKS T, 1985, P NATL ACAD SCI USA, V82, P4539, DOI 10.1073/pnas.82.13.4539; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; FUCHS J, 1991, MED HYPOTHESES, V36, P60, DOI 10.1016/0306-9877(91)90164-T; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; GOUGEON ML, 1991, CR ACAD SCI III-VIE, V312, P529; GRAFF G, 1990, ANAL BIOCHEM, V188, P38, DOI 10.1016/0003-2697(90)90525-E; GREENSPAN HC, 1993, MED HYPOTHESES, V40, P85, DOI 10.1016/0306-9877(93)90133-B; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; Gunzler WA, 1985, CRC HDB METHODS OXYG, P285; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HALLIWELL B, 1991, ARCH INTERN MED, V151, P29, DOI 10.1001/archinte.151.1.29; HALLIWELL B, 1984, BIOCHEM J, V210, P1; HARLAN JM, 1984, J CLIN INVEST, V73, P706, DOI 10.1172/JCI111263; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LEGRANDPOELS S, 1990, AIDS RES HUM RETROV, V6, P1389, DOI 10.1089/aid.1990.6.1389; LIN FB, 1992, CANCER RES, V52, P5282; MASUTANI H, 1992, AIDS RES HUM RETROV, V9, P1707; MATSUYAMA T, 1991, AIDS, V5, P1405, DOI 10.1097/00002030-199112000-00001; MATTHEWS N, 1987, IMMUNOLOGY, V62, P153; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; NATHAN CF, 1979, J EXP MED, V149, P100, DOI 10.1084/jem.149.1.100; OCHI H, 1992, ARCH BIOCHEM BIOPHYS, V294, P407, DOI 10.1016/0003-9861(92)90704-Z; REID T, 1991, J BIOL CHEM, V266, P16580; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; SANDSTROM PA, 1993, IN PRESS AIDS RES HU; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; STAAL FJT, 1992, AIDS RES HUM RETROV, V8, P305, DOI 10.1089/aid.1992.8.305; STAAL FJT, 1993, AIDS RES HUM RETROV, V9, P299, DOI 10.1089/aid.1993.9.299; SUFFYS P, 1987, BIOCHEM BIOPH RES CO, V149, P735, DOI 10.1016/0006-291X(87)90429-3; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; WAHL LM, 1989, P NATL ACAD SCI USA, V86, P621, DOI 10.1073/pnas.86.2.621; WONG GHW, 1991, P NATL ACAD SCI USA, V88, P4372, DOI 10.1073/pnas.88.10.4372; ZILLI D, 1992, BIOCHEM BIOPH RES CO, V188, P177, DOI 10.1016/0006-291X(92)92366-6	47	192	194	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					798	801						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288627				2022-12-25	WOS:A1994MR22000004
J	TAKAHASHI, S; WANG, JL; ROUSSEAU, DL; ISHIKAWA, K; YOSHIDA, T; HOST, JR; IKEDASAITO, M				TAKAHASHI, S; WANG, JL; ROUSSEAU, DL; ISHIKAWA, K; YOSHIDA, T; HOST, JR; IKEDASAITO, M			HEME-HEME OXYGENASE COMPLEX STRUCTURE OF THE CATALYTIC SITE AND ITS IMPLICATION FOR OXYGEN ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-TRYPTOPHAN 2,3-DIOXYGENASES; FERRIC APLYSIA MYOGLOBIN; CYTOCHROME-C PEROXIDASE; RAT-LIVER MICROSOMES; RESONANCE RAMAN; ELECTROMAGNETIC PROPERTIES; AXIAL COORDINATION; SPIN EQUILIBRIUM; IRON; PURIFICATION	Heme oxygenase, a central monooxygenase enzyme of the heme catabolism and the associated generation of carbon monoxide, forms a 1:1 stoichiometric complex with iron protoporphyrin IX, which is a prosthetic active center and at the same time the substrate of the enzyme. By using EPR, resonance Raman, and optical absorption spectroscopic techniques, we have determined the axial ligand coordination of the enzyme-heme complex. The ferric heme iron in the heme-enzyme complex at neutral pH is six-coordinate high spin, while at alkaline pH (pK(a) 7.6), the complex becomes low spin. Spectra of ferrous forms of the complex indicate that histidine serves as the iron proximal axial ligand and that the residue is in its neutral imidazole rather than its imidazolate protonation state. Thus, the active site of the heme-heme oxygenase complex has a myoglobin-like structure rather than an active site similar to the large cytochrome P-450 class of monooxygenases. As a consequence, the activated form of the heme-heme oxygenase complex, a peroxo intermediate, is different from that of the cytochrome P-450 monooxygenases, in which the activated form is an oxo intermediate. The overall catalytic mechanism is probably more closely related to that of other monooxygenases with myoglobin-like active sites, such as secondary amine monooxygenase.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA; AT&T BELL LABS, MURRAY HILL, NJ 07974 USA; YAMAGATA UNIV, SCH MED, DEPT BIOCHEM, YAMAGATA 99023, JAPAN	Case Western Reserve University; AT&T; Nokia Corporation; Nokia Bell Labs; Yamagata University			Ikeda-Saito, Masao/K-2703-2015; Ikeda-Saito, Masao/A-5992-2008		NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048714, R01GM039492] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05659] Funding Source: Medline; NIGMS NIH HHS [GM39492, GM48714] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTA JA, 1989, J BIOL CHEM, V264, P20467; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BROWN SB, 1976, BIOCHEM SOC T, V4, P197, DOI 10.1042/bst0040197; BRUNE B, 1987, MOL PHARMACOL, V32, P497; CHO KC, 1981, BIOCHIM BIOPHYS ACTA, V668, P186, DOI 10.1016/0005-2795(81)90162-8; DASGUPTA S, 1989, J BIOL CHEM, V264, P654; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; EGEBERG KD, 1990, BIOCHEMISTRY-US, V29, P9783, DOI 10.1021/bi00494a004; GIACOMETTI GM, 1981, J MOL BIOL, V146, P363, DOI 10.1016/0022-2836(81)90393-4; HORI H, 1981, J BIOL CHEM, V256, P7849; IIZUKA T, 1969, BIOCHIM BIOPHYS ACTA, V194, P351, DOI 10.1016/0005-2795(69)90096-8; IKEDASAITO M, 1985, J BIOL CHEM, V260, P1688; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; ISHIKAWA K, 1992, BIOCHEM BIOPH RES CO, V182, P981, DOI 10.1016/0006-291X(92)91828-E; JUNG C, 1991, BIOCHIM BIOPHYS ACTA, V1076, P130, DOI 10.1016/0167-4838(91)90229-S; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MAINES MD, 1986, J BIOL CHEM, V261, P411; MAKINO R, 1980, J BIOL CHEM, V255, P1883; MANTHEY JA, 1986, J BIOL CHEM, V261, P6734; MCCOUBREY WK, 1993, ARCH BIOCHEM BIOPHYS, V302, P402, DOI 10.1006/abbi.1993.1231; MCCOUBREY WK, 1992, ARCH BIOCHEM BIOPHYS, V295, P13, DOI 10.1016/0003-9861(92)90481-B; MIEYAL JJ, 1976, J BIOL CHEM, V251, P3436; MORIKIS D, 1990, J BIOL CHEM, V265, P12143; MULLER RM, 1987, J BIOL CHEM, V262, P6795; NAGAI K, 1983, BIOCHEMISTRY-US, V22, P1305, DOI 10.1021/bi00274a048; NOGUCHI M, 1983, J BIOCHEM, V93, P1027, DOI 10.1093/oxfordjournals.jbchem.a134226; OCARRA P, 1975, PORPHYRINS METALLOPO, P123; Ortiz de Montellano PR, 1986, CYTOCHROME P450 STRU, P217; POULOS TL, 1988, ADV INORG BIOCHEM, V7, P1; ROTENBERG MO, 1991, ARCH BIOCHEM BIOPHYS, V290, P336, DOI 10.1016/0003-9861(91)90549-X; ROUSSEAU DL, 1989, J BIOL CHEM, V264, P7878; SITTER AJ, 1988, J BIOL CHEM, V263, P13032; SPIRO TG, 1979, J AM CHEM SOC, V101, P2648, DOI 10.1021/ja00504a027; SUZUKI T, 1992, BIOCHEM INT, V28, P887; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; UCHIDA K, 1983, J BIOL CHEM, V258, P2519; VARADARAJAN R, 1989, BIOCHEMISTRY-US, V28, P3771, DOI 10.1021/bi00435a022; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WILKS A, 1993, J INORG BIOCHEM, V51, P269; YONETANI T, 1972, J BIOL CHEM, V247, P2447; YONETANI T, 1987, J BIOL CHEM, V262, P9547; YOSHIDA T, 1991, EUR J BIOCHEM, V199, P729, DOI 10.1111/j.1432-1033.1991.tb16177.x; YOSHIDA T, 1978, J BIOL CHEM, V253, P4230; YOSHIDA T, 1989, BIOCHEM BIOPH RES CO, V163, P1086, DOI 10.1016/0006-291X(89)92332-2; YOSHIDA T, 1978, J BIOL CHEM, V253, P4224; YOSHIDA T, 1979, J BIOL CHEM, V254, P4487; YOSHIDA T, 1982, J BIOL CHEM, V257, P9345; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7778	49	133	136	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1010	1014						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288555				2022-12-25	WOS:A1994MR22000038
J	FANDL, JP; TOBKES, NJ; MCDONALD, NQ; HENDRICKSON, WA; RYAN, TE; NIGAM, S; ACHESON, A; CUDNY, H; PANAYOTATOS, N				FANDL, JP; TOBKES, NJ; MCDONALD, NQ; HENDRICKSON, WA; RYAN, TE; NIGAM, S; ACHESON, A; CUDNY, H; PANAYOTATOS, N			CHARACTERIZATION AND CRYSTALLIZATION OF RECOMBINANT HUMAN NEUROTROPHIN-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; MOLECULAR-CLONING; ESCHERICHIA-COLI; FACTOR FAMILY; BRAIN; EXPRESSION; PROTEIN; MEMBER; PROLIFERATION; RECEPTOR	Neurotrophin-4 (NT-4) is the most recently discovered member of the neurotrophin family. We have expressed, refolded, and purified recombinant human NT-4 from Escherichia coli and compared it with recombinant human NT-4 secreted into the culture medium of baculovirus-infected insect cells. Both preparations were characterized and determined to be indistinguishable according to several biochemical criteria. Recombinant NT-4 from E. coli was crystallized in a form suitable for x-ray analysis, and characterization of these crystals indicated that NT-4 was present as a dimer within the asymmetric unit. NT-4 was active in promoting the survival of rat TrkB receptor-expressing fibroblasts, but was inactive on embryonic chicken sensory neurons, unlike the other members of the neurotrophin family and in contrast to the reported activities of partially purified NT-4.	REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Regeneron; Columbia University; Columbia University; Howard Hughes Medical Institute								BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BOTHWELL MA, 1977, J BIOL CHEM, V252, P8532; BRUNGER AT, 1990, XPLOR MANUAL VERSION; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHAUDHARY T, 1993, 41ST P ASMS C MASS S; Creighton T E, 1986, Methods Enzymol, V131, P83; DAVIES AM, 1986, J NEUROSCI, V6, P1897; DICOU E, 1989, J NEUROSCI RES, V22, P13, DOI 10.1002/jnr.490220103; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P916; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HOBER S, 1992, BIOCHEMISTRY-US, V31, P1749, DOI 10.1021/bi00121a024; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HU GL, 1988, GENE, V70, P57; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAISHO Y, 1990, FEBS LETT, V266, P187, DOI 10.1016/0014-5793(90)81536-W; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MASIAKOWSKI P, 1991, J NEUROCHEM, V57, P1003, DOI 10.1111/j.1471-4159.1991.tb08250.x; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; Miller J.H., 1972, EXPT MOL GENETICS; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NEGRO A, 1992, BIOCHEM BIOPH RES CO, V186, P1553, DOI 10.1016/S0006-291X(05)81584-0; NEGRO A, 1992, GENE, V110, P251, DOI 10.1016/0378-1119(92)90657-B; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; RADZIEJEWSKI C, 1992, BIOCHEMISTRY-US, V31, P4431, DOI 10.1021/bi00133a007; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; WLODAWER A, 1975, P NATL ACAD SCI USA, V72, P777, DOI 10.1073/pnas.72.3.777; YANG JT, 1986, METHOD ENZYMOL, V130, P208	38	39	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					755	759						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276879				2022-12-25	WOS:A1994MR21900118
J	PERIDES, G; SAFRAN, RM; DOWNING, LA; CHARNESS, ME				PERIDES, G; SAFRAN, RM; DOWNING, LA; CHARNESS, ME			REGULATION OF NEURAL CELL-ADHESION MOLECULE AND L1 BY THE TRANSFORMING GROWTH-FACTOR-BETA SUPERFAMILY - SELECTIVE EFFECTS OF THE BONE MORPHOGENETIC PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOGENIC PROTEIN-1; EXPRESSION; DIFFERENTIATION; PATTERN; GENE; EMBRYOGENESIS; RECEPTORS; BINDING; FAMILY; MOUSE	The transforming growth factor-beta (TGF-beta) superfamily plays a role in embryogenesis and regeneration. We have reported that osteogenic protein-1 (OP-1) promotes cell aggregation and induces the expression of the neural cell adhesion molecules N-CAM and L1 in proliferating neuroblastoma x glioma hybrid NG108-15 cells (Perides, G., Safran, R. M., Rueger, D. C., and Charness, M. E. (1992) Proc. Natl. Acad. Sci. U. S. A. 89,10326-10330; Perides, G., Hu, G., Rueger, D. C., and Charness, M. E. (1993) J. Biol. Chem. 268, 25197-25205). Here we show that the structurally homologous bone morphogenetic proteins (BMP) BMP-2 and BMP-4 are 10-50-fold more potent in these actions than the subfamily comprising BMP-5, BMP-6, and OP-1 (BMP-7). In contrast, members of the TGF-beta subfamily, activin-A, inhibin-A, and 29 additional growth factors and cytokines did not induce N-CAM. The addition of serum to cella growing in serum-free medium caused a concentration-dependent increase in N-CAM and Li expression; however, serum did not potentiate the induction of N-CAM and L1 by 40 ng/ml OP-1. These findings suggest the presence in NG108-15 cells of a BMP-2/BMP-4 receptor that discriminates subtle differences in structure among homologous members of the TGF-beta superfamily. An endogenous ligand for this receptor may be present in serum.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; DEPT VET AFFAIRS MED CTR,SPINAL CORD INJURY LAB,BOSTON,MA 02132; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT NEUROL,DIV NEUROL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV NEUROL,PROGRAM NEUROSCI,BOSTON,MA 02115; DEPT VET AFFAIRS MED CTR,NEUROL SECT,BOSTON,MA 02132	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School				Charness, Michael/0000-0002-3301-8966	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006662] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA06662] Funding Source: Medline; NINDS NIH HHS [NS 13034] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; COULOMBE JN, 1993, NEURON, V10, P899, DOI 10.1016/0896-6273(93)90205-6; DOHERTY P, 1988, J CELL BIOL, V107, P333, DOI 10.1083/jcb.107.1.333; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; HIRN M, 1981, BRAIN RES, V214, P43; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; JIANG TX, 1993, DEV BIOL, V155, P545, DOI 10.1006/dbio.1993.1051; JONES CM, 1991, DEVELOPMENT, V111, P531; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; LEE YS, 1992, J BONE MINER RES, V7, P1435; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LEPAGE T, 1992, DEVELOPMENT, V114, P147; LYLES JM, 1993, J NEUROSCI RES, V34, P273, DOI 10.1002/jnr.490340304; LYONS KM, 1990, DEVELOPMENT, V109, P833; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCPHERRON AC, 1993, J BIOL CHEM, V268, P3444; MESSING RO, 1991, BRAIN RES, V565, P301, DOI 10.1016/0006-8993(91)91662-K; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; OZKAYNAK E, 1991, BIOCHEM BIOPH RES CO, V179, P116, DOI 10.1016/0006-291X(91)91342-A; OZKAYNAK E, 1992, J BIOL CHEM, V267, P25220; PARALKAR VM, 1992, J CELL BIOL, V119, P1721, DOI 10.1083/jcb.119.6.1721; PERIDES G, 1993, J BIOL CHEM, V268, P25197; PERIDES G, 1992, P NATL ACAD SCI USA, V89, P10326, DOI 10.1073/pnas.89.21.10326; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; ROUBIN R, 1990, J CELL BIOL, V111, P673, DOI 10.1083/jcb.111.2.673; SAMPATH TK, 1992, J BIOL CHEM, V267, P20352; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T	31	74	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					765	770						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276880				2022-12-25	WOS:A1994MR21900120
J	HENDERSON, BR; SEISER, C; KUHN, LC				HENDERSON, BR; SEISER, C; KUHN, LC			CHARACTERIZATION OF A 2ND RNA-BINDING PROTEIN IN RODENTS WITH SPECIFICITY FOR IRON-RESPONSIVE ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRITIN MESSENGER-RNA; TRANSFERRIN RECEPTOR EXPRESSION; UNTRANSLATED REGION; REGULATORY FACTOR; 5-AMINOLEVULINATE SYNTHASE; DEPENDENT REGULATION; CYTOSOLIC PROTEIN; GENE-REGULATION; SULFUR CLUSTER; PURIFICATION	Iron regulatory factor (IRF) is a cytoplasmic RNA-binding protein involved in regulating iron homeostasis. IRF controls expression of ferritin and transferrin receptor post-transcriptionally via specific binding to stem-loop iron-responsive elements (IREs) located in the untranslated regions of the respective mRNAs. We have confirmed by RNA band-shift analysis that a second IRE-protein complex observed in different rodent cell extracts is, like IRF, regulated by intracellular iron levels. This faster migrating complex appears to represent a specific interaction between the ferritin IRE and an iron-regulated protein that is distinct from IRF, as concluded from the following lines of evidence. First, UV cross-linking and partial digestion with different proteases revealed different peptide patterns for the two IRE-protein complexes. Second, antiserum raised against IRF peptides immunoprecipitated only authentic IRF and not the protein of the faster migrating complex, as determined by band-shift analysis. Following separation of the two IRE-binding proteins by ion-exchange chromatography, only the IRF-containing fraction reacted with the antibodies on Western blots. The second protein binds IREs with an affinity similar to that of IRF as demonstrated by competition with a ferritin IRE and related stem-loop RNAs. UV cross-linking experiments indicate that this second protein, tentatively named IRF(B), has a molecular mass of approximately 105 kDa. Analysis of mouse tissues revealed differences in the distribution of IRF and IRF(B). Whereas IRF protein and IRE binding activity were predominant in liver, intestine, and kidney, the IRF(B) protein(s) revealed highest binding activity in intestine and brain. Our data support the existence of two distinct iron-regulated IRE-binding proteins in rodents.	SWISS INST EXPTL CANC RES,CH BOVERESSES 155,CH-1066 EPALINGES,SWITZERLAND	Swiss Institute Experimental Cancer Research				Seiser, Christian/0000-0002-7046-9352				AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BARTON HA, 1990, J BIOL CHEM, V265, P7000; BETTANY AJE, 1992, J BIOL CHEM, V267, P16531; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; HIRLING H, 1992, NUCLEIC ACIDS RES, V20, P33, DOI 10.1093/nar/20.1.33; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; MAY BK, 1990, MOL BIOL MED, V7, P405; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1992, EUR J BIOCHEM, V208, P597, DOI 10.1111/j.1432-1033.1992.tb17224.x; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; PATINO MM, 1992, J BIOL CHEM, V267, P19011; PHILPOTT CC, 1991, NUCLEIC ACIDS RES, V19, P6333, DOI 10.1093/nar/19.22.6333; ROSEN CA, 1991, GENE EXPRESSION, V1, P85; ROTHENBERGER S, 1990, NUCLEIC ACIDS RES, V18, P1175, DOI 10.1093/nar/18.5.1175; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; Sambrook J, 1989, MOL CLONING LABORATO; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; YU Y, 1992, J BIOL CHEM, V267, P19005	34	152	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27327	27334						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262972				2022-12-25	WOS:A1993MM26200071
J	KIM, IY; VERES, Z; STADTMAN, TC				KIM, IY; VERES, Z; STADTMAN, TC			BIOCHEMICAL-ANALYSIS OF ESCHERICHIA-COLI SELENOPHOSPHATE SYNTHETASE MUTANTS - LYSINE-20 IS ESSENTIAL FOR CATALYTIC ACTIVITY AND CYSTEINE-17-19 FOR 8-AZIDO-ATP DERIVATIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; SELD GENE-PRODUCT; SELENOCYSTEINE SYNTHASE; SELENIUM METABOLISM; SEQUENCE; BINDING; 5-METHYLAMINOMETHYL-2-SELENOURIDINE; PURIFICATION; NUCLEOSIDE; EXPRESSION	A labile selenium donor compound, selenophosphate, is formed from selenide and ATP by selenophosphate synthetase. A cysteine residue (Cys-17) that is essential for catalytic activity of the enzyme (Kim, I. Y., Veres, Z., and Stadtman, T. C. (1992) J. Biol. Chem. 267, 19650-19654) is located in a glycine-rich segment near the N terminus of the protein. The possibility that this peptide sequence (HGAGCGCK) defines the ATP-binding site of the enzyme, as does a conserved ATP or GTP binding sequence (GXXXXGKS/T) found in several other proteins, was tested by site-specific mutagenesis. Thus His-13 and Gly-18 were changed to Asn and Val, respectively, and Lys-20 to Arg or Gln. Catalytic activity was markedly decreased by mutation of Lys-20 to Arg and abolished by mutation of Lys-20 to Gln. The mutation of Cys-19 and His-13 did not substantially alter the ATP K(m) and V(max) values, whereas the Gly-18 mutation resulted in a 4-fold increase in the ATP K(m) value compared with that of the wild type. ATP binding properties of the mutant enzymes were determined using Mn-[P-32]ATP or Mn-[C-14]ATP and gel filtration. Photoaffinity labeling of the proteins with [gamma-P-32]8-azido-ATP showed that all mutant enzymes could be labeled with the ATP analog except those in which Cys-17 or Cys-19 were replaced with serine.	NHLBI,BIOCHEM LAB,BLDG 3,RM 108,9000 ROCKVILLE PIKE,BETHESDA,MD 20892; HUNGARIAN ACAD SCI,CENT RES INST CHEM,H-1025 BUDAPEST,HUNGARY	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences								BAGNARA AS, 1972, ANAL BIOCHEM, V45, P24, DOI 10.1016/0003-2697(72)90004-8; Bock A, 1988, Biofactors, V1, P245; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; Czarnecki J, 1979, Methods Enzymol, V56, P642; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6318; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6324; HADDOCK BA, 1982, BIOCHEM SOC T, V10, P478, DOI 10.1042/bst0100478; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; JULIN DA, 1987, J BIOL CHEM, V262, P9044; KIM IY, 1992, J BIOL CHEM, V267, P19650; KRAMER GF, 1988, J BACTERIOL, V170, P736, DOI 10.1128/jb.170.2.736-743.1988; LEINFELDER W, 1988, J BACTERIOL, V170, P540, DOI 10.1128/jb.170.2.540-546.1988; LEINFELDER W, 1990, P NATL ACAD SCI USA, V87, P543, DOI 10.1073/pnas.87.2.543; LIU F, 1992, J BIOL CHEM, V267, P2388; PECK HD, 1957, J BACTERIOL, V73, P706, DOI 10.1128/JB.73.6.706-721.1957; PHILLIPS NFB, 1993, FASEB J, V7, pA1272; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; STADTMAN T C, 1989, Biofactors, V2, P35; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VERES Z, 1992, P NATL ACAD SCI USA, V89, P2975, DOI 10.1073/pnas.89.7.2975; WITTWER AJ, 1986, ARCH BIOCHEM BIOPHYS, V248, P540, DOI 10.1016/0003-9861(86)90507-2; WITTWER AJ, 1984, BIOCHEMISTRY-US, V23, P4650, DOI 10.1021/bi00315a021	26	37	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27020	27025						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262938				2022-12-25	WOS:A1993MM26200030
J	TAM, LT; MANNING, D; COX, DJ; RIGGS, AF				TAM, LT; MANNING, D; COX, DJ; RIGGS, AF			THE HEMOGLOBINS OF THE BULLFROG, RANA-CATESBEIANA - DEOXYGENATION-LINKED ASSOCIATION OF TETRAMERIC COMPONENT-B AND COMPONENT-C TO FORM THE TRIMER BC(2) - SEDIMENTATION ANALYSIS AND OXYGEN EQUILIBRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CHAIN; COOPERATIVITY; BINDING	Hemolysates from the adult bullfrog, Rana catesbeiana, show an unusually high degree of cooperativity of oxygen binding with Hill coefficients greater than 4. The principal components of the tetrameric hemoglobin, B and C, do not show this high cooperativity when isolated, but it reappears when the components are mixed. Sedimentation velocity measurements show that the unusual behavior results from the mixed association of components B and C to form complexes larger than tetramers. Computer simulation of the sedimentation behavior of mixtures of deoxygenated B and C components shows that the gradient profiles can be satisfactorily described in terms of an equilibrium between the B and C tetramers and a BC2 trimer. The simplest model consistent with the results is the mixed association: B + C reversible BC and BC + C reversible BC2, with the second binding constant being higher than the first, indicating significant cooperativity. The extent of association is highest at low pH and low temperature. The dissociation of the B.C complex with low oxygen affinity to higher affinity B and C molecules during oxygenation results in greatly increased cooperativity of oxygen binding with higher Hill coefficients than possessed by either component alone in equilibria measured between 5 and 25-degrees-C and between pH 6 and 8.	UNIV TEXAS,DEPT ZOOL,AUSTIN,TX 78712; KANSAS STATE UNIV AGR & APPL SCI,DEPT BIOCHEM,MANHATTAN,KS 66506	University of Texas System; University of Texas Austin; Kansas State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035847] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35847] Funding Source: Medline; PHS HHS [22243] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; AGGARWAL SJ, 1969, J BIOL CHEM, V244, P2372; ATHA DH, 1979, J BIOL CHEM, V254, P2390; ATHA DH, 1982, HEMOGLOBIN OXYGEN BI, P269; BONAVENTURA J, 1968, J BIOL CHEM, V243, P980; BROYLES RH, 1981, HEMOGLOBINS DEV DIFF, P179; COBB JA, 1992, J BIOL CHEM, V267, P1183; Cox D. J, 1978, METHOD ENZYMOL, V48F, P212; COX DJ, 1981, PROTEIN PROTEIN INTE, P173; DeLoid G, 1984, THESIS KANSAS STATE; DOLMAN D, 1978, ANAL BIOCHEM, V87, P127, DOI 10.1016/0003-2697(78)90576-6; DORN AR, 1982, P NATL ACAD SCI-BIOL, V79, P5592, DOI 10.1073/pnas.79.18.5592; EDELSTEIN SJ, 1986, J MOL BIOL, V187, P277, DOI 10.1016/0022-2836(86)90234-2; EDSALL JT, 1958, BIOPHYS CHEM, V1, P452; ELLI R, 1970, COMP BIOCHEM PHYSIOL, V36, P163, DOI 10.1016/0010-406X(70)90662-6; GILBERT GA, 1959, PROC R SOC LON SER-A, V250, P377, DOI 10.1098/rspa.1959.0070; GILL SJ, 1979, J MOL BIOL, V130, P175, DOI 10.1016/0022-2836(79)90425-X; GILOL SJ, 1978, SCIENCE, V201, P362; HOLLAND RAB, 1993, OXYGEN TRANSPORT TIS, V15; KITCHEN H, 1964, SCIENCE, V144, P1237, DOI 10.1126/science.144.3623.1237; LYKKEBOE G, 1978, RESP PHYSIOL, V35, P119, DOI 10.1016/0034-5687(78)90017-8; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; SHIMIZU K, 1983, HEMOGLOBIN, V7, P15, DOI 10.3109/03630268309038399; SMITH DJ, 1993, J BIOL CHEM, V268, P26961; TAM LT, 1986, J BIOL CHEM, V261, P8290; TAM LT, 1984, J BIOL CHEM, V259, P2610; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4	27	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26972	26977						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262932				2022-12-25	WOS:A1993MM26200023
J	HUANG, L; TURCHI, JJ; WAHL, AF; BAMBARA, RA				HUANG, L; TURCHI, JJ; WAHL, AF; BAMBARA, RA			ACTIVITY OF CALF THYMUS DNA HELICASE-E ON CIS-DIAMMINEDICHLOROPLATINUM-(II)-DAMAGED DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; ANTITUMOR DRUG CIS-DIAMMINEDICHLOROPLATINUM(II); UVRABC EXCISION NUCLEASE; SACCHAROMYCES-CEREVISIAE; POLYMERASE-EPSILON; HUMAN-FIBROBLASTS; REPAIR; ADDUCTS; DELTA; IDENTIFICATION	Calf DNA helicase E (hel E) is a moderately processive, 3' to 5' helicase, active on nicked DNA, that we have proposed to have a role in DNA repair (Turchi, J. J., Murante, R. S., and Bambara, R. A. (1992) Nucleic Acids Res. 20, 6075-6080). Here we have examined its activity on a series of cis-diamminedichloroplatinum (II) (cis-DDP)-modified DNA substrates. Hel E was capable of efficiently displacing a primer strand containing, in an internal position, a cis-DDP-modified dGG. In a two-primer model system, calf DNA polymerase epsilon could successfully extend an upstream primer through a cis-DDP-modified downstream primer, to the end of the complementary template strand, in a reaction dependent on hel E. However, the translocation of hel E was blocked by cis-DDP modification of the template strand. Primer displacement was completely prevented if the modified site was located just upstream of the primer. The DNA-dependent ATPase activity of helicase E was also reduced by cis-DDP modification of the template DNA. Substrate competition experiments indicated that cis-DDP-modified DNA templates did not sequester hel E. Substrate titration experiments suggested that there is a short delay without ATP hydrolysis before dissociation of helicase E from cis-DDP-modified template sites. Interestingly, hel E could displace a primer if the cis-DDP modification was on the template within the annealed region. Possible explanations for this are discussed. Taken together, these results are consistent with the proposal that hel E participates in DNA repair by displacing segments of damaged DNA.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT GROWTH REGULAT,SEATTLE,WA 98121; UNIV ROCHESTER,SCH MED & DENT,CTR CANC,ROCHESTER,NY 14642	University of Rochester; Bristol-Myers Squibb; University of Rochester			Turchi, John J/B-5807-2015	Turchi, John J/0000-0001-5375-2992	NATIONAL CANCER INSTITUTE [P30CA011198, T32CA009363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER; NCI NIH HHS [CA11198, T32-CA09363] Funding Source: Medline; NIGMS NIH HHS [GM24441] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1985, DNA REPAIR; BECK DJ, 1985, NUCLEIC ACIDS RES, V13, P7395, DOI 10.1093/nar/13.20.7395; BROWN WC, 1989, J BIOL CHEM, V264, P6748; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CALSOU P, 1992, NUCLEIC ACIDS RES, V20, P6363, DOI 10.1093/nar/20.23.6363; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DIJT FJ, 1988, CANCER RES, V48, P6058; EASTMAN A, 1988, BIOCHEMISTRY-US, V27, P4730, DOI 10.1021/bi00413a022; EASTMAN A, 1983, BIOCHEMISTRY-US, V22, P3927, DOI 10.1021/bi00285a031; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; FOCHER F, 1989, NUCLEIC ACIDS RES, V17, P1805, DOI 10.1093/nar/17.5.1805; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; HAROSH I, 1989, J BIOL CHEM, V264, P20532; HOEIJMAKERS JHJ, 1991, J CELL SCI, V100, P687; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUANG L, 1993, BIOCHEMISTRY-US, V32, P841, DOI 10.1021/bi00054a015; HUSAIN I, 1985, P NATL ACAD SCI USA, V82, P6774, DOI 10.1073/pnas.82.20.6774; JONES JC, 1991, J BIOL CHEM, V266, P7101; KESTI T, 1991, J BIOL CHEM, V266, P6336; LEE SH, 1991, J BIOL CHEM, V266, P22707; MARROT L, 1989, BIOCHEMISTRY-US, V28, P1454, DOI 10.1021/bi00430a005; MASUDA H, 1990, CANCER RES, V50, P1863; MASUDA H, 1988, CANCER RES, V48, P5713; NAEGELI H, 1993, BIOCHEMISTRY-US, V32, P613, DOI 10.1021/bi00053a029; NISHIDA C, 1988, J BIOL CHEM, V263, P501; REYNOLDS RJ, 1981, J BACTERIOL, V146, P692, DOI 10.1128/JB.146.2.692-704.1981; RICE JA, 1988, P NATL ACAD SCI USA, V85, P4158, DOI 10.1073/pnas.85.12.4158; Sambrook J, 1989, MOL CLONING LABORATO; SENGUPTA DJ, 1992, SCIENCE, V256, P1656, DOI 10.1126/science.256.5064.1656; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIEGAL G, 1992, J BIOL CHEM, V267, P13629; SIEGAL G, 1992, J BIOL CHEM, V267, P3991; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; SZYMKOWSKI DE, 1992, P NATL ACAD SCI USA, V89, P10772, DOI 10.1073/pnas.89.22.10772; TURCHI JJ, 1992, NUCLEIC ACIDS RES, V20, P6075, DOI 10.1093/nar/20.22.6075; TURCHI JJ, 1992, BIOCHEMISTRY-US, V31, P9008, DOI 10.1021/bi00152a043; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WILCOX DR, 1981, J BACTERIOL, V148, P618, DOI 10.1128/JB.148.2.618-623.1981	38	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26731	26737						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253808				2022-12-25	WOS:A1993MK42500105
J	NEGISHI, M; NAMBA, T; SUGIMOTO, Y; IRIE, A; KATADA, T; NARUMIYA, S; ICHIKAWA, A				NEGISHI, M; NAMBA, T; SUGIMOTO, Y; IRIE, A; KATADA, T; NARUMIYA, S; ICHIKAWA, A			OPPOSITE COUPLING OF PROSTAGLANDIN-E RECEPTOR EP(3C) WITH G(S) AND G(0) - STIMULATION OF G(S) AND INHIBITION OF G(0)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEIN; ADENYLATE-CYCLASE; PERTUSSIS-TOXIN; RAT; G0; RECONSTITUTION; VESICLES	We recently identified four isoforms of bovine prostaglandin E receptor EP3 subtype, which are coupled to different signaling pathways; EP3A is coupled to inhibition of adenylate cyclase, while EP3B and EP3C are coupled to its stimulation and EP3D is coupled to phosphatidylinositol turnover, in addition to the adenylate cyclase system (Namba, T., Sugimoto, Y., Negishi, M., Irie, A., Ushikubi, F., Kakizuka, Ito, S., A., Ichikawa, A., and Narumiya, S. (1993) Nature 365, 166-170). We examined here the identity of coupled G proteins and their regulation by one of the isoforms, EP3C, in the membranes of EP3C cDNA-transfected Chinese hamster ovary cells. M&B 28767, an EP3 agonist, stimulated the GTPase activity in the pertussis toxin (PT)-treated cell membrane, but inhibited it in the cholera toxin (CT)-treated cell membrane, while the agonist neither stimulated nor inhibited it in the both PT- and CT-treated cell membrane. In the PT- and CT-treated cell membrane reconstituted with various G proteins, M&B 28767 inhibited the GTPase activity of G(o), but stimulated that of G(s). On the other hand, M&B 28767 did not affect the GTPase activity of G(i1), G(i2), or G(i3). M&B 28767 increased the apparent affinity of G(o) for GDP without any change in that for GTP, as assessed by displacement of [S-35]GTPgammaS (guanosine 5'-O-(3-thiotriphosphate)) binding to G(o). In contrast, M&B 28767 increased the apparent affinity of G(s) for GTP but decreased that for GDP. These results demonstrated that the EP3 receptor isoform is coupled to two different G proteins, and oppositely regulates their activities, inhibition of G(o), and stimulation of G(s).	UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,SAKYO KU,TOKYO 113,JAPAN; KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,TOKYO 113,JAPAN	University of Tokyo; Kyoto University; University of Tokyo			Sugimoto, Yukihiko/AAV-6470-2021	Sugimoto, Yukihiko/0000-0001-6973-932X				ASANO T, 1984, BIOCHEMISTRY-US, V23, P5460, DOI 10.1021/bi00318a013; ASANO T, 1988, J NEUROCHEM, V50, P1164, DOI 10.1111/j.1471-4159.1988.tb10588.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; COLEMAN R A, 1987, British Journal of Pharmacology, V91, p407P; COLEMAN RA, 1989, COMPREHENSIVE MED CH, V3, P643; EDET S, 1990, J PHARMACOL EXP THER, V255, P11; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; KATADA T, 1986, J BIOL CHEM, V261, P8182; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KRALL JF, 1984, J ENDOCRINOL, V102, P329, DOI 10.1677/joe.0.1020329; LAW SF, 1993, J BIOL CHEM, V268, P10721; MONCADA S, 1985, PHARMACOL BASIS THER, P660; MORISHITA R, 1989, BIOCHEM BIOPH RES CO, V161, P1280, DOI 10.1016/0006-291X(89)91381-8; MULLANEY I, 1993, BIOCHEM J, V289, P125, DOI 10.1042/bj2890125; NAKAO A, 1989, AM J PHYSIOL, V256, pC652, DOI 10.1152/ajpcell.1989.256.3.C652; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SHIOZAKI K, 1992, BIOCHEMISTRY-US, V31, P10634, DOI 10.1021/bi00158a028; TANAKA T, 1990, J NEUROCHEM, V54, P86, DOI 10.1111/j.1471-4159.1990.tb13286.x; UEDA H, 1990, FEBS LETT, V266, P178, DOI 10.1016/0014-5793(90)81534-U	25	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26067	26070						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253719				2022-12-25	WOS:A1993MK42500010
J	TATHAM, AS; FIELD, JM; MORRIS, VJ; IANSON, KJ; CARDLE, L; DUFTON, MJ; SHEWRY, PR				TATHAM, AS; FIELD, JM; MORRIS, VJ; IANSON, KJ; CARDLE, L; DUFTON, MJ; SHEWRY, PR			SOLUTION CONFORMATIONAL-ANALYSIS OF THE ALPHA-ZEIN PROTEINS OF MAIZE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; CIRCULAR-DICHROISM; SEQUENCE-ANALYSIS; PREDICTIONS; REVEALS; SUBUNIT; GLUTEN	Small angle x-ray scattering and viscometric analyses of the alpha-zeins of maize in solution indicated that the molecules were asymmetric. Structure predictions of consensus sequences for the two classes of alpha-zeins, Z19 and Z22, were in good agreement with the alpha-helical contents determined by circular dichroism. Dimensions determined by small angle x-ray scattering and viscometry indicated a predominantly alpha-helical conformation. The data are discussed in relation to models for the solution conformation and to earlier models for alpha-zeins structure.	ZENECA SEEDS UK LTD, CTR PLANT BREEDING & RES, NORFOLK PE31 8LS, ENGLAND; INST FOOD RES, NORWICH LAB, NORWICH NR4 7UA, NORFOLK, ENGLAND; UNIV STRATHCLYDE, DEPT PURE & APPL CHEM, GLASGOW G1 1XL, SCOTLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; University of Strathclyde	TATHAM, AS (corresponding author), UNIV BRISTOL, LONG ASHTON RES STN, DEPT AGR SCI, AFRC, INST ARABLE CROPS RES, BRISTOL BS18 9AF, AVON, ENGLAND.			Milne, Linda/0000-0002-1798-8022; Tatham, Arthur/0000-0001-5080-5585				ARGOS P, 1982, J BIOL CHEM, V257, P9984; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLARK DC, 1989, J AGR FOOD CHEM, V37, P627, DOI 10.1021/jf00087a011; CONIO G, 1970, J BIOL CHEM, V245, P3355; DANZER LA, 1975, BIOCHIM BIOPHYS ACTA, V386, P26, DOI 10.1016/0005-2795(75)90242-1; DIFONZO N, 1991, PLANT MOL BIOL, V2, P627; DUFTON MJ, 1977, J MOL BIOL, V115, P177, DOI 10.1016/0022-2836(77)90095-X; Elliott MA, 1939, J AM CHEM SOC, V61, P718, DOI 10.1021/ja01872a051; ESEN A, 1990, J PROTEIN CHEM, V9, P453, DOI 10.1007/BF01024621; FIELD JM, 1987, BIOCHEM J, V247, P215, DOI 10.1042/bj2470215; FOSTER JF, 1945, J AM CHEM SOC, V67, P617, DOI 10.1021/ja01220a034; GARRATT R, 1993, PROTEINS, V15, P88, DOI 10.1002/prot.340150111; Gianazza E., 1976, Maydica, V21, P1; Gortner Ross Aiken, 1944, CEREAL CHEM, V21, P324; HEIDECKER G, 1991, GENOMICS, V10, P719, DOI 10.1016/0888-7543(91)90456-O; KRETSCHMER CB, 1957, J PHYS CHEM-US, V61, P1627, DOI 10.1021/j150558a014; LEVITT M, 1978, BIOCHEMISTRY-US, V17, P4277, DOI 10.1021/bi00613a026; MARKS MD, 1985, J BIOL CHEM, V260, P6451; MATSUSHIMA N, 1992, BIOCHEM BIOPH RES CO, V186, P1057, DOI 10.1016/0006-291X(92)90854-E; MEHL J. W., 1940, SCIENCE, V92, P132, DOI 10.1126/science.92.2380.132; MILES MJ, 1991, P NATL ACAD SCI USA, V88, P68, DOI 10.1073/pnas.88.1.68; MULLER K, 1985, SMALL ANGLE XRAY SCA, P215; NUCCA R, 1978, MAYDICA, V23, P239; ONCLEY JL, 1949, J PHYS COLLOID CHEM, V53, P162, DOI 10.1021/j150466a013; PEZOLET M, 1992, FEBS LETT, V299, P247, DOI 10.1016/0014-5793(92)80125-Z; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rubenstein I., 1986, Advances in Cereal Science and Technology, V8, P297; Simha R, 1940, J PHYS CHEM-US, V44, P25, DOI 10.1021/j150397a004; THOMPSON GA, 1992, PLANT MOL BIOL, V18, P827, DOI 10.1007/BF00020030; THOMSON NH, 1992, ULTRAMICROSCOPY, V42, P1204, DOI 10.1016/0304-3991(92)90425-J; Watson C C, 1936, NATURE, V137, P322; WILLIAMS JW, 1938, COLD SPRING HARB SYM, V6, P208; WILSON CM, 1985, CEREAL CHEM, V62, P361; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; WU YV, 1983, CEREAL CHEM, V60, P342; Wyman J, 1931, J BIOL CHEM, V90, P443	36	81	86	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26253	26259						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253747				2022-12-25	WOS:A1993MK42500039
J	KLOSE, M; STORIKO, A; STIERHOF, YD; HINDENNACH, I; MUTSCHLER, B; HENNING, U				KLOSE, M; STORIKO, A; STIERHOF, YD; HINDENNACH, I; MUTSCHLER, B; HENNING, U			MEMBRANE ASSEMBLY OF THE OUTER-MEMBRANE PROTEIN OMPA OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ENVELOPE MEMBRANE; BACTERIOPHAGE RECEPTOR; RHODOBACTER-CAPSULATUS; TRANSLATIONAL CONTROL; PORIN OVEREXPRESSION; ELECTRON-MICROSCOPY; MAJOR PROTEINS; II-STAR; K-12; EXPORT	The membrane part (residues 1 to approximately 170) of the 325-residue Escherichia coli outer membrane protein OmpA is thought to exist in the membrane as an 8-stranded beta-barrel, subdividing this part into four segments. The influence of proline residues on membrane assembly of the protein has been studied. These were introduced, using site-directed mutagenesis, into each of seven of the antiparallel beta-strands. One important parameter for allowing or not allowing membrane assembly was the potential H(beta)(i) which is the potential to form an amphiphilic beta-strand. When H(beta)(i) remained unaltered, 2 prolines were tolerated. Lowering H(beta)(i) in most cases caused failure of assembly when 2 such residues were present. An insert of 10 residues, including 3 prolines, did not alter H(beta)(i) and was tolerated, but caused ''looping out'' of the strand to the outer face of the membrane; displacement to its inner side would not have allowed for an amphiphilic beta-strand. Thus, a beta-structured protein is as adaptable as it has been shown for an alpha-helix. The wild type segment order 1-2-3-4 has been changed to 1-3-3-4 and 1-4-3-4. Since the proteins were found associated with the outer membrane but could not be incorporated into it, it appears that sorting is less sensitive to alterations than assembly. A regulatory circuit was affected (missense mutants of outer membrane proteins can cause inhibition of synthesis of other such proteins); expression of the two rearranged genes effected a strong inhibition of synthesis of the unrelated porins OmpC and F as well as that of the maltoporin LamB and wild type OmpA. Hence, outer membrane proteins are designed not only for efficient membrane assembly but also for proper regulation of their synthesis.	MAX PLANCK INST BIOL,D-72076 TUBINGEN,GERMANY	Max Planck Society								BECK E, 1980, NUCLEIC ACIDS RES, V8, P3011, DOI 10.1093/nar/8.13.3011; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; CARLEMALM E, 1982, J MICROSC-OXFORD, V126, P123, DOI 10.1111/j.1365-2818.1982.tb00362.x; CATRON KM, 1987, J BACTERIOL, V169, P4237; CHEN R, 1980, P NATL ACAD SCI-BIOL, V77, P4592, DOI 10.1073/pnas.77.8.4592; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLICK EM, 1989, J BACTERIOL, V171, P616, DOI 10.1128/jb.171.1.616-619.1989; CLICK EM, 1988, J BACTERIOL, V170, P2005, DOI 10.1128/jb.170.5.2005-2011.1988; COLE ST, 1983, J BACTERIOL, V153, P581, DOI 10.1128/JB.153.2.581-587.1983; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DATTA DB, 1977, J BACTERIOL, V131, P821, DOI 10.1128/JB.131.3.821-829.1977; DORNMAIR K, 1990, J BIOL CHEM, V265, P18907; FREUDL R, 1986, J MOL BIOL, V188, P491, DOI 10.1016/0022-2836(86)90171-3; FREUDL R, 1986, J BIOL CHEM, V261, P1355; FREUDL R, 1985, EMBO J, V4, P3593, DOI 10.1002/j.1460-2075.1985.tb04122.x; FREUDL R, 1989, GENE, V82, P229, DOI 10.1016/0378-1119(89)90048-6; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HEINZ DW, 1993, NATURE, V361, P561, DOI 10.1038/361561a0; HELLER KB, 1978, J BACTERIOL, V134, P1181, DOI 10.1128/JB.134.3.1181-1183.1978; JAHNIG F, 1990, TRENDS BIOCHEM SCI, V15, P93, DOI 10.1016/0968-0004(90)90188-H; JAHNIG F, 1989, PREDICTION PROTEIN S, P707; KELLENBERGER E, 1990, MOL MICROBIOL, V4, P697, DOI 10.1111/j.1365-2958.1990.tb00640.x; KLOSE M, 1989, J BIOL CHEM, V264, P21842; KLOSE M, 1988, J BIOL CHEM, V263, P13291; KLOSE M, 1988, J BIOL CHEM, V263, P13297; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACINTYRE S, 1991, MOL GEN GENET, V227, P224; MACINTYRE S, 1987, J BIOL CHEM, V262, P8416; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; Miller J.H., 1972, EXPT MOL GENETICS; MIZUNO T, 1983, J BIOL CHEM, V258, P6932; MORONA R, 1984, J BACTERIOL, V159, P570, DOI 10.1128/JB.159.2.570-578.1984; MORONA R, 1982, J BACTERIOL, V150, P1016, DOI 10.1128/JB.150.3.1016-1023.1982; MORONA R, 1985, J BACTERIOL, V164, P539, DOI 10.1128/JB.164.2.539-543.1985; MORONA R, 1985, EUR J BIOCHEM, V150, P161, DOI 10.1111/j.1432-1033.1985.tb09002.x; MOVVA NR, 1980, J MOL BIOL, V143, P317, DOI 10.1016/0022-2836(80)90193-X; PAUL C, 1985, EMBO J, V4, P1593, DOI 10.1002/j.1460-2075.1985.tb03822.x; RIED G, 1990, J MOL BIOL, V216, P39, DOI 10.1016/S0022-2836(05)80059-2; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1990, NUCLEIC ACIDS RES, V18, P7465, DOI 10.1093/nar/18.24.7465; SARSERO JP, 1991, J BACTERIOL, V173, P3231, DOI 10.1128/JB.173.10.3231-3234.1991; SAUER UH, 1992, J BIOL CHEM, V267, P2393; SCHILTZ E, 1991, EUR J BIOCHEM, V199, P587, DOI 10.1111/j.1432-1033.1991.tb16158.x; SCHWEIZER M, 1978, EUR J BIOCHEM, V82, P211, DOI 10.1111/j.1432-1033.1978.tb12013.x; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SURREY T, 1992, P NATL ACAD SCI USA, V89, P7457, DOI 10.1073/pnas.89.16.7457; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOGEL H, 1986, J MOL BIOL, V190, P191, DOI 10.1016/0022-2836(86)90292-5; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WARNER HR, 1978, NATURE, V272, P32, DOI 10.1038/272032a0; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; YANISCHPERRON Y, 1985, GENE, V38, P103	56	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25664	25670						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245002				2022-12-25	WOS:A1993MK10000057
J	KNEZEVIC, I; BORG, C; LEBRETON, GC				KNEZEVIC, I; BORG, C; LEBRETON, GC			IDENTIFICATION OF G(Q) AS ONE OF THE G-PROTEINS WHICH COPURIFY WITH HUMAN PLATELET THROMBOXANE-A(2) PROSTAGLANDIN-H(2) RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEIN; STIMULATE PHOSPHOLIPASE-C; ALPHA-SUBUNITS; REGULATORY PROTEINS; POLYACRYLAMIDE GELS; BETA-1 ISOZYME; PURIFICATION; ACTIVATION; MEMBRANES; MECHANISM	The present study employed ligand affinity and immunoaffinity chromatography to isolate human platelet thromboxane A2/prostaglandin H-2 (TXA2/PGH2) receptor-coupled G-proteins. Purification of TXA2/PGH2 receptors by ligand (SQ31,491)-affinity chromatography resulted in the elution of receptor binding and GTPase activity in the same fraction. GTPase activity of this fraction was enriched (6-fold) relative to solubilized platelet membranes, was stimulated (65%) by 500 nM U46619, and was blocked (74%) by 250 nM SQ29,548. Furthermore, GTP (100 muM) increased [H-3]SQ29,548 receptor binding by 48%. Immunoblotting of this fraction against QL antiserum identified a 42-kDa protein as a member of the G(q) family. In separate experiments, TXA2/PGH2 receptors were purified by immunoaffinity chromatography using P1Ab, P2Ab, and TxAb affinity columns. QL-immunoreactive proteins at 42 kDa were found in all three column eluates. Studies using G(alpha,common) antiserum (GA/1) demonstrated immunoblotting of two proteins of approximately 42 and 85 kDa in both the ligand and P2Ab affinity column fractions. On the other hand, the P1Ab and TxAb affinity column eluates contained GA/1 immunoreactivity only in the 42 kDa region. Collectively, these data identify G(q) as a TXA2/PGH2 receptor-coupled G-protein and suggest the association of this receptor with additional G(alpha) subunits.	UNIV ILLINOIS,DEPT PHARMACOL MC 868,835 S WOLCOTT AVE,CHICAGO,IL 60680	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024530] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24530] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVDONIN PV, 1985, THROMB RES, V40, P101, DOI 10.1016/0049-3848(85)90354-8; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BORG C, 1993, BIOCHEM PHARMACOL, V45, P2071, DOI 10.1016/0006-2952(93)90018-R; BORG C, 1993, FASEB J, V7, P656; BORG C, 1992, BLOOD, V80, P217; BRACE LD, 1985, PROSTAGLANDINS LEUKO, P333; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASS LF, 1988, J BIOL CHEM, V263, P5348; BRASS LF, 1987, J CLIN INVEST, V79, P1269, DOI 10.1172/JCI112947; BROWN AM, 1991, FASEB J, V5, P2175, DOI 10.1096/fasebj.5.8.1708737; FITZGERALD GA, 1987, FASEB J, V46, P154; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; GRESELE P, 1984, LANCET, V1, P991; HALUSHKA PV, 1988, CELLULAR MOL ASPECTS, P335; HOUSLAY MD, 1986, BIOCHEM J, V234, P737, DOI 10.1042/bj2340737; IM MJ, 1990, J BIOL CHEM, V265, P18944; KAWAHARA Y, 1986, THROMB RES, V41, P811, DOI 10.1016/0049-3848(86)90379-8; KIM SO, 1992, BIOCHEM PHARMACOL, V43, P313; KNEZEVIC I, 1992, J PHARMACOL EXP THER, V260, P947; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBRETON GC, 1979, P NATL ACAD SCI USA, V76, P4097; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUNSHI R, 1989, J BIOL CHEM, V264, P14853; MURRAY R, 1989, P NATL ACAD SCI USA, V86, P124, DOI 10.1073/pnas.86.1.124; NAKAHATA N, 1989, EUR J PHARMACOL, V162, P407, DOI 10.1016/0014-2999(89)90331-2; PANG IH, 1990, J BIOL CHEM, V265, P18707; POLLOCK WK, 1984, BIOCHEM J, V219, P833, DOI 10.1042/bj2190833; RYBICKI JP, 1983, BIOCHIM BIOPHYS ACTA, V751, P66, DOI 10.1016/0005-2760(83)90257-6; SENOGLES SE, 1987, J BIOL CHEM, V262, P4860; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIESS W, 1985, BLOOD, V65, P1141; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SUGANUMA A, 1992, THROMB HAEMOSTASIS, V68, P341; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; TAYLOR SJ, 1991, FEBS LETT, V286, P214, DOI 10.1016/0014-5793(91)80976-A; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WU KK, 1981, J CLIN INVEST, V67, P1801, DOI 10.1172/JCI110221; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999	40	101	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					26011	26017						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245033				2022-12-25	WOS:A1993MK10000102
J	MARKLUND, U; BRATTSAND, G; OSTERMAN, O; OHLSSON, PI; GULLBERG, M				MARKLUND, U; BRATTSAND, G; OSTERMAN, O; OHLSSON, PI; GULLBERG, M			MULTIPLE SIGNAL-TRANSDUCTION PATHWAYS INDUCE PHOSPHORYLATION OF SERINE-16, SERINE-25, AND SERINE-38 OF ONCOPROTEIN-18 IN T-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CELL ANTIGEN RECEPTOR; NEURON-ENRICHED PHOSPHOPROTEIN; TYROSINE PHOSPHORYLATION; MAP KINASE; DEPENDENT PHOSPHORYLATION; PHOSPHOLIPASE C-GAMMA-1; RAPID PHOSPHORYLATION; MONOCLONAL-ANTIBODY; DOWN-REGULATION	A multitude of external signals induce extensive phosphorylation of Oncoprotein 18 (Op18), which suggests a putative role for this protein in signal transduction. We have recently identified two distinct proline-directed kinase families that phosphorylates Op18 with overlapping but distinct site preference. These two kinase families, mitogen-activated protein (MAP) kinases and cyclin-dependent cdc2 kinases, are involved in receptor- and cell cycle-regulated phosphorylation events, respectively. In the present study, site-specific phosphorylation of Op18 in response to stimulation of the antigen receptor-associated CD3 complex was analyzed in the Jurkat T cell-line. The results show that CD3-induced phosphorylation of Ser-25 of Op18, which is the primary MAP kinase phosphorylation site, can be induced by an apparently protein kinase C (PKC)-independent signal transduction pathway. We also demonstrate that Ser-16 of Op18 is specifically phosphorylated in response to the Ca2+ signal generated by CD3 stimulation or by the Ca2+ ionophore ionomycin. Ser-16 phosphorylation occurs independently of both PKC and MAP kinase activation. Using site-specific Op18 mutants and tryptic phosphopeptide mapping, we show that phosphorylation of Ser-16 of Op18 together with Ser-25, or Ser-25 and Ser-38, generates two Op18 phosphoisomers showing a dramatic electrophoretic retardation. In conclusion, site-mapping studies of Op18 reveal that CD3 stimulation results in an apparently PKC-independent activation of both the MAP kinase and a Ca2+-regulated kinase pathway, which results in phosphorylation of distinct sites of Op18. The data also pinpoints the specific phosphorylation events that result in electrophoretic retardation of Op18.	UMEA UNIV,DEPT CELL & MOLEC BIOL,S-90187 UMEA,SWEDEN; UMEA UNIV,DEPT PHYSIOL CHEM,S-90187 UMEA,SWEDEN	Umea University; Umea University				Gullberg, Martin/0000-0002-3984-4572				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRATTSAND G, 1993, LEUKEMIA, V7, P569; CANTRELL DA, 1989, J IMMUNOL, V142, P1626; CAO TO, 1992, J BIOL CHEM, V267, P19876; CHNEIWEISS H, 1989, J NEUROCHEM, V53, P856, DOI 10.1111/j.1471-4159.1989.tb11783.x; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; COOPER HL, 1991, J IMMUNOL, V146, P3689; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DASGUPTA JD, 1992, J EXP MED, V175, P285, DOI 10.1084/jem.175.1.285; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOYE V, 1992, DIFFERENTIATION, V50, P89, DOI 10.1111/j.1432-0436.1992.tb00489.x; DOYE V, 1989, J BIOL CHEM, V264, P12134; DOYE V, 1990, J BIOL CHEM, V265, P11650; FRIEDRICH B, 1988, IMMUNOBIOLOGY, V176, P465, DOI 10.1016/S0171-2985(88)80027-5; GRATIOTDEANS J, 1992, J CLIN INVEST, V90, P1576, DOI 10.1172/JCI116026; GRAVES JD, 1992, J IMMUNOL, V148, P2417; GULLBERG M, 1990, J BIOL CHEM, V265, P17499; HAILAT N, 1990, ONCOGENE, V5, P1615; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HANEKOM C, 1989, BIOCHEM J, V262, P449, DOI 10.1042/bj2620449; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOSHI M, 1989, EUR J BIOCHEM, V184, P477, DOI 10.1111/j.1432-1033.1989.tb15040.x; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LUO KX, 1991, METHOD ENZYMOL, V201, P149; Maniatis T, 1989, DECONTAMINATION DILU; MARKLUND U, 1993, J BIOL CHEM, V268, P15039; MELHEM RF, 1991, BIOCHEM BIOPH RES CO, V179, P1649, DOI 10.1016/0006-291X(91)91764-4; MELHEM RF, 1991, J BIOL CHEM, V266, P17747; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NEL AE, 1990, J IMMUNOL, V144, P2683; NGHIEM P, 1993, J BIOL CHEM, V268, P5471; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PASMANTIER R, 1986, ENDOCRINOLOGY, V199, P1229; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; SCHUBART UK, 1987, J BIOL CHEM, V262, P11871; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SOBEL A, 1989, J BIOL CHEM, V264, P3765; STRAHLER JR, 1992, J IMMUNOL, V149, P1191; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHU XX, 1989, J BIOL CHEM, V264, P14556	62	69	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25671	25680						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245003				2022-12-25	WOS:A1993MK10000058
J	GAN, ZR; LI, YP; CHEN, ZG; LEWIS, SD; SHAFER, JA				GAN, ZR; LI, YP; CHEN, ZG; LEWIS, SD; SHAFER, JA			IDENTIFICATION OF BASIC-AMINO-ACID RESIDUES IN THROMBIN ESSENTIAL FOR HEPARIN-CATALYZED INACTIVATION BY ANTITHROMBIN-III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; PRO-ARG CHLOROMETHYLKETONE; MOLECULAR-WEIGHT HEPARIN; HIGH-AFFINITY HEPARIN; FACTOR-XA; PROTEASE INACTIVATION; TRANSIENT KINETICS; CRYSTAL-STRUCTURE; BINDING; MECHANISM	The therapeutically important anticoagulant heparin catalyzes inactivation of thrombin by antithrombin III via formation of an intermediary ternary thrombin-heparin-antithrombin III complex that is subsequently converted to a stable thrombin-antithrombin III complex with the release of heparin. Point mutations at Arg-180, Arg-245, Lys-248, and Lys-252 in thrombin markedly reduced the efficiency of heparin catalysis by decreasing the stability of the ternary intermediate, whereas the inactivation of thrombin by antithrombin alone was not affected by these mutations. These results together with an analysis of the x-ray crystal structure of thrombin yielded a model for the thrombin-heparin interaction, wherein heparin forms salt linkages along a groove in thrombin defined by Lys-252, Lys-248, Arg-245, Arg-89, Arg-98, and Arg-180.	MERCK SHARP & DOHME LTD, DEPT BIOL CHEM, W POINT, PA 19486 USA	Merck & Company								BERESFORD CH, 1990, INT J BIOCHEM, V22, P121, DOI 10.1016/0020-711X(90)90172-Y; BJORK I, 1992, J BIOL CHEM, V267, P1976; BJORK I, 1989, HEPARIN CHEM BIOL PR, P229; BLOMBACK B, 1978, NATURE, V275, P501, DOI 10.1038/275501a0; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, PROTEIN SCI, V1, P426; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; Choay J, 1981, Ann N Y Acad Sci, V370, P644, DOI 10.1111/j.1749-6632.1981.tb29770.x; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; ESMON CT, 1986, ANN NY ACAD SCI, V485, P215, DOI 10.1111/j.1749-6632.1986.tb34583.x; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; GAN ZR, 1991, BIOCHEMISTRY-US, V30, P11694, DOI 10.1021/bi00114a013; GAN ZR, 1993, ARCH BIOCHEM BIOPHYS, V301, P228, DOI 10.1006/abbi.1993.1138; GRIFFITH MJ, 1983, P NATL ACAD SCI-BIOL, V80, P5460, DOI 10.1073/pnas.80.18.5460; HORNE A, 1992, BIOCHEMISTRY-US, V31, P2286, DOI 10.1021/bi00123a011; HOYER LW, 1981, J LAB CLIN MED, V97, P50; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; JORDAN RE, 1980, J BIOL CHEM, V255, P81; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; LAU HK, 1980, J BIOL CHEM, V255, P5885; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NESHEIM ME, 1983, J BIOL CHEM, V258, P4708; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; OLSON ST, 1986, J BIOL CHEM, V261, P3151; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1981, J BIOL CHEM, V256, P1065; POMERANTZ MW, 1978, BIOCHIM BIOPHYS ACTA, V535, P66, DOI 10.1016/0005-2795(78)90033-8; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; ROSENBERG RD, 1987, HEMOSTASIS THROMBOSI, P1373; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; SHAFER JA, 1988, CRIT REV CL LAB SCI, V26, P1; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2	41	127	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1301	1305						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288594				2022-12-25	WOS:A1994MR22000084
J	KHERA, PK; BLUMENTHAL, KM				KHERA, PK; BLUMENTHAL, KM			ROLE OF THE CATIONIC RESIDUES ARGININE-14 AND LYSINE-48 IN THE FUNCTION OF THE CARDIOTONIC POLYPEPTIDE ANTHOPLEURIN-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-ANEMONE TOXIN; NUCLEAR MAGNETIC-RESONANCE; RESISTANT NA+ CHANNELS; AMINO-ACID SEQUENCE; SECONDARY STRUCTURE; PHARMACOLOGICAL PROPERTIES; H-1-NMR ASSIGNMENTS; CARDIAC STIMULANT; AP-A; SULCATA	Polypeptide neurotoxins from sea anemones have been useful biological probes for sodium channel function. Cationic residues, specifically Arg-14, which is conserved in essentially all known sea anemone toxins, have been generally thought to be important determinants of their binding affinity and/or efficacy. In the present study, we have constructed site-directed mutants of the Anthopleura xanthogrammica toxin anthopleurin B (ApB) at Arg-14 and Lys-48 to characterize the roles played by these cationic residues in the biological activity of the toxin. Using a bacterial expression system developed in this laboratory, we have produced recombinant proteins having three substitutions at each of these positions. The proteins produced have been purified to homogeneity and have structures and conformational stabilities identical to wild-type ApB. We have assayed the mutants by determining their ability to enhance the veratridine-dependent uptake of sodium by both N1E-115 neuroblastoma cells and RT4-B cells, which express the cardiac/denervated skeletal muscle sodium channel. All mutants showed activities only slightly reduced from that of wild-type ApB, with the greatest reductions (4- and 6-fold) being observed for the mutants R14A and K48A, respectively. We conclude that contrary to results from chemical modification studies, Arg-14 is not essential for the biological activity of the toxin. Our data also indicate that Lys-48 plays a small but discernible role in the toxin-receptor interaction.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University of Cincinnati					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041543] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41543] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALSEN C, 1983, FED PROC, V42, P101; ALSEN C, 1976, N-S ARCH PHARMACOL, V295, P55, DOI 10.1007/BF00509773; BARHANIN J, 1981, J BIOL CHEM, V256, P5764; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARIELLO L, 1989, BIOCHEMISTRY-US, V28, P2484, DOI 10.1021/bi00432a020; CATTERALL WA, 1981, MOL PHARMACOL, V20, P533; CATTERALL WA, 1984, SCIENCE, V223, P653, DOI 10.1126/science.6320365; CATTERALL WA, 1977, J BIOL CHEM, V252, P8660; Cleland W W, 1979, Methods Enzymol, V63, P103; DONAHUE LM, 1991, DEV BIOL, V147, P415, DOI 10.1016/0012-1606(91)90299-I; FRELIN C, 1984, MOL PHARMACOL, V26, P70; GALLAGHER MJ, 1994, J BIOL CHEM, V269, P254; GALLAGHER MJ, 1992, J BIOL CHEM, V267, P13958; GOOLEY PR, 1986, BIOCHEMISTRY-US, V25, P2349, DOI 10.1021/bi00357a008; GOULD AR, 1990, EUR J BIOCHEM, V189, P145, DOI 10.1111/j.1432-1033.1990.tb15471.x; GROSS GJ, 1985, EUR J PHARMACOL, V110, P271, DOI 10.1016/0014-2999(85)90223-7; KOLKENBROCK HJ, 1983, 5TH P EUR S AN PLANT; MABBUTT BC, 1990, EUR J BIOCHEM, V187, P555, DOI 10.1111/j.1432-1033.1990.tb15337.x; MAHNIR VM, 1989, TOXICON, V27, P1075, DOI 10.1016/0041-0101(89)90001-9; NEWCOMB R, 1980, FRONTIERS PROTEIN CH, P539; NORTON RS, 1979, J BIOL CHEM, V254, P220; NORTON RS, 1991, TOXICON, V29, P1051, DOI 10.1016/0041-0101(91)90205-6; RAVENS U, 1976, N-S ARCH PHARMACOL, V296, P73, DOI 10.1007/BF00498842; REIMER NS, 1985, J BIOL CHEM, V260, P8690; RENAUD JF, 1986, EUR J PHARMACOL, V120, P161, DOI 10.1016/0014-2999(86)90536-4; ROMEY G, 1976, P NATL ACAD SCI USA, V73, P4055, DOI 10.1073/pnas.73.11.4055; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHWEITZ H, 1981, BIOCHEMISTRY-US, V20, P5245, DOI 10.1021/bi00521a023; SCRIABINE A, 1979, J CARDIOVASC PHARM, V1, P571, DOI 10.1097/00005344-197909000-00009; SHIBATA S, 1976, J PHARMACOL EXP THER, V199, P298; WIDMER H, 1988, EUR J BIOCHEM, V171, P177, DOI 10.1111/j.1432-1033.1988.tb13774.x; ZENG D, 1993, 1993 SOC NEUR ANN M	32	24	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					921	925						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288644				2022-12-25	WOS:A1994MR22000025
J	WENTHOLD, RJ; TRUMPY, VA; ZHU, WS; PETRALIA, RS				WENTHOLD, RJ; TRUMPY, VA; ZHU, WS; PETRALIA, RS			BIOCHEMICAL AND ASSEMBLY PROPERTIES OF GLUR6 AND KA2, 2 MEMBERS OF THE KAINATE RECEPTOR FAMILY, DETERMINED WITH SUBUNIT-SPECIFIC ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID BINDING-SITES; SELECTIVE GLUTAMATE RECEPTORS; HIGH-AFFINITY KAINATE; RAT-BRAIN; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; NERVOUS-SYSTEM; NMDA RECEPTOR; CHANNELS; AMPA	To examine subunit assembly and biochemical properties of two members of the kainate family of glutamate receptors (GluR), antibodies were made to synthetic peptides corresponding to the carboxyl termini of GluR6 and KA2. lmmunoblot analysis of membranes from human embryonic kidney cells transfected with glutamate receptor cDNAs showed that these antibodies are selective for their respective receptor subunit except that the antibody to GluR6 also recognizes GluR7, which is expected due to the sequence homology between the two subunits at the carboxyl terminus. In transfected cell membranes, immunoblot analysis with the antibody to GluR6 showed a major immunoreactive band at 118 kDa and minor bands at 103 and 28 kDa. The 103-kDa band appears to be a deglycosylated form of GluR6 since deglycosylation eliminates staining at 118 kDa and increases staining of the 103-kDa band. lmmunoblot analysis of KA2 transfected cell membranes shows a major band at 123 kDa and minor bands at 109 and 37 kDa. Deglycosylation converts the 123-kDa band into a 109-kDa. band. Analysis of brain tissues shows that both antibodies label single major bands which migrate at the same molecular masses as those from transfected cell membranes, 118 and 123 kDa for GluR6 and KA2, respectively. lmmunoprecipitation studies showed that antibodies to GluR6 and KA2 selectively immunoprecipitated [H-3]kainate binding activity, but not H-3-labeled alpha-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA) binding activity, from Triton X-100-solubilized rat brain membranes. Furthermore, each antibody co-immunoprecipitated GluR6 and KA2 from cells co-transfected with GluR6 and KA2 cDNAs and from detergent-solubilized rat brain membranes, indicating that these two subunits can coassemble into a molecular complex. Interestingly, GluR1 and GluR2, subunits of the AMPA receptor, also co-immunoprecipitated with GluR6 in cells co-transfected with GluR6 and GluR1 or GluR2 cDNAs. Such complexes appear to be present to a limited extent in the brain.			WENTHOLD, RJ (corresponding author), NIH,NATL INST DEAFNESS & COMMUN DIS,NEUROCHEM LAB,BLDG 36,RM 5D08,BETHESDA,MD 20892, USA.							BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BETTLER B, 1992, NEURON, V8, P257, DOI 10.1016/0896-6273(92)90292-L; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; HAMPSON DR, 1987, J NEUROCHEM, V49, P1209, DOI 10.1111/j.1471-4159.1987.tb10012.x; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; HUNTER C, 1990, J NEUROCHEM, V54, P118, DOI 10.1111/j.1471-4159.1990.tb13290.x; ISHII T, 1993, J BIOL CHEM, V268, P2836; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMELI H, 1992, FEBS LETT, V307, P139, DOI 10.1016/0014-5793(92)80753-4; MARTIN LJ, 1993, NEUROSCIENCE, V53, P327, DOI 10.1016/0306-4522(93)90199-P; MOLNAR E, 1993, NEUROSCIENCE, V53, P307, DOI 10.1016/0306-4522(93)90198-O; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONAGHAN DT, 1986, NEUROCHEM RES, V11, P1073, DOI 10.1007/BF00965595; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; PATEL S, 1986, NEUROSCI LETT, V70, P301, DOI 10.1016/0304-3940(86)90569-0; PAULSON HL, 1991, J CELL BIOL, V113, P1371, DOI 10.1083/jcb.113.6.1371; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; SAKIMURA K, 1992, NEURON, V8, P267, DOI 10.1016/0896-6273(92)90293-M; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1992, EMBO J, V11, P1651, DOI 10.1002/j.1460-2075.1992.tb05211.x; SOMMER B, 1992, TRENDS PHARMACOL SCI, V13, P291, DOI 10.1016/0165-6147(92)90088-N; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNNERSTALL JR, 1983, EUR J PHARMACOL, V86, P361, DOI 10.1016/0014-2999(83)90185-1; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WENTHOLD RJ, 1990, FEBS LETT, V276, P147, DOI 10.1016/0014-5793(90)80529-R; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0	37	106	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1332	1339						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288598				2022-12-25	WOS:A1994MR22000088
J	WOLINS, NE; DONALDSON, RP				WOLINS, NE; DONALDSON, RP			SPECIFIC BINDING OF THE PEROXISOMAL PROTEIN TARGETING SEQUENCE TO GLYOXYSOMAL MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION SEQUENCES; CASTOR-BEAN ENDOSPERM; ACYL-COA OXIDASE; ELECTRON-TRANSPORT; IMPORT RECEPTOR; SIGNAL; YEAST	It has been demonstrated that the carboxyl-terminal amino acid sequence, serine-lysine-leucine (SKL), is sufficient to direct a polypeptide to peroxisomes in vivo, and that this sequence is functional in plants, animals, and yeasts. Furthermore, many peroxisomal proteins have SKL carboxyl termini, including rat acyl-CoA oxidase. We have synthesized a I-125-peptide with the sequence of the last 12 amino acids of acyl-CoA oxidase, D-Tyr-HKHLKPLQSKL (SKLp), and used it to detect a receptor that recognizes SKL containing proteins targeted to glyoxysomes. SKLp binding to alkali-stripped glyoxysomal membranes was saturable and 80% of the binding could be displaced by 1 muM unlabeled SKLp or 8 mug/ml glyoxysomal matrix proteins. Very little specific binding was associated with endoplasmic reticulum or mitochondrial membranes. Specific binding was affected by the ionic composition of the medium; the binding was optimal at pH 6.5 and was inhibited by mono- and divalent cations. Scatchard analysis of SKLp binding to glyoxysomal membranes indicated that there were two binding sites with K(d) values of 160 and 1450 nM and abundances of 17 and 43 nmol/mg glyoxysomal membrane protein, respectively. Protease treatment of the alkali-stripped glyoxysomal membranes lowered the number of high affinity sites and destroyed all the low affinity sites. These results demonstrate, for the first time, that there is an integral membrane protein in glyoxysomes that has the characteristics of a receptor for protein import.	GEORGE WASHINGTON UNIV,DEPT BIOL SCI,WASHINGTON,DC 20052	George Washington University								ALANI AA, 1990, PLANT PHYSIOL, V94, P1842, DOI 10.1104/pp.94.4.1842; CHAPMAN KD, 1991, J CELL BIOL, V115, P995, DOI 10.1083/jcb.115.4.995; COOPER TG, 1969, J BIOL CHEM, V244, P3514; FANG TK, 1987, PLANTA, V172, P1, DOI 10.1007/BF00403023; FUJIKI Y, 1985, J BIOL CHEM, V260, P5603; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; LUSTER DG, 1987, PLANT PHYSIOL, V85, P796, DOI 10.1104/pp.85.3.796; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; PFALLER R, 1987, EMBO J, V9, P2635; SANTOS MJ, 1988, J BIOL CHEM, V263, P10502; SILVER P, 1989, J CELL BIOL, V109, P983, DOI 10.1083/jcb.109.3.983; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; SPARACE SA, 1979, PLANT PHYSIOL, V63, P963, DOI 10.1104/pp.63.5.963; STOCHAJ U, 1992, J CELL BIOL, V117, P473, DOI 10.1083/jcb.117.3.473; SUBRAMANI S, 1992, J MEMBRANE BIOL, V125, P99; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; WALTON PA, 1992, MOL CELL BIOL, V12, P531, DOI 10.1128/MCB.12.2.531; WILSON DW, 1993, J BIOL CHEM, V268, P7465	20	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1149	1153						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288574				2022-12-25	WOS:A1994MR22000060
J	ETTINGER, RA; ISMAIL, R; DELUCA, HF				ETTINGER, RA; ISMAIL, R; DELUCA, HF			CDNA CLONING AND CHARACTERIZATION OF A VITAMIN-D(3) HYDROXYLASE-ASSOCIATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY; 1,25-DIHYDROXYVITAMIN-D 24-HYDROXYLASE; SUBMITOCHONDRIAL LOCALIZATION; SUBCELLULAR-LOCALIZATION; ADRENAL-CORTEX; 25-HYDROXYCHOLECALCIFEROL; MITOCHONDRIA; METABOLISM; METHIONINE; ENZYMES	We previously reported the generation of monoclonal antibodies which immunoprecipitate a fraction of the total chick kidney 1,25-dihydroxyvitamin D3-24R-hydroxylase activity. These antibodies were used to screen a chick kidney lambdagt11 cDNA library resulting in the isolation of a full-length cDNA encoding a protein that is not the 1,25-dihydroxyvitamin D3-24R-hydroxylase but another protein we term the vitamin D3 hydroxylase-associated protein (VDHAP). The deduced amino acid sequence agreed with an NH2-terminal amino acid sequence from the isolated VDHAP. Gene and protein bank search did not identify homology to known sequences or functional domains in the VDHAP cDNA. VDHAP mRNA levels are not altered by conditions which either induce 1,25-dihydroxyvitamin D3-24R-hydroxylase activity (78-fold) or 25-hydroxyvitamin D3-1alpha-hydroxylase activity (30-fold). Northern analysis of poly(A)+ RNA from chick tissues revealed VDHAP only in kidney. Cellular fractionation experiments demonstrated that VDHAP and the 25-hydroxyvitamin D3-1alpha-hydroxylase are colocalized in the inner membrane of mitochondria. The VDHAP antibody immunoprecipitates 14% of the total 1,25-dihydroxyvitamin D3-24R-hydroxylase activity (7-fold over background) and immunoprecipitates 21% of the total 25-hydroxyvitamin D3-1alpha-hydroxylase activity (2-fold over background). VDHAP is a novel chick kidney-specific inner membrane protein of mitochondria, which associates with a fraction of the 1,25-dihydroxyvitamin D3-24R-hydroxylase and 25-hydroxyvitamin D3-1alpha-hydroxylase.	UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, 420 HENRY MALL, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NIDDK NIH HHS [DK-14881] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK014881] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1992, CURRENT PROTOCOLS MO; BOISSEL JP, 1985, P NATL ACAD SCI USA, V82, P8448, DOI 10.1073/pnas.82.24.8448; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN AJ, 1987, ANAL BIOCHEM, V164, P424, DOI 10.1016/0003-2697(87)90514-8; BURGOSTRINIDAD M, 1990, ANAL BIOCHEM, V190, P102, DOI 10.1016/0003-2697(90)90141-U; BURGOSTRINIDAD M, 1992, J BIOL CHEM, V267, P3498; BURGOSTRINIDAD M, 1991, BIOCHIM BIOPHYS ACTA, V1078, P226, DOI 10.1016/0167-4838(91)90562-E; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHEN KS, 1993, P NATL ACAD SCI USA, V90, P4543, DOI 10.1073/pnas.90.10.4543; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAME MC, 1986, BIOCHEMISTRY-US, V25, P4523, DOI 10.1021/bi00364a011; DeLuca HF, 1984, VITAMIN D BASIC CLIN, P1; DHANAKOTI SN, 1992, BIOCHEM J, V282, P369, DOI 10.1042/bj2820369; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; FRASER DR, 1970, NATURE, V228, P764, DOI 10.1038/228764a0; GARABEDIAN M, 1978, ENDOCRINOLOGY, V102, P1262, DOI 10.1210/endo-102-4-1262; GHAZARIAN JG, 1974, J BIOL CHEM, V49, P3026; GLOVER LA, 1992, BIOCHEM J, V284, P609, DOI 10.1042/bj2840609; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; GRAY R, 1971, SCIENCE, V172, P1232, DOI 10.1126/science.172.3989.1232; GRAY RW, 1972, J BIOL CHEM, V247, P7528; GRIBSKOV M, 1988, COMPUT APPL BIOSCI, V4, P61; HARLOW E, 1988, ANTIBODIES LABORATOR; HART LE, 1984, J NUTR, V114, P2059, DOI 10.1093/jn/114.11.2059; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; KALRA J, 1974, J BIOL CHEM, V249, P3255; KNUTSON JC, 1974, BIOCHEMISTRY-US, V13, P1543, DOI 10.1021/bi00704a034; KOHN J, 1982, BIOCHEM BIOPH RES CO, V107, P878, DOI 10.1016/0006-291X(82)90604-0; KUMAR R, 1978, J BIOL CHEM, V253, P3804; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCHE JL, 1978, J AM CHEM SOC, V100, P2226, DOI 10.1021/ja00475a040; MITANI F, 1982, J HISTOCHEM CYTOCHEM, V30, P1066, DOI 10.1177/30.10.6813370; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NEILANDS JB, 1955, METHOD ENZYMOL, V1, P449, DOI 10.1016/0076-6879(55)01074-4; NIMMOSMITH R, 1961, BIOCHIM BIOPHYS ACTA, V50, P166, DOI 10.1016/0006-3002(61)91074-5; OHYAMA Y, 1991, FEBS LETT, V278, P195, DOI 10.1016/0014-5793(91)80115-J; OHYAMA Y, 1991, J BIOL CHEM, V266, P8690; OKAMOTO Y, IN PRESS P SOC EXP B; OMDAHL J, 1971, BIOCHEMISTRY-US, V10, P2935, DOI 10.1021/bi00791a022; ORMEJOHNSON WH, 1969, J BIOL CHEM, V244, P6143; PFANNER N, 1987, J BIOL CHEM, V262, P14851; REEVE L, 1983, J BIOL CHEM, V258, P3615; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SHINKI T, 1992, J BIOL CHEM, V267, P13757; SNOKE JE, 1956, J BIOL CHEM, V223, P271; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; SUGIYAMA T, 1975, FEBS LETT, V52, P145, DOI 10.1016/0014-5793(75)80658-2; TSUNASAWA S, 1985, J BIOL CHEM, V260, P5382; YAGO N, 1970, J BIOCHEM, V68, P775, DOI 10.1093/oxfordjournals.jbchem.a129414; YAN X, 1987, BIOCHEM CELL BIOL, V65, P673, DOI 10.1139/o87-089; YOSHIDA A, 1972, J BIOL CHEM, V247, P952; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	54	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					176	182						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276793				2022-12-25	WOS:A1994MR21900035
J	VANDEKLUNDERT, FAJM; JANSEN, HJ; BLOEMENDAL, H				VANDEKLUNDERT, FAJM; JANSEN, HJ; BLOEMENDAL, H			A PROXIMAL PROMOTER ELEMENT IN THE HAMSTER DESMIN UPSTREAM REGULATORY REGION IS RESPONSIBLE FOR ACTIVATION BY MYOGENIC DETERMINATION FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC ENHANCER; DNA-BINDING; SUBUNIT GENE; MYC HOMOLOGY; MYOD FAMILY; EXPRESSION; CELLS; TRANSCRIPTION; PROTEINS; DISTINCT	The muscle-specific intermediate filament protein desmin is up-regulated during skeletal muscle differentiation. When myoblasts leave the cell cycle and fusion into multinucleated myotubes starts, genes associated with myogenesis become activated. The activation is believed to be mediated by the muscle-specific determination factors. We present evidence that both MyoD and myogenin are able to activate the transcription of the hamster desmin gene. A proximal promoter fragment of 89 base pairs is sufficient for this transactivation process. The single E-box in this region is essential for desmin promoter activity in mouse C2 skeletal muscle cells and upon co-transfection of a myogenin expression vector also in human primary fibroblasts. Mutation of this MyoD binding site abrogates desmin transcription, and transactivation of the promoter no longer occurs. By using gel electrophoretic mobility shift assays, we were able to demonstrate that nuclear proteins from C2 muscle cells and myogenin/E12 glutathione S-transferase fusion proteins are able to bind to the functional E-box consensus sequence. A second E-box, situated in a more upstream regulatory region, which also binds to purified Helix-Loop-Helix proteins in vitro is only moderately affected by site-directed in vitro mutagenesis.			VANDEKLUNDERT, FAJM (corresponding author), CATHOLIC UNIV NIJMEGEN,FAC SCI,DEPT BIOCHEM,6500 HB NIJMEGEN,NETHERLANDS.			Jansen, Hans/0000-0002-8563-4146				BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FINKEL T, 1993, J BIOL CHEM, V268, P5; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; FUJISAWASEHARA A, 1992, J BIOL CHEM, V267, P10031; GILMOUR BP, 1991, J BIOL CHEM, V266, P19871; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; KRIMPENFORT PJ, 1988, EMBO J, V7, P941, DOI 10.1002/j.1460-2075.1988.tb02899.x; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LI H, 1993, NUCLEIC ACIDS RES, V21, P335, DOI 10.1093/nar/21.2.335; LI ZL, 1991, J BIOL CHEM, V266, P6562; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAKATSUJI Y, 1992, MOL CELL BIOL, V12, P4384, DOI 10.1128/MCB.12.10.4384; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OTT MO, 1991, DEVELOPMENT, V111, P1097; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; PIEPER FR, 1987, EMBO J, V6, P3611, DOI 10.1002/j.1460-2075.1987.tb02692.x; PIEPER FR, 1988, MOL BIOL REP, V13, P59, DOI 10.1007/BF00805640; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; PRODY CA, 1992, NUCLEIC ACIDS RES, V20, P2367, DOI 10.1093/nar/20.9.2367; QUAX W, 1984, P NATL ACAD SCI-BIOL, V81, P5970, DOI 10.1073/pnas.81.19.5970; QUAX W, 1985, CELL, V43, P327, DOI 10.1016/0092-8674(85)90038-8; RAMAEKERS FCS, 1983, AM J SURG PATHOL, V7, P381, DOI 10.1097/00000478-198306000-00010; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; Sambrook J, 1989, MOL CLONING LABORATO; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VANDEKLUNDERT FAJM, 1992, GENE, V122, P337, DOI 10.1016/0378-1119(92)90223-C; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1; YAFFE D, 1977, DIFFERENTIATION, V7, P159, DOI 10.1111/j.1432-0436.1977.tb01507.x; YUTZEY KE, 1992, NUCLEIC ACIDS RES, V20, P5105, DOI 10.1093/nar/20.19.5105	58	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					220	225						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276797				2022-12-25	WOS:A1994MR21900041
J	WANG, SY				WANG, SY			A RETINOIC ACID-INDUCIBLE GATA-BINDING PROTEIN BINDS TO THE REGULATORY REGION OF J6 SERPIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; MOUSE TERATOCARCINOMA CELLS; EMBRYONAL CARCINOMA-CELLS; 5' FLANKING REGION; RESPONSIVE ELEMENT; MESSENGER-RNA; CDNA CLONES; STEM-CELLS; DIFFERENTIAL EXPRESSION; ENDOTHELIAL-CELLS	Transcription of the J6 gene (a member of the serpin family) is induced in murine F9 teratocarcinoma cells 24-48 h after retinoic acid (RA) treatment. Previously, we have identified a region of the J6 5'-flanking region (-1050 to -738) that is involved in regulating transcription of this gene. In this report, we show that a RA-induced nuclear protein in the F9 cell extract recognizes the GAGATAG sequence which is repeated four times in this regulatory region of the J6 gene. The kinetics of RA induction of the GAGATAG-binding protein correlates with that of J6 mRNA, suggesting that the GAGATAG-binding protein may be involved in the transactivation of the J6 gene in RA-treated F9 cells. Competition experiments demonstrate further that the RA- induced GAGATAG-binding protein is related to the transcription factors GATA-1 and GATA-2. Furthermore, insertion of the RA regulatory region of the J6 gene into a thymidine kinase promotor/chloramphenicol acetyltransferase expression vector causes an increase in chloramphenicol acetyltransferase expression by 5-8-fold in human HeLa cells when co-transfected with human GATA-2 or GATA-3 expression vectors. This suggests that the J6 gene is likely to be transactivated by the GATA-2, GATA-3, or related transcription factor, which is activated by retinoic acid during F9 cell differentiation.			WANG, SY (corresponding author), SUNY ALBANY,DEPT BIOL SCI,ALBANY,NY 12222, USA.				NATIONAL CANCER INSTITUTE [R29CA044955] Funding Source: NIH RePORTER; NCI NIH HHS [R29CA44955] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; BRULET P, 1983, P NATL ACAD SCI-BIOL, V80, P5641, DOI 10.1073/pnas.80.18.5641; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CLARKE EP, 1991, J BIOL CHEM, V266, P17230; COLBERGPOLEY AM, 1985, NATURE, V314, P713, DOI 10.1038/314713a0; CROCE CM, 1981, P NATL ACAD SCI-BIOL, V78, P5754, DOI 10.1073/pnas.78.9.5754; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DUDLER R, 1984, CELL, V38, P391, DOI 10.1016/0092-8674(84)90494-X; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GALSON DL, 1988, MOL CELL BIOL, V8, P381, DOI 10.1128/MCB.8.1.381; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GUDAS LJ, 1990, ANN NY ACAD SCI, V580, P245, DOI 10.1111/j.1749-6632.1990.tb17933.x; HIRAYOSHI K, 1991, MOL CELL BIOL, V11, P4036, DOI 10.1128/MCB.11.8.4036; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KURKINEN M, 1983, NUCLEIC ACIDS RES, V11, P6199, DOI 10.1093/nar/11.18.6199; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVINE RA, 1984, MOL CELL BIOL, V4, P2142, DOI 10.1128/MCB.4.10.2142; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARTIN CA, 1990, P NATL ACAD SCI USA, V87, P4804, DOI 10.1073/pnas.87.12.4804; MURPHY D, 1983, CELL, V35, P865, DOI 10.1016/0092-8674(83)90119-8; MURPHY SP, 1988, P NATL ACAD SCI USA, V85, P5587, DOI 10.1073/pnas.85.15.5587; NAGATA K, 1988, J BIOL CHEM, V263, P8344; NAGATA K, 1986, J CELL BIOL, V103, P223, DOI 10.1083/jcb.103.1.223; OSTAPCHUK P, 1986, P NATL ACAD SCI USA, V83, P8550, DOI 10.1073/pnas.83.22.8550; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; SCHIER AF, 1992, NATURE, V356, P804, DOI 10.1038/356804a0; SHERMAN MI, 1986, RETINOIDS CELL DIFFE; STACEY AJ, 1984, EMBO J, V3, P2279, DOI 10.1002/j.1460-2075.1984.tb02126.x; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WANG SY, 1990, J BIOL CHEM, V265, P15818; WANG SY, 1985, DEV BIOL, V107, P75, DOI 10.1016/0012-1606(85)90377-X; WANG SY, 1992, J BIOL CHEM, V267, P15362; WANG SY, 1983, P NATL ACAD SCI-BIOL, V80, P5880, DOI 10.1073/pnas.80.19.5880; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	56	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					607	613						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276858				2022-12-25	WOS:A1994MR21900096
J	EISENSTEIN, RS; TUAZON, PT; SCHALINSKE, KL; ANDERSON, SA; TRAUGH, JA				EISENSTEIN, RS; TUAZON, PT; SCHALINSKE, KL; ANDERSON, SA; TRAUGH, JA			IRON-RESPONSIVE ELEMENT-BINDING PROTEIN - PHOSPHORYLATION BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRITIN MESSENGER-RNA; TRANSFERRIN RECEPTOR EXPRESSION; SULFUR CLUSTER; SUBSTRATE-SPECIFICITY; RABBIT RETICULOCYTES; CYTOSOLIC ACONITASE; REGULATORY PROTEIN; REPRESSOR PROTEIN; IRE-BP; TRANSLATION	The iron-responsive element-binding protein (IRE-BP) is a cytosolic RNA-binding protein that functions in the maintenance of iron homeostasis by post-transcriptionally regulating transferrin receptor and ferritin synthesis. Little is known concerning how factors other than iron may modulate the activity of this central regulator of cellular iron utilization. We present evidence indicating that phosphorylation of the IRE-BP by protein kinase C (PKC) could provide a mechanism for regulation of IRE-BP function. Purified rat liver IRE-BP was phosphorylated by PKC up to 1.3 mol of phosphate/mol of protein with Ser the modified amino acid. Ser was also the phosphoacceptor in the IRE-BP in intact cells. The K(m) of PKC for the IRE-BP was 0.4 muM. Tryptic phosphopeptide mapping identified one major phosphopeptide plus several other peptides with lesser amounts of phosphate. Synthetic peptides of the IRE-BP containing Ser 138 (site A) and Ser 711 (site B) were phosphorylated by PKC. In HL 60 cells, addition of phorbol 12-myristate 13-acetate (PMA) stimulated IRE-BP phosphorylation within 30 min and increased high affinity IRE RNA binding activity 2-fold. After 90 min, the level of phosphorylation had increased further, and high affinity IRE RNA binding activity had increased 3-fold above the control. Incorporation of [S-35]Met into immunoprecipitable IRE-BP was not altered in cells treated with PMA for 30 or 90 min. PMA also stimulated IRE-BP phosphorylation in rat fibroblasts. Taken together, our studies begin to define a novel mechanism by which hormones, growth factors, and other agents may regulate cellular iron utilization through specific phosphoregulation of the IRE-BP.	UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA	University of California System; University of California Riverside	EISENSTEIN, RS (corresponding author), UNIV WISCONSIN, DEPT NUTR SCI, 1415 LINDEN DR, MADISON, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026738] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26738] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS ML, 1989, BIOCHIM BIOPHYS ACTA, V1012, P243, DOI 10.1016/0167-4889(89)90104-3; ANDREESEN R, 1984, BLUT, V49, P195, DOI 10.1007/BF00319822; BARTON HA, 1990, J BIOL CHEM, V265, P7000; BETTANY AJE, 1992, J BIOL CHEM, V267, P16531; BOMFORD AB, 1985, HEPATOLOGY, V5, P870, DOI 10.1002/hep.1840050528; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHAN LNL, 1992, J BIOL CHEM, V267, P8254; CHOU CC, 1986, MOL CELL BIOL, V6, P566, DOI 10.1128/MCB.6.2.566; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DAVIS RJ, 1987, J BIOL CHEM, V262, P6832; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; EMERYGOODMAN A, 1993, NUCLEIC ACIDS RES, V21, P1457, DOI 10.1093/nar/21.6.1457; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GOESSLING LS, 1992, SCIENCE, V256, P670, DOI 10.1126/science.1316633; GOOSSEN B, 1990, EMBO J, V9, P4127, DOI 10.1002/j.1460-2075.1990.tb07635.x; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; Hathaway G M, 1979, Methods Enzymol, V60, P495; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HENTZE MW, 1991, NUCLEIC ACIDS RES, V19, P1739, DOI 10.1093/nar/19.8.1739; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HIRLING H, 1992, NUCLEIC ACIDS RES, V20, P33, DOI 10.1093/nar/20.1.33; HO PTC, 1989, CANCER RES, V49, P1989; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KONIJN AM, 1981, BRIT J HAEMATOL, V49, P361, DOI 10.1111/j.1365-2141.1981.tb07238.x; Krebs EG, 1986, ENZYMES, V17, P3, DOI 10.1016/S1874-6047(08)60426-6; KUMAGAI N, 1987, J IMMUNOL, V139, P1391; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRICK JW, 1979, J SUPRAMOL STR CELL, V11, P579, DOI 10.1002/jss.400110415; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; MELEFORS O, 1993, J BIOL CHEM, V268, P5974; MISKIMINS WK, 1986, J CELL BIOL, V103, P1781, DOI 10.1083/jcb.103.5.1781; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MUNRO HN, 1992, NUTRITION GENE EXPRE, P525; NEMANI R, 1989, J BIOL CHEM, V264, P15361; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PALEN E, 1987, J BIOL CHEM, V262, P3518; PALEN E, 1990, FEBS LETT, V274, P12, DOI 10.1016/0014-5793(90)81317-H; PALEN E, 1991, BIOCHEMISTRY-US, V30, P5586, DOI 10.1021/bi00236a035; PATINO MM, 1992, J BIOL CHEM, V267, P19011; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PHILPOTT CC, 1991, NUCLEIC ACIDS RES, V19, P6333, DOI 10.1093/nar/19.22.6333; PRODROMOU C, 1992, EUR J BIOCHEM, V204, P599, DOI 10.1111/j.1432-1033.1992.tb16673.x; ROGERS JT, 1990, J BIOL CHEM, V265, P14572; ROUAULT TA, 1992, BIOMETALS, V5, P131, DOI 10.1007/BF01061319; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; Schmitz M L, 1991, Trends Cell Biol, V1, P130, DOI 10.1016/0962-8924(91)90118-S; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; TAHARA SM, 1981, J BIOL CHEM, V256, P1558; TANG CK, 1992, J BIOL CHEM, V267, P24466; TEIXEIRA S, 1991, EUR J BIOCHEM, V202, P819, DOI 10.1111/j.1432-1033.1991.tb16438.x; TESTA U, 1989, J BIOL CHEM, V264, P13181; TESTA U, 1991, J BIOL CHEM, V266, P13925; THEIL EC, 1990, J BIOL CHEM, V265, P4771; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; UMPHRESS JL, 1992, EUR J BIOCHEM, V203, P239, DOI 10.1111/j.1432-1033.1992.tb19852.x; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; VENEMA RC, 1991, J BIOL CHEM, V266, P5298; VINCENT JB, 1990, FASEB J, V4, P3009, DOI 10.1096/fasebj.4.12.2394317; YU Y, 1992, J BIOL CHEM, V267, P19005; ZHENG LM, 1992, ARCH BIOCHEM BIOPHYS, V299, P356, DOI 10.1016/0003-9861(92)90287-7; ZHENG LM, 1990, J BIOL CHEM, V265, P2814	75	116	117	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27363	27370						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262977				2022-12-25	WOS:A1993MM26200076
J	FUNK, CD; FURCI, L; FITZGERALD, GA; GRYGORCZYK, R; ROCHETTE, C; BAYNE, MA; ABRAMOVITZ, M; ADAM, M; METTERS, KM				FUNK, CD; FURCI, L; FITZGERALD, GA; GRYGORCZYK, R; ROCHETTE, C; BAYNE, MA; ABRAMOVITZ, M; ADAM, M; METTERS, KM			CLONING AND EXPRESSION OF A CDNA FOR THE HUMAN PROSTAGLANDIN-E RECEPTOR-EP(1) SUBTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG; SMOOTH-MUSCLE; CELL-LINE; AGONIST; PROTEIN	A functional cDNA clone coding for the human prostaglandin E receptor EP1 subtype has been isolated from a human erythroleukemia cell cDNA library probed by low-stringency hybridization using a polymerase chain reaction fragment of the human thromboxane receptor. The human EP1 receptor is comprised of 402 amino acids with a predicted molecular mass of 41,858 and has the topography common to all G-protein-coupled receptors with seven predicted transmembrane spanning domains. Prostaglandin (PG) E2 challenge of Xenopus oocytes injected with EP1 cDNA resulted in an increase in intracellular Ca2+. In addition, the rank order of potency for prostaglandins in competition for [H-3]PGE2 specific binding to membranes prepared from EP1 cDNA transfected COS cells was PGE2 > PGE1 > PGF2alpha > PGD2. Furthermore, the EP1 receptor-selective antagonists AH 6809 and SC19220 were more potent than the EP2 receptor-selective agonist butaprost in these competition binding assays. In summary, therefore, we have cloned the human EP1 receptor subtype which is functionally coupled to an increase in intracellular Ca2+.	MERCK FROST CTR THERAPEUT RES,DEPT PHARMACOL,POB 1005,POINTE CLAIRE,DORVAL H9R 4P8,PQ,CANADA; MERCK FROSST CTR THERAPEUT RES,DEPT MOLEC BIOL,DORVAL H9R 4P8,PQ,CANADA; VANDERBILT UNIV,MED CTR,SCH MED,DIV CLIN PHARMACOL,NASHVILLE,TN 37232	Merck & Company; Vanderbilt University			FitzGerald, Garret A/A-4222-2010; Funk, Colin D/A-9518-2010; Furci, Lucinda/I-8752-2012	Grygorczyk, Ryszard/0000-0002-9798-7651; Funk, Colin/0000-0001-7029-4233	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002710, R01HL030400] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02710, HL30400] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUNCE KT, 1987, GASTROENTEROLOGY, V92, P1332; Campbell W. B., 1990, PHARMACOL BASIS THER, P600; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN RA, 1985, PROSTAGLANDINS, V29, P363, DOI 10.1016/0090-6980(85)90096-6; COLEMAN RA, 1990, COMPREHENSIVE MED CH, V3, P643; Coleman RA, 1985, BRIT J PHARMACOL, V85, P273; Colman A., 1984, TRANSCRIPTION TRANSL, P49; DONG YJ, 1986, BRIT J PHARMACOL, V87, P97, DOI 10.1111/j.1476-5381.1986.tb10161.x; EGLEN RM, 1988, BRIT J PHARMACOL, V94, P591, DOI 10.1111/j.1476-5381.1988.tb11565.x; EHRENPREIS S, 1973, NATURE-NEW BIOL, V245, P280, DOI 10.1038/newbio245280a0; FREY EA, 1993, EUR J PHARM-MOLEC PH, V244, P239, DOI 10.1016/0922-4106(93)90149-4; GARDINER PJ, 1986, BRIT J PHARMACOL, V87, P45, DOI 10.1111/j.1476-5381.1986.tb10155.x; GILADI E, 1991, BIOTECHNIQUES, V10, P744; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HEDGVIST P, 1972, NEUROPHARMACOLOGY, V11, P177; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HONDA A, 1993, J BIOL CHEM, V268, P7759; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAWRENCE RA, 1992, BRIT J PHARMACOL, V105, P817, DOI 10.1111/j.1476-5381.1992.tb09063.x; LAWRENCE RA, 1992, BRIT J PHARMACOL, V105, P271, DOI 10.1111/j.1476-5381.1992.tb14245.x; LOUTTIT JB, 1992, 8TH INT C PROST REL; MCKENNIFF M, 1988, EUR J PHARMACOL, V153, P149, DOI 10.1016/0014-2999(88)90601-2; Sambrook J, 1989, MOL CLONING LABORATO; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; WATABE A, 1993, J BIOL CHEM, V268, P20175; WATANABE T, 1991, BLOOD, V78, P2328	31	275	303	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26767	26772						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253813				2022-12-25	WOS:A1993MK42500110
J	JACONI, MEE; LEW, DP; MONOD, A; KRAUSE, KH				JACONI, MEE; LEW, DP; MONOD, A; KRAUSE, KH			THE REGULATION OF STORE-DEPENDENT CA2+ INFLUX IN HL-60 GRANULOCYTES INVOLVES GTP-SENSITIVE ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-NEUTROPHILS; BINDING PROTEINS; PLASMA-MEMBRANE; INOSITOL PHOSPHATES; CHOLERA-TOXIN; CA-2+ INFLUX; CELLS; INHIBITION; ENTRY	In granulocytes, emptying of intracellular Ca2+ stores activates Ca2+ influx across the plasma membrane. To study the putative role of GTP-binding proteins in this process, we have introduced non-hydrolyzable guanosine phosphate analogues into the cytosol of non-permeabilized HL-60 granulocytes using an endocytosis-hypoosmotic shock procedure. At the cytosolic concentrations obtained (100-500 muM), neither guanosine 5'-3-O-(thio)triphosphate (GTPgammaS) nor guanosine 5'-3-O-(thio)diphosphate (GDPbetaS) affected basal [Ca2+]i. Call release in response to the receptor agonist fMet-Leu-Phe, the Ca2+-ATPase inhibitor thapsigargin, or the Ca2+ ionophore ionomycin was also unaffected by GTPgammaS or GDPbetaS. In contrast, the activation of the Ca2+ influx pathway by fMet-Leu-Phe or by thapsigargin was blocked by GTPgammaS but not by GDPbetaS. The GTPgammaS effect was mimicked by NaF. The GTPgammaS and NaF effects were independent of protein kinase C activation and actin polymerization. Our results demonstrate that a GTP-sensitive element is involved in the signaling between intracellular Ca2+ stores and plasma membrane Ca2+ channels. The identical effects of GTPgammaS and NaF suggest that the GTP-sensitive element is a heterotrimeric G-protein.			JACONI, MEE (corresponding author), UNIV GENEVA,HOP CANTONAL,DIV INFECT DIS,CH-1211 GENEVA 4,SWITZERLAND.			Jaconi, Marisa/0000-0002-2004-8226				BENGTSSON T, 1990, P NATL ACAD SCI USA, V87, P2921, DOI 10.1073/pnas.87.8.2921; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; CLAPHAM DE, 1993, NATURE, V364, P763, DOI 10.1038/364763a0; DEMAUREX N, 1993, J PHYSIOL-LONDON, V466, P329; DEMAUREX N, 1992, J CLIN INVEST, V90, P830, DOI 10.1172/JCI115958; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; FASOLATO C, 1993, J BIOL CHEM, V288, P20737; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOUY H, 1991, J IMMUNOL, V147, P757; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; INGUEZLLUHI J, 1993, TRENDS CELL BIOL, V3, P230; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KRAUSE KH, 1993, BLOOD CELLS, V19, P165; KRAUSE KH, 1985, J CLIN INVEST, V76, P1348, DOI 10.1172/JCI112109; MONTERO M, 1993, J BIOL CHEM, V268, P13055; NARASIMHAN V, 1988, J BIOL CHEM, V263, P19626; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; Penner R, 1993, Curr Opin Neurobiol, V3, P368, DOI 10.1016/0959-4388(93)90130-Q; PITTET D, 1989, J BIOL CHEM, V264, P7251; PRENTKI M, 1984, J BIOL CHEM, V259, P3777; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RECHSTEINER M, 1992, METHOD ENZYMOL, V149, P42; RODBELL M, 1992, CURR TOP CELL REGUL, V32, P1; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	32	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26075	26078						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253721				2022-12-25	WOS:A1993MK42500012
J	MORI, Y; MATSUBARA, H; FOLCO, E; SIEGEL, A; KOREN, G				MORI, Y; MATSUBARA, H; FOLCO, E; SIEGEL, A; KOREN, G			THE TRANSCRIPTION OF A MAMMALIAN VOLTAGE-GATED POTASSIUM CHANNEL IS REGULATED BY CAMP IN A CELL-SPECIFIC MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CYCLIC-AMP; GENE-EXPRESSION; RESPONSE ELEMENT; FACTOR CREB; SOMATOSTATIN GENE; NERVOUS-SYSTEM; RAT-BRAIN; BINDING; SHAKER	The transcript of Kv1.5, a Shaker-like delayed rectifier K+ channel cloned in our laboratory, is regulated in both tissue and developmentally specific manners. In this study we characterized the 5'-flanking region of the Kv1.5 gene. The gene lacks a canonical TATA box, has several transcription start sites, and the 5'-noncoding sequence is intronless. A cAMP response element (CRE) consensus signal was identified in the 5'-noncoding region. cAMP regulates the expression of Kv1.5 gene in a cell-specific manner. In primary cardiac cells, cAMP induces a 6-fold increase in the steady state levels of Kv1.5 transcript. However, in GH3 cells cAMP induces a 5-6-fold decrease in steady state levels of Kv1.5 transcript. The half-life of Kv1.5 transcript is 37 min and is not affected by cAMP. Nuclear run-on experiments show that in GH3 cells, cAMP reduces the transcription rate of Kv1.5 gene. Transient transfection assays using 5'-deletion mutations of Kv1.5 5'-flanking sequences revealed that the CRE located at +636 can confer the cAMP inducibility to Kv1.5 reporter gene constructs and binds to CRE-binding protein (CREB) and CRE modulator protein (CREM) in electromobility gel shift assays. Furthermore, KCl-induced depolarization can increase the steady state levels of Kv1.5 transcript in primary atrial cells and decrease it in GH3 cells. We conclude that cAMP and depolarization play an important role in regulating K+ channel expression and thus may induce long term effects on the pattern of electrical activity of excitable cells.	BRIGHAM & WOMENS HOSP,DIV CARDIOL,75 FRANCIS ST,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046005] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 46005] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSBEL FM, 1988, CURRENT PROTOCOLS MO; BECKH S, 1990, EMBO J, V9, P777, DOI 10.1002/j.1460-2075.1990.tb08173.x; BERGER SL, 1987, METHODS ENZYMOLOGY G; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; CELENO P, 1989, BIOTECHNIQUES, V7, P942; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COLLINS S, 1990, J BIOL CHEM, V265, P19330; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GRIESHAMMER U, 1992, CELL, V69, P79, DOI 10.1016/0092-8674(92)90120-2; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; ILBOURNE EJ, 1992, J BIOL CHEM, V267, P7563; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; Kaczmarek LK, 1987, NEUROMODULATION BIOC; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; KOREN G, 1990, NEURON, V2, P39; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; MAHDAVI V, 1989, CELLULAR MOL BIOL MU, P369; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MATSUBARA H, 1991, J BIOL CHEM, V266, P13324; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MEYER TE, 1993, ENDOCRINOLOGY, V132, P770, DOI 10.1210/en.132.2.770; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NGUYEN TV, 1990, J NEUROSCI, V10, P285; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STROKE IL, 1985, J MOL BIOL, V184, P183, DOI 10.1016/0022-2836(85)90372-9; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242	42	97	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26482	26493						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253777				2022-12-25	WOS:A1993MK42500071
J	OHTAKI, T; MASUDA, Y; ISHIBASHI, Y; KITADA, C; ARIMURA, A; FUJINO, M				OHTAKI, T; MASUDA, Y; ISHIBASHI, Y; KITADA, C; ARIMURA, A; FUJINO, M			PURIFICATION AND CHARACTERIZATION OF THE RECEPTOR FOR PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; BINDING-SITES; HIGH-AFFINITY; RAT-BRAIN; HYPOTHALAMIC POLYPEPTIDE; MOLECULAR-IDENTIFICATION; STRUCTURAL REQUIREMENTS; HORMONE-RECEPTOR; PEPTIDE PACAP; CELLS	Pituitary adenylate cyclase-activating polypeptide (PACAP) is a 38-amino acid peptide (PACAP38) or a truncated peptide with the same 27 amino-terminal residues (PACAP27). The PACAP receptor was solubilized from bovine brain membranes with digitonin and purified 30-fold by the combination of DEAE-Toyopearl and hydroxylapatite chromatographic analyses. The partially purified PACAP receptors were mixed with biotinylated PACAP27 to form receptor-ligand complexes and then adsorbed onto avidin-agarose. The adsorbed PACAP receptors were eluted with an acidic buffer containing 1.0 M NaCl (pH 4.0). The eluted receptors were purified further by hydroxylapatite and gel filtration chromatography. A single protein band with a M(r) 55,000-60,000 was found in the final preparation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and silver staining. Affinity labeling of the purified receptors with I-125-PACAP27 labeled the M(r) 55,000-60,000 protein specifically. The dissociation constant and the specific activity of the purified receptors were 25.8 pM and 17.2 nmol of ligand binding per mg of protein, respectively. Inhibitory constants determined by competitive binding experiments were 30.0 pM for PACAP27, 4.6 pM for PACAP38, and 37.3 nM for vasoactive intestinal peptide. Therefore, the purified PACAP receptor retained high affinity and ligand specificity. The sequence of the amino-terminal 29 residues was derived from the purified receptor.	TULANE UNIV,HEBERT CTR,US JAPAN BIOMED RES LABS,BELLE CHASSE,LA 70037; TULANE UNIV,SCH MED,DEPT MED,NEW ORLEANS,LA 70112; TULANE UNIV,SCH MED,DEPT ANAT,NEW ORLEANS,LA 70112; TULANE UNIV,SCH MED,DEPT PHYSIOL,NEW ORLEANS,LA 70112	Tulane University; Tulane University; Tulane University; Tulane University	OHTAKI, T (corresponding author), TAKEDA CHEM IND LTD,DIV DISCOVERY RES,DISCOVERY RES LABS 1,WADAI 10,TSUKUBA,IBARAKI 30042,JAPAN.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCAIL L, 1990, FEBS LETT, V262, P77, DOI 10.1016/0014-5793(90)80158-F; CAUVIN A, 1991, REGUL PEPTIDES, V35, P161, DOI 10.1016/0167-0115(91)90478-Y; CAUVIN A, 1990, PEPTIDES, V11, P773, DOI 10.1016/0196-9781(90)90194-A; CHANG KJ, 1975, BIOCHIM BIOPHYS ACTA, V406, P294, DOI 10.1016/0005-2736(75)90011-5; CULLER MD, 1991, ENDOCRINOLOGY, V129, P2260, DOI 10.1210/endo-129-4-2260; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; EPPLER CM, 1992, J BIOL CHEM, V267, P15603; FELDMAN RI, 1990, J BIOL CHEM, V265, P17364; GOTTSCHALL PE, 1990, ENDOCRINOLOGY, V127, P272, DOI 10.1210/endo-127-1-272; GOTTSCHALL PE, 1991, FASEB J, V5, P194, DOI 10.1096/fasebj.5.2.1848519; GOURLET P, 1991, EUR J BIOCHEM, V195, P535, DOI 10.1111/j.1432-1033.1991.tb15734.x; HAZUM E, 1986, J BIOL CHEM, V261, P3043; HOSOYA M, 1993, BIOCHEM BIOPH RES CO, V194, P133, DOI 10.1006/bbrc.1993.1795; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; KAWAI K, 1992, LIFE SCI, V50, P257, DOI 10.1016/0024-3205(92)90332-J; KIMURA C, 1990, BIOCHEM BIOPH RES CO, V166, P81, DOI 10.1016/0006-291X(90)91914-E; KOZUKA M, 1991, J BIOL CHEM, V266, P16892; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM HC, 1990, EUR J BIOCHEM, V193, P725, DOI 10.1111/j.1432-1033.1990.tb19392.x; MASUDA Y, 1990, BIOCHEM BIOPH RES CO, V172, P709, DOI 10.1016/0006-291X(90)90732-3; MASUO Y, 1992, BRAIN RES, V575, P113, DOI 10.1016/0006-8993(92)90430-H; MAZELLA J, 1988, J BIOL CHEM, V263, P144; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1990, BIOCHEM BIOPH RES CO, V170, P643, DOI 10.1016/0006-291X(90)92140-U; MURPHY JB, 1960, BIOCHIM BIOPHYS ACTA, V45, P382, DOI 10.1016/0006-3002(60)91464-5; OGI K, 1990, BIOCHEM BIOPH RES CO, V173, P1271, DOI 10.1016/S0006-291X(05)80924-6; OHTAKI T, 1990, BIOCHEM BIOPH RES CO, V171, P838, DOI 10.1016/0006-291X(90)91222-E; ROBBERECHT P, 1992, EUR J BIOCHEM, V207, P239, DOI 10.1111/j.1432-1033.1992.tb17043.x; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHIVERS BD, 1991, ENDOCRINOLOGY, V128, P3055, DOI 10.1210/endo-128-6-3055; TATSUNO I, 1990, BIOCHEM BIOPH RES CO, V168, P1027, DOI 10.1016/0006-291X(90)91132-C; TATSUNO I, 1991, ENDOCRINOLOGY, V129, P1797, DOI 10.1210/endo-129-4-1797; WATANABE T, 1992, BIOCHEM BIOPH RES CO, V182, P403, DOI 10.1016/S0006-291X(05)80159-7; WATANABE T, 1990, BIOCHEM BIOPH RES CO, V173, P252, DOI 10.1016/S0006-291X(05)81049-6	35	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26650	26657						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253796				2022-12-25	WOS:A1993MK42500092
J	TERRY, MJ; MAINES, MD; LAGARIAS, JC				TERRY, MJ; MAINES, MD; LAGARIAS, JC			INACTIVATION OF PHYTOCHROME-CHROMOPHORE AND PHYCOBILIPROTEIN-CHROMOPHORE PRECURSORS BY RAT-LIVER BILIVERDIN REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG HYPOCOTYL MUTANTS; INVITRO ATTACHMENT; BILE-PIGMENTS; EXPRESSION; ADDUCT; APOPHYCOCYANIN; BIOSYNTHESIS; ARABIDOPSIS; VARIANTS; BILINS	The phytochrome chromophore precursor, 3E-phytochromobilin, and the phycobiliprotein chromophore precursors, 3E-phycocyanobilin and 3E-phycoerythrobilin, are enzymatically converted to novel rubinoid products by purified rat liver biliverdin reductase. Phytochromobilin and phycocyanobilin are particularly good substrates for biliverdin reductase with K(m) and V(max) values very similar to those of the natural substrate, biliverdin IXalpha. Phycoerythrobilin is the least preferred of the three bilin substrates. H-1 NMR spectroscopy of phycocyanorubin, the product of phycocyanobilin catalysis by biliverdin reductase, and comparison of absorption spectra of all three rubinoid products reveal that the C10 methine bridge is selectively reduced by biliverdin reductase without altering the A-ring ethylidene substituent. In vitro phytochrome assembly experiments demonstrate that the phytorubin products do not form photoactive adducts with recombinant apophytochrome. These results suggest that ectopic expression of biliverdin reductase in plants will prevent assembly of the functional photoreceptor and thus will potentially alter light-mediated plant growth and development.	UNIV CALIF DAVIS,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616; UNIV ROCHESTER,EASTMAN SCH MUS,DEPT BIOPHYS,ROCHESTER,NY 14627	University of California System; University of California Davis; University of Rochester			Lagarias, John Clark/L-3139-2013; Terry, Matthew/B-3000-2012; Terry, Matthew/ABE-6419-2020	Lagarias, John Clark/0000-0002-2093-0403; Terry, Matthew/0000-0001-5002-2708; Terry, Matthew/0000-0001-5002-2708	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004066] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES04066] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARCIERO DM, 1988, J BIOL CHEM, V263, P18343; ARCIERO DM, 1988, J BIOL CHEM, V263, P18358; ARCIERO DM, 1988, J BIOL CHEM, V263, P18350; AWRUCH J, 1984, BIOCHIM BIOPHYS ACTA, V87, P146; BEALE SI, 1993, CHEM REV, V93, P785, DOI 10.1021/cr00018a008; BEALE SI, 1991, J BIOL CHEM, V266, P22333; CHAPMAN DJ, 1967, J AM CHEM SOC, V89, P5976, DOI 10.1021/ja00999a058; CHORY J, 1989, PLANT CELL, V1, P867, DOI 10.1105/tpc.1.9.867; COLE WJ, 1967, J AM CHEM SOC, V89, P3643, DOI 10.1021/ja00990a055; CORNEJO J, 1992, J BIOL CHEM, V267, P14790; ELICH TD, 1989, J BIOL CHEM, V264, P12902; ELICH TD, 1989, J BIOL CHEM, V264, P183; FAKHRAI H, 1992, J BIOL CHEM, V267, P4023; Falk H., 1989, CHEM LINEAR OLIGOPYR; FRYDMAN RB, 1987, BIOCHIM BIOPHYS ACTA, V916, P500, DOI 10.1016/0167-4838(87)90197-X; GLAZER AN, 1989, J BIOL CHEM, V264, P1; GOSSAUER A, 1974, LIEBIGS ANN CHEM, P1496; HUANG TJ, 1989, ARCH BIOCHEM BIOPHYS, V274, P617, DOI 10.1016/0003-9861(89)90477-3; HUANG TJ, 1990, MOL PHARMACOL, V37, P25; HUANG TJ, 1989, J BIOL CHEM, V264, P7844; KUTTY RK, 1981, J BIOL CHEM, V256, P3956; LAGARIAS JC, 1987, PHOTOCHEM PHOTOBIOL, V46, P5, DOI 10.1111/j.1751-1097.1987.tb04729.x; LI LM, 1992, J BIOL CHEM, V267, P19204; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAINES MD, 1990, MOL PHARMACOL, V38, P481; MCDONAGH AF, 1980, BIOCHEM J, V189, P193, DOI 10.1042/bj1890193; NAGATANI A, 1993, PLANT PHYSIOL, V102, P269, DOI 10.1104/pp.102.1.269; PARKS BM, 1991, PLANT CELL, V3, P1177, DOI 10.1105/tpc.3.11.1177; PARKS BM, 1989, PLANT MOL BIOL, V12, P425, DOI 10.1007/BF00017582; QUAIL PH, 1991, ANNU REV GENET, V25, P389, DOI 10.1146/annurev.ge.25.120191.002133; SINGLETON JW, 1965, J BIOL CHEM, V240, P4780; STOLL MS, 1977, BIOCHEM J, V163, P59, DOI 10.1042/bj1630059; TERRY MJ, 1991, J BIOL CHEM, V266, P22215; TERRY MJ, 1993, ARCH BIOCHEM BIOPHYS, V306, P1, DOI 10.1006/abbi.1993.1473; WAHLEITHNER JA, 1991, P NATL ACAD SCI USA, V88, P10387, DOI 10.1073/pnas.88.23.10387; WELLER JP, 1980, CHEM BER-RECL, V113, P1603, DOI 10.1002/cber.19801130439	36	96	101	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26099	26106						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253726				2022-12-25	WOS:A1993MK42500017
J	VIDUGIRIS, GJA; HARRINGTON, JP; FRIEDMAN, JM; HIRSCH, RE				VIDUGIRIS, GJA; HARRINGTON, JP; FRIEDMAN, JM; HIRSCH, RE			ABSENCE OF LIGAND BINDING-INDUCED TERTIARY CHANGES IN THE MULTIMERIC EARTHWORM LUMBRICUS-TERRESTRIS HEMOGLOBIN - A RESONANCE RAMAN-STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR HEMOGLOBIN; QUATERNARY STRUCTURE; HEME PROTEINS; DISSOCIATION; DYNAMICS; PH; REASSOCIATION; SPECTROSCOPY; SCATTERING; SUBUNIT	In vertebrate hemoglobins, changes in protein tertiary structure induced by either ligand binding or changes in quaternary state are manifested at the heme as reflected in resonance Raman spectral changes involving the iron-proximal histidine stretching mode. No such changes are observed for Lumbricus terrestris hemoglobin. The iron-histidine stretching mode and the porphyrin breathing motion in the deoxy-, oxy-, or CO-photodissociated forms of Lumbricus hemoglobin and human hemoglobin A (pH 7.0 and 9.2, the latter to effect Lumbricus hemoglobin subunit dissociation) were studied using pulsed (10 ns) light at 435 nm. In contrast to that observed for hemoglobin A, a comparison of the spectra of the deoxy and photoproduct forms of Lumbricus hemoglobin reveal minimal differences in the region of the iron-histidine and the pi electron distribution in the heme moiety. The spectral frequencies are similar to that observed in R-state vertebrate hemoglobins. Such average behavior of the approximately 192 hemes present in Lumbricus hemoglobin is more analogous to the Raman spectral properties observed in myoglobin.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PHYSIOL BIOPHYS,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,DIV HEMATOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT ANAT & STRUCT BIOL,BRONX,NY 10461; UNIV SO ALABAMA,DEPT CHEM,MOBILE,AL 36688	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of South Alabama					NIDDK NIH HHS [DK 41253] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041253] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHAMPION PM, 1992, J RAMAN SPECTROSC, V23, P557, DOI 10.1002/jrs.1250231008; FINDSEN EW, 1985, J AM CHEM SOC, V107, P3355, DOI 10.1021/ja00297a056; FRIEDMAN JM, 1982, SCIENCE, V218, P1244, DOI 10.1126/science.7146910; FRIEDMAN JM, 1982, ANNU REV PHYS CHEM, V33, P471, DOI 10.1146/annurev.pc.33.100182.002351; FRIEDMAN JM, 1985, SCIENCE, V228, P1273, DOI 10.1126/science.4001941; FUSHITANI K, 1986, J BIOL CHEM, V261, P8414; GIBSON QH, 1991, J BIOL CHEM, V266, P13097; HARRINGT.JP, 1973, BIOCHIM BIOPHYS ACTA, V328, P61, DOI 10.1016/0005-2795(73)90330-9; HARRINGTON JP, 1991, BIOCHIM BIOPHYS ACTA, V1076, P351, DOI 10.1016/0167-4838(91)90475-F; HERSKOVITS TT, 1975, BIOCHEMISTRY-US, V14, P4964, DOI 10.1021/bi00693a027; KAPP OH, 1984, J BIOL CHEM, V259, P628; KITAGAWA T, 1976, J AM CHEM SOC, V98, P5169, DOI 10.1021/ja00433a019; MAINWARING MG, 1986, J BIOL CHEM, V261, P899; OWNBY DW, 1993, J BIOL CHEM, V268, P13539; ROUSSEAU DL, 1993, J BIOL CHEM, V268, P5719; ROUSSEAU DL, 1983, ANNU REV BIOPHYS BIO, V12, P357, DOI 10.1146/annurev.bb.12.060183.002041; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; SCOTT TW, 1984, J AM CHEM SOC, V106, P5677, DOI 10.1021/ja00331a044; SPIRO TG, 1990, BIOCHEMISTRY-US, V29, P4497, DOI 10.1021/bi00471a001; Vinogrador S.N., 1986, P25; VINOGRADOV SN, 1988, COMP BIOCHEM PHYS B, V91, P577, DOI 10.1016/0305-0491(88)90024-7; VINOGRADOV SN, 1986, P NATL ACAD SCI USA, V83, P8034, DOI 10.1073/pnas.83.21.8034; VINOGRADOV SN, 1991, J BIOL CHEM, V266, P13091	23	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26190	26192						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253738				2022-12-25	WOS:A1993MK42500029
J	BRADSHER, JN; JACKSON, KW; CONAWAY, RC; CONAWAY, JW				BRADSHER, JN; JACKSON, KW; CONAWAY, RC; CONAWAY, JW			RNA POLYMERASE-II TRANSCRIPTION FACTOR-SIII .1. IDENTIFICATION, PURIFICATION, AND PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENERAL INITIATION-FACTOR; MAJOR LATE PROMOTER; ELONGATION FACTOR-SII; ASCITES TUMOR-CELLS; RAT-LIVER; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-ANALYSIS; UPSTREAM ELEMENT; FACTOR-EPSILON; FACTOR-TAU	A transcription factor that stimulates synthesis of accurately initiated transcripts by RNA polymerase II has been identified and purified to apparent homogeneity from rat liver nuclear extracts. This factor, which we designate SIII, has a native molecular mass of approximately 140 kDa and is composed of three polypeptides of 110, 18, and 15 kDa. All three polypeptides are required to reconstitute SIII transcriptional activity. SIII appears distinct from previously identified mammalian transcription factors.	OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,825 NE 13TH ST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,WILLIAM K WARREN MED RES INST,OKLAHOMA CITY,OK 73190	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center				Conaway, Joan/0000-0002-2786-0663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041628, R37GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHAFIN DR, 1991, J BIOL CHEM, V266, P9256; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1990, J BIOL CHEM, V265, P7552; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; EGLY JM, 1984, EMBO J, V3, P363; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1992, J BIOL CHEM, V267, P2786; GARRETT KP, 1992, J BIOL CHEM, V267, P23942; GERARD M, 1991, J BIOL CHEM, V266, P20940; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HENRY NL, 1992, J BIOL CHEM, V267, P23388; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KRAUSKOPF A, 1991, MOL CELL BIOL, V11, P3515, DOI 10.1128/MCB.11.7.3515; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MONCOLLIN V, 1986, EMBO J, V5, P2577, DOI 10.1002/j.1460-2075.1986.tb04537.x; NATORI S, 1973, J BIOCHEM, V73, P879, DOI 10.1093/oxfordjournals.jbchem.a130150; NUGENT KD, 1988, J CHROMATOGR, V443, P381, DOI 10.1016/S0021-9673(00)94809-X; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; PETERSON MG, 1991, NATURE, V354, P369; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; PUGH BF, 1992, J BIOL CHEM, V267, P679; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; RANISH JA, 1991, J BIOL CHEM, V266, P19320; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINBERG D, 1987, J BIOL CHEM, V262, P3322; REINES D, 1989, J BIOL CHEM, V264, P10799; SAMUELS M, 1986, J BIOL CHEM, V261, P2003; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SEKIMIZU K, 1979, BIOCHEMISTRY-US, V18, P1582, DOI 10.1021/bi00575a031; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; TSCHOCHNER H, 1992, P NATL ACAD SCI USA, V89, P11292, DOI 10.1073/pnas.89.23.11292; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; USUDA Y, 1991, EMBO J, V10, P2305, DOI 10.1002/j.1460-2075.1991.tb07767.x; WIEST DK, 1992, J BIOL CHEM, V267, P7733; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	62	120	126	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25587	25593						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8244996				2022-12-25	WOS:A1993MK10000047
J	MACDONALD, NJ; DELAROSA, A; BENEDICT, MA; FREIJE, JMP; KRUTSCH, H; STEEG, PS				MACDONALD, NJ; DELAROSA, A; BENEDICT, MA; FREIJE, JMP; KRUTSCH, H; STEEG, PS			A SERINE PHOSPHORYLATION OF NM23, AND NOT ITS NUCLEOSIDE DIPHOSPHATE KINASE-ACTIVITY, CORRELATES WITH SUPPRESSION OF TUMOR METASTATIC POTENTIAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; DUCTAL BREAST CARCINOMAS; 2 CELLULAR PROTEINS; LARGE T-ANTIGEN; WILD-TYPE; SV40-TRANSFORMED CELLS; TRANSFORMING PROTEINS; PROGESTERONE-RECEPTOR; CHEMICAL-PROPERTIES; MYXOCOCCUS-XANTHUS	We describe a serine phosphorylation of the putative metastasis suppressor protein Nm23, and present evidence of its relevance to the signal transduction and tumor metastatic processes. Nm23 was previously demonstrated to exhibit nucleoside diphosphate kinase (NDPK) activity, which transfers a phosphate among nucleoside tri- and diphosphates via an Nm23-phosphohistidine intermediate. Recent data have dissociated the NDPK activity of Nm23 from its phenotypic effects; therefore we have asked whether Nm23 possesses additional biochemical functions. An acid-stable (nonhistidine) phosphorylation was identified on autophosphorylated purified recombinant Nm23 proteins and [P-32]orthophosphate-labeled human breast carcinoma and murine melanoma Nm23. Phosphoamino acid analysis identified serine as the acid-stable phosphorylation and serine 44 as the major site of phosphorylation. The acid stable phosphorylation (serine) of Nm23 was inhibited by cAMP in vitro and forskolin in vivo, suggesting that this phosphorylation pathway is regulated in signal transduction. No effect of cAMP was observed on Nm223 NDPK activity. Once phosphorylated, Nm23-phosphoserine can release free phosphate in vitro. The biological relevance of the novel phosphorylation identified herein is suggested by the direct correlation of in vivo Nm23 acid-stable phosphorylation levels, but not Nm23 NDPK activity, with suppression of tumor metastatic potential among control and nm23-1 transfected murine melanoma cells.	UNIV OVIEDO, DEPT BIOL FUNCT, E-33006 OVIEDO, SPAIN	University of Oviedo	MACDONALD, NJ (corresponding author), NCI, PATHOL LAB, WOMENS CANC SECT, BLDG 10, RM 2A33, BETHESDA, MD 20892 USA.		Freije, José M.P./A-6535-2008	Freije, José M.P./0000-0002-4688-8266				ADKINS B, 1982, J VIROL, V43, P448, DOI 10.1128/JVI.43.2.448-455.1982; ALBERTY RA, 1969, J BIOL CHEM, V244, P3290; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BARNES R, 1991, AM J PATHOL, V139, P245; BERG P, 1953, NATURE, V172, P1008, DOI 10.1038/1721008a0; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; CALIGO MA, 1992, ANTICANCER RES, V12, P969; CARLIER MF, 1989, INT REV CYTOL, V115, P139; COHN KH, 1991, LANCET, V338, P722, DOI 10.1016/0140-6736(91)91444-Y; COLOMB MG, 1966, BIOCHEM BIOPH RES CO, V24, P909, DOI 10.1016/0006-291X(66)90336-6; DAYAN J, 1963, BIOCHIM BIOPHYS ACTA, V77, P446, DOI 10.1016/0006-3002(63)90519-5; DEAROLF CR, 1988, DEV BIOL, V129, P169, DOI 10.1016/0012-1606(88)90171-6; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; DOUGHERTY JJ, 1984, J BIOL CHEM, V259, P8004; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; EDLUND B, 1969, EUR J BIOCHEM, V9, P451, DOI 10.1111/j.1432-1033.1969.tb00630.x; ELMAGHRABI MR, 1980, J BIOL CHEM, V255, P668; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLORENES VA, 1992, CANCER RES, V52, P6088; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FUKUCHI T, 1993, IN PRESS GENE AMST; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GOLDEN A, 1993, ONCOGENES TUMOR SUPP, P345; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HEMMERICH S, 1992, BIOCHEMISTRY-US, V31, P4580, DOI 10.1021/bi00134a007; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; HIGASHIYAMA M, 1992, BRIT J CANCER, V66, P533, DOI 10.1038/bjc.1992.308; HIRAYAMA R, 1991, J NATL CANCER I, V83, P1249, DOI 10.1093/jnci/83.17.1249; HOSSLER FE, 1971, BIOCHEM BIOPH RES CO, V43, P530, DOI 10.1016/0006-291X(71)90646-2; INESI G, 1992, ADV ENZYMOL RAMB, V65, P185; ISHIKAWA N, 1992, J BIOL CHEM, V267, P14366; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; KANTOR JD, 1993, CANCER RES, V53, P1971; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Krebs EG, 1986, ENZYMES, V17, P3, DOI 10.1016/S1874-6047(08)60426-6; KREIL G, 1964, BIOCHEM BIOPH RES CO, V16, P551, DOI 10.1016/0006-291X(64)90191-3; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LAKSO M, 1992, CELL GROWTH DIFFER, V3, P873; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LASCU I, 1992, J BIOL CHEM, V267, P12775; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P2325; LEONE A, 1993, ONCOGENE, V8, P855; LEONE A, 1991, CANCER RES, V51, P2490; LERCH K, 1975, BIOCHEMISTRY-US, V14, P2015, DOI 10.1021/bi00680a032; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIPSICH LA, 1982, MOL CELL BIOL, V2, P875, DOI 10.1128/MCB.2.7.875; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; MUNOZDORADO J, 1993, J BACTERIOL, V175, P1176; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2707; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; NAKAYAMA H, 1993, JPN J CANCER RES, V84, P184, DOI 10.1111/j.1349-7006.1993.tb02853.x; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; NICOLSON GL, 1987, CANCER RES, V47, P1473; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; RABINOWITZ M, 1960, J BIOL CHEM, V235, P1043; RADINSKY R, 1992, CANCER RES, V52, P5808; RANDAZZO PA, 1991, SCIENCE, V254, P850, DOI 10.1126/science.1658935; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REDEUILH G, 1987, J BIOL CHEM, V262, P6969; RENOIR JM, 1986, BIOCHEMISTRY-US, V25, P6405, DOI 10.1021/bi00369a010; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; ROYDS JA, 1993, J NATL CANCER I, V85, P727, DOI 10.1093/jnci/85.9.727; SANCHEZ ER, 1986, J STEROID BIOCHEM, V24, P9, DOI 10.1016/0022-4731(86)90025-7; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; SBURLATI AR, 1993, BIOCHEMISTRY-US, V32, P4587, DOI 10.1021/bi00068a015; SCHMID SL, 1985, J BIOL CHEM, V260, P57; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201; SHIMADA N, 1993, J BIOL CHEM, V268, P2583; SHIZUTA Y, 1975, J BIOL CHEM, V250, P6891; STAHL JA, 1991, CANCER RES, V51, P445; STEEG P S, 1992, Current Opinion in Oncology, V4, P134, DOI 10.1097/00001622-199202000-00018; STEEG PS, 1993, BREAST CANCER RES TR, V25, P175, DOI 10.1007/BF00662142; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; SU ZZ, 1993, ONCOGENE, V8, P1211; TAKEMOTO F, 1992, PFLUG ARCH EUR J PHY, V421, P302, DOI 10.1007/BF00374216; TENG DHF, 1991, NATURE, V353, P437, DOI 10.1038/353437a0; URANO T, 1992, FEBS LETT, V309, P358, DOI 10.1016/0014-5793(92)80807-S; WALINDER O, 1968, J BIOL CHEM, V243, P3947; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG LM, 1993, CANCER RES, V53, P717; WEI YF, 1991, METHOD ENZYMOL, V200, P388; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZIEMIECKI A, 1986, VIROLOGY, V151, P265, DOI 10.1016/0042-6822(86)90048-6	97	207	218	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25780	25789						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245015				2022-12-25	WOS:A1993MK10000074
J	HIBI, K; YAMAKAWA, K; UEDA, R; HORIO, Y; MURATA, Y; TAMARI, M; UCHIDA, K; TAKAHASHI, T; NAKAMURA, Y; TAKAHASHI, T				HIBI, K; YAMAKAWA, K; UEDA, R; HORIO, Y; MURATA, Y; TAMARI, M; UCHIDA, K; TAKAHASHI, T; NAKAMURA, Y; TAKAHASHI, T			ABERRANT UP-REGULATION OF A NOVEL INTEGRIN ALPHA-SUBUNIT GENE AT 3P21.3 IN SMALL-CELL LUNG-CANCER	ONCOGENE			English	Article							ADHESION RECEPTOR; SHORT ARM; EXPRESSION; VLA-4; FIBRONECTIN; CARCINOMA; DISTINCT; DELETION; FAMILY; ABNORMALITIES	Our recent identification of homozygous deletions at 3p21.3 in lung cancer has provided further support for the presence of a tumor suppressor gene in this chromosomal region. As a part of our efforts for positional cloning of a tumor suppressor gene at 3p21.3, we have characterized a transcriptional unit within this region using genomic fragments with interspecies conservation. The identified gene was found to encode a novel integrin alpha subunit, termed alpha(RLC), which is closely related to alpha(4) in structure but clearly different from alpha(4) in its expression pattern in the physiological and pathological setting of the lung. This finding and the exact localization of the gene suggest that it is a good candidate for a tumor suppressor gene in lung cancer, but our extensive search covering one third of the gene did not reveal any somatic mutations within the coding region. Interestingly, however, alpha(RLC) was abundantly expressed in fetal lung and lung cancers, particularly small cell lung cancers (SCLC). Its aberrant upregulation in the SCLC samples, both cell lines and primary tumors, which might have been caused by a yet unidentified mutations or by deletions of other gene, and its homology to alpha which is thought to play a role in metastasis, suggest that altered alpha(RLC) expression may contribute to the acquisition of malignant phenotypes of this type of lung cancer.	AICHI CANC CTR,RES INST,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,RES INST,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 1,SHOWA KU,NAGOYA,AICHI 466,JAPAN; CANC INST,DEPT BIOCHEM,TOSHIMA KU,TOKYO,TOKYO 170,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Nagoya University; Japanese Foundation for Cancer Research			Yamakawa, Kazuhiro/N-5050-2015; Takahashi, Takashi/I-7262-2014; Tamari, Mayumi/N-5378-2015	Yamakawa, Kazuhiro/0000-0002-1478-4390; Takahashi, Takashi/0000-0003-0615-7001; Horio, Yoshitsugu/0000-0003-4661-6399				BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HIBI K, 1992, ONCOGENE, V7, P445; HIBI K, 1991, ONCOGENE, V6, P2291; HIDA T, 1993, JPN J CLIN ONCOL, V23, P14; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KORETZ K, 1991, AM J PATHOL, V138, P741; KOUKOULIS GK, 1991, AM J PATHOL, V139, P787; MATTILA P, 1992, INT J CANCER, V52, P918, DOI 10.1002/ijc.2910520615; MINNA JD, 1991, MOL MECHANISMS THEIR, P63; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SAKAKURA T, 1983, UNDERSTANDING BREAST, P261; SUZUKI H, 1992, CANCER RES, V52, P734; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; SUZUKI S, 1993, JPN J CANCER RES, V84, P168, DOI 10.1111/j.1349-7006.1993.tb02851.x; Szebenyi DME, 1981, NATURE, V294, P327, DOI 10.1038/294327a0; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKAHASHI T, 1989, CANCER RES, V49, P2683; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1986, CANCER RES, V46, P4770; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TSUKAMOTO T, 1992, CANCER RES, V52, P3506; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; YAMAKAWA K, 1993, ONCOGENE, V8, P327; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YOKOYAMA S, 1992, CANCER RES, V52, P873; YOSHIKAI Y, 1984, NATURE, V312, P521, DOI 10.1038/312521a0; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	37	59	67	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					611	619						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290272				2022-12-25	WOS:A1994MW24800029
J	LALLE, P; DELATOUR, M; RIO, P; BIGNON, YJ				LALLE, P; DELATOUR, M; RIO, P; BIGNON, YJ			DETECTION OF ALLELIC LOSSES ON 17Q12-Q21 CHROMOSOMAL REGION IN BENIGN LESIONS AND MALIGNANT-TUMORS OCCURRING IN A FAMILIAL CONTEXT	ONCOGENE			English	Article							HUMAN-BREAST-CANCER; DINUCLEOTIDE REPEAT POLYMORPHISM; HUMAN OVARIAN CARCINOMAS; ADENOMATOUS POLYPOSIS; ESTROGEN-RECEPTOR; HETEROZYGOSITY; GENE; ALLELOTYPE; DISEASE; MUTATIONS	A predisposing gene (BRCA-1) for breast and ovarian cancer has been located on chromosomal region 17q12-21. According to Knudson's hypothesis if this gene is a tumor suppressor gene, allelic losses would be found in tumors occurring in families with cancer aggregations. We studied 25 samples of both benign lesions and malignant tumors, from breast cancer site-specific families and other familial cancer aggregations. Allelic losses seem to be more frequent in tumors from breast site-specific families but also include the predisposing locus in other syndromes, suggesting a role of BRCA-1 in such families. Finding of allele losses near this locus in benign lesions suggests that such alterations may represent a first step in breast carcinogenesis. It is noteworthy that allele losses involve larger chromosome fragments in malignant tumors than in benign lesions where BRCA-1 is not lost, suggesting a similar mechanism for genomic deletion in the tumorigenesis of the colon and of the breast.	CTR JEAN PERRIN,ONCOL MOLEC LAB,F-63011 CLERMONT 1,FRANCE; CTR JEAN PERRIN,SERV ANAT PATHOL,F-63011 CLERMONT 1,FRANCE; INSERM,U71,F-63005 CLERMONT FERRAND,FRANCE	UNICANCER; Centre Jean Perrin; UNICANCER; Centre Jean Perrin; Institut National de la Sante et de la Recherche Medicale (Inserm)			LALLE, Philippe/G-7734-2018; , bignon/Y-3243-2019; Rio, Pascale/N-5237-2018					ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; BOWCOCK AM, 1993, AM J HUM GENET, V52, P730; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DEINARD AS, 1992, NUCLEIC ACIDS RES, V20, P1171, DOI 10.1093/nar/20.5.1171-a; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DEVILEE P, 1991, ONCOGENE, V6, P1705; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; EASTON DF, 1993, AM J HUM GENET, V52, P679; ECCLES DM, 1992, ONCOGENE, V7, P2069; ECCLES DM, 1990, ONCOGENE, V5, P1599; EHLEN T, 1990, ONCOGENE, V5, P219; FOULKES W, 1991, LANCET, V338, P444, DOI 10.1016/0140-6736(91)91065-3; FUTREAL PA, 1992, CANCER RES, V52, P2624; FUTREAL PA, 1992, HUM MOL GENET, V1, P66, DOI 10.1093/hmg/1.1.66-a; GARCIA T, 1989, NUCLEIC ACIDS RES, V17, P8364; GENUARDI M, 1989, AM J HUM GENET, V45, P73; HALL JM, 1992, AM J HUM GENET, V50, P1235; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE JH, 1990, CANCER RES, V50, P2724; LEONE A, 1991, CANCER RES, V51, P2490; LINDBLOM A, 1993, HUM GENET, V91, P6; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; MACKAY J, 1988, LANCET, V2, P1384; MAZOYER S, 1993, AM J HUM GENET, V52, P754; MIYAKI M, 1990, CANCER RES, V50, P7166; NAROD SA, 1991, LANCET, V338, P82; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SATO T, 1991, CANCER RES, V51, P5118; SATO T, 1990, CANCER RES, V50, P7184; SEIZINGER BR, 1987, P NATL ACAD SCI USA, V84, P5419, DOI 10.1073/pnas.84.15.5419; SKOLNICK MH, 1990, SCIENCE, V250, P1715, DOI 10.1126/science.2270486; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; STEPHENSON CF, 1992, CANCER GENET CYTOGEN, V63, P32, DOI 10.1016/0165-4608(92)90060-L; TULINIUS H, 1992, BRIT MED J, V305, P855, DOI 10.1136/bmj.305.6858.855; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; ZIEGLER M, 1992, GENETICS MOL BIOL BR, P83; ZUPPAN P, 1991, AM J HUM GENET, V48, P1065	48	29	31	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					437	442						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290255				2022-12-25	WOS:A1994MW24800010
J	MCINTYRE, GF; GODBOLD, GD; ERICKSON, AH				MCINTYRE, GF; GODBOLD, GD; ERICKSON, AH			THE PH-DEPENDENT MEMBRANE ASSOCIATION OF PROCATHEPSIN-L IS MEDIATED BY A 9-RESIDUE SEQUENCE WITHIN THE PROPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCES; MOUSE CATHEPSIN-D; DICTYOSTELIUM-DISCOIDEUM; HEPG2 CELLS; YEAST; PROTEINASE; NUCLEOTIDE; LYSOSOMES; CLONING; CDNA	The lysosomal proprotease procathepsin L binds to mouse fibroblast microsomal membranes at pH 5, but mature active cathepsin L does not (McIntyre, G. F., and Erickson, A. H. (1991) J. Biol. Chem. 266, 15438-15445). This binding is not dependent on N-linked carbohydrate as procathepsin L synthesized in cells treated with tunicamycin still shows pH-dependent membrane association. These results suggest that the propeptide (Thr18-Lys113) of the cysteine protease mediates its pH-dependent membrane association. Synthetic peptides containing either 24 or 9 residues from the N-terminal portion of the mouse procathepsin L propeptide inhibited the binding of mouse procathepsin L to microsomal membranes at pH 5. In contrast, the pH-dependent membrane association was not inhibited either by a scrambled version of the 24-residue peptide, in which 3 adjacent residues likely to be positively charged at pH 5 were dispersed, or by a second control peptide containing the 11 N-terminal residues from mature mouse cathepsin L. The 24-residue peptide chemically coupled to horseradish peroxidase bound to microsomes at pH 5, but not at pH 7. On ligand blots, the same conjugate bound specifically to a 43-kDa integral membrane protein, identifying the microsomal protein that mediates the proenzyme binding. The 9-residue propeptide sequence that inhibits the membrane association of procathepsin L at pH 5 resembles the vacuolar sorting sequences in the propeptides of yeast proteinase A and carboxypeptidase Y. This suggests that the membrane association of procathepsin L may play a role in the transport of the proenzyme to lysosomes, the vacuolar equivalent in mammalian cells.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill								AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BURGE V, 1991, BIOCHEM J, V275, P797, DOI 10.1042/bj2750797; CARDELLI JA, 1986, J CELL BIOL, V102, P1264, DOI 10.1083/jcb.102.4.1264; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; DIEDRICH JF, 1990, NUCLEIC ACIDS RES, V18, P7184, DOI 10.1093/nar/18.23.7184; DIMENT S, 1988, J BIOL CHEM, V263, P6901; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GAL S, 1988, BIOCHEM J, V253, P303, DOI 10.1042/bj2530303; GRUSBY MJ, 1990, NUCLEIC ACIDS RES, V18, P4008, DOI 10.1093/nar/18.13.4008; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; KARRER KM, 1993, P NATL ACAD SCI USA, V90, P3063, DOI 10.1073/pnas.90.7.3063; KING TP, 1978, BIOCHEMISTRY-US, V17, P1499, DOI 10.1021/bi00601a022; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KLIONSKY DJ, 1992, J BIOL CHEM, V267, P3416; LACOSTE CH, 1992, J BIOL CHEM, V267, P5942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; MCINTYRE GF, 1993, IN PRESS P NATL ACAD; MIERENDORF RC, 1985, J CELL BIOL, V100, P1777, DOI 10.1083/jcb.100.5.1777; PORTNOY DA, 1986, J BIOL CHEM, V261, P4697; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; SEEMAN P, 1967, J CELL BIOL, V32, P55, DOI 10.1083/jcb.32.1.55; TKACZ JS, 1975, BIOCHEM BIOPH RES CO, V65, P248, DOI 10.1016/S0006-291X(75)80086-6; VALLS LA, 1990, J CELL BIOL, V111, P361, DOI 10.1083/jcb.111.2.361; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7	29	77	78	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					567	572						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276852				2022-12-25	WOS:A1994MR21900090
J	RINALDICARMONA, M; PRABONNAUD, V; BOUABOULA, M; POINOTCHAZEL, C; CASELLAS, P; LEFUR, G; HERBERT, JM				RINALDICARMONA, M; PRABONNAUD, V; BOUABOULA, M; POINOTCHAZEL, C; CASELLAS, P; LEFUR, G; HERBERT, JM			REGULATION OF 5-HYDROXYTRYPTAMINE(2) (5-HT(2)) RECEPTOR EXPRESSION IN CULTURED RAT AORTIC SMOOTH-MUSCLE CELLS BY SR-46349B, A SELECTIVE 5-HT(2) RECEPTOR ANTAGONIST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; SEROTONIN BINDING-SITES; RAPID DESENSITIZATION; DOWN-REGULATION; AGONIST; CORTEX; BRAIN; HYDROLYSIS; RITANSERIN; LIGAND	Regulation of 5-hydroxytryptamine (5-HT2) receptor expression by SR 46349B, a potent and selective 5-HT2 receptor antagonist, was investigated in cultured rat aortic smooth muscle cells. Binding of [H-3]SR 46349B to rat vascular smooth muscle cells was time-dependent, reversible, and saturable. [H-3]SR 46349B bound to one class of specific binding sites with high affinity (K(D) = 1.3 +/- 0.3 nm; B(max) = 176 +/- 42 fmol/10(5) cells). Exposure of cells to a 1 muM concentration of the 5-HT2 agonist (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane ((+/-)-DOI) or the antagonist ketanserin led to a significant decrease in 5-HT2 receptor density as measured by [H-3]SR 46349B binding. In contrast, exposure of cells to 1 muM SR 46349B caused a marked increase in the maximal binding capacity of [H-3]SR 46349B, with a maximal effect at 24 h (73% increase). The affinity constant was not affected by prior exposure to (+/-)-DOI, ketanserin, or SR 46349B. Furthermore, exposure of cells to 1 muM (+/-)-DOI or ketanserin produced, 48 h later, a decrease in the ability of (+/-)-DOI to stimulate phosphoinositide turnover in the cells, whereas treatment with SR 46349B induced a significant stimulation of the 5-HT2 receptor-linked signal transduction. This effect occurred with no changes in the amount of 5-HT2 receptor mRNAs as measured by quantitative polymerase chain reaction. These results indicate that SR 46349B increases 5-HT2 receptor binding and functions without altering steady-state 5-HT2 mRNA levels in cultured rat aortic smooth muscle cells.	SANOFI RECH,195 ROUTE ESPAGNE,F-31036 TOULOUSE,FRANCE; SANOFI RECH,F-34184 MONTPELLIER 04,FRANCE	Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France								ANDREE TH, 1986, J NEUROCHEM, V46, P191, DOI 10.1111/j.1471-4159.1986.tb12944.x; BALL SG, 1985, J CARDIOVASC PHARM, V7, P120; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BLACKSHEAR MA, 1983, N-S ARCH PHARMACOL, V324, P125, DOI 10.1007/BF00497017; BLACKSHEAR MA, 1986, NEUROPHARMACOLOGY, V25, P1267, DOI 10.1016/0028-3908(86)90146-2; BOUABOULA M, 1992, J BIOL CHEM, V267, P21830; BUCKHOLTZ NS, 1988, LIFE SCI, V42, P2439, DOI 10.1016/0024-3205(88)90342-6; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; GOODWIN GM, 1984, BRIT J PHARMACOL, V83, P235, DOI 10.1111/j.1476-5381.1984.tb10140.x; HADCOCK JR, 1991, TRENDS NEUROSCI, V14, P242, DOI 10.1016/0166-2236(91)90124-D; IVINS KJ, 1991, J PHARMACOL EXP THER, V259, P423; JACOBS S, 1975, BIOCHEM BIOPH RES CO, V66, P687, DOI 10.1016/0006-291X(75)90564-1; JAZAYERI A, 1989, EUR J PHARMACOL, V169, P183, DOI 10.1016/0014-2999(89)90832-7; LEYSEN JE, 1989, EUR J PHARMACOL, V163, P145, DOI 10.1016/0014-2999(89)90409-3; LEYSEN JE, 1986, PSYCHOPHARMACOLOGY, V88, P434, DOI 10.1007/BF00178504; MCKENNA DJ, 1989, NEUROPSYCHOPHARMACOL, V2, P81, DOI 10.1016/0893-133X(89)90010-9; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PAUL R, 1987, THROMB RES, V46, P793, DOI 10.1016/0049-3848(87)90071-5; PAUWELS PJ, 1988, NEUROCHEM INT, V13, P409, DOI 10.1016/0197-0186(88)90016-2; PAUWELS PJ, 1990, LIFE SCI, V47, P2009, DOI 10.1016/0024-3205(90)90435-T; PEROUTKA SJ, 1980, SCIENCE, V210, P88, DOI 10.1126/science.6251550; PRANZATELLI MR, 1991, BIOCHEM PHARMACOL, V42, P1099, DOI 10.1016/0006-2952(91)90294-F; PRITCHETT DB, 1988, EMBO J, V7, P4135, DOI 10.1002/j.1460-2075.1988.tb03308.x; RINALDICARMONA M, 1992, J PHARMACOL EXP THER, V262, P759; RINALDICARMONA M, 1993, MOL PHARMACOL, V43, P84; RINALDICARMONA M, 1993, EUR J PHARM-MOLEC PH, V246, P73, DOI 10.1016/0922-4106(93)90012-X; ROTH B, 1992, BIOL PSYCHIAT, V31, pA110; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; TWIST EC, 1990, BIOCHEM PHARMACOL, V39, P161, DOI 10.1016/0006-2952(90)90660-D	32	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					396	401						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276825				2022-12-25	WOS:A1994MR21900067
J	BAEK, KJ; DAS, T; GRAY, C; ANTAR, S; MURUGESAN, G; IM, MJ				BAEK, KJ; DAS, T; GRAY, C; ANTAR, S; MURUGESAN, G; IM, MJ			EVIDENCE THAT THE G(H) PROTEIN IS A SIGNAL MEDIATOR FROM ALPHA(1)-ADRENOCEPTOR TO A PHOSPHOLIPASE-C .1. IDENTIFICATION OF ALPHA(1)-ADRENOCEPTOR-COUPLED G(H) FAMILY AND PURIFICATION OF G(H7) FROM BOVINE HEART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-ADRENERGIC RECEPTOR SUBTYPES; MOLECULAR-CLONING; ALPHA-SUBUNITS; ADRENERGIC-RECEPTOR; BINDING-PROTEINS; CDNA; EXPRESSION; ACTIVATION; RECONSTITUTION; MEMBRANE	Our previous studies on alpha1-adrenoceptor-mediated signaling suggested that G(h) is a signal mediator. G(h) consists of a 74-kDa GTP-binding alpha-subunit and a 50-kDa beta-subunit. Studies using the alpha1-agonist-receptor-G-protein ternary complexes from various tissues and species revealed that the intensity (GTP-binding) of the [alpha-P-32]GTP-labeled proteins resulting from activating the alpha1-receptor was significantly attenuated by phentolamine. The molecular masses of GTP-binding proteins were 74 kDa in rat heart and liver, 77 kDa in dog heart, 78 kDa (G(h7alpha)) in bovine heart and liver, and 80 kDa in human heart. Supporting these observations, a specific antibody to G(h7alpha) not only recognized these GTP-binding proteins in the ternary complex preparations, but also co-immunoprecipitated alpha1-adrenoceptors, indicating a tight association of these GTP-binding proteins with the alpha1-adrenoceptor. These results also demonstrate that functional and structural similarities exist among these GTP-binding proteins. Additionally, one of the identified G-proteins (termed G(h7)) was purified from bovine heart. G(h7) consisted of the 78-kDa GTP-binding protein and a 50-kDa protein.	CLEVELAND CLIN FDN,RES INST,DEPT CARDIOVASC BIOL,FFB1-37,9500 EUCLID AVE,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NIGMS NIH HHS [GM45985] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045985] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEK KJ, 1993, J BIOL CHEM, V268, P27398; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DOLHMAN H, 1991, ANN REV BIOCH, V60, P653; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HARRIS BA, 1985, SCIENCE, V229, P1274, DOI 10.1126/science.3839937; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1990, J BIOL CHEM, V265, P18944; IM MJ, 1992, J BIOL CHEM, V267, P8887; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; MAY DC, 1988, BIOCHEMISTRY-US, V27, P4888, DOI 10.1021/bi00413a045; MINNEMAN KP, 1988, PHARMACOL REV, V40, P87; MINNEMAN KP, 1988, MOL PHARMACOL, V33, P509; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; PFEUFFER T, 1988, CURR TOP CELL REGUL, V29, P129; PRPIC V, 1984, J BIOL CHEM, V259, P1382; SCHWINN DA, 1990, J BIOL CHEM, V265, P8183; UHING RJ, 1986, J BIOL CHEM, V261, P2140; VOIGT MM, 1990, NUCLEIC ACIDS RES, V18, P1053, DOI 10.1093/nar/18.4.1053; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811	26	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27390	27397						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262980				2022-12-25	WOS:A1993MM26200079
J	CAO, X; ROSS, FP; ZHANG, LM; MACDONALD, PN; CHAPPEL, J; TEITELBAUM, SL				CAO, X; ROSS, FP; ZHANG, LM; MACDONALD, PN; CHAPPEL, J; TEITELBAUM, SL			CLONING OF THE PROMOTER FOR THE AVIAN INTEGRIN BETA(3) SUBUNIT GENE AND ITS REGULATION BY 1,25-DIHYDROXYVITAMIN-D-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN INTESTINAL RECEPTOR; RETINOIC ACID; RESPONSE ELEMENTS; OSTEOCALCIN GENE; THYROID-HORMONE; CELL-ADHESION; EXPRESSION; IDENTIFICATION; DIFFERENTIATION; BINDING	We have cloned the promoter of the avian beta3 integrin gene. Using a probe comprising the 5'-untranslated region of an avian macrophage beta3 cDNA, characterized by 5' rapid amplification of cDNA ends, several clones were isolated from an avian genomic library. One major and one minor transcriptional start site were identified at +1 and -47 base pairs, respectively, with the latter coinciding with a consensus sequence of an initiator. DNA sequence analysis of 800 base pairs 5' of the transcriptional start site fails to reveal either a TATA or CAAT box. In addition to an initiator, the first 200 base pairs contain consensus sequences for the binding of AP-1 and SP-1. A 3.5-kilobase fragment located immediately upstream of the transcriptional start site exhibits functional promoter activity, and deletion analysis reveals both suppressor and enhancer elements. In light of our observation that 1,25-dihydroxyvitamin D3 (D3) accelerates beta3 transcription, we determined whether the avian beta3 promoter contains a vitamin D response element (VDRE). Transfected reporter constructs containing the first 1.5 kilobases upstream of the major beta3 transcriptional start site respond to D3 with enhanced luciferase activity. Analysis of this region reveals a classical VDRE consensus sequence, located at -756 to -770. The following observations support the hypothesis that this sequence represents a functional VDRE: 1) a 600-base pair genomic fragment or a 29-base pair oligomer, each containing the putative VDRE, respond to D3 when transfected into HD11 cells; 2) a 67-base pair DNA fragment derived from genomic DNA and containing the candidate beta3 VDRE specifically binds the vitamin D receptor-retinoid X receptor beta complex; and 3) avian osteoclast precursor-derived nuclear extracts bind to a synthetic oligomer containing the beta3 VDRE-like sequence and, in turn, are specifically displaced by unlabeled beta3 VDRE and anti-vitamin D receptor antibody.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT PATHOL & LAB MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV RENAL,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL)				Teitelbaum, Steven/0000-0002-4054-6679	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032788, R01AR042404] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR32788, AR42404] Funding Source: Medline; NIDCR NIH HHS [DE05413] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALBELDA SM, 1993, LAB INVEST, V68, P4; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BARSHAVIT Z, 1983, P NATL ACAD SCI-BIOL, V80, P5907, DOI 10.1073/pnas.80.19.5907; BEUG H, 1979, CELL, V18, P579; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CERVELLA P, 1993, J BIOL CHEM, V268, P5148; CHIBA M, 1993, J BONE MINER RES, V8, pS144; CLOHISY DR, 1987, J BIOL CHEM, V262, P15922; DARWISH HM, 1992, P NATL ACAD SCI USA, V89, P603, DOI 10.1073/pnas.89.2.603; DEAN DC, 1987, P NATL ACAD SCI USA, V84, P1876, DOI 10.1073/pnas.84.7.1876; DEDHAR S, 1991, J BIOL CHEM, V266, P21846; DEFILIPPI P, 1991, J BIOL CHEM, V266, P7638; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; DENICHILO MO, 1993, P NATL ACAD SCI USA, V90, P2517, DOI 10.1073/pnas.90.6.2517; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; FREEDMAN LP, 1993, J CELL BIOCHEM, V51, P140, DOI 10.1002/jcb.240510205; GILL RK, 1993, P NATL ACAD SCI USA, V90, P2984, DOI 10.1073/pnas.90.7.2984; HICKSTEIN DD, 1992, P NATL ACAD SCI USA, V89, P2105, DOI 10.1073/pnas.89.6.2105; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KRISSANSEN GW, 1990, J BIOL CHEM, V265, P823; LAKONISHOK M, 1992, DEV BIOL, V152, P209, DOI 10.1016/0012-1606(92)90129-5; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; MACDONALD PN, 1991, J BIOL CHEM, V266, P18808; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; MEDHORA MM, 1993, J BIOL CHEM, V268, P1456; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; PERKINS SL, 1991, ENDOCRINOLOGY, V128, P303, DOI 10.1210/endo-128-1-303; PHILLIPS DR, 1988, BLOOD, V71, P831; PIKE JW, 1987, J BIOL CHEM, V262, P1305; PRANDINI MH, 1988, BIOCHEM BIOPH RES CO, V156, P595, DOI 10.1016/S0006-291X(88)80884-2; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; ROSS FP, 1993, J BIOL CHEM, V268, P9901; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Sambrook J, 1989, MOL CLONING LABORATO; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHEPPARD D, 1992, J BIOL CHEM, V267, P17409; SIMPSON RU, 1982, P NATL ACAD SCI-BIOL, V79, P16, DOI 10.1073/pnas.79.1.16; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZIMRIN AB, 1990, J BIOL CHEM, V265, P8590	47	120	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27371	27380						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262978				2022-12-25	WOS:A1993MM26200077
J	ECCLESTON, JF; MOORE, KJM; MORGAN, L; SKINNER, RH; LOWE, PN				ECCLESTON, JF; MOORE, KJM; MORGAN, L; SKINNER, RH; LOWE, PN			KINETICS OF INTERACTION BETWEEN NORMAL AND PROLINE-12 RAS AND THE GTPASE-ACTIVATING PROTEINS, P120-GAP AND NEUROFIBROMIN - THE SIGNIFICANCE OF THE INTRINSIC GTPASE RATE IN DETERMINING THE TRANSFORMING ABILITY OF RAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 NEUROFIBROMATOSIS; ESCHERICHIA-COLI; GENE-PRODUCT; MOLECULAR SWITCH; CATALYTIC DOMAIN; NF1 GENE; GAP; P21; MECHANISM; CELLS	Single turnover and equilibrium binding measurements on the interaction of Gly-12 and Pro-12 Ras.GTP with the catalytic domains of the GTPase-activating proteins, p120-GAP and neurofibromin, have been made utilizing fluorescent 2'(3')O-(N-methylanthraniloyl)-nucleotides. These have enabled the equilibrium dissociation constants (K(d)) for their initial binding and the rate constants of the hydrolysis step to be measured. p120-GAP binds to both Ras proteins with a K(d) of 17 muM, whereas neurofibromin binds to both Ras proteins with a K(d) of 1 muM. Both p120-GAP and neurofibromin increased the rate constant of the GTP hydrolysis step of Pro-12 Ras, but the maximal activation at 30-degrees-C was 120-fold and 560-fold, as compared with 70,000- and 52,000-fold, with Gly-12 Ras. The affinity with which p120-GAP and neurofibromin binds to either Gly-12 or Pro-12 Ras protein was decreased dramatically by increasing ionic strength caused by addition of NaCl. The rate constant of the cleavage step of hydrolysis catalyzed by neuroribromin increases with increasing ionic strength, whereas that catalyzed by p120-GAP appears to be unaffected. The high ionic strength within the cell might result in a much lower overall GTPase-activating protein activity than is measured under conditions of low ionic strength in vitro, with p120-GA-P being more severely inhibited. The GTP hydrolysis rate of Pro-12 Ras is 2-fold faster than that of normal Ras. The low oncogenicity of Pro-12 ras is explained by a model in which the intrinsic rates of hydrolysis and exchange, as well as GTPase-activating protein- and exchange factor-stimulated rates, are determinants of the biological activity of Ras proteins in fibroblasts.	WELLCOME RES LABS,DEPT CELL BIOL,BECKENHAM BR3 3BS,KENT,ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories	ECCLESTON, JF (corresponding author), NATL INST MED RES,DIV PHYS BIOCHEM,MILL HILL,LONDON NW7 1AA,ENGLAND.							ANTONNY B, 1991, BIOCHEMISTRY-US, V30, P8287, DOI 10.1021/bi00098a002; BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; COLBY WW, 1986, MOL CELL BIOL, V6, P730, DOI 10.1128/MCB.6.2.730; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; ECCLESTON JF, 1991, BIOCHEM SOC T, V19, P432, DOI 10.1042/bst0190432; ECCLESTON JF, 1987, SPECTROPHOTOMETRY SP, P137; FUJITAYOSHIGAKI J, 1992, J PROTEIN CHEM, V11, P731, DOI 10.1007/BF01024974; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HALL A, 1986, J BIOL CHEM, V261, P19636; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; JOHN J, 1989, J BIOL CHEM, V264, P13086; JOHN J, 1988, J BIOL CHEM, V263, P11792; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LOWE PN, 1991, J BIOL CHEM, V266, P1672; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOORE KJM, 1993, BIOCHEMISTRY-US, V32, P7451, DOI 10.1021/bi00080a016; MOORE KJM, 1992, PHILOS T ROY SOC B, V336, P49, DOI 10.1098/rstb.1992.0043; NEAL SE, 1988, J BIOL CHEM, V263, P19718; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; REINSTEIN J, 1991, J BIOL CHEM, V266, P17700; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; RICKETTS MH, 1988, MOL CELL BIOL, V8, P1460, DOI 10.1128/MCB.8.4.1460; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SIGAL IS, 1987, ANTI-CANCER DRUG DES, V2, P107; SKINNER RH, 1991, J BIOL CHEM, V266, P14163; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WEBB MR, 1992, BIOCHEM J, V287, P555, DOI 10.1042/bj2870555; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P	48	93	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27012	27019						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262937				2022-12-25	WOS:A1993MM26200029
J	REHAKRANTZ, LJ; NONAY, RL				REHAKRANTZ, LJ; NONAY, RL			GENETIC AND BIOCHEMICAL-STUDIES OF BACTERIOPHAGE-T4 DNA-POLYMERASE 3'-]5'-EXONUCLEASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' EXONUCLEASE ACTIVITY; AMINO-ACID; 3'-5' EXONUCLEASE; ESCHERICHIA-COLI; SPONTANEOUS MUTATION; SITE; REPLICATION; EXPRESSION; POLYMERIZATION; MUTAGENESIS	DNA polymerase exonucleolytic proofreading is important in attaining high fidelity DNA replication. One of the most well characterized proofreading activities is the 3'-->5'-exonuclease activity of bacteriophage T4 DNA polymerase. We have used genetic analyses and protein sequence comparisons to Escherichia coli DNA polymerase I to identify amino acids in the N-terminal region of T4 DNA polymerase that are required for exonucleolytic proofreading. Mutant DNA polymerases with amino acid substitutions D112A/E114A, D219A, or D324A reduced 3'-->5'-exonuclease activity 10(2)-10(4)-fold in various in vitro assays and decreased DNA replication fidelity in vivo. DNA replication activity was also reduced for the exonuclease-deficient DNA polymerases in vitro and in vivo. Reduction in DNA replication appeared to be due primarily to the interdependence of T4 DNA polymerase replication and proofreading activities; T4 DNA polymerase requires 3'-->5'-exonuclease activity to repair primer termini that are not suitable substrates for extension. Observations reported here provide further evidence in support of the proposal that DNA polymerases have distinct 3'-->5'-exonuclease and polymerase active sites.			REHAKRANTZ, LJ (corresponding author), UNIV ALBERTA,DEPT GENET,EDMONTON T6G 2E9,AB,CANADA.							BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BESSMAN MJ, 1977, J MOL BIOL, V116, P115, DOI 10.1016/0022-2836(77)90122-X; BLANCO L, 1992, GENE, V112, P139, DOI 10.1016/0378-1119(92)90316-H; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GIBBS JS, 1991, MOL CELL BIOL, V11, P4786, DOI 10.1128/MCB.11.9.4786; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; KUNKEL TA, 1988, CELL, V53, P837, DOI 10.1016/S0092-8674(88)90189-4; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1992, J BIOL CHEM, V267, P18251; LIN TC, 1987, P NATL ACAD SCI USA, V84, P7000, DOI 10.1073/pnas.84.20.7000; MCPHEETERS DS, 1986, NUCLEIC ACIDS RES, V14, P5813, DOI 10.1093/nar/14.14.5813; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; NEWPORT JW, 1980, MECHANISTIC STUDIES, V19, P485; NOSSAL NG, 1969, J BIOL CHEM, V244, P218; NOSSAL NG, 1971, J BIOL CHEM, V246, P5414; OLESON AE, 1964, J BIOL CHEM, V239, P2935; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PETRUSKA J, 1985, J BIOL CHEM, V260, P7533; REDDY MK, 1992, J BIOL CHEM, V267, P14157; REHAKRANTZ LJ, 1986, J MOL BIOL, V189, P261, DOI 10.1016/0022-2836(86)90508-5; REHAKRANTZ LJ, 1993, J VIROL, V67, P60, DOI 10.1128/JVI.67.1.60-66.1993; REHAKRANTZ LJ, 1989, J VIROL, V63, P4762, DOI 10.1128/JVI.63.11.4762-4766.1989; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; REHAKRANTZ LJ, 1988, J MOL BIOL, V202, P711, DOI 10.1016/0022-2836(88)90552-9; REHAKRANTZ LJ, 1984, GENETICS, V106, P335; ROZOVSKAYA T A, 1981, Molekulyarnaya Biologiya (Moscow), V15, P1205; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; SPICER EK, 1988, J BIOL CHEM, V263, P7478; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1989, J BIOL CHEM, V264, P6447; VENKATESAN M, 1982, J BIOL CHEM, V257, P2435; WANG Y, 1992, J VIROL, V66, P1814, DOI 10.1128/JVI.66.3.1814-1816.1992	40	72	79	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27100	27108						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262948				2022-12-25	WOS:A1993MM26200041
J	SAIKI, K; MOGI, T; HORI, H; TSUBAKI, M; ANRAKU, Y				SAIKI, K; MOGI, T; HORI, H; TSUBAKI, M; ANRAKU, Y			IDENTIFICATION OF THE FUNCTIONAL DOMAINS IN HEME-O SYNTHASE - SITE-DIRECTED MUTAGENESIS STUDIES ON THE CYOE GENE OF THE CYTOCHROME-BO OPERON IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROBIC RESPIRATORY-CHAIN; LOW-SPIN HEME; C-OXIDASE; TERMINAL OXIDASE; PARACOCCUS-DENITRIFICANS; UBIQUINOL OXIDASE; SUBUNIT-I; RHODOBACTER-SPHAEROIDES; QUINOL OXIDASE; PROTON PUMP	The cytochrome bo complex is a terminal ubiquinol oxidase in the aerobic respiratory chain of Escherichia coli and is encoded by the cyoABCDE operon. Recently, we have demonstrated that heme O at the high-spin heme-binding site is essential for redox-coupled proton pumping by the oxidase and suggested that the cyoE gene encodes a novel enzyme for heme O biosynthesis, protoheme IX farnesyltransferase (heme O synthase) (Saiki, K., Mogi, T., and Anraku, Y. (1992) Biochem. Biophys. Res. Commun. 189,1491-1497). This study was focused to define the catalytic domain(s) of the CyoE protein via a site-directed mutagenesis approach. We have individually substituted 40 amino acid residues including 22 invariant residues with alanines and found that 23 mutant oxidases were nonfunctional and exhibited a specific loss of the CO binding activity at the site of the high-spin heme. Characterizations of the purified D65A, Y120A, and W172A mutant oxidases, which represent the mutations of different topological domains, revealed that their defects are attributable to substitution of protoheme IX for heme O present in the high-spin heme-binding site. Based on the above observations, we suggest that the conserved amino acid residues present in the cytoplasmic loops II/III and IV/V are part of the catalytic center of heme O synthase.	UNIV TOKYO,GRAD SCH SCI,DEPT PLANT SCI,BUNKYO KU,TOKYO 113,JAPAN; OSAKA UNIV,FAC ENGN SCI,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN; HIMEJI INST TECHNOL,FAC SCI,DEPT LIFE SCI,HYOGO 67812,JAPAN	University of Tokyo; Osaka University; University of Hyogo								ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; ANRAKU Y, 1988, ANNU REV BIOCHEM, V57, P101, DOI 10.1146/annurev.bi.57.070188.000533; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; AU DCT, 1985, J BACTERIOL, V161, P123, DOI 10.1128/JB.161.1.123-127.1985; BABCOCK GT, 1983, BIOCHEMISTRY-US, V22, P2314, DOI 10.1021/bi00279a002; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; CAO J, 1992, J BIOL CHEM, V267, P24273; CARATTOLI A, 1991, J BIOL CHEM, V266, P5854; CASTOR LN, 1959, J BIOL CHEM, V234, P1587; CAUGHEY WS, 1975, J BIOL CHEM, V250, P7602; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; CHEPURI V, 1990, J BIOL CHEM, V265, P12978; GENNIS RB, 1991, BIOCHIM BIOPHYS ACTA, V1058, P21, DOI 10.1016/S0005-2728(05)80260-9; GEORGIOU CD, 1988, J BACTERIOL, V170, P961, DOI 10.1128/jb.170.2.961-966.1988; GOLLUB EG, 1977, J BIOL CHEM, V252, P2846; HANSSON M, 1993, FEMS MICROBIOL LETT, V107, P121; HATA A, 1985, BIOCHIM BIOPHYS ACTA, V810, P62, DOI 10.1016/0005-2728(85)90206-3; HILL J, 1992, BIOCHEMISTRY-US, V31, P11435, DOI 10.1021/bi00161a023; ISHIZUKA M, 1992, EBEC SHORT REP, V7, P50; KITA K, 1982, J BIOL CHEM, V257, P7933; KITA K, 1984, J BIOL CHEM, V259, P3368; KITA K, 1984, J BIOL CHEM, V259, P3375; LEMIEUX LJ, 1992, J BIOL CHEM, V267, P2105; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; MATSUSHITA K, 1992, J BACTERIOL, V174, P122, DOI 10.1128/jb.174.1.122-129.1992; MATSUSHITA K, 1984, BIOCHEMISTRY-US, V23, P4703, DOI 10.1021/bi00315a028; MINAGAWA J, 1992, J BIOL CHEM, V267, P2096; MINAGAWA J, 1990, J BIOL CHEM, V265, P11198; MINGHETTI KC, 1992, BIOCHEMISTRY-US, V31, P6917, DOI 10.1021/bi00145a008; MIYAMOTO K, 1991, J MOL BIOL, V219, P393, DOI 10.1016/0022-2836(91)90180-E; MULLER M, 1988, BIOCHEMISTRY-US, V27, P7546; NAKAMURA H, 1990, J BIOL CHEM, V265, P11193; NAKAMURA H, 1991, THESIS U TOKYO; NICHOLS BP, 1992, J BACTERIOL, V174, P5309, DOI 10.1128/JB.174.16.5309-5316.1992; NISHIMURA K, 1992, J BACTERIOL, V174, P5762, DOI 10.1128/JB.174.17.5762-.1992; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; ONDRIAS MR, 1980, BIOCHEM BIOPH RES CO, V93, P29, DOI 10.1016/S0006-291X(80)80241-5; PORRA RJ, 1993, FEBS LETT, V323, P31, DOI 10.1016/0014-5793(93)81442-3; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; PUUSTINEN A, 1992, BIOCHEMISTRY-US, V31, P10363, DOI 10.1021/bi00157a026; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; QUIRK PG, 1993, J BIOL CHEM, V268, P678; RAITIO M, 1987, EMBO J, V6, P2825, DOI 10.1002/j.1460-2075.1987.tb02579.x; SAIKI K, 1992, BIOCHEM BIOPH RES CO, V189, P1491, DOI 10.1016/0006-291X(92)90243-E; SALERNO JC, 1990, J BIOL CHEM, V265, P4364; SARASTE M, 1991, EUR J BIOCHEM, V195, P517, DOI 10.1111/j.1432-1033.1991.tb15732.x; SHAPLEIGH JP, 1992, P NATL ACAD SCI USA, V89, P4786, DOI 10.1073/pnas.89.11.4786; SHBY MN, 1992, J BIOL CHEM, V267, P4128; SIEBERT M, 1992, FEBS LETT, V307, P347, DOI 10.1016/0014-5793(92)80710-X; SINCLAIR P, 1967, BIOCHIM BIOPHYS ACTA, V143, P427, DOI 10.1016/0005-2728(67)90097-7; SONE N, 1991, FEBS LETT, V288, P154, DOI 10.1016/0014-5793(91)81024-3; SONE N, 1990, FEBS LETT, V262, P249, DOI 10.1016/0014-5793(90)80202-T; STEINRUCKE P, 1991, J BIOL CHEM, V266, P7676; SVENNSON B, 1992, EBEC SHORT REPORTS, V7, P36; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; UNO T, 1985, J BIOL CHEM, V260, P6755; VANDEROOST J, 1991, J BIOENERG BIOMEMBR, V23, P257, DOI 10.1007/BF00762221; WOODRUFF WH, 1991, P NATL ACAD SCI USA, V88, P2588, DOI 10.1073/pnas.88.6.2588; WU W, 1992, J AM CHEM SOC, V114, P1182, DOI 10.1021/ja00030a009	64	47	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26927	26934						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262927				2022-12-25	WOS:A1993MM26200017
J	SMITH, DJ; ZHU, H; KOLATKAR, PR; TAM, LT; BALDWIN, TO; ROE, BA; BROYLES, RH; RIGGS, AF				SMITH, DJ; ZHU, H; KOLATKAR, PR; TAM, LT; BALDWIN, TO; ROE, BA; BROYLES, RH; RIGGS, AF			THE HEMOGLOBINS OF THE BULLFROG, RANA-CATESBEIANA - THE CDNA-DERIVED AMINO-ACID-SEQUENCES OF THE ALPHA-CHAINS OF ADULT HEMOGLOBIN-B AND HEMOGLOBIN-C - THEIR ROLES IN DEOXYGENATION-INDUCED AGGREGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; XENOPUS-LAEVIS; MESSENGER-RNA; BETA-CHAIN; OXYGEN; COOPERATIVITY; COMPONENT; PROTEINS; TADPOLE; BINDING	The adult bullfrog (Rana catesbeiana) has two major tetrameric hemoglobins, B and C, which share a common beta chain but have different alpha chains. Components B and C associate upon deoxygenation to form a complex of the form BC2, a trimer of tetramers that depends on contacts between the alpha(B) and alpha(C) chains. Nucleotide sequences of cDNA transcripts for these chains have been determined. Transcripts were identified by analysis of the amino acid compositions of the tryptic peptides of the components and by partial amino acid sequencing. These results, together with the amino acid sequence of the beta chain (Tam, L.-T., Gray, G. P., and Riggs, A. F. (1986) J. Biol. Chem. 261, 8290-8294), permit an analysis of the structures of the alpha2beta2 tetramers of hemoglobins B and C. Molecular modeling suggests possible residues at the alpha(B)-alpha(C) interfaces in the BC2 trimer and additional alpha(C)-alpha(C) contacts that would form a closed ring of six alpha chain subunits that would further stabilize the BC2 trimer. Phylogenetic analysis of the alpha(B) sequence suggests that it may be a ''tadpole'' chain, the temporal expression of which has shifted from larva to adult.	UNIV TEXAS,DEPT ZOOL,AUSTIN,TX 78712; UNIV TEXAS,DEPT CHEM & BIOCHEM,AUSTIN,TX 78712; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73190; UNIV OKLAHOMA,DEPT CHEM & BIOCHEM,NORMAN,OK 73019	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma - Norman				kolatkar, prasanna/0000-0003-4970-5944	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021764] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041878] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 21764] Funding Source: Medline; NIGMS NIH HHS [GM-05818, GM41878] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; AGGARWAL SJ, 1969, J BIOL CHEM, V244, P2372; AHERN E, 1976, FEBS LETT, V69, P99, DOI 10.1016/0014-5793(76)80662-X; Anson ML, 1930, J GEN PHYSIOL, V13, P469, DOI 10.1085/jgp.13.4.469; ATHA DH, 1979, J BIOL CHEM, V254, P3393; BALDWIN TO, 1974, J BIOL CHEM, V249, P6110; BANVILLE D, 1983, J BIOL CHEM, V258, P7924; BONAVENTURA J, 1967, SCIENCE, V158, P800, DOI 10.1126/science.158.3802.800-a; BROWN JR, 1966, BIOCHEM J, V101, P214, DOI 10.1042/bj1010214; Broyles R.H., 1981, P461; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU AH, 1981, J BIOL CHEM, V256, P1199; COBB JA, 1992, J BIOL CHEM, V267, P1183; CULVERT SJ, 1993, RESPIR PHYSL, V91, P99; DEWITT W, 1967, BIOCHEM BIOPH RES CO, V27, P236, DOI 10.1016/S0006-291X(67)80067-6; DINTZIS HM, 1961, P NATL ACAD SCI USA, V47, P247, DOI 10.1073/pnas.47.3.247; DORN AR, 1982, P NATL ACAD SCI-BIOL, V79, P5592, DOI 10.1073/pnas.79.18.5592; FAITH DP, 1991, SYST ZOOL, V40, P366, DOI 10.2307/2992329; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FERMI G, 1975, J MOL BIOL, V97, P237, DOI 10.1016/S0022-2836(75)80037-4; FISHER WK, 1977, AUST J BIOL SCI, V30, P487, DOI 10.1071/BI9770487; GAO J, 1989, SCIENCE, V244, P1069, DOI 10.1126/science.2727695; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; Hall FG, 1934, J PHYSIOL-LONDON, V83, P222, DOI 10.1113/jphysiol.1934.sp003223; Haurowitz F, 1930, H-S Z PHYSIOL CHEM, V186, P141, DOI 10.1515/bchm2.1930.186.4-6.141; HOLLAND RAB, 1988, RESP PHYSIOL, V73, P69, DOI 10.1016/0034-5687(88)90128-4; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Jordan HE, 1923, J EXP MED, V38, P529, DOI 10.1084/jem.38.5.529; Jordan HE, 1923, AM J ANAT, V32, P155, DOI 10.1002/aja.1000320203; KAY RM, 1983, NUCLEIC ACIDS RES, V11, P1537, DOI 10.1093/nar/11.5.1537; KLEINSCHMIDT T, 1987, BIOL CHEM H-S, V368, P579; KNUTH A, 1979, ACTA HAEMATOL-BASEL, V61, P121, DOI 10.1159/000207643; MAEDA N, 1982, J BIOL CHEM, V257, P2806; Maniatis T., 1982, MOL CLONING; MANNING DR, 1984, BIOPHYS J, V45, pA368; MAPLES PB, 1986, DEV BIOL, V117, P337, DOI 10.1016/0012-1606(86)90303-9; MATSUURA MSA, 1989, J BIOL CHEM, V264, P5515; MCCARTHY EARL F., 1933, JOUR PHYSIOL, V80, P206, DOI 10.1113/jphysiol.1933.sp003083; Mccutcheon FH, 1936, J CELL COMPAR PHYSL, V8, P63, DOI 10.1002/jcp.1030080107; MCDONALD MJ, 1985, J MOL BIOL, V183, P105, DOI 10.1016/0022-2836(85)90284-0; McKinney ML, 1991, HETEROCHRONY EVOLUTI, P437; MOSS B, 1968, J MOL BIOL, V32, P481, DOI 10.1016/0022-2836(68)90336-7; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; PATIENT RK, 1983, J BIOL CHEM, V258, P8521; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; QUEEN C, 1984, NUCLEIC ACIDS RES, V12, P581, DOI 10.1093/nar/12.1Part2.581; RIGGS A, 1951, J GEN PHYSIOL, V35, P23, DOI 10.1085/jgp.35.1.23; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; Swofford David L., 1990, P411; TAM LT, 1986, J BIOL CHEM, V261, P8290; TAM LT, 1993, J BIOL CHEM, V268, P26972; TAM LT, 1984, J BIOL CHEM, V259, P2610; TIBBEN EA, 1991, RESP PHYSIOL, V84, P93, DOI 10.1016/0034-5687(91)90021-A; TRADER CD, 1966, J BIOL CHEM, V241, P357; YOKOTA E, 1984, J BIOL CHEM, V259, P4739	56	12	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26961	26971						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262931				2022-12-25	WOS:A1993MM26200022
J	HANSSON, L; BLACKBERG, L; EDLUND, M; LUNDBERG, L; STROMQVIST, M; HERNELL, O				HANSSON, L; BLACKBERG, L; EDLUND, M; LUNDBERG, L; STROMQVIST, M; HERNELL, O			RECOMBINANT HUMAN-MILK BILE SALT-STIMULATED LIPASE - CATALYTIC ACTIVITY IS RETAINED IN THE ABSENCE OF GLYCOSYLATION AND THE UNIQUE PROLINE-RICH REPEATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC CHOLESTEROL ESTERASE; BOVINE PAPILLOMA-VIRUS; CDNA CLONING; PREMATURE-INFANTS; LYSOPHOSPHOLIPASE; DIGESTION; IDENTITY; CALCIUM; GENE; FAT	Human milk bile salt-stimulated lipase ensures efficient utilization of triacylglycerol by breast-fed infants. Cloning and sequencing of cDNA have revealed that the peptide chain consists of 722 amino acid residues showing only little homology to typical lipases. The sequence is identical to that of pancreatic carboxylic-ester hydrolase. The COOH-terminal part contains 16 proline-rich repeats of 11 residues with O-linked carbohydrate. The only N-linked sugar chain is situated close to the active-site serine. Using C127 cells and a bovine papilloma virus vector, high and stable expression of full-length lipase and of several variants, obtained by site-directed mutagenesis, was achieved. The produced proteins were purified and further characterized. Variants lacking all, or all but two, repeats were active with similar specific activity and the same bile salt dependence as the native milk enzyme. Changing the asparagine necessary for N-glycosylation gave the same principal results. Active recombinant full-length lipase was also produced in a bacterial system. We conclude that neither glycosylation (N- or O-linked) nor the proline-rich repeats are essential for catalytic activity or bile salt activation of human milk bile salt-stimulated lipase.	UMEA UNIV,DEPT MED BIOCHEM & BIOPHYS,S-90187 UMEA,SWEDEN; UMEA UNIV,DEPT PEDIAT,S-90187 UMEA,SWEDEN; ASTRA HASSLE AB,PRECLIN RES & DEV,S-43183 MOLNDAL,SWEDEN	Umea University; Umea University	HANSSON, L (corresponding author), SYMBICOM AB,S-90124 UMEA,SWEDEN.							ABOUAKIL N, 1989, BIOCHIM BIOPHYS ACTA, V1002, P225, DOI 10.1016/0005-2760(89)90291-9; ATKINSON SA, 1981, J PEDIATR-US, V99, P617, DOI 10.1016/S0022-3476(81)80275-2; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BABA T, 1991, BIOCHEMISTRY-US, V30, P500, DOI 10.1021/bi00216a028; BERNBACK S, 1990, J CLIN INVEST, V85, P1221, DOI 10.1172/JCI114556; BJORKSTEN B, 1980, BRIT MED J, V201, P267; BLACKBERG L, 1983, FEBS LETT, V157, P337, DOI 10.1016/0014-5793(83)80571-7; BLACKBERG L, 1981, EUR J BIOCHEM, V116, P221, DOI 10.1111/j.1432-1033.1981.tb05322.x; BLACKBERG L, 1993, FEBS LETT, V323, P207, DOI 10.1016/0014-5793(93)81340-6; CHAPPELL JE, 1986, J PEDIATR-US, V108, P439, DOI 10.1016/S0022-3476(86)80893-9; FONTAINE RN, 1991, BIOCHEMISTRY-US, V30, P7008, DOI 10.1021/bi00242a028; FREDRIKZON B, 1978, PEDIATR RES, V12, P1048, DOI 10.1203/00006450-197811000-00004; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMOSH M, 1986, FED PROC, V45, P1452; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HERNELL O, 1975, EUR J CLIN INVEST, V5, P267, DOI 10.1111/j.1365-2362.1975.tb02294.x; Hernell O., 1989, Textbook of gastroenterology and nutrition in infancy., P209; HERNELL O, 1991, ENCY HUMAN BIOL, V3, P47; HUI DY, 1990, FEBS LETT, V276, P131, DOI 10.1016/0014-5793(90)80525-N; KYGER EM, 1989, BIOCHEM BIOPH RES CO, V164, P1302, DOI 10.1016/0006-291X(89)91811-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSKY M, 1984, CELL, V36, P391, DOI 10.1016/0092-8674(84)90232-0; NILSSON J, 1990, EUR J BIOCHEM, V192, P543, DOI 10.1111/j.1432-1033.1990.tb19259.x; Patton J.S., 1981, PHYSL GASTROINTESTIN, P1123; PAVLAKIS GN, 1983, P NATL ACAD SCI-BIOL, V80, P397, DOI 10.1073/pnas.80.2.397; REUE K, 1991, J LIPID RES, V32, P267; SARVER N, 1982, P NATL ACAD SCI-BIOL, V79, P7147, DOI 10.1073/pnas.79.23.7147; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WILLIAMSON S, 1978, ARCH DIS CHILD, V53, P555, DOI 10.1136/adc.53.7.555	30	72	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26692	26698						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253803				2022-12-25	WOS:A1993MK42500099
J	KITAGAWA, H; NAKADA, H; FUKUI, S; FUNAKOSHI, I; KAWASAKI, T; TATE, S; INAGAKI, F; YAMASHINA, I				KITAGAWA, H; NAKADA, H; FUKUI, S; FUNAKOSHI, I; KAWASAKI, T; TATE, S; INAGAKI, F; YAMASHINA, I			NOVEL GANGLIOSIDES CONTAINING THE SIALYL-LE(A) STRUCTURE FROM A HUMAN RECTAL ADENOCARCINOMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-FUCOPENTAOSE-II; MONOCLONAL-ANTIBODY; HUMAN-MILK; LEA STRUCTURE; OLIGOSACCHARIDES; ANTIGEN; CANCER; MUCIN; GLYCOPROTEINS; RECOGNIZES	Oligosaccharides were released from the gangliosides of a human rectal adenocarcinoma with endoglycoceramidase (Rhodococcus sp. G-74-2) and then purified by affinity chromatography on a column of an immobilized monoclonal antibody, MSW 113. Structural studies, involving 600-MHz H-1 NMR spectrometry, indicated the structures of these compounds to be as follows. [GRAPHICS]. Three of these oligosaccharides, 2, 3, and 4, are novel as to ganglioside sugar chains and contain both lacto series types 1 and 2 chains. Oligosaccharides 3 and 4 are unique in that they contain the sialyl-Le(a)-X structure in linear and branched structures. Gangliosides with the oligosaccharide structures presented above might be new potential tumor markers.	KYOTO SANGYO UNIV,FAC ENGN,DEPT BIOTECHNOL,KITA KU,KYOTO 603,JAPAN; KYOTO UNIV,FAC PHARMACEUT SCI,DEPT BIOL CHEM,SAKYO KU,KYOTO 606,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC PHYSIOL,BUNKYO KU,TOKYO 113,JAPAN	Kyoto Sangyo University; Kyoto University; Tokyo Metropolitan Institute of Medical Science			Tate, Shin-ichi/E-3057-2015; Kitagawa, Hiroshi/AAJ-1344-2020	Tate, Shin-ichi/0000-0002-5556-7712; Kitagawa, Hiroshi/0000-0002-9307-7079				FUKUI S, 1988, JPN J CANCER RES, V79, P1119, DOI 10.1111/j.1349-7006.1988.tb01535.x; FUKUSHI Y, 1986, BIOCHEMISTRY-US, V25, P2859, DOI 10.1021/bi00358a018; HAKOMORI S, 1985, CANCER RES, V45, P2405; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; HAKOMORI S, 1981, BIOCHEM BIOPH RES CO, V100, P1578, DOI 10.1016/0006-291X(81)90699-9; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; ITO M, 1986, J BIOL CHEM, V261, P14278; JOURDIAN GW, 1971, J BIOL CHEM, V246, P430; KITAGAWA H, 1988, J BIOCHEM-TOKYO, V104, P817, DOI 10.1093/oxfordjournals.jbchem.a122555; KITAGAWA H, 1988, J BIOCHEM-TOKYO, V104, P591, DOI 10.1093/oxfordjournals.jbchem.a122516; KITAGAWA H, 1990, J BIOL CHEM, V265, P4859; KITAGAWA H, 1989, BIOCHEMISTRY-US, V28, P8891, DOI 10.1021/bi00448a031; KITAGAWA H, 1991, BIOCHEMISTRY-US, V30, P2869, DOI 10.1021/bi00225a020; KITAGAWA H, 1991, BIOCHEM BIOPH RES CO, V178, P1429, DOI 10.1016/0006-291X(91)91053-F; KUROSAKA A, 1988, J BIOL CHEM, V263, P8724; KUROSAKA A, 1987, FEBS LETT, V215, P137, DOI 10.1016/0014-5793(87)80128-X; LANGONE JJ, 1980, METHOD ENZYMOL, V70, P365; LEDEEN RW, 1973, J NEUROCHEM, V21, P829, DOI 10.1111/j.1471-4159.1973.tb07527.x; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; MAGNANI JL, 1983, CANCER RES, V43, P5489; MARTENSSON S, 1988, CANCER RES, V48, P2125; NUDELMAN E, 1986, J BIOL CHEM, V261, P5487; NUMATA Y, 1990, BIOCHEM BIOPH RES CO, V170, P981, DOI 10.1016/0006-291X(90)90488-9; SMITH DF, 1987, J BIOL CHEM, V262, P12040; WIERUSZESKI JM, 1985, CARBOHYD RES, V137, P127, DOI 10.1016/0008-6215(85)85154-5; YAMASHITA K, 1977, J BIOL CHEM, V252, P5408	26	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26541	26545						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253783				2022-12-25	WOS:A1993MK42500077
J	ARDAIL, D; GASNIER, F; LERME, F; SIMONOT, C; LOUISOT, P; GATEAUROESCH, O				ARDAIL, D; GASNIER, F; LERME, F; SIMONOT, C; LOUISOT, P; GATEAUROESCH, O			INVOLVEMENT OF MITOCHONDRIAL CONTACT SITES IN THE SUBCELLULAR COMPARTMENTALIZATION OF PHOSPHOLIPID BIOSYNTHETIC-ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ENDOPLASMIC-RETICULUM; PHOSPHATIDYLSERINE IMPORT; PROTEIN TRANSLOCATION; LIPOPROTEIN SECRETION; OUTER-MEMBRANE; FRACTION; PHOSPHATIDYLETHANOLAMINE; HETEROGENEITY; DOLICHOL	The concerted synthesis of phospholipids derived from serine involving two microsomal enzymes (phosphatidylserine synthase and phosphatidylethanolamine N-methyltransferase) and a mitochondrial one (phosphatidylserine decarboxylase) occurs in reconstituted cell-free systems. Subfractionation of crude mitochondria after swelling and separating on a sucrose density gradient resulted in the isolation of two contact site-enriched fractions from total outer membranes and inner membranes, respectively. Estimation of marker enzyme activities shows a high recovery of glucose-6-phosphate phosphatase (a marker for the endoplasmic reticulum) associated with contact site-enriched fractions. Accordingly, the linked synthesis of phosphatidylserine, phosphatidylethanolamine, and at a lesser extent phosphatidylcholine can occur. This biosynthetic pathway was absent from purified contact site-enriched fractions correlative with the absence of glucose-6-phosphate phosphatase activity. Reconstitution experiments, including contact site-enriched fractions incubated with endoplasmic reticulum-rich fraction, led to the restoration of the linked synthesis of phospholipids, thereby demonstrating that a reversible association between these two fractions can occur. These functional interactions between the endoplasmic reticulum and mitochondria are confirmed at the ultra-structural level using either chemical or physical fixation before resin embedding. These results show that the interorganelle trafficking of lipids may involve only highly specialized microdomains of both membranes, thereby allowing the maintenance of a specific lipid composition and distribution within membranes.	LYON SUD MED SCH, DEPT BIOCHEM, CNRS 189, INSERM, BP 12, F-69921 OULLINS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)								AMARCOSTESEC A, 1981, J THEOR BIOL, V89, P217, DOI 10.1016/0022-5193(81)90309-X; ARDAIL D, 1990, J BIOL CHEM, V265, P18797; ARDAIL D, 1991, J BIOL CHEM, V266, P7978; ARDAIL D, 1989, BIOCHEM BIOPH RES CO, V164, P1009, DOI 10.1016/0006-291X(89)91770-1; BARANSKA J, 1980, BIOCHIM BIOPHYS ACTA, V619, P258, DOI 10.1016/0005-2760(80)90074-0; BIERMANS W, 1990, BIOCHIM BIOPHYS ACTA, V1018, P225, DOI 10.1016/0005-2728(90)90254-2; BRDICZKA D, 1991, BIOCHIM BIOPHYS ACTA, V1071, P291, DOI 10.1016/0304-4157(91)90018-R; CASCARANO J, 1982, EXP CELL RES, V139, P39, DOI 10.1016/0014-4827(82)90316-0; DEPIERRE JW, 1975, BIOCHIM BIOPHYS ACTA, V415, P411, DOI 10.1016/0304-4157(75)90006-4; ERIKSSON LC, 1977, CELL TISSUE RES, V179, P17; FOLCH J, 1957, J BIOL CHEM, V226, P497; GASNIER F, 1989, BIOCHIM BIOPHYS ACTA, V980, P339, DOI 10.1016/0005-2736(89)90322-2; GATEAU O, 1978, EUR J BIOCHEM, V88, P613, DOI 10.1111/j.1432-1033.1978.tb12488.x; GIEROW P, 1989, BIOCHEM J, V262, P55, DOI 10.1042/bj2620055; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; Humbel B. M., 1989, IMMUNOGOLD LABELING, P115; LEWIS JA, 1973, J CELL SCI, V13, P447; MEIER PJ, 1981, BIOCHIM BIOPHYS ACTA, V646, P283, DOI 10.1016/0005-2736(81)90335-7; MONTISANO DF, 1982, ANAT RECORD, V203, P441, DOI 10.1002/ar.1092030403; OHLENDIECK K, 1986, BIOCHIM BIOPHYS ACTA, V860, P672, DOI 10.1016/0005-2736(86)90567-5; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; PFANNER N, 1990, BIOCHIM BIOPHYS ACTA, V1018, P239, DOI 10.1016/0005-2728(90)90257-5; PON L, 1989, J CELL BIOL, V109, P2603, DOI 10.1083/jcb.109.6.2603; RIDGWAY ND, 1987, J BIOL CHEM, V262, P17231; ROJO M, 1991, J BIOL CHEM, V266, P20290; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHMID PC, 1981, J LIPID RES, V22, P882; SIMBENI R, 1991, J BIOL CHEM, V266, P10047; SIMBENI R, 1990, J BIOL CHEM, V265, P281; VANCE JE, 1986, J BIOL CHEM, V261, P4486; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VANCE JE, 1991, J BIOL CHEM, V266, P89; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VANDENBOSCH H, 1991, METHOD ENZYMOL, V197, P365; VOELKER DR, 1989, J BIOL CHEM, V264, P8019; VOELKER DR, 1989, P NATL ACAD SCI USA, V86, P9921, DOI 10.1073/pnas.86.24.9921	36	95	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25985	25992						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245031				2022-12-25	WOS:A1993MK10000099
J	YOST, JC; SAGE, EH				YOST, JC; SAGE, EH			SPECIFIC INTERACTION OF SPARC WITH ENDOTHELIAL-CELLS IS MEDIATED THROUGH A CARBOXYL-TERMINAL SEQUENCE CONTAINING A CALCIUM-BINDING EF HAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; PLASMINOGEN-ACTIVATOR; EXTRACELLULAR-MATRIX; ANGIOGENESIS INVITRO; NONMINERALIZED TISSUES; PROTEIN SPARC; IMMUNE-SYSTEM; GLYCOPROTEIN; RECEPTOR; THROMBOSPONDIN	SPARC is a secreted, Ca2+-binding protein that modulates cell shape and gene expression (Sage, E. H., and Bornstein, P. (1991) J. Biol. Chem. 266, 14831-14834). In the present study we questioned whether SPARC interacted with an endothelial cell surface receptor. The binding of I-125-SPARC to bovine aortic endothelial cells was dependent on Ca2+ and was sensitive to small changes in extracellular pH; maximal binding occurred at pH 7.1. Scatchard analysis indicated approximately 2.3 x 10(7) binding sites/cell with an apparent K(I) of 1.1 nM. The interaction was diminished specifically by competition with synthetic peptides corresponding to amino acids 54-73 (SPARC54-73) and 254-273 (SPARC254-273). The binding of I-125-SPARC254-273, a sequence containing a Ca2+-binding EF-hand, was saturated within 45 min at a concentration of 5 muM; Scatchard analysis indicated 4.2 x 10(7) sites/cell and a K(I) of 2.4 nM. Iodinated proteins from plasma membranes were affinity-chromatographed on SPARC254-273; several proteins with apparent masses ranging from 153 to 100 kDa (unreduced) or from 153 to 122 kDa (reduced) were eluted with the soluble peptide. These proteins represent candidates for a SPARC receptor(s) that mediates the biological activity of this protein on endothelial cells.	UNIV WASHINGTON,DEPT BIOL STRUCT,SM-20,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040711] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL08571, HL03174] Funding Source: Medline; NIGMS NIH HHS [GM 40711] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADET J, 1989, P NATL ACAD SCI USA, V86, P8427, DOI 10.1073/pnas.86.21.8427; BEEBE DP, 1989, BLOOD, V74, P2034; BENNETT JS, 1991, ANN NY ACAD SCI, V614, P214, DOI 10.1111/j.1749-6632.1991.tb43704.x; CLEZARDIN P, 1988, EUR J BIOCHEM, V175, P275, DOI 10.1111/j.1432-1033.1988.tb14194.x; DARDIK R, 1989, EUR J BIOCHEM, V185, P581, DOI 10.1111/j.1432-1033.1989.tb15153.x; ENGEL J, 1987, BIOCHEMISTRY-US, V26, P6958, DOI 10.1021/bi00396a015; ENGSTROM U, 1992, J BIOL CHEM, V267, P16581; FLAUMENHAFT R, 1992, MOL BIOL CELL, V3, P1057, DOI 10.1091/mbc.3.10.1057; FUNK SE, 1991, P NATL ACAD SCI USA, V88, P2648, DOI 10.1073/pnas.88.7.2648; FUNK SE, 1992, J CELL PHYSL, V154, P53; HASSELAAR P, 1991, J BIOL CHEM, V266, P13178; HASSELAAR P, 1992, J CELL BIOCHEM, V49, P272, DOI 10.1002/jcb.240490310; HERMAN IM, 1987, TISSUE CELL, V19, P1, DOI 10.1016/0040-8166(87)90052-8; HOLLAND PWH, 1987, J CELL BIOL, V105, P473, DOI 10.1083/jcb.105.1.473; IRUELAARISPE ML, 1991, ARTERIOSCLER THROMB, V11, P805, DOI 10.1161/01.ATV.11.4.805; IRUELAARISPE ML, 1991, LAB INVEST, V64, P174; KHACHIGIAN LM, 1992, J BIOL CHEM, V267, P7478; KNIGHTON D, 1987, CURRENT COMMUNICATIO, P150; KOSFELD MD, 1992, J BIOL CHEM, V267, P16230; LANE TF, 1992, J BIOL CHEM, V267, P16736; LANE TF, 1990, J CELL BIOL, V111, P3065, DOI 10.1083/jcb.111.6.3065; LAWLER J, 1989, BLOOD, V74, P2022; LEUNG LLK, 1992, J BIOL CHEM, V267, P18244; LIBBY P, 1991, LAB INVEST, V64, P5; MADRI JA, 1988, AM J PATHOL, V132, P18; MALAVAL L, 1987, J BONE MINER RES, V2, P457; MASON IJ, 1986, EMBO J, V5, P1465, DOI 10.1002/j.1460-2075.1986.tb04383.x; MAYER U, 1991, EUR J BIOCHEM, V198, P141, DOI 10.1111/j.1432-1033.1991.tb15996.x; MORRIS JC, 1990, J BIOL CHEM, V265, P1881; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; PAULI BU, 1988, LAB INVEST, V58, P379; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PURCELL L, 1993, J EXP ZOOL, V265, P153, DOI 10.1002/jez.1402650207; RAINES EW, 1992, P NATL ACAD SCI USA, V89, P1281, DOI 10.1073/pnas.89.4.1281; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RYBAK ME, 1989, BLOOD, V73, P1534; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SAGE H, 1986, J CELL PHYSIOL, V127, P373, DOI 10.1002/jcp.1041270305; SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341; SAGE H, 1989, J HISTOCHEM CYTOCHEM, V37, P819, DOI 10.1177/37.6.2723400; SAGE H, 1986, VASCULAR ENDOTHELIUM, V2, P198; SANZO MA, 1990, BIOCHEM J, V269, P475, DOI 10.1042/bj2690475; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SIMIONESCU N, 1988, ENDOTHELIAL CELL BIO; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; VANZOELEN EJJ, 1989, BIOCHEM J, V262, P549, DOI 10.1042/bj2620549; WIGHT TN, 1989, ARTERIOSCLEROSIS, V9, P1, DOI 10.1161/01.ATV.9.1.1; WRENN DS, 1988, J BIOL CHEM, V263, P2280	49	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25790	25796						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245016				2022-12-25	WOS:A1993MK10000075
J	CATERINA, MJ; MILNE, JLS; DEVREOTES, PN				CATERINA, MJ; MILNE, JLS; DEVREOTES, PN			MUTATION OF THE 3RD INTRACELLULAR LOOP OF THE CAMP RECEPTOR, CAR1, OF DICTYOSTELIUM YIELDS MUTANTS IMPAIRED IN MULTIPLE SIGNALING PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; SITE-DIRECTED MUTAGENESIS; CYCLIC-AMP RECEPTOR; ADENYLATE-CYCLASE; SACCHAROMYCES-CEREVISIAE; ALPHA-SUBUNITS; LIGAND-BINDING; DISCOIDEUM; CELL; PROTEIN	Seven-membrane span receptors transduce a wide range of signals across the plasma membrane. One member of this family, the cAMP receptor, cAR1, of Dictyostelium, mediates some responses (eg. adenylyl cyclase activation, multicellular aggregation) which require G-proteins and others (e.g. Ca2+ influx, loss of ligand binding, cAR1 phosphorylation) which appear to be G-protein-independent. In this study, we randomly mutagenized the NH2-terminal eight amino acids of the third intracellular loop of cAR1 and examined the ability of these mutants to exhibit the three G-protein-independent responses listed above. Most mutants (classes I, II) exhibited wild-type or mildly defective responses. Several mutants (class III), however, were severely impaired in all three processes but not in cAMP binding. Furthermore, these mutants failed to couple productively with G-proteins and could not replace cAR1 in a car1- cell. For these reasons, we propose that class III mutations interfere with the formation of an ''active'' conformation of the receptor.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,520 WBSB,725 N WOLFE ST,BALTIMORE,MD 21205	Johns Hopkins University					PHS HHS [34933] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AU DC, 1989, BIOCHEMISTRY-US, V28, P2772, DOI 10.1021/bi00433a005; BONNER JT, 1982, DEV DICTYOSTELIUM DI, P1; BOYMARCOTTE E, 1984, MOL GEN GENET, V193, P406, DOI 10.1007/BF00382076; CATERINA MJ, 1991, FASEB J, V5, P3078, DOI 10.1096/fasebj.5.15.1743439; CHEUNG AH, 1989, MOL PHARMACOL, V34, P132; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; COUKELL MB, 1983, DEV GENET, V3, P283; COUKELL MB, 1990, J CELL SCI, V97, P649; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DEVREOTES P, 1987, METHOD CELL BIOL, V28, P299; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; DOWD BF, 1988, J BIOL CHEM, V263, P15985; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; FRANKE J, 1977, P NATL ACAD SCI USA, V74, P2157, DOI 10.1073/pnas.74.5.2157; HADWIGER JA, 1991, P NATL ACAD SCI USA, V88, P8213, DOI 10.1073/pnas.88.18.8213; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; JACQUET M, 1988, MOL GEN GENET, V211, P441, DOI 10.1007/BF00425698; JOHNSON RL, 1991, BIOCHEMISTRY-US, V30, P6982, DOI 10.1021/bi00242a025; JOHNSON RL, 1992, J BIOL CHEM, V267, P4600; JOHNSON RL, 1993, GENE DEV, V7, P273, DOI 10.1101/gad.7.2.273; KESBEKE F, 1988, J CELL BIOL, V107, P521, DOI 10.1083/jcb.107.2.521; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KLEIN C, 1977, CELL, V10, P329, DOI 10.1016/0092-8674(77)90227-6; KLEIN C, 1979, J BIOL CHEM, V254, P2573; KLEIN P, 1987, J BIOL CHEM, V262, P358; KLEIN P, 1985, J BIOL CHEM, V260, P1757; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; KUSPA A, 1992, P NATL ACAD SCI USA, V89, P8803, DOI 10.1073/pnas.89.18.8803; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILNE JL, 1991, J CELL BIOL, V112, P103, DOI 10.1083/jcb.112.1.103; MILNE JL, 1993, MOL BIOL CELL, V4, P283, DOI 10.1091/mbc.4.3.283; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PUPILLO M, 1989, P NATL ACAD SCI USA, V86, P4892, DOI 10.1073/pnas.86.13.4892; PUPILLO M, 1992, MOL BIOL CELL, V3, P1229, DOI 10.1091/mbc.3.11.1229; RANDERATH E, 1965, ANAL BIOCHEM, V12, P83, DOI 10.1016/0003-2697(65)90145-4; SALAMON Y, 1979, ADV CYCLIC NUCL RES, V10, P35; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sambrook J, 1989, MOL CLONING LABORATO; SAXE CL, 1993, GENE DEV, V7, P262, DOI 10.1101/gad.7.2.262; SAXE CL, 1992, DEV GENET, V12, P6; SNAARJAGALSKA BE, 1988, J BIOL CHEM, V263, P897; SUN TJ, 1990, J CELL BIOL, V110, P1549, DOI 10.1083/jcb.110.5.1549; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; VANHAASTERT PJM, 1987, J BIOL CHEM, V262, P7700; VANHAASTERT PJM, 1985, BIOCHIM BIOPHYS ACTA, V845, P254, DOI 10.1016/0167-4889(85)90184-3; VANHAASTERT PJM, 1984, BIOCHEM BIOPH RES CO, V124, P597, DOI 10.1016/0006-291X(84)91596-1; VANHAASTERT PJM, 1992, MOL BIOL CELL, V3, P603, DOI 10.1091/mbc.3.6.603; VAUGHAN RA, 1988, J BIOL CHEM, V263, P14538; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WEINER JL, 1993, J BIOL CHEM, V268, P8070; WU LJ, 1991, BIOCHEM BIOPH RES CO, V179, P1141, DOI 10.1016/0006-291X(91)91690-E; YU SS, 1993, J BIOL CHEM, V268, P337; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N	59	74	74	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1523	1532						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288619				2022-12-25	WOS:A1994MR22000114
J	OHMICHI, M; MATUOKA, K; TAKENAWA, T; SALTIEL, AR				OHMICHI, M; MATUOKA, K; TAKENAWA, T; SALTIEL, AR			GROWTH-FACTORS DIFFERENTIALLY STIMULATE THE PHOSPHORYLATION OF SHC PROTEINS AND THEIR ASSOCIATION WITH GRB2 IN PC-12 PHEOCHROMOCYTOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRK PROTOONCOGENE PRODUCT; SRC HOMOLOGY DOMAIN; SIGNAL TRANSDUCTION; TYROSINE KINASES; INSULIN-RECEPTOR; RAS; RAF-1; ACTIVATION; PHOSPHOLIPASE-C-GAMMA-1; MEMBRANE	Growth factor receptor tyrosine kinases can form stable associations with intracellular proteins that contain src homology (SH) 2 domains, including two proteins, Shc and Grb2, that are thought to lie upstream from the ras protooncogene in a signaling cascade. The phosphorylation and molecular associations of these proteins were evaluated in PC-12 pheochromocytoma cells treated with nerve growth factor (NGF), epidermal growth factor (EGF), and insulin. Both NGF and EGF stimulated the tyrosine phosphorylation of Shc proteins and their subsequent association with the receptors. In contrast, insulin had no effect on Shc phosphorylation, despite the expression of functional insulin receptors in these cells at levels comparable to those observed for NGF and EGF. NGF and EGF also induced the association of Shc proteins with a Grb2 fusion protein or endogenous Grb2, whereas insulin had no effect. All of the tyrosine-phosphorylated Shc proteins associated with the Grb2 fusion protein, although only about half of the endogenous She was phosphorylated in response to NGF or EGF. However, aH three hormones induced the association of several additional tyrosine phosphorylated proteins with Grb2, some of which also coprecipitated with antiserum against the 85-kDa subunit of phosphatidylinositol-3 kinase. Moreover, these growth factors stimulated the association of phosphatidylinositol-3 kinase activity with the Grb2 fusion protein, although this activity was not detected in anti-Shc immunoprecipitates. These results provide further evidence for the divergence of signaling pathways in insulin action, and suggest that Grb2 forms separate complexes with tyrosine-phosphorylated proteins in PC-12 cells.	UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48104; PARKE DAVIS & CO,DIV PHARMACEUT RES,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105; UNIV TOKYO,INST MED SCI,DEPT MOLEC ONCOL,TOKYO 108,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,ITABASHI KU,TOKYO 173,JAPAN	University of Michigan System; University of Michigan; Pfizer; University of Tokyo			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; CARPENTER G, 1979, J BIOL CHEM, V254, P4884; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COUGHLIN SR, 1989, SCIENCE, V243, P1191; HATTORI S, 1992, J BIOL CHEM, V267, P20346; JAISWAL RK, 1993, J BIOL CHEM, V268, P7055; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOVACINA KS, 1990, J BIOL CHEM, V265, P1215; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1990, EMBO J, V9, P4357; MATHUDA Y, 1987, J BIOL CHEM, V262, P2832; MATSUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; OHMICHI M, 1992, J BIOL CHEM, V267, P21601; OHMICHI M, 1992, J BIOL CHEM, V267, P14604; OHMICHI M, 1991, BIOCHEM BIOPH RES CO, V179, P217, DOI 10.1016/0006-291X(91)91357-I; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SALTIEL AR, 1991, MOL CELL ENDOCRINOL, V81, pC197, DOI 10.1016/0303-7207(91)90198-2; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; THIES RS, 1989, J BIOL CHEM, V263, P8912; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHU GC, 1992, P NATL ACAD SCI USA, V89, P9559, DOI 10.1073/pnas.89.20.9559; ZHU GC, 1993, J BIOL CHEM, V268, P1775	39	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1143	1148						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288573				2022-12-25	WOS:A1994MR22000059
J	ENYEDI, A; VERMA, AK; HEIM, R; ADAMO, HP; FILOTEO, AG; STREHLER, EE; PENNISTON, JT				ENYEDI, A; VERMA, AK; HEIM, R; ADAMO, HP; FILOTEO, AG; STREHLER, EE; PENNISTON, JT			THE CA2+ AFFINITY OF THE PLASMA-MEMBRANE CA2+ PUMP IS CONTROLLED BY ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CALMODULIN-BINDING	The plasma membrane Ca2+ pump is a calmodulin-regulated P-type ATPase that is an essential element in controlling intracellular Ca2+ concentration. Studies on the gene structure of this pump have revealed an alternate splice option that changes the structure of the calmodulin-binding domain. This change in the structure of the enzyme results in a reduced calmodulin affinity. Tests of the enzyme's activity in the presence of a high calmodulin concentration, approximating that found inside living cells, show that this reduced calmodulin affinity causes a reduced apparent affinity of the enzyme for Ca2+. This shift in the Ca2+ activation occurs in a Ca2+ concentration range crucial to cellular function and is probably the physiologically important consequence of the alternate splice.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; SWISS FED INST TECHNOL,BIOCHEM LAB,CH-8092 ZURICH,SWITZERLAND	Mayo Clinic; ETH Zurich			Adamo, Hugo Pedro/ABB-8338-2021; Enyedi, Agnes/N-9742-2013	Adamo, Hugo Pedro/0000-0002-1712-8049; Enyedi, Agnes/0000-0002-7366-9376	NIGMS NIH HHS [GM 28835] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; GOUGH AH, 1993, J CELL BIOL, V121, P1095, DOI 10.1083/jcb.121.5.1095; HEIM R, 1992, J BIOL CHEM, V267, P24476; KEETON TP, 1993, J BIOL CHEM, V268, P2740; KESSLER F, 1992, BIOCHEMISTRY-US, V31, P11785, DOI 10.1021/bi00162a016; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; Penniston J T, 1980, Ann N Y Acad Sci, V356, P245, DOI 10.1111/j.1749-6632.1980.tb29615.x; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586	13	121	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					41	43						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276828				2022-12-25	WOS:A1994MR21900011
J	YENUSH, L; KUNDRA, V; WHITE, MF; ZETTER, BR				YENUSH, L; KUNDRA, V; WHITE, MF; ZETTER, BR			FUNCTIONAL DOMAINS OF THE INSULIN-RECEPTOR RESPONSIBLE FOR CHEMOTACTIC SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS SUBSTRATE PHOSPHORYLATION; HUMAN INTERLEUKIN-8 RECEPTOR; TYROSINE KINASE-ACTIVITY; BC3H-1 MURINE MYOCYTES; GROWTH-FACTOR; JUXTAMEMBRANE REGION; BETA-SUBUNIT; PROTEIN; CELLS; AUTOPHOSPHORYLATION	The insulin receptor mediates a variety of cellular responses to insulin, including glucose transport, endocytosis, and cell proliferation. The role of the insulin receptor in mediating cellular motility has not, however, been extensively investigated. In this report, we demonstrate that chinese hamster ovary (CHO) cells that normally have low concentrations of insulin receptor display chemotaxis toward insulin after overexpression of the wild type human insulin receptor. Chemotaxis toward insulin proceeded through a pertussis toxin-sensitive pathway and required both tyrosine kinase activity and tyrosine autophosphorylation of the regulatory region of the beta-subunit. In contrast, the autophosphorylation sites in the carboxyl terminus of the receptor were not required for chemotactic activity. A mutation in the juxtamembrane region, which disabled tyrosine phosphorylation of the insulin receptor substrate-1 (IRS-1), also prevented the chemotactic response, suggesting a possible role for IRS-1 in chemotactic signaling. In the absence of insulin receptor, however, the presence of excess transfected IRS-1 was not sufficient to mediate chemotaxis toward insulin. These results demonstrate that the intact insulin receptor can stimulate a chemotactic signaling pathway and that this initial pathway more closely correlates with that for insulin-stimulated cell proliferation than for insulin-stimulated receptor endocytosis.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT SURG,300 LONGWOOD AVE,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM CELL & DEV BIOL,BOSTON,MA 02115; JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Joslin Diabetes Center, Inc.			Yenush, Lynne/J-8815-2014	Yenush, Lynne/0000-0001-8589-7002	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038712, R01DK038712, R01DK043808, R55DK038712] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38712, DK 43808] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1991, BIOCHEMISTRY-US, V30, P6366, DOI 10.1021/bi00240a003; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BEGUM N, 1993, J BIOL CHEM, V268, P7917; BOTWELL D, 1992, P NATL ACAD SCI USA, V89, P6511; Donahue WL, 1954, J PEDIATR, V45, P505; FEENER EP, 1993, J BIOL CHEM, V268, P11256; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; KNIGHT AB, 1981, P NATL ACAD SCI-BIOL, V78, P2554, DOI 10.1073/pnas.78.4.2554; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LUTTRELL L, 1990, J BIOL CHEM, V265, P16873; LUTTRELL LM, 1988, J BIOL CHEM, V263, P6134; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; NALDINI L, 1991, ONCOGENE, V6, P501; OBERMAIERKUSSER B, 1989, J BIOL CHEM, V264, P9497; PIENTA KJ, 1991, CANCER SURV, V11, P255; ROTHENBERG PL, 1988, J BIOL CHEM, V263, P15546; SCHILLING EE, 1979, P NATL ACAD SCI USA, V76, P5877, DOI 10.1073/pnas.76.11.5877; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; ZETTER BR, 1980, NATURE, V285, P41, DOI 10.1038/285041a0	33	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					100	104						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276780				2022-12-25	WOS:A1994MR21900023
J	ZEGERS, I; HAIKAL, AF; PALMER, R; WYNS, L				ZEGERS, I; HAIKAL, AF; PALMER, R; WYNS, L			CRYSTAL-STRUCTURE OF RNASE T1 WITH 3'-GUANYLIC ACID AND GUANOSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEAST-SQUARES REFINEMENT; 3-DIMENSIONAL STRUCTURE; MACROMOLECULAR STRUCTURES; GPN TRANSESTERIFICATION; SUBSITE INTERACTIONS; SUBSTRATE-BINDING; 1.9-A RESOLUTION; X-RAY; RIBONUCLEASE-T1; COMPLEX	A modified method for the synthesis and separation of endo and exo guanosine 2',3'-cyclophosphorothioate (cGPS) has been developed. The exo diastereoisomer has been co-crystallized with RNase T1. cGPS is known to be a RNase T1 inhibitor but is also a very slow substrate. It was hydrolyzed during the crystallization, leaving 3'-guanylic acid (3'-GMP) in the active site. As a guanosine was also found to be bound in a subsite, the enzyme contains the products of the reaction of guanylyl-3',5'-guanosine. The structure was refined to a resolution of 1.7 angstrom and yielded a final R value of 14.5%. In contrast to previous 3'-GMP complexes of RNase T1, the ribose phosphate moiety of the inhibitor is in contact with all the active site residues. The phosphate forms hydrogen bonds with Asn36, Tyr38, Arg77, His92, and with Asn49 from a symmetry-related molecule. The ribose 2'-OH is hydrogen-bonded to both Glu58 and His40. The interactions in the active site of the present structure are compared to those found in the 2'-GMP complex of RNase T1.	UNIV LONDON BIRKBECK COLL,DEPT CRYSTALLOG,LONDON WC1E 7HX,ENGLAND	University of London; Birkbeck University London	ZEGERS, I (corresponding author), VRIJE UNIV BRUSSELS,INST MOLEC BIOL,PAARDENSTR 65,B-1640 RHODE ST GENESE,BELGIUM.							ALTONA C, 1972, J AM CHEM SOC, V94, P8205, DOI 10.1021/ja00778a043; ARNI R, 1988, J BIOL CHEM, V263, P15358; DING JP, 1991, J BIOL CHEM, V266, P15128; ECKSTEIN F, 1972, BIOCHEMISTRY-US, V11, P3507, DOI 10.1021/bi00769a002; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; HEINEMANN U, 1982, NATURE, V299, P27, DOI 10.1038/299027a0; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HILL C, 1983, TRENDS BIOCHEM SCI, V8, P364, DOI 10.1016/0968-0004(83)90363-8; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KOEPKE J, 1989, J MOL BIOL, V206, P475, DOI 10.1016/0022-2836(89)90495-6; KOSTREWA D, 1989, BIOCHEMISTRY-US, V28, P7592, DOI 10.1021/bi00445a014; LENZ A, 1991, J BIOL CHEM, V266, P7661; LENZ A, 1993, EUR J BIOCHEM, V211, P311, DOI 10.1111/j.1432-1033.1993.tb19900.x; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; NISHIKAWA S, 1987, BIOCHEMISTRY-US, V26, P8620, DOI 10.1021/bi00400a019; PACE CN, 1991, ANGEW CHEM INT EDIT, V30, P343, DOI 10.1002/anie.199103433; PLETINCKX J, 1993, IN PRESS BIOCHEMISTR; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SHERIFF S, 1987, J APPL CRYSTALLOGR, V20, P55, DOI 10.1107/S0021889887087132; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; STEYAERT J, 1991, BIOCHEMISTRY-US, V30, P8661, DOI 10.1021/bi00099a024; STEYAERT J, 1990, BIOCHEMISTRY-US, V29, P9064, DOI 10.1021/bi00490a025; STEYAERT J, 1991, BIOCHEMISTRY-US, V30, P8666, DOI 10.1021/bi00099a025; SUGIO S, 1985, FEBS LETT, V183, P115, DOI 10.1016/0014-5793(85)80966-2; SUGIO S, 1988, J BIOCHEM-TOKYO, V103, P354, DOI 10.1093/oxfordjournals.jbchem.a122274; SUSSMAN JL, 1977, ACTA CRYSTALLOGR A, V33, P800, DOI 10.1107/S0567739477001958; TAKAHASHI K, 1971, J BIOCHEM, V70, P945, DOI 10.1093/oxfordjournals.jbchem.a129724; Takahashi K., 1982, ENZYMES, V15, p435 468; WALZ FG, 1977, BIOCHEMISTRY-US, V16, P5509, DOI 10.1021/bi00644a018; ZEGERS I, 1992, BIOCHEMISTRY-US, V31, P11317, DOI 10.1021/bi00161a009	32	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					127	133						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276784				2022-12-25	WOS:A1994MR21900027
J	PENA, A; REDDY, CD; WU, SJ; HICKOK, NJ; REDDY, EP; YUMET, G; SOPRANO, DR; SOPRANO, KJ				PENA, A; REDDY, CD; WU, SJ; HICKOK, NJ; REDDY, EP; YUMET, G; SOPRANO, DR; SOPRANO, KJ			REGULATION OF HUMAN ORNITHINE DECARBOXYLASE EXPRESSION BY THE C-MYC.MAX PROTEIN COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; DNA-BINDING; MYC PROTEIN; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; GENE; CELLS; MAX; GROWTH; DOMAINS	The presence of a CACGTG element within a region of the human ornithine decarboxylase (ODC) promoter located at -491 to -474 base pairs 5' to the start site of transcription suggested that the c-Myc.Max protein complex may play a role in the regulation of ODC expression during growth. Electrophoretic mobility shift assays and methylation interference analysis showed that the nuclei of WI-38 cells expressing ODC contained proteins that bound to this region of the ODC gene in a manner that correlated with growth-associated ODC expression. Also, use of antibodies against c-Myc and Max and purified recombinant c-Myc and Max protein in the electrophoretic mobility shift assay confirmed that these proteins can specifically bind this portion of the human ODC promoter. Transient transfection studies showed that increase in the level of c-Myc and/or Max led to a significant enhancement of expression of a human ODC promoter-CAT reporter construct. Moreover, treatment of actively growing WI-38 cells with an antisense oligomer to c-Myc reduced the amount of endogenous protein complex formed and the amount of endogenous ODC mRNA expressed. These studies show that the c-Myc.Max protein complex plays a role in the transcriptional regulation of human ODC in vivo.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS RES INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; THOMAS JEFFERSON UNIV,DEPT DERMATOL & BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University			Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [CA 10817, CA 56309] Funding Source: Medline; NIAMS NIH HHS [AR 40022] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA056309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR040022] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAHAMSEN MS, 1990, MOL CELL BIOL, V10, P5525, DOI 10.1128/MCB.10.10.5525; ABRAHAMSEN MS, 1992, J BIOL CHEM, V267, P18866; AUGENLICHT LH, 1974, EXP CELL RES, V8, P255; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BACON TA, 1991, ONCOGENE RES, V6, P21; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERBERICH S, 1992, ONCOGENE, V7, P775; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRABANT M, 1988, P NATL ACAD SCI USA, V85, P2200, DOI 10.1073/pnas.85.7.2200; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CARTER R, 1991, ONCOGENE, V6, P229; COSENZA SC, 1988, J BIOL CHEM, V263, P12751; CRISTOFALO VJ, 1973, EXP CELL RES, V76, P419, DOI 10.1016/0014-4827(73)90394-7; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HALMEKYTO M, 1989, BIOCHEM BIOPH RES CO, V162, P528, DOI 10.1016/0006-291X(89)92029-9; HEBBY O, 1990, TRENDS BIOCHEM SCI, V15, P153; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HICKOK NJ, 1990, GENE, V93, P257, DOI 10.1016/0378-1119(90)90233-H; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOLTTA E, 1989, GENE, V83, P125, DOI 10.1016/0378-1119(89)90410-1; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KATZ A, 1988, J BIOL CHEM, V263, P7604; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LU L, 1991, BIOCHEM J, V277, P671, DOI 10.1042/bj2770671; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MOSHIER JA, 1992, NUCLEIC ACIDS RES, V20, P2581, DOI 10.1093/nar/20.10.2581; OLSON EN, 1986, MOL CELL BIOL, V6, P2792, DOI 10.1128/MCB.6.8.2792; OWEN TA, 1990, J CELL PHYSIOL, V142, P137, DOI 10.1002/jcp.1041420117; OWEN TA, 1987, J BIOL CHEM, V262, P15111; PALVIMO JJ, 1991, NUCLEIC ACIDS RES, V19, P3921, DOI 10.1093/nar/19.14.3921; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1988, CANCER RES, V48, P759; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; REDDY CD, 1992, ONCOGENE, V7, P2085; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SETH A, 1986, GENE, V42, P49, DOI 10.1016/0378-1119(86)90149-6; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TOSCANI A, 1987, ANAL BIOCHEM, V165, P309, DOI 10.1016/0003-2697(87)90274-0; WEN L, 1989, J BIOL CHEM, V264, P9016; WETTERS TV, 1989, MOL CELL BIOL, V9, P5484, DOI 10.1128/MCB.9.12.5484; WETTERS TV, 1989, NUCLEIC ACIDS RES, V17, P9843, DOI 10.1093/nar/17.23.9843; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	61	131	133	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27277	27285						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262968				2022-12-25	WOS:A1993MM26200064
J	TATE, CG; HENDERSON, PJF				TATE, CG; HENDERSON, PJF			MEMBRANE TOPOLOGY OF THE L-RHAMNOSE-H+ TRANSPORT PROTEIN (RHAT) FROM ENTEROBACTERIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BETA-LACTAMASE; CYTOPLASMIC MEMBRANE; GENE-PRODUCT; CLONING; PURIFICATION; INSERTION; SEQUENCE; VECTOR; EXPORT	The L-rhamnose-H+ symporter (RhaT) is a 344-amino acid integral membrane protein, found in many Enterobacteria, which couples the uptake of the sugar L-rhamnose with the inward movement of protons. Based on its hydropathy profile and the application of von Heijne's ''positive inside'' rule (von Heijne, G. (1992) J. Mol. Biol. 225, 487-494), a model of the L-rhamnose-H+ symport protein (RhaT) is proposed containing 10 transmembrane helices with the NH2 and COOH termini in the periplasm. This model was tested by the creation of random beta-lactamase (Bla) fusions. The data from 33 unique, randomly generated, RhaT-Bla fusions and from 5 site-specific fusions supported the proposed topology between transmembrane helices 2-10. However, the localization of the putative first hydrophilic loop and the NH2 terminus was not possible because the beta-lactamase fusions in this region were shown to be unreliable indicators of the topology of RhaT.	UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND; UNIV LEEDS,DEPT BIOCHEM & MOLEC BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of Cambridge; University of Leeds			Henderson, Peter JF/Q-1907-2018	Tate, Christopher/0000-0002-2008-9183; Henderson, Peter/0000-0002-9187-0938	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSSON H, 1992, J BIOL CHEM, V267, P1491; BALDOMA L, 1990, FEMS MICROBIOL LETT, V72, P103, DOI 10.1016/0378-1097(90)90353-R; BOWLER LD, 1989, MOL MICROBIOL, V3, P1277, DOI 10.1111/j.1365-2958.1989.tb00278.x; BROOMESMITH JK, 1986, GENE, V49, P341, DOI 10.1016/0378-1119(86)90370-7; BROOMESMITH JK, 1990, MOL MICROBIOL, V4, P1637, DOI 10.1111/j.1365-2958.1990.tb00540.x; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CROWE JS, 1991, NUCLEIC ACIDS RES, V19, P184, DOI 10.1093/nar/19.1.184; EDELMAN A, 1987, MOL MICROBIOL, V1, P101, DOI 10.1111/j.1365-2958.1987.tb00533.x; GARCIAMARTIN C, 1992, J GEN MICROBIOL, V138, P1109, DOI 10.1099/00221287-138-6-1109; GERMINO J, 1984, P NATL ACAD SCI-BIOL, V81, P4692, DOI 10.1073/pnas.81.15.4692; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; HENDERSON PJF, 1986, METHOD ENZYMOL, V125, P387; KAMPFENKEL K, 1993, J BIOL CHEM, V268, P6050; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEWIS MJ, 1992, J BIOL CHEM, V267, P3482; LEWIS MJ, 1990, J BIOL CHEM, V265, P10541; Maniatis T., 1982, MOL CLONING; MOORE KE, 1987, J BIOL CHEM, V262, P8806; MUIRY JAR, 1993, BIOCHEM J, V290, P833, DOI 10.1042/bj2900833; MUIRY JAR, 1989, THESIS U CAMBRIDGE; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; TATE CG, 1992, J BIOL CHEM, V267, P6923; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WANG RC, 1991, J MOL BIOL, V217, P441, DOI 10.1016/0022-2836(91)90748-U; WEINER JH, 1993, J BIOL CHEM, V268, P3238; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1; WU JH, 1992, J BIOL CHEM, V267, P12570	34	17	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26850	26857						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262918				2022-12-25	WOS:A1993MM26200007
J	ORNELASSOARES, A; DELENCASTRE, H; DEJONGE, B; GAGE, D; CHANG, YS; TOMASZ, A				ORNELASSOARES, A; DELENCASTRE, H; DEJONGE, B; GAGE, D; CHANG, YS; TOMASZ, A			THE PEPTIDOGLYCAN COMPOSITION OF A STAPHYLOCOCCUS-AUREUS MUTANT SELECTED FOR REDUCED METHICILLIN RESISTANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSERTIONAL INACTIVATION; STRAIN; GENE; TN551	The peptidoglycan of a Tn551 mutant of Staphylococcus aureus (RUSA208) selected for reduced methicillin resistance was analyzed by reversed-phase high pressure liquid chromatography and mass spectrometry. RUSA208 is a member of a cluster of Tn551 mutants located on fragment A of SmaI digests but is distinct from the femA and femB class of mutants. The peptidoglycan of RUSA208 contained normal parental muropeptides but in diminished amounts only. The major muropeptides of RUSA208 were new components eluting with somewhat longer retention times from the column. Amino acid analysis of these new muropeptides showed identical compositions to the corresponding peaks in the parental strain, but mass spectrometry revealed increased molecular weights by the following mass units: 1 (in monomers), 1 or 2 (in dimers), and 2 or 3 (in trimers). These observations suggest that in RUSA208 the mutational block may be in the amidation of the stem peptide glutamate residues, resulting in the replacement of isoglutamine with free glutamic acid in one or more of the cell wall stem peptides.	INST TECNOL QUIM & BIOL,OEIRAS,PORTUGAL; MICHIGAN STATE UNIV,E LANSING,MI 48824; MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Michigan State University; Massachusetts Institute of Technology (MIT)	ORNELASSOARES, A (corresponding author), ROCKEFELLER UNIV,NEW YORK,NY 10021, USA.		DeJonge, Boudewijn/AAR-6717-2020	Ornelas-Soares, Antonio/0000-0002-2080-2858; Tomasz, Alexander/0000-0003-1520-1983; /0000-0001-6816-8932; Chang, Yoon-Seok/0000-0002-0623-2932				BERGERBACHI B, 1983, J BACTERIOL, V154, P479; BERGERBACHI B, 1992, ANTIMICROB AGENTS CH, V36, P1367, DOI 10.1128/AAC.36.7.1367; DEJONGE BLM, 1993, J BACTERIOL, V175, P2779, DOI 10.1128/JB.175.9.2779-2782.1993; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11255; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; DELENCASTRE H, 1991, ANTIMICROB AGENTS CH, V35, P632, DOI 10.1128/AAC.35.4.632; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; GOERING RV, 1990, J CLIN MICROBIOL, V28, P426, DOI 10.1128/JCM.28.3.426-429.1990; GUSTAFSON JE, 1993, 93RD P GEN M AM SOC; KORNBLUM J, 1986, EUR J CLIN MICROBIOL, V5, P714, DOI 10.1007/BF02013311; LINDBERG M, 1972, J BACTERIOL, V109, P844, DOI 10.1128/JB.109.2.844-847.1972; MATTHEWS P, 1990, ANTIMICROB AGENTS CH, V34, P1777, DOI 10.1128/AAC.34.9.1777; MURAKAMI K, 1989, J BACTERIOL, V171, P874, DOI 10.1128/jb.171.2.874-879.1989; PATTEE PA, 1987, GENET MAPS, V4, P148; Sambrook J, 1989, MOL CLONING LABORATO; SIEWERT G, 1968, J BIOL CHEM, V243, P783; SINHA RK, 1991, ANTIMICROB AGENTS CH, V35, P1753, DOI 10.1128/AAC.35.9.1753; TOMASZ A, 1989, ANTIMICROB AGENTS CH, V33, P1869, DOI 10.1128/AAC.33.11.1869; TOMASZ A, 1990, MOL BIOL STAPHYLOCOC, P565	19	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26268	26272						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253748				2022-12-25	WOS:A1993MK42500041
J	ROBINSON, LJ; RAZZACK, ZF; LAWRENCE, JC; JAMES, DE				ROBINSON, LJ; RAZZACK, ZF; LAWRENCE, JC; JAMES, DE			MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATION IS NOT SUFFICIENT FOR STIMULATION OF GLUCOSE-TRANSPORT OR GLYCOGEN-SYNTHASE IN 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; SKELETAL-MUSCLE; INSULIN; PHOSPHORYLATION; TRANSLOCATION; LOCALIZATION; PRECEDES; CELLS; RAS	The role of mitogen-activated protein (MAP) kinase in the regulation of glucose metabolism has been investigated by comparing the effects of insulin and epidermal growth factor (EGF) on MAP kinase activation, glucose transport, and glycogen synthase in 3T3-L1 adipocytes. Insulin or EGF treatment for 5 min increased p42mapk and p44mapk activity to the same extent as determined by myelin basic protein kinase activity measurements and phosphotyrosine immunoblotting. The profiles of myelin basic protein kinase activity following MonoQ chromatography of extracts obtained from cells incubated with insulin or EGF were almost identical. Insulin increased glucose transport and GLUT4 translocation to the cell surface by 15- and 7-fold, respectively. EGF had no significant effect on these processes. Insulin increased the glycogen synthase ratio (-Glc-6-P/+Glc-6-P) by 7.5- and 3.5-fold in the presence and absence of glucose, respectively. EGF increased the ratios by only 2- and 1.3-fold, respectively. EGF did not appear to inhibit downstream of MAP kinase, because when adipocytes were incubated with insulin plus EGF, the stimulation of glucose transport and glycogen synthase was similar to that observed with insulin alone. These findings indicate that activation of the MAP kinase isoforms p42mapk and p44mapk is not sufficient for the activation of glucose transport and glycogen synthase in 3T3-L1 adipocytes.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)				James, David/0000-0001-5946-5257	NIDDK NIH HHS [DK42503, DK28312] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042503, R01DK028312] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1993, J BIOL CHEM, V268, P8204; BARSAGI D, 1987, BIOSCIENCE REP, V7, P427, DOI 10.1007/BF01362505; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CHAN CP, 1987, J BIOL CHEM, V262, P276; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHENG HC, 1986, J BIOL CHEM, V261, P989; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; GIBBS EM, 1986, J BIOL CHEM, V261, P3944; GIBBS EM, 1988, BIOCHEMISTRY-US, V27, P6681, DOI 10.1021/bi00418a006; HAYSTEAD TAJ, 1986, BIOCHEM J, V234, P279, DOI 10.1042/bj2340279; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LAWRENCE JC, 1978, J BIOL CHEM, V253, P2104; LAWRENCE JC, 1992, ANNU REV PHYSIOL, V54, P177, DOI 10.1146/annurev.ph.54.030192.001141; LOTEN EG, 1970, BIOCHEM J, V120, P187, DOI 10.1042/bj1200187; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; PORRAS A, 1992, J BIOL CHEM, V267, P21124; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; REED BC, 1977, P NATL ACAD SCI USA, V74, P4876, DOI 10.1073/pnas.74.11.4876; ROBINSON LJ, 1992, AM J PHYSIOL, V263, pE383, DOI 10.1152/ajpendo.1992.263.2.E383; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; STAGSTED J, 1993, J BIOL CHEM, V268, P1770; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9	29	128	128	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26422	26427						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253768				2022-12-25	WOS:A1993MK42500062
J	WAY, BA; MOONEY, RA				WAY, BA; MOONEY, RA			ACTIVATION OF PHOSPHATIDYLINOSITOL-3-KINASE BY PLATELET-DERIVED GROWTH-FACTOR AND INSULIN-LIKE GROWTH FACTOR-I IS INHIBITED BY A TRANSMEMBRANE PHOSPHOTYROSINE PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDGF BETA-RECEPTOR; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; FACTOR-I; KINASE-ACTIVITY; RAT ADIPOCYTES; GLUCOSE-TRANSPORT; SH2 DOMAINS; ASSOCIATION; PROTEIN	Expression of the transmembrane phosphotyrosine phosphatase (PTPase) CD45 has been shown to inhibit hormone-dependent tyrosine phosphorylation and mitogenesis (Mooney, R. A., Freund, G. G., Way, B. A., and Bordwell, K. L. (1992) J. Biol. Chem. 267, 23443-23446). Here the impact of PTPase expression on insulin-like growth factor-1 (IGF-1) and platelet-derived growth factor- (PDGF) dependent activation of PI-3-K was investigated. In PTPase+ cells, IGF-I and PDGF-dependent PI-3-K activity in antiphosphotyrosine immunoprecipitates was decreased by 62 +/- 13 and 46 +/- 17%, respectively, compared to control cells. Similar decreases in PI-3-K activity associated with anti-PDGF receptor and anti-insulin receptor substrate-1 (IRS-1) immunoprecipitates were also observed. Association of PI-3-K with the hormone-activated PDGF receptor decreased approximately 55%, paralleling its loss of activation in PTPase+ cells. Tyrosine phosphorylation of the 85-kDa subunit of PI-3-K was also inhibited. Similarly, IGF-1 dependent tyrosine phosphorylation of IRS-1 was decreased by 45%, and its association with PI-3-K was decreased by 65% in PTPase+ cells. Finally, PDGF-dependent tyrosine phosphorylation of phospholipase C-gamma1 and GTPase-activating protein was reduced by 60-70% in the PTPase+ cells as was tyrosine phosphorylation of the PDGF receptor associated with these proteins. In summary, expression of a transmembrane PTPase decreased hormone-dependent PI-3-K activation, tyrosine phosphorylation of receptor substrates, and their association with signaling complexes. These data support a role for transmembrane PTPases in the regulation of receptor signal transduction pathways.	UNIV ROCHESTER,SCH MED & DENT,DEPT PATHOL & LAB MED,601 ELMWOOD AVE,ROCHESTER,NY 14642	University of Rochester					NIDDK NIH HHS [DK-38138] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038138] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUGHLIN SR, 1989, SCIENCE, V243, P1191; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; EZAKI O, 1989, J BIOL CHEM, V264, P16118; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FROST SC, 1987, J BIOL CHEM, V262, P9872; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GOLD MR, 1993, J IMMUNOL, V150, P377; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3419; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P3991; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MOONEY RA, 1992, J BIOL CHEM, V267, P23443; MOONEY RA, 1992, J BIOL CHEM, V267, P14054; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; STREULI M, 1988, J IMMUNOL, V141, P3910; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; SUNG CK, 1992, BIOCHEM BIOPH RES CO, V189, P1024, DOI 10.1016/0006-291X(92)92306-I; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAMAMOTO K, 1992, J BIOL CHEM, V267, P11337; YAMAMOTO K, 1992, ENDOCRINOLOGY, V130, P1490, DOI 10.1210/en.130.3.1490; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; ZHANG B, 1992, J BIOL CHEM, V267, P18320	45	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26409	26415						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253766				2022-12-25	WOS:A1993MK42500060
J	ZIOBER, BL; VU, MP; WALEH, N; CRAWFORD, J; LIN, CS; KRAMER, RH				ZIOBER, BL; VU, MP; WALEH, N; CRAWFORD, J; LIN, CS; KRAMER, RH			ALTERNATIVE EXTRACELLULAR AND CYTOPLASMIC DOMAINS OF THE INTEGRIN-ALPHA-7 SUBUNIT ARE DIFFERENTIALLY EXPRESSED DURING DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMININ-BINDING INTEGRIN; CELL-ADHESION RECEPTORS; AMINO-ACID-SEQUENCE; MESSENGER-RNA; ALPHA-SUBUNIT; ONCOGENIC TRANSFORMATION; MEMBRANE GLYCOPROTEIN; FIBRONECTIN RECEPTOR; MOLECULAR-CLONING; EPITHELIAL-CELLS	Examination of cDNAs for the laminin-binding alpha7 integrin subunit identified two different sequences (designated X1 and X2) coding for the variable region between the III and IV homology repeat domains near the putative ligand-binding site. Sequencing of a mouse alpha7 genomic clone established that the X1 and X2 regions are derived by mutually exclusive alternative mRNA splicing. Reverse transcriptase-polymerase chain reaction analysis of alpha7 mRNA indicated that the X1 and X2 isoforms were present in equal amounts in mouse skeletal myoblasts and adult heart. However, in adult skeletal muscle, the X2 variant was exclusively expressed. Amino acid sequence homologies in the III/IV segment suggest that alpha3 and alpha6 are also alternatively spliced at this site. We identified alternatively spliced exons in a human alpha6 genomic clone that encode X1- and X2-like segments. Analysis of the alpha7 cytoplasmic domain indicated that this region was also alternatively spliced and like alpha3 and alpha6 could exist as the A or B form. In mouse skeletal and cardiac muscle the B form of alpha7 was strongly expressed. However, we identified alpha7A in neonate and adult skeletal muscle but not in cardiac tissue. High levels of alpha7A were detected in differentiating myotubes, but in proliferating myoblasts only the alpha7B isoform was present. These results indicate that alternative splicing of alpha7 mRNA is differentially regulated during development and generates variant integrin chains with structurally and presumably functionally unique ligand-binding and cytoplasmic domains.	UNIV CALIF SAN FRANCISCO, DEPT STOMATOL & ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; SRI INT, MENLO PK, CA 94025 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; SRI International					NCI NIH HHS [CA51884, CA33834] Funding Source: Medline; NIDCR NIH HHS [DE10356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051884, R01CA033834] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BRAY PF, 1990, J BIOL CHEM, V265, P9587; BROWN NH, 1989, CELL, V59, P185, DOI 10.1016/0092-8674(89)90880-5; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER HM, 1991, J CELL BIOL, V115, P843, DOI 10.1083/jcb.115.3.843; DECURTIS I, 1991, J CELL BIOL, V113, P405, DOI 10.1083/jcb.113.2.405; DEDHAR S, 1992, EXP CELL RES, V203, P270, DOI 10.1016/0014-4827(92)90064-F; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; ERLE DJ, 1991, AM J RESP CELL MOL, V5, P170, DOI 10.1165/ajrcmb/5.2.170; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GEHLSEN KR, 1989, J BIOL CHEM, V264, P19034; GEHLSEN KR, 1988, SCIENCE, V241, P1228, DOI 10.1126/science.2970671; GEORGEWEINSTEIN M, 1993, DEV BIOL, V156, P209, DOI 10.1006/dbio.1993.1071; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HIERCK BP, 1993, CELL ADHES COMMUN, V1, P1; HIRANO S, 1991, DEVELOPMENT, V113, P1007; HOGERVORST F, 1993, J CELL BIOL, V121, P179, DOI 10.1083/jcb.121.1.179; HOGERVORST F, 1991, EUR J BIOCHEM, V199, P425, DOI 10.1111/j.1432-1033.1991.tb16140.x; HOGERVORST F, 1993, J BIOL CHEM, V268, P18427; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; KRAMER RH, 1989, J BIOL CHEM, V264, P15642; KRAMER RH, 1993, MOL CELLULAR ASPECTS, P239; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LANGUINO LR, 1992, J BIOL CHEM, V267, P7116; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; MANITIAS T, 1989, MOL CLONING LABORATO; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RAMOS DM, 1991, INVAS METAST, V11, P125; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TAMURA RN, 1991, P NATL ACAD SCI USA, V88, P10183, DOI 10.1073/pnas.88.22.10183; TSUJI T, 1990, J BIOL CHEM, V265, P7016; TSUJI T, 1991, J BIOCHEM-TOKYO, V109, P659, DOI 10.1093/oxfordjournals.jbchem.a123436; VANKUPPEVELT THMSM, 1989, P NATL ACAD SCI USA, V86, P5415; VONDERMARK H, 1991, J BIOL CHEM, V266, P23593; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651	61	133	136	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26773	26783						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253814				2022-12-25	WOS:A1993MK42500111
J	HENRIKSSON, M; BAKARDJIEV, A; KLEIN, G; LUSCHER, B				HENRIKSSON, M; BAKARDJIEV, A; KLEIN, G; LUSCHER, B			PHOSPHORYLATION SITES MAPPING IN THE N-TERMINAL DOMAIN OF C-MYC MODULATE ITS TRANSFORMING POTENTIAL	ONCOGENE			English	Article							CASEIN KINASE-II; GLYCOGEN-SYNTHASE KINASE-3; HIERARCHICAL PROTEIN-PHOSPHORYLATION; NUCLEOTIDE-SEQUENCE ANALYSIS; MYELOCYTOMATOSIS VIRUS MC29; E-MU-MYC; V-MYC; TRANSGENIC MICE; CELL-LINES; NEOPLASTIC TRANSFORMATION	The nuclear proto-oncoprotein c-Myc is involved in the regulation of cell growth and differentiation. c-Myc is phosphorylated at multiple sites in vivo, two of which we have identified near the amino terminus. In chicken Thr-61/Ser-65 are phosphorylated, as are the comparable positions, Thr-58/Ser-62 in human c-Myc. These residues are located within a domain that is implicated in transactivation and is important for the transforming potential of the protein. Furthermore, these phosphorylation sites or nearby amino acids are frequently mutated in v-myc and in several c-myc genes from Burkitt's lymphoma cells. In vitro these two phosphorylation sites can be modified by glycogen synthase kinase 3 and mitogen activated protein kinase. To address their biological importance we mutated these amino terminal phosphorylation sites separately and together. Stably transfected Rat1A cells expressing the mutated proteins have an increased growth potential in soft agar Compared to wt-c-myc transfectants. These altered transformation characteristics indicate that Myc function may be negatively regulated by the amino terminal phosphorylation.	HANNOVER MED SCH, INST MOLEC BIOL, D-30623 HANNOVER, GERMANY; KAROLINSKA INST, DEPT TUMOR BIOL, S-10401 STOCKHOLM, SWEDEN	Hannover Medical School; Karolinska Institutet			Henriksson, Marie Arsenian/F-5010-2015; Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67; ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BIEGALKE BJ, 1987, J VIROL, V61, P2138, DOI 10.1128/JVI.61.7.2138-2142.1987; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DENT P, 1989, FEBS LETT, V248, P67, DOI 10.1016/0014-5793(89)80433-8; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; FIRZLAFF J M, 1989, New Biologist, V1, P44; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; FRYKBERG L, 1987, ONCOGENE, V1, P415; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HAYASHI K, 1987, NUCLEIC ACIDS RES, V15, P6419, DOI 10.1093/nar/15.16.6419; HAYFLICK J, 1985, P NATL ACAD SCI USA, V82, P2718, DOI 10.1073/pnas.82.9.2718; HEANEY ML, 1986, J VIROL, V60, P167, DOI 10.1128/JVI.60.1.167-176.1986; HIHARA H, 1974, NATL I ANIM HEALTH Q, V14, P163; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lenoir GM, 1987, ADV VIRAL ONCOL, V7, P173; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; OVERELL RW, 1989, ONCOGENE, V4, P1425; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SAKSELA K, 1992, ONCOGENE, V7, P347; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SETH A, 1991, J BIOL CHEM, V266, P23521; SETH A, 1992, J BIOL CHEM, V267, P24796; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; STREET AJ, 1990, CURR TOP MICROBIOL, V166, P251; SYMONDS G, 1989, ONCOGENE, V4, P285; VANBENEDEN RJ, 1986, P NATL ACAD SCI USA, V83, P3698; VENNSTROM B, 1982, J VIROL, V42, P773, DOI 10.1128/JVI.42.3.773-779.1982; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WALKER CW, 1992, ONCOGENE, V7, P2007; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P3642, DOI 10.1073/pnas.80.12.3642; WESTAWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P843, DOI 10.1073/pnas.81.3.843; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3	74	161	162	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3199	3209						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247524				2022-12-25	WOS:A1993MG78200002
J	BERGELSON, S; PINKUS, R; DANIEL, V				BERGELSON, S; PINKUS, R; DANIEL, V			INDUCTION OF AP-1 (FOS/JUN) BY CHEMICAL-AGENTS MEDIATES ACTIVATION OF GLUTATHIONE-S-TRANSFERASE AND QUINONE REDUCTASE GENE-EXPRESSION	ONCOGENE			English	Article							YA-SUBUNIT GENE; ELECTROPHILE-RESPONSIVE ELEMENT; INDUCIBLE EXPRESSION; REGULATORY ELEMENTS; C-JUN; PROTO-ONCOGENE; PROTEINS; STRESS; CELLS; FOS	A regulatory element, EpRE, was found to be responsible for the induction of mouse glutathione S-transferase (GST) Ya gene expression by a variety of chemical agents such as planar aromatic hydrocarbons, diphenols, phorbol ester, phenobarbital and electrophilic compounds. The EpRE is composed of two adjacent AP-1-like binding sites and was recently found to be activated by Fos/Jun heterodimeric complex (AP-1). In this report we show that regulatory elements ARE, previously demonstrated to mediate the chemical induction of rat GST Ya and quinone reductase genes, have a similar structure with EpRE and are activated by Fos/Jun complex. The activation of GST Ya and quinone reductase genes by a variety of chemical inducers is found to be associated with an increase in AP-1 binding activity. We present evidence that chemical agents induce expression of c-fos and c-jun proto-oncogenes and an enhanced synthesis of protein components of AP-1 complex. We suggest that the increased synthesis of AP-1 complex followed by an AP-l-mediated transcriptional activation of GST Ya and quinone reductase genes may provide a molecular mechanism for the induction of these drug-metabolizing enzymes by chemical agents.	WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794; DANIEL V, 1989, DNA-J MOLEC CELL BIO, V8, P399, DOI 10.1089/dna.1.1989.8.399; DANIEL V, 1993, STRUCTURE FUNCTION G, P129; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; KIM YJ, 1983, J CELL BIOL, V96, P393, DOI 10.1083/jcb.96.2.393; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LI GC, 1983, J CELL PHYSIOL, V115, P116, DOI 10.1002/jcp.1041150203; LI Y, 1992, J BIOL CHEM, V267, P15097; MACKENZIE PI, 1990, J BIOL CHEM, V265, P11328; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; PINKUS R, 1993, BIOCHEM J, V290, P637, DOI 10.1042/bj2900637; PROCHASKA HJ, 1988, CANCER RES, V48, P4776; PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHELTON KR, 1986, J BIOL CHEM, V261, P1935; Talalay P, 1987, CANCER BIOL THERAPEU, P187	29	99	99	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					565	571						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290267				2022-12-25	WOS:A1994MW24800024
J	BOBE, R; BREDOUX, R; WUYTACK, F; QUARCK, R; KOVACS, T; PAPP, B; CORVAZIER, E; MAGNIER, C; ENOUF, J				BOBE, R; BREDOUX, R; WUYTACK, F; QUARCK, R; KOVACS, T; PAPP, B; CORVAZIER, E; MAGNIER, C; ENOUF, J			THE RAT PLATELET 97-KDA CA2+ATPASE ISOFORM IS THE SARCOENDOPLASMIC RETICULUM CA2+ATPASE-3 PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELL; MESSENGER-RNA; CALCIUM PUMPS; SARCOPLASMIC-RETICULUM; MEMBRANE-VESICLES; INTRACELLULAR MEMBRANES; CA-2+-ATPASE GENE; CA2+ PUMP; EXPRESSION; DISTINCT	We recently showed that human and rat platelets express two types of SERCAs (Sarco Endoplasmic Reticulum Ca2+ ATPases): a 100-kDa SERCA2b isoform and a 97-kDa SERCA isoform. Here, we explored the possibility that the rat 97-kDa isoform is identical to the SERCA3 protein. For this purpose, we first attempted to detect SERCA3 mRNA in rat platelet total RNA by reverse transcription-polymerase chain reaction using SERCA3-specific primers, and demonstrated the presence of this mRNA species by sequencing the amplification product. We then searched for a relationship between the expression of the SERCA3 mRNA and of the 97-kDa protein using either rat aortic smooth muscle cells, previously found not to express the 97-kDa SERCA isoform (negative model), or platelets of spontaneously hypertensive rats (SHR), which overexpress this isoform (overexpression model) but express the 100-kDa SERCA2b isoform normally. No expression of SERCA3 mRNA was detectable by analysis of smooth muscle cell RNA, but comparison by reverse transcription-polymerase chain reaction of the SERCA2b and SERCA3 mRNAs from the platelets of normotensive (Wistar-Kyoto, WKY) rats and SHR clearly demonstrated a 238 +/- 43% increase in the expression of the SERCA3 mRNA in SHR platelets only. Last, by comparative Western blotting of WKY rat and SHR platelet membranes using a recently developed polyclonal anti-SERCA3 antibody, we established that the 97-kDa SERCA and the SERCA3 protein are identical, as immunostaining of the 97-kDa protein revealed a 230 +/- 25% increase in the expression of this protein in SHR versus WKY rat platelets. It is concluded that the 97-kDa platelet SERCA isoform, which is up-regulated in SHR, is the SERCA3 protein. As far as we know, this constitutes the first demonstration of the actual presence of this Ca2+ ATPase isoform in normal cells, in addition to the artificial transfection systems.	CATHOLIC UNIV LEUVEN, FYSIOL LAB, B-3000 LOUVAIN, BELGIUM; NATL INST HAEMATOL & BLOOD TRANSFUS, H-1113 BUDAPEST, HUNGARY	KU Leuven	BOBE, R (corresponding author), HOP LARBOISIERE, INSERM, U348, F-75010 PARIS, FRANCE.		Kovács, Tünde/O-6020-2017; BOBE, Regis/F-4951-2016; Quarck, Rozenn/J-8067-2018	Kovács, Tünde/0000-0003-1064-2616; BOBE, Regis/0000-0002-8225-9117; Quarck, Rozenn/0000-0002-8293-6261; Papp, Bela/0000-0002-5025-3087				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURK SE, 1989, J BIOL CHEM, V264, P18561; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEAN WL, 1989, CELL CALCIUM, V10, P289, DOI 10.1016/0143-4160(89)90055-9; DEAN WL, 1982, J BIOL CHEM, V257, P4390; DEMETZ M, 1984, BIOCHIM BIOPHYS ACTA, V770, P159; DESMEDT H, 1991, J BIOL CHEM, V266, P7092; DJAFFAR I, 1991, THROMB RES, V62, P127, DOI 10.1016/0049-3848(91)90187-2; ENOUF J, 1988, J BIOL CHEM, V263, P13922; ENOUF J, 1992, BIOCHEM J, V286, P135, DOI 10.1042/bj2860135; ENOUF J, 1987, J BIOL CHEM, V262, P9293; ENYEDI A, 1986, J BIOL CHEM, V261, P9558; FISCHER TH, 1985, J BIOL CHEM, V260, P8996; FISCHER TH, 1987, BIOCHEMISTRY-US, V26, P8024, DOI 10.1021/bi00398a070; HACK N, 1986, BIOCHEM J, V233, P661, DOI 10.1042/bj2330661; JAVORS MA, 1982, BIOCHIM BIOPHYS ACTA, V691, P220, DOI 10.1016/0005-2736(82)90410-2; KASERGLANZMANN R, 1977, BIOCHIM BIOPHYS ACTA, V466, P429, DOI 10.1016/0005-2736(77)90336-4; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPEUCH CJ, 1983, BIOCHIM BIOPHYS ACTA, V731, P456, DOI 10.1016/0005-2736(83)90041-X; LYTTON J, 1992, J BIOL CHEM, V267, P14483; MAGNIER C, 1992, J BIOL CHEM, V267, P15808; MARUYAMA K, 1989, CELL MOTIL CYTOSKEL, V14, P26, DOI 10.1002/cm.970140107; MENASHI S, 1984, BIOCHEM J, V222, P413, DOI 10.1042/bj2220413; NAGAI R, 1989, P NATL ACAD SCI USA, V86, P2966, DOI 10.1073/pnas.86.8.2966; NEWMAN PJ, 1988, J CLIN INVEST, V82, P739, DOI 10.1172/JCI113656; PAPP B, 1992, BIOCHEM J, V288, P297, DOI 10.1042/bj2880297; PAPP B, 1993, BIOCHEM J, V295, P685, DOI 10.1042/bj2950685; PAPP B, 1991, J BIOL CHEM, V266, P14593; ROBBLEE LS, 1973, J GEN PHYSIOL, V61, P462, DOI 10.1085/jgp.61.4.462; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; ROTH GJ, 1989, BIOCHEM BIOPH RES CO, V160, P705, DOI 10.1016/0006-291X(89)92490-X; SARKADI B, 1988, BIOCHIM BIOPHYS ACTA, V939, P40, DOI 10.1016/0005-2736(88)90044-2; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WICKI AN, 1989, THROMB HAEMOSTASIS, V61, P448; WUYTACK F, 1994, J BIOL CHEM, V269, P1410; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670	38	106	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1417	1424						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288609				2022-12-25	WOS:A1994MR22000100
J	CALKIN, PA; BARNES, EM				CALKIN, PA; BARNES, EM			GAMMA-AMINOBUTYRIC ACID-A [GABA(A)] AGONISTS DOWN-REGULATE GABA(A) BENZODIAZEPINE RECEPTOR POLYPEPTIDES FROM THE SURFACE OF CHICK CORTICAL-NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBRAL NEURONS; COMPLEX; ACTIVATION; SUBUNITS; PROTEINS; EXPOSURE; CURRENTS; CELLS	The impermeant SH-cleavable reagent, I-125-labeled 3,3'-dithiopropionyl 1-sulfosuccinimidyl 1'-glycyltyrosine (DPSgt) and specific immunoprecipitation were used to quantitate gamma-aminobutyric acid-A (GABA(A)) receptor polypeptides with domains exposed on the surface of chick cortical neurons. The I-125 label incorporated into 50- and 53-kDa receptor subunits was completely removed by washing the cells with glutathione (GSH) buffer. A single dose of 100 muM GABA or GABA agonist was added to the neurons, and after 5 days in culture the cells were washed and labeled with I-125-DPSgt. This treatment with GABA or isoguvacine reduced the level of the receptor I-125-labeled subunits by 50-60%, while the reduction by 4,5,6,7-tetrahydroisoazolo[5,4-c]pyridin-3-ol was less than 17%. The subunit down-regulation by agonist was prevented by the GABA(A) antagonist 3alpha-hydroxy-16-imino-5beta-17-aza-androstan-11-one (R5135). Direct iodination of membranes isolated from treated cells revealed a similar loss of subunits, indicating that the down-regulated polypeptides are not retained intracellularly. Furthermore, the level of intracellular [H-3]flunitrazepam binding (per mg of protein) did not change significantly during chronic GABA treatment, while the fraction of intracellular binding rose from 7% to 15% of the total, owing to a decline in surface binding. The fate of the surface subunits during acute agonist exposure was examined by labeling intact neurons with I-125-DPSgt at 0-degrees-C, incubating with GABA for 2-4 h at 37-degrees-C and then washing with GSH buffer. Of the 50-53-kDa receptor peptides originally on the surface, 16 +/- 2% became protected from GSH during the 2-h GABA treatment. This sequestration was not found in cells incubated without GABA, with GABA + R5135, or with GABA at 0-degrees-C. A consistently lower level of sequestered subunits was recovered after a 4- versus 2-h GABA treatment at 37-degrees-C, suggesting polypeptide degradation. Overall, the results indicate that GABA(A) receptor sequestration and subsequent degradation play an important role in agonist-dependent down-regulation.	BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA	Baylor College of Medicine					NIDDK NIH HHS [DK17436] Funding Source: Medline; NIMH NIH HHS [MH47715] Funding Source: Medline; NINDS NIH HHS [NS11535] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017436] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH047715] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS011535, P50NS011535] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BORDEN LA, 1988, MOL PHARMACOL, V34, P354; BORDEN LA, 1984, SCIENCE, V226, P857, DOI 10.1126/science.6093257; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; BUREAU M, 1990, MOL PHARMACOL, V37, P497; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; CALKIN PA, 1992, T AM SOC NEUROCHEM, V23, P228; DELOREY TM, 1992, J BIOL CHEM, V267, P16747; FIRESTONE GL, 1990, METHOD ENZYMOL, V182, P688; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HABLITZ JJ, 1989, BRAIN RES, V501, P332, DOI 10.1016/0006-8993(89)90650-1; HEBEBRAND J, 1987, J NEUROCHEM, V48, P1103, DOI 10.1111/j.1471-4159.1987.tb05633.x; KANG I, 1991, BRIT J PHARMACOL, V103, P1285, DOI 10.1111/j.1476-5381.1991.tb09781.x; MALOTEAUX JM, 1987, EUR J PHARMACOL, V144, P173, DOI 10.1016/0014-2999(87)90517-6; MCCONAHEY P, 1980, IMMUNOCHEMICAL TEC A, V70, P210; MEHTA AK, 1992, MOL BRAIN RES, V16, P29, DOI 10.1016/0169-328X(92)90190-M; MISTRY DK, 1990, PFLUG ARCH EUR J PHY, V416, P454, DOI 10.1007/BF00370754; MONTPIED P, 1991, J BIOL CHEM, V266, P6011; NUMANN RE, 1984, NEUROSCI LETT, V47, P289, DOI 10.1016/0304-3940(84)90528-7; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; ROCA DJ, 1990, MOL PHARMACOL, V37, P37; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SIGEL E, 1983, J BIOL CHEM, V258, P6965; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TEHRANI MHJ, 1986, DEV BRAIN RES, V25, P91; TEHRANI MHJ, 1988, NEUROSCI LETT, V87, P288, DOI 10.1016/0304-3940(88)90463-6; TEHRANI MHJ, 1993, J NEUROCHEM, V60, P1755; TEHRANI MHJ, 1991, J NEUROCHEM, V57, P1307, DOI 10.1111/j.1471-4159.1991.tb08295.x; THAMPY KG, 1983, DEV BRAIN RES, V8, P101, DOI 10.1016/0165-3806(83)90161-X; TIMMONS TM, 1990, METHOD ENZYMOL, V182, P679; VITORICA J, 1988, J NEUROSCI, V8, P615; WEISS DS, 1988, J NEUROPHYSIOL, V59, P495, DOI 10.1152/jn.1988.59.2.495; WEISS DS, 1988, J NEUROPHYSIOL, V59, P514, DOI 10.1152/jn.1988.59.2.514; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	33	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1548	1553						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288621				2022-12-25	WOS:A1994MR22000117
J	DAILEY, TA; MEISSNER, P; DAILEY, HA				DAILEY, TA; MEISSNER, P; DAILEY, HA			EXPRESSION OF A CLONED PROTOPORPHYRINOGEN OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DIPHENYL ETHER HERBICIDES; PURIFICATION; OXIDATION; STEP; HEME; CHLOROPHYLL; ORGANELLES	The previously cloned hem Y gene of Bacillus subtilis (Hansson, M., and Hederstedt, L. (1992) J. Bacteriol. 174, 8081-8093) has been expressed in Escherichia coli. The expressed protein has been shown to be the penultimate enzyme of the heme biosynthetic pathway, protoporphyrinogen oxidase (EC 1.3.3.4) and, thus, the gene designation should be hem G. This represents the first report of the expression of a cloned protoporphyrinogen oxidase from any source. The enzyme is present in the soluble cytoplasmic fraction and is, thus, unlike all previously reported eukaryotic or prokaryotic protoporphyrinogen oxidases, which are membrane-bound. It utilizes molecular oxygen as a terminal electron acceptor, and protoporphyrinogen IX, mesoporphyrinogen IX, and coproporphyrinogen III serve as substrates. The diphenyl ether herbicide acifluorfen, which is a strong inhibitor of the eukaryotic enzyme, is only weakly inhibitory. The enzyme has a predicted molecular weight of 51,200, which corresponds well with molecular weight determination via high performance liquid chromatography and SDS-polyacrylamide gel electrophoresis. In addition the enzyme contains a putative dinucleotide binding region at the amino terminus, which is consistent with the previously demonstrated presence of a flavin moiety in the characterized mammalian enzymes.	UNIV GEORGIA,DEPT MICROBIOL,ATHENS,GA 30602; UNIV GEORGIA,CTR METALLOENZYME STUDIES,ATHENS,GA 30602; UNIV CAPE TOWN,SCH MED,CTR LIVER RES,DEPT MED,CAPE TOWN 7925,SOUTH AFRICA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University of Cape Town					NIDDK NIH HHS [DK 35898, DK 32303, R56 DK032303] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032303, R01DK035898] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhtar M., 1991, BIOSYNTHESIS TETRAPY, P67; BRENNER DA, 1980, CLIN CHIM ACTA, V100, P259, DOI 10.1016/0009-8981(80)90275-2; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; DAILEY HA, 1987, BIOCHEMISTRY-US, V26, P2697, DOI 10.1021/bi00384a007; FERREIRA GC, 1988, BIOCHEM J, V250, P597, DOI 10.1042/bj2500597; HANSSON M, 1992, J BACTERIOL, V174, P8081, DOI 10.1128/JB.174.24.8081-8093.1992; JACOBS JM, 1987, BIOCHEM J, V244, P219, DOI 10.1042/bj2440219; JACOBS JM, 1992, J BIOCHEM TOXICOL, V7, P87, DOI 10.1002/jbt.2570070206; JACOBS JM, 1984, ARCH BIOCHEM BIOPHYS, V229, P312, DOI 10.1016/0003-9861(84)90157-7; JACOBS NJ, 1981, ARCH BIOCHEM BIOPHYS, V211, P305, DOI 10.1016/0003-9861(81)90458-6; KLEMM DJ, 1987, J BACTERIOL, V169, P5209, DOI 10.1128/jb.169.11.5209-5215.1987; Labbe-Bois R, 1990, BIOSYNTHESIS HEME CH, P235; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATRINGE M, 1989, BIOCHEM J, V260, P231, DOI 10.1042/bj2600231; PROULX KL, 1992, PROTEIN SCI, V1, P801, DOI 10.1002/pro.5560010612; SIEPKER LJ, 1987, BIOCHIM BIOPHYS ACTA, V913, P349, DOI 10.1016/0167-4838(87)90146-4; TABOR S, 1991, CURRENT PROTOCOLS MO; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5; WILSON K, 1990, CURRENT PROTOCOLS MO	19	73	92	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					813	815						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288631				2022-12-25	WOS:A1994MR22000008
J	BACIU, PC; ACASTER, C; GOETINCK, PF				BACIU, PC; ACASTER, C; GOETINCK, PF			MOLECULAR-CLONING AND GENOMIC ORGANIZATION OF CHICKEN SYNDECAN-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; HUMAN-LUNG FIBROBLASTS; ROUS-SARCOMA VIRUS; CELL-SURFACE; MEMBRANE PROTEOGLYCAN; CORE PROTEIN; SEQUENCE-ANALYSIS; GROWTH-FACTOR; RECEPTOR; INTEGRIN	We have cloned and determined the genomic organization of the core protein of the chicken transmembrane proteoglycan, syndecan-4. Identification of the initial cDNA was accomplished using polyclonal antibodies directed against the cytoplasmic domain of murine syndecan-1 core protein. The cDNA for chicken syndecan-4 encodes a putative core protein of 197 amino acids which consists of a 19-amino acid signal peptide, a 125-amino acid ectodomain, a 25-amino acid transmembrane domain, and a 28-amino acid cytoplasmic domain. The predicted molecular mass of the mature core protein is 19,639 daltons. The ectodomain of chicken syndecan-4 core protein contains three potential sites for glycosaminoglycan attachment, two sites for N-glycosylation, and lacks a dibasic protease cleavage site proximal to the membrane-spanning region found in other syndecan family members. Comparison of the complete amino acid sequence with human syndecan-4 (amphlican (David, G., van der Schueren, B., Marynen, P., Cassiman, J. J., and van den Berghe, H. (1992) J. Cell Biol. 118, 961-969)) and rat syndecan-4 (ryudocan (Kojima, T., Shworak, N. W., and Rosenberg, R. D. (1992) J. Biol. Chem. 267, 4870-4877)) indicates an overall identity of 58 and 56%, respectively, with a 91 and 92% identity in the highly conserved transmembrane and cytoplasmic domains. The core protein of chicken syndecan-4 synthesized by chicken cells is modified with heparan sulfate side chains yielding a proteoglycan with a molecular mass of >200 kDa in LMH cells (immortalized male leghorn LM strain hepatocytes) and primary skin fibroblasts. Syndecan-4 isolated from chondrocyte cultures runs as a diffuse band between 100 and 200 kDa. Northern analysis of chicken syndecan-4 indicates three messages with distinct sizes of 0.9, 1.3, and 2.9 kb and a wide mRNA tissue distribution. The chicken syndecan-4 gene is divided into 5 exons encoding distinct regions which contain the signal peptide, the glycosaminoglycan attachment sites, a small spacer of unknown function, the glycosylation sites and the transmembrane and cytoplasmic domains.	HARVARD UNIV, MASSACHUSETTS GEN HOSP,SCH MED, CUTANEOUS BIOL RES CTR,MAH E BLDG 149, 13TH ST, BOSTON, MA 02129 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital					NCI NIH HHS [T32 CA 09579] Funding Source: Medline; NICHD NIH HHS [HD 22050, HD 25938] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022050, P01HD025938] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009579] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BENOIT R, 1982, P NATL ACAD SCI-BIOL, V79, P917, DOI 10.1073/pnas.79.3.917; BERNFIELD M, 1990, PHILOS T R SOC B, V327, P171, DOI 10.1098/rstb.1990.0052; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BOURDON MA, 1986, J BIOL CHEM, V261, P2534; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; DESIMONE DW, 1988, J BIOL CHEM, V263, P5333; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOEGE K, 1987, J BIOL CHEM, V262, P17757; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; GOETINCK PF, 1991, CURR TOP DEV BIOL, V25, P111; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; HINKES M T, 1991, Journal of Cell Biology, V115, p125A; HUBER S, 1988, J BIOL CHEM, V263, P752; KAWAGUCHI T, 1987, CANCER RES, V47, P4460; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KJELLEN L, 1981, P NATL ACAD SCI-BIOL, V78, P5371, DOI 10.1073/pnas.78.9.5371; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KOKENYESI R, 1992, MOL BIOL CELL, V3, pA64; KOZAK M, 1982, J MOL BIOL, V156, P807, DOI 10.1016/0022-2836(82)90143-7; KUGELMAN LC, 1992, J INVEST DERMATOL, V99, P381, DOI 10.1111/1523-1747.ep12616092; MALI M, 1990, J BIOL CHEM, V265, P6884; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; PACIFICI M, 1977, CELL, V11, P891, DOI 10.1016/0092-8674(77)90300-2; PIERCE A, 1992, J BIOL CHEM, V267, P3894; RAUCH U, 1992, J BIOL CHEM, V267, P19536; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SELDIN DC, 1985, J BIOL CHEM, V260, P1131; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TAPLEY P, 1989, ONCOGENE, V4, P325; TOMINAGA S, 1988, FEBS LETT, V238, P315, DOI 10.1016/0014-5793(88)80503-9; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WARREN W, 1991, BIOTECHNIQUES, V10, P216; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	45	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					696	703						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276871				2022-12-25	WOS:A1994MR21900109
J	SANTRA, M; DANIELSON, KG; IOZZO, RV				SANTRA, M; DANIELSON, KG; IOZZO, RV			STRUCTURAL AND FUNCTIONAL-CHARACTERIZATION OF THE HUMAN DECORIN GENE PROMOTER - A HOMOPURINE-HOMOPYRIMIDINE S1 NUCLEASE-SENSITIVE REGION IS INVOLVED IN TRANSCRIPTIONAL CONTROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; DERMATAN SULFATE PROTEOGLYCAN; MESSENGER-RNA LEVELS; HUMAN-COLON-CARCINOMA; KI-RAS PROMOTER; EXTRACELLULAR-MATRIX; NEOPLASTIC MODULATION; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; BINDING PROTEINS	Decorin is a leucine-rich, chondroitin/dermatan sulfate proteoglycan which binds collagen and growth factors. We have recently completed the genomic organization of human decorin and discovered two alternatively spliced leader exons, designated exon Ia and Ib, in the 5'-untranslated region. Initial analysis of the sequences upstream to these two exons showed that promoter Ia contained only two GC boxes while promoter Ib contained a CAAT and two TATA boxes in close proximity to the transcription start site. To determine if these 5'-flanking sequences exhibited promoter activity, chimeric chloramphenicol acetyltransferase expression plasmids containing the promoter region of either exon Ia or Ib were transfected into HeLa and MG-63 osteosarcoma cells. The results showed that only the region flanking exon Ib was functional. In vitro transcription assay generated two transcripts of 92 and 82 base pairs (bp) indicating that both TATA boxes could be used. Using stepwise 5' deletion analysis we found that the minimum promoter region at -140 bp from the transcription start site, which contained only the CAAT and the two TATA boxes, exhibited strong promoter activity. When a larger construct containing an additional 800 bp of upstream region was tested, a significant increase in transcriptional activity was observed. Interestingly, this promoter region contained several putative binding sites for ubiquitous factors (AP1, AP5, and NF-kappaB) and for transforming growth factor-beta and a 150-bp homopurine/homopyrimidine element with several mirror repeats. When contained in a supercoiled plasmid, this sequence exhibited sensitivity to endonuclease S1, an enzyme that preferentially digests single-stranded DNA. Precise S1 mapping, obtained by direct sequencing of nine distinct Sl-generated clones, revealed that in all cases the borders of the sensitive sequence resided within the pur/pyr segment. We propose that this region of the promoter could adopt an intramolecular hairpin triplex structure in vivo and may play a role in the chromatin organization at the decorin gene locus. In addition, this region was able to up-regulate a minimal heterologous promoter in transient transfection assays. The results show that the structure of the decorin gene promoter is different from that of any other proteoglycan promoter characterized so far and indicate that the pur/pyr segment plays a role in the regulation of gene transcription.	THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, RM 249, JEFFERSON ALUMNI HALL, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, PHILADELPHIA, PA 19107 USA	Jefferson University; Jefferson University			Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [CA-47282, CA-39481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047282, R01CA039481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMSON SR, 1992, BIOCHIM BIOPHYS ACTA, V1132, P225, DOI 10.1016/0167-4781(92)90019-V; ADANY R, 1991, BIOCHEM J, V276, P301, DOI 10.1042/bj2760301; ADANY R, 1990, J BIOL CHEM, V265, P11389; BALVAY L, 1993, BIOESSAYS, V15, P165, DOI 10.1002/bies.950150304; BASSOLS A, 1988, J BIOL CHEM, V263, P3039; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BEHREND EI, 1993, J BIOL CHEM, V268, P11172; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BIGGIN MD, 1989, TRENDS GENET, V5, P377, DOI 10.1016/0168-9525(89)90173-X; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BREUER B, 1990, BIOCHEM J, V269, P551, DOI 10.1042/bj2690551; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN IR, 1993, IN PRESS P NATL ACAD; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DODGE GR, 1991, GENOMICS, V10, P673, DOI 10.1016/0888-7543(91)90451-J; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FINER MH, 1987, J BIOL CHEM, V262, P13323; FISHER LW, 1991, J BIOL CHEM, V266, P14371; FISHER LW, 1993, DERMATAN SULPHATE PR, P103; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEINO J, 1988, BIOCHEM J, V252, P309, DOI 10.1042/bj2520309; HINKES MT, 1993, J BIOL CHEM, V268, P11440; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; IBARAKI K, 1993, GENE, V130, P225, DOI 10.1016/0378-1119(93)90423-Z; IOZZO R V, 1982, Journal of Biological Chemistry, V257, P11135; IOZZO RV, 1993, EXPERIENTIA, V49, P447, DOI 10.1007/BF01923588; IOZZO RV, 1985, J BIOL CHEM, V260, P7464; IOZZO RV, 1989, J CELL BIOCHEM, V39, P355, DOI 10.1002/jcb.240390403; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; KAHARI VM, 1991, J BIOL CHEM, V266, P10608; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOLLER E, 1991, NUCLEIC ACIDS RES, V19, P485, DOI 10.1093/nar/19.3.485; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LI W, 1992, ARCH BIOCHEM BIOPHYS, V296, P190, DOI 10.1016/0003-9861(92)90562-B; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MCKEON C, 1984, J BIOL CHEM, V259, P6636; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NICODEMUS CF, 1990, J BIOL CHEM, V265, P5889; PESTOV DG, 1991, NUCLEIC ACIDS RES, V19, P6527, DOI 10.1093/nar/19.23.6527; ROMARIS M, 1991, BIOCHIM BIOPHYS ACTA, V1093, P229, DOI 10.1016/0167-4889(91)90127-J; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SACCOMANNO CF, 1992, BIOTECHNIQUES, V13, P846; Sambrook J, 1989, MOL CLONING LABORATO; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; VETTER U, 1993, GENOMICS, V15, P161, DOI 10.1006/geno.1993.1023; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VONIOZZO R, 1982, LAB INVEST, V47, P124; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YARON I, 1987, ARTHRITIS RHEUM, V30, P424, DOI 10.1002/art.1780300410; YOUNG MF, 1992, INT CONGR SER, V1002, P243; YOUNG MF, 1989, J BIOL CHEM, V264, P450	63	82	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					579	587						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276854				2022-12-25	WOS:A1994MR21900092
J	WEINANDER, R; ANDERSON, C; MORGENSTERN, R				WEINANDER, R; ANDERSON, C; MORGENSTERN, R			IDENTIFICATION OF N-ACETYLCYSTEINE AS A NEW SUBSTRATE FOR RAT-LIVER MICROSOMAL GLUTATHIONE TRANSFERASE - A STUDY OF THIOL LIGANDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-TRANSFERASES; ACTIVATION; SERIES; PURIFICATION; INHIBITORS; MECHANISM; RESIDUES; ANALOGS; SITE	N-Acetyl-L-cysteine serves as an efficient substrate for the rat liver microsomal glutathione transferase with 1-chloro-2,4-dinitrobenzene as second substrate (8.8 +/-0.37 mumol/min mg). The activity is actually higher than that obtained with glutathione (2-4 mumol/min mg). In examining the activity of liver subcellular fractions, no activity with N-acetyl-L-Cys could be detected in dialyzed or N-ethylmaleimide-treated (in order to remove endogenous glutathione) cytosol. The activity in rat liver microsomes was 0.11 +/- 0.007 mumol/min mg, which is accounted for by the content of microsomal glutathione transferase. Thus, N-acetyl-L-Cys can be used as a specific substrate for determining the conjugating activity of microsomal glutathione transferase. N-Acetyl-L-Cys was also shown to function as a substrate for the enzyme when other second substrates than 1-chloro-2,4-dinitrobenzene (with varying electrophilicity) are used. The pH dependence of microsomal glutathione transferase was studied. The k(cat)/K(m(1-chloro-2,4-dinitrobenzene)) was dependent on pH with an apparent pK(a) of 6, greater-than-or-equal-to 9, and greater-than-or-equal-to 8 with saturating glutathione, gamma-L-Glu-L-Cys, and N-acetyl-L-cysteine, respectively. Apparently the enzyme has the ability to lower the pK(a) of glutathione by 3 orders of magnitude. The k(cat)/K(m(thiol) did not vary appreciably with pH (except for N-acetyl-L-cysteine), indicating that no rate-determining deprotonation occurs on the enzyme itself between pH 5.5 and 9. The abilities of histidine-, lysine-, and arginine-selective reagents to inactivate the enzyme when N-acetyl-L-cysteine and gamma-L-Glu-L-Cys were used as substrates were investigated. The activity toward N-acetyl-L-cysteine was decreased considerably less after treatment with the arginine-selective reagent phenylglyoxal, as compared to the activity toward GSH andy-L-Glu-L-Cys. This indicates that an arginine makes contact with the gamma-L-Glu residue in GSH. With the other reagent/substrate combinations tested the enzyme was inactivated almost completely. The ability of microsomal glutathione transferase to stabilize the Meisenheimer complex formation between 1,3,5-trinitrobenzene and various glutathione analogues, including non-substrate thiols, has been examined. It is shown that, in general, substrates exhibited higher formation constants (approaching 50 mM-1) than non-substrates (4.5 +/- 1.7 mM-1, n = 7), whereas simpler thiols did not yield enzyme-bound complexes. The fact that the enzyme can stabilize Meisenheimer complexes from non-substrate thiol analogues of glutathione offers new possibilities for examining the substrate interactions of glutathione transferases.	UNIV STOCKHOLM,DEPT BIOCHEM,WALLENBERG LAB,BIOCHEM TOXICOL UNIT,S-10691 STOCKHOLM,SWEDEN	Stockholm University	WEINANDER, R (corresponding author), KAROLINSKA INST,INST ENVIRONM MED,DIV TOXICOL,BOX 210,S-17177 STOCKHOLM,SWEDEN.		Morgenstern, Ralf/GZH-0158-2022					ADANG AEP, 1988, BIOCHEM J, V255, P715; ADANG AEP, 1990, BIOCHEM J, V269, P47, DOI 10.1042/bj2690047; ANDERSSON C, 1990, BIOCHEM J, V272, P479, DOI 10.1042/bj2720479; ANDERSSON C, 1991, J BIOL CHEM, V266, P2076; ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; BOYER TD, 1982, BIOCHEM J, V207, P57, DOI 10.1042/bj2070057; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; DEJONG JL, 1988, J BIOL CHEM, V263, P8430; ERNSTER L, 1962, J CELL BIOL, V15, P541, DOI 10.1083/jcb.15.3.541; GAN LH, 1977, AUST J CHEM, V30, P1475, DOI 10.1071/CH9771475; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P6252, DOI 10.1021/bi00441a017; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HARGUS SJ, 1991, BIOCHEMISTRY-US, V30, P717, DOI 10.1021/bi00217a020; HARRIS JM, 1991, BIOCHEM J, V278, P137, DOI 10.1042/bj2780137; JUNG G, 1972, EUR J BIOCHEM, V24, P438, DOI 10.1111/j.1432-1033.1972.tb19704.x; KEEN JH, 1976, J BIOL CHEM, V251, P6183; KOHN MC, 1979, COMPUT BIOMED RES, V12, P461, DOI 10.1016/0010-4809(79)90032-6; LIU SX, 1992, J BIOL CHEM, V267, P4296; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MORGENSTERN R, 1989, BIOCHEM J, V260, P577, DOI 10.1042/bj2600577; MORGENSTERN R, 1983, FEBS LETT, V160, P264, DOI 10.1016/0014-5793(83)80979-X; MORGENSTERN R, 1982, EUR J BIOCHEM, V128, P243; MORGENSTERN R, 1983, EUR J BIOCHEM, V134, P591, DOI 10.1111/j.1432-1033.1983.tb07607.x; MORGENSTERN R, 1988, J BIOL CHEM, V263, P6671; Morgenstern R, 1985, REV BIOCHEM TOXICOL, V7, P67; MORGENSTERN R, 1988, GLUTATHIONE CONJUGAT, P157; MOSIALOU E, 1989, ARCH BIOCHEM BIOPHYS, V275, P289, DOI 10.1016/0003-9861(89)90375-5; MOSIALOU E, 1990, CHEM-BIOL INTERACT, V74, P275, DOI 10.1016/0009-2797(90)90044-N; PERSHT A, 1985, ENZYME STRUCTURE MEC; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; STOLE E, 1991, J BIOL CHEM, V266, P17850	31	36	36	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					71	76						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276873				2022-12-25	WOS:A1994MR21900019
J	MERRILL, AH; VANECHTEN, G; WANG, E; SANDHOFF, K				MERRILL, AH; VANECHTEN, G; WANG, E; SANDHOFF, K			FUMONISIN-B(1) INHIBITS SPHINGOSINE (SPHINGANINE) N-ACYLTRANSFERASE AND DE-NOVO SPHINGOLIPID BIOSYNTHESIS IN CULTURED NEURONS IN-SITU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HAMSTER OVARY CELLS; PORCINE SUBMAXILLARY-GLANDS; GROWTH-FACTOR RECEPTOR; LONG-CHAIN BASES; FUSARIUM-MONILIFORME; SERINE PALMITOYLTRANSFERASE; RAT-LIVER; PHOSPHATIDATE PHOSPHOHYDROLASE; GLUCOSYLCERAMIDE SYNTHESIS	Fumonisins, mycotoxins produced by Fusarium moniliforme and a number of other fungi, cause neuronal degeneration, liver and renal toxicity, cancer, and other injury to animals. Recent work with rat hepatocytes (Wang, E., Norred, W. P., Bacon, C. W., Riley, R. T., and Merrill, A. H., Jr. (1991) J. Biol. Chem. 266, 14486-14490) found that fumonisins block sphingosine biosynthesis by inhibiting the conversion of sphinganine to dihydroceramides, which precedes introduction of the 4,5-trans-double bond of sphingosine. The current study utilized mouse cerebellar neurons in culture to evaluate how this affects the distribution of newly synthesized ceramides among different complex sphingolipids. Fumonisin B1 inhibited ceramide synthase in mouse brain microsomes with a competitive-like kinetic behavior with respect to both sphinganine and stearoyl-CoA. Fumonisin B1 inhibited sphingolipid biosynthesis in cultured cerebellar neurons in situ as reflected by accumulation of free sphinganine, a reduction in the mass of total sphingolipids, reductions in the incorporation of [C-14]serine into glucosylceramide, lactosylceramide, sphingomyelin, and gangliosides (G(M1), G(D3), G(D1a), G(D1b), G(T1b), and G(Q1b)), and inhibition of the incorporation of [C-14]galactose and [H-3]sphinganine into complex sphingolipids. Dose-response studies revealed that the labeling of sphingomyelin (IC50 of 0.7 muM) was more sensitive to inhibition by fumonisin B1 than was glycolipid formation (IC50 of approximately 7 muM) in these cells. A similar effect was seen when beta-fluoroalanine was added to inhibit the activity of serine palmitoyltransferase, the first enzyme of the pathway. The inhibition of complex sphingolipid synthesis was reversible, and nearly normal labeling profiles were obtained 48 h after removing the mycotoxin. These studies establish that fumonisin B1 inhibits de novo sphingolipid biosynthesis by neuronal cells and, moreover, that limiting ceramide synthesis differentially affects the formation of sphingomyelin versus glycosphingolipids.	UNIV BONN,INST ORGAN CHEM & BIOCHEM,W-5300 BONN 1,GERMANY	University of Bonn	MERRILL, AH (corresponding author), EMORY UNIV,SCH MED,DEPT BIOCHEM,4113 ROLLINS RES CTR,ATLANTA,GA 30322, USA.			Merrill, Alfred/0000-0002-6673-968X	NIGMS NIH HHS [GM33369] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033369] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEZUIDENHOUT SC, 1988, J CHEM SOC CHEM COMM, P743, DOI 10.1039/c39880000743; COSTE H, 1985, BIOCHIM BIOPHYS ACTA, V814, P1, DOI 10.1016/0005-2736(85)90412-2; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; FAUCHER M, 1988, J BIOL CHEM, V263, P5319; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; GELDERBLOM WCA, 1991, CARCINOGENESIS, V12, P1247, DOI 10.1093/carcin/12.7.1247; GELDERBLOM WCA, 1988, CARCINOGENESIS, V9, P1405, DOI 10.1093/carcin/9.8.1405; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; Harrison L R, 1990, J Vet Diagn Invest, V2, P217; HOEKSTRA D, 1992, BIOCHIM BIOPHYS ACTA, V1113, P277, DOI 10.1016/0304-4157(92)90002-R; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KALLEN KJ, 1993, BIOCHEM J, V289, P307, DOI 10.1042/bj2890307; KRIEK NPJ, 1981, ONDERSTEPOORT J VET, V48, P129; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LIN M, 1980, GENETIC ENV FACTORS, P139; MANDON EC, 1991, EUR J BIOCHEM, V198, P667, DOI 10.1111/j.1432-1033.1991.tb16065.x; MANDON EC, 1992, J BIOL CHEM, V267, P11144; Marasas W. F. O., 1982, CANCER ESOPHAGUS, V1, P29; MARASAS WFO, 1984, INT J CANCER, V34, P383, DOI 10.1002/ijc.2910340315; MARASAS WFO, 1988, ONDERSTEPOORT J VET, V55, P197; MARASAS WFO, 1984, TOXIGENIC FUSARIUM S; MEDLOCK KA, 1988, BIOCHEM BIOPH RES CO, V157, P232, DOI 10.1016/S0006-291X(88)80037-8; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1993, ADV LIPID RES, V26, P215; MERRILL AH, 1993, ADV LIPID RES, V25, P1; MERRILL AH, 1983, BIOCHIM BIOPHYS ACTA, V754, P284, DOI 10.1016/0005-2760(83)90144-3; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; MORELL P, 1970, J BIOL CHEM, V245, P342; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; NORRED WP, 1992, MYCOPATHOLOGIA, V117, P73, DOI 10.1007/BF00497281; OISHI K, 1990, J BIOL CHEM, V265, P70; ONG DE, 1973, J BIOL CHEM, V248, P3884; RILEY RT, 1993, TOXICOL APPL PHARM, V118, P105, DOI 10.1006/taap.1993.1015; ROSS PF, 1990, APPL ENVIRON MICROB, V56, P3225, DOI 10.1128/AEM.56.10.3225-3226.1990; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; SCHWARZMANN G, 1987, METHOD ENZYMOL, V138, P318; SLIFE CW, 1989, J BIOL CHEM, V264, P10371; STEVENS VL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P37, DOI 10.1016/0167-4889(90)90171-9; STOFFEL W, 1974, H-S Z PHYSIOL CHEM, V355, P911, DOI 10.1515/bchm2.1974.355.2.911; STOFFEL W, 1970, H-S Z PHYSIOL CHEM, V351, P635, DOI 10.1515/bchm2.1970.351.1.635; STOFFEL W, 1969, H-S Z PHYSIOL CHEM, V350, P1233, DOI 10.1515/bchm2.1969.350.2.1233; SYDENHAM EW, 1991, J AGR FOOD CHEM, V39, P2014, DOI 10.1021/jf00011a028; SYDENHAM EW, 1990, J AGR FOOD CHEM, V38, P285, DOI 10.1021/jf00091a064; VALSECCHI M, 1993, J NEUROCHEM, V60, P193, DOI 10.1111/j.1471-4159.1993.tb05837.x; VANECHTEN G, 1989, J NEUROCHEM, V52, P207; VANECHTEN G, 1990, J BIOL CHEM, V265, P9333; VOSS KA, 1990, MYCOPATHOLOGIA, V112, P81, DOI 10.1007/BF00436503; WANG E, 1991, J BIOL CHEM, V266, P14486; WEDEGAERTNER PB, 1989, J BIOL CHEM, V264, P11346; YANG CS, 1980, CANCER RES, V40, P2633; YOO HS, 1992, TOXICOL APPL PHARM, V114, P9, DOI 10.1016/0041-008X(92)90090-F; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	62	322	324	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27299	27306						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262970				2022-12-25	WOS:A1993MM26200067
J	PREUSS, U; GU, XB; GU, TJ; YU, RK				PREUSS, U; GU, XB; GU, TJ; YU, RK			PURIFICATION AND CHARACTERIZATION OF CMP-N-ACETYLNEURAMINIC ACID-LACTOSYLCERAMIDE (ALPHA-2-3) SIALYLTRANSFERASE (G(M3)-SYNTHASE) FROM RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; TISSUE-SPECIFIC EXPRESSION; SIALIC ACID; CHROMATOGRAPHY; BIOSYNTHESIS; LIVER; GLYCOLIPIDS; HOMOGENEITY; PROTEINS; INVITRO	CMP-N-acetylneuraminic acid:lactosylceramide (alpha2-3) sialyltransferase (G(M3)-synthase) was purified to homogeneity from a Triton CF-54 extract of young rat brain. The enzyme was separated by affinity chromatography on CDP-Sepharose column and resolved by linear NaCl gradient elution from the same adsorbent. Final purification of G(M3)-synthase was achieved by chromatography on a ''lactosylceramide acid''-Sepharose column and specific elution with lactosylceramide. The enzyme activity was highest at pH 6.5 and required the presence of Triton CF-54 (0.15%) and Mn2+ (10 mM) for its full activity. The product of the reaction catalyzed by the enzyme was identified as G(M3) based on its mobility on thin layer chromatographic plates using two different solvent systems. Comparison with several glycolipid substrates showed high specificity of G(M3)-synthase for lactosylceramide. The apparent K(m) value for lactosylceramide and CMP-N-acetylneuraminic acid were 80 and 210 muM, respectively. The apparent molecular mass of the enzyme determined on SDS-polyacrylamide gel electrophoresis was 76 kDa.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT BIOCHEM & MOLEC BIOPHYS,RICHMOND,VA 23298; MED COLL SHANGHAI,DEPT BIOCHEM,SHANGHAI,PEOPLES R CHINA	Virginia Commonwealth University					NINDS NIH HHS [NS 11853] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011853] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BASU M, 1987, METHOD ENZYMOL, V138, P575; Basu S, 1982, GLYCOCONJUGATES, V3, P265; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCZAK JD, 1984, BIOCHIM BIOPHYS ACTA, V804, P442, DOI 10.1016/0167-4889(84)90072-7; BURCZAK JD, 1984, J LIPID RES, V25, P1541; CHATTERJEE S, 1992, J BIOL CHEM, V267, P7148; CUATRECASAS P, 1970, J BIOL CHEM, V245, P3059; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; GU TJ, 1990, FEBS LETT, V275, P83, DOI 10.1016/0014-5793(90)81444-S; GU XB, 1990, ANAL BIOCHEM, V185, P151, DOI 10.1016/0003-2697(90)90271-A; GU XB, 1990, BIOCHEM BIOPH RES CO, V166, P387, DOI 10.1016/0006-291X(90)91957-T; HAKOMORI S, 1984, MONOCLONAL ANTIBODIE, P67; JOZIASSE DH, 1985, J BIOL CHEM, V260, P4941; KEENAN TW, 1974, J BIOL CHEM, V249, P310; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDEEN R, 1985, TRENDS NEUROSCI, V8, P169, DOI 10.1016/0166-2236(85)90064-5; LEDEEN RW, 1989, NEUROBIOLOGY GLYCOCO, P43; MACDONALD DL, 1980, J LIPID RES, V21, P642; MELKERSONWATSON LJ, 1991, J BIOL CHEM, V266, P4448; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; NAKAMURA M, 1987, ANAL BIOCHEM, V166, P230, DOI 10.1016/0003-2697(87)90569-0; OHANLON TP, 1989, J BIOL CHEM, V264, P17389; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; SCHACTER H, 1990, BIOCH GLYCOPROTEINS, P85; STOFFYN A, 1975, BIOCHIM BIOPHYS ACTA, V409, P97, DOI 10.1016/0005-2760(75)90084-3; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; SVENSSON EC, 1992, J BIOL CHEM, V267, P3466; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; Wilchek M, 1974, Methods Enzymol, V34, P475; XIA XJ, 1989, J LIPID RES, V30, P181; YU RK, 1988, J NEUROCHEM, V50, P1825, DOI 10.1111/j.1471-4159.1988.tb02484.x; YU RK, 1976, J BIOL CHEM, V251, P198	33	28	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26273	26278						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253749				2022-12-25	WOS:A1993MK42500042
J	ROMI, R; CREST, M; GOLA, M; SAMPIERI, F; JACQUET, G; ZERROUK, H; MANSUELLE, P; SOROKINE, O; VANDORSSELAER, A; ROCHAT, H; MARTINEAUCLAIRE, MF; VANRIETSCHOTEN, J				ROMI, R; CREST, M; GOLA, M; SAMPIERI, F; JACQUET, G; ZERROUK, H; MANSUELLE, P; SOROKINE, O; VANDORSSELAER, A; ROCHAT, H; MARTINEAUCLAIRE, MF; VANRIETSCHOTEN, J			SYNTHESIS AND CHARACTERIZATION OF KALIOTOXIN - IS THE 26-32 SEQUENCE ESSENTIAL FOR POTASSIUM CHANNEL RECOGNITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY BINDING-SITES; PERFORMANCE LIQUID-CHROMATOGRAPHY; CA-2+-ACTIVATED K+ CHANNEL; AORTIC SMOOTH-MUSCLE; RAT-BRAIN; PEPTIDYL INHIBITOR; DIRECT ASSOCIATION; SCORPION TOXINS; CHARYBDOTOXIN; VENOM	Kaliotoxin (KTX), a scorpion toxin characterized as a 37-residue inhibitor of the neuronal high conductance Ca2+-activated K+ channels (KCa channels), has been chemically synthesized. Differences were observed between natural toxin and the two peptides, KTX(1-37) and KTX(1-37)-amide. Re-examination of the KTX sequence showed that an extra lysine residue was present at the C-terminal end. The 38-residue synthetic peptide was found identical with natural toxin. All three peptides had comparable activities, with LD50 Values of 6-9 pmol/mouse after intracerebroventricular injection, and K(d) = 2-8 nM for blockage of the whole cell and unitary molluscan KCa currents. Pairing of the disulfide bonds in synthetic KTX corresponded to that in charybdotoxin and iberiotoxin. A competition assay between I-125-KTX(1-37) and different toxins (KTX, dendrotoxin, charybdotoxin, MCD peptide, and iberiotoxin) for binding to rat brain synaptosomal membranes suggested that KTX interacts also with voltage-gated K+ channels. Shorter peptides, KTX(25-35)-amide and KTX(26-32)amide, expressed no KTX activity, but were able to compete in binding. They were further shown to antagonize KTX in both its toxicity and blocking activity. The (26-32) sequence of KTX, which is a highly conserved region, may contain a low affinity binding subsite essential for potassium channel recognition.	CNRS,NEUROBIOL LAB,F-13402 MARSEILLE 20,FRANCE; CNRS,CHIM ORGAN SUBST NAT LAB,F-67084 STRASBOURG,FRANCE; INST PASTEUR,PURIFICAT PROT LAB,CASABLANCA,MOROCCO	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	ROMI, R (corresponding author), FAC MED NORD,BIOCHIM LAB,CNRS,URA 1455,BLVD PIERRE DRAMARD,F-13916 MARSEILLE 20,FRANCE.			mansuelle, pascal/0000-0002-4504-6809				BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BLAUSTEIN MP, 1991, MOL PHARMACOL, V40, P932; BONTEMS F, 1992, BIOCHEMISTRY-US, V31, P7756, DOI 10.1021/bi00149a003; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; BRIAND JB, 1990, PEPTIDES; CARBONE E, 1982, NATURE, V296, P90, DOI 10.1038/296090a0; CEARD B, 1992, TOXICON, V30, P105, DOI 10.1016/0041-0101(92)90506-Z; CREST M, 1990, J EXP BIOL, V152, P211; CREST M, 1992, J BIOL CHEM, V267, P1640; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DEUTSCH C, 1991, J BIOL CHEM, V266, P3668; DREYER F, 1990, REV PHYSL BIOCH PHAR, V15, P94; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; GIANGIACOMO KM, 1992, BIOCHEMISTRY-US, V31, P6719, DOI 10.1021/bi00144a011; GOLA M, 1990, J PHYSIOL-LONDON, V420, P73, DOI 10.1113/jphysiol.1990.sp017902; GORDON D, 1984, BIOCHIM BIOPHYS ACTA, V778, P349, DOI 10.1016/0005-2736(84)90379-1; GROSS E, 1961, J AM CHEM SOC, V83, P1510, DOI 10.1021/ja01467a052; HALLIWELL JV, 1986, P NATL ACAD SCI USA, V83, P493, DOI 10.1073/pnas.83.2.493; HARVEY AL, 1980, N-S ARCH PHARMACOL, V312, P1, DOI 10.1007/BF00502565; HAWKE D, 1982, ANAL BIOCHEM, V120, P302, DOI 10.1016/0003-2697(82)90351-7; HERMANN A, 1987, J GEN PHYSIOL, V90, P27, DOI 10.1085/jgp.90.1.27; JOHNSON BA, 1992, BIOCHEMISTRY-US, V31, P8151, DOI 10.1021/bi00150a006; JOVER E, 1980, BIOCHEM BIOPH RES CO, V95, P1607, DOI 10.1016/S0006-291X(80)80082-9; JOVER E, 1980, BIOCHEMISTRY-US, V19, P463, DOI 10.1021/bi00544a010; MARTIN MF, 1987, J BIOL CHEM, V262, P4452; MARTIN MF, 1986, TOXICON, V24, P1131, DOI 10.1016/0041-0101(86)90139-X; MCKINNON R, 1991, NATURE, V350, P232; MCKINNON R, 1988, J GEN PHYSIOL, V91, P335; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; NIALL HD, 1972, J CHEM BIOL PEPTIDE, V3, P695; NOBLE RL, 1976, J AM CHEM SOC, V98, P2324, DOI 10.1021/ja00424a055; PARK CS, 1992, BIOCHEMISTRY-US, V31, P7749, DOI 10.1021/bi00149a002; PONGS O, 1992, TRENDS PHARMACOL SCI, V13, P359, DOI 10.1016/0165-6147(92)90109-J; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; REINHART PH, 1989, NEURON, V2, P1031, DOI 10.1016/0896-6273(89)90227-4; ROBITAILLE R, 1992, J NEUROSCI, V12, P297; SCHWEITZ H, 1989, BIOCHEMISTRY-US, V28, P9708, DOI 10.1021/bi00451a025; SEAGAR MJ, 1984, J BIOL CHEM, V259, P1491; SUGG EE, 1990, J BIOL CHEM, V265, P18745; VALVIDIA HV, 1988, FEBS LETT, V226, P280; VANDORSSELAER A, 1990, BIOMED ENVIRON MASS, V19, P692, DOI 10.1002/bms.1200191108; VANRIETSCHOTEN J, 1975, EUR J BIOCHEM, V56, P35, DOI 10.1111/j.1432-1033.1975.tb02204.x; VAZQUEZ J, 1990, J BIOL CHEM, V265, P15564; VAZQUEZ J, 1989, J BIOL CHEM, V264, P20902	45	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26302	26309						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253752				2022-12-25	WOS:A1993MK42500046
J	KHANNA, KK; LAVIN, MF				KHANNA, KK; LAVIN, MF			IONIZING-RADIATION AND UV INDUCTION OF P53 PROTEIN BY DIFFERENT PATHWAYS IN ATAXIA-TELANGIECTASIA CELLS	ONCOGENE			English	Article							RADIORESISTANT DNA-SYNTHESIS; FLOW CYTOMETRIC ANALYSIS; WILD-TYPE P53; LATE G1 PHASE; CYCLE CHECKPOINT; TOPOISOMERASE-II; KINASE-C; CANCER; PERTURBATIONS; IRRADIATION	Cell cycle anomalies have been described in ataxia-telangiectasia cells after exposure to ionizing radiation. A recent report demonstrates that cells from these patients lack the ionizing radiation-induced increase in p53 protein seen in controls. We report here that an ionizing radiation-induced p53 response is reduced and/or delayed in cells from four ataxia-telangiectasia complementation groups. On the other hand, p53 induction is normal in all A-T complementation groups after exposure to UV-B light, an agent to which these cells are not hypersensitive. Specific inhibitors of protein kinase C and serine/threonine phosphatases prevented the radiation induction of p53 protein. Agents that produced double-strand breaks in DNA and/or inhibition of transcription caused an induction of p53 in the absence of radiation in control cells but not in ataxia-telangiectasia, but inhibitors of cell cycle progression such as mimosine and aphidicolin led to an increase in p53 in both cell types in the absence of radiation. These results suggest that there is more than one signal transduction pathway responsible for activation of p53, one of which is less efficient in ataxia-telangiectasia cells.	QUEENSLAND INST MED RES, BANCROFT CTR, QUEENSLAND CANC FUND RES UNIT, BRISBANE, QLD 4029, AUSTRALIA	QIMR Berghofer Medical Research Institute			Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769; Khanna, Kum Kum/0000-0001-8650-5381				ABDELLA BR, 1984, ENV HLTH PERSPECT, V64, P3; AURIAS A, 1980, MUTAT RES, V69, P369, DOI 10.1016/0027-5107(80)90101-3; BATES P, 1985, MUTAT RES, V218, P165; BAXTER G, 1988, IMMUNOL CELL BIOL, V67, P57; BEAMISH H, IN PRESS RAD RES; BODER E, 1985, ATAXIA TELANGIECTASI, V19, P1; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHEN P, 1984, MUTAT RES, V129, P165, DOI 10.1016/0027-5107(84)90149-0; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; DAVIES SM, 1989, NUCLEIC ACIDS RES, V17, P1337, DOI 10.1093/nar/17.4.1337; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EDWARDS MJ, 1980, NATURE, V287, P745, DOI 10.1038/287745a0; FORD MD, 1981, NUCLEIC ACIDS RES, V9, P1395, DOI 10.1093/nar/9.6.1395; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUJIKI H, 1990, ADV SEC MESS PHOSPH, V24, P340; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HANAWALT PC, 1986, TRENDS GENET, V2, P124, DOI 10.1016/0168-9525(86)90201-5; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; IMRAY FP, 1983, MUTAT RES, V112, P369; JASPERS NGJ, 1982, MUTAT RES, V92, P439, DOI 10.1016/0027-5107(82)90242-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAVIN MF, 1987, MOL CELL BIOCHEM, V73, P45; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEHMANN AR, 1982, CELLULAR MOL LINK CA, P347; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; MCFARLIN DE, 1972, MEDICINE, V51, P281, DOI 10.1097/00005792-197207000-00002; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MIRZAYANS R, 1989, CANCER RES, V49, P5523; MOHAMED R, 1989, BIOCHEM BIOPH RES CO, V158, P749, DOI 10.1016/0006-291X(89)92785-X; MORGAN JL, 1968, AM J DIS CHILD, V116, P557, DOI 10.1001/archpedi.1968.02100020561022; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1981, MUTAT RES, V84, P183, DOI 10.1016/0027-5107(81)90061-0; PATERSON MC, 1979, CANCER RES, V39, P3225; PEDRALINOY G, 1980, NUCLEIC ACIDS RES, V8, P377, DOI 10.1093/nar/8.2.377; PETERSON RD, 1964, LANCET, V1, P1193; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SINGH SP, 1988, NUCLEIC ACIDS RES, V16, P3919, DOI 10.1093/nar/16.9.3919; SONG Q, 1993, BIOCHEM BIOPH RES CO, V190, P45; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; TEALE B, IN PRESS J BIOL CHEM; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651	58	282	288	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3307	3312						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247533				2022-12-25	WOS:A1993MG78200014
J	GALLOWAY, AM; LIUZZI, M; PATERSON, MC				GALLOWAY, AM; LIUZZI, M; PATERSON, MC			METABOLIC PROCESSING OF CYCLOBUTYL PYRIMIDINE DIMERS AND (6-4) PHOTOPRODUCTS IN UV-TREATED HUMAN-CELLS - EVIDENCE FOR DISTINCT EXCISION-REPAIR PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRADIMER PHOSPHODIESTER LINKAGE; COMPLEMENTATION GROUP-C; XERODERMA-PIGMENTOSUM; ENZYMATIC ANALYSIS; HUMAN-FIBROBLASTS; DNA-REPAIR; ISOMERIC TRITHYMIDYLATES; MICROCOCCUS-LUTEUS; MYC GENE; DAMAGE	A new nuclease digestion assay was developed to elucidate the human excision-repair system operating on cyclobutyl pyrimidine dimers and (6-4) photoproducts. We analyzed lesions that accumulated in excised oligonucleotide fragments during incubation of UV-treated cultured fibroblasts. (6-4) photoproducts were removed intact, whereas excised cyclobutyl dimers often contained ruptured interpyrimidine phosphodiester bonds, raising the possibility that the intradimer backbone-cleavage reaction may help promote the bypass of unexcised dimers by the DNA replication or RNA transcription machinery. Cell strains representing eight different inherited forms of the cancer-prone skin disease xeroderma pigmentosum (XP) were generally found to exhibit characteristic abilities to excise the two classes of photolesions, ranging from total deficiency in groups A and G to normal proficiency in the variant. The capacity of any given XP group to act on one class of photoproducts in no way predicted its ability to act on the other. Finally, in those XP strains displaying significant levels of dimer removal, the ratio of intact-versus-modified dimers was normal, implying that rupture of the intradimer backbone linkage occurs independently of subsequent excision-repair reactions. Our data indicate that cyclobutyl dimers and (6-4) photoproducts are processed by distinct nucleotide-excision-repair pathways in human cells.	CROSS CANC INST, MOLEC ONCOL PROGRAM, EDMONTON T6G 1Z2, ALBERTA, CANADA; UNIV ALBERTA, DEPT GENET, ALBERTA T6G 2Z3, AB, CANADA; UNIV ALBERTA, DEPT ONCOL, DEPT ONCOL, ALBERTA T6G 2Z3, AB, CANADA; UNIV ALBERTA, DEPT BIOCHEM, ALBERTA T6G 2Z3, AB, CANADA	University of Alberta; University of Alberta; University of Alberta; University of Alberta								BOHR VA, 1987, CANCER RES, V47, P6426; BRASH DE, 1982, NATURE, V298, P189, DOI 10.1038/298189a0; BRASH DE, 1987, P NATL ACAD SCI USA, V84, P3782, DOI 10.1073/pnas.84.11.3782; BUHL SN, 1972, INT J RADIAT BIOL RE, V22, P417, DOI 10.1080/09553007214551301; Carrier W. L., 1971, METHODS ENZYMOLOGY D, V21, P230; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; CLEAVER JE, 1991, PHOTOCHEM PHOTOBIOL, V54, P393, DOI 10.1111/j.1751-1097.1991.tb02033.x; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; EHMANN UK, 1978, BIOPHYS J, V22, P249, DOI 10.1016/S0006-3495(78)85487-3; FRANKLIN WA, 1982, J BIOL CHEM, V257, P13535; HIRAMOTO T, 1989, J INVEST DERMATOL, V93, P703, DOI 10.1111/1523-1747.ep12319907; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; LABELLE M, 1982, PHOTOCHEM PHOTOBIOL, V36, P319, DOI 10.1111/j.1751-1097.1982.tb04381.x; LIUZZI M, 1992, J BIOL CHEM, V267, P22421; LIUZZI M, 1989, J BIOL CHEM, V264, P6355; MCWHINNEY C, 1990, NUCLEIC ACIDS RES, V18, P1233, DOI 10.1093/nar/18.5.1233; MITCHELL DL, 1984, PHOTOCHEM PHOTOBIOL, V40, P735; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; MULLENDERS LHF, 1984, MUTAT RES, V141, P75, DOI 10.1016/0165-7992(84)90014-9; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PATERSON MC, 1987, J CELL SCI, P161; PATERSON MC, 1973, MUTAT RES, V19, P245, DOI 10.1016/0027-5107(73)90083-3; PATERSON MC, 1992, ADP RIBOSYLATION REA, P97; REARDON JT, 1991, NUCLEIC ACIDS RES, V19, P4623, DOI 10.1093/nar/19.17.4623; ROZA L, 1990, CANCER RES, V50, P1905; SAMBROOK S, 1989, MOL CLONING LABORATO; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SETLOW RB, 1969, P NATL ACAD SCI USA, V64, P1035, DOI 10.1073/pnas.64.3.1035; SIBGHATULLAH, 1990, BIOCHEMISTRY-US, V29, P5711, DOI 10.1021/bi00476a011; SMITH PJ, 1982, PHOTOCHEM PHOTOBIOL, V36, P333, DOI 10.1111/j.1751-1097.1982.tb04383.x; SPENCER CA, 1991, ADV CANCER RES, V56, P1; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; WANG SY, 1967, BIOCHEM BIOPH RES CO, V29, P543, DOI 10.1016/0006-291X(67)90519-0; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WEINFELD M, 1989, J BIOL CHEM, V264, P6364; WEINFELD M, 1986, BIOCHEMISTRY-US, V25, P2656, DOI 10.1021/bi00357a055; ZELLE B, 1979, MUTAT RES, V62, P363, DOI 10.1016/0027-5107(79)90091-5	42	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					974	980						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288650				2022-12-25	WOS:A1994MR22000033
J	GUSTAVSSON, L; MOEHREN, G; TORRESMARQUEZ, ME; BENISTANT, C; RUBIN, R; HOEK, JB				GUSTAVSSON, L; MOEHREN, G; TORRESMARQUEZ, ME; BENISTANT, C; RUBIN, R; HOEK, JB			THE ROLE OF CYTOSOLIC CA2+, PROTEIN-KINASE-C, AND PROTEIN KINASE-A IN HORMONAL-STIMULATION OF PHOSPHOLIPASE-D IN RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT PERITONEAL NEUTROPHILS; PHOSPHATIDYLCHOLINE HYDROLYSIS; D ACTIVATION; CA-2+-MOBILIZING HORMONES; INTRACELLULAR CALCIUM; DEPENDENT ACTIVATION; ENDOTHELIAL-CELLS; RESPIRATORY BURST; PHORBOL ESTER; CALPHOSTIN-C	Ca2+-dependent and protein kinase C-dependent mechanisms of phospholipase D (PLD) activation were studied in rat hepatocytes by measuring phosphatidylethanol (Peth) formation in the presence of ethanol. Stimulation of Peth formation by 12-O-tetradecanoylphorbol 13-acetate (TPA), vasopressin, or A23187 was inhibited by multiple protein kinase C inhibitors or by protein kinase C down-regulation, indicating that this enzyme is involved in the action of all these agents. A controlled elevation of the cytosolic Ca2+ concentration ([Ca2+]cyt) over the range of 0.1-2.0 muM activated Peth formation in the absence of other agonists. Staurosporin potentiated Ca2+-induced Peth formation by shifting the [Ca2+]cyt dose-response curve to the left. Other protein kinase C inhibitors (calphostin C, bisindolylmaleimide) inhibited Ca2+-mediated Peth formation, but this inhibition was reduced in staurosporin-treated cells. Okadaic acid potentiated PLD activation by TPA, but suppressed PLD activation by elevated [Ca2+]cyt. Desensitization of TPA-induced PLD activity did not affect PLD activation by Ca2+. These data indicate that [Ca2+]cyt and protein kinase C control distinct pathways of PLD activation, but the Ca2+-mediated pathway is suppressed by a staurosporin-sensitive protein kinase. Both mechanisms contribute to vasopressin-induced Peth formation in intact hepatocytes. Activation of protein kinase A enhanced vasopressin-induced Peth formation, but not TPA-stimulated or Ca2+-stimulated Peth formation. Protein kinase A acted by enhancing hormonal Ca2+ mobilization, rather than by directly activating PLD, and thereby shifted the balance of Ca2+-dependent and protein kinase C-dependent activation mechanisms of PLD in intact cells.	THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, PHILADELPHIA, PA 19107 USA; LUND UNIV, DEPT PSYCHIAT & NEUROCHEM, S-22009 LUND, SWEDEN; INSA, INSERM, UNITE 205, CHIM BIOL LAB, F-69621 VILLEURBANNE, FRANCE	Jefferson University; Lund University; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon			Benistant, Christine/M-5771-2018	Hoek, Jan/0000-0001-7127-4218	NIAAA NIH HHS [AA07215, AA08714, AA07186] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186, R01AA008714] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOURGOIN S, 1992, CELL SIGNAL, V4, P487; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DEWALD B, 1989, BIOCHEM J, V264, P879, DOI 10.1042/bj2640879; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; EXTON JH, 1992, CIBA F SYMP, V164, P36; EXTON JH, 1991, MOL CELL BIOCHEM, V104, P81; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; GOPALAKRISHNA R, 1992, FEBS LETT, V314, P149, DOI 10.1016/0014-5793(92)80962-G; GUSTAVSSON L, 1987, BIOCHEM BIOPH RES CO, V142, P958, DOI 10.1016/0006-291X(87)91507-5; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HIGASHI K, 1991, J BIOL CHEM, V266, P2178; HUANG CF, 1992, J BIOL CHEM, V267, P16859; HUANG CF, 1990, J BIOL CHEM, V265, P17468; KANAHO Y, 1992, J BIOL CHEM, V267, P23554; KANAHO Y, 1992, J IMMUNOL, V149, P622; KANOH H, 1992, J NEUROCHEM, V59, P1786, DOI 10.1111/j.1471-4159.1992.tb11011.x; KASZKIN M, 1992, BIOCHEM J, V287, P51, DOI 10.1042/bj2870051; KESSELS GCR, 1991, J BIOL CHEM, V266, P23152; KISS Z, 1990, J BIOL CHEM, V265, P7345; KISS Z, 1990, PROG LIPID RES, V29, P141, DOI 10.1016/0163-7827(90)90001-2; KOBAYASHI M, 1987, J NEUROCHEM, V48, P1597, DOI 10.1111/j.1471-4159.1987.tb05707.x; LASSEGUE B, 1991, BIOCHEM J, V276, P19, DOI 10.1042/bj2760019; LAVIE Y, 1990, FEBS LETT, V277, P7, DOI 10.1016/0014-5793(90)80796-L; LIN PY, 1992, EUR J BIOCHEM, V207, P163, DOI 10.1111/j.1432-1033.1992.tb17033.x; LISCOVITCH M, 1991, CELL REGUL, V2, P1011, DOI 10.1091/mbc.2.12.1011; MARTIN TW, 1989, BIOCHEM BIOPH RES CO, V165, P319, DOI 10.1016/0006-291X(89)91072-3; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MATTINGLY RR, 1992, FEBS LETT, V296, P225, DOI 10.1016/0014-5793(92)80385-T; MOEHREN G, 1994, J BIOL CHEM, V269, P838; NIGAM S, 1992, BIOCHIM BIOPHYS ACTA, V1135, P301, DOI 10.1016/0167-4889(92)90235-4; PACHTER JA, 1992, J BIOL CHEM, V267, P9826; PAI JK, 1991, CELL REGUL, V2, P897, DOI 10.1091/mbc.2.11.897; PERIANIN A, 1993, FEBS LETT, V315, P33, DOI 10.1016/0014-5793(93)81127-L; PIROTTON S, 1990, J CELL PHYSIOL, V142, P449, DOI 10.1002/jcp.1041420303; PITTNER RA, 1990, BIOCHIM BIOPHYS ACTA, V1043, P211, DOI 10.1016/0005-2760(90)90298-C; PITTNER RA, 1991, BIOCHEM J, V277, P371, DOI 10.1042/bj2770371; PLEIN P, 1992, BIOL CHEM H-S, V373, P151, DOI 10.1515/bchm3.1992.373.1.151; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; SIDDIQUI RA, 1992, J BIOL CHEM, V267, P5755; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; WANG P, 1991, J BIOL CHEM, V266, P14877; WONG K, 1992, BIOCHEM J, V283, P499, DOI 10.1042/bj2830499; WU H, 1992, BIOCHEMISTRY-US, V31, P3370, DOI 10.1021/bi00128a010	54	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					849	859						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288638				2022-12-25	WOS:A1994MR22000016
J	CHRISTIANSEN, K; WESTERGAARD, O				CHRISTIANSEN, K; WESTERGAARD, O			CHARACTERIZATION OF INTRAMOLECULAR AND INTERMOLECULAR DNA LIGATION-MEDIATED BY EUKARYOTIC TOPOISOMERASE-I - ROLE OF BIPARTITE DNA INTERACTION IN THE LIGATION PROCESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; TYPE-1 TOPOISOMERASE; BINDING SEQUENCE; CLEAVAGE INVITRO; RAT-LIVER; SV40 DNA; SITES; CAMPTOTHECIN; CHROMATIN; BREAKAGE	The capacity of eukaryotic topoisomerase I to catalyze intra- and intermolecular DNA strand transfer via a two-step cleavage/ligation reaction was investigated by use of purified enzyme and defined DNA substrates. Topoisomerase I-mediated cleavage requires separate interaction with a duplex region encompassing the cleavage site (region A) and a duplex region located on the side holding the 5'-OH end generated by cleavage (region B). Cleaved topoisomerase 1-DNA complexes containing enzyme covalently attached at internal and terminal positions were employed to characterize the intra- and intermolecular ligation reactions. Enzyme attached covalently at an internal position of a partially single-stranded DNA molecule is able to catalyze ligation of a complementary dinucleotide within region A in the absence of interaction with region B. Moreover, the dinucleotide confines the minimal DNA acceptor for intramolecular ligation. Topoisomerase I attached covalently to DNA at a terminal position can ligate the cleaved strand to heterologous duplex DNA regardless of sequence, whereas ligation does not proceed with single-stranded DNA. When these features are considered together with the observation that intermolecular ligation is inhibited by 1 m NaCl, it suggests that the reaction requires bipartite DNA interaction. A model is proposed that relates the bipartite DNA binding of eukaryotic topoisomerase I to the catalytic functions.	AARHUS UNIV, DEPT MOLEC BIOL, CF MOLLERS ALLE, BLDG 130, DK-8000 AARHUS, DENMARK	Aarhus University								ANDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P6237, DOI 10.1021/bi00441a015; BAUER WR, 1993, P NATL ACAD SCI USA, V90, P833, DOI 10.1073/pnas.90.3.833; BEEN MD, 1981, P NATL ACAD SCI-BIOL, V78, P2883, DOI 10.1073/pnas.78.5.2883; BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; BEEN MD, 1984, J MOL BIOL, V180, P515, DOI 10.1016/0022-2836(84)90025-1; BJORNSTI MA, 1989, CANCER RES, V49, P6318; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; BROWN T, 1985, NATURE, V315, P604, DOI 10.1038/315604a0; BUSK H, 1987, NATURE, V327, P638, DOI 10.1038/327638a0; CAMILLONI G, 1989, P NATL ACAD SCI USA, V86, P3080, DOI 10.1073/pnas.86.9.3080; CASERTA M, 1989, NUCLEIC ACIDS RES, V17, P8462; CHRISTIANSEN K, 1993, J BIOL CHEM, V268, P9690; CHRISTIANSEN K, 1987, J MOL BIOL, V193, P517, DOI 10.1016/0022-2836(87)90264-6; CHRISTIANSEN K, 1993, ALFRED BENZON SYMP S, V35, P361; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; Der Garabedian P A, 1991, Biochemistry, V30, P9940, DOI 10.1021/bi00105a018; EDWARDS KA, 1982, NUCLEIC ACIDS RES, V10, P2565, DOI 10.1093/nar/10.8.2565; FRANK R, 1979, NUCLEIC ACIDS RES, V6, P2069, DOI 10.1093/nar/6.6.2069; HALLIGAN BD, 1982, J BIOL CHEM, V257, P3995; KIRKEGAARD K, 1984, COLD SPRING HARB SYM, V49, P411, DOI 10.1101/SQB.1984.049.01.047; KRASNOW MA, 1982, J BIOL CHEM, V257, P2687; KROGH S, 1991, NUCLEIC ACIDS RES, V19, P1235, DOI 10.1093/nar/19.6.1235; NESS PJ, 1988, J MOL BIOL, V200, P127, DOI 10.1016/0022-2836(88)90338-5; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; PILCH DS, 1990, P NATL ACAD SCI USA, V87, P1942, DOI 10.1073/pnas.87.5.1942; PRELL B, 1980, EUR J BIOCHEM, V108, P389, DOI 10.1111/j.1432-1033.1980.tb04734.x; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1992, J BIOL CHEM, V267, P16755; STEVNSNER T, 1989, J BIOL CHEM, V264, P10110; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; SVEJSTRUP JQ, 1990, J BIOL CHEM, V265, P12529; THOMSEN B, 1987, EMBO J, V6, P1817, DOI 10.1002/j.1460-2075.1987.tb02436.x; TSEDINH YC, 1986, J BIOL CHEM, V261, P931; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	38	60	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					721	729						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276874				2022-12-25	WOS:A1994MR21900113
J	HAZARD, AL; SENIOR, AE				HAZARD, AL; SENIOR, AE			MUTAGENESIS OF SUBUNIT-DELTA FROM ESCHERICHIA-COLI F1F0-ATP SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; SENSITIVITY-CONFERRING PROTEIN; B UNCF-PROTEIN; ADENOSINE-TRIPHOSPHATASE; ELECTRON-MICROSCOPY; NUCLEOTIDE-SEQUENCE; H+-ATPASE; CRYOELECTRON MICROSCOPY; DIRECTED MUTAGENESIS; MEMBRANE ATTACHMENT	In Escherichia coli, the F1 sector of the F1F0-ATP synthase is connected to the membrane-embedded F0 sector by a narrow stalk, thought to be formed by subunits delta and b. Mutagenic analysis was used here to study the structure and function of subunit delta. First, random mutations in the protein were generated by bisulfite mutagenesis. Two single missense mutations causing impaired growth by oxidative phosphorylation were found, namely deltaA149T and deltaG150D. Both occur at the conserved C-terminal region, which has been suggested previously to be functionally important. Two techniques were applied to study the C-terminal region in greater detail. Cassette mutagenesis was used to randomly mutate the sequence from delta145 to delta167, and residues delta4,149 and deltaG150 were specifically mutated by site-directed mutagenesis to obtain multiple substitutions at each position. Fifteen of the residues between delta145 and delta167 were mutated. None was found to be absolutely essential for function. However, the properties of the mutants obtained, which included partial impairment of growth by oxidative phosphorylation, temperature sensitivity, and specific structural requirements at residues deltaA149 and deltaG150, confirmed that this region is important for enzyme function. Based on these studies, and on secondary and tertiary structure predictions, a model for subunit delta and its orientation in F1F0-ATP synthase is proposed.			HAZARD, AL (corresponding author), UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,ROCHESTER,NY 14642, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025349, R37GM025349] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1993, EMBO J, V12, P1775, DOI 10.1002/j.1460-2075.1993.tb05825.x; BECKERS G, 1992, BIOCHIM BIOPHYS ACTA, V1101, P97, DOI 10.1016/0167-4838(92)90473-Q; BLACKLOW SC, 1991, BIOCHEMISTRY-US, V30, P8470, DOI 10.1021/bi00098a026; BOEKEMA EJ, 1986, BIOCHIM BIOPHYS ACTA, V851, P353, DOI 10.1016/0005-2728(86)90071-X; BOEKEMA EJ, 1992, BIOCHIM BIOPHYS ACTA, V1098, P131, DOI 10.1016/S0005-2728(05)80328-7; COX GB, 1984, BIOCHIM BIOPHYS ACTA, V768, P201, DOI 10.1016/0304-4173(84)90016-8; DECKERSHEBESTR G, 1992, J BIOL CHEM, V267, P12634; DOWNIE JA, 1981, J BACTERIOL, V145, P200, DOI 10.1128/JB.145.1.200-210.1981; DUNN SD, 1992, J BIOL CHEM, V267, P7630; DUPUIS A, 1983, BIOCHEMISTRY-US, V22, P5951, DOI 10.1021/bi00294a039; ENGELBRECHT S, 1990, BIOCHIM BIOPHYS ACTA, V1015, P379, DOI 10.1016/0005-2728(90)90072-C; ENGELBRECHT S, 1991, Z NATURFORSCH C, V46, P759; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; GIBSON F, 1977, BIOCHEM J, V162, P665, DOI 10.1042/bj1620665; GIZA PE, 1981, GENE, V15, P331, DOI 10.1016/0378-1119(81)90176-1; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; HAZARD AL, J BIOL CHEM, V269, P427; HERMES JD, 1990, P NATL ACAD SCI USA, V87, P696, DOI 10.1073/pnas.87.2.696; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; HILL DE, 1987, METHOD ENZYMOL, V155, P558; JANS DA, 1985, J BACTERIOL, V162, P420, DOI 10.1128/JB.162.1.420-426.1985; JOSHI S, 1992, J BIOL CHEM, V267, P12860; JOUNOUCHI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P376, DOI 10.1016/0003-9861(92)90005-H; KIMURA T, 1990, J BIOL CHEM, V265, P6079; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; MABUCHI K, 1981, BIOCHEM BIOPH RES CO, V102, P172, DOI 10.1016/0006-291X(81)91504-7; MAGGIO MB, 1988, J BIOL CHEM, V263, P4619; Maniatis T., 1982, MOL CLONING; MCCARTHY JEG, 1988, J BIOENERG BIOMEMBR, V20, P19, DOI 10.1007/BF00762136; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; Miller J.H., 1972, EXPT MOL GENETICS; PANCIC PG, 1991, FEBS LETT, V280, P387, DOI 10.1016/0014-5793(91)80338-4; PARSONAGE D, 1987, J BIOL CHEM, V262, P8022; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; PERLIN DS, 1985, ARCH BIOCHEM BIOPHYS, V236, P603, DOI 10.1016/0003-9861(85)90664-2; PORTER ACG, 1985, J BIOL CHEM, V260, P8182; RAO R, 1988, J BIOL CHEM, V263, P15957; RASMUSSEN OF, 1992, BIOCHEM J, V285, P881, DOI 10.1042/bj2850881; SENIOR AE, 1979, BIOCHEM J, V180, P111, DOI 10.1042/bj1800111; SENIOR AE, 1983, BIOCHIM BIOPHYS ACTA, V726, P81, DOI 10.1016/0304-4173(83)90001-0; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SMITH JB, 1977, BIOCHEMISTRY-US, V16, P306, DOI 10.1021/bi00621a023; STEFFENS K, 1987, J BIOL CHEM, V262, P5866; STERNWEIS PC, 1977, BIOCHEMISTRY-US, V16, P4020, DOI 10.1021/bi00637a013; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; WAGNER R, 1988, FEBS LETT, V230, P109, DOI 10.1016/0014-5793(88)80652-5; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WALKER JE, 1982, NATURE, V298, P867, DOI 10.1038/298867a0	51	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					418	426						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276830				2022-12-25	WOS:A1994MR21900071
J	ZHU, BT; EZELL, EL; LIEHR, JG				ZHU, BT; EZELL, EL; LIEHR, JG			CATECHOL-O-METHYLTRANSFERASE-CATALYZED RAPID O-METHYLATION OF MUTAGENIC FLAVONOIDS - METABOLIC INACTIVATION AS A POSSIBLE REASON FOR THEIR LACK OF CARCINOGENICITY IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LIVER; QUERCETIN; RAT; ESTROGENS; RUTIN; INHIBITION; ACTIVATION; HAMSTERS; CANCER; CELLS	Quercetin is highly mutagenic in vitro, yet is not carcinogenic when administered chronically at large doses to rodents for 12 months. We hypothesized that catechol-O-methyltransferase-catalyzed O-methylation of quercetin and other mutagenic catechol-containing flavonoids may provide an efficient inactivation in vivo and may therefore prevent tumor induction by these flavonoids. After one intraperitoneal administration of 50 mg/kg quercetin to hamsters, a urinary ether extract contained 2% quercetin and 97% 3'-O-methylquercetin. When the urine was treated first with bea-glucuronidase and sulfatase, 13% quercetin and 87% 3'-O-methylquercetin were recovered. Quercetin was rapidly O-methylated by either porcine liver or hamster kidney catechol-O-methyltransferase, with K(m) values of 6.1 and 6.9 muM and V(max) values of 14,870 and 200 pmol/mg of protein/min, respectively. S-Adenosyl-L-homocysteine exhibited a potent feedback inhibition of the catechol-O-methyltransferase-catalyzed O-methylation of quercetin by a competitive mechanism with respect to S-adenosyl-L-methionine and by a competitive plus noncompetitive mechanism with respect to the substrate. A comparison of the O-methylation rates and kinetic characteristics (K(m), V(max), and V(max)/K(m)) demonstrated that rates of O-methylation of quercetin and fisetin were up to three orders of magnitude higher than those of catechol estrogens and catecholamines. In conclusion, the rapid metabolic inactivation of mutagenic flavonoids catalyzed by catechol-O-methyltransferase may be a major reason for the lack of their carcinogenic activities in vivo.	UNIV TEXAS, MED BRANCH, DEPT PHARMACOL & TOXICOL, J-31, GALVESTON, TX 77555 USA; UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOCHEM & GENET, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston					NATIONAL CANCER INSTITUTE [R37CA043233, R01CA043233] Funding Source: NIH RePORTER; NCI NIH HHS [CA 43233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; AXELROD J, 1966, PHARMACOL REV, V18, P95; AXELROD J, 1965, J PHARMACOL EXP THER, V149, P16; AZELROD J, 1971, J PHARMACOL EXP THER, V176, P650; BACHUR NR, 1978, CANCER RES, V38, P1745; BALL P, 1972, EUR J BIOCHEM, V26, P560, DOI 10.1111/j.1432-1033.1972.tb01799.x; BALL P, 1990, AM J OBSTET GYNECOL, V163, P2163, DOI 10.1016/0002-9378(90)90558-O; BALL P, 1972, J CLIN ENDOCR METAB, V34, P736, DOI 10.1210/jcem-34-4-736; BJELDANES LF, 1977, SCIENCE, V197, P577, DOI 10.1126/science.327550; BOOTH AN, 1956, J BIOL CHEM, V223, P251; BOOTH AN, 1958, J BIOL CHEM, V230, P661; Borchardt R T, 1981, Methods Enzymol, V77, P267; BROWN JP, 1979, MUTAT RES, V66, P223, DOI 10.1016/0165-1218(79)90083-1; BROWN JP, 1977, BIOCHEM SOC T, V5, P1489, DOI 10.1042/bst0051489; CZECZOT H, 1990, MUTAT RES, V240, P209, DOI 10.1016/0165-1218(90)90060-F; DAS NP, 1973, BIOCHEM J, V136, P903, DOI 10.1042/bj1360903; DESCHNER EE, 1991, CARCINOGENESIS, V12, P1193, DOI 10.1093/carcin/12.7.1193; EICH G, 1982, J AM CHEM SOC, V104, P3731, DOI 10.1021/ja00377a036; FULLER RW, 1984, J PHARM PHARMACOL, V36, P419, DOI 10.1111/j.2042-7158.1984.tb04416.x; GRIFFITHS LA, 1972, ANGIOLOGICA, V9, P162; GRIFFITHS LA, 1972, BIOCHEM J, V128, P901, DOI 10.1042/bj1280901; GRIFFITHS LA, 1972, BIOCHEM J, V130, P141, DOI 10.1042/bj1300141; GROSSMAN MH, 1992, LIFE SCI, V50, P473, DOI 10.1016/0024-3205(92)90386-4; GUGLER R, 1975, EUR J CLIN PHARMACOL, V9, P229, DOI 10.1007/BF00614022; HIRONO I, 1981, CANCER LETT, V13, P15, DOI 10.1016/0304-3835(81)90081-1; ITO N, 1989, JPN J CANCER RES, V80, P317, DOI 10.1111/j.1349-7006.1989.tb02313.x; KATO R, 1983, CARCINOGENESIS, V4, P1301, DOI 10.1093/carcin/4.10.1301; Kuhnau J, 1976, World Rev Nutr Diet, V24, P117; LIEHR JG, 1986, J BIOL CHEM, V261, P6865; LIEHR JG, 1990, FREE RADICAL BIO MED, V8, P415, DOI 10.1016/0891-5849(90)90108-U; MACGREGOR JT, 1978, MUTAT RES, V54, P297, DOI 10.1016/0165-1161(78)90020-1; MACGREGOR JT, 1979, TOXICOL APPL PHARM, V48, pA47; MARUTA A, 1979, GANN, V70, P273; MORINO K, 1982, CARCINOGENESIS, V3, P93, DOI 10.1093/carcin/3.1.93; MULDER GJ, 1984, DRUGS NUTRITIENTS IN, P119; NAGAO M, 1981, ENVIRON MUTAGEN, V3, P401, DOI 10.1002/em.2860030402; NIKODEJEVIC B, 1970, J PHARMACOL EXP THER, V174, P83; ROY D, 1988, J BIOL CHEM, V263, P3646; Saito D, 1980, Teratog Carcinog Mutagen, V1, P213; SASAKI S, 1985, HDB PROTON NMR SPECT, V5, P97; SUGIMURA T, 1977, P JPN ACAD B-PHYS, V53, P194, DOI 10.2183/pjab.53.194; THOR H, 1982, J BIOL CHEM, V257, P2419; UENO I, 1983, JPN J EXP MED, V53, P41; UMEZAWA K, 1977, TOXICOL LETT, V1, P175; VERMA AK, 1988, CANCER RES, V48, P5754; ZHU BT, 1993, ENDOCRINOLOGY, V132, P577, DOI 10.1210/en.132.2.577; ZHU BT, 1993, ARCH BIOCHEM BIOPHYS, V304, P248, DOI 10.1006/abbi.1993.1346	47	217	221	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					292	299						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276810				2022-12-25	WOS:A1994MR21900052
J	TAKEUCHI, K; IRWIN, DM; GALLUP, M; SHINBROT, E; KAI, H; STEWART, CB; BASBAUM, C				TAKEUCHI, K; IRWIN, DM; GALLUP, M; SHINBROT, E; KAI, H; STEWART, CB; BASBAUM, C			MULTIPLE CDNA SEQUENCES OF BOVINE TRACHEAL LYSOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN LOCUS; STOMACH LYSOZYMES; IMMUNOCYTOCHEMICAL LOCALIZATION; GENE; RUMINANTS; EXPRESSION; EVOLUTION; TISSUES; ORGANIZATION; CONVERGENCE	The principal role of lysozyme is to prevent bacterial invasion at body surfaces. We are interested in how lysozyme is regulated at the surface of the respiratory tract, where the serous gland cell is regarded as the primary cellular source of this enzyme. Since the cow genome contains at least 10 lysozyme-like genes, our objective was to determine which of them are expressed in the cow tracheal gland serous cell. By screening tracheal cDNA libraries with a probe constructed from the cDNA encoding stomach lysozyme 2, we obtained 3 lysozyme cDNAs: 5a (1023 base pairs (bp)), 7a (1060 bp), and 14d (1249 bp). cDNA 7a corresponds to a previously reported gene (showing sequence identity to the stomach 2 lysozyme gene), whereas cDNAs 5a and 14d correspond to lysozyme genes not previously reported. Northern blot analysis of cow tracheal RNA showed lysozyme mRNAs of three distinct lengths. Based on hybridization with probes specific for each cDNA, we determined that the longest transcript corresponded to cDNA 5a, the shortest to 7a, and the intermediate-length transcript to 14d. Cultured cow tracheal gland serous cell RNA, reverse transcribed and amplified by the polymerase chain reaction with primers common to all three cDNAs, yielded a product that hybridized to oligonucleotide probes specific for all three cDNAs but most strongly to that for 5a. These results indicate that multiple lysozyme mRNAs are expressed in the cow trachea and that the lysozyme encoded by cDNA 5a is the major form expressed in the tracheal gland serous cell. This serous cell lysozyme is predicted to differ importantly in structure from both 7a and 14d lysozymes, with an arginine:lysine ratio almost 10-fold higher. The sequence differences may underlie functional differences, including variable resistance to proteolysis and variable affinity for large polyanions (e.g. mucins) found in the respiratory tract lumen.	UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5G 1L5,ONTARIO,CANADA; SUNY ALBANY,DEPT BIOL SCI,ALBANY,NY 12222	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Toronto; State University of New York (SUNY) System; State University of New York (SUNY) Albany			Shinbrot, Eve/V-2784-2019	Shinbrot, Eve/0000-0002-8879-3150; Irwin, David/0000-0001-6131-4933	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL24136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOAT TF, 1977, PEDIATR RES, V11, P977, DOI 10.1203/00006450-197709000-00009; BOWES D, 1977, THORAX, V32, P163, DOI 10.1136/thx.32.2.163; BUTTLE DJ, 1990, SCAND J CLIN LAB INV, V50, P509, DOI 10.3109/00365519009089165; CASTANON MJ, 1988, GENE, V66, P223, DOI 10.1016/0378-1119(88)90359-9; CROSS M, 1988, P NATL ACAD SCI USA, V85, P6232, DOI 10.1073/pnas.85.17.6232; DOBSON DE, 1984, J BIOL CHEM, V259, P1607; DORING G, 1983, J INFECT DIS, V147, P744, DOI 10.1093/infdis/147.4.744; FERAMISCO JR, 1982, J BIOL CHEM, V257, P1024; FINKBEINER WE, 1986, IN VITRO CELL DEV B, V22, P561, DOI 10.1007/BF02623514; Fleming A, 1922, P R SOC LOND B-CONTA, V93, P306, DOI 10.1098/rspb.1922.0023; HAMMER MF, 1987, J MOL EVOL, V24, P272, DOI 10.1007/BF02111240; HANKE PD, 1988, MOL CELL BIOL, V8, P3591, DOI 10.1128/MCB.8.9.3591; IRWIN DM, 1992, ANIM GENET, V23, P193, DOI 10.1111/j.1365-2052.1992.tb00131.x; IRWIN DM, 1989, J BIOL CHEM, V264, P11387; IRWIN DM, 1989, IMMUNE RESPONSE TO STRUCTURALLY DEFINED PROTEINS : THE LYSOZYME MODEL, P73; IRWIN DM, 1992, J MOL EVOL, V35, P355; IZZO P, 1988, EUR J BIOCHEM, V174, P569, DOI 10.1111/j.1432-1033.1988.tb14136.x; JOLLES J, 1990, J MOL EVOL, V30, P370, DOI 10.1007/BF02101891; JOLLES J, 1989, J MOL EVOL, V28, P528, DOI 10.1007/BF02602933; JOLLES P, 1984, J BIOL CHEM, V259, P1617; JUAREGUIADELL J, 1975, ANAL BIOCHEM, V69, P468; KLOCKARS M, 1975, J HISTOCHEM CYTOCHEM, V23, P932, DOI 10.1177/23.12.1104708; KLOCKARS M, 1974, J HISTOCHEM CYTOCHEM, V22, P139, DOI 10.1177/22.3.139; KONSTAN MW, 1982, EXP LUNG RES, V3, P175, DOI 10.3109/01902148209063291; KYLE H, 1990, J APPL PHYSIOL, V68, P135, DOI 10.1152/jappl.1990.68.1.135; LEWIS CE, 1990, IMMUNOLOGY, V69, P402; LI QL, 1991, GENOMICS, V9, P488, DOI 10.1016/0888-7543(91)90415-B; MASON DY, 1975, J CLIN PATHOL, V28, P124, DOI 10.1136/jcp.28.2.124; MASSON P, 1973, SPUTUM, V438, P412; PETERS CWB, 1989, EUR J BIOCHEM, V182, P507, DOI 10.1111/j.1432-1033.1989.tb14857.x; PRIEUR DJ, 1986, COMP BIOCHEM PHYS B, V85, P349, DOI 10.1016/0305-0491(86)90011-8; PUCHELLE E, 1987, European Journal of Respiratory Diseases Supplement, V71, P117; SAMUELSON LC, 1990, MOL CELL BIOL, V10, P2513, DOI 10.1128/MCB.10.6.2513; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SPENCE SE, 1985, NUCLEIC ACIDS RES, V13, P2171, DOI 10.1093/nar/13.6.2171; SPICER SS, 1977, LAB INVEST, V36, P282; STEWART CB, 1987, COLD SPRING HARB SYM, V52, P891, DOI 10.1101/SQB.1987.052.01.097; SWANSON KW, 1991, J MOL EVOL, V33, P418, DOI 10.1007/BF02103133	39	17	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27440	27446						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262986				2022-12-25	WOS:A1993MM26200085
J	ATKINSON, YH; GOGOLINEWENS, KJ; HOUNSELL, EF; DAVIES, MJ; BRANDON, MR; SEAMARK, RF				ATKINSON, YH; GOGOLINEWENS, KJ; HOUNSELL, EF; DAVIES, MJ; BRANDON, MR; SEAMARK, RF			CHARACTERIZATION OF PLACENTATION-SPECIFIC BINUCLEATE CELL GLYCOPROTEINS POSSESSING A NOVEL CARBOHYDRATE - EVIDENCE FOR A NEW FAMILY OF PREGNANCY-ASSOCIATED MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; CARCINOEMBRYONIC ANTIGEN; STRUCTURAL DETERMINANTS; POLYACRYLAMIDE GELS; SUGAR CHAINS; PROTEINS; SHEEP; BETA-1-GLYCOPROTEIN; IDENTIFICATION; IMPLANTATION	The ovine binucleate cell-specific glycoproteins recognized by the monoclonal antibody SBU-3 first appear at the initiation of placentation, and their expression continues throughout gestation. These placenta-specific proteins have not been detected in any other adult or fetal sheep tissues and are specific to the materno-fetal interface. The SBU-3 monoclonal antibody recognizes the carbohydrate epitope common to a group of proteins ranging in molecular mass from 30 to 200 kDa whose function during pregnancy remains undefined. The biochemical properties of these uniquely expressed glycoproteins were investigated by analyzing both the carbohydrate and protein portion of the molecules. Analysis of phytohemagglutinin and concanavalin A binding to electrophoretically separated SBU-3 proteins revealed that the major proteins between 40 and 70 kDa bind phytohemagglutinin. In contrast, concanavalin A bound only to minor proteins in the SBU-3 glycoprotein preparation. Analysis of the carbohydrate conjugated to the SBU-3 glycoproteins revealed that the major chains are sialylated O-linked and complex partially sialylated multiple antennary N-linked chains. The presence of N-glycolylneuraminic acid in an N-linked structure indicates the unique nature of this carbohydrate epitope. The differential binding to phytohemagglutinin and concanavalin A provided a method for further purification and characterization of the major protein components with monoclonal antibody immunoaffinity-purified SBU-3 proteins being further separated by concanavalin A-Sepharose chromatography. Microsequence analysis of the major non-concanavalin A-binding proteins (69, 62, and 57 kDa) revealed partial homology to ovine and bovine pregnancy-associated glycoprotein and rabbit pepsinogen F. Immunoblot analysis of the SBU-3 proteins showed cross-reactivity with polyclonal antisera directed against ovine placental-associated glycoprotein and pregnancy-specific glycoprotein B. These results suggest that together these glycoproteins represent members of a binucleate cell-derived family of pregnancy-associated molecules in the ruminant placenta.	UNIV MELBOURNE,SCH VET SCI,CTR ANIM BIOTECHNOL,PARKVILLE,VIC 3052,AUSTRALIA; CLIN RES CTR,GLYCOCONJUGATES SECT,HARROW HA1 3UJ,MIDDX,ENGLAND	University of Melbourne	ATKINSON, YH (corresponding author), UNIV ADELAIDE,DEPT OBSTET & GYNAECOL,ADELAIDE,SA 5001,AUSTRALIA.		Hounsell, Elizabeth F/C-5177-2008					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BOHN H, 1971, ARCH GYNAKOL, V210, P440, DOI 10.1007/BF01628222; CHAI WG, 1992, EUR J BIOCHEM, V207, P973, DOI 10.1111/j.1432-1033.1992.tb17132.x; CHAUDHURI TR, 1987, PREP BIOCHEM, V17, P93, DOI 10.1080/00327488708062478; CORFIELD AP, 1982, SIALIC ACIDS CHEM ME, P5; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; ENDO T, 1988, J BIOCHEM-TOKYO, V103, P182, DOI 10.1093/oxfordjournals.jbchem.a122228; ENDO Y, 1979, J BIOCHEM-TOKYO, V85, P669; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; GOGOLINEWENS KJ, 1986, PLACENTA, V7, P243, DOI 10.1016/S0143-4004(86)80162-X; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; HIGASHI H, 1977, BIOCHEM BIOPH RES CO, V79, P388, DOI 10.1016/0006-291X(77)90169-3; HORNE CHW, 1976, EXPERIENTIA, V32, P1197, DOI 10.1007/BF01927624; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; KAWASAKI T, 1976, J BIOL CHEM, V251, P1296; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CS, 1986, J REPROD FERTIL, V78, P653; LYNCH R A, 1992, Biology of Reproduction, V46, P73; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORGAN G, 1987, J CELL SCI, V88, P503; MURRAY FA, 1978, BIOL REPROD, V19, P15, DOI 10.1095/biolreprod19.1.15; PAXTON RJ, 1987, P NATL ACAD SCI USA, V84, P920, DOI 10.1073/pnas.84.4.920; Reimers TJ, 1985, BIOL REPROD S1, V32, P65; SEGERSON E C, 1988, Journal of Animal Science, V66, P420; SMITH PL, 1992, J BIOL CHEM, V267, P19140; TAKAMOTO M, 1989, J BIOCHEM-TOKYO, V105, P742, DOI 10.1093/oxfordjournals.jbchem.a122738; TAKAMOTO M, 1989, J BIOCHEM-TOKYO, V106, P228, DOI 10.1093/oxfordjournals.jbchem.a122837; TAKASAKI S, 1980, J BIOCHEM-TOKYO, V88, P1587, DOI 10.1093/oxfordjournals.jbchem.a133133; TATARINOV Y S, 1970, Byulleten' Eksperimental'noi Biologii i Meditsiny, V69, P66; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WASSARMAN PM, 1987, ANNU REV CELL BIOL, V3, P109, DOI 10.1146/annurev.cellbio.3.1.109; WATANABE S, 1988, BIOCHEM BIOPH RES CO, V152, P762, DOI 10.1016/S0006-291X(88)80103-7; WATANABE S, 1988, J BIOL CHEM, V263, P2049; WOODING FBP, 1992, PLACENTA, V13, P101, DOI 10.1016/0143-4004(92)90025-O; XIE SC, 1991, P NATL ACAD SCI USA, V88, P10247, DOI 10.1073/pnas.88.22.10247; YAMASHITA K, 1983, J BIOL CHEM, V258, P4753; ZOLI AP, 1991, BIOL REPROD, V45, P1, DOI 10.1095/biolreprod45.1.1	38	49	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26679	26685						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253801				2022-12-25	WOS:A1993MK42500097
J	MIYAGI, T; KONNO, K; EMORI, Y; KAWASAKI, H; SUZUKI, K; YASUI, A; TSUIKI, S				MIYAGI, T; KONNO, K; EMORI, Y; KAWASAKI, H; SUZUKI, K; YASUI, A; TSUIKI, S			MOLECULAR-CLONING AND EXPRESSION OF CDNA-ENCODING RAT SKELETAL-MUSCLE CYTOSOLIC SIALIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; NEURAMINIDASE GENE; INFLUENZA-VIRUS; TRYPANOSOMA-CRUZI; AVIAN INFLUENZA; MESSENGER-RNA; LIVER; AMPLIFICATION; BACTERIAL; TISSUES	We have isolated a cDNA clone encoding the cytosolic sialidase of rat skeletal muscle. Degenerate oligonucleotides, based on amino acid sequence data for the purified enzyme, were used as primers to amplify fragments of the gene from rat skeletal muscle cDNA by the polymerase chain reaction. The amplified cDNA fragment was then applied as probe to screen a rat skeletal muscle cDNA library. The longest cDNA clone thus isolated was incomplete at the 5'-end, and therefore an amplified cDNA from the 5'-end portion of the gene was further generated by polymerase chain reaction. These two cDNAs were used to construct a cDNA encoding the entire sequence of rat sialidase. The composite sequence encodes an open reading frame of 379 amino acids that include all sequenced peptides. Although the deduced amino acid sequence is not largely similar to those of bacterial and parasite sialidases, it contains two Asp blocks, the conserved sequence of the sialidases from these microorganisms. When the cDNA was inserted into an expression vector followed by transformation in Escherichia coli, sialidase activity appeared in the cell extract. The sialidase could be completely immunoprecipitated by antiserum against the cytosolic sialidase of rat skeletal muscle.	TOHOKU UNIV,INST DEV AGING & CANC,SENDAI,MIYAGI 980,JAPAN; UNIV TOKYO,FAC SCI,TOKYO 113,JAPAN; UNIV TOKYO,INST APPL MICROBIOL,TOKYO 113,JAPAN; TOKYO METROPOLITAN INST MED SCI,TOKYO 113,JAPAN; TOHOKU COLL PHARMACEUT SCI,SENDAI,MIYAGI 983,JAPAN	Tohoku University; University of Tokyo; University of Tokyo; Tokyo Metropolitan Institute of Medical Science; Tohoku Medical & Pharmaceutical University	MIYAGI, T (corresponding author), MIYAGI CANC CTR,RES INST,DIV BIOCHEM,47-1 NODAYAMA,MEDESHIMA SHIODE,NATORI,MIYAGI 98112,JAPAN.		Kawasaki, Hiroshi/C-3048-2011	Kawasaki, Hiroshi/0000-0002-2517-159X				AIR GM, 1990, VIROLOGY, V177, P578, DOI 10.1016/0042-6822(90)90523-T; AIR GM, 1987, VIROLOGY, V160, P346, DOI 10.1016/0042-6822(87)90005-5; DAIRAKU K, 1986, BIOCHEM INT, V13, P741; DALE B, 1986, VIROLOGY, V155, P460, DOI 10.1016/0042-6822(86)90207-2; FIELDS S, 1981, NATURE, V290, P213, DOI 10.1038/290213a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HARLEY VR, 1989, VIROLOGY, V169, P239, DOI 10.1016/0042-6822(89)90063-9; HITI AL, 1982, J VIROL, V41, P730, DOI 10.1128/JVI.41.2.730-734.1982; HOYER LL, 1992, MOL MICROBIOL, V6, P873, DOI 10.1111/j.1365-2958.1992.tb01538.x; JORGENSEN ED, 1987, VIROLOGY, V156, P12, DOI 10.1016/0042-6822(87)90431-4; KAHN S, 1991, P NATL ACAD SCI USA, V88, P4481, DOI 10.1073/pnas.88.10.4481; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAUSS JH, 1988, ARCH MICROBIOL, V150, P584, DOI 10.1007/BF00408254; MARKOFF L, 1982, VIROLOGY, V119, P288, DOI 10.1016/0042-6822(82)90089-7; MIURA N, 1985, FEBS LETT, V188, P112, DOI 10.1016/0014-5793(85)80885-1; MIYAGI T, 1985, J BIOL CHEM, V260, P6710; MIYAGI T, 1990, J BIOCHEM-TOKYO, V107, P794, DOI 10.1093/oxfordjournals.jbchem.a123127; MIYAGI T, 1984, EUR J BIOCHEM, V141, P75, DOI 10.1111/j.1432-1033.1984.tb08159.x; MIYAGI T, 1990, J BIOCHEM-TOKYO, V107, P787, DOI 10.1093/oxfordjournals.jbchem.a123126; MIYAGI T, 1993, GLYCOCONJUGATE J, V10, P45, DOI 10.1007/BF00731186; MOREMEN KW, 1989, P NATL ACAD SCI USA, V86, P5276, DOI 10.1073/pnas.86.14.5276; PEREIRA MEA, 1991, J EXP MED, V174, P179, DOI 10.1084/jem.174.1.179; POTIER M, 1990, BIOCHEM BIOPH RES CO, V173, P449, DOI 10.1016/S0006-291X(05)81079-4; ROGGENTIN P, 1989, GLYCOCONJUGATE J, V6, P349, DOI 10.1007/BF01047853; ROGGENTIN P, 1988, FEBS LETT, V238, P31, DOI 10.1016/0014-5793(88)80219-9; ROTH J, 1992, SCIENCE, V256, P673, DOI 10.1126/science.1585182; ROTHE B, 1989, J GEN MICROBIOL, V135, P3087; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAUER R, 1985, TRENDS BIOCHEM SCI, V10, P357, DOI 10.1016/0968-0004(85)90112-4; SHAW MW, 1982, P NATL ACAD SCI-BIOL, V79, P6817, DOI 10.1073/pnas.79.22.6817; STEULER H, 1984, VIROLOGY, V135, P118, DOI 10.1016/0042-6822(84)90122-3; VIMR ER, 1988, J BACTERIOL, V170, P1495, DOI 10.1128/jb.170.4.1495-1504.1988	34	110	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26435	26440						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253770				2022-12-25	WOS:A1993MK42500064
J	STAUFFER, TP; HILFIKER, H; CARAFOLI, E; STREHLER, EE				STAUFFER, TP; HILFIKER, H; CARAFOLI, E; STREHLER, EE			QUANTITATIVE-ANALYSIS OF ALTERNATIVE SPLICING OPTIONS OF HUMAN PLASMA-MEMBRANE CALCIUM-PUMP GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; CA-2+ PUMP; MOLECULAR-CLONING; MESSENGER-RNAS; CA2+ PUMP; CA-2+-TRANSPORTING ATPASE; SEQUENCE-ANALYSIS; SKELETAL-MUSCLE; SMOOTH-MUSCLE; ISOFORMS	The alternative splicing options and the quantitative tissue distribution of the transcripts of the four currently known human plasma membrane calcium pump (PMCA) genes have been analyzed in seven tissues (cerebral cortex, skeletal and heart muscle, stomach, liver, lung, and kidney) by quantitative polymerase chain reaction on reverse transcribed mRNA with glyceraldehyde-3-phosphate dehydrogenase as the internal standard. The mRNAs of genes 1 and 4 were found to be present in similar amounts in all tissues, whereas the transcripts of genes 2 and 3 were expressed in a tissue-specific manner, i.e. their amounts were highest in fetal skeletal muscle and brain. Alternative splicing was found to occur in the PMCA transcripts at two major regulatory sites (sites A and C), adjacent to the amino-terminal phospholipid-responsive region and within the carboxyl-terminal calmodulin binding domain, respectively. Novel splicing variants not described previously for human genes were detected for hPMCA3 and 4 at site A and for hPMCA1, 2, and 3 at site C. For all genes a common splice variant was found at both splice sites. The common splice variant at site A was characterized by the inclusion of a small exon (hPMCA1, 39 base pairs (bp); hPMCA2, 42 bp; hPMCA3, 42 bp; hPMCA4, 36 bp). In the common splice variant at site C, an exon (hPMCA1, 154 bp; hPMCA2, 227 bp; hPMCA3, 154 bp; hPMCA4, 178 bp) was excluded in the mRNA. All genes normally express these main splice variants in all tissues in which the corresponding isoform is present. The splicing complexity at site C was found to be augmented in the transcripts of PMCA2 and PMCA3 through the use of additional exons, and in PMCA1 and 3 through the use of additional internal splice sites in the single alternatively spliced 154-base pair exon.	SWISS FED INST TECHNOL,BIOCHEM LAB,CH-8092 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				ADAMO HP, 1992, BIOCHEM J, V283, P355, DOI 10.1042/bj2830355; BRANDT P, 1992, J BIOL CHEM, V267, P4376; BURK SE, 1992, J BIOL CHEM, V267, P19683; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEJAEGERE S, 1990, BIOCHEM J, V271, P655, DOI 10.1042/bj2710655; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIEFFENBACH CW, 1989, J BIOL CHEM, V264, P13281; Dveksler G S, 1992, PCR Methods Appl, V1, P283; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; GREEB J, 1989, J BIOL CHEM, V264, P18569; HEIM R, 1992, EUR J BIOCHEM, V205, P333, DOI 10.1111/j.1432-1033.1992.tb16784.x; HILFIKER H, 1993, J BIOL CHEM, V268, P19717; HOFMANN F, 1993, J BIOL CHEM, V268, P10252; HOWARD A, 1992, BIOCHEM BIOPH RES CO, V183, P499, DOI 10.1016/0006-291X(92)90510-R; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; KEETON TP, 1993, J BIOL CHEM, V268, P2740; KESSLER F, 1992, BIOCHEMISTRY-US, V31, P11785, DOI 10.1021/bi00162a016; KHAN I, 1991, BIOCHEM J, V277, P345, DOI 10.1042/bj2770345; MAGOCSI M, 1992, AM J PHYSIOL, V263, pF7, DOI 10.1152/ajprenal.1992.263.1.F7; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SIEBERT P, 1991, HUMAN GENOME, V3; SIEBERT P, 1991, RT PCR METHODS APPLI, P29; STAHL WL, 1992, MOL BRAIN RES, V16, P223, DOI 10.1016/0169-328X(92)90229-5; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; STREHLER EE, 1989, HORM CELL REGUL, V198, P105; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; WANG KKW, 1991, J BIOL CHEM, V266, P9078; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220	38	146	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25993	26003						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	8245032				2022-12-25	WOS:A1993MK10000100
